PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wang, X; Hu, B; Weiss, RS; Wang, Y				Wang, X; Hu, B; Weiss, RS; Wang, Y			The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining	ONCOGENE			English	Article						Hus1; IR (ionizing radiation); DNA damage; DNA repair; NHEJ (nonhomologous end-joining); HRR (homologous recombination repair)	DNA-DAMAGE; GENOMIC INSTABILITY; MAMMALIAN-CELLS; MOUSE HUS1; HUMAN RAD9; CHECKPOINT; CHK1; PHOSPHORYLATION; ACTIVATION; RESPONSES	Mammalian Hus1 plays an important role in maintaining genomic integrity. Cells lacking mouse Hus1 are hypersensitive to DNA damage inducers including UV and camptothecin ( CPT). By using clonogenic assay, we show here that Hus1 deficient mouse cells are hypersensitive to ionizing radiation ( IR) compared with their Hus1-positive counterparts. However, these cells show similar induction levels and similar rejoining rates of DNA double strand breaks ( DSBs) following IR, indicating that the effect of Hus1 on cell radiosensitivity is independent of nonhomologous end-joining (NHEJ). By combining an I-SceI-induced-DNA DSBs system and a siRNA approach, we also show that knocking down Hus1 decreases the efficiency of homologous recombination repair ( HRR), which is associated with the cellular sensitivity to IR-induced killing. Together, these results indicate that the role of Hus1 affecting the sensitivity of cells to IR-induced killing is independent of NHEJ but might be linked to HRR.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; Beijing Inst Biotechnol, Beijing, Peoples R China	Jefferson University; Jefferson University; Cornell University	Wang, Y (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Thompson Bldg Room B-1,1020 Sansom St, Philadelphia, PA 19107 USA.	ya.wang@mail.tju.edu			NCI NIH HHS [R01 CA108773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Hu BC, 2005, CANCER RES, V65, P8613, DOI 10.1158/0008-5472.CAN-05-1966; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Nickoloff Jac A, 2004, Methods Mol Biol, V262, P35; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Wang X, 2004, NUCLEIC ACIDS RES, V32, P767, DOI 10.1093/nar/gkh243; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1	18	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1980	1983		10.1038/sj.onc.1209212	http://dx.doi.org/10.1038/sj.onc.1209212			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16278671	Green Submitted			2022-12-28	WOS:000236224800015
J	Yates, DR; Rehman, I; Meuth, M; Cross, SS; Hamdy, FC; Catto, JWF				Yates, DR; Rehman, I; Meuth, M; Cross, SS; Hamdy, FC; Catto, JWF			Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls	ONCOGENE			English	Article						epigenetic; DNA methylation; bladder cancer; urinalysis	DNA METHYLATION; HYPERMETHYLATION; URINE; GENE; NEOPLASIA	Tumour suppressor gene ( TSG) methylation has been proposed as a diagnostic marker for urothelial cancer (UC). Here, we compare the frequency of urinary TSG methylation in young and elderly patients, with and without UC. Urine samples were obtained prospectively from 35 UC patients, 35 benign controls over the age of 70 years and 34 healthy volunteers under the age of 40 years. Methylation analysis was performed for eight gene promoters using quantitative methylation-specific PCR. Methylation was detected in urine DNA from all three patient groups. The highest frequencies were seen in UC patients. Significantly less methylation was present in control samples than UC cases for RASSF1a and APC ( P < 0.034). The 'methylation index' and level of methylation was highest in the UC group and lowest in the young control group. A marker panel of RASSF1a, E-cad and APC generated a sensitivity of 69%, a specificity of 60% and a diagnostic accuracy of 86%. TSG methylation is detectable in urine DNA from patients with and without bladder cancer. The frequency and extent of methylation appears to increase with age and malignancy. The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice.	Univ Sheffield, Acad Urol Unit, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Inst Canc Studies, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Pathol Unit, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield	Catto, JWF (corresponding author), Univ Sheffield, Acad Urol Unit, Royal Hallamshire Hosp, K Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	J.Catto@sheffield.ac.uk		catto, james/0000-0003-2787-8828; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754				Ahuja N, 1998, CANCER RES, V58, P5489; Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163; Chan MWY, 2002, CLIN CANCER RES, V8, P464; Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127; Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; HARNDEN SV, 2003, CLIN CANCER RES, V9, P370; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Maruyama R, 2001, CANCER RES, V61, P8659; Molinie V, 2001, ANN PATHOL, V21, P361; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Usadel H, 2002, CANCER RES, V62, P371	20	77	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1984	1988		10.1038/sj.onc.1209209	http://dx.doi.org/10.1038/sj.onc.1209209			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288222				2022-12-28	WOS:000236224800016
J	Yang, F; Foekens, JA; Yu, J; Sieuwerts, AM; Timmermans, M; Klijn, JGM; Atkins, D; Wang, Y; Jiang, Y				Yang, F; Foekens, JA; Yu, J; Sieuwerts, AM; Timmermans, M; Klijn, JGM; Atkins, D; Wang, Y; Jiang, Y			Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways	ONCOGENE			English	Article						breast tumors; laser microdissection; DNA microarray; gene profiling; estrogen receptor	GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; EXPRESSION PROFILES; CANCER CELLS; CAPTURE MICRODISSECTION; CDNA MICROARRAY; MESSENGER-RNA; EPH RECEPTORS; P-CADHERIN; IDENTIFICATION	About 70-80% of breast cancers express estrogen receptor alpha (ER-alpha), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size, and histological grade, ER status is considered as one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. To investigate genes and pathways that are associated with ER status and epithelial cells in breast tumor, we applied laser capture microdissection (LCM) technology to capture epithelial tumor cells from 28 lymph node-negative breast tumor samples, in which 17 patients had ER-alpha + tumors, and 11 patients have ER-alpha- tumors. Gene expression profiles were analysed on Affymetrix Hu133A GeneChip. Meanwhile, gene profiles using total RNA isolated from bulk tumors of the same 28 patients were also generated. In total, 146 ;genes and 112 genes with significant P-value and having significant differential expression between ER-alpha + and ER-alpha- tumors were identified from the LCM data set and bulk tissue data set, respectively. A total of 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathways may play roles related to ER. The gene pro. ling with LCM-captured tumor cells provides a unique approach to study epithelial tumor cells and to gain an insight into signaling pathways associated with ER.	Veridex LLC, Johnson & Johnson Co, San Diego, CA 92121 USA; Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands	Johnson & Johnson; Johnson & Johnson USA; Erasmus University Rotterdam; Erasmus MC	Jiang, Y (corresponding author), Veridex LLC, Johnson & Johnson Co, 3210 Merryfield Row, San Diego, CA 92121 USA.	jjiang2@vrxus.jnj.com						Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FOEKENS JA, 1989, CANCER RES, V49, P5823; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Gruvberger S, 2001, CANCER RES, V61, P5979; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Kamme F, 2004, METH MOLEC MED, P215; Khoo C, 1997, PROTEIN EXPRES PURIF, V9, P379, DOI 10.1006/prep.1996.0709; Kim H, 2001, BIOCHEM SOC T, V29, P216, DOI 10.1042/BST0290216; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Luzzi V, 2003, J MOL DIAGN, V5, P9, DOI 10.1016/S1525-1578(10)60445-X; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Malbert-Colas L, 2003, PFLUG ARCH EUR J PHY, V447, P35, DOI 10.1007/s00424-003-1152-6; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Matsui H, 2003, ANTICANCER RES, V23, P195; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Mokbel K, 2003, CURR MED RES OPIN, V19, P683, DOI 10.1185/030079903125002397; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Nishidate T, 2004, INT J ONCOL, V25, P797; Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795; Parl F.F., 2000, ESTROGENS ESTROGEN R; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polacek DC, 2003, PHYSIOL GENOMICS, V13, P147, DOI 10.1152/physiolgenomics.00173.2002; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Seth A, 2003, ANTICANCER RES, V23, P2043; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Sun JM, 2005, EXP CELL RES, V302, P96, DOI 10.1016/j.yexcr.2004.08.015; Tamini Y, 2004, INVEST OPHTH VIS SCI, V45, P3904, DOI 10.1167/iovs.04-0628; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Weisz A, 2004, J CELL PHYSIOL, V200, P440, DOI 10.1002/jcp.20039; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wu KM, 2003, J BIOL CHEM, V278, P51673, DOI 10.1074/jbc.M310021200; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yim SH, 2003, TOXICOL PATHOL, V31, P295, DOI 10.1080/01926230309753	47	51	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1413	1419		10.1038/sj.onc.1209165	http://dx.doi.org/10.1038/sj.onc.1209165			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16261164				2022-12-28	WOS:000235708200015
J	Mongiat-Artus, P; Miquel, C; Van der Aa, M; Buhard, O; Hamelin, R; Soliman, H; Bangma, C; Janin, A; Teillac, P; van der Kwast, T; Praz, F				Mongiat-Artus, P; Miquel, C; Van der Aa, M; Buhard, O; Hamelin, R; Soliman, H; Bangma, C; Janin, A; Teillac, P; van der Kwast, T; Praz, F			Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract	ONCOGENE			English	Article						upper urinary tract; urothelial cell carcinoma; renal pelvis; hereditary non-polyposis colorectal cancer; microsatellite instability; MSI phenotype	NONPOLYPOSIS COLORECTAL-CANCER; REPAIR-DEFICIENT CANCERS; MISMATCH-REPAIR; MONONUCLEOTIDE REPEATS; FRAMESHIFT MUTATIONS; MRE11 EXPRESSION; TARGET GENES; TUMORS; HMLH1; LINES	A subset of upper urinary tract urothelial cell carcinomas (UUC), arising sporadically or as a manifestation of hereditary non-polyposis colorectal cancer, displays microsatellite instability (MSI). MSI tumours are characterized by defective mismatch repair and accumulation of frameshift mutations in numerous genes harbouring repeats in their coding sequences. We have evaluated the incidence of MSI in UUC and the intratumoral distribution of mutations in 13 candidate target genes. A total of 58 unselected UUC were screened for MSI using the panel of five mononucleotide markers recently recommended by the National Cancer Institute for a precise MSI assessment. Four tumours displayed MSI (7%), among which at least three had alterations in the genes MSH3, BAX, MRE11, RAD50. Mutations in genes involved in key cellular pathways (ATR, DNA-PKcs, MBD4, TCF-4, MSH6, and BLM) were further detected. BAX and MRE11 mutations tend to present homogeneously within the three MSI UUC. Immunohistochemistry (MLH1, MSH2, MSH6) showed that loss of mismatch repair protein expression occurred in all MSI UUC de. ning the gene defect and that MRE11 and RAD50 mutations were associated with their concomitant loss expression. In conclusion, MSI UUC represent a small proportion of UUC in which BAX and MRE11 mutations are frequent and may play a role early in UUC tumorigenesis.	Univ Paris 07, Hop St Louis, Dept Urol, Paris, France; CNRS, UPR 2169, Villejuif, France; Erasmus Med Ctr, Dept Pathol, Rotterdam, Netherlands; INSERM, Ctr Etud Polymorphisme Humain, U434, Paris, France; Hop St Louis, CNRS, UPR 9051, Dept Biochem, Paris, France; Erasmus Med Ctr, Dept Urol, Rotterdam, Netherlands; Hop St Louis, INSERM, U728, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mongiat-Artus, P (corresponding author), Hop St Louis, Dept Urol, 1 Ave Claude Vellefaux, F-75010 Paris, France.	pierre.mongiat-artus@sls.aphp.fr	PRAZ, Françoise/A-7291-2008; PRAZ, Françoise/AAF-7761-2020; miquel, catherine/B-5536-2013	PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889; Van der Kwast, Theodorus/0000-0001-8640-5786				Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Aben KKH, 2002, INT J CANCER, V98, P274, DOI 10.1002/ijc.10191; Barnetson R, 2000, GENE CHROMOSOME CANC, V29, P130, DOI 10.1002/1098-2264(200010)29:2<130::AID-GCC1023>3.0.CO;2-Z; Blaszyk H, 2002, MODERN PATHOL, V15, P790, DOI 10.1097/01.MP.0000024263.25043.0C; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Buhard O, 2004, DIS MARKERS, V20, P251, DOI 10.1155/2004/159347; Catto JWF, 2003, ONCOGENE, V22, P8699, DOI 10.1038/sj.onc.1206964; Dietmaier W, 1997, CANCER RES, V57, P4749; Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, CANCER RES, V62, P2447; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Ericson KM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-23; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Hartmann A, 2003, HUM PATHOL, V34, P222, DOI 10.1053/hupa.2003.22; Hartmann A, 2002, CANCER RES, V62, P6796; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacob S, 2005, NUCLEIC ACIDS RES, V33, P106, DOI 10.1093/nar/gki154; Kane MF, 1997, CANCER RES, V57, P808; Kim NG, 2001, CANCER RES, V61, P36; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Parc Y, 2004, GUT, V53, P371, DOI 10.1136/gut.2003.019190; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roupret M, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.017871; Sijmons RH, 1998, J UROLOGY, V160, P466, DOI 10.1016/S0022-5347(01)62926-4; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Verma L, 1999, J MED GENET, V36, P678; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421	36	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	14					2113	2118		10.1038/sj.onc.1209229	http://dx.doi.org/10.1038/sj.onc.1209229			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288216				2022-12-28	WOS:000236359700014
J	Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL				Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL			HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells	ONCOGENE			English	Article						FAK; HEF1; CAS; Crk-associated substrate; glioblastoma; migration	FOCAL ADHESION KINASE; SRC FAMILY KINASES; GROWTH-FACTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; ASTROCYTIC TUMORS; SIGNALING PATHWAY; COMPLEX-FORMATION; V-SRC	The highly invasive behavior of glioblastoma cells contributes to the morbidity and mortality associated with these tumors. The integrin-mediated adhesion and migration of glioblastoma cells on brain matrix proteins is enhanced by stimulation with growth factors, including platelet-derived growth factor (PDGF). As focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, has been shown to promote cell migration in various other cell types, we analysed its role in glioblastoma cell migration. Forced overexpression of FAK in serum-starved glioblastoma cells plated on recombinant (rec)osteopontin resulted in a twofold enhancement of basal migration and a ninefold enhancement of PDGF-BB-stimulated migration. Both expression of mutant FAK(397F) and the downregulation of FAK with small interfering(si) RNA inhibited basal and PDGF-stimulated migration. FAK overexpression and PDGF stimulation was found to increase the phosphorylation of the Crk-associated substrate (CAS) family member human enhancer of filamentation 1 (HEF1), but not p130CAS or Src-interacting protein (Sin)/Efs, although the levels of expression of these proteins was similar. Moreover downregulation of HEF1 with siRNA, but not p130CAS, inhibited basal and PDGF-stimulated migration. The phosphorylated HEF1 colocalized with vinculin and was associated almost exclusively with 0.1% Triton X-100 insoluble material, consistent with its signaling at focal adhesions. FAK overexpression promoted invasion through normal brain homogenate and siHEF1 inhibited this invasion. Results presented here suggest that HEF1 acts as a necessary and specific downstream effector of FAK in the invasive behavior of glioblastoma cells and may be an effective target for treatment of these tumors.	Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA; Univ Alabama, Dept Med, Div Hematol Oncol, Biostat Sect, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Fox Chase Cancer Center; Columbia University; University of Alabama System; University of Alabama Birmingham	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu		McFarland, Braden C./0000-0002-7517-9688; Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P50CA097247, R01CA109748, R01CA097110] Funding Source: NIH RePORTER; NCI NIH HHS [CA97247, CA97110, CA109748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 2003, IMMUNOL REV, V192, P181, DOI 10.1034/j.1600-065X.2003.00021.x; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200; Ding Q, 2002, CANCER RES, V62, P5336; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fashena SJ, 2002, J CELL SCI, V115, P99; ffrench-Constant C, 2004, TRENDS CELL BIOL, V14, P678, DOI 10.1016/j.tcb.2004.10.005; GLADSON CL, 1995, J CELL SCI, V108, P947; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; HERMANSON M, 1992, CANCER RES, V52, P3213; Ishino M, 1995, ONCOGENE, V11, P2331; Jones G, 2001, CANCER RES, V61, P4978; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lipinski CA, 2003, MOL CANCER RES, V1, P323; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MERLO A, 2004, SCI STKE, V229, P18; Merrill RA, 2004, DEV DYNAM, V231, P564, DOI 10.1002/dvdy.20159; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang DY, 2000, J CELL SCI, V113, P4221; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zagzag D, 2000, PEDIATR NEUROSURG, V33, P49, DOI 10.1159/000028975; Zrihan-Licht S, 2004, INT J ONCOL, V24, P153	50	156	164	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1721	1732		10.1038/sj.onc.1209199	http://dx.doi.org/10.1038/sj.onc.1209199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288224				2022-12-28	WOS:000236013700004
J	Okuda, H; Toyota, M; Ishida, W; Furihata, M; Tsuchiya, M; Kamada, M; Tokino, T; Shuin, T				Okuda, H; Toyota, M; Ishida, W; Furihata, M; Tsuchiya, M; Kamada, M; Tokino, T; Shuin, T			Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma	ONCOGENE			English	Article						methylation; HOXB13; renal cell carcinoma; RCC	HYPERMETHYLATION-ASSOCIATED INACTIVATION; PROSTATE-CANCER CELLS; CPG-ISLAND; DNA METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; GASTRIC-CANCER; CLEAR-CELL; COLORECTAL-CANCER; SOMATIC MUTATIONS	Epigenetic alterations like DNA methylation and the resulting inactivation of cancer-related genes often contribute to the development of various cancers. To identify the genes that are silenced by aberrant methylation in renal cell carcinoma (RCC), we subjected two RCC lines to methylated CpG island amplification/representational difference analysis. This identified 27 CpG islands. Combined bisulfite restriction analysis of these CpG islands in primary RCC cases revealed that four were methylated in a tumor-specific manner. One of these was identified as the human homeo-box gene B13 (HOXB13) gene, but the remaining three CpG islands were not associated with known genes. The methylation frequencies of HOXB13 in primary RCC samples and lines were 30 and 73%, respectively. The methylation status of HOXB13 correlated with the loss of its expression both in RCC lines and primary tumors, and methyltransferase inhibitor treatment induced the recovery of its expression. Exogenous expression of HOXB13 in RCC cells that lacked endogenous HOXB13 expression suppressed colony formation and induced apoptotic features. Furthermore, HOXB13 methylation correlated positively with tumor grade and microvessel invasion. These results suggest that HOXB13 is a novel candidate tumor suppressor gene in RCC and that its inactivation may play an important role in both RCC tumorigenesis and progression.	Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Kochi Med Sch, Dept Ophthalmol, Nankoku, Kochi 7838505, Japan; Kochi Med Sch, Dept Tumor Pathol, Nankoku, Kochi 7838505, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido, Japan	Kochi University; Sapporo Medical University; Kochi University; Kochi University; Sapporo Medical University	Okuda, H (corresponding author), Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan.	okudah@med.kochi-u.ac.jp	Tokino, Takashi/AAI-9887-2021					Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9; Esteller M, 2000, CANCER RES, V60, P129; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Japanese Urological Association the Japanese Society of Pathology and the Japan Radiological Society, 1999, GEN RUL CLIN PATH ST, V4th; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Mertens F, 1997, CANCER RES, V57, P2765; MORITA R, 1991, CANCER RES, V51, P820; Morrissey C, 2001, CANCER RES, V61, P7277; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Ogi K, 2002, CLIN CANCER RES, V8, P3164; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888; Satoh A, 2003, CANCER RES, V63, P8606; SHUIN T, 1994, CANCER RES, V54, P2852; Shuin T, 1999, Contrib Nephrol, V128, P1; Sreenath T, 1999, PROSTATE, V41, P203, DOI 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tokinaga K, 2004, ONCOL REP, V12, P805; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P4535; Ueki T, 2001, CANCER RES, V61, P8540; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zeltser L, 1996, DEVELOPMENT, V122, P2475	46	67	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1733	1742		10.1038/sj.onc.1209200	http://dx.doi.org/10.1038/sj.onc.1209200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278676				2022-12-28	WOS:000236013700005
J	Williams, YN; Masuda, M; Sakurai-Yageta, M; Maruyama, T; Shibuya, M; Murakami, Y				Williams, YN; Masuda, M; Sakurai-Yageta, M; Maruyama, T; Shibuya, M; Murakami, Y			Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4	ONCOGENE			English	Article						TSLL2/IGSF4C; cell adhesion; tumor-suppressor gene; prostate cancer; TSLC1/IGSF4	CANCER AGGRESSIVENESS; PROMOTER METHYLATION; TSLC1 GENE; TUMORIGENICITY; IDENTIFICATION; INVOLVEMENT; LINKAGE; CLONING; TSLL2; LINE	The TSLL2/ IGSF4C encodes an immunoglobulin (Ig) superfamily molecule showing significant homology with a lung tumor suppressor, TSLC1. The TSLL2 protein of 55 kDa is mainly expressed in the kidney, bladder, and prostate in addition to the brain. Here, we report the biological signifance of TSLL2 in the urinary tissues. An immunohistochemical study reveals that TSLL2 is expressed at the cell-cell attachment sites in the renal tubules, the transitional epithelia of the bladder, and the glandular epithelia of the prostate. Confocal microscopy analysis demonstrates that TSLL2 is localized in the lateral membranes in polarized Mardin-Darby canine kidney (MDCK) cells. TSLL2 forms homo-dimers and its overexpression induces aggregation of suspended MDCK cells in a Ca2+/Mg2+ -independent manner, suggesting that it is involved in cell adhesion through homophilic trans-interaction. The TSLL2 gene is mapped on the chromosomal region 19q13.2, whose loss of heterozygosity has been frequently reported in prostate cancer. TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1. Introduction of TSLL2 into PPC-1 strongly suppresses subcutaneous tumor formation in nude mice. These results suggest that TSLL2 is a new member of the Ig superfamily cell adhesion molecules and is a tumor-suppressor candidate in prostate cancer.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; National Cancer Center - Japan	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Astbury C, 2001, GENE CHROMOSOME CANC, V31, P143, DOI 10.1002/gcc.1128; Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, GENE, V323, P11, DOI 10.1016/j.gene.2003.09.018; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Ito T, 2003, CANCER RES, V63, P6320; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Neville PJ, 2003, GENE CHROMOSOME CANC, V36, P332, DOI 10.1002/gcc.10165; Ozen M, 2000, ANTICANCER RES, V20, P1905; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Slager SL, 2003, AM J HUM GENET, V72, P759, DOI 10.1086/368230; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7	27	43	49	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1446	1453		10.1038/sj.onc.1209192	http://dx.doi.org/10.1038/sj.onc.1209192			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261159				2022-12-28	WOS:000235890400002
J	Ichwan, SJA; Yamada, S; Sumrejkanchanakij, P; Ibrahim-Auerkari, E; Eto, K; Ikeda, MA				Ichwan, SJA; Yamada, S; Sumrejkanchanakij, P; Ibrahim-Auerkari, E; Eto, K; Ikeda, MA			Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells	ONCOGENE			English	Article						p53; phosphorylation; p53 resistance; apoptosis; tumor suppressor	INTERACTING PROTEIN KINASE-2; TRANSCRIPTIONAL ACTIVITY; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; POTENTIAL MEDIATOR; UV-RADIATION; IN-VIVO; ACTIVATION; PATHWAY	To investigate whether dysregulation of p53 phosphorylation confers tumor resistance to p53, we analysed the effects of wild-type p53 on oral squamous cell carcinoma (SCC) cell lines carrying various mutations of p53. Introduction of exogenous p53 neither induced apoptosis nor suppressed colony formation in HSC-3 cells lacking any detectable p53 and HSC-4 cells expressing mutant p53R248Q protein. Consistently, exogenous p53 did not induce proapoptotic p53-target genes in these p53-resistant cells. We found that phosphorylation of exogenous p53 on serine 46 (Ser46) was severely impaired in HSC-3 but not HSC-4 cells. A mutant mimicking Ser46-phosphorylation (p53S46D) enhanced proapoptotic Noxa promoter activity, and overcame the resistance to p53-mediated apoptosis and growth suppression in HSC-3 cells. Conversely, a mutant defective for Ser46-phosphorylation (p53S46A) failed to suppress the growth of p53-sensitive HSC-2 cells. In contrast to HSC-3 cells, p53S46D had no effect on HSC-4 cells, and inhibition of endogenous p53R248Q by siRNA restored p53-mediated apoptosis in HSC-4 cells, indicating a dominant-negative effect of p53R248Q protein on wild-type p53 function. These results demonstrate that the defect in Ser46 phosphorylation accounts for the p53 resistance of HSC-3 cells, and provide evidence for a mechanism underlying the acquisition of p53 resistance in oral SCC.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Sect Maxillofacial Surg, Tokyo, Japan; Chulalongkorn Univ, Fac Dent, Dept Anat, Bangkok, Thailand; Univ Indonesia, Fac Dent, Dept Oral Biol, Jakarta, Indonesia	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Chulalongkorn University; University of Indonesia	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	mikeda.emb@tmd.ac.jp	Auerkari, Elza Ibrahim/F-7406-2017; Ichwan, Solachuddin/E-6027-2016; ARIEF, SOLACHUDDIN JAUHARI/K-3011-2019	Auerkari, Elza Ibrahim/0000-0002-5680-7925; Ichwan, Solachuddin/0000-0002-2780-2455; 				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohtani S, 2004, MOL CANCER THER, V3, P93; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prives C, 1999, J PATHOL, V187, P112; Restle A, 2005, ONCOGENE, V24, P4380, DOI 10.1038/sj.onc.1208639; Rodicker F, 2003, CANCER RES, V63, P2737; SAKAI E, 1992, ONCOGENE, V7, P927; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Tamamori-Adachi M, 2003, CIRC RES, V92, pE12, DOI 10.1161/01.RES.0000049105.15329.1C; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	43	50	50	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1216	1224		10.1038/sj.onc.1209158	http://dx.doi.org/10.1038/sj.onc.1209158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247456				2022-12-28	WOS:000235537500009
J	Heller, G; Fong, KM; Girard, L; Seidl, S; End-Pfutzenreuter, A; Lang, G; Gazdar, AF; Minna, JD; Zielinski, CC; Zochbauer-Muller, S				Heller, G; Fong, KM; Girard, L; Seidl, S; End-Pfutzenreuter, A; Lang, G; Gazdar, AF; Minna, JD; Zielinski, CC; Zochbauer-Muller, S			Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas	ONCOGENE			English	Article						tumor suppressor gene; TSLC1; DAL-1; MPP3; methylation; lung cancer	TUMOR-SUPPRESSOR TSLC1; CANCER-CELL-LINES; PROMOTER METHYLATION; BREAST-CANCER; ASSOCIATION; PROFILES; ADHESION; ABSENCE; GROWTH; DAL-1	TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion. TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large. Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas. However, little is known about the other two genes in this cascade, DAL-1 and MPP3. Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples. By reverse transcription-polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44%) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9%) small-cell lung cancer (SCLC) cell lines, while loss of DAL- 1 expression was seen in 14 of 16 (87%) NSCLC cell lines and in four of 11 (36%) SCLC cell lines. By contrast, MPP3 expression was found in all tumor cell lines analysed. Similar results were obtained by microarray analysis. TSLC1 methylation was seen in 13 of 39 (33%) NSC LC cell lines, in one of 11 (9%) SCLC cell lines and in 100 of 268 (37%) primary NSCLCs. DAL-1 methylation was observed in 17 of 39 (44%) NSCLC cell lines, in three of 11 (27%) SCLC cell lines and in 147 of 268 (55%) primary NSCLCs. In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease. A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found. Overall, 65% of primary NSCLCs had either TSLC1 or DAL-1 methylated. Methylation of one of these genes was detected in 59% of NSCLC cell lines; however, in SCLC cell lines, methylation was much less frequently observed. The majority of nonmalignant lung tissue samples was not TSLC1 and DAL-1 methylated. Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2$-deoxy-cytidine. Our results suggest that methylation of TSLC1 and/or DAL-1, leading to loss of their expression, is an important event in the pathogenesis of NSCLC.	Univ Hosp Vienna, Div Clin Oncol, Dept Med 1, A-1090 Vienna, Austria; Univ Hosp Vienna, Ctr Excellence Clin & Expt Oncol, A-1090 Vienna, Austria; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Univ Texas, SW Med Ctr, Hamon Ctr Theapeut Oncol Res, Dallas, TX USA; Univ Hosp Vienna, Dept Thorac Surg, Vienna, Austria; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX USA	University Hospital Vienna; University Hospital Vienna; Prince Charles Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University Hospital Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zochbauer-Muller, S (corresponding author), Univ Hosp Vienna, Div Clin Oncol, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	sabine.zoechbauer-mueller@meduniwien.ac.at	Fong, Kwun M/G-6369-2010; Zöchbauer-Müller, Sabine/B-8399-2012; heller, gerwin/E-6521-2011; Lang, György/O-5256-2017	Zöchbauer-Müller, Sabine/0000-0002-6777-1729; heller, gerwin/0000-0001-8742-5631; Lang, György/0000-0002-8839-6649; Fong, Kwun/0000-0002-6507-1403	NCI NIH HHS [P50 CA 70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Esteller M, 2001, CANCER RES, V61, P3225; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; GIRARD L, 2005, UNPUB; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ito T, 2003, CANCER RES, V63, P6320; Kikuchi S, 2005, CLIN CANCER RES, V11, P2954, DOI 10.1158/1078-0432.CCR-04-2206; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; LAM CL, 2005, UNPUB; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MAO X, 2004, ONCOGENE, V7, P7; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Toyooka S, 2001, MOL CANCER THER, V1, P61; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843; Yageta M, 2002, CANCER RES, V62, P5129; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	65	81	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					959	968		10.1038/sj.onc.1209115	http://dx.doi.org/10.1038/sj.onc.1209115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205641				2022-12-28	WOS:000235212700015
J	Chow, LSN; Lam, CW; Chan, SYY; Tsao, SW; To, KF; Tong, SF; Hung, WK; Dammann, R; Huang, DP; Lo, KW				Chow, LSN; Lam, CW; Chan, SYY; Tsao, SW; To, KF; Tong, SF; Hung, WK; Dammann, R; Huang, DP; Lo, KW			Identification of RASSF1A modulated genes in nasopharyngeal carcinoma	ONCOGENE			English	Article						RASSF1A; Id2; microarray; tumor suppressor; nasopharyngeal carcinoma	TUMOR-SUPPRESSOR RASSF1A; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; EPITHELIAL-CELLS; PROTEIN; 3P21.3; LUNG; EXPRESSION; APOPTOSIS; INTERACTS	RASSF1A is a tumor suppressor gene on 3p21.3 frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma (NPC). To identify RASSF1A target genes in NPC, we have investigated the expression pro. le of the stable RASSF1A transfectants and controls by high-density oligonucleotide array. A total of 57 genes showed differential expression in the RASSF1A-expressing cells. These RASSF1A target genes were involved in multiple cellular regulatory processes such as transcription, signal transduction, cell adhesion and RNA processing. The RASSF1A-modulated expression of eight selected genes with the highest fold changes (ATF5, TCRB, RGS1, activin beta E, HNRPH1, HNRPD, Id2 and CKS2) by RASSF1A was confirmed in both stable and transient transfectants. Compared with the RASSF1A transfectants, an inverse expression pattern of activin bE, Id2 and ATF5 was shown in the immortalized nasopharyngeal epithelial cells treated with siRNA against RASSF1A. The findings imply that the expression of activin bE, Id2 and ATF5 was tightly regulated by RASSF1A and may associate with its tumor suppressor function. Strikingly, overexpression of Id2 is common in NPC and RASSF1A-induced repression of Id2 was mediated by the overexpression of activin bE. The results suggest a novel RASSF1A pathway in which both activin bE and Id2 are involved.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle An Der Saale, Germany	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; Martin Luther University Halle Wittenberg	Lo, KW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.	kwlo@cuhk.edu.hk						Agathanggelou A, 2003, CANCER RES, V63, P5344; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Coppe JP, 2003, EXP CELL RES, V285, P131, DOI 10.1016/S0014-4827(03)00014-4; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kwong J, 2002, CLIN CANCER RES, V8, P131; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu WJ, 2004, BIOCHEM BIOPH RES CO, V321, P954, DOI 10.1016/j.bbrc.2004.07.053; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2001, CANCER RES, V61, P3877; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tommasi S, 2005, CANCER RES, V65, P92; TSAO SW, 2002, BIOCHIM BIOPHYS ACTA, V12, P158; TSAO SW, 2002, BIOCHIM BIOPHYS ACTA, V12, P1590; Vejda S, 2003, CARCINOGENESIS, V24, P1801, DOI 10.1093/carcin/bgg154; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	27	46	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					310	316		10.1038/sj.onc.1209001	http://dx.doi.org/10.1038/sj.onc.1209001			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116475				2022-12-28	WOS:000234583600016
J	Chen, J; Lee, BH; Williams, IR; Kutok, JL; Mitsiades, CS; Duclos, N; Cohen, S; Adelsperger, J; Okabe, R; Coburn, A; Moore, S; Huntly, BJP; Fabbro, D; Anderson, KC; Griffin, JD; Gilliland, DG				Chen, J; Lee, BH; Williams, IR; Kutok, JL; Mitsiades, CS; Duclos, N; Cohen, S; Adelsperger, J; Okabe, R; Coburn, A; Moore, S; Huntly, BJP; Fabbro, D; Anderson, KC; Griffin, JD; Gilliland, DG			FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies	ONCOGENE			English	Article						fibroblast growth factor receptor 3 (FGFR3); multiple myeloma; small molecule tyrosine inhibitor; murine bone marrow transplant (BMT) assay	GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; KINASE INHIBITOR; TYROSINE KINASE; ACTIVATING MUTATIONS; SIGNAL-TRANSDUCTION; IMATINIB MESYLATE; CELL-LINES; TRANSLOCATION; EXPRESSION	Reccurent chromosomal translocation t(4;14) (p16.3;q32.3) occurs in patients with multiple myeloma (MM) and is associated with ectopic overexpression of fibroblast growth factor receptor 3 (FGFR3) that sometimes may contain the activation mutations such as K650E thanatophoric dysplasia type II (TDII). Although there have been significant advances in therapy for MM including the use of proteasome inhibitors, t(4;14) MM has a particularly poor prognosis and most patients still die from complications related to their disease or therapy. One potential therapeutic strategy is to inhibit FGFR3 in those myeloma patients that overexpress the receptor tyrosine kinase due to chromosomal translocation. Here we evaluated PKC412, a small molecule tyrosine kinase inhibitor, for treatment of FGFR3-induced hematopoietic malignancies. PKC412 inhibited kinase activation and proliferation of hematopoietic Ba/F3 cells transformed by FGFR3 TDII or a TEL-FGFR3 fusion. Similar results were obtained in PKC412 inhibition of several different t(4;14)-positive human MM cell lines. Further more, treatment with PKC412 resulted in a statistically significant prolongation of survival in murine bone marrow transplant models of FGFR3 TDII-induced pre-B cell lymphoma, or a peripheral T-cell lymphoma associated TEL-FGFR3 fusion-induced myeloproliferative disease. These data indicate that PKC412 may be a useful molecularly targeted therapy for MM associated with overexpression of FGFR3, and perhaps other diseases associated with dysregulation of FGFR3 or related mutants.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharma AG, Basel, Switzerland	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Emory University; Harvard University; Dana-Farber Cancer Institute; Novartis	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Div Hematol, Childrens Hosp Res Bldg,1 Blackfan Circle,5th Flo, Boston, MA 02115 USA.	ggilliland@rics.bwh.harvard.edu	huntly, brian JP/E-6725-2014; Williams, Ifor R/D-3648-2011	huntly, brian JP/0000-0003-0312-161X; Williams, Ifor R/0000-0002-8810-2911	NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; PHS HHS [P0-1 78378, R01 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREJAUSKASBUCHDUNGER E, 1992, CANCER RES, V52, P5353; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Bastuji-Garin S, 2002, J INVEST DERMATOL, V119, P1020, DOI 10.1046/j.1523-1747.2002.19502.x; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cavo M, 2000, BLOOD, V96, P355, DOI 10.1182/blood.V96.1.355.013k02_355_357; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chen J, 2005, BLOOD, V106, P328, DOI 10.1182/blood-2004-09-3686; Chen J, 2004, BLOOD, V104, P535, DOI 10.1182/blood-2004-01-0169; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; De Angelo DJ, 2003, BLOOD, V102, p65A; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Estey EH, 2003, BLOOD, V102, p614A; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Golla A, 1997, J MED GENET, V34, P683, DOI 10.1136/jmg.34.8.683; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; Heffner LT, 2003, DRUGS, V63, P1621, DOI 10.2165/00003495-200363160-00001; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Lemoli RM, 2000, BLOOD, V95, P2234, DOI 10.1182/blood.V95.7.2234.007k25_2234_2239; Li ZH, 2001, BLOOD, V97, P2413, DOI 10.1182/blood.V97.8.2413; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Martinelli G, 2000, J CLIN ONCOL, V18, P2273, DOI 10.1200/JCO.2000.18.11.2273; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paterson JL, 2004, BRIT J HAEMATOL, V124, P595, DOI 10.1111/j.1365-2141.2004.04814.x; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richardson P, 2002, BIOMED PHARMACOTHER, V56, P115, DOI 10.1016/S0753-3322(02)00168-3; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; San Miguel JF, 1999, HAEMATOLOGICA, V84, P36; Santra M, 2003, BLOOD, V101, P2374, DOI 10.1182/blood-2002-09-2801; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yagasaki F, 2001, CANCER RES, V61, P8371	47	73	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8259	8267		10.1038/sj.onc.1208989	http://dx.doi.org/10.1038/sj.onc.1208989			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091734				2022-12-28	WOS:000233956500005
J	Mao, JH; Li, JZ; Jiang, T; Li, Q; Wu, D; Perez-Losada, J; DelRosario, R; Peterson, L; Balmain, A; Cai, WW				Mao, JH; Li, JZ; Jiang, T; Li, Q; Wu, D; Perez-Losada, J; DelRosario, R; Peterson, L; Balmain, A; Cai, WW			Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice	ONCOGENE			English	Article						p53; genomic instability; radiation; thymic lymphoma	IONIZING-RADIATION; CHROMOSOMAL INSTABILITY; P53-DEFICIENT MICE; ARRAY CGH; CANCER; TUMORIGENESIS; GENE; TRANSFORMATION; AMPLIFICATION; IRRADIATION	Although radiation can directly induce DNA damage and is a known human and animal carcinogen, the number of genetic changes in radiation-induced tumors, and the pathways responsible for generating them, are unknown. We have used high-density BAC arrays covering > 95% of the mouse genome for analysis of genomic patterns of aberrations in spontaneous and radiation-induced mouse lymphomas. The majority of radiation-induced tumors exhibit one of three 'signatures' based on gene copy number changes. Some exhibit extensive scrambling of the genome, with very high numbers of recurrent gains and losses. Two other signatures are characterized by excess gains but relatively few losses, or vice versa. Changes in spontaneous tumors often involve whole chromosomes, whereas radiation-induced tumors exhibit a high frequency of localized deletion/amplification events. The number of copy number abnormalities does not correlate with the latency or pathology of the tumors. We propose that specific early events following radiation exposure induce changes in 'caretaker' genes that control specific downstream pathways involved in DNA damage repair. The nature of these early events may determine the overall genomic signature observed in the resulting tumor.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine	Cai, WW (corresponding author), Univ Calif San Francisco, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu; wcai@bcm.tmc.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021; Peterson, Leif/0000-0002-1187-0883	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; Azzam EI, 2003, ONCOGENE, V22, P7050, DOI 10.1038/sj.onc.1206961; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gregory SG, 2002, NATURE, V418, P743, DOI 10.1038/nature00957; Hande MP, 2003, AM J HUM GENET, V72, P1162, DOI 10.1086/375041; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KENNEDY AR, 1984, RADIAT RES, V99, P228, DOI 10.2307/3576368; KENNEDY AR, 1984, NATURE, V307, P85, DOI 10.1038/307085a0; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kinzler KW, 1997, NATURE, V386, P763; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; LOEB LA, 1974, CANCER RES, V34, P2311; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mitelman F, 2005, MITELMAN DATABASE CH; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Peterson LE, 2002, COMPUT METH PROG BIO, V69, P179, DOI 10.1016/S0169-2607(01)00189-4; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sigurdson AJ, 2003, ONCOGENE, V22, P7018, DOI 10.1038/sj.onc.1206989; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UNO M, 1987, INT J CANCER, V40, P540, DOI 10.1002/ijc.2910400418; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824	38	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7924	7934		10.1038/sj.onc.1208926	http://dx.doi.org/10.1038/sj.onc.1208926			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116484				2022-12-28	WOS:000233463000011
J	Fischer, M; Schwieger, M; Horn, S; Niebuhr, B; Ford, A; Roscher, S; Bergholz, U; Greaves, M; Lohler, J; Stocking, C				Fischer, M; Schwieger, M; Horn, S; Niebuhr, B; Ford, A; Roscher, S; Bergholz, U; Greaves, M; Lohler, J; Stocking, C			Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model	ONCOGENE			English	Article						acute lymphoblastic leukemia (ALL); RUNX1; ETV6/TEL; translocation(12;21)	HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; PUTATIVE TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSION; MURINE MODEL; TEL; GENE; AML1; TEL-AML1; TRANSLOCATION	The t(12;21) translocation, generating the TEL/AML1 fusion protein, is the most common genetic lesion in childhood cancer. Using a bone marrow transplantation model, we demonstrate that TEL/AML1 expression impinges on normal hematopoietic differentiation, leading to the in vivo accumulation and persistence of an early progenitor compartment with a Sca1(+)/Kit(hi)/CD11b(+) phenotype and an increased self- renewal capacity, as documented by replating assays in vitro. Differ entiation of these cells is not blocked, but the frequency of mature blood cells arising from TEL/AML1- transduced progenitors is low. Impa ired differentiation is prominently observed in the pro- B- cell compartment, resulting in an proportional increase in early progenitors in vivo, consistent with the t(12;21) ALL phenotype. Desp ite the accumulation of both multipotent and B- cell progenitors in vivo, no leukemia induction was observed during an observation period of over 1 year. These results are consistent with. ndings in twins with concordant ALL, showing that TEL/AML1 generates a preleukemic clone in utero that persists for several years in a clinically covert fashion. Fur thermore, our studies showed that the pointed domain of TEL/AML1, which recruits transcriptional repressors and directs oligomerization with either TEL/AML1 or wild-type TEL, was essential for the observed differentiation impairment and could not be replaced with another oligomerization domain.	Heinrich Pette Inst Expt Virol & Immunol, Mol Pathol Grp, D-20251 Hamburg, Germany; Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Heinrich Pette Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Stocking, C (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, POB 201652, D-20206 Hamburg, Germany.	stocking@hpi.uni-hamburg.de						Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Bernardi R, 2002, ONCOGENE, V21, P3445, DOI 10.1038/sj.onc.1205313; Bernardin F, 2002, CANCER RES, V62, P3904; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ERICKSON P, 1992, BLOOD, V80, P1825; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li ZX, 2003, EXP HEMATOL, V31, P1206, DOI 10.1016/j.exphem.2003.08.008; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; McLean TW, 1996, BLOOD, V88, P4252; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PUTZ G, 2005, UNPUB ONCOGENE; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	59	68	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7579	7591		10.1038/sj.onc.1208931	http://dx.doi.org/10.1038/sj.onc.1208931			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044150				2022-12-28	WOS:000233333800007
J	Lievre, A; Landi, B; Cote, JF; Veyrie, N; Zucman-Rossi, J; Berger, A; Laurent-Puig, P				Lievre, A; Landi, B; Cote, JF; Veyrie, N; Zucman-Rossi, J; Berger, A; Laurent-Puig, P			Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers	ONCOGENE			English	Article						colorectal cancer; KLF6; mutation	PROSTATE-CANCER; MICROSATELLITE INSTABILITY; P53 MUTATIONS; DNA-SYNTHESIS; KIRSTEN-RAS; CELL-LINES; SURVIVAL; GLIOBLASTOMAS; POLYMERASES; CARCINOMA	The KLF6 gene encodes the Kruppel-like factor 6, a transcription factor that has been individualized as a tumor-suppressor gene involved in the regulation of cell proliferation and differentiation. Recently, high frequency (42%) of KLF6 mutations have been reported in colorectal cancers (CRC) as in prostate cancers, astrocytic gliomas and hepatocellular carcinomas. The aims of the study was to confirm the frequency of KLF6 mutations in a larger series of CRC than that previously published by using DNA extracted from frozen tissue samples, which have been proved to generate less mutational artefact than that extracted from formalin-fixed paraffin-embedded tissue samples, in order to compare KLF6 mutation frequency with that of other common genetic alterations and to determine genotype-phenotype correlations. Amplification and direct sequencing of KLF6 exon 2 of 76 CRC and matched normal frozen tissues was performed. Polymorphisms were observed in 14 cases, among which two (T35T and S116S) had not already been reported. No KLF6 somatic mutation was observed. Our data suggest a minor role of KLF6 mutation in colorectal carcinogenesis and underline the fact that the validity of sequence informations obtained from DNA extracted from formalin-fixed tissues may be limited.	Univ Paris 05, INSERM, UMR, U490,Lab Toxicol Mol S490, F-75006 Paris, France; Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Gastroenterol, F-75015 Paris, France; INSERM, U674 Genom Tumeurs Solides, F-75010 Paris, France; Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Chirurg Gen Digest & Oncol, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Laurent-Puig, P (corresponding author), Univ Paris 05, INSERM, UMR, U490,Lab Toxicol Mol S490, 45 Rue St Peres, F-75006 Paris, France.	pierre.laurent-puig@univ-paris5.fr	j, zucman-rossi/AAV-3594-2021; Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013; zucman-rossi, Jessica/B-5098-2009	j, zucman-rossi/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334				Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Boyault S, 2005, HEPATOLOGY, V41, P681, DOI 10.1002/hep.20588; Chen Han-kui, 2002, Ai Zheng, V21, P1047; CHO YG, 2005, ONCOGENE        0411; Choi SW, 2002, CLIN CANCER RES, V8, P2311; Duarte V, 2000, NUCLEIC ACIDS RES, V28, P1555, DOI 10.1093/nar/28.7.1555; Feldman M Y, 1973, Prog Nucleic Acid Res Mol Biol, V13, P1, DOI 10.1016/S0079-6603(08)60099-9; Ferraz JM, 2004, INT J CANCER, V110, P183, DOI 10.1002/ijc.20124; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kohler B, 2004, INT J CANCER, V111, P644, DOI 10.1002/ijc.20302; Koivisto PA, 2004, INT J CANCER, V111, P642, DOI 10.1002/ijc.20301; Koivisto PA, 2004, J UROLOGY, V172, P506, DOI 10.1097/01.ju.0000129242.88182.e1; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Montanini L, 2004, INT J CANCER, V111, P640, DOI 10.1002/ijc.20303; Muhlbauer KR, 2003, BRIT J CANCER, V89, P687, DOI 10.1038/sj.bjc.6601164; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Quach Nancy, 2004, BMC Clin Pathol, V4, P1, DOI 10.1186/1472-6890-4-1; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2; Wong C, 1998, CANCER GENET CYTOGEN, V107, P21, DOI 10.1016/S0165-4608(98)00079-X; Yngveson A, 1999, CANCER EPIDEM BIOMAR, V8, P433; Zhou CZ, 2002, WORLD J GASTROENTERO, V8, P668, DOI 10.3748/wjg.v8.i4.668	34	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7253	7256		10.1038/sj.onc.1208867	http://dx.doi.org/10.1038/sj.onc.1208867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044160				2022-12-28	WOS:000232990100014
J	Fontemaggi, G; Gurtner, A; Damalas, A; Costanzo, A; Higashi, Y; Sacchi, A; Strano, S; Piaggio, G; Blandino, G				Fontemaggi, G; Gurtner, A; Damalas, A; Costanzo, A; Higashi, Y; Sacchi, A; Strano, S; Piaggio, G; Blandino, G			delta EF1 repressor controls selectively p53 family members during differentiation	ONCOGENE			English	Article						p73; p63; p53 family; delta EF1 transcriptional repressor	DROSOPHILA ZFH-1; ZINC-FINGER; P73; P63; EXPRESSION; PROLIFERATION; KERATINOCYTES; REGULATOR; PROTEINS; HOMOLOG	The discovery of two new p53 homologs, p73 and p63, has defined a family of transcription factors heavily involved in the control of growth suppression, apoptosis, differentiation and development. While p53-deficient mice undergo spontaneous tumors, p73 and p63 knockout mice exhibit severe developmental defects. We demonstrate here that p73 gene is an in vivo transcriptional target of the muscle regulatory factors MyoD, myogenin, Myf5 and Myf6. Ectopic expression of the transcriptional repressor delta EF1/ZEB/ zfhx1a counteracts MyoD/ Myf5-or MyoD/ Myf6- mediated transcriptional activation of p73. A distinct pattern of in vivo recruitment of muscle regulatory factors and delta EF1 on p73 regulatory regions was found between proliferating and differentiating muscle cells. We also found that dEF1 plays a role in the transcriptional regulation of p53 family members during keratinocytic differentiation. Mouse embryo. fibroblasts derived from delta EF1-deficient mice exhibit unbalanced expression of DNp63, TAp73 and Delta Np73 but not of TAp63 and p53. The analysis of tissues derived from delta EF1+/- mice exhibit a selective enrichment of DNp63 in skin.	Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy; Rome Oncogenom Ctr, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; Osaka University	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro,156, I-00158 Rome, Italy.	blandino@ifo.it	Costanzo, Antonio/D-3896-2012; Gurtner, Aymone/J-7217-2018; Fontemaggi, Giulia/K-9702-2016; gurtner, aymone/AAB-8843-2020; strano, sabrina/B-6743-2013; Piaggio, Giulia/J-7214-2018; Piaggio, Giulia/AAD-7336-2022; Costanzo, Antonio/GZG-2433-2022; Higashi, Yukihito/G-5343-2019; Blandino, Giovanni/B-1137-2013; Strano, Sabrina/K-9654-2016	Gurtner, Aymone/0000-0002-7661-9059; Fontemaggi, Giulia/0000-0001-8332-8842; gurtner, aymone/0000-0002-7661-9059; strano, sabrina/0000-0002-6341-4230; Piaggio, Giulia/0000-0003-2114-1892; Costanzo, Antonio/0000-0001-9697-2557; Blandino, Giovanni/0000-0002-6970-2241; 	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Blandino G, 2004, CELL CYCLE, V3, P886; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morena A, 2002, BLOOD, V100, P96, DOI 10.1182/blood.V100.1.96; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Takagi T, 1998, DEVELOPMENT, V125, P21; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	19	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7273	7280		10.1038/sj.onc.1208891	http://dx.doi.org/10.1038/sj.onc.1208891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007124				2022-12-28	WOS:000233142100003
J	Takada, Y; Murakami, A; Aggarwal, BB				Takada, Y; Murakami, A; Aggarwal, BB			Zerumbone abolishes NF-kappa B and I kappa B alpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion	ONCOGENE			English	Article						carcinogens; NF-kappa B; TNF; IKK; inflammation; apoptosis; metastasis	TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; P65 PHOSPHORYLATION; TRANSCRIPTIONAL REGULATION; GINGER SESQUITERPENE; DEPENDENT INDUCTION; SUBTROPICAL GINGER; ENDOTHELIAL-CELLS; CYCLIN D1; INHIBITOR	Zerumbone found in subtropical ginger Zingiber zerumbet Smith exhibits antiproliferative and antiinflammatory activityies but underlying molecular mechanisms are poorly understood. As several genes that regulate proliferation and apoptosis are regulated by nuclear factor (NF)-kappa B, we hypothesized that zerumbone mediates its activity through the modulation of NF-kappa B activation. We found that zerumbone suppressed NF-kappa B activation induced by tumor necrosis factor (TNF), okadaic acid, cigarette smoke condensate, phorbol myristate acetate, and H2O2 and that the suppression was not cell type specific. Interestingly, alpha-humulene, a structural analogue of zerumbone lacking the carbonyl group, was completely inactive. Besides being inducible, constitutively active NF-kappa B was also inhibited. NF-kappa B inhibition by zerumbone correlated with sequential suppression of the I kappa B alpha kinase activity, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acylation. Zerumbone also inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappa B. NF-kappa B regulated gene products, such as cyclin D1, COX-2, MMP-9 ICAM-1, c-Myc, survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-x(L), Bfl-1/A1, TRAF1 and FLIP, were all downregulated by zerumbone. This downregulation led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents. Zerumbone's inhibition of expression of these NF-kappa B regulated genes also correlated with the suppression of TNF-induced invasion activity. Overall, our results indicated that zerumbone inhibits the activation of NF-kappa B and NF-kappa B regulated gene expression induced by carcinogens and that this inhibition may provide a molecular basis for the prevention and treatment of cancer by zerumbone.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6068502, Japan	University of Texas System; UTMD Anderson Cancer Center; Kyoto University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844, P50 CA97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DEV S, 1956, CHEM IND-LONDON, P1051; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kirana C, 2003, NUTR CANCER, V45, P218, DOI 10.1207/S15327914NC4502_12; Kitayama T, 1999, J ORG CHEM, V64, P2667, DOI 10.1021/jo981593n; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Morris KR, 2003, INFECT IMMUN, V71, P1442, DOI 10.1128/IAI.71.3.1442-1452.2003; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Murakami A, 2004, INT J CANCER, V110, P481, DOI 10.1002/ijc.20175; Murakami A, 2003, BIOCHEM PHARMACOL, V66, P1253, DOI 10.1016/S0006-2952(03)00446-5; Murakami A, 2003, CANCER LETT, V195, P17, DOI 10.1016/S0304-3835(03)00058-2; Murakami A, 2003, MUTAT RES-FUND MOL M, V523, P151, DOI 10.1016/S0027-5107(02)00331-7; Murakami A, 2002, CARCINOGENESIS, V23, P795, DOI 10.1093/carcin/23.5.795; Murakami A, 1999, BIOSCI BIOTECH BIOCH, V63, P1811, DOI 10.1271/bbb.63.1811; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; OZAKI Y, 1991, CHEM PHARM BULL, V39, P2353, DOI 10.1248/cpb.39.2353; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shiraga M, 2002, CANCER RES, V62, P5967; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; STEVE PO, 2002, J BIOL CHEM, V277, P35150; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka T, 2001, LIFE SCI, V69, P1935, DOI 10.1016/S0024-3205(01)01277-2; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	61	153	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6957	6969		10.1038/sj.onc.1208845	http://dx.doi.org/10.1038/sj.onc.1208845			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007145				2022-12-28	WOS:000232701700010
J	Kronblad, A; Hedenfalk, I; Nilsson, E; Pahlmann, S; Landberg, G				Kronblad, A; Hedenfalk, I; Nilsson, E; Pahlmann, S; Landberg, G			ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ER alpha: a combination therapy potentially targeting hypoxic and dormant tumor cells	ONCOGENE			English	Article						breast cancer; ERK1/2; MAPK; ER alpha; hypoxia; tamoxifen	HUMAN BREAST-CANCER; ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR-ALPHA; POOR RESPONSE; BONE-MARROW; RT-PCR; EXPRESSION; GROWTH; RESISTANCE; PATHWAYS	Tumor hypoxia is associated with cancer invasiveness, metastasis and treatment failure. Recent data suggest that the major target for endocrine treatment in breast cancer, ER alpha, is downregulated during hypoxia, but the mechanism behind this remains unknown. MAPK signaling as well as ER alpha regulation has earlier been independently linked to hypoxia and we now demonstrate HIF-1 alpha and ERK1/2-activation in vivo towards the necrotic zone in DCIS of the breast, parallel with ER alpha downregulation. Hypoxia further caused transcriptional downregulation of ER alpha via activation of ERK1/2 in cell lines and, importantly, MEK1/2 inhibitors (U0126 or PD184352) or ERK1/2 suppression by siRNA partially restored the ERa expression. U0126 combined with tamoxifen accordingly produced an increased efficacy of the anti-estrogens during hypoxia. Base don these findings, we suggest a promising novel therapy for ER alpha-positive breast cancer where a combination of endocrine treatment and ERK1/2 inhibitors may increase treatment response by improved targeting of dormant hypoxic tumor cells.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden; Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se		Hedenfalk, Ingrid/0000-0002-6840-3397				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Cho JY, 2005, MOL ENDOCRINOL, V19, P1191, DOI 10.1210/me.2004-0162; Clarke M, 1998, LANCET, V351, P1451; Cooper C, 2004, CLIN CANCER RES, V10, P8720, DOI 10.1158/1078-0432.CCR-04-1235; Coutts AS, 1998, CANCER RES, V58, P4071; Dokladda K, 2005, FEBS LETT, V579, P236, DOI 10.1016/j.febslet.2004.11.084; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hedenfalk Ingrid, 2005, Cancer Genomics & Proteomics, V2, P83; Helczynska K, 2003, CANCER RES, V63, P1441; Holloway JN, 2004, MOL ENDOCRINOL, V18, P1396, DOI 10.1210/me.2004-0048; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Kronblad A, 2003, IN VIVO, V17, P311; Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349-7006.2001.tb01064.x; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; LICHTMAN MA, 1981, EXP HEMATOL, V9, P391; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Nicholson RI, 2004, CLIN CANCER RES, V10, p346S, DOI 10.1158/1078-0432.CCR-031206; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Rostagno P, 1996, BREAST CANCER RES TR, V37, P77, DOI 10.1007/BF01806634; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SPATARO V, 1992, ANN ONCOL, V3, P733, DOI 10.1093/oxfordjournals.annonc.a058330; Stoner M, 2002, MOL ENDOCRINOL, V16, P2231, DOI 10.1210/me.2001-0347; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VAUPEL P, 1989, CANCER RES, V49, P6449; Woelfle U, 2003, CANCER RES, V63, P5679; Yang ZB, 2004, CLIN CANCER RES, V10, P3621, DOI 10.1158/1078-0432.CCR-0740-3	40	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2005	24	45					6835	6841		10.1038/sj.onc.1208830	http://dx.doi.org/10.1038/sj.onc.1208830			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007158				2022-12-28	WOS:000232527800011
J	Lucas, B; Grigo, K; Erdmann, S; Lausen, J; Klein-Hitpass, L; Ryffel, GU				Lucas, B; Grigo, K; Erdmann, S; Lausen, J; Klein-Hitpass, L; Ryffel, GU			HNF4 alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma	ONCOGENE			English	Article						HNF4 alpha; proliferation; microarray; renal cell carcinoma	TRANSCRIPTION FACTORS; C/EBP-ALPHA; EXPRESSION; LIVER; DIFFERENTIATION; CLASSIFICATION; HNF-4-ALPHA; INHIBITION; MUTATIONS; DISCOVERY	Hepatocyte nuclear factor 4 alpha (HNF4 alpha) is a tissue-specific transcription factor known to regulate a large number of genes in hepatocytes and pancreatic beta cells. Although HNF4 alpha is highly expressed in some sections of the kidney, little is known about its role in this organ and about HNF4 alpha-regulated genes in the kidney cells. The abundance and activity of HNF4 alpha are frequently reduced in renal cell carcinoma (RCC) indicating some tumor suppressing function of HNF4 alpha in renal cells. To determine the potential role of HNF4 alpha in RCC, we used Flp recombinase-mediated gene integration to generate human embryonic kidney cells (HEK293) that conditionally express wild-type or mutated HNF4a. Expression of wild-type HNF4 alpha but not of the mutants led to reduction of proliferation and alterations of cell morphology. These effects were reversible and induced at physiological concentrations of HNF4 alpha. Using gene expression pro. ling by microarrays, we determined genes regulated by HNF4 alpha. Interestingly, many of the genes regulated by HNF4 alpha have been shown to be deregulated in RCC microarray studies. These genes (ACY1, WT1, SELENBP1, COBL, EFHD1, AGXT2L1, ALDH5A1, THEM2, ABCB1, FLJ14146, CSPG2, TRIM9 and HEY1) are good candidates for genes whose activity is changed upon the decrease of HNF4 alpha in RCC.	Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany	University of Duisburg Essen	Ryffel, GU (corresponding author), Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany.	gerhart.ryffel@uni-essen.de						[Anonymous], 2001, NUCL RECEPTORS GENET; Berasain C, 2003, HEPATOLOGY, V38, P148, DOI 10.1053/jhep.2003.50269; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; Chabardes-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chiba H, 2005, EXP CELL RES, V302, P11, DOI 10.1016/j.yexcr.2004.08.014; Choi JK, 2004, FEBS LETT, V565, P93, DOI 10.1016/j.febslet.2004.03.081; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; Drewes T, 1996, MOL CELL BIOL, V16, P925; Gieseg MA, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-26; Grewal JS, 2005, BIOCHEM J, V387, P609, DOI 10.1042/BJ20041465; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; Ishiyama T, 2003, CANCER SCI, V94, P757, DOI 10.1111/j.1349-7006.2003.tb01515.x; Jiang Shuying, 2003, Nucl Recept, V1, P5, DOI 10.1186/1478-1336-1-5; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Laine B, 2000, FEBS LETT, V479, P41, DOI 10.1016/S0014-5793(00)01864-0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li JX, 2000, GENE DEV, V14, P464; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Ryffel GU, 2000, MECH DEVELOP, V90, P65, DOI 10.1016/S0925-4773(99)00230-0; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Sel S, 1996, CANCER LETT, V101, P205, DOI 10.1016/0304-3835(96)04136-5; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; STUMPF H, 1995, CARCINOGENESIS, V16, P143, DOI 10.1093/carcin/16.1.143; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; Thomas H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh144; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Werdien D, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e53; Xu L, 2001, CANCER RES, V61, P3176; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	45	74	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6418	6431		10.1038/sj.onc.1208794	http://dx.doi.org/10.1038/sj.onc.1208794			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007190				2022-12-28	WOS:000232038200009
J	Wang, J; Zhang, X; Thomas, SM; Grandis, JR; Wells, A; Chen, Z; Ferris, RL				Wang, J; Zhang, X; Thomas, SM; Grandis, JR; Wells, A; Chen, Z; Ferris, RL			Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR	ONCOGENE			English	Article						CCR7; EGFR; PI3K; Akt; PLC gamma-1	GASTRIN-RELEASING-PEPTIDE; GROWTH-FACTOR RECEPTOR; UP-REGULATION; DENDRITIC CELLS; CARCINOMA; PROTEIN; 3-KINASE; SIGNAL; EXPRESSION; AKT	Chemokine receptor 7 (CCR7) upregulation, which mediates immune cell survival and migration to lymph nodes, has recently been associated with nodal metastasis of squamous cell carcinoma of the head and neck (SCCHN). However, the mechanism of CCR7 in tumor progression, its downstream signaling mediators, and interactions with other pathways contributing to metastasis of SCCHN have not been determined. We hypothesized that inflammatory chemokine-mediated signals could also promote tumor proliferation and mitogenic effects. Functional assays showed that chemotaxis and invasion of metastatic SCCHN cells were dependent on phosphoinositide-3 kinase (PI3K) and its substrate, activated phospholipase C gamma-1. In addition, treatment of CCR7(+) metastatic SCCHN cells with CCL19 (MIP-3 beta) showed rapid activation of the prosurvival, PI3K/Akt pathway. Transactivation of EGFR-mediated and mitogen-activated protein kinase signaling pathways, which can promote migration and survival in parallel, did not appear to contribute to the functional or biochemical effects of CCR7 stimulation. Thus, proinflammatory chemokine signals that mediate activation, trafficking and survival of tumor-infiltrating immune cells in the tumor microenvironment actually appear to induce signals for progression of cancer cells. The CCR7-mediated pathway in metastatic SCCHN cells functions independently of EGFR signal transduction and therefore may represent an additional target for therapeutic intervention to prevent tumor progression and metastasis.	Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Immunol, Sch Med, Pittsburgh, PA 15213 USA; Emory Univ, Winship Canc Ctr, Dept Hematol & Oncol, Atlanta, GA 30332 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ferris, RL (corresponding author), Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Sch Med, Res Wing,Room 1-19D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	ferrisrl@upmc.edu	Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Wells, Alan/0000-0002-1637-8150				Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007; Curnock AP, 2003, J IMMUNOL METHODS, V273, P29, DOI 10.1016/S0022-1759(02)00416-7; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HEO DS, 1989, CANCER RES, V49, P5167; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Lango MN, 2002, J NATL CANCER I, V94, P375; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Murakami T, 2003, J EXP MED, V198, P1337, DOI 10.1084/jem.20030593; Pilkington KR, 2004, J BIOL CHEM, V279, P40276, DOI 10.1074/jbc.M405808200; Sanchez-Sanchez N, 2004, BLOOD, V104, P619, DOI 10.1182/blood-2003-11-3943; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Thomas SM, 2003, CANCER RES, V63, P5629; Tosi L, 2005, HEAD NECK-J SCI SPEC, V27, P130, DOI 10.1002/hed.20120; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008-5472.CAN-03-2968; WELLS A, 2004, SCI STKE, V253, P47	31	84	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5897	5904		10.1038/sj.onc.1208740	http://dx.doi.org/10.1038/sj.onc.1208740			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007209				2022-12-28	WOS:000231590400012
J	Lausen, J; Liu, S; Fliegauf, M; Lubbert, M; Werner, MH				Lausen, J; Liu, S; Fliegauf, M; Lubbert, M; Werner, MH			ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO	ONCOGENE			English	Article						acute myeloid leukemia; neutrophil elastase; gene regulation; AML1-ETO	ACUTE MYELOID-LEUKEMIA; ENCODING NEUTROPHIL ELASTASE; T(8/21) FUSION PROTEIN; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; TARGET GENE; C-MYB; N-COR; ETO; T(8-21)	A 117 bp fragment of the human ELA2 promoter has been characterized that can act as a minimal promoter for the expression of neutrophil elastase. Chromatin immunoprecipitation and siRNAs revealed that expression of ELA2 is regulated by the acute myeloid human leukemia 1 protein (AML1), C/EBP alpha, PU.1 and c-Myb transcription factors. ELA2 has also been investigated as a possible target of the leukemic fusion protein AML1-ETO resulting from the t(8;21) chromosomal translocation. AML1-ETO, like AML1, binds the ELA2 promoter in the myeloid cell lines Kasumi-1 and U937, but unexpectedly fails to significantly alter expression of ELA2. Although AML1-ETO downregulates the expression of C/EBP alpha, changes in C/EBP alpha expression do not correlate with changes in the expression of ELA2. Our observations indicate that AML1-ETO may not be a constitutive repressor of gene expression in every case in which it can associate with DNA, either on its own or in conjunction with C/EBP alpha. Since neither ETO nor AML1-ETO are typically expressed in hematopoietic progenitors, we hypothesize that it is the interactions between AML1-ETO and regulatory cofactors in disease-state cells that alter gene expression programs during hematopoiesis. These protein-protein interactions may not require simultaneous DNA binding by AML1-ETO for the deleterious effects of the fusion protein to be realized.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Univ Freiburg, Ctr Med, Div Hematol & Oncol, Dept Med, Freiburg, Germany	Rockefeller University; University of Freiburg	Werner, MH (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave,Box 42, New York, NY 10021 USA.	mwerner@portugal.rockefeller.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ancliff PJ, 2001, BLOOD, V98, P2645, DOI 10.1182/blood.V98.9.2645; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; ERICKSON P, 1992, BLOOD, V80, P1825; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; Lane AA, 2005, MOL CELL BIOL, V25, P23, DOI 10.1128/MCB.25.1.23-33.2005; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Shimada H, 2000, BLOOD, V96, P655; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wildonger J, 2005, DEVELOPMENT, V132, P2263, DOI 10.1242/dev.01824; YAN M, 2004, P NATL ACAD SCI USA, V49, P17186; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	48	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1349	1357		10.1038/sj.onc.1209181	http://dx.doi.org/10.1038/sj.onc.1209181			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247445				2022-12-28	WOS:000235708200008
J	Ji, H; Houghton, AM; Mariani, TJ; Perera, S; Kim, CB; Padera, R; Tonon, G; McNamara, K; Marconcini, LA; Hezel, A; El-Bardeesy, N; Bronson, RT; Sugarbaker, D; Maser, RS; Shapiro, SD; Wong, KK				Ji, H; Houghton, AM; Mariani, TJ; Perera, S; Kim, CB; Padera, R; Tonon, G; McNamara, K; Marconcini, LA; Hezel, A; El-Bardeesy, N; Bronson, RT; Sugarbaker, D; Maser, RS; Shapiro, SD; Wong, KK			K-ras activation generates an inflammatory response in lung tumors	ONCOGENE			English	Article						K-ras; inflammation; lung cancer; macrophages; neutrophils	PEPTIDE ENA-78; CANCER; INTERLEUKIN-8; EXPRESSION; CELL; IDENTIFICATION; TUMORIGENESIS; ANGIOGENESIS; INDUCTION; GROWTH	Activating mutations in K-ras are one of the most common genetic alterations in human lung cancer. To dissect the role of K-ras activation in bronchial epithelial cells during lung tumorigenesis, we created a model of lung adenocarcinoma by generating a conditional mutant mouse with both Clara cell secretory protein (CC10)-Cre recombinase and the Lox-Stop-Lox K-ras(G12D) alleles. The activation of K-ras mutant allele in CC10 positive cells resulted in a progressive phenotype characterized by cellular atypia, adenoma and ultimately adenocarcinoma. Surprisingly, K-ras activation in the bronchiolar epithelium is associated with a robust inflammatory response characterized by an abundant infiltration of alveolar macrophages and neutrophils. These mice displayed early mortality in the setting of this pulmonary inflammatory response with a median survival of 8 weeks. Bronchoalveolar lavage fluid from these mutant mice contained the MIP-2, KC, MCP-1 and LIX chemokines that increased significantly with age. Cell lines derived from these tumors directly produced MIP-2, LIX and KC. This model demonstrates that K-ras activation in the lung induces the elaboration of inflammatory chemokines and provides an excellent means to further study the complex interactions between inflammatory cells, chemokines and tumor progression.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Wong, KK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, 44 Binney St,M413, Boston, MA 02115 USA.	kwong1@partners.org	Tonon, Giovanni/J-9804-2018; Maser, Richard/B-2970-2012	Tonon, Giovanni/0000-0003-2973-5038; 	NHLBI NIH HHS [R01 HL70321] Funding Source: Medline; NIA NIH HHS [K08AG 2400401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BAGGIOLINI M, 1994, CHEST, V105, pS95, DOI 10.1378/chest.105.3_Supplement.95S; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Doll RJ, 2004, CURR OPIN DRUG DISC, V7, P478; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karin M, 2005, NAT MED, V11, P20, DOI 10.1038/nm0105-20; Karp JE, 2001, CURR OPIN ONCOL, V13, P470, DOI 10.1097/00001622-200111000-00009; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Linnoila RI, 2000, ANN NY ACAD SCI, V923, P249; LUKACS NW, 1995, AM J PHYSIOL-LUNG C, V268, pL856, DOI 10.1152/ajplung.1995.268.5.L856; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Ono M, 1999, CANCER CHEMOTH PHARM, V43, pS69, DOI 10.1007/s002800051101; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Poznansky MC, 2002, J CLIN INVEST, V109, P1101, DOI 10.1172/JCI200213853; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WATNICK RS, 2003, CANCER CELL, V6, P447	34	209	213	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2105	2112		10.1038/sj.onc.1209237	http://dx.doi.org/10.1038/sj.onc.1209237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288213				2022-12-28	WOS:000236359700013
J	Rotzer, D; Krampert, M; Sulyok, S; Braun, S; Stark, HJ; Boukamp, P; Werner, S				Rotzer, D; Krampert, M; Sulyok, S; Braun, S; Stark, HJ; Boukamp, P; Werner, S			Id proteins: Novel targets of activin action, which regulate epidermal homeostasis	ONCOGENE			English	Article						epidermis; skin; TGF-beta; wound	BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; TRANSGENIC MICE REVEALS; KERATINOCYTE CELL-LINE; LOOP-HELIX PROTEINS; WOUND REPAIR; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; BINDING PROTEINS; EPITHELIAL-CELLS	Activin is a member of the transforming growth factor beta (TGF-beta) family, which plays a crucial role in skin morphogenesis and wound healing. To gain insight into the underlying mechanisms of action, we searched for activin-regulated genes in cultured keratinocytes. One of the identified target genes encodes Id1, a negative regulator of helix-loop-helix transcription factors. We show that Id1, Id2, and Id3 are strongly downregulated by activin in keratinocytes in vitro and in vivo. To determine the role of Id1 in keratinocyte biology, we generated stable HaCaT keratinocyte cell lines overexpressing this protein. Our results revealed that enhanced levels of Id1 do not affect proliferation of keratinocytes in monoculture under exponential culture conditions or in response to activin or TGF-beta 1. However, in three-dimensional organotypic cultures, Id1-overexpressing HaCaT cells formed a hyperthickened and disorganized epithelium that was characterized by enhanced keratinocyte proliferation, abnormal differentiation, and an increased rate of apoptosis. These results identify an important function of Id1 in the regulation of epidermal homeostasis.	ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; German Canc Res Ctr, Dept Genet Skin Carcinogenesis, Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Werner, S (corresponding author), ETH, Inst Cell Biol, Dept Biol, HPM D42, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Bamberger C, 2005, AM J PATHOL, V167, P733, DOI 10.1016/S0002-9440(10)62047-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bjorntorp E, 2003, ACTA DERM-VENEREOL, V83, P403, DOI 10.1080/00015550310015806; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chaturvedi V, 2003, EXP DERMATOL, V12, P255, DOI 10.1034/j.1600-0625.2003.00066.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cruise BA, 2004, DEV BIOL, V271, P1, DOI 10.1016/j.ydbio.2004.04.003; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; HARA E, 1994, J BIOL CHEM, V269, P2139; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lin CQ, 1999, ENDOCR-RELAT CANCER, V6, P49, DOI 10.1677/erc.0.0060049; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, RECEPTOR, V3, P173; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; Schaefer BM, 2001, EXP CELL RES, V266, P250, DOI 10.1006/excr.2001.5215; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Seishima M, 1999, J INVEST DERMATOL, V112, P432, DOI 10.1046/j.1523-1747.1999.00558.x; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Werner S, 2001, ONCOGENE, V20, P7494, DOI 10.1038/sj.onc.1204937; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yamashita S, 2004, J AM SOC NEPHROL, V15, P91, DOI 10.1097/01.ASN.0000103225.68136.E6; Zhang L, 2005, MOL CELL BIOL, V25, P60, DOI 10.1128/MCB.25.1.60-65.2005	50	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2070	2081		10.1038/sj.onc.1209230	http://dx.doi.org/10.1038/sj.onc.1209230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288215				2022-12-28	WOS:000236359700010
J	Belka, C				Belka, C			The fate of irradiated tumor cells	ONCOGENE			English	Editorial Material						apoptosis; cell cycle arrest; radiation P21(CIP/WAF1); cell death	MITOTIC CATASTROPHE; DNA-DAMAGE; SUPPRESSION; CARCINOMA; APOPTOSIS; P53	Radiotherapy remains a key component of modern multimodal anticancer treatment approaches. Although most clinically relevant improvements in radiation oncology are based on optimized radiation technology, it now becomes obvious that biology-based approaches will further boost the efficacy of modern radiation oncology. Of relevance to this is the question of the ultimate fate of an irradiated cell and the mechanistic basis of the induced cell death or inactivation observed. Research bearing on this question is reported in this issue of Oncogene by Wendt et al. (2005), who show that the levels of p21(CIP/WAF1) play a key role in determining whether an irradiated tumour cell is arrested in the G2 phase of the cell cycle, rather than apoptosing. The demonstration that caffeine treatment can abrogate this G2 arrest, and that the cells go on to die, has implications for overcoming treatment resistance imposed by radiation- induced upregulation of p21(CIP/WAF1).	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de						Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; WENDT J, 2005, IN PRESS ONCOGENE	9	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	7					969	971		10.1038/sj.onc.1209175	http://dx.doi.org/10.1038/sj.onc.1209175			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247448	Bronze			2022-12-28	WOS:000235361000001
J	Anderson, CJ; Hoare, SF; Ashcroft, M; Bilsland, AE; Keith, WN				Anderson, CJ; Hoare, SF; Ashcroft, M; Bilsland, AE; Keith, WN			Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms	ONCOGENE			English	Article						telomerase; hTR; hTERT; hypoxia; RNA splicing; chromatin	STRESS-INDUCED APOPTOSIS; HUMAN CANCER-CELLS; INDUCIBLE FACTOR-1-ALPHA; BACTERIAL NITROREDUCTASE; REVERSE-TRANSCRIPTASE; TUMOR-GROWTH; LIFE-SPAN; IN-VIVO; ACTIVATION; HTERT	Basal telomerase activity is dependent on expression of the hTERT and hTR genes and upregulation of telomerase gene expression is associated with tumour development. It is therefore possible that signal transduction pathways involved in tumour development and features of the tumour environment itself may influence telomerase gene regulation. The majority of solid tumours contain regions of hypoxia and it has recently been demonstrated that hypoxia can increase telomerase activity by mechanisms that are still poorly defined. Here, we show that hypoxia induces the transcriptional activity of both hTR and hTERT gene promoters. While endogenous hTR expression is regulated at the transcriptional level, hTERT is subject to regulation by alternative splicing under hypoxic conditions, which involves a switch in the splice pattern in favour of the active variant. Furthermore, analysis of the chromatin landscape of the telomerase promoters reveals dynamic recruitment of a transcriptional complex involving the hypoxia- inducible factor-1 transcription factor, p300, RNA polymerase II and TFIIB, to both promoters during hypoxia, which traffics along and remains associated with the hTERT gene as transcription proceeds. These studies show that hTERT and hTR are subject to similar controls under hypoxia and highlight the rapid and dynamic regulation of the telomerase genes in vivo.	Univ Glasgow, Canc Res UK, Beatson Labs, Ctr Oncol & Appl Pharmacol, Glasgow G61 1BD, Lanark, Scotland; Inst Canc Res, Canc Res UK, Ctr Canc Therapeut, Sutton, Surrey, England	Beatson Institute; Cancer Research UK; University of Glasgow; Cancer Research UK; University of London; Institute of Cancer Research - UK	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK, Beatson Labs, Ctr Oncol & Appl Pharmacol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Cairney, Claire/H-6989-2012; Bilsland, Alan/G-2629-2010; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Bilsland, Alan/0000-0003-0957-3908; Cairney, Claire/0000-0001-6531-245X				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ASHCROFT M, 2004, BIOESSAYS, V26, P262; ATKINSON SP, 2005, IN PRESS CANC RES; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; Blasco MA, 2003, TRENDS CELL BIOL, V13, P289, DOI 10.1016/S0962-8924(03)00085-0; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Elsby LM, 2004, BIOCHEM SOC T, V32, P1098, DOI 10.1042/BST0321098; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Munch C, 2003, J NEUROSCI RES, V71, P819, DOI 10.1002/jnr.10536; Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Reynolds TY, 1996, CANCER RES, V56, P5754; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Ulaner GA, 1998, CANCER RES, V58, P4168; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Zaffaroni N, 2002, J PATHOL, V198, P37, DOI 10.1002/path.1178; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zhang LQ, 2003, CANCER RES, V63, P4552	34	76	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					61	69		10.1038/sj.onc.1209011	http://dx.doi.org/10.1038/sj.onc.1209011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170363				2022-12-28	WOS:000234406400007
J	Knauth, K; Bex, C; Jemth, P; Buchberger, A				Knauth, K; Bex, C; Jemth, P; Buchberger, A			Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1 alpha interactions	ONCOGENE			English	Article						VHL; RCC; HIF-1 alpha	TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLATION/; LIGASE ACTIVITY; REGULATE HIF; VHL DISEASE; IN-VIVO; MUTATIONS; BINDING; COMPLEX; GENE	The von Hippel-Lindau (VHL) tumor suppressor protein is the substrate binding subunit of the CBCVHL E3 ubiquitin ligase complex. Mutations in the VHL gene cause a variety of tumors with complex genotype/ phenotype correlations. Type 2A and type 2B VHL disease are characterized by a low or high risk of renal cell carcinoma, respectively. To investigate the molecular basis underlying the difference between disease types 2A and 2B, we performed a detailed biochemical analysis of the two most frequent type 2A mutations, Y98H and Y112 H, in comparison to type 2B mutations in the same residues, Y98N and Y112N. While none of these mutations affected the assembly of CBCVHL complexes, the type 2A mutant proteins exhibited higher stabilities at physiological temperature. Moreover, the type 2A mutant proteins possessed higher binding affinities for the key cellular substrate, hypoxia-inducible transcription factor 1 (HIF-1 alpha). Consistent with these results, type 2A but not type 2B mutant VHL proteins retained significant ubiquitin ligase activity towards HIF-1 alpha in vitro. We propose that this residual ubiquitin ligase activity is sufficient to suppress renal cell carcinogenesis in vivo.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany; MRC, Ctr Prot Engn, Cambridge, England	Max Planck Society; University of Cambridge	Buchberger, A (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	buchberg@biochem.mpg.de	Buchberger, Alexander/AAF-4728-2019; Buchberger, Alexander/J-4070-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Pfander, Claudia/0000-0002-9574-9553				Allen DL, 1998, PROTEIN SCI, V7, P1262, DOI 10.1002/pro.5560070524; Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buchberger A, 1999, J BIOL CHEM, V274, P38017, DOI 10.1074/jbc.274.53.38017; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Killenberg-Jabs M, 2002, BIOPHYS CHEM, V96, P259, DOI 10.1016/S0301-4622(02)00017-0; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Li ZB, 2003, EMBO J, V22, P1857, DOI 10.1093/emboj/cdg173; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657	41	55	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					370	377		10.1038/sj.onc.1209062	http://dx.doi.org/10.1038/sj.onc.1209062			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16261165				2022-12-28	WOS:000234714100005
J	Bi, XL; Jones, T; Abbasi, F; Lee, H; Stultz, B; Hursh, DA; Mortin, MA				Bi, XL; Jones, T; Abbasi, F; Lee, H; Stultz, B; Hursh, DA; Mortin, MA			Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells	ONCOGENE			English	Article						caliban; Sdccag1; tumor suppressor; nuclear export; lung cancer; interference RNA	PROSPERO GENE; CRM1; LOCALIZATION; HOMOLOG; REVEALS; ENCODES; SIGNALS; PROTEIN; SYSTEM; DOMAIN	We previously showed that the Drosophila DNA binding homeodomain of Prospero included a 28 amino-acid sequence (HDA) that functions as a nuclear export signal. We describe here the identification of a protein we named Caliban, which can directly interact with the HDA. Caliban is homologous to human Sdccag1, which has been implicated in colon and lung cancer. Here we show that Caliban and Sdccag1 are mediators of nuclear export in fly and human cells, as interference RNA abrogates export of EYFP-HDA in normal fly and human lung cells. Caliban functions as a bipartite mediator nuclear export as the carboxy terminus binds HDA and the amino terminus itself functions as an NES, which directly binds the NES receptor Exportin. Finally, while non-cancerous lung cells have functional Sdccag1, five human lung carcinoma cell lines do not, even though Exportin still functions in these cells. Expression of fly Caliban in these human lung cancer cells restores EYFP-HDA nuclear export, reduces a cell's ability to form colonies on soft agar and reduces cell invasiveness. We suggest that Sdccag1 inactivation contributes to the transformed state of human lung cancer cells and that Caliban should be considered a candidate for use in lung cancer gene therapy.	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA)	Mortin, MA (corresponding author), NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.	mortinm@mail.nih.gov	Bi, Xiaolin/C-7038-2014; Bi, Xiaolin/E-7469-2010; Mortin, Mark A/B-4251-2008	Bi, Xiaolin/0000-0003-2837-9457; Bi, Xiaolin/0000-0002-7172-7851; Hursh, Deborah/0000-0002-5614-7111	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001005] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000367] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bi XL, 2003, MOL CELL BIOL, V23, P1014, DOI 10.1128/MCB.23.3.1014-1024.2003; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BURGLIN TR, 1994, TRENDS BIOCHEM SCI, V19, P70, DOI 10.1016/0968-0004(94)90035-3; Carbonnelle D, 2001, INT J CANCER, V92, P388, DOI 10.1002/ijc.1197; Collier S, 2000, GENETICS, V155, P1799; Demidenko Z, 2001, DEVELOPMENT, V128, P1359; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Ryter JM, 2002, STRUCTURE, V10, P1541, DOI 10.1016/S0969-2126(02)00883-3; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yousef M, 2005, STRUCTURE, V13, P601, DOI 10.1016/j.str.2005.01.023	21	19	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8229	8239		10.1038/sj.onc.1208962	http://dx.doi.org/10.1038/sj.onc.1208962			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103875				2022-12-28	WOS:000233956500002
J	Barber, GN				Barber, GN			VSV-tumor selective replication and protein translation	ONCOGENE			English	Review						VSV; translation; oncolytic; virus; interferon; cancer	VESICULAR STOMATITIS-VIRUS; NUCLEOTIDE EXCHANGE FACTOR; CAP-DEPENDENT TRANSLATION; MESSENGER-RNA TRANSLATION; INITIATION-FACTOR EIF2B; MATRIX PROTEIN; MALIGNANT-TRANSFORMATION; TARGETED DISRUPTION; CATALYTIC DOMAIN; INNATE IMMUNITY	The emergence of vesicular stomatatis virus ( VSV) as a potent antitumor agent has made a dissection of the molecular determinants of host-cell permissiveness to this virus an important objective. Such insight would not only enable the intelligent design of future generations of recombinant VSV vectors to combat disease, but may also resolve general features of cellular transformation that may be exploited by this virus, and perhaps other oncolytic viruses. The defective pathways underlining the oncolytic activity of VSV remain to be fully determined but recent data indicates that flaws in innate immune responses, involving the interferon ( IFN) system, may commonly occur in tumor cells and thus play a large role in facilitating oncolysis. Aside from the IFN system, however, it is almost certain that other key cellular pathways may be similarly defective and therefore cooperatively contribute towards mediating rapid oncolytic virus activity. Recent data have indicated that defects in cancer cell translational regulation could be one area that may be exploited by VSV. Certainly, all viruses require cellular protein synthesis pathways to facilitate their replication and many have devised numerous mechanisms to ensure that viral mRNAs become translated at the expense of the host. Using VSV as a model, this review will discuss some of the recent developments in the fields of innate immunity and translational regulation that may help explain mechanisms of viral oncolysis.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Sylvester Comprehens Canc Ctr, Room 511,Papanicolaou Bldg,1550 NW 10th St M710, Miami, FL 33136 USA.	gbarber@med.miami.edu						Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Ball LA, 1999, J VIROL, V73, P4705, DOI 10.1128/JVI.73.6.4705-4712.1999; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Barber GN, 2004, VIRAL IMMUNOL, V17, P516, DOI 10.1089/vim.2004.17.516; Barber GN, 2000, SEMIN CANCER BIOL, V10, P103, DOI 10.1006/scbi.2000.0313; Bergman I, 2003, VIROLOGY, V316, P337, DOI 10.1016/j.virol.2003.07.010; Bergmann M, 2001, CANCER RES, V61, P8188; BI ZB, 1995, J VIROL, V69, P6466, DOI 10.1128/JVI.69.10.6466-6472.1995; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Carneiro FA, 2002, J VIROL, V76, P3756, DOI 10.1128/JVI.76.8.3756-3764.2002; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Clemens MJ, 2001, PROG MOLEC, V27, P57; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connor JH, 2005, J BIOL CHEM, V280, P13512, DOI 10.1074/jbc.M501156200; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; DEMATTOS C, 2001, RHABDOVIRIDAE VIRUSE; Desforges M, 2001, VIRUS RES, V76, P87, DOI 10.1016/S0168-1702(01)00251-9; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Ebert O, 2004, CANCER RES, V64, P3265, DOI 10.1158/0008-5472.CAN-03-3753; Enninga J, 2002, SCIENCE, V295, P1523, DOI 10.1126/science.1067861; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; HAMMON WMD, 1963, J NATL CANCER I, V31, P329; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hii SI, 2004, INT J CANCER, V109, P329, DOI 10.1002/ijc.11714; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lamberti A, 2004, AMINO ACIDS, V26, P443, DOI 10.1007/s00726-004-0088-2; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LODISH HF, 1980, J VIROL, V36, P719, DOI 10.1128/JVI.36.3.719-733.1980; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Pitha PM, 2000, SEMIN CANCER BIOL, V10, P69, DOI 10.1006/scbi.2000.0309; PLAKHOV IV, 1995, VIROLOGY, V209, P257, DOI 10.1006/viro.1995.1252; Porosnicu M, 2003, CANCER RES, V63, P8366; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998; Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rose JKWMA., 2001, RHABDOVIRIDAE VIRUSE; Rose NF, 2000, J VIROL, V74, P10903, DOI 10.1128/JVI.74.23.10903-10910.2000; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; Tough DF, 2004, LEUKEMIA LYMPHOMA, V45, P257, DOI 10.1080/1042819031000149368; van den Pol AN, 2002, J VIROL, V76, P1309, DOI 10.1128/JVI.76.3.1309-1327.2002; Varghese S, 2002, CANCER GENE THER, V9, P967, DOI 10.1038/sj.cgt.7700537; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Williams DD, 2001, J BIOL CHEM, V276, P24697, DOI 10.1074/jbc.M011788200; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	92	119	127	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7710	7719		10.1038/sj.onc.1209042	http://dx.doi.org/10.1038/sj.onc.1209042			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299531				2022-12-28	WOS:000233372600007
J	Altomare, DA; Testa, JR				Altomare, DA; Testa, JR			Perturbations of the AKT signaling pathway in human cancer	ONCOGENE			English	Review						AKT/ PKB kinases; tumor suppressor genes; oncogenes; human malignancy; targeted therapy	AKT/PROTEIN-KINASE-B; HUMAN PANCREATIC-CANCER; PROSTATE INTRAEPITHELIAL NEOPLASIA; TUMOR-CELL GROWTH; OVARIAN-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; FREQUENT ACTIVATION; TUBEROUS-SCLEROSIS; INDUCED APOPTOSIS; BREAST CANCERS	AKT/PKB ( protein kinase B) kinases mediate signaling pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases regulate diverse cellular processes including cell proliferation and survival, cell size and response to nutrient availability, tissue invasion and angiogenesis. Many oncoproteins and tumor suppressors implicated in cell signaling/metabolic regulation converge within the AKT signal transduction pathway in an equilibrium that is altered in many human cancers by activating and inactivating mechanisms, respectively, targeting these inter-related proteins. We review a burgeoning literature implicating aberrant AKT signaling in many sporadic human cancers as well as in several dominantly inherited cancer syndromes known as phakomatoses. The latter include disorders caused by germline mutations of certain tumor suppressor genes, that is, PTEN, TSC2/TSC1, LKB1, NF1, and VHL, encoding proteins that intersect with the AKT pathway. We also review various pathogenic mechanisms contributing to activation of the AKT pathway in human malignancy as well as current pharmacologic strategies to target therapeutically components of this pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	joseph.testa@fccc.edu			NCI NIH HHS [P30 CA006927, P50 CA083638, CA77429, R01 CA077429, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P50CA083638, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Arboleda MJ, 2003, CANCER RES, V63, P196; Arranz E, 1996, CANCER GENET CYTOGEN, V87, P1, DOI 10.1016/0165-4608(95)00230-8; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Boulay A, 2004, CANCER RES, V64, P252, DOI 10.1158/0008-5472.CAN-3554-2; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brognard J, 2001, CANCER RES, V61, P3986; Byun DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grille SJ, 2003, CANCER RES, V63, P2172; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu LM, 2002, CANCER RES, V62, P1087; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kenerson HL, 2002, CANCER RES, V62, P5645; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089; Lian ZL, 2005, ONCOGENE, V24, P7394, DOI 10.1038/sj.onc.1209089; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu AX, 1998, CANCER RES, V58, P2973; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Page C, 2000, ANTICANCER RES, V20, P407; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Philp AJ, 2001, CANCER RES, V61, P7426; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Robertson GP, 2005, CANCER METAST REV, V24, P273, DOI 10.1007/s10555-005-1577-9; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, CANCER RES, V61, P2194; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Sun S, 2002, J GEN VIROL, V83, P1651, DOI 10.1099/0022-1317-83-7-1651; Tanno S, 2001, CANCER RES, V61, P589; Terakawa N, 2003, ENDOCR-RELAT CANCER, V10, P203, DOI 10.1677/erc.0.0100203; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; Tucker M, 2000, J NATL CANCER I, V92, P530, DOI 10.1093/jnci/92.7.530; Waldmann V, 2001, ARCH DERMATOL RES, V293, P368, DOI 10.1007/s004030100236; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Whang YE, 2004, VITAM HORM, V67, P409; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xu XD, 2004, ONCOL REP, V11, P25; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057	103	1053	1089	2	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7455	7464		10.1038/sj.onc.1209085	http://dx.doi.org/10.1038/sj.onc.1209085			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288292				2022-12-28	WOS:000233201900008
J	Ahlbory, DR; Appl, H; Lang, D; Klempnauer, KH				Ahlbory, DR; Appl, H; Lang, D; Klempnauer, KH			Disruption of B-myb in DT40 cells reveals novel function for B-Myb in the response to DNA-damage	ONCOGENE			English	Article						B-myb; DT40; homologous recombination; DNA-damage	DROSOPHILA-MYB; C-MYB; PROTEIN; GENE; PROLIFERATION; EXPRESSION; APOPTOSIS	B-Myb is a highly conserved vertebrate member of the Myb transcription factor family, which is expressed in virtually all proliferating cells. A large body of evidence suggests that B-Myb plays an important role in cell cycle regulation; however, the exact nature of its function has not yet been clarified. We have used gene targeting in chicken DT40 cells, a cell line exhibiting very high rates of homologous recombination, to create cells expressing endogenous B-myb in a doxycyclin-dependent manner. We find that the cells proliferate well in the absence of B-Myb, suggesting that B-Myb is not essential for cell proliferation per se. However, cells lacking B-Myb are more sensitive to DNA-damage induced by UV-irradiation and alkylation. Our work provides the first direct evidence for a novel function of B-Myb in the response to DNA-damage. The cells described here should be a useful model to characterize this function in more detail.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Munster, Dept Med D, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Davidson CJ, 2005, GENETICS, V169, P215, DOI 10.1534/genetics.104.034132; Fitzpatrick CA, 2002, DEVELOPMENT, V129, P4497; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Grassilli E, 1999, CANCER RES, V59, P2451; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Kamano H, 1995, ONCOGENE, V11, P2575; Katzen AL, 1998, GENE DEV, V12, P831, DOI 10.1101/gad.12.6.831; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lang D, 2002, J IMMUNOL, V168, P6152, DOI 10.4049/jimmunol.168.12.6152; Lang G, 2005, IMMUNOLOGY, V114, P25, DOI 10.1111/j.1365-2567.2004.02073.x; Manak JR, 2002, P NATL ACAD SCI USA, V99, P7438, DOI 10.1073/pnas.122231599; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	29	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7127	7134		10.1038/sj.onc.1208869	http://dx.doi.org/10.1038/sj.onc.1208869			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170378				2022-12-28	WOS:000232990100002
J	Zhang, Z; Wang, H; Li, M; Rayburn, ER; Agrawal, S; Zhang, RW				Zhang, Z; Wang, H; Li, M; Rayburn, ER; Agrawal, S; Zhang, RW			Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway	ONCOGENE			English	Article						MDM2; E2F1; ubiquitination; protein-protein interaction	IN-VIVO ACTIVITIES; ANTISENSE ANTI-MDM2 OLIGONUCLEOTIDES; MIXED-BACKBONE OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR E2F-1; HUMAN CANCER; PROSTATE-CANCER; BREAST-CANCER; CELL-GROWTH; P53; EXPRESSION	Although previous studies suggested that the tumorigenicity of mouse double minute 2 (MDM2) was due to its negative regulation of p53, the p53-independent interactions may be equally as important. During recent studies utilizing MDM2 inhibitors, we noted that E2F transcription factor 1 (E2F1) was downregulated upon inhibition of MDM2, regardless of the p53 status of the cancer. The present study investigated the mechanisms responsible for the MDM2-mediated increase in E2F1 expression. MDM2 prolongs the half-life of the E2F1 protein by inhibiting its ubiquitination. MDM2 displaces SCFSKP2, the E2F1 E3 ligase. Direct binding between MDM2 and E2F1 is necessary for the negative effects of MDM2 on E2F1 ubiquitination, and deletion of the MDM2 nuclear localization signal does not result in loss of the ability to increase the E2F1 protein level. The downregulation of E2F1 upon MDM2 inhibition was not due to either pRB or p14(Arf). In addition, E2F1 was responsible for at least part of the inhibition of cell proliferation induced by MDM2 knockdown. In conclusion, the present study provides evidence that stabilization of the E2F1 protein is likely another p53-independent component of MDM2-mediated tumorigenesis. More knowledge about the MDM2-E2F1 interaction may be helpful in developing novel anticancer therapies.	Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Hybridon Inc, Cambridge, MA 02139 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhang, RW (corresponding author), Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	ruiwen.zhang@ccc.uab.edu		Agrawal, Sudhir/0000-0003-4275-2510	NCI NIH HHS [CA 112029, CA80698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arakawa Y, 2004, BIOCHEM BIOPH RES CO, V322, P297, DOI 10.1016/j.bbrc.2004.04.208; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Bartel F, 2004, MOL CANCER RES, V2, P29; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; Deb SP, 2003, MOL CANCER RES, V1, P1009; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Imai MA, 2004, J CANCER RES CLIN, V130, P320, DOI 10.1007/s00432-003-0538-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liang HL, 2004, GENE, V338, P217, DOI 10.1016/j.gene.2004.05.015; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin WC, 2001, GENE DEV, V15, P1833; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Meek DW, 2003, MOL CANCER RES, V1, P1017; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Onda M, 2004, J HUM GENET, V49, P312, DOI 10.1007/s10038-004-0146-3; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Stanelle J, 2005, CELL DEATH DIFFER, V12, P347, DOI 10.1038/sj.cdd.4401532; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Wang H, 2003, ANN NY ACAD SCI, V1002, P217, DOI 10.1196/annals.1281.025; Wang H, 1999, INT J ONCOL, V15, P653; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; Wang H, 2001, CLIN CANCER RES, V7, P3613; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Yamazaki K, 2003, PATHOL RES PRACT, V199, P23, DOI 10.1078/0344-0338-00348; Zhang RW, 2005, CURR CANCER DRUG TAR, V5, P43, DOI 10.2174/1568009053332663; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang Z, 2004, CLIN CANCER RES, V10, P1263, DOI 10.1158/1078-0432.CCR-0245-03; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	58	101	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7238	7247		10.1038/sj.onc.1208814	http://dx.doi.org/10.1038/sj.onc.1208814			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170383				2022-12-28	WOS:000232990100012
J	Miccadei, S; Provenzano, C; Mojzisek, M; Natali, PG; Civitareale, D				Miccadei, S; Provenzano, C; Mojzisek, M; Natali, PG; Civitareale, D			Retinoblastoma protein acts as Pax 8 transcriptional coactivator	ONCOGENE			English	Article						Pax 8; retinoblastoma protein; thyroid; transcription; coactivator	CELL-CYCLE; EPITHELIAL-CELLS; FAMILY PROTEINS; RB/E2F PATHWAY; DNA-BINDING; GENE; DIFFERENTIATION; PROMOTER; RB; PRB	Control of cell proliferation and differentiation by the retinoblastoma protein (pRb) depends on its interactions with key cellular substrates. Available data indicate that pRb and the transcription factor Pax 8 play a crucial role in the differentiation of thyroid follicular cells. In this study, we show that pRb takes part in the complex assembled on the thyroperoxidase gene promoter acting as a transcriptional coactivator of Pax 8. Accordingly, pRb interacts with and potentiates Pax 8 transcriptional activity. In addition, we show that the downregulation of pRb gene expression, in thyrocytes, through RNA interference results in a reduction of the thyroperoxidase gene promoter activity mediated by the Pax 8-binding site. In agreement with these results and with the ability of the adenoviral protein E1A to bind pRb, we show that E1A downregulates Pax 8 activity and that such inhibition requires the E1A-Rb interaction. Furthermore, we show that the Pax 8/pRb synergy plays a role on the sodium/iodide symporter gene expression as well.	Italian Natl Council Res, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Regina Elena Inst Canc Res, Mol Pathol Lab, I-00158 Rome, Italy; Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50001, Czech Republic	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Charles University Prague; University Hospital Hradec Kralove	Civitareale, D (corresponding author), Italian Natl Council Res, Inst Neurobiol & Mol Med, Via Fosso Cavaliere 100, I-00133 Rome, Italy.	dciv@yahoo.com	, stefaniamiccadei/J-2640-2017; Civitareale, Donato/B-4889-2015	, stefaniamiccadei/0000-0001-8890-6998; Civitareale, Donato/0000-0001-5719-9098				Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; De Leo R, 2000, J BIOL CHEM, V275, P34100, DOI 10.1074/jbc.M003043200; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; DIMAGLIANO P, 2000, P NATL ACAD SCI USA, V93, P465; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 1999, CANCER RES, V59, p1716S; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Goodman RH, 2000, GENE DEV, V14, P1553; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iuliano R, 2000, EXP CELL RES, V260, P257, DOI 10.1006/excr.2000.5023; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Perrone L, 2000, BIOCHEM BIOPH RES CO, V275, P203, DOI 10.1006/bbrc.2000.3232; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Suzuki K, 1998, MOL CELL BIOL, V18, P7410, DOI 10.1128/MCB.18.12.7410; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Wang XC, 1997, T NONFERR METAL SOC, V7, P45; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Yuan SSF, 2002, BIOCHEM BIOPH RES CO, V296, P1019, DOI 10.1016/S0006-291X(02)02032-6; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	52	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					6993	7001		10.1038/sj.onc.1208861	http://dx.doi.org/10.1038/sj.onc.1208861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007137				2022-12-28	WOS:000232833200001
J	Gallo, RC				Gallo, RC			History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2	ONCOGENE			English	Article						human retroviruses; discovery; human T-cell lymphotropicvirus 1 and 2; human leukemia viruses	T-CELL LEUKEMIA; DEPENDENT DNA POLYMERASE; NORMAL HUMAN LYMPHOCYTES; REVERSE-TRANSCRIPTASE; DEOXYTHYMIDINE SYNTHESIS; HUMAN LEUKOCYTES; ENZYMATIC MECHANISMS; SEROLOGICAL ANALYSIS; HUMAN LYMPHOBLASTS; SARCOMA-VIRUS	HTLV-1 was discovered in the US in 1979, and published in 1980. This was rapidly followed by four additional reports in early 1981 describing additional isolates, characterization of some of the HTLV-1 proteins, serological assays for specific antibodies indicative of HTLV-1 infection, and evidence for integrated DNA proviruses in infected cells. None of this early work was dependent upon or influenced by the subclassiffication of some T-cell malignancies as ATL (in Japan). Instead, I was stimulated by prior work from many investigators in the US and Europe on retroviruses which caused leukemia in animals and our discoveries were made possible by our technical approaches developed in the 1970s involving especially sensitive assays for RT as a surrogate marker for a retrovirus and our discovery of Il-2 which made it possible to culture human T cells. However, following our reports the same virus was isolated in Japan, and both groups provided evidence that HTLV-1 caused ATL, a subclassification of T-cell malignancies first recognized in Japan.	Inst Human Virol, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore	Gallo, RC (corresponding author), Inst Human Virol, Baltimore, MD USA.	gallo@umbi.umd.edu						BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BOBROW SN, 1972, P NATL ACAD SCI USA, V69, P3228, DOI 10.1073/pnas.69.11.3228; FERRER JF, 1975, BIBL HAEMATOL, V40, P59; GALLO RC, 1967, J BIOL CHEM, V242, P5059; GALLO RC, 1981, CANCER RES, V41, P4738; GALLO RC, 1972, MEDICINE, V51, P159; GALLO RC, 1968, J BIOL CHEM, V243, P4936; GALLO RC, 1978, VIROLOGY, V84, P359, DOI 10.1016/0042-6822(78)90255-6; GALLO RC, 1968, J BIOL CHEM, V243, P4943; GALLO RC, 1970, J MOL BIOL, V52, P195, DOI 10.1016/0022-2836(70)90025-2; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KALYANARAMAN VS, 1981, J VIROL, V38, P906, DOI 10.1128/JVI.38.3.906-915.1981; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KETTMANN R, 1975, ACTA HAEMATOL-BASEL, V54, P201, DOI 10.1159/000208076; LOTEM J, 1986, EMBO J, V5, P2163, DOI 10.1002/j.1460-2075.1986.tb04480.x; METCALF D, 1979, INT J CANCER, V24, P616, DOI 10.1002/ijc.2910240515; MIER JW, 1982, J IMMUNOL, V128, P1122; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; PRIVAL JT, 1974, J NATL CANCER I, V53, P1583; REITZ MS, 1974, BIOCHEM BIOPH RES CO, V57, P934, DOI 10.1016/0006-291X(74)90635-4; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; ROBERT MS, 1972, SCIENCE, V176, P798, DOI 10.1126/science.176.4036.798; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROBERTGUROFF M, 1981, J EXP MED, V154, P1957, DOI 10.1084/jem.154.6.1957; ROBERTGUROFF M, 1977, BIOCHEMISTRY-US, V16, P2874, DOI 10.1021/bi00632a011; RUSCETTI FW, 1977, J IMMUNOL, V119, P131; SARNGADHARAN MG, 1972, NATURE-NEW BIOL, V240, P67, DOI 10.1038/newbio240067a0; SCHRECKER AW, 1974, CANCER RES, V34, P286; SCHRECKER AW, 1972, CANCER RES, V32, P1547; SMITH RG, 1975, J BIOL CHEM, V250, P1702; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Ting R C, 1975, Bibl Haematol, P693; TING RC, 1972, NATURE-NEW BIOL, V236, P163, DOI 10.1038/newbio236163a0; TING RC, 1973, COMP LEUKEMIA RES, P693; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1981, NATURE, V294, P273, DOI 10.1038/294273a0; YANG SS, 1972, J NATL CANCER I, V49, P7	43	89	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					5926	5930		10.1038/sj.onc.1208980	http://dx.doi.org/10.1038/sj.onc.1208980			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155599				2022-12-28	WOS:000231623400002
J	Lairmore, MD; Silverman, L; Ratner, L				Lairmore, MD; Silverman, L; Ratner, L			Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation	ONCOGENE			English	Review						HTLV-1; animal models; leukemia; lymphoma	CELL LEUKEMIA-VIRUS; MONKEYS SAIMIRI-SCIUREUS; I-ASSOCIATED MYELOPATHY; COMBINED IMMUNODEFICIENT MICE; TROPICAL SPASTIC PARAPARESIS; TAX-TRANSGENIC MICE; NF-KAPPA-B; CHRONIC PROGRESSIVE MYELONEUROPATHY; RESEMBLING RHEUMATOID-ARTHRITIS; PROTEASOME INHIBITOR PS-341	Over the past 25 years, animal models of human T-lymphotropic virus type 1 (HTLV-1) infection and transformation have provided critical knowledge about viral and host factors in adult T-cell leukemia/ lymphoma (ATL). The virus consistently infects rabbits, some non-human primates, and to a lesser extent rats. In addition to providing fundamental concepts in viral transmission and immune responses against HTLV- 1 infection, these models have provided new information about the role of viral proteins in carcinogenesis. Mice and rats, in particular immuno-deficient strains, are useful models to assess immunologic parameters mediating tumor outgrowth and therapeutic invention strategies against lymphoma. Genetically altered mice including both transgenic and knockout mice offer important models to test the role of specific viral and host genes in the development of HTLV-1-associated lymphoma. Novel approaches in genetic manipulation of both HTLV-1 and animal models are available to address the complex questions that remain about viral-mediated mechanisms of cell transformation and disease. Current progress in the understanding of the molecular events of HTLV-1 infection and transformation suggests that answers to these questions are approachable using animal models of HTLV-1-associated lymphoma.	Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; Washington Univ, Sch Med, Dept Med Pathl & Mol Microbiol, Div Biol & Biol Sci, St Louis, MO 63110 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Washington University (WUSTL)	Lairmore, MD (corresponding author), Ohio State Univ, Ctr Retrovirus Res, 1925 Coffey Rd, Columbus, OH 43210 USA.	lairmore.1@osu.edu		Ratner, Lee/0000-0003-2744-7294	NCI NIH HHS [P01 CA100730-02, P01 CA100730-069003, P01 CA100730-03, CA-100730, T32 CA009338, CA-70529, P01 CA100730, CA-09338] Funding Source: Medline; NCRR NIH HHS [R01 RR014324, RR-14324, T32 RR007073-07, R01 RR014324-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009338, P01CA100730] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014324, T32RR007073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKAGI T, 1985, JPN J CANCER RES, V76, P86; Akari H, 1997, VACCINE, V15, P1391, DOI 10.1016/S0264-410X(97)00055-8; Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7; Asquith B, 2000, PHILOS T ROY SOC B, V355, P1013, DOI 10.1098/rstb.2000.0638; Bangham CRM, 2003, INT J HEMATOL, V78, P297, DOI 10.1007/BF02983553; Bangham CRM, 2000, J CLIN PATHOL, V53, P581, DOI 10.1136/jcp.53.8.581; Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; Beilke MA, 1996, ARTHRITIS RHEUM, V39, P610, DOI 10.1002/art.1780390410; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CHEN YMA, 1991, J IMMUNOL, V147, P2368; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; CIMINALE V, 1995, VIROLOGY, V209, P445, DOI 10.1006/viro.1995.1277; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; COCKERELL GL, 1990, INT J CANCER, V45, P127, DOI 10.1002/ijc.2910450123; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Collins ND, 1996, J VIROL, V70, P7241, DOI 10.1128/JVI.70.10.7241-7246.1996; Conrad S F, 1995, Biomed Pept Proteins Nucleic Acids, V1, P83; D'Agostino DM, 2000, AIDS RES HUM RETROV, V16, P1765, DOI 10.1089/08892220050193281; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128/JVI.77.9.5286-5294.2003; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Etoh K, 1997, CANCER RES, V57, P4862; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Feng RQ, 1999, JPN J CANCER RES, V90, P48, DOI 10.1111/j.1349-7006.1999.tb00664.x; Feng RQ, 2001, JPN J CANCER RES, V92, P410, DOI 10.1111/j.1349-7006.2001.tb01110.x; FEUER G, 1993, BLOOD, V82, P722; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Frangione-Beebe M, 2000, VACCINE, V19, P1068, DOI 10.1016/S0264-410X(00)00340-6; Fujisawa K, 1996, J CLIN INVEST, V98, P271, DOI 10.1172/JCI118789; Furuta RA, 2002, J VIROL, V76, P2703, DOI 10.1128/JVI.76.6.2703-2713.2002; Furuya T, 1999, J NEUROIMMUNOL, V95, P185, DOI 10.1016/S0165-5728(98)00263-X; Gabet AS, 2003, INT J CANCER, V107, P74, DOI 10.1002/ijc.11329; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Gessain A, 1996, ADV VIRUS RES, V47, P377, DOI 10.1016/S0065-3527(08)60740-X; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Grossman WJ, 1997, BLOOD, V90, P783, DOI 10.1182/blood.V90.2.783.783_783_794; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hakata Y, 2001, J VIROL, V75, P11515, DOI 10.1128/JVI.75.23.11515-11525.2001; Hall AP, 1998, J PATHOL, V186, P209; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hasegawa A, 2003, J VIROL, V77, P2956, DOI 10.1128/JVI.77.5.2956-2963.2003; HIROSE S, 1988, VIROLOGY, V162, P487, DOI 10.1016/0042-6822(88)90492-8; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOMMA T, 1984, SCIENCE, V225, P716, DOI 10.1126/science.6087453; Horn F, 2000, IMMUNOBIOLOGY, V202, P151, DOI 10.1016/S0171-2985(00)80061-3; IBRAHIM F, 1994, INT J CANCER, V58, P446, DOI 10.1002/ijc.2910580324; Ibuki K, 1997, J GEN VIROL, V78, P147, DOI 10.1099/0022-1317-78-1-147; Imada K, 1996, JPN J CANCER RES, V87, P887, DOI 10.1111/j.1349-7006.1996.tb02116.x; IMADA K, 1995, BLOOD, V86, P2350, DOI 10.1182/blood.V86.6.2350.bloodjournal8662350; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; ISHIHARA S, 1992, JPN J CANCER RES, V83, P320, DOI 10.1111/j.1349-7006.1992.tb00108.x; IWAHARA Y, 1990, INT J CANCER, V45, P980, DOI 10.1002/ijc.2910450534; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; IWAKURA Y, 1995, J IMMUNOL, V155, P1588; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kanki P J, 1985, Haematol Blood Transfus, V29, P345; Kannagi M, 2000, AIDS RES HUM RETROV, V16, P1737, DOI 10.1089/08892220050193236; Kasai T, 1999, ACTA NEUROPATHOL, V97, P107, DOI 10.1007/s004010050962; KATAOKA R, 1990, BLOOD, V76, P1657; Kato H, 1998, J VIROL, V72, P7289, DOI 10.1128/JVI.72.9.7289-7293.1998; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2001, J VIROL, V75, P5939, DOI 10.1128/JVI.75.13.5939-5948.2001; Kazanji M, 2000, AIDS RES HUM RETROV, V16, P1741, DOI 10.1089/08892220050193245; Kazanji M, 2000, J VIROL, V74, P4860, DOI 10.1128/JVI.74.10.4860-4867.2000; Kehn K, 2004, FRONT BIOSCI-LANDMRK, V9, P2347, DOI 10.2741/1401; Kim SJ, 2003, J BIOL CHEM, V278, P15550, DOI 10.1074/jbc.M210210200; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; Kimzey AL, 1999, J BIOL CHEM, V274, P34226, DOI 10.1074/jbc.274.48.34226; Kindt TJ, 2000, MICROBES INFECT, V2, P1139, DOI 10.1016/S1286-4579(00)01268-5; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KONDO A, 1993, BLOOD, V82, P2501; KONDO T, 1989, INT J CANCER, V43, P1061, DOI 10.1002/ijc.2910430618; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; KOTANI S, 1986, INT J CANCER, V37, P843, DOI 10.1002/ijc.2910370608; KUSHIDA S, 1993, JPN J CANCER RES, V84, P831, DOI 10.1111/j.1349-7006.1993.tb02052.x; Kushida Shigeki, 1997, Leukemia (Basingstoke), V11, P260; LAIRMORE MD, 1992, INT J CANCER, V50, P124, DOI 10.1002/ijc.2910500125; LAL RB, 1991, J GEN VIROL, V72, P2321, DOI 10.1099/0022-1317-72-9-2321; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Liu YX, 2002, LEUKEMIA RES, V26, P561, DOI 10.1016/S0145-2126(01)00169-2; Mahieux R, 2000, AIDS RES HUM RETROV, V16, P1677, DOI 10.1089/08892220050193137; McGinn TM, 2002, VIROLOGY, V304, P364, DOI 10.1006/viro.2002.1705; Michael Bindhu, 2004, Retrovirology, V1, P39, DOI 10.1186/1742-4690-1-39; Mitra-Kaushik S, 2004, BLOOD, V104, P3305, DOI 10.1182/blood-2004-01-0266; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Miyoshi I, 1984, Princess Takamatsu Symp, V15, P121; MIYOSHI I, 1985, INT J CANCER, V35, P81, DOI 10.1002/ijc.2910350113; MIYOSHI I, 1992, LEUKEMIA, V6, P24; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; Murata N, 1996, LEUKEMIA, V10, P1971; NAKAMURA H, 1987, INT J CANCER, V40, P403, DOI 10.1002/ijc.2910400320; NAKAMURA H, 1986, INT J CANCER, V38, P867, DOI 10.1002/ijc.2910380614; NERENBERG MI, 1990, CURR TOP MICROBIOL, V160, P121; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nitta T, 2003, BIOCHEM BIOPH RES CO, V309, P161, DOI 10.1016/S0006-291X(03)01543-2; Nomura M, 2004, J VIROL, V78, P3827, DOI 10.1128/JVI.78.8.3827-3836.2004; OGAWA K, 1989, LEUKEMIA RES, V13, P399, DOI 10.1016/0145-2126(89)90080-5; Ohashi T, 1999, J VIROL, V73, P6031, DOI 10.1128/JVI.73.7.6031-6040.1999; OHSUGI T, 1994, J VET MED SCI, V56, P601, DOI 10.1292/jvms.56.601; Ohsugi T, 2004, LAB INVEST, V84, P263, DOI 10.1038/labinvest.3700034; Ohya O, 2000, APMIS, V108, P459, DOI 10.1034/j.1600-0463.2000.d01-83.x; Ohya Osamu, 1997, Leukemia (Basingstoke), V11, P255; OSAME M, 1990, ANN NEUROL, V28, P50, DOI 10.1002/ana.410280110; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; Richard V, 2001, AM J PATHOL, V158, P2219, DOI 10.1016/S0002-9440(10)64694-9; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; SAWADA T, 1991, J INFECT DIS, V164, P1193, DOI 10.1093/infdis/164.6.1193; Scholz C, 1996, J NEUROSCI RES, V45, P786; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SETO A, 1988, JPN J CANCER RES, V79, P335, DOI 10.1111/j.1349-7006.1988.tb01596.x; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128/JVI.78.8.3837-3845.2004; Simpson RM, 1996, J INFECT DIS, V173, P722, DOI 10.1093/infdis/173.3.722; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Stewart SA, 1996, VIROLOGY, V226, P167, DOI 10.1006/viro.1996.0643; SUGA T, 1991, INT J CANCER, V49, P764, DOI 10.1002/ijc.2910490522; Sun B, 1999, J NEUROL SCI, V167, P16, DOI 10.1016/S0022-510X(99)00128-8; Sundaram R, 2004, J BIOL CHEM, V279, P24141, DOI 10.1074/jbc.M313210200; TAGUCHI H, 1993, LAB INVEST, V69, P336; TAKEHARA N, 1989, INT J CANCER, V44, P332, DOI 10.1002/ijc.2910440224; Takemura T, 2002, J VIROL, V76, P1642, DOI 10.1128/JVI.76.4.1642-1648.2002; Tan C, 2002, CANCER RES, V62, P1083; Tanaka M, 2001, J VIROL, V75, P4420, DOI 10.1128/JVI.75.9.4420-4423.2001; TANAKA Y, 1991, J IMMUNOL, V147, P354; TANAKA Y, 1994, J VIROL, V68, P6323, DOI 10.1128/JVI.68.10.6323-6331.1994; Tomaru U, 2003, J NEUROVIROL, V9, P530, DOI 10.1080/13550280390241160; Trovato R, 1999, J VIROL, V73, P6460, DOI 10.1128/JVI.73.8.6460-6467.1999; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Tsuruma T, 1996, ARTIF ORGANS, V20, P895, DOI 10.1111/j.1525-1594.1996.tb04565.x; Uchiyama T, 1996, J CLIN IMMUNOL, V16, P305, DOI 10.1007/BF01541665; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; UEMURA Y, 1986, JPN J CANCER RES, V77, P970; UEMURA Y, 1987, BLOOD, V69, P1255; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Wilks R, 1996, INT J CANCER, V65, P272, DOI 10.1002/(SICI)1097-0215(19960117)65:2<272::AID-IJC23>3.0.CO;2-E; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; YAMAGUCHI K, 1993, CLIN HAEMATOL, V6, P899; YAMAMOTO H, 1993, ARTHRITIS RHEUM-US, V36, P1612, DOI 10.1002/art.1780361117; YAMAMOTO N, 1984, MED MICROBIOL IMMUN, V173, P57, DOI 10.1007/BF02123570; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshiki T, 1995, INTERVIROLOGY, V38, P229, DOI 10.1159/000150437; Yoshiki Takahashi, 1997, Leukemia (Basingstoke), V11, P245; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang ML, 2005, BLOOD, V105, P1231, DOI 10.1182/blood-2004-05-1709; Zhang ML, 2002, BLOOD, V100, P208, DOI 10.1182/blood-2002-01-0107; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000; Zhang Z, 2003, CANCER RES, V63, P6453; Zhang Z, 2003, BLOOD, V102, P284, DOI 10.1182/blood-2002-11-3601; ZHAO TM, 1995, J VIROL, V69, P2024, DOI 10.1128/JVI.69.4.2024-2030.1995; ZHAO TM, 1993, VIROLOGY, V195, P271, DOI 10.1006/viro.1993.1373; Zhao TM, 2002, AIDS RES HUM RETROV, V18, P253, DOI 10.1089/088922202753472829	177	55	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6005	6015		10.1038/sj.onc.1208974	http://dx.doi.org/10.1038/sj.onc.1208974			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155607	Bronze, Green Accepted			2022-12-28	WOS:000231623400010
J	Proietti, FA; Carneiro-Proietti, ABF; Catalan-Soares, BC; Murphy, EL				Proietti, FA; Carneiro-Proietti, ABF; Catalan-Soares, BC; Murphy, EL			Global epidemiology of HTLV-I infection and associated diseases	ONCOGENE			English	Review						HTLV-I; epidemiology; transmission; geographic distribution	VIRUS TYPE-I; T-LYMPHOTROPIC VIRUS; CELL LEUKEMIA-VIRUS; TROPICAL SPASTIC PARAPARESIS; INTRAVENOUS-DRUG-USERS; BLOOD-DONORS; RISK-FACTORS; PROVIRAL LOAD; RHEUMATOID-ARTHRITIS; SEXUAL TRANSMISSION	Epidemiologic aspects of human T-lymphotropic virus type I (HTLV-I) infection have been thoroughly studied over the course of approximately 25 years since its first description. The geographic distribution of the virus has been defined, with Japan, Africa, Caribbean islands and South America emerging as the areas of highest prevalence. The reasons for HTLV-I clustering, such as the high ubiquity in southwestern Japan but low prevalence in neighboring regions of Korea, China and eastern Russia are still unknown. The major modes of transmission are well understood, although better quantitative data on the incidence of transmission, and on promoting/inhibiting factors, are needed. Epidemiologic proof has been obtained for HTLV-I's causative role in major disease associations: adult T-cell leukemia (ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-associated uveitis and infective dermatitis. However, more and better studies are needed for other apparent disease outcomes such as rheumatologic, psychiatric and infectious diseases. Since curative treatment of ATL and HAM/TSP is lacking and a vaccine is unavailable, the social and financial cost for the individual, his/her family and the health system is immense. For this reason, public health interventions aimed at counseling and educating high-risk individuals and populations are of paramount importance.	Univ Fed Minas Gerais, Sch Med, Dept Social & Prevent Med, BR-30130100 Belo Horizonte, MG, Brazil; Minas Gerais State Blood Ctr, Fdn Hemominas, BR-30130110 Belo Horizonte, MG, Brazil; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Blood Syst Res Inst, San Francisco, CA 94118 USA	Universidade Federal de Minas Gerais; University of California System; University of California San Francisco; Vitalant; Vitalant Research Institute	Proietti, FA (corresponding author), Univ Fed Minas Gerais, Sch Med, Dept Social & Prevent Med, Ave Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil.	proietti@medicina.ufmg.br						Andersson S, 1997, J ACQ IMMUN DEF SYND, V15, P320, DOI 10.1097/00042560-199708010-00014; Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0; Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; Bartholomew C, 1998, J Hum Virol, V1, P302; BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2604, DOI 10.1001/jama.257.19.2604; BEILKE MA, 1991, J MED VIROL, V33, P64, DOI 10.1002/jmv.1890330113; Beilke MA, 1996, ARTHRITIS RHEUM, V39, P610, DOI 10.1002/art.1780390410; Belza MJ, 2004, EUR J EPIDEMIOL, V19, P279, DOI 10.1023/B:EJEP.0000020443.29480.d0; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; Bittencourt AL, 2001, J ACQ IMMUN DEF SYND, V26, P490, DOI 10.1097/00126334-200104150-00016; BLATTNER WA, 1986, P NATL ACAD SCI USA, V83, P4895, DOI 10.1073/pnas.83.13.4895; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; Carneiro-Proietti ABF, 2002, J BIOMED SCI, V9, P587, DOI 10.1007/BF02254986; Castillo LC, 2000, ACTA NEUROL SCAND, V101, P405, DOI 10.1034/j.1600-0404.2000.80180.x; Catalan-Soares B, 2004, REV PANAM SALUD PUBL, V16, P387, DOI 10.1590/S1020-49892004001200004; CATOVSKY D, 1982, LANCET, V1, P639; CHAVANCE M, 1990, AM J EPIDEMIOL, V131, P395, DOI 10.1093/oxfordjournals.aje.a115514; Chiavetta JA, 2003, CAN MED ASSOC J, V169, P767; COUROUCE AM, 1993, AIDS, V7, P841, DOI 10.1097/00002030-199306000-00013; CRUICKSHANK E K, 1956, West Indian Med J, V5, P147; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; DeVita DA, 2003, AIDS RES HUM RETROV, V19, pS46; DONEGAN E, 1990, ANN INTERN MED, V113, P555, DOI 10.7326/0003-4819-113-7-555; DUMAS M, 1991, AIDS RES HUM RETROV, V7, P447, DOI 10.1089/aid.1991.7.447; Eguchi K, 1996, ARTHRITIS RHEUM, V39, P463, DOI 10.1002/art.1780390314; EGUCHI K, 1992, ANN RHEUM DIS, V51, P673, DOI 10.1136/ard.51.5.673; EHRLICH GD, 1992, VIROLOGY, V186, P619, DOI 10.1016/0042-6822(92)90028-N; EHRLICH GD, 1988, CLIN LAB MED, V8, P65, DOI 10.1016/S0272-2712(18)30698-X; Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996; Etzel A, 2001, J ACQ IMMUN DEF SYND, V26, P185, DOI 10.1097/00126334-200102010-00015; FEIGAL E, 1991, J INFECT DIS, V164, P36, DOI 10.1093/infdis/164.1.36; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; Figueroa JP, 1997, J ACQ IMMUN DEF SYND, V15, P232, DOI 10.1097/00042560-199707010-00007; Fouchard N, 1998, LEUKEMIA, V12, P578, DOI 10.1038/sj.leu.2400956; Freitas V, 1997, ARQ NEURO-PSIQUIAT, V55, P325, DOI 10.1590/S0004-282X1997000200024; Fujino T, 1999, OBSTET GYNECOL, V94, P279, DOI 10.1016/S0029-7844(99)00322-1; Fujino T, 2000, J REPROD IMMUNOL, V47, P197, DOI 10.1016/S0165-0378(00)00054-1; FUJIYOSHI F, 1995, INT J CANCER, V63, P510, DOI 10.1002/ijc.2910630409; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; GALLO RC, 1973, AM J CLIN PATHOL, V60, P80; GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x; Gastaldello R, 2004, JAIDS-J ACQ IMM DEF, V35, P301, DOI 10.1097/00126334-200403010-00012; GERARD Y, 1995, INT J CANCER, V60, P773, DOI 10.1002/ijc.2910600607; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; Gessain A, 1996, J ACQ IMMUN DEF SYND, V13, pS228, DOI 10.1097/00042560-199600001-00034; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1988, J INFECT DIS, V157, P1226, DOI 10.1093/infdis/157.6.1226; GESSAIN A, 1991, P NATL ACAD SCI USA, V88, P7694, DOI 10.1073/pnas.88.17.7694; GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361; Goncalves DU, 1999, INT J STD AIDS, V10, P336, DOI 10.1258/0956462991914078; GOTO K, 1994, JPN J OPHTHALMOL, V38, P175; GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607; Guiltinan AM, 1998, TRANSFUSION, V38, P1056, DOI 10.1046/j.1537-2995.1998.38111299056317.x; HANCHARD B, 1990, HUMAN RETROVIROLOGY : HTLV, P173; Hanchard B, 1996, J ACQ IMMUN DEF SYND, V13, pS20, DOI 10.1097/00042560-199600001-00005; Hayashi J, 1997, AM J TROP MED HYG, V56, P71, DOI 10.4269/ajtmh.1997.56.71; Hino Shigeo, 1997, Leukemia (Basingstoke), V11, P57; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561; IANNONE R, 1992, J ACQ IMMUN DEF SYND, V5, P810; IJICHI S, 1990, ANN RHEUM DIS, V49, P718, DOI 10.1136/ard.49.9.718; INOSE M, 1992, J NEUROL SCI, V110, P73, DOI 10.1016/0022-510X(92)90012-A; Ishak Ricardo, 2003, Cad. Saúde Pública, V19, P901; Ishikawa T, 2003, INT J HEMATOL, V78, P304, DOI 10.1007/BF02983554; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; IWASAKI Y, 1990, J NEUROL SCI, V96, P103, DOI 10.1016/0022-510X(90)90060-Z; Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848; KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851; Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014; Kasahata N, 2000, No To Shinkei, V52, P1003; Kawai H, 1989, Rinsho Shinkeigaku, V29, P588; KAWAI H, 1992, J MED VIROL, V38, P138, DOI 10.1002/jmv.1890380212; Kazanji Mirdad, 2003, Cad. Saúde Pública, V19, P1227, DOI 10.1590/S0102-311X2003000500002; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; Kimura I, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P787; KINOSHITA K, 1984, GANN, V75, P103; KORALNIK IJ, 1994, J VIROL, V68, P2693, DOI 10.1128/JVI.68.4.2693-2707.1994; KRAMER A, 1995, AM J EPIDEMIOL, V142, P1212; LAGRENADE L, 1990, LANCET, V336, P1345; LaGrenade L, 1996, J ACQ IMMUN DEF SYND, V13, pS46, DOI 10.1097/00042560-199600001-00009; Larsen O, 2000, J ACQ IMMUN DEF SYND, V25, P157, DOI 10.1097/00126334-200010010-00010; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE HH, 1990, J INFECT DIS, V162, P347, DOI 10.1093/infdis/162.2.347; LEHKY TJ, 1995, ANN NEUROL, V37, P167, DOI 10.1002/ana.410370206; León Graciela, 2003, Rev Panam Salud Publica, V13, P117, DOI 10.1590/S1020-49892003000200012; Li H, 2003, AIDS RES HUM RETROV, V19, pS31; Liu H, 2001, VIROLOGY, V279, P90, DOI 10.1006/viro.2000.0632; Mahieux R, 2000, J CLIN MICROBIOL, V38, P4049, DOI 10.1128/JCM.38.11.4049-4057.2000; Mahieux R, 1997, J VIROL, V71, P6253, DOI 10.1128/JVI.71.8.6253-6258.1997; Maloney EM, 1998, J ACQ IMMUN DEF SYND, V17, P167, DOI 10.1097/00042560-199802010-00011; MALONEY EM, 1991, AM J EPIDEMIOL, V133, P1125, DOI 10.1093/oxfordjournals.aje.a115825; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4; MANNS A, 1991, TRANSFUSION, V31, P67, DOI 10.1046/j.1537-2995.1991.31191096189.x; Marsh BJ, 1996, CLIN INFECT DIS, V23, P138, DOI 10.1093/clinids/23.1.138; MATHIEUX R, 2003, REV CLIN EXP HEMATOL, V7, P336; MATUTES E, 1994, LEUKEMIA, V8, P1092; Mauclere P, 1997, J INFECT DIS, V176, P505, DOI 10.1086/514071; Mbanya DN, 2003, TRANSFUSION MED, V13, P267, DOI 10.1046/j.1365-3148.2003.00453.x; McCallum RM, 1997, MED CLIN N AM, V81, P261, DOI 10.1016/S0025-7125(05)70514-9; MCKHANN G, 1989, J INFECT DIS, V160, P371, DOI 10.1093/infdis/160.3.371; MILLER GJ, 1994, J INFECT DIS, V170, P44, DOI 10.1093/infdis/170.1.44; MILLER GJ, 1986, INT J CANCER, V38, P801, DOI 10.1002/ijc.2910380604; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MIYOSHI I, 1981, CANCER GENET CYTOGEN, V3, P251, DOI 10.1016/0165-4608(81)90092-3; MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943; MUELLER N, 1991, CANCER CAUSE CONTROL, V2, P37, DOI 10.1007/BF00052359; Mueller PR, 1996, SEMIN INTERVENT RAD, V13, P1, DOI 10.1055/s-2008-1057886; Mufti GJ, 1998, BRIT J HAEMATOL, V100, P453, DOI 10.1046/j.1365-2141.1998.00582.x; Murphy EL, 1998, VIROLOGY, V242, P425, DOI 10.1006/viro.1997.9009; Murphy EL, 2004, J INFECT DIS, V190, P504, DOI 10.1086/422398; Murphy EL, 2004, EMERG INFECT DIS, V10, P109, DOI 10.3201/eid1001.020714; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; Murphy EL, 1996, INT J EPIDEMIOL, V25, P1083, DOI 10.1093/ije/25.5.1083; Murphy EL, 1999, J INFECT DIS, V180, P1777, DOI 10.1086/315139; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; Nakane S, 2000, J NEUROVIROL, V6, P275, DOI 10.3109/13550280009030753; NAKASHIMA K, 1995, AM J EPIDEMIOL, V141, P305, DOI 10.1093/aje/141.4.305; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Ono A, 1998, JPN J CANCER RES, V89, P608, DOI 10.1111/j.1349-7006.1998.tb03262.x; Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA; OSAME M, 1986, LANCET, V1, P1031; OSAME M, 1986, LANCET, V2, P104; PASSOS VMA, 1998, CAD SAUDE PUBL, V14, P109; PINHEIRO S, 1990, J ACQ IMMUN DEF SYND, V20, pA67; Pinheiro S R, 1996, Rev Soc Bras Med Trop, V29, P383, DOI 10.1590/S0037-86821996000400014; PINHEIRO SRAA, 1995, ARQ NEURO-PSIQUIAT, V53, P777, DOI 10.1590/S0004-282X1995000500011; Plancoulaine S, 2000, J INFECT DIS, V182, P405, DOI 10.1086/315741; Poiesz BJ, 2003, CANCER INVEST, V21, P253, DOI 10.1081/CNV-120016422; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pombo-de-Oliveira MS, 2001, LEUKEMIA LYMPHOMA, V42, P135, DOI 10.3109/10428190109097685; POMBODEOLIVEIRA MS, 1998, INT J CANCER, V83, P291; Pouliquen JF, 2004, J CLIN MICROBIOL, V42, P2020, DOI 10.1128/JCM.42.5.2020-2026.2004; Price J, 2001, VOX SANG, V80, P148, DOI 10.1046/j.1423-0410.2001.00030.x; Quintas S, 2004, REV NEUROLOGIA, V39, P1133, DOI 10.33588/rn.3912.2003611; RODGERS P E, 1965, West Indian Med J, V14, P36; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; Roucoux DF, 2005, J INFECT DIS, V191, P1490, DOI 10.1086/429410; Sanchez-Palacios C., 2003, International Journal of Infectious Diseases, V7, P132, DOI 10.1016/S1201-9712(03)90009-9; Sarkodie F, 2001, VOX SANG, V80, P142, DOI 10.1046/j.1423-0410.2001.00023.x; Satoh M, 2002, ONCOGENE, V21, P2466, DOI 10.1038/sj.onc.1205329; Schreiber GB, 1997, J ACQ IMMUN DEF SYND, V14, P263, DOI 10.1097/00042560-199703010-00011; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SHERMAN MP, 1992, J VIROL, V66, P2556, DOI 10.1128/JVI.66.4.2556-2563.1992; SHIMAMOTO Y, 1992, LEUKEMIA LYMPHOMA, V7, P37, DOI 10.3109/10428199209053600; Slattery JP, 1999, GENOME RES, V9, P525; Soares BC, 2003, REV SAUDE PUBL, V37, P470, DOI 10.1590/S0034-89102003000400012; SONODA S, 1990, HUMAN RETROVIROLOGY : HTLV, P315; SOWA JM, 1992, J RHEUMATOL, V19, P316; Stigum H, 2000, INT J EPIDEMIOL, V29, P1076, DOI 10.1093/ije/29.6.1076; STUVER SO, 1993, J INFECT DIS, V167, P57, DOI 10.1093/infdis/167.1.57; Sugaya T, 2002, EXP MOL PATHOL, V72, P56, DOI 10.1006/exmp.2001.2415; Takahashi Y, 1996, AM J PERINAT, V13, P15, DOI 10.1055/s-2007-994195; TAKATSUKI K, 1985, CANCER RES, V45, P4644; TAKATSUKI K, 1985, CURR TOP MICROBIOL, V115, P89; Takenouchi N, 2003, J NEUROVIROL, V9, P29, DOI 10.1080/13550280390173418; Taylor A, 1996, ENVIRON HIST, V1, P6, DOI 10.2307/3985275; Taylor GP, 2005, JAIDS-J ACQ IMM DEF, V38, P104, DOI 10.1097/00126334-200501010-00018; TKATSUKI K, 1977, TOPICS HEMATOLOGY, P73; Tseliou PM, 2003, TRANSFUSION, V43, P1641, DOI 10.1046/j.1537-2995.2003.00569.x; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Ureta-Vidal A, 1999, INT J CANCER, V82, P832, DOI 10.1002/(SICI)1097-0215(19990909)82:6&lt;832::AID-IJC11&gt;3.0.CO;2-P; USUKU K, 1988, ANN NEUROL, V23, pS143, DOI 10.1002/ana.410230733; VANDAMME AM, 1994, VIROLOGY, V202, P212, DOI 10.1006/viro.1994.1337; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Wilks R, 1996, INT J CANCER, V65, P272, DOI 10.1002/(SICI)1097-0215(19960117)65:2<272::AID-IJC23>3.0.CO;2-E; WILLIAMS AE, 1988, SCIENCE, V240, P643, DOI 10.1126/science.2896386; Yakova Maria, 2005, Retrovirology, V2, P4, DOI 10.1186/1742-4690-2-4; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; Yamaguchi K, 2002, INT J HEMATOL, V76, P240, DOI 10.1007/BF03165123; YAMAGUCHI K, 1994, LANCET, V343, P213, DOI 10.1016/S0140-6736(94)90994-6; Yamamoto JH, 1999, ARCH OPHTHALMOL-CHIC, V117, P513, DOI 10.1001/archopht.117.4.513; YANAGIHARA R, 1995, CELL MOL BIOL, V41, pS145; Yashiki S, 2001, AIDS RES HUM RETROV, V17, P1047, DOI 10.1089/088922201300343735; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	176	646	675	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6058	6068		10.1038/sj.onc.1208968	http://dx.doi.org/10.1038/sj.onc.1208968			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155612				2022-12-28	WOS:000231623400015
J	Stabach, PR; Thiyagarajan, MM; Woodfield, GW; Weigel, RJ				Stabach, PR; Thiyagarajan, MM; Woodfield, GW; Weigel, RJ			AP2 alpha alters the transcriptional activity and stability of p53	ONCOGENE			English	Article						AP2 alpha; AP-2; p53; transcription; stability; p21	INVASIVE BREAST-CANCER; APOPTOTIC CELL-DEATH; FACTOR AP-2; GENE PROMOTER; ESTROGEN-RECEPTOR; MAMMARY-CARCINOMA; EPITHELIAL-CELLS; DOWN-REGULATION; RETINOIC ACID; BINDING-SITE	AP2 alpha and p53 form nuclear complexes that establish a functional partnership, which regulates the expression of certain genes involved in cell growth and metastasis. The growth effects of AP2 alpha are mediated through p21(WAF1/CIP1) and the ability for AP2 alpha to coactivate p21 requires p53. Herein, we have localized the AP2-binding region of p53 to amino acids 305-375. Analysis of 26 distinct p53 alleles established a correlation between AP2a binding and transcriptional coactivation. The L350P point mutation was the only nonbinding allele that retained normal transcriptional activity by reporter assay. Although both wild-type and L350P alleles facilitated binding of AP2 alpha to the p21 promoter, the L350P allele was significantly reduced in its ability to induce the endogenous p21 gene, demonstrating a striking difference in activity comparing reporter assays with activation of endogenous p53 target genes. Interestingly, expression of AP2 in the absence of radiation repressed p53-mediated induction of p21 and this effect was explained by a reduction in p53 stability induced by AP2 alpha overexpression. We conclude that AP2 alpha has competing effects on p53 activity through coactivation and decreased stability. These findings may provide a mechanism to account for the discrepancies reported for the association between AP2 and p21 expression in tumor tissue.	Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	University of Iowa; Jefferson University	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,Room 1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu		Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA77350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttila MA, 2000, BRIT J CANCER, V82, P1974; ASTROM A, 1992, J BIOL CHEM, V267, P25251; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Brokx RD, 2003, J BIOL CHEM, V278, P2327, DOI 10.1074/jbc.M208528200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Katsel PL, 2001, J BIOL CHEM, V276, P752, DOI 10.1074/jbc.M007553200; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim HS, 2001, J NEUROCHEM, V76, P280, DOI 10.1046/j.1471-4159.2001.00044.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leung KM, 2002, CANCER RES, V62, P4890; Lipponen P, 2000, EUR UROL, V37, P573, DOI 10.1159/000020195; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214; REN Y, 2001, J BIOL CHEM, V13, P13; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Terui T, 2003, CANCER RES, V63, P8948; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	54	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2148	2159		10.1038/sj.onc.1209250	http://dx.doi.org/10.1038/sj.onc.1209250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288208				2022-12-28	WOS:000236581200002
J	Maeda, T; Desouky, J; Friedl, A				Maeda, T; Desouky, J; Friedl, A			Syndecan-1 expression by stromal. broblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis	ONCOGENE			English	Article						tumor stroma; breast carcinoma; syndecan-1; epithelial-stromal interactions; angiogenesis	HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; EPITHELIAL MESENCHYMAL INTERACTIONS; MULTIPLE-MYELOMA; BINDING; CANCER; RECEPTORS; MATRIX; FGF	The induction of the cell surface heparan sulfate proteoglycan syndecan-1 (Sdc1) in stromal fibroblasts is observed in more than 70% of human breast carcinomas. Using a coculture model, we have recently shown that stromal cell-derived Sdc1 stimulates carcinoma cell proliferation in vitro, and that this activity requires Sdc1 glycanation. In the present study, we investigated the effect of stromal cell Sdc1 on breast carcinoma growth in vivo. MDA-MB-231 human breast carcinoma cells were inoculated into the flanks of athymic nude mice either alone, or as mixed suspensions with Sdc1-transfected or mock-transfected 3T3 mouse fibroblasts. The mixed tumors showed an intimate association between carcinoma cells and stromal fibroblasts and histologically closely resembled poorly differentiated human breast carcinomas. The presence of fibroblasts led to significantly accelerated tumor growth, which was further augmented (88% increase) by forced expression of stromal Sdc1. The hyperemic macroscopic appearance of tumors containing Sdc1-positive stromal cells contrasted with pale tumors developing in the presence of mock-transfected fibroblasts, which prompted us to examine tumor microvessels. Stromal Sdc1 expression was associated with a significantly elevated microvessel density (36% increase) and a larger vessel area (153% increase). To evaluate the relevance of this finding in human breast cancer, the relationship between stromal Sdc1 and tumor vascularity was also examined in a tissue array containing 207 human breast carcinoma samples. Similar to the xenografts, stromal Sdc1 expression correlated with both vessel density (P = 0.013) and total vessel area (P = 0.0026). In conclusion, stromal fibroblast-derived Sdc1 stimulates breast carcinoma growth and angiogenesis in vivo.	Univ Wisconsin, Clin Sci Ctr K4812, Dept Pathol & Lab Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Clin Sci Ctr K4812, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA.	afriedl@wisc.edu			NATIONAL CANCER INSTITUTE [P30CA014520, R01CA107012] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA107012, CA14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Bayer-Garner IB, 2001, MODERN PATHOL, V14, P1052, DOI 10.1038/modpathol.3880435; Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Burbach BJ, 2004, EXP CELL RES, V300, P234, DOI 10.1016/j.yexcr.2004.07.001; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Friedl A, 2001, Methods Mol Biol, V171, P535; Ito Y, 2003, HISTOPATHOLOGY, V43, P157, DOI 10.1046/j.1365-2559.2003.01656.x; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Mennerich D, 2004, EUR J CANCER, V40, P1373, DOI 10.1016/j.ejca.2004.01.038; Mukunyadzi P, 2003, MODERN PATHOL, V16, P796, DOI 10.1097/01.MP.0000081731.17549.53; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Radisky D, 2002, CANCER INVEST, V20, P139, DOI 10.1081/CNV-120000374; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102; TESSLER S, 1994, J BIOL CHEM, V269, P12456; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Weaver VM, 2004, J CELL SCI, V117, P1287, DOI 10.1242/jcs.01137; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610	29	115	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1408	1412		10.1038/sj.onc.1209168	http://dx.doi.org/10.1038/sj.onc.1209168			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247452				2022-12-28	WOS:000235708200014
J	de Abajo, AS; de la Hoya, M; van Puijenbroek, M; Godino, J; Diaz- Rubio, E; Morreau, H; Caldes, T				de Abajo, AS; de la Hoya, M; van Puijenbroek, M; Godino, J; Diaz- Rubio, E; Morreau, H; Caldes, T			Dual role of LOH at MMR loci in hereditary non-polyposis colorectal cancer?	ONCOGENE			English	Article						LOH; HNPCC; MMR	MISMATCH REPAIR DEFICIENCY; HMLH1 PROMOTER; MICROSATELLITE INSTABILITY; COLON-CANCER; GERMLINE MUTATIONS; CELL-LINES; TUMORS; HYPERMETHYLATION; MLH1; INACTIVATION	hMLH1 and hMSH2 can be considered tumor suppressor genes, as both alleles must be inactivated in order to lose the mismatch repair (MMR) function. In this regard, it has been proposed that LOH at MMR loci is a common Knudson's second-hit mechanism in HNPCC patients. However, experimental evidence supporting this view is scarcely found in the literature. We have performed a comprehensive analysis of LOH in 45 HNPCC tumors carrying a germline alteration in MMR loci. Overall, we have detected LOH at MMR loci in 56% of the cases. However, up to 40% of the LOH events targeted the mutant allele, arguing against a second-hit role in these tumors. Interestingly, the age at diagnosis was significantly older in these patients. To explain this and previous data, we propose a dual role for LOH at MMR loci in HNPCC.	Hosp Clin San Carlos, Oncol Mol Lab, E-28040 Madrid, Spain; Leiden Univ Ctr, Dept Pathol, Leiden, Netherlands; Hosp Clin San Carlos, Dept Clin Oncol, Madrid, Spain	Hospital Clinico San Carlos; Leiden University; Leiden University - Excl LUMC; Hospital Clinico San Carlos	Caldes, T (corresponding author), Hosp Clin San Carlos, Oncol Mol Lab, Martin Lagos S-N, E-28040 Madrid, Spain.	tcaldes@hcsc.es	de la Hoya, MIguel/Z-2911-2019; Godino, Javier/M-3753-2018	Godino, Javier/0000-0002-5653-2722; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Ahuja N, 1998, CANCER RES, V58, P5489; Caldes T, 2002, INT J CANCER, V98, P774, DOI 10.1002/ijc.10240; Cunningham JM, 1998, CANCER RES, V58, P3455; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; de la Hoya M, 1999, CLIN CHEM, V45, P2028; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; Lynch HT, 1999, J MED GENET, V36, P801; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Osorio A, 2002, INT J CANCER, V99, P305, DOI 10.1002/ijc.10337; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968	24	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2124	2130		10.1038/sj.onc.1209233	http://dx.doi.org/10.1038/sj.onc.1209233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288214				2022-12-28	WOS:000236359700016
J	Radhakrishnan, SK; Gierut, J; Gartel, AL				Radhakrishnan, SK; Gierut, J; Gartel, AL			Multiple alternate p21 transcripts are regulated by p53 in human cells	ONCOGENE			English	Article						p21; alternate transcript; p53; basal transcription	CANCER CELLS; EXPRESSION; PUMA; P21(WAF1/CIP1); APOPTOSIS; STABILITY; MEDIATOR; PROMOTER; BINDING; GENE	The p53 tumor-suppressor is a transcription factor that is stabilized in response to cellular stress leading to growth arrest or apoptosis. p21(WAF1/CIP1) is a major transcriptional target of p53 and it plays a critical role in p53-dependent cell cycle arrest. In this study, we identified multiple alternate human p21 transcripts that have their transcriptional start sites in the direct proximity of the distal p53 response element. These transcripts are upregulated as a result of DNA damage-induced p53 activation. Furthermore, the basal expression of these alternate transcripts is strongly regulated by p53 and they are undetectable in p53-knocked down cells. This is in contrast to classical p21 transcripts, which have reduced, albeit detectable expression levels in the absence of p53. The existence of the alternate transcripts underscores the complexity of the human p21 genomic locus and opens up new avenues for further investigation.	Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498	NCI NIH HHS [CA91146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Chen B, 2000, CANCER RES, V60, P3290; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 2004, ONCOGENE, V23, P8154, DOI 10.1038/sj.onc.1207820; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	23	32	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1812	1815		10.1038/sj.onc.1209195	http://dx.doi.org/10.1038/sj.onc.1209195			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261158				2022-12-28	WOS:000236013700013
J	Lee, JY; Moon, HJ; Lee, WK; Chun, HJ; Han, CW; Jeon, YW; Lim, Y; Kim, YH; Yao, TP; Lee, KH; Jun, TY; Rha, HK; Kang, JK				Lee, JY; Moon, HJ; Lee, WK; Chun, HJ; Han, CW; Jeon, YW; Lim, Y; Kim, YH; Yao, TP; Lee, KH; Jun, TY; Rha, HK; Kang, JK			Merlin facilitates ubiquitination and degradation of transactivation-responsive RNA-binding protein	ONCOGENE			English	Article						Nf2; merlin; tarbp2; TRBP; ubiquitination; degradation	NF2 TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GROWTH SUPPRESSION; UNITED-KINGDOM; ERM PROTEINS; GENE-PRODUCT; KINASE PKR; PHOSPHORYLATION; DOMAIN; TRBP	The Nf2 tumor suppressor codes for merlin, a protein whose function is largely unknown. We have previously demonstrated a novel interaction between merlin and TRBP, which inhibits the oncogenic activity of TRBP. In spite of the significance of their functional interaction, its molecular mechanism still remains to be elucidated. In this report, we investigated how merlin inhibits the oncogenic activity of TRBP in association with cell growth conditions. In the human embryonic kidney 293 cell line, the level of endogenous merlin increased, whereas that of endogenous TRBP significantly decreased along with the increase in cell confluence. We demonstrated that the carboxyl-terminal region of TRBP was responsible for this phenomenon using stable cell lines expressing deletion mutants of TRBP. The overexpression of merlin decreased the protein level of TRBP, and the ubiquitin-like subdomain of merlin's FERM domain was important for this activity. We also demonstrated that TRBP is ubiquitinylated and the ubiquitinylated forms of TRBP are accumulated by ectopically expressed merlin or cell confluence in the presence of MG132, a proteasome inhibitor. Furthermore, we showed that the regulation of TRBP in response to cell confluence was abolished upon knockdown of merlin expression by specific small interfering RNA. Finally, we showed that ectopically expressed merlin restored cell-cell contact inhibition in cells stably expressing TRBP but not in TRBP Delta c. These results suggest that merlin is involved in the regulation of TRBP protein level by facilitating its ubiquitination in response to such cues as cell-cell contacts.	Catholic Univ Korea, Neurosci Gen Res Cr, Catholic Res Inst Med Sci, Socho Ku, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul, South Korea; Catholic Univ Korea, Dept Biomed Sci, Seoul, South Korea; Catholic Univ Korea, Dept Orthoped Surg, Seoul, South Korea; Catholic Univ Korea, Dept Psychiat, Seoul, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul, South Korea; Duke Univ, Durham, NC USA; Catholic Univ Korea, Dept Neurosurg, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Duke University; Catholic University of Korea	Kim, YH (corresponding author), Catholic Univ Korea, Neurosci Gen Res Cr, Catholic Res Inst Med Sci, Socho Ku, 4011,505 Banpo Dong, Seoul 137701, South Korea.	ngrc@catholic.ac.kr		Chun, Heung Jae/0000-0002-0446-9901				Bannwarth S, 2001, J BIOL CHEM, V276, P48803, DOI 10.1074/jbc.M104645200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Giovannini M, 2000, GENE DEV, V14, P1617; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lee JY, 2004, J BIOL CHEM, V279, P30265, DOI 10.1074/jbc.M312083200; Lee RB, 1996, IEEE MICRO, V16, P6, DOI 10.1109/MM.1996.526920; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	35	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1143	1152		10.1038/sj.onc.1209150	http://dx.doi.org/10.1038/sj.onc.1209150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247459				2022-12-28	WOS:000235537500002
J	Kondo, S; Kubota, S; Mukudai, Y; Moritani, N; Nishida, T; Matsushita, H; Matsumoto, S; Sugahara, T; Takigawa, M				Kondo, S; Kubota, S; Mukudai, Y; Moritani, N; Nishida, T; Matsushita, H; Matsumoto, S; Sugahara, T; Takigawa, M			Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3 '-untranslated region interacting with a cellular protein in human chondrosarcoma cells	ONCOGENE			English	Article						hypoxia; connective tissue growth factor; CCN family; mRNA stability; 3 '-UTR; post-transcriptional regulation	VASCULAR ENDOTHELIAL-CELLS; INDUCIBLE FACTOR-I; GENE-EXPRESSION; CTGF/HCS24 GENE; RICH SEQUENCE; BINDING; ANGIOGENESIS; IDENTIFICATION; ELEMENT; VITRO	Connective tissue growth factor (CTGF/CCN2) can be induced by various forms of stress such as exposure to high glucose, mechanical load, or hypoxia. Here, we investigated the molecular mechanism involved in the induction of ctgf/ccn2 by hypoxia in a human chondrosarcoma cell line, HCS-2/8. Hypoxia increased the ctgf/ccn2 mRNA level by altering the 3'-untranslated region (UTR)-mediated mRNA stability without requiring de novo protein synthesis. After a series of extensive analyses, we eventually found that the cis-repressive element of 84 bases within the 3'-UTR specifically bound to a cytoplasmic/nuclear protein. By conducting a UV crosslinking assay, we found the cytoplasmic/nuclear protein to be a 35 kDa molecule that bound to the cis-element in a hypoxia-inducible manner. These results suggest that a cis-element in the 3'-UTR of ctgf/ccn2 mRNA and trans-factor counterpart(s) play an important role in the post-transcriptional regulation by determining the stability of ctgf/ccn2 mRNA.	Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Biol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Oral & Maxillofacial Reconstruct Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan; Nichirei Corp, Biosci Business Div, Chuo Ku, Tokyo, Japan	Okayama University; Okayama University; Nichirei Corporation	Takigawa, M (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Biol, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	takigawa@md.okayama-u.ac.jp	Kondo, Seiji/ABD-3982-2020; Kondo, Seiji/I-4332-2017; Mukudai, Yoshiki/L-4459-2019	Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Mukudai, Yoshiki/0000-0002-9600-4430				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eguchi T, 2001, J BIOCHEM, V130, P79, DOI 10.1093/oxfordjournals.jbchem.a002965; FAN XC, 1998, P NATL ACAD SCI US, V95; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kubota S, 2000, ONCOGENE, V19, P4773, DOI 10.1038/sj.onc.1203835; Kubota S, 2005, FEBS LETT, V579, P3751, DOI 10.1016/j.febslet.2005.05.068; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; Kubota S, 2003, BONE, V33, P694, DOI 10.1016/S8756-3282(03)00227-8; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Kunz M, 2003, J BIOL CHEM, V278, P45651, DOI 10.1074/jbc.M301373200; KUNZ M, 2003, MOL CANCER, V2, P1, DOI DOI 10.1186/1476-4598-2-1.PUBMED:12537587; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Mukudai Y, 2005, J BIOL CHEM, V280, P3166, DOI 10.1074/jbc.M411632200; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Shih SC, 1998, INT J EXP PATHOL, V79, P347, DOI 10.1046/j.1365-2613.1998.00088.x; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; TAKIGAWA M, 1989, CANCER RES, V49, P3996; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	45	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1099	1110		10.1038/sj.onc.1209129	http://dx.doi.org/10.1038/sj.onc.1209129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247469				2022-12-28	WOS:000235361000014
J	Liu, F; Lei, W; O'Rourke, JP; Ness, SA				Liu, F; Lei, W; O'Rourke, JP; Ness, SA			Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb	ONCOGENE			English	Article						Myb oncogene; leukemia; hematopoiesis; differentiation; transformation	DNA-BINDING DOMAIN; V-MYB; GENE-EXPRESSION; DIFFERENTIATION; TRANSFORMATION; SPECIFICITY; PROMOTER; TARGET; TRANSACTIVATION; PRODUCT	The v-Myb oncoprotein encoded by Avian Myeloblastosis Virus is highly oncogenic, induces leukemias in chickens and mice and transforms immature hematopoietic cells in vitro. The v-Myb protein is a mutated and truncated version of c-Myb, a DNA-binding transcription factor expressed in many cell types that is essential for normal hematopoiesis. Previous studies suggested that two types of differences, DNA binding domain mutations and the deletion of a C-terminal negative regulatory domain were important for increasing the transforming activity of v-Myb. Here, we combined structure-function studies of the v-Myb and c-Myb proteins with unbiased microarray-based transcription assays to compare the transcriptional specificities of the two proteins. In human cells, the v-Myb and c-Myb proteins displayed strikingly different activities and regulated overlapping, but largely distinct sets of target genes. Each type of mutation that distinguished v-Myb from c-Myb, including the N- and C-terminal deletions, DNA binding domain changes and mutations in the transcriptional activation domain, affected different sets of target genes and contributed to the different activities of c-Myb and v-Myb. The results suggest that v-Myb is not just a de-repressed version of c-Myb. Instead, it is a distinct transcriptional regulator with a unique set of activities.	Univ New Mexico, HSC, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico	Ness, SA (corresponding author), Univ New Mexico, HSC, Dept Mol Genet & Microbiol, MSC08 4660, Albuquerque, NM 87131 USA.	ness@unm.edu	Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NATIONAL CANCER INSTITUTE [R01CA058443, P30CA118100] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58443, P30 CA118100, R01 CA058443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Butz NV, 2004, GENE, V342, P67, DOI 10.1016/j.gene.2004.07.024; Chayka O, 2005, MOL CELL BIOL, V25, P499, DOI 10.1128/MCB.25.1.499-511.2005; Chen XY, 2004, MOL CELL BIOL, V24, P10416, DOI 10.1128/MCB.24.23.10416-10424.2004; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Frykberg L, 1988, Oncogene Res, V3, P313; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GRASSER FA, 1992, ONCOGENE, V7, P1005; Hodges LC, 2003, MOL CANCER RES, V1, P300; Hou DX, 1997, FEBS LETT, V413, P60, DOI 10.1016/S0014-5793(97)00879-X; INOUE T, 1994, J BIOL CHEM, V269, P32451; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Lei WL, 2005, BLOOD, V105, P3855, DOI 10.1182/blood-2004-08-3342; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PLAZA S, 1995, ONCOGENE, V10, P329; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; SunHoffman L, 1996, ONCOGENE, V13, P1037; SZCZYLIK C, 1993, J EXP MED, V178, P997, DOI 10.1084/jem.178.3.997; Takahashi H, 2005, DEV GROWTH DIFFER, V47, P173; TANNO B, 2002, J BIOL CHEM, V24, P24; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAVALI S, 1991, ONCOGENE, V6, P887; Weston K M, 1990, Semin Cancer Biol, V1, P371; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383	43	37	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					795	805		10.1038/sj.onc.1209105	http://dx.doi.org/10.1038/sj.onc.1209105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205643				2022-12-28	WOS:000235068800014
J	Ndisang, D; Faulkes, DJ; Gascoyne, D; Lee, SA; Ripley, BJ; Sindos, M; Singer, A; Budhram-Mahadeo, V; Cason, J; Latchman, DS				Ndisang, D; Faulkes, DJ; Gascoyne, D; Lee, SA; Ripley, BJ; Sindos, M; Singer, A; Budhram-Mahadeo, V; Cason, J; Latchman, DS			Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a	ONCOGENE			English	Article						Brn-3a; HPV-16; cervical cancer; URR; E6	CERVICAL INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; ELEVATED EXPRESSION; BINDING-SITES; CANCER CELLS; FACTOR PLAYS; YOUNG-WOMEN; TYPE-16; PROMOTER; INFECTION	The Brn-3a POU family transcription factor is over-expressed in human cervical carcinoma biopsies and is able to activate expression of the human papilloma virus type 16 (HPV-16) upstream regulatory region ( URR), which drives the expression of the E6 and E7 oncoproteins. Inhibition of Brn-3a expression in human cervical cancer cells inhibits HPV gene expression and reduces cellular growth and anchorage independence in vitro as well as the ability to form tumours in vivo. Here, we show that Brn-3a differentially regulates different HPV-16 variants that have previously been shown to be associated with different risks of progression to cervical carcinoma. In human cervical material, Brn-3a levels correlate directly with HPV E6 levels in individuals infected with a high risk variant of HPV-16, whereas this is not the case for a low-risk variant. Moreover, the URRs of high- and intermediate-risk variants are activated by Brn-3a in transfection assays, whereas the URR of a low-risk variant is not. The change of one or two bases in a low-risk variant URR to their equivalent in a higher-risk URR can render the URR responsive to Brn-3a and vice versa. These results help explain why the specific interplay between viral and cellular factors necessary for the progression to cervical carcinoma only occurs in a minority of those infected with HPV-16.	UCL, Inst Child Hlth, Med Mol Biol Unit, London, England; Whittington Hosp, Dept Womens & Childrens Hlth, London N19 5NF, England; Kings Coll London, Sch Med, Richard Dimbelby Lab Canc Virol, GKT, London SE5 9PJ, England; Univ London Birkbeck Coll, London WC1E 7HX, England	University of London; University College London; University of London; University College London; University of London; King's College London; University of London; Birkbeck University London	Latchman, DS (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London, England.	d.latchman@ich.ucl.ac.uk						Bible JM, 2000, J GEN VIROL, V81, P1517, DOI 10.1099/0022-1317-81-6-1517; BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; COX MF, 1986, LANCET, V2, P157; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Gascoyne DM, 2004, ONCOGENE, V23, P3830, DOI 10.1038/sj.onc.1207497; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hudson CD, 2004, J NEUROSCI RES, V78, P803, DOI 10.1002/jnr.20299; Kammer C, 2000, J GEN VIROL, V81, P1975, DOI 10.1099/0022-1317-81-8-1975; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Miller AB, 2001, LANCET, V357, P1816, DOI 10.1016/S0140-6736(00)05008-X; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NAKSHATRI H, 1990, VIROLOGY, V178, P92, DOI 10.1016/0042-6822(90)90382-2; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisang D, 2001, ONCOGENE, V20, P4899, DOI 10.1038/sj.onc.1204634; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Ripley BJM, 2005, ARTHRITIS RHEUM-US, V52, P1171, DOI 10.1002/art.21000; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Sindos M, 2003, GYNECOL ONCOL, V90, P366, DOI 10.1016/S0090-8258(03)00261-0; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	33	9	11	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					51	60		10.1038/sj.onc.1209006	http://dx.doi.org/10.1038/sj.onc.1209006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247485	Green Accepted			2022-12-28	WOS:000234406400006
J	Ahtiainen, P; Rulli, SB; Shariatmadari, R; Pelliniemi, LJ; Toppari, J; Poutanen, M; Huhtaniemi, IT				Ahtiainen, P; Rulli, SB; Shariatmadari, R; Pelliniemi, LJ; Toppari, J; Poutanen, M; Huhtaniemi, IT			Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice	ONCOGENE			English	Article						fetal Leydig cell; adult Leydig cell; tumor; hCG	LUTEINIZING-HORMONE RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; GENE-EXPRESSION; REPRODUCTIVE-ORGANS; ACTIVATING MUTATION; MOUSE; TESTIS; STEROIDOGENESIS; TUMORIGENESIS; MECHANISMS	We have previously demonstrated that male transgenic (TG) mice overexpressing human chorionic gonadotropin (hCG+) develop reproductive organ defects, but no tumors, in adult age. In this study, the effects of persistently elevated hCG were followed in TG males between day 5 postpartum and adulthood. Leydig cell (LC) adenomas were found in prepubertal mice, most prominently at the age of 10 days, but not in adult age. Serum testosterone concentrations were signifi. cantly increased in TG males at all ages studied. The phenotype of the prepubertal hCG+ males resembled that found in boys upon expression of constitutively activating luteinizing hormone (LH) receptor mutations. The temporal expression patterns of the fetal LC marker gene, thrombospondin 2, and those of adult LCs, hydroxysteroid dehydrogenase-6, delta(5)-3-beta and prostaglandin D synthase, were similar in wild-type and hCG+ males. Hence, the postnatal adenomas resemble functionally fetal LCs, and only these cells are susceptible to hCG-induced tumorigenesis. Our findings demonstrate a novel intriguing difference between the fetal and adult LC populations and provide further insight into the potential tumorigenic effects of gonadotropins.	Univ London Imperial Coll Sci & Technol, Inst Reprod & Dev Biol, London W12 0NN, England; Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Consejo Nacl Invest Cient & Tecn, Inst Biol & Exot Med, RA-1428 Buenos Aires, DF, Argentina; Univ Turku, Electron Microscopy Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland	Imperial College London; University of Turku; University of Turku; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Turku; University of Turku	Huhtaniemi, IT (corresponding author), Univ London Imperial Coll Sci & Technol, Inst Reprod & Dev Biol, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@imperial.ac.uk	Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ariyaratne HBS, 2000, BIOL REPROD, V62, P680, DOI 10.1095/biolreprod62.3.680; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; CHEMES HE, 1996, LEYDIG CELL, P175; CHRISTENSEN AK, 1980, BIOL REPROD, V22, P383; Clegg ED, 1997, REPROD TOXICOL, V11, P107, DOI 10.1016/S0890-6238(96)00203-1; Cook JC, 1999, CRIT REV TOXICOL, V29, P169, DOI 10.1080/10408449991349203; Habert R, 2001, MOL CELL ENDOCRINOL, V179, P47, DOI 10.1016/S0303-7207(01)00461-0; HARDY MP, 1989, ENDOCRINOLOGY, V124, P762, DOI 10.1210/endo-124-2-762; Hirakawa T, 2002, ENDOCRINOLOGY, V143, P1026, DOI 10.1210/en.143.3.1026; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; HUHTANIEMI IT, 1985, BIOL REPROD, V32, P721, DOI 10.1095/biolreprod32.4.721; HUHTANIEMI IT, 1982, ENDOCRINOLOGY, V111, P1711, DOI 10.1210/endo-111-5-1711; HUSEBY RA, 1980, CANCER RES, V40, P1006; Kananen K, 1997, ENDOCRINOLOGY, V138, P3521, DOI 10.1210/en.138.8.3521; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; Keri RA, 2000, P NATL ACAD SCI USA, V97, P383, DOI 10.1073/pnas.97.1.383; KERR JB, 1988, DEVELOPMENT, V103, P535; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; Kumar TR, 1996, ENDOCRINOLOGY, V137, P4210, DOI 10.1210/en.137.10.4210; KUOPIO T, 1989, BIOL REPROD, V40, P135, DOI 10.1095/biolreprod40.1.135; Li XD, 2001, ENDOCRINOLOGY, V142, P2435, DOI 10.1210/en.142.6.2435; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; Ma XP, 2004, P NATL ACAD SCI USA, V101, P17294, DOI 10.1073/pnas.0404743101; Matzuk MM, 2003, BIOL REPROD, V69, P338, DOI 10.1095/biolreprod.102.013953; Mikola M, 2003, ONCOGENE, V22, P3269, DOI 10.1038/sj.onc.1206518; NAVICKIS RJ, 1981, CANCER RES, V41, P1646; O'Shaughnessy PJ, 1998, ENDOCRINOLOGY, V139, P1141, DOI 10.1210/en.139.3.1141; O'Shaughnessy PJ, 2002, BIOL REPROD, V66, P966, DOI 10.1095/biolreprod66.4.966; O'Shaughnessy PJ, 2002, J CELL SCI, V115, P3491; PAKARINEN P, 1990, ENDOCRINOLOGY, V127, P2469, DOI 10.1210/endo-127-5-2469; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; PRAHALADA S, 1994, FUND APPL TOXICOL, V22, P211, DOI 10.1006/faat.1994.1025; Richter-Unruh A, 2002, J CLIN ENDOCR METAB, V87, P1052, DOI 10.1210/jc.87.3.1052; Rulli SB, 2003, ENDOCRINOLOGY, V144, P4980, DOI 10.1210/en.2003-0403; Rulli SB, 2002, ENDOCRINOLOGY, V143, P4084, DOI 10.1210/en.2002-220490; SIMON WE, 1983, J NATL CANCER I, V70, P839; Sundstrom J, 1999, BRIT J CANCER, V80, P149, DOI 10.1038/sj.bjc.6990334; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67; ZHANG FP, 1994, ENDOCRINOLOGY, V134, P2206, DOI 10.1210/en.134.5.2206; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172	41	38	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7301	7309		10.1038/sj.onc.1208893	http://dx.doi.org/10.1038/sj.onc.1208893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007123	Green Published			2022-12-28	WOS:000233142100006
J	Marimpietri, D; Nico, B; Vacca, A; Mangieri, D; Catarsi, P; Ponzoni, M; Ribatti, D				Marimpietri, D; Nico, B; Vacca, A; Mangieri, D; Catarsi, P; Ponzoni, M; Ribatti, D			Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin	ONCOGENE			English	Article						angiogenesis; cytostatic; mTOR inhibitor; neuroblastoma; tumor progression; vessel growth	ENDOTHELIAL GROWTH-FACTOR; ANTIANGIOGENIC DRUGS; CELL PROLIFERATION; TUMOR ANGIOGENESIS; IN-VIVO; THERAPY; CANCER; TUMORIGENESIS; COMBINATION; EXPRESSION	The aim of this study was to evaluate the synergistic antiangiogenic effect of low dose of vinblastine (VBL) and rapamycin (RAP) in neuroblastoma (NB). Both in vitro (endothelial cells proliferation assay; TUNEL assay; phosphatidylserine exposure and cell cycle analysis) and in vivo (chick embryo chorioallantoic membrane, CAM) assays were used. Each compound alone was able to induce a significant dose- and time-response inhibition of in vitro endothelial cells (EC) growth. Interaction index evaluation indicates that a synergistic effect was found when both drugs were combined at very low doses. Comparable effects were obtained when EC were preincubated with conditioned medium (CM) derived from the human NB cell line HTLA-230. Morphological changes were induced by each drug, and their combination resulted in a clear and stronger effect. Apoptosis was demonstrated by the TUNEL assay and confirmed by Annexin V-FITC staining of EC treated with VBL, showing an increase in the percentage of cells with a G2-M and sub-G1 DNA content, whereas in those treated with RAP a block in the G1 cell fraction and inhibition of progression to the S phase were observed. Here too, the combination resulted in a synergistic cell cycle arrest and induction of apoptosis. Similar results were obtained in vivo with the CAM assay. The angiogenic responses induced by HTLA-230-derived CM, NB tumor xenografts, and human NB biopsy specimens were inhibited by each drug and more significantly by their combination. The observation that these well-known drugs display synergistic effects as antiangiogenics when administered frequently at very low dose may be of significance in the designing of new ways of treating NB.	Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy; G Gaslini Childrens Hosp, Differentiat Therapy Unit, Lab Oncol, I-16148 Genoa, Italy; Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70125 Bari, Italy; G Gaslini Childrens Hosp, Lab Pathophysiol Uremia, I-16148 Genoa, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, Piazza G Cesare 11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022; Marimpietri, Danilo/J-5975-2016; Marimpietri, Danilo/AAA-7283-2020; Catarsi, Paolo/J-4463-2016; Ponzoni, Mirco/J-7713-2016	Vacca, Angelo/0000-0002-4567-8216; Marimpietri, Danilo/0000-0001-6360-1661; Catarsi, Paolo/0000-0002-1862-8168; Ponzoni, Mirco/0000-0002-6164-4286; Mangieri, Domenica/0000-0003-4871-1701; Mangieri, Domenica/0000-0001-7350-9383				Abdollahi A, 2003, CANCER RES, V63, P8890; Baker CH, 2002, CANCER RES, V62, P1996; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bogenmann E, 1996, INT J CANCER, V67, P379, DOI 10.1002/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eggert A, 2000, CLIN CANCER RES, V6, P1900; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kaicker S, 2003, INT J ONCOL, V23, P1651; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Keselman HJ, 2004, PSYCHOL SCI, V15, P47, DOI 10.1111/j.0963-7214.2004.01501008.x; Kim ES, 2002, J PEDIATR SURG, V37, P518, DOI 10.1053/jpsu.2002.30855; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Nagabuchi E, 1997, J PEDIATR SURG, V32, P287, DOI 10.1016/S0022-3468(97)90196-2; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pastorino F, 2003, CANCER RES, V63, P86; PHILLIPS P, 1976, INT J CANCER, V17, P549, DOI 10.1002/ijc.2910170502; PONZONI M, 1995, CANCER RES, V55, P853; Ribatti D, 2002, EUR J CANCER, V38, P750, DOI 10.1016/S0959-8049(01)00337-9; Ribatti D, 1998, INT J CANCER, V77, P449; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Svensson A, 2002, PEDIATR RES, V51, P607, DOI 10.1203/01.PDR.0000013688.03134.5A; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Velde EAT, 2002, BRIT J SURG, V89, P1302, DOI 10.1046/j.1365-2168.2002.02183.x; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wassberg E, 1997, PEDIATR RES, V41, P327, DOI 10.1203/00006450-199703000-00004; WASSBERG E, 1997, AM J PATHOL, V1154, P395; Yokoyama Y, 2000, CANCER RES, V60, P2190	43	52	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6785	6795		10.1038/sj.onc.1208829	http://dx.doi.org/10.1038/sj.onc.1208829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007159				2022-12-28	WOS:000232527800006
J	Muraoka-Cook, RS; Shin, I; Yi, JY; Easterly, E; Barcellos-Hoff, MH; Yingling, JM; Zent, R; Arteaga, CL				Muraoka-Cook, R. S.; Shin, I.; Yi, J. Y.; Easterly, E.; Barcellos-Hoff, M. H.; Yingling, J. M.; Zent, R.; Arteaga, C. L.			Activated type I TGF beta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression	ONCOGENE			English	Article						TGF beta; mammary cancer; transgenic mice; PI-3 kinase; involution; oncogenes	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; SIGNAL-TRANSDUCTION; GLAND INVOLUTION; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; TGF-BETA-1 EXPRESSION; CANCER-CELLS; MICE	We have examined the effects of transforming growth factor-beta (TGF beta) signaling on mammary epithelial cell survival. Transgenic mice expressing an active mutant of Alk5 in the mammary gland (MMTV-Alk5(T204D)) exhibited reduced apoptosis in terminal endbuds and during postlactational involution. Transgene-expressing mammary cells contained lower Smad2/3 and higher c-myc levels than controls, high ligand-independent phosphatidylinositol-3 kinase (PI3K) and Akt activities, and were insensitive to TGF beta-mediated growth arrest. Treatment with a proteasome inhibitor increased Smad2/3 levels and ligand-independent Smad transcriptional reporter activity, as well as reduced both c-myc protein and basal cell proliferation. Treatment with an Alk5 kinase small-molecule inhibitor upregulated Smad2/3 levels, reduced PI3K activity, P-Akt, and c-myc, and inhibited cell survival. Although Alk5(T204D)-expressing mice did not develop mammary tumors, bigenic MMTV-Alk(T204D) x Neu mice developed cancers that were more metastatic than those occurring in MMTV-Neu transgenics. These data suggest that (1) TGF beta can signal to PI3K/Akt and enhance mammary epithelial cell survival in vivo before cytological or histological evidence of transformation, and (2) TGF beta signaling can provide epithelial cells with a 'gain-of-function' effect that synergizes with oncogene-induced transformation.	Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Vet Affairs Hosp, Dept Med Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA; Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea	Vanderbilt University; Vanderbilt University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Eli Lilly; Vanderbilt University; Hanyang University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Yin, Ji-Ye/AAE-6794-2020		NCI NIH HHS [P50 CA98131, R01 CA80195, R010 CA62212, P30 CA68485] Funding Source: Medline; NIA NIH HHS [R01 AG022413] Funding Source: Medline; NIDDK NIH HHS [R01 DK069921] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA098131, P30CA068485, R01CA062212, R01CA080195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bottinger EP, 1997, CANCER RES, V57, P5564; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; Engle SJ, 1999, CANCER RES, V59, P3379; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Glick AB, 1996, CANCER RES, V56, P3645; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; Gotzmann J, 2002, J CELL SCI, V115, P1189; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; Peng SB, 2005, BIOCHEMISTRY-US, V44, P2293, DOI 10.1021/bi048851x; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stambolic V, 2000, CANCER RES, V60, P3605; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yang YA, 2002, CELL GROWTH DIFFER, V13, P123; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200	58	113	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3408	3423		10.1038/sj.onc.1208964	http://dx.doi.org/10.1038/sj.onc.1208964			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16186809				2022-12-28	WOS:000238448100006
J	Hossini, AM; Geilen, CC; Fecker, LF; Daniel, PT; Eberle, J				Hossini, AM; Geilen, CC; Fecker, LF; Daniel, PT; Eberle, J			A novel Bcl-x splice product, Bcl-x(AK), triggers apoptosis in human melanoma cells without BH3 domain	ONCOGENE			English	Article						Bcl-x; apoptosis; alternative splicing; melanoma; chemotherapeutics	HUMAN MALIGNANT-MELANOMA; CANCER-CELLS; CONDITIONAL EXPRESSION; ANTIAPOPTOTIC PROTEIN; FAMILY PROTEINS; MESSENGER-RNA; IN-VITRO; DEATH; BAX; LINES	Pro- and antiapoptotic proteins of the large Bcl-2 family are critical regulators of apoptosis via the mitochondrial pathway. Whereas antiapoptotic proteins of the family share all four Bcl-2 homology domains (BH1-BH4), proapoptotic members may lack some of these domains, but all so far described proapoptotic Bcl-2 proteins enclose BH3. The bcl-x gene gives rise to several alternative splice products resulting in proteins with distinct functions as the antiapoptotic Bcl-x(L) and proapoptotic Bcl-x(S). Here, we describe a novel Bcl-x splice product of 138 amino acids termed Bcl-x(AK) (Atypical Killer), which encloses the Bcl-2 homology domains BH2 and BH4 as well as the transmembrane domain, but lacks BH1 and BH3. Weak endogenous expression of Bcl-x(AK) was seen in melanoma and other tumor cells. Interestingly, its overexpression by applying a tetracycline-inducible expression system-resulted in significant induction of apoptosis in melanoma cells, which occurred in synergism with drug-induced apoptosis. After exogenous overexpression, Bcl-x(AK) was localized both in mitochondrial and in cytosolic cell fractions. By these findings, a completely new class of Bcl-2-related proteins is introduced, which promotes apoptosis independently from the BH3 domain and implies additional, new mechanisms for apoptosis regulation in melanoma cells.	Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, D-12203 Berlin, Germany; Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, Campus Benjamin Franklin,Fabeckstr 60-62, D-12203 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519				Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BEAN MA, 1975, CANCER RES, V35, P2902; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DEL PL, 1997, SCIENCE, V278, P687; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fecker LF, 2002, J INVEST DERMATOL, V118, P1019, DOI 10.1046/j.1523-1747.2002.01744.x; FULTS D, 1992, J NEUROPATH EXP NEUR, V51, P272, DOI 10.1097/00005072-199205000-00005; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hipp ML, 1997, ONCOGENE, V15, P791, DOI 10.1038/sj.onc.1201247; HOLZMANN B, 1988, INT J CANCER, V41, P542; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; HOSSINI AM, 2003, ARCH DERMATOL RES, V294, P499; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Jin KL, 2001, J NEUROCHEM, V77, P1508, DOI 10.1046/j.1471-4159.2001.00361.x; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LIAO SK, 1975, J NATL CANCER I, V54, P1037; Lindenboim L, 2000, ONCOGENE, V19, P1783, DOI 10.1038/sj.onc.1203495; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ogata Y, 2003, DRUG NEWS PERSPECT, V16, P446, DOI 10.1358/dnp.2003.16.7.829356; OPPERMANN M, 2005, ONCOGENE; Oxford SME, 2004, CURR MED CHEM, V11, P1031, DOI 10.2174/0929867043455486; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Renshaw SA, 2004, J BIOL CHEM, V279, P2846, DOI 10.1074/jbc.M309769200; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Schmitt E, 2004, ONCOGENE, V23, P3915, DOI 10.1038/sj.onc.1207554; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	62	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2160	2169		10.1038/sj.onc.1209253	http://dx.doi.org/10.1038/sj.onc.1209253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288206				2022-12-28	WOS:000236581200003
J	Huang, M; Kamasani, U; Prendergast, GC				Huang, M; Kamasani, U; Prendergast, GC			RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3	ONCOGENE			English	Article						Ras; Rho; Akt; cancer	FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLATED RHOB; PROTEIN-KINASE; PHOSPHORYLATION; TRANSFORMATION; GROWTH; CANCER; DEGRADATION; SUPPRESSION; EXPRESSION	The small GTPase RhoB suppresses cancer in part by limiting cell proliferation. However, the mechanisms it uses to achieve this are poorly understood. Recent studies link RhoB to trafficking of Akt, which through its regulation of glycogen synthase kinase-3 (GSK-3) has an important role in controlling the stability of the c-Myc oncoprotein. c-Myc stabilization may be a root feature of human tumorigenesis as it phenocopies an essential contribution of SV40 small T antigen in human cell transformation. In this study we show that RhoB directs efficient turnover of c-Myc in established or transformed mouse fibroblasts and that the attenuation of RhoB which occurs commonly in human cancer is a sufficient cause to elevate c-Myc levels. Increased levels of c-Myc elicited by RhoB deletion increased the proliferation of nullizygous cells, whereas restoring RhoB in null cells decreased the stability of c-Myc and restrained cell proliferation. Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc. RhoB deletion restricted nuclear localization of GSK-3, reduced T58 phosphorylation, and stabilized c-Myc. These effects were not associated with changes in phosphorylation or localization of Akt, however, differences were observed in phosphorylation and localization of the GSK-3 regulatory Akt-related kinase, serum- and glucocorticoid-inducible protein kinase (SGK). The ability of RhoB to support GSK-3-dependent turnover of c-Myc offers a mechanism by which RhoB acts to limit the proliferation of neoplastically transformed cells.	Lankenau Inst Med Res, Canc Cell Signaling Lab, Wynnewood, PA 19096 USA; Thomas Jefferson Univ, Sch Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, Canc Cell Signaling Lab, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org			NCI NIH HHS [CA82222, R01 CA100123, CA100123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100123, R01CA082222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Du W, 1999, MOL CELL BIOL, V19, P1831; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; PULVERER BJ, 1994, ONCOGENE, V9, P59; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; WANG S, 2004, NOVART FDN SYMP, V259, P245; WANG S, 2004, NOVART FDN SYMP, V259, P285; Wang Shaowen, 2004, Novartis Found Symp, V259, P238; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wherlock M, 2004, J CELL SCI, V117, P3221, DOI 10.1242/jcs.01193; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zeng PY, 2003, ONCOGENE, V22, P1124, DOI 10.1038/sj.onc.1206181	48	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1281	1289		10.1038/sj.onc.1209174	http://dx.doi.org/10.1038/sj.onc.1209174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247449				2022-12-28	WOS:000235708200001
J	Jean, D; Rousselet, N; Frade, R				Jean, D; Rousselet, N; Frade, R			Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms	ONCOGENE			English	Article						gene amplification; DNA methylation; transcription regulation; mRNA stability	HUMAN-MELANOMA CELLS; CHAIN VARIABLE FRAGMENT; CLEAVES HUMAN C3; 3RD COMPONENT; CYSTEINE PROTEINASE; PROCATHEPSIN-L; L GENE; METASTATIC PROPERTIES; COMPLEMENT; PROMOTER	Cathepsin L, a cysteine protease, is overexpressed in human tumor cells and plays a major role in melanoma progression. Our aim was herein to identify molecular mechanisms, which contribute to its overexpression. We found that cathepsin L protein expression correlated with mRNA level in tumor cells. Therefore, we focused on mechanisms involved in cathepsin L mRNA regulation. CpG island was localized in the 5' region of cathepsin L gene that encompassed regulatory regions identified as essential for promoter activity. CpG dinucleotides, not methylated in any melanoma cells analysed, were methylated in a B lymphoma cell line, which poorly express cathepsin L. Our data demonstrate that in lymphoma cells, cathepsin L silencing was methylation-dependent. Furthermore, gene amplification was involved in cathepsin L overexpression in one melanoma cell line, while transcriptional mechanisms but not mRNA stability are responsible of cathepsin L overexpression in others melanoma cells. In addition, NF-Y, Sp1, Sp2 and Sp3 transcription factors, essential to basal cathepsin L transcription, are not directly involved in overexpression. Thus, our data provides the first demonstration that cathepsin L expression in tumor cells is under the control of distinct molecular mechanisms.	INSERM, U 672, U 354, F-91030 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Jean, D (corresponding author), INSERM, U 672, U 354, Batiment G8,Campus 1,5 Rue Henri Desbrueres,Genop, F-91030 Evry, France.	jean354@genopole.evry.inserm.fr	Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404				Abdollahi A, 1999, J SOC GYNECOL INVEST, V6, P32, DOI 10.1016/S1071-5576(98)00048-3; Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; Charron M, 2003, BIOL REPROD, V68, P1649, DOI 10.1095/biolreprod.102.012328; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; Frade R, 1999, IMMUNOPHARMACOLOGY, V42, P39, DOI 10.1016/S0162-3109(99)00028-4; Frade R, 2000, CANCER RES, V60, P6585; Frade R, 1998, CANCER RES, V58, P2733; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Guillaume-Rousselet N, 2002, BIOCHEM J, V367, P219, DOI 10.1042/BJ20020350; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; Ishidoh K, 1997, BIOCHEM BIOPH RES CO, V238, P665, DOI 10.1006/bbrc.1997.7349; Jean D, 1996, CANCER RES, V56, P254; Jean D, 1997, IMMUNOL LETT, V58, P107, DOI 10.1016/S0165-2478(97)00030-8; Jean D, 2002, BIOCHEM J, V361, P173, DOI 10.1042/0264-6021:3610173; Jean D, 1995, BIOCHEM J, V312, P961, DOI 10.1042/bj3120961; KAMBOJ RC, 1993, BIOCHIMIE, V75, P873, DOI 10.1016/0300-9084(93)90042-Q; Kawada A, 1997, ARCH DERMATOL RES, V289, P87, DOI 10.1007/s004030050160; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; Luca MR, 1998, HISTOL HISTOPATHOL, V13, P1225, DOI 10.14670/HH-13.1225; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mao X, 2000, CANCER GENET CYTOGEN, V122, P87, DOI 10.1016/S0165-4608(00)00278-8; Ohashi K, 2003, BBA-PROTEINS PROTEOM, V1649, P30, DOI 10.1016/S1570-9639(03)00152-3; Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; Sriraman V, 2004, ENDOCRINOLOGY, V145, P582, DOI 10.1210/en.2003-0963; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Turk V, 2002, ADV ENZYME REGUL, V42, P285, DOI 10.1016/S0065-2571(01)00034-6	33	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1474	1484		10.1038/sj.onc.1209196	http://dx.doi.org/10.1038/sj.onc.1209196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261157				2022-12-28	WOS:000235890400005
J	Segrelles, C; Moral, M; Lara, MF; Ruiz, S; Santos, M; Leis, H; Garcia-Escudero, R; Martinez-Cruz, AB; Martinez-Palacio, J; Hernandez, P; Ballestin, C; Paramio, JM				Segrelles, C; Moral, M; Lara, MF; Ruiz, S; Santos, M; Leis, H; Garcia-Escudero, R; Martinez-Cruz, AB; Martinez-Palacio, J; Hernandez, P; Ballestin, C; Paramio, JM			Molecular determinants of Akt-induced keratinocyte transformation	ONCOGENE			English	Article						Akt; myc; CycD; keratinocyte; HNSCC; Wnt pathway	SQUAMOUS-CELL CARCINOMA; GLYCOGEN-SYNTHASE KINASE; MOUSE SKIN CARCINOGENESIS; INTEGRIN-LINKED KINASE; BETA-CATENIN; CYCLIN D1; C-MYC; DEREGULATED EXPRESSION; MAMMALIAN TARGET; TUMOR-SUPPRESSOR	The PI3K/PTEN/Akt signaling pathway has emerged in recent years as a main player in human cancers, increasing proliferation and decreasing apoptosis of transformed cells, and thus becoming a potential target for therapeutic intervention. Our previous data have demonstrated that Akt-mediated signaling is of a key relevance in the mouse skin carcinogenesis system, one of the best-known models of experimental carcinogenesis. Here, we investigated the involvement of several pathways as mediators of Akt-induced increased proliferation and tumorigenesis in keratinocytes. Tumors produced by subcutaneous injection of Akt-transformed keratinocytes showed increased Foxo3a phosphorylation, but no major alterations in p21(Cip1/WAF1), p27(Kip1) or mdm2 expression and/or localization. In contrast, we found increased expression and nuclear localization of Delta Np63, beta-catenin and Lef1. Concomitantly, we also found increased expression of c-myc and CycD1, targets of the beta-catenin/Tcf pathway. Such increase is associated with increased phosphorylation and stabilization of c-myc protein as well as increased translation of c-myc and CycD1 due to mTOR activation. Using immunohistochemistry approaches in samples of oral dysplasias and human head and neck squamous cell carcinomas, we confirmed that increased Akt activation significantly correlates with increased Delta Np63 and CycD expression, c-myc phosphorylation and nuclear accumulation of beta-catenin. Collectively, these results demonstrate that Akt is able to transform keratinocytes by specific mechanisms involving transcriptional and post-transcriptional processes.	CIEMAT, Dept Cell & Mol Biol, E-28040 Madrid, Spain; Hosp 12 Octubre, Dept Pathol, E-28041 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Hospital Universitario 12 de Octubre	Paramio, JM (corresponding author), CIEMAT, Dept Cell & Mol Biol, Ave Complutense 22, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Santos, Mirentxu/AAA-1727-2020; Segrelles, Carmen/E-3655-2016; Garcia-Escudero, Ramon/A-2735-2012; Paramio, Jesus M/M-8482-2014; Martinez, Jesus/M-3791-2014; Cabanás, María Lara/AAH-3621-2019; Ruiz, Sergio/G-1561-2016	Segrelles, Carmen/0000-0001-9340-2102; Garcia-Escudero, Ramon/0000-0001-5640-6542; Paramio, Jesus M/0000-0001-7520-3177; Martinez, Jesus/0000-0002-9521-8744; Ruiz, Sergio/0000-0002-0177-6965				Ambrosch P, 2000, ANTICANCER RES, V20, P3151; Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Balz V, 2005, ADV OTO-RHINO-LARYNG, V62, P58; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bhatia N, 2005, MOL CARCINOGEN, V42, P213, DOI 10.1002/mc.20077; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Brown J, 2003, CARCINOGENESIS, V24, P171, DOI 10.1093/carcin/24.2.171; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Casanova ML, 2002, CANCER RES, V62, P3402; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Desbois-Mouthon C, 2002, HEPATOLOGY, V36, P1528, DOI 10.1053/jhep.2002.37192; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Segrelles C, 2004, CARCINOGENESIS, V25, P1137, DOI 10.1093/carcin/bgh132; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Suzuki A, 2003, CANCER RES, V63, P674; Thurfjell N, 2005, ADV OTO-RHINO-LARYNG, V62, P49; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Warnakulasuriya KAAS, 1998, J ORAL PATHOL MED, V27, P376; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	75	79	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1174	1185		10.1038/sj.onc.1209155	http://dx.doi.org/10.1038/sj.onc.1209155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247457				2022-12-28	WOS:000235537500005
J	D'Costa, AM; Robinson, JK; Maududi, T; Chaturvedi, V; Nickoloff, BJ; Denning, MF				D'Costa, AM; Robinson, JK; Maududi, T; Chaturvedi, V; Nickoloff, BJ; Denning, MF			The proapoptotic tumor suppressor protein kinase C-delta is lost in human squamous cell carcinomas	ONCOGENE			English	Article						protein kinase C-delta; skin cancer; squamous cell carcinoma; tumor suppressor gene	GROWTH-FACTOR RECEPTOR; RADIATION-INDUCED APOPTOSIS; INDUCED CUTANEOUS DAMAGE; PKC-DELTA; HUMAN KERATINOCYTES; TRANSGENIC MICE; RAS ONCOGENE; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; PHORBOL ESTER	Protein kinase C (PKC)-delta is proapoptotic in human keratinocytes, and is downregulated or inactivated in keratinocytes expressing the activated Ha-ras oncogene, making it a candidate tumor suppressor gene for squamous cell carcinoma (SCC). We evaluated the significance of PKC-delta loss in transformed human keratinocytes using tumorigenic HaCaT Ras II-4 cells that have significantly reduced PKC-delta levels. Re-expression of PKC-delta by retro virus transduction caused an increase in apoptosis and growth inhibition in culture. The growth inhibition induced by PKC-delta could be partially reversed by Bcl-(xL) expression, indicating that apoptosis was in part responsible for PKC-delta-induced growth inhibition. PKC-delta re-expression suppressed the tumor-igenicity of HaCaT Ras II-4 cells in nude mice (P < 0.05), and the small tumors that did form contained elevated levels of activated caspase-3, indicating increased apoptosis. In addition, we found that 29% (12/42) of human Bowen's disease ( squamous carcinoma in situ) or SCC cases had absent or reduced PKC-delta when compared to the surrounding normal epidermis. These results indicate that PKC-delta inhibits transformed keratinocyte growth by inducing apoptosis, and that PKC-delta may function as a tumor suppressor in human SCCs where its loss in cells harboring activated ras could provide a growth advantage by conferring resistance to apoptosis.	Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Skin Canc Res Program, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, 2160 S 1st Ave,Room 304, Maywood, IL 60153 USA.	mdennin@lumc.edu			NCI NIH HHS [CA83784] Funding Source: Medline; NIAMS NIH HHS [AR47814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashton KJ, 2003, ARCH DERMATOL, V139, P876, DOI 10.1001/archderm.139.7.876; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BOUKAMP P, 1990, CANCER RES, V50, P2840; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURNS FJ, 1976, CANCER RES, V36, P1422; Cataldi A, 2002, J CELL BIOCHEM, V86, P553, DOI 10.1002/jcb.10251; Chida K, 2003, CANCER RES, V63, P2404; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; Dlugosz AA, 1997, CANCER RES, V57, P3180; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; Dobler M, 1999, INT J ONCOL, V14, P571; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Einspahr Janine G., 1999, Neoplasia (New York), V1, P468, DOI 10.1038/sj.neo.7900061; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; Frey MR, 2001, BIOCHEM PHARMACOL, V61, P1093, DOI 10.1016/S0006-2952(01)00596-2; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; Hansen LA, 2000, CANCER RES, V60, P3328; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Jansen AP, 2001, CANCER RES, V61, P808; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LEE E, 1992, CARCINOGENESIS, V13, P2367, DOI 10.1093/carcin/13.12.2367; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu JH, 2003, CANCER RES, V63, P1153; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; Papp H, 2004, CELL MOL LIFE SCI, V61, P1095, DOI 10.1007/s00018-004-4014-2; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wheeler DL, 2005, PHOTOCHEM PHOTOBIOL, V81, P9, DOI 10.1562/2004-08-12-RA-271.1; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Wheeler DL, 2003, CANCER RES, V63, P6547; Wheeler DL, 2002, ONCOGENE, V21, P3620, DOI 10.1038/sj.onc.1205451; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	64	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					378	386		10.1038/sj.onc.1209065	http://dx.doi.org/10.1038/sj.onc.1209065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158048				2022-12-28	WOS:000234714100006
J	Lu, Z; Luo, RZ; Peng, H; Huang, M; Nishmoto, A; Hunt, KK; Helin, K; Liao, WSL; Yu, Y				Lu, Z; Luo, RZ; Peng, H; Huang, M; Nishmoto, A; Hunt, KK; Helin, K; Liao, WSL; Yu, Y			E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer	ONCOGENE			English	Article						ARHI; tumor suppressor gene; transcriptional regulation; E2F; HDAC; breast cancer	CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTORS; HISTONE H3; IN-VIVO; E2F; EXPRESSION; CARCINOGENESIS; REPLICATION; METHYLATION; REPRESSION	ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor - trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F - HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.	UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA; European Inst Oncol, Dept Expt Oncol, Milan, Italy; Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; IRCCS European Institute of Oncology (IEO); University of Copenhagen; University of Texas System; UTMD Anderson Cancer Center	Yu, Y (corresponding author), UT MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 354, Houston, TX 77030 USA.	yyu@mdanderson.org	Lu, Zhen/E-5221-2015; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097	NCI NIH HHS [CA 64602, CA 80957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; Hisatomi H, 2002, ONCOLOGY-BASEL, V62, P136, DOI 10.1159/000048259; Lu Z H, 2001, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V23, P324; Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; Shi Zonggao, 2002, Zhonghua Zhongliu Zazhi, V24, P475; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang L, 2003, CLIN CANCER RES, V9, P3660; Weber F, 2005, J CLIN ENDOCR METAB, V90, P1149, DOI 10.1210/jc.2004-1447; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Yuan JH, 2003, CANCER RES, V63, P4174; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	27	51	51	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					230	239		10.1038/sj.onc.1209025	http://dx.doi.org/10.1038/sj.onc.1209025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158053				2022-12-28	WOS:000234583600007
J	Song, SM; Lippman, SM; Zou, YY; Ye, XF; Ajani, JA; Xu, XC				Song, SM; Lippman, SM; Zou, YY; Ye, XF; Ajani, JA; Xu, XC			Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta(2) expression	ONCOGENE			English	Article						RAR-beta(2); COX-2; Erk1/2; AP-1; BPDE; esophageal cancer	ACID RECEPTOR-BETA; RETINOIC ACID; UP-REGULATION; LUNG-CANCER; RAR-BETA; PROMOTER HYPERMETHYLATION; DIFFERENTIAL EXPRESSION; BRONCHIAL EPITHELIUM; 13-CIS-RETINOIC ACID; CELL-PROLIFERATION	Benzo[a] pyrene diol epoxide (BPDE, a carcinogen present in tobacco smoke and environmental pollution) has been shown to suppress retinoic acid receptor-beta2 (RAR-beta(2)) and induce cyclooxygenase-2 (COX-2) expression. Restoration of RAR-beta 2 inhibited growth and colony formation of esophageal cancer cells, which was correlated with COX-2 suppression. In this study, we investigated the molecular mechanisms for RAR-beta(2)-mediated suppression of COX-2 expression using BPDE as a tool. We found that BPDE-induced COX-2 expression was through inhibition of RAR-beta 2 and consequently, induction of epidermal growth factor receptor (EGFR), extracellular signal-regulated protein kinases 1/2 (Erk1/2) phosphorylation, and c-Jun expression. Esophageal cancer cells that do not express RAR-beta 2 did not respond to BPDE for induction of COX-2. BPDE was also unable to induce COX-2 expression after RAR-beta 2 expression was manipulated in these esophageal cancer cells. Furthermore, BPDE induced time-dependent methylation of RAR-beta 2 gene promoter in esophageal cancer cells. Transfection of RAR-beta 2 expression vector into esophageal cancer cells suppressed expression of EGFR, Erk1/2 phosphorylation, c-Jun, and COX-2. In addition, co-treatment of RAR-beta 2-positive cells with BPDE and the MEK1/2 inhibitor U0126 caused little change in c-Jun and COX-2 expression. This study demonstrated that BPDE-suppressed expression of RAR-beta 2 results in COX-2 induction and restoration of RAR-beta 2 expression reduces COX-2 protein in esophageal cancer cells, thereby further supporting our previous finding that RAR-beta 2 plays an important role in suppressing esophageal carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med Oncol GI, Unit 1360, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Xu, XC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xxu@mdanderson.org						Alberts D, 2004, CLIN CANCER RES, V10, P1875, DOI 10.1158/1078-0432.CCR-03-0188; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Berg WJ, 1999, CLIN CANCER RES, V5, P1671; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dragnev KH, 2003, CANCER BIOL THER, V2, pS150; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; GEBERT JF, 1991, ONCOGENE, V6, P1859; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Khuri FR, 2001, CLIN CANCER RES, V7, P861; Kim YT, 2005, ANN THORAC SURG, V79, P1180, DOI 10.1016/j.athoracsur.2004.09.060; Koch Timothy R, 2003, Curr Gastroenterol Rep, V5, P187, DOI 10.1007/s11894-003-0018-6; Kong G, 2005, CANCER RES, V65, P3462, DOI 10.1158/0008-5472.CAN-03-2912; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Kurie JM, 2000, CLIN CANCER RES, V6, P2973; Kuroki T, 2003, CANCER RES, V63, P3724; Lam S, 2003, INT J ONCOL, V23, P1607; Lango M, 2003, CLIN CANCER RES, V9, P4205; Li M, 2002, ONCOGENE, V21, P411, DOI 10.1038/sj.onc.1205106; Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000; Lin F, 2000, CANCER RES, V60, P3271; Liu ZM, 2004, WORLD J GASTROENTERO, V10, P771; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; Mayne ST, 2002, J NUTR, V132, p3467S, DOI 10.1093/jn/132.11.3467S; McCann J, 1999, J NATL CANCER I, V91, P497, DOI 10.1093/jnci/91.6.497; McGregor F, 2002, CANCER RES, V62, P4757; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POSNER MC, 2002, CANC UPPER GASTROINT; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Qiu HM, 2000, GENE CHROMOSOME CANC, V28, P196, DOI 10.1002/(SICI)1098-2264(200006)28:2<196::AID-GCC8>3.0.CO;2-L; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Su H, 2003, CANCER RES, V63, P3872; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wang XD, 1999, J NATL CANCER I, V91, P60, DOI 10.1093/jnci/91.1.60; Wang YM, 2003, CLIN CANCER RES, V9, P5257; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Xu M, 2002, WORLD J GASTROENTERO, V8, P200; Xu X.-C., 1999, HANDB EXP PHARM, P323; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317; Xu XC, 2002, CANCER EPIDEM BIOMAR, V11, p1148S; Xu XC, 2002, ANTI-CANCER DRUG, V13, P127, DOI 10.1097/00001813-200202000-00003; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang W, 2001, J CANCER RES CLIN, V127, P237, DOI 10.1007/s004320000183; Zhuang Y, 2003, MOL CANCER RES, V1, P619; 2004, US SURG GEN REPORT	56	45	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8268	8276		10.1038/sj.onc.1208992	http://dx.doi.org/10.1038/sj.onc.1208992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170369				2022-12-28	WOS:000233956500006
J	Annicotte, JS; Chavey, C; Servant, N; Teyssier, J; Bardin, A; Licznar, A; Badia, E; Pujol, P; Vignon, F; Maudelonde, T; Lazennec, G; Cavailles, V; Fajas, L				Annicotte, JS; Chavey, C; Servant, N; Teyssier, J; Bardin, A; Licznar, A; Badia, E; Pujol, P; Vignon, F; Maudelonde, T; Lazennec, G; Cavailles, V; Fajas, L			The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene	ONCOGENE			English	Article						breast cancer; E2; estrogen receptor; Ftz-F1; LRH-1; nuclear receptors; transcription	CYCLIN D1; BREAST-CANCER; INDEPENDENT ACTIVATION; REGULATES EXPRESSION; LRH-1; ELEMENT; PROLIFERATION; RECRUITMENT; PROGRESSION; AROMATASE	Liver receptor homolog-1 (LRH-1) is a nuclear receptor previously known to have distinct functions during mouse development and essential roles in cholesterol homeostasis. Recently, a new role for LRH-1 has been discovered in tumor progression, giving LRH-1 potential transforming functions. In order to identify critical factors stimulating LRH-1 expression leading to deregulated cellular proliferation, we studied its expression and its regulation in several breast cancer cell lines. We observed that LRH-1 expression was increased in estrogen receptor (ER) alpha expressing cell lines, whereas weak-to-no expression was found in nonexpressing ER alpha cell lines. In MCF7, LRH-1 expression was highly induced after treatment with 17 beta-estradiol (E2). This transcriptional regulation was the result of a direct binding of the ER to the LRH-1 promoter, as demonstrated by gelshift and chromatin immunoprecipitation assays. Interestingly, siRNA-mediated inactivation of LRH-1 decreased the E2-dependent proliferation of MCF7 cells. Finally, LRH-1 protein expression was detected by immunohistochemistry in tumor cells of human mammary ductal carcinomas. Altogether, these data demonstrate that LRH-1 is transcriptionally regulated by the ER a and reinforce the hypothesis that LRH-1 could exert potential oncogenic effects during breast cancer formation.	INSERM, Equipe Avenir, U540, F-34090 Montpellier, France; INSERM, Equipe Avenir, F-34090 Montpellier, France; CHU Arnaud Villeneuve, Biol Cellulaire Lab, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Fajas, L (corresponding author), INSERM, Equipe Avenir, U540, 60 Rue Navacelles, F-34090 Montpellier, France.	fajas@montp.inserm.fr	cavailles, vincent/C-6277-2017; Coll, Lluis Fajas/C-8567-2014; Annicotte, Jean-Sébastien/H-4641-2018; Cavailles, Vincent/Y-5379-2019	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Cavailles, Vincent/0000-0002-7160-3074; Lazennec, Gwendal/0000-0002-8522-1763; Fajas, Lluis/0000-0002-1283-9503; BADIA, Eric/0000-0002-8922-9834; Chavey, Carine/0000-0002-5267-5638				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Falender AE, 2003, ENDOCRINOLOGY, V144, P3598, DOI 10.1210/en.2002-0137; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Hinshelwood MM, 2003, MOL CELL ENDOCRINOL, V207, P39, DOI 10.1016/S0303-7207(03)00257-0; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; SCHOONJANS K, 2005, P NATL ACAD SCI US; Zhou J, 2005, CANCER RES, V65, P657; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	24	81	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2005	24	55					8167	8175		10.1038/sj.onc.1208950	http://dx.doi.org/10.1038/sj.onc.1208950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091743	Green Accepted, Green Submitted			2022-12-28	WOS:000233809400008
J	Gomez-Bougie, P; Oliver, L; Le Gouill, S; Bataille, R; Amiot, M				Gomez-Bougie, P; Oliver, L; Le Gouill, S; Bataille, R; Amiot, M			Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex	ONCOGENE			English	Article						multiple myeloma; melphalan; Mcl-1; Bcl-2; BH3-only Bim	BCL-2 FAMILY; SURVIVAL; PROTEIN; DEATH; MITOCHONDRIA; AMPLIFICATION; BCL-X(L); MOLECULE	Multiple myeloma ( MM) is a rapidly fatal plasma-cell malignancy that evolves mainly in the bone marrow. Melphalan is widely used to treat patients with MM but as yet its mechanisms of action are poorly documented. In the current study, we demonstrate that melphalan induces a drastic downregulation of Mcl-1L, Bcl-x(L) and BimEL in human melphalan-sensitive myeloma cells while the most potent proapoptotic isoforms, BimL and S, are affected to a lesser extent. Moreover, Mcl-1L and BimEL disappearance is associated with the generation of proapoptotic cleaved forms generated by a caspase cleavage. In myeloma cells, we have previously shown that Mcl-1 neutralizes the proapoptotic function of Bim and therefore, prevents the activation of death effectors. In this study, we demonstrate that melphalan disrupts the Mcl-1/Bim complex whereas the Bcl-2/Bim complex is not modified. The disappearance of full length Mcl-1 allows the release of Bim isoforms, particularly L and S, which can exert their proapoptotic function and leads to Bax activation and cytochrome c release. Thus, we can hypothesize that the cleaved 26 kDa proapoptotic Mcl-1 and the 19 and 12 kDa of Bim, generated during melphalan treatment could contribute to the amplification loop of apoptosis.	INSERM, UMR601, Dept Rech Cancerol, Equipe 5 Labelisee,Inst Biol, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Amiot, M (corresponding author), INSERM, UMR601, Dept Rech Cancerol, Equipe 5 Labelisee,Inst Biol, LNC 2005,9 Quai Moncousu, F-44093 Nantes, France.	mamiot@nantes.inserm.fr	Oliver, Lisa J/L-3070-2015; Amiot, Martine/K-9076-2015	Oliver, Lisa J/0000-0002-5588-7564; le gouill, steven/0000-0001-9840-2128; Amiot, Martine/0000-0003-0428-7355; Gomez Bougie, Patricia/0000-0002-4846-4782				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	27	56	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8076	8079		10.1038/sj.onc.1208949	http://dx.doi.org/10.1038/sj.onc.1208949			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091744				2022-12-28	WOS:000233656600013
J	Plas, DR; Thompson, CB				Plas, DR; Thompson, CB			Akt-dependent transformation: there is more to growth than just surviving	ONCOGENE			English	Article						glycolysis; metabolism; forkhead; FOXO; TSC2; feedback	FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; MULTIPLE TRANSLATION FACTORS; FACTOR-INDEPENDENT SURVIVAL; TUBEROUS SCLEROSIS COMPLEX; TUMOR-SUPPRESSOR PROTEINS; P70 S6 KINASE; AMINO-ACID; CELL-GROWTH; GLUCOSE-TRANSPORT	Activation of the Akt/PKB protein kinase family triggers increases in cell size, metabolism and survival. Akt coordinately regulates these fundamental cellular processes through phosphorylation-dependent inactivation of tumor suppressors and activation of trophic signaling. Akt signaling stimulates transport and metabolism of both glucose and amino acids, which in turn support mTOR-dependent increases in protein translation. In addition, Akt activation directs cells to undertake a metabolic conversion from oxidative phosphorylation to aerobic glycolysis. Although this conversion promotes cell growth, it also renders cell survival dependent on a continuous supply of extracellular nutrients, which themselves are required regulatory elements in Akt signal transduction.	Univ Cincinnati, Dept Genome Sci, Genome Res Inst, Cincinnati, OH 45237 USA; Univ Penn, Abramson Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19146 USA	University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine	Plas, DR (corresponding author), Univ Cincinnati, Dept Genome Sci, Genome Res Inst, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.	plasd@uc.edu						Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; BARNES D, 1976, J CELL PHYSIOL, V89, P633, DOI 10.1002/jcp.1040890420; Barnes K, 2005, ONCOGENE, V24, P3257, DOI 10.1038/sj.onc.1208461; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; BAUER DE, IN PRESS ONCOGENE; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; BOERNER P, 1985, P NATL ACAD SCI USA, V82, P1350, DOI 10.1073/pnas.82.5.1350; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dan HC, 2002, J BIOL CHEM, V11, P11; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Edinger AL, 2003, CANCER RES, V63, P8451; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kaestner KH, 2000, GENE DEV, V14, P142; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VANDERHEIDE LP, 2005, IN PRESS BIOCH J; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamada E, 2005, J CELL BIOL, V168, P921, DOI 10.1083/jcb.200408182; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	96	335	349	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7435	7442		10.1038/sj.onc.1209097	http://dx.doi.org/10.1038/sj.onc.1209097			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288290				2022-12-28	WOS:000233201900006
J	Somasundaram, K; Reddy, SP; Vinnakota, K; Britto, R; Subbarayan, M; Nambiar, S; Hebbar, A; Samuel, C; Shetty, M; Sreepathi, HK; Santosh, V; Hegde, AS; Hegde, S; Kondaiah, P; Rao, MRS				Somasundaram, K; Reddy, SP; Vinnakota, K; Britto, R; Subbarayan, M; Nambiar, S; Hebbar, A; Samuel, C; Shetty, M; Sreepathi, HK; Santosh, V; Hegde, AS; Hegde, S; Kondaiah, P; Rao, MRS			Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma	ONCOGENE			English	Article						glioma; astrocytoma; ASCL1; Notch signaling; glioblastoma multiforme; microarray	GROWTH-FACTOR; ACHAETE-SCUTE; GENE-EXPRESSION; NEUROENDOCRINE DIFFERENTIATION; TUMOR-SUPPRESSOR; HUMAN GLIOMAS; MICROARRAY; PROTEIN; CANCER; BRAIN	Astrocytoma is the most common type of brain cancer constituting more than half of all brain tumors. With an aim to identify markers describing astrocytoma progression, we have carried out microarray analysis of astrocytoma samples of different grades using cDNA microarray containing 1152 cancer-specific genes. Data analysis identified several differentially regulated genes between normal brain tissue and astrocytoma as well as between grades II/III astrocytoma and glioblastoma multiforme (GBM; grade IV). We found several genes known to be involved in malignancy including Achaetescute complex-like 1(Drosophila) (ASCL1; Hash 1). As ASCL has been implicated in neuroendocrine, medullary thyroid and small-cell lung cancers, we chose to examine the role of ASCL1 in the astrocytoma development. Our data revealed that ASCL1 is overexpressed in progressive astrocytoma as evidenced by increased levels of ASCL1 transcripts in 85.71% (6/7) of grade II diffuse astrocytoma (DA), 90% (9/10) of grade III anaplastic astrocytoma (AA) and 87.5% (7/8) of secondary GBMs, while the majority of primary de novo GBMs expressed similar to or less than normal brain levels (66.67%; 8/12). ASCL1 upregulation in progressive astrocytoma is accompanied by inhibition of Notch signaling as seen by uninduced levels of HES1, a transcriptional target of Notch1, increased levels of HES6, a dominant-negative inhibitor of HES1-mediated repression of ASCL1, and increased levels of Notch ligand Delta1, which is capable of inhibiting Notch signaling by forming intracellular Notch ligand autonomous complexes. Our results imply that inhibition of Notch signaling may be an important early event in the development of grade II DA and subsequent progression to grade III AA and secondary GBM. Furthermore, ASCL1 appears to be a putative marker to distinguish primary GBM from secondary GBM.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Mol Reproduct Dev & Genet, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India; Sri Satya Sai Inst Higher Med Sci, Bangalore 560066, Karnataka, India; Manipal Hosp, Bangalore 560017, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); National Institute of Mental Health & Neurosciences - India	Rao, MRS (corresponding author), Indian Inst Sci, Dept Biochem, CV Raman Ave, Bangalore 560012, Karnataka, India.	mrsrao@biochem.iisc.ernet.in	Reddy, Sreekanth/B-3395-2008	Britto, Ramona/0000-0003-1011-5410				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bae SK, 2000, DEVELOPMENT, V127, P2933; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Brock CS, 1997, MED ONCOL, V14, P103, DOI 10.1007/BF02990955; Campomenosi P, 1996, CANCER GENET CYTOGEN, V88, P95, DOI 10.1016/0165-4608(95)00359-2; Casarosa S, 1999, DEVELOPMENT, V126, P525; Cavenee WK, 2000, GLIOBLASTOMA, P29; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fathallah-Shaykh HM, 2002, ONCOGENE, V21, P7164, DOI 10.1038/sj.onc.1205654; FLEMING TP, 1992, CANCER RES, V52, P4550; FREDERICK L, 2000, ANN INTERN MED, V138, P658; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; Gibert JM, 2003, INT J DEV BIOL, V47, P643; Godard S, 2003, CANCER RES, V63, P6613; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Heitzler P, 1996, DEVELOPMENT, V122, P161; HERMANSON M, 1992, CANCER RES, V52, P3213; Hermanson M, 1996, CANCER RES, V56, P164; Hill JR, 1999, ARCH NEUROL-CHICAGO, V56, P439, DOI 10.1001/archneur.56.4.439; Ito T, 2000, DEVELOPMENT, V127, P3913; JAMES CD, 1991, CANCER RES, V51, P1684; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Jordanova ES, 2003, INT J CANCER, V103, P393, DOI 10.1002/ijc.10824; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kumanogoh A, 2002, NATURE, V419, P629, DOI 10.1038/nature01037; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liau LM, 2000, CANCER RES, V60, P1353; Ljubimova JY, 2001, CANCER RES, V61, P5601; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; Mischel PS, 2001, BRAIN TUMOR IMMUNOTHERAPY, P3; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Nutt CL, 2003, CANCER RES, V63, P1602; OLOPADE OI, 1992, CANCER RES, V52, P2523; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phatak P, 2002, J BIOSCIENCES, V27, P673, DOI 10.1007/BF02708375; Post LC, 2000, MECH DEVELOP, V98, P95, DOI 10.1016/S0925-4773(00)00432-9; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rickman DS, 2001, CANCER RES, V61, P6885; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sallinen SL, 2000, CANCER RES, V60, P6617; Satow T, 2001, J NEUROSCI, V21, P1265; Scheffer GL, 2002, BRIT J CANCER, V86, P1943, DOI 10.1038/sj.bjc.6600354; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tanwar MK, 2002, CANCER RES, V62, P4364; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Wang H, 2003, CANCER RES, V63, P4315; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Watson MA, 2001, CANCER RES, V61, P1825; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	78	92	100	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7073	7083		10.1038/sj.onc.1208865	http://dx.doi.org/10.1038/sj.onc.1208865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16103883				2022-12-28	WOS:000232833200009
J	Khalili, P; Arakelian, A; Chen, GP; Singh, G; Rabbani, SA				Khalili, P; Arakelian, A; Chen, GP; Singh, G; Rabbani, SA			Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer	ONCOGENE			English	Article						Her-2; antibody; bone metastases	TRASTUZUMAB HERCEPTIN; ZD1839 IRESSA; NUDE-MICE; IN-VIVO; GROWTH; HER2/NEU; CELLS; BONE; ONCOGENE; KINASE	We examined the effects of Herceptin, a bioengineered monoclonal antibody directed against Her-2/neu oncogene on skeletal metastasis using a xenograft model of breast cancer. Treatment of Her-2 overexpressing human breast cancer cells BT-474 with Herceptin caused a dose-dependent decrease in cell proliferation. In in vivo studies, BT-474 cells (1 x 10(5)) were injected into the left ventricle of female BALB/c nu/nu mice. Intraperitoneal (i.p.) infusion of Herceptin (1 mg/kg twice a week for 5 weeks) from the day of tumor cell inoculation or at the time of radiologically detectable skeletal metastasis either slowed the development or prevented the progression of skeletal metastasis as compared to control groups of animals receiving nonspecific IgG. Bone histological analysis of long bones showed the ability of Herceptin to reduce the ratio of tumor volume to bone volume as well as mitotic index, effects that were more pronounced when Herceptin treatment was initiated from the day of tumor cell inoculation. While immunohistochemical analysis of long bones showed no difference in the production of Her-2, phosphorylated (P) Her-2 and MAPK, a significantly lower level of P-MAPK was seen in bones of Herceptin treated animals. These studies demonstrate the ability of Herceptin to inhibit the development and abrogate the progression of skeletal metastases associated with breast cancer by blocking the HER-2-mediated signaling pathways.	McGill Univ, Ctr Hlth, Dept Med & Oncol, Montreal, PQ H3A 1A1, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada	McGill University; McMaster University	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med & Oncol, 687 Pine Ave W,Room H4-61, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca	Singh, Gurmit/C-6744-2014	rabbani, shafaat/0000-0001-5594-3899				ADEWALE A, 2002, CLIN CANCER RES, V8, P1747; Baselga J, 1998, CANCER RES, V58, P2825; Bell R, 2002, ONCOLOGY-BASEL, V63, P39, DOI 10.1159/000066200; Bendre MS, 2002, CANCER RES, V62, P5571; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Chen CN, 2000, J INF SCI ENG, V16, P1; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Duivenvoorden WCM, 2002, CANCER RES, V62, P1588; El Abdaimi K, 2000, CANCER RES, V60, P4412; Esteva FJ, 2001, ONCOLOGIST, V6, P133, DOI 10.1634/theoncologist.6-2-133; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; Kurebayashi  J, 2001, Breast Cancer, V8, P45, DOI 10.1007/BF02967477; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; MARGOLESE TG, 2003, CANC MED, P1879; Masood S, 2002, MICROSC RES TECHNIQ, V59, P102, DOI 10.1002/jemt.10181; Mayfield S, 2001, BREAST CANCER RES TR, V70, P123, DOI 10.1023/A:1012999012192; Moasser MM, 2001, CANCER RES, V61, P7184; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Park JW, 2002, CLIN CANCER RES, V8, P1172; Rabbani SA, 2005, ENDOCRINOLOGY, V146, P2885, DOI 10.1210/en.2005-0062; ROODMAN DG, 2003, CANCER, V97, P733; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; van der Pluijm G, 2000, CANCER TREAT REV, V26, P11, DOI 10.1053/ctrv.1999.0143; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zhou BP, 2003, SEMIN ONCOL, V30, P38, DOI 10.1053/j.seminoncol.2003.08.006	29	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6657	6666		10.1038/sj.onc.1208790	http://dx.doi.org/10.1038/sj.onc.1208790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16091754				2022-12-28	WOS:000232367800007
J	Wegiel, B; Bjartell, A; Ekberg, J; Gadaleanu, V; Brunhoff, C; Persson, JL				Wegiel, B; Bjartell, A; Ekberg, J; Gadaleanu, V; Brunhoff, C; Persson, JL			A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer	ONCOGENE			English	Article						cyclin A1; VEGF; androgen; androgen receptor; Rb; prostate cancer	TUMOR-GROWTH; FACTOR VEGF; ANDROGEN; ANGIOGENESIS; PROGRESSION; RECEPTORS; PROTEIN; CELLS	Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor ( VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was manifested upon the R1881 treatment. Cyclin A1 failed to mediate VEGF activation in DU-145 cells lacking a functional Rb and an androgen receptor (AR). Although AR expression was induced into DU-145 cells, cyclin A1 was unable to mediate VEGF expression. However, induced coexpression of cyclin A1, Rb and AR in DU-145 cells in the presence of R1881 greatly promoted VEGF promoter activity. This suggests that cyclin A1 mediates VEGF expression in cooperation with Rb- and androgen-dependent pathways in prostate cancer.	Lund Univ, Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden; Lund Univ, Univ Hosp, Dept Urol, Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Persson, JL (corresponding author), Lund Univ, Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden.	jenny.persson@pat.mas.lu.se		Persson, Jenny/0000-0001-7682-7678				Ali IU, 2001, UROLOGY, V57, P143, DOI 10.1016/S0090-4295(00)00961-4; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Borre M, 2000, CLIN CANCER RES, V6, P1882; Chevalier S, 2002, MOL CELL ENDOCRINOL, V189, P169, DOI 10.1016/S0303-7207(01)00728-6; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Ekberg J, 2004, ONCOGENE, V23, P9082, DOI 10.1038/sj.onc.1208090; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Haggstrom S, 1999, J UROLOGY, V161, P1620, DOI 10.1016/S0022-5347(05)68994-X; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hrouda D, 2003, UROL RES, V30, P347, DOI 10.1007/s00240-002-0287-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson MW, 2002, CANCER RES, V62, P854; Jozkowicz A, 2004, BIOCHEM BIOPH RES CO, V314, P31, DOI 10.1016/j.bbrc.2003.12.059; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kimura K, 2001, CANCER RES, V61, P5611; Klocker H, 1999, EUR UROL, V35, P413, DOI 10.1159/000019918; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; LILJA H, 1991, CLIN CHEM, V37, P1618; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Strohmeyer D, 2000, PROSTATE, V45, P216, DOI 10.1002/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Sweeney C, 1996, DEVELOPMENT, V122, P53; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913	39	46	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6385	6393		10.1038/sj.onc.1208795	http://dx.doi.org/10.1038/sj.onc.1208795			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007189				2022-12-28	WOS:000232038200006
J	Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG				Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG			Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR	ONCOGENE			English	Article						telomerase; hTR; ribbon antisense; DPL transfection	CATALYTIC SUBUNIT; IN-VITRO; MAMMALIAN TELOMERASE; INDUCED APOPTOSIS; RNA COMPONENT; INHIBITION; EXPRESSION; CANCER; OLIGONUCLEOTIDES; GENE	Ribbon antisense (RiAS) to the hTR RNA, a component of the telomerase complex, was employed to inhibit telomerase activity and cancer cell growth. The antisense molecule, hTR-RiAS, combined with enhanced cellular uptake was shown to effectively inhibit telomerase activity and cause rapid cell death in various cancer cell lines. When cancer cells were treated with hTR-RiAS, the level of hTR RNA was reduced by more than 90% accompanied with reduction in telomerase activity. When checked for cancer cell viability, cancer cell lines treated with hTR-RiAS using DNA+Peptide+Lipid complex showed 70-80% growth inhibition in 3 days. The reduced cell viability was due to apoptosis as the percentage of cells exhibiting the sub-G(0) arrest and DNA fragmentation increased after antisense treatment. Further, when subcutaneous tumors of a colon cancer cell line (SW480) were treated intratumorally with hTR-RiAS, tumor growth was markedly suppressed with almost total ablation of hTR RNA in the tumor tissue. Cells in the tumor tissue were also found to undergo apoptosis after hTR-RiAS treatment. These results suggest that hTR-RiAS is an effective anticancer reagent, with a potential for broad efficacy to diverse malignant tumors.	Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, Joongu, Daegu, South Korea; WelGENE Inc 71B4L, Dalseogu 704230, Daegu, South Korea; Keimyung Univ, Sch Med, Chron Dis Res Ctr, Taegu, South Korea; Keimyung Univ, Sch Med, Inst Med Sci, Taegu, South Korea	Keimyung University; Keimyung University; Keimyung University	Park, JG (corresponding author), Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, 194 Dongsadong, Joongu, Daegu, South Korea.	jonggu@kmu.ac.kr						Avilion AA, 1996, CANCER RES, V56, P645; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Ishikawa T, 1999, CANCER LETT, V141, P187, DOI 10.1016/S0304-3835(99)00103-2; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 2000, ONCOGENE, V19, P2205, DOI 10.1038/sj.onc.1203538; Kosciolek BA, 2003, MOL CANCER THER, V2, P209; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Moon IJ, 2000, BIOCHEM J, V346, P295, DOI 10.1042/0264-6021:3460295; Moon IJ, 2000, J BIOL CHEM, V275, P4647, DOI 10.1074/jbc.275.7.4647; Mukai S, 2000, CANCER RES, V60, P4461; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x	34	7	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6492	6501		10.1038/sj.onc.1208731	http://dx.doi.org/10.1038/sj.onc.1208731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16170384				2022-12-28	WOS:000232204100003
J	Strizzi, L; Bianco, C; Normanno, N; Salomon, D				Strizzi, L; Bianco, C; Normanno, N; Salomon, D			Cripto-1: A multifunctional modulator during embryogenesis and oncogenesis	ONCOGENE			English	Review						Cripto-1; embryogenesis; oncogenesis; EHT; engiogenesis; therapy	MAMMARY EPITHELIAL-CELLS; EMBRYONIC STEM-CELLS; GROWTH-FACTOR-ALPHA; ONE-EYED-PINHEAD; EGF-CFC FAMILY; DIFFERENTIAL IMMUNOHISTOCHEMICAL DETECTION; CERVICAL-CARCINOMA CELLS; HUMAN BREAST CARCINOMAS; FACTOR-RELATED PROTEINS; TRANSGENIC MICE	It is increasingly evident that genes known to perform critical roles during early embryogenesis, particularly during stem cell renewal, pluripotentiality and survival, are also expressed during the development of cancer. In this regard, oncogenesis may be considered as the recapitulation of embryogenesis in an inappropriate temporal and spatial manner. The epidermal growth factor-Cripto-1/FRL1/cryptic family of proteins consists of extracellular and cell-associated proteins that have been identified in several vertebrate species. During early embryogenesis, epidermal growth factor-Cripto-1/FRL1/ cryptic proteins perform an obligatory role as coreceptors for the transforming growth factor-beta subfamily of proteins, which includes Nodal. Cripto-1 has also been shown to function as a ligand through a Nodal/Alk4-independent signaling pathway that involves binding to glypican-1 and the subsequent activation through src of phosphoinositol-3 kinase/Akt and ras/mitogen-activated protein kinase intracellular pathways. Expression of Cripto-1 is increased in several human cancers and its overexpression is associated with the development of mammary tumors in mice. Here, we review the role of Cripto-1 during embryogenesis, cell migration, invasion and angiogenesis and how these activities may relate to cellular transformation and tumorigenesis. We also briefly discuss evidence suggesting that Cripto-1 may be involved in stem cell maintenance.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, NIH,Ctr Canc Res, Bethesda, MD 20892 USA; ITN Fdn Pascale, Div Haematol Oncol, I-80131 Naples, Italy; ITN Fdn Pascale, Dept Expt Oncol, I-80131 Naples, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Salomon, D (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, NIH,Ctr Canc Res, Bldg 37,Room 118B, Bethesda, MD 20892 USA.	salomond@mail.nih.gov	Normanno, Nicola/AAT-1107-2021	Normanno, Nicola/0000-0002-7158-2605	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackland ML, 2003, LAB INVEST, V83, P435, DOI 10.1097/01.LAB.0000059927.97515.FD; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Bamford RN, 2000, NAT GENET, V26, P365, DOI 10.1038/81695; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bianco C, 2005, J NATL CANCER I, V97, P132, DOI 10.1093/jnci/dji011; Bianco C, 2004, GROWTH FACTORS, V22, P133, DOI 10.1080/08977190410001723290; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bianco C, 1999, J BIOL CHEM, V274, P8624, DOI 10.1074/jbc.274.13.8624; Bianco C, 2001, BREAST CANCER RES TR, V66, P1, DOI 10.1023/A:1010648923432; Bianco C, 2002, J CELL PHYSIOL, V190, P74, DOI 10.1002/jcp.10037; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Byrne RL, 1998, J PATHOL, V185, P108; Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; Conlon FL, 1999, DEV BIOL, V213, P85, DOI 10.1006/dbio.1999.9330; D'Antonio A, 2002, INT J ONCOL, V21, P941; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; De Angelis E, 1999, INT J ONCOL, V14, P437; de la Cruz JM, 2002, HUM GENET, V110, P422, DOI 10.1007/s00439-002-0709-3; De Santis ML, 1997, CELL GROWTH DIFFER, V8, P1257; De Santis ML, 2000, CELL DEATH DIFFER, V7, P189, DOI 10.1038/sj.cdd.4400588; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 1999, CANCER RES, V59, P4502; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Escaffit F, 2005, EXP CELL RES, V302, P206, DOI 10.1016/j.yexcr.2004.08.033; Fontanini G, 1998, CLIN CANCER RES, V4, P241; FRIESS H, 1994, INT J CANCER, V56, P668, DOI 10.1002/ijc.2910560511; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Griffin KJP, 2003, DEV BIOL, V264, P456, DOI 10.1016/j.ydbio.2003.09.008; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kemler R, 2004, DEVELOPMENT, V131, P5817, DOI 10.1242/dev.01458; Kenney N., 1997, PATHOGENESIS, V1, P57; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Kleber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006; Kodjabachian L, 2001, CURR BIOL, V11, pR655, DOI 10.1016/S0960-9822(01)00385-2; Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; KUNIYASU H, 1991, JPN J CANCER RES, V82, P969, DOI 10.1111/j.1349-7006.1991.tb01929.x; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liguori G, 1996, MAMM GENOME, V7, P344, DOI 10.1007/s003359900100; LIU D, 1994, INT J CANCER, V56, P603, DOI 10.1002/ijc.2910560423; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu X, 2003, CANCER RES, V63, P7760; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Matsui Y, 2005, BIOESSAYS, V27, P136, DOI 10.1002/bies.20178; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Minchiotti G, 2001, DEVELOPMENT, V128, P4501; Mincione G, 1998, J CELL PHYSIOL, V176, P383, DOI 10.1002/(SICI)1097-4652(199808)176:2<383::AID-JCP17>3.0.CO;2-4; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Muller WJ, 1998, BIOCHEM SOC SYMP, P149; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; Parish CL, 2005, STEM CELLS, V23, P471, DOI 10.1634/stemcells.2004-0294; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Polakis P, 2000, GENE DEV, V14, P1837; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robb L, 2004, SEMIN CELL DEV BIOL, V15, P543, DOI 10.1016/j.semcdb.2004.04.005; Rodriguez-Esteban C, 2001, DEVELOPMENT, V128, P3189; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; SAEKI T, 1992, CANCER RES, V52, P3467; SAEKI T, 1994, INT J ONCOL, V5, P445; SAEKI T, 1994, INT J ONCOL, V5, P215; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 1997, DEVELOPMENT, V124, P429; Sonntag KC, 2005, MOL CELL NEUROSCI, V28, P417, DOI 10.1016/j.mcn.2004.06.003; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; STROMBERG K, 1994, INT J GYNECOL PATHOL, V13, P342, DOI 10.1097/00004347-199410000-00008; SU ZZ, 1993, ONCOGENE, V8, P1211; SUN Y, 2005, IN PRESS AM J PATHOL; Tabata T, 2004, DEVELOPMENT, V131, P703, DOI 10.1242/dev.01043; Tanegashima K, 2004, INT J DEV BIOL, V48, P275, DOI 10.1387/ijdb.041805kt; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Thisse B, 2000, NATURE, V403, P425, DOI 10.1038/35000200; TSUTSUMI M, 1994, JPN J CANCER RES, V85, P118, DOI 10.1111/j.1349-7006.1994.tb02069.x; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; Warga RA, 2003, DEV BIOL, V261, P391, DOI 10.1016/S0012-1606(03)00328-2; Wechselberger C, 2005, ONCOGENE, V24, P4094, DOI 10.1038/sj.onc.1208417; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; WEILS RA, 1984, J CELL BIOL, V98, P1397; Welss T, 2003, INT J CANCER, V104, P66, DOI 10.1002/ijc.10912; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Xu CH, 1999, DEVELOPMENT, V126, P483; Yamashita YM, 2005, J CELL SCI, V118, P665, DOI 10.1242/jcs.01680; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; Zhang YQ, 2004, DIABETES, V53, P2024, DOI 10.2337/diabetes.53.8.2024	136	134	147	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5731	5741		10.1038/sj.onc.1208918	http://dx.doi.org/10.1038/sj.onc.1208918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123806				2022-12-28	WOS:000231452800008
J	Kim, H; Laing, M; Muller, W				Kim, H; Laing, M; Muller, W			c-Src-null mice exhibit defects in normal mammary gland development and ER alpha signaling	ONCOGENE			English	Article						estrogen receptor; c-Src; mammary gland	ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; ESTRADIOL-RECEPTOR; INDEPENDENT ACTIVATION; TARGETED DISRUPTION; SURVIVAL SIGNAL; KINASE PATHWAY; PHOSPHORYLATION; TYROSINE	The c-Src tyrosine kinase has been implicated to play an integral role in modulating growth factor receptor, integrin and steroid receptor function. One class of steroid receptors that c-Src modulates is the estrogen receptor a (ER alpha). Although there is strong biochemical evidence supporting a role for c-Src in ER alpha signaling, the consequence of this association is unclear at the biological level. To explore the significance of c-Src in ER alpha signaling, we studied the development of various reproductive organs that are dependent on ER alpha in c-Srcdeficient mice. We show that the loss of the c-Src tyrosine kinase correlates with defects in ductal development as well as in uterine and ovarian development. Genetic and biochemical analyses of c-Src-deficient mammary epithelial cells also revealed defects in the ability of mammary epithelial cells to activate a number of signaling pathways in response to exogenous estrogen stimulation. Taken together, these studies demonstrate that c-Src plays a role in ER alpha signaling in vivo.	McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; McMaster University	Muller, W (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Mol Oncol Grp, Room H5-63A,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca						Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; BISWAS R, 1987, CANCER RES, V47, P3509; Brisken C, 2000, GENE DEV, V14, P650; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Cunha GR, 1997, J MAMMARY GLAND BIOL, V2, P393, DOI 10.1023/A:1026303630843; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DiDomenico M, 1996, CANCER RES, V56, P4516; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jackson D, 1997, J CELL SCI, V110, P1261; Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIPPMAN M, 1976, CANCER RES, V36, P4595; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Schomberg DW, 1999, ENDOCRINOLOGY, V140, P2733, DOI 10.1210/en.140.6.2733; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	64	49	50	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5629	5636		10.1038/sj.onc.1208718	http://dx.doi.org/10.1038/sj.onc.1208718			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007215				2022-12-28	WOS:000231296100009
J	Kuninaka, S; Nomura, M; Hirota, T; Iida, SI; Hara, T; Honda, S; Kunitoku, N; Sasayama, T; Arima, Y; Marumoto, T; Koja, K; Yonehara, S; Saya, H				Kuninaka, S; Nomura, M; Hirota, T; Iida, SI; Hara, T; Honda, S; Kunitoku, N; Sasayama, T; Arima, Y; Marumoto, T; Koja, K; Yonehara, S; Saya, H			The tumor suppressor WARTS activates the Omi/HtrA2-dependent pathway of cell death	ONCOGENE			English	Article						mitotic kinases; mitochondria; apoptosis; PDZ domain; IAPs; caspases; cancer	SERINE-PROTEASE OMI/HTRA2; ANTI-APOPTOTIC PROTEIN; PROMOTES APOPTOSIS; HUMAN HOMOLOG; MITOTIC APPARATUS; CASPASE ACTIVITY; MAMMALIAN-CELLS; IAP PROTEINS; CYCLE EXIT; DROSOPHILA	Drosophila tumor suppressor WARTS (Wts) is an evolutionally conserved serine/threonine kinase and participates in a signaling complex that regulates both proliferation and apoptosis to ensure the proper size and shape of the fly. Human counterparts of this complex have been found to be frequently downregulated or mutated in cancers. WARTS, a human homolog of Wts, is also known as tumor suppressor and mitotic regulator, but its molecular implications in tumorigenesis are still obscure. Here, we show that WARTS binds via its C-terminus to the PDZ domain of a proapoptotic serine protease Omi/HtrA2. Depletion of WARTS inhibited Omi/HtrA2-mediated cell death, whereas overexpression of WARTS promoted this process. Furthermore, WARTS can enhance the protease activity of Omi/HtrA2 both in vivo and in vitro. Activation of Omi/HtrA2-mediated cell death is thus a potential mechanism for the tumor suppressive activity of WARTS.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Univ Ryukyus, Sch Med, Dept Surg 2, Okinawa 9030215, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kumamoto University; University of the Ryukyus; Kyoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Arima, Yoshimi/J-8057-2013; Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013	Sasayama, Takashi/0000-0002-5593-9045; Arima, Yoshimi/0000-0002-2384-1406				Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmitt CA, 1999, J PATHOL, V187, P127; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang XD, 2001, GENE DEV, V15, P2922; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	51	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5287	5298		10.1038/sj.onc.1208682	http://dx.doi.org/10.1038/sj.onc.1208682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007220				2022-12-28	WOS:000231158500003
J	Burek, M; Maddika, S; Burek, CJ; Daniel, PT; Schulze-Osthoff, K; Los, M				Burek, M; Maddika, S; Burek, CJ; Daniel, PT; Schulze-Osthoff, K; Los, M			Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1dependent	ONCOGENE			English	Article						Apaf-1; apoptin; apoptosis; caspases; Bcl-2; Bcl-xL	CHICKEN ANEMIA VIRUS; TUMOR-CELLS; INDUCED APOPTOSIS; PROTEIN APOPTIN; NUCLEAR-LOCALIZATION; CASPASE ACTIVATION; BH3-ONLY PROTEINS; CANCER; INDUCTION; SIGNAL	Apoptin, a chicken anemia virus-derived protein, selectively induces apoptosis in transformed but not in normal cells, thus making it a promising candidate as a novel anticancer therapeutic. The mechanism of apoptin-induced apoptosis is largely unknown. Here, we report that contrary to previous assumptions, Bcl-2 and Bcl-x(L) inhibit apoptin-induced cell death in several tumor cell lines. In contrast, deficiency of Bax conferred resistance, whereas Bax expression sensitized cells to apoptin-induced death. Cell death induction by apoptin was associated with cytochrome c release from mitochondria as well as with caspase-3 and -7 activation. Benzyloxy-carbonyl-Val-Ala-Asp-fluoromethyl ketone, a broad spectrum caspase inhibitor, was highly protective against apoptin-induced cell death. Apoptosis induced by apoptin required Apaf-1, as immortalized Apaf-1-deficient fibroblasts as well as tumor cells devoid of Apaf-1 were strongly protected. Thus, our data indicate that apoptin-induced apoptosis is not only Bcl-2- and caspase dependent, but also engages an Apaf-1 apoptosome-mediated mitochondrial death pathway.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, Munster, Germany; Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada	Heinrich Heine University Dusseldorf; University of Munster; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Manitoba	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Burek, Malgorzata/AAF-3283-2021; Schulze-Osthoff, Klaus/N-9025-2013	Burek, Malgorzata/0000-0001-6148-2195; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411	Canadian Institutes of Health Research [81237] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Adair BM, 2000, DEV COMP IMMUNOL, V24, P247, DOI 10.1016/S0145-305X(99)00076-2; ALMAZAN G, 1992, BRAIN RES, V579, P234, DOI 10.1016/0006-8993(92)90056-F; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Bouillet P, 2002, J CELL SCI, V115, P1567; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Danen-Van Oorschot AAAM, 1999, ADV EXP MED BIOL, V457, P245; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Everett H, 2001, VIROLOGY, V288, P1, DOI 10.1006/viro.2001.1081; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Ghavami S, 2004, J LEUKOCYTE BIOL, V76, P169, DOI 10.1189/jlb.0903435; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; JAATTELA M, 1995, ONCOGENE, V10, P2297; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; LAMKANFI M, 2002, CASPASES THEIR ROLE; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oro C, 2004, CURR DRUG TARGETS, V5, P179, DOI 10.2174/1389450043490631; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Schoop RAL, 2004, INT J CANCER, V109, P38, DOI 10.1002/ijc.11675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Somai S, 2003, INT J CANCER, V105, P607, DOI 10.1002/ijc.11147; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3; Teodoro JG, 2004, GENE DEV, V18, P1952, DOI 10.1101/gad.1198404; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; Wadia JS, 2004, J VIROL, V78, P6077, DOI 10.1128/JVI.78.11.6077-6078.2004; Zhang YH, 2003, EXP CELL RES, V289, P36, DOI 10.1016/S0014-4827(03)00188-5; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	52	62	73	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2213	2222		10.1038/sj.onc.1209258	http://dx.doi.org/10.1038/sj.onc.1209258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288204	Green Accepted, Green Published			2022-12-28	WOS:000236581200008
J	Abdul-Ghani, R; Serra, V; Gyorffy, B; Jurchott, K; Solf, A; Dietel, M; Schafer, R				Abdul-Ghani, R; Serra, V; Gyorffy, B; Jurchott, K; Solf, A; Dietel, M; Schafer, R			The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1	ONCOGENE			English	Article						phosphoinositol 3-kinase; LY294002; multidrug resistance-associated protein MRP1; colon cancer; doxorubicin	BREAST-CANCER CELLS; MULTIDRUG-RESISTANCE; INDUCED APOPTOSIS; ADENOCARCINOMA CELLS; SIGNALING PATHWAY; ACTIVATION LEADS; ERK ACTIVATION; RAS ONCOGENES; EXPRESSION; 3-KINASE	Multidrug resistance may be achieved by the activation of membrane transporters, detoxification, alterations in DNA repair or failure in apoptotic pathways. Recent data have suggested an involvement of mitogenic signalling pathways mediated by Ras and phosphoinositol-3-kinase (PI3K/Akt) in controlling multidrug resistance. Since these pathways are important targets for therapeutic interference, we sought to investigate whether blocking effectors kinases by specific inhibitors would result in a sensitization toward cytotoxic drugs. We found that cotreatment of drug-resistant HT29RDB colon cancer cells with the topoisomerase inhibitor doxorubicin and the PI3K-inhibitor LY294002 resulted in massive apoptosis, while cotreatment with the Mek inhibitors PD98059 or U0126 had no effect. This suggested that the PI3K-pathways controls cell survival and drug resistance in these cells. Besides blocking Akt phosphorylation, the PI3K-inibitor increased the intracellular doxorubicin concentration threefold. LY294002 inhibits drug export in a competitive manner as revealed by measuring drug efflux in the presence and the absence of inhibitor. The efficacy of drug efflux inhibition by LY294002 was similar to that achieved by the MRP1 inhibitors MK571 and genistein. We conclude that the PI3K inhibitor LY294002 may have therapeutic potential when combined with doxorubicin in the treatment of MRP1-mediated drug resistance.	Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Gyorffy, Balazs/AAA-9135-2021; Serra, Violeta/AAG-8328-2019; Schäfer, Reinhold/AAB-5110-2021	Gyorffy, Balazs/0000-0002-5772-3766; Jurchott, Karsten/0000-0003-1589-0037; Serra, Violeta/0000-0001-6620-1065				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; BERG J, 2002, BIOCH ENYZMES BASIC; BOS JL, 1989, CANCER RES, V49, P4682; Brognard J, 2001, CANCER RES, V61, P3986; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; Chang FM, 2003, INT J ONCOL, V22, P469; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chen ZH, 2003, MOL CANCER THER, V2, P543; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Clark AS, 2002, MOL CANCER THER, V1, P707; Ding S, 2001, BRIT J CANCER, V85, P1175, DOI 10.1054/bjoc.2001.2044; DiSimone D, 1997, ANTICANCER RES, V17, P3587; Filipeanu CM, 2000, FEBS LETT, V474, P107, DOI 10.1016/S0014-5793(00)01585-4; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GYORFFY B, 2005, IN PRESS ONCOGENE; Han JW, 1997, CANCER RES, V57, P176; Hu LM, 2002, CANCER RES, V62, P1087; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; KOPNIN BP, 1995, ONCOL RES, V7, P299; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liu XM, 2001, BRIT J CANCER, V85, P1403, DOI 10.1054/bjoc.2001.2107; Mizutani H, 2005, LIFE SCI, V76, P1439, DOI 10.1016/j.lfs.2004.05.040; Nakashio A, 2000, CANCER RES, V60, P5303; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Ng SSW, 2000, CANCER RES, V60, P5451; Plasschaert SLA, 2003, CLIN CANCER RES, V9, P5171; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95; van Zanden JJ, 2004, BIOCHEM PHARMACOL, V67, P1607, DOI 10.1016/j.bcp.2003.12.032; van Zuylen L, 2000, INVEST NEW DRUG, V18, P205, DOI 10.1023/A:1006487003814; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang QD, 2002, CLIN CANCER RES, V8, P1940; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yu DH, 1996, ONCOGENE, V13, P1359; Zhao YQ, 2004, J CELL BIOCHEM, V91, P621, DOI 10.1002/jcb.10751; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	54	94	108	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1743	1752		10.1038/sj.onc.1209201	http://dx.doi.org/10.1038/sj.onc.1209201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288223				2022-12-28	WOS:000236013700006
J	Worrillow, LJ; Allan, JM				Worrillow, LJ; Allan, JM			Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia	ONCOGENE			English	Article						therapy-related AML; DNA mismatch repair; homologous recombination repair; alkylating agents; embryonic stem cells; clones	ACUTE MYELOID-LEUKEMIA; MISMATCH REPAIR; MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; P53 MUTATIONS; HUMAN RAD51; MSH2 GENE; MECHANISMS; RESISTANCE; EXPRESSION	Chemotherapeutic regimes involving alkylating agents, such as methylators and cross linking nitrogen mustards, represent a major risk factor for acute myeloid leukaemia. A high frequency of microsatellite instability and evidence of MSH2 loss in alkylating chemotherapy-related acute myeloid leukaemia (t-AML) suggests that DNA mismatch repair (MMR) dysfunction may be an initiating event in disease evolution. Subsequent accumulation of secondary genetic changes as a result of DNA MMR loss may ultimately lead to the gross chromosomal abnormalities seen in t-AML. Homologous recombination repair (HRR) maintains chromosomal stability by the repair of DNA double-strand breaks, and is therefore a possible target for deregulation in MMR dysfunctional t-AML. In order to test this hypothesis Msh2-proficient and -defficient murine embryonic stem (ES) cells were used to examine the effects of MMR status and methylating agent treatment on cellular expression of DNA double-strand break repair genes. HRR gene expression was significantly deregulated in Msh2 null ES cell clones compared to wild-type clones. Furthermore, some Msh2 null clones expressed high levels of Rad51 specifically, a critical component of HRR. Such Rad51 superexpressing clones were also observed when expression was determined in monocytic myeloid cells differentiated from ES cells. A deregulated HRR phenotype could be partially recapitulated in MMR-competent wild-type cells by treatment with the methylating agent, N-methyl-N-nitrosourea. Furthermore, treatment with melphalan, a leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected against cells with deregulated HRR. These data suggest a t-AML mechanism whereby DNA MMR loss promotes the emergence of HRR gene superexpressing clones, with concomitant chromosomal instability. However, melphalan selection against clones with deregulated HRR suggests that persistence and expansion of unstable clones may require additional genetic alterations that promote cell survival.	Univ York, Dept Biol Epidemiol & Genet, York YO10 5DD, N Yorkshire, England	University of York - UK	Allan, JM (corresponding author), Univ York, Dept Biol Epidemiol & Genet, York YO10 5DD, N Yorkshire, England.	jim.allan@egu.york.ac.uk	Allan, James/B-4448-2009	Allan, James/0000-0002-7580-5087				Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BenYehuda D, 1996, BLOOD, V88, P4296; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Boulton E, 2003, BLOOD, V101, P2349, DOI 10.1182/blood-2002-08-2394; Casorelli I, 2003, DNA REPAIR, V2, P547, DOI 10.1016/S1568-7864(03)00020-X; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Clark DJ, 1996, GENE CHROMOSOME CANC, V16, P238, DOI 10.1002/(SICI)1098-2264(199608)16:4<238::AID-GCC3>3.3.CO;2-L; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Davies SM, 2001, MED PEDIATR ONCOL, V36, P536, DOI 10.1002/mpo.1126; Delwail V, 2002, BRIT J HAEMATOL, V118, P189, DOI 10.1046/j.1365-2141.2002.03564.x; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Gaymes TJ, 2002, CANCER RES, V62, P2791; Giot L, 1997, GENETICS, V146, P1239; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hatch SB, 2005, CLIN CANCER RES, V11, P2180, DOI 10.1158/1078-0432.CCR-04-0234; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Karran P, 2003, BIOCHIMIE, V85, P1149, DOI 10.1016/j.biochi.2003.10.007; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; Loeb LA, 2001, CANCER RES, V61, P3230; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Mohammad H, 2002, BRIT J HAEMATOL, V117, P359, DOI 10.1046/j.1365-2141.2002.03458.x; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Pedersen-Bjergaard J, 2002, BLOOD, V99, P1909, DOI 10.1182/blood.V99.6.1909; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; Qin XS, 2000, CARCINOGENESIS, V21, P833, DOI 10.1093/carcin/21.4.833; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Thirman MJ, 1996, HEMATOL ONCOL CLIN N, V10, P293, DOI 10.1016/S0889-8588(05)70340-3; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang ZM, 2001, J NATL CANCER I, V93, P1473, DOI 10.1093/jnci/93.19.1473; Worrillow LJ, 2003, CLIN CANCER RES, V9, P3012; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	47	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1709	1720		10.1038/sj.onc.1209208	http://dx.doi.org/10.1038/sj.onc.1209208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278672				2022-12-28	WOS:000236013700003
J	Deep, G; Singh, RP; Agarwal, C; Kroll, DJ; Agarwal, R				Deep, G; Singh, RP; Agarwal, C; Kroll, DJ; Agarwal, R			Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin	ONCOGENE			English	Article						prostate cancer; silibinin; silymarin; cell cycle arrest; cyclin-dependent kinase	DEPENDENT KINASE INHIBITORS; THISTLE SILYBUM-MARIANUM; CARCINOMA DU145 CELLS; DNA-DAMAGE; CHECKPOINT CONTROL; BREAST-CANCER; MILK THISTLE; FLAVONOID ANTIOXIDANT; CDC25B PHOSPHATASE; MAMMALIAN-CELLS	Here, we assessed and compared the anticancer efficacy and associated mechanisms of silymarin and silibinin in human prostate cancer (PCA) PC3 cells; silymarin is comprised of silibinin and its other stereoisomers, including isosilybin A, isosilybin B, silydianin, silychristin and isosilychristin. Silymarin and silibinin (50-100 mu g/ml) inhibited cell proliferation, induced cell death, and caused G1 and G2-M cell cycle arrest in a dose/time-dependent manner. Molecular studies showed that G1 arrest was associated with a decrease in cyclin D1, cyclin D3, cyclin E, cyclin-dependent kinase (CDK)4, CDK6 and CDK2 protein levels, and CDK2 and CDK4 kinase activity, together with an increase in CDK inhibitors (CDKIs) Kip1/p27 and Cip1/p21. Further, both agents caused cytoplasmic sequestration of cyclin D1 and CDK2, contributing to G1 arrest. The G2-M arrest by silibinin and silymarin was associated with decreased levels of cyclin B1, cyclin A, pCdc2 (Tyr15), Cdc2, and an inhibition of Cdc2 kinase activity. Both agents also decreased the levels of Cdc25B and cell division cycle 25C (Cdc25C) phosphatases with an increased phosphorylation of Cdc25C at Ser216 and its translocation from nucleus to the cytoplasm, which was accompanied by an increased binding with 14-3-3 beta. Both agents also increased checkpoint kinase (Chk)2 phosphorylation at Thr68 and Ser19 sites, which is known to phosphorylate Cdc25C at Ser216 site. Chk2-specific small interfering RNA largely attenuated the silymarin and silibinin-induced G2-M arrest. An increase in the phosphorylation of histone 2AX and ataxia telangiectasia mutated was also observed. These findings indicate that silymarin and silibinin modulate G1 phase cyclins-CDKs-CDKIs for G1 arrest, and the Chk2-Cdc25C-Cdc2/cyclin B1 pathway for G2-M arrest, together with an altered subcellular localization of critical cell cycle regulators. Overall, we observed comparable effects for both silymarin and silibinin at equal concentrations by weight, suggesting that silibinin could be a major cell cycle-inhibitory component in silymarin. However, other silibinin stereo-isomers present in silymarin also contribute to its efficacy, and could be of interest for future investigation.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80202 USA; Ctr Organ & Med Chem, Nat Prod Lab, Res Triangle Pk, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu	Deep, Gagan/H-1853-2012		NATIONAL CANCER INSTITUTE [R01CA104286, R01CA102514] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102514, R01 CA104286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; *AM CANC SOC, 2008, CANC FACTS FIG 2008, P1; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BARTKOVA J, 1995, CANCER RES, V55, P949; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Flora K, 1998, AM J GASTROENTEROL, V93, P139, DOI 10.1111/j.1572-0241.1998.00139.x; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GILLETT C, 1994, CANCER RES, V54, P1812; GRANA X, 1995, ONCOGENE, V11, P211; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hou DX, 2004, J BIOMED BIOTECHNOL, P321, DOI 10.1155/S1110724304403040; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kim NC, 2003, ORG BIOMOL CHEM, V1, P1684, DOI 10.1039/b300099k; Koivisto P, 1998, AM J PATHOL, V152, P1; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lammer C, 1998, J CELL SCI, V111, P2445; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lyon MA, 2002, NAT REV DRUG DISCOV, V1, P961, DOI 10.1038/nrd963; Mallikarjuna G, 2004, CANCER RES, V64, P6349, DOI 10.1158/0008-5472.CAN-04-1632; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McDonald ER, 2000, INT J ONCOL, V16, P871; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Neuhouser ML, 2004, NUTR CANCER, V50, P1, DOI 10.1207/s15327914nc5001_1; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pares A, 1998, J HEPATOL, V28, P615, DOI 10.1016/S0168-8278(98)80285-7; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Sharma G, 2003, ANTICANCER RES, V23, P2649; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh RP, 2004, CLIN CANCER RES, V10, P8641, DOI 10.1158/1078-0432.CCR-04-1435; Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Takagaki N, 2005, INT J ONCOL, V26, P185; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thelen P, 2004, J UROLOGY, V171, P1934, DOI 10.1097/01.ju.0000121329.37206.1b; Turowski P, 2003, MOL BIOL CELL, V14, P2984, DOI 10.1091/mbc.E02-08-0515; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; von Zglinicki T, 2005, MECH AGEING DEV, V126, P111, DOI 10.1016/j.mad.2004.09.034; WAGNER H, 1974, ARZNEIMITTEL-FORSCH, V24, P466; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang ES, 2003, J BIOL CHEM, V278, P46862, DOI 10.1074/jbc.M306340200; Ye RQ, 2004, DNA REPAIR, V3, P235, DOI 10.1016/j.dnarep.2003.10.014; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yih LH, 2000, CANCER RES, V60, P6346; Yim D, 2005, CANCER RES, V65, P1035; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zheng Xiang-Yi, 2004, Ai Zheng, V23, P215; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	85	132	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1053	1069		10.1038/sj.onc.1209146	http://dx.doi.org/10.1038/sj.onc.1209146			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205633				2022-12-28	WOS:000235361000010
J	Arroyo, JD; Hahn, WC				Arroyo, JD; Hahn, WC			Involvement of PP2A in viral and cellular transformation	ONCOGENE			English	Review						protein phosphatase 2A; SV40ST; transformation	PROTEIN PHOSPHATASE 2A; SMALL-T-ANTIGEN; SMALL TUMOR-ANTIGEN; SV40 LARGE-T; SIMIAN-VIRUS-40 LARGE-T; ANCHORAGE-INDEPENDENT GROWTH; PPP2R1B GENE ALTERATIONS; REGULATORY-A-SUBUNIT; MAP KINASE PATHWAY; VIRUS 40 GENE	Although the small DNA tumor virus SV40 ( simian virus 40) fails to replicate in human cells, understanding how SV40 transforms human and murine cells has and continues to provide important insights into cancer initiation and maintenance. The early region of SV40 encodes two oncoproteins: the large T ( LT) and small t ( ST) antigens. SV40 LT contributes to murine and human cell transformation in part by inactivating the p53 and retinoblastoma protein tumor suppressor proteins. SV40 ST inhibits the activity of the protein phosphatase 2A ( PP2A) family of serine-threonine phosphatases, and this interaction is required for SV40-mediated transformation of human cells. PP2A regulates multiple signaling pathways, suggesting many possible targets important for viral replication and cell transformation. Genetic manipulation of particular PP2A subunits has confirmed a role for specific complexes in transformation, and recent work implicates the perturbation of the phosphatidylinositol 3-kinase/Akt pathway and c-Myc stability in transformation by ST and PP2A. Mutations in PP2A subunits occur at low frequency in human tumors, suggesting that alterations of PP2A signaling play a role in both experimentally induced and spontaneously arising cancers. Unraveling the complexity of PP2A signaling will not only provide further insights into cancer development but may identify novel targets with promise for therapeutic manipulation.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Harvard Univ, Broad Inst, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Dana 710C, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu		Arroyo, Jason/0000-0002-5674-6739	NCI NIH HHS [P01 CA50661, K01 CA94223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050661, K01CA094223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIKEL I, 1986, MOL CELL BIOL, V6, P1172, DOI 10.1128/MCB.6.4.1172; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CHANG LS, 1985, VIROLOGY, V146, P246, DOI 10.1016/0042-6822(85)90008-X; CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cole CN, 1996, FIELDS VIROLOGY, P1997; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; CRAWFORD LV, 1978, P NATL ACAD SCI USA, V75, P117, DOI 10.1073/pnas.75.1.117; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Deichmann M, 2001, MELANOMA RES, V11, P577, DOI 10.1097/00008390-200112000-00004; DERONDE A, 1989, VIROLOGY, V171, P260, DOI 10.1016/0042-6822(89)90534-5; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; Francia G, 1999, INT J CANCER, V82, P709, DOI 10.1002/(SICI)1097-0215(19990827)82:5<709::AID-IJC14>3.3.CO;2-I; GLUZMAN Y, 1982, VIROLOGY, V123, P78, DOI 10.1016/0042-6822(82)90296-3; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; MARTIN RG, 1975, J VIROL, V15, P599, DOI 10.1128/JVI.15.3.599-612.1975; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Moreno CS, 2004, CANCER RES, V64, P6978, DOI 10.1158/0008-5472.CAN-04-1150; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PAUCHA E, 1978, P NATL ACAD SCI USA, V75, P2165, DOI 10.1073/pnas.75.5.2165; Porras A, 1996, J VIROL, V70, P6902; PRIVES C, 1977, P NATL ACAD SCI USA, V74, P457, DOI 10.1073/pnas.74.2.457; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; RUBIN H, 1982, CELL, V30, P469, DOI 10.1016/0092-8674(82)90244-6; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; RUNDELL K, 1982, J VIROL, V42, P1135, DOI 10.1128/JVI.42.3.1135-1137.1982; RUNDELL K, 1981, J VIROL, V37, P1090, DOI 10.1128/JVI.37.3.1090-1093.1981; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SEGAWA K, 1993, ONCOGENE, V8, P543; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; SILVA OBDC, 1987, FEBS LETT, V226, P176; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stevens I, 2003, EUR J BIOCHEM, V270, P376, DOI 10.1046/j.1432-1033.2003.03398.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Suzuki K, 2003, INT J ONCOL, V23, P1263; Suzuki K, 2005, J CELL PHYSIOL, V203, P487, DOI 10.1002/jcp.20249; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tamaki M, 2004, ONCOL REP, V11, P655; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; USUI H, 1988, J BIOL CHEM, V263, P3752; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1988, J VIROL, V62, P4760, DOI 10.1128/JVI.62.12.4760-4762.1988; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YANG YC, 1979, J VIROL, V32, P147, DOI 10.1128/JVI.32.1.147-154.1979; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	143	181	191	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7746	7755		10.1038/sj.onc.1209038	http://dx.doi.org/10.1038/sj.onc.1209038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299534				2022-12-28	WOS:000233372600010
J	Mathieu, J; Giraudier, S; Lanotte, M; Besancon, F				Mathieu, J; Giraudier, S; Lanotte, M; Besancon, F			Retinoid-induced activation of NF-kappa B in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; ROS; JNK; ATRA; APL	ACUTE PROMYELOCYTIC LEUKEMIA; EWING SARCOMA-CELLS; ALPHA-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; JNK ACTIVATION; NEUTROPHIL APOPTOSIS; SIGNAL-TRANSDUCTION; MOLECULAR-BIOLOGY; ACID SYNDROME	All-trans retinoic acid (ATRA) significantly improves the survival of patients with acute promyelocytic leukemia (APL) by inducing granulocytic differentiation of leukemia cells. Since an activation of the transcription factor NF-kappa B occurs during ATRA-induced maturation of APL cells, a mechanistic link between these two processes was investigated. Using an in vitro model for APL, we report that ectopic overexpression of a repressor of NF-kappa B activation did not affect granulocytic differentiation. Importantly, NF-kappa B inhibition markedly resulted in a decreased viability of the differentiated cells, which correlated with increased apoptosis. Apoptosis was accompanied by a sustained activation of the c-Jun N-terminal kinase (JNK). Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal. Furthermore, impairment of NF-kappa B activation resulted in increased levels of reactive oxygen species (ROS) upon ATRA treatment. ROS accumulation was suppressed by the antioxidant butylated hydroxyanisol, which also abolished ATRA-induced JNK activation and apoptosis. Altogether, our results demonstrate an antiapoptotic effect of NF-kappa B activation during ATRA-induced differentiation of NB4 cells and identify repression of ROS-mediated JNK activation as a mechanism for this effect. Our observations also suggest that NF-kappa B signalling may contribute to an accumulation of mature APL cells and participate in the development of ATRA syndrome.	Hop St Louis, INSERM, U685, Ctr Hayem, F-75475 Paris, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Besancon, F (corresponding author), Hop St Louis, INSERM, U685, Ctr Hayem, 1 Ave Claude Vellefaux, F-75475 Paris, France.	francoise.besancon@stlouis.inserm.fr						Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akgul C, 2003, CELL MOL LIFE SCI, V60, P2402, DOI 10.1007/s00018-003-3110-z; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Berry DM, 2002, EXP CELL RES, V272, P176, DOI 10.1006/excr.2001.5410; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen F, 2003, CANCER RES, V63, P7689; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grolleau A, 1999, J IMMUNOL, V162, P3491; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Komura E, 2005, CANCER RES, V65, P3281, DOI 10.1158/0008-5472.CAN-04-2339; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LANOTTE M, 1991, BLOOD, V77, P1080; Larson RS, 2003, BEST PRACT RES CL HA, V16, P453, DOI 10.1016/S1521-6926(03)00043-4; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Puccetti E, 2004, LEUKEMIA, V18, P1169, DOI 10.1038/sj.leu.2403367; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Slack JL, 1999, CANC TREAT, V99, P75; Tallman MS, 2000, BLOOD, V95, P90; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	64	20	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7145	7155		10.1038/sj.onc.1208889	http://dx.doi.org/10.1038/sj.onc.1208889			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044154				2022-12-28	WOS:000232990100004
J	Kanda, A; Kawai, H; Suto, S; Kitajima, S; Sato, S; Takata, T; Tatsuka, M				Kanda, A; Kawai, H; Suto, S; Kitajima, S; Sato, S; Takata, T; Tatsuka, M			Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation	ONCOGENE			English	Article						transformation susceptibility; Ras; Src; Raf; Aurora; kinase	AURORA-B KINASE; CHROMOSOMAL PASSENGER COMPLEX; HAMSTER EMBRYO CELLS; HISTONE H3; NEOPLASTIC TRANSFORMATION; ONCOGENIC TRANSFORMATION; MITOTIC PHOSPHORYLATION; CLEAVAGE FURROW; CYTOKINESIS; SURVIVIN	Aurora-B, previously known as AIM-1, is a conserved eukaryotic mitotic protein kinase. In mammals, this kinase plays an essential role in chromosomal segregation processes, including chromosome condensation, alignment, control of spindle checkpoints, chromosome segregation, and cytokinesis. Aurora-B is overexpressed in various cancer cells, suggesting that the kinase activity perturbs chromosomal segregation processes. Its forced overexpression induces chromosomal number instability and progressive tumorigenicity in rodent cells in vitro and in vivo. Nevertheless, based on focus formation in BALB/c 3T3 A31-1-1 cells, Aurora-B is not oncogenic. Here, we show that Aurora- B kinase activity augments Ras-mediated cell transformation. RNA interference with short hairpin RNA inhibits transformation by Ras and its upstream oncogene Src, but not by the downstream oncogene Raf. In addition, the inner centromere protein, which is a passenger protein associated with Aurora-B, has a similar ability to potentiate the activity of oncogenic Ras. These data indicate that elevated Aurora-B activity promotes transformation by oncogenic Ras by enhancing oncogenic signaling and by converting chromosome number-stable cells to aneuploid cells.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Div Genome Biol, Dept Mol Radiobiol,Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Oral & Maxillofacial Pathobiol,Minami Ku, Hiroshima 734, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Tatsuka, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	haruo@hiroshima-u.ac.jp		Kawai, Hidehiko/0000-0003-2213-7166; Kitajima, Shojiro/0000-0002-4000-0473				Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen JG, 2002, CANCER RES, V62, P1935; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Fukuda S, 2004, BIOCHEM BIOPH RES CO, V323, P636, DOI 10.1016/j.bbrc.2004.08.149; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; HEI TK, 1993, CANCER RES, V53, P1368; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KAKUNAGA T, 1985, TRANSFORMATION ASSAY; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; KIZAKA S, 1989, MOL CELL BIOL, V9, P5669, DOI 10.1128/MCB.9.12.5669; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Ota T, 2002, CANCER RES, V62, P5168; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; SHIMIZU T, 1995, JPN J CANCER RES, V86, P546, DOI 10.1111/j.1349-7006.1995.tb02433.x; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; Tatsuka M, 1998, CANCER RES, V58, P4811; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TATSUKA M, 2005, SIGNAL TRANSDUCTION; Temme A, 2005, BIOCHEM BIOPH RES CO, V327, P765, DOI 10.1016/j.bbrc.2004.12.075; Temme A, 2003, MOL BIOL CELL, V14, P78, DOI 10.1091/mbc.E02-04-0182; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; TSUTSUI T, 1984, CARCINOGENESIS, V5, P89, DOI 10.1093/carcin/5.1.89; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; YAGI T, 1989, MOL CARCINOGEN, V1, P222, DOI 10.1002/mc.2940010404; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	50	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7266	7272		10.1038/sj.onc.1208884	http://dx.doi.org/10.1038/sj.onc.1208884			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027732				2022-12-28	WOS:000233142100002
J	Bernassola, F; Oberst, A; Melino, G; Pandolfi, PP				Bernassola, F; Oberst, A; Melino, G; Pandolfi, PP			The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63	ONCOGENE			English	Article						p63; PML; nuclear body; transcription	PREMATURE SENESCENCE; ONCOGENIC RAS; P53 HOMOLOG; PML; EXPRESSION; P73; CANCER; DELTA-NP63-ALPHA; CARCINOMAS; ENCODES	p63 plays unique developmental roles in epidermal morphogenesis, despite its structural similarity with p53. The p63 gene has two distinct promoters, coding for proteins containing an N-terminal transactivation domain ( TA isoforms) and for proteins lacking this region (Delta N isoforms). The full-length transcriptionally active TAp63 isoforms are capable of transactivating the majority of the p53 target promoters thus inducing cell cycle arrest and apoptosis. On the contrary, the Delta Np63 isoforms seem to counteract the transactivation activities of p53 and TAp63 proteins, thus possibly conferring a proliferative advantage to cancer cells. However, the molecular mechanisms controlling the transcriptional activity of p63 remain largely unclear. Here we present data indicating that (i) the promyelocytic leukaemia protein ( PML) physically interacts with p63, (ii) p63 is localized into the PML nuclear-bodies ( PML-NBs) in vivo, and (iii) PML regulates p63 transcriptional activity. We show that the interaction of p63 with PML increases the levels of p63 in cultured cells as well as its ability to transactivate the p53-responsive elements of the GADD45, p21 and bax promoters. These data are consistent with a general role for PML as a functional modulator of all the p53 family members. Our findings strengthen the relevance of the cross talk between PML and the p53 family members, imply a new tumour suppressive function of PML and unveil a possible role for PML in epidermal morphogenesis and differentiation.	Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA; Univ Roma Tor Vergata, Dept Expt Med, IDI, IRCCS,Biochem Lab, I-00133 Rome, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Memorial Sloan Kettering Cancer Center; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Leicester	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org			NCI NIH HHS [CA-71692] Funding Source: Medline; Telethon [GGP04110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA071692, R01CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Weber A, 2002, VIRCHOWS ARCH, V441, P428, DOI 10.1007/s00428-002-0705-y; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	29	39	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6982	6986		10.1038/sj.onc.1208843	http://dx.doi.org/10.1038/sj.onc.1208843			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007146				2022-12-28	WOS:000232701700013
J	Tynan, JA; Wen, F; Muller, WJ; Oshima, RG				Tynan, JA; Wen, F; Muller, WJ; Oshima, RG			Ets2-dependent microenvironmental support of mouse mammary tumors	ONCOGENE			English	Article						Ets2; breast cancer; Cre recombinase; stroma	EXPRESSION; ONCOGENE; MODEL; ETS2; MICE	Decreasing the amount of active mouse Ets2 transcription factor by half in mice or use of a MAP kinase insensitive hypomorphic targeted Ets2 allele restricts the appearance of transgenic mammary tumors caused by either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2. In addition, the early growth of transplanted mammary tumors is limited by restricted Ets2 activity of the host. Here we have tested genetically, with the use of a conditional Ets2(flox) allele and tissue specific Cre recombinase expression, whether Ets2 also functions within tumor cells by inactivating Ets2 within mammary luminal epithelial cells from which transgenic PyMTY315/(322F) tumors arise. We find that inactivation of Ets2 within tumor cells has no effect on tumor appearance or growth. By contrast, complete inactivation of Ets2 in both epithelial and stromal cells moderates the early hyperplastic phase of tumor development and the time of tumor appearance but does not prevent tumor occurrence and has no detectable effect on tumor growth. Thus, Ets2 supports mammary tumors exclusively through their microenvironment.	Burnham Inst, Canc Res Ctr, Oncodev Biol Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92093 USA; McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; McGill University	Oshima, RG (corresponding author), Burnham Inst, Canc Res Ctr, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@burnham.org			NCI NIH HHS [1T32CA77109-04, CA098778, CA74547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074547, T32CA077109, R01CA098778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hayakawa T, 2001, J STAT PLAN INFER, V97, P101, DOI 10.1016/S0378-3758(00)00348-7; Hever A, 2003, EXP CELL RES, V290, P132, DOI 10.1016/S0014-4827(03)00315-X; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Neznanov N, 1999, CANCER RES, V59, P4242; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; Sapi E, 1998, CANCER RES, V58, P1027; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	15	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6870	6876		10.1038/sj.onc.1208856	http://dx.doi.org/10.1038/sj.onc.1208856			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007139	Green Submitted			2022-12-28	WOS:000232701700002
J	Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL			E12 and E47 modulate cellular localization and proteasome-mediated degradation of MyoD and Id1	ONCOGENE			English	Article						E12; E47; Id1; MyoD; ubiquitin proteasome degradation	KAPPA-B-ALPHA; NUCLEAR-LOCALIZATION; DNA-BINDING; PROTEINS; PHOSPHORYLATION	Programs of tissue differentiation are likely controlled by factors regulating gene expression and protein degradation. In muscle, the degradation of the muscle transcription factor MyoD and its inhibitor Id1 occurs via the ubiquitin-proteasome system. E12 and E47, splice products of the E2A gene, interact with MyoD to activate transcription of the muscle program and are also degraded by the ubiquitin-proteasome system (t(1/2) = similar to 6 h). E12 and E47 each contain two regions of basic amino acids, which, when mutated, lead to cytoplasmic accumulation of the proteins. These NLS mutants ( E12(NLS), E47(NLS)) are degraded with a half-life similar to the wild-type proteins. In nonmuscle cells, cotransfection of either E12 or E47 with MyoD extended MyoD's half-life from similar to 1 to similar to 4h. In addition, cotransfection of either E12 or E47 with Id1 led to a marked reduction in Id1's degradation rate from t(1/2) of similar to 1 to similar to 8 h. Furthermore, the cotransfection of NLS deficient mutants of MyoD or Id1 with E12 or E47 resulted in altered intracellular localization of the proteins largely dependent upon the E12 or E47 moiety. Cotransfection of wild-type MyoD or Id1 with NLS deficient mutants of E12 or E47 also led to an altered intracellular localization of MyoD and Id1. These results demonstrate in vivo that E12 and E47 modulate both MyoD and Id1 degradation and may have implications for the physiological regulation of muscle development.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Collavoli A, 2003, J MOL CELL CARDIOL, V35, P1191, DOI 10.1016/S0022-2828(03)00231-1; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	19	43	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6376	6384		10.1038/sj.onc.1208789	http://dx.doi.org/10.1038/sj.onc.1208789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007194				2022-12-28	WOS:000232038200005
J	Lin, HK; Bergmann, S; Pandolfi, PP				Lin, HK; Bergmann, S; Pandolfi, PP			Deregulated TGF-beta signaling in leukemogenesis	ONCOGENE			English	Article						TGF-beta; cPML; SARA; Smad2/3; PML-RAR alpha	GROWTH-FACTOR-BETA; ACUTE PROMYELOCYTIC LEUKEMIA; FYVE DOMAIN PROTEIN; MONOCYTIC DIFFERENTIATION; TARGETED DISRUPTION; HEMATOPOIETIC-CELLS; EARLY ENDOSOMES; PML PROTEIN; LIPID RAFTS; IN-VIVO	Cellular homeostasis is tightly controlled by the various pathways that regulate cell proliferation and cell death. Breaking this balance is often associated with cancer development. The transforming growth factor-beta (TGF-beta) pathway plays an important role in cellular homeostasis by regulating cell growth inhibition, cellular senescence, differentiation and apoptosis. Deregulated TGF-beta signaling is known to be involved in a variety of human cancers, including those of the colon, pancreas, breast and prostate. While TGF-beta is a potent negative regulator of hematopoiesis, the role of aberrant TGF-beta signaling in leukemogenesis remains largely unknown. Recently, evidence demonstrating deregulated TGF-beta signaling in leukemogenesis, particularly in acute promyelocytic leukemia (APL), has started to emerge. In this review, we summarize the current progress towards the understanding of the molecular mechanisms by which aberrant TGF-beta signaling may participate in leukemogenesis.	Sloan Kettering Inst, Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Sloan Kettering Inst, Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org						Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fortunel NO, 2000, BLOOD, V96, P2022; Fortunel NO, 2003, ONCOL RES, V13, P445; GOEY H, 1989, J IMMUNOL, V143, P877; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jordan CT, 2004, ONCOGENE, V23, P7178, DOI 10.1038/sj.onc.1207935; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; KRONENWETT R, 2005, IN PRESS ONCOGENE; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Le Roy C, 2004, NATURE, V431, P142, DOI 10.1038/431142a; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LeBousseKerdiles MC, 1996, BLOOD, V88, P4534, DOI 10.1182/blood.V88.12.4534.bloodjournal88124534; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Martinez-Alvarez C, 2004, DEV BIOL, V265, P207, DOI 10.1016/j.ydbio.2003.09.022; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mori A, 2000, ACTA HAEMATOL-BASEL, V103, P220, DOI 10.1159/000041054; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RAZA A, 1992, BLOOD, V79, P1037; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; TESTA U, 1993, J IMMUNOL, V150, P2418; TESTA U, 1994, CANCER RES, V54, P4508; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VanRanst PCF, 1996, EXP HEMATOL, V24, P1509; Wang ZG, 1998, SCIENCE, V279, P1547; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	65	39	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5693	5700		10.1038/sj.onc.1208923	http://dx.doi.org/10.1038/sj.onc.1208923			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123802				2022-12-28	WOS:000231452800004
J	Zuo, X; Wu, Y; Morris, JS; Stimmel, JB; Leesnitzer, LM; Fischer, SM; Lippman, SM; Shureiqi, I				Zuo, X; Wu, Y; Morris, JS; Stimmel, JB; Leesnitzer, LM; Fischer, SM; Lippman, SM; Shureiqi, I			Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity	ONCOGENE			English	Article						15-lipoxygenase-1; PPAR-gamma; PPAR-delta; colon cancer	PROLIFERATOR-ACTIVATED RECEPTOR; COLORECTAL-CANCER CELLS; ADIPOCYTE DIFFERENTIATION; COLON CARCINOGENESIS; NUCLEAR RECEPTORS; DELTA; APOPTOSIS; LIGANDS; 15-LIPOXYGENASE-1; EXPRESSION	Peroxisome proliferator-activated receptors (PPARs) are transcription factors that strongly influence molecular events in normal and cancer cells. PPAR-beta/delta (PPAR-b/d) overexpression suppresses the activity of PPAR-gamma (PPAR-g) and PPAR-alpha. This interaction has been questioned, however, by studies with synthetic ligands of PPARs in PPAR-b/d-null cells, and it is not known whether an interaction between PPAR-b/d and PPAR-g exists, especially in relation to the signaling by natural PPAR ligands. Oxidative metabolites of linoleic and arachidonic acids are natural ligands of PPARs. 13-S-hydroxyoctadecadienoic acid (13-S-HODE), the main product of 15-lipoxygenase-1 (15-LOX-1) metabolism of linoleic acid, downregulates PPAR-b/d. We tested (a) whether PPAR-b/d expression modulates PPAR-g activity in experimental models of the loss and gain of PPAR-b/d function in colon cancer cells and (b) whether 15-LOX-1 formation of 13-S-HODE influences the interaction between PPAR-b/d and PPAR-g. We found that (a) 15-LOX-1 formation of 13-S-HODE promoted PPAR-gactivity, (b) PPAR-b/d expression suppressed PPAR-gactivity in models of both loss and gain of PPAR-b/d function, (c) 15-LOX-1 activated PPAR-g by downregulating PPAR-b/d, and (d) 15-LOX-1 expression induced apoptosis in colon cancer cells via modulating PPAR-b/d suppression of PPAR-g. These findings elucidate a novel mechanism of the signaling by natural ligands of PPARs, which involves modulating the interaction between PPAR-b/d and PPAR-g.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77230 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX USA; GlaxoSmithKline Inc, Dept Screening & Cmpd Profiling, Res Triangle Pk, NC USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360,1515 Holcombe Blvd, Houston, TX 77230 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Zuo, Xiangsheng/0000-0002-8593-1132; Shureiqi, Imad/0000-0003-2019-938X	NATIONAL CANCER INSTITUTE [R01CA104278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104278] Funding Source: Medline; NIEHS NIH HHS [ES07784, P30 ES007784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bull AW, 2003, CARCINOGENESIS, V24, P1717, DOI 10.1093/carcin/bgg131; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Matsusue K, 2004, FASEB J, V18, P1477, DOI 10.1096/fj.04-1944fje; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Nixon JB, 2003, PROSTAG LEUKOTR ESS, V68, P323, DOI 10.1016/S0952-3278(03)00023-1; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2003, BBA-MOL CELL BIOL L, V1632, P80, DOI 10.1016/S1388-1981(03)00065-9; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rusinol AE, 2000, J BIOL CHEM, V275, P7296, DOI 10.1074/jbc.275.10.7296; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Yu JS, 2003, CANCER RES, V63, P6170	36	84	87	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 23	2006	25	8					1225	1241		10.1038/sj.onc.1209160	http://dx.doi.org/10.1038/sj.onc.1209160			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16288226	Green Accepted			2022-12-28	WOS:000235537500010
J	Feng, Z; Jin, S; Zupnick, A; Hoh, J; de Stanchina, E; Lowe, S; Prives, C; Levine, AJ				Feng, Z; Jin, S; Zupnick, A; Hoh, J; de Stanchina, E; Lowe, S; Prives, C; Levine, AJ			p53 tumor suppressor protein regulates the levels of huntingtin gene expression	ONCOGENE			English	Article						p53; hungtingtin; Huntington's disease; p53-responsive element; transcription regulation; gene expression	MONOZYGOTIC TWINS	The p53 protein is a transcription factor that integrates various cellular stress signals. The accumulation of the mutant huntingtin protein with an expanded polyglutamine tract plays a central role in the pathology of human Huntington's disease. We found that the huntingtin gene contains multiple putative p53-responsive elements and p53 binds to these elements both in vivo and in vitro. p53 activation in cultured human cells, either by a temperature-sensitive mutant p53 protein or by gamma-irradiation (gamma-irradiation), increases huntingtin mRNA and protein expression. Similarly, murine huntingtin also contains multiple putative p53-responsive elements and its expression is induced by p53 activation in cultured cells. Moreover, gamma-irradiation, which activates p53, increases huntingtin gene expression in the striatum and cortex of mouse brain, the major pathological sites for Huntington's disease, in p53+/+ but not the isogenic p53 -/- mice. These results demonstrate that p53 protein can regulate huntingtin expression at transcriptional level, and suggest that a p53 stress response could be a modulator of the process of Huntington's disease.	Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA; Univ Med & Dent New Jersey, Dept Pharmacol, Piscataway, NJ 08854 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Cold Spring Harbor Labs, Cold Spring Harbor, NY USA; Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Yale University; Cold Spring Harbor Laboratory; Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu						Anca MH, 2004, AM J MED GENET A, V124A, P89, DOI 10.1002/ajmg.a.20328; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dixon KT, 2003, GENE EXPRESSION, V11, P221, DOI 10.3727/000000003783992234; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Georgiou N, 1999, MOVEMENT DISORD, V14, P320, DOI 10.1002/1531-8257(199903)14:2<320::AID-MDS1018>3.0.CO;2-Z; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Jin SK, 2001, J CELL SCI, V114, P4139; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	20	77	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					1	7		10.1038/sj.onc.1209021	http://dx.doi.org/10.1038/sj.onc.1209021			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16278683				2022-12-28	WOS:000234406400001
J	Hara, T; Abe, M; Inoue, H; Yu, LR; Veenstra, TD; Kang, YH; Lee, KS; Miki, T				Hara, T; Abe, M; Inoue, H; Yu, LR; Veenstra, TD; Kang, YH; Lee, KS; Miki, T			Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341 in G2/M phase	ONCOGENE			English	Article						exchange factor; Rho GTPases; Cdk1; interacting proteins; cell division	EXCHANGE FACTOR ECT2; RHOA; SPINDLE; MIDBODY; DOMAINS; GTPASES; CDK1; CDC2	The Rho activator ECT2 functions as a key regulator in cytokinesis. ECT2 is phosphorylated during G2/M phase, but the physiological significance of this event is not well known. In this study, we show that phosphorylation of ECT2 at threonine-341 (T341) affects the autoregulatory mechanism of ECT2. In G2/M phase, ECT2 was phosphorylated at T341 most likely by Cyclin B/Cyclindependent kinase 1 (Cdk1), and then dephosphorylated before cytokinesis. Depletion of ECT2 by RNA interference (RNAi) efficiently induced multinucleate cells. Expression of the phospho-deficient mutant of ECT2 at T341 suppressed the multinucleation induced by RNAi to ECT2, indicating that ECT2 is biologically active even when it is not phosphorylated at T341. However, the phospho-mimic mutation at T341 weakly stimulates the catalytic activity of ECT2 as detected by serum response element reporter gene assays. As T341 is located at the hinge region of the N-terminal regulatory domain and C-terminal catalytic domain, phosphorylation of T341 may help accessing downstream signaling molecules to further activate ECT2. We found that the phospho-mimic mutation T341D increases binding with itself or the N-terminal half of ECT2. These results suggest a conformational change of ECT2 upon phosphorylation at T341. Therefore, ECT2 activity might be regulated by the phosphorylation status of T341. We propose that T341 phosphorylation by Cyclin B/Cdk1 could be a trigger for further activation of ECT2.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, Bethesda, MD 20892 USA; NCI, Lab Prote & Analyt Technol, SAIC Frederick Inc, Frederick, MD 21701 USA; NCI, Lab Metab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, Bldg 37,Room 2144,37 Convent Dr MSC 4256, Bethesda, MD 20892 USA.	toru@helix.nih.gov	Abe, Mitsuhiro/C-3602-2017	Yu, Li-Rong/0000-0001-6084-991X	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; James P, 1996, GENETICS, V144, P1425; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lowery DM, 2004, CELL CYCLE, V3, P128; Matuliene J, 2004, MOL BIOL CELL, V15, P3083, DOI 10.1091/mbc.E03-12-0888; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; O'Keefe L, 2001, CELL STRUCT FUNCT, V26, P619, DOI 10.1247/csf.26.619; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Yoshizaki H, 2004, J BIOL CHEM, V279, P44756, DOI 10.1074/jbc.M402292200	26	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					566	578		10.1038/sj.onc.1209078	http://dx.doi.org/10.1038/sj.onc.1209078			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170345				2022-12-28	WOS:000234897400008
J	Joshi, S; Guleria, R; Pan, J; DiPette, D; Singh, US				Joshi, S; Guleria, R; Pan, J; DiPette, D; Singh, US			Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells	ONCOGENE			English	Article						neuroblastoma; SH-SY5Y; IMR-32; retinoic acid; RAR; RXR; tissue-transglutaminase	CENTRAL-NERVOUS-SYSTEM; GROWTH IN-VIVO; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; UP-REGULATION; TUMOR-GROWTH; MATRIX-METALLOPROTEINASE-9 EXPRESSION; MATRIX-METALLOPROTEINASE; KINASE PATHWAYS; ACTIVATION	Long-term treatment with all trans-retinoic acid ( RA) induces neuronal differentiation and apoptosis. However, the effect of short-term RA treatment on cell proliferation, migration and invasion of neuroblastoma cell lines (SH-SY5Y and IMR-32) remains unclear. RA induces expression of tissue-transglutaminase ( TGase) and promotes migration and invasion after 24 h of treatment in SH-SY5Y cells, but not in IMR-32 cells. RA receptor (RAR) agonist (4-(E-2-[5,6,7,8-tetrahydro-5,5,8,8-tetramethy-2- naphthalenyl]-1-propenyl) benzoic acid) and RAR/retinoid X receptor (RXR) agonist (9-cis-RA) promote expression of TGase, migration and invasion of SH-SY5Y cells, while RXR agonist has no significant effect. RAR antagonist blocks RA effect on migration and invasion, indicating that RAR receptors are required. Retinoid receptors are expressed and activated by RA in both cell lines. However, only transient activation of RAR is observed in IMR-32 cells. These findings suggest that different responses observed in SH-SY5Y and IMR-32 cells could be due to differential activation of retinoid receptors. Overexpression of TGase has no effect on migration or invasion, while overexpression of antisense TGase blocks RA-induced migration and invasion, indicating that other molecules along with TGase mediate RA effects. In addition to the long-term effects of RA that are coupled with cell differentiation, short-term effects involve migration and invasion of neuroblastoma SH-SY5Y cells.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Dept Internal Med,Coll Med, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Temple, TX USA; Cent Texas Vet Hlth Care Syst, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center	Singh, US (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Dept Internal Med,Coll Med, Bldg 205,1901 S 1st St, Temple, TX 76504 USA.	Usingh@medicine.tamhsc.edu						Abel EL, 2001, J PEDIATR-US, V138, P295, DOI 10.1067/mpd.2001.107612; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Arvidsson Y, 2001, CELL DEATH DIFFER, V8, P1029, DOI 10.1038/sj.cdd.4400922; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; CICCARONE V, 1989, CANCER RES, V49, P219; DAVIES PJA, 1992, RETINOIDS NORMAL DEV; DENNING MF, 1991, BIOCHEM BIOPH RES CO, V175, P344, DOI 10.1016/S0006-291X(05)81241-0; Eggert A, 2002, CANCER RES, V62, P1802; Emionite L, 2003, ANTICANCER RES, V23, P13; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Farina AR, 2002, CELL GROWTH DIFFER, V13, P343; FESTUCCIA C, 1996, INT J CANC PRED ONCO, V69, P1; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; JULIANO R, 1994, CANCER METAST REV, V13, P25, DOI 10.1007/BF00690416; Kang SK, 2004, J BIOL CHEM, V279, P36593, DOI 10.1074/jbc.M402084200; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Klaassen I, 2001, INT J CANCER, V92, P661, DOI 10.1002/1097-0215(20010601)92:5<661::AID-IJC1251>3.0.CO;2-O; Leelawat K, 2005, CANCER LETT, V224, P303, DOI 10.1016/j.canlet.2004.10.016; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; MACKAY AR, 1992, INVAS METAST, V12, P168; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; NILES RM, 2004, MUTAT RES, V55, P97; Palm-Leis A, 2004, J BIOL CHEM, V279, P54905, DOI 10.1074/jbc.M407383200; PAN J, 2005, J NEUROCHEM, V10, P1; Phuangsab A, 2001, CANCER LETT, V172, P27, DOI 10.1016/S0304-3835(01)00617-6; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Ponthan F, 2001, MED PEDIATR ONCOL, V36, P127, DOI 10.1002/1096-911X(20010101)36:1<127::AID-MPO1030>3.0.CO;2-B; Ponthan F, 2003, INT J CANCER, V104, P418, DOI 10.1002/ijc.10954; PRAISE L, 2000, SEMIN CANCER BIOL, V10, P407; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; QUI H, 1999, AM J PATHOL, V155, P1519; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SATO H, 1992, ONCOGENE, V7, P77; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Soprano KJ, 2002, J NUTR, V132, p3809S, DOI 10.1093/jn/132.12.3809S; SPORN MB, 1994, RETINOIDS BIOL MED; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Sugiura Y, 1998, CANCER RES, V58, P2209; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Voigt A, 2003, MED PEDIATR ONCOL, V40, P205, DOI 10.1002/mpo.10250; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; XU C, 1997, CANCER RES, V57, P4992; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; XU XC, 1994, CANCER RES, V54, P3580; YAO M, 1995, J NEUROSCI RES, V41, P792, DOI 10.1002/jnr.490410610; Zang CB, 2000, J CANCER RES CLIN, V126, P33, DOI 10.1007/PL00008462; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	71	64	70	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					240	247		10.1038/sj.onc.1209027	http://dx.doi.org/10.1038/sj.onc.1209027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158052				2022-12-28	WOS:000234583600008
J	Li, X; Deng, W; Nail, CD; Bailey, SK; Kraus, MH; Ruppert, JM; Lobo-Ruppert, SM				Li, X; Deng, W; Nail, CD; Bailey, SK; Kraus, MH; Ruppert, JM; Lobo-Ruppert, SM			Snail induction is an early response to Gli1 that determines the effciency of epithelial transformation	ONCOGENE			English	Article						basal cell carcinoma; hedgehog; Snail; Gli1; epithelial cell; E-cadherin	BASAL-CELL CARCINOMAS; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; HAIR FOLLICLE MORPHOGENESIS; HEDGEHOG SIGNALING PATHWAY; SONIC-HEDGEHOG; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; REPRESSOR SNAIL	Gli family members mediate constitutive Hedgehog signaling in the common skin cancer, basal cell carcinoma (BCC). Snail/Snai1 is rapidly induced by Gli1 in vitro, and is coexpressed with Gli1 in human hair follicles and skin tumors. In the current study, we generated a dominant-negative allele of Snail, SnaZFD, composed of the zinc-finger domain and flanking sequence. In promoter -reporter assays, SnaZFD blocked the activity of wildtype Snail on the E-cadherin promoter. Snail loss-of-function mediated by SnaZFD or by one of several short hairpin RNAs inhibited transformation of RK3E epithelial cells by Gli1. Conversely, enforced expression of Snail promoted transformation in vitro by Gli1, but not by other genes that were tested, including Notch1, ErbB2, and N-Ras. As observed for Gli1, wild-type Snail repressed E-cadherin in RK3E cells and induced blebbing of the cytoplasmic membrane. Induction of a conditional Gli1 transgene in the basal keratinocytes of mouse skin led to rapid upregulation of Snail transcripts and to cell proliferation in the interfollicular epidermis. Established Gli1-induced skin lesions exhibited molecular similarities to BCC, including loss of E-cadherin. The results identify Snail as a Gli1-inducible effector of transformation in vitro, and an early Gli1-responsive gene in the skin.	Univ Alabama, Sch Med, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lobo-Ruppert, SM (corresponding author), Univ Alabama, Sch Med, Dept Med, Room 570 WTI, Birmingham, AL 35294 USA.	sruppert@uab.edu		Kammerud, Sarah/0000-0002-4808-1618	NCI NIH HHS [R01 CA065686, P50 CA097247, CA65686, P50CA097247, P30CA13148, CA094030, P30 CA013148, P50 CA089019, R29 CA065686, CA89019, R01 CA094030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097247, P30CA013148, R29CA065686, R01CA094030, R01CA065686, P50CA089019] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DEFIORE PP, 1987, SCIENCE, V237, P178; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hay ED, 1995, ACTA ANAT, V154, P8; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Ling G, 2001, ONCOGENE, V20, P7770, DOI 10.1038/sj.onc.1204946; Louro ID, 2002, CANCER RES, V62, P5867; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Miller SJ, 1995, CLIN DERMATOL, V13, P527, DOI 10.1016/0738-081X(95)00062-K; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; PIZARRO A, 1994, BRIT J CANCER, V69, P157, DOI 10.1038/bjc.1994.26; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	67	153	160	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					609	621		10.1038/sj.onc.1209077	http://dx.doi.org/10.1038/sj.onc.1209077			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158046	Green Accepted			2022-12-28	WOS:000234897400012
J	Nagano, K; Itagaki, C; Izumi, T; Nunomura, K; Soda, Y; Tani, K; Takahashi, N; Takenawa, T; Isobe, T				Nagano, K; Itagaki, C; Izumi, T; Nunomura, K; Soda, Y; Tani, K; Takahashi, N; Takenawa, T; Isobe, T			Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase	ONCOGENE			English	Article						Rb; Abl; tyrosine phosphorylation; chronic myelogenous leukemia; apoptosis	RETINOBLASTOMA PROTEIN; C-ABL; HISTONE DEACETYLASE; SUPPRESSOR; E2F; INHIBITION; MECHANISMS; APOPTOSIS; PEPTIDE; BINDING	The retinoblastoma (Rb) gene product is a tumor suppressor that is mutated or inactivated in many types of human cancers. Although Rb is known to be an upstream negative regulator of Abl protein tyrosine kinase, we propose here that Rb also functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive chronic myelogenous leukemia (CML). We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. We also show that ectopic expression of Rb induces apoptosis in Abl-dependent tumor cells by inhibiting the Abl tyrosine kinase activity, and that Rb-induced apoptosis is compromised by Abl-catalysed phosphorylation of Rb at Y805. Furthermore, the silencing of endogenous Rb by RNA interference induced apoptosis in Abl-dependent tumor cells. Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML.	Univ Tokyo, Inst Med Sci, Div Prote Res, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Div Mol Therapy, Adv Clin Res Ctr, Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Adv Mol & Cell Therapy, Higashi Ku, Fukuoka 812, Japan; Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Fuchu, Tokyo 183, Japan; Univ Tokyo, Inst Med Sci, Div Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; Kyushu University; Tokyo University of Agriculture & Technology; University of Tokyo	Isobe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Prote Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	isobe-toshiaki@c.metro-u.ac.jp	TAKAHASHI, Nobuhiro/G-1129-2013					BALTIMORE D, 1995, ANN NY ACAD SCI, V758, P339, DOI 10.1111/j.1749-6632.1995.tb24839.x; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Cujec TP, 2002, CHEM BIOL, V9, P253, DOI 10.1016/S1074-5521(02)00098-4; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Guo XYD, 1999, ONCOGENE, V18, P1589, DOI 10.1038/sj.onc.1202479; Harata M, 2004, BLOOD, V104, P1442, DOI 10.1182/blood-2004-02-0588; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318	35	18	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					493	502		10.1038/sj.onc.1208996	http://dx.doi.org/10.1038/sj.onc.1208996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158058				2022-12-28	WOS:000234897400001
J	Ren, J; Bharti, A; Raina, D; Chen, W; Ahmad, R; Kufe, D				Ren, J; Bharti, A; Raina, D; Chen, W; Ahmad, R; Kufe, D			MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90	ONCOGENE			English	Article						MUC1; heregulin; c-Src; HSP70; HSP90; mitochondria	CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; BREAST-CARCINOMA; MONOCLONAL-ANTIBODY; GENE-TRANSCRIPTION; CYTOPLASMIC TAIL; TYROSINE KINASE; PROTEIN IMPORT; MAMMARY-GLAND	The MUC1 heterodimeric transmembrane glycoprotein is aberrantly overexpressed by most human carcinomas. The MUC1 C-terminal subunit localizes to mitochondria and blocks stress-induced activation of the intrinsic apoptotic pathway. How MUC1 is delivered to mitochondria is not known. The present studies demonstrate that MUC1 forms intracellular complexes with HSP70 and HSP90. We show that the MUC1 cytoplasmic domain binds directly to HSP70 in vitro. By contrast, binding of MUC1 to HSP90 in vitro is induced by c-Src-mediated phosphorylation of the MUC1 cytoplasmic domain. c-Src also increases binding of MUC1 to HSP90 in cells. In concert with these results, we show that heregulin (HRG), a ligand for ErbB receptors, activates c-Src and, in turn, stimulates binding of MUC1 to HSP90. We also show that inhibitors of c-Src or HSP90 block HRG-induced targeting of MUC1 to mitochondria and integration of MUC1 into the mitochondrial outer membrane. These findings indicate that MUC1 is delivered to mitochondria by a mechanism involving activation of the ErbB receptor-c-Src pathway and transport by the molecular chaperone HSP70/HSP90 complex.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Huang L, 2003, CANCER BIOL THER, V2, P702; Kharbanda S, 1996, CANCER RES, V56, P3617; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LEVITAN F, 2005, IN PRESS J BIOL CHEM; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; MERLO GR, 1989, CANCER RES, V49, P6966; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586; PEREY L, 1992, CANCER RES, V52, P2563; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	43	106	114	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					20	31		10.1038/sj.onc.1209012	http://dx.doi.org/10.1038/sj.onc.1209012			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16158055				2022-12-28	WOS:000234406400003
J	Zu, K; Bihani, T; Lin, A; Park, YM; Mori, K; Ip, C				Zu, K; Bihani, T; Lin, A; Park, YM; Mori, K; Ip, C			Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells	ONCOGENE			English	Article						selenium; unfolded protein response; BiP/GRP78 knockdown; ER stress signalings	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; TRANSCRIPTION FACTOR ATF6; ER STRESS; MESSENGER-RNA; DIMERIZATION DOMAIN; INDUCIBLE PROTEIN; MAMMALIAN-CELLS; ACTIVATION; APOPTOSIS	Redox modi. cation of thiol/disulfide interchange in proteins by selenium could lead to protein unfolding. When this occurs in the endoplasmic reticulum ( ER), a process known as unfolded protein response (UPR) is orchestrated for survival through activation of PERK eIF2 alpha (PERK: double-stranded RNA-activated protein kinase-like ER kinase; eIF2 alpha: eucaryotic initiation factor 2 alpha), ATF alpha ( ATF alpha: activating transcription factor 6) and inositol requiring 1 (IRE1)-x-box-binding protein 1 (XBP1) signalings. All three UPR transducer pathways were upregulated very rapidly when PC-3 cells were exposed to selenium. These changes were accompanied by increased expression of UPR target genes, including immunoglobulin heavy chain-binding protein/glucoseregulated protein, 78 kDa and CCAAT/enhancer binding protein-homologous protein/growth arrest- and DNA damage-inducible gene (CHOP/GADD153). Induction of BiP/ GRP78, an ER-resident chaperone, is part of the damage control mechanism, while CHOP/GADD153 is a transcription factor associated with growth arrest and apoptosis in the event of prolonged ER stress. Knocking down BiP/ GRP78 induction by small interference RNA produced a differential response of the three transducers to selenium, suggesting that the signaling intensity of each transducer could be fine-tuned depending on BiP/ GRP78 availability. In the presence of selenium, CHOP/GADD153 expression was raised even higher by BiP/ GRP78 knockdown. Under this condition, the selenium effect on wild-type p53-activated fragment p21 (p21(WAF)), cyclin-dependent kinase (CDK)1 and CDK2 was also magnified in a manner consistent with enhanced cell growth arrest. Additional experiments with CHOP/ GADD153 siRNA knockdown strongly suggested that CHOP/ GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null). Collectively, the above findings support the idea that UPR could be an important mechanism in mediating the anticancer activity of selenium.	Roswell Pk Canc Inst, Dept Canc Chemoprevent, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto, Japan	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Kyoto University	Ip, C (corresponding author), Roswell Pk Canc Inst, Dept Canc Chemoprevent, Elm & Carlton St, Buffalo, NY 14263 USA.	clement.ip@roswellpark.org	Longo, Kenneth A/A-5631-2010; Mori, Kazutoshi/K-6106-2015		NCI NIH HHS [P30 CA016056, P30 CA 16056, R01 CA097963-03, CA 09796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097963, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDNARD K, 2004, BASIC CLIN PHARMACOL, V94, P124; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Dong Y, 2003, CANCER RES, V63, P52; El-Bayoumy K, 2004, MUTAT RES-FUND MOL M, V551, P181, DOI 10.1016/j.mrfmmm.2004.02.023; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Friedman AD, 1996, CANCER RES, V56, P3250; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; IP C, 1990, CANCER RES, V50, P1206; Ip C, 2000, CANCER RES, V60, P2882; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; IP C, 1991, CANCER RES, V51, P595; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Kadowaki H, 2004, J CHEM NEUROANAT, V28, P93, DOI 10.1016/j.jchemneu.2004.05.004; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lehotsky J, 2003, PHYSIOL RES, V52, P269; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2003, J BIOL CHEM, V278, P17680, DOI 10.1074/jbc.M300418200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Park Eun-Mi, 2005, Cancer Genomics & Proteomics, V2, P25; SATOH M, 1993, EXP CELL RES, V205, P76, DOI 10.1006/excr.1993.1060; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zu K, 2003, CANCER RES, V63, P6988	51	87	91	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					546	554		10.1038/sj.onc.1209071	http://dx.doi.org/10.1038/sj.onc.1209071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16205645	Green Accepted			2022-12-28	WOS:000234897400006
J	Novoselov, SV; Calvisi, DF; Labunskyy, VM; Factor, VM; Carlson, BA; Fomenko, DE; Moustafa, ME; Hatfield, DL; Gladyshev, VN				Novoselov, SV; Calvisi, DF; Labunskyy, VM; Factor, VM; Carlson, BA; Fomenko, DE; Moustafa, ME; Hatfield, DL; Gladyshev, VN			Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice	ONCOGENE			English	Article						selenoprotein; selenocysteine; selenium; cancer prevention; redox regulation	GROWTH-FACTOR-ALPHA; CANCER PREVENTION; THIOREDOXIN REDUCTASE; MOUSE MODEL; ACCELERATED HEPATOCARCINOGENESIS; GLUTATHIONE PEROXIDASE-1; PROSTATE-CANCER; LIVER-CANCER; C-MYC; SELENOCYSTEINE	The micronutrient element selenium ( Se) has been shown to be effective in reducing the incidence of cancer in animal models and human clinical trials. Selenoproteins and low molecular weight Se compounds were implicated in the chemopreventive effect, but specific mechanisms are not clear. We examined the role of Se and selenoproteins in liver tumor formation in TGF alpha/c-Myc transgenic mice, which are characterized by disrupted redox homeostasis and develop liver cancer by 6 months of age. In these mice, both Se deficiency and high levels of Se compounds suppressed hepatocarcinogenesis. In addition, both treatments induced expression of detoxification genes, increased apoptosis and inhibited cell proliferation. Within low-to-optimal levels of dietary Se, tumor formation correlated with expression of most selenoproteins. These data suggest that changes in selenoprotein expression may either suppress or promote tumorigenesis depending on cell type and genotype. Since dietary Se may have opposing effects on cancer, it is important to identify the subjects who will benefit from Se supplementation as well as those who will not.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; NCI, Expt Carcinogenesis Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, N 151 Beadle Ctr,1901 Vine St, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Labunskyy, Vyacheslav/AAC-8489-2020; Gladyshev, Vadim N/A-9894-2013; Moustafa, Mohamed E/E-9002-2018; Gladyshev, Vadim N/J-6187-2013; Moustafa, Mohamed/AAM-2211-2021	Moustafa, Mohamed/0000-0003-1308-6221; Labunskyy, Vyacheslav/0000-0001-9317-1076; Novoselov, Sergey/0000-0003-0104-6492; Gladyshev, Vadim/0000-0002-0372-7016	NCI NIH HHS [CA080946] Funding Source: Medline; NIA NIH HHS [AG021518] Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005317, ZIABC005317, R01CA080946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bock A, 2000, Biofactors, V11, P77; Burk Raymond F, 2002, Nutr Clin Care, V5, P75, DOI 10.1046/j.1523-5408.2002.00006.x; BURK RF, 1983, FUND APPL TOXICOL, V3, P218, DOI 10.1016/S0272-0590(83)80129-8; Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; El-Bayoumy K, 2004, MUTAT RES-FUND MOL M, V551, P181, DOI 10.1016/j.mrfmmm.2004.02.023; Factor VM, 2000, P NATL ACAD SCI USA, V97, P2196, DOI 10.1073/pnas.040428797; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; Felix K, 2004, CANCER RES, V64, P2910, DOI 10.1158/0008-5472.CAN-03-2672; Fu YX, 2001, J BIOL CHEM, V276, P43004, DOI 10.1074/jbc.M106946200; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gouaze V, 2002, J BIOL CHEM, V277, P42867, DOI 10.1074/jbc.M203067200; Hatfield D. L., 2001, SELENIUM ITS MOL BIO; HILL KE, 1984, TOXICOL APPL PHARM, V72, P32, DOI 10.1016/0041-008X(84)90246-1; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Ip C, 1998, ANTICANCER RES, V18, P9; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; Klein EA, 2000, PROSTATE CANCER P D, V3, P145, DOI 10.1038/sj.pcan.4500412; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Milner JA, 2001, NUTR CANCER, V41, P1, DOI 10.1207/S15327914NC41-1&amp;2_1; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; REITER R, 1984, BIOCHEM PHARMACOL, V33, P1923, DOI 10.1016/0006-2952(84)90548-3; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sunde R. A., 1994, Selenium in biology and human health., P45; Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu SY, 1997, BIOL TRACE ELEM RES, V56, P117, DOI 10.1007/BF02778987; Zhao HJ, 2004, MOL BIOL CELL, V15, P506, DOI 10.1091/mbc.E03-07-0501	36	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8003	8011		10.1038/sj.onc.1208940	http://dx.doi.org/10.1038/sj.onc.1208940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170372	hybrid			2022-12-28	WOS:000233656600007
J	Schwerk, C; Schulze-Osthoff, K				Schwerk, C; Schulze-Osthoff, K			Methyltransferase inhibition induces p53-dependent apoptosis and a novel form of cell death	ONCOGENE			English	Article						adenosine dialdehyde; apoptosis; actin; methyltransferases; p53	DNA-DAMAGE RESPONSE; ACTIN DEPOLYMERIZATION; MEDIATED CYTOTOXICITY; UNDERGO APOPTOSIS; EPITHELIAL-CELLS; IN-VIVO; ROCK-I; METHYLATION; ACTIVATION; P53	We have analysed the importance of proper substrate methylation by S-adenosylmethionine-dependent methyl-transferases for cell survival and cell cycle progression. We show that treatment of cells with the methyltransferase inhibitor adenosine dialdehyde (AdOx) causes cell cycle arrest and death in different cell types. The phenotypical outcome and form of cell death was strikingly dependent on the AdOx concentration. Lower AdOx concentrations led to a G2 arrest and predominantly caused apoptosis, as judged by biochemical and morphological criteria. Apoptotic cell death was largely dependent on the presence of the tumour suppressor p53, but did not require the Bcl-2 family member Bax. Interestingly, higher concentrations of AdOx led to a novel and so far undescribed form of cell death, which was characterized by distinct, caspase-independent alterations of the cell shape including a marked protuberation of the nucleus, cytoplasmic extensions, actin aggregation, and incomplete chromatin condensation. Although this latter form of cell death was clearly distinguishable from apoptosis, early apoptotic features such as Bax activation were detected, indicating a commitment but incomplete execution of apoptosis. Altogether, these data show that methylation reactions play a distinct role in cell survival, which might influence the decision between different phenotypic forms of cell death.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schwerk, C (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Christian.Scherk@uni-duesseldorf.de	Schwerk, Christian/GNP-5375-2022; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				BARTEL RL, 1984, MOL PHARMACOL, V25, P418; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bursch W, 2000, J CELL SCI, V113, P1189; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Di Simone N, 2003, BIOL REPROD, V69, P1129, DOI 10.1095/biolreprod.103.015800; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Grzanka A, 2003, BIOCHEM PHARMACOL, V66, P1611, DOI 10.1016/S0006-2952(03)00532-X; HENNESSEY ES, 1993, BIOCHEM J, V291, P657, DOI 10.1042/bj2910657; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jamison JM, 2002, BIOCHEM PHARMACOL, V63, P1773, DOI 10.1016/S0006-2952(02)00904-8; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; Mehlhorn H, 1999, PARASITOL RES, V85, P625, DOI 10.1007/s004360050607; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Rao JY, 1999, J CELL BIOCHEM, V75, P686, DOI 10.1002/(SICI)1097-4644(19991215)75:4<686::AID-JCB14>3.0.CO;2-F; Ratter F, 1999, INT IMMUNOL, V11, P519, DOI 10.1093/intimm/11.4.519; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sgarra R, 2003, CELL DEATH DIFFER, V10, P386, DOI 10.1038/sj.cdd.4401184; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Song ZY, 2004, HEPATOLOGY, V40, P989, DOI 10.1002/hep.20412; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stancheva I, 2001, EMBO J, V20, P1963, DOI 10.1093/emboj/20.8.1963; Suarez-Huerta N, 2000, J CELL PHYSIOL, V184, P239, DOI 10.1002/1097-4652(200008)184:2<239::AID-JCP12>3.0.CO;2-R; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	42	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7002	7011		10.1038/sj.onc.1208855	http://dx.doi.org/10.1038/sj.onc.1208855			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007140				2022-12-28	WOS:000232833200002
J	Kim, EH; Kim, HS; Kim, SU; Noh, EJ; Lee, JS; Choi, KS				Kim, EH; Kim, HS; Kim, SU; Noh, EJ; Lee, JS; Choi, KS			Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; sodium butyrate; apoptosis; glioma	HISTONE DEACETYLASE INHIBITORS; X-LINKED INHIBITOR; COLON-CANCER CELLS; LIGAND TRAIL; ANTITUMOR-ACTIVITY; EPITHELIAL-CELLS; DEATH RECEPTORS; TRICHOSTATIN-A; LEUKEMIA-CELLS; TUMOR-CELLS	In TNF-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, co-treatment with nontoxic doses of sodium butyrate and TRAIL resulted in a marked increase of TRAIL-induced apoptosis. This combined treatment was also cytotoxic to glioma cells overexpressing Bcl-2 or Bcl-xL, but not to normal human astrocytes, thus offering an attractive strategy for safely treating resistant gliomas. Cotreatment with sodium butyrate facilitated completion of proteolytic processing of procaspase-3 that was partially blocked by treatment with TRAIL alone. We also found that treatment with sodium butyrate significantly decreased the protein levels of survivin and X-linked inhibitor of apoptosis protein (XIAP), two major caspase inhibitors. Overexpression of survivin and XIAP attenuated sodium butyratestimulated TRAIL-induced apoptosis, suggesting its involvement in conferring TRAIL resistance to glioma cells. Furthermore, the kinase activities of Cdc2 and Cdk2 were significantly decreased following sodium butyrate treatment, accompanying downregulation of cyclin A and cyclin B, as well as upregulation of p21. Forced expression of Cdc2 plus cyclin B, but not Cdk2 plus cyclin A, attenuated sodium butyrate/TRAIL-induced apoptosis, overriding sodium butyrate-mediated downregulation of survivin and XIAP. Therefore, Cdc2-mediated downregulation of survivin and XIAP by sodium butyrate may contribute to the recovery of TRAIL sensitivity in glioma cells.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; Univ British Columbia, UBC Hosp, Div Neurol, Vancouver, BC V5Z 1M9, Canada	Ajou University; Ajou University; University of British Columbia	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, San 5,Wonchon Dong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Guo F, 2004, CANCER RES, V64, P2580, DOI 10.1158/0008-5472.CAN-03-2629; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; HEERDT BG, 1994, CANCER RES, V54, P3288; Hernandez A, 2001, SURGERY, V130, P265, DOI 10.1067/msy.2001.115897; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ito N, 2001, NEUROSURGERY, V49, P430, DOI 10.1097/00006123-200108000-00031; Kamitani H, 2002, NEURO-ONCOLOGY, V4, P95, DOI 10.1093/neuonc/4.2.95; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kramer A, 1997, CANCER RES, V57, P5117; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Lipinski CA, 2003, MOL CANCER RES, V1, P323; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Misra A, 2000, J NEURO-ONCOL, V48, P1, DOI 10.1023/A:1006435201961; Nair AR, 2001, CANCER LETT, V166, P55, DOI 10.1016/S0304-3835(01)00418-9; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Sawa Hiroki, 2002, Brain Tumor Pathol, V19, P77, DOI 10.1007/BF02478931; Seol DW, 2001, CANCER RES, V61, P1138; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	60	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6877	6889		10.1038/sj.onc.1208851	http://dx.doi.org/10.1038/sj.onc.1208851			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007142				2022-12-28	WOS:000232701700003
J	Mainou, BA; Everly, DN; Raab-Traub, N				Mainou, BA; Everly, DN; Raab-Traub, N			Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K	ONCOGENE			English	Article						EBV; LMP1; CTAR; Rat-1; PI3K; transformation	NF-KAPPA-B; MEMBRANE-PROTEIN 1; SYNTHASE KINASE 3-BETA; GROWTH-FACTOR RECEPTOR; TRAF-BINDING-SITE; LYMPHOCYTE TRANSFORMATION; SIGNALING PATHWAYS; EPITHELIAL-CELLS; BETA-CATENIN; LMP1	Epstein-Barr virus (EBV) is a ubiquitous herpesvirus associated with a variety of malignancies including nasopharyngeal carcinoma. The EBV-encoded latent membrane protein 1 (LMP1) is considered the EBV oncogene as it is necessary for EBV-induced B-lymphocyte transformation and has been shown to transform rodent fibroblasts. LMP1 contains two signaling domains, the carboxy-terminal activating region 1 and 2 (CTAR1 and CTAR2), by which NF-kappa B, phosphatidylinositol 3-kinase (PI3K), mitogen- activated protein kinase, and c-Jun N-terminal kinase are activated. In this study, the role of CTAR1 and CTAR2 in LMP1-mediated transformation of rodent fibroblasts was analysed. CTAR1 was found to be necessary for rodent. broblast transformation, whereas CTAR2 was dispensable. The activation of the PI3K pathway in Rat-1 cells by LMP1 and LMP1-CTAR1 in transformed cells resulted in phosphorylated Akt and phosphorylated glycogen synthase kinase 3 beta. The role of PI3K and NF-kappa B activation in LMP1-mediated transformation was further analysed using the chemical inhibitors LY294002 and BAY 11-7085. LY294002 inhibited CTAR1-induced focus formation and anchorage independent growth, whereas BAY 11-7085 did not inhibit focus formation or anchorage-independent growth. Similar studies in human fibroblasts confirmed that LMP1-CTAR1 also mediates aberrant growth, phosphorylation of Akt, and decreased levels of p27. These findings indicate that LMP1-mediated rodent. broblast transformation is dependent upon activation of PI3K and Akt and is independent of activation of NF-kappa B.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu	Mainou, Bernardo A./H-4164-2019	Mainou, Bernardo A./0000-0002-7721-183X	NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32979, CA 19014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Everly DN, 2004, J VIROL, V78, P13470, DOI 10.1128/JVI.78.24.13470-13478.2004; Everly DN, 2004, J VIROL, V78, P11648, DOI 10.1128/JVI.78.21.11648-11655.2004; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; He ZM, 2000, CANCER RES, V60, P1845; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 2001, FIELDS VIROLOGY, P2511; LIEBOWITZ D, 1989, J VIROL, V63, P4051, DOI 10.1128/JVI.63.9.4051-4054.1989; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Mehl AM, 2001, J BIOL CHEM, V276, P984, DOI 10.1074/jbc.M003758200; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1998, ONCOGENE, V16, P1869, DOI 10.1038/sj.onc.1201696; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; Morrison JA, 2004, CANCER RES, V64, P5251, DOI 10.1158/0008-5472.CAN-04-0538; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Puls A, 1999, J CELL SCI, V112, P2983; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; REYNOLDS VL, 1987, CANCER RES, V47, P6384; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Thornburg NJ, 2003, CANCER RES, V63, P8293; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	44	101	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6917	6924		10.1038/sj.onc.1208846	http://dx.doi.org/10.1038/sj.onc.1208846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007144				2022-12-28	WOS:000232701700006
J	Yu, CR; Bruzek, LM; Meng, XW; Gores, GJ; Carter, CA; Kaufmann, SH; Adjei, AA				Yu, CR; Bruzek, LM; Meng, XW; Gores, GJ; Carter, CA; Kaufmann, SH; Adjei, AA			The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006	ONCOGENE			English	Article						Mcl-1; apoptosis; BAY 43-9006 (sorafenib); MEK; Raf; adaphostin	CHRONIC LYMPHOCYTIC-LEUKEMIA; CELLS IN-VITRO; B-RAF; KINASE ACTIVATION; SIGNALING PATHWAY; HUMAN CANCER; BRAF GENE; APOPTOSIS; MUTATIONS; EXPRESSION	BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor cell proliferation in vitro and inhibits diverse human tumor xenografts in vivo. The mechanism of action of BAY 43-9006 remains incompletely defined. In the present study, the effects of BAY 43-9006 on the antiapoptotic Bcl-2 family member Mcl-1 were examined. Treatment of A549 lung cancer cells with BAY 43-9006 diminished Mcl-1 levels in a time- and dose-dependent manner without affecting other Bcl-2 family members. Similar BAY 43-9006-induced Mcl-1 downregulation was observed in ACHN (renal cell), HT-29 (colon), MDA-MB-231 (breast), KMCH (cholangiocarcinoma), Jurkat (acute T-cell leukemia), K562 (chronic myelogenous leukemia) and MEC-2 ( chronic lymphocytic leukemia) cells. Mcl-1 mRNA levels did not change in BAY 43-9006-treated cells. Instead, BAY 43-9006 enhanced proteasome-mediated Mcl-1 degradation. This Mcl-1 downregulation was followed by mitochondrail cytochrome c release and caspase activation as well as enhanced sensitivity to other proapoptotic agents. The caspase inhibitor Boc-D-fmk inhibited BAY 43-9006-induced caspase activation but not cytochrome c release. In contrast, Mcl-1 overexpression inhibited cytochrome c release and other features of BAY 43-9006-induced apoptosis. Conversely, Mcl-1 downregulation by short hairpin RNA enhanced BAY 43-9006-induced apoptosis. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006.	Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Bayer Healthcare, West Haven, CT 06516 USA	Mayo Clinic; Mayo Clinic; Bayer AG; Bayer Healthcare Pharmaceuticals	Adjei, AA (corresponding author), Mayo Clin & Mayo Fdn, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	adjei.alex@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [R01 CA69008] Funding Source: Medline; NIDDK NIH HHS [R01 DK59427] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, CLIN CANCER RES, V7, P1438; Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028; Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; FLAHERTY KT, 2004, P AM SOC CLIN ONCOL, V23; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOBAYASHI S, 2005, IN PRESS GASTROENTER; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Ratain MJ, 2004, J CLIN ONCOL, V22, p382S; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; STRUMBERG D, 2004, J CLIN ONCOL, V21, P21; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737	37	234	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6861	6869		10.1038/sj.onc.1208841	http://dx.doi.org/10.1038/sj.onc.1208841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007148				2022-12-28	WOS:000232701700001
J	Bloor, AJC; Kotsopoulou, E; Hayward, P; Champion, BR; Green, AR				Bloor, AJC; Kotsopoulou, E; Hayward, P; Champion, BR; Green, AR			RFP represses transcriptional activation by bHLH transcription factors	ONCOGENE			English	Article						RFP; SCL; bHLH; transcription factor; repression	RET FINGER PROTEIN; LOOP-HELIX PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; TRIPARTITE MOTIF; NUCLEAR-BODIES; FUSION PROTEIN; SCL GENE; MYOD; EXPRESSION; INTERACTS	Basic helix-loop-helix (bHLH) transcription factors play a pivotal role in the regulation of tumorigenesis, and also in a wide range of other developmental processes in diverse species from yeast to humans. Here we demonstrate for the first time that Ret finger protein (RFP), a member of the TRIM family of proteins initially identified as a recombined transforming gene from a human lymphoma, is a novel interaction partner for four different bHLH proteins (SCL, E47, MyoD and mASH-1), but does not interact with GATA-1 or PU.1. Interaction with SCL required the B-box and first coiled-coil region of RFP together with the bHLH domain of SCL. RFP was able to repress transcriptional activation by E47, MyoD and mASH-1, but not by members of several other transcription factor families. Transcriptional repression by RFP was trichostatin A sensitive and did not involve an Id-like mechanism or ubiquitination with subsequent degradation of bHLH proteins. Instead, our results suggest that bHLH transcription factors are regulated by a previously undescribed interaction with RFP, which functions to recruit HDAC and/or Polycomb proteins and thus repress target genes of bHLH proteins. These results reveal an unexpected link between the bHLH and TRIM protein families.	Univ Cambridge, Dept Haematol, Cambridge Inst Met Res, Cambridge CB2 2XY, England; Lorantis Ltd, Cambridge CB4 0WG, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Met Res, Hills Rd, Cambridge CB2 2XY, England.	arg1000@cam.ac.uk		Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Begley CG, 1999, BLOOD, V93, P2760; Bloor AJC, 2002, J HEMATOTH STEM CELL, V11, P195, DOI 10.1089/152581602753658402; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Farah MH, 2000, DEVELOPMENT, V127, P693; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Hall MA, 2003, P NATL ACAD SCI USA, V100, P992, DOI 10.1073/pnas.0237324100; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Sinclair AM, 2002, BLOOD, V99, P3931, DOI 10.1182/blood.V99.11.3931; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TANIGAWA T, 1994, CELL GROWTH DIFFER, V5, P557; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	39	10	10	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6729	6736		10.1038/sj.onc.1208828	http://dx.doi.org/10.1038/sj.onc.1208828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007160				2022-12-28	WOS:000232527800001
J	Ni, HH; Dydensborg, AB; Herring, FE; Basora, N; Gagne, D; Vachon, PH; Beaulieu, JF				Ni, HH; Dydensborg, AB; Herring, FE; Basora, N; Gagne, D; Vachon, PH; Beaulieu, JF			Upregulation of a functional form of the beta(4) integrin subunit in colorectal cancers correlates with c-Myc expression	ONCOGENE			English	Article						laminin receptor; integrin; colon; adenocarcinoma cells; epithelial cells	SUCRASE-ISOMALTASE EXPRESSION; HUMAN-COLON CARCINOMA; CRYPT-VILLUS AXIS; DIFFERENTIAL EXPRESSION; CYTOPLASMIC DOMAIN; ALPHA(6)BETA(4) INTEGRIN; ADHESION; LAMININ-5; MECHANISM; SEQUENCE	The integrin beta(4) subunit has been shown to be involved in various aspects of cancer progression. The aim of the present work was to evaluate the expression of beta(4) in primary colon cancers and to investigate the occurrence of a previously identified intestinal nonfunctional variant of beta(4) (beta(ctd-)(4)) for adhesion to laminin. Immunodetection of beta(4) using a panel of antibodies and RT-PCR analyses were performed on series of paired primary colon tumors and corresponding resection margins. The beta(4) subunit was found to be significantly overexpressed in cancer specimens at both the protein and transcript levels. Surprisingly, beta(4) levels of expression were closely correlated with those of the oncogene c-Myc in individual specimens. In vitro studies of c-Myc overexpression showed an upregulation of beta(4) promoter activity. Finally, the beta(ctd-)(4) form was identified in the normal proliferative colonic cells but was found to be predominantly absent in colon cancer cells, both in situ and in vitro. We concluded that the beta(ctd-)(4) form is lost from colon cancer cells, while the level of the wildtype form of beta(4), which is functional for adhesion to laminin, is increased in primary tumors in relation with the expression of c-Myc.	Univ Sherbrooke, CIHR Grp Funct Dev & Physiopathol Digest Tract, Dept Anat & Biol Cellulaire, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Beaulieu, JF (corresponding author), Univ Sherbrooke, CIHR Grp Funct Dev & Physiopathol Digest Tract, Dept Anat & Biol Cellulaire, Fac Med, Sherbrooke, PQ J1H 5N4, Canada.	Jean-Francois.Beaulieu@USherbrooke.ca	Beaulieu, Jean-Francois/D-2054-2010					ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; Basora N, 1999, J BIOL CHEM, V274, P29819, DOI 10.1074/jbc.274.42.29819; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1994, GASTROENTEROLOGY, V106, P829, DOI 10.1016/0016-5085(94)90740-4; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1990, GASTROENTEROLOGY, V98, P1467, DOI 10.1016/0016-5085(90)91077-J; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; CHANTRET I, 1988, CANCER RES, V48, P1936; CLARKE AS, 1994, CELL ADHES COMMUN, V2, P1, DOI 10.3109/15419069409014197; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Escaffit F, 2005, J CELL PHYSIOL, V203, P15, DOI 10.1002/jcp.20189; FALCIONI R, 1994, INT J ONCOL, V5, P573; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Liu SC, 2000, J CELL SCI, V113, P3563; Lohi J, 2000, APMIS, V108, P161, DOI 10.1034/j.1600-0463.2000.d01-40.x; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Nishida K, 1997, BIOCHEM BIOPH RES CO, V241, P258, DOI 10.1006/bbrc.1997.7808; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sanders RJ, 1998, CANCER INVEST, V16, P329, DOI 10.3109/07357909809084653; SCHUG J, 1997, ISMB, V5, P268; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; STALLMACH A, 1992, GUT, V33, P342, DOI 10.1136/gut.33.3.342; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; Tani T, 1997, AM J PATHOL, V151, P1289; Tani T, 1996, AM J PATHOL, V149, P781; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; vanLeusden MR, 1997, BIOCHEM BIOPH RES CO, V235, P826, DOI 10.1006/bbrc.1997.6892; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0	58	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6820	6829		10.1038/sj.onc.1208848	http://dx.doi.org/10.1038/sj.onc.1208848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007143				2022-12-28	WOS:000232527800009
J	Umar, S; Wang, Y; Sellin, JH				Umar, S; Wang, Y; Sellin, JH			Epithelial proliferation induces novel changes in APC expression	ONCOGENE			English	Article						APC; colon; in vivo	POLYPOSIS-COLI PROTEIN; TUMOR-SUPPRESSOR PROTEIN; COLONIC-MUCOSA HYPERPROLIFERATION; BETA-CATENIN; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; GENE-PRODUCT; IN-VIVO; DOWN-REGULATION; ASSOCIATION	The role of wild-type adenomatous polyposis coli (APC) protein in native epithelia is poorly understood. The present study examined the relationships between wildtype APC and beta-catenin expression in an established model of hyperproliferation, transmissible murine colonic hyperplasia (TMCH). Distal colonic crypts isolated from normal or TMCH mice were: (i) fractionated into cytosolic and nuclear components for Western blotting and immunoprecipitation (IP),( ii) extracted for total RNA isolation for Northern blotting and,(iii) analysed immunohistochemically by confocal microscopy. Western blots performed sequentially through day 12 TMCH with N-terminal APC antibodies revealed increased abundance of similar to 312 kDa (p312) protein by day 6 (4.0 +/- 0.75-fold, n = 6) that peaked by day 9, before declining by day 12. A similar to 130 kDa ( p130) band appeared at day 9 and increased by day 12 (1.5 +/- 0.11-fold, n = 6). A C-terminal antibody detected only p312. APC mRNA level did not change during TMCH and appearance of p130 was not due to alternative splicing. Co-IP with N-terminal anti-APC antibodies, revealed APC's association with b-catenin both at day 6 and day 12. p130, but not p312, associated predominantly with beta-catenin at day 12 during co-IP with anti-beta-catenin. p130 also selectively accumulated in the nucleus, bound to nuclear beta-catenin at day 12. Immunocytochemistry with N-terminal antibodies revealed an increasing crypt base : surface gradient of APC within the apical pole/apical-lateral membranes at day 6. At day 12, intense apical/cytoplasmic and occasional nuclear staining along the longitudinal crypt axis was observed. Full-length APC increases during epithelial hyperproliferation and may represent a homoeostatic response. The dramatic increase in cytoplasmic and sporadic nuclear APC staining at day 12 with N-terminal antibodies may represent p130. The nuclear accumulation of p130 may be a novel mechanism regulating nuclear beta-catenin function during TMCH.	Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Umar, S (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, 301 Univ Blvd,1108 Strand, Galveston, TX 77555 USA.	shumar@utmb.edu			NCI NIH HHS [CA 099121] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA099121] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BARTHOLD SW, 1979, CANCER RES, V39, P24; BARTHOLD SW, 1977, LAB ANIM SCI, V27, P938; BARTHOLD SW, 1978, VET PATHOL, V15, P223, DOI 10.1177/030098587801500209; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; OSHIMA M, 1993, CANCER RES, V53, P5589; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Roura S, 2003, BIOCHEM BIOPH RES CO, V309, P830, DOI 10.1016/j.bbrc.2003.08.075; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Santoro IM, 1997, CANCER RES, V57, P488; Sellin JH, 2001, CANCER RES, V61, P2899; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; THLIVERIS A, 1994, CANCER RES, V54, P2991; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG765, DOI 10.1152/ajpgi.2000.278.5.G765; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG753, DOI 10.1152/ajpgi.2000.278.5.G753; Umar S, 2000, AM J PHYSIOL-GASTR L, V279, pG223, DOI 10.1152/ajpgi.2000.279.1.G223; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; White RL, 1997, PATHOL BIOL, V45, P240; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	56	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6709	6718		10.1038/sj.onc.1208820	http://dx.doi.org/10.1038/sj.onc.1208820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007167	Bronze			2022-12-28	WOS:000232367800012
J	Cepero, E; King, AM; Coffey, LM; Perez, RG; Boise, LH				Cepero, E; King, AM; Coffey, LM; Perez, RG; Boise, LH			Caspase-9 and effector caspases have sequential and distinct effects on mitochondria	ONCOGENE			English	Article						mitochondria; apoptosis; caspase; ROS	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS; COMPLEX-I; MEMBRANE; NECROSIS; DEATH; BAX; INHIBITION	Proapoptotic Bcl-2 family members alter mitochondrial permeability resulting in the release of apoptogenic factors that initiate a caspase cascade. These changes are well described; however, the effects of caspases on mitochondrial function are less well characterized. Here we describe the consequence of caspase-9 and effector caspase inhibition on mitochondrial physiology during intrinsic cell death. Caspase inhibition prevents the complete loss of mitochondrial membrane potential without affecting cytochrome c release. When effector caspases are inhibited, mitochondria become uncoupled and produce reactive oxygen species. Interestingly, the effector caspase-mediated depolarization of the mitochondria occurs independent of the activity of complexes I-IV of the electron transport chain. In contrast, caspase-9 inhibition prevents mitochondrial uncoupling and ROS production and allows for continued electron transport despite the release of cytochrome c. Taken together, these data suggest that activated caspase-9 prevents the accessibility of cytochrome c to complex III, resulting in the production of reactive oxygen species, and that effector caspases may depolarize mitochondria to terminate ROS production and preserve an apoptotic phenotype.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138,RMSB Room 3045A,1600 NW 10th Ave, Miami, FL 33101 USA.	lboise@med.miami.edu	Perez, Ruth G./AAK-9844-2020; Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065813, F31GM020435] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM20435, R01 GM65813] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Burlacu A, 2001, CELL TISSUE RES, V306, P409, DOI 10.1007/s004410100424; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Higuchi Y, 2002, ARCH BIOCHEM BIOPHYS, V400, P133, DOI 10.1006/abbi.2002.2784; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Ryan CA, 2002, BIOCHEM J, V366, P595, DOI 10.1042/BJ20020863; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	47	33	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6354	6366		10.1038/sj.onc.1208793	http://dx.doi.org/10.1038/sj.onc.1208793			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007191				2022-12-28	WOS:000232038200003
J	Manel, N; Battini, JL; Taylor, N; Sitbon, M				Manel, N; Battini, JL; Taylor, N; Sitbon, M			HTLV-1 tropism and envelope receptor	ONCOGENE			English	Review						HTLV-1; GLUT1; envelope glycoproteins; receptor; tropism; glucose transporter	T-CELL LEUKEMIA; VIRUS TYPE-I; HUMAN-IMMUNODEFICIENCY-VIRUS; MONKEYS SAIMIRI-SCIUREUS; UBIQUITOUS GLUCOSE-TRANSPORTER; MEDIATED SYNCYTIUM FORMATION; HUMAN-ENDOTHELIAL CELLS; AMINO-ACID TRANSPORTER; CENTRAL-NERVOUS-SYSTEM; SPASTIC PARAPARESIS	The identification of CD4 as the primary receptor for HIV followed shortly after the discovery of the virus, but the HTLV receptor remained long elusive, until its recent identification as the GLUT1 glucose transporter. In the present review, we describe the status of the literature that surrounded this discovery as well as the in vitro and in vivo observations that led to the identification of GLUT1. Also, we will explore a few tracks to conciliate the in vitro and in vivo data on HTLV-1 tropism within the context of the HTLV literature that has accumulated over the past 25 years. A close examination of these data leads us to conclude that the preferential detection of HTLV-1 in CD4+ T lymphocyte subsets in vivo, even in the absence of leukemia, is not likely to be directly related to envelope receptor interactions, but rather to an array of postentry selection bottlenecks in vivo. Furthermore, we propose that infection of other hematopoietic and nonhematopoietic cells is likely to take place during the lifetime of an individual, with a burst early during the infection.	CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 122, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Sitbon, M (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 122, 1919 Route Mende, F-34293 Montpellier, France.	marc.sitbon@igmm.cnrs.fr	Sitbon, Marc/A-6771-2010; Manel, Nicolas/E-2128-2011; Taylor, Naomi/H-4016-2014	Sitbon, Marc/0000-0003-3616-2338; Manel, Nicolas/0000-0002-1481-4430; Battini, Jean-Luc/0000-0002-5884-9934				AKAGI T, 1985, JPN J CANCER RES, V76, P86; Al-Fahim A, 1999, CELL IMMUNOL, V198, P1, DOI 10.1006/cimm.1999.1580; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Anderson MM, 2000, SCIENCE, V287, P1828, DOI 10.1126/science.287.5459.1828; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; Benit L, 2001, J VIROL, V75, P11709, DOI 10.1128/JVI.75.23.11709-11719.2001; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; BONVENTO G, 2005, IN PRESS J CEREB BLO; Brighty DW, 2001, J VIROL, V75, P10472, DOI 10.1128/JVI.75.21.10472-10478.2001; CHAKRABARTI R, 1994, J IMMUNOL, V152, P2660; CLAPHAM P, 1983, SCIENCE, V222, P1125, DOI 10.1126/science.6316502; CLAPHAM P, 1984, P NATL ACAD SCI-BIOL, V81, P2886, DOI 10.1073/pnas.81.9.2886; CORNFORD EM, 1994, J CEREBR BLOOD F MET, V14, P106, DOI 10.1038/jcbfm.1994.15; Daenke S, 1999, J GEN VIROL, V80, P1429, DOI 10.1099/0022-1317-80-6-1429; Daenke S, 2000, AIDS RES HUM RETROV, V16, P1731, DOI 10.1089/08892220050193227; Delamarre L, 1996, J ACQ IMMUN DEF SYND, V13, pS85, DOI 10.1097/00042560-199600001-00015; DENESVRE C, 1995, J VIROL, V69, P4149, DOI 10.1128/JVI.69.7.4149-4157.1995; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; Eiraku N, 1998, J IMMUNOL, V161, P6674; Ericsson TA, 2003, P NATL ACAD SCI USA, V100, P6759, DOI 10.1073/pnas.1138025100; EVANS LH, 1990, J VIROL, V64, P6176, DOI 10.1128/JVI.64.12.6176-6183.1990; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; FRANCHINI G, 1985, LEUKEMIA RES, V9, P1305, DOI 10.1016/0145-2126(85)90116-X; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; GAVALCHIN J, 1993, VIROLOGY, V194, P1, DOI 10.1006/viro.1993.1228; Geijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31; Goetz M, 1997, J PEPT SCI, V3, P347, DOI 10.1002/(SICI)1099-1387(199709)3:5<347::AID-PSC110>3.0.CO;2-E; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; HAYAMI M, 1984, JPN J CANCER RES, V75, P99; Heams T, 2003, BIOTECHNIQUES, V34, P712, DOI 10.2144/03344bm06; Hein S, 2003, J VIROL, V77, P5926, DOI 10.1128/JVI.77.10.5926-5932.2003; Hildreth JEK, 1998, J VIROL, V72, P9544, DOI 10.1128/JVI.72.12.9544-9552.1998; Hildreth JEK, 1997, J VIROL, V71, P1173, DOI 10.1128/JVI.71.2.1173-1180.1997; HO DD, 1984, P NATL ACAD SCI-BIOL, V81, P7588, DOI 10.1073/pnas.81.23.7588; Hocini H, 1999, J INFECT DIS, V179, pS448, DOI 10.1086/314802; HOFFMAN PM, 1992, P NATL ACAD SCI USA, V89, P11784, DOI 10.1073/pnas.89.24.11784; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; HOXIE JA, 1984, P NATL ACAD SCI-BIOL, V81, P7591, DOI 10.1073/pnas.81.23.7591; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; IMAI T, 1992, J IMMUNOL, V149, P2879; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; Jassal SR, 2001, J VIROL, V75, P8317, DOI 10.1128/JVI.75.17.8317-8328.2001; Jolly C, 2004, TRAFFIC, V5, P643, DOI 10.1111/j.1600-0854.2004.00209.X; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; Kacem K, 1998, GLIA, V23, P1; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2000, J VIROL, V74, P4860, DOI 10.1128/JVI.74.10.4860-4867.2000; Kim Felix J, 2004, Retrovirology, V1, P41, DOI 10.1186/1742-4690-1-41; Kim FJ, 2000, J BIOL CHEM, V275, P23417, DOI 10.1074/jbc.C901002199; Kim FJ, 2004, VIROLOGY, V318, P183, DOI 10.1016/j.virol.2003.09.026; Kim FJ, 2003, J VIROL, V77, P963, DOI 10.1128/JVI.77.2.963-969.2003; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451; KUMAGAI AK, 1994, INVEST OPHTH VIS SCI, V35, P2887; Lavillette D, 1998, J VIROL, V72, P9955, DOI 10.1128/JVI.72.12.9955-9965.1998; LEHKY TJ, 1995, ANN NEUROL, V37, P167, DOI 10.1002/ana.410370206; LeVasseur R J, 1998, J Hum Virol, V1, P214; Levin MC, 1997, BLOOD, V89, P346; LONGO DL, 1984, NATURE, V310, P505, DOI 10.1038/310505a0; Loureiro P, 2000, AM J HEMATOL, V65, P256; Ludwig IS, 2004, J VIROL, V78, P8322, DOI 10.1128/jvi.78.15.8322-8332.2004; MACATONIA SE, 1992, AIDS RES HUM RETROV, V8, P1699, DOI 10.1089/aid.1992.8.1699; Malik HS, 2000, GENOME RES, V10, P1307, DOI 10.1101/gr.145000; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Manel N, 2004, FRONT BIOSCI-LANDMRK, V9, P3218, DOI 10.2741/1474; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; Marechal V, 1998, J VIROL, V72, P2208; Marechal V, 2001, J VIROL, V75, P11166, DOI 10.1128/JVI.75.22.11166-11177.2001; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; MOCHIZUKI M, 1996, J ACQ IMMUN DEF SYND, V13, P50; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Muul LM, 2003, BLOOD, V101, P2563, DOI 10.1182/blood-2002-09-2800; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Nath MD, 2003, BLOOD, V101, P3085, DOI 10.1182/blood-2002-07-2277; Nisole Sebastien, 2004, Retrovirology, V1, P9, DOI 10.1186/1742-4690-1-9; Nobile C, 2005, J VIROL, V79, P5386, DOI 10.1128/JVI.79.9.5386-5399.2005; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; Okuma K, 1999, VIROLOGY, V254, P235, DOI 10.1006/viro.1998.9530; Okuma K, 2003, J VIROL, V77, P8562, DOI 10.1128/JVI.77.15.8562-8569.2003; Pearson MN, 2002, J VIROL, V76, P5301, DOI 10.1128/JVI.76.11.5301-5304.2002; Pellerin L, 2003, J CEREBR BLOOD F MET, V23, P1282, DOI 10.1097/01.WCB.0000096064.12129.3D; Pinon JD, 2003, J VIROL, V77, P9922, DOI 10.1128/JVI.77.18.9922-9930.2003; Pique C, 2000, VIROLOGY, V276, P455, DOI 10.1006/viro.2000.0538; Quigley JG, 2000, BLOOD, V95, P1093, DOI 10.1182/blood.V95.3.1093.003k01_1093_1099; RALSTON S, 1989, J BIOL CHEM, V264, P16343; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROCANCOURT D, 1990, J VIROL, V64, P2660, DOI 10.1128/JVI.64.6.2660-2668.1990; Sagara Y, 1996, J VIROL, V70, P1564, DOI 10.1128/JVI.70.3.1564-1569.1996; Sagara Y, 1998, J VIROL, V72, P535, DOI 10.1128/JVI.72.1.535-541.1998; Sagara Y, 2001, AIDS RES HUM RETROV, V17, P125, DOI 10.1089/08892220150217210; Setoyama M, 1998, AM J PATHOL, V152, P683; Setoyama M, 1999, INT J CANCER, V80, P652, DOI 10.1002/(SICI)1097-0215(19990301)80:5<652::AID-IJC3>3.0.CO;2-P; Smith TAD, 1998, NUCL MED COMMUN, V19, P97, DOI 10.1097/00006231-199802000-00002; SOMMERFELT MA, 1988, SCIENCE, V242, P1557, DOI 10.1126/science.3201246; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Spivack SD, 2004, CANCER RES, V64, P6805, DOI 10.1158/0008-5472.CAN-04-1771; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; SUGA T, 1991, INT J CANCER, V49, P764, DOI 10.1002/ijc.2910490522; Sutton RE, 1996, J VIROL, V70, P7322, DOI 10.1128/JVI.70.10.7322-7326.1996; Tailor CS, 1999, J VIROL, V73, P6500, DOI 10.1128/JVI.73.8.6500-6505.1999; Tailor CS, 2003, CURR TOP MICROBIOL, V281, P29; Tailor CS, 1999, J VIROL, V73, P4470, DOI 10.1128/JVI.73.5.4470-4474.1999; Tajima Y, 1997, SOMAT CELL MOLEC GEN, V23, P225, DOI 10.1007/BF02721374; Tanaka M, 2001, J VIROL, V75, P4420, DOI 10.1128/JVI.75.9.4420-4423.2001; Tangy F, 1999, J INFECT DIS, V179, P497, DOI 10.1086/314588; Trejo SR, 2000, VIROLOGY, V268, P41, DOI 10.1006/viro.2000.0143; Uchiyama T, 1996, J ACQ IMMUN DEF SYND, V13, pS114, DOI 10.1097/00042560-199600001-00019; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Virgintino D, 1997, J SUBMICR CYTOL PATH, V29, P365; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Wielgosz MM, 2005, AIDS RES HUM RETROV, V21, P43, DOI 10.1089/aid.2005.21.43; YAMAMOTO N, 1982, NATURE, V299, P367, DOI 10.1038/299367a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88; Younes M, 1996, CANCER RES, V56, P1164; Zhao TM, 2002, AIDS RES HUM RETROV, V18, P253, DOI 10.1089/088922202753472829	127	57	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6016	6025		10.1038/sj.onc.1208972	http://dx.doi.org/10.1038/sj.onc.1208972			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155608				2022-12-28	WOS:000231623400011
J	Echizenya, M; Kondo, S; Takahashi, R; Oh, J; Kawashima, S; Kitayama, H; Takahashi, C; Noda, M				Echizenya, M; Kondo, S; Takahashi, R; Oh, J; Kawashima, S; Kitayama, H; Takahashi, C; Noda, M			The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors	ONCOGENE			English	Article						RECK; MyoD; MRF4; myogenesis	SKELETAL-MUSCLE; MYOTENDINOUS JUNCTIONS; MRF4; CELL; EXPRESSION; GENE; DIFFERENTIATION; MEMBER; SP1; MATRIX-METALLOPROTEINASE-9	The membrane-anchored MMP-regulator RECK is down regulated in many solid tumors; the extent of RECK down regulation correlates with poor prognosis. Forced expression of RECK in tumor cells results in suppression of angiogenesis, invasion, and metastasis. Studies on the roles and the mechanisms of regulation of the RECK gene during normal development may therefore yield important insights into how the malignant behaviors of tumor cells arise and how they can be controlled. Our previous studies indicate that mice lacking RECK die around E10.5 with reduced tissue integrity. In the present study, we have found that in later stage wild-type embryos, RECK is abundantly expressed in skeletal muscles, especially in the areas where the myoblast differentiation factor MRF4 is expressed. Consistent with this finding, the RECK-promoter is activated by MRF4 in cultured cells. In contrast, a myoblast determination factor MyoD suppresses the RECK-promoter. Myoblastic cells lacking RECK expression give rise to myotubes at higher efficiency than the cells expressing RECK, indicating that RECK suppresses myotube formation. These findings suggest that MyoD down regulates RECK to facilitate myotube formation, whereas MRF4 up regulates RECK to promote other aspects of myogenesis that require extracellular matrix integrity.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Dept Cellular Differentiat, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Korea Univ, Grad Sch Med, Ansan, South Korea; Kyoto Univ, Grad Sch Med, COE Program, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University; Korea University; Korea University Medicine (KU Medicine); Kyoto University	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp		Oh, Junseo/0000-0002-0754-4946				Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Birk DE, 1997, EUR J CELL BIOL, V72, P352; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Caron NJ, 1999, CELL TRANSPLANT, V8, P465, DOI 10.1177/096368979900800502; Chang THT, 2004, DEV BIOL, V269, P595, DOI 10.1016/j.ydbio.2004.02.013; Chen EH, 2004, TRENDS CELL BIOL, V14, P452, DOI 10.1016/j.tcb.2004.07.008; Chin JR, 1997, DEVELOPMENT, V124, P1519; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; El Fahime E, 2000, EXP CELL RES, V258, P279, DOI 10.1006/excr.2000.4962; Ferguson JW, 2003, CELL TISSUE RES, V313, P93, DOI 10.1007/s00441-003-0743-z; Fomin M, 2004, DEV BIOL, V272, P498, DOI 10.1016/j.ydbio.2004.04.017; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Lewis MP, 2000, J MUSCLE RES CELL M, V21, P223, DOI 10.1023/A:1005670507906; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SCHOLLMEYER JE, 1986, EXP CELL RES, V162, P411, DOI 10.1016/0014-4827(86)90346-0; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TIDBALL JG, 1994, DEV BIOL, V163, P447, DOI 10.1006/dbio.1994.1161; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zhu ZM, 1997, DEV DYNAM, V209, P233, DOI 10.1002/(SICI)1097-0177(199706)209:2<233::AID-AJA9>3.3.CO;2-D	33	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5850	5857		10.1038/sj.onc.1208733	http://dx.doi.org/10.1038/sj.onc.1208733			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007210	Green Submitted, Bronze			2022-12-28	WOS:000231590400007
J	Zavadil, J; Bottinger, EP				Zavadil, J; Bottinger, EP			TGF-beta and epithelial-to-mesenchymal transitions	ONCOGENE			English	Review						Smad; metastasis; fibrosis; cancer; signal transduction; mesenchyme	GROWTH-FACTOR-BETA; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; ACTIVATED PROTEIN-KINASE; CELL-ADHESION SYSTEM; REPRESSES E-CADHERIN; REGULATES E-CADHERIN; BREAST-CANCER; RENAL FIBROSIS; MYOFIBROBLAST TRANSDIFFERENTIATION	Remarkable phenotype plasticity of epithelial cells underlies morphogenesis, epithelial repair and tumor invasiveness. Detailed understanding of the contextual cues and molecular mediators that control epithelial plasticity will be required in order to develop viable therapeutic approaches targeting epithelial-to-mesenchymal transition (EMT), an advanced manifestation of epithelial plasticity. Members of the transforming growth factor (TGF-beta) family of growth factors can initiate and maintain EMT in a variety of biological systems and pathophysiological context by activating major signaling pathways and transcriptional regulators integrated in extensive signaling networks. Here we will review the distinct physiological contexts of EMT and the underlying molecular signaling networks controlled by TGF-beta.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	New York University; New York University; Icahn School of Medicine at Mount Sinai	Bottinger, EP (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.	erwin.bottinger@mssm.edu	Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562	NIDDK NIH HHS [R01 DK060043, R01 DK056077, P50 DK064236-010003] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056077, R01DK060043, P50DK064236] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUERSPERG N, 1994, LAB INVEST, V71, P510; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Bates RC, 2005, CANCER BIOL THER, V4, P365; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Camenisch TD, 2002, DEV BIOL, V248, P170, DOI 10.1006/dbio.2002.0731; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng SF, 2003, AM J PATHOL, V162, P1937, DOI 10.1016/S0002-9440(10)64327-1; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; CZERNOBILSKY B, 1985, EUR J CELL BIOL, V37, P175; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; ElGhouzzi V, 1997, NAT GENET, V15, P42; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fan JM, 2001, AM J KIDNEY DIS, V37, P820, DOI 10.1016/S0272-6386(01)80132-3; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Ge RR, 2004, BIOCHEM PHARMACOL, V68, P41, DOI 10.1016/j.bcp.2004.03.011; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, CANCER RES, V62, P1613; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hay ED, 1995, ACTA ANAT, V154, P8; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ino Y, 2002, P NATL ACAD SCI USA, V99, P365, DOI 10.1073/pnas.012425299; Inoue T, 2005, KIDNEY INT, V67, P2488, DOI 10.1111/j.1523-1755.2005.00358.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Le Hir M, 2005, HISTOCHEM CELL BIOL, V123, P335, DOI 10.1007/s00418-005-0788-z; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Manotham K, 2004, KIDNEY INT, V65, P871, DOI 10.1111/j.1523-1755.2004.00461.x; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; Morrissey J, 2002, J AM SOC NEPHROL, V13, pS14; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nawshad A, 2003, J CELL BIOL, V163, P1291, DOI 10.1083/jcb.200306024; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Piek E, 1999, J CELL SCI, V112, P4557; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Rastaldi MP, 2002, KIDNEY INT, V62, P137, DOI 10.1046/j.1523-1755.2002.00430.x; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156; Saika S, 2004, AM J PATHOL, V164, P651, DOI 10.1016/S0002-9440(10)63153-7; Sakata Y, 2002, P NATL ACAD SCI USA, V99, P16197, DOI 10.1073/pnas.252648999; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; STOKER M, 1985, J CELL SCI, V77, P209; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Subramanian G, 2004, CANCER RES, V64, P5200, DOI 10.1158/0008-5472.CAN-04-0018; Tanaka T, 2004, MOL VIS, V10, P462; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Vongwiwatana A, 2005, AM J TRANSPLANT, V5, P1367, DOI 10.1111/j.1600-6143.2005.00843.x; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang JW, 2005, J AM SOC NEPHROL, V16, P68, DOI 10.1681/ASN.2003090795; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	131	1310	1401	2	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5764	5774		10.1038/sj.onc.1208927	http://dx.doi.org/10.1038/sj.onc.1208927			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123809				2022-12-28	WOS:000231452800011
J	Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T				Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T			Human diploid fibroblasts are resistant to MEK/ERK-mediated disruption of the actin cytoskeleton and invasiveness stimulated by Ras	ONCOGENE			English	Article						ras; ROCK/LIMK/Cofilin pathway; tropomyosin; morphological change; MEK/ERK pathway	ONCOGENIC RAS; DIFFERENTIAL EXPRESSION; TRANSFORMED FIBROBLASTS; TUMOR-SUPPRESSOR; DOWN-REGULATION; CANCER-CELLS; RHO GTPASES; LIM-KINASE; TROPOMYOSIN; PATHWAY	Ras-induced transformation is characterized not only by uncontrolled proliferation but also by drastic morphological changes accompanied by the disruption of the actin cytoskeleton. Previously, we reported that human fibroblasts are more resistant than rodent fibroblasts to Ras-induced transformation. To explore the molecular basis for the difference in susceptibility to Ras-induced transformation, we investigated the effect of activated H-Ras on the actin cytoskeleton in human diploid fibroblasts and in rat embryo fibroblasts, both of which are immortalized by SV40 early region. We demonstrate here that Ras-induced morphological changes, decreased expression of tropomyosin isoforms, and suppression of the ROCK/LIMK/Cofilin pathway observed in the rat fibroblasts were not detected in the human fibroblasts even with high expression levels of Ras. We also show that activation of the MEK/ERK pathway sufficed to induce all of these alterations in the rat fibroblasts, whereas the human fibroblasts were refractory to these MEK/ERKmediated changes. In addition to morphological changes, we demonstrated that the expression of activated Ras induced an invasive phenotype in the rat, but not in the human fibroblasts. These studies provide evidence for the existence of human-specific mechanisms that resist Ras/MEK/ERK-mediated transformation.	Osaka Biosci Inst, Mol Oncol Lab, Suita, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan	Osaka University	Akagi, T (corresponding author), Osaka Biosci Inst, Mol Oncol Lab, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	takagi@obi.or.jp						Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GABBIANI G, 1976, AM J PATHOL, V83, P457; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hashimoto Y, 1996, CANCER RES, V56, P5266; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Janssen RAJ, 2003, MOL CELL BIOL, V23, P1786, DOI 10.1128/MCB.23.5.1786-1797.2003; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TAKENAGA K, 1988, MOL CELL BIOL, V8, P3934, DOI 10.1128/MCB.8.9.3934; TANAKA M, 1995, CANCER RES, V55, P3228; Wang FL, 1996, CANCER RES, V56, P3634; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	37	9	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5648	5655		10.1038/sj.onc.1208724	http://dx.doi.org/10.1038/sj.onc.1208724			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007212				2022-12-28	WOS:000231296100011
J	Mazieres, J; You, L; He, B; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM				Mazieres, J; You, L; He, B; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM			Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis	ONCOGENE			English	Article						Wnt; Wnt16; leukemia; apoptosis; human antibody; RNA interference	PRE-B; SIGNALING PATHWAY; E2A-PBX1; GENE; ACTIVATION; EXPRESSION; CLASSIFICATION; CANCER	The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis. Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia. Less is known concerning acute leukemia. One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis. Wnt16 has been shown to be targeted by E2A-Pbx1. We performed a differential gene expression array in acute leukemia cell lines displaying or not displaying the t(1;19) translocation. We found that Wnt16 and many Wnt signaling-related genes were upregulated in the translocation-containing cells. As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines. We then directly addressed the role played by both isoforms in this type of leukemia. Using specific short interfering RNA (siRNA) and an anti-Wnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death. We also demonstrated that Wnt16b mediates its effect through the canonical Wnt pathway involving dishevelled-2, beta-catenin and survivin. We thus propose that Wnt16 plays an important role in leukemogenesis, raising its therapeutic interest.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; Inst Claudius Regaud, INSERM, U563, Dept Innovat Therapeut & Oncol Mol, F-31052 Toulouse, France	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093708, R01 CA093708-01A3] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspland SE, 2001, ONCOGENE, V20, P5708, DOI 10.1038/sj.onc.1204592; Carroll William L, 2003, Hematology Am Soc Hematol Educ Program, P102; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fear MW, 2000, BIOCHEM BIOPH RES CO, V278, P814, DOI 10.1006/bbrc.2000.3852; Fu XY, 1999, ONCOGENE, V18, P4920, DOI 10.1038/sj.onc.1202874; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	22	89	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5396	5400		10.1038/sj.onc.1208568	http://dx.doi.org/10.1038/sj.onc.1208568			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007226				2022-12-28	WOS:000231158500014
J	Wang, Y; Zhang, Z; Yao, R; Jia, D; Wang, D; Lubet, RA; You, M				Wang, Y; Zhang, Z; Yao, R; Jia, D; Wang, D; Lubet, RA; You, M			Prevention of lung cancer progression by bexarotene in mouse models	ONCOGENE			English	Article						chemoprevention; bexarotene; lung cancer; mouse models	RETINOID-X-RECEPTOR; SELECTIVE LIGAND LGD1069; MAMMARY-CARCINOMA; TARGRETIN; TUMORS; TAMOXIFEN; EFFICACY; MUTATION; KRAS2; TRIAL	Bexarotene (Targretin((R)), Ligand Pharmaceuticals Inc.) is a synthetic high-affinity RXR receptor agonist with limited affinity for RAR receptors. Bexarotene has shown efficacy in a phase I/II trial of non-small-cell lung cancers. However, the chemopreventive efficacy of bexarotene has not been determined in mouse lung cancer models. In this study, we have investigated the ability of bexarotene to inhibit lung tumor progression in the mutant A/J mouse models with genetic alterations in p53 or K-ras, two of the most commonly altered genes in human lung tumorigenesis. Mice were administered vinyl carbamate ( VC), a carcinogen, by a single intraperitoneal injection (i.p.) at 6 weeks of age. Bexarotene was given by gavage starting at 16 weeks after VC and was continued for 12 weeks. Although all mice developed lung tumors, only 7% of lung tumors were adenocarcinomas in wild-type mice, whereas 22 and 26% of lung tumors were adenocarcinomas in p53 transgenic or K-ras heterozygous deficient mice. Bexarotene inhibited both tumor multiplicity and tumor volume in mice of all three genotypes. Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by similar to 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice. Thus, bexarotene appears to be an effective preventive agent against lung tumor growth and progression.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; Chemoprevent Agent Dev Res Grp, NCI, Rockville, MD USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, N01CN25104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Bischoff ED, 1998, CANCER RES, V58, P479; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; Gottardis MM, 1996, CANCER RES, V56, P5566; Herzog CR, 1997, J CELL BIOCHEM, P49; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofseth LJ, 2004, CHEST, V125, p83S, DOI 10.1378/chest.125.5_suppl.83S-a; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; Konopleva M, 2002, CURR OPIN HEMATOL, V9, P294, DOI 10.1097/00062752-200207000-00006; Lee KW, 2002, J ENDOCRINOL, V175, P33, DOI 10.1677/joe.0.1750033; Li J, 2003, ONCOGENE, V22, P1243, DOI 10.1038/sj.onc.1206192; Lubet RA, 2005, CARCINOGENESIS, V26, P441, DOI 10.1093/carcin/bgh338; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; NASONBURCHENAL K, 1999, HANDB EXP PHARM, V139, P301; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sherman SI, 1999, NEW ENGL J MED, V340, P1075, DOI 10.1056/NEJM199904083401404; STONER GD, 1991, EXP LUNG RES, V17, P405, DOI 10.3109/01902149109064428; Tong LZ, 1996, CANCER, V78, P1004, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1004::AID-CNCR10>3.0.CO;2-6; Wang Y, 2003, CANCER RES, V63, P4389; Wu KD, 2002, CANCER RES, V62, P6376; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2004, ONCOGENE, V23, P3841, DOI 10.1038/sj.onc.1207496; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2000, CANCER RES, V60, P901	32	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1320	1329		10.1038/sj.onc.1209180	http://dx.doi.org/10.1038/sj.onc.1209180			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247446				2022-12-28	WOS:000235708200005
J	Abu-Amero, KK; Alzahrani, AS; Zou, M; Shi, Y				Abu-Amero, KK; Alzahrani, AS; Zou, M; Shi, Y			Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome	ONCOGENE			English	Article						mitochondria; mutation; medullary thyroid neoplasm; RET oncogene; multiple endocrine neoplasia	OXIDATIVE STRESS; CLINICAL-FEATURES; SOMATIC MUTATIONS; HIGH-FREQUENCY; RET; CANCER; REPAIR; TUMORS; GENE; ACTIVATION	Medullary thyroid carcinoma (MTC) is a malignant tumour of the calcitonin-secreting parafollicular C cells of the thyroid, and occurs sporadically or as a component of the multiple endocrine neoplasia (MEN) type 2/familial medullary thyroid carcinoma (FMTC) syndromes. In the present study, we investigated the frequency of mtDNA mutations in 26 MTC tumour specimens (13 sporadic and 13 familial MTC) and their matched normal tissues by sequencing the entire coding regions of mitochondrial genome. Nonsynonymous mutations were detected in 20 MTC samples (76.9%): nine out of 13 sporadic MTC (69.2%) and 11 out of 13 (84.6%) familial MTC/MEN2. Both transition and transversion types of mutations were found in the samples. Interestingly, 76.2% (16/21) of transversion mutations were found in FMTC/MEN2 patients, whereas 66.7% (12/18) of transition mutations were in sporadic MTC. Synonymous mutations were found in 12 MTC samples. In total, we identified 27 transversion mutations (21 nonsynonymous and six synonymous) in MTC. Of them, 22 (81.5%) were from FMTC/MEN2, and five (18.5%) were from sporadic MTC. The association of transversion mutation with familial MTC/MEN2 was statistically significant (P = 0.0015, binomial test). Majority of the mutations were involved in the genes located in the complex I of the mitochondrial genome, and were often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. Mitochondrial respiratory function was also compromised in a TT cell line, which carries mtDNA mutation at nt 4917 and 11 720, and in peripheral lymphocytes of MTC patients with mtDNA mutations. These data suggest that mtDNA mutation may be involved in MTC tumourigenesis and progression. Given that mtDNA mutation spectra are different between sporadic and familial MTC, different mechanisms of oxidative DNA damage may occur in the disease process.	King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC03, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, Y (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC03, POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Alzahrani, Ali S/L-3664-2017; Shi, Yufei/ABG-5228-2020; Abu-Amero, Khaled/A-5579-2010	Alzahrani, Ali S/0000-0003-4294-3624; Shi, Yufei/0000-0002-6999-0191; 				Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; ABUAMERO KK, 2005, ARCH PATHOL LABMED, V129, P62; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261; Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Vita G, 2000, CANCER RES, V60, P3727; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P3579, DOI 10.1210/jc.2003-031898; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; FARID NR, 1995, ENDOCRIN METAB CLIN, V24, P865, DOI 10.1016/S0889-8529(18)30024-0; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Girelli ME, 1998, THYROID, V8, P517, DOI 10.1089/thy.1998.8.517; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartman P, 2004, MECH AGEING DEV, V125, P417, DOI 10.1016/j.mad.2004.02.007; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Ishii T, 2005, CANCER RES, V65, P203; Jones JB, 2001, CANCER RES, V61, P1299; Kang D, 2003, CLIN CHEM LAB MED, V41, P1281, DOI 10.1515/CCLM.2003.195; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kino K, 2005, MUTAT RES-FUND MOL M, V571, P33, DOI 10.1016/j.mrfmmm.2004.10.010; Kino K, 2001, CHEM BIOL, V8, P369, DOI 10.1016/S1074-5521(01)00019-9; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Ludwig L, 2001, CANCER RES, V61, P4526; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; Marsh DJ, 1997, HORM RES, V47, P168, DOI 10.1159/000185461; Massoll N, 2004, CLIN LAB MED, V24, P49, DOI 10.1016/j.cll.2004.01.006; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Punales MK, 2003, J CLIN ENDOCR METAB, V88, P2644, DOI 10.1210/jc.2002-021422; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Shi Y, 1999, BRIT J CANCER, V79, P1234, DOI 10.1038/sj.bjc.6690198; SHI YF, 1991, CANCER RES, V51, P2690; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Stevnsner T, 2002, EXP GERONTOL, V37, P1189, DOI 10.1016/S0531-5565(02)00142-0; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; Zhang HX, 2004, ACTA PHARMACOL SIN, V25, P385	54	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					677	684		10.1038/sj.onc.1209094	http://dx.doi.org/10.1038/sj.onc.1209094			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205644				2022-12-28	WOS:000235068800003
J	Grandinetti, KB; Spengler, BA; Biedler, JL; Ross, RA				Grandinetti, KB; Spengler, BA; Biedler, JL; Ross, RA			Loss of one HuD allele on chromosome # 1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells	ONCOGENE			English	Article						HuD; N-myc; human neuroblastoma; RNA-binding protein; chromosome 1p deletion; gene amplification	PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN; RESISTANT CHINESE-HAMSTER; RNA-BINDING PROTEIN; GENE AMPLIFICATION; SHORT ARM; EXPRESSION; ELAV; LINES; HETEROZYGOSITY; HYBRIDIZATION	In human neuroblastoma tumors, amplification of the N-myc proto-oncogene and loss of all or part of the short arm of chromosome #1 are both associated with a poor prognosis. Accruing evidence indicates that it is the absence of one allele of the HuD (ELAVL4) gene, encoding the neuronal-specific RNA-binding protein HuD and localized to 1p34, that is linked to amplification. In 12 human neuroblastoma cell lines, N-myc amplification correlates with loss of one HuD allele and decreased HuD expression. Transfection experiments demonstrate that modulating HuD expression affects N-myc gene copy number as well as expression. Introduction of a sense HuD construct into two N-myc amplified cell lines considerably increases N-myc expression whereas gene copy number decreases. Conversely, expression of antisense HuD in N-myc nonamplified SH-SY5Y cells reduces HuD and N-myc mRNA levels even as cells show amplification of the N-myc gene. Thus, N-myc gene copy number is modulated by alteration of HuD expression. We propose that haploinsufficiency of HuD due to chromosome #1p deletion in neuroblastoma selects for cells that amplify N-myc genes. Application of these findings could lead to more effective therapies in the treatment of those patients with the worst prognosis.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA	Fordham University	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Rd, Bronx, NY 10458 USA.	rross@fordham.edu			NCI NIH HHS [CA77593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; Ball NS, 1997, CLIN CANCER RES, V3, P1859; BELLO MJ, 1995, CANCER GENET CYTOGEN, V83, P160, DOI 10.1016/0165-4608(95)00064-V; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1979, PROGR CANC RES THERP, V12, P881; BIEDLER JL, 1983, RATIONAL BASIS CHEMO, P71; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; FOLEY J, 1991, CANCER RES, V51, P6338; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Han J, 1996, GENOMICS, V36, P189, DOI 10.1006/geno.1996.0444; Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; ISCN, 1995, INT SYST HUM CYT NOM; Izbicki T, 2003, ANTICANCER RES, V23, P755; KING PH, 1994, J NEUROSCI, V14, P1943; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lutz W, 1996, ONCOGENE, V13, P803; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; Mora J, 2001, ONCOLOGIST, V6, P263, DOI 10.1634/theoncologist.6-3-263; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MURESU R, 1994, CYTOGENET CELL GENET, V65, P177, DOI 10.1159/000133626; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Sivak LE, 1999, MOL CELL BIOL, V19, P155; Spengler BA, 1997, ONCOL RES, V9, P467; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Valent A, 2001, AM J PATHOL, V158, P1579, DOI 10.1016/S0002-9440(10)64112-0; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985	47	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					706	712		10.1038/sj.onc.1209095	http://dx.doi.org/10.1038/sj.onc.1209095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16278682				2022-12-28	WOS:000235068800006
J	Hu, B; Tack, DC; Liu, T; Wu, Z; Ullenbruch, MR; Phan, SH				Hu, B; Tack, DC; Liu, T; Wu, Z; Ullenbruch, MR; Phan, SH			Role of Smad3 in the regulation of rat telomerase reverse transcriptase byTGF beta	ONCOGENE			English	Article						telomerase; Smad3; c-myc; TGF beta	CATALYTIC SUBUNIT HTERT; CANCER-CELLS; IN-VITRO; C-MYC; HEPATOCELLULAR CARCINOMAS; PROMOTER REGION; GENE-EXPRESSION; DIRECT BINDING; RNA COMPONENT; ACTIVATION	Telomerase is induced in certain pathological conditions such as cancer and tissue injury and repair. This induction in fibroblasts from injured lung is repressed by trans forming growth factor beta(TGF beta) via yet unknown mechanisms. In this study, the role of Smad3 in the inhibition of telomerase reverse transcriptase ( TERT) gene transcription by TGF beta was investigated. The rat TERT (rTERT) gene promoter was cloned by PCR amplification and fused with a luciferase reporter gene. This construct was used to analyse regulation of promoter activity in. broblasts isolated from bleomycin-injured lung with induced telomerase activity. The results showed that TGFb inhibited rTERT transcription while stimulating Smad3 expression. Interestingly, TGFb also inhibited the expression of c-myc. Cotransfection with a Smad3 expressing plasmid further repressed rTERT transcription and c-myc expression, while cotransfection with the corresponding antisense Smad3 construct had the opposite effect. Mutation of an E-box in the rTERT promoter suppressed its activity, which could be further reduced by TGF beta treatment. In contrast, mutation at a Smad binding element enhanced promoter activity whose inhibition was impaired by TGF beta treatment. Thus TGFb inhibition of rTERT gene expression was directly mediated by Smad3 via the Smad binding element, while c-myc appears to primarily regulate its constitutive or induced expression.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Phan, SH (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1150 W Med Ctr Dr,MSI 4204, Ann Arbor, MI 48109 USA.	shphan@umich.edu	Hu, Biao/G-6084-2010; Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052285, R01HL077297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77297, HL52285] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Avilion AA, 1996, CANCER RES, V56, P645; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Djojosubroto MW, 2003, MOL CELLS, V15, P164; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Gilley D, 2005, INT J BIOCHEM CELL B, V37, P1000, DOI 10.1016/j.biocel.2004.09.003; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER C W, 1992, Current Biology, V2, P62, DOI 10.1016/0960-9822(92)90190-L; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Groneberg DA, 2004, EXP LUNG RES, V30, P223, DOI 10.1080/01902140490276320; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horikawa I, 1999, CANCER RES, V59, P826; Hu B, 2004, J IMMUNOL, V173, P4661, DOI 10.4049/jimmunol.173.7.4661; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu TJ, 2002, AM J RESP CELL MOL, V26, P534, DOI 10.1165/ajrcmb.26.5.4668; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nozaki Y, 2000, AM J RESP CELL MOL, V23, P460, DOI 10.1165/ajrcmb.23.4.3958; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PAYS E, 1985, ANN INST PASTEUR IMM, VC136, P25, DOI 10.1016/S0769-2625(85)80037-4; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; TAHARA H, 1995, CANCER RES, V55, P2734; Takakura M, 1999, CANCER RES, V59, P551; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tsujiuchi T, 1998, CANCER LETT, V122, P115, DOI 10.1016/S0304-3835(97)00378-9; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang H, 2001, CELL GROWTH DIFFER, V12, P119; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao Hong, 2003, Yan Ke Xue Bao, V19, P60	57	37	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1030	1041		10.1038/sj.onc.1209140	http://dx.doi.org/10.1038/sj.onc.1209140			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205635				2022-12-28	WOS:000235361000008
J	Majid, SM; Liss, AS; You, M; Bose, HR				Majid, SM; Liss, AS; You, M; Bose, HR			The suppression of SH3BGRL is important for v-Rel-mediated transformation	ONCOGENE			English	Article						v-rel; NF-kappa B; SH3BGRL; SH3BGR; transformation	NF-KAPPA-B; HUMAN PROSTATE-CANCER; C-REL; RETICULOENDOTHELIOSIS VIRUS; DNA-BINDING; BREAST-CANCER; ANDROGEN-INDEPENDENCE; MOLECULAR ALTERATIONS; TRANSCRIPTION FACTORS; SELECTIVE ACTIVATION	The v-rel oncogene is the most efficient transforming member of the Rel/NF-kappa B family of transcription factors. v-Rel induces avian and mammalian lymphoid cell tumors and transforms chicken embryo fibroblasts in culture by the aberrant regulation of genes under the control of Rel/NF-kappa B proteins. Here we report that the expression of SH3BGRL, a member of the SH3BGR (SH3 domain-binding glutamicacid-rich) family of proteins, is down-regulated in v-Rel-expressing fibroblasts, lymphoid cells, and splenic tumor cells. Chromatin immunoprecipitation experiments demonstrated that v-Rel binds to the sh3bgrl promoter in transformed cells. Coexpression of SH3BGRL with v-Rel in primary splenic lymphocytes reduced the number of colonies formed by 76%. Mutations in the predicted SH3-binding domain of SH3BGRL abolished the suppressive effect on v-Rel transformation and resulted in colony numbers comparable to those formed by v-Rel alone. However, mutations in the predicted EVH1-binding domain of SH3BGRL only had a modest effect on suppression of v-Rel transformation. This study provides the first example of a gene that is down-regulated in v-Rel-expressing cells that also plays a role in v-Rel transformation.	Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bose, HR (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019		NCI NIH HHS [CA33192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; Barzik M, 2001, J MOL BIOL, V309, P155, DOI 10.1006/jmbi.2001.4640; Berleth ES, 2000, INT J IMMUNOPHARMACO, V22, P1137, DOI 10.1016/S0192-0561(00)00071-0; Berleth ES, 1999, CANCER RES, V59, P5497; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Deindl E, 2001, BIOTECHNIQUES, V31, P1250, DOI 10.2144/01316bm04; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; Fujii M, 1996, ONCOGENE, V12, P2193; Gasparian AV, 2002, J CELL SCI, V115, P141; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P104; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Henn AD, 2001, FASEB J, V15, P1315, DOI 10.1096/fj.00-0543fje; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Kralova J, 1996, ONCOGENE, V12, P2595; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; Madrid Lee V, 2003, Methods Mol Biol, V223, P523; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9; Mazzocco M, 2001, BIOCHEM BIOPH RES CO, V285, P540, DOI 10.1006/bbrc.2001.5169; Mecham BH, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh071; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOSCOVICI C, 1998, EXPRESSION DIFFERNTI, P435; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nelson DM, 1998, HUM GENE THER, V9, P2401, DOI 10.1089/hum.1998.9.16-2401; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; PETSKO G, 2002, CURRENT PROTOCOLS BI; RAO A, 1990, CANCER RES, V50, P4764; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR S, 1993, ONCOGENE, V8, P2245; Scartezzini P, 1997, HUM GENET, V99, P387, DOI 10.1007/s004390050377; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Thalmann GN, 2000, PROSTATE, V44, P91; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; You MJ, 1998, METHODS, V16, P373, DOI 10.1006/meth.1998.0692; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; Zhou JR, 2004, INT J CANCER, V110, P800, DOI 10.1002/ijc.20206; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266	82	32	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					756	768		10.1038/sj.onc.1209107	http://dx.doi.org/10.1038/sj.onc.1209107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186799				2022-12-28	WOS:000235068800011
J	Mei, J; Webb, S; Zhang, B; Shu, HB				Mei, J; Webb, S; Zhang, B; Shu, HB			The p53-inducible apoptotic protein AMID is not required for normal development and tumor suppression	ONCOGENE			English	Article						AMID; p53; apoptosis; knockout; tumor suppression	PROGRAMMED CELL-DEATH; CYTOCHROME-C; FACTOR AIF; P53; MITOCHONDRIA; PATHWAYS; GENE; LETHALITY; HOMOLOG; GROWTH	AMID is an apoptosis-inducing factor (AIF)-homologous and mitochondria-associated protein that has been implicated in caspase-independent apoptosis. Transcription of human AMID gene is upregulated by p53 and downregulated in tumors in comparison to their matched normal tissues, suggesting the possibility that AMID is involved in the downstream effects of p53. To investigate the physiological functions of AMID, we generated AMID-deficient mice by gene targeting. AMID-deficient mice are viable and fertile, develop normally and lack obvious phenotypic changes compared to wild-type mice up to 1 year old. AMID(-/-) mice up to 1 year old have no spontaneous tumors and show similar fibrosarcoma incidence after MCA inoculation compared to wild-type mice. AMID(-/-) embryonic fibroblasts exhibit normal proliferation but slightly increased resistance to genotoxin-induced growth arrest. These findings suggest that AMID is not required for normal development and p53-mediated tumor suppression.	Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China; Natl Jewish Med & Res Ctr, Denver, CO USA	Wuhan University; National Jewish Health	Shu, HB (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.	shuh@whu.edu.cn			NATIONAL CANCER INSTITUTE [R01CA108771] Funding Source: NIH RePORTER; NCI NIH HHS [CA 108771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Prives C, 1999, J PATHOL, V187, P112; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang PM, 2002, NAT GENET, V30, P31, DOI 10.1038/ng797	28	19	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					849	856		10.1038/sj.onc.1209121	http://dx.doi.org/10.1038/sj.onc.1209121			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16186796				2022-12-28	WOS:000235212700004
J	Ko, MJ; Murata, K; Hwang, DS; Parvin, JD				Ko, MJ; Murata, K; Hwang, DS; Parvin, JD			Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle	ONCOGENE			English	Article						BRCA1; centrosome; cell cycle; breast cancer	AMPLIFICATION; INSTABILITY; CHECKPOINT; NUMBER; CANCER	BRCA1-dependent ubiquitination activity regulates centrosome number in several tissue culture cell lines derived from breast cells. In these experiments, we asked how BRCA1 inhibits centrosome amplification. In general, supernumerary centrosomes can accumulate by three mechanisms: (1) failed cytokinesis and the accumulation of centrosomes by duplication in a repeated S-phase of the cell cycle, (2) disruption of the licensing of centrosome doubling such that they duplicate at inappropriate times in the cell cycle, or (3) fragmentation of the centrosomes. In this study, we found that inhibition of BRCA1 caused premature separation of centrioles and reduplication. By blocking cells in early S-phase before centrosome amplification secondary to BRCA1 inhibition could occur and then releasing, we found that inhibition of BRCA1 caused centrosome amplification between late S-phase and G2/M before the cell divided. These results suggest that normal BRCA1 function is critical in these cell lines to prevent centriole separation and centrosome reduplication before mitosis.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Seoul National University (SNU); Harvard University; Harvard Medical School	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Hsu LC, 2001, CANCER RES, V61, P7713; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pihan GA, 2003, CANCER RES, V63, P1398; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Suto K, 1999, MOL BIOL CELL, V10, P3331, DOI 10.1091/mbc.10.10.3331; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Wyllie FS, 1996, ONCOGENE, V12, P1077; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	16	40	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					298	303		10.1038/sj.onc.1209028	http://dx.doi.org/10.1038/sj.onc.1209028			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170356				2022-12-28	WOS:000234583600014
J	Liu, S; Ishikawa, H; Tsuyama, N; Li, FJ; Abroun, S; Otsuyama, KI; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM				Liu, S; Ishikawa, H; Tsuyama, N; Li, FJ; Abroun, S; Otsuyama, KI; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM			Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression ofVDAC1	ONCOGENE			English	Article						apoptosis; Ca2+; CD45; myeloma; ROS; VDAC1	DEPENDENT ANION CHANNEL; TYROSINE PROTEIN-KINASE; PLASMA-CELLS; CYTOCHROME-C; BONE-MARROW; ACTIVATION; BCL-2; SRC; PROLIFERATION; FAMILY	Expression of CD45 is quite variable in human myeloma cells and cell lines, such as U266, and CD45(+) U266 proliferates in response to a growth factor, interleukin-6. Here, we show that CD45(+) myeloma cell lines were more sensitive to various apoptotic stimuli, such as oxidative stress and endoplasmic reticulum ( ER)-stress, than CD45(-) cells. Reactive oxygen species and calcium ion seemed to be involved in the susceptibility to apoptosis of CD45(+) U266. The activation of the src family kinases associated with CD45 phosphatase played an important role in the augmented apoptosis in CD45(+) U266 by oxidative stress. These results indicate that the CD45- expression renders myeloma cells competent for not only mitogenic but also apoptotic stimuli, resulting in either proliferation or apoptosis of CD45(+) myeloma cells dependently upon the circumstantial stimuli. Furthermore, voltage-dependent anion channel ( VDAC) 1 was identified as a gene highly expressed in CD45(+) U266 by cDNA subtraction. The increased expression of VDAC1 seemed to augment the sensitivity to the ER-stress because the VDAC1-transfected U266 was more susceptible to the thapsigargininduced apoptosis. Thus, CD45 expression accompanied by the increased VDAC1 expression sensitizes myeloma cells to the various extracellular stimuli that trigger apoptosis via the mitochondrial pathways.	Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Lab Cellular Signal Anal, Ube, Yamaguchi 755, Japan	Yamaguchi University	Ishikawa, H (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Lab Cellular Signal Anal, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755, Japan.	hishika@yamaguchi-u.ac.jp	ABROUN, SAEID/GPF-5006-2022					Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood-2003-07-2187; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Decaudin D, 1997, CANCER RES, V57, P62; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fujii R, 1999, BRIT J HAEMATOL, V105, P131, DOI 10.1046/j.1365-2141.1999.01281.x; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Joshua D, 1996, BRIT J HAEMATOL, V94, P76, DOI 10.1046/j.1365-2141.1996.d01-1784.x; Justement L B, 2001, Int Rev Immunol, V20, P713, DOI 10.3109/08830180109045587; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KAWANO MM, 1995, BLOOD, V85, P487; KAWANO MM, 1993, BLOOD, V82, P564; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li FJ, 2005, BLOOD, V105, P3295, DOI 10.1182/blood-2004-10-4083; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Mahmoud MS, 1998, BLOOD, V92, P3887, DOI 10.1182/blood.V92.10.3887.422a48_3887_3897; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Schneider U, 1997, BRIT J HAEMATOL, V97, P56, DOI 10.1046/j.1365-2141.1997.d01-2115.x; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU S, 1993, LEUKEMIA, V7, P274; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Takagi-Morishita Y, 2003, BIOL REPROD, V68, P1178, DOI 10.1095/biolreprod.102.007997; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	43	28	30	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					419	429		10.1038/sj.onc.1208982	http://dx.doi.org/10.1038/sj.onc.1208982			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247487				2022-12-28	WOS:000234714100010
J	Mai, RT; Yeh, TS; Kao, CF; Sun, SK; Huang, HH; Lee, YHW				Mai, RT; Yeh, TS; Kao, CF; Sun, SK; Huang, HH; Lee, YHW			Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression	ONCOGENE			English	Article						HCV core protein; B23; YY1; p300; B23 promoter	HISTONE ACETYLTRANSFERASE ACTIVITY; HEPATOCELLULAR-CARCINOMA; ADENOVIRUS E1A; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; DNA-DAMAGE; NON-A; P53; ACTIVATION; NUCLEOPHOSMIN/B23	Hepatitis C virus (HCV) core has a pleiotropic effect on various promoters. In this study, we found that the expression of nucleolar phosphoprotein B23 was enhanced in HCV core-expressing cells and, moreover, HCV core interacts directly with the C-terminal end of B23. Using sucrose gradient centrifugation analysis and immunoprecipitation assays, HCV core was found in a large complex containing B23 and its interacting partner transcription factor YY1. Both B23 and HCV core associated with YY1 in the central GA/GK-rich and C-terminal zinc finger domain. These physical interactions between core, B23, and YY1 led to ternary complex formation that was bound to the YY1 response element. In a transient cotransfection experiment, relief of the transsuppression activity of YY1 on the YY1-response element-driven reporter by core and B23 was found. This is also true when examining the effects of these three constructs on the B23 promoter-driven reporter. Additionally, chromatin immunoprecipitation assays indicated that a transcriptional activation complex consisting of core, together with B23, p300, and YY1, was recruited to the YY1 response element of B23 promoter, and this probably occurred through complex formation between core and these three cellular transcription regulators. This is different from the situation in the absence of core, where YY1 and histone deacetylase 1, but not B23 and p300, were associated on the YY1 element as the transcription repression complex. Together, our results indicate that HCV core can recruit B23 and p300 to relieve the repression effect of YY1 on B23 promoter activity, a property that requires the intrinsic histone acetyltransferase activity of p300. Thus, because these three core-associated cellular transcription regulators have a multitude of cellular interacting proteins and are involved in a versatility of cellular processes, the complex formation described here may partially account for the pleiotropic effects of core protein on gene expression and cellular function in HCV-infected cells.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155 Li Nog St Sect 2,Shih Pai, Taipei 112, Taiwan.	yhwulee@ym.edu.tw		Mai, Ru-Tsun/0000-0002-9935-4268; Lee Wu, Yan-Hwa/0000-0001-7299-7354				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; BRUIX J, 1989, LANCET, V2, P1004; Chan HM, 2001, J CELL SCI, V114, P2363; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Gomez-Gonzalo M, 2004, VIROLOGY, V328, P120, DOI 10.1016/j.virol.2004.06.044; Goodman RH, 2000, GENE DEV, V14, P1553; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; HSIEH CL, 1995, BIOCHEM BIOPH RES CO, V214, P910, DOI 10.1006/bbrc.1995.2373; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Kao CF, 2004, J BIOMED SCI, V11, P72, DOI 10.1159/000075291; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Krippner-Heidenreich A, 2005, MOL CELL BIOL, V25, P3704, DOI 10.1128/MCB.25.9.3704-3714.2005; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Machida K, 2004, J VIROL, V78, P8835, DOI 10.1128/JVI.78.16.8835-8843.2004; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sun HJ, 2004, MOL IMMUNOL, V41, P1241, DOI 10.1016/j.molimm.2004.05.013; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Takemura M, 2002, EXP CELL RES, V276, P233, DOI 10.1006/excr.2002.5523; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; van Pelt JF, 2004, CANCER LETT, V209, P197, DOI 10.1016/j.canlet.2003.11.035; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Watashi K, 2003, CANCER SCI, V94, P937, DOI 10.1111/j.1349-7006.2003.tb01381.x; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	67	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					448	462		10.1038/sj.onc.1209052	http://dx.doi.org/10.1038/sj.onc.1209052			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170350				2022-12-28	WOS:000234714100013
J	Stuart, JR; Kawai, H; Tsai, KKC; Chuang, EY; Yuan, ZM				Stuart, JR; Kawai, H; Tsai, KKC; Chuang, EY; Yuan, ZM			c-Abl regulates early growth response protein (EGR1) in response to oxidative stress	ONCOGENE			English	Article						c-Abl; EGR1; oxidative stress; tyrosine kinase	FINGER TRANSCRIPTION FACTOR; TYROSINE KINASE; IONIZING-RADIATION; DNA-DAMAGE; ACTIVATION; GENE; EXPRESSION; P53; UPSTREAM; CELLS	c-Abl is a tyrosine kinase that can act as a regulator of cell growth and apoptosis in response to stress. Using cell lines expressing c-Abl in an inducible manner, we identified genes whose expression was regulated by c-Abl kinase activity. Microarray analysis indicated that Early Growth Response-1 (EGR1) gene expression is induced by c-Abl kinase activity, which was confirmed at the message and protein levels. Promoter mapping experiments revealed that c-Abl utilizes three distal serum response elements (SREs) in the EGR1 promoter, which are transactivated by mitogen/extracellular receptor kinase (MEK/ERK) signaling. PD 95089, a specific inhibitor of MEK/ERK signaling, attenuated c-Abl-mediated upregulation of EGR1 expression in a dose-dependent manner. Similar results were obtained by using a dominant-negative mutant of mitogen/extracellular kinase. Significantly, hydrogen peroxide-induced EGR1 expression appears to be mediated by c-Abl, as cells expressing dominant negative c-Abl, and c-Abl(-/-) murine embryonic fibroblasts, are completely defective in hydrogen peroxide-induced EGR1 expression. In addition, c-Abl-induced apoptosis is partially mitigated by EGR1 activity, as cells devoid of EGR1 expression undergo reduced rates of c-Abl-induced apoptosis. Together, these results indicate that c-Abl promotes the induction of EGR1 through the MEK/ERK pathway in regulating apoptotic response to oxidative stress.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave,HSPH-1,Room 508, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Tsai, Kun-Chih/C-1371-2010	Tsai, Kelvin/0000-0002-1612-2868; Kawai, Hidehiko/0000-0003-2213-7166	NCI NIH HHS [R29 CA85679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; DANIEL R, 1995, ONCOGENE, V10, P1607; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; GOGA A, 1995, ONCOGENE, V11, P791; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Park JO, 2002, J CLIN INVEST, V110, P403, DOI 10.1172/JCI200215548; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	33	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8085	8092		10.1038/sj.onc.1208953	http://dx.doi.org/10.1038/sj.onc.1208953			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091742				2022-12-28	WOS:000233809400001
J	Schramm, A; Schulte, JH; Klein-Hitpass, L; Havers, W; Sieverts, H; Berwanger, B; Christiansen, H; Warnat, P; Brors, B; Eils, J; Eils, R; Eggert, A				Schramm, A; Schulte, JH; Klein-Hitpass, L; Havers, W; Sieverts, H; Berwanger, B; Christiansen, H; Warnat, P; Brors, B; Eils, J; Eils, R; Eggert, A			Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling	ONCOGENE			English	Article						neuroblastoma; expression profiling; outcome prediction; microarray	N-MYC; GENES; AMPLIFICATION; CANCER; CLASSIFICATION; IDENTIFICATION; MICROARRAYS; DIAGNOSIS; SURVIVAL; 17Q	Neuroblastoma is a common childhood tumor comprising cases with rapid disease progression as well as spontaneous regression. Although numerous prognostic factors have been identified, risk evaluation in individual patients remains difficult. To de. ne a reliable prognostic predictor and gene signatures characteristic of biological subgroups, we performed mRNA expression profiling of 68 neuroblastomas of all stages. Expression data were analysed using support vector machines (SVM-rbf), prediction analysis of microarrays (PAM), k-nearest neighbors (k-NN) algorithms and multiple decision trees. SVM-rbf performed best of all methods, and predicted recurrence of neuroblastoma with an accuracy of 85% (sensitivity 77%, specificity 94%). PAM identified a classifer of 39 genes reliably predicting outcome with an accuracy of 80%. In comparison, conventional risk strati. cation based on stage, age and MYCN-status only reached a predictive accuracy of 64%. Kaplan-Meier analysis using the PAM classifer indicated a 5-year survival of 20 versus 78% for patients with unfavorably versus favorably predicted neuroblastomas, respectively (P=0.0001). Significance analysis of microarrays (SAM) identified additional genes differentially expressed among subgroups. MYCN-amplification and high expression of NTRK1/TrkA demonstrated a strong association with specific gene expression patterns. Our data suggest that microarray-derived data in addition to traditional clinical factors will be useful for risk assessment and de. ning biological properties of neuroblastoma.	Univ Hosp Essen, Dept Pediat Oncol & Hematol, D-45122 Essen, Germany; Univ Hosp Essen, Inst Cell Biol, Essen, Germany; Univ Childrens Hosp, Dept Pediat Oncol, Heidelberg, Germany; Univ Childrens Hosp, Dept Hematol, Heidelberg, Germany; Univ Childrens Hosp, Marburg, Germany; German Canc Res Ctr, DKFZ, Div Intelligent Bioinformat Syst, Heidelberg, Germany	University of Duisburg Essen; University of Duisburg Essen; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Eggert, A (corresponding author), Univ Hosp Essen, Dept Pediat Oncol & Hematol, Hufelandstr 55, D-45122 Essen, Germany.	angelika.eggert@uni-essen.de	Eils, Roland/B-6121-2009; Schulte, Johannes H/G-3981-2010; Eggert, Angelika/AAE-6907-2022; Schulte, Johannes H./V-2474-2018; Schramm, Alexander/G-5688-2010; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Eggert, Angelika/0000-0003-3476-8184; Schramm, Alexander/0000-0001-7670-7529; Brors, Benedikt/0000-0001-5940-3101; Schulte, Johannes Hubertus/0000-0003-0671-1201				Alaminos M, 2003, CANCER RES, V63, P4538; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Chang CC, 2001, NEURAL COMPUT, V13, P2119, DOI 10.1162/089976601750399335; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Elbaz N, 2000, MOL ENDOCRINOL, V14, P795, DOI 10.1210/me.14.6.795; Godfried MB, 2002, ONCOGENE, V21, P2097, DOI 10.1038/sj.onc.1205259; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hiyama E, 2004, PEDIATR SURG INT, V20, P33, DOI 10.1007/s00383-003-1077-3; Hiyama E, 2003, J PEDIATR SURG, V38, P1730, DOI 10.1016/j.jpedsurg.2003.08.042; Katoh M, 2003, INT J ONCOL, V23, P1219; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Nutt CL, 2003, CANCER RES, V63, P1602; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Quinlan J.R., 1993, C4 5 PROGRAMS MACHIN; Rosenwald A, 2002, SEMIN ONCOL, V29, P258, DOI 10.1053/sonc.2002.32901; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schulte JH, 2003, KLIN PADIATR, V215, P298; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Scott D, 2003, CANCER LETT, V197, P81, DOI 10.1016/S0304-3835(03)00086-7; Su WT, 2004, CANCER GENET CYTOGEN, V154, P131, DOI 10.1016/j.cancergencyto.2004.02.009; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; WITTEN A, 2002, DATA MINING PRACTICA; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265	40	91	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7902	7912		10.1038/sj.onc.1208936	http://dx.doi.org/10.1038/sj.onc.1208936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16103881				2022-12-28	WOS:000233463000009
J	Weitzman, MD; Ornelles, DA				Weitzman, MD; Ornelles, DA			Inactivating intracellular antiviral responses during adenovirus infection	ONCOGENE			English	Review						adenovirus; DNA repair; DNA damage response; protein translation	DEPENDENT PROTEIN-KINASE; LATE GENE-EXPRESSION; STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; ADENOASSOCIATED VIRUS GENOME; TELANGIECTASIA-LIKE DISORDER; E1B 55-KILODALTON PROTEIN; P53 TUMOR-SUPPRESSOR; E4 ORF3 PROTEIN; EARLY REGION-4	DNA viruses promote cell cycle progression, stimulate unscheduled DNA synthesis, and present the cell with an extraordinary amount of exogenous DNA. These insults elicit vigorous responses mediated by cellular factors that govern cellular homeostasis. To ensure productive infection, adenovirus has developed means to inactivate these intracellular antiviral responses. Among the challenges to the host cell is the viral DNA genome, which is viewed as DNA damage and elicits a cellular response to inhibit replication. Adenovirus therefore encodes proteins that dismantle the cellular DNA damage machinery. Studying virus-host interactions has yielded insights into the molecular functioning of fundamental cellular mechanisms. In addition, it has suggested ways that viral cytotoxicity can be exploited to offer a selective means of restricted growth in tumor cells as a therapy against cancer. In this review, we discuss aspects of the intracellular response that are unique to adenovirus infection and how adenoviral proteins produced from the early region E4 act to neutralize antiviral defenses, with a particular focus on DNA damage signaling.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Salk Institute; Wake Forest University	Weitzman, MD (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	weitzman@salk.edu			NATIONAL CANCER INSTITUTE [R01CA077342, R01CA097093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035589, R01AI043341] Funding Source: NIH RePORTER; NCI NIH HHS [CA77342, CA97093] Funding Source: Medline; NIAID NIH HHS [AI35589, AI43341] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM SA, 1987, J VIROL, V61, P3276, DOI 10.1128/JVI.61.10.3276-3283.1987; ANDERSON KP, 1987, J VIROL, V61, P787, DOI 10.1128/JVI.61.3.787-795.1987; ARAUJO FD, 2005, IN PRESS J VIROL; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bell J. C., 2002, Current Gene Therapy, V2, P243, DOI 10.2174/1566523024605582; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; BRIDGE E, 1993, VIROLOGY, V193, P794, DOI 10.1006/viro.1993.1188; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cascallo M, 2003, CANCER RES, V63, P5544; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Chen Y, 2001, CANCER RES, V61, P5453; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Cuesta R, 2001, COLD SPRING HARB SYM, V66, P259, DOI 10.1101/sqb.2001.66.259; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; De Jong RN, 2003, CURR TOP MICROBIOL, V272, P187; Dilley J, 2005, CANCER GENE THER, V12, P715, DOI 10.1038/sj.cgt.7700835; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; DIX I, 1993, J VIROL, V67, P3226, DOI 10.1128/JVI.67.6.3226-3231.1993; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Duan DS, 2003, J VIROL, V77, P4751, DOI 10.1128/JVI.77.8.4751-4759.2003; Evans JD, 2005, J VIROL, V79, P6207, DOI 10.1128/JVI.79.10.6207-6215.2005; Evans JD, 2003, J VIROL, V77, P5295, DOI 10.1128/JVI.77.9.5295-5304.2003; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; FALGOUT B, 1987, J VIROL, V61, P3759, DOI 10.1128/JVI.61.12.3759-3768.1987; Fessler SP, 2004, CURR TOP MICROBIOL, V273, P113; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; GHADGE GD, 1994, J VIROL, V68, P4137, DOI 10.1128/JVI.68.7.4137-4151.1994; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Gonzalez RA, 2002, J VIROL, V76, P4507, DOI 10.1128/JVI.76.9.4507-4519.2002; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hart LS, 2005, J BIOL CHEM, V280, P1474, DOI 10.1074/jbc.M409934200; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Horwitz MS, 2001, VIROLOGY, V279, P1, DOI 10.1006/viro.2000.0738; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Kaempfer R, 2003, EMBO REP, V4, P1043, DOI 10.1038/sj.embor.7400005; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; Kleinberger T, 2004, PROG MOL SUBCELL BIO, V36, P245; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leppard KN, 1997, J GEN VIROL, V78, P2131, DOI 10.1099/0022-1317-78-9-2131; Li YH, 2001, CANCER RES, V61, P6428; Lichtenstein DL, 2004, INT REV IMMUNOL, V23, P75, DOI 10.1080/08830180490265556; Lilley CE, 2005, P NATL ACAD SCI USA, V102, P5844, DOI 10.1073/pnas.0501916102; Liu H, 2003, CURR TOP MICROBIOL, V272, P131; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; McNees AL, 2002, VIRUS RES, V88, P87, DOI 10.1016/S0168-1702(02)00122-3; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Miller DG, 2004, NAT GENET, V36, P767, DOI 10.1038/ng1380; MUNDSCHAU LJ, 1994, BIOCHIMIE, V76, P792, DOI 10.1016/0300-9084(94)90083-3; MUNOZFONTELA C, 2005, IN PRESS ONCOGENE; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; RILEY D, 1993, J VIROL, V67, P3586, DOI 10.1128/JVI.67.6.3586-3595.1993; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Russell A, 2004, PROG MOL SUBCELL BIO, V36, P207; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SHCAACK J, 2005, VIRAL IMMUNOL, V18, P79; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; Shepard RN, 2003, J VIROL, V77, P8593, DOI 10.1128/JVI.77.15.8593-8595.2003; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; SKALKA AM, 2005, CELL DEATH DIFFER; Steegenga WT, 1999, ONCOGENE, V18, P5032, DOI 10.1038/sj.onc.1202886; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stracker TH, 2005, J VIROL, V79, P6664, DOI 10.1128/JVI.79.11.6664-6673.2005; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAKEDA T, 1994, J IMMUNOL, V153, P4573; Tauber B, 2001, GENE, V278, P1, DOI 10.1016/S0378-1119(01)00722-3; Tauber B, 2001, ONCOGENE, V20, P7847, DOI 10.1038/sj.onc.1204914; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Thompson SR, 2000, CURR OPIN MICROBIOL, V3, P366, DOI 10.1016/S1369-5274(00)00106-5; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Wilkinson DE, 2004, J VIROL, V78, P4783, DOI 10.1128/JVI.78.9.4783-4796.2004; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Xi QR, 2004, GENE DEV, V18, P1997, DOI 10.1101/gad.1212504; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986; Zentilin L, 2001, J VIROL, V75, P12279, DOI 10.1128/JVI.75.24.12279-12287.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	146	82	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7686	7696		10.1038/sj.onc.1209063	http://dx.doi.org/10.1038/sj.onc.1209063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299529				2022-12-28	WOS:000233372600005
J	Astrinidis, A; Henske, EP				Astrinidis, A; Henske, EP			Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease	ONCOGENE			English	Article						tuberous sclerosis complex; lymphangiomyomatosis; mammalian target of Rapamycin; Rheb; AKT/ PKB	TUMOR-SUPPRESSOR GENE; S6 KINASE ACTIVATION; TSC2 GAP ACTIVITY; B-RAF KINASE; CELL-GROWTH; MAMMALIAN TARGET; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; MUTATIONAL ANALYSIS; RENAL ANGIOMYOLIPOMAS; 3-KINASE/AKT PATHWAY	The most exciting advances in the tuberous sclerosis complex (TSC) field occurred in 1993 and 1997 with the cloning of the TSC2 and TSC1 genes, respectively, and in 2003 with the identification of Rheb as the target of tuberin's ( TSC2) GTPase activating protein ( GAP) domain. Rheb has a dual role: it activates mTOR and inactivates B-Raf. Activation of mTOR leads to increased protein synthesis through phosphorylation of p70S6K and 4E-BP1. Upon insulin or growth factor stimulation, tuberin is phosphorylated by several kinases, including AKT/PKB, thereby suppressing its GAP activity and activating mTOR. Phosphorylation of hamartin (TSC1) by CDK1 also negatively regulates the activity of the hamartin/tuberin complex. Despite these biochemical advances, exactly how mutations in TSC1 or TSC2 lead to the clinical manifestations of TSC is far from being understood. Two of the most unusual phenotypes in TSC are the apparent metastasis of benign cells carrying TSC1 and TSC2 mutations, resulting in pulmonary lymphangio-myomatosis, and the ability of cells with TSC1 or TSC2 mutations to differentiate into the separate components of renal angiomyolipomas (vessels, smooth muscle and fat). We will discuss how the TSC signaling pathways are affected by mutations in TSC1 or TSC2, focusing on how these mutations may lead to the renal and pulmonary manifestations of TSC.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Henske, EP (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Elizabeth.Henske@fccc.edu	Astreinidis, Aristotelis/AAK-5137-2020; Astrinidis, Aristotelis/A-1396-2010; Astreinidis, Aristotelis/ABA-6715-2021	Astrinidis, Aristotelis/0000-0001-7098-1391				Astrinidis A, 2003, J BIOL CHEM, V278, P51372, DOI 10.1074/jbc.M303956200; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; El-Hashemite N, 2003, CANCER RES, V63, P5173; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova E, 2004, J CELL BIOL, V167, P1171, DOI 10.1083/jcb.200405130; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Govindarajan B, 2003, CLIN CANCER RES, V9, P3469; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Haddad LA, 2002, J BIOL CHEM, V277, P44180, DOI 10.1074/jbc.M207211200; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Han S, 2004, CANCER RES, V64, P812, DOI 10.1158/0008-5472.CAN-03-3277; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Henske EP, 1996, AM J HUM GENET, V59, P400; Henske EP, 2004, CURR MOL MED, V4, P825, DOI 10.2174/1566524043359610; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HOWE SR, 1995, ENDOCRINOLOGY, V136, P4996, DOI 10.1210/en.136.11.4996; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2003, AM J RESP CRIT CARE, V167, P976, DOI 10.1164/rccm.200208-969OC; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kenerson HL, 2002, CANCER RES, V62, P5645; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kinoshita Masaharu, 1995, Kurume Medical Journal, V42, P141; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kwiatkowska J, 1998, ANN HUM GENET, V62, P277, DOI 10.1046/j.1469-1809.1998.6240277.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Liu MY, 2003, CANCER RES, V63, P2675; Logginidou H, 2000, CHEST, V117, P25, DOI 10.1378/chest.117.1.25; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Mak BC, 2005, AM J PATHOL, V167, P107, DOI 10.1016/S0002-9440(10)62958-6; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nellist M, 2005, BIOCHEM BIOPH RES CO, V333, P818, DOI 10.1016/j.bbrc.2005.05.175; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; Plank TL, 1999, MODERN PATHOL, V12, P539; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ramesh V, 2003, BIOCHEM SOC T, V31, P579, DOI 10.1042/bst0310579; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sato T, 2002, J HUM GENET, V47, P20, DOI 10.1007/s10038-002-8651-8; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Slegtenhorst M, 1999, J MED GENET, V36, P285; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wienecke R, 1996, ONCOGENE, V13, P913; York B, 2005, FASEB J, V19, P1202, DOI 10.1096/fj.04-3142fje; Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	86	151	157	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7475	7481		10.1038/sj.onc.1209090	http://dx.doi.org/10.1038/sj.onc.1209090			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288294	Bronze			2022-12-28	WOS:000233201900010
J	Hamdi, M; Kool, J; Cornelissen-Steijger, P; Carlotti, F; Popeijus, HE; van der Burgt, C; Janssen, JM; Yasui, A; Hoeben, RC; Terleth, C; Mullenders, LH; van Dam, H				Hamdi, M; Kool, J; Cornelissen-Steijger, P; Carlotti, F; Popeijus, HE; van der Burgt, C; Janssen, JM; Yasui, A; Hoeben, RC; Terleth, C; Mullenders, LH; van Dam, H			DNA damage in transcribed genes induces apoptosis via the JNK pathway and the JNK-phosphatase MKP-1	ONCOGENE			English	Article						AP-1; DNA damage; MKP-1; JNK; transcription-coupled repair	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCISION-REPAIR; SIGNAL-TRANSDUCTION PATHWAY; JUN NH2-TERMINAL KINASE; CANCER-PRONE SYNDROMES; HERPES-SIMPLEX VIRUS; C-JUN; MAP KINASE; COUPLED REPAIR; XERODERMA-PIGMENTOSUM	The nucleotide excision repair (NER) system consists of two subpathways, global genome repair (GGR) and transcription-coupled repair (TCR), which exhibit distinct functions in the cellular response to genotoxic stress. Defects in TCR result in prolonged UV light-induced stalling of RNA polymerase II and hypersensitivity to apoptosis induced by UV and certain chemotherapeutic drugs. Here, we show that low doses of UV trigger delayed activation of the stress-induced MAPkinase JNK and its proapoptotic targets c-Jun and ATF-3 in TCR-deficient primary human fibroblasts from Xeroderma Pigmentosum (XP) and Cockayne syndrome (CS) patients. This delayed activation of the JNK pathway is not observed in GGR-deficient TCR-proficient XP cells, is independent of functional p53, and is established through repression of the JNK-phosphatase MKP-1 rather than by activation of the JNK kinases MKK4 and 7. Enzymatic reversal of UV-induced cyclobutane pyrimidine dimers (CPDs) by CPD photolyase abrogated JNK activation, MKP-1 repression, and apoptosis in TCR-deficient XPA cells. Ectopic expression of MKP-1 inhibited DNA-damage-induced JNK activity and apoptosis. These results identify both MKP-1 and JNK as sensors and downstream effectors of persistent DNA damage in transcribed genes and suggest a link between the JNK pathway and UV-induced stalling of RNApol II.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2333 AL Leiden, Netherlands; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Tohoku University	van Dam, H (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wasswnaarseweg 72, NL-2333 AL Leiden, Netherlands.	vdam@lumc.nl	Carlotti, Françoise/AAN-5018-2021; Carlotti, Françoise/H-1060-2014; Hoeben, Rob C./A-5771-2008	Carlotti, Françoise/0000-0001-7929-8468; Carlotti, Françoise/0000-0001-7929-8468; Hoeben, Rob C./0000-0001-9443-8377; Janssen, Josephine Martine/0000-0002-3430-7014; van Dam, Hans/0000-0002-8307-4325				Abrahams PJ, 1998, MUTAT RES-DNA REPAIR, V407, P189, DOI 10.1016/S0921-8777(98)00009-3; ABRAHAMS PJ, 1992, CANCER RES, V52, P53; ABRAHAMS PJ, 1988, CANCER RES, V48, P6054; ALESSI DR, 1993, ONCOGENE, V8, P2015; Bazuine M, 2004, MOL ENDOCRINOL, V18, P1697, DOI 10.1210/me.2003-0213; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002-220769; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; Hai T, 1999, GENE EXPRESSION, V7, P321; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; Herrlich P, 1999, CR ACAD SCI III-VIE, V322, P121, DOI 10.1016/S0764-4469(99)80033-X; Jaspers NGJ, 2002, DNA REPAIR, V1, P1027, DOI 10.1016/S1568-7864(02)00166-0; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakajima S, 2004, J BIOL CHEM, V279, P46674, DOI 10.1074/jbc.M406070200; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Queille S, 2001, J INVEST DERMATOL, V117, P1162, DOI 10.1046/j.0022-202x.2001.01533.x; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spivak G, 2002, DNA REPAIR, V1, P629, DOI 10.1016/S1568-7864(02)00056-3; Svejstrup JQ, 2002, MOL CELL, V9, P1151, DOI 10.1016/S1097-2765(02)00553-1; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Xu QH, 2004, FREE RADICAL BIO MED, V36, P985, DOI 10.1016/j.freeradbiomed.2004.01.009; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200	75	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7135	7144		10.1038/sj.onc.1208875	http://dx.doi.org/10.1038/sj.onc.1208875			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044158				2022-12-28	WOS:000232990100003
J	Bangham, CRM; Osame, M				Bangham, CRM; Osame, M			Cellular immune response to HTLV-1	ONCOGENE			English	Article						cytotoxic T lymphocyte; HTLV-1; genetics; microarray; virological synapse; lymphocyte dynamics; HAM/TSP; host defence	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; CYTOTOXIC T-LYMPHOCYTES; BLOOD MONONUCLEAR-CELLS; CENTRAL-NERVOUS-SYSTEM; TYPE-1 PROVIRAL LOAD; NEUROLOGICAL-DISEASE; PERIPHERAL-BLOOD; ASYMPTOMATIC CARRIERS; CEREBROSPINAL-FLUID	There is strong evidence at the individual level and the population level that an efficient cytotoxic T lymphocyte (CTL) response to HTLV-1 limits the proviral load and the risk of associated in. ammatory diseases such as HAM/TSP. This evidence comes from host population genetics, viral genetics, DNA expression microarrays and assays of lymphocyte function. However, until now there has been no satisfactory and rigorous means to de. ne or to measure the efficiency of an antiviral CTL response. Recently, methods have been developed to quantify lymphocyte turnover rates in vivo and the efficiency of anti-HTLV-1 CTLs ex vivo. Data from these new techniques appear to substantiate the conclusion that variation between individual hosts in the rate at which a single CTL kills HTLV-1-infected lymphocytes is an important determinant, perhaps the decisive determinant, of the proviral load and the risk of HAM/TSP. With these experimental data, it is becoming possible to re. ne, parameterize and test mathematical models of the immune control of HTLV-1, which are a necessary part of an understanding of this complex dynamic system.	Univ London Imperial Coll Sci & Technol, Dept Immunol, London W2 1PG, England; Kagoshima Univ, Fac Med, Dept Internal Med 3, Univ Hosp, Kagoshima 8908520, Japan	Imperial College London; Kagoshima University	Bangham, CRM (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Immunol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	c.bangham@imperial.ac.uk		Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176; Asquith B, 2003, P ROY SOC B-BIOL SCI, V270, P1651, DOI 10.1098/rspb.2003.2386; Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2; Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0; Asquith B, 2000, PHILOS T ROY SOC B, V355, P1013, DOI 10.1098/rstb.2000.0638; Bangham CRM, 1996, SEMIN VIROL, V7, P41, DOI 10.1006/smvy.1996.0006; Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borducchi DM, 2003, BRIT J HAEMATOL, V123, P954, DOI 10.1046/j.1365-2141.2003.04711.x; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Cavrois M, 1996, ONCOGENE, V12, P2419; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; DAENKE S, 1990, J VIROL, V64, P1278, DOI 10.1128/JVI.64.3.1278-1282.1990; DAENKE S, 1994, CLIN EXP IMMUNOL, V96, P179; Eiraku N, 1998, J IMMUNOL, V161, P6674; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; Etoh K, 1997, CANCER RES, V57, P4862; FUJIHARA K, 1991, J NEUROL SCI, V105, P99, DOI 10.1016/0022-510X(91)90125-Q; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Furukawa Y, 2000, J INFECT DIS, V182, P1343, DOI 10.1086/315897; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; Goon PKC, 2004, J INFECT DIS, V189, P2294, DOI 10.1086/420832; Goon PKC, 2004, J IMMUNOL, V172, P1735, DOI 10.4049/jimmunol.172.3.1735; Goon PKC, 2003, J VIROL, V77, P9716, DOI 10.1128/JVI.77.17.9716-9722.2003; Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Harashima N, 2004, CANCER RES, V64, P391, DOI 10.1158/0008-5472.CAN-03-1452; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; Higuchi I, 1996, ACTA NEUROPATHOL, V92, P358, DOI 10.1007/s004010050530; Hisada M, 2004, J INFECT DIS, V190, P1605, DOI 10.1086/424598; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; IJICHI S, 1993, MED HYPOTHESES, V41, P542, DOI 10.1016/0306-9877(93)90111-3; ISHIHARA S, 1994, J ACQ IMMUN DEF SYND, V7, P199; IWASAKI Y, 1992, AM J PATHOL, V140, P1003; IWASAKI Y, 1993, BRAIN PATHOL, V3, P1, DOI 10.1111/j.1750-3639.1993.tb00719.x; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; JACOBSON S, 1986, CONCEPTS VIRAL PATHO, V2, P187; Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848; Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278; KANNAGI M, 1984, J IMMUNOL, V133, P1037; KANNAGI M, 1991, INT IMMUNOL, V3, P761, DOI 10.1093/intimm/3.8.761; KANNAGI M, 1983, J IMMUNOL, V130, P2942; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; KINOSHITA T, 1991, INT J CANCER, V47, P491, DOI 10.1002/ijc.2910470403; KIRA J, 1992, J NEUROL SCI, V107, P98, DOI 10.1016/0022-510X(92)90215-7; Kitze B, 1998, CLIN EXP IMMUNOL, V111, P278; Kodama D, 2004, J NEUROIMMUNOL, V156, P188, DOI 10.1016/j.jneuroim.2004.07.007; KOMURIAN F, 1991, J VIROL, V65, P3770, DOI 10.1128/JVI.65.7.3770-3778.1991; Kubota R, 2000, AIDS RES HUM RETROV, V16, P1705, DOI 10.1089/08892220050193182; Kubota R, 2000, J NEUROIMMUNOL, V102, P208, DOI 10.1016/S0165-5728(99)00175-7; LEHKY TJ, 1995, ANN NEUROL, V37, P167, DOI 10.1002/ana.410370206; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Matsuoka E, 1998, ACTA NEUROPATHOL, V96, P340, DOI 10.1007/s004010050903; McGinn TM, 2004, AIDS RES HUM RETROV, V20, P443, DOI 10.1089/088922204323048195; Moritoyo T, 1999, J NEUROVIROL, V5, P241, DOI 10.3109/13550289909015810; Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225; NAGASATO K, 1991, J NEUROL SCI, V103, P203, DOI 10.1016/0022-510X(91)90165-4; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; Niewiesk S, 1996, J MOL EVOL, V42, P452, DOI 10.1007/BF02498639; NIEWIESK S, 1994, J VIROL, V68, P6778, DOI 10.1128/JVI.68.10.6778-6781.1994; NISHIMURA Y, 1991, TISSUE ANTIGENS, V37, P230, DOI 10.1111/j.1399-0039.1991.tb01877.x; Nomura M, 2004, J VIROL, V78, P3827, DOI 10.1128/JVI.78.8.3827-3836.2004; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Overbaugh J, 2001, SCIENCE, V292, P1106, DOI 10.1126/science.1059128; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; Pende D, 2001, EUR J IMMUNOL, V31, P1076, DOI 10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Plancoulaine S, 2000, J INFECT DIS, V182, P405, DOI 10.1086/315741; Rafatpanah H, 2004, HUM IMMUNOL, V65, P839, DOI 10.1016/j.humimm.2004.05.006; Sabouri AH, 2005, J GEN VIROL, V86, P773, DOI 10.1099/vir.0.80509-0; Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942; Saito M, 2003, BLOOD, V102, P577, DOI 10.1182/blood-2002-09-2855; Slattery JP, 1999, GENOME RES, V9, P525; Smith MJ, 2001, J VIROL, V75, P2301, DOI 10.1128/JVI.75.5.2301-2313.2001; Sonoda S, 1996, J ACQ IMMUN DEF SYND, V13, pS119, DOI 10.1097/00042560-199600001-00020; Sutherland CL, 2002, J IMMUNOL, V168, P671, DOI 10.4049/jimmunol.168.2.671; USUKU K, 1990, EUR J IMMUNOL, V20, P1603, DOI 10.1002/eji.1830200729; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121; Vine AM, 2002, J INFECT DIS, V186, P932, DOI 10.1086/342953; Wodarz D, 2001, P ROY SOC B-BIOL SCI, V268, P1215, DOI 10.1098/rspb.2001.1608; Wodarz D, 2000, J MOL EVOL, V50, P448, DOI 10.1007/s002390010047; YU F, 1991, J NEUROIMMUNOL, V33, P121, DOI 10.1016/0165-5728(91)90056-D	94	146	155	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					6035	6046		10.1038/sj.onc.1208970	http://dx.doi.org/10.1038/sj.onc.1208970			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155610				2022-12-28	WOS:000231623400013
J	Grassmann, R; Aboud, M; Jeang, KT				Grassmann, R; Aboud, M; Jeang, KT			Molecular mechanisms of cellular transformation by HTLV-1 Tax	ONCOGENE			English	Review						HTLV; leukemia; T-lymphocyte; cell cycle; transformation; immortalization; Tax; ATLL apoptosis	VIRUS TYPE-I; NF-KAPPA-B; HUMAN T-CELLS; INTERLEUKIN-2 GENE-EXPRESSION; PRIMARY HUMAN-LYMPHOCYTES; TUMOR-SUPPRESSOR GENES; ACUTE MYELOID-LEUKEMIA; CREB BINDING-PROTEIN; LONG TERMINAL REPEAT; ONCOGENE PRODUCT TAX	The HTLV Tax protein is crucial for viral replication and for initiating malignant transformation leading to the development of adult T-cell leukemia. Tax has been shown to be oncogenic, since it transforms and immortalizes rodent. broblasts and human T-lymphocytes. Through CREB, NF-kappa B and SRF pathways Tax transactivates cellular promoters including those of cytokines (IL-13, IL-15), cytokine receptors (IL- 2R alpha) and costimulatory surface receptors (OX40/OX40L) leading to upregulated protein expression and activated signaling cascades ( e. g. Jak/STAT, PI3Kinase, JNK). Tax also stimulates cell growth by direct binding to cyclin-dependent kinase holenzymes and/or inactivating tumor suppressors (e.g. p53, DLG). Moreover, Tax silences cellular checkpoints, which guard against DNA structural damage and chromosomal missegregation, thereby favoring the manifestation of a mutator phenotype in cells.	Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Erlangen, Germany; Ben Gurion Univ Negev, Dept Microbiol, IL-84105 Beer Sheva, Israel; NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Grassmann, R (corresponding author), Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Schlossgarten 4, Erlangen, Germany.	Ralph.Grassmann@viro.med.uni-erlangen.de	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Azimi N, 1999, J IMMUNOL, V163, P4064; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038/sj.onc.1208645; Azran Inbal, 2004, Retrovirology, V1, P20; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Ching Yick-Pang, 2004, Retrovirology, V1, P18, DOI 10.1186/1742-4690-1-18; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Chlichlia K, 2002, ANTIOXID REDOX SIGN, V4, P471, DOI 10.1089/15230860260196263; Chowdhury IH, 2003, INT J CANCER, V107, P603, DOI 10.1002/ijc.11316; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; D'Agostino DM, 2002, J BIOL CHEM, V277, P34424, DOI 10.1074/jbc.M203023200; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Duensing Stefan, 2003, Prog Cell Cycle Res, V5, P383; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Etoh K, 1997, CANCER RES, V57, P4862; FLINT J, 1994, AM J HUM GENET, V55, P505; FUJITA M, 1995, ONCOGENE, V11, P15; Fung MM, 2005, ONCOGENE, V24, P4624, DOI 10.1038/sj.onc.1208507; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Haller K, 2000, AIDS RES HUM RETROV, V16, P1683, DOI 10.1089/08892220050193146; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Huang H, 1997, J IMMUNOL, V159, P3731; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; INOUE H, 1994, EXP CELL RES, V215, P68, DOI 10.1006/excr.1994.1316; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 2001, VIROLOGY, V291, P292, DOI 10.1006/viro.2001.1200; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Kirken RA, 2000, J IMMUNOL, V165, P5097, DOI 10.4049/jimmunol.165.9.5097; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lefebvre L, 2002, J VIROL, V76, P1400, DOI 10.1128/JVI.76.3.1400-1414.2002; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Mariner JM, 2001, J IMMUNOL, V166, P2602, DOI 10.4049/jimmunol.166.4.2602; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005; Moon JJ, 2004, J BIOL CHEM, V279, P5520, DOI 10.1074/jbc.M308998200; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; OSAME M, 1986, LANCET, V1, P1031; Pankow R, 2000, J IMMUNOL, V165, P263, DOI 10.4049/jimmunol.165.1.263; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2002, CANCER RES, V62, P3562; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Rasnick D, 2002, CANCER GENET CYTOGEN, V136, P66, DOI 10.1016/S0165-4608(01)00665-3; REID RL, 1993, ONCOGENE, V8, P3029; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Robek MD, 2000, J VIROL, V74, P11988, DOI 10.1128/JVI.74.24.11988-11992.2000; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 2000, BLOOD, V95, P3939; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; Xu X, 1996, ONCOGENE, V13, P135; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	157	305	319	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5976	5985		10.1038/sj.onc.1208978	http://dx.doi.org/10.1038/sj.onc.1208978			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155604				2022-12-28	WOS:000231623400007
J	Christensen, C; Guldberg, P				Christensen, C; Guldberg, P			Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF	ONCOGENE			English	Article						malignant melanoma; B-RAF; RNA interference; apoptosis; senescence; growth factors	POLYMERASE-III TRANSCRIPTION; ACTIVATED PROTEIN-KINASE; SHORT-INTERFERING RNAS; MALIGNANT-MELANOMA; HUMAN MELANOCYTES; METASTATIC MELANOMA; BRAF MUTATIONS; ONCOGENIC MUTATIONS; THERAPEUTIC TARGET; A-RAF	Constitutive activation of the RAS-RAF-MEK-ERK signaling cascade is a hallmark of cutaneous malignant melanoma. A single activating mutation (c. 1799T > A; p. V600E) in the gene encoding the serine/threonine kinase B-RAF occurs in > 60% of the tumors. Previous work has shown that knockdown of B-V600E-RAFby RNA interference induces a variety of phenotypic changes in cultured melanoma cells, including lower proliferation rates, reduced anchorage-independent growth and apoptosis. Here, we show that the majority of melanomas harboring the B-V600E-RAF mutation have retained the wild-type (WT) B-RAF allele, and that these cells can be rescued from the effects of B-V600E-RAF knockdown by stimulation with growth factors. Ectopic expression of short hairpin RNAs specifically suppressing B-V600E-RAF in melanoma cell lines reduced colony formation by similar to 80%. This response could be rescued by basic fibroblast growth factor, hepatocyte growth factor or, to a lesser extent, endothelin-1. Rescue with growth factors was not possible in cell lines lacking B-WT-RAF. Single-cell clones with efficient knockdown of B-V600E-RAF could be propagated in the presence of basic fibroblast growth factor but underwent apoptosis or senescence-like growth arrest upon withdrawal of this growth factor. The ability of growth factors to modulate the response of B-V600E-RAF knockdown in melanoma cells may have both experimental and therapeutic implications.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	perg@cancer.dk						ALBINO AP, 1991, CANCER RES, V51, P4815; Bastian BC, 1998, CANCER RES, V58, P2170; Berking C, 2001, AM J PATHOL, V158, P943, DOI 10.1016/S0002-9440(10)64041-2; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Collisson EA, 2003, CANCER RES, V63, P5669; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong JL, 2003, CANCER RES, V63, P3883; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gorden A, 2003, CANCER RES, V63, P3955; Guldberg P, 1997, CANCER RES, V57, P3660; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hingorani SR, 2003, CANCER RES, V63, P5198; Huang SY, 1996, ONCOGENE, V13, P2339; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Imokawa G, 2000, J BIOL CHEM, V275, P33321, DOI 10.1074/jbc.M004346200; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Otsuka T, 1998, CANCER RES, V58, P5157; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; STORM SM, 1990, ONCOGENE, V5, P345; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427	46	42	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6292	6302		10.1038/sj.onc.1208758	http://dx.doi.org/10.1038/sj.onc.1208758			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007203				2022-12-28	WOS:000231877100010
J	Launay, S; Hermine, O; Fontenay, M; Kroemer, G; Solary, E; Garrido, C				Launay, S; Hermine, O; Fontenay, M; Kroemer, G; Solary, E; Garrido, C			Vital functions for lethal caspases	ONCOGENE			English	Review						caspase; differentiation; programmed cell death; immune system; cell cycle	TUMOR-NECROSIS-FACTOR; T-CELL PROLIFERATION; HUMAN EPIDERMAL-KERATINOCYTES; LENS FIBER DIFFERENTIATION; FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; BONE-MARROW-CELLS; NF-KAPPA-B; TERMINAL DIFFERENTIATION; MYELODYSPLASTIC SYNDROMES	Caspases are a family of cysteine proteases expressed as inactive zymogens in virtually all animal cells. These enzymes play a central role in most cell death pathways leading to apoptosis but growing evidences implicate caspases also in nonapoptotic functions. Several of these enzymes, activated in molecular platforms referred to as inflammasomes, play a role in innate immune response by processing some of the cytokines involved in inflammatory response. Caspases are requested for terminal differentiation of specific cell types, whether this differentiation process leads to enucleation or not. These enzymes play also a role in T and B lymphocyte proliferation and, in some circumstances, appear to be cytoprotective rather than cytotoxic. These pleiotropic functions implicate caspases in the control of life and death but the. ne regulation of their dual effect remains poorly understood. The nonapoptotic functions of caspases implicate that cells can restrict the proteolytic activity of these enzymes to selected substrates. Deregulation of the pathways in which caspases exert these nonapoptotic functions is suspected to play a role in the pathophysiology of several human diseases.	INSERM, U 517, IFR100, Fac Med, F-21033 Dijon, France; Hop Necker Enfants Malad, Dept Adult Hematol, F-75743 Paris, France; INSERM, Inst Cochin, Dept Hematol, U 567, F-75679 Paris, France; Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Garrido, C (corresponding author), INSERM, U 517, IFR100, Fac Med, 7 Blvd Jeanne Arc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Hermine, Olivier/Q-7072-2018; Garrido, carmen/G-1633-2018; KROEMER, Guido/B-4263-2013; Garrido, Carolina/GWM-5557-2022; Kroemer, Guido/AAY-9859-2020	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Solary, Eric/0000-0002-8629-1341; Hermine, Olivier/0000-0003-2574-3874; Fontenay, Michaela/0000-0002-5492-6349				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Ahn EY, 2002, INT J CANCER, V100, P445, DOI 10.1002/ijc.10516; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Allombert-Blaise C, 2003, CELL DEATH DIFFER, V10, P850, DOI 10.1038/sj.cdd.4401245; Antonopoulos H, 2001, J IMMUNOL, V166, P3672, DOI 10.4049/jimmunol.166.6.3672; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Barnoy S, 2003, FEBS LETT, V546, P213, DOI 10.1016/S0014-5793(03)00573-8; Beisner DR, 2003, J IMMUNOL, V171, P247, DOI 10.4049/jimmunol.171.1.247; Boissonnas A, 2002, EUR J IMMUNOL, V32, P3007, DOI 10.1002/1521-4141(2002010)32:10<3007::AID-IMMU3007>3.0.CO;2-9; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Cai JY, 2004, ARCH BIOCHEM BIOPHYS, V424, P119, DOI 10.1016/j.abb.2004.02.012; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chien AJ, 2002, BIOCHEM BIOPH RES CO, V296, P911, DOI 10.1016/S0006-291X(02)02015-6; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Claessens YE, 2002, BLOOD, V99, P1594, DOI 10.1182/blood.V99.5.1594; CLAESSENS YE, 2005, IN PRESS BLOOD; Cohen Z, 2004, THROMB RES, V113, P387, DOI 10.1016/j.thromres.2004.03.020; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; DeChant AK, 2002, ONCOGENE, V21, P5268, DOI 10.1038/sj.onc.1205648; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Foley JD, 2004, J BIOL CHEM, V279, P32142, DOI 10.1074/jbc.M313683200; Franchi L, 2003, BLOOD, V102, P2910, DOI 10.1182/blood-2003-03-0967; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gersuk GM, 1996, BLOOD, V88, P1122, DOI 10.1182/blood.V88.3.1122b.bloodjournal8831122b; Goss S J, 1978, Int Rev Cytol Suppl, VSuppl 8, P127; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Hawkins PN, 2004, ARTHRITIS RHEUM-US, V50, P607, DOI 10.1002/art.20033; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Krieser RJ, 2002, CELL DEATH DIFFER, V9, P956, DOI 10.1038/sj.cdd.4401056; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Reilly LA, 2004, CELL DEATH DIFFER, V11, P724, DOI 10.1038/sj.cdd.4401408; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Oomman S, 2004, J COMP NEUROL, V476, P154, DOI 10.1002/cne.20223; Peller S, 2003, ONCOGENE, V22, P4648, DOI 10.1038/sj.onc.1206541; Plenchette S, 2004, BLOOD, V104, P2035, DOI 10.1182/blood-2004-01-0065; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Rieux-Laucat F, 2003, CURR OPIN IMMUNOL, V15, P325, DOI 10.1016/S0952-7915(03)00042-6; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Sanders EJ, 2002, J ANAT, V201, P121, DOI 10.1046/j.1469-7580.2002.00081.x; Schmidt-Mende J, 2001, LEUKEMIA, V15, P742, DOI 10.1038/sj.leu.2402110; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Sun SS, 2000, J CELL BIOCHEM, V76, P44; Tai TS, 2004, CELL DEATH DIFFER, V11, P69, DOI 10.1038/sj.cdd.4401316; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; Testa U, 2004, LEUKEMIA, V18, P1176, DOI 10.1038/sj.leu.2403383; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vischioni B, 2004, EXP CELL RES, V298, P535, DOI 10.1016/j.yexcr.2004.04.040; Vonarbourg C, 2002, EUR J IMMUNOL, V32, P2376, DOI 10.1002/1521-4141(200208)32:8<2376::AID-IMMU2376>3.0.CO;2-V; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Watanabe Y, 1999, J CELL PHYSIOL, V179, P45, DOI 10.1002/(SICI)1097-4652(199904)179:1<45::AID-JCP6>3.0.CO;2-H; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Yang JY, 2004, MOL CELL BIOL, V24, P10425, DOI 10.1128/MCB.24.23.10425-10436.2004; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yang XL, 2002, CANCER BIOL THER, V1, P407, DOI 10.4161/cbt.1.4.16; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 2003, CELL DEATH DIFFER, V10, P905, DOI 10.1038/sj.cdd.4401255; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603; 2004, SCIENCE, V303, P1138	129	185	196	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5137	5148		10.1038/sj.onc.1208524	http://dx.doi.org/10.1038/sj.onc.1208524			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	16079910				2022-12-28	WOS:000230964600001
J	Charafe-Jauffret, E; Ginestier, C; Monville, F; Finetti, P; Adelaide, J; Cervera, N; Fekairi, S; Xerri, L; Jacquemier, J; Birnbaum, D; Bertucci, F				Charafe-Jauffret, E; Ginestier, C; Monville, F; Finetti, P; Adelaide, J; Cervera, N; Fekairi, S; Xerri, L; Jacquemier, J; Birnbaum, D; Bertucci, F			Gene expression profiling of breast cell lines identifies potential new basal markers	ONCOGENE			English	Article						basal; breast cancer; DNA microarray; epithelium; expression profiling; luminal; breast cell lines	MOLECULAR CLASSIFICATION; PROGENITOR CELLS; CANCER-CELLS; C-MET; CARCINOMA; TUMORS; PREDICTION; TISSUE; SUBCLASSES; PHENOTYPE	A better molecular characterization of breast cell lines (BCL) may help discover new markers to apply to tumour samples. We performed gene and protein expression pro. ling of 31 BCL using whole-genome DNA microarrays and immunohistochemistry (IHC) on 'cell microarrays' (CMA), respectively. Global hierarchical clustering discriminated two groups of BCL: group I corresponded to luminal cell lines, group II to basal and mesenchymal cell lines. Correlations with centroids calculated from a published 'intrinsic 500-gene set' assigned 15 cell lines as luminal, eight as basal and four as mesenchymal. A set of 1.233 genes was differentially expressed between basal and luminal samples. Mesenchymal and basal subtypes were rather similar and discriminated by only 227 genes. The expression of 10 proteins (CAV1, CD44, EGFR, MET, ETS1, GATA3, luminal cytokeratin CK19, basal cytokeratin CK5/6, CD10, and ERM protein moesin) encoded by luminal vs basal discriminator genes confirmed the subtype classification and the validity of the identified markers. Our BCL basal/luminal signature correctly re-classified the published series of tumour samples that originally served to identify the molecular subtypes, suggesting that the identified markers should be useful for tumour classification and might represent promising targets for disease management.	Inst J Paoli I Calmettes, Marseille Canc Inst, Mol Oncol Lab, UMR599,Inserm, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, Marseille, France; Univ Mediterranee, UFR Med, Marseille, France; Inst Paoli Calmettes, INSERM, UMR599, Dept Med Oncol,Marseille Canc Inst, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, Marseille Canc Inst, Mol Oncol Lab, UMR599,Inserm, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Ginestier, Christophe/M-8828-2017; Charafe-Jauffret, emmanuelle/P-6009-2017; Finetti, Pascal/O-8669-2017	ADELAIDE, José JA/0000-0003-4364-9857; Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Finetti, Pascal/0000-0002-2674-3123				Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Birnbaum D, 2004, INT J ONCOL, V25, P249; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; Carmeci C, 1998, SURGERY, V124, P211, DOI 10.1016/S0039-6060(98)70122-9; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Clarke CL, 2004, J PATHOL, V204, P147, DOI 10.1002/path.1647; Condeelis J, 2005, ANNU REV CELL DEV BI, V21, P695, DOI 10.1146/annurev.cellbio.21.122303.120306; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ETHIER SP, 1993, CANCER RES, V53, P627; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacquemier J, 2005, CANCER RES, V65, P767; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Leibl S, 2005, AM J SURG PATHOL, V29, P347, DOI 10.1097/01.pas.0000152133.60278.d2; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Mobus VJ, 1998, INT J CANCER, V77, P415, DOI 10.1002/(SICI)1097-0215(19980729)77:3<415::AID-IJC18>3.0.CO;2-6; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Nugoli M, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-13; Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Sangiorgio Vanessa, 2004, Ital J Biochem, V53, P98; Schindelmann S, 2002, TUMOR BIOL, V23, P139, DOI 10.1159/000064030; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sprenger RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/elps.200305675; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Tomlinson GE, 1998, CANCER RES, V58, P3237; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Walker JA, 2003, HISTOPATHOLOGY, V42, P300, DOI 10.1046/j.1365-2559.2003.15361.x; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; Zhao H, 2004, INT J CANCER, V109, P65, DOI 10.1002/ijc.11676	57	410	427	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2273	2284		10.1038/sj.onc.1209254	http://dx.doi.org/10.1038/sj.onc.1209254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288205				2022-12-28	WOS:000236581200014
J	Djafarzadeh, R; Noessner, E; Engelmann, H; Schendel, DJ; Notohamiprodjo, M; von Luettichau, I; Nelson, PJ				Djafarzadeh, R; Noessner, E; Engelmann, H; Schendel, DJ; Notohamiprodjo, M; von Luettichau, I; Nelson, PJ			GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing	ONCOGENE			English	Article						renal cell carcinoma; cell surface engineering; FAS apoptosis; TIMP-1; GPI anchor	TUMOR-INFILTRATING LYMPHOCYTES; TISSUE INHIBITOR; IN-VIVO; MATRIX METALLOPROTEINASES; PANCREATIC-CANCER; EPITHELIAL-CELLS; MEDIATED LYSIS; DEATH; CYTOTOXICITY; APOPTOSIS	The resistance of tumours to immune-mediated lysis has been linked to the biology of matrix metalloproteinases (MMPs), and specically to the cell surface expression of MMPs by the tumour cell. The endogenous tissue inhibitors of metalloproteinases (TIMPs) exhibit diverse physiological/biological functions including the moderation of tumour growth, metastasis and apoptosis. These biologic activities are mediated in part by the stoichiometry of TIMP/MMP/cell surface protein interactions. A glycosylphosphatidylinositol (GPI) anchor was fused to TIMP-1 to focus defined concentrations of this inhibitory protein on the surface of three renal cell carcinoma (RCC) cell lines (RCC-26, RCC-53 and A498) independently of cell surface protein-protein interactions. Exogenously added TIMP-1-GPI efficiently inserted into the RCC cell membrane and dramatically altered the association of MMPs with the cell surface. TIMP-1-GPI treatment inhibited RCC proliferation and rendered the normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis but did not alter perforin-mediated lysis by cytotoxic effector cells. The increased sensitivity to FAS-mediated apoptosis correlated with an alteration in the balance of pro- and antiapoptotic BCL-2-family proteins. By interfering with the proliferative capacity and inducing sensitivity to immune effector mechanisms GPI-anchored TIMP-1 may represent a more effective version of the TIMP-1 protein for therapeutic strategies.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; GSF Inst Mol Immunol, Munich, Germany; Univ Munich, Inst Immunol, D-80336 Munich, Germany; Tech Univ Munich, Childrens Hosp, Med Ctr, D-8000 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Munich; University of Munich	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.	peter.nelson@med.uni-muenchen.de						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BARNSTABLE CJ, 1978, BRIT MED BULL, V34, P241, DOI 10.1093/oxfordjournals.bmb.a071504; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Brand Karsten, 2002, Current Gene Therapy, V2, P255, DOI 10.2174/1566523024605564; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown O, 2000, GENE THER, V7, P1947, DOI 10.1038/sj.gt.3301325; Djafarzadeh R, 2004, BIOL CHEM, V385, P655, DOI 10.1515/BC.2004.081; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Frost P, 2003, INT J ONCOL, V22, P431; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GONG JH, 1994, LEUKEMIA, V8, P652; Hemmerlein B, 2004, INT J ONCOL, V24, P1069; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; JOHNSON JP, 1988, IMMUNOBIOLOGY, V178, P275, DOI 10.1016/S0171-2985(88)80071-8; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KIRBY AC, 1995, BIOCHEM BIOPH RES CO, V214, P200, DOI 10.1006/bbrc.1995.2275; Klier CM, 2001, BIOL CHEM, V382, P1405, DOI 10.1515/BC.2001.173; Lang R, 2004, J MOL BIOL, V336, P213, DOI 10.1016/j.jmb.2003.12.022; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; Rigg AS, 2001, CANCER GENE THER, V8, P869, DOI 10.1038/sj.cgt.7700387; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Schendel DJ, 2000, GENE THER, V7, P2007, DOI 10.1038/sj.gt.3301349; Schendel DJ, 1997, J MOL MED-JMM, V75, P400, DOI 10.1007/s001090050125; SCHENDEL DJ, 1993, J IMMUNOL, V151, P4209; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Span PN, 2004, J PATHOL, V202, P395, DOI 10.1002/path.1528; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Zacchigna S, 2004, CANCER GENE THER, V11, P73, DOI 10.1038/sj.cgt.7700657	44	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1496	1508		10.1038/sj.onc.1209188	http://dx.doi.org/10.1038/sj.onc.1209188			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261161				2022-12-28	WOS:000235890400007
J	Hayes, CS; DeFeo, K; Lan, L; Paul, B; Sell, C; Gilmour, SK				Hayes, CS; DeFeo, K; Lan, L; Paul, B; Sell, C; Gilmour, SK			Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells	ONCOGENE			English	Article						polyamines; ornithine decarboxylase; invasion; Raf/ERK; Akt	MOUSE EPIDERMAL-CELLS; BINDING PROTEIN RHO; EPITHELIAL-CELLS; RAS TRANSFORMATION; TRANSGENIC MICE; ONCOGENIC RAS; ALPHA-DIFLUOROMETHYLORNITHINE; SIGNALING PATHWAYS; TUMOR PROMOTION; HUMAN CANCER	Ornithine decarboxylase (ODC) overexpression coupled with activated Ras is fully sufficient to oncogenically transform primary keratinocytes. To determine the Ras effector pathways that represent the minimal essential contribution to full oncogenic transformation in this context, we evaluated the cooperativity of different Ras effector mutants with overexpressed ODC in an in vivo tracheal xenotransplantation assay for epithelial cell invasiveness. Primary keratinocytes, isolated from either K6/ODC transgenic mouse skin (expressing increased ODC) or from normal littermate skin were infected with retrovirus producing an activated RasV12 or partial loss-of-function effector mutants of RasV12 that selectively induce only the Raf/ERK, RalGDS, or the PI3-kinase signaling pathway. Whereas keratinocytes expressing a fully activated RasV12 are not invasive in tracheal xenotransplants, ODC-overexpressing keratinocytes acquire an invasive phenotype with additional expression of either RasV12 or activation of the Raf/ERK pathway. Independent of a mutated ras, elevated levels of ODC activate the Akt/mTOR signaling pathway as well as the Rho/Rac pathway in primary keratinocytes. Thus, Raf/ERK signaling is sufficient to cooperate with increased ODC activity in the conversion of normal keratinocytes to invasive cells. In order to promote invasiveness in keratinocytes, elevated levels of ODC may cooperate with Raf/ERK via activation of the Akt and Rho/Rac signaling pathway.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA	Lankenau Medical Center; Lankenau Institute for Medical Research	Gilmour, SK (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	gilmours@mlhs.org			NCI NIH HHS [CA070739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Bedogni B, 2004, CANCER RES, V64, P2552, DOI 10.1158/0008-5472.CAN-03-3327; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; Feith DJ, 2001, CANCER RES, V61, P6073; Feith DJ, 2005, CANCER RES, V65, P572; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Gilmour SK, 2001, J INVEST DERMATOL, V117, P1674, DOI 10.1046/j.0022-202x.2001.01597.x; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jaffer ZM, 2004, J BIOL CHEM, V279, P35123, DOI 10.1074/jbc.R400010200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lan L, 2000, CANCER RES, V60, P5696; Lan L, 2005, J INVEST DERMATOL, V124, P602, DOI 10.1111/j.0022-202X.2005.23620.x; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; McFarlin DR, 2003, CARCINOGENESIS, V24, P99, DOI 10.1093/carcin/24.1.99; MEGOSH L, 1995, CANCER RES, V55, P4205; OBrien TG, 1997, CANCER RES, V57, P2630; OBRIEN TG, 1975, CANCER RES, V35, P1662; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PEGG AE, 1988, CANCER RES, V48, P759; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Ray RM, 2003, J BIOL CHEM, V278, P13039, DOI 10.1074/jbc.M208741200; Ray RM, 2005, J BIOL CHEM, V280, P31091, DOI 10.1074/jbc.M503041200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Shantz LM, 1998, CANCER RES, V58, P2748; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Smith MK, 1997, CANCER RES, V57, P2104; STRUGILL TW, 1988, NATURE, V334, P715; Sturge J, 2002, J CELL SCI, V115, P699; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAKIGAWA M, 1983, CANCER RES, V43, P3732; Tang XW, 2004, J CLIN INVEST, V113, P867, DOI 10.1172/JCI200420732; Tarutani M, 2003, CANCER RES, V63, P319; Ulku AS, 2003, MOL CANCER RES, V1, P1077; VAN AL, 1997, GENE DEV, V11, P2295; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	68	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1543	1553		10.1038/sj.onc.1209198	http://dx.doi.org/10.1038/sj.onc.1209198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278677				2022-12-28	WOS:000235890400011
J	Itoh, M; Murata, T; Suzuki, T; Shindoh, M; Nakajima, K; Imai, K; Yoshida, K				Itoh, M; Murata, T; Suzuki, T; Shindoh, M; Nakajima, K; Imai, K; Yoshida, K			Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells	ONCOGENE			English	Article						STAT3; EGF; MMP; c-JUN; migration; tumorigenesis	MATRIX-METALLOPROTEINASE; CONSTITUTIVE ACTIVATION; ONCOSTATIN-M; IN-VITRO; SIGNAL TRANSDUCER; C-JUN; EXPRESSION; TRANSCRIPTION; INHIBITOR; PROTEIN	Signal transducers and activators of transcription (STATs) are latent transcription factors that mediate cytokine- and growth factor-induced transcription. Constitutive activation of STAT3 has been shown in human cancers and transformed cell lines. We report that STAT3, but not STAT1 and STAT5, becomes phosphorylated in response to epidermal growth factor (EGF) and achieves maximal induction of collagenase-1 (MMP1) transcription by interacting with c-JUN. Phosphorylation of STAT3 protein is biphasic: the first peak within 30 min and the second peak between 4 and 8 h. Association of STAT3 with c-JUN is detected and its constituting STAT3 is increasingly phosphorylated. The STAT and AP-1 elements are necessary for effective induction of MMP-1 promoter by EGF. Mutation of AP-1 element closely located at the STAT site abolishes the binding not only of c-JUN but also of STAT3 to MMP-1 promoter, resulting in the loss of the responsiveness to EGF. By blocking STAT3 activity with the dominant-negative form, we show the requirement of STAT3 for EGF induction of MMP-1 and MMP-10 (stromelysin-2). Furthermore, expression of the dominant-negative STAT3 is sufficient to inhibit the constitutive and EGF-inducible cell migration and invasion and the tumor formation in nude mice. These results demonstrate that STAT3 phosphorylation and its possible interaction with c-JUN are required for the strong responsiveness of MMP-1 to EGF, and STAT3 activation is crucial for exhibition of malignant characteristics in T24 bladder cancer cells.	Sapporo Med Univ, Sch Med, Dept Biol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Kita Ku, Sapporo, Hokkaido, Japan; Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, Osaka 558, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido, Japan	Sapporo Medical University; Hokkaido University; Osaka Metropolitan University; Sapporo Medical University	Yoshida, K (corresponding author), Sapporo Med Univ, Sch Med, Dept Biol, Chuo Ku, S1,W17, Sapporo, Hokkaido 0608556, Japan.	kyoshida@sapmed.ac.jp	Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dominguez-Escrig JL, 2004, CLIN CANCER RES, V10, P4874, DOI 10.1158/1078-0432.CCR-04-0034; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Higashino F, 2005, J CELL BIOL, V170, P15, DOI 10.1083/jcb.200405112; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Horton R M, 1997, Methods Mol Biol, V67, P141; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; KOOP S, 1994, CANCER RES, V54, P4791; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Masuda M, 2002, CANCER RES, V62, P3351; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shibata T, 1996, TUMOR BIOL, V17, P168, DOI 10.1159/000217979; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	46	138	162	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1195	1204		10.1038/sj.onc.1209149	http://dx.doi.org/10.1038/sj.onc.1209149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205632				2022-12-28	WOS:000235537500007
J	Bossi, G; Lapi, E; Strano, S; Rinaldo, C; Blandino, G; Sacchi, A				Bossi, G; Lapi, E; Strano, S; Rinaldo, C; Blandino, G; Sacchi, A			Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression	ONCOGENE			English	Article						mutant p53; gain of function; human cancer cells; RNA interference	GENE-EXPRESSION; WILD-TYPE; MUTATIONS; DOXORUBICIN; RESISTANCE; SUPPRESSOR; REQUIRES	Mutations in the TP53 tumor suppressor gene are the most frequent genetic alteration in human cancers. These alterations are mostly missense point mutations that cluster in the DNA binding domain. There is growing evidence that many of these mutations generate mutant p53 proteins that have acquired new biochemical and biological properties. Through this gain of function activity, mutant p53 is believed to contribute to tumor malignancy. The purpose of our study was to explore mutant p53 as a target for novel anticancer treatments. To this aim, we inhibited mutant p53 expression by RNA interference in three different cancer cell lines endogenously expressing mutant p53 proteins, and evaluated the effects on the biological activities through which mutant p53 exerts gain of function. We found that depletion of mutant p53 reduces cell proliferation, in vitro and in vivo tumorigenicity, and resistance to anticancer drugs. Our results demonstrate that mutant p53 knocking down weakens the aggressiveness of human cancer cells, and provides further insight into the comprehension of mutant p53 gain of function activity in human tumor.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Sacchi, A (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	bossi@ifo.it; sacchi@ifo.it	Blandino, Giovanni/B-1137-2013; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/ABH-6846-2020; Strano, Sabrina/K-9654-2016; Rinaldo, Cinzia/A-4252-2015; Lapi, Eleonora/ABF-9748-2021; strano, sabrina/B-6743-2013; Bossi, Gianluca/B-9394-2017	Blandino, Giovanni/0000-0002-6970-2241; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Rinaldo, Cinzia/0000-0001-6124-762X; Lapi, Eleonora/0000-0003-4052-0361; strano, sabrina/0000-0002-6341-4230; Bossi, Gianluca/0000-0002-2947-1063				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Care A, 2001, CANCER RES, V61, P6532; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sigal A, 2000, CANCER RES, V60, P6788; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tsang WP, 2005, INT J CANCER, V114, P331, DOI 10.1002/ijc.20818; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wang LH, 1998, ANTICANCER RES, V18, P321; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	24	168	173	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					304	309		10.1038/sj.onc.1209026	http://dx.doi.org/10.1038/sj.onc.1209026			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170357				2022-12-28	WOS:000234583600015
J	Baxendale, AJ; Dawson, CW; Stewart, SE; Mudaliar, V; Reynolds, G; Gordon, J; Murray, PG; Young, LS; Eliopoulos, AG				Baxendale, AJ; Dawson, CW; Stewart, SE; Mudaliar, V; Reynolds, G; Gordon, J; Murray, PG; Young, LS; Eliopoulos, AG			Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth	ONCOGENE			English	Article						CD40; NF-kappa B; transformation; oncogenesis	EPSTEIN-BARR-VIRUS; TUMOR-NECROSIS-FACTOR; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; BURKITT-LYMPHOMA CELLS; FACTOR-ALPHA; T-CELLS; RHEUMATOID-ARTHRITIS; EPITHELIAL-CELLS; CARCINOMA-CELLS	CD40, a tumour necrosis factor (TNF) receptor family member, is expressed in a variety of cell types, including B lymphocytes, macrophages, fibroblasts, endothelial and epithelial cells, and this widespread expression is likely to account for its central role in normal physiology and disease pathogenesis. In this study, we provide evidence to support a role for constitutive CD40 signalling in cell transformation. We show that the ligand for CD40 (CD40L/CD154) is expressed in CD40-positive human breast tumour biopsies, suggesting that the constitutive activation of the CD40 receptor in vivo may contribute to the oncogenic process. Coexpression of CD40 and CD40L confers oncogenic effects on immortalized human epithelial cells in vitro, increasing their proliferation, motility and invasion. Expression of LMP:CD40, a hybrid molecule comprising the N-terminus and transmembrane domains of the Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) fused to the cytoplasmic tail of CD40, mimics a constitutively active CD40 receptor and promotes the transformation of immortalized rodent fibroblasts in vitro and their oncogenicity in vivo. The observed effects of aberrant CD40 activation on cell transformation are largely diminished upon suppression of the oncogenic NF-kappa B signalling pathway. Taken together, our results suggest a role for the constitutive engagement of the CD40L/CD40/NF-kappa B activation pathway in cell transformation and neoplastic growth. Strategies that neutralize this pathway may therefore be useful in cancer treatment and prevention.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Royal Shrewsbury Hosp, Dept Histopathol, Shrewsbury SY3 8LR, Salop, England; Univ Birmingham, Sch Med, MRC Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham; University of Birmingham	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Vincent Dr, Birmingham B15 2TA, W Midlands, England.	A.G.Eliopoulos@bham.ac.uk	Reynolds, Gary/F-8641-2014; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; ELIOPOULOS, ARISTIDES/R-9449-2018	Reynolds, Gary/0000-0002-3250-0582; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				Adawi A, 1998, CLIN IMMUNOL IMMUNOP, V89, P222, DOI 10.1006/clin.1998.4606; Anderson GM, 2004, CURR OPIN PHARMACOL, V4, P314, DOI 10.1016/j.coph.2004.04.004; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Challa A, 2002, BLOOD, V99, P3411, DOI 10.1182/blood.V99.9.3411; Cooke PW, 1999, J PATHOL, V188, P38; Costello RT, 1999, IMMUNOL TODAY, V20, P488, DOI 10.1016/S0167-5699(99)01507-8; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Eggermont AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 2004, CURR OPIN PHARMACOL, V4, P360, DOI 10.1016/j.coph.2004.02.008; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Fulda S, 2004, CURR OPIN PHARMACOL, V4, P327, DOI 10.1016/j.coph.2004.02.005; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghamande S, 2001, CANCER RES, V61, P7556; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He ZM, 2000, CANCER RES, V60, P1845; Henriquez NV, 1999, J IMMUNOL, V162, P3298; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hill SC, 2005, J IMMUNOL, V174, P41, DOI 10.4049/jimmunol.174.1.41; Hirano A, 1999, BLOOD, V93, P2999; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Kiener PA, 1997, J IMMUNOL, V159, P1594; Kyburz D, 2000, ARTHRITIS RHEUM, V43, P2571, DOI 10.1002/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4; Liao Zhongxing, 2004, Expert Rev Anticancer Ther, V4, P543, DOI 10.1586/14737140.4.4.543; MacDonald KPA, 1997, J CLIN INVEST, V100, P2404, DOI 10.1172/JCI119781; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MOHAN C, 1995, J IMMUNOL, V154, P1470; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ohta Y, 2004, DERMATOLOGY, V209, P21, DOI 10.1159/000078582; Ottaiano A, 2004, CLIN CANCER RES, V10, P2824, DOI 10.1158/1078-0432.CCR-0139-03; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; Phipps RP, 2000, P NATL ACAD SCI USA, V97, P6930, DOI 10.1073/pnas.97.13.6930; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Tong AW, 2001, CLIN CANCER RES, V7, P691; Tutt AL, 1998, J IMMUNOL, V161, P3176; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wykes M, 1998, EUR J IMMUNOL, V28, P548, DOI 10.1002/(SICI)1521-4141(199802)28:02<548::AID-IMMU548>3.0.CO;2-2; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; Zhang Y, 1998, J IMMUNOL, V160, P1053; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	62	47	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7913	7923		10.1038/sj.onc.1208929	http://dx.doi.org/10.1038/sj.onc.1208929			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091748				2022-12-28	WOS:000233463000010
J	Freeman-Cook, LL; DiMaio, D				Freeman-Cook, LL; DiMaio, D			Modulation of cell function by small transmembrane proteins modeled on the bovine papillomavirus E5 protein	ONCOGENE			English	Review						growth factor receptors; transformation; oncogene; selection; transmembrane domain	FACTOR-BETA-RECEPTOR; GROWTH-FACTOR RECEPTOR; HELIX-HELIX ASSOCIATION; OPEN READING FRAME; MOUSE C127 CELLS; TRANSFORMING PROTEIN; MEMBRANE-PROTEINS; AMINO-ACID; ERYTHROPOIETIN RECEPTOR; PRODUCTIVE INTERACTION	Viruses have been subjected to intense study because of their medical importance and because they can provide fundamental insights into normal and pathological cellular processes. Indeed, much of our knowledge about basic cellular biology and biochemistry was acquired through the study of viruses, and some of medicine's greatest triumphs and challenges involve viruses. Since viruses have evolved to exploit important cell processes, they can provide tools and approaches to manipulate cell function. The small transmembrane E5 protein of bovine papillomavirus type 1 transforms cells by a unique mechanism involving ligand-independent activation of the platelet-derived growth factor beta receptor. Experiments summarized in this review suggest that it may be possible to use the E5 protein as a model to design an entirely new class of small, modular transmembrane proteins with novel biological activities.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	daniel.dimaio@yale.edu						Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Bennasroune A, 2004, MOL BIOL CELL, V15, P3464, DOI 10.1091/mbc.E03-10-0753; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Brosig B, 1998, PROTEIN SCI, V7, P1052; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Clemons PA, 1999, CURR OPIN CHEM BIOL, V3, P112, DOI 10.1016/S1367-5931(99)80020-9; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; Constantinescu SN, 2003, J BIOL CHEM, V278, P43755, DOI 10.1074/jbc.M302974200; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DeGrado WF, 2003, PROTEIN SCI, V12, P647, DOI 10.1110/ps.0236503; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; Freeman-Cook LL, 2005, J MOL BIOL, V345, P907, DOI 10.1016/j.jmb.2004.10.072; Freeman-Cook LL, 2004, J MOL BIOL, V338, P907, DOI 10.1016/j.jmb.2004.03.044; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; George SR, 2003, J PHARMACOL EXP THER, V307, P481, DOI 10.1124/jpet.103.053843; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Huynh NT, 2003, IMMUNOLOGY, V108, P458, DOI 10.1046/j.1365-2567.2003.01614.x; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lai CC, 2005, J VIROL, V79, P1924, DOI 10.1128/JVI.79.3.1924-1929.2005; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Leeds JA, 2001, J MOL BIOL, V313, P181, DOI 10.1006/jmbi.2001.5007; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; Nappi VM, 2002, J BIOL CHEM, V277, P47149, DOI 10.1074/jbc.M209582200; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Partridge AW, 2002, BIOCHEMISTRY-US, V41, P3647, DOI 10.1021/bi0120502; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4032; RIESE DJ, 1995, ONCOGENE, V10, P1431; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; Surti T, 1998, PROTEINS, V33, P601; Takeda M, 2002, J VIROL, V76, P1391, DOI 10.1128/JVI.76.3.1391-1399.2002; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	82	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7756	7762		10.1038/sj.onc.1209039	http://dx.doi.org/10.1038/sj.onc.1209039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299535				2022-12-28	WOS:000233372600011
J	Hut, HMJ; Rembacz, KP; van Waarde, MAWH; Lemstra, W; van Cappellen, WA; Kampinga, HH; Sibon, OCM				Hut, HMJ; Rembacz, KP; van Waarde, MAWH; Lemstra, W; van Cappellen, WA; Kampinga, HH; Sibon, OCM			Dysfunctional BRCA1 is only indirectly linked to multiple centrosomes	ONCOGENE			English	Article						BRCA1; EGFP; BRCA1; BF3; cancer; centrosomes	AMPLIFICATION; INSTABILITY	A remarkable and yet unexplained phenomenon in cancer cells is the presence of multiple centrosomes, organelles required for normal cell division. Previously, it was demonstrated that the tumor suppressor BRCA1 is a component of centrosomes. This observation led to the hypothesis that defective BRCA1 results in malfunctioning centrosomes and faulty centrosomes are a possible cause of cancer. Using EGFP-tagged fusion proteins and BRCA1-/- cells we show that although some BRCA1 antibodies do label centrosomes under certain. xation conditions, BRCA1 is not a centrosomal protein. Therefore, it is unlikely that a mutation in BRCA1 directly alters centrosome structure and function. BRCA1 plays an established role in DNA damage repair and in G(2)/M checkpoint regulation. We present evidence that multiple centrosomes can arise in any cell when G(2)/M checkpoint fails and entrance into mitosis occurs in the presence of DNA damage.	Univ Groningen, Dept Radiat & Stress Cell Biol, UMCG, NL-9713 AV Groningen, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	University of Groningen; Erasmus University Rotterdam	Sibon, OCM (corresponding author), Univ Groningen, Dept Radiat & Stress Cell Biol, UMCG, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	o.c.m.sibon@med.umcg.nl		Kampinga, Harm/0000-0002-8966-8466; Sibon, Ody/0000-0002-6836-6063				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Johannsson OT, 2003, LAB INVEST, V83, P387, DOI 10.1097/01.LAB.0000060030.10652.8C; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	22	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7619	7623		10.1038/sj.onc.1208859	http://dx.doi.org/10.1038/sj.onc.1208859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16205648				2022-12-28	WOS:000233333800011
J	Pavio, N; Battaglia, S; Boucreux, D; Arnulf, B; Sobesky, R; Hermine, O; Brechot, C				Pavio, N; Battaglia, S; Boucreux, D; Arnulf, B; Sobesky, R; Hermine, O; Brechot, C			Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway	ONCOGENE			English	Article						HCV; core protein; tumor; Smad3; TGF-beta; hepatocellularcarcinoma	HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVATION; NONSTRUCTURAL PROTEINS; TRANSGENIC MICE; CELLS; DISEASE; BINDING; REGION; HOST; PKR	Hepatitis C virus (HCV) is a major risk factor for human hepatocellular carcinoma (HCC) but the mechanisms underlying HCV-induced carcinogenesis are still poorly understood. We have hypothesized that viral variants, selected during long-term infection, might contribute to cellular transformation. To address this issue, we have investigated the effect of natural HCV core variants isolated from liver tumors (T), or their non-tumor (NT) counterparts, on the tumor growth factor-b (TGF-beta) pathway, a major regulator of cellular proliferation, differentiation and apoptosis. We have found a significant reduction in TGF-beta reporter gene activity with the expression of core sequences isolated from liver tumors. In contrast, moderate or no effects were observed with non-tumor mutants or a core reference sequence. The molecular mechanisms have been characterized and involved the inhibition, by tumor-derived cores, of the DNA-binding activity of the Smad3/4 transcription factors complex. This inhibition occurs through a direct interaction between the central domain ( amino acids 59 - 126) of tumor-derived core and the MH1 DNA-binding domain of Smad3, thus preventing its binding to DNA. We have therefore identified a new cell-signaling pathway targeted by HCV core and inhibited by tumor-derived core sequences. These results suggest that during chronic infection, there is selection of viral variants that may promote cell transformation by providing, to clonally expanding cells, resistance to TGF-beta antiproliferative effects.	Univ Paris 05, INSERM, U370, F-75730 Paris, France; Univ Paris 05, Necker Hosp, CNRS, UMR 8137, F-75743 Paris, France; Univ Paris 05, Necker Hosp, Dept Hematol, F-75743 Paris, France; Univ Florence, Dept Internal Med, I-50121 Florence, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Florence	Pavio, N (corresponding author), Univ Paris 05, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris, France.	pavio@necker.fr; hermine@necker.fr	Sobesky, Rodolphe/T-7723-2018; Hermine, Olivier/Q-7072-2018	Hermine, Olivier/0000-0003-2574-3874				Alam SS, 2002, ACTA MED OKAYAMA, V56, P141; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bartenschlager Ralf, 2004, Hepatology, V39, P835, DOI 10.1002/hep.20122; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Duvoux C, 1999, J HEPATOL, V31, P593, DOI 10.1016/S0168-8278(99)80336-5; Fukuda M, 2002, VIROLOGY, V302, P310, DOI 10.1006/viro.2002.1619; KOBAYASHI S, 1994, CANCER, V73, P48, DOI 10.1002/1097-0142(19940101)73:1<48::AID-CNCR2820730110>3.0.CO;2-L; Kunkel M, 2004, FEBS LETT, V557, P174, DOI 10.1016/S0014-5793(03)01486-8; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Laporte J, 2003, BLOOD, V101, P52, DOI 10.1182/blood-2002-03-0818; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Marcellin P, 2002, HEPATOLOGY, V36, pS47, DOI 10.1053/jhep.2002.36993; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nelson DR, 1997, J VIRAL HEPATITIS, V4, P29, DOI 10.1046/j.1365-2893.1997.00124.x; Neuman MG, 2002, J VIRAL HEPATITIS, V9, P134, DOI 10.1046/j.1365-2893.2002.00343.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogata S, 2003, J CLIN MICROBIOL, V41, P2835, DOI 10.1128/JCM.41.7.2835-2841.2003; Pavio N, 2002, J VIROL, V76, P1265, DOI 10.1128/JVI.76.3.1265-1272.2002; Pellerin M, 2004, J VIROL, V78, P4617, DOI 10.1128/JVI.78.9.4617-4627.2004; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Ruster B, 2001, J MED VIROL, V63, P128, DOI 10.1002/1096-9071(20000201)63:2&lt;128::AID-JMV1007&gt;3.0.CO;2-S; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shiffman ML, 2004, SEMIN LIVER DIS, V24, P1, DOI 10.1055/s-2004-832921; Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Zemel R, 2000, DIGEST DIS SCI, V45, P2199, DOI 10.1023/A:1026475421668	42	67	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6119	6132		10.1038/sj.onc.1208749	http://dx.doi.org/10.1038/sj.onc.1208749			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007207				2022-12-28	WOS:000231718100006
J	Feuer, G; Green, PL				Feuer, G; Green, PL			Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2	ONCOGENE			English	Review						HTLV-1; HTLV-2; tax; cellular transformation; immortalization; leukemia	NF-KAPPA-B; I TAX PROTEIN; HUMAN-ENDOTHELIAL-CELLS; INTRAVENOUS-DRUG-USERS; READING FRAME II; LEUKEMIA-VIRUS; PDZ DOMAIN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; POTENTIAL MECHANISM	HTLV-1 and HTLV-2 are highly related complex retroviruses that have been studied intensely for nearly three decades because of their association with neoplasia, neuropathology, and/or their capacity to transform primary human T lymphocytes. The study of HTLV also represents an attractive model that has allowed investigators to dissect the mechanism of various cellular processes, several of which may be critical steps in HTLV-mediated pathogenesis. Both HTLV-1 and HTLV-2 can efficiently immortalize and transform T lymphocytes in cell culture and persist in infected individuals or experimental animals. However, the clinical manifestations of these two viruses differ significantly. HTLV-1 is associated with adult T-cell leukemia (ATL) and a variety of immune-mediated disorders including the chronic neurological disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). In contrast, HTLV-2 is much less pathogenic with reports of only a few cases of variant hairy cell leukemia and neurological disease associated with infection. The limited number of individuals shown to harbor HTLV-2 in association with specific diseases has, to date, precluded convincing epidemiological demonstration of a definitive etiologic role of HTLV-2 in human disease. Therefore, it has become clear that comparative studies designed to elucidate the mechanisms by which HTLV-1 and HTLV-2 determine distinct outcomes are likely to provide fundamental insights into the initiation of multistep leukemogenesis.	Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; SUNY Syracuse, Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Green, PL (corresponding author), Ohio State Univ, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.	green.466@osu.edu			NATIONAL CANCER INSTITUTE [P01CA100730] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA100730, P01 CA100730-02, P01 CA100730-069003, CA100730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Akagi T, 1996, ONCOGENE, V12, P1645; AKAGI T, 1992, ACTA NEUROPATHOL, V84, P147, DOI 10.1007/BF00311387; AKGI T, 1997, ONCOGENE, V14, P2071; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BOHNLEIN E, 1989, J VIROL, V63, P1578; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Cockerell GL, 1996, BLOOD, V87, P1030, DOI 10.1182/blood.V87.3.1030.bloodjournal8731030; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Dooneief G, 1996, NEUROLOGY, V46, P1556, DOI 10.1212/WNL.46.6.1556; EJIMA E, 1993, BLOOD, V81, P1017; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GESSAIN A, 1993, J ACQ IMMUN DEF SYND, V6, P324; GOUBAU P, 1993, AIDS RES HUM RETROV, V9, P709, DOI 10.1089/aid.1993.9.709; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Green P. L., 2001, FIELDS VIROLOGY, P1941; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hall AP, 1998, J PATHOL, V186, P209; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harris BZ, 2001, J CELL SCI, V114, P3219; HENEINE W, 1991, NEW ENGL J MED, V324, P565, DOI 10.1056/NEJM199102213240815; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HJELLE B, 1990, BLOOD, V76, P450; HO DD, 1984, P NATL ACAD SCI-BIOL, V81, P7588, DOI 10.1073/pnas.81.23.7588; HOFFMAN PM, 1992, P NATL ACAD SCI USA, V89, P11784, DOI 10.1073/pnas.89.24.11784; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; KHABBAZ RF, 1991, J INFECT DIS, V163, P252, DOI 10.1093/infdis/163.2.252; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LAL RB, 1993, BLOOD, V81, P1827; LAL RB, 1993, LEUKEMIA RES, V17, P31, DOI 10.1016/0145-2126(93)90138-B; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LEVINE PH, 1993, AIDS RES HUM RETROV, V9, P123, DOI 10.1089/aid.1993.9.123; Lewis MJ, 2002, VIROLOGY, V295, P182, DOI 10.1006/viro.2002.1357; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; LINDHOLM P, 1991, NEW BIOL, V2, P1034; Los M, 1998, J IMMUNOL, V161, P3050; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; MIYAMOTO K, 1991, JPN J CANCER RES, V82, P1178, DOI 10.1111/j.1349-7006.1991.tb01775.x; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Murphy EL, 1997, NEUROLOGY, V48, P315, DOI 10.1212/WNL.48.2.315; Nagai M, 2001, ANN NEUROL, V50, P807, DOI 10.1002/ana.10065; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Newbound GC, 1996, J VIROL, V70, P2101, DOI 10.1128/JVI.70.4.2101-2106.1996; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Nicot C, 1997, VIROLOGY, V236, P47, DOI 10.1006/viro.1997.8720; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; NIMER S, 1991, NEW BIOL, V3, P997; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; Ohya Osamu, 1997, Leukemia (Basingstoke), V11, P255; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Ross TM, 1997, J VIROL, V71, P8912, DOI 10.1128/JVI.71.11.8912-8917.1997; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Saggioro D, 2001, EXP CELL RES, V269, P245, DOI 10.1006/excr.2001.5310; SAXON A, 1978, J IMMUNOL, V120, P777; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sieburg M, 2004, J VIROL, V78, P10399, DOI 10.1128/JVI.78.19.10399-10409.2004; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128/JVI.78.8.3837-3845.2004; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEDDER RS, 1984, LANCET, V2, P125; Toro C, 2005, J CLIN VIROL, V33, P65, DOI 10.1016/j.jcv.2004.10.004; Tripp A, 2003, J VIROL, V77, P12152, DOI 10.1128/JVI.77.22.12152-12164.2003; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YAMAOKA S, 1992, ONCOGENE, V7, P433; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Ye JX, 2003, J VIROL, V77, P7728, DOI 10.1128/JVI.77.14.7728-7735.2003; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; Younis I, 2005, FRONT BIOSCI-LANDMRK, V10, P431, DOI 10.2741/1539; Zehender G, 2001, VIROLOGY, V281, P43, DOI 10.1006/viro.2000.0765; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	137	120	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5996	6004		10.1038/sj.onc.1208971	http://dx.doi.org/10.1038/sj.onc.1208971			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155606	Green Accepted			2022-12-28	WOS:000231623400009
J	Kuns, R; Kissil, JL; Newsham, IF; Jacks, T; Gutmann, DH; Sherman, LS				Kuns, R; Kissil, JL; Newsham, IF; Jacks, T; Gutmann, DH; Sherman, LS			Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation	ONCOGENE			English	Article						protein 4.1B; erbB2; mammary epithelial cells; pregnancy; mammary carcinoma	BREAST-CANCER CELLS; NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; EPIDERMAL-GROWTH-FACTOR; FUNCTIONAL-CHARACTERIZATION; CARCINOMA-CELLS; FAMILY MEMBERS; LUNG-CANCER; FERM DOMAIN; EZRIN; GENE	4.1B is a member of the protein 4.1 superfamily of proteins that link transmembrane proteins to the actin cytoskeleton. The 4.1B gene localizes to chromosome 18p11.3, which undergoes loss of heterozygosity in mammary tumors. Here, we examine the expression of 4.1B in murine mammary epithelium and find that 4.1B is dramatically upregulated in mammary epithelial cells during pregnancy when there is extensive cell proliferation. In contrast, 4.1B is not expressed in virgin, lactating, or involuting mammary epithelium. To examine the consequence of 4.1B loss on mammary epithelial cell proliferation, we analysed mammary glands in 4.1B-null mice. 4.1B loss results in a significant increase in mammary epithelial cell proliferation during pregnancy, but has no effect on mammary epithelial cell proliferation, in virgin or involuting mice. Furthermore, we show that 4.1B inhibits the proliferation of mammary epithelial cell lines by inducing a G(1) cell cycle arrest, characterized by decreased cyclin A expression and reduced Rb phosphorylation, and accompanied by reduced erbB2 phosphorylation. This cell cycle arrest does not involve alterations in the activities of MAPK, JNK, or Akt. Collectively, our findings demonstrate that 4.1B regulates mammary epithelial cell proliferation during pregnancy and suggest that its loss may influence mammary carcinoma pathogenesis in multiparous women.	Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Univ Cincinnati, Sch Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Wistar Inst Anat & Biol, Mol & Cellular Oncogenom Program, Philadelphia, PA 19104 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Hermelin Lab Mol Oncogenet, Detroit, MI 48202 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Oregon Health & Science University; Oregon National Primate Research Center; University System of Ohio; University of Cincinnati; The Wistar Institute; Henry Ford Health System; Henry Ford Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL)	Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520, R01NS039550] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NINDS NIH HHS [NS41520, NS39550] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395, DOI 10.1006/bbrc.1999.0653; Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; Batchelor CL, 2004, EXP CELL RES, V296, P208, DOI 10.1016/j.yexcr.2004.02.010; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chu I, 2005, CANCER RES, V65, P18; Cuppen E, 1999, J CELL SCI, V112, P3299; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Gascard P, 2004, BBA-GENE STRUCT EXPR, V1680, P71, DOI 10.1016/j.bbaexp.2004.08.006; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; GERDES J, 1984, J IMMUNOL, V133, P1710; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hall IJ, 2005, AM J EPIDEMIOL, V161, P40, DOI 10.1093/aje/kwh331; Hunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Singh PK, 2002, MODERN PATHOL, V15, P526, DOI 10.1038/modpathol.3880558; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stull MA, 2004, J MAMMARY GLAND BIOL, V9, P15, DOI 10.1023/B:JOMG.0000023585.95430.f4; Surace EI, 2004, J NEUROPATH EXP NEUR, V63, P1015, DOI 10.1093/jnen/63.10.1015; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Whiteman MK, 2004, OBSTET GYNECOL, V104, P146, DOI 10.1097/01.AOG.0000128173.01611.ff; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yageta M, 2002, CANCER RES, V62, P5129; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	53	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6502	6515		10.1038/sj.onc.1208813	http://dx.doi.org/10.1038/sj.onc.1208813			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007173	Bronze			2022-12-28	WOS:000232204100004
J	Banelli, B; Gelvi, I; Di Vinci, A; Scaruffi, P; Casciano, I; Allemanni, G; Bonassi, S; Tonini, GP; Romani, M				Banelli, B; Gelvi, I; Di Vinci, A; Scaruffi, P; Casciano, I; Allemanni, G; Bonassi, S; Tonini, GP; Romani, M			Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors	ONCOGENE			English	Article						neuroblastoma; ganglioneuroma; methylation; methylator phenotype	RECEPTOR-BETA EXPRESSION; DNA METHYLATION; P73 GENE; PROMOTER METHYLATION; COLORECTAL-CANCER; BREAST-CANCER; HYPERMETHYLATION; DELTA-NP73; TUMORIGENESIS; PHENOTYPE	The hypermethylation of CpG islands within gene promoter regions is an epigenetic phenomenon that is often, but not always, associated with the transcriptional silencing of downstream genes and contributes to carcinogenesis. We have determined the pattern of methylation of several genes involved in distinct biological pathways, including cell proliferation and apoptosis, in neuroblastoma and in the nonmalignant ganglioneuroma. The purpose of this work was to search for epigenetic signatures that could be associated with defined clinical and biological parameters and that, in prospective, could identify specific risk categories among the patients. We have analysed 31 malignant neuroblastoma with or without MYCN amplification and 13 benign ganglioneuroma and we have observed dramatic differences in the methylation pattern of five genes (CASP8, 14.3.3 sigma, Delta N p73, RASSF1A and DCR2) between these tumors indicating that this phenomenon is not tissue-specific and can be considered as cancer-dependent. Furthermore, the methylation pattern of 14.3.3 sigma, RASSF1A and of an intragenic segment of CASP8 was significantly different between MYCN amplified and single copy neuroblastoma suggesting a specific role of epigenetic alterations in aggressive neuroblastoma.	Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Romani, M (corresponding author), Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	massimo.romani@istge.it	Bonassi, Stefano/ABI-6281-2020; Banelli, Barbara/Y-1151-2019; Scaruffi, Paola/AAB-3999-2020	Bonassi, Stefano/0000-0003-3833-6717; Banelli, Barbara/0000-0003-1505-7141; casciano, ida/0000-0003-1776-670X; scaruffi, paola/0000-0001-9799-1661				Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Corn PG, 1999, CANCER RES, V59, P3352; Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KALBFLEISCH JD, 1980, STAT ANAL FAILTURE T; Kawano S, 1999, BLOOD, V94, P1113; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TONINI GP, 1993, EUR J CANCER, V28, P1000; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van Noesel MM, 2002, CANCER RES, V62, P2157; van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331	32	60	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5619	5628		10.1038/sj.onc.1208722	http://dx.doi.org/10.1038/sj.onc.1208722			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16044164				2022-12-28	WOS:000231296100008
J	Howlin, J; McBryan, J; Napoletano, S; Lambe, T; McArdle, E; Shioda, T; Martin, F				Howlin, J; McBryan, J; Napoletano, S; Lambe, T; McArdle, E; Shioda, T; Martin, F			CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis	ONCOGENE			English	Article						mammary gland; development; ductal morphogenesis; puberty; CITED1; amphiregulin	GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; NUCLEAR-PROTEIN; TGF-BETA; EXPRESSION; GLAND; GENES	Expression microarray analysis identified CITED1 among a group of genes specifically upregulated in the pubertal mouse mammary gland. At puberty, CITED1 localizes to the luminal epithelial cell population of the mammary ducts and the body cells of the terminal end buds. Generation of CITED1 gene knockout mice showed that homozygous null mutants exhibit retarded mammary ductal growth at puberty and, in addition, dilated ductal structures with a lack of spatial restriction of the subtending branches. Analysis of CITED1 homozygous null and heterozygous null mammary gland gene expression using microarrays suggested that the mammary specific phenotype seen in the homozygous null females is due to a disturbance in the transcription of a number of key mediators of pubertal ductal morphogenesis. These include estrogen and TGF beta responsive genes, such as the EGFR/ErbB2 ligand, amphiregulin, whose transcription we suggest is directly or indirectly regulated by CITED1.	Univ Coll Dublin, Conway Inst, Dublin 4, Ireland; Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin 4, Ireland; Massachusetts Gen Hosp, Ctr Canc, Lab Tumour Biol, Charlestown, MA USA	University College Dublin; University College Dublin; Harvard University; Massachusetts General Hospital	Martin, F (corresponding author), Univ Coll Dublin, Conway Inst, Dublin 4, Ireland.	finian.martin@ucd.ie	Lambe, Teresa/E-5733-2016; Howlin, Jill/G-9665-2011	Lambe, Teresa/0000-0001-7711-897X; Howlin, Jill/0000-0002-2766-3002; McBryan, Jean/0000-0002-7568-2208	NCI NIH HHS [CA082230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Berking C, 2001, CANCER RES, V61, P8306; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; D'Cruz CM, 2002, MOL ENDOCRINOL, V16, P2034, DOI 10.1210/me.2002-0073; Daniel CW, 1996, J MAMMARY GLAND BIOL, V1, P331, DOI 10.1007/BF02017389; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Ewan KBR, 2005, AM J PATHOL, V167, P409, DOI 10.1016/S0002-9440(10)62985-9; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Gallagher J, 2003, FEBS LETT, V551, P8, DOI 10.1016/S0014-5793(03)00823-8; Humphreys RC, 1999, J MAMMARY GLAND BIOL, V4, P213, DOI 10.1023/A:1018733426625; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; Morse DL, 2005, ANAL BIOCHEM, V342, P69, DOI 10.1016/j.ab.2005.03.034; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; Nair SS, 2001, PIGM CELL RES, V14, P206, DOI 10.1034/j.1600-0749.2001.140311.x; NEGOESCU A, 1995, EXP CELL RES, V217, P404, DOI 10.1006/excr.1995.1103; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Connell FC, 2000, CELL DEATH DIFFER, V7, P360, DOI 10.1038/sj.cdd.4400647; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Prasad ML, 2004, THYROID, V14, P169, DOI 10.1089/105072504773297830; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Sid B, 2004, CRIT REV ONCOL HEMAT, V49, P245, DOI 10.1016/j.critrevonc.2003.09.009; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stewart HJS, 1995, GLIA, V15, P419, DOI 10.1002/glia.440150406; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	48	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1532	1542		10.1038/sj.onc.1209183	http://dx.doi.org/10.1038/sj.onc.1209183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278680				2022-12-28	WOS:000235890400010
J	Liu, J; Lian, Z; Han, S; Waye, MMY; Wang, H; Wu, MC; Wu, K; Ding, J; Arbuthnot, P; Kew, M; Fan, D; Feitelson, MA				Liu, J; Lian, Z; Han, S; Waye, MMY; Wang, H; Wu, MC; Wu, K; Ding, J; Arbuthnot, P; Kew, M; Fan, D; Feitelson, MA			Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma	ONCOGENE			English	Article						hepatitis B virus; hepatitis B X antigen; E-cadherin; migration; hepatocellular carcinoma; beta-catenin	BETA-CATENIN; HBX PROTEIN; CELL-LINES; EXPRESSION; GENE; METHYLATION; ADHESION; LIVER; P53; PROGRESSION	Hepatitis B virus (HBV)-encoded X antigen (HBxAg) contributes to the development of hepatocellular carcinoma (HCC). A frequent characteristic of HCC is reduced or absent expression of the cell adhesion protein, E-cadherin, although it is not known whether HBxAg plays a role. To address this, the levels of E-cadherin were determined in HBxAg-positive and - negative HepG2 cells in culture, and in tumor and surrounding nontumor liver from a panel of HBV carriers. The results showed an inverse relationship between HBxAg and E-cadherin expression both in tissue culture and in vivo. In HBxAg-positive cells, E-cadherin was suppressed at both the mRNA and protein levels. This was associated with hypermethylation of the E-cadherin promoter. Depressed E-cadherin correlated with HBxAg trans-activation function, as did the migration of HepG2 cells in vitro. Decreased expression of E-cadherin was also associated with the accumulation of beta-catenin in the cytoplasm and/or nuclei in tissues and cell lines, which is characteristic of activated beta-catenin. Additional work showed that HBxAg-activated beta-catenin. Together, these results suggest that the HBxAg is associated with decreased expression of E-cadherin, accumulation of beta-catenin in the cytoplasm and nucleus, and increased cell migration, which may contribute importantly to hepatocarcinogenesis.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Dept Digest Dis, Xian 710032, Shaanxi, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; Second Mil Med Univ, Shanghai Eastern Hosp, Shanghai, Peoples R China; Second Mil Med Univ, Inst Hepatobil Surg, Shanghai, Peoples R China; Univ Witwatersrand, Dept Med, Mol Hepatol Res Unit, ZA-2001 Johannesburg, South Africa; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Air Force Military Medical University; Chinese University of Hong Kong; Naval Medical University; Naval Medical University; University of Witwatersrand; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Mark.Feitelson@jefferson.edu	Han, Shuang/AAE-6982-2020; Arbuthnot, Patrick Brian/B-8163-2009; Lian, Zhaorui/AAW-2379-2020; Wang, Hongyang/B-1340-2010; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008	韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917	NATIONAL CANCER INSTITUTE [R29CA048656, R01CA048656, R01CA066971] Funding Source: NIH RePORTER; NCI NIH HHS [CA66971, CA48656] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SH, 2002, KOREAN J HEPATOL, V8, P297; Calvisi DF, 2004, LAB INVEST, V84, P1137, DOI 10.1038/labinvest.3700147; CASELMANN WH, 1995, J HEPATOL, V22, P34; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Feitelson MA, 1999, FALK SYMP, V103C, P156; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inayoshi J, 2003, J GASTROEN HEPATOL, V18, P673, DOI 10.1046/j.1440-1746.2003.03021.x; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X; Kanai Y, 1997, INT J CANCER, V71, P355; Kondoh N, 2001, INT J ONCOL, V18, P1271; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5; Lian ZR, 2003, NEOPLASIA, V5, P229, DOI 10.1016/S1476-5586(03)80055-6; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liu J, 2004, METH MOLEC MED, V95, P71; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orsulic S, 1999, J CELL SCI, V112, P1237; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593	43	87	100	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1008	1017		10.1038/sj.onc.1209138	http://dx.doi.org/10.1038/sj.onc.1209138			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247464				2022-12-28	WOS:000235361000006
J	Bhonde, MR; Hanski, ML; Notter, M; Gillissen, BF; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Notter, M; Gillissen, BF; Daniel, PT; Zeitz, M; Hanski, C			Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth	ONCOGENE			English	Article						colon carcinoma; chemotherapy; irinotecan; apoptosis; cell cycle arrest	COLORECTAL-CANCER CELLS; POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE; HUMAN GLIOBLASTOMA CELLS; P53 WILD-TYPE; G(2) ARREST; MITOTIC CATASTROPHE; IRINOTECAN CPT-11; IN-VITRO; SENESCENCE; LINES	Knowledge of the type of biological reaction to chemotherapy is a prerequisite for its rational enhancement. We previously showed that irinotecan-induced DNA damage triggers in the HCT116p53(wt) colon carcinoma cell line a long-term cell cycle arrest and in HCT116p53(-/-) cells apoptosis (Magrini et al., 2002). To compare the contribution of long-term cell cycle arrest and that of apoptosis to inhibition of cell proliferation after irinotecan-induced DNA damage, we used this isogenic system as well as the cell lines LS174T (p53(wt)) and HT-29 (p53(mut)). Both p53wt cell lines responded to damage by undergoing a long-term tetraploid G1 arrest, whereas the p53mut cell lines underwent apoptosis. Cell cycle arrest as well as apoptosis caused a similar delay in cell proliferation. Irinotecan treatment also induced in mouse tumours derived from the p53wt cell lines a tetraploid G1 arrest and in those derived from the p53-deficient cell lines a transient G2/M arrest and apoptosis. The delay of tumour growth was in the same range in both groups, that is, arrest-and apoptosis-mediated tumour growth inhibition was comparable. In conclusion, cell cycle arrest as well as apoptosis may be equipotent mechanisms mediating the chemotherapeutic effects of irinotecan.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; Charite Univ Med Berlin, Dept Hematol, Berlin, Germany; Charite, Dept Clin & Mol Oncol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hanski, ML (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de		Gillissen, Bernhard/0000-0002-1815-2091				Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299; Andreassen PR, 2001, CANCER RES, V61, P7660; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bartussek C, 1999, EXP CELL RES, V253, P432, DOI 10.1006/excr.1999.4654; Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Brown JM, 1999, CANCER RES, V59, P1391; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Clifford B, 2003, CANCER RES, V63, P4074; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Cusack JC, 2001, CANCER RES, V61, P3535; Ducreux M, 2003, ANN ONCOL, V14, P17, DOI 10.1093/annonc/mdg724; Goldwasser F, 1996, CANCER RES, V56, P4430; Gunasekar P, 2001, TOXICOL SCI, V64, P83, DOI 10.1093/toxsci/64.1.83; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hirose Y, 2001, CANCER RES, V61, P1957; Jacob S, 2001, CANCER RES, V61, P6555; Jansen WJM, 1997, INT J CANCER, V70, P335, DOI 10.1002/(SICI)1097-0215(19970127)70:3<335::AID-IJC15>3.0.CO;2-E; Koike M, 2004, CANCER SCI, V95, P541, DOI 10.1111/j.1349-7006.2004.tb03246.x; Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Paradis V, 2001, HUM PATHOL, V32, P327, DOI 10.1053/hupa.2001.22747; Pavillard V, 2002, CANCER CHEMOTH PHARM, V49, P329, DOI 10.1007/s00280-001-0416-0; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Roninson IB, 2003, CANCER RES, V63, P2705; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2001, DRUG RESIST UPDATE, V4, P132, DOI 10.1054/drup.2001.0188; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; te Poele RH, 2002, CANCER RES, V62, P1876; te Poele RH, 1999, BRIT J CANCER, V81, P1285; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; Waxman DJ, 2003, CANCER RES, V63, P8563; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	52	40	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					165	175		10.1038/sj.onc.1209017	http://dx.doi.org/10.1038/sj.onc.1209017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170360				2022-12-28	WOS:000234583600001
J	Cezar-de-Mello, PFT; Nascimento-Silva, V; Villela, CG; Fierro, IM				Cezar-de-Mello, PFT; Nascimento-Silva, V; Villela, CG; Fierro, IM			Aspirin-triggered Lipoxin A(4) inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly	ONCOGENE			English	Article						lipoxins; angiogenesis; cytoskeleton; FAK; p38	15-EPI-LIPOXIN A(4); EICOSANOID REGULATION; PHOSPHORYLATION; ACTIVATION; KINASE; ANGIOGENESIS; CYCLOOXYGENASE-2; PROLIFERATION; RECRUITMENT; LEUKOTRIENE	Angiogenesis, the growth of new capillaries from preexisting ones, occurs through dynamic functions of the endothelial cells (EC), including migration, which is essential to achieve an organized formation of the vessel sprout. We demonstrated previously that an aspirintriggered lipoxin analog, 15-epi-16-(para-fluoro)- phenoxylipoxin A4 (ATL-1), inhibits vascular endothelial growth factor (VEGF)- induced EC migration. In the present study, we investigated the effects of ATL-1 in the actin cytoskeleton reorganization of EC stimulated with VEGF. Pretreatment of EC with ATL-1 caused a reduction in VEGF-induced stress. bers and therefore reduced the intracellular content of lamentous actin. A concomitant impairment in stress-activated protein kinase (SAPK2/p38) phosphorylation suggests that ATL inhibition of VEGF- stimulated actin polymerization involves the SAPK2 p38 pathway. Moreover, ATL-1 treatment inhibited focal adhesion clustering due to inhibition of focal adhesion kinase (FAK) phosphorylation and the subsequent association of FAK with the actin cytoskeleton. This final event, which ultimately allows cell migration, was reverted by an LX receptor antagonist, but not by a cys-LT1R antagonist, indicating an effect via the Gproteinlinked LXA4 receptor. Together our results provide evidence that ATL-1 inhibits EC migration via the concerted inhibition of actin polymerization and proper assembly of focal adhesions, supporting a role for these novel lipid mediators as angiogenesis modulators.	Univ Estado Rio de Janeiro, Dept Farmacol & Psicobiol, Inst Biol Roberto Alcantara Gomes, BR-20551030 Rio De Janeiro, Brazil	Universidade do Estado do Rio de Janeiro	Fierro, IM (corresponding author), Univ Estado Rio de Janeiro, Dept Farmacol & Psicobiol, Inst Biol Roberto Alcantara Gomes, Av 28 Setembro 87 Fundos,5o Andar,Sala 2,Vila Isa, BR-20551030 Rio De Janeiro, Brazil.	iolanda@uerj.br	Fierro, Iolanda/AAJ-2705-2021	Fernandes Tavares Cezar de Mello, Paula/0000-0002-9293-9773				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ARENBERG AD, 1999, GALLIN JI SNYDERMAN, P851; Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; GRANESS A, 2000, BIOCHEM J, V15, P441; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Lynch KR, 1999, NATURE, V399, P789; Maderna P, 2000, AM J PHYSIOL-CELL PH, V279, pC945, DOI 10.1152/ajpcell.2000.279.4.C945; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Ohira T, 2004, J IMMUNOL, V173, P2091, DOI 10.4049/jimmunol.173.3.2091; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SERHAN CN, 1999, INFLAMMATION BASIC P, P373; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Shtivelband MI, 2003, J THROMB HAEMOST, V1, P2225, DOI 10.1046/j.1538-7836.2003.00446.x; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Vane J, 2000, THORAX, V55, pS3, DOI 10.1136/thorax.55.suppl_2.S3; Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008; Zachary I, 2003, BIOCHEM SOC T, V31, P1171	39	72	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					122	129		10.1038/sj.onc.1209002	http://dx.doi.org/10.1038/sj.onc.1209002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16132039				2022-12-28	WOS:000234406400013
J	DeAngelis, T; Chen, J; Wu, A; Prisco, M; Baserga, R				DeAngelis, T; Chen, J; Wu, A; Prisco, M; Baserga, R			Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling	ONCOGENE			English	Article						T antigen; growth factor signaling; transformation	GROWTH-FACTOR-I; BREAST-CANCER CELLS; RIBOSOMAL GENE-TRANSCRIPTION; MOUSE EMBRYO FIBROBLASTS; LARGE TUMOR-ANTIGEN; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; HEMATOPOIETIC-CELLS; SIMIAN VIRUS-40	Previous work has shown that the Simian Virus 40 T antigen (T antigen) cannot transform mouse embryo. fibroblasts (MEFs) that do not express the type 1 insulin-like growth factor receptor (IGF-IR). We have now investigated the mechanism(s) by which the transforming activity of T antigen is affected by IGF-IR signaling. We demonstrate that transformation by T antigen of MEFs and several other cell lines requires an insulin receptor substrate-1 (IRS-1) phosphorylated on tyrosines. If IRS-1 is not expressed, or is serine phosphorylated or otherwise inactive, T antigen fails to transform cells in culture. For instance, while T antigen cannot transform 32D myeloid cells (that do not express IRS-1), its transforming activity is restored by the expression of a wild-type IRS-1, but not of an IRS-1 mutated at the PI3K binding sites. The importance of IRS-1 activation of PI3K in T-antigen transformation is supported by the. finding that a constitutively activated p110 subunit of PI3K, a target of IRS-1, overcomes the inability of T antigen to transform MEFs with a serine phosphorylated IRS-1. Taken together, these results indicate that the IRS-1/PI3K signaling is one of the mechanisms regulating transformation by the SV40 T antigen. We propose that the requirement for a tyrosyl-phosphorylated IRS-1 provides a mechanism to explain the failure of T antigen to transform MEFs with deleted IGF- IR genes.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020956] Funding Source: NIH RePORTER; NCI NIH HHS [CA89640] Funding Source: Medline; NIA NIH HHS [AG 20956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Baserga Renato, 2004, VVolume 42, P235; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; CASTLES CG, 1993, CANCER RES, V53, P5934; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LIEBERMAN I, 1963, J BIOL CHEM, V238, P2141; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 2001, ONCOGENE, V20, P4842, DOI 10.1038/sj.onc.1204649; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SANTOS M, 1982, J CELL BIOCHEM, V19, P127, DOI 10.1002/jcb.240190204; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOPRANO KJ, 1979, P NATL ACAD SCI USA, V76, P3885, DOI 10.1073/pnas.76.8.3885; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VALENTINIS B, 1994, ONCOGENE, V9, P825; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White Robert J., 2004, VVolume 42, P371; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	61	50	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					32	42		10.1038/sj.onc.1209013	http://dx.doi.org/10.1038/sj.onc.1209013			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170362				2022-12-28	WOS:000234406400004
J	Maeno, K; Masuda, A; Yanagisawa, K; Konishi, H; Osada, H; Saito, T; Ueda, R; Takahashi, T				Maeno, K; Masuda, A; Yanagisawa, K; Konishi, H; Osada, H; Saito, T; Ueda, R; Takahashi, T			Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers	ONCOGENE			English	Article						c-jun; lung cancer; anchorage; independent growth; K-ras	BRONCHIAL EPITHELIAL-CELLS; NEOPLASTIC TRANSFORMATION; EMBRYO FIBROBLASTS; RAT-1A CELLS; TARGET GENE; RAT1A CELLS; EXPRESSION; APOPTOSIS; RAS; TRANSACTIVATION	The c-jun oncogene is frequently overexpressed in non-small-cell lung cancers (NSCLC), but its functional involvement in lung cancer development has not been clearly elucidated. In this study, we found that among the immediate-early serum responsible genes, exemplified by c-jun, c-fos and c-myc, induction of c-jun in a human bronchial epithelial cell line, BEAS-2B, was dependent on anchorage, in contrast to clear induction of c-fos and c-myc under both anchorage-dependent and - independent conditions. In fact, forced expression of c-jun in BEAS-2B cells significantly increased cell viability and colony formation in soft agar. Furthermore, we also found that such anchorage-dependent regulation of c-jun was lost in a significant fraction of human lung cancer cell lines. Interestingly, suppressed anchorage-independent but not anchorage-dependent growth was noted by constitutive expression of a dominant-negative c-jun mutant in a lung cancer cell line showing dysregulated and sustained c-jun expression in the absence of anchorage. These findings suggest that dysregulated c-jun expression may be involved in the acquisition of anchorage independence in the process of human lung carcinogenesis.	Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Grad Sch Med,Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med, Nagoya, Aichi, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Sci, Nagoya, Aichi, Japan	Nagoya University; Aichi Cancer Center; Nagoya City University; Nagoya City University	Takahashi, T (corresponding author), Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				AMSTAD P, 1988, MOL CARCINOGEN, V1, P151, DOI 10.1002/mc.2940010303; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; BENEZRA JM, 1994, AM J PATHOL, V145, P1036; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; FUJITA M, 1995, ONCOGENE, V11, P15; HIDA T, 1989, CANCER RES, V49, P4785; Hommura F, 2004, MOL CANCER RES, V2, P305; IKEGAKI N, 1994, CANCER RES, V54, P6; Katabami M, 2005, J BIOL CHEM, V280, P16728, DOI 10.1074/jbc.M413892200; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; Lu AP, 2002, J BIOL CHEM, V277, P31364, DOI 10.1074/jbc.M201060200; Masuda A, 1997, CANCER RES, V57, P4898; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Reddel R R, 1988, Oncogene Res, V3, P401; REDDEL RR, 1995, INT J CANCER, V61, P199; REDDEL RR, 1988, CANCER RES, V48, P1904; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Szabo E, 1996, CANCER RES, V56, P305; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	36	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					271	277		10.1038/sj.onc.1209018	http://dx.doi.org/10.1038/sj.onc.1209018			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158054				2022-12-28	WOS:000234583600011
J	Wang, Q; Zhou, Y; Wang, X; Evers, BM				Wang, Q; Zhou, Y; Wang, X; Evers, BM			Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase	ONCOGENE			English	Article						GSK-3; MAPK; ERK; PKC delta; siRNA; colon cancer cells	NF-KAPPA-B; INTESTINAL-CELL DIFFERENTIATION; ACTIVATED PROTEIN-KINASES; TUMOR-NECROSIS-FACTOR; COLON-CANCER CELLS; C-DELTA; BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; DOWN-REGULATION	Glycogen-synthase kinase-3 (GSK- 3) and extracellular signal-regulated kinase (ERK) are critical downstream signaling proteins for the PI3-kinase/ Akt and Ras/Raf/ MEK-1 pathway, respectively, and regulate diverse cellular processes including embryonic development, cell differentiation and apoptosis. Here, we show that inhibition of GSK-3 using GSK- 3 inhibitors or RNA interference (RNAi) signifi. cantly induced the phosphorylation of ERK1/2 in human colon cancer cell lines HT29 and Caco-2. Pretreatment with the PKC delta-selective inhibitor rottlerin or transfection with PKC delta siRNA attenuated the phosphorylation of ERK1/2 induced by the GSK-3 inhibitor SB-216763 and, furthermore, treatment with SB-216763 or transfection with GSK-3 delta and GSK-3 beta siRNA increased PKCd activity, thus identifying a role for PKCd in the induction of ERK1/2 phosphorylation by GSK-3 inhibition. Treatment with SB-216763 increased expression of cyclooxygenase-2 (COX-2) and IL-8, which are downstream targets of ERK1/2 activation; this induction was abolished by MEK/ERK inhibition, suggesting GSK-3 inhibition induced COX-2 and IL-8 through ERK1/2 activation. The transcriptional induction of COX-2 and IL-8 by GSK- 3 inhibition was further demonstrated by the increased COX-2 and IL-8 promoter activity after SB-216763 treatment or transfection with GSK-3 alpha or GSK- 3b siRNA. Importantly, our. findings identify GSK-3, acting through PKCd, as a negative regulator of ERK1/2, thus revealing a novel crosstalk mechanism between these critical signaling pathways.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu			NIA NIH HHS [R37 AG010885, R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [R01 DK048498, P01 DK35608, P01 DK035608, R01 DK48498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK048498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen BC, 2004, J BIOL CHEM, V279, P20889, DOI 10.1074/jbc.M311279200; Choi JH, 2004, J BIOL CHEM, V279, P49430, DOI 10.1074/jbc.M402088200; Claria J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding QM, 2001, BIOCHEM BIOPH RES CO, V284, P282, DOI 10.1006/bbrc.2001.4969; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takahashi-Yanaga F, 2004, BIOCHEM BIOPH RES CO, V316, P411, DOI 10.1016/j.bbrc.2004.02.061; Tang QB, 2001, CANCER RES, V61, P4329; Tominaga K, 2004, ALIMENT PHARM THER, V20, P143, DOI 10.1111/j.1365-2036.2004.01986.x; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	60	97	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					43	50		10.1038/sj.onc.1209004	http://dx.doi.org/10.1038/sj.onc.1209004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16278684	Green Accepted			2022-12-28	WOS:000234406400005
J	Yang, WL; Roland, IH; Godwin, AK; Xu, XX				Yang, WL; Roland, IH; Godwin, AK; Xu, XX			Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells	ONCOGENE			English	Article						cyclooxygenases; ovarian epithelial cells; ovarian carcinomas; TNF-alpha	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CYCLOOXYGENASE-2 EXPRESSION; SIGNAL-TRANSDUCTION; PROSTAGLANDIN E-2; UP-REGULATION; IN-VITRO; INHIBITOR; OVULATION; APOPTOSIS	Cyclooxygenase 2 (COX-2) is often found overexpressed in cancer and is thought to have a role in carcinogenic promotion, and thus is a target for therapeutic intervention. Here, we investigated the regulation of COX-2 expression in normal and cancer ovarian surface epithelial cells. Tumor necrosis factor alpha (TNF-alpha) is a potent inducer of COX-2 expression in the ovarian surface epithelium and this regulation is a critical step in ovulation. We observed that TNF-alpha stimulated COX-2 expression in human primary and immortalized epithelial (HIO) cell lines. The stimulation was suppressed by inhibitors of several signaling pathways, indicating the collaboration of TNF-alpha-activated signaling pathways mediates the regulation of COX-2 expression. In five ovarian cancer cell lines analysed, four did not express detectable COX-2 and TNF-alpha failed to elicit COX-2 expression. In NIH:OVCAR-5, the only ovarian cancer cell line expressing COX-2, signal pathway inhibitors no longer affected TNF-alpha-induced COX-2 expression. Thus, we conclude that TNF-a mediated signaling is uncoupled from the modulation of COX-2 expression in ovarian cancer. The loss of COX-2 expression was also observed to associate closely with epithelial neoplastic morphological transformation. The frequent loss of COX-2 expression suggests in ovarian cancer, unlike in other epithelial cancers, COX-2 expression does not contribute to ovarian cancer malignancy.	Fox Chase Canc Ctr, Ovarian Canc Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	x_xu@fccc.edu			NCI NIH HHS [R01 CA75389, P50 CA83638, R01 CA79716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638, R01CA079716, R01CA075389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHMEDKHANOV AA, 2001, SOC GYNECOL ONCOL, V80, P286; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes MN, 2002, CA-CANCER J CLIN, V52, P216, DOI 10.3322/canjclin.52.4.216; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANNSTROM M, 1995, REPROD FERT DEVELOP, V7, P67, DOI 10.1071/RD9950067; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Cramer DW, 1998, LANCET, V351, P104, DOI 10.1016/S0140-6736(97)08064-1; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Dore M, 1998, J HISTOCHEM CYTOCHEM, V46, P77, DOI 10.1177/002215549804600110; DOWNS SM, 1982, AM J ANAT, V164, P265, DOI 10.1002/aja.1001640307; Duffy DM, 2001, MOL HUM REPROD, V7, P731, DOI 10.1093/molehr/7.8.731; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Ferrandina G, 2002, GYNECOL ONCOL, V85, P305, DOI 10.1006/gyno.2002.6620; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gupta RA, 2003, CANCER RES, V63, P906; HAMILTON TC, 1984, CANCER RES, V44, P5286; Howe LR, 2002, SEMIN ONCOL, V29, P111, DOI 10.1053/sonc.2002.34063; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Klimp AH, 2001, CANCER RES, V61, P7305; KOMORI A, 1993, CANCER RES, V53, P1982; Lal G, 2001, CANCER RES, V61, P6131; Leahy KM, 2002, CANCER RES, V62, P625; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; MALIK STA, 1989, INT J CANCER, V44, P918, DOI 10.1002/ijc.2910440529; Masferrer J, 2001, CANCER J, V7, pS144; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsumoto Y, 2001, INT J MOL MED, V8, P31; Moore BC, 2000, CURR MED CHEM, V7, P1131, DOI 10.2174/0929867003374273; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168, DOI 10.1016/S1071-5576(02)00141-7; Murdoch WJ, 1997, J ANIM SCI, V75, P1601; Nabors LLB, 2003, CANCER RES, V63, P4181; Nasi ML, 2002, ANN ONCOL, V13, P1169, DOI 10.1093/annonc/mdf312; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Ness RB, 2000, JNCI-J NATL CANCER I, V92, P163, DOI 10.1093/jnci/92.2.163; Norman RJ, 2001, LANCET, V358, P1287, DOI 10.1016/S0140-6736(01)06455-8; Okamura H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P597; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pall M, 2001, HUM REPROD, V16, P1323, DOI 10.1093/humrep/16.7.1323; PRESCOTT SM, 2000, BIOCHIM BIOPHYS ACTA, V1470, P69, DOI [10.1016/s0304-419x(00)00006-8), DOI 10.1016/S0304-419X(00)00006-8]; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202; Roland IH, 2003, CANCER-AM CANCER SOC, V98, P2607, DOI 10.1002/cncr.11847; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; Shigemasa K, 2003, INT J ONCOL, V22, P99; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; Singer CA, 2003, AM J PHYSIOL-LUNG C, V285, pL1087, DOI 10.1152/ajplung.00409.2002; Smith ER, 2004, CANCER EPIDEM BIOMAR, V13, P144, DOI 10.1158/1055-9965.EPI-461-2; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Suganuma M, 1999, CANCER RES, V59, P4516; Terranova PF, 1997, AM J REPROD IMMUNOL, V37, P50; Tiano HF, 2002, CANCER RES, V62, P3395; Tokuyama O, 2001, INT J MOL MED, V8, P603; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Tsafriri A, 1999, EXP CLIN ENDOCR DIAB, V107, P1, DOI 10.1055/s-0029-1212066; Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; Yang WL, 2004, CANCER RES, V64, P1534, DOI 10.1158/0008-5472.CAN-03-2928	72	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7991	8002		10.1038/sj.onc.1208943	http://dx.doi.org/10.1038/sj.onc.1208943			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16044148				2022-12-28	WOS:000233656600006
J	McCormick, F				McCormick, F			Future prospects for oncolytic therapy	ONCOGENE			English	Review						oncolytic viruses; adenovirus; targeted therapy; oncology	AGENTS; POTENT	Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.	mccormick@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Nemunaitis J, 2002, CANCER GENE THER, V9, P987, DOI 10.1038/sj.cgt.7700547; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; YU C, 2001, CANCER RES, V61, P5453	11	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2005	24	52					7817	7819		10.1038/sj.onc.1209064	http://dx.doi.org/10.1038/sj.onc.1209064			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299540	Bronze			2022-12-28	WOS:000233372600016
J	Bockbrader, KM; Tan, MJ; Sun, Y				Bockbrader, KM; Tan, MJ; Sun, Y			A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						apoptosis; IAPs; Smac; anticancer drug; breast cancer	STRUCTURAL BASIS; LUNG-CANCER; CHEMOTHERAPEUTIC-AGENTS; PROTECTS CELLS; IAP FAMILY; XIAP; SMAC/DIABLO; ACTIVATION; INHIBITOR; CASPASE-3	Inhibitor of apoptosis protein (IAP) suppresses apoptosis through binding and inhibiting active caspases-3,-7 and -9 via its baculoviral IAP repeat (BIR) domains. During apoptosis the caspase inhibition by IAPs can be negatively regulated by a mitochondrial protein second mitochondrial-derived activator of caspase (Smac). Smac physically interacts with multiple IAPs and relieves their inhibitory effect on caspases-3,-7 and -9. Recently, a small molecule Smac-mimic compound (Smac-mimic), which potentiates TNF-related apoptosis-inducing ligand (TRAIL) and tumor necrosis factor (TNF)-alpha mediated cell death in glioblastoma T98G cells and HeLa cells, was identified and characterized. To determine the efficacy of this compound in breast cancer cells, we first measured protein expression of three IAPs: XIAP, cIAP-1, and cIAP-2 in nine independent breast cancer cell lines. Three cell lines were chosen: a high IAPs expressing line MDAMB231, and two low IAPs expressing lines, T47D and MDA-MB-453. The cell lines were tested for their sensitivity to Smac-mimic alone or in combination with TRAIL or etoposide. Acting alone, Smac-mimic was quite potent with a cytotoxic IC50 of 3.8 nM in high IAPs expressing MDA-MB-231 cells, but was inactive at a much higher concentration in low IAPs expressing T47D and MDA-MB-453 cells. In fact, as low as 2.5 nM of Smac-mimic alone was sufficient to activate caspase-3 and induce apoptosis in MDA-MB-231 cells. In combinational treatments with TRAIL or etoposide, Smac-mimic significantly sensitized cells to growth suppression in MDA-MB-231 cells, but to a lesser extent in T47D and MDA-MB-453 cells. Furthermore, it significantly synergized MDA-MB-231, but not T47D cells to apoptosis induced by either TRAIL or etoposide. Thus, in these cell lines, Smac-mimic acts in an apparent IAPs dependent manner to induce apoptosis alone as well as sensitizes breast cancer cells to TRAIL or etoposide induced apoptosis via caspase-3 activation.	Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287				Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Garber K, 2005, NAT BIOTECHNOL, V23, P409, DOI 10.1038/nbt0405-409; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang L, 2003, CANCER RES, V63, P6815; Yang LL, 2003, CANCER RES, V63, P831; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	37	133	155	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7381	7388		10.1038/sj.onc.1208888	http://dx.doi.org/10.1038/sj.onc.1208888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044155				2022-12-28	WOS:000233142100014
J	Frigola, J; Munoz, M; Clark, SJ; Moreno, V; Capella, G; Peinado, MA				Frigola, J; Munoz, M; Clark, SJ; Moreno, V; Capella, G; Peinado, MA			Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy	ONCOGENE			English	Article						colorectal cancer; tumor progression; cancer marker; cancer epigenetics; genetic instability	HISTONE DEACETYLASE INHIBITION; GENE; CELLS; ACTIVATION; GROWTH	Inactivation of specific tumor suppressor genes by transcriptional silencing associated with hypermethylation of the promoter is a common event in cancer. We have applied the amplification of intermethylated sites (AIMS) technique to a 100 human colorectal cancers and seven cell lines to identify recurrent alterations that may unveil silenced tumor suppressor genes. Bisulfite sequencing was used to con. firm differential DNA methylation results. Gene expression analysis was performed by real-time RT-PCR. An AIMS band recurrently displayed in tumors but not in normal tissues was isolated and identified as part of the CpG island of the prostacyclin synthase (PTGIS) gene promoter. PTGIS promoter was hypermethylated in 43 out of 100 colorectal cancers and in all cell lines. Bisulfite sequencing and clonal analysis confirmed the results obtained by AIMS and demonstrated biallelic hypermethylation of PTGIS promoter. Hypermethylation of the PTGIS promoter was associated with diminished gene expression, that was restored after treatment with demethylating and histone deacetylases inhibitor agents. PTGIS hypermethylation was associated with aneuploidy and p53 mutations. In the adjusted model, PTGIS methylation, but not p53 mutation, maintained the association with aneuploidy. We conclude that epigenetic inactivation of the PTGIS gene is a recurrent alteration in colorectal carcinogenesis.	Hosp Duran & Reynals, Inst Recerca Oncol, IDIBELL, Barcelona 08907, Spain; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; IDIBELL, Inst Catala Oncol, Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, Lab Bioestadistica & Epidemiol, E-08193 Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Garvan Institute of Medical Research; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Autonomous University of Barcelona; University of Barcelona	Peinado, MA (corresponding author), Hosp Duran & Reynals, Inst Recerca Oncol, IDIBELL, Gran Via Km 2-7, Barcelona 08907, Spain.	mpeinado@iro.es	Clark, Susan J/U-7365-2019; Capella, Gabriel/I-1879-2015; Clark, Susan J/B-2272-2008; Frigola, Jordi/N-4602-2015; Peinado, Miguel A./A-5591-2008; Moreno, Victor/A-1697-2010	Clark, Susan J/0000-0001-5925-5030; Capella, Gabriel/0000-0002-4669-7320; Clark, Susan J/0000-0001-5925-5030; Frigola, Jordi/0000-0002-7231-3853; Peinado, Miguel A./0000-0002-4090-793X; Moreno, Victor/0000-0002-2818-5487				Amano S, 2004, RESPIROLOGY, V9, P184, DOI 10.1111/j.1440-1843.2004.00568.x; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cutler NS, 2003, CANCER RES, V63, P1748; Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028; Frigola J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e28; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Keith RL, 2002, CANCER RES, V62, P734; Lim H, 2002, ENDOCRINOLOGY, V143, P3207, DOI 10.1210/en.2002-220159; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Pradono P, 2002, CANCER RES, V62, P63; Risques RA, 2001, LAB INVEST, V81, P307, DOI 10.1038/labinvest.3780239; Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Yang XW, 2001, CANCER RES, V61, P7025; Yokoyama C, 1996, GENOMICS, V36, P296, DOI 10.1006/geno.1996.0465	22	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7320	7326		10.1038/sj.onc.1208883	http://dx.doi.org/10.1038/sj.onc.1208883			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007128				2022-12-28	WOS:000233142100008
J	Wattel, S; Mircescu, H; Venet, D; Burniat, A; Franc, B; Frank, S; Andry, G; Van Sande, J; Rocmans, P; Dumont, JE; Detours, V; Maenhaut, C				Wattel, S; Mircescu, H; Venet, D; Burniat, A; Franc, B; Frank, S; Andry, G; Van Sande, J; Rocmans, P; Dumont, JE; Detours, V; Maenhaut, C			Gene expression in thyroid autonomous adenomas provides insight into their physiopathology	ONCOGENE			English	Article						thyroid; autonomous adenoma; gene expression; microarray	THYROTROPIN RECEPTOR MUTATIONS; BLOOD CAPILLARY ENLARGEMENT; DOG PRIMARY THYROCYTES; C-MYC EXPRESSION; PROTEIN-KINASE-A; CYCLIC-AMP; TRANSGENIC MICE; MICROARRAY DATA; GROWTH-FACTORS; TSH RECEPTOR	The purpose of this study was to use the microarray technology to de. ne expression profiles characteristic of thyroid autonomous adenomas and relate these findings to physiological mechanisms. Experiments were performed on a series of separated adenomas and their normal counterparts on Micromax cDNA microarrays covering 2400 genes (analysis I), and on a pool of adenomatous tissues and their corresponding normal counterparts using microarrays of 18 000 spots (analysis II). Results for genes present on the two arrays corroborated and several gene regulations previously determined by Northern blotting or microarrays in similar lesions were confirmed. Five overexpressed and 24 underexpressed genes were also confirmed by real-time RT-PCR in some of the samples used for microarray analysis, and in additional tumor specimens. Our results show: (1) a change in the cell populations of the tumor, with a marked decrease in lymphocytes and blood cells and an increase in endothelial cells. The latter increase would correspond to the establishment of a close relation between thyrocytes and endothelial cells and is related to increased N-cadherin expression. It explains the increased blood flow in the tumor; (2) a homogeneity of tumor samples correlating with their common physiopathological mechanism: the constitutive activation of the thyrotropin (TSH)/cAMP cascade; (3) a low proportion of regulated genes consistent with the concept of a minimal deviation tumor; (4) a higher expression of genes coding for specific functional proteins, consistent with the functional hyperactivity of the tumors; (5) an increase of phosphodiesterase gene expression which explains the relatively low cyclic AMP levels measured in these tumors; (6) an overexpression of antiapoptotic genes and underexpression of proapoptotic genes compatible with their low apoptosis rate; (7) an overexpression of N-cadherin and downregulation of caveolins, which casts doubt about the use of these expressions as markers for malignancy.	Free Univ Brussels, Sch Med, IRIBHM, Int Interdisciplinary Res, B-1070 Brussels, Belgium; Univ Versailles, Hop Ambroise Pare, AP HP, Serv Anat & Cytol Pathol, St Quentin en Yvelines, France; Inst Jules Bordet, Dept Surg, B-1000 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut Jules Bordet	Maenhaut, C (corresponding author), Free Univ Brussels, Sch Med, IRIBHM, Int Interdisciplinary Res, 808 Route Lennik,Campus Erasme,Bldg C, B-1070 Brussels, Belgium.	cmaenhau@ulb.ac.be						Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Aldred MA, 2003, CANCER RES, V63, P2864; Aust G, 2001, J CLIN ENDOCR METAB, V86, P3368, DOI 10.1210/jc.86.7.3368; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; Bauch K, 1998, EXP CLIN ENDOCR DIAB, V106, pS16, DOI 10.1055/s-0029-1212050; Becker D, 1997, J CLIN ULTRASOUND, V25, P63, DOI 10.1002/(SICI)1097-0096(199702)25:2<63::AID-JCU3>3.0.CO;2-H; Bourdeau I, 2004, ONCOGENE, V23, P1575, DOI 10.1038/sj.onc.1207277; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cho-Chung YS, 2004, BBA-PROTEINS PROTEOM, V1697, P71, DOI 10.1016/j.bbapap.2003.11.014; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Deleu S, 2000, THYROID, V10, P131, DOI 10.1089/thy.2000.10.131; Detours V, 2005, BRIT J CANCER, V92, P1545, DOI 10.1038/sj.bjc.6602521; DRALLE H, 1977, VIRCHOWS ARCH A, V374, P285, DOI 10.1007/BF00432652; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056; ERMANS AM, 1972, ACTA ENDOCRINOL-COP, V70, P463, DOI 10.1530/acta.0.0700463; Eszlinger M, 2004, ONCOGENE, V23, P795, DOI 10.1038/sj.onc.1207186; Eszlinger M, 2001, J CLIN ENDOCR METAB, V86, P4834, DOI 10.1210/jc.86.10.4834; Finley DJ, 2004, J CLIN ENDOCR METAB, V89, P3214, DOI 10.1210/jc.2003-031811; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gerard AC, 2002, J CLIN ENDOCR METAB, V87, P1291, DOI 10.1210/jc.87.3.1291; Goffard JC, 2004, MOL ENDOCRINOL, V18, P194, DOI 10.1210/me.2003-0249; HAMBURGER JI, 1987, ENDOCR REV, V8, P439, DOI 10.1210/edrv-8-4-439; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; Haugen DRF, 2003, THYROID, V13, P613; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Karsten SL, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e4; KETELBANTBALASSE P, 1976, HORM METAB RES, V8, P212, DOI 10.1055/s-0028-1093662; Knudsen N, 2000, EUR J ENDOCRINOL, V143, P485, DOI 10.1530/eje.0.1430485; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krohn K, 2000, J PATHOL, V192, P37; Krohn K, 1998, J CLIN ENDOCR METAB, V83, P130, DOI 10.1210/jc.83.1.130; Lania A, 1998, J CLIN ENDOCR METAB, V83, P1624, DOI 10.1210/jc.83.5.1624; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NEVE P, 1970, Experimental Cell Research, V63, P285, DOI 10.1016/0014-4827(70)90215-6; NILSON JH, 1980, ENDOCRINOLOGY, V107, P262, DOI 10.1210/endo-107-1-262; O'Donovan N, 2002, J ENDOCRINOL, V174, P517, DOI 10.1677/joe.0.1740517; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PIRSON I, 1994, EXP CELL RES, V210, P33, DOI 10.1006/excr.1994.1005; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; REUSE S, 1990, EXP CELL RES, V189, P33, DOI 10.1016/0014-4827(90)90253-7; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; Savonet V, 1997, ANAL BIOCHEM, V247, P165, DOI 10.1006/abio.1997.2055; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; Tonacchera M, 2000, J CLIN ENDOCR METAB, V85, P2270, DOI 10.1210/jc.85.6.2270; Tonacchera M, 1999, J CLIN ENDOCR METAB, V84, P4155, DOI 10.1210/jc.84.11.4155; VANDENHOVEVANDENBROUCKE MF, 1976, J CLIN ENDOCR METAB, V43, P178, DOI 10.1210/jcem-43-1-178; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; VANSANDE J, 1980, J CLIN ENDOCR METAB, V50, P776, DOI 10.1210/jcem-50-4-776; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VANSANDE J, 1988, J CLIN ENDOCR METAB, V66, P570, DOI 10.1210/jcem-66-3-570; Vanvooren V, 2002, EUR J ENDOCRINOL, V147, P287, DOI 10.1530/eje.0.1470287; Venet D, 2001, Bioinformatics, V17 Suppl 1, pS279; Venet D, 2003, BIOINFORMATICS, V19, P659, DOI 10.1093/bioinformatics/btg046; Voigt C, 2004, J ENDOCRINOL, V182, P173, DOI 10.1677/joe.0.1820173; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Weber G, 2002, ADV ENZYME REGUL, V42, P83; WOLLMAN SH, 1982, ENDOCRINOLOGY, V111, P1867, DOI 10.1210/endo-111-6-1867; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; Yamazaki K, 2003, THYROID, V13, P149, DOI 10.1089/105072503321319459; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yano Y, 2004, CLIN CANCER RES, V10, P2035, DOI 10.1158/1078-0432.CCR-0807-03; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133	74	21	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2005	24	46					6902	6916		10.1038/sj.onc.1208849	http://dx.doi.org/10.1038/sj.onc.1208849			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16027733				2022-12-28	WOS:000232701700005
J	Rokhlin, OW; Taghiyev, AF; Guseva, NV; Glover, RA; Chumakov, PM; Kravchenko, JE; Cohen, MB				Rokhlin, OW; Taghiyev, AF; Guseva, NV; Glover, RA; Chumakov, PM; Kravchenko, JE; Cohen, MB			Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP	ONCOGENE			English	Article						androgen; androgen receptor; Akt; p53; caspase-2; apoptosis	PROSTATE-CANCER-CELLS; FAS-MEDIATED APOPTOSIS; LINE LNCAP; RECEPTOR; ACTIVATION; CASPASE-2; PROTEIN; DEATH; MITOCHONDRIA; P53	It has been suggested in many studies that combined treatment with chemotherapeutic agents and apoptosis-inducing ligands belonging to TNFR family is a more effective strategy for cancer treatment. However, the role of androgen regulation of TNFR family-induced apoptosis in prostate cancer is poorly understood. In this study, we investigated the dose-dependent effects of androgen on TNF-alpha and TRAIL-mediated apoptosis in LNCaP. To investigate the interaction between the androgen receptor (AR) and the caspase-2 gene, chromatin immunoprecipitation analysis was used, and we are the first to identify that AR interacts in vivo with an androgen-responsive elements in intron 8 of caspase-2 gene. We have found that DHT inhibited apoptosis in dose-dependent manner. There is a direct, androgen-dependent correlation between the levels of activated Akt and caspase activation after treatment with TNF-alpha and TRAIL. W e have also found that there are at least two different regulatory mechanisms of p53 expression by androgen: at the gene and protein levels. At the same time, the level of AR was found to be higher in LNCaP-si-p53 compared to LNCaP-mock cells. The se data indicate that there is a mutual regulation of expression between p53 and AR. Our study suggests that androgen-dependent outcome of apoptotic treatment can occur, at least in part, via the caspase-2, Akt and p53-mediated pathways.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	University of Iowa; Cleveland Clinic Foundation	Rokhlin, OW (corresponding author), Univ Iowa, Dept Pathol, 1163 ML, Iowa City, IA 52242 USA.	oskar-rokhlin@uiowa.edu	Chumakov, Peter M/E-7731-2014	Chumakov, Peter/0000-0002-8078-2908	NATIONAL CANCER INSTITUTE [R01CA104903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025278] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104903, R01 CA104903-01A1, CA 87717] Funding Source: Medline; NIA NIH HHS [R01 AG025278, R01 AG025278-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Guseva NV, 2004, J CELL BIOCHEM, V91, P70, DOI 10.1002/jcb.10707; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104-26; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Linja MJ, 2001, CANCER RES, V61, P3550; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; NANTERMET PV, 2004, SCIENCE, V304, P843; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pinski J, 2001, CANCER RES, V61, P6372; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 2002, CANCER BIOL THER, V1, P631, DOI 10.4161/cbt.311; Rokhlin OW, 2002, J BIOL CHEM, V277, P33213, DOI 10.1074/jbc.M204612200; Rokhlin OW, 2004, CANCER BIOL THER, V3, P761, DOI 10.4161/cbt.3.8.970; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Rokhlin OW, 1997, CANCER RES, V57, P1758; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; THALMANN GN, 1994, CANCER RES, V54, P2577; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	40	67	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2005	24	45					6773	6784		10.1038/sj.onc.1208833	http://dx.doi.org/10.1038/sj.onc.1208833			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007156	Green Accepted			2022-12-28	WOS:000232527800005
J	Wang, YH; Zhou, XB; Zhu, HX; Liu, S; Zhou, CQ; Zhang, G; Xue, LY; Lu, N; Quan, LP; Bai, JF; Zhan, QM; Xu, NZ				Wang, YH; Zhou, XB; Zhu, HX; Liu, S; Zhou, CQ; Zhang, G; Xue, LY; Lu, N; Quan, LP; Bai, JF; Zhan, QM; Xu, NZ			Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway	ONCOGENE			English	Article						esophageal cancer; overexpression; EB1; APC; beta-catenin	ADENOMATOUS POLYPOSIS-COLI; C-MYC; EXPRESSION; GENE; APC; TARGET	Esophageal squamous cell carcinoma (ESCC) has a multifactorial etiology involving environmental and/or genetic factors. End-binding protein 1 (EB1), which was cloned as an interacting partner of the adenomatous polyposis coli (APC) tumor suppressor protein, was previously found overexpressed in ESCC. However, the precise role of EB1 in the development of this malignancy has not yet been elucidated. In this study, we analysed freshly resected ESCC specimens and demonstrated that EB1 was overexpressed in approximately 63% of tumor samples compared to matched normal tissue. We report that overexpression of EB1 in the ESCC line EC9706 significantly promotes cell growth, whereas suppression of EB1 protein level by RNA interference significantly inhibited growth of esophageal tumor cells. In addition, EB1 overexpression induced nuclear accumulation of beta-catenin and promoted the transcriptional activity of beta-catenin/T-cell factor (TCF). These effects were partially or completely abolished by coexpression of APC or Delta N TCF4, respectively. Also, we found that EB1 affected the interaction between beta-catenin and APC. Furthermore, EB1 overexpression was correlated with cytoplasmic/nuclear accumulation of beta-catenin in primary human ESCC. Taken together, these results support the novel hypothesis that EB1 overexpression may play a role in the development of ESCC by affecting APC function and activating the beta-catenin/TCF pathway.	Chinese Acad Med Sci, Canc Inst & Canc Hosp, Lab Cell & Mol Biol, Beijing 100021, Peoples R China; Peking Union Med Coll, New York, NY 10021 USA; Chinese Acad Med Sci, Canc Inst & Canc Hosp, Dept Pathol, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Canc Inst & Canc Hosp, Natl Lab Mol Oncol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Xu, NZ (corresponding author), Chinese Acad Med Sci, Canc Inst & Canc Hosp, Lab Cell & Mol Biol, Beijing 100021, Peoples R China.	xningzhi@public.bta.net.cn	Zhou, Cuiqi/B-1568-2010; Liu, Shuang/J-1798-2012; Zhang, Guo/Q-8513-2016	Wang, Yihua/0000-0001-5561-0648				Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Louie RK, 2004, J CELL SCI, V117, P1117, DOI 10.1242/jcs.00939; Polakis P, 2000, GENE DEV, V14, P1837; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; SU LK, 1995, CANCER RES, V55, P2972; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Uys P, 2003, MOL CARCINOGEN, V36, P82, DOI 10.1002/mc.10100; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M; Zhang G, 2005, PATHOL INT, V55, P310, DOI 10.1111/j.1440-1827.2005.01840.x; Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642; ZHOU J, 1999, CHINESE J MED GENET, V16, P303; Zhou Xiao-bo, 2002, Ai Zheng, V21, P877; ZOU XN, 2002, B CHIN CANC, V11, P446	24	68	74	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6637	6645		10.1038/sj.onc.1208819	http://dx.doi.org/10.1038/sj.onc.1208819			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007168				2022-12-28	WOS:000232367800005
J	Markova, M; Koratkar, RA; Silverman, KA; Sollars, VE; Mac-Phee-Pellini, M; Walters, R; Palazzo, JP; Buchberg, AM; Siracusa, LD; Farber, SA				Markova, M; Koratkar, RA; Silverman, KA; Sollars, VE; Mac-Phee-Pellini, M; Walters, R; Palazzo, JP; Buchberg, AM; Siracusa, LD; Farber, SA			Diversity in secreted PLA(2)-IIA activity among inbred mouse strains that are resistant or susceptible to Apc(Min/+) tumorigenesis	ONCOGENE			English	Article						APC; PLA2; phospholipase; Mom1; intestine; cancer; mouse; BODIPY	PHOSPHOLIPASE A(2); INTESTINAL NEOPLASIA; GROUP-II; GROUP-V; MAJOR MODIFIER; LOCUS; GENE; ENZYMES; IDENTIFICATION; BIOSYNTHESIS	The secreted phospholipase A(2) type IIA (Pla2g2a) gene was previously identified as a modifier of intestinal adenoma multiplicity in Apc(Min/+) mice. To determine if intestinal secreted phospholipase A(2) (sPLA(2)) activity was also attenuated in susceptible strains, we developed a sensitive assay to directly quantitate sPL2 activity in the murine intestinal tract utilizing a fluorescent BODIPY-labeled phospholipid substrate. Here, we report assay conditions that distinguish between secreted and cytosolic PLA(2) enzyme activities in extracts of intestinal tissue. The small intestine exhibited higher activity levels than the large intestine. Consistent with predictions from the sPLA(2)-IIA gene sequence in inbred strains, we detected low levels of enzyme activity in inbred strains containing sPLA(2)-IIA mutations; these strains were also associated with greater numbers of intestinal polyps. Additionally, the assay was able to distinguish differences in levels of sPLA(2) activity between neoplasia-resistant strains, which were then shown by sequencing to carry variant wild-type sPLA(2)-IIA alleles. Immunohistochemical analyses of intestinal tissues were consistent with sPLA(2)-IIA activity levels. This approach enables further studies of the mechanisms of sPLA(2) action influencing the development and tumorigenesis of the small intestine and colon in both mice and humans.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Surg Pathol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Siracusa, LD (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	siracusa@mail.jci.tju.edu; farber@ciwemb.edu	Sollars, Vincent/R-3769-2019; Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; Sollars, Vincent/0000-0002-5602-3610; Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [P01CA72027, R01 CA89560] Funding Source: Medline; NIDDK NIH HHS [R01 DK060369] Funding Source: Medline; NINDS NIH HHS [F32 NS010326] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089560, P01CA072027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Dahim M, 2002, BIOPHYS J, V83, P1511, DOI 10.1016/S0006-3495(02)73921-0; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Farber SA, 1999, J BIOL CHEM, V274, P19338, DOI 10.1074/jbc.274.27.19338; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kirtane BM, 2002, J BIOSCIENCES, V27, P489, DOI 10.1007/BF02705045; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koratkar R, 2004, GENOMICS, V84, P844, DOI 10.1016/j.ygeno.2004.07.010; Koratkar R, 2002, CANCER RES, V62, P5413; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Rouault M, 2003, BIOCHEMISTRY-US, V42, P11494, DOI 10.1021/bi0349930; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Silver L.M., 1995, MOUSE GENETICS CONCE; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4	36	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6450	6458		10.1038/sj.onc.1208791	http://dx.doi.org/10.1038/sj.onc.1208791			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007193	Green Accepted			2022-12-28	WOS:000232038200012
J	Lung, HL; Bangarusamy, DK; Xie, D; Cheung, AKL; Cheng, Y; Kumaran, MK; Miller, L; Liu, ETB; Guan, XY; Sham, JS; Fang, Y; Li, LQ; Wang, N; Protopopov, AI; Zabarovsky, ER; Tsao, SW; Stanbridge, EJ; Lung, ML				Lung, HL; Bangarusamy, DK; Xie, D; Cheung, AKL; Cheng, Y; Kumaran, MK; Miller, L; Liu, ETB; Guan, XY; Sham, JS; Fang, Y; Li, LQ; Wang, N; Protopopov, AI; Zabarovsky, ER; Tsao, SW; Stanbridge, EJ; Lung, ML			THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma	ONCOGENE			English	Article						chromosome 11; THY1; nasopharyngeal carcinoma; microcell hybrid; oligo-microarray	HUMAN OVARIAN-CANCER; CELL-LINE; REGION; ADHESION	Using oligonucleotide microarray analysis, THY1, mapping close to a previously defined 11q22-23 nasopharyngeal carcinoma (NPC) critical region was identified as showing consistent downregulated expression in the tumour segregants, as compared to their parental tumour-suppressing microcell hybrids (MCHs). Gene expression and protein analyses show that THY1 was not expressed in the NPC HONE1 recipient cells, tumour segregants, and other NPC cell lines; THY1 was exclusively expressed in the non-tumourigenic MCHs. The mechanism of THY1 gene inactivation in these cell lines was attributed to hypermethylation. Clinical study showed that in 65% of NPC specimens there was either downregulation or loss of THY1 gene expression. Using a tissue microarray and immunohistochemical staining, 44% of the NPC cases showed downregulated expression of THY1 and 9% lost THY1 expression. The frequency of THY1 downregulated expression in lymph node metastatic NPC was 63%, which was significantly higher than in the primary tumour (33%). After transfection of THY1 gene into HONE1 cells, a dramatic reduction of colony formation ability was observed. These findings suggest that THY1 is a good candidate tumour suppressor gene in NPC, which is significantly associated with lymph node metastases.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Genome Inst Singapore, Inst Biomed Sci, Singapore, Singapore; Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Inst Canc, Guangzhou, Peoples R China; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of Hong Kong; Sun Yat Sen University; University of Rochester; Karolinska Institutet; University of Hong Kong; University of California System; University of California Irvine	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bomaria@ust.hk	Miller, Lance/A-5633-2009; Cheung, Arthur Kwok Leung/H-8940-2013; Cheng, Yue/E-9853-2010; Lung, Hong Lok/C-4494-2009; Zabarovsky, Eugene R/A-6645-2010; Guan, Xin-Yuan/A-3639-2009; Lung, Maria Li/C-4495-2009	Cheng, Yue/0000-0002-2472-1879; Guan, Xin-Yuan/0000-0002-4485-6017; Miller, Lance/0000-0003-3799-2528; Lung, Maria Li/0000-0003-2559-3626				Abeysinghe HR, 2004, CANCER GENET CYTOGEN, V149, P1, DOI 10.1016/S0165-4608(03)00234-6; Abeysinghe HR, 2003, CANCER GENET CYTOGEN, V143, P125, DOI 10.1016/S0165-4608(02)00855-5; Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; BONEWALD L, 1984, J IMMUNOGENET, V11, P283; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chan KT, 2004, CANCER CHEMOTH PHARM, V53, P519, DOI 10.1007/s00280-004-0767-4; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; CRAWFORD JM, 1986, LAB INVEST, V54, P122; Diaz-Romero J, 2005, J CELL PHYSIOL, V202, P731, DOI 10.1002/jcp.20164; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lung HL, 2004, INT J CANCER, V112, P628, DOI 10.1002/ijc.20454; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Robertson G P, 1999, Mol Cell Biol Res Commun, V2, P1, DOI 10.1006/mcbr.1999.0141; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514	20	105	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6525	6532		10.1038/sj.onc.1208812	http://dx.doi.org/10.1038/sj.onc.1208812			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007174				2022-12-28	WOS:000232204100006
J	Himes, SR; Cronau, S; Mulford, C; Hume, DA				Himes, SR; Cronau, S; Mulford, C; Hume, DA			The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages	ONCOGENE			English	Article						Runx1; macrophage; CSF-1; survival	CORE-BINDING-FACTOR; ACUTE MYELOMONOCYTIC LEUKEMIA; AML1/ETO FUSION TRANSCRIPT; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; C-FMS; FACTOR BETA; DEFINITIVE HEMATOPOIESIS	Gene translocations that repress the function of the Runx1 transcription factor play a critical role in the development of myeloid leukemia. In this report, we demonstrate that Runx1 precisely regulates c-fms (CSF-1 receptor) gene expression. Runx1 controlled expression by binding to multiple sites within the mouse c-fms gene, allowing interaction between promoter and downstream enhancer elements. The runx1 and c-fms genes showed an identical pattern of expression in mature macrophages. Runx1 expression was repressed in CSF-1 stimulated, proliferating bone marrow-derived macrophages (BMM) and significantly increased in quiescent, CSF-1 starved cells. The RAW264.7 and Mono-Mac-6, macrophage-like cell lines expressed low levels of Runx1 and both showed growth arrest and cell death with ectopic expression of Runx1. The EM-3 cell line, which represents an early myeloid progenitor cell line, showed growth arrest with Runx1 expression in the absence of any detectable changes in cell differentiation. These findings suggest that Runx1 regulates growth and survival of myeloid cells and provide a novel insight into the role of Runx family gene translocations in leukemogenesis.	Univ Queensland, Inst Mol Biosci, CRC Chron Inflammatory Dis, Queensland Biosci Precint, Brisbane, Qld 4072, Australia	University of Queensland	Hume, DA (corresponding author), Univ Queensland, Inst Mol Biosci, CRC Chron Inflammatory Dis, Queensland Biosci Precint, Bldg 80,Serv Rd, Brisbane, Qld 4072, Australia.	d.hume@imb.uq.edu.au	Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Cecchini MG, 1997, MOL REPROD DEV, V46, P75; Cochet O, 1998, MOL IMMUNOL, V35, P1097, DOI 10.1016/S0161-5890(98)00105-9; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DOWNING JR, 1993, BLOOD, V81, P2860; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Hume DA, 1997, MOL REPROD DEV, V46, P46; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Levanon D, 2003, BLOOD CELL MOL DIS, V30, P161, DOI 10.1016/S1079-9796(03)00023-8; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; MARUYAMA F, 1993, CANCER RES, V53, P4449; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sudo T, 1995, ONCOGENE, V11, P2469; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; THOMPSON PW, 1991, CANCER GENET CYTOGEN, V55, P269, DOI 10.1016/0165-4608(91)90089-D; Tracey WD, 2000, SEMIN CELL DEV BIOL, V11, P337, DOI 10.1006/scdb.2000.0186; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Yang YD, 2002, CANCER RES, V62, P2232; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	36	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5278	5286		10.1038/sj.onc.1208657	http://dx.doi.org/10.1038/sj.onc.1208657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007221	Bronze			2022-12-28	WOS:000231158500002
J	Wu, M; Wallace, MR; Muir, D				Wu, M; Wallace, MR; Muir, D			Nf1 haploinsufficiency augments angiogenesis	ONCOGENE			English	Article						neurofibromatosis; vasculature; Nf1 haploinsufficiency; endothelial cell; inflammatory cells	DEFICIENT SCHWANN-CELLS; NEUROFIBROMATOSIS 1; FACTOR MIDKINE; MAST-CELLS; EXPRESSION; MOUSE; COMPLICATION; ENCODES; CULTURE	Mutations in the NF1 tumor-suppressor gene underlie neuro. bromatosis type 1 (NF1), in which patients are predisposed to certain tumors such as neuro. bromas and may associate with vascular disorder. Plexiform neuro. bromas are slow growing benign tumors that are highly vascular and can progress to malignancy. The development of neuro. bromas requires loss of both Nf1 alleles in Schwann cells destined to become neoplastic and may be exacerbated by Nf1 heterozygosity in other non-neoplastic cells. This study tested the hypothesis that Nf1 heterozygosity exaggerates angiogenesis. We found that Nf1 heterozygous mice showed increased neovascularization in both the retina and cornea in response to hypoxia and bFGF, respectively, compared to their wild-type litter-mates. The increase in corneal neovascularization was associated with heightened endothelial cell proliferation and migration, and increased infiltration of inflammatory cells. In addition, Nf1 heterozygous endothelial cell cultures showed an exaggerated proliferative response to angiogenic factors, particularly to bFGF. These findings support the conclusion that Nf1 heterozygosity in endothelial cells and perhaps inflammatory cells augments angiogenesis, which may promote neurofibroma formation in NF1.	Univ Florida, Dept Pediat, Div Neurol, Gainesville, FL 32610 USA; Univ Florida, Dept Microbiol & Mol Genet, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, M (corresponding author), Univ Florida, Coll Med, Dept Pediat Neuro, Box 100296, Gainesville, FL 32610 USA.	wumin@ufl.edu						Arbiser JL, 1998, J AM ACAD DERMATOL, V38, P950, DOI 10.1016/S0190-9622(98)70158-6; Bajenaru ML, 2003, CANCER RES, V63, P8573; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DUPREZ K, 1991, MICROSURG, V12, P1, DOI 10.1002/micr.1920120102; Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Hamilton SJ, 2001, AM J MED GENET, V100, P95, DOI 10.1002/1096-8628(20010422)100:2<95::AID-AJMG1235>3.0.CO;2-T; Hamilton SJ, 2000, CLIN GENET, V58, P341, DOI 10.1034/j.1399-0004.2000.580501.x; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JOHNSON MD, 1989, ARCH PATHOL LAB MED, V113, P1263; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; Morello F, 2001, J VASC INTERV RADIOL, V12, P773, DOI 10.1016/S1051-0443(07)61454-7; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; MUIR D, 1990, ANAL BIOCHEM, V185, P377, DOI 10.1016/0003-2697(90)90310-6; Ozerdem Ugur, 2004, Angiogenesis, V7, P307, DOI 10.1007/s10456-004-6643-3; Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299; Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121; RICCARDI VM, 1981, BIRTH DEFECTS-ORIG, V17, P129; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SIDE L, 1998, NEUROFIBROMATOSIS TY; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Song L, 2003, IN VITRO CELL DEV-AN, V39, P313; Wolkenstein P, 2001, ARCH DERMATOL, V137, P233; Wu M, 2005, J NEUROSCI RES, V82, P357, DOI 10.1002/jnr.20646; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	36	39	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2297	2303		10.1038/sj.onc.1209264	http://dx.doi.org/10.1038/sj.onc.1209264			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16288202				2022-12-28	WOS:000236764300002
J	Pozzi, S; Rossetti, S; Bistulfi, G; Sacchi, N				Pozzi, S; Rossetti, S; Bistulfi, G; Sacchi, N			RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells	ONCOGENE			English	Article						RAR alpha; RAR beta 2; Cyp26a1; epigenetic regulation; embryocarcinoma	RETINOIC ACID; DIFFERENTIATION; EXPRESSION; ALPHA; FEEDBACK; GENE	Retinoic acid (RA) is a signaling molecule that plays a pivotal role in major cellular processes and vertebrate development. RA action is mediated by specialized transcription factors, the nuclear RA receptors (RARs), which regulate the transcription of genes containing a RA-responsive element (RARE). Here we demonstrate that the genes for the RA-receptor RAR beta 2 and the cytochrome P450 RA-specific hydrolase Cyp26a1 involved in RA catabolism are coordinately regulated by RA. We found that both RAR beta 2 and Cyp26a1 genes are epigenetically silenced in the absence of DNA methylation in RAC65, a P19 embryocarcinoma cell line derivative carrying a dominant-negative RAR alpha mutant and resistant to the growth-inhibitory and differentiation effects of RA. In response to RA, RAR beta 2 transcription is epigenetically regulated by RAR alpha. Similarly, we found that Cyp26a1 transcription is epigenetically regulated by RAR beta 2. Knocking down RAR beta 2 transcription by RNA interference in wild-type P19 cells, with an intact RAR alpha, induced Cyp26a1 transcriptional repression in the absence of DNA methylation. Concomitantly, cells developed RA resistance and did not undergo RA-induced neuron differentiation. Apparently, RAR alpha, RAR beta 2 and Cyp26a1 are components of a RA-regulated gene network. Factors affecting an upstream gene of the network can trigger repressive chromatin changes-which are propagated in a domino fashion-at downstream genes of the network. This study also shows that chromatin inactivity, and consequent transcriptional silencing, can be achieved in the absence of DNA methylation.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sacchi, N (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,C&V Bldg,Rm 226, Buffalo, NY 14263 USA.	nicoletta.sacchi@roswellpark.org						Arney KL, 2004, J CELL SCI, V117, P4355, DOI 10.1242/jcs.01390; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dobbs-McAuliffe B, 2004, MECH DEVELOP, V121, P339, DOI 10.1016/j.mod.2004.02.008; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; LAUDET V, 2002, NUCL RECEPTOR FACTS, P6; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirchia SM, 2002, CANCER RES, V62, P2455; Sonneveld E, 1999, DEV BIOL, V213, P390, DOI 10.1006/dbio.1999.9381; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200	25	28	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1400	1407		10.1038/sj.onc.1209173	http://dx.doi.org/10.1038/sj.onc.1209173			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16261163				2022-12-28	WOS:000235708200013
J	Beitzinger, M; Oswald, C; Beinoraviciute-Kellner, R; Stiewe, T				Beitzinger, M; Oswald, C; Beinoraviciute-Kellner, R; Stiewe, T			Regulation of telomerase activity by the p53 family member p73	ONCOGENE			English	Article						telomerase; hTERT; p53; p73	REVERSE-TRANSCRIPTASE GENE; HUMAN TUMOR-CELLS; WILD-TYPE P53; DOWN-REGULATION; IN-VIVO; NEGATIVE REGULATION; IMMORTAL CELLS; FEEDBACK LOOP; CANCER-CELLS; C-MYC	The terminal ends of eukaryotic chromosomes, termed telomeres, progressively shorten during each round of cell division eventually leading cells into senescence. Tumor cells typically overcome this barrier to unlimited proliferation by activation of the human telomerase reverse transcriptase (hTERT) gene. In contrast, in most human somatic cells hTERT expression is tightly repressed by multiple tumor suppressors. Here, we studied the regulation of hTERT by the p53 family member p73. We show that forced expression of p73 or activation of endogenous p73 by E2F1 results in the downregulation of telomerase activity. Vice versa, siRNA-mediated knockdown of p73 induces hTERT expression. Responsiveness to p73 is conferred by Sp1 binding sites within the hTERT core promoter. In tumor cells, p73 isoforms lacking the transactivation domain (DNp73) are frequently over-expressed and believed to function as oncogenes. We show that DNp73 antagonizes the repressive effect of the proapoptotic p53 family members on hTERT expression and, in addition, induces hTERT expression in telomerase-negative cells by interfering with E2F-RB-mediated repression of the hTERT core promoter. These data provide evidence that the p73 gene functions as an important regulator of telomerase activity with implications for embryonic development, cellular differentiation and tumorigenesis.	Univ Wurzburg, Mol Tumor Biol Grp, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany	University of Wurzburg	Stiewe, T (corresponding author), Univ Wurzburg, Mol Tumor Biol Grp, Rudolf Virchow Ctr, Verbacher Str 9, D-97078 Wurzburg, Germany.	thorsten.stiewe@virchow.uni-wuerzburg.de		Stiewe, Thorsten/0000-0003-0134-7826				Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guilleret I, 2002, CARCINOGENESIS, V23, P2025, DOI 10.1093/carcin/23.12.2025; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Moll UM, 2004, MOL CANCER RES, V2, P371; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Slade N, 2004, CELL DEATH DIFFER, V11, P357, DOI 10.1038/sj.cdd.4401335; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Suske G, 2000, Methods Mol Biol, V130, P175; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; WALDMAN T, 1995, CANCER RES, V55, P5187; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Won J, 2004, P NATL ACAD SCI USA, V101, P11328, DOI 10.1073/pnas.0401801101; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	56	39	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					813	826		10.1038/sj.onc.1209125	http://dx.doi.org/10.1038/sj.onc.1209125			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205639				2022-12-28	WOS:000235212700001
J	Gespach, C				Gespach, C			Crosstalk between the cell cycle regulator Cdk2 and the Cdx2 tumor suppressor at the proliferation-differentiation interface	ONCOGENE			English	Editorial Material									Univ Paris 06, INSERM U673, Hop St Antoine, F-75571 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Gespach, C (corresponding author), Univ Paris 06, INSERM U673, Hop St Antoine, 12 Rue Cuvier, F-75571 Paris, France.	christian.gespach@st-antoine.inserm.fr						Boulanger J, 2005, J BIOL CHEM, V280, P18095, DOI 10.1074/jbc.M502184200; GROSS I, 2005, ONCOGENE        0718; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659	4	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 1	2005	24	54					7953	7954		10.1038/sj.onc.1209084	http://dx.doi.org/10.1038/sj.onc.1209084			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170344				2022-12-28	WOS:000233656600001
J	Tomasini, R; Seux, M; Nowak, J; Bontemps, C; Carrier, A; Dagorn, JC; Pebusque, MJ; Iovanna, JL; Dusetti, NJ				Tomasini, R; Seux, M; Nowak, J; Bontemps, C; Carrier, A; Dagorn, JC; Pebusque, MJ; Iovanna, JL; Dusetti, NJ			TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity	ONCOGENE			English	Article						TP53INP1; p73; apoptosis; transcriptional activity	TUMOR-SUPPRESSOR P53; INDUCED PROTEIN SIP; C-ABL; P53-DEPENDENT APOPTOSIS; REGULATES P73; CANCER-CELLS; DNA-DAMAGE; EXPRESSION; P63; CISPLATIN	TP53INP1 is an alternatively spliced gene encoding two nuclear protein isoforms (TP53INP1 alpha and TP53INP1 beta), whose transcription is activated by p53. When overexpressed, both isoforms induce cell cycle arrest in G1 and enhance p53-mediated apoptosis. TP53INP1s also interact with the p53 gene and regulate p53 transcriptional activity. We report here that TP53INP1 expression is induced during experimental acute pancreatitis in p53(-/-) mice and in cisplatin-treated p53(-/-) mouse embryo fibroblasts (MEFs). We demonstrate that ectopic expression of p73, a p53 homologue, leads to TP53INP1 induction in p53-deficient cells. In turn, TP53INP1s alters the transactivation capacity of p73 on several p53-target genes, including TP53INP1 itself, demonstrating a functional association between p73 and TP53INP1s. Also, when overexpressed in p53-deficient cells, TP53INP1s inhibit cell growth and promote cell death as assessed by cell cycle analysis and colony formation assays. Finally, we show that TP53INP1s potentiate the capacity of p73 to inhibit cell growth, that effect being prevented when the p53 mutant R175H is expressed or when p73 expression is blocked by a siRNA. These results suggest that TP53INP1s are functionally associated with p73 to regulate cell cycle progression and apoptosis, independently from p53.	Univ Mediterranee, IFR 137,Inst Cancerol & Immunol Marseille, INSERM, U624, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Dusetti, NJ (corresponding author), Univ Mediterranee, IFR 137,Inst Cancerol & Immunol Marseille, INSERM, U624, Parc Sci & Technol Luminy,Case 915, F-13288 Marseille, France.	dusetti@marseille.inserm.fr	tomasini, richard/F-1130-2017; Dusetti, Nelson/O-7919-2017; Iovanna, Juan/M-9805-2017	tomasini, richard/0000-0003-0869-0811; Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Das S, 2003, ONCOGENE, V22, P8394, DOI 10.1038/sj.onc.1206908; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dusetti NJ, 2000, BIOCHEM BIOPH RES CO, V277, P660, DOI 10.1006/bbrc.2000.3734; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Hamer G, 2001, ONCOGENE, V20, P4298, DOI 10.1038/sj.onc.1204568; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; MIYASHITA T, 1995, CELL, V80, P293; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Oniscu A, 2004, J CLIN PATHOL, V57, P492, DOI 10.1136/jcp.2003.012559; Rodicker F, 2003, CANCER RES, V63, P2737; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Shinbo J, 2002, BIOCHEM BIOPH RES CO, V295, P501, DOI 10.1016/S0006-291X(02)00707-6; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Tsuji K, 2002, J BIOL CHEM, V277, P2951, DOI 10.1074/jbc.M108535200; Tullo A, 2003, ONCOGENE, V22, P8738, DOI 10.1038/sj.onc.1206967; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	40	107	115	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8093	8104		10.1038/sj.onc.1208951	http://dx.doi.org/10.1038/sj.onc.1208951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16044147				2022-12-28	WOS:000233809400002
J	Vega, MI; Huerta-Yepez, S; Jazirehi, AR; Garban, H; Bonavida, B				Vega, MI; Huerta-Yepez, S; Jazirehi, AR; Garban, H; Bonavida, B			Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis	ONCOGENE			English	Article						non-Hodgkin's lymphoma; Fas; NF-kappa B; YY1; sensitization	NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; IN-VIVO; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; MONOCLONAL-ANTIBODY; DOWN-REGULATION; UP-REGULATION	Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase-polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab- induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor kappa of B cells (NF-kappa B) activity. The involvement of NF-kappa B and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-kappa B (Ramos I kappa B-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab- mediated inhibition of the p38 MAPK/NF-kappa B/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonnson Comprehens Canc Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Garban, Hermes/0000-0001-7754-5357; Vega, Mario I/0000-0002-3932-2483	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alas S, 2001, CLIN CANCER RES, V7, P709; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; Emmanouilides C, 2003, HEMATOL ONCOL, V21, P99, DOI 10.1002/hon.712; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HONGO F, 2004, 95 ANN M AM ASS CANC, V45, P105; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2005, CANCER RES, V65, P264; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Ogasawara T, 2003, INT J HEMATOL, V77, P364, DOI 10.1007/BF02982645; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; REFF ME, 1994, BLOOD, V83, P435; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336	31	81	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8114	8127		10.1038/sj.onc.1208954	http://dx.doi.org/10.1038/sj.onc.1208954			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16103877				2022-12-28	WOS:000233809400004
J	Su, ZZ; Emdad, L; Sauane, M; Lebedeva, IV; Sarkar, D; Gupta, P; James, CD; Randolph, A; Valerie, K; Walter, MR; Dent, P; Fisher, PB				Su, ZZ; Emdad, L; Sauane, M; Lebedeva, IV; Sarkar, D; Gupta, P; James, CD; Randolph, A; Valerie, K; Walter, MR; Dent, P; Fisher, PB			Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells	ONCOGENE			English	Article						cancer gene therapy; apoptosis; radiation sensitization; tumor cell invasion; diffusion bystander assay; normal-cell-secreted mda-7/IL-24	DIFFERENTIATION-ASSOCIATED GENE-7; APOPTOSIS INDUCING CYTOKINE; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; PANCREATIC-CANCER; MDA-7 GENE; IN-VITRO; SUBTRACTION HYBRIDIZATION; GLIOMA-CELLS; ENHANCES RADIOSENSITIVITY	Melanoma differentiation associated gene-7 (mda-7) was cloned using subtraction hybridization from terminally differentiated human melanoma cells. Based on structural and functional properties, mda-7 is now recognized as interleukin-24 (IL-24), a new member of the expanding IL-10 gene family. Unique properties of mda-7/IL-24 include its ability to selectively induce growth suppression, apoptosis and radiosensitization in diverse human cancer cells, without causing similar effects in normal cells. The utility of mda-7/IL-24, administered by means of a replication-incompetent adenovirus, as a gene therapy for cancer has recently received validation in patients, highlighting an important phenomenon initially observed in pancreatic tumor cells, namely a 'potent bystander apoptosis-inducing effect' in adjacent tumor cells not initially receiving this gene product. We presently investigated the contribution of mda-7/IL-24 secreted by normal cells in mediating this 'bystander effect', and document that normal cells induced to produce mda-7/IL-24 following infection with recombinant adenoviruses expressing this cytokine secrete mda-7/IL-24, which modifies the anchorage-independent growth, invasiveness, survival and sensitivity to radiation of cancer cells that contain functional IL-20/IL-22 receptors, but not in cancer cells that lack a complete set of receptors. Moreover, the combination of secreted mda-7/IL-24 and radiation engenders a 'bystander antitumor effect' not only in inherently mda-7/IL-24 or radiation-sensitive cancer cells, but also in tumor cells overexpressing the antiapoptotic proteins bcl-2 or bcl-xL and displaying resistance to either treatment alone. The present studies provide definitive evidence that secreted mda-7/IL-24 from normal cells can induce direct antitumor and radiation-enhancing effects that are dependent on the presence of canonical receptors for this cytokine on tumor cells. Moreover, we now describe a novel means of enhancing mda-7/IL-24's therapeutic potential by targeting normal cells to produce and release this cancer-specific apoptosis-inducing cytokine, a strategy that could be employed as an innovative way of using this unique gene product for treating metastatic disease.	Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pathol,Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Neurosurg, New York, NY 10032 USA; Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY 10032 USA	Columbia University; Mayo Clinic; Virginia Commonwealth University; University of Alabama System; University of Alabama Birmingham; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pathol,Herbert Irving Comprehens Canc Ctr, 630 W 168th St,Black Bldg,Rm 1501, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008; James, Charles D/E-2721-2012; Valerie, Kristoffer/AAL-8299-2021	Lebedeva, Irina V/0000-0002-1693-9392; James, Charles D/0000-0002-1027-203X; 	NATIONAL CANCER INSTITUTE [R01CA097318, P01CA104177, R01CA088906, R01CA098712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA098712, CA097318, CA088906, CA104177] Funding Source: Medline; NIAID NIH HHS [AI47300] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chada S, 2005, MOL THER, V11, P724, DOI 10.1016/j.ymthe.2004.12.021; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Emdad L, 2005, J CELL PHYSIOL, V202, P135, DOI 10.1002/jcp.20097; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Frank DK, 1998, CLIN CANCER RES, V4, P2521; Gazdar AF, 2001, P NATL ACAD SCI USA, V98, P10028, DOI 10.1073/pnas.191379998; Gopalkrishnan RV, 2004, INT IMMUNOPHARMACOL, V4, P635, DOI 10.1016/j.intimp.2004.01.015; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Hruban RH, 2001, CANCER J, V7, P251; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MELBER K, 1989, CANCER RES, V49, P3650; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Nishikawa T, 2004, MOL THER, V9, P818, DOI 10.1016/j.ymthe.2004.03.014; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; PESTKA S, 2003, ENCY HORMONES, P507; Ramesh R, 2004, MOL THER, V9, P510, DOI 10.1016/j.ymthe.2004.01.019; RAMESH R, 2003, CANCER RES, V63, P5113; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Sauane M, 2004, CANCER RES, V64, P2988, DOI 10.1158/0008-5472.CAN-04-0200; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Su ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623	58	125	136	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7552	7566		10.1038/sj.onc.1208911	http://dx.doi.org/10.1038/sj.onc.1208911			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044151				2022-12-28	WOS:000233333800005
J	Ghosh, MK; Sharma, P; Harbor, PC; O Rahaman, S; Haque, SJ				Ghosh, MK; Sharma, P; Harbor, PC; O Rahaman, S; Haque, SJ			PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells	ONCOGENE			English	Article						glioblastoma multiforme; apoptosis; Stat3; AKT; EGFR	EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR RECEPTOR GENE; CONSTITUTIVE ACTIVATION; MOLECULAR-MECHANISMS; MALIGNANT GLIOMA; PHOSPHATASE 2A; EXPRESSION; APOPTOSIS; TYROSINE	Glioblastoma multiforme (GBM) cells frequently harbor amplification and/or gain-of-function mutation of the EGFR gene leading to the activation of mul tiple signaling pathways. Blockade of EGFR activation inhibited the activation of both AKT and Stat3 in U87 and D54 GBM cells and induced spontaneous apoptosis, which were associated with reduction in the steady-state level of Mcl-1. Surprisingly, inhibition of PI3 kinase (PI3K) activity, which in turn inhibited AKT activation, significantly increased the DNA-binding activity of Stat3 in U87 and D54 cells. This was not due to an increase in the level of tyrosine-phosphorylated Stat3. Conversely, ectopic expression of constitutively activated AKT significantly decreased the DNA-binding activity of Stat3 in 293T cells. Interestingly, blockade of protein phosphatase 2A activity in GBM or 293T cells by calyculin A, which activated AKT, stabilized the phosphorylation of mul tiple Ser/Thr residues that were located in the transactivation domain (TAD) of Stat3 and this in turn completely ablated the DNA-binding activity of Stat3. Collectively, these results suggest that both Stat3 and AKT provide survival signals in U87 and D54 cells, and Ser/Thr phosphorylation of Stat3-TAD by the PI3K-AKT pathway negatively controls the DNA-binding function of Stat3.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Brain Tumor Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, NB4-85,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@ccf.org	Sharma, Pankaj/AAH-7468-2019; sharma, pankaj/HGE-4423-2022	Sharma, Pankaj/0000-0001-7405-1706; 	NATIONAL CANCER INSTITUTE [R01CA095006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA095006] Funding Source: Medline; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Goswami S, 1998, J NEUROCHEM, V71, P1837; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAITI NR, 2005, IN PRESS J INTERFERO; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; VAN MEIR E, 1990, CANCER RES, V50, P6683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	52	46	52	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7290	7300		10.1038/sj.onc.1208894	http://dx.doi.org/10.1038/sj.onc.1208894			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007122				2022-12-28	WOS:000233142100005
J	Kumar, RN; Shore, SK; Dhanasekaran, N				Kumar, RN; Shore, SK; Dhanasekaran, N			Neoplastic transformation by the gep oncogene, G alpha(12), involves signaling by STAT3	ONCOGENE			English	Article						gep; G alpha(12); STAT3; transformation; JAK3; PDGFR alpha	N-TERMINAL KINASE; PROTEIN-KINASE; CONSTITUTIVE ACTIVATION; SERINE PHOSPHORYLATION; MAXIMAL ACTIVATION; ALPHA-SUBUNIT; HUMAN OVARIAN; C-DELTA; SRC; GROWTH	G alpha(12), the alpha-subunit of G12, which has been referred to as the gep oncogene, stimulates mitogenic pathways in different cell types and readily induces neoplastic transformation of. fibroblast cell lines. Recently, we have shown that the oncogenic pathway activated by G alpha(12) involves the receptor tyrosine kinase platelet derived growth factor receptor-alpha ( PDGFR alpha) and JAK3. In the present study, we demonstrate that the GTPase-deficient activated mutant of G alpha(12) activates signal transducer and activator of transcription 3 (STAT3) via PDGFRa as well as JAK3. Here we show that G alpha(12) stimulates the phosphorylation of STAT3 at both Tyrosine-705 and Serine-727 residues. Studies to delineate the mechanism by which G alpha(12) stimulates STAT3 have indicated that the Tyrosine-705-phosphorylation of STAT3 involves the tyrosine kinases, Janus Kinase-3 as well as Src kinase, whereas the Serine-727 phosphorylation of STAT3 occurs via the receptor tyrosine kinase, PDGFRa and phosphatidylinositol 3-OH kinase pathway. Our results also indicate that the coexpression of the dominant negative, DNA binding mutant of STAT3 (STAT3DB) inhibits the foci formation as well as anchorage- independent growth of G alpha(12)QL-transfectants, thereby establishing the critical role of STAT3 in G alpha(12)QL-mediated neoplastic cell growth. The results presented here demonstrate, for the. rst time, the ability of G alpha(12) to recruit multiple receptor-, nonreceptor-, and Ser/Thr kinases to stimulate STAT3-signaling to promote neoplastic transformation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,556 AHB, Philadelphia, PA 19140 USA.	danny001@temple.edu			NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berclaz G, 2001, INT J ONCOL, V19, P1155; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Kumar RN, 2004, CELL BIOCHEM BIOPHYS, V41, P63, DOI 10.1385/CBB:41:1:063; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Pedranzini L, 2004, J CLIN INVEST, V114, P619, DOI 10.1172/JCI200422800; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Sambrook J., 2001, MOL CLONING LAB MANU; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; SHORE SK, 1989, ONCOGENE, V4, P1411; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200	47	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					899	906		10.1038/sj.onc.1209132	http://dx.doi.org/10.1038/sj.onc.1209132			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247467				2022-12-28	WOS:000235212700009
J	Pickering, MT; Kowalik, TF				Pickering, MT; Kowalik, TF			Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation	ONCOGENE			English	Article						Rb inactivation; double-strand breaks; DSBs; E2F1; c-Myc	S-PHASE; C-MYC; DAMAGE CHECKPOINT; HISTONE H2AX; APOPTOSIS; E2F1; PHOSPHORYLATION; INSTABILITY; CELLS; P53	Although it is unclear which cellular factor(s) is responsible for the genetic instability associated with initiating and sustaining cell transformation, it is known that many cancers have mutations that inactivate the Rb-mediated proliferation pathway. We show here that pRb inactivation and the resultant deregulation of one E2F family member, E2F1, leads to DNA double-strand break (DSB) accumulation in normal diploid human cells. These DSBs occur independent of Atm, p53, caspases, reactive oxygen species, and apoptosis. Moreover, E2F1 does not contribute to c-Myc-associated DSBs, indicating that the DSBs associated with these oncoproteins arise through distinct pathways. We also find E2F1-associated DSBs in an Rb mutated cancer cell line in the absence of an exogenous DSB stimulus. These basal, E2F1-associated DSBs are not observed in a p16(ink4a) inactivated cancer cell line that retains functional pRb, unless pRb is depleted. Thus, Rb status is key to regulating both the proliferation promoting functions associated with E2F and for preventing DNA damage accumulation if E2F1 becomes deregulated. Taken together, these data suggest that loss of Rb creates strong selective pressure, via DSB accumulation, for inactivating p53 mutations and that E2F1 contributes to the genetic instability associated with transformation and tumorigenesis.	Univ Massachusetts, Med Ctr, Sch Med, Program Immunol & Virol,Dept Mol Genet & Microbio, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Kowalik, TF (corresponding author), Univ Massachusetts, Med Ctr, Sch Med, Program Immunol & Virol,Dept Mol Genet & Microbio, Room S5-216,55 Lake Ave N, Worcester, MA 01655 USA.	timothy.kowalik@umassmed.edu		Pickering, Mary/0000-0002-0515-7248	NATIONAL CANCER INSTITUTE [R01CA086038] Funding Source: NIH RePORTER; NCI NIH HHS [CA86038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Duensing S, 2002, CANCER RES, V62, P7075; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OLIVE PL, 1991, CANCER RES, V51, P4671; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Powers JT, 2004, MOL CANCER RES, V2, P203; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	27	89	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					746	755		10.1038/sj.onc.1209103	http://dx.doi.org/10.1038/sj.onc.1209103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186801				2022-12-28	WOS:000235068800010
J	Faust, D; Dolado, I; Cuadrado, A; Oesch, F; Weiss, C; Nebreda, AR; Dietrich, C				Faust, D; Dolado, I; Cuadrado, A; Oesch, F; Weiss, C; Nebreda, AR; Dietrich, C			P38 alpha MAPK is required for contact inhibition	ONCOGENE			English	Article						contact inhibition; p38 MAPK; fibroblasts	CELL-CYCLE ARREST; PLASMA-MEMBRANE GLYCOPROTEINS; DEPENDENT INHIBITION; PROTEIN-KINASE; HUMAN-FIBROBLASTS; GROWTH; ACTIVATION; PATHWAY; SIGNAL; D1	Proliferation of nontransformed cells is regulated by cell cell contacts, which are referred to as contact-inhibition. Despite its generally accepted importance for cell cycle control, knowledge about the intracellular signalling pathways involved in contact inhibition is scarce. In the present work we show that p38 alpha mitogen-activated protein kinase (MAPK) is involved in the growth-inhibitory signalling cascade of contact inhibition in fibroblasts. p38 alpha activity is increased in confluent cultures of human fibroblasts compared to proliferating cultures. Time course studies show a sustained activation of p38 alpha in response to cell-cell contacts in contrast to a transient activation after serum stimulation. The induction of contact inhibition by addition of glutaraldehyde-fixed cells is impaired by pharmacological inhibition of p38 as well as in p38 alpha-/- fibroblasts. Further evidence for a central role of p38a in contact inhibition comes from the observation that p38 alpha-/- fibroblasts show a higher saturation density compared to wild-type (wt) fibroblasts, which is reversed by reconstituted expression of p38 alpha. In agreement with a defect in contact inhibition, p27(Kip1) accumulation is impaired in p38 alpha-/- fibroblasts compared to wt fibroblasts. Hence, our work shows a new role for p38 alpha in contact inhibition and provides a mechanistic basis for the recently proposed tumour suppressive function of this MAPK pathway.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; CNIO, Spanish Natl Canc Ctr, Madrid 28029, Spain	Johannes Gutenberg University of Mainz; Centro Nacional de Investigaciones Oncologicas (CNIO)	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.	cdietric@uni-mainz.de	Weiss, Carsten/I-1811-2013; Nebreda, Angel Rodriguez/R-9594-2019; Cuadrado, Ana/AAA-9277-2019; Cuadrado, Ana/HGU-4777-2022; Oesch, Franz/AAA-8746-2020	Weiss, Carsten/0000-0002-5380-3208; Cuadrado, Ana/0000-0002-9752-5932; 				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; Haq R, 2002, CANCER RES, V62, P5076; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Nakatsuji Y, 1998, GLIA, V22, P379, DOI 10.1002/(SICI)1098-1136(199804)22:4<379::AID-GLIA7>3.0.CO;2-Z; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; OESCH F, 1987, EUR J CELL BIOL, V43, P403; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WIESER RJ, 1995, GLYCOCONJUGATE J, V12, P672, DOI 10.1007/BF00731264	33	59	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7941	7945		10.1038/sj.onc.1208948	http://dx.doi.org/10.1038/sj.onc.1208948			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027723	Bronze			2022-12-28	WOS:000233463000013
J	Sander, S; Bullinger, L; Karlsson, A; Giuriato, S; Hernandez-Boussard, T; Felsher, DW; Pollack, JR				Sander, S; Bullinger, L; Karlsson, A; Giuriato, S; Hernandez-Boussard, T; Felsher, DW; Pollack, JR			Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model	ONCOGENE			English	Article						array CGH; microarray; mouse model; lymphoma; expression profiling	COPY-NUMBER CHANGES; CYTOGENETIC ANALYSIS; RESOLUTION; CANCER; TUMOR; EXPRESSION; ONCOGENES; SURVIVAL; REVEALS; MCL-1	Microarray-based formats offer a high-resolution alternative to conventional, chromosome-based comparative genomic hybridization (CGH) methods for assessing DNA copy number alteration (CNA) genome-wide in human cancer. For murine tumors, array CGH should provide even greater advantage, since murine chromosomes are more difficult to individually discern. We report here the adaptation and evaluation of a cDNA microarray-based CGH method for the routine characterization of CNAs in murine tumors, using mouse cDNA microarrays representing similar to 14 000 different genes, thereby providing an average mapping resolution of 109 kb. As a first application, we have characterized CNAs in a set of 10 primary and recurrent lymphomas derived from a Myc-induced murine lymphoma model. In primary lymphomas and more commonly in Myc- independent relapses, we identified a recurrent genomic DNA loss at chromosome 3G3-3H4, and recurrent amplifications at chromosome 3F2.1-3G3 and chromosome 15E1/ E2 - 15F3, the boundaries of which we defined with high resolution. Further, by pro. ling gene expression using the same microarray platform, we identifed within CNAs the relevant subset of candidate cancer genes displaying comparably altered expression, including Mcl1 ( myeloid cell leukemia sequence 1), a highly expressed antiapoptotic gene residing within the chr 3 amplicon peak. CGH on mouse cDNA microarrays therefore represents a reliable method for the high-resolution characterization of CNAs in murine tumors, and a powerful approach for elucidating the molecular events in tumor development and progression in murine models.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Med Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany	Stanford University; Stanford University; Stanford University; Ulm University	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR Bldg,Room 3245Am 269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Bullinger, Lars/AAL-7965-2020; Giuriato, Sylvie/A-9113-2010	Giuriato, Sylvie/0000-0003-3274-3397; Bullinger, Lars/0000-0002-5890-5510; Sander, Sandrine/0000-0003-4645-3366	NCI NIH HHS [CA97139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Cho-Vega JH, 2004, HUM PATHOL, V35, P1095, DOI 10.1016/j.humpath.2004.04.018; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Coleman AE, 1999, LEUKEMIA, V13, P1592, DOI 10.1038/sj.leu.2401518; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Giuriato S, 2004, SEMIN CANCER BIOL, V14, P3, DOI 10.1016/j.semcancer.2003.11.002; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Hackett CS, 2003, CANCER RES, V63, P5266; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jackson-Grusby L, 2002, ONCOGENE, V21, P5504, DOI 10.1038/sj.onc.1205603; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li JZ, 2004, NAT GENET, V36, P952, DOI 10.1038/ng1417; Lichter P, 2000, SEMIN HEMATOL, V37, P348, DOI 10.1053/shem.2000.16594; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; O'Hagan RC, 2003, CANCER RES, V63, P5352; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pollack JR, 2002, NAT GENET, V32, P515, DOI 10.1038/ng1035; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Vrana JA, 2002, CANCER RES, V62, P892; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	36	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6101	6107		10.1038/sj.onc.1208751	http://dx.doi.org/10.1038/sj.onc.1208751			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007205				2022-12-28	WOS:000231718100004
J	Cordes, N; Seidler, J; Durzok, R; Geinitz, H; Brakebusch, C				Cordes, N; Seidler, J; Durzok, R; Geinitz, H; Brakebusch, C			beta 1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury	ONCOGENE			English	Article						beta 1-integrin; ECM; Akt; PI3K; p130Cas; ionizing radiation	FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; HUMAN-TUMOR; INTEGRINS; GROWTH; FAK; EXPRESSION; PROTEINS; MICROENVIRONMENT	Integrin-mediated adhesion to extracellular matrix proteins confers resistance to radiation- or drug-induced genotoxic injury. To analyse the underlying mechanisms specific for beta 1-integrins, wild-type beta 1A-integrin-expressing GD25 beta 1A cells were compared to GD25 beta 1B cells, which express signaling-incompetent beta 1B variants. Cells grown on fibronectin, collagen-III, beta 1-integrin-IgG or poly-l-lysine were exposed to 0-6 Gy X-rays in presence or depletion of growth factors and phosphatidylinositol-3 kinase (PI3K) inhibitors (LY294002, wortmannin). In order to test the relevance of these findings in tumor cells, human A-172 glioma cells were examined under the same conditions after siRNA-mediated silencing of beta 1-integrins. We found that beta 1A-integrin-mediated adhesion to fibronectin, collagen-III or beta 1-IgG was essential for cell survival after radiation- induced genotoxic injury. Mediated by PI3K, pro-survival beta 1A-integrin/Akt signaling was critically involved in this process. Additionally, the beta 1-integrin downstream targets p130Cas and paxillin-impaired survival-regulating PI3K-dependent JNK. In A-172 glioma cells, beta 1-integrin knockdown and PI3K inhibition confirmed the central role of beta 1-integrins in Akt- and p130Cas/paxillin-mediated prosurvival signaling. These findings suggest beta 1-integrins as critical regulators of cell survival after radiation- induced genotoxic injury. Elucidation of the molecular circuitry of prosurvival beta 1-integrin-mediated signaling in tumor cells may promote the development of innovative molecular-targeted therapeutic antitumor strategies.	Tech Univ Dresden, Med Fac, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Tech Univ, Klinikum Isar, Dept Radiat Oncol, Munich, Germany; Max Planck Inst Biochem, Dept Mol Med, Martinsried, Germany	Technische Universitat Dresden; Technical University of Munich; Max Planck Society	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac, Fetscherstr 74-PF 86, D-01307 Dresden, Germany.	Nils.Cordes@mailbox.tu-dresden.de		Cordes, Nils/0000-0001-5684-629X; Brakebusch, Cord/0000-0002-9342-1634				Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Armulik A, 2000, EXP CELL RES, V254, P55, DOI 10.1006/excr.1999.4722; Armulik A, 2002, FRONT BIOSCI-LANDMRK, V7, pD219, DOI 10.2741/armulik; Barcellos-Hoff MH, 2001, J MAMMARY GLAND BIOL, V6, P213, DOI 10.1023/A:1011317009329; Beinke C, 2003, INT J RADIAT BIOL, V79, P721, DOI 10.1080/09553000310001610231; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cook JA, 2004, SEMIN RADIAT ONCOL, V14, P259, DOI 10.1016/j.semradonc.2004.04.001; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2003, BRIT J CANCER, V89, P2122, DOI 10.1038/sj.bjc.6601429; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Oguey D, 2000, GENE THER, V7, P1292, DOI 10.1038/sj.gt.3301236; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Unger Meredith, 2003, Methods Mol Biol, V223, P315; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	46	130	132	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1378	1390		10.1038/sj.onc.1209164	http://dx.doi.org/10.1038/sj.onc.1209164			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247454				2022-12-28	WOS:000235708200011
J	He, YY; Huang, JL; Chignell, CF				He, YY; Huang, JL; Chignell, CF			Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization	ONCOGENE			English	Article						EGFR; caspase; apoptosis; internalization	DOWN-REGULATION; HUMAN KERATINOCYTES; KINASE-ACTIVITY; CELL-DEATH; ACTIVATION; CANCER; UVA; CHOLESTEROL	Epidermal growth factor receptor ( EGFR) plays a critical role in cell proliferation, differentiation, and transformation. EGFR downregulation attenuates its signaling intensity and duration to maintain cellular homeostasis. Here, we report that during apoptosis EGFR is cleaved by activated caspase-3 or related proteases at its C-terminus domain. EGFR downregulation by activation of caspases is neither stimulus- nor cell type-specific. EGFR internalization during apoptosis required dynamin and cholesterol since dominant-negative dynamin (K44A) or cholesterol depletion by methyl-beta-cyclodextrin prevented EGFR internalization. However, EGFR downregulation did not require its internalization. The EGFR cleavage fragment was detected in the membrane blebs in addition to the cell pellets. Mutations at the consensus sequence (DXXD) at the C-terminus domain revealed that DVVD1012 and to a lesser extent DNPD1172 may be target sites for active recombinant caspase-3 in vitro and activated caspase-3 or related proteases in vivo. We have detected the N-terminus and C-terminus fragments in vitro and in vivo. A cleavage-deficient EGFR mutant delayed apoptosis process. We conclude that the evolutionarily conserved C-terminus domain of EGFR is the target of caspases and subjected to degradation during apoptosis to shut down its signaling.	NIEHS, Chem Pharmacol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Chem Pharmacol Lab, NIH, MD F0-06,111 Alexander Dr,PO 12233, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050046, Z01ES050046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akunda JK, 2004, FASEB J, V18, P185, DOI 10.1096/fj.02-1192fje; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; HELDIN CH, 1979, NATURE, V282, P419, DOI 10.1038/282419a0; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Nusbaum P, 2005, J BIOL CHEM, V280, P5843, DOI 10.1074/jbc.M413405200; Park IC, 2000, INT J ONCOL, V16, P1243; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rowinsky EK, 2004, ANNU REV MED, V55, P433, DOI 10.1146/annurev.med.55.091902.104433; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	29	43	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1521	1531		10.1038/sj.onc.1209184	http://dx.doi.org/10.1038/sj.onc.1209184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247443				2022-12-28	WOS:000235890400009
J	Essayem, S; Kovacic-Milivojevic, B; Baumbusch, C; McDonagh, S; Dolganov, G; Howerton, K; Larocque, N; Mauro, T; Ramirez, A; Ramos, DM; Fisher, SJ; Jorcano, JL; Beggs, HE; Reichardt, LF; Ilic, D				Essayem, S; Kovacic-Milivojevic, B; Baumbusch, C; McDonagh, S; Dolganov, G; Howerton, K; Larocque, N; Mauro, T; Ramirez, A; Ramos, DM; Fisher, SJ; Jorcano, JL; Beggs, HE; Reichardt, LF; Ilic, D			Hair cycle and wound healing in mice with a keratinocyte-restricted deletion of FAK	ONCOGENE			English	Article						FAK; wound healing; hair; migration; proliferation; keratinocytes; stem cells	FOCAL ADHESION KINASE; STEM-CELLS; GROWTH-FACTOR; IN-VITRO; EXPRESSION; DIFFERENTIATION; ACTIVATION; MIGRATION; SKIN; BETA-1-INTEGRINS	Focal adhesion kinase (FAK) is a critical component in transducing signals downstream of both integrins and growth factor receptors. To determine how the loss of FAK affects the epidermis in vivo, we have generated a mouse model with a keratinocyte-restricted deletion of fak (FAK(K5 KO) mice). FAKK5 KO mice displayed three major phenotypes-irregularities of hair cycle, sebaceous glands hypoplasia, and a thinner epidermis-pointing to defects in the proliferative capacity of multipotent stem cells found in the bulge. FAK-null keratinocytes in conventional primary culture undergo massive apoptosis hindering further analyses, whereas the defects observed in vivo do not shorten the mouse lifespan. These results suggest that the structure and the signaling environment of the native tissue may overcome the lack of signaling through FAK. Our findings point to the importance of in vivo and three-dimensional in vitro models in analyses of cell migration, proliferation, and survival. Surprisingly, the difference between FAK(loxP/+) and FAK(K5) (KO) mice in wound closure was not statistically significant, suggesting that in vivo loss of FAK does not affect migration/proliferation of basal keratinocytes in the same way as it affects multipotent stem cells of the skin.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pulm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; CIEMAT, Dept Epithelial Damage, Repair & Tissue Engn Program, E-28040 Madrid, Spain; Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ilic, D (corresponding author), StemLifeLine Inc, 1300 Ind Rd,13, San Carlos, CA 94070 USA.	dilic@stemlifeline.com	Ramirez, Angel/A-4800-2018	Ramirez, Angel/0000-0001-7745-5108; ILIC, DUSKO/0000-0003-1647-0026	NCI NIH HHS [CA87652, K01 CA087652] Funding Source: Medline; NCRR NIH HHS [C06 RR016490, C06RR16490] Funding Source: Medline; NINDS NIH HHS [R01 NS019090-25, R01 NS019090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA087652] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR016490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Cary LA, 1996, J CELL SCI, V109, P1787; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Cui CY, 2003, HUM MOL GENET, V12, P2931, DOI 10.1093/hmg/ddg325; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FURUTA Y, 1995, ONCOGENE, V11, P1989; Grose R, 2002, DEVELOPMENT, V129, P2303; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2001, CANCER RES, V61, P7079; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Ma DR, 2004, ANN ACAD MED SINGAP, V33, P784; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morasso MI, 2005, BIOL CELL, V97, P173; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	43	46	47	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1081	1089		10.1038/sj.onc.1209130	http://dx.doi.org/10.1038/sj.onc.1209130			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247468	Green Accepted			2022-12-28	WOS:000235361000012
J	Muhlisch, J; Schwering, A; Grotzer, M; Vince, GH; Roggendorf, W; Hagemann, C; Sorensen, N; Rickert, CH; Osada, N; Jurgens, H; Fruhwald, MC				Muhlisch, J; Schwering, A; Grotzer, M; Vince, GH; Roggendorf, W; Hagemann, C; Sorensen, N; Rickert, CH; Osada, N; Jurgens, H; Fruhwald, MC			Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoit tumors (AT/RT) of childhood	ONCOGENE			English	Article						brain tumors; epigenetics; methylation; childhood; sPNET; AT/ RT	COMPARATIVE GENOMIC HYBRIDIZATION; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; ABERRANT PROMOTER METHYLATION; MOLECULAR ANALYSIS; PEDIATRIC TUMORS; SUPPRESSOR GENE; EXPRESSION; HYPERMETHYLATION; MEDULLOBLASTOMAS	Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood. Epigenetic changes hold great potential as possible disease mechanisms and may be manipulated therapeutically. We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR. In all, 17 samples of autopsy-derived normal appearing brain served as controls. Opposed to control tissues 19/24 sPNET and 4/6 AT/RT demonstrated aberrant methylation for the RASSF1A promoter region. Treatment of cell lines using 5-Aza-2'-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. A 5'-CpG-rich region of CASP8 was methylated in normal tissues and in tumors. However, CASP8 showed inconsistent expression patterns in normal and tumor tissues. Our results indicate that aberrant methylation of the RASSF1A promoter region maybe of importance in the origin and progression of sPNET and AT/RT while the analysed 5'-CpG rich region of the CASP8 gene does not seem to play an important role in these tumors. Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.	Univ Munster, Childrens Hosp, Dept Paediat Haematol & Oncol, D-48149 Munster, Germany; Univ Zurich, Childrens Hosp, Zurich, Switzerland; Univ Hosp Wuerzburg, Dept Neurosurg, Wurzburg, Germany; Univ Hosp Wuerzburg, Inst Neuropathol, Wurzburg, Germany; Univ Hosp Munster, Inst Neuropathol & Pathol, Munster, Germany; Univ Munster, Dept Med Informat & Biomath, Munster, Germany	University of Munster; University Children's Hospital Zurich; University of Zurich; University of Wurzburg; University of Wurzburg; University of Munster; University of Munster	Fruhwald, MC (corresponding author), Univ Munster, Childrens Hosp, Dept Paediat Haematol & Oncol, Albert Schweitzer Str 33, D-48149 Munster, Germany.	fruhwald@uni-muenster.de	Hagemann, Carsten/AAC-8037-2019	Grotzer, Michael/0000-0002-1154-2732; Vince, Giles/0000-0002-0222-8733				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; BIEGEL JA, 1992, GENE CHROMOSOME CANC, V5, P104, DOI 10.1002/gcc.2870050203; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2004, CLIN CANCER RES, V10, P2997, DOI 10.1158/1078-0432.CCR-03-0083; Fruhwald MC, 2002, MOL GENET METAB, V75, P1, DOI 10.1006/mgme.2001.3265; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Fruhwald MC, 2000, J MED GENET, V37, P501, DOI 10.1136/jmg.37.7.501; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Harada K, 2002, CANCER RES, V62, P5897; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; KELLY WK, 2005, J CLIN ONCOL, V16, P16; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kortmann RD, 2000, INT J RADIAT ONCOL, V46, P269, DOI 10.1016/S0360-3016(99)00369-7; Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055; Lusher ME, 2002, CANCER RES, V62, P5906; Melnick AM, 2005, J CLIN ONCOL, V23, P3957, DOI 10.1200/JCO.2005.14.498; Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Rickert CH, 2004, CHILD NERV SYST, V20, P221, DOI 10.1007/s00381-003-0909-8; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scheurlen WG, 1998, J CLIN ONCOL, V16, P2478, DOI 10.1200/JCO.1998.16.7.2478; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Zhang F, 2002, GENE CHROMOSOME CANC, V34, P398, DOI 10.1002/gcc.10078; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	31	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1111	1117		10.1038/sj.onc.1209137	http://dx.doi.org/10.1038/sj.onc.1209137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16186793				2022-12-28	WOS:000235361000015
J	Saha, T; Vardhini, D; Tang, Y; Katuri, V; Jogunoori, W; Volpe, EA; Haines, D; Sidawy, A; Zhou, X; Gallicano, I; Schlegel, R; Mishra, B; Mishra, L				Saha, T; Vardhini, D; Tang, Y; Katuri, V; Jogunoori, W; Volpe, EA; Haines, D; Sidawy, A; Zhou, X; Gallicano, I; Schlegel, R; Mishra, B; Mishra, L			RING finger-dependent ubiquitination by PRAJA is dependent on TGF-beta and potentially defines the functional status of the tumor suppressor ELF	ONCOGENE			English	Article						ELF; PRAJA; TGF-beta; ubiquitination; half-life	LIVER DEVELOPMENT; LIGASE ACTIVITY; PARTIAL-HEPATECTOMY; SIGNALING PATHWAY; CELL-MEMBRANE; I RECEPTOR; DEGRADATION; GROWTH; PROTEIN; CANCER	In gastrointestinal cells, biological signals for transforming growth factor-beta (TGF-beta) are transduced through transmembrane serine/threonine kinase receptors that signal to Smad proteins. Smad4, a tumor suppressor, is often mutated in human gastrointestinal cancers. The mechanism of Smad4 inactivation, however, remains uncertain and could be through E3-mediated ubiquitination of Smad4/adaptor protein complexes. Disruption of ELF (embryonic liver fodrin), a Smad4 adaptor protein, modulates TGF-beta signaling. We have found that PRAJA, a RING-H2 protein, interacts with ELF in a TGF-beta-dependent manner, with a fivefold increase of PRAJA expression and a subsequent decrease in ELF and Smad4 expression, in gastrointestinal cancer cell lines (P < 0.05). Strikingly, PRAJA manifests substantial E3-dependent ubiquitination of ELF and Smad3, but not Smad4. Delta-PRAJA, which has a deleted RING finger domain at the C terminus, abolishes ubiquitination of ELF. A stable cell line that overexpresses PRAJA exhibits low levels of ELF in comparison to a D-PRAJA stable cell line, where ELF expression is high compared to normal controls. The alteration of ELF and/or Smad4 expression and/or function in the TGF-b signaling pathway may be induced by enhancement of ELF degradation, which is mediated by a high-level expression of PRAJA in gastrointestinal cancers. In hepatocytes, half-life (t(1/2)) and rate constant for degradation (k(D)) of ELF is 1.91 hand 21.72 min(-1) when coupled with ectopic expression of PRAJA in cells stimulated by TGF-beta, compared to PRAJA-transfected unstimulated cells (t(1/2) = 4.33 hand k(D) 9.6 min(-1)). These studies reveal a mechanism for tumorigenesis whereby defects in adaptor proteins for Smads, such as ELF, can undergo degradation by PRAJA, through the ubiquitin-mediated pathway.	Georgetown Univ, Lab Dev Mol Biol, Lombardi Comprehens Canc Ctr, Dept Surg Sci, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC 20007 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA; Georgetown Univ, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Dept Pathol, Washington, DC 20007 USA; Dept Vet Affairs Med Ctr, Washington, DC USA	Georgetown University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Georgetown University; Georgetown University	Mishra, B (corresponding author), Georgetown Univ, Lab Dev Mol Biol, Lombardi Comprehens Canc Ctr, Dept Surg Sci, Med Dent Bldg,Rooms NW210-213,3900 Reservoir Rd,N, Washington, DC 20007 USA.	bm72@georgetown.edu; lm229@georgetown.edu	Volpe, Eugene A./D-2000-2012	Volpe, Eugene A./0000-0002-9128-754X; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106614-01A2] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bhanumathy CD, 2002, DEV DYNAM, V223, P59, DOI 10.1002/dvdy.1235; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Janse DM, 2004, J BIOL CHEM, V279, P21415, DOI 10.1074/jbc.M402954200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moser MJ, 2001, DIGEST DIS SCI, V46, P907, DOI 10.1023/A:1010791915733; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pan Y, 1999, CANCER RES, V59, P2064; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Wieser R, 2001, CURR OPIN ONCOL, V13, P70, DOI 10.1097/00001622-200101000-00014; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	61	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					693	705		10.1038/sj.onc.1209123	http://dx.doi.org/10.1038/sj.onc.1209123			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247473				2022-12-28	WOS:000235068800005
J	Ahuja, D; Saenz-Robles, MT; Pipas, JM				Ahuja, D; Saenz-Robles, MT; Pipas, JM			SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation	ONCOGENE			English	Review						SV40; polyomavirus; transformation; cell-type specificity	SIMIAN-VIRUS-40 LARGE-T; LARGE TUMOR-ANTIGEN; VIRAL-DNA REPLICATION; VILLUS-ASSOCIATED ENTEROCYTES; ANCHORAGE-INDEPENDENT GROWTH; METASTATIC PROSTATE-CANCER; MOUSE EMBRYO FIBROBLASTS; PRB-RELATED PROTEINS; LI-FRAUMENI-SYNDROME; TRANSGENIC MICE	DNA tumor viruses such as simian virus 40 ( SV40) express dominant acting oncoproteins that exert their effects by associating with key cellular targets and altering the signaling pathways they govern. Thus, tumor viruses have proved to be invaluable aids in identifying proteins that participate in tumorigenesis, and in understanding the molecular basis for the transformed phenotype. The roles played by the SV40-encoded 708 amino-acid large T antigen ( T antigen), and 174 amino acid small T antigen ( t antigen), in transformation have been examined extensively. These studies have firmly established that large T antigen's inhibition of the p53 and Rb-family of tumor suppressors and small T antigen's action on the pp2A phosphatase, are important for SV40-induced transformation. It is not yet clear if the Rb, p53 and pp2A proteins are the only targets through which SV40 transforms cells, or whether additional targets await discovery. Finally, expression of SV40 oncoproteins in transgenic mice results in effects ranging from hyperplasia to invasive carcinoma accompanied by metastasis, depending on the tissue in which they are expressed. Thus, the consequences of SV40 action on these targets depend on the cell type being studied. The identification of additional cellular targets important for transformation, and understanding the molecular basis for the cell type-specific action of the viral T antigens are two important areas through which SV40 will continue to contribute to our understanding of cancer.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pipas, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, 559 Crawford Hall, Pittsburgh, PA 15260 USA.	pipas@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA098956, R01CA040586, R37CA040586] Funding Source: NIH RePORTER; NCI NIH HHS [CA098956, CA40586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ali SH, 2004, J VIROL, V78, P2749, DOI 10.1128/JVI.78.6.2749-2757.2004; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; ARRINGTON AS, 2001, HUMAN POLYOMAVIRUSES, P461; Asa SL, 1996, VIRCHOWS ARCH, V427, P595; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Beachy TM, 2002, J VIROL, V76, P3145, DOI 10.1128/JVI.76.7.3145-3157.2002; BELL RH, 1990, CARCINOGENESIS, V11, P1393, DOI 10.1093/carcin/11.8.1393; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; Berjanskii MV, 2000, J BIOL CHEM, V275, P36094, DOI 10.1074/jbc.M006572200; Berkovich I, 2001, DIABETES, V50, P2260, DOI 10.2337/diabetes.50.10.2260; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CANTALUPO P, 2005, J VIROL; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CECI JD, 1991, ONCOGENE, V6, P323; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEN JD, 1991, MOL CELL BIOL, V11, P5968, DOI 10.1128/MCB.11.12.5968; Chen Q, 2004, J BIOL CHEM, V279, P17667, DOI 10.1074/jbc.M311678200; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1989, ONCOGENE, V4, P1103; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; Fewell SW, 2002, P NATL ACAD SCI USA, V99, P2002, DOI 10.1073/pnas.042670999; FISCHERFANTUZZI L, 1986, VIROLOGY, V153, P87, DOI 10.1016/0042-6822(86)90010-3; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Genevaux P, 2003, J VIROL, V77, P10706, DOI 10.1128/JVI.77.19.10706-10713.2003; Gingrich JR, 1996, CANCER RES, V56, P4096; GIRARDI AJ, 1962, P SOC EXP BIOL MED, V109, P649, DOI 10.3181/00379727-109-27298; Goodman RH, 2000, GENE DEV, V14, P1553; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; Gum JR, 2004, MOL CANCER RES, V2, P504; Gum JR, 2001, CANCER RES, V61, P3472; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Herring BP, 1999, J BIOL CHEM, V274, P17725, DOI 10.1074/jbc.274.25.17725; Hocker M, 1998, ANN NY ACAD SCI, V859, P160, DOI 10.1111/j.1749-6632.1998.tb11120.x; JIANG D, 1993, ONCOGENE, V8, P2805; Johnston SD, 1996, J VIROL, V70, P1191, DOI 10.1128/JVI.70.2.1191-1202.1996; Kasper S, 1998, LAB INVEST, V78, pI; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LEE YC, 1992, J BIOL CHEM, V267, P10705; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MANOS MM, 1984, MOL CELL BIOL, V4, P1125, DOI 10.1128/MCB.4.6.1125; Markovics JA, 2005, J VIROL, V79, P7492, DOI 10.1128/JVI.79.12.7492-7502.2005; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; Masumori N, 2001, CANCER RES, V61, P2239; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Nemethova M, 2004, MOL CELL BIOL, V24, P10986, DOI 10.1128/MCB.24.24.10986-10994.2004; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PAULUS U, 1993, J CELL SCI, V106, P473; PEDEN KWC, 1985, J VIROL, V55, P1; PEDEN KWC, 1992, VIRUS GENES, V6, P107, DOI 10.1007/BF01703060; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Poulin DL, 2004, J VIROL, V78, P8245, DOI 10.1128/JVI.78.15.8245-8253.2004; PRIVES C, 1983, MOL CELL BIOL, V3, P1958, DOI 10.1128/MCB.3.11.1958; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; Ratineau C, 2000, GASTROENTEROLOGY, V119, P1305, DOI 10.1053/gast.2000.19278; ROTH KA, 1992, AM J PHYSIOL, V263, pG174, DOI 10.1152/ajpgi.1992.263.2.G174; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Rushton JJ, 1997, J VIROL, V71, P5620, DOI 10.1128/JVI.71.7.5620-5623.1997; Sachsenmeier KF, 2001, VIROLOGY, V283, P40, DOI 10.1006/viro.2001.0866; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; SPENCE SL, 1994, VIROLOGY, V204, P200, DOI 10.1006/viro.1994.1524; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2004, VIROLOGY, V320, P218, DOI 10.1016/j.virol.2003.10.035; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997; Tevethia MJ, 1998, VIROLOGY, V243, P303, DOI 10.1006/viro.1998.9056; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Upchurch BH, 1996, DEVELOPMENT, V122, P1157; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOODS C, 1994, ONCOGENE, V9, P2943; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	143	380	410	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7729	7745		10.1038/sj.onc.1209046	http://dx.doi.org/10.1038/sj.onc.1209046			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299533				2022-12-28	WOS:000233372600009
J	Shmulevitz, M; Marcato, P; Lee, PWK				Shmulevitz, M; Marcato, P; Lee, PWK			Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer	ONCOGENE			English	Review						cancer; oncolytic virus; oncolysis; reovirus; translation; Ras	DEPENDENT PROTEIN-KINASE; VIRAL ATTACHMENT PROTEIN; HOST-CELL PERMISSIVENESS; HUMAN BREAST-CANCER; MESSENGER-RNA; MALIGNANT-TRANSFORMATION; PERSISTENT INFECTION; ADAPTER PROTEINS; EXCHANGE FACTORS; MEASLES-VIRUS	Reovirus has an inherent preference for replicating in cells with dysregulated growth factor signaling cascades that comprise Ras activation. Precisely how reovirus exploits the host cell Ras pathway is unclear, but there is evidence suggesting that activated Ras signaling is important for efficient viral protein synthesis. De. ning the molecular mechanism of reovirus oncolysis will shed light on reovirus replication and important aspects of cellular transformation, Ras signaling cascades and regulation of protein translation.	Dalhousie Univ, Dept Microbiol, Halifax, NS B3K 1X5, Canada; Dalhousie Univ, Dept Immunol, Halifax, NS B3K 1X5, Canada	Dalhousie University; Dalhousie University	Lee, PWK (corresponding author), Dalhousie Univ, Dept Microbiol, 7P Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3K 1X5, Canada.	patrick.lee@dal.ca		Marcato, Paola/0000-0001-8619-283X				AHMED R, 1981, CELL, V25, P325, DOI 10.1016/0092-8674(81)90050-7; Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884; ARMSTRONG GD, 1984, VIROLOGY, V138, P37, DOI 10.1016/0042-6822(84)90145-4; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Bergmann M, 2001, CANCER RES, V61, P8188; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; BOS JL, 1989, CANCER RES, V49, P4682; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COHEN JA, 1988, MICROBIOL SCI, V5, P265; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DERMODY TS, 1993, J VIROL, V67, P2055, DOI 10.1128/JVI.67.4.2055-2063.1993; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Grote D, 2001, BLOOD, V97, P3746, DOI 10.1182/blood.V97.12.3746; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hirasawa K, 2002, CANCER RES, V62, P1696; Hirasawa K, 2003, CANCER RES, V63, P348; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JANES PW, 1994, ONCOGENE, V9, P3601; KAUFFMAN RS, 1983, VIROLOGY, V131, P79, DOI 10.1016/0042-6822(83)90535-4; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; McCormick F, 2000, SEMIN CANCER BIOL, V10, P453, DOI 10.1006/scbi.2000.0336; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MUNDSCHAU LJ, 1994, BIOCHIMIE, V76, P792, DOI 10.1016/0300-9084(94)90083-3; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Nussbaum JM, 2003, CANCER LETT, V196, P207, DOI 10.1016/S0304-3835(03)00276-3; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; PACITTI AF, 1987, J VIROL, V61, P1407, DOI 10.1128/JVI.61.5.1407-1415.1987; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RODRIGUEZVICIAN.P, 1997, CELL, V89, P47; RUBIN DH, 1985, J VIROL, V53, P391, DOI 10.1128/JVI.53.2.391-398.1985; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413; Sieczkarski SB, 2005, CURR TOP MICROBIOL, V285, P1; Sinkovics JG, 2000, J CLIN VIROL, V16, P1, DOI 10.1016/S1386-6532(99)00072-4; Skabkin MA, 2004, NUCLEIC ACIDS RES, V32, P5621, DOI 10.1093/nar/gkh889; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; STRONG JE, 1993, VIROLOGY, V197, P405, DOI 10.1006/viro.1993.1602; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yang WQ, 2004, CLIN CANCER RES, V10, P8561, DOI 10.1158/1078-0432.CCR-04-0940; Yang WQ, 2003, CANCER RES, V63, P3162	94	69	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7720	7728		10.1038/sj.onc.1209041	http://dx.doi.org/10.1038/sj.onc.1209041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299532				2022-12-28	WOS:000233372600008
J	Gonzalez-Polo, RA; Carvalho, G; Braun, T; Decaudin, D; Fabre, C; Larochette, N; Perfettini, JL; Djavaheri-Mergny, M; Youlyouz-Marfak, I; Codogno, P; Raphael, M; Feuillard, J; Kroemer, G				Gonzalez-Polo, RA; Carvalho, G; Braun, T; Decaudin, D; Fabre, C; Larochette, N; Perfettini, JL; Djavaheri-Mergny, M; Youlyouz-Marfak, I; Codogno, P; Raphael, M; Feuillard, J; Kroemer, G			PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor	ONCOGENE			English	Article						autophagy; caspase; Bcl-2; NF-kappaB	DEPENDENT ANION CHANNEL; CELL-CYCLE ARREST; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CANCER-CELLS; LEUKEMIA-CELLS; LIGAND; BCL-2; RESISTANCE; LONIDAMINE; INHIBITOR	1-(2-Chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is a prototypic ligand of the peripheral benzodiazepine receptor (PBR), a mitochondrial outer membrane protein. PK11195 can be used to chemosensitize tumor cells to a variety of chemotherapeutic agents, both in vitro and in vivo. PK11195 has been suggested to exert this effect via inhibition of the multiple drug resistance (MDR) pump and by direct mitochondrial effects which could be mediated by the PBR. Here, we established a model system in which PK11195 and another PBR ligand, 7-chloro-5-(4-chlorophenyl)- 1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2- one (Ro5-4864), sensitize to nutrient depletion-induced cell death. In this MDR-independent model, PK11195 and Ro5-4864 are fully active even when the PBR is knocked down by small interfering RNA. Cells that lack PBR possess low-affinity binding sites for PK11195 and Ro5-4864. The starvation-sensitizing effects of PK11195 are not due to a modulation of the adaptive response of starved cells, namely autophagy and NF-kappa B activation. Rather, it appears that the combination of PK11195 with autophagy or NF-kappa B inhibitors has a potent synergistic death-inducing effect. Starved cells treated with PK11195 exhibit characteristics of apoptosis, including loss of the mitochondrial transmembrane potential, mitochondrial cytochrome c release, caspase activation and chromatin condensation. Accordingly, stabilization of mitochondria by overexpression of Bcl-2 or expression of the viral mitochondrial inhibitor (vMIA) from cytomegalovirus inhibits cell death induced by PK11195 plus starvation. Thus, PK11195 potently sensitizes to apoptosis via a pathway that involves mitochondria, yet does not involve the PBR.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Curie, Dept Hematol, F-75005 Paris, France; Inst Andre Lwoff, INSERM, U504, F-94807 Villejuif, France; CNRS, UMR 6101, Limoges, France; Fac Med, Hematol Lab, Limoges, France; CHU Dupuytren, Limoges, France; CHU Kremlin Bicetre, U473, Serv Hematol Biol, Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CHU Limoges; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Codogno, Patrice/G-1384-2013; González-Polo, Rosa A./I-6076-2016; Djavaheri-Mergny, Mojgan/N-6315-2017; KROEMER, Guido/B-4263-2013; Braun, Thorsten/GRJ-8918-2022; LAROCHETTE, Nathanael/R-4298-2017; Djavaheri-Mergny, Mojgan/L-3890-2019; PERFETTINI, Jean-Luc/N-4699-2017; Kroemer, Guido/AAY-9859-2020; Feuillard, Jean/O-8587-2016	Codogno, Patrice/0000-0002-5492-3180; González-Polo, Rosa A./0000-0002-0163-2953; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Youlyouz-Marfak, Ibtissam/0000-0002-9853-1592; Feuillard, Jean/0000-0001-6223-2454				ANSSEAU M, 1991, PHARMACOPSYCHIATRY, V24, P8, DOI 10.1055/s-2007-1014425; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Baran-Marszak F, 2004, BLOOD, V104, P2475, DOI 10.1182/blood-2003-10-3508; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Boitano A, 2003, CANCER RES, V63, P6870; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Carayon P, 1996, BLOOD, V87, P3170, DOI 10.1182/blood.V87.8.3170.bloodjournal8783170; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Chauhan D, 2004, BLOOD, V104, P2458, DOI 10.1182/blood-2004-02-0547; Chen J, 2002, MOL CANCER THER, V1, P981; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Decaudin D, 2004, ANTI-CANCER DRUG, V15, P737, DOI 10.1097/00001813-200409000-00001; Decaudin D, 2002, CANCER RES, V62, P1388; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; FERRY A, 1989, FUNDAM CLIN PHARM, V3, P383, DOI 10.1111/j.1472-8206.1989.tb00679.x; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Galiegue S, 2004, CLIN CANCER RES, V10, P2058, DOI 10.1158/1078-0432.CCR-03-0988; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harborth J, 2001, J CELL SCI, V114, P4557; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jakubikova J, 2002, NEOPLASMA, V49, P231; Jorda EG, 2005, APOPTOSIS, V10, P91, DOI 10.1007/s10495-005-6064-9; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maaser K, 2005, CLIN CANCER RES, V11, P1751, DOI 10.1158/1078-0432.CCR-04-1955; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; Miccoli L, 1998, CANCER RES, V58, P5777; Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052; Okaro AC, 2002, GUT, V51, P556, DOI 10.1136/gut.51.4.556; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rochard P, 2004, GENE EXPRESSION, V12, P13, DOI 10.3727/000000004783992170; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SNYDER SH, 1990, NEUROCHEM RES, V15, P119, DOI 10.1007/BF00972201; Sutter AP, 2004, J HEPATOL, V41, P799, DOI 10.1016/j.jhep.2004.07.015; Sutter AP, 2003, BRIT J CANCER, V89, P564, DOI 10.1038/sj.bjc.6601125; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; Weisinger G, 2004, BIOCHEMISTRY-US, V43, P12315, DOI 10.1021/bi030251v	50	83	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7503	7513		10.1038/sj.onc.1208907	http://dx.doi.org/10.1038/sj.onc.1208907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16091749				2022-12-28	WOS:000233333800001
J	Mahon, FX				Mahon, FX			JAK the trigger	ONCOGENE			English	Editorial Material						tyrosine kinases; leukemia; JAK2	TYROSINE KINASE; MUTATION	A somatic mutation that leads to activation of the JAK2 tyrosine kinase has recently been identified as a recurrent genetic abnormality in several different myeloproliferative disorders. A translocation generating the constitutively activated fusion protein PCM1-JAK2 has also been recently found in atypical chronic myelogenous leukemia and acute leukemia. This recent spate of independent studies (one of which is published in this issue of Oncogene) establish abnormal JAK2 activation as the underlying defect in a significant number of cases of myeloproliferative disease, and JAK2 as an important new therapeutic target.	Univ Bordeaux 2, CHU Bordeau, INSERM, E0217,Serv Malad Sang,Lab Hematopoiese Leucem & C, F-33076 Bordeaux, France	CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Mahon, FX (corresponding author), Univ Bordeaux 2, CHU Bordeau, INSERM, E0217,Serv Malad Sang,Lab Hematopoiese Leucem & C, 146 Rue Leo Saignat,Boite 50, F-33076 Bordeaux, France.	francois-xavier.mahon@umr5540.u-bordeaux2.fr						Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263	8	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7125	7126		10.1038/sj.onc.1208885	http://dx.doi.org/10.1038/sj.onc.1208885			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007127				2022-12-28	WOS:000232990100001
J	Roman-Gomez, J; Jimenez-Velasco, A; Agirre, X; Cervantes, F; Sanchez, J; Garate, L; Barrios, M; Castillejo, JA; Navarro, G; Colomer, D; Prosper, F; Heiniger, A; Torres, A				Roman-Gomez, J; Jimenez-Velasco, A; Agirre, X; Cervantes, F; Sanchez, J; Garate, L; Barrios, M; Castillejo, JA; Navarro, G; Colomer, D; Prosper, F; Heiniger, A; Torres, A			RETRACTED: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (Retracted article. See vol. 32, pg. 804, 2013)	ONCOGENE			English	Article; Retracted Publication						CML; hypomethylation; retrotransposons; LINE-1; blast crisis	DNA HYPOMETHYLATION; C-MET; L1 RETROTRANSPOSONS; COLORECTAL-CANCER; IN-VITRO; METHYLATION; INSTABILITY; EXPRESSION; TRANSLOCATION; BREAKPOINT	Aberrant genome-wide hypomethylation is thought to be related to tumorigenesis by promoting genomic instability. Since DNA methylation is considered an important mechanism for the silencing of retroelements, hypomethylation in human tumors may lead to their reactivation. However, the role of DNA hypomethylation in chronic myeloid leukemia (CML) remains to be elucidated. In this study, the methylation status of the LINE-1 (L1) retrotransposon promoter was analysed in CML samples from the chronic-phase (CP, n = 140) and the blast crisis (BC, n = 47). L1 hypomethylation was significantly more frequent in BC (74.5%) than in CP (38%) (P < 0.0001). Furthermore, L1 hypomethylation led to activation of both ORF1 sense transcription (P < 0.0001) and c-MET gene antisense transcription (P < 0.0001), and was significantly associated with high levels of BCR-ABL (P = 0.02) and DNMT3b4 (P = 0.001) transcripts. Interestingly, in CP-CML, extensive L1 hypomethylation was associated with poorer prognosis in terms of cytogenetic response to interferon (P = 0.004) or imatinib (P = 0.034) and progression-free survival (P = 0.005). The above results strongly suggest that activation of both sense and antisense transcriptions by aberrant promoter hypomethylation of the L1 elements plays a role in the progression and clinical behavior of the CML.	Reina Sofia Hosp, Dept Hematol, Cordoba 14004, Spain; Carlos Haya Hosp, Dept Hematol, Malaga, Spain; Univ Navarra, Sch Med, Clin Univ, Hematol Dept,Cellular Therapy Area,Fdn Appl Med R, E-31080 Pamplona, Spain; Hosp Clin Barcelona, Dept Hematol, IDIBAPS, Barcelona, Spain	Hospital Universitario Reina Sofia - Cordoba; Hospital Carlos Haya; University of Navarra; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Roman-Gomez, J (corresponding author), Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.	peperosa@teleline.es	Agirre, Xabier/ABE-4110-2020; Prosper, Felipe/H-6859-2017; COLOMER, DOLORS/ABG-6894-2020	Prosper, Felipe/0000-0001-6115-8790; COLOMER, DOLORS/0000-0001-7486-8484				Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BRATTHAUER GL, 1992, ONCOGENE, V7, P507; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Christensen JG, 2003, CANCER RES, V63, P7345; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; DANTE R, 1992, ANTICANCER RES, V12, P559; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; Deutsch E, 2003, BLOOD, V101, P4583, DOI 10.1182/blood-2002-10-3011; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGUMANN P, 2002, GENOMICS, V79, P628; Huntly BJP, 2003, BLOOD, V102, P1160, DOI 10.1182/blood-2003-01-0123; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lin CH, 2001, CANCER RES, V61, P4238; Liu J, 1997, GENE CHROMOSOME CANC, V18, P232, DOI 10.1002/(SICI)1098-2264(199703)18:3<232::AID-GCC10>3.0.CO;2-K; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12; MIKI Y, 1992, CANCER RES, V52, P643; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NAGARAJAN L, 1990, BLOOD, V75, P82; Ovchinnikov I, 2002, P NATL ACAD SCI USA, V99, P10522, DOI 10.1073/pnas.152346799; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; Prak ETL, 2000, NAT REV GENET, V1, P134; Rizwana R, 1999, J CELL SCI, V112, P4513; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Santourlidis S, 1999, PROSTATE, V39, P166; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493	51	172	189	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7213	7223		10.1038/sj.onc.1208866	http://dx.doi.org/10.1038/sj.onc.1208866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170379				2022-12-28	WOS:000232990100010
J	Linnerth, NM; Baldwin, M; Campbell, C; Brown, M; McGowan, H; Moorehead, RA				Linnerth, NM; Baldwin, M; Campbell, C; Brown, M; McGowan, H; Moorehead, RA			IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells	ONCOGENE			English	Article						IGF-II; CREB; lung cancer; transformation	GROWTH-FACTOR-I; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR CREB; HUMAN-MELANOMA CELLS; GENE-EXPRESSION; BREAST-CANCER; FACTOR FAMILY; FACTOR RECEPTOR; TUMOR-GROWTH; MICE	We have previously shown that lung tumors arising in MMTV-IGF-II transgenic mice displayed elevated levels of phospho rylated cAMP response element binding protein (CREB). To investigate the role that insulin-like growth factor II (IGF-II) and CREB play in human lung tumorigenesis, A549 and NCI-H358 cells were examined. In these cell lines, IGF-II administration enhances human tumor cell survival and CREB phosphorylation. Further, the effects of IGF-II on cell survival and CREB phosphorylation appeared to be mediated, at least in part, by activation of the Erk pathways, as inhibition of these signaling pathways reduced tumor cell survival and CREB phosphorylation. Specifi. cally, Erk5 appeared as the predominant mediator of CRE B phosporylation. To further verify the importance of CREB in human lung tumorigenesis, A549 and NCI-H358 cells were stably transfected with a vector containing a dominant negative CREB construct (KCREB). KCREB transfection significantly inhibited the soft agar growth of both human tumor cell lines. In contrast, overexpression of wild-type CREB in the normal human bronchial epithelial cell line, HBE135, enhanced soft agar growth. Therefore, our results indicate that CREB and its associated proteins play a significant role in lung adenocarcinoma and IGF-II induces CREB phosphorylation, at least in part, via the Erk5 signaling pathway.	Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada	University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Alvarez-Lopez C, 2004, NEUROSCI LETT, V357, P223, DOI 10.1016/j.neulet.2003.12.099; Arteaga CL, 1996, CANCER RES, V56, P1098; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Fowden AL, 2003, PLACENTA, V24, P803, DOI 10.1016/S0143-4004(03)00080-8; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Grothey A, 1999, J CANCER RES CLIN, V125, P166, DOI 10.1007/s004320050259; HABENER JF, 1989, HORM RES, V32, P61, DOI 10.1159/000181246; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Luciani P, 2003, EUR J ENDOCRINOL, V148, P579, DOI 10.1530/eje.0.1480579; MALKINSON AM, 1991, ENVIRON HEALTH PERSP, V93, P149, DOI 10.2307/3431183; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; OFIR R, 1991, GENE EXPRESSION, V1, P55; Pavelic J, 2002, MOL MED, V8, P149, DOI 10.1007/BF03402007; Pavelic K, 1999, J PATHOL, V188, P69; Peri A, 2002, EUR J ENDOCRINOL, V146, P759, DOI 10.1530/eje.0.1460759; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rabelo FLA, 2003, BIOCHEM BIOPH RES CO, V303, P968, DOI 10.1016/S0006-291X(03)00454-6; Reddy SPM, 2002, AM J RESP CELL MOL, V27, P64, DOI 10.1165/ajrcmb.27.1.20020003oc; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; REHM S, 1991, EXP LUNG RES, V17, P181, DOI 10.3109/01902149109064410; Rosenberg D, 2002, ENDOCR RES, V28, P765, DOI 10.1081/ERC-120017071; Rosenberg D, 2002, ANN NY ACAD SCI, V968, P65, DOI 10.1111/j.1749-6632.2002.tb04327.x; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; RUBIN R, 1995, LAB INVEST, V73, P311; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; Saeki K, 2001, LEUKEMIA, V15, P238, DOI 10.1038/sj.leu.2402014; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Scapoli L, 2004, ONCOGENE, V23, P805, DOI 10.1038/sj.onc.1207163; Shankar DB, 2004, LEUKEMIA LYMPHOMA, V45, P265, DOI 10.1080/1042819031000151095; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takanami I, 1996, J SURG ONCOL, V61, P205, DOI 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; YOSHIDA K, 1995, J NEUROCHEM, V65, P1499	58	44	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7310	7319		10.1038/sj.onc.1208882	http://dx.doi.org/10.1038/sj.onc.1208882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16158061				2022-12-28	WOS:000233142100007
J	Papoutsaki, M; Moretti, F; Lanza, M; Marinari, B; Sartorelli, V; Guerrini, L; Chimenti, S; Levrero, M; Costanzo, A				Papoutsaki, M; Moretti, F; Lanza, M; Marinari, B; Sartorelli, V; Guerrini, L; Chimenti, S; Levrero, M; Costanzo, A			A p38-dependent pathway regulates Delta Np63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes	ONCOGENE			English	Article						p53; p63; apoptosis; p38; keratinocytes	JUN NH2-TERMINAL KINASE; P53; P63; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DAMAGE	The p53 protein plays a pivotal role in determining the quality of the response to DNA damage through its transcriptional activity. Upon DNA damage, p53 is activated by post-translational modi. cations, binds its cognate sequences on the promoters of its target genes and stimulates transcription. In proliferating keratinocytes, the activity of p53 is blunted by its inhibitor Delta Np63 alpha. Here, we describe a novel mechanism through which Delta Np63 functions in order to prevent the survival and propagation of ultraviolet (UV)-damaged keratinocytes. We found that UVB stimulation induces the rapid phosphorylation of DNp63, which precedes DNp63 transcriptional downregulation and protein degradation, which is mediated by the p38 MAPK. Phosphorylated Delta Np63 has a lower affinity for p53REs and detaches from cell cycle arrest and apoptotic promoters, thus allowing the rapid activation of p53-dependent transcriptional apoptotic program.	Univ Roma Tor Vergata, Dept Dermatol, Dermatol Clin, I-00133 Rome, Italy; CRS Regina Elena Canc Ctr, Fondaz A Cesalpino, I-00153 Rome, Italy; NIMAS, Muscle Biol Lab, Muscle Gene Express Grp, NIH, Bethesda, MD USA; Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20122 Milan, Italy; Univ Roma La Sapienza, Dept Internal Med, Rome, Italy	University of Rome Tor Vergata; National Institutes of Health (NIH) - USA; University of Milan; Sapienza University Rome	Levrero, M (corresponding author), Univ Roma Tor Vergata, Dept Dermatol, Dermatol Clin, Viale Oxford 81, I-00133 Rome, Italy.	levmax@tin.it; antonio.costanzo@uniroma2.it	Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041126, Z01AR041126] Funding Source: NIH RePORTER; Telethon [E.1325] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		BODE AM, 2003, SCI STKE, pRE2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hildesheim J, 2002, CANCER RES, V62, P7305; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liefer KM, 2000, CANCER RES, V60, P4016; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Park BJ, 2000, CANCER RES, V60, P3370; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	27	39	41	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6970	6975		10.1038/sj.onc.1208835	http://dx.doi.org/10.1038/sj.onc.1208835			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007154				2022-12-28	WOS:000232701700011
J	Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN				Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN			Activated AKT regulates NF-kappa B activation, p53 inhibition and cell survival in HTLV-1-transformed cells	ONCOGENE			English	Article						HTLV-1; p53; NF-kappa B; AKT; p65; IKK	VIRUS TYPE-I; SERINE-THREONINE KINASE; HTLV-I; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVITY; CLINICAL ENTITY; HUMAN CANCER; IKK-BETA; PATHWAY; LEUKEMIA	AKT activation enhances resistance to apoptosis and induces cell survival signaling through multiple downstream pathways. We now present evidence that AKT is activated in HTLV-1-transformed cells and that Tax activation of AKT is linked to NF-kappa B activation, p53 inhibition and cell survival. Overexpression of AKT wild type (WT), but not a kinase dead (KD) mutant, resulted in increased Tax-mediated NF-kappa B activation. Blocking AKT with the PI3K/AKT inhibitor LY294002 or AKT SiRNA prevented NF-kappa B activation and inhibition of p53. Treatment of C81 cells with LY294002 resulted in an increase in the p53-responsive gene MDM2, suggesting a role for AKT in the Tax-mediated regulation of p53 transcriptional activity. Further, we show that LY294002 treatment of C81cells abrogates in vitro IKK beta phosphorylation of p65 and causes a reduction of p65 Ser-536 phosphorylation in vivo, steps critical to p53 inhibition. Interestingly, blockage of AKT function did not affect IKKb phosphorylation of I kappa Ba in vitro suggesting selective activity of AKT on the IKKb complex. Finally, AKT prosurvival function in HTLV-1-transformed cells is linked to expression of Bcl-xL. We suggest that AKT plays a role in the activation of prosurvival pathways in HTLV-1-transformed cells, possibly through NF-kappa B activation and inhibition of p53 transcription activity.	Natl Canc Inst, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brady, JN (corresponding author), Natl Canc Inst, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bldg 41-B201,9000 Rockville Pike, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005691, Z01BC005691] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GESSAIN A, 1985, LANCET, V2, P407; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hovelmann S, 2004, BRIT J CANCER, V90, P2370, DOI 10.1038/sj.bjc.6601876; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1989, LANCET, V1, P441; OSAME M, 1986, LANCET, V1, P1031; Ozes ON, 1999, NATURE, V401, P82; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren S, 2003, BIOCHEM BIOPH RES CO, V308, P120, DOI 10.1016/S0006-291X(03)01309-3; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VERNANT JC, 1988, LANCET, V1, P177; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	159	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6719	6728		10.1038/sj.onc.1208825	http://dx.doi.org/10.1038/sj.onc.1208825			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007163				2022-12-28	WOS:000232367800013
J	Liu, TC; Kirn, D				Liu, TC; Kirn, D			Viruses with deletions in antiapoptotic genes as potential oncolytic agents	ONCOGENE			English	Review						oncolytic; virus; cancer; apoptosis; virology; gene therapy	E1B 19-KILODALTON PROTEIN; NECROSIS-FACTOR-ALPHA; APOPTOTIC CELL-DEATH; TYPE-1 US11 PROTEIN; INFLUENZA-A VIRUS; INFECTED-CELLS; DL1520 ONYX-015; HOST-RANGE; IN-VIVO; ADENOVIRUS PROTEINS	Replication-selective oncolytic viruses have emerged as a new treatment platform for cancers. However, selectivity and potency need to be improved before virotherapy can become a standard treatment modality. In addition, mechanisms that can be incorporated to enable targeting a broad range of cancer types are highly desirable. Cancer cells are well known to have multiple blocks in apoptosis pathways. On the other hand, viruses have evolved to express numerous antiapoptotic genes to antagonize apoptosis induced upon infection. Viruses with deletions in antiapoptotic genes can therefore be complemented by antiapoptotic genetic changes in cancer cells for efficient replication and oncolysis. In this review, we summarize the recent development of this concept, the potential obstacles, and future directions for optimization.	Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Mol Neurosurg Lab, Boston, MA 02114 USA; Univ Oxford, Dept Clin Pharmacol, Oxford OX1 2JD, England; Jennnerex Biotherapeut Inc, Mountain View, CA USA	Harvard University; Harvard University; Massachusetts General Hospital; University of Oxford	Liu, TC (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.	tachiangliu@yahoo.com; dkirn@jennerex.com		Liu, Ta-Chiang/0000-0002-2800-9360				Alcami A, 1999, J GEN VIROL, V80, P949, DOI 10.1099/0022-1317-80-4-949; ALCAMI A, 1995, J VIROL, V69, P4633; Alcami A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230-11239.2000; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Beattie E, 1996, VIRUS GENES, V12, P89, DOI 10.1007/BF00370005; Bennett JJ, 2002, CANCER GENE THER, V9, P935, DOI 10.1038/sj.cgt.7700510; Bergmann M, 2001, CANCER RES, V61, P8188; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; CANALE VC, 1967, J PEDIATR-US, V70, P891, DOI 10.1016/S0022-3476(67)80262-2; CARROLL K, 1993, J BIOL CHEM, V268, P12837; Cascallo M, 2003, CANCER RES, V63, P5544; Cassady KA, 2002, J VIROL, V76, P2029, DOI 10.1128/jvi.76.5.2029-2035.2002; Chen P, 1998, J BIOL CHEM, V273, P5815, DOI 10.1074/jbc.273.10.5815; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Gomez-Manzano C, 2004, ONCOGENE, V23, P1821, DOI 10.1038/sj.onc.1207321; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hallden G, 2003, MOL THER, V8, P412, DOI 10.1016/S1525-0016(03)00199-0; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; KETTLE S, 1995, VIROLOGY, V206, P136, DOI 10.1016/S0042-6822(95)80028-X; Kim J, 2002, CANCER GENE THER, V9, P725, DOI 10.1038/sj.cgt.7700494; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kirn D, 2001, EXPERT OPIN BIOL TH, V1, P525, DOI 10.1517/14712598.1.3.525; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; Langland JO, 2002, VIROLOGY, V299, P133, DOI 10.1006/viro.2002.1479; Legrand FA, 2004, J VIROL, V78, P2770, DOI 10.1128/JVI.78.6.2770-2779.2004; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu TC, 2004, MOL THER, V9, P786, DOI 10.1016/j.ymthe.2004.03.017; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; McNees AL, 2002, VIRUS RES, V88, P87, DOI 10.1016/S0168-1702(02)00122-3; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Moise AR, 2002, J VIROL, V76, P1578, DOI 10.1128/JVI.76.4.1578-1587.2002; MOSS B, 1977, J VIROL, V23, P234, DOI 10.1128/JVI.23.2.234-239.1977; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nava VE, 1997, J VIROL, V71, P4118, DOI 10.1128/JVI.71.5.4118-4122.1997; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Peters GA, 2002, J VIROL, V76, P11054, DOI 10.1128/JVI.76.21.11054-11064.2002; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Roth W, 2002, NAT MED, V8, P216, DOI 10.1038/nm0302-216; Russell SJ, 2002, CANCER GENE THER, V9, P961, DOI 10.1038/sj.cgt.7700535; Sauthoff H, 2000, HUM GENE THER, V11, P379, DOI 10.1089/10430340050015851; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TELLING GC, 1994, J VIROL, V68, P541, DOI 10.1128/JVI.68.1.541-547.1994; Todo T, 2000, MOL THER, V2, P588, DOI 10.1006/mthe.2000.0200; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Verardi PH, 2001, J VIROL, V75, P11, DOI 10.1128/JVI.75.1.11-18.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang YH, 2003, NAT BIOTECHNOL, V21, P1328, DOI 10.1038/nbt887; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; Wickham TJ, 2003, NAT MED, V9, P135, DOI 10.1038/nm0103-135; YANG J, 1997, SCIENCE, V275, P1132; Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002	90	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 8	2005	24	40					6069	6079		10.1038/sj.onc.1208734	http://dx.doi.org/10.1038/sj.onc.1208734			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16155595	Bronze			2022-12-28	WOS:000231718100001
J	Fukui, T; Kondo, M; Ito, G; Maeda, O; Sato, N; Yoshioka, H; Yokoi, K; Ueda, Y; Shimokata, K; Sekido, Y				Fukui, T; Kondo, M; Ito, G; Maeda, O; Sato, N; Yoshioka, H; Yokoi, K; Ueda, Y; Shimokata, K; Sekido, Y			Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer	ONCOGENE			English	Article						chromosome 8p; hypermethylation; non small-cell lung cancer; SFRP1; tumor suppressor gene	WNT ANTAGONIST SFRP1; COLORECTAL-CANCER; BREAST-CANCER; GENE; INACTIVATION; EXPRESSION; CATENIN; ADENOCARCINOMAS; HETEROZYGOSITY; MESOTHELIOMA	Secreted frizzled related protein 1 (SFRP1) is an antagonist of the transmembrane frizzled receptor, a component of the Wnt signaling pathway, and has been suggested to be a candidate tumor suppressor in several human malignancies. Since SFRP1 is located at chromosome 8p11, where lung cancers also exhibit frequent allelic loss, we hypothesized that the inactivation of SFRP1 is also involved in lung carcinogenesis. To substantiate this, we performed mutational analysis of SFRP1 for 29 nonsmall-cell lung cancer (NSCLC) and 25 small-cell lung cancer (SCLC) cell lines, and expression analysis for the same cell lines. Although somatic mutations were not detected in the coding sequence, downregulation of SFRP1 was observed in 14 (48%) NSCLC and nine (36%) SCLC cell lines. We analysed epigenetic alteration of the SFRP1 promoter region and detected hypermethylation in 15 (52%) of 29 NSCLC cell lines, two (8%) of 25 SCLC cell lines, and 44 (55%) of 80 primary lung tumors. By comparing the methylation status with SFRP1 expression, we found a significant correlation between them. We also performed loss of heterozygosity (LOH) analysis and found that 15 (38%) of 40 informative surgical specimens had LOH in the SFRP1 gene locus. Furthermore, we performed colony formation assay of two NSCLC cell lines (NCI-H460 and NCI-H2009) and found the reduction of colony formation with SFRP1 transfection. In addition, we also detected that SFRP1 inhibits the transcriptional activity of beta-catenin, which is thought to be a downstream molecule of SFRP1, with luciferase reporter assay. Our current studies demonstrated that the SFRP1 gene is frequently downregulated by promoter hypermethylation and suppresses tumor growth activity of lung cancer cells, which suggests that SFRP1 is a candidate tumor suppressor gene for lung cancer.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Resp Med, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Kondo, Masashi/I-7378-2014; Yokoi, Kohei/I-7261-2014; Fukui, Takayuki/AAR-2292-2021; Sekido, Yoshitaka/P-9756-2015; FUKUI, Takayuki/I-7443-2014	Sekido, Yoshitaka/0000-0002-2428-3848				Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; EMI M, 1992, CANCER RES, V52, P5368; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Girard L, 2000, CANCER RES, V60, P4894; HORII A, 1992, CANCER RES, V52, P6696; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041; Klopocki E, 2004, INT J ONCOL, V25, P641; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Minna JD, 2002, CANCER J, V8, pS41; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Polakis P, 2000, GENE DEV, V14, P1837; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Toyooka S, 2002, CLIN CANCER RES, V8, P2292; Uchiyama M, 2003, INT J CANCER, V107, P962, DOI 10.1002/ijc.11493; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Wistuba II, 1999, CANCER RES, V59, P1973; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291	30	148	153	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6323	6327		10.1038/sj.onc.1208777	http://dx.doi.org/10.1038/sj.onc.1208777			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007200				2022-12-28	WOS:000231877100013
J	Golestaneh, N; Mishra, B				Golestaneh, N; Mishra, B			TGF-beta, neuronal stem cells and glioblastoma	ONCOGENE			English	Review						TGF-beta; CNS cancer; glioblastoma; ELF; Smad	TRANSFORMING-GROWTH-FACTOR; PROTEASOME INHIBITOR PS-341; RECEPTOR-TYPE-II; FACTOR-KAPPA-B; CANCER-CELLS; MICROSATELLITE INSTABILITY; PROGENITOR CELLS; BRAIN SPECTRIN; GLIOMA-CELLS; AUTOCRINE HYPOTHESIS	Transforming growth factor beta (TGF-beta) signaling leads to a number of biological end points involving cell growth, differentiation, and morphogenesis. Typically, the cellular effect accompanies an induction of mesodermal cell fate and inhibition of neural cell differentiation. However, during pathological conditions, these defined effects of TGF-beta can be reversed; for example, the growth-inhibitory effect is replaced with its tumor promoting ability. A multitude of factors and cross-signaling pathways have been reported to be involved in modulating the dual effects of TGF-beta. In this review, we focus on the potential role of TGF-beta signal transduction during development of neural progenitor cells and its relation to glioblastoma development from neural stem cells.	Georgetown Univ, Sch Med, Dev Neurobiol Lab, Washington, DC 20007 USA	Georgetown University	Mishra, B (corresponding author), Georgetown Univ, Sch Med, Dev Neurobiol Lab, Med Dent Bldg NW,Room 211-213,3900 Reservoir Rd N, Washington, DC 20007 USA.	bm72@georgetown.edu			NIDDK NIH HHS [R01 DK58637] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BIRKENMEIER CS, 1988, P NATL ACAD SCI USA, V85, P8121, DOI 10.1073/pnas.85.21.8121; BODMER S, 1989, J IMMUNOL, V143, P3222; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chesnutt C, 2004, DEV BIOL, V274, P334, DOI 10.1016/j.ydbio.2004.07.019; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; Dahmane N, 2001, DEVELOPMENT, V128, P5201; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DE M, 2000, J CELL SCI, V113, P2331; Deng MJ, 2004, TISSUE ENG, V10, P1597, DOI 10.1089/1076327042500409; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; Galter D, 1999, J NEUROSCI RES, V56, P531, DOI 10.1002/(SICI)1097-4547(19990601)56:5<531::AID-JNR8>3.0.CO;2-O; Goggins M, 1998, CANCER RES, V58, P5329; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Grady WM, 1999, CANCER RES, V59, P320; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Halatsch ME, 2003, ANTICANCER RES, V23, P2315; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hayes NVL, 2000, J CELL SCI, V113, P2023; Held-Feindt J, 2000, J PHYSIOLOGY-PARIS, V94, P251, DOI 10.1016/S0928-4257(00)00213-8; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hitoshi S, 2002, DEVELOPMENT, V129, P233; HORST HA, 1992, HUM PATHOL, V23, P1284, DOI 10.1016/0046-8177(92)90297-G; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; Isoe S, 1998, J NEUROSURG, V88, P529, DOI 10.3171/jns.1998.88.3.0529; Izumoto S, 1997, CANCER LETT, V112, P251, DOI 10.1016/S0304-3835(96)04583-1; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JENNINGS MT, 1994, HUM PATHOL, V25, P464, DOI 10.1016/0046-8177(94)90118-X; Jennings MT, 1997, J NEURO-ONCOL, V31, P233, DOI 10.1023/A:1005767616500; JOHNSON MD, 1993, HUM PATHOL, V24, P457, DOI 10.1016/0046-8177(93)90156-B; Kawase Y, 2004, EXP CELL RES, V295, P194, DOI 10.1016/j.yexcr.2003.12.027; Kawauchi S, 2004, DEV NEUROSCI-BASEL, V26, P166, DOI 10.1159/000082135; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Kumada T, 2004, DEV NEUROSCI-BASEL, V26, P68, DOI 10.1159/000080714; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Lo LC, 2002, DEVELOPMENT, V129, P1553; Lopez-Coviella I, 2002, J PHYSIOLOGY-PARIS, V96, P53, DOI 10.1016/S0928-4257(01)00080-8; Mann KM, 2004, J CELL BIOL, V165, P483, DOI 10.1083/jcb.200402105; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mentlein R, 2001, INT J CANCER, V92, P545, DOI 10.1002/ijc.1223; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; MOON RT, 1987, BIOESSAYS, V7, P159, DOI 10.1002/bies.950070405; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Okano-Uchida T, 2004, P NATL ACAD SCI USA, V101, P1211, DOI 10.1073/pnas.0307972100; Panchision DM, 2002, CURR OPIN GENET DEV, V12, P478, DOI 10.1016/S0959-437X(02)00329-5; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PAULUS W, 1995, J NEUROPATH EXP NEUR, V54, P236, DOI 10.1097/00005072-199503000-00010; Peng Y, 2002, NEUROSCIENCE, V109, P657, DOI 10.1016/S0306-4522(01)00526-7; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; PLATE KH, 1992, LAB INVEST, V67, P529; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reiss M, 1997, ONCOL RES, V9, P447; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SAMUELS V, 1989, AM J PATHOL, V134, P895; Schier AF, 2001, INT J DEV BIOL, V45, P289; Setoguchi T, 2004, EXP NEUROL, V189, P33, DOI 10.1016/j.expneurol.2003.12.007; Sieber-Blum M, 1997, J ANAT, V191, P493, DOI 10.1046/j.1469-7580.1997.19140493.x; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; SIKORSKI AF, 1991, BRAIN RES BULL, V27, P195, DOI 10.1016/0361-9230(91)90067-T; Sikorski AF, 2000, BRAIN RES, V852, P161, DOI 10.1016/S0006-8993(99)02253-2; Sonntag KC, 2005, MOL CELL NEUROSCI, V28, P417, DOI 10.1016/j.mcn.2004.06.003; Sporn MB, 1999, MICROBES INFECT, V1, P1251, DOI 10.1016/S1286-4579(99)00260-9; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Temple S, 2001, NAT REV NEUROSCI, V2, P513, DOI 10.1038/35081577; Tsai RYL, 2000, J NEUROSCI, V20, P3725, DOI 10.1523/JNEUROSCI.20-10-03725.2000; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tsai RYL, 2002, DEV CELL, V2, P707, DOI 10.1016/S1534-5807(02)00195-8; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wurdak H, 2005, GENE DEV, V19, P530, DOI 10.1101/gad.317405; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yung SY, 2002, P NATL ACAD SCI USA, V99, P16273, DOI 10.1073/pnas.232586699; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhou YX, 2003, J BIOL CHEM, V278, P42313, DOI 10.1074/jbc.M308287200; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	129	69	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5722	5730		10.1038/sj.onc.1208925	http://dx.doi.org/10.1038/sj.onc.1208925			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123805				2022-12-28	WOS:000231452800007
J	Letterio, JJ				Letterio, JJ			TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia	ONCOGENE			English	Review						transforming growth factor beta ( TGF-beta); lymphocyte; neoplasia; leukemia; inflammation; Smad3	TRANSFORMING-GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; SMAD3 MUTANT MICE; DOWN-REGULATION; IN-VIVO; TUMOR-SUPPRESSOR; THYMOCYTE PROLIFERATION; LYMPHOBLASTIC-LEUKEMIA; INFLAMMATORY RESPONSE; IL-12 RESPONSIVENESS	Transforming growth factor-beta (TGF-beta) plays an essential role in regulating the homeostasis of cells in the lymphoid lineage. TGF-beta signaling is not required for normal thymopoiesis, but is essential for regulating the expansion, activation, and effector function of the mature CD4(+) and CD8(+) T cells in the peripheral lymphoid organs and target tissues. Recent studies in both mice and humans have elucidated an important and complex role for TGF-beta in regulatory T-cell biology. Disruption of TGF-beta signaling in T cells impairs the maintenance of regulatory T cells, results in the expansion of activated effector T cells, and is associated with the production of cytokines that have major effects on cells in their environment. While autoimmunity and inflammation are the principal phenotypes associated with the abrogation of TGF-beta signaling in T cells in mice, emerging evidence now also directly links Smad-dependent TGF-beta signaling in T cells to the suppression of epithelial neoplasia. The TGF-beta receptor-activated Smad3 plays a critical role in mediating many of the inhibitory effects of TGF-beta signaling in T cells, and has now been established as an important suppressor of leukemogenesis. These studies are increasing our awareness of the many complex mechanisms through which TGF-beta signaling controls the pathogenesis of cancer.	NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Letterio, JJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bldg 41,Room C629,41 Lib Dr, Bethesda, MD 20892 USA.	letterij@mail.nih.gov						Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Baroni T, 2003, J PERIODONTOL, V74, P1447, DOI 10.1902/jop.2003.74.10.1447; Beck C, 2001, MICROSC RES TECHNIQ, V52, P387, DOI 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Becker C, 2005, CELL CYCLE, V4, P217; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; Bright JJ, 1998, J IMMUNOL, V161, P1772; Brown KA, 2004, BREAST CANCER RES, V6, pR130, DOI 10.1186/bcr762; Campbell JDM, 2001, J IMMUNOL, V167, P553, DOI 10.4049/jimmunol.167.1.553; CHANTRY D, 1989, EUR J IMMUNOL, V19, P783, DOI 10.1002/eji.1830190433; Chen CH, 2003, J EXP MED, V197, P1689, DOI 10.1084/jem.20021170; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; CHRIST M, 1994, J IMMUNOL, V153, P1936; Chrobak Pavel, 2003, Acta Medica (Hradec Kralove), V46, P131; Coste A, 1998, ARCH OTOLARYNGOL, V124, P1361, DOI 10.1001/archotol.124.12.1361; DANGEAC AD, 1991, J CELL PHYSIOL, V147, P460, DOI 10.1002/jcp.1041470312; DANGEAC AD, 1993, J CELL PHYSIOL, V154, P44, DOI 10.1002/jcp.1041540107; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Downing JR, 2004, NEW ENGL J MED, V351, P528, DOI 10.1056/NEJMp048121; Ebert EC, 1999, CLIN EXP IMMUNOL, V115, P415; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Fox SW, 2003, J IMMUNOL, V170, P3679, DOI 10.4049/jimmunol.170.7.3679; Fu TH, 2000, INT J CANCER, V87, P680, DOI 10.1002/1097-0215(20000901)87:5<680::AID-IJC10>3.0.CO;2-P; Fuchs O, 2005, Cas Lek Cesk, V144, P90; Garba ML, 2002, J IMMUNOL, V168, P2247, DOI 10.4049/jimmunol.168.5.2247; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Gorham JD, 1998, J IMMUNOL, V161, P1664; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Herrmann S, 1996, ANN NY ACAD SCI, V795, P168, DOI 10.1111/j.1749-6632.1996.tb52665.x; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; INGE TH, 1992, CANCER RES, V52, P1386; Iwamoto T, 2002, HISTOL HISTOPATHOL, V17, P887, DOI 10.14670/HH-17.887; JACOBSEN SEW, 1993, J IMMUNOL, V151, P4534; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; Kaklamani Virginia G, 2004, Expert Rev Anticancer Ther, V4, P649, DOI 10.1586/14737140.4.4.649; Kao JY, 2003, J IMMUNOL, V170, P3806, DOI 10.4049/jimmunol.170.7.3806; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kulkarni Ashok B., 2002, Current Molecular Medicine (Hilversum), V2, P303; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Laouar Y, 2005, NAT IMMUNOL, V6, P600, DOI 10.1038/ni1197; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Letterio JJ, 1996, J CLIN INVEST, V98, P2109, DOI 10.1172/JCI119017; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin JT, 2005, J IMMUNOL, V174, P5950, DOI 10.4049/jimmunol.174.10.5950; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lucas PJ, 2004, CANCER RES, V64, P6524, DOI 10.1158/0008-5472.CAN-04-0896; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Lyakh LA, 2005, J IMMUNOL, V174, P2061, DOI 10.4049/jimmunol.174.4.2061; Mamura M, 2004, BLOOD, V103, P4594, DOI 10.1182/blood-2003-08-2897; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARTINSGREEN M, 1994, CANCER RES, V54, P4334; McKarns SC, 2000, IMMUNOPHARMACOLOGY, V48, P101, DOI 10.1016/S0162-3109(00)00183-1; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Monteleone G, 2004, GASTROENTEROLOGY, V126, P674, DOI 10.1053/j.gastro.2003.11.048; MOSSALAYI MD, 1995, BLOOD, V85, P3594, DOI 10.1182/blood.V85.12.3594.bloodjournal85123594; Moustakas A, 2003, GENE DEV, V17, P2855, DOI 10.1101/gad.1161403; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Mukamoto M, 2000, VET IMMUNOL IMMUNOP, V77, P121, DOI 10.1016/S0165-2427(00)00223-3; MULE JJ, 1988, CANCER IMMUNOL IMMUN, V26, P95; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Ohta K, 2000, INVEST OPHTH VIS SCI, V41, P2591; Pardoux C, 1999, BLOOD, V93, P1448, DOI 10.1182/blood.V93.5.1448.403k36_1448_1455; Park HB, 2004, INT IMMUNOL, V16, P1203, DOI 10.1093/intimm/dxh123; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; PLUM J, 1995, J IMMUNOL, V154, P5789; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Rosendahl A, 2003, INT IMMUNOL, V15, P1401, DOI 10.1093/intimm/dxg139; RUSCETTI F W, 1991, Progress in Growth Factor Research, V3, P159, DOI 10.1016/S0955-2235(05)80006-7; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sitnicka E, 1996, BLOOD, V88, P82; Smeltz RB, 2005, IMMUNOLOGY, V114, P484, DOI 10.1111/j.1365-2567.2005.02115.x; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sudarshan C, 1999, J IMMUNOL, V162, P2974; TADA T, 1991, J IMMUNOL, V146, P1077; TAKAHAMA Y, 1994, J EXP MED, V179, P1495, DOI 10.1084/jem.179.5.1495; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang JH, 1997, J IMMUNOL, V159, P117; Terabe M, 2003, J EXP MED, V198, P1741, DOI 10.1084/jem.20022227; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Touw IP, 2000, MOL CELL ENDOCRINOL, V160, P1, DOI 10.1016/S0303-7207(99)00206-3; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; WEISKIRCH LM, 1994, CANCER IMMUNOL IMMUN, V38, P215, DOI 10.1007/BF01533512; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; Williamson E A, 1995, Curr Opin Hematol, V2, P29; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Yamagiwa S, 2001, J IMMUNOL, V166, P7282, DOI 10.4049/jimmunol.166.12.7282; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang L, 2004, J BIOL CHEM, V279, P28315, DOI 10.1074/jbc.C400115200; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	127	59	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5701	5712		10.1038/sj.onc.1208922	http://dx.doi.org/10.1038/sj.onc.1208922			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123803				2022-12-28	WOS:000231452800005
J	Mishra, L; Shetty, K; Tang, Y; Stuart, A; Byers, SW				Mishra, L; Shetty, K; Tang, Y; Stuart, A; Byers, SW			The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer	ONCOGENE			English	Review						TGF-beta; Wnt; Smad; ELF; cancer; stem cells	TRANSFORMING-GROWTH-FACTOR; II RECEPTOR GENE; NONPOLYPOSIS COLORECTAL-CANCER; TUMOR-SUPPRESSOR SMAD4/DPC4; HEPATIC PROGENITOR CELLS; POLYPOSIS-COLI GENE; BONE-MARROW; JUVENILE POLYPOSIS; EPITHELIAL-CELLS; MUTANT MICE	The past three decades have seen an unremitting quest to identify and understand gastrointestinal stem cells, their plasticity in differentiating across cell types, as well as their role in normal, regenerative, and cancer cells. A fascinating hallmark of stem cells is their ability to undergo assymetric cell division, which entails replication of the DNA followed by division of the nucleus and partitioning of the cytoplasm to yield two different daughter cells: a stem cell as well as a committed progenitor cell, the latter proliferating into differentiated progeny. We are only just beginning to understand how normally quiescent, tissue-specific stem cells interpret a vast array of signals to develop into the gastrointestinal system. These signaling pathways include the transforming growth factor-beta (TGF-beta) superfamily, Wnt, FGFs, Hedgehog, Hox proteins that originate from surrounding mesodermal/stromal tissue as well as endodermal/epithelial tissue. TGF-beta and wnt proteins are key morphogens that ultimately influence cell division and cell fate, so that gut endodermal stem cells enter the cell cycle, and undergo cell division that ultimately leads to differentiated cells such as functional hepatocytes, gastric parietal cells, or gut epithelial cells. Disruptions and errors in this process usually lead to tissue-specific gastrointestinal cancers such as hepatocellular cancers, gastric adenocarcinomas, and colonic adenocarcinomas. An increasingly complex and coherent view of stem/progenitor cell signaling networks, which coordinate cell growth, proliferation, stress management, and survival, is helping to de. ne the fragile areas where malignancies are likely to develop and shows promise for the development of better cancer therapies.	Georgetown Univ, Lab GI Dev Biol, Dept Surg, Washington, DC 20007 USA; DVAMC, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Mishra, L (corresponding author), Georgetown Univ, Lab GI Dev Biol, Dept Surg, Med Dent Bldg,NW 210-12,3900 Reservoir Rd,NW, Washington, DC 20007 USA.	lopamishra@yahoo.com			NCI NIH HHS [R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111, R01 DK58196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058196, R01DK056111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; ALPINI G, 2004, PATHOPHYSIOLOGY BILI; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bissell M J, 1981, Int Rev Cytol, V70, P27, DOI 10.1016/S0074-7696(08)61130-4; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Bjerknes M, 1999, AM J PATHOL, V154, P1831, DOI 10.1016/S0002-9440(10)65439-9; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Bonner-Weir S, 2002, J PATHOL, V197, P519, DOI 10.1002/path.1158; Brittan M, 2002, J PATHOL, V197, P492, DOI 10.1002/path.1155; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Chang J, 1997, CANCER RES, V57, P2856; Clements D, 2001, INT REV CYTOL, V203, P383; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DE M, 2000, J CELL SCI, V113, P2331; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Dubreuil RR, 2001, CELL TISSUE RES, V306, P167, DOI 10.1007/s004410100422; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Forbes S, 2002, J PATHOL, V197, P510, DOI 10.1002/path.1163; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Ganz T, 2000, NAT IMMUNOL, V1, P99, DOI 10.1038/77884; Goggins M, 1998, CANCER RES, V58, P5329; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grady W, 1998, Gastrointest Endosc, V48, P647; Grady WM, 1999, CANCER RES, V59, P320; GRANA X, 1995, ONCOGENE, V11, P211; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Horne-Badovinac S, 2003, SCIENCE, V302, P662, DOI 10.1126/science.1085397; HOUSSAINT E, 1981, CELL DIFFER DEV, V10, P243, DOI 10.1016/0045-6039(81)90007-5; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jacoby RF, 1997, AM J MED GENET, V70, P361, DOI 10.1002/(SICI)1096-8628(19970627)70:4<361::AID-AJMG6>3.0.CO;2-W; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEDOUARI.N, 1967, CR ACAD SCI D NAT, V264, P1872; LEMIRE JM, 1991, AM J PATHOL, V139, P535; Lengyel J A, 1998, Cell Res, V8, P273; Libbrecht L, 2000, J PATHOL, V192, P373, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH700&gt;3.0.CO;2-5; Libbrecht L, 2001, AM J SURG PATHOL, V25, P1388, DOI 10.1097/00000478-200111000-00006; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Lu SL, 1996, CANCER RES, V56, P4595; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumoto A, 2002, ANAT EMBRYOL, V205, P53, DOI 10.1007/s00429-001-0226-5; Mishra B, 2004, LIVER INT, V24, P637, DOI 10.1111/j.1478-3231.2004.0958.x; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Monga SPS, 2001, CELL TRANSPLANT, V10, P81; MOSES HL, 1991, CIBA F SYMP, V157, P66; Murphy SJ, 2004, MOL BIOL CELL, V15, P2853, DOI 10.1091/mbc.E04-02-0097; Murtaugh LC, 2003, ANNU REV CELL DEV BI, V19, P71, DOI 10.1146/annurev.cellbio.19.111301.144752; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Nucci MR, 1997, HUM PATHOL, V28, P1396, DOI 10.1016/S0046-8177(97)90230-6; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PARSONS R, 1995, CANCER RES, V55, P5548; Pasche B, 1999, CANCER RES, V59, P5678; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Preston SL, 2003, CANCER RES, V63, P3819; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Redman RS, 2005, J ORAL PATHOL MED, V34, P23, DOI 10.1111/j.1600-0714.2004.00246.x; Reiss M, 1997, ONCOL RES, V9, P447; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Roberts DJ, 2000, DEV DYNAM, V219, P109, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1047>3.3.CO;2-Y; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Satterwhite DJ, 2004, CELL CYCLE, V3, P1069; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SHAFRITZ DA, 1987, MONOGR PATHOL, V28, P136; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Sormunen RT, 1999, J PATHOL, V187, P416; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stainier DYR, 2005, SCIENCE, V307, P1902, DOI 10.1126/science.1108709; Stainier DYR, 2002, GENE DEV, V16, P893, DOI 10.1101/gad.974902; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Taketo MM, 2000, CYTOKINE GROWTH F R, V11, P147, DOI 10.1016/S1359-6101(99)00038-6; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Theise ND, 2002, SEMIN CELL DEV BIOL, V13, P411, DOI 10.1016/S1084952102001283; Theise ND, 1999, HEPATOLOGY, V30, P1425, DOI 10.1002/hep.510300614; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tosh D, 2005, J HEPATOL, V42, pS75, DOI 10.1016/j.jhep.2004.12.009; Tran Hien, 2003, Sci STKE, V2003, pRE5, DOI 10.1126/stke.2003.172.re5; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; YOUNES M, 1989, AM J PATHOL, V135, P1197; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	155	130	141	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5775	5789		10.1038/sj.onc.1208924	http://dx.doi.org/10.1038/sj.onc.1208924			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123810				2022-12-28	WOS:000231452800012
J	Simbulan-Rosenthal, CM; Trabosh, V; Velarde, A; Chou, FP; Daher, A; Tenzin, F; Tokino, T; Rosenthal, DS				Simbulan-Rosenthal, CM; Trabosh, V; Velarde, A; Chou, FP; Daher, A; Tenzin, F; Tokino, T; Rosenthal, DS			Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation	ONCOGENE			English	Article						Id2; keratinocyte; differentiation; promoter; ETS	LOOP-HELIX PROTEINS; HUMAN-PAPILLOMAVIRUS; ULTRAVIOLET-B; TRANSCRIPTIONAL ACTIVATION; EPIDERMAL DIFFERENTIATION; 5-FLANKING REGION; ENHANCER-BINDING; GENE-EXPRESSION; CELL-GROWTH; DNA-BINDING	Solar ultraviolet B (UVB) acts as both an initiator and promoter in models of multistage skin carcinogenesis. We found that, whereas UVB induces apoptosis in human papillomavirus-16 E6/7-immortalized keratinocytes, it inhibits markers of differentiation in human foreskin keratinocytes (HFK). Potential mechanisms for this differential response were examined by DNA microarray, which revealed that UVB alters the expression of three of the four human inhibitor of differentiation/DNA binding (Id) proteins that comprise a class of helix-loop-helix family of transcription factors involved in proliferation, differentiation, apoptosis, and carcinogenesis. These results were verified by RT-PCR and immunoblot analysis of control and UVB-irradiated primary and immortalized keratinocytes. Whereas Id1 was down-regulated in both cell types, Id2 expression was upregulated in primary HFK, but not immortalized cells. In contrast, Id3 expression was significantly increased only in immortalized cells. The differential expression pattern of Id2 in response to UVB was recapitulated in reporter constructs containing the 5' regulatory regions of this gene. Id2 promoter activity increased in response to UVB in HFK, but not in immortalized cells. To identify the regulatory elements in the Id2 promoter that mediate transcriptional activation by UVB in HFK, promoter deletion/mutation analysis was performed. Deletion analysis revealed that transactivation involves a 166 bp region immediately upstream to the Id2 transcriptional start site and is independent of c-Myc. The consensus E twenty-six (ETS) binding site at -120 appears to mediate UVB transcriptional activation of Id2 because point mutations at this site completely abrogated this response. Chromatin immunoprecipitation and electrophoretic mobility-shift assays verified that the Id2 promoter interacts with known Id2 promoter (ETS) binding factors Erg1/2 and Fli1, but not with c-Myc; and this interaction is enhanced after UVB exposure. Similar to the effects of UVB exposure, ectopic expression of Id2 protein in primary HFK resulted in inhibition of differentiation, as shown by decreased levels of the terminal differentiation marker keratin K1 and inhibition of involucrin crosslinking. Reduction of Id2 expression by small interfering RNAs attenuated the UVB-induced inhibition of differentiation in these cells. These results suggest that UVB-induced inhibition of differentiation of primary HFK is at least, in part, due to the upregulation of Id2, and that upregulation of Id2 by UVB might predispose keratinocytes to carcinogenesis by preventing their normal differentiation program.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Sapporo Med Univ, Sch Med, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan	Georgetown University; Sapporo Medical University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Feng-Pai, Chou/AGS-4250-2022; Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014; Tokino, Takashi/AAI-9887-2021	Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342; Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHS [R01 CA100443-04, R01 CA100443-02, R01 CA100443, R01 CA100443-03, R01 CA100443-05, 5R01 CA100443-02, R01 CA100443-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BAGHDOYAN S, 2005, J BIOL CHEM, V3, P3; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bavinck JNB, 2000, BRIT J DERMATOL, V142, P103, DOI 10.1046/j.1365-2133.2000.03248.x; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Brellier F, 2004, CANCER RES, V64, P2699, DOI 10.1158/0008-5472.CAN-03-3477; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BROWN L, 1994, MOL CELL BIOL, V14, P1245, DOI 10.1128/MCB.14.2.1245; Brown VL, 2004, J INVEST DERMATOL, V122, P1284, DOI 10.1111/j.0022-202X.2004.22501.x; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; D'Errico M, 2004, BRIT J DERMATOL, V150, P47, DOI 10.1111/j.1365-2133.2004.05714.x; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; Del Bino S, 2004, BRIT J DERMATOL, V150, P658, DOI 10.1111/j.0007-0963.2004.05886.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ELIEZRI YD, 1990, J AM ACAD DERMATOL, V23, P836, DOI 10.1016/0190-9622(90)70299-W; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; GUERINREVERCHON I, 1990, J CANCER RES CLIN, V116, P295, DOI 10.1007/BF01612906; Hacker C, 2003, NAT IMMUNOL, V4, P380, DOI 10.1038/ni903; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karen J, 1999, CANCER RES, V59, P474; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; KETTLER AH, 1990, ARCH DERMATOL, V126, P777, DOI 10.1001/archderm.126.6.777; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kleeff J, 1998, CANCER RES, V58, P3769; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KURABAYASHI M, 1995, GENE, V156, P311, DOI 10.1016/0378-1119(95)00017-Z; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; Liu J, 2000, BIOCHEM BIOPH RES CO, V273, P1042, DOI 10.1006/bbrc.2000.3055; Maki K, 2004, MOL CELL BIOL, V24, P3227, DOI 10.1128/MCB.24.8.3227-3237.2004; Mammone T, 2000, CELL BIOL TOXICOL, V16, P293, DOI 10.1023/A:1026746330146; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; MURAKAMI K, 1993, ONCOGENE, V8, P1559; Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Poignee M, 2001, CANCER RES, V61, P7118; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Rundhaug JE, 2005, MOL CARCINOGEN, V42, P40, DOI 10.1002/mc.20064; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Simbulan-Rosenthal CM, 2002, J BIOL CHEM, V277, P24709, DOI 10.1074/jbc.M200281200; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Takao J, 2002, PHOTODERMATOL PHOTO, V18, P5, DOI 10.1034/j.1600-0781.2002.180102.x; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Wilson JW, 2001, CANCER RES, V61, P8803; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wingender Edgar, 2004, In Silico Biology, V4, P55; Xiao XD, 2003, EXP MOL PATHOL, V75, P238, DOI 10.1016/S0014-4800(03)00092-3; Yeh KC, 2000, GENE, V254, P163, DOI 10.1016/S0378-1119(00)00274-2; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	89	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5443	5458		10.1038/sj.onc.1208709	http://dx.doi.org/10.1038/sj.onc.1208709			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007217				2022-12-28	WOS:000231222300005
J	Pouponnot, C; Sii-Felice, K; Hmitou, I; Rocques, N; Lecoin, L; Druillennec, S; Felder-Schmittbuhl, MP; Eychene, A				Pouponnot, C; Sii-Felice, K; Hmitou, I; Rocques, N; Lecoin, L; Druillennec, S; Felder-Schmittbuhl, MP; Eychene, A			Cell context reveals a dual role for Maf in oncogenesis	ONCOGENE			English	Article						AP-1; Jun; transformation; differentiation; tumor suppressor; multiple myeloma	TISSUE-SPECIFIC EXPRESSION; CRYSTALLIN GENE-REGULATION; FACTOR C-MAF; TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; LENS DIFFERENTIATION; TUMOR-SUPPRESSOR; DISTINCT ROLES; GROWTH-FACTOR; INSULIN GENE	Maf b-Zip transcription factors are involved in both terminal differentiation and oncogenesis. To investigate this apparent contradiction, we used two different primary cell types and performed an extensive analysis of transformation parameters induced by Maf proteins. We show that MafA and c-Maf are potent oncogenes in chicken embryo fibroblasts, while MafB appears weaker. We also provide the first evidence that MafA can confer growth factor independence and promote cell division at low density. Moreover, using MafA as a model, we identified several parameters that are critical for Maf transforming activities. Indeed, MafA ability to induce anchorage-independent cell growth was sensitive to culture conditions. In addition, the transforming activity of MafA was dependent on its phosphorylation state, since mutation on Ser65 impaired its ability to induce growth at low density and anchorage-independent growth. We next examined transforming activity of large Maf proteins in embryonic neuroretina cells, where they are known to induce differentiation. Unlike v-Jun, MafA, MafB and c-Maf did not show oncogenic activity in these cells. Moreover, they counteracted transformation induced by constitutive activation of the Ras/Raf/MEK pathway. Taken together, our results show that Maf proteins could display antagonistic functions in oncogenesis depending on the cellular context, and support a dual role for Maf as both oncogenes and tumor suppressor-like proteins.	Ctr Univ, CNRS, Inst Curie Rech, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Pouponnot, C (corresponding author), Ctr Univ, CNRS, Inst Curie Rech, UMR 146, Lab 110, F-91405 Orsay, France.	Celio.Pouponnot@curie.u-psud.fr; Alain.Eychene@curie.u-psud.fr	Hmitou, Isabelle/H-8341-2017; Eychene, Alain/M-8838-2017; DRUILLENNEC, Sabine/B-2572-2019	Hmitou, Isabelle/0000-0001-7320-6075; DRUILLENNEC, Sabine/0000-0003-0237-1465; LECOIN, Laure/0000-0001-5259-4339; Karine, SII FELICE/0000-0002-8695-8652; EYCHENE, Alain/0000-0002-6818-7225				Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Blanchi B, 2003, NAT NEUROSCI, V6, P1091, DOI 10.1038/nn1129; Boersma-Vreugdenhil GR, 2004, BRIT J HAEMATOL, V126, P355, DOI 10.1111/j.1365-2141.2004.05050.x; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; GOLDE A, 1961, VIROLOGY, V15, P36, DOI 10.1016/0042-6822(61)90074-5; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Lecoin L, 2004, GENE EXPR PATTERNS, V4, P35, DOI 10.1016/S1567-133X(03)00152-2; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Manzanares M, 1999, DEVELOPMENT, V126, P759; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Nishizawa M, 2003, ONCOGENE, V22, P7882, DOI 10.1038/sj.onc.1206526; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; OSTRER H, 1981, DEV BIOL, V86, P403, DOI 10.1016/0012-1606(81)90198-6; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ring BZ, 2000, DEVELOPMENT, V127, P307; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sii-Felice K, 2005, FEBS LETT, V579, P3547, DOI 10.1016/j.febslet.2005.04.086; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Yoshida K, 2001, CURR EYE RES, V23, P116, DOI 10.1076/ceyr.23.2.116.5479; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	55	38	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1299	1310		10.1038/sj.onc.1209171	http://dx.doi.org/10.1038/sj.onc.1209171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247450				2022-12-28	WOS:000235708200003
J	Angelastro, JM; Canoll, PD; Kuo, J; Weicker, M; Costa, A; Bruce, JN; Greene, LA				Angelastro, JM; Canoll, PD; Kuo, J; Weicker, M; Costa, A; Bruce, JN; Greene, LA			Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5	ONCOGENE			English	Article						ATF5; astrocytes; glioma; apoptosis; brain tumor	NEURAL PROGENITOR CELLS; MALIGNANT GLIOMA; DIFFERENTIATION; TRANSCRIPTION; CHECKPOINT; FAMILY; GROWTH; LINE; P53	Glioblastoma multifome is the most common and most aggressive primary brain tumor with no current curative therapy. We found expression of the bZip transcription factor ATF5 in all 29 human glioblastomas and eight human and rat glioma cell lines assessed. ATF5 is not detectably expressed by mature brain neurons and astrocytes, but is expressed by reactive astrocytes. Interference with ATF5 function or expression in all glioma cell lines tested causes marked apoptotic cell death. In contrast, such manipulations do not affect survival of ATF5-expressing cultured astrocytes or of several other cell types that express this protein. In a proof-of-principle experiment, retroviral delivery of a function-blocking mutant form of ATF5 into a rat glioma model evokes death of the infected tumor cells, but not of infected brain cells outside the tumors. The widespread expression of ATF5 in glioblastomas and the selective effect of interference with ATF5 function/expression on their survival suggest that ATF5 may be an attractive target for therapeutic intervention in such tumors.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY USA	Columbia University; Columbia University; Columbia University	Angelastro, JM (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 2165 Haring Hall,1 Shields Ave, Davis, CA 95616 USA.	jmangelastro@ucdavis.edu	Kuo, John S/D-3561-2013; Bruce, Jeffrey N/AAC-5307-2022	Kuo, John S/0000-0001-6809-4806; 				AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Badie B, 1999, CANCER GENE THER, V6, P155, DOI 10.1038/sj.cgt.7700009; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Collins V P, 2004, J Neurol Neurosurg Psychiatry, V75 Suppl 2, pii2, DOI 10.1136/jnnp.2004.040337; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Hansen MB, 2002, GENOMICS, V80, P344, DOI 10.1006/geno.2002.6838; Hirose Y, 2001, CANCER RES, V61, P5843; JENSEN AM, 1991, J NEUROSCI, V11, P1674; KLEIHUES P, 1993, HISTOLOGY TYPING TUM; KO L, 1980, ACTA NEUROPATHOL, V51, P23, DOI 10.1007/BF00688846; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; LEVISON SW, 1991, ASTROGLIA CULTURE, P309; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; MCLENDON RE, 1998, RUSSELL RUBINSTEINS, P307; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Pati D, 1999, MOL CELL BIOL, V19, P5001; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; PINKERTON H, 1976, P SOC EXP BIOL MED, V151, P532; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; Qi YP, 1997, J NEUROSCI, V17, P1217; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonoda Y, 2001, CANCER RES, V61, P4956; Vogelbaum MA, 1999, J NEUROSURG, V91, P483, DOI 10.3171/jns.1999.91.3.0483; Yamagishi N, 1995, J RADIAT RES, V36, P239, DOI 10.1269/jrr.36.239	33	71	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					907	916		10.1038/sj.onc.1209116	http://dx.doi.org/10.1038/sj.onc.1209116			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170340	Bronze			2022-12-28	WOS:000235212700010
J	Khanzada, UK; Pardo, OE; Meier, C; Downward, J; Seckl, MJ; Arcaro, A				Khanzada, UK; Pardo, OE; Meier, C; Downward, J; Seckl, MJ; Arcaro, A			Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling	ONCOGENE			English	Article						lung cancer; statins; ras; protein kinase B; receptor tyrosine kinase	PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; CARCINOMA-CELLS; PATHWAY; STATINS; PROLIFERATION; SUPPRESSION; PROGRESSION; LINES; MEK	The impact of the 3-hydroxy-3methylglutaryl CoA reductase inhibitor simvastatin on human small-cell lung cancer (SCLC) cell growth and survival was investigated. Simvastatin profoundly impaired basal and growth factor-stimulated SCLC cell growth in vitro and induced apoptosis. SCLC cells treated with simvastatin were sensitized to the effects of the chemotherapeutic agent etoposide. Moreover, SCLC tumour growth in vivo was inhibited by simvastatin. These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Constitutive activation of the Erk pathway was sufficient to rescue SCLC cell from the effects of simvastatin. The drug did not directly affect activation of c-Kit or its localization to lipid rafts, but in addition to its ability to block Ras membrane localization, it selectively downregulated H-Ras protein levels at the post-translational level. Downregulation of either H- or K-Ras by RNA interference (RNAi) did not impair Erk activation by growth factors, whereas an RNAi specific for N-Ras inhibited activation of Erk, PKB and SCLC cell growth. Together our data demonstrate that inhibiting Ras signalling with simvastatin potently disrupts growth and survival in human SCLC cells.	Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, Div Med,Lung Canc Biol Grp, London, England; CRUK London Res Inst, London, England	University Children's Hospital Zurich; Imperial College London; Cancer Research UK	Arcaro, A (corresponding author), Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Alexandre.Arcaro@kispi.unizh.ch	Arcaro, Alexandre/G-1711-2010; Pardo, Oliver/AEM-2071-2022; Downward, Julian/A-3251-2012	Arcaro, Alexandre/0000-0001-9107-2947; Pardo, Oliver/0000-0003-2223-1435; Downward, Julian/0000-0002-2331-4729				Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Chun KH, 2003, CANCER RES, V63, P4796; Furst J, 2002, CELL PHYSIOL BIOCHEM, V12, P19, DOI 10.1159/000047823; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hirai A, 1997, J BIOL CHEM, V272, P13; Hiwasa T, 1998, BIOCHEM BIOPH RES CO, V250, P741, DOI 10.1006/bbrc.1998.9386; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Johnson BE, 2004, CLIN CANCER RES, V10, p4254S, DOI 10.1158/1078-0432.CCR-040016; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kusama T, 2001, CANCER RES, V61, P4885; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Moore SM, 1998, CANCER RES, V58, P5239; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Tsao H, 2000, CANCER RES, V60, P1800; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200	24	93	99	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					877	887		10.1038/sj.onc.1209117	http://dx.doi.org/10.1038/sj.onc.1209117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170339				2022-12-28	WOS:000235212700007
J	Longley, DB; Wilson, TR; McEwan, M; Allen, WL; McDermott, U; Galligan, L; Johnston, PG				Longley, DB; Wilson, TR; McEwan, M; Allen, WL; McDermott, U; Galligan, L; Johnston, PG			c-FLIP inhibits chemotherapy-induced colorectal cancer cell death	ONCOGENE			English	Article						c-FLIP; 5-fluorouracil; oxaliplatin; irinotecan; apoptosis	LIGAND-INDEPENDENT ACTIVATION; MULTICENTER RANDOMIZED-TRIAL; RECEPTOR-INDUCED APOPTOSIS; UP-REGULATION; 1ST-LINE TREATMENT; CARCINOMA-CELLS; FAS; 5-FLUOROURACIL; FLUOROURACIL; RESISTANCE	FLIP inhibits caspase 8 activation and apoptosis mediated by death receptors such as Fas and DR5. We studied the effect of c-FLIP on the apoptotic response to chemotherapies used in colorectal cancer (CRC) (5-fluorouracil, oxaliplatin and irinotecan). Simultaneous downregulation of both c-FLIP splice forms c-FLIPL and c-FLIPS with siRNA synergistically enhanced chemotherapy-induced apoptosis in p53 wild-type (HCT116p53(+/+), RKO), null (HCT116p53(-/-)) and mutant (H630) CRC cell lines. Furthermore, overexpression of c-FLIPL, but not c-FLIPS, potently inhibited apoptosis induced by chemotherapy in HCT116p53(-/-) cells, suggesting that c-FLIPL was the more important splice form in mediating chemoresistance. In support of this, siRNA specifically targeted against c-FLIPL synergistically enhanced chemotherapy-induced apoptosis in a manner similar to the siRNA targeted against both splice forms. Inhibition of caspase 8 blocked the enhanced apoptosis induced by c-FLIP-targeted (FT) siRNA and chemotherapy. Furthermore, we found that downregulating cell surface DR5, but not Fas, also inhibited apoptosis induced by FT siRNA and chemotherapy. Interestingly, these effects were not dependent on activation of DR5 by its ligand TRAIL. These results indicate that c-FLIP inhibits TRAIL-independent, DR5- and caspase 8-dependent apoptosis in response to chemotherapy in CRC cells. Moreover, targeting c-FLIP in combination with existing chemotherapies may have therapeutic potential for the treatment of CRC.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Grp, Belfast BT9 7AB, Antrim, North Ireland	Queens University Belfast	Longley, DB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Grp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.longley@qub.ac.uk	Wilson, Timothy R/F-8210-2012; McEwan, Miranda V/A-6900-2012	McDermott, Ultan/0000-0001-9032-4700	Medical Research Council [G0400302] Funding Source: Medline; MRC [G0400302] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHINNAIYAN AM, 1995, CELL, V81, P512; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Conticello C, 2004, J IMMUNOL, V172, P5467, DOI 10.4049/jimmunol.172.9.5467; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fulda S, 2000, CANCER RES, V60, P3947; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Gniadecki R, 2004, BIOCHEM BIOPH RES CO, V320, P165, DOI 10.1016/j.bbrc.2004.05.145; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Iordanov MS, 2005, APOPTOSIS, V10, P167, DOI 10.1007/s10495-005-6071-x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jin TG, 2004, J BIOL CHEM, V279, P55594, DOI 10.1074/jbc.M401056200; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Matta H, 2002, CANCER BIOL THER, V1, P652, DOI 10.4161/cbt.315; Maxwell PJ, 2003, CANCER RES, V63, P4602; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Poulaki V, 2002, AM J PATHOL, V161, P643, DOI 10.1016/S0002-9440(10)64220-4; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Santiago B, 2004, J IMMUNOL, V172, P560, DOI 10.4049/jimmunol.172.1.560; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238	39	163	173	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	6					838	848		10.1038/sj.onc.1209122	http://dx.doi.org/10.1038/sj.onc.1209122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247474				2022-12-28	WOS:000235212700003
J	Miller, CT; Lin, L; Casper, AM; Lim, J; Thomas, DG; Orringer, MB; Chang, AC; Chambers, AF; Giordano, TJ; Glover, TW; Beer, DG				Miller, CT; Lin, L; Casper, AM; Lim, J; Thomas, DG; Orringer, MB; Chang, AC; Chambers, AF; Giordano, TJ; Glover, TW; Beer, DG			Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma	ONCOGENE			English	Article						MET oncogene; esophageal adenocarcinoma; gene amplification; FRA7G	RECEPTOR TYROSINE KINASE; BREAST-CANCER CELLS; LUNG ADENOCARCINOMAS; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; UNITED-STATES; GROWTH; TUMOR; OVEREXPRESSION; DYSPLASIA	Esophageal adenocarcinoma (EA) is characterized by a poor prognosis making the identification of clinically targetable proteins essential for improving patient outcome. We report the involvement of multiple alterations of the MET pathway in EA development and progression. Microarray analysis of Barrett's metaplasia, dysplasia, and EA revealed overexpression of the MET oncogene in EAs but only those with MET gene amplication. STS-amplication mapping revealed that the boundary of the MET amplicon in these EAs is defined by fragile site FRA7G. We also identified an amplicon at 11p13 that resulted in amplication and overexpression of CD44, a gene involved in MET autophosphorylation upon HGF stimulation. Tissue microarrays with phospho-MET-specific antibodies demonstrated a uniformly high abundance of MET activation in primary EA and cells metastatic to lymph nodes but to a lesser extent in a subset of metaplastic and dysplastic Barrett's samples. Increased expression of multiple genes in the MET pathway associated with invasive growth, for example, many MMPs and osteopontin, also was found in EAs. Treatment of EA-derived cell lines with geldanamycin, an inhibitor for tyrosine kinases including MET receptor kinase, reduced cell migration and induced EA cell apoptosis. The data indicate that upregulation of the MET pathway may contribute to the poor outcome of EA patients and that therapeutic agents targeting this pathway may help improve patient survival.	Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; London Reg Canc Ctr, Dept Oncol, London, England	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, MSRB 2 B560,Box 0686, Ann Arbor, MI 48109 USA.	dgbeer@umich.edu	Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123; Giordano, Thomas/0000-0003-0641-8873; Chang, Andrew/0000-0001-9506-0425; Casper, Anne/0000-0003-4975-5749	NATIONAL CANCER INSTITUTE [R01CA071606, R01CA043222] Funding Source: NIH RePORTER; NCI NIH HHS [CA43222, CA71606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Christensen JG, 2003, CANCER RES, V63, P7345; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Farrow DC, 1996, CANCER CAUSE CONTROL, V7, P322, DOI 10.1007/BF00052937; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Huang NN, 1998, J CHIN INST ENG, V21, P159, DOI 10.1080/02533839.1998.9670381; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; Hughes SJ, 1997, CANCER RES, V57, P5571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lin J, 2004, CLIN CANCER RES, V10, P5708, DOI 10.1158/1078-0432.CCR-04-0468; Lin L, 2000, CANCER RES, V60, P1341; Lin L, 2002, CANCER RES, V62, P5273; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Miller CT, 2003, CLIN CANCER RES, V9, P4819; Miller CT, 2003, CANCER RES, V63, P4136; NALDINI L, 1991, EMBO J, V10, P2857; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Recio JA, 2003, CANCER RES, V63, P1576; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rosenberg C, 2002, CANCER GENET CYTOGEN, V135, P35, DOI 10.1016/S0165-4608(01)00639-2; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Weber GF, 2002, CANCER RES, V62, P2281; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wong DJ, 1997, CANCER RES, V57, P2619; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhang YW, 2004, CANCER CELL, V6, P5, DOI 10.1016/j.ccr.2004.07.003	47	126	137	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					409	418		10.1038/sj.onc.1209057	http://dx.doi.org/10.1038/sj.onc.1209057			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186806				2022-12-28	WOS:000234714100009
J	Ware, MD; DeSilva, D; Sinilnikova, OM; Stoppa-Lyonnet, D; Tavtigian, SV; Mazoyer, S				Ware, MD; DeSilva, D; Sinilnikova, OM; Stoppa-Lyonnet, D; Tavtigian, SV; Mazoyer, S			Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?	ONCOGENE			English	Article						BRCA2; ovarian cancer cluster region; nonsense-mediated mRNA decay; genotype-phenotype correlation	PREMATURE TERMINATION CODONS; DNA-REPAIR; PROTEIN; TRANSCRIPTS; BREAST; SUSCEPTIBILITY; RECOMBINATION; TRANSLATION; EXPRESSION; MUTATIONS	BRCA2 (BReast CAncer susceptibility gene 2) germline mutation carriers are at increased risk for breast and ovarian cancers. Mutations occurring in the ovarian cancer cluster region (OCCR) are linked to higher ovarian cancer and/or lower breast cancer risk(s) than mutations occurring elsewhere in BRCA2. Most BRCA2 germline mutations introduce premature termination codons (PTCs), making their mRNAs likely targets of nonsense-mediated mRNA decay (NMD), a mechanism that eliminates PTC-bearing transcripts to prevent expression of truncated proteins. Contradictory evidence exists regarding whether NMD can be triggered by PTCs located far upstream of the nearest exon-exon junction (EEJ). Since the OCCR comprises a major portion of the 4.9 kb exon 11 of BRCA2, we investigated if transcripts bearing PTCs in this large exon are unable to trigger NMD, and if this might contribute to the phenotypic difference associated with the OCCR. We examined cDNA from 18 carriers of PTC-introducing germline mutations located throughout BRCA2, and found that PTC-bearing transcripts were 1.4-3.3-fold less prevalent than their nonmutated counterparts irregardless of PTC position. We conclude that NMD can recognize PTCs up to 4.5 kb upstream of the nearest EEJ, demonstrating that a general inability of NMD to recognize PTCs in exon 11 is unlikely to explain the genotype-phenotype correlation associated with the OCCR.	Univ Lyon 1, CNRS, UMR 5201, Fac Med Rockefeller,Lab Genet Mol Signalisat & Ca, F-69373 Lyon 08, France; Int Agcy Res Canc, F-69372 Lyon, France; Hosp Civils Lyon, Ctr Leon Berard, Plate Forme Mixte Genet Constitut Canc Frequents, Lyon, France; Inst Curie, Serv Genet Oncol, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mazoyer, S (corresponding author), Univ Lyon 1, CNRS, UMR 5201, Fac Med Rockefeller,Lab Genet Mol Signalisat & Ca, 8 Ave Rockefeller, F-69373 Lyon 08, France.	sylvie.mazoyer@sante.univ-lyon1.fr	Mazoyer, Sylvie/N-7559-2017	Mazoyer, Sylvie/0000-0002-2135-0160				Chatr-aryamontri A, 2004, HUM MUTAT, V24, P526, DOI 10.1002/humu.20117; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Gismondi V, 1998, GENE CHROMOSOME CANC, V22, P278, DOI 10.1002/(SICI)1098-2264(199808)22:4<278::AID-GCC3>3.3.CO;2-Q; Harries LW, 2004, DIABETES, V53, P500, DOI 10.2337/diabetes.53.2.500; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Lubinski Jan, 2004, Fam Cancer, V3, P1; Maquat LE, 2001, RNA, V7, P445, DOI 10.1017/S1355838201002229; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Neu-Yilik G, 2001, EMBO J, V20, P532, DOI 10.1093/emboj/20.3.532; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Rodningen OK, 1999, HUM MUTAT, V13, P186, DOI 10.1002/(SICI)1098-1004(1999)13:3<186::AID-HUMU2>3.0.CO;2-K; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Tournier I, 2004, HUM MUTAT, V23, P379, DOI 10.1002/humu.20008; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	25	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					323	328		10.1038/sj.onc.1209033	http://dx.doi.org/10.1038/sj.onc.1209033			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170354				2022-12-28	WOS:000234583600018
J	Sansom, OJ; Griffiths, DFR; Reed, KR; Winton, DJ; Clarke, AR				Sansom, OJ; Griffiths, DFR; Reed, KR; Winton, DJ; Clarke, AR			Apc deficiency predisposes to renal carcinoma in the mouse	ONCOGENE			English	Article						Apc; kidney; Wnt; Cre; renal cancer	BETA-CATENIN GENE; WILMS-TUMORS; EMBRYONIC LETHALITY; CELL CARCINOMAS; TSC2 MUTATION; P53 GENE; EXPRESSION; MICE; CARCINOGENESIS; INACTIVATION	Deregulation of Wnt signalling has recently been implicated in human renal cancer. Here, we directly test this association by using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine renal epithelium. Mice homozygous for a conditional Apc allele were intercrossed with mice transgenic for Cre recombinase under control of the Cyp1A promoter, which delivers constitutive recombination within a proportion of cells in the renal epithelium. Inactivation of Apc leads to the accumulation of nuclear beta-catenin and the rapid development of multiple dysplastic foci. Renal carcinoma was observed with an earliest onset of 4 months. This predisposition was accelerated by p53 deficiency, reducing the earliest onset to 2 months. Compared to other murine models of kidney neoplasia, this represents particularly rapid onset of disease, and so implicates an important role for Apc in suppressing renal carcinoma.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales; Univ Wales Coll Cardiff, Coll Med, Dept Pathol, Cardiff CF10 3US, Wales; Cambridge Inst Med Res, Canc Res UK, Dept Oncol, Cambridge CB2 2XY, England	Cardiff University; Cardiff University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales.	clarkear@cf.ac.uk	Reed, Karen/B-8813-2011; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Reed, Karen/0000-0002-7467-1718; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilim V, 2000, CLIN CANCER RES, V6, P460; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Guo LM, 2001, ONCOL REP, V8, P521; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Kusafuka T, 2002, INT J MOL MED, V10, P395; Menke AL, 2002, CANCER RES, V62, P6615; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pecina-Slaus N, 1999, J MOL MED-JMM, V77, P446, DOI 10.1007/s001090050375; Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Zang T, 2001, CHINESE MED J-PEKING, V114, P152; Zhu XD, 2000, PATHOL INT, V50, P945, DOI 10.1046/j.1440-1827.2000.01139.x	26	55	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8205	8210		10.1038/sj.onc.1208956	http://dx.doi.org/10.1038/sj.onc.1208956			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16116480				2022-12-28	WOS:000233809400012
J	O'Shea, CC				O'Shea, CC			Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction	ONCOGENE			English	Editorial Material						oncolytic; virus; cancer therapy; transformation	REPLICATION		Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; O'Shea CC, 2005, ONCOGENE, V24, P7640, DOI 10.1038/sj.onc.1209047; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045	15	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7636	7639		10.1038/sj.onc.1209035	http://dx.doi.org/10.1038/sj.onc.1209035			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299525				2022-12-28	WOS:000233372600001
J	Bousquet, M; Quelen, C; De Mas, V; Duchayne, E; Roquefeuil, B; Delsol, G; Laurent, G; Dastugue, N; Brousset, P				Bousquet, M; Quelen, C; De Mas, V; Duchayne, E; Roquefeuil, B; Delsol, G; Laurent, G; Dastugue, N; Brousset, P			The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene	ONCOGENE			English	Article						atypical chronic myeloid leukaemia; JAK2; PCM1	TYROSINE KINASE JAK2; MUTATION; RECEPTOR; BCR; CARCINOMA; PDGFRA; TARGET	Several tyrosine kinase genes are involved in chromosomal translocations in chronic myeloproliferative disorders, but there are still uncharacterized translocations in some cases. We report two such cases corresponding to atypical chronic myeloid leukaemia with a t(8; 9) p22; p24) translocation. By fluorescence in situ hybridisation ( FISH) on the corresponding metaphases with a bacterial artificial chromosome probe encompassing the janus kinase 2 (JAK2) gene at 9p24, we observed a split for both patients, suggesting that this gene was rearranged. The locus at 8p22 contains different candidate genes including the pericentriolar material 1 gene (PCM1), already implicated in reciprocal translocations. The rearrangement of the PCM1 gene was demonstrated by FISH, for both patients. By RT-PCR, we confirmed the fusion of 30 part of JAK2 with the 50 part of PCM1. Sequence analysis of the chimeric PCM1-JAK2 mRNA suggests that the putative protein displays the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2. This newtranslocation identifies JAK2 as a possible therapeutic target for compounds with antityrosine kinase activity.	CHU Purpan, INSERM, U563, CPTP, F-31059 Toulouse, France; CHU Purpan, Lab Cytogenet Hemopathies, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Brousset, P (corresponding author), CHU Purpan, INSERM, U563, CPTP, Pl Baylac, F-31059 Toulouse, France.	brousset.p@chu-toulouse.fr	Bousquet, Marina/H-2901-2016; QUELEN, Cathy/G-4974-2017	Bousquet, Marina/0000-0001-8333-1144; Quelen, Cathy/0000-0003-0576-2234				BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Baxter EJ, 2003, BRIT J HAEMATOL, V120, P251, DOI 10.1046/j.1365-2141.2003.04051.x; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bhattacharya N, 2003, INDIAN J MED RES, V118, P77; Carron C, 2000, BLOOD, V95, P3891; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; EMI M, 1992, CANCER RES, V52, P5368; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; Trempat P, 2003, ONCOGENE, V22, P5702, DOI 10.1038/sj.onc.1206543; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje	23	98	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7248	7252		10.1038/sj.onc.1208850	http://dx.doi.org/10.1038/sj.onc.1208850			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16091753				2022-12-28	WOS:000232990100013
J	Gupta, M; Gupta, SK; Balliet, AG; Hollander, MC; Fornace, AJ; Hoffman, B; Liebermann, DA				Gupta, M; Gupta, SK; Balliet, AG; Hollander, MC; Fornace, AJ; Hoffman, B; Liebermann, DA			Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis	ONCOGENE			English	Article						gadd45-deficient mice; apoptosis; hematopoietic cells; genotoxic stress; DNA damage	NEGATIVE GROWTH-CONTROL; P53-REGULATED PROTEIN GADD45; RESPONSE GENE MYD118; NUCLEAR ANTIGEN; DNA-REPAIR; ARREST; EXPRESSION; ACTIVATION; INDUCTION; RADIATION	Gadd45a, gadd45b and gadd45g (Gadd45/MyD118/CR6) are genes that are rapidly induced by genotoxic stress. However, the exact function of Gadd45 proteins in the response of mammalian cells to genotoxic stress is unclear. Here, advantage was taken of gadd45a- and gadd45b-deficient mice to determine the role gadd45a- and gadd45b play in the response of bone marrow ( BM) cells to genotoxic stress. BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wildtype (wt) cells. The increased apoptosis in gadd45a- and gadd45b-deficient cells was evident also by enhanced activation of caspase-3 and poly-ADP-ribose polymerase cleavage and decreased expression of c-inhibitor of apoptotic protein-1, Bcl-2, Bcl-xL compared to wt cells. Reintroduction of gadd45 into gadd45-deficient BM cells restored the wt apoptotic phenotype. Both gadd45a- and gadd45b-deficient BM cells also displayed defective G2/M arrest following exposure to UVC and VP-16, but not to DNR, indicating the existence of different G2/M checkpoints that are either dependent or independent of gadd45. Taken together, these findings identify gadd45a and gadd45b as antiapoptotic genes that increase the survival of hematopoietic cells following exposure to UV radiation and certain anticancer drugs.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Room 331,3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@temple.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL CANCER INSTITUTE [R01CA089718] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89718-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL 70530-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Balliet AG, 2001, DNA CELL BIOL, V20, P239, DOI 10.1089/104454901750219125; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V274, P29592; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749	27	85	92	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7170	7179		10.1038/sj.onc.1208847	http://dx.doi.org/10.1038/sj.onc.1208847			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170381				2022-12-28	WOS:000232990100006
J	Oppermann, M; Geilen, CC; Fecker, LF; Gillissen, B; Daniel, PT; Eberle, J				Oppermann, M; Geilen, CC; Fecker, LF; Gillissen, B; Daniel, PT; Eberle, J			Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik	ONCOGENE			English	Article						Nbk/Bik; BH3-only; melanoma; apoptosis	CERAMIDE-MEDIATED APOPTOSIS; BCL-2 FAMILY-MEMBERS; CONDITIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; MALIGNANT-MELANOMA; IN-VITRO; DEATH; BIK; RESISTANCE; CATHEPSIN	The proapoptotic BH3-only protein natural born killer/Bcl-2 interacting killer (Nbk/Bik) has been described to inhibit Bcl-2 and Bcl-x(L), thereby supporting the death promoting ability of Bax. In order to evaluate its function in melanoma, we investigated the response after Nbk/Bik overexpression in cultured human melanoma cells and in a melanoma mouse model. Untransfected melanoma cell lines expressed Nbk/Bik only weakly at the mRNA and protein level. Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate. For investigating the effects of Nbk/Bik in vivo, stably transfected melanoma cells were subcutaneously injected into nude mice. Signifi. cantly delayed tumor growth was the result when mice received doxycycline for induction of Nbk/Bik expression. By investigating the mechanism of Nbk/Bik-induced cell death, typical hallmarks of apoptosis such as DNA fragmentation and chromatin condensation were seen after induction. Interestingly, no indications for cytochrome c release and caspase processing were found, and selective caspase inhibition remained without effect. These data indicate the high potential of Nbk/Bik in regulating apoptosis in melanoma by a caspase-independent pathway and may corroborate the potency of novel antimelanoma strategies based on activation of BH3-only proteins such as Nbk/Bik.	Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, Charite Campus Benjamin Franklin, D-14195 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519; Gillissen, Bernhard/0000-0002-1815-2091				Bang B, 2004, ARCH DERMATOL RES, V296, P67, DOI 10.1007/s00403-004-0473-4; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; BOYD JM, 1995, ONCOGENE, V11, P1921; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Fecker LF, 2005, J INVEST DERMATOL, V124, P221, DOI 10.1111/j.0022-202X.2004.23572.x; Festjens N, 2003, ACTA HAEMATOL-BASEL, V111, P7, DOI 10.1159/000074483; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FISCHER U, 2005, IN PRESS CELL DEATH; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garbe C, 2001, SKIN PHARMACOL APPL, V14, P280, DOI 10.1159/000056358; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Han J, 1996, MOL CELL BIOL, V16, P5857; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Juin P, 2004, BBA-MOL CELL RES, V1644, P251, DOI 10.1016/j.bbamcr.2003.10.010; LOCKSHIN A, 1985, CANCER RES, V45, P345; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orth R, 1997, J BIOL CHEM, V272, P8841; Paquet C, 2004, APOPTOSIS, V9, P815, DOI 10.1023/B:APPT.0000045791.55282.91; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Theodorakis P, 2002, CANCER RES, V62, P3373; Tong Y, 2001, MOL CANCER THER, V1, P95; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025	52	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7369	7380		10.1038/sj.onc.1208890	http://dx.doi.org/10.1038/sj.onc.1208890			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007125				2022-12-28	WOS:000233142100013
J	Rosty, C; Sheffer, M; Tsafrir, D; Stransky, N; Tsafrir, I; Peter, M; de Cremoux, P; de La Rochefordiere, A; Salmon, R; Dorval, T; Thiery, JP; Couturier, J; Radvanyi, F; Domany, E; Sastre-Garau, X				Rosty, C; Sheffer, M; Tsafrir, D; Stransky, N; Tsafrir, I; Peter, M; de Cremoux, P; de La Rochefordiere, A; Salmon, R; Dorval, T; Thiery, JP; Couturier, J; Radvanyi, F; Domany, E; Sastre-Garau, X			Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma	ONCOGENE			English	Article						cervical cancer; gene expression; HPV; prognosis; bioinformatics	HUMAN-PAPILLOMAVIRUS TYPE-16; UTERINE CERVIX; MYC GENES; CANCER; INTEGRATION; AMPLIFICATION; RADIOTHERAPY; MICROARRAYS; PROGNOSIS; WORLDWIDE	Specific HPV DNA sequences are associated with more than 90% of invasive carcinomas of the uterine cervix. Viral E6 and E7 oncogenes are key mediators in cell transformation by disrupting TP53 and RB pathways. To investigate molecular mechanisms involved in the progression of invasive cervical carcinoma, we performed a gene expression study on cases selected according to viral and clinical parameters. Using Coupled Two-Way Clustering and Sorting Points Into Neighbourhoods methods, we identified a 'cervical cancer proliferation cluster' composed of 163 highly correlated transcripts. Most of these transcripts corresponded to E2F pathway genes controlling cell division or proliferation, whereas none was known as TP53 primary target. The average expression level of the genes of this cluster was higher in tumours with an early relapse than in tumours with a favourable course (P = 0.026). Moreover, we found that E6/E7 mRNA expression level was positively correlated with the expression level of the cluster genes and with viral DNA load. These findings suggest that HPV E6/E7 expression level plays a key role in the progression of invasive carcinoma of the uterine cervix via the deregulation of cellular genes controlling tumour cell proliferation. HPV expression level may thus provide a biological marker useful for prognosis assessment and specific therapy of the disease.	Inst Curie, Dept Biol Tumeurs, F-75248 Paris, France; Inst Curie, CNRS, Oncol Mol UMR 144, F-75248 Paris, France; Inst Curie, Dept Radiotherapy, F-75248 Paris, France; Inst Curie, Dept Chirurg, F-75248 Paris, France; Inst Curie, Dept Med Oncol, F-75248 Paris, France; Inst Curie, Dept Tranfert, F-75248 Paris, France; Weizmann Inst Sci, Dept Phys Complex Syst, Rehovot, Israel	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Weizmann Institute of Science	Sastre-Garau, X (corresponding author), Inst Curie, Med Sect, Dept Pathol, 26 Rue Ulm, F-75248 Paris, France.	xavier.sastre@curie.net	Rosty, Christophe/F-1796-2010; DOMANY, EYTAN/K-1560-2012; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Sheffer, Michal/0000-0001-5934-9950; Sastre-Garau, Xavier/0000-0001-5992-2083; Rosty, Christophe/0000-0001-7671-2651; Thiery, Jean Paul/0000-0003-0478-5020				BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; Chen Y, 2003, CANCER RES, V63, P1927; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Dalstein W, 2003, INT J CANCER, V106, P396, DOI 10.1002/ijc.11222; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FERLAY F, 2001, GLOBOCAN 2000 CANC I; Fisher RA, 1935, J R STAT SOC, V98, P39, DOI 10.2307/2342435; GERBAULET AL, 1992, RADIOTHER ONCOL, V23, P66, DOI 10.1016/0167-8140(92)90337-T; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; IKENBERG H, 1994, INT J CANCER, V59, P322, DOI 10.1002/ijc.2910590306; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Klaes R, 1999, CANCER RES, V59, P6132; Lai HC, 1999, INT J CANCER, V84, P553, DOI 10.1002/(SICI)1097-0215(19991222)84:6&lt;553::AID-IJC2&gt;3.0.CO;2-4; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lombard I, 1998, J CLIN ONCOL, V16, P2613, DOI 10.1200/JCO.1998.16.8.2613; Markey MP, 2002, CANCER RES, V62, P6587; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MILYAVSKY M, IN PRESS CANC RES; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Omura GA, 1997, J CLIN ONCOL, V15, P165, DOI 10.1200/JCO.1997.15.1.165; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Rosty C, 2004, INT J GYNECOL PATHOL, V23, P13, DOI 10.1097/01.pgp.0000092137.88121.8d; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; Sopov I, 2004, INT J CANCER, V112, P33, DOI 10.1002/ijc.20351; TABACH Y, UNPUB; Thierry F, 2004, CANCER RES, V64, P895, DOI 10.1158/0008-5472.CAN-03-2349; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tsafrir D, 2005, BIOINFORMATICS, V21, P2301, DOI 10.1093/bioinformatics/bti329; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang HLL, 2004, AM J SURG PATHOL, V28, P901, DOI 10.1097/00000478-200407000-00009; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Wong YF, 2003, CLIN CANCER RES, V9, P5486; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	44	105	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7094	7104		10.1038/sj.onc.1208854	http://dx.doi.org/10.1038/sj.onc.1208854			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007141	Green Submitted			2022-12-28	WOS:000232833200011
J	Wisdom, R; Huynh, L; Hsia, D; Kim, S				Wisdom, R; Huynh, L; Hsia, D; Kim, S			RAS and TGF-beta exert antagonistic effects on extracellular matrix gene expression and fibroblast transformation	ONCOGENE			English	Article						transformation; matrix; TGF-beta	INDEPENDENT PATHWAYS; CELLS; JUN; INVASION; CANCER; FOS; IDENTIFICATION; SUPPRESSION; REPRESSION; MUTATIONS	Ras, Raf, and Fos function as components in a signal transduction pathway that is constitutively active in many cancers. Many of the changes that underlie cell transformation arise through changes in gene expression. We have used gene expression pro. ling of 3T3 cells transformed by Ras, Raf, and Fos to de. ne the common and distinct targets of transcriptional control by each of these oncogenes. In this analysis, the most strongly conserved feature of cell transformation at the transcriptional level is the transcriptional repression of genes that encode components of the extracellular matrix (ECM). TGF-beta treatment of fibroblasts is known to increase production of ECM, suggesting that TGF-beta might selectively reverse some of the gene expression changes that occur during cell transformation. Using gene expression pro. ling of the TGF-beta response, we show that the ability of TGF-beta to reverse the changes in gene expression brought about by cellular transformation is essentially confined to genes that encode components of the ECM and the cytoskeleton. This selective reversal of transformation-induced changes in gene expression is associated with partial reversal of many parameters of cell transformation. The results demonstrate a correlation between gene repression by the Ras/Raf/ERK signaling pathway, gene activation by the TGF-beta signaling pathway, and the transformed phenotype in fibroblasts.	Univ Calif Davis, Sch Med, Ctr Canc, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Div Hematol & Oncol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Wisdom, R (corresponding author), Univ Calif Davis, Sch Med, Ctr Canc, Res Bldg 3,Room 1100,4645 2nd Ave, Sacramento, CA 95817 USA.	ronald.wisdom@ucdmc.ucdavis.edu			NATIONAL CANCER INSTITUTE [R01CA064118] Funding Source: NIH RePORTER; NCI NIH HHS [CA64118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe N, 2000, CANCER RES, V60, P3117; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McGarry LC, 2004, ONCOGENE, V23, P5284, DOI 10.1038/sj.onc.1207687; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Moustakas A, 1999, J CELL SCI, V112, P1169; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; PARSONS R, 1995, CANCER RES, V55, P5548; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sprowles A, 2003, ONCOGENE, V22, P498, DOI 10.1038/sj.onc.1206165; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wood LJ, 2000, CANCER RES, V60, P4256; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	39	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7043	7054		10.1038/sj.onc.1208870	http://dx.doi.org/10.1038/sj.onc.1208870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007133				2022-12-28	WOS:000232833200006
J	Lee, S; Privalsky, ML				Lee, S; Privalsky, ML			Multiple mutations contribute to repression by the v-Erb A oncoprotein	ONCOGENE			English	Article						v-Erb A; c-Erb A; thyroid hormone receptor; T3R; dominant negative; c-Jun	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; DOMINANT-NEGATIVE ACTIVITY; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-BINDING; X-RECEPTOR; C-ERBA; RESPONSE ELEMENTS; TRANSCRIPTIONAL REPRESSION; ERYTHROID-DIFFERENTIATION	The v-Erb A oncoprotein of avian erythroblastosis virus is derived from c-Erb A, a hormone-activated transcription factor. Notably, v-Erb A has sustained multiple mutations relative to c-Erb A and functions as a constitutive transcriptional repressor. We report here an analysis of the contributions of these different mutations to v-Erb A function. Our experiments demonstrate that two amino-acid differences between v-Erb A and c-Erb A, located in the 'I-box,' alter the dimerization properties of the viral protein, resulting in more stable homodimer formation, increased corepressor binding, and increased target gene repression. An additional amino-acid difference between v-and c-Erb A, located in helix 3 of the hormone binding domain, renders corepressor binding by the viral protein more resistant to release by thyroid hormone. Finally, we report that a C-terminal truncation in v-Erb A not only inhibits exchange of corepressor and coactivator, as previously noted, but also permits v-Erb A to recruit both SMRT and N-CoR corepressors, whereas c-Erb A is selective for N-CoR. The latter two mutations in v-Erb A also impair its ability to suppress c-Jun function in response to T3 hormone. We propose that the acquisition of oncogenic potential by the v-Erb A protein was a multistep process involving a series of mutations that alter the transcriptional repressive properties of the viral protein through multiple mechanisms.	Univ Calif Davis, Biol Sect, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Biol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu		Lee, Sangho/0000-0003-3771-7761	NCI NIH HHS [R37-CA53394, R37 CA053394-10, R37 CA053394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, ONCOGENE, V6, P2129; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1989, INT J CANCER, P26; Farboud B, 2004, MOL ENDOCRINOL, V18, P2839, DOI 10.1210/me.2004-0236; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORREST D, 1990, ONCOGENE, V5, P309; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GHYSDAEL J, 1992, CANCER SURV, V14, P169; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harbers M, 1998, J STEROID BIOCHEM, V67, P181, DOI 10.1016/S0960-0760(98)00100-9; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAIN B, 1990, New Biologist, V2, P284; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PINCUS MR, 1992, ANN CLIN LAB SCI, V22, P323; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; Samarut J, 1996, CURR TOP MICROBIOL, V212, P163; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1992, ONCOGENE, V7, P953; Shen Q, 2000, J BIOL CHEM, V275, P41018, DOI 10.1074/jbc.M006111200; Soucek L, 2002, CANCER CELL, V1, P406, DOI 10.1016/S1535-6108(02)00077-6; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stunnenberg HG, 1999, BBA-REV CANCER, V1423, pF15, DOI 10.1016/S0304-419X(98)00036-5; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Usala S J, 1991, Thyroid, V1, P361, DOI 10.1089/thy.1991.1.361; Vennstrom B, 1987, Horm Metab Res Suppl, V17, P14; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wahlstrom GM, 1996, ONCOGENE, V13, P843; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Wondisford FE, 2003, J INVEST MED, V51, P215, DOI 10.1136/jim-51-04-22; YEN PM, 1994, J BIOL CHEM, V269, P903; YEN PM, 1992, J BIOL CHEM, V267, P23248; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Yoh Sunnie M, 2002, Methods Mol Biol, V202, P129; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zubkova I, 2004, MOL BIOL REP, V31, P131, DOI 10.1023/B:MOLE.0000031412.25988.30; Zubkova I, 2003, MOL CELL ENDOCRINOL, V199, P61, DOI 10.1016/S0303-7207(02)00299-X; Zubkova I, 2002, BIOCHEM BIOPH RES CO, V294, P35, DOI 10.1016/S0006-291X(02)00428-X	94	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6737	6752		10.1038/sj.onc.1208826	http://dx.doi.org/10.1038/sj.onc.1208826			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007162	Green Accepted			2022-12-28	WOS:000232527800002
J	Tosi, GM; Trimarchi, C; Macaluso, M; La Sala, D; Ciccodicola, A; Lazzi, S; Massaro-Giordano, M; Caporossi, A; Giordano, A; Cinti, C				Tosi, GM; Trimarchi, C; Macaluso, M; La Sala, D; Ciccodicola, A; Lazzi, S; Massaro-Giordano, M; Caporossi, A; Giordano, A; Cinti, C			Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach	ONCOGENE			English	Article						sporadic retinoblastoma; Rb2/p130 mutation; methylation; demethylating agent; 5-Aza-dC	DNA METHYLATION; P53; APOPTOSIS; RB; EXPRESSION; PROTEIN; P73; ACCUMULATION; PROMOTER; MUTATION	Human retinoblastoma occurs in two forms (familial and sporadic) both due to biallelic mutation of the RB1/p105 gene even if its loss is insufficient for malignancy. We have recently reported that loss of expression of the retinoblastoma-related protein pRb2/p130 correlates with low apoptotic index, suggesting that RB2/p130 gene could be involved in retinoblastoma. Mutational analysis of RB2/p130 in primary tumors showed a tight correlation between Exon 1 mutations and pRb2/p130 expression level in sporadic retinoblastoma. These mutations are located within a CpG-enriched region prone to de novo methylation. Analysis of RB2/p130 methylation status revealed that epigenetic events, most probably consequent to the Exon 1 mutations, determined the observed phenotype. Treatment of Weri-Rb1 cell line by 5-Aza-dC induced an increase in expression level of pRb2/p130, E2F1, p73 and p53. Overall, our results highlight a crucial role of epigenetic events in sporadic retinoblastoma, which opens a perspective for new therapeutic approaches.	Univ Siena, CNR, IFC,Pathol Anat Unit, Inst Clin Physiol,Dept Human Pathol & Oncol, I-53100 Siena, Italy; CNR, Inst Clin Physiol, Siena, Italy; CNR, Inst Genet & Biophys, Naples, Italy; Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; CNR, Inst Neurosci, I-56100 Pisa, Italy; Univ Siena, Dept Ophthalmol & Neurosurg, I-53100 Siena, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Siena	Cinti, C (corresponding author), Univ Siena, CNR, IFC,Pathol Anat Unit, Inst Clin Physiol,Dept Human Pathol & Oncol, Via Scotte 6, I-53100 Siena, Italy.	cinti@area.bo.cnr.it	Giordano, Antonio/F-1927-2010; Lazzi, Stefano/P-8265-2018	Giordano, Antonio/0000-0002-5959-016X; Lazzi, Stefano/0000-0002-2218-3771; Ciccodicola, Alfredo/0000-0002-9924-1482; Cinti, Caterina/0000-0001-8049-0369; CAPOROSSI, Aldo/0000-0002-8680-3773				Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bender CM, 1998, CANCER RES, V58, P95; Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Choy KW, 2004, INVEST OPHTH VIS SCI, V45, P3404, DOI 10.1167/iovs.03-1273; CINTI C, 2003, REGULATION G1 PHASE, P200; CINTI C, 2000, EMERGING THER TARGET, V4, P765; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Douc-Rasy S, 2004, M S-MED SCI, V20, P317, DOI 10.1051/medsci/2004203317; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Gallie BL, 1999, CANCER RES, V59, p1731S; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KALIBIC T, 2003, ANN NY ACAD SCI, V983, P278; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kusek JC, 2001, BRAIN RES BULL, V54, P187, DOI 10.1016/S0361-9230(00)00447-0; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lai H, 2003, J CELL BIOCHEM, V88, P121, DOI 10.1002/jcb.10283; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MAYOL X, 1993, ONCOGENE, V8, P2561; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stirzaker C, 1997, CANCER RES, V57, P2229; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	39	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5827	5836		10.1038/sj.onc.1208630	http://dx.doi.org/10.1038/sj.onc.1208630			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007224				2022-12-28	WOS:000231590400005
J	Ito, S; Ito, Y; Senga, T; Hattori, S; Matsuo, S; Hamaguchi, M				Ito, S; Ito, Y; Senga, T; Hattori, S; Matsuo, S; Hamaguchi, M			v-Src requires Ras signaling for the suppression of gap junctional intercellular communication	ONCOGENE			English	Article						v-Src; Ras; gap junction; cell-cell communication; Connexin43	TYROSINE PHOSPHORYLATION; PROTEIN; CONNEXIN-43; INHIBITION; TRANSFORMATION; PERMEABILITY; MUTANT; STAT3	Cell transformation by v-Src causes suppression of gap junctional intercellular communication (GJIC). Although tyrosine phosphorylation of connexin43 (Cx43), a gap junctional component, appears to be necessary for the suppression, involvement of other signaling remains unclear. We investigated the role of Ras signaling in the suppression of GJIC by v-Src. Conditional expression of either S17N Ras or mtGap1m dramatically recovered GJIC in v-Src-transformed cells. Although expression of S17N Ras or mtGap1m substantially decreased the levels of active Ras, tyrosine phosphorylation of cellular proteins including Cx43 remained unchanged. Similarly, treatment of v-Src-transfomed cells with a Ras farnesyltransferase inhibitor, manumycin A, restored GJIC, whereas tyrosine phosphorylation of Cx43 remained unchanged. Thus, these results strongly suggest that, in addition to Cx43 phosphorylation, constitutive activation of Ras signaling is required for the suppression of GJIC by v-Src.	Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Div Clin Immunol,Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Div Cellular Genome Prote, Minato Ku, Tokyo, Japan	Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mhamagu@med.nagoya-u.ac.jp						ATKINSON M, 1984, J CELL BIOL, V99, pA401; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; Warn-Cramer BJ, 2004, BBA-BIOMEMBRANES, V1662, P81, DOI 10.1016/j.bbamem.2003.10.018; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	28	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2420	2424		10.1038/sj.onc.1209263	http://dx.doi.org/10.1038/sj.onc.1209263			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16301992				2022-12-28	WOS:000236764300013
J	Royds, JA; Hibma, M; Dix, BR; Hananeia, L; Russell, IA; Wiles, A; Wynford-Thomas, D; Braithwaite, AW				Royds, JA; Hibma, M; Dix, BR; Hananeia, L; Russell, IA; Wiles, A; Wynford-Thomas, D; Braithwaite, AW			P53 promotes adenoviral replication and increases late viral gene expression	ONCOGENE			English	Article						p53; adenovirus; E1b55kDa; oncology	CARCINOMA CELL-LINES; MAJOR LATE PROMOTER; PHASE-II TRIAL; TUMOR-CELLS; 55-KILODALTON PROTEIN; NUCLEAR-LOCALIZATION; DELETED ADENOVIRUS; BINDING PROTEIN; NECK-CANCER; ONYX-015	The tumor suppressor protein, p53, plays a critical role in viro-oncology. However, the role of p53 in adenoviral replication is still poorly understood. In this paper, we have explored further the effect of p53 on adenoviral replicative lysis. Using well-characterized cells expressing a functional p53 (A549, K1neo, RKO) and isogenic derivatives that do not (K1scx, RKOp53.13), we show that virus replication, late virus protein expression and both wtAd5 and ONYX-015 virus-induced cell death are impaired in cells deficient in functional p53. Conversely, by transfecting p53 into these and other cells (IIICF/c, HeLa), we increase late virus protein expression and virus yield. We also show, using reporter assays in IIICF/c, HeLa and K1scx cells, that p53 can cooperate with E1a to enhance transcription from the major late promoter of the virus. Late viral protein production is enhanced by exogenous p53. Taken together, our data suggest that functional p53 can promote the adenovirus (Ad) lytic cycle. These results have implications for the use of Ad mutants that are defective in p53 degradation, such as ONYX-015, as agents for the treatment of cancers.	Univ Otago, Dept Pathol, Dunedin 9001, New Zealand; Univ Otago, Dept Microbiol, Dunedin 9001, New Zealand; Univ Cardiff Wales, Coll Med, Dept Pathol, Cardiff, Wales	University of Otago; University of Otago; Cardiff University	Royds, JA (corresponding author), Univ Otago, Dept Pathol, POB 913, Dunedin 9001, New Zealand.	janice.royds@stonebow.otago.ac.nz						BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1981, J VIROL, V39, P331, DOI 10.1128/JVI.39.2.331-340.1981; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Dix BR, 2000, CANCER RES, V60, P2666; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; Edwards SJ, 2002, J VIROL, V76, P12483, DOI 10.1128/JVI.76.24.12483-12490.2002; Geoerger B, 2002, CANCER RES, V62, P764; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Hann B, 2003, J VIROL, V77, P11588, DOI 10.1128/JVI.77.21.11588-11595.2003; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Koch P, 2001, CANCER RES, V61, P5941; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KRUIJER W, 1981, NUCLEIC ACIDS RES, V9, P4439, DOI 10.1093/nar/9.18.4439; Lee H, 2000, INT J CANCER, V88, P454, DOI 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T; LEHMAN TA, 1991, CANCER RES, V51, P4090; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Rauen KA, 2002, CANCER RES, V62, P3812; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Rogulski KR, 2000, CANCER RES, V60, P1193; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Sauthoff H, 2002, HUM GENE THER, V13, P1859, DOI 10.1089/104303402760372954; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENK T, 1996, VIROLOGY, V2, P2111; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WEYER U, 1985, EMBO J, V4, P3015, DOI 10.1002/j.1460-2075.1985.tb04037.x; WILLIAMS JF, 1974, COLD SPRING HARB SYM, V39, P427, DOI 10.1101/SQB.1974.039.01.055; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357	53	34	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1509	1520		10.1038/sj.onc.1209185	http://dx.doi.org/10.1038/sj.onc.1209185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247442				2022-12-28	WOS:000235890400008
J	Stanhill, A; Levin, V; Hendel, A; Shachar, I; Kazanov, D; Arber, N; Kaminski, N; Engelberg, D				Stanhill, A; Levin, V; Hendel, A; Shachar, I; Kazanov, D; Arber, N; Kaminski, N; Engelberg, D			Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells	ONCOGENE			English	Article						ras; HSF1; HSP70b	HEAT-SHOCK FACTOR-1; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; DNA-BINDING ACTIVITY; FACTOR-I; NEURONAL DIFFERENTIATION; MOLECULAR CHAPERONES; PC12 CELLS; PROGNOSTIC IMPLICATIONS; INCREASING COMPLEXITY	Heat shock proteins (Hsps) are overexpressed in many tumors, but are downregulated in some tumors. To check for a direct effect of Ha-Ras(va112) on HSP70 transcription, we transiently expressed the oncoprotein in Rat1 fibro-blasts and monitored its effect on HSP70b promoter-driven reporter gene. We show that expression of Ha-Ras(va112) induced this promoter. Promoter analysis via systematic deletions and point mutations revealed that Ha-Ras(va112) induces HSP70b transcription via heat shock elements (HSEs). Also, Ha-Ras(va112) induction of HSE-mediated transcription was dramatically reduced in HSF1 -/- cells. Yet, residual effect of Ha-Ras(va112) that was still measured in HSF1 -/- cells suggests that some of the Ha-Ras(va112) effect is Hsf1-independent. When HSF1 -/- cells, stably expressing Ha-Ras(va112), were grown on soft agar only small colonies were formed suggesting a role for heat shock factor 1 (Hsf1) in Ha-Ras(va112)-mediated transformation. Although Ha-ras(Val12) seems to be an inducer of HSP70's expression, we found that in Ha-ras(Va112-)transformed fibroblasts expression of this gene is suppressed. This suppression is correlated with higher sensitivity of Ha-ras(va112)-transformed cells to heat shock. We suggest that Ha-ras(Va112) is involved in Hsf1 activation, thereby inducing the cellular protective response. Cells that repress this response are perhaps those that acquire the capability to further proliferate and become transformed clones.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Chaim Sheba Med Ctr, Dept Funct Genom, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, GI Oncol Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Gastroenterol, IL-69978 Tel Aviv, Israel; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA	Hebrew University of Jerusalem; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	Engelber@mail.ls.huji.ac.il	Hendel, Ayal/GMW-7991-2022	Arber, Nadir/0000-0001-5283-6991; Kaminski, Naftali/0000-0001-5917-4601; Hendel, Ayal/0000-0002-3388-6202				Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Brown JM, 1999, CANCER RES, V59, P1391; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Dwyer DS, 1996, NEUROCHEM RES, V21, P659, DOI 10.1007/BF02527722; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Han SI, 2002, FEBS LETT, V515, P141, DOI 10.1016/S0014-5793(02)02459-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatayama T, 1997, J BIOCHEM-TOKYO, V122, P904; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MIVECHI NF, 1995, CANCER RES, V55, P5512; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; Myung Jae-Kyung, 2004, Proteome Sci, V2, P8, DOI 10.1186/1477-5956-2-8; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Santarosa M, 1997, EUR J CANCER, V33, P873, DOI 10.1016/S0959-8049(97)00002-6; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; TETU B, 1992, CANCER RES, V52, P2325; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Voellmy R, 2004, PROG NUCLEIC ACID RE, V78, P143, DOI 10.1016/S0079-6603(04)78004-6; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	79	22	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1485	1495		10.1038/sj.onc.1209193	http://dx.doi.org/10.1038/sj.onc.1209193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278678				2022-12-28	WOS:000235890400006
J	Takeda, H; Miyoshi, H; Kojima, Y; Oshima, M; Taketo, MM				Takeda, H; Miyoshi, H; Kojima, Y; Oshima, M; Taketo, MM			Accelerated onsets of gastric hamartomas and hepatic adenomas/carcinomas in Lkb1(+/-)p53(-/-) compound mutant mice	ONCOGENE			English	Article						LKB1; p53; Peutz-Jeghers syndrome; hamartoma; HCC	PEUTZ-JEGHERS-SYNDROME; CELL-CYCLE ARREST; INTESTINAL METAPLASIA; KNOCKOUT MICE; LKB1 GENE; CANCER; MUTATIONS; KINASE; P53; CARCINOMA	Germline mutations in the LKB1 gene are responsible for Peutz-Jeghers syndrome (PJS), which is characterized by gastrointestinal hamartomas and increasing risk of cancer. Mice with Lkb1(-/+) mutation develop gastric hamartomas after > 20 weeks of age, and hepatocellular adenomas and carcinomas > 30 weeks. It has been reported that, in PJS patients, carcinomas progressed from hamartomas contain p53 mutations, and that LKB1 regulates p53-dependent apoptosis. To investigate the roles of LKB1 and p53 mutations in tumorigenesis, we constructed compound mutant mice of Lkb1 and p53 genes. In the Lkb1(+/-) p53(-/-) mice, formation of gastric hamartomas and hepatic tumors was accelerated. However, histopathology of hamartomas was similar between Lkb1(+/-) p53(-/-) and Lkb1(+/-) mice, and Lkb1 genotype remained heterozygous, suggesting that the p53 mutation affected hamartoma initiation. Contrary to the heterozygous hamartomas in the stomach and duodenum, the hepatic adenomas in Lkb1(+/-) p53(-/-) mice showed loss of Lkb1 heterozygosity (LOH), suggesting that lack of p53 stimulated Lkb1 LOH and tumor initiation in the liver. Taken together, these results indicate that lack of p53 causes earlier onsets of gastric hamartomas and hepatic tumors in Lkb1(-/-) p53(-/-) mice.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bronner MP, 2003, MODERN PATHOL, V16, P359, DOI 10.1097/01.MP.0000062992.54036.E4; Crowe SE, 2005, CURR OPIN GASTROEN, V21, P32; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Miyaki M, 2000, CANCER RES, V60, P6311; Miyoshi H, 2002, CANCER RES, V62, P2261; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Nakau M, 2002, CANCER RES, V62, P4549; Papageorgiou T, 2002, INT J GYNECOL CANCER, V12, P337, DOI 10.1046/j.1525-1438.2002.01147.x; Seno H, 2002, INT J ONCOL, V21, P769; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Takahashi M, 2004, J GASTROENTEROL, V39, P1210, DOI 10.1007/s00535-004-1474-y; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	23	24	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1816	1820		10.1038/sj.onc.1209207	http://dx.doi.org/10.1038/sj.onc.1209207			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278673	Green Submitted			2022-12-28	WOS:000236013700014
J	Chen, YR; Fu, YN; Lin, CH; Yang, ST; Hu, SF; Chen, YT; Tsai, SF; Huang, SF				Chen, YR; Fu, YN; Lin, CH; Yang, ST; Hu, SF; Chen, YT; Tsai, SF; Huang, SF			Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants	ONCOGENE			English	Article						NSCLC; EGFR; mutation; gefitinib; tyrosine phosphorylation	GROWTH-FACTOR-RECEPTOR; NONSMALL CELL LUNG; TYROSINE KINASE; CANCER; MUTATIONS; ENDOCYTOSIS; INHIBITOR; GENE; RESPONSIVENESS; EXPRESSION	Mutations in the kinase domain of epidermal growth factor receptor ( EGFR) are associated with clinical responsiveness to gefitinib in patients with non-small-cell lung cancers (NSCLC). Recently, we have identified many novel EGFR mutations in NSCLC tissues. In this study, we found that gefitinib could suppress the tyrosine phosphorylation of most EGFR mutants better than the wild-type receptor. However, gefitinib had quite variable growth-suppressive effects on different EGFR mutant-expressing cells. All tested EGFR mutants have high basal phosphorylation at multiple tyrosine residues. Upon EGF stimulation, the mutated EGFRs did not have apparently stronger phosphorylation at tyrosines 845, 992, 1068, and 1173 than the wild-type receptor. However, stronger phosphorylation at tyrosine 1045 was observed in the S768I, L861Q, E709G, and G719S mutants. The E746-A750 deletion mutant was less responsive to EGF than the wild-type and other mutant receptors. The S768I, L861Q, E709G, and G719S mutants were refractory to EGF-induced ubiquitination and had more sustained tyrosine phosphorylation. E709G and G719S also lacked EGF-induced receptor downregulation. Our results indicate that, in addition to sensitivity to gefitinib, EGFR mutations also caused various changes in EGFR's regulatory mechanisms, which may contribute to the constitutive activation of EGFR mutants and oncogenesis in NSCLC.	Natl Hlth Res Inst, Div Mol & Gen Med, Zhunan 350, Taiwan; Natl Yang Ming Univ, Inst Genet & Gen Res Ctr, Taipei 112, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan; Municipal Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; Taipei Med Univ, Sch Med, Dept Pathol, Taipei, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University	Huang, SF (corresponding author), Natl Hlth Res Inst, Div Mol & Gen Med, 35,Keyan Rd, Zhunan 350, Taiwan.	sfhuang@nhri.org.tw	Chen, Yi-Rong/CAF-2186-2022; Tsai, Shih-Feng/E-3997-2010; Huang, Shiu-Feng Kathy/E-3977-2010; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002				Amann J, 2005, CANCER RES, V65, P226; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Herbst RS, 2003, CLIN CANCER RES, V9, P5813; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RUSCH V, 1993, CANCER RES, V53, P2379; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637	29	107	117	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1205	1215		10.1038/sj.onc.1209159	http://dx.doi.org/10.1038/sj.onc.1209159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205628				2022-12-28	WOS:000235537500008
J	Lau, SH; Sham, JST; Xie, D; Tzang, CH; Tang, D; Ma, N; Hu, L; Wang, Y; Wen, JM; Xiao, G; Zhang, WM; Lau, GKK; Yang, M; Guan, XY				Lau, SH; Sham, JST; Xie, D; Tzang, CH; Tang, D; Ma, N; Hu, L; Wang, Y; Wen, JM; Xiao, G; Zhang, WM; Lau, GKK; Yang, M; Guan, XY			Clusterin plays an important role in hepatocellular carcinoma metastasis	ONCOGENE			English	Article						clusterin; hepatocellular carcinoma; metastasis; YKL-40; microarray	SMOOTH-MUSCLE-CELLS; SERUM YKL-40; PROSTATE-CANCER; MIGRATION; MARKER; GENE; OVEREXPRESSION; MICROARRAY; EXPRESSION; PROTEIN	To identify genes associated with tumor metastasis in hepatocellular carcinoma (HCC), gene expression profiles between a pair of primary HCC (H2-P) and their matched metastatic HCC (H2-M) were compared. Overexpression of clusterin (CLU) was found in H2-M cells. To determine the roles CLU played in HCC metastasis, CLU was transfected into H2-P cells. Overexpression of CLU in H2-P cells increased cell migration by twofold in vitro and formation of metastatic tumor nodules in liver by eightfold in vivo. To evaluate the correlation of CLU expression with HCC metastasis, the expression levels of CLU in HCCs were investigated using a tissue microarray (TMA) containing 104 pairs of primary HCCs and their matched metastases. The frequency of CLU overexpression increased significantly in metastatic HCCs (59.1%) compared with that in primary tumors (32.6%, P < 0.001). To gain additional insight into the function of CLU, the expression pro. le of H2P-CLU was compared with vector-transfected H2-P cells by cDNA microarray. A total of 35 upregulated and 14 downregulated genes were detected in H2P-CLU. One of the upregulated genes known as YKL-40, which is implicated in matrix-remodeling and metastasis, was further studied using TMA. A significant correlation (P < 0.001) between the expression levels of YKL-40 and CLU was observed, implying that the CLU-YKL-40 pathway may play an important role in HCC metastasis.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Ctr Canc, State Key Lab Oncol So China, Guangzhou, Peoples R China; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China; Sun Yat Sen Univ, Dept Pathol, Guangzhou, Peoples R China; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; City University of Hong Kong; Naval Medical University; Sun Yat Sen University; University of Hong Kong	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,Estate Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Lau, George/AAQ-2085-2021; Yang, Mengsu/I-5750-2015; Yang, Mo/C-4455-2009; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	Yang, Mengsu/0000-0003-2083-2296; /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017				BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Dehn H, 2003, ACTA OBSTET GYN SCAN, V82, P287, DOI 10.1034/j.1600-0412.2003.00010.x; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hu L, 2004, CANCER GENET CYTOGEN, V148, P80, DOI 10.1016/S0165-4608(03)00206-1; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Johansen JS, 2004, LUNG CANCER-J IASLC, V46, P333, DOI 10.1016/j.lungcan.2004.05.010; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Lau SH, 2005, ACTA PHARMACOL SIN, V26, P659, DOI 10.1111/j.1745-7254.2005.00126.x; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Millis AJT, 2001, J CELL PHYSIOL, V186, P210, DOI 10.1002/1097-4652(200102)186:2<210::AID-JCP1019>3.0.CO;2-N; Mitsunobu M, 1996, CLIN EXP METASTAS, V14, P520, DOI 10.1007/BF00115112; Miyake H, 2002, J UROLOGY, V167, P2203, DOI 10.1016/S0022-5347(05)65129-4; Miyata M, 2001, CIRCULATION, V104, P1407, DOI 10.1161/hc3701.095583; NAGAO T, 1990, ANN SURG, V211, P28, DOI 10.1097/00000658-199001000-00005; Nishikawa KC, 2003, EXP CELL RES, V287, P79, DOI 10.1016/S0014-4827(03)00069-7; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tanwar MK, 2002, CANCER RES, V62, P4364; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Xie D, 2005, CANCER-AM CANCER SOC, V103, P277, DOI 10.1002/cncr.20765	29	124	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1242	1250		10.1038/sj.onc.1209141	http://dx.doi.org/10.1038/sj.onc.1209141			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247463				2022-12-28	WOS:000235537500011
J	Kobayashi, Y; Ohtsuki, M; Murakami, T; Kobayashi, T; Sutheesophon, K; Kitayama, H; Kano, Y; Kusano, E; Nakagawa, H; Furukawa, Y				Kobayashi, Y; Ohtsuki, M; Murakami, T; Kobayashi, T; Sutheesophon, K; Kitayama, H; Kano, Y; Kusano, E; Nakagawa, H; Furukawa, Y			Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma	ONCOGENE			English	Article						melanoma; histone deacetylase inhibitor; Raf; MAP kinase; Rap1; apoptosis	ACTIVATED PROTEIN-KINASE; DEPENDENT ACTIVATION; BRAF MUTATIONS; T-CELL; B-RAF; DEPSIPEPTIDE FR901228; ONCOGENIC MUTATIONS; CYCLIN D1; GENE; EXPRESSION	Histone deacetylase ( HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we examined the effect of the HDAC inhibitor FK228 on malignant melanoma, as well as its molecular mechanisms. FK228 was highly effective against melanoma compared with other commonly used drugs. By comparing the gene expression profiles of melanoma cells and normal melanocytes, we defined a subset of genes specifically upregulated in melanoma cells by FK228, which included Rap1, a small GTP-binding protein of the Ras family. The expression of Rap1 mRNA and protein increased in FK228-treated melanoma cells in both a dose- and a time-dependent manner. A decrease in the phosphorylation of c-Raf, MEK1/2, and ERK1/2 was accompanied by an increase in Rap1 expression in both FK228-treated and Rap1-overexpressing cells. Inhibition of Rap1 upregulation by small interfering RNA ( siRNA) abrogated the induction of apoptosis and suppression of ERK1/2 phosphorylation in FK228-treated melanoma cells. These results indicate that the cytotoxic effects of FK228 are mediated via the upregulation of Rap1. Furthermore, we found that Rap1 was overexpressed and formed a complex with B-Raf in melanoma cell lines with a V599E mutation of B-Raf. The siRNA-mediated abrogation of Rap1 overexpression increased the viability of these cells, suggesting that Rap1 is also an endogenous regulator of Ras-MAP kinase signaling in melanomas.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Dermatol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Organ Transplantat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Nephrol, Minami Kawachi, Tochigi 3290498, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi, Japan; Jikei Univ, Sch Med, Dept Dermatol, Minato Ku, Tokyo, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Kyoto University; Tochigi Prefectural Cancer Center; Jikei University	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; BYERS HR, 1991, AM J PATHOL, V139, P423; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; D'Silva NJ, 2003, J CELL PHYSIOL, V196, P532, DOI 10.1002/jcp.10331; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Derjuga A, 2001, J BIOL CHEM, V276, P37815; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Francken AB, 2004, ANN SURG ONCOL, V11, P426, DOI 10.1245/ASO.2004.07.014; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Furumai R, 2002, CANCER RES, V62, P4916; Gore SD, 2002, CLIN CANCER RES, V8, P963; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Skov S, 2003, BLOOD, V101, P1430, DOI 10.1182/blood-2002-07-2073; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Somech R, 2004, CANCER TREAT REV, V30, P461, DOI 10.1016/j.ctrv.2004.04.006; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; SWOPE VB, 1995, EXP CELL RES, V217, P453, DOI 10.1006/excr.1995.1109; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; UEDA H, 1994, J ANTIBIOT, V47, P301; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	57	47	50	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					512	524		10.1038/sj.onc.1209072	http://dx.doi.org/10.1038/sj.onc.1209072			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186804				2022-12-28	WOS:000234897400003
J	Linggi, B; Cheng, QC; Rao, AR; Carpenter, G				Linggi, B; Cheng, QC; Rao, AR; Carpenter, G			The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase	ONCOGENE			English	Article						ErbB-4; tyrosine kinase; growth factor	GROWTH-FACTOR RECEPTOR; NUCLEAR EXPRESSION; CELL CARCINOMA; MAMMARY-GLAND; EGF RECEPTOR; CLEAVAGE; ACTIVATION; DIFFERENTIATION; IDENTIFICATION; ASSOCIATION	The ErbB-4 receptor tyrosine kinase homo- and heterodimerizes following heregulin binding, which provokes increased levels of tyrosine autophosphorylation. Unique to the ErbB family, ErbB-4 is then proteolytically cleaved by alpha- and gamma-secretase to produce an 80 kDa intracellular domain (s80 ICD) fragment. This fragment is found in both the cytoplasm and nucleus of many normal and cancer cells and can interact with transcription factors in the cytoplasm and nucleus. Since the s80 ICD lacks ectodomain sequences known to play a major role in dimerization of ErbB family members, we asked whether the s80 ICD is an active tyrosine kinase. Here, we demonstrate that the s80 ICD is a constitutively active tyrosine kinase and can form homodimers. The s80 ICD is autophosphorylated in cells and can phosphorylate an exogenous substrate in vitro. Also, the s80 ICD can coassociate and dimers are detected by chemical cross-linking. This is the first example of constitutive kinase activation and dimerization totally within the cytoplasmic domain of an ErbB receptor and suggests that the s80 ICD may function to phosphorylate substrates in the cytoplasm or nucleus.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu			NCI NIH HHS [P30 CA6845, T32 CA009582, CA97456] Funding Source: Medline; NIDDK NIH HHS [P30 DK20593, P30 DK020593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097456, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aifa S, 2005, EXP CELL RES, V302, P108, DOI 10.1016/j.yexcr.2004.08.032; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Bei R, 2004, J PATHOL, V204, P317, DOI 10.1002/path.1642; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Srinivasan R, 2000, CANCER RES, V60, P1483; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	33	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					160	163		10.1038/sj.onc.1209003	http://dx.doi.org/10.1038/sj.onc.1209003			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170367				2022-12-28	WOS:000234406400018
J	Watanabe, H; Mizutani, T; Haraguchi, T; Yamamichi, N; Minoguchi, S; Yamamichi-Nishina, M; Mori, N; Kameda, T; Sugiyama, T; Iba, H				Watanabe, H; Mizutani, T; Haraguchi, T; Yamamichi, N; Minoguchi, S; Yamamichi-Nishina, M; Mori, N; Kameda, T; Sugiyama, T; Iba, H			SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines	ONCOGENE			English	Article						SWI/SNF complex; nonsmall cell lung carcinoma; NRSF; neuronal differentiation; histone deacetylation	RESTRICTIVE SILENCER FACTOR; SWI-SNF COMPLEX; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; POSTTRANSCRIPTIONAL LEVEL; REMODELING COMPLEXES; HISTONE DEACETYLASE; BRM GENES; EXPRESSION; CANCER	Mammalian chromatin remodelingfact or, SWI/ SNF complex contains a single molecule of either Brm or BRG1 as the ATPase catalytic subunit. Here, we show that the SWI/ SNF complex forms a larger complex with neuron-restrictive silencer factor (NRSF) and its corepressors, mSin3A and CoREST, in human nonsmall cell lung carcinoma cell lines. We also demonstrate that the strong transcriptional suppression of such neuron-specific genes as synaptophysin and SCG10 by NRSF in these non-neural cells requires the functional SWI/ SNF complex; these neuronal genes were elevated in cell lines deficient in both Brm and BRG1, whereas retrovirus vectors expressing siRNAs targeting integral components of SWI/ SNF complex (Brm/BRG1 or Ini1) induced expression of these neuronal genes in SWI/ SNF-competent cell lines. In cell lines deficient in both Brm and BRG1, exogenous Brm or BRG1 suppressed expression of these neuronal genes in an ATP-dependent manner and induced efficient and specific deacetylation of histone H4 around the NRSF binding site present in the synaptophysin gene by a large complex containing the recruited functional SWI/ SNF complex. Patients with Brm/BRG1 deficient lung carcinoma have been reported to carry poor prognosis; derepression of NRSF-regulated genes including these neuron-specific genes could contribute to enhance tumorigenicity and also would provide selective markers for Brm/BRG1-deficient tumors.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan; Nagasaki Univ, Sch Med, Dept Anat & Neurobiol, Nagasaki 852, Japan; Akita Univ, Sch Med, Dept Biochem, Akita 010, Japan	University of Tokyo; Nagasaki University; Akita University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp	Watanabe, Hirotaka/GZA-8002-2022					Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Carnaghi C, 2001, ANN ONCOL, V12, pS119, DOI 10.1093/annonc/12.suppl_2.S119; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coulson JM, 2000, CANCER RES, V60, P1840; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Furumai R, 2002, CANCER RES, V62, P4916; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Gurrola-Diaz C, 2003, ONCOGENE, V22, P5636, DOI 10.1038/sj.onc.1206790; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Linnoila RI, 1996, J CELL BIOCHEM, P92; LINNOILA RI, 1995, LUNG CANCER, P73; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tabuchi A, 2002, BIOCHEM BIOPH RES CO, V290, P415, DOI 10.1006/bbrc.2001.6194; Ui M, 1999, GENE THER, V6, P1670, DOI 10.1038/sj.gt.3301009; Van Lommel A, 1999, ARCH HISTOL CYTOL, V62, P1, DOI 10.1679/aohc.62.1; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	51	57	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					470	479		10.1038/sj.onc.1209068	http://dx.doi.org/10.1038/sj.onc.1209068			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247481				2022-12-28	WOS:000234714100015
J	Uren, AG; Kool, J; Berns, A; van Lohuizen, M				Uren, AG; Kool, J; Berns, A; van Lohuizen, M			Retroviral insertional mutagenesis: past, present and future	ONCOGENE			English	Review						retroviral insertional mutagenesis; murine leukemia virus; genetic screens; cancer; common insertion site; lymphoma	MURINE LEUKEMIA-VIRUS; E-MU-MYC; SLEEPING-BEAUTY TRANSPOSON; LONG TERMINAL REPEAT; T-CELL LYMPHOMAS; LARGE-SCALE IDENTIFICATION; IN-VITRO AMPLIFICATION; TARGET SITE SELECTION; ZINC-FINGER PROTEIN; C-MYC	Retroviral insertion mutagenesis screens in mice are powerful tools for efficient identification of oncogenic mutations in an in vivo setting. Many oncogenes identified in these screens have also been shown to play a causal role in the development of human cancers. Sequencing and annotation of the mouse genome, along with recent improvements in insertion site cloning has greatly facilitated identification of oncogenic events in retro-virus-induced tumours. In this review, we discuss the features of retroviral insertion mutagenesis screens, covering the mechanisms by which retroviral insertions mutate cellular genes, the practical aspects of insertion site cloning, the identification and analysis of common insertion sites, and finally we address the potential for use of somatic insertional mutagens in the study of non-haematopoietic and nonmammary tumour types.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl; m.v.lohuizen@nki.nl	Uren, Anthony G/A-5784-2009	Uren, Anthony G/0000-0002-6019-7111				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Arnold C, 1991, PCR Methods Appl, V1, P39; Bahrami S, 2004, J VIROL, V78, P9343, DOI 10.1128/JVI.78.17.9343-9351.2004; Beatty J, 2002, CANCER RES, V62, P7175; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; BEN-DAVID Y, 1990, New Biologist, V2, P1015; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Carlson CM, 2003, GENETICS, V165, P243; Cavazzana-Calvo Marina, 2005, Annu Rev Med, V56, P585, DOI 10.1146/annurev.med.56.090203.104142; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHO BC, 1995, J VIROL, V69, P7138, DOI 10.1128/JVI.69.11.7138-7146.1995; Clark KJ, 2004, GENESIS, V39, P225, DOI 10.1002/gene.20049; CLAUSSE N, 1993, VIROLOGY, V194, P157, DOI 10.1006/viro.1993.1245; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; Cui ZB, 2002, J MOL BIOL, V318, P1221, DOI 10.1016/S0022-2836(02)00237-1; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; CUYPERS HT, 1984, CELL, V37, P141; Dave UP, 2004, SCIENCE, V303, P333, DOI 10.1126/science.1091667; DAVID YB, 1988, ONCOGENE, V3, P179; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; DESGROSEILLERS L, 1984, J VIROL, V52, P945, DOI 10.1128/JVI.52.3.945-952.1984; DESGROSEILLERS L, 1984, J VIROL, V52, P448, DOI 10.1128/JVI.52.2.448-456.1984; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; DOMEN J, 1987, ONCOGENE RES, V1, P103; Dudley JP, 2002, LEUKEMIA, V16, P1086, DOI 10.1038/sj.leu.2402451; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; Ethelberg S, 1997, J VIROL, V71, P7273, DOI 10.1128/JVI.71.10.7273-7280.1997; Ethelberg S, 1997, J VIROL, V71, P1196, DOI 10.1128/JVI.71.2.1196-1206.1997; Feldman BJ, 2000, BLOOD, V96, P1906, DOI 10.1182/blood.V96.5.1906.h8001906_1906_1913; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Grabher C, 2003, GENE, V322, P57, DOI 10.1016/j.gene.2003.09.009; GRAVES BJ, 1985, MOL CELL BIOL, V5, P1948, DOI 10.1128/MCB.5.8.1948; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HALLBERG B, 1991, J VIROL, V65, P4177, DOI 10.1128/JVI.65.8.4177-4181.1991; Hamer L, 2001, CURR OPIN CHEM BIOL, V5, P67, DOI 10.1016/S1367-5931(00)00162-9; Han JS, 2004, NATURE, V429, P314, DOI 10.1038/nature02535; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Hanlon L, 2003, J VIROL, V77, P1059, DOI 10.1128/JVI.77.2.1059-1068.2003; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; HERMAN SA, 1986, J VIROL, V60, P497, DOI 10.1128/JVI.60.2.497-505.1986; Hirai H, 2001, CANCER CHEMOTH PHARM, V48, pS35, DOI 10.1007/s002800100303; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Joosten M, 2002, ONCOGENE, V21, P7247, DOI 10.1038/sj.onc.1205813; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; Largaespada David A, 2003, Reprod Biol Endocrinol, V1, P80, DOI 10.1186/1477-7827-1-80; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li L, 2000, J VIROL, V74, P10965, DOI 10.1128/JVI.74.23.10965-10974.2000; Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Liu GY, 2005, J MOL BIOL, V346, P161, DOI 10.1016/j.jmb.2004.09.086; Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Ma SL, 2003, VIROLOGY, V313, P638, DOI 10.1016/S0042-6822(03)00379-9; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320; Martin-Hernandez J, 2001, J VIROL, V75, P11907, DOI 10.1128/JVI.75.23.11907-11912.2001; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mikkers H, 2002, ONCOGENE, V21, P6559, DOI 10.1038/sj.onc.1205930; Miskey C, 2003, NUCLEIC ACIDS RES, V31, P6873, DOI 10.1093/nar/gkg910; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nielsen AA, 2005, J VIROL, V79, P67, DOI 10.1128/JVI.79.1.67-78.2005; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; OCHMAN H, 1988, GENETICS, V120, P621; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; REISMAN D, 1990, FEBS LETT, V277, P209, DOI 10.1016/0014-5793(90)80846-B; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Roh M, 2003, CANCER RES, V63, P8079; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; Rosenberg N., 1997, P475; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schmidt M, 2005, BLOOD, V105, P2699, DOI 10.1182/blood-2004-07-2648; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shore SK, 2002, ONCOGENE, V21, P8568, DOI 10.1038/sj.onc.1206084; Sorensen AB, 1996, J VIROL, V70, P4063; SORENSEN AB, 1993, J VIROL, V67, P7118; Sorensen KD, 2004, J VIROL, V78, P13216, DOI 10.1128/JVI.78.23.13216-13231.2004; Starkey CR, 1998, J VIROL, V72, P1078, DOI 10.1128/JVI.72.2.1078-1084.1998; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Suzuki Y, 2004, EMBO J, V23, P4670, DOI 10.1038/sj.emboj.7600452; SWAIN A, 1993, J VIROL, V67, P6265, DOI 10.1128/JVI.67.10.6265-6269.1993; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TSICHLIS PN, 1983, NATURE, V302, P445, DOI 10.1038/302445a0; Uhrbom L, 1998, CANCER RES, V58, P5275; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1982, NUCLEIC ACIDS RES, V10, P577, DOI 10.1093/nar/10.2.577; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Vigdal TJ, 2002, J MOL BIOL, V323, P441, DOI 10.1016/S0022-2836(02)00991-9; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WALKER GT, 1992, P NATL ACAD SCI USA, V89, P392, DOI 10.1073/pnas.89.1.392; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; Wotton S, 2002, CANCER RES, V62, P7181; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yan YX, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng068; Yant SR, 2002, NAT BIOTECHNOL, V20, P999, DOI 10.1038/nbt738; Yant SR, 2004, MOL CELL BIOL, V24, P9239, DOI 10.1128/MCB.24.20.9239-9247.2004; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	176	201	209	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7656	7672		10.1038/sj.onc.1209043	http://dx.doi.org/10.1038/sj.onc.1209043			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299527				2022-12-28	WOS:000233372600003
J	Prentice, LM; Shadeo, A; Lestou, VS; Miller, MA; DeLeeuw, RJ; Makretsov, N; Turbin, D; Brown, LA; Macpherson, N; Yorida, E; Cheang, MCU; Bentley, J; Chia, S; O Nielsen, T; Gilks, CB; Lam, W; Huntsman, DG				Prentice, LM; Shadeo, A; Lestou, VS; Miller, MA; DeLeeuw, RJ; Makretsov, N; Turbin, D; Brown, LA; Macpherson, N; Yorida, E; Cheang, MCU; Bentley, J; Chia, S; O Nielsen, T; Gilks, CB; Lam, W; Huntsman, DG			NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis	ONCOGENE			English	Article						NRG1; breast cancer; amplicon; SPFH2; 8p	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; CHROMOSOME ARM 8P; TISSUE MICROARRAY; GAMMA-HEREGULIN; GROWTH-FACTOR; CELL-LINES; FUSION GENE; CARCINOMA; TRANSLOCATION	Rearrangements of the neuregulin (NRG1) gene have been implicated in breast carcinoma oncogenesis. To determine the frequency and clinical significance of NRG1 aberrations in clinical breast tumors, a breast cancer tissue microarray was screened for NRG1 aberrations by fluorescent in situ hybridization (FISH) using a two-color split-apart probe combination. flanking the NRG1 gene. Rearrangements of NRG1 were identified in 17/382 cases by FISH, and bacterial artifi. cial chromosome array comparative genomic hybridization was applied to. five of these cases to further map the chromosome 8p abnormalities. In all. five cases, there was a novel amplicon centromeric to NRG1 with a minimum common region of amplifi. cation encompassing two genes, SPFH2 and FLJ14299. Subsequent FISH analysis for the novel amplicon revealed that it was present in 63/262 cases. Abnormalities of NRG1 did not correlate with patient outcome, but the novel amplicon was associated with poor prognosis in univariate analysis, and in multivariate analysis was of prognostic significance independent of nodal status, tum or grade, estrogen receptor status, and human epidermal growth factor receptor (HER)2 overexpression. Of the two genes in the novel amplicon, expression of SPFH2 correlated most significantly with amplication. This amplicon may emerge as a result of breakpoints and chromosomal rearrangements within the NRG1 locus.	British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada; Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Dept Pathol & Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Pathol & Lab Med, British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Res Ctr, Dept Canc Genet & Dev Biol, Vancouver, BC V5Z 1L3, Canada; Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada; British Columbia Canc Agcy, Dept Med Oncol, Victoria, BC V8R 6V5, Canada; British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); British Columbia Cancer Agency; British Columbia Cancer Agency	Huntsman, DG (corresponding author), British Columbia Canc Agcy, Dept Pathol & Lab Med, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	dhuntsman@bccancer.bc.ca	Huntsman, David/ABE-6082-2020	Cheang, Maggie Chon U/0000-0001-5718-2501; Shadeo, Ashleen/0000-0002-0866-0519; Brown, Lindsay/0000-0002-2790-5112				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Adelaide J, 2000, INT J ONCOL, V16, P683; Atlas E, 2003, MOL CANCER RES, V1, P165; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bernardino L, 1998, GENE CHROMOSOME CANC, V23, P100, DOI 10.1002/(SICI)1098-2264(199810)23:2<100::AID-GCC2>3.0.CO;2-6; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Cuny M, 2000, CANCER RES, V60, P1077; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Jacobson KK, 2004, GENE CHROMOSOME CANC, V40, P19, DOI 10.1002/gcc.20019; Jong K, 2003, LECT NOTES COMPUT SC, V2611, P54; Khoury H, 2003, MODERN PATHOL, V16, P716, DOI 10.1097/01.MP.0000077515.68734.85; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Makretsov N, 2004, GENE CHROMOSOME CANC, V40, P152, DOI 10.1002/gcc.20028; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Parker RL, 2002, AM J CLIN PATHOL, V117, P723; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Sprenger RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/elps.200305675; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Wiseman SM, 2005, CANCER-AM CANCER SOC, V103, P1770, DOI 10.1002/cncr.20970; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	38	58	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7281	7289		10.1038/sj.onc.1208892	http://dx.doi.org/10.1038/sj.onc.1208892			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027731				2022-12-28	WOS:000233142100004
J	Formisano, P; Perruolo, G; Libertini, S; Santopietro, S; Troncone, G; Raciti, GA; Oriente, F; Portella, G; Miele, C; Beguinot, F				Formisano, P; Perruolo, G; Libertini, S; Santopietro, S; Troncone, G; Raciti, GA; Oriente, F; Portella, G; Miele, C; Beguinot, F			Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development	ONCOGENE			English	Article						ped/pea-15; transgenic mice; chemical carcinogenesis; skin cancer; apoptosis	MAP KINASE; PEA-15; DEATH; APOPTOSIS; CELLS; MOUSE; ASTROCYTES; ACTIVATION; GROWTH; CANCER	ped/pea-15 is a cytosolic protein performing a broad antiapoptotic function. We show that, upon DMBA/TPA-induced skin carcinogenesis, transgenic mice overexpressing ped/pea-15 (Tg(ped/pea-15)) display early development of papillomas and a four-fold increase in papilloma number compared to the nontransgenic littermates (P < 0.001). The malignant conversion frequency was 24% for the Tg(ped/pea-15) mice and only 5% in controls (P < 0.01). The isolated application of TPA, but not that of DMBA, was sufficient to reversibly upregulate ped/pea-15 in both untransformed skin and cultured keratinocytes. ped/pea15 protein levels were also increased in DMBA/TPA-induced papillomas of both Tg(ped/pea-15) and control mice. Isolated TPA applications induced Caspase-3 activation and apoptosis in nontransformed mouse epidermal tissues. The induction of both Caspase-3 and apoptosis by TPA were four-fold inhibited in the skin of the Tg(ped/pea-15) compared to the nontransgenic mice, accompanied by a similarly sized reduction in TPA-induced JNK and p38 stimulation and by constitutive induction of cytoplasmic ERK activity in the transgenics. ped/pea-15 expression was stably increased in cell lines from DMBA/TPA-induced skin papillomas and carcinomas, paralleled by protection from TPA apoptosis. In the A5 spindle carcinoma cell line, antisense inhibition of ped/pea-15 expression simultaneously rescued sensitivity to TPA-induced Caspase-3 function and apoptosis. The antisense also reduced A5 cell ability to grow in semisolid media by 65% (P < 0.001) and increased by three-fold tumor latency time (P < 0.01). Thus, the expression levels of ped/pea-15 control Caspase-3 function and epidermal cell apoptosis in vivo and determine susceptibility to skin tumor development.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Sci Biomorfol & Funzionali, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, Via Sergio Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	Libertini, Silvana/A-3531-2011; Portella, Giuseppe/AFU-6826-2022; giuseppe, perruolo/AAW-3869-2021; Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Libertini, Silvana/0000-0003-2633-1564; PORTELLA, Giuseppe/0000-0001-8276-9769; Formisano, Pietro/0000-0001-7020-6870; Perruolo, Giuseppe/0000-0003-0479-8729; RACITI, GREGORYALEXANDER/0000-0003-2742-5634; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Baldi A, 2004, EXP DERMATOL, V13, P93, DOI 10.1111/j.0906-6705.2004.00136.x; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BURNS FJ, 1978, CARCINOGENESIS MECH; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Dong G, 2001, CANCER RES, V61, P4797; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Hao CH, 2001, CANCER RES, V61, P1162; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kitsberg D, 1999, J NEUROSCI, V19, P8244; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Vaidyanathan H, 2003, J BIOL CHEM, V278, P32367, DOI 10.1074/jbc.M303988200; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004	24	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7012	7021		10.1038/sj.onc.1208871	http://dx.doi.org/10.1038/sj.onc.1208871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044159				2022-12-28	WOS:000232833200003
J	Weber, A; Hengge, UR; Bardenheuer, W; Tischoff, I; Sommerer, F; Markwarth, A; Dietz, A; Wittekind, C; Tannapfel, A				Weber, A; Hengge, UR; Bardenheuer, W; Tischoff, I; Sommerer, F; Markwarth, A; Dietz, A; Wittekind, C; Tannapfel, A			SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition	ONCOGENE			English	Article						SOCS; squamous cell carcinoma; head and neck; precursor lesions; methylation; tumor suppressor	TUMOR-SUPPRESSOR GENES; CPG ISLAND HYPERMETHYLATION; CONSTITUTIVE ACTIVATION; HEPATOCELLULAR-CARCINOMA; ABERRANT METHYLATION; NEGATIVE REGULATOR; SIGNAL TRANSDUCER; IN-VIVO; CANCER; STAT3	The suppressors of cytokine signaling ( SOCS) are inhibitors of cytokine signaling that function via the Janus kinase (JAK)/signal transducers and activators of transcription ( STAT) pathway. Recently, methylation of SOCS-1 and SOCS-3 has been implicated in the tumorigenesis of liver and lung cancer. This study was performed to elucidate the role of SOCS-1 and SOCS-3 in squamous cell carcinoma of the head and neck (HNSCC) and its precursor lesions. HNSCC of 94 patients and corresponding normal mucosa, lymph node metastases as well as 16 high- and 21 low-grade squamous cell dysplasias were studied by using methylation-specific PCR (MSP) for the SOCS-1 and SOCS-3 promoter after microdissection. The presence of SOCS-3 mRNA transcripts was confirmed by semiquantitative real-time PCR, and the SOCS-3 protein was analysed immunohistochemically. SOCS-3 hypermethylation was found in 85/94 HNSCC (90%) and in 10/16 high- grade and 9/21 low-grade dysplasias (63 and 43%, respectively). SOCS-1 promoter hypermethylation was detected in 10/94 HNSCC samples (11%) and in 2/16 high-grade and 1/21 low-grade dysplasias (13 and 5%, respectively). Lymph node metastases exhibited an identical methylation status as the primary tumors. Methylation of the SOCS-3 promoter correlated with downregulation of SOCS-3 transcripts and protein expression in these tumors and various cell lines. In the cell lines tested, SOCS-3 and SOCS-1 transcripts increased upon treatment with the demethylation compound 5-aza-2-deoxycytidine (5-AZA-DC). Overexpression of wild-type SOCS-3 in carcinoma cells with methylated SOCS-3 resulted in the induction of apoptosis and growth suppression as well as downregulation of STAT3, bcl-2 as well as bcl-xL. Our data suggest that promoter methylation and subsequent transcript downregulation of SOCS-3 transcripts and, to a much lesser extent, SOCS-1 are involved in the multistep carcinogenesis of HNSCC. During its involvement in tumor growth, restoration of SOCS-3 may hold treatment potential for HNSCC.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Univ Leipzig, Dept Otorhinolaryngol Head & Neck Surg, D-04103 Leipzig, Germany; Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany	Leipzig University; Leipzig University; Heinrich Heine University Dusseldorf	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany.	tana@medizin.uni-leipzig.de						Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin SY, 2004, ONCOL REP, V11, P341; Melzner I, 2003, BLOOD, V102, P1554, DOI 10.1182/blood-2003-04-1083; Mora LB, 2002, CANCER RES, V62, P6659; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nagai H, 2002, CANCER LETT, V186, P59, DOI 10.1016/S0304-3835(02)00244-6; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sriuranpong V, 2003, CANCER RES, V63, P2948; Tannapfel A, 2001, EUR ARCH OTO-RHINO-L, V258, P83, DOI 10.1007/s004050000303; Tannapfel A, 2001, VIRCHOWS ARCH, V439, P1, DOI 10.1007/s004280100401; Uehara E, 2003, INT J ONCOL, V23, P693; Union for International Cancer Control, 2017, TNM CLASSIFICATION M; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	34	154	167	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6699	6708		10.1038/sj.onc.1208818	http://dx.doi.org/10.1038/sj.onc.1208818			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007169				2022-12-28	WOS:000232367800011
J	Nicot, C; Harrod, RL; Ciminale, V; Franchini, G				Nicot, C; Harrod, RL; Ciminale, V; Franchini, G			Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions	ONCOGENE			English	Article						HTLV-1; retrovirus; genes; proteins	OPEN READING FRAMES; HTLV-I; P13(II) PROTEIN; LEUKEMIA-LYMPHOMA; VIRAL INFECTIVITY; MESSENGER-RNAS; SH3 DOMAINS; P12(I); EXPRESSION; CREB	The human T-cell leukemia/lymphoma virus (HTLV) genome, in addition to the structural Gag and Env proteins and retroviral enzymes, carries a region at its 30 end originally designated pX. To date, we know that this region encodes two essential transcriptional and post-transcriptional positive regulators of viral expression, the Tax and Rex proteins, respectively (reviewed elsewhere in this issue). Here, we will review current knowledge of the functions of three additional proteins encoded in the pX region, p12(I), p13(II), and p30(II).	NCI, Anim Models & Retroviral Vaccines Sect, Bethesda, MD 20892 USA; Univ Kansas, Med Ctr, Dept Microbiol, Kansas City, KS 66160 USA; So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Kansas; University of Kansas Medical Center; Southern Methodist University; IRCCS Istituto Oncologico Veneto (IOV); University of Padua	Franchini, G (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, 41-D804, Bethesda, MD 20892 USA.	franchig@mail.nih.gov	Ciminale, Vincenzo/L-1416-2016	Ciminale, Vincenzo/0000-0001-6197-1802	NATIONAL CANCER INSTITUTE [R01CA106258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106258] Funding Source: Medline; NIAID NIH HHS [R01 AI058944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; Chen HL, 1997, ACTA MED OKAYAMA, V51, P141; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; D'Agostino DM, 2005, ADV CANCER RES, V94, P87, DOI 10.1016/S0065-230X(05)94003-7; D'Agostino DM, 2005, CELL DEATH DIFFER, V12, P905, DOI 10.1038/sj.cdd.4401576; D'Agostino DM, 2002, J BIOL CHEM, V277, P34424, DOI 10.1074/jbc.M203023200; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; Dekaban GA, 2000, VIROLOGY, V274, P86, DOI 10.1006/viro.2000.0406; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Ding W, 2001, J VIROL, V75, P7672, DOI 10.1128/JVI.75.16.7672-7682.2001; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIRARAGI H, 2005, IN PRESS J VIROL; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; KORALNIK IJ, 1992, AIDS RES HUM RETROV, V8, P1845, DOI 10.1089/aid.1992.8.1845; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; KORALNIK IJ, 1995, J GEN VIROL, V76, P1909, DOI 10.1099/0022-1317-76-8-1909; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lefebvre L, 2002, J VIROL, V76, P1400, DOI 10.1128/JVI.76.3.1400-1414.2002; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Martins ML, 2002, AIDS RES HUM RETROV, V18, P899, DOI 10.1089/088922202760265560; Mayer BJ, 2001, J CELL SCI, V114, P1253; Michael Bindhu, 2004, Retrovirology, V1, P39, DOI 10.1186/1742-4690-1-39; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; Nair A, 2005, AIDS RES HUM RETROV, V21, P273, DOI 10.1089/aid.2005.21.273; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; RURUKAWA Y, 2004, AIDS RES HUM RETROV, V20, P1092; Silic-Benussi M, 2004, P NATL ACAD SCI USA, V101, P6629, DOI 10.1073/pnas.0305502101; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128/JVI.78.8.3837-3845.2004; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Trovato R, 1999, J VIROL, V73, P6460, DOI 10.1128/JVI.73.8.6460-6467.1999; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	54	78	83	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6026	6034		10.1038/sj.onc.1208977	http://dx.doi.org/10.1038/sj.onc.1208977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155609	Green Published			2022-12-28	WOS:000231623400012
J	Tahmatzopoulos, A; Sheng, SJ; Kyprianou, N				Tahmatzopoulos, A; Sheng, SJ; Kyprianou, N			Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis	ONCOGENE			English	Article						prostate cancer; alpha-blockers; apoptosis	ALPHA-1-ADRENOCEPTOR ANTAGONISTS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; CARCINOMA CELLS; INDUCTION; ANGIOGENESIS; METASTASIS; EXPRESSION; INVASION; TERAZOSIN	Maspin is a mammary serine protease inhibitor or serpin with tumor suppressive and antiangiogenic activity that inhibits tumor motility, invasion and metastasis, at least by its actions on cell membrane and extracellular matrix (ECM) proteins. Previous studies documented that the quinazoline-derived alpha 1-adrenoceptor antagonist doxazosin affects the attachment and migration of prostate cancer cells. In this study, we investigated the effect of maspin overexpression on the apoptotic/antiadhesion response of prostate cancer cells to doxazosin. The response of maspin-overexpressing clones of human prostate cancer cells DU-145 to doxazosin was evaluated by determining cell viability, apoptosis and cell proliferation on the basis of the trypan blue exclusion assay/methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Hoechst staining and caspase-3 activation, and [H-3] thymidine incorporation assay. Vascular endothelial growth factor (VEGF), transforming growth factor beta RII (TGF beta RII), Smad4 (a TGF beta intracellular effector) and bax expression was evaluated at the mRNA and protein level using reverse transcriptase-polymerase chain reaction and Western blotting, respectively. The effect of doxazosin on cell attachment of maspin-expressing prostate cancer cells was evaluated on collagen- and fibronectin-coated plates. Cell migration was assessed using the wounding assay. In response to tumor necrosis factor-related apoptosis-inducing ligand, DU-145-maspin expressing cells undergo apoptosis, via poly(ADP-ribose) polymerasecleavage and caspase-3 activation. DU-145-maspin cells exhibited higher sensitivity to doxazosin and an earlier temporal activation of caspase-3. The number of apoptotic cells detected in response to doxazosin was significantly higher compared to the neo control (P < 0.0001). Doxazosin resulted in dramatic downregulation of the 189 isoform of VEGF in maspin transfectants, while a fivefold induction of Smad4 mRNA expression was detected in those cells after 24 h of treatment. Maspin overexpression in prostate cancer cells resulted in an increased ability to attach to ECM-coated plates, and doxazosin treatment considerably antagonized this effect by decreasing the attachment potential to collagen and fibronectin. The present study supports the ability of maspin to enhance the apoptotic threshold of prostate cancer cells to the quinazoline-based alpha 1-adrenoceptor antagonist doxazosin. These findings may have therapeutic significance in the development of antiangiogenic targeting by doxazosin and derivative agents for advanced prostate cancer.	Univ Kentucky, Med Ctr, Dept Surg, Div Oncol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Kentucky, Coll Med, Dept Pathol, Lexington, KY USA	University of Kentucky; University of Kentucky; Wayne State University; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Med Ctr, Dept Surg, Div Oncol, 800 Rose St,MS-283, Lexington, KY 40536 USA.	nkypr2@uky.edu			NCI NIH HHS [R01 CA107575-03, R01 CA107575-02, R01 CA107575, CA10757-01, R01 CA107575-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Bare R L, 1998, Cancer Treat Res, V94, P69; Benning CM, 2002, CANCER RES, V62, P597; BILIRAN JH, 2001, CANCER RES, V61, P676; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Bruckheimer EM, 2000, CELL TISSUE RES, V301, P153, DOI 10.1007/s004410000196; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Keledjian K, 2005, J CELL BIOCHEM, V94, P374, DOI 10.1002/jcb.20240; Keledjian K, 2003, J UROLOGY, V169, P1150, DOI 10.1097/01.ju.0000042453.12079.77; Keledjian K, 2001, PROSTATE, V48, P71, DOI 10.1002/pros.1083; Kyprianou N, 2000, CANCER RES, V60, P4550; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Oades G M, 2000, Curr Urol Rep, V1, P97, DOI 10.1007/s11934-000-0043-z; Partin JV, 2003, BRIT J CANCER, V88, P1615, DOI 10.1038/sj.bjc.6600961; Raghavan D, 1997, EUR J CANCER, V33, P566, DOI 10.1016/S0959-8049(96)00510-2; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2001, CANCER RES, V61, P6945; Sternberg CN, 2003, EUR J CANCER, V39, P136, DOI 10.1016/S0959-8049(02)00665-2; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Yang G, 1997, PROSTATE, V33, P157; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	29	35	39	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5375	5383		10.1038/sj.onc.1208684	http://dx.doi.org/10.1038/sj.onc.1208684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007219	Green Accepted			2022-12-28	WOS:000231158500011
J	Morgan-Lappe, S; Woods, KW; Li, Q; Anderson, MG; Schurdak, ME; Luo, Y; Giranda, VL; Fesik, SW; Leverson, JD				Morgan-Lappe, S; Woods, KW; Li, Q; Anderson, MG; Schurdak, ME; Luo, Y; Giranda, VL; Fesik, SW; Leverson, JD			RNAi-based screening of the human kinome identies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors	ONCOGENE			English	Article						siRNA; Akt; kinome; multitargeted inhibitors	INOSITOL PHOSPHATE MULTIKINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; INTERFERING RNAS; MAMMALIAN-CELLS; CANCER-THERAPY; HUMAN HOMOLOG; DNA-PK; PATHWAY; EXPRESSION	Tumors comprise genetically heterogeneous cell populations, whose growth and survival depend on multiple signaling pathways. This has spurred the development of multitargeted therapies, including small molecules that can inhibit multiple kinases. A major challenge in designing such molecules is to determine which kinases to inhibit in each cancer to maximize efficacy and therapeutic index. We describe an approach to this problem implementing RNA interference technology. In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. siRNAs targeting casein kinase I gamma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-mediated cell killing, and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation. Small molecules targeting CSNK1G3 and/or IPMK in addition to Akt may thus exhibit increased efficacy and have the potential for improved therapeutic index.	Abbott Labs, Canc Res, Abbott Pk, IL 60064 USA; Abbott Labs, Adv Technol, Abbott Pk, IL USA	Abbott Laboratories; Abbott Laboratories	Leverson, JD (corresponding author), Abbott Labs, Canc Res, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	joel.leverson@abbott.com		Schurdak, Mark/0000-0002-1146-3268				Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Caffrey JJ, 2001, FEBS LETT, V499, P6, DOI 10.1016/S0014-5793(01)02500-5; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Deininger MWN, 2004, CANCER CELL, V6, P108, DOI 10.1016/j.ccr.2004.08.006; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Kusuda J, 1998, CYTOGENET CELL GENET, V83, P101, DOI 10.1159/000015143; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Melnikova I, 2004, NAT REV DRUG DISCOV, V3, P993, DOI 10.1038/nrd1600; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mouritzen P, 2004, BIOTECHNIQUES, V37, P492, DOI 10.2144/04373AF02; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Piccolo E, 2004, ONCOGENE, V23, P1754, DOI 10.1038/sj.onc.1207296; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	48	50	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1340	1348		10.1038/sj.onc.1209169	http://dx.doi.org/10.1038/sj.onc.1209169			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247451				2022-12-28	WOS:000235708200007
J	Heyninck, K; Beyaert, R				Heyninck, K; Beyaert, R			A novel link between Lck, Bak expression and chemosensitivity	ONCOGENE			English	Editorial Material						apoptosis; chemotherapy; Bcl-2 family; Lck	TYROSINE KINASE LCK; NF-KAPPA-B; APOPTOSIS; INVOLVEMENT; ACTIVATION; P56(LCK); LIGAND; GENE; P53	Protein kinases are critically involved in signaling pathways that regulate cell growth, differentiation, activation, and survival. Lck, a member of the Src family of protein tyrosine kinases, plays a key role in T-lymphocyte activation and differentiation. However, under certain conditions Lck is also involved in the induction of apoptosis. In Oncogene volume 25 pages 186 - 197, Samraj et al. used the Lck-defective JCaM1.6 cell line to demonstrate the critical role of Lck in the apoptotic response of T-cell leukemia cells to several chemotherapeutic drugs. They further showed that Lck controls the mitochondrial death pathway by regulating proapoptotic Bak expression. This chemosensitizing effect of Lck is independent of T-cell receptor signaling and does not require the kinase activity of Lck. These findings demonstrate that Lck might be part of two independent signaling pathways leading to either cell proliferation or apoptosis, and reveal a hitherto unrecognized link between Lck, Bak, and chemosensitivity of human leukemic cells.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi.beyaert@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hur YG, 2004, J IMMUNOL, V172, P79, DOI 10.4049/jimmunol.172.1.79; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Rouer E, 1999, ONCOGENE, V18, P4262, DOI 10.1038/sj.onc.1202720; Samraj AK, 2006, ONCOGENE, V25, P186, DOI 10.1038/sj.onc.1209034; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	20	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1693	1695		10.1038/sj.onc.1209157	http://dx.doi.org/10.1038/sj.onc.1209157			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16186791				2022-12-28	WOS:000236013700001
J	Yuan, J; Kramer, A; Matthess, Y; Yan, R; Spankuch, B; Gatje, R; Knecht, R; Kaufmann, M; Strebhardt, K				Yuan, J; Kramer, A; Matthess, Y; Yan, R; Spankuch, B; Gatje, R; Knecht, R; Kaufmann, M; Strebhardt, K			Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo	ONCOGENE			English	Article						RNA interference; cyclin B1; inhibition in vivo; apoptosis; taxol	CLINICAL-SIGNIFICANCE; NUCLEAR-LOCALIZATION; CANCER; OVEREXPRESSION; INHIBITION; EXPRESSION; PHOSPHORYLATION; ACTIVATION; KINASE; PROLIFERATION	Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibit ion of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL USA; So Illinois Univ, Sch Med, Inst Canc, Springfield, IL USA; Goethe Univ Frankfurt, Sch Med, Dept Otorhinolaryngol, D-6000 Frankfurt, Germany	Goethe University Frankfurt; Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Goethe University Frankfurt	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de; Strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Chang THT, 1996, J CELL BIOCHEM, V60, P161, DOI 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-V; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hassan KA, 2002, CANCER RES, V62, P6414; Hassan KA, 2001, CLIN CANCER RES, V7, P2458; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kao GD, 1997, CANCER RES, V57, P753; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Korenaga D, 2002, SURGERY, V131, pS114, DOI 10.1067/msy.2002.119362; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Matthess Y, 2005, ONCOGENE, V24, P2973, DOI 10.1038/sj.onc.1208472; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Park M, 2000, CANCER RES, V60, P542; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shen ML, 2004, CANCER RES, V64, P1607, DOI 10.1158/0008-5472.CAN-03-3321; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Soria JC, 2000, CANCER RES, V60, P4000; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Viallard JF, 1999, EXP CELL RES, V247, P208, DOI 10.1006/excr.1998.4352; Walsh S, 2003, MOL CANCER RES, V1, P280; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yasuda M, 2002, J CANCER RES CLIN, V128, P412, DOI 10.1007/s00432-002-0359-9; Yin XY, 2001, CANCER RES, V61, P6487; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; Yuan J, 2005, LETT DRUG DES DISCOV, V2, P274, DOI 10.2174/1570180054038378; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	45	101	113	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1753	1762		10.1038/sj.onc.1209202	http://dx.doi.org/10.1038/sj.onc.1209202			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278675				2022-12-28	WOS:000236013700007
J	Tsutsumi, S; Namba, T; Tanaka, KI; Arai, Y; Ishihara, T; Aburaya, M; Mima, S; Hoshino, T; Mizushima, T				Tsutsumi, S; Namba, T; Tanaka, KI; Arai, Y; Ishihara, T; Aburaya, M; Mima, S; Hoshino, T; Mizushima, T			Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells	ONCOGENE			English	Article						celecoxib; endoplasmic reticulum chaperones; apoptosis; calcium	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UNFOLDED-PROTEIN RESPONSE; STRESS-RESPONSE; CANCER CELLS; ER STRESS; MUCOSAL CELLS; CYCLOOXYGENASE-2 INHIBITOR; INTRACELLULAR CALCIUM; PROSTAGLANDIN E-2; GENE-EXPRESSION	Nonsteroidal anti-inflammatory drugs (NSAIDs) induce apoptosis in cancer cells and this effect is involved in their antitumor activity. We recently demonstrated that NSAIDs upregulate GRP78, an endoplasmic reticulum ( ER) chaperone, in gastric mucosal cells in primary culture. In the present study, induction of ER chaperones by NSAIDs and the effect of those chaperones on NSAID-induced apoptosis were examined in human gastric carcinoma cells. Celecoxib, an NSAID, upregulated ER chaperones ( GRP78 and its cochaperones ERdj3 and ERdj4) but also C/EBP homologous transcription factor ( CHOP), a transcription factor involved in apoptosis. Celecoxib also upregulated GRP78 in xenograft tumors, accompanying with the suppression of tumor growth in nude mice. Celecoxib caused phosphorylation of eukaryotic translation initiation factor 2 kinase ( PERK) and eukaryotic initiation factor-2 alpha (eIF2a) and production of activating transcription factor (ATF)4 mRNA. Suppression of ATF4 expression by small interfering RNA ( siRNA) partially inhibited the celecoxib-dependent upregulation of GRP78. Celecoxib increased the intracellular Ca2+ concentration, while 1,2-bis(2-aminophenoxy) ethane-N,N,N'N'-tetraacetic acid, an intracellular Ca2+ chelator, inhibited the upregulation of GRP78 and ATF4. These results suggest that the Ca2+- dependent activation of the PERK-eIF2 alpha-ATF4 pathway is involved in the upregulation of ER chaperones by celecoxib. Overexpression of GRP78 partially suppressed the apoptosis and induction of CHOP in the presence of celecoxib and this suppression was stimulated by coexpression of either ERdj3 or ERdj4. On the other hand, suppression of GRP78 expression by siRNA drastically stimulated cellular apoptosis and production of CHOP in the presence of celecoxib. These results show that upregulation of ER chaperones by celecoxib protects cancer cells from celecoxib-induced apoptosis, thus may decrease the potential antitumor activity of celecoxib.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan	Kumamoto University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, 5-1,Oehonmachi, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp	Tanaka, Ken-ichiro/J-8557-2013					Ben-Chetrit E, 2005, RHEUMATOL INT, V25, P332, DOI 10.1007/s00296-004-0442-4; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bush KT, 1997, J BIOL CHEM, V272, P9086; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dong DZ, 2005, CANCER RES, V65, P5785, DOI 10.1158/0008-5472.CAN-05-0754; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hong M, 2004, J CELL BIOCHEM, V92, P723, DOI 10.1002/jcb.20118; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hu PJ, 2004, GUT, V53, P195, DOI 10.1136/gut.2003.021477; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Huo R, 2004, CELL TISSUE RES, V316, P359, DOI 10.1007/s00441-004-0885-7; Husain SS, 2002, AM J GASTROENTEROL, V97, P542; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005; Koki Alane T, 2002, Cancer Control, V9, P28; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Kurisu J, 2003, GENES CELLS, V8, P189, DOI 10.1046/j.1365-2443.2003.00625.x; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; Leahy KM, 2002, CANCER RES, V62, P625; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Lopez-Parra M, 2005, J HEPATOL, V42, P75, DOI 10.1016/j.jhep.2004.09.011; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Mima S, 2005, CANCER RES, V65, P1868, DOI 10.1158/0008-5472.CAN-04-2770; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Okada K, 2000, CANCER GENET CYTOGEN, V118, P99, DOI 10.1016/S0165-4608(99)00182-X; Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877; PIAZZA GA, 1995, CANCER RES, V55, P3110; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp-75-9-1088; Ristimaki A, 1997, CANCER RES, V57, P1276; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Schroeder CR, 2004, CANCER BIOL THER, V3, P847, DOI 10.4161/cbt.3.9.1037; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Song MS, 2001, CANCER RES, V61, P8322; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200; Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205; Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; Wang JL, 2004, BIOCHEM PHARMACOL, V67, P1123, DOI 10.1016/j.bcp.2003.11.004; Williams CS, 2000, CANCER RES, V60, P6045; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Xu WM, 2004, NAT CELL BIOL, V6, P1129, DOI 10.1038/ncb1188; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zweifel BS, 2002, CANCER RES, V62, P6706	68	109	117	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1018	1029		10.1038/sj.onc.1209139	http://dx.doi.org/10.1038/sj.onc.1209139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205636				2022-12-28	WOS:000235361000007
J	Chen, N; Szentirmay, MN; Pawar, SA; Sirito, M; Wang, J; Wang, Z; Zhai, Q; Yang, HX; Peehl, DM; Ware, JL; Sawadogo, M				Chen, N; Szentirmay, MN; Pawar, SA; Sirito, M; Wang, J; Wang, Z; Zhai, Q; Yang, HX; Peehl, DM; Ware, JL; Sawadogo, M			Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis	ONCOGENE			English	Article						USF; transcription factor; tumor-suppressor gene; prostate cancer	HELIX-LOOP-HELIX; EPITHELIAL-CELLS; CANCER CELLS; DNA-BINDING; RECEPTOR; PROMOTER; TUMORIGENICITY; PROLIFERATION; EXPRESSION; NKX3.1	Although the transcription factor USF2 has been implicated in the regulation of cellular growth and proliferation, it is unknown whether alterations in USF2 contribute to tumorigenesis and tumor development. We examined the role of USF2 in prostate tumorigenesis. Western blot analysis revealed markedly decreased USF2 levels in three androgen-independent prostate cancer cell lines, PC-3, DU145, and M12, as compared to nontumorigenic prostate epithelial cells or the androgen-dependent cell line, LNCaP. Ectopic expression of USF2 in PC-3 cells did not affect the cell proliferation rate of PC-3 cells on plastic surfaces. However, it dramatically decreased anchorage-independent growth of PC-3 cells in soft agar (90-98% inhibition) and the invasion capability (80% inhibition) of PC-3 cells in matrix gel assay. Importantly, expression of USF2 in PC-3 cells inhibited the tumorigenicity of PC-3 cells in an in vivo nude mice xenograft model (80-90% inhibition). These results suggest that USF2 has tumor-suppression function. Consistent with its function in tumor suppression, we found that the USF2 protein is present in normal prostate epithelial cells but absent in 18 of 42 (43%) human prostate cancer tissues (P = 0.015). To further examine the functional role of USF2 in vivo, we generated mice with genetic deletion of USF2 gene. We found that USF2-null mice displayed marked prostate hyperplasia at a young age, suggesting that USF2 is involved in the normal growth and differentiation of prostate. Together, these studies demonstrate that USF2 has tumor-suppressor function and plays a role in prostate carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Methodist Hosp, Dept Pathol, Houston, TX 77030 USA; Stanford Univ, Dept Urol, Stanford, CA 94305 USA; Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; Stanford University; Virginia Commonwealth University	Chen, N (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	nanchen@mdanderson.org	Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; Astbury C, 2001, GENE CHROMOSOME CANC, V31, P143, DOI 10.1002/gcc.1128; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bookstein R, 2001, CONT CANC RES, P61; Bowen C, 2000, CANCER RES, V60, P6111; Choe C, 2005, EXP CELL RES, V302, P1, DOI 10.1016/j.yexcr.2004.08.013; Colella R, 2004, BIOTECH HISTOCHEM, V79, P121, DOI 10.1080/10520290400010572; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; GAO X, 1999, ADV ONCOBIOL, V3, P85; Gonzalgo ML, 2003, J UROLOGY, V170, P2444, DOI 10.1097/01.ju.0000085381.20139.b6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Karayi MK, 2004, PROSTATE CANCER P D, V7, P6, DOI 10.1038/sj.pcan.4500697; Kivinen A, 2004, PROSTATE, V59, P190, DOI 10.1002/pros.20015; KOZLOWSKI JM, 1999, HUMAN CELL CULTURE, V2, P305; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Pawar SA, 2004, ONCOGENE, V23, P6125, DOI 10.1038/sj.onc.1207806; Peehl DM, 2002, CULTURE EPITHELIAL C, P171; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RUDDON RW, 1995, CANC BIOL, P96; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMID HP, 1992, AM J SURG PATHOL, V16, P184, DOI 10.1097/00000478-199202000-00012; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Voeller HJ, 1997, CANCER RES, V57, P4455	44	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					579	587		10.1038/sj.onc.1209079	http://dx.doi.org/10.1038/sj.onc.1209079			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186802				2022-12-28	WOS:000234897400009
J	Kim, YH; Girard, L; Giacomini, CP; Wang, P; Hernandez-Boussard, T; Tibshirani, R; Minna, JD; Pollack, JR				Kim, YH; Girard, L; Giacomini, CP; Wang, P; Hernandez-Boussard, T; Tibshirani, R; Minna, JD; Pollack, JR			Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification	ONCOGENE			English	Article						small cell lung cancer; array CGH; expression profiling; DNA amplification; MYC	COMPARATIVE GENOMIC HYBRIDIZATION; DNA-BINDING; N-MYC; C-MYC; IDENTIFICATION; COMPLEX; PROTEIN; DEATH; MECHANISMS; DATABASE	DNA amplifications and deletions frequently contribute to the development and progression of lung cancer. To identify such novel alterations in small cell lung cancer (SCLC), we performed comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA microarrays representing similar to 22 000 human genes (providing an average mapping resolution of < 70 kb). We identified localized DNA amplifi. cations corresponding to oncogenes known to be amplified in SCLC, including MYC (8q24), MYCN (2p24) and MYCL1 (1p34). Additional highly localized DNA amplifi. cations suggested candidate oncogenes not previously identified as amplifified in SCLC, including the antiapoptotic genes TNFRSF4 (1p36), DAD1 (14q11), BCL2L1 (20q11) and BCL2L2 (14q11). Likewise, newly discovered PCR-validated homozygous deletions suggested candidate tumor-suppressor genes, including the proapoptotic genes MAPK10 (4q21) and TNFRSF6 (10q23). To characterize the effect of DNA amplifi. cation on gene expression patterns, we performed expression pro. ling using the same microarray platform. Among our findings, we identified sets of genes whose expression correlated with MYC, MYCN or MYCL1 amplification, with surprisingly little overlap among gene sets. While both MYC and MYCN ampli. cation were associated with increased and decreased expression of known MYC upregulated and downregulated targets, respectively, MYCL1 amplification was associated only with the latter. Our. findings support a role of altered apoptotic balance in the pathogenesis of SCLC, and suggest that MYC family genes might affect oncogenesis through distinct sets of targets, in particular implicating the importance of transcriptional repression.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; Stanford University; Stanford University	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 269 Campus Dr,CCSR 3245A, Stanford, CA 94305 USA.	pollack1@stanford.edu		Wang, Pei/0000-0002-6890-6453	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bednarek AK, 2001, CANCER RES, V61, P8068; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARNEY DN, 1985, CANCER RES, V45, P2913; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cory S, 1999, CANCER RES, V59, p1685S; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; MA A, 1993, ONCOGENE, V8, P1093; Malynn BA, 2000, GENE DEV, V14, P1390; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; PERLAKY L, 1992, CANCER RES, V52, P428; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Raetz EA, 2003, CANCER, V98, P841, DOI 10.1002/cncr.11584; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	46	145	151	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					130	138		10.1038/sj.onc.1208997	http://dx.doi.org/10.1038/sj.onc.1208997			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16116477				2022-12-28	WOS:000234406400014
J	Tanaka, Y; Kanai, F; Ichimura, T; Tateishi, K; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Imamura, J; Ikenoue, T; Ijichi, T; Kawabe, T; Isobe, T; Omata, M				Tanaka, Y; Kanai, F; Ichimura, T; Tateishi, K; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Imamura, J; Ikenoue, T; Ijichi, T; Kawabe, T; Isobe, T; Omata, M			The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1	ONCOGENE			English	Article						HBV; HBx; AP-1; Jab1; HCC	STABLE RNA INTERFERENCE; COP9 SIGNALOSOME; HBX PROTEIN; C-JUN; TRANSCRIPTION FACTORS; BINDING PROTEIN; GENE-EXPRESSION; CELL-CYCLE; COMPLEX; KINASES	Hepatitis B virus X protein (HBx) has many cellular functions and is a major factor in hepatitis and hepatocellular carcinoma caused by HBV infection. A proteomic approach was used to search for HBx-interacting proteins in order to elucidate the molecular mechanism of hepatocarcinogenesis. HBx was attached to myc and flag tags (MEF tags) and expressed in 293T cells; the protein complex formed within the cells was purified and characterized by mass spectrometry. COP9 signalosome (CSN) subunits 3 and 4 were subsequently identified as HBx-interacting proteins. In addition, CSN subunit 5, Jun activation domain-binding protein 1 (Jab1), was shown to be a novel cellular target of HBx. In vivo and in vitro interactions between HBx and Jab1 were confirmed by standard immunoprecipitation and GST pull-down assays. An analysis of HBx deletion constructs showed that amino acids 30-125 of HBx were responsible for binding to Jab1. Confocal laser microscopy demonstrated that HBx was mainly localized in the cytoplasm, while Jab1 was found mainly in the nucleus and partially in the cytoplasm, and that the two proteins colocalized in the cytoplasm. The cotransfection of HBx and Jab1 resulted in substantial activator protein 1 (AP-1) activation and knockdown of endogenous Jab1 attenuated AP-1 activation caused by HBx. In addition, the coexpression of HBx and Jab1 potentiated phosphorylation of JNK, leading to the subsequent phosphorylation of c-Jun, whereas the level of c-Jun and JNK phosphorylation induced by HBx was decreased in Jab1 knockdown cells. These results suggest that the interaction between HBx and Jab1 enhances HBx-mediated AP-1 activation.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 113, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Hachioji, Tokyo 19203, Japan	University of Tokyo; University of Tokyo; Tokyo Metropolitan University	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Isobe, Toshiaki/Q-9279-2017; IJICHI, Hideaki/AGZ-2874-2022; Ijichi, Hideaki/AAE-6692-2022; Asaoka, Yoshinari/ABC-5412-2021	IJICHI, Hideaki/0000-0002-2379-7986; Ijichi, Hideaki/0000-0002-2379-7986; Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chopra S, 2002, J BIOL CHEM, V277, P32413, DOI 10.1074/jbc.C200311200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Liu P, 2002, J HEPATOL, V37, P63, DOI 10.1016/S0168-8278(02)00064-8; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Nijhara R, 2001, FEBS LETT, V504, P59, DOI 10.1016/S0014-5793(01)02773-9; Omata M, 1998, NEW ENGL J MED, V339, P114, DOI 10.1056/NEJM199807093390209; Oron E, 2002, DEVELOPMENT, V129, P4399; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V318, P461, DOI 10.1016/j.bbrc.2004.04.046; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Zhang SM, 2005, ARCH VIROL, V150, P1579, DOI 10.1007/s00705-005-0521-1; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	54	77	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					633	642		10.1038/sj.onc.1209093	http://dx.doi.org/10.1038/sj.onc.1209093			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247477				2022-12-28	WOS:000234897400014
J	Thornburg, NJ; Kulwichit, W; Edwards, RH; Shair, KHY; Bendt, KM; Raab-Traub, N				Thornburg, NJ; Kulwichit, W; Edwards, RH; Shair, KHY; Bendt, KM; Raab-Traub, N			LMP1 signaling and activation of NF-kappa B in LMP1 transgenic mice	ONCOGENE			English	Article						NF-kappa B; Epstein-Barr virus; LMP1	EPSTEIN-BARR-VIRUS; LATENT INFECTION MEMBRANE-PROTEIN-1; RECEPTOR-ASSOCIATED FACTOR-1; GROWTH-FACTOR RECEPTOR; REED-STERNBERG CELLS; PROTEIN 1 ENGAGES; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; P53 GENE; EXPRESSION	Transgenic mice expressing Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) under the control of an immunoglobulin heavy-chain promoter and enhancer develop lymphoma at a threefold higher incidence than LMP1-negative mice. In vitro, LMP1 activates numerous signaling pathways including p38, c-Jun N terminal kinase (JNK), phosphatidylinositol 3 kinase (PI3K)/Akt, and NF-kappa B through interactions with tumor necrosis receptor-associated factors (TRAFs). These pathways are frequently activated in EBV-associated malignancies, although their activation cannot be definitively linked to LMP1 expression in vivo. In this study, interactions between LMP1 and TRAFs and the activation of PI3K/Akt, JNK, p38, and NF-kappa B were examined in LMP1 transgenic mice. LMP1 co-immunoprecipitated with TRAFs 1, 2, and 3. Akt, JNK, and p38 were activated in LMP1-positive and -negative splenocytes as well as LMP1-positive and -negative lymphomas. Multiple forms of NF-kappa B were activated in healthy splenocytes from LMP1 transgenic mice, in contrast to healthy splenocytes from LMP1-negative mice. However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappa B c-Rel, was specifically activated. Similarly to EBV-associated malignancies, p53 protein was detected at high levels in the transgenic lymphomas, although mutations were not detected in the p53 gene. These data indicate that NF-kappa B is activated in LMP1-positive healthy splenocytes; however, NF-kappa B c-Rel is specifically activated in both the transgenic lymphomas and in the rare lymphomas that develop in negative mice. The LMP1-mediated activation of NF-kappa B may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, CB 7295,Room 102,Mason Farm Rd, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu		Shair, Kathy Ho Yen/0000-0002-9556-1745; Thornburg, Natalie/0000-0003-3523-3616	NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NCI NIH HHS [CA 19014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ardila-Osorio H, 1999, INT J CANCER, V81, P645, DOI 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BALLERINI P, 1993, BLOOD, V81, P166; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Durkop H, 1999, BLOOD, V93, P617, DOI 10.1182/blood.V93.2.617.402k14_617_623; EDWARDS RH, 1994, J VIROL, V68, P1309, DOI 10.1128/JVI.68.3.1309-1315.1994; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liebowitz D, 1998, NEW ENGL J MED, V338, P1413, DOI 10.1056/NEJM199805143382003; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Murray PG, 2001, J PATHOL, V194, P158, DOI 10.1002/path.873; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pai S, 2002, J VIROL, V76, P1914, DOI 10.1128/JVI.76.4.1914-1921.2002; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Panagopoulos D, 2004, J VIROL, V78, P13253, DOI 10.1128/JVI.78.23.13253-13261.2004; Stunz LL, 2004, IMMUNITY, V21, P255, DOI 10.1016/j.immuni.2004.07.008; Thornburg NJ, 2003, CANCER RES, V63, P8293; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9	47	73	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					288	297		10.1038/sj.onc.1209023	http://dx.doi.org/10.1038/sj.onc.1209023			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16247482				2022-12-28	WOS:000234583600013
J	Zou, GM; Chen, JJ; Ni, J				Zou, GM; Chen, JJ; Ni, J			LIGHT induces differentiation of mouse embryonic stem cells associated with activation of ERK5	ONCOGENE			English	Article						LIGHT; ES cells; ERK5; MKP-3; differentiation	TNF SUPERFAMILY; DENDRITIC CELLS; SIGNAL; ALPHA; PROLIFERATION; PHOSPHORYLATION; PLURIPOTENCY; ANGIOGENESIS; EXPRESSION; MATURATION	LT-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells ( LIGHT) is a recently cloned type II transmembrane protein belonging to the TNF family that was originally identified as a weak inducer of apoptosis. This cytokine has been extensively defined in its role on T-cell regulation and dendritic cell maturation. However, whether this cytokine regulates stem cell proliferation and/or differentiation remains unknown. In this study, we transduced exogenous LIGHT into embryonic stem cells (ES cells) and found it induced their differentiation. The expression of phospho-STAT3, Nanog and Oct-4 was reduced in LIGHT-transduced ES cells compared with wild-type ES cells. LIGHT-transduced ES cells exhibit a low level of SSEA-1 surface antigen and alkaline phosphatase staining compared with wild-type cells. Introduction of LIGHT into ES cells results in the dephosphorylation of MKP-3 and activation of extracellular signal-regulated kinase (ERK)5. When ERK5 was inhibited by the specific inhibitor PD184352 or knocked down by ERK5 siRNA, reduction of Oct-4 and SSEA-1 expression was rescued. We conclude that LIGHT overrides leukemia inhibitory factor to induce ES cell differentiation associated with activation of ERK5.	Univ Iowa, Sch Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA; Shanghai Fuchun Zhongnan Biotech Co Ltd, Shanghai, Peoples R China	University of Iowa; University of Chicago; University of Chicago Medical Center	Zou, GM (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, 1044 W Walnut St,Rm402, Indianapolis, IN 46202 USA.	gzou@iupui.edu	Zou, Gang-Ming/F-1085-2016					Bode JG, 2003, J IMMUNOL, V171, P257, DOI 10.4049/jimmunol.171.1.257; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen Y, 2003, FASEB J, V17, P2231, DOI 10.1096/fj.03-0030com; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fandrich F, 2002, NAT MED, V8, P171, DOI 10.1038/nm0202-171; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Morel Y, 2001, J IMMUNOL, V167, P2479, DOI 10.4049/jimmunol.167.5.2479; Nakaoka Y, 2003, CIRC RES, V93, P221, DOI 10.1161/01.RES.0000085562.48906.4A; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Sato M, 2001, INTERNAL MED, V40, P195, DOI 10.2169/internalmedicine.40.195; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Tamada K, 2000, NAT MED, V6, P283; Wang YC, 2004, DEV DYNAM, V231, P72, DOI 10.1002/dvdy.20114; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wu DY, 2005, CELL RES, V15, P317, DOI 10.1038/sj.cr.7290300; Wuu YD, 1998, BIOL REPROD, V58, P1416, DOI 10.1095/biolreprod58.6.1416; Zou GM, 2005, J CELL PHYSIOL, V205, P437, DOI 10.1002/jcp.20420; Zou GM, 2000, AM J REPROD IMMUNOL, V43, P240, DOI 10.1111/j.8755-8920.2000.430409.x; Zou GM, 2004, CANCER IMMUNOL IMMUN, V53, P681, DOI 10.1007/s00262-004-0518-8; Zou GM, 2003, TRANSPL P, V35, P2827, DOI 10.1016/j.transproceed.2003.09.044; Zou GM, 2003, BIOL CELL, V95, P365, DOI 10.1016/S0248-4900(03)00079-0	32	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					463	469		10.1038/sj.onc.1208987	http://dx.doi.org/10.1038/sj.onc.1208987			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247486				2022-12-28	WOS:000234714100014
J	Egler, RA; Fernandes, E; Rothermund, K; Sereika, S; de Souza-Pinto, N; Jaruga, P; Dizdaroglu, M; Prochownik, EV				Egler, RA; Fernandes, E; Rothermund, K; Sereika, S; de Souza-Pinto, N; Jaruga, P; Dizdaroglu, M; Prochownik, EV			Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1	ONCOGENE			English	Article						peroxiredoxin 1; c-Myc; c-Abl; reactive oxygen species; DNA damage; Ras; Omnibank (R)	CHROMATOGRAPHY-MASS SPECTROMETRY; REPRESSES TRANSCRIPTION; CELL-PROLIFERATION; HYDROGEN-PEROXIDE; TUMOR-SUPPRESSOR; REPAIR PATHWAY; GROWTH-FACTORS; TARGET GENE; LIFE-SPAN; EXPRESSION	Overexpression of c-Myc results in transformation and multiple other phenotypes, and is accompanied by the deregulation of a large number of target genes. We previously demonstrated that peroxiredoxin 1 (Prdx1), a scavenger of reactive oxygen species (ROS), interacts with a region of the c-Myc transcriptional regulatory domain that is essential for transformation. This results either in the suppression or enhancement of some c-Myc functions and in the altered expression of select target genes. Most notably, c-Myc-mediated transformation is inhibited, implying a tumor suppressor role for Prdx1. Consistent with this, prdx1 -/- mice develop age-dependent hemolytic anemias and/or malignancies. We now show that erythrocytes and embryonic fibroblasts from these animals contain higher levels of ROS, and that the latter cells show evidence of c-Myc activation, including the ability to be transformed by a ras oncogene alone. In contrast, other primary cells from prdx1 -/- mice do not have elevated ROS, but nonetheless show increased oxidative DNA damage. This apparent paradox can be explained by the fact that ROS localize primarily to the cytoplasm of prdx1 -/- cells, whereas in prdx1 -/- cells, much higher levels of nuclear ROS are seen. We suggest that increased DNA damage and tumor susceptibility in prdx1 -/- animals results from this shift in intracellular ROS. prdx1 -/- mice should be useful in studying the role of oxidative DNA damage in the causation of cancer and its prevention by antioxidants. They should also help in studying the relationship between oncogenes such as c-Myc and DNA damage.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA; NIH, Lab Mol Gerontol, Baltimore, MD 21224 USA; Univ Maryland, Dept Chem & Biochem Engn, Baltimore, MD 21250 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Dept Pediat, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu	Jaruga, Pawel/M-4378-2015; Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; Jaruga, Pawel/0000-0001-9192-6084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD042987] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000727, ZIAAG000727] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline; NICHD NIH HHS [T32 HD042987] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barker N, 2000, ADV CANCER RES, V77, P1; Birincioglu M, 2003, J AM CHEM SOC, V125, P11607, DOI 10.1021/ja0352146; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bubendorf L, 1999, CANCER RES, V59, P803; Bubendorf L, 1999, CANCER RES, V59, P1388; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Dizdaroglu M, 2001, FREE RADICAL BIO MED, V30, P774, DOI 10.1016/S0891-5849(01)00464-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisen JA, 2000, GENOME BIOL, V1; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Iritani BM, 2002, EMBO J, V21, P4820, DOI 10.1093/emboj/cdf492; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Jaruga PW, 2001, FREE RADICAL BIO MED, V31, P336, DOI 10.1016/S0891-5849(01)00594-9; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Kuraoka I, 2001, J BIOL CHEM, V276, P49283, DOI 10.1074/jbc.M107779200; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Marietta C, 2002, DNA REPAIR, V1, P967, DOI 10.1016/S1568-7864(02)00148-9; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Naidu R, 2002, INT J MOL MED, V9, P189; Nakahara H, 1998, FREE RADICAL BIO MED, V24, P85, DOI 10.1016/S0891-5849(97)00164-0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PARADA LF, 1985, PROG MED VIROL, V32, P115; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PIETILAINEN T, 1995, ANTICANCER RES, V15, P959; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Senturker S, 1999, FREE RADICAL BIO MED, V27, P370, DOI 10.1016/S0891-5849(99)00069-6; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Smith DR, 1996, CLIN CANCER RES, V2, P1049; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; Trzeciak AR, 2004, CARCINOGENESIS, V25, P1359, DOI 10.1093/carcin/bgh144; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; YUAN L, 1993, EXP CELL RES, V209, P375, DOI 10.1006/excr.1993.1323	99	183	191	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8038	8050		10.1038/sj.onc.1208821	http://dx.doi.org/10.1038/sj.onc.1208821			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170382				2022-12-28	WOS:000233656600010
J	Gross, I; Lhermitte, B; Domon-Dell, C; Duluc, I; Martin, E; Gaiddon, C; Kedinger, M; Freund, JN				Gross, I; Lhermitte, B; Domon-Dell, C; Duluc, I; Martin, E; Gaiddon, C; Kedinger, M; Freund, JN			Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation	ONCOGENE			English	Article						Cdx; colon cancer; intestine; CDK2; 4S motif	HOMEOBOX TRANSCRIPTION FACTOR; SUCRASE-ISOMALTASE; MUTANT MICE; INTESTINAL METAPLASIA; CELL DIFFERENTIATION; HOMEODOMAIN PROTEINS; GENE-EXPRESSION; DOWN-REGULATION; BETA-CATENIN; COLON	The Caudal-related homeodomain transcription factor Cdx2 plays a key role in intestinal cell fate determination. Reduction of Cdx2 expression is a feature of many human colon carcinomas and inactivation of one cdx2 allele facilitates the development of invasive adenocarcinoma in the murine colon. Here, we investigated the post-translational regulation of Cdx2. We showed that various forms of Cdx2 coexist in the intestine and colon cancer cell lines, some of them being phosphorylated forms. We found that cyclin-dependent kinase 2 phosphorylated Cdx2 in vitro and in vivo. Using site-specific mutagenesis, we identified serine 281 as a new key residue for Cdx2 phosphorylation. Intriguingly, serine 281 belongs to a conserved motif of four evenly spaced serines (the 4S motif) similar to the one controlling beta-catenin degradation by the proteasome pathway. A nonphosphorylated mutant Cdx2 lacking the 4S motif (4S > A) exhibited reduced polyubiquitination upon proteasome inhibition and increased stability compared to wild-type Cdx2. In addition, we found that this mutant was less efficient to suppress colony formation than wild-type Cdx2. Thus, our data highlight a novel post-translational mechanism controlling Cdx2 degradation via phosphorylation and polyubiquitination, which may be of importance for intestinal development and cancer.	INSERM, Unit 682, F-67200 Strasbourg, France; INSERM, Unit 692, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM, Unit 682, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasbg.fr	Gross, Isabelle/I-4972-2016; DULUC, Isabelle/AAA-7062-2022; Gaiddon, Christian/F-7321-2012; Domon-Dell, Claire/P-2368-2017; Duluc, Isabelle/O-1972-2017; Gross, Isabelle/P-9859-2019; Freund, Jean-Noel/R-4383-2016	Gross, Isabelle/0000-0002-2783-8773; DULUC, Isabelle/0000-0001-8396-6385; Gaiddon, Christian/0000-0003-4315-3851; Duluc, Isabelle/0000-0001-8396-6385; Gross, Isabelle/0000-0002-2783-8773; Freund, Jean-Noel/0000-0002-0971-3774; DOMON-DELL, Claire/0000-0002-8445-9593				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boulanger J, 2005, J BIOL CHEM, V280, P18095, DOI 10.1074/jbc.M502184200; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; CHANTRET I, 1994, J CELL SCI, V107, P213; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; EE HC, 1995, AM J PATHOL, V147, P586; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gautier-Stein A, 2003, NUCLEIC ACIDS RES, V31, P5238, DOI 10.1093/nar/gkg747; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kedinger M, 1998, PHILOS T R SOC B, V353, P847, DOI 10.1098/rstb.1998.0249; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Rodolosse A, 1996, BIOCHEM J, V315, P301, DOI 10.1042/bj3150301; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tamai Y, 1999, CANCER RES, V59, P2965; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Zhu ZL, 2002, DEV CELL, V3, P557, DOI 10.1016/S1534-5807(02)00270-8	44	38	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7955	7963		10.1038/sj.onc.1208945	http://dx.doi.org/10.1038/sj.onc.1208945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027724				2022-12-28	WOS:000233656600002
J	Reichman, C; Singh, K; Liu, Y; Singh, S; Li, H; Fajardo, JE; Fiser, A; Birge, RB				Reichman, C; Singh, K; Liu, Y; Singh, S; Li, H; Fajardo, JE; Fiser, A; Birge, RB			Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain	ONCOGENE			English	Article						Crk; Abl; SH3 domain; atypical; covariation; protein modeling; kinase activation	TERMINAL SH3 DOMAIN; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAIN; C-ABL; TYROSINE KINASE; STRUCTURAL BASIS; HIGH-AFFINITY; ACTIVATION; RECOGNITION; BINDING	To gain a better understanding of how Crk II regulates the function of the Abl tyrosine kinase, we explored the function of the C-terminal linker and SH3 domain, a region of Crk II that is still poorly understood. Molecular modeling, tryptophan. fluorescence, and covariation sequence alignment indicate that the Crk-SH3-C has a unique binding groove and RT loop not observed in typical SH3 domains. Based on these models, we made a series of mutations in the linker and in residues predicted to destabilize the putative binding pocket and RT loop. In Abl transactivation assays, Y222F and P225A mutations in the linker resulted in strong transactivation of Abl by Crk II. However, mutations predicted to be at the surface of the Crk SH3-C were not activators of Abl. Interestingly, combinations of activating mutations of Crk II with mutations in the highly conserved PNAY sequence in the SH3-C inactivated the activating mutations, suggesting that the SH3-C is necessary for activation. Our data provide insight into the role of highly conserved residues in the Crk-SH3-C, suggesting a mechanism for how the linker and the Crk-SH3-C function in the transactivation of the Abl tyrosine kinase.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine	Birge, RB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu		Li, Hong/0000-0001-5731-5335; Singh, Sukhwinder/0000-0002-7061-0096	NIGMS NIH HHS [GMS55760] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kurakin A, 2002, J BIOMOL STRUCT DYN, V19, P1015, DOI 10.1080/07391102.2002.10506805; Kurakin AV, 2003, J BIOL CHEM, V278, P34102, DOI 10.1074/jbc.M305264200; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lewitzky M, 2004, J BIOL CHEM, V279, P28724, DOI 10.1074/jbc.M402745200; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; OGAWA S, 1994, ONCOGENE, V9, P1669; Pires JR, 2003, J MOL BIOL, V326, P1427, DOI 10.1016/S0022-2836(03)00039-1; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith KM, 2001, J BIOL CHEM, V276, P24372, DOI 10.1074/jbc.M100786200; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173	54	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8187	8199		10.1038/sj.onc.1208988	http://dx.doi.org/10.1038/sj.onc.1208988			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16158059				2022-12-28	WOS:000233809400010
J	Wei, JS; Whiteford, CC; Cenacchi, N; Son, CG; Khan, J				Wei, JS; Whiteford, CC; Cenacchi, N; Son, CG; Khan, J			BBC3 mediates fenretinide-induced cell death in neuroblastoma	ONCOGENE			English	Article						fenretinide (4-HPR); apoptosis; microarray; BBC3; neuroblastoma; N-[4-hydroxyphenyl]retinamide; PUMA	INDUCED APOPTOSIS; BH3-ONLY PROTEINS; GENE-EXPRESSION; RETINOIC-ACID; IN-VITRO; LINES; INDUCTION; DIFFERENTIATION; SENSITIVITY; GADD153	Fenretinide (4-HPR) is a synthetic retinoid whose apoptosis-inducing effects have been demonstrated in many tumor types. The precise mechanism of its apoptotic action is not fully understood. To further study the mechanism by which 4-HPR exerts its biological effects in neuroblastoma ( NB) and to identify the genes that contribute to the induction of apoptosis, we determined the sensitivity of eight NB cell lines to 4-HPR. Additionally, cDNA microarray analysis was performed on a 4-HPR-sensitive cell line to investigate the temporal changes in gene expression, primarily focusing on the induction of proapoptotic genes. BBC3, a transcriptionally regulated proapoptotic member of the BCL2 family, was the most highly induced proapoptotic gene. Western analysis confirmed the induction of BBC3 protein by 4-HPR. Furthermore, the induction of BBC3 was associated with the sensitivity to this agent in the cell lines tested. Finally we demonstrated that BBC3 alone is sufficient to induce cell death in the 4-HPR-sensitive and resistant NB cell lines, and that siRNA against BBC3 significantly decreases apoptosis induced by 4-HPR. Our results indicate that BBC3 mediates cell death in NB cells in response to 4-HPR.	NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; Daejeon Univ, Coll Oriental Med, Dept Internal Med, Taejon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Daejeon University	Khan, J (corresponding author), NCI, Pediat Oncol Branch, 8717 Grovemont Circle, Bethesda, MD 20892 USA.	khanjav@mail.nih.gov	Khan, Javed/P-9157-2014; son, chang gue/ABC-2215-2021		NCI NIH HHS [Z01 BC010594-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010594, ZIABC010594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; Bouillet P, 2002, J CELL SCI, V115, P1567; Brodeur Garrett M., 1997, P761; Chen Y., 1997, BIOMED OPTICS, V2, P364; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferrari N, 2003, ONCOL REP, V10, P973; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hsieh TC, 1995, BIOCHEM MOL BIOL INT, V37, P499; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Lovat PE, 2003, CANCER LETT, V197, P157, DOI 10.1016/S0304-3835(03)00098-3; Lovat PE, 2003, CANCER RES, V63, P7310; Lovat PE, 2002, CANCER RES, V62, P5158; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; Pahlman S, 2000, NEUROBLASTOMA, P9; Pearson ADJ, 2000, NEUROBLASTOMA, P551; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PONZONI M, 1995, CANCER RES, V55, P853; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reynolds CP, 2000, MED PEDIATR ONCOL, V35, P597, DOI 10.1002/1096-911X(20001201)35:6<597::AID-MPO23>3.0.CO;2-B; ROSS RA, 1983, J NATL CANCER I, V71, P741; SLAWIN K, 1993, CANCER RES, V53, P4461; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZIV Y, 1994, ANTICANCER RES, V14, P2005	33	14	14	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7976	7983		10.1038/sj.onc.1208947	http://dx.doi.org/10.1038/sj.onc.1208947			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091745	Green Accepted			2022-12-28	WOS:000233656600004
J	Aghi, M; Martuza, RL				Aghi, M; Martuza, RL			Oncolytic viral therapies - the clinical experience	ONCOGENE			English	Review						oncolytic virus; clinical trials; adenovirus; herpesvirus; vaccinia virus; Newcastle disease virus	HERPES-SIMPLEX-VIRUS; REPLICATION-SELECTIVE ADENOVIRUS; PHASE-I TRIAL; RECURRENT PROSTATE-CANCER; NEWCASTLE-DISEASE VIRUS; SUICIDE GENE-THERAPY; LONG-TERM SURVIVAL; NECK-CANCER; ATTENUATED ADENOVIRUS; MALIGNANT GLIOMA	It has been 9 years since the beginning of the first clinical trial in which an oncolytic virus was administered to cancer patients. Since then, oncolytic viruses from five different species have been taken to phase I and II clinical trials in over 300 cancer patients. While additional studies will be required to ascertain if the efficacy of any of these agents is high enough to warrant adding them to the existing therapeutic regimen, it has been reassuring that DNA viruses engineered to achieve tumor selectivity and RNA viruses with relative inherent natural tumor selectivity have proven reasonably safe at the wide range of doses that were tested. Here, we review the biology and clinical results of these five species of viruses and discuss lessons learned and challenges for the future.	Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Aghi, M (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, White Bldg Room 502,55 Fruit St, Boston, MA 02114 USA.	maghi@partners.org						Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q; Batliwalla FM, 1998, MOL MED, V4, P783, DOI 10.1007/BF03401771; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; BOVIATSIS EJ, 1994, GENE THER, V1, P323; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Cohen J, 2002, SCIENCE, V298, P2312, DOI 10.1126/science.298.5602.2312; DeWeese TL, 2001, CANCER RES, V61, P7464; EDELSTEIN M, 2005, J GENE MED; FONG YKN, 2002, 38 ANN M AM SOC CLIN; FREEMAN AI, 2004, 40 ANN M AM SOC CLIN; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; Ganly I, 2000, CLIN CANCER RES, V6, P798; Gomella LG, 2001, J UROLOGY, V166, P1291, DOI 10.1016/S0022-5347(05)65755-2; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Groot-Wassink T, 2002, HUM GENE THER, V13, P1723, DOI 10.1089/104303402760293565; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Habib NA, 2001, HUM GENE THER, V12, P219, DOI 10.1089/10430340150218369; Hamid O, 2003, J CLIN ONCOL, V21, P1498, DOI 10.1200/JCO.2003.09.114; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Heise CC, 1999, CANCER RES, V59, P2623; Hermann LL, 2004, J VIROL, V78, P6171, DOI 10.1128/JVI.78.12.6171-6179.2004; HOTTE SJ, 2003, 39 ANN M AM SOC CLIN; HU JCM, 2003, 39 ANN M AM SOC CLIN; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; LEE SS, 1994, CANCER RES, V54, P3325; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; MacKay JA, 2005, BRAIN RES, V1035, P139, DOI 10.1016/j.brainres.2004.12.007; MacKie RM, 2001, LANCET, V357, P525, DOI 10.1016/S0140-6736(00)04048-4; Makower D, 2003, CLIN CANCER RES, V9, P693; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 1999, CANCER GENE THER, V6, P409, DOI 10.1038/sj.cgt.7700066; Mohr I, 1996, EMBO J, V15, P4759, DOI 10.1002/j.1460-2075.1996.tb00853.x; Morley S, 2004, CLIN CANCER RES, V10, P4357, DOI 10.1158/1078-0432.CCR-03-0443; MORRIS DG, 2002, 38 ANN M AM SOC CLIN; Mukherjee S, 2000, CANCER GENE THER, V7, P663, DOI 10.1038/sj.cgt.7700133; Mulvihlll S, 2001, GENE THER, V8, P308, DOI 10.1038/sj.gt.3301398; *NAT I HLTH REC DN, 2002, ASS AD VECT SAF TOX, V13, P3; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nemunaitis J, 2003, CANCER GENE THER, V10, P341, DOI 10.1038/sj.cgt.7700585; Nemunaitis J, 2001, GENE THER, V8, P746, DOI 10.1038/sj.gt.3301424; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Rauen KA, 2002, CANCER RES, V62, P3812; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER RES, V62, P6070; Rogulski KR, 2000, CANCER RES, V60, P1193; Rudin CM, 2003, J CLIN ONCOL, V21, P4546, DOI 10.1200/JCO.2003.03.544; SOUTHAM CHESTER M., 1960, TRANS NEW YORK ACAD SCI, V22, P657; Todo T, 1999, HUM GENE THER, V10, P2741, DOI 10.1089/10430349950016483; Vasey PA, 2002, J CLIN ONCOL, V20, P1562, DOI 10.1200/JCO.20.6.1562; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang Q, 1997, GENE THER, V4, P1300, DOI 10.1038/sj.gt.3300535; Wein LM, 2003, CANCER RES, V63, P1317; Wu JT, 2004, B MATH BIOL, V66, P605, DOI 10.1016/j.bulm.2003.08.016; Xu Rui-Hua, 2003, Ai Zheng, V22, P1307; Yuan Zhong-Yu, 2003, Ai Zheng, V22, P310	69	232	247	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7802	7816		10.1038/sj.onc.1209037	http://dx.doi.org/10.1038/sj.onc.1209037			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299539	Bronze			2022-12-28	WOS:000233372600015
J	Nakamura, Y; Yujiri, T; Nawata, R; Tagami, K; Tanizawa, Y				Nakamura, Y; Yujiri, T; Nawata, R; Tagami, K; Tanizawa, Y			MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells	ONCOGENE			English	Article						Bcr-Abl; MEKK1; STAT3; embryonic stem cell	CHRONIC MYELOID-LEUKEMIA; CYTOKINE RECEPTORS; ACTIVATION; SURVIVAL; BINDING; GROWTH; RAC	BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia, arises in a primitive hematopoietic stem cell that has the capacity for both differentiation and self-renewal. Its product, Bcr-Abl protein, has been shown to activate signal transducers and activators of transcription 3 (STAT3) and to promote self-renewal in embryonic stem (ES) cells, even in the absence of leukemia inhibitory factor (LIF). MEK kinase 1 (MEKK1) is a 196-kDa mitogen-activated protein kinase (MAPK) kinase kinase involved in Bcr-Abl signal transduction. To investigate the role of MEKK1 in Bcr-Abl-induced transformation of stem cells, p210 Bcr-Abl was stably transfected into wildtype (WTp210) and MEKK1-/- (MEKK1-/-(p210)) ES cells. Bcr-Abl enhanced MEKK1 expression in ES transfectants, as it does in other Bcr-Abl-transformed cells. In the absence of LIF, WTp210 cells showed constitutive STAT3 activation and formed rounded, compact colonies having strong alkaline phosphatase activity, a characteristic phenotype of undifferentiated ES cells. MEKK1-/-(p210) cells, by contrast, showed less STAT3 activity than WTp210 cells and formed large, flattened colonies having weak alkaline phosphatase activity, a phenotype of differentiated ES cells. These results indicate that MEKK1 plays a key role in Bcr-Abl-induced STAT3 activation and in ES cells' capacity for LIF-independent self-renewal, and may thus be involved in Bcr-Abl-mediated leukemogenesis in stem cells.	Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, Ube, Yamaguchi 7558505, Japan	Yamaguchi University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	yujirit@yamaguchi-u.ac.jp	Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	18	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7592	7598		10.1038/sj.onc.1208899	http://dx.doi.org/10.1038/sj.onc.1208899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044153				2022-12-28	WOS:000233333800008
J	Einav, U; Tabach, Y; Getz, G; Yitzhaky, A; Ozbek, U; Amariglio, N; Izraeli, S; Rechavi, G; Domany, E				Einav, U; Tabach, Y; Getz, G; Yitzhaky, A; Ozbek, U; Amariglio, N; Izraeli, S; Rechavi, G; Domany, E			Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer	ONCOGENE			English	Article						gene expression; ALL; class discovery; interferon pathway; viral infection	T-CELLS; CLASSIFICATION; VIRUS; PREDICTION; SEQUENCES; DISCOVERY; HYPERMUTATION; INFLAMMATION; PATHOGENESIS; CHROMOSOMES	On the basis of epidemiological studies, infection was suggested to play a role in the etiology of human cancer. While for some cancers such a role was indeed demonstrated, there is no direct biological support for the role of viral pathogens in the pathogenesis of childhood leukemia. Using a novel bioinformatic tool that alternates between clustering and standard statistical methods of analysis, we performed a 'double-blind' search of published gene expression data of subjects with different childhood acute lymphoblastic leukemia (ALL) subtypes, looking for unanticipated partitions of patients, induced by unexpected groups of genes with correlated expression. We discovered a group of about 30 genes, related to the interferon response pathway, whose expression levels divide the ALL samples into two subgroups; high in 50, low in 285 patients. Leukemic subclasses prevalent in early childhood (the age most susceptible to infection) are over-represented in the high-expression subgroup. Similar partitions, induced by the same genes, were found also in breast and ovarian cancer but not in lung cancer, prostate cancer and lymphoma. About 40% of breast cancer samples expressed the 'interferon-related' signature. It is of interest that several studies demonstrated mouse mammary tumor virus-like sequences in about 40% of breast cancer samples. Our discovery of an unanticipated strong signature of an interferon-induced pathway provides molecular support for a role for either inflammation or viral infection in the pathogenesis of childhood leukemia as well as breast and ovarian cancer.	Safa Childrens Hosp, Sheba Med Ctr, Dept Pediat Hematol & Oncol, IL-52621 Tel Hashomer, Israel; Weizmann Inst Sci, Dept Phys, IL-76100 Rehovot, Israel; Istanbul Univ, DETAE, Dept Genet, Expt Med Res Inst, Istanbul, Turkey; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Weizmann Institute of Science; Istanbul University; Tel Aviv University; Sackler Faculty of Medicine	Rechavi, G (corresponding author), Safa Childrens Hosp, Sheba Med Ctr, Dept Pediat Hematol & Oncol, IL-52621 Tel Hashomer, Israel.	gidi.rechavi@sheba.health.gov.il; eytan.domany@weizmann.ac.il	Ozbek, Ugur/C-9513-2017; DOMANY, EYTAN/K-1560-2012; Tabach, Yuval/Q-8488-2019	Ozbek, Ugur/0000-0001-5319-0547; 				Akyerli CB, 2005, LEUKEMIA RES, V29, P283, DOI 10.1016/j.leukres.2004.07.007; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ben-Dor A, 2000, J COMPUT BIOL, V7, P559, DOI 10.1089/106652700750050943; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blatt M, 1997, NEURAL COMPUT, V9, P1805, DOI 10.1162/neco.1997.9.8.1805; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Califano A, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P75; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Cheng Y., 2000, P 8 INT C INT SYST M, P93; Colonna M, 2002, CURR OPIN IMMUNOL, V14, P373, DOI 10.1016/S0952-7915(02)00349-7; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Ford CE, 2003, CLIN CANCER RES, V9, P1118; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Georgiannos SN, 2003, SURGERY, V134, P827, DOI 10.1016/S0039-6060(03)00292-7; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; HASLE H, 1995, LEUKEMIA, V9, P605; Heerema NA, 2000, J CLIN ONCOL, V18, P1876, DOI 10.1200/JCO.2000.18.9.1876; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ito C, 1999, BLOOD, V93, P315, DOI 10.1182/blood.V93.1.315.401k35_315_320; KEYDAR I, 1984, P NATL ACAD SCI-BIOL, V81, P4188, DOI 10.1073/pnas.81.13.4188; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; Kinlen LJ, 2001, LANCET, V357, P858, DOI 10.1016/S0140-6736(00)04208-2; Koushik A, 2001, CANCER CAUSE CONTROL, V12, P483, DOI 10.1023/A:1011266413087; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; MacKenzie J, 1999, BRIT J CANCER, V81, P898, DOI 10.1038/sj.bjc.6690783; MacKenzie J, 2001, LEUKEMIA, V15, P415, DOI 10.1038/sj.leu.2402049; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mele A, 2003, BLOOD, V102, P996, DOI 10.1182/blood-2002-10-3230; Ness RB, 2003, J INFECT DIS, V187, P1147, DOI 10.1086/368380; Nzula S, 2003, CANCER RES, V63, P3275; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Tabori U, 2001, LEUKEMIA, V15, P866, DOI 10.1038/sj.leu.2402102; Tanay Amos, 2002, Bioinformatics, V18 Suppl 1, pS136; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wall L, 2003, GYNECOL ONCOL, V88, pS149, DOI 10.1006/gyno.2002.6707; WANG Y, 1995, CANCER RES, V55, P5173; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	65	56	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6367	6375		10.1038/sj.onc.1208797	http://dx.doi.org/10.1038/sj.onc.1208797			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007187	Green Submitted			2022-12-28	WOS:000232038200004
J	Niwa, Y; Kanda, H; Shikauchi, Y; Saiura, A; Matsubara, K; Kitagawa, T; Yamamoto, J; Kubo, T; Yoshikawa, H				Niwa, Y; Kanda, H; Shikauchi, Y; Saiura, A; Matsubara, K; Kitagawa, T; Yamamoto, J; Kubo, T; Yoshikawa, H			Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma	ONCOGENE			English	Article						SOCS-3; FAK; JAK/ STAT; HCC	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; CONSTITUTIVE ACTIVATION; LIVER; OVEREXPRESSION; INACTIVATION; ASSOCIATION; PP125(FAK); ASSIGNMENT; FRAGMENTS	We identified that suppressor of cytokine signaling-3 (SOCS-3) gene was aberrantly methylated in its CpG island in three of 10 human hepatocellular carcinoma ( HCC) cell lines. SOCS-3 RNA was undetectable in five of the 10 HCC cell lines including the three methylated cell lines, and a demethylating agent, 5-aza-2'-deoxycytidine, reactivated SOCS-3 expression in three cell lines tested. The DNA region where we found aberrant DNA methylation includes a signal transducers and activators of transcription ( STAT) binding consensus sequence. When the DNA region was used as a promoter, DNA methylation markedly reduced promoter activity. SOCS-3 was also aberrantly methylated in six of 18 primary HCC samples. SOCS-3 expression was reduced in three of the three methylated and one of the three unmethylated primary samples examined. Restoration of SOCS-3 in cells lacking SOCS-3 expression suppressed STAT3 phosphorylation and cell growth. We found that IL-6 acted as a growth factor in HCC cells. Inhibition of SOCS-3 expression in cells whose growth was induced by IL-6 enhanced STAT3 phosphorylation and cell growth. In addition, AG490, a chemical JAK2 inhibitor, suppressed cell growth and downregulated STAT3 phosphorylation, but not FAK phosphorylation. We also found that SOCS-3 physically interacted with phosphorylated FAK and Elongin B in HCC cells. Restoration of SOCS-3 decreased FAK phosphorylation as well as FAK protein level. Inhibition of SOCS-3 expression increased FAK phosphorylation, resulting in enhancement of cell migration. These data indicate that SOCS-3 negatively regulates cell growth and cell motility by inhibiting Janus kinase (JAK)/STAT and FAK signalings in HCC cells. Thus, loss of SOCS-3 by the associated DNA methylation confers cells advantage in growth and migration.	Japanese Fdn Canc Res, Inst Canc, Dept Epigenet Carcinogenesis, Koto Ku, Tokyo 1358550, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Koto Ku, Tokyo 1358550, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Surg, Koto Ku, Tokyo 1358550, Japan; DNA Chip Res Inc, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; DNA Chip Research Inc.	Yoshikawa, H (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Epigenet Carcinogenesis, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	hirohide.yoshikawa@jfcr.or.jp						Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Cary LA, 1996, J CELL SCI, V109, P1787; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ILLC D, 1995, NATURE, V377, P539; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kubo T, 2004, CANCER RES, V64, P5172, DOI 10.1158/0008-5472.CAN-03-3314; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Nagamori S, 2000, J GASTROENTEROL, V35, P493, DOI 10.1007/s005350070071; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OWENS LV, 1995, CANCER RES, V55, P2752; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; WeberNordt RM, 1996, BLOOD, V88, P809; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005; Yoshikawa H, 1997, GENE, V197, P129, DOI 10.1016/S0378-1119(97)00251-5; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zimmers TA, 2003, HEPATOLOGY, V38, P326, DOI 10.1053/jhep.2003.50318	39	273	310	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6406	6417		10.1038/sj.onc.1208788	http://dx.doi.org/10.1038/sj.onc.1208788			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007195				2022-12-28	WOS:000232038200008
J	Hall, WW; Fujii, M				Hall, WW; Fujii, M			Deregulation of cell-signaling pathways in HTLV-1 infection	ONCOGENE			English	Review						HTLV-1; tax; cell signaling	LEUKEMIA-VIRUS TYPE-1; LARGE TUMOR-SUPPRESSOR; NF-KAPPA-B; PAPILLOMAVIRUS E6 PROTEINS; TRANSFORMED T-CELLS; I TAX PROTEIN; PROTEASOME-MEDIATED DEGRADATION; TRANSCRIPTION FACTOR AP-1; SERUM RESPONSE FACTOR; IMMEDIATE-EARLY GENES	Human T-lymphotropic virus type 1 (HTLV-1) infection is associated with the clonal expansion and transformation of mature T lymphocytes. While the mechanisms involved are incompletely understood the viral regulatory protein Tax plays a central role in these processes. Recent studies employing genomic and proteomic approaches have demonstrated the marked complexity of gene deregulation associated with Tax expression and confirmed the remarkable pleiotropism of this protein as evidenced by the numerous Tax-cellular protein interactions in infected cells. In this review, we summarize the role of Tax in the deregulation of selected cellular-signaling pathways. Specifically, this has focused on the influence and interaction of Tax with the AP-1 and NF-AT transcription factors, PDZ domain-containing proteins, RhoGTPases, and the Janus kinase/signal transducer and activator of transcription and transforming growth factor-beta-signaling pathways. In addition to identifying the deregulation of events within these pathways, attempts have been made to highlight differences between HTLV-1 and -2, which may relate to differences in their pathogenic properties.	Univ Coll Dublin, Dept Med Microbiol, Ctr Res Infect Dis, Dublin 4, Ireland; Niigata Univ, Grad Sch Med & Dent Sci, Div Virol, Niigata 9518510, Japan	University College Dublin; Niigata University	Hall, WW (corresponding author), Univ Coll Dublin, Dept Med Microbiol, Ctr Res Infect Dis, Dublin 4, Ireland.	William.hall@ucd.ie						Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; Araujo A, 2004, ANN NEUROL, V56, P10, DOI 10.1002/ana.20126; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; Azran Inbal, 2004, Retrovirology, V1, P20; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Blot V, 2004, J CELL SCI, V117, P3983, DOI 10.1242/jcs.01266; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De la Fuente C, 2000, AIDS RES HUM RETROV, V16, P1695, DOI 10.1089/08892220050193164; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Ding W, 2003, J VIROL, V77, P11027, DOI 10.1128/JVI.77.20.11027-11039.2003; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fabre S, 2000, MOL BIOL REP, V27, P217, DOI 10.1023/A:1011008313677; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FUJII M, 1995, ONCOGENE, V11, P7; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Fujii M, 1995, INTERVIROLOGY, V38, P221, DOI 10.1159/000150436; FUJII M, 1992, AIDS RES HUM RETROV, V16, P1603; Fujii MI, 2000, AIDS RES HUM RETROV, V16, P1603, DOI 10.1089/08892220050193029; FUNG MM, 2005, ONCOGENE        0228; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Green P. L., 2001, FIELDS VIROLOGY, P1941; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; HUBBARD GB, 1993, LAB ANIM SCI, V43, P301; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; IWAKURA Y, 1995, VIRUS GENES, V9, P161, DOI 10.1007/BF01702659; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Liu XD, 1999, J GEN VIROL, V80, P3073, DOI 10.1099/0022-1317-80-12-3073; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Loh C, 1996, MOL CELL BIOL, V16, P3945; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Mamane Y, 2002, ONCOGENE, V21, P6751, DOI 10.1038/sj.onc.1205843; Mariner JM, 2002, J IMMUNOL, V168, P5667, DOI 10.4049/jimmunol.168.11.5667; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; Mohapatra S, 2003, CANCER RES, V63, P8523; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Mori N, 2000, BLOOD, V95, P3915; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; NAGAI M, 1995, CLIN IMMUNOL IMMUNOP, V77, P324, DOI 10.1006/clin.1995.1159; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakamura N, 1999, ONCOGENE, V18, P2667, DOI 10.1038/sj.onc.1202608; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; NIITSU Y, 1988, BLOOD, V71, P263; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pise-Masison CA, 2002, CANCER RES, V62, P3562; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Reddy TR, 1998, P NATL ACAD SCI USA, V95, P702, DOI 10.1073/pnas.95.2.702; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; SALVETTI A, 1993, EUR J CELL BIOL, V61, P383; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shuh M, 2000, J VIROL, V74, P11394, DOI 10.1128/JVI.74.23.11394-11397.2000; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sun SC, 1999, ONCOGENE, V18, P1401, DOI 10.1038/sj.onc.1202430; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; TAKATSUKI K, 1985, CANCER RES, V45, P4644; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Trihn D, 1997, J BIOMED SCI, V4, P47, DOI 10.1007/BF02255593; Tsuboi K, 2000, LEUKEMIA, V14, P449, DOI 10.1038/sj.leu.2401696; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Voevodin A, 1996, J VIROL, V70, P1633, DOI 10.1128/JVI.70.3.1633-1639.1996; VOLKMAN DJ, 1985, J IMMUNOL, V134, P4237; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Xu X, 1996, ONCOGENE, V13, P135; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; ZHANG Q, 1999, LEUKEMIA RES, V4, P373	155	87	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5965	5975		10.1038/sj.onc.1208975	http://dx.doi.org/10.1038/sj.onc.1208975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155603				2022-12-28	WOS:000231623400006
J	Yin, D; Xie, D; Sakajiri, S; Miller, CW; Zhu, H; Popoviciu, ML; Said, JW; Black, KL; Koeffler, HP				Yin, D; Xie, D; Sakajiri, S; Miller, CW; Zhu, H; Popoviciu, ML; Said, JW; Black, KL; Koeffler, HP			DLK1: increased expression in gliomas and associated with oncogenic activities	ONCOGENE			English	Article						DLK1; expression; oncogenic activities; glioma	EPIDERMAL-GROWTH-FACTOR; EGF-LIKE REPEATS; PROTEIN DLK; DELTA-LIKE; CELL-LINE; ADIPOCYTE DIFFERENTIATION; FETAL ANTIGEN-1; HUMAN HOMOLOG; GENE; PREF-1	DLK1 ( delta-like) is a transmembrane and secreted protein in the epidermal growth factor- like homeotic family. Although expressed widely during embryonic development, only a few tissues retain the expression in adults. Neuroendocrine tumors often highly express this protein; therefore, we hypothesized that brain tumors might also express it. This study found that the expression of DLK1 in gliomas was higher than that in normal brain (P < 0.05). After stable transfection of a DLK1 cDNA expression vector into GBM cell lines, their proliferation was increased. Furthermore, they lost contact inhibition, had enhanced anchorage-independent growth in soft agar, and had significantly greater capacity to migrate. Western blot studies showed that expression of cyclin D1, CDK2, and E2F4 were increased, and Rb levels were decreased in these cells. DLK1 was found on the cell surface and secreted in the medium from the transfected GBM cells. DLK1-enriched condition medium stimulated the growth of glioblastoma multiforme cell lines and explants. DLK1 antibody blocked cell growth stimulated by DLK1. In summary, these results suggest that DLK1 may play a role in the formation or progression of gliomas.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Chinese Acad Sci, Inst Nutr Sci, SIBS, Shanghai, Peoples R China	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Yin, D (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, 8700 Beverly Blvd,Davis Bldg 5022 Room, Los Angeles, CA 90048 USA.	Dong.Yin@cshs.org		Black, Keith/0000-0002-0546-4934; Xie, Dong/0000-0002-1150-8657				Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Boney CM, 1996, ENDOCRINOLOGY, V137, P2923, DOI 10.1210/en.137.7.2923; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CARPENTER G, 1986, EXP CELL RES, V164, P1, DOI 10.1016/0014-4827(86)90449-0; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Edwards PAW, 1999, CANCER METAST REV, V18, P175, DOI 10.1023/A:1006304821464; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Floridon C, 2000, DIFFERENTIATION, V66, P49, DOI 10.1046/j.1432-0436.2000.066001049.x; GAETANO C, 1992, CANCER RES, V52, P4402; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; JENSEN CH, 1993, HUM REPROD, V8, P635, DOI 10.1093/oxfordjournals.humrep.a138110; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Samulewicz SJ, 2002, WOUND REPAIR REGEN, V10, P215, DOI 10.1046/j.1524-475X.2002.10404.x; Schmidt JV, 2000, GENE DEV, V14, P1997; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stockhausen MT, 2005, BRIT J CANCER, V92, P751, DOI 10.1038/sj.bjc.6602309; Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; Tornehave D, 1996, HISTOCHEM CELL BIOL, V106, P535; TORNEHAVE D, 1993, ANAT EMBRYOL, V187, P335; van Limpt V, 2000, MED PEDIATR ONCOL, V35, P554, DOI 10.1002/1096-911X(20001201)35:6<554::AID-MPO13>3.0.CO;2-R; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031	44	69	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2006	25	13					1852	1861		10.1038/sj.onc.1209219	http://dx.doi.org/10.1038/sj.onc.1209219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288219				2022-12-28	WOS:000236224800002
J	Bastien, J; Plassat, JL; Payrastre, B; Rochette-Egly, C				Bastien, J; Plassat, JL; Payrastre, B; Rochette-Egly, C			The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells	ONCOGENE			English	Article						retinoic acid receptors; PI3K; Akt; p85 alpha; F9 cells	PROTEIN-KINASE; SIGNALING PATHWAY; DEPENDENT MECHANISM; LEUKEMIA-CELLS; BREAST-CANCER; RAR-GAMMA; ACTIVATION; PHOSPHORYLATION; PKB/AKT; BETA	Retinoic acid ( RA) induces cell growth arrest and differentiation through two families of nuclear receptors, the RARs and the RXRs. The phosphoinositide 3-kinase (PI3K)/Akt pathway also plays key roles in these processes, that is, cell cycle progression, cell differentiation and cell survival. We report that, in mouse embryocarcinoma cells (F9 cells), RA induces an early activation of PI3K and Akt via an increase in the expression of the p85 alpha regulatory subunit. This effect is followed by an inhibition of Akt. Both effects require the integrity of the RA pathway as they are not observed in RA-resistant RAR gamma null cells. We propose a model through which RA induces a biphasic regulation of Akt with an activation participitating to the differentiation process, followed by an inhibition, which has been correlated to the RA-induced growth arrest.	CU Strasbourg, Dept Cell Biol & Signal Transduct, IGBMC, CNRS,INSERM,ULP, F-67404 Illkirch Graffenstaden, France; CHU Purpan, CPTP, Unite INSERM 563, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Rochette-Egly, C (corresponding author), CU Strasbourg, Dept Cell Biol & Signal Transduct, IGBMC, CNRS,INSERM,ULP, BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr		, Bernard/0000-0002-8693-0190				Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cabane C, 2004, CELL SIGNAL, V16, P1405, DOI 10.1016/j.cellsig.2004.05.003; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carter CA, 2003, EXP MOL PATHOL, V75, P34, DOI 10.1016/S0014-4800(03)00033-9; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; del Rincon SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Ishida S, 2004, BIOCHEM PHARMACOL, V68, P2177, DOI 10.1016/j.bcp.2004.08.017; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kocki J, 2003, J APPL GENET, V44, P553; Lal L, 2005, BLOOD, V105, P1669, DOI 10.1182/blood-2004-06-2078; Laudet V, 2002, NUCL RECEPTOR FACTSB; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Neri LM, 2003, MOL CANCER RES, V1, P234; Oridate N, 1996, ONCOGENE, V12, P2019; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Puscheck EE, 1998, MOL REPROD DEV, V49, P386, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;386::AID-MRD5&gt;3.0.CO;2-J; Rieusset J, 2001, FEBS LETT, V502, P98, DOI 10.1016/S0014-5793(01)02674-6; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarker KP, 2004, ONCOGENE, V23, P6064, DOI 10.1038/sj.onc.1207819; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	42	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2040	2047		10.1038/sj.onc.1209241	http://dx.doi.org/10.1038/sj.onc.1209241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288212				2022-12-28	WOS:000236359700007
J	Bose, S; Morgan, LJ; Booth, DR; Goudie, DR; Ferguson-Smith, MA; Richards, FM				Bose, S; Morgan, LJ; Booth, DR; Goudie, DR; Ferguson-Smith, MA; Richards, FM			The elusive multiple self-healing squamous epithelioma (MSSE) gene: further mapping, analysis of candidates, and loss of heterozygosity	ONCOGENE			English	Article						skin cancer; tumour suppressor gene; chromosome 9q22.3; CDC14B; MSSE	ANEMIA GROUP-C; CELL CARCINOMA; HUMAN GENOME; CHROMOSOMAL LOCALIZATION; HUMAN HOMOLOG; HUMAN CDNA; REGION; 9Q22.3; CANCER; MAPS	The MSSE gene predisposes to multiple invasive but self-healing skin tumours ( multiple self-healing epitheliomata). MSSE was previously mapped to chromosome 9q22-q31 and a shared haplotype in affected families suggested a founder mutation. We have refined the MSSE critical region (< 1 cM, < 1 Mb) between the zinc-finger gene ZNF169 and the Fanconi anaemia gene FANCC. By genetic mapping we have excluded ZNF169 and FANCC as well as PTCH (PATCHED) and TGFBR1 ( transforming growth factor beta receptor type-1) genes. The CDC14B cell cycle phosphatase gene also lies in the region but screening of the complete coding region revealed no mutation in MSSE patients. Somatic cell hybrids created by haploid conversion of an MSSE patient's cells enabled screening of the MSSE chromosome 9 and showed no CDC14B deletion or mutation that abrogates CDC14B mRNA expression. Thus, CDC14B is unlikely to be the MSSE gene. We also report the first molecular analysis of MSSE tumours showing loss of heterozygosity of the MSSE region, with loss of the normal allele, providing the first evidence that MSSE is a tumour suppressor gene.	Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham, W Midlands, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Ninewells Hosp & Med Sch, Dept Pathol, Dundee, Scotland; Univ Cambridge, Dept Vet Clin Med, Cambridge, England	University of Birmingham; University of Cambridge; University of Dundee; University of Cambridge	Richards, FM (corresponding author), Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	fran.richards@daniolabs.com		Booth, Daniel/0000-0001-6231-5911				Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Byrom J, 2004, INT J ONCOL, V24, P1271; Chadwick BP, 1998, GENOMICS, V47, P58, DOI 10.1006/geno.1997.5084; Chadwick BP, 1997, GENOMICS, V41, P390, DOI 10.1006/geno.1997.4692; Chatterjee TK, 1997, GENOMICS, V45, P429, DOI 10.1006/geno.1997.4929; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P250, DOI 10.1159/000134349; Eichler EE, 2004, NAT REV GENET, V5, P345, DOI 10.1038/nrg1322; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; Jorgenson E, 2005, AM J HUM GENET, V76, P276, DOI 10.1086/427926; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; Levanat S, 1997, CYTOGENET CELL GENET, V76, P208, DOI 10.1159/000134551; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Martignetti JA, 2000, GENE CHROMOSOME CANC, V27, P191, DOI 10.1002/(SICI)1098-2264(200002)27:2<191::AID-GCC11>3.0.CO;2-L; Nishiu J, 1998, GENOMICS, V52, P378, DOI 10.1006/geno.1998.5455; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Richards FM, 1997, HUM GENET, V101, P317, DOI 10.1007/s004390050635; Savoia A, 1996, MOL CELL PROBE, V10, P213, DOI 10.1006/mcpr.1996.0029; SLAUGENHAUPT SA, 1995, GENOMICS, V25, P730, DOI 10.1016/0888-7543(95)80019-I; Suzuki M, 1999, J HUM GENET, V44, P300, DOI 10.1007/s100380050164; WICKING C, 1995, CYTOGENET CELL GENET, V68, P119, DOI 10.1159/000133904; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	31	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					806	812		10.1038/sj.onc.1209092	http://dx.doi.org/10.1038/sj.onc.1209092			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16170343				2022-12-28	WOS:000235068800015
J	Gladden, AB; Woolery, R; Aggarwal, P; Wasik, MA; Diehl, JA				Gladden, AB; Woolery, R; Aggarwal, P; Wasik, MA; Diehl, JA			Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma	ONCOGENE			English	Article						CDK4; cyclin D1; mantle cell lymphoma; apoptosis	TUMOR-SUPPRESSOR PATHWAY; EARLY PRE-B; C-MYC; DEPENDENT KINASE; TRANSGENIC MICE; CDK INHIBITORS; P53 MUTATIONS; T-CELLS; TRANSFORMATION; APOPTOSIS	Mantle cell lymphoma (MCL) is a B- cell lymphoma characterized by overexpression of cyclin D1 due to the t(11;14) chromosomal translocation. While expression of cyclin D1 correlates with MCL development, expression of wild- type (WT) cyclin D1 transgene in murine lymphocytes is unable to drive B- cell lymphoma. As cyclin D1 mutants that are refractory to nuclear export display heighten oncogenicity in vitro compared with WT D1, we generated mice expressing FLAG-D1/T286A, a constitutively nuclear mutant, under the control of the immunoglobulin enhancer, E mu. D1/T286A transgenic mice universally develop a mature B- cell lymphoma. Expression of D1/T286A in B lymphocytes results in S phase entry in resting lymphocytes and increased apoptosis in spleens of young premalignant mice. Lymphoma onset correlates with perturbations in p53/MDM2/p19(Arf) expression and with BcL-2 overexpression suggesting that alterations in one or both of these pathways may contribute to lymphoma development. Our results describe a cyclin D1-driven model of B-cell lymphomagenesis and provide evidence that nuclear-retention of cyclin D1 is oncogenic in vivo.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Ctr Canc, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [R01 CA093237, R01 CA093237-05, R01 CA089194, CA93237, CA89194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089194, R01CA093237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AKIYAMA N, 1994, CANCER RES, V54, P377; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z; Chen WG, 1996, LAB INVEST, V75, P519; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hernandez L, 1999, LEUKEMIA, V13, P2087, DOI 10.1038/sj.leu.2401599; Hosokawa Y, 1999, INT J CANCER, V81, P616, DOI 10.1002/(SICI)1097-0215(19990517)81:4<616::AID-IJC18>3.3.CO;2-J; Howe D, 2001, HAEMATOLOGICA, V86, P563; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lai R, 2002, LEUKEMIA RES, V26, P849, DOI 10.1016/S0145-2126(02)00013-9; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lu FM, 2003, CANCER RES, V63, P7056; Martinez N, 2003, CANCER RES, V63, P8226; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SETO M, 1992, ONCOGENE, V7, P1401; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; STRASSER A, 1993, ONCOGENE, V8, P1; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	46	102	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					998	1007		10.1038/sj.onc.1209147	http://dx.doi.org/10.1038/sj.onc.1209147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247460	Green Accepted			2022-12-28	WOS:000235361000005
J	Koshikawa, N; Maejima, C; Miyazaki, K; Nakagawara, A; Takenaga, K				Koshikawa, N; Maejima, C; Miyazaki, K; Nakagawara, A; Takenaga, K			Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors	ONCOGENE			English	Article						hypoxia; ER stress; apoptosis; Mcl-1; metastasis	CANCER-CELLS; REGULATED PROTEIN; UP-REGULATION; RESISTANCE; PROGRESSION; EXPRESSION; MITOCHONDRIAL; INDUCTION; BNIP3; DEATH	Low oxygen tension (hypoxia) is a common feature of solid tumors and stimulates the expressions of a variety of genes including those related to angiogenesis, apoptosis and endoplasmic reticulum (ER) stress response. Here we show a close correlation between metastatic potential and the resistance to hypoxia- and ER stress-induced apoptosis among the cell lines with differing metastatic potential derived from Lewis lung carcinoma. An apoptosis-specific expression pro. ling and immunoblot analyses revealed that the expression of antiapoptotic Mcl-1 increased as the resistance to apoptosis increased. Downregulation of the Mcl-1 expression in the high-metastatic cells by Mcl-1 small interfering RNA increased the sensitivity to hypoxia-induced apoptosis and decreased the metastatic ability. The hypoxia-induced apoptosis was not associated with p53 accumulation, although at present it is not possible to conclude that apoptosis-induced apoptosis is p53-independent. There was no correlation between the expression levels of ER stress-response proteins GADD153, GRP78 and ORP150 and the resistance to hypoxia or ER stresses. In vitro, small numbers of the high-metastatic cells overtook the low-metastatic cells after exposure to several rounds of hypoxia and reoxygenation. In solid tumors initially established from equal mixtures, the proportion of the high-metastatic cells to low-metastatic cells was significantly higher in hypoxic areas. Moreover, the high-metastatic cells were overtaking the low-metastatic cells in some of the tumors. Thus, tumor hypoxia and ER stress may provide a physiological selective pressure for the expansion of the high-metastatic cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors.	Chiba Canc Ctr, Div Chemotherapy, Res Inst, Chuoh Ku, Chiba 2608717, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba, Japan; Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba, Japan	Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center	Takenaga, K (corresponding author), Chiba Canc Ctr, Div Chemotherapy, Res Inst, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	keizo@chiba-cc.jp						Brizel DM, 1996, CANCER RES, V56, P941; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Brown JM, 1998, CANCER RES, V58, P1408; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; BUFALO DD, 1997, FASEB J, V11, P947; Cairns RA, 2001, CANCER RES, V61, P8903; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Dachs GU, 1998, SEMIN RADIAT ONCOL, V8, P208, DOI 10.1016/S1053-4296(98)80046-5; Durand RE, 1998, INT J RADIAT ONCOL, V42, P711, DOI 10.1016/S0360-3016(98)00305-8; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Friedman AD, 1996, CANCER RES, V56, P3250; Glinsky GV, 1997, CRIT REV ONCOL HEMAT, V25, P175, DOI 10.1016/S1040-8428(97)00234-5; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HILL RP, 1990, CANCER METAST REV, V9, P137, DOI 10.1007/BF00046340; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 1996, CANCER RES, V56, P4509; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kim CY, 1997, CANCER RES, V57, P4200; Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LORD EM, 1993, CANCER RES, V53, P5721; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Maeta Yoshihiko, 2004, Gastric Cancer, V7, P78; McConkey DJ, 1996, CANCER RES, V56, P5594; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; RUSSO CA, 1995, CANCER RES, V55, P1122; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takasu M, 1999, CLIN EXP METASTAS, V17, P409, DOI 10.1023/A:1006632819086; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wong CW, 2001, CANCER RES, V61, P333; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371	44	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					917	928		10.1038/sj.onc.1209128	http://dx.doi.org/10.1038/sj.onc.1209128			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247470				2022-12-28	WOS:000235212700011
J	Polak, P; Oren, A; Ben-Dror, I; Steinberg, D; Sapoznik, S; Arditi-Duvdevany, A; Vardimon, L				Polak, P; Oren, A; Ben-Dror, I; Steinberg, D; Sapoznik, S; Arditi-Duvdevany, A; Vardimon, L			The cytoskeletal network controls c-Jun translation in a UTR-dependent manner	ONCOGENE			English	Article						c-Jun; translation control; UTRs; cytoskeletal network; cell density	ACTIVATED PROTEIN-KINASES; MAMMALIAN UV RESPONSE; NECROSIS-FACTOR-ALPHA; GLUCOCORTICOID-RECEPTOR; BINDING PROTEIN; MESSENGER-RNAS; GROWTH-FACTORS; CELL LIFE; INDUCTION; AGENTS	The cytoskeleton is a dynamic network that undergoes restructuring during various cellular events, influencing cell proliferation, differentiation, and apoptosis. Here, we report that accumulation of c-Jun, a member of the AP1 family of transcription factors that play a key role in normal and aberrant cell growth, dramatically increases upon depolymerization of the cytoskeleton, and that, unexpectedly, this increase is controlled translationally. Depolymerization of the actin or microtubule network induces an increase in c-Jun accumulation with no corresponding increase in c-Jun mRNA or in the half-life of the c-Jun protein, but rather in the translatability of its transcript. This increase is mediated by the untranslated regions (UTRs) of c-Jun mRNA, and is not dependent on activated mitogen-activated protein kinase pathways. This novel mechanism of c-Jun regulation might be relevant to physiological conditions in which c-Jun plays a pivotal role.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Vardimon, L (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	vardi@post.tau.ac.il		Polak, Pazit/0000-0001-8363-0734				Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oren A, 1999, MOL CELL BIOL, V19, P1742; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; REISFELD S, 1994, MOL ENDOCRINOL, V8, P1224, DOI 10.1210/me.8.9.1224; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sehgal A, 2000, ONCOGENE, V19, P2836, DOI 10.1038/sj.onc.1203601; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Xiao DH, 2003, CANCER RES, V63, P6825; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	43	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					665	676		10.1038/sj.onc.1209114	http://dx.doi.org/10.1038/sj.onc.1209114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247475				2022-12-28	WOS:000235068800002
J	Chen, A; Xu, J; Johnson, AC				Chen, A; Xu, J; Johnson, AC			Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1	ONCOGENE			English	Article						colon cancer; receptors; phyto-chemical; gene expression; chemo-prevention	NF-KAPPA-B; SERUM RESPONSE ELEMENTS; TERNARY COMPLEX FACTORS; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; MALIGNANCIES; CONTRIBUTES; INDUCTION; APOPTOSIS	High expression of epidermal growth factor receptor (EGFR) is found in a variety of solid tumors, including colorectal cancer. EGFR has been identified as a rational target for anticancer therapy. Curcumin, the yellow pigment of turmeric in curry, has received attention as a promising dietary supplement for cancer prevention and treatment. We recently reported that curcumin inhibited the growth of human colon cancer-derived Moser cells by suppressing gene expression of cyclinD1 and EGFR. The aim of the present study was to explore the molecular mechanisms underlying curcumin inhibition of gene expression of EGFR in colon cancer cells. The generality of the inhibitory effect of curcumin on gene expression of EGFR was verified in other human colon cancer-derived cell lines, including Caco-2 and HT-29 cells. Promoter deletion assays and site-directed mutageneses identified a binding site for the transcription factor early growth response-1 (Egr-1) in egfr promoter as a putative curcumin response element in regulating the promoter activity of the gene in Moser cells. Electrophoretic mobility shift assays demonstrated that curcumin significantly reduced the DNA-binding activity of the transcription factor Egr-1 to the curcumin response element. In addition, curcumin reduced the trans-activation activity of Egr-1 by suppressing egr-1 gene expression, which required interruption of the ERK signal pathway and reduction of the level of phosphorylation of Elk-1 and its activity. Taken together, our results demonstrated that curcumin inhibited human colon cancer cell growth by suppressing gene expression of EGFR through reducing the trans-activation activity of Egr-1. These results provided novel insights into the mechanisms of curcumin inhibition of colon cancer cell growth and potential therapeutic strategies for treatment of colon cancer.	Louisiana State Univ, HSC, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA USA; NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chen, A (corresponding author), Louisiana State Univ, HSC, Dept Pathol, BRI F8-20,1501 Kings Hwy, Shreveport, LA 71130 USA.	achen@lsuhsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Baselga J, 2000, ANN ONCOL, V11, P187, DOI 10.1023/A:1011144502974; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chauhan DP, 2002, CURR PHARM DESIGN, V8, P1695, DOI 10.2174/1381612023394016; Chen AP, 2002, BIOCHEM J, V368, P695, DOI 10.1042/BJ20020894; Chen AP, 2005, AM J PHYSIOL-GASTR L, V288, pG447, DOI 10.1152/ajpgi.00209.2004; Chen AP, 2002, AM J PHYSIOL-GASTR L, V283, pG864, DOI 10.1152/ajpgi.00524.2001; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Chen CC, 2004, J CELL BIOCHEM, V93, P1063, DOI 10.1002/jcb.20257; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Giri RK, 2004, J NEUROCHEM, V91, P1199, DOI 10.1111/j.1471-4159.2004.02800.x; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harja E, 2004, CIRC RES, V94, P333, DOI 10.1161/01.RES.0000112405.61577.95; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jobin C, 1999, J IMMUNOL, V163, P3474; Kamimura M, 2004, HYPERTENSION, V44, P944, DOI 10.1161/01.HYP.0000146908.75091.99; LEVINE AE, 1985, CANCER RES, V45, P2248; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Mohandas K M, 1999, Indian J Gastroenterol, V18, P118; Nishi H, 2002, CANCER RES, V62, P827; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Pendurthi UR, 2000, THROMB RES, V97, P179, DOI 10.1016/S0049-3848(99)00148-6; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rowinsky E, 2000, DRUGS, V60, P41; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schaefer A, 2004, CELL SIGNAL, V16, P223, DOI 10.1016/j.cellsig.2003.07.001; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Xu JY, 2003, AM J PHYSIOL-GASTR L, V285, pG20, DOI 10.1152/ajpgi.00474.2002; Zheng Liduan, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P55	48	217	231	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					278	287		10.1038/sj.onc.1209019	http://dx.doi.org/10.1038/sj.onc.1209019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170359				2022-12-28	WOS:000234583600012
J	Kuphal, S; Bosserhoff, AK				Kuphal, S; Bosserhoff, AK			Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma	ONCOGENE			English	Article						E-cadherin; NF kappa B; N-cadherin regulation; cell contact	EPITHELIAL-MESENCHYMAL TRANSITION; CELL-ADHESION MOLECULE; UVOMORULIN-CATENIN COMPLEX; BREAST-CANCER CELLS; KAPPA-B; P-CADHERIN; TUMOR PROGRESSION; GASTRIC-CANCER; ALPHA-CATENIN; UP-REGULATION	E-cadherin is known to be an important molecule in epithelial-mesenchymal transition (EMT). Malignant transformation of melanocytes frequently attends with loss of E-cadherin expression and induction of expression of mesenchymal molecules like N-cadherin. The switch of the cadherin class is an interesting phenomenon of melanoma cells and in EMT in general. Therefore, we analysed the capacity of E-cadherin to regulate expression of N-cadherin in melanocytic cells. Our experiments revealed that melanoma cells downregulate endogenous N-cadherin expression after transient transfection of full-length E-cadherin, but also of the cytoplasmic domain of E-cadherin. Therefore, we concluded that the extracellular domain of E-cadherin and cell-cell contacts are not necessary for negative regulation of N-cadherin. Melanoma cells re-expressing full-length or cytoplasmatic E-cadherin have reduced NF kappa B activity in comparison to mock-transfected cells. Downregulation of NF kappa B activity, either directly or by re-expression of E-cadherin, led to a suppression of N-cadherin promoter activity and N-cadherin expression. Consequently, an NF kappa B-binding site in the N-cadherin promoter was characterized. In summary, our results suggest that N-cadherin is directly regulated by E-cadherin. Loss of E-cadherin induces NF kappa B activity and N-cadherin expression in tumorigenic EMT.	Univ Regensburg, Inst Pathol, D-93053 Bavaria, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Bavaria, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022; Kuphal, Silke/AAW-2702-2020	Bosserhoff, Anja/0000-0001-8147-394X				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bates RC, 2004, EXP CELL RES, V299, P315, DOI 10.1016/j.yexcr.2004.05.033; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, EXP SUPPL, V59, P109; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Buckley CD, 1997, MOL MED TODAY, V3, P449, DOI 10.1016/S1357-4310(97)01128-3; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Fukata M, 1999, J CELL SCI, V112, P4491; Furukawa F, 1997, MICROSC RES TECHNIQ, V38, P343; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haass NK, 2004, J MOL HISTOL, V35, P309; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Huber MA, 2004, CELL CYCLE, V3, P1477, DOI 10.4161/cc.3.12.1280; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kuphal S, 2004, ONCOGENE, V23, P8509, DOI 10.1038/sj.onc.1207831; Li B, 1997, GENE, V191, P7, DOI 10.1016/S0378-1119(97)00006-1; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2001, CANCER RES, V61, P3819; Melki JR, 2000, BLOOD, V95, P3208; NAVARRO P, 1993, J CELL SCI, V105, P923; Nieman MT, 1999, J CELL SCI, V112, P1621; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Soler C, 1998, CELL ADHES COMMUN, V5, P13, DOI 10.3109/15419069809005595; SOMMERS CL, 1994, CANCER RES, V54, P3544; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomita K, 2000, CANCER RES, V60, P3650; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhu AJ, 1996, J CELL SCI, V109, P3013	58	78	87	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					248	259		10.1038/sj.onc.1209054	http://dx.doi.org/10.1038/sj.onc.1209054			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16132038				2022-12-28	WOS:000234583600009
J	Yemelyanov, A; Gasparian, A; Lindholm, P; Dang, L; Pierce, JW; Kisseljov, F; Karseladze, A; Budunova, I				Yemelyanov, A; Gasparian, A; Lindholm, P; Dang, L; Pierce, JW; Kisseljov, F; Karseladze, A; Budunova, I			Effects of IKK inhibitor PS1145 on NF-kappa B function, proliferation, apoptosis and invasion activity in prostate carcinoma cells	ONCOGENE			English	Article						prostate carcinoma; NF-kappa B; IKK; apoptosis; invasion	NECROSIS-FACTOR-ALPHA; CANCER CELLS; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; THERAPEUTIC TARGET; BINDING-SITES; TNF-ALPHA; IN-VITRO; KINASE	A key antiapoptotic transcription factor, nuclear factor kappa-B (NF-kappa B), is known to be critically important for tumor cell growth, angiogenesis and development of metastatic lesions. We and others showed previously that NF-kappa B transcription factor was constitutively activated in androgen- independent prostate carcinoma (PC) cell lines due to the upregulated activity of inhibitor of NF-kappa B kinases (IKK). In this work, using luciferase assay, electrophoretic mobility shift assay and Northern blot analysis of expression of endogenous kappa B-responsive genes, we demonstrate that a novel highly specific small-molecule IKK inhibitor, PS1145, efficiently inhibited both basal and induced NF-kappa B activity in PC cells. We found that PS1145 induced caspase 3/7-dependent apoptosis in PC cells and significantly sensitized PC cells to apoptosis induced by tumor necrosis factor alpha. We also showed that PS1145 inhibited PC cell proliferation. Effects of PS1145 on proliferation and apoptosis correlated with inhibition of interleukin (IL)- 6, cyclin D1, D2, inhibitor of apoptosis (IAP)-1 and IAP-2 gene expression and decreased IL-6 protein level. In addition, we found that incubation with PS1145 inhibited the invasion activity of highly invasive PC3-S cells in invasion chamber assay in a dose-dependent manner. Overall, this study provides the framework for development of a novel therapeutic approach targeting NF-kappa B transcription factor to treat advanced PC.	Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; NN Nlokhin Russian Canc Res Ctr, Moscow, Russia; Millennium Pharmaceut Inc, Cambridge, MA USA	Northwestern University; Feinberg School of Medicine; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Budunova, I (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i-budunova@northwestern.edu						Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Castro AC, 2003, BIOORG MED CHEM LETT, V13, P2419, DOI 10.1016/S0960-894X(03)00408-6; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Figueroa B, 2004, BIOTECHNOL BIOENG, V85, P589, DOI 10.1002/bit.10913; Gasparian AV, 2002, J CELL SCI, V115, P141; GASPARIAN AV, 2003, P AACR, V44, P1451; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lam LT, 2005, CLIN CANCER RES, V11, P28; Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776; Lindholm PF, 2001, CLIN EXP METASTAS, V18, P471, DOI 10.1023/A:1011845725394; Lyakh LA, 2000, J IMMUNOL, V165, P3647, DOI 10.4049/jimmunol.165.7.3647; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Murata T, 2004, BIOORG MED CHEM LETT, V14, P4013, DOI 10.1016/j.bmcl.2004.05.040; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Peter Marcus E, 2004, Biochem J, V382, pe1; Rapp UR, 2004, BBA-MOL CELL RES, V1644, P149, DOI 10.1016/j.bbamcr.2003.10.015; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROSENBERG IM, 1996, BENCHTOP TECHNIQUES; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yasui H, 2003, ANN NY ACAD SCI, V1010, P273, DOI 10.1196/annals.1299.047; Zerbini LF, 2003, CANCER RES, V63, P2206; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	57	98	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					387	398		10.1038/sj.onc.1209066	http://dx.doi.org/10.1038/sj.onc.1209066			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170348				2022-12-28	WOS:000234714100007
J	Popov, N; Wahlstrom, T; Hurlin, PJ; Henriksson, M				Popov, N; Wahlstrom, T; Hurlin, PJ; Henriksson, M			Mnt transcriptional repressor is functionally regulated during cell cycle progression	ONCOGENE			English	Article						Myc; Mnt; mSin3; transcriptional repression; phosphorylation; HDAC activity	MAX-INTERACTING PROTEIN; HISTONE DEACETYLASE ACTIVITY; DNA-BINDING ACTIVITY; C-MYC; INDUCED-DIFFERENTIATION; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; DROSOPHILA MYC; GROWTH; DOMAIN	The Myc/Max/Mad network of transcription factors regulates cell proliferation, differentiation, and transformation. Similar to other proteins of the network, Mnt forms heterodimers with Max and binds CACGTG E-Box elements. Transcriptional repression by Mnt is mediated through association with mSin3, and deletion of the mSin3-interacting domain (SID) converts Mnt to a transcriptional activator. Mnt is coexpressed with Myc in proliferating cells and has been suggested to be a modulator of Myc function. We report that Mnt is expressed both in growth-arrested and proliferating mouse fibroblasts and is phosphorylated when resting cells are induced to re-enter the cell cycle. Importantly, the interaction between Mnt and mSin3 is disrupted upon serum stimulation resulting in decreased Mnt-associated HDAC activity. Furthermore, we demonstrate that Mnt binds and recruits mSin3 to the Myc target gene cyclin D2 in quiescent mouse fibroblasts. Interference with Mnt expression by RNAi resulted in upregulation of cyclin D2 expression in growth-arrested fibroblasts, supporting the view that Mnt represses cyclin D2 transcription in quiescent cells. Our data suggest a model in which phosphorylation of Mnt at cell cycle entry results in disruption of Mnt-mSin3-HDAC1 interaction, which allows induction of Myc target genes by release of Mnt-mediated transcriptional repression.	Karolinska Inst, Microbiol & Tumor Biol Ctr, SE-17177 Stockholm, Sweden; Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Karolinska Institutet; Oregon Health & Science University	Henriksson, M (corresponding author), Karolinska Inst, Microbiol & Tumor Biol Ctr, Box 280, SE-17177 Stockholm, Sweden.	Marie.Henriksson@mtc.ki.se	Henriksson, Marie Arsenian/F-5010-2015	Arsenian Henriksson, Marie/0000-0001-6376-7792				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2120; Barrera-Hernandez G, 2000, MOL CELL BIOL, V20, P4253, DOI 10.1128/MCB.20.12.4253-4264.2000; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BOUSSET K, 1993, ONCOGENE, V8, P3211; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Cvekl A, 2004, EUR J CANCER, V40, P2525, DOI 10.1016/j.ejca.2004.08.005; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; Hurlin PJ, 2004, CELL CYCLE, V3, P97; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nigro Cristina Lo, 1998, Genomics, V49, P275, DOI 10.1006/geno.1998.5241; Nilsson JA, 2004, CELL CYCLE, V3, P588; Nilsson JA, 2004, MOL CELL BIOL, V24, P1560, DOI 10.1128/MCB.24.4.1560-1569.2004; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith AG, 2004, J CELL BIOCHEM, V92, P1282, DOI 10.1002/jcb.20121; Sommer A, 1999, INT J CANCER, V82, P810, DOI 10.1002/(SICI)1097-0215(19990909)82:6<810::AID-IJC7>3.0.CO;2-V; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takahashi T, 1998, JPN J CANCER RES, V89, P347, DOI 10.1111/j.1349-7006.1998.tb00569.x; Toyo-oka K, 2004, HUM MOL GENET, V13, P1057, DOI 10.1093/hmg/ddh116; Walker W, 2005, J CELL BIOL, V169, P405, DOI 10.1083/jcb.200411013; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	53	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8326	8337		10.1038/sj.onc.1208961	http://dx.doi.org/10.1038/sj.onc.1208961			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103876				2022-12-28	WOS:000233956500011
J	Syed, V; Zhang, X; Lau, KM; Cheng, R; Mukherjee, K; Ho, SM				Syed, V; Zhang, X; Lau, KM; Cheng, R; Mukherjee, K; Ho, SM			Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells	ONCOGENE			English	Article						erythrocyte adducin alpha subunit clone; 5.1 RNA-binding protein S1; nuclear protein SkiP; Rap-2 plexin A3; sex gene	HORMONE REPLACEMENT THERAPY; SUPPRESSES TUMOR-FORMATION; SKI-INTERACTING PROTEIN; MESSENGER-RNA; BREAST-CANCER; IN-VITRO; INDUCED APOPTOSIS; KINASE-C; RECEPTOR; GROWTH	Estrogens regulate normal ovarian surface epithelium (OSE) cell functions but also affect epithelial ovarian cancer (OCa) development. Little is known about how estrogens play such opposing roles. Transcriptional pro. ling using a cDNA microarray containing 2400 named genes identified 155 genes whose expression was altered by estradiol-17 beta (E2) in three immortalized normal human ovarian surface epithelial (HOSE) cell lines and 315 genes whose expression was affected by the hormone in three established OCa (OVCA) cell lines. All but 19 of the genes in these two sets were different. Among the 19 overlapping genes, five were found to show discordant responses between HOSE and OVCA cell lines. The five genes are those that encode clone 5.1 RNA-binding protein (RNPS1), erythrocyte adducin a subunit (ADD1), plexin A3 (PLXNA3 or the SEX gene), nuclear protein SkiP (SKIIP), and Rap-2 (rap-2). RNPS1, ADD1, rap-2, and SKIIP were upregulated by E2 in HOSE cells but downregulated by estrogen in OVCA cells, whereas PLXNA3 showed the reverse pattern of regulation. The estrogen effects was observed within 6 18 h of treatment. In silicon analyses revealed presence of estrogen response elements in the proximal promoters of all five genes. RNPS1, ADD1, and PLXNA3 were underexpressed in OVCA cell lines compared to HOSE cell lines, while the opposite was true for rap-2 and SKIIP. Functional studies showed that RNPS1 and ADD1 exerted multiple antitumor actions in OVCA cells, while PLXNA3 only inhibited cell invasiveness. In contrast, rap-2 was found to cause significant oncogenic effects in OVCA cells, while SKIIP promotes only anchorage-independent growth. In sum, gene pro. ling data reveal that (1) E2 exerts different actions on HOSE cells than on OVCA cells by affecting two distinct transcriptomes with few overlapping genes and (2) among the overlapping genes, a set of putative oncogenes/tumor suppressors have been identified due to their differential responses to E2 between the two cell types. These findings may explain the paradoxical roles of estrogens in regulating normal and malignant OSE cell functions.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Room 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-Mei.Ho@umassmed.edu	Zhang, Xiang/D-3632-2009; Cheng, Robert/E-9799-2013	Cheng, Robert/0000-0003-0287-6439; Lau, Kin-Mang/0000-0001-5888-1937	NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA94221, CA091250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AACR, 2005, STAT; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Badolato J, 1995, GENE, V166, P323, DOI 10.1016/0378-1119(95)00571-4; Bai WL, 2000, IN VITRO CELL DEV-AN, V36, P657; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Bardin A, 2004, CANCER RES, V64, P5861, DOI 10.1158/0008-5472.CAN-04-0552; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Birkenmeier CS, 2004, J PATHOL, V204, P450, DOI 10.1002/path.1636; Bowen SL, 2003, J PATHOL, V201, P119, DOI 10.1002/path.1389; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Folk P, 1996, GENE, V181, P229, DOI 10.1016/S0378-1119(96)00483-0; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; Gorringe KL, 2005, CARCINOGENESIS, V26, P923, DOI 10.1093/carcin/bgi032; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; Hough CD, 2001, CANCER RES, V61, P3869; JANOUEIXLEROSEY I, 1992, BIOCHEM BIOPH RES CO, V189, P455, DOI 10.1016/0006-291X(92)91580-J; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kim K, 2005, MOL ENDOCRINOL, V19, P843, DOI 10.1210/me.2004-0326; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; LANGDON SP, 1990, BRIT J CANCER, V62, P213, DOI 10.1038/bjc.1990.263; LANGDON SP, 1993, INT J CANCER, V55, P459, DOI 10.1002/ijc.2910550323; LANGDON SP, 1994, EUR J CANCER, V30A, P682, DOI 10.1016/0959-8049(94)90545-2; Lassus H, 2003, GYNECOL ONCOL, V91, P504, DOI 10.1016/j.ygyno.2003.08.034; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Lee BC, 2004, INT J ONCOL, V24, P847; Leong GM, 2004, BIOCHEM BIOPH RES CO, V315, P1070, DOI 10.1016/j.bbrc.2004.02.004; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NASH JD, 1989, OBSTET GYNECOL, V73, P1009; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Okamura H, 2003, MOL CELL ENDOCRINOL, V202, P37, DOI 10.1016/S0303-7207(03)00060-1; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Prathapam T, 2002, NUCLEIC ACIDS RES, V30, P5261, DOI 10.1093/nar/gkf658; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Roche J, 2001, Clin Lung Cancer, V3, P145, DOI 10.3816/CLC.2001.n.026; RUNGE HM, 1986, EUR J CANCER CLIN ON, V22, P691, DOI 10.1016/0277-5379(86)90167-7; RUNGE HM, 1986, CANCER CHEMOTH PHARM, V16, P58; Sakamoto M, 2001, Hum Cell, V14, P305; Santin AD, 2004, BRIT J CANCER, V90, P1814, DOI 10.1038/sj.bjc.6601791; Simpson BJB, 1998, J STEROID BIOCHEM, V64, P137, DOI 10.1016/S0960-0760(97)00159-3; Sit ASY, 2002, GYNECOL ONCOL, V86, P118, DOI 10.1006/gyno.2002.6746; Song J, 2005, CANCER LETT, V220, P57, DOI 10.1016/j.canlet.2004.04.024; Stopper H, 2003, MUTAGENESIS, V18, P243, DOI 10.1093/mutage/18.3.243; Sugimura M, 2004, ONCOLOGY-BASEL, V66, P53, DOI 10.1159/000076335; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Taube M, 2002, INT J ONCOL, V20, P589; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tse C, 2002, CANCER RES, V62, P542; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Xiang RH, 2002, CANCER RES, V62, P2637; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	88	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8128	8143		10.1038/sj.onc.1208959	http://dx.doi.org/10.1038/sj.onc.1208959			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16116479				2022-12-28	WOS:000233809400005
J	Lee, BH; Williams, IR; Anastasiadou, E; Boulton, CL; Joseph, SW; Amaral, SM; Curley, DP; Duclos, N; Huntly, BJP; Fabbro, D; Griffin, JD; Gilliland, DG				Lee, BH; Williams, IR; Anastasiadou, E; Boulton, CL; Joseph, SW; Amaral, SM; Curley, DP; Duclos, N; Huntly, BJP; Fabbro, D; Griffin, JD; Gilliland, DG			FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model	ONCOGENE			English	Article						FLT3 tyrosine kinase; transgenic; mouse; leukemia	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; HEMATOPOIETIC-CELLS; CONSTITUTIVE ACTIVATION; EXPRESSION; GENE; TRANSFORMATION; COMPARTMENT; PKC412; LIGAND	Activating FMS-like tyrosine kinase 3 (FLT3) mutations have been identified in similar to 30% of patients with acute myelogenous leukemia (AML), and recently in a smaller subset of patients with acute lymphoblastic leukemia (ALL). To explore the in vivo consequences of an activating FLT3 internal tandem duplication mutation (FLT3-ITD), we created a transgenic mouse model in which FLT3-ITD was expressed under the control of the vav hematopoietic promoter. Five independent lines of vavFLT3-ITD transgenic mice developed a myeloproliferative disease with high penetrance and a disease latency of 6-12 months. The phenotype was characterized by splenomegaly, megakaryocytic hyperplasia, and marked thrombocythemia, but without leukocytosis, polycythemia, or marrow fibrosis, displaying features reminiscent of the human disease essential thrombocythemia (ET). Clonal immature B- or T-lymphoid disease was observed in two additional founder mice, respectively, that could be secondarily transplanted to recipient mice that rapidly developed lymphoid disease. Treatment of these mice with the FLT3 tyrosine kinase inhibitor, PKC412, resulted in suppression of disease and a statistically significant prolongation of survival. These results demonstrate that FLT3-ITD is capable of inducing myeloproliferative as well as lymphoid disease, and indicate that small-molecule tyrosine kinase inhibitors may be an effective treatment for lymphoid malignancies in humans that are associated with activating mutations in FLT3.	Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Novartis Pharma AG, Basel, Switzerland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Emory University; Novartis; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Div Hematol, Dept Med, Childrens Hosp Res Bldg,1 Blackfan Circle,5th Flo, Boston, MA 02115 USA.	ggilliland@rics.bwh.harvard.edu	huntly, brian JP/E-6725-2014; Williams, Ifor R/D-3648-2011	huntly, brian JP/0000-0003-0312-161X; Williams, Ifor R/0000-0002-8810-2911	NCI NIH HHS [CA66996] Funding Source: Medline; NHLBI NIH HHS [5T32HL 07627-16] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P1076, DOI 10.1046/j.1365-2141.2001.02821.x; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; BRASEL K, 1995, LEUKEMIA, V9, P1212; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; DASILVA N, 1994, LEUKEMIA, V8, P885; DELAPEYRIERE O, 1995, DIFFERENTIATION, V58, P351, DOI 10.1007/s002580050094; Drexler HG, 1996, LEUKEMIA, V10, P588; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Griffin JD, 2001, BLOOD, V97, P2193; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Ishii E, 1999, PEDIATR HEMAT ONCOL, V16, P437, DOI 10.1080/088800199276994; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MAROC N, 1993, ONCOGENE, V8, P909; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; Rosnet O, 1996, LEUKEMIA, V10, P238; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Turner AM, 1996, BLOOD, V88, P3383, DOI 10.1182/blood.V88.9.3383.bloodjournal8893383; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	33	59	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7882	7892		10.1038/sj.onc.1208933	http://dx.doi.org/10.1038/sj.onc.1208933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116483				2022-12-28	WOS:000233463000007
J	Hosoda, M; Ozaki, T; Miyazaki, K; Hayashi, S; Furuya, K; Watanabe, K; Nakagawa, T; Hanamoto, T; Todo, S; Nakagawara, A				Hosoda, M; Ozaki, T; Miyazaki, K; Hayashi, S; Furuya, K; Watanabe, K; Nakagawa, T; Hanamoto, T; Todo, S; Nakagawara, A			UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination	ONCOGENE			English	Article						E3 ligase; p53; p73; ubiquitin; UFD2a	KINASE C-ABL; APOPTOTIC RESPONSE; P53-RELATED PROTEIN; REGULATES P73; P53; REGION; DOMAIN; DELTA-NP73; P73-ALPHA; FAMILY	p73 protein level is kept extremely low in mammalian cultured cells and its stability may be regulated by not only the ubiquitin/proteasome-dependent proteolysis but also through other unidentified mechanisms. Here, we found for the first time that p73 is physically as well as functionally associated with the U-box-type E3/E4 ubiquitin ligase UFD2a. The immunoprecipitation experiments demonstrated that this interaction is mediated by the COOH-terminal region of p73 alpha containing SAM domain. During the cisplatin-induced apoptosis in SHSY5Y neuroblastoma cells, p73a accumulated at a protein level, whereas the endogenous UFD2a was significantly reduced in response to cisplatin. Ectopic expression of UFD2a decreased the half-life of p73 alpha in association with a significant inhibition of the p73 alpha-mediated transactivation as well as proapoptotic activity. Downregulation of endogenous UFD2a by antisense strategy resulted in a remarkable accumulation of p73a. Unexpectedly, UFD2a-mediated degradation of p73 alpha was sensitive to the proteasomal inhibitor, however, UFD2a did not affect the ubiquitination levels of p73 alpha. Taken together, our present findings imply that UFD2a might promote the proteasomal turnover of p73 in a ubiquitination-independent manner, and also suggest that UFD2a might play an important role in the regulation of cisplatin-induced apoptosis mediated by p73.	Chiba Canc Ctr, Inst Res, Div Biochem, Chuo Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Inst Res, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Hosoda, Mitsuchika/A-7534-2012					Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Mahoney JA, 2002, BIOCHEM J, V361, P587, DOI 10.1042/0264-6021:3610587; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura Y, 1997, EUR J CANCER, V33, P1986, DOI 10.1016/S0959-8049(97)00333-X; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Osada M, 2001, BIOCHEM BIOPH RES CO, V283, P1135, DOI 10.1006/bbrc.2001.4905; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Schultz J, 1997, PROTEIN SCI, V6, P249; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Stiewe T, 2002, CANCER RES, V62, P3598; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tsai KKC, 2003, CANCER RES, V63, P3418; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu LQ, 2004, ONCOGENE, V23, P4032, DOI 10.1038/sj.onc.1207538; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	43	50	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7156	7169		10.1038/sj.onc.1208872	http://dx.doi.org/10.1038/sj.onc.1208872			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170377				2022-12-28	WOS:000232990100005
J	Inamura, K; Fujiwara, T; Hoshida, Y; Isagawa, T; Jones, MH; Virtanen, C; Shimane, M; Satoh, Y; Okumura, S; Nakagawa, K; Tsuchiya, E; Ishikawa, S; Aburatani, H; Nomura, H; Ishikawa, Y				Inamura, K; Fujiwara, T; Hoshida, Y; Isagawa, T; Jones, MH; Virtanen, C; Shimane, M; Satoh, Y; Okumura, S; Nakagawa, K; Tsuchiya, E; Ishikawa, S; Aburatani, H; Nomura, H; Ishikawa, Y			Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization	ONCOGENE			English	Article						lung; squamous cell carcinoma; cDNA microarray; hierarchical clustering; non-negative matrix factorization	PROTEIN-KINASE; POOR-PROGNOSIS; CANCER; ADENOCARCINOMA; OVEREXPRESSION; CDNA; HYPERMETHYLATION; CLASSIFICATION; MICROARRAYS; APOPTOSIS	Current clinical and histopathological criteria used to define lung squamous cell carcinomas (SCCs) are insufficient to predict clinical outcome. To make a clinically useful classification by gene expression profiling, we used a 40 386 element cDNA microarray to analyse 48 SCC, nine adenocarcinoma, and 30 normal lung samples. Initial analysis by hierarchical clustering (HC) allowed division of SCCs into two distinct subclasses. An additional independent round of HC induced a similar partition and consensus clustering with the non-negative matrix factorization approach indicated the robustness of this classification. Kaplan-Meier analysis with the log-rank test pointed to a nonsignificant difference in survival (P = 0.071), but the likelihood of survival to 6 years was significantly different between the two groups (40.5 vs 81.8%, P = 0.014, Z-test). Biological process categories characteristic for each subclass were identified statistically and upregulation of cell-proliferation-related genes was evident in the subclass with poor prognosis. In the subclass with better survival, genes involved in differentiated intracellular functions, such as the MAPKKK cascade, ceramide metabolism, or regulation of transcription, were upregulated. This work represents an important step toward the identification of clinically useful classification for lung SCC.	Japanese Fdn Canc Res, Dept Pathol, Inst Canc, Koto Ku, Tokyo 1358550, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo, Japan; Chugai Pharmaceut Co Ltd, Tokyo, Japan; Japanese Fdn Canc Res, Canc Inst Hosp, Dept Chest Surg, Tokyo 170, Japan; Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan	Japanese Foundation for Cancer Research; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Japanese Foundation for Cancer Research; Kanagawa Prefectural Cancer Center	Ishikawa, Y (corresponding author), Japanese Fdn Canc Res, Dept Pathol, Inst Canc, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	ishikawa@jfcr.or.jp	Hoshida, Yujin/R-7513-2019; Inamura, Kentaro/G-4229-2018	Inamura, Kentaro/0000-0001-6444-3861; Jones, Michael/0000-0002-2251-1990				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Arboleda MJ, 2003, CANCER RES, V63, P196; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 2001, CANCER RES, V61, P3225; Fukumoto S, 2005, CLIN CANCER RES, V11, P1776, DOI 10.1158/1078-0432.CCR-04-1238; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Grille SJ, 2003, CANCER RES, V63, P2172; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miura K, 2002, CANCER RES, V62, P3244; Miyoshi T, 2003, AM J SURG PATHOL, V27, P101, DOI 10.1097/00000478-200301000-00011; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Palackal NT, 2002, J BIOL CHEM, V277, P24799, DOI 10.1074/jbc.M112424200; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wikman H, 2004, J PATHOL, V203, P584, DOI 10.1002/path.1552; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yoo SH, 2003, LUNG CANCER, V42, P195, DOI 10.1016/S0169-5002(03)00287-3	33	75	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7105	7113		10.1038/sj.onc.1208858	http://dx.doi.org/10.1038/sj.onc.1208858			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007138				2022-12-28	WOS:000232833200012
J	Kasperczyk, H; La Ferla-Bruhl, K; Westhoff, MA; Behrend, L; Zwacka, RM; Debatin, KM; Fulda, S				Kasperczyk, H; La Ferla-Bruhl, K; Westhoff, MA; Behrend, L; Zwacka, RM; Debatin, KM; Fulda, S			Betulinic acid as new activator of NF-kappa B: molecular mechanisms and implications for cancer therapy	ONCOGENE			English	Article						apoptosis; betulinic acid; cancer; NF-kappa B	MELANOMA-CELLS; TUMOR-CELLS; APOPTOSIS; EXPRESSION; PATHWAY; KINASE; CHEMOTHERAPY; INHIBITION; GROWTH; POTENT	Recent evidence demonstrates that the anticancer activity of betulinic acid (BetA) can be markedly increased by combination protocols, for example with chemotherapy, ionizing radiation or TRAIL. Since nuclear factor kappaB (NF-kappa B), a key regulator of stress-induced transcriptional activation, has been implicated in mediating apoptosis resistance, we investigated the role of NF-kappa B in BetA-induced apoptosis. Here, we provide for the first time evidence that BetA activates NF-kappa B in a variety of tumor cell lines. NF-kappa B DNA-binding complexes induced by BetA consisted of p50 and p65 subunits. Nuclear translocation of p65 was also confirmed by immunofluoresence microscopy. BetA-induced NF-kappa B activation involved increased IKK activity and phosphorylation of I kappa B-alpha at serine 32/36 followed by degradation of I kappa B-alpha. Reporter assays revealed that NF-kappa B activated by BetA is transcriptionally active. Interestingly, inhibition of BetA-induced NF-kappa B activation by different chemical inhibitors ( proteasome inhibitor, antioxidant, IKK inhibitor) attenuated BetA-induced apoptosis. Importantly, specific NF-kappa B inhibition by transient or stable expression of I kappa B-alpha super-repressor inhibited BetA-induced apoptosis in SHEP neuroblastoma cells, while transient expression of I kappa B-alpha super-repressor had no influence on BetA-induced apoptosis in two other cell lines. Thus, our. ndings that activation of NF-kappa B by BetA promotes BetA-induced apoptosis in a cell type-specific fashion indicate that NF-kappa B inhibitors in combination with BetA would have no therapeutic benefit or could even be contraproductive in certain tumors, which has important implications for the design of BetA-based combination protocols.	Univ Ulm, Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany	Ulm University; Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Dept Hematol Oncol, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Ibrahim, Essam Hassan/G-1960-2018; Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Ibrahim, Essam Hassan/0000-0003-0130-2257; Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Zwacka, Ralf/0000-0003-2821-0387				Algul H, 2002, J GASTROINTEST CANC, V31, P71, DOI 10.1385/IJGC:31:1-3:71; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fulda S, 1999, INT J CANCER, V82, P435, DOI 10.1002/(SICI)1097-0215(19990730)82:3<435::AID-IJC18>3.0.CO;2-1; Fulda S, 2004, ONCOGENE, V23, P7611, DOI 10.1038/sj.onc.1207970; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sawada N, 2004, BRIT J CANCER, V90, P1672, DOI 10.1038/sj.bjc.6601746; Selzer E, 2000, J INVEST DERMATOL, V114, P935, DOI 10.1046/j.1523-1747.2000.00972.x; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Younes A, 2003, LEUKEMIA LYMPHOMA, V44, P929, DOI 10.1080/1042819031000067558; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	31	121	125	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6945	6956		10.1038/sj.onc.1208842	http://dx.doi.org/10.1038/sj.onc.1208842			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007147				2022-12-28	WOS:000232701700009
J	Giordano, TJ; Kuick, R; Thomas, DG; Misek, DE; Vinco, M; Sanders, D; Zhu, ZW; Ciampi, R; Roh, M; Shedden, K; Gauger, P; Doherty, G; Thompson, NW; Hanash, S; Koenig, RJ; Nikiforov, YE				Giordano, TJ; Kuick, R; Thomas, DG; Misek, DE; Vinco, M; Sanders, D; Zhu, ZW; Ciampi, R; Roh, M; Shedden, K; Gauger, P; Doherty, G; Thompson, NW; Hanash, S; Koenig, RJ; Nikiforov, YE			Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis	ONCOGENE			English	Article						thyroid cancer; molecular profiling; DNA microarray; activating mutation; RET/RAS/RAF/MAPK signaling pathway	GROWTH-FACTOR-RECEPTOR; TALL-CELL VARIANT; FOLLICULAR VARIANT; HIGH PREVALENCE; CLINICAL-IMPLICATIONS; ONCOGENE ACTIVATION; ANTITUMOR-ACTIVITY; IMMUNE-RESPONSE; LUNG-CANCER; EARLY EVENT	Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC1 and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutation-specific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Cincinnati, Sch Med, Dept Pathol, Cincinnati, OH USA; Univ Michigan, Sch Med, Dept Stat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Giordano, TJ (corresponding author), Univ Michigan, Sch Med, Dept Pathol, UH 2G3320054, Ann Arbor, MI 48109 USA.	Giordano@umich.edu	Gauger, Paul/W-8176-2019; Ciampi, Raffaele/E-5350-2015	Giordano, Thomas/0000-0003-0641-8873; Ciampi, Raffaele/0000-0001-6345-9343; Doherty, Gerard/0000-0002-1685-9552	NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA46592, CA84952] Funding Source: Medline; NIDDK NIH HHS [DK58771, DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Allander SV, 2001, CANCER RES, V61, P8624; BAKER JR, 1995, J CLIN ENDOCR METAB, V80, P3419, DOI 10.1210/jc.80.12.3419; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Batistatou A, 2002, ENDOCR PATHOL, V13, P111, DOI 10.1385/EP:13:2:111; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Begum S, 2004, MODERN PATHOL, V17, P1359, DOI 10.1038/modpathol.3800198; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bongarzone I, 2003, TUMORI, V89, P514, DOI 10.1177/030089160308900510; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2003, J CLIN ENDOCR METAB, V88, P1897, DOI 10.1210/jc.2002-021278; Chevillard S, 2004, CLIN CANCER RES, V10, P6586, DOI 10.1158/1078-0432.CCR-04-0053; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Ciro M, 2003, CURR OPIN CELL BIOL, V15, P213, DOI 10.1016/S0955-0674(03)00007-3; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; Dancey JE, 2004, CANCER CELL, V5, P411, DOI 10.1016/S1535-6108(04)00122-9; De Micco C, 2003, AM J CLIN PATHOL, V120, P803; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DeLellis RA., 2004, TUMOURS ENDOCRINE OR; DOBASHI Y, 1994, DIAGN MOL PATHOL, V3, P9, DOI 10.1097/00019606-199403010-00003; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Ezzat S, 1996, THYROID, V6, P409, DOI 10.1089/thy.1996.6.409; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; Finley DJ, 2004, J CLIN ENDOCR METAB, V89, P3214, DOI 10.1210/jc.2003-031811; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Giuffrida D, 2000, ANN ONCOL, V11, P1083, DOI 10.1023/A:1008322002520; Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Juhasz F, 1996, J CLIN ENDOCR METAB, V81, P4175, DOI 10.1210/jcem.81.11.8923882; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; Kimura ET, 2003, CANCER RES, V63, P1454; LiVolsi V A, 1996, Clin Oncol (R Coll Radiol), V8, P281, DOI 10.1016/S0936-6555(05)80712-5; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lowinger TB, 2002, CURR PHARM DESIGN, V8, P2269, DOI 10.2174/1381612023393125; Luo J, 2003, CANCER INVEST, V21, P937, DOI 10.1081/CNV-120025096; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Machens A, 2004, LANGENBECK ARCH SURG, V389, P278, DOI 10.1007/s00423-004-0485-8; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nardone HC, 2003, CANCER, V98, P1386, DOI 10.1002/cncr.11638; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2002, INT J SURG PATHOL, V10, P15, DOI 10.1177/106689690201000104; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Prendiville S, 2000, OTOLARYNG HEAD NECK, V122, P352, DOI 10.1016/S0194-5998(00)70047-7; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Ruco LP, 2001, J PATHOL, V194, P4, DOI 10.1002/path.847; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Sawyers CL, 2003, GENE DEV, V17, P2998, DOI 10.1101/gad.1152403; Schaefer KL, 2004, CANCER RES, V64, P3395, DOI 10.1158/0008-5472.CAN-03-0809; Schwartz DR, 2002, CANCER RES, V62, P4722; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SMANIK PA, 1994, BIOCHEM BIOPH RES CO, V198, P948, DOI 10.1006/bbrc.1994.1135; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STONE M, 1977, BIOMETRIKA, V64, P29; SUAREZ HG, 1988, ONCOGENE, V2, P403; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tanaka T, 1996, J PATHOL, V179, P89; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wreesmann VB, 2004, CANCER RES, V64, P3780, DOI 10.1158/0008-5472.CAN-03-1460; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	83	289	309	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6646	6656		10.1038/sj.onc.1208822	http://dx.doi.org/10.1038/sj.onc.1208822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007166				2022-12-28	WOS:000232367800006
J	Wallick, CJ; Gamper, I; Thorne, M; Feith, DJ; Takasaki, KY; Wilson, SM; Seki, JA; Pegg, AE; Byus, CV; Bachmann, AS				Wallick, CJ; Gamper, I; Thorne, M; Feith, DJ; Takasaki, KY; Wilson, SM; Seki, JA; Pegg, AE; Byus, CV; Bachmann, AS			Key role for p27(Kip1), retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G(1) cell cycle arrest in MYCN-amplified human neuroblastoma cells	ONCOGENE			English	Article						DFMO; SAM486A; MYCN-amplified neuroblastoma; p27(Kip1); Rb; cell cycle	S-ADENOSYLMETHIONINE DECARBOXYLASE; ALPHA-DIFLUOROMETHYLORNITHINE; N-MYC; ORNITHINE DECARBOXYLASE; PHASE-I; BIOSYNTHESIS INHIBITOR; RETINOIC ACID; POSTRADIOTHERAPY CHEMOTHERAPY; NEURO-BLASTOMA; BREAST-CANCER	Alpha-difluoromethylornithine (DFMO) inhibits the protooncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest. However, the effect of DFMO on human neuroblastoma (NB) cells and the exact mechanism of DFMO-induced cell death are largely unknown. Treatment with DFMO in combination with SAM486A, an S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, has been shown to enhance polyamine pool depletion. Therefore, we analysed the mechanism of action of DFMO and/or SAM486A in two established MYCN-amplified human NB cell lines. DFMO and SAM486A caused rapid cell growth inhibition, polyamine depletion, and G(1) cell cycle arrest without apoptosis in cell lines LAN-1 and NMB-7. These effects were enhanced with combined inhibitors and largely prevented by cotreatment with exogenous polyamines. The G(1) cell cycle arrest was concomitant with an increase in cyclin-dependent kinase inhibitor p27(Kip1). In a similar fashion, DFMO and DFMO/SAM486A inhibited the phosphorylation of the G(1)/S transition-regulating retinoblastoma protein Rb at residues Ser795 and Ser807/811. Moreover, we observed a dramatic decrease in MYCN protein levels. Overexpression of MYCN induces an aggressive NB phenotype with malignant behavior. We show for the first time that DFMO and SAM486A induce G(1) cell cycle arrest in NB cells through p27(Kip1) and Rb hypophosphorylation.	Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	Cancer Research Center of Hawaii; University of Hawaii System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California Riverside	Bachmann, AS (corresponding author), Univ Hawaii, Canc Res Ctr Hawaii, 1236 Lauhala St, Honolulu, HI 96813 USA.	abachmann@crch.hawaii.edu			NCI NIH HHS [R01CA18138, R01 CA018138, R01CA79909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079909, R01CA018138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmann Andre S, 2004, Hawaii Med J, V63, P371; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Carbone PP, 2001, CANCER EPIDEM BIOMAR, V10, P657; CHAPMAN SK, 1980, LIFE SCI, V26, P1359, DOI 10.1016/0024-3205(80)90097-1; Coleman C S, 1998, Methods Mol Biol, V79, P41; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; DORHOUT B, 1995, INT J CANCER, V62, P738, DOI 10.1002/ijc.2910620615; Eskens FALM, 2000, CLIN CANCER RES, V6, P1736; Fabian CJ, 2002, CLIN CANCER RES, V8, P3105; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; GILBERT RS, 1991, ANAL BIOCHEM, V199, P86, DOI 10.1016/0003-2697(91)90273-V; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Kramer DL, 2001, CANCER RES, V61, P7754; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Levin VA, 2000, CLIN CANCER RES, V6, P3878; Levin VA, 2003, CLIN CANCER RES, V9, P981; Lu XH, 2003, CANCER LETT, V197, P125, DOI 10.1016/S0304-3835(03)00096-X; Lutz W, 1996, ONCOGENE, V13, P803; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; McKenzie PP, 2003, CANCER RES, V63, P3840; MELINO G, 1991, PROG CLIN BIOL RES, V366, P283; MELINO G, 1988, EXP CELL RES, V179, P429, DOI 10.1016/0014-4827(88)90281-9; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Paridaens R, 2000, BRIT J CANCER, V83, P594, DOI 10.1054/bjoc.2000.1305; PEGG AE, 1988, CANCER RES, V48, P759; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; Porter C. W., 1992, V62, P301; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; REGENASS U, 1994, CANCER RES, V54, P3210; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shantz L M, 1998, Methods Mol Biol, V79, P45; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Singh R, 2001, CARCINOGENESIS, V22, P1863, DOI 10.1093/carcin/22.11.1863; Siu LL, 2002, CLIN CANCER RES, V8, P2157; Svensson F, 1997, BIOCHEM J, V322, P297, DOI 10.1042/bj3220297; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Takahashi Y, 2000, INT J CANCER, V85, P243, DOI 10.1002/(SICI)1097-0215(20000115)85:2<243::AID-IJC15>3.0.CO;2-2; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327	50	71	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5606	5618		10.1038/sj.onc.1208808	http://dx.doi.org/10.1038/sj.onc.1208808			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007177				2022-12-28	WOS:000231296100007
J	Duong, V; Licznar, A; Margueron, R; Boulle, N; Busson, M; Lacroix, M; Katzenellenbogen, BS; Cavailles, V; Lazennec, G				Duong, V; Licznar, A; Margueron, R; Boulle, N; Busson, M; Lacroix, M; Katzenellenbogen, BS; Cavailles, V; Lazennec, G			ER alpha and ER beta expression and transcriptional activity are differentially regulated by HDAC inhibitors	ONCOGENE			English	Article						estrogen receptor; histone deacetylase; breast cancer; transcription; proliferation	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITION; ANDROGEN RECEPTOR; CARCINOMA-CELLS; TRICHOSTATIN-A; PROLIFERATION; ACETYLATION; TRANSACTIVATION; ACTIVATION	The proliferative action of ER alpha largely accounts for the carcinogenic activity of estrogens. By contrast, recent data show that ER beta displays tumor-suppressor properties, thus supporting the interest to identify compounds that could increase its activity. Here, we show that histone deacetylase inhibitors (HDI) upregulated ER beta protein levels, whereas it decreased ER alpha expression. Part of this regulation took place at the mRNA level through a mechanism independent of de novo protein synthesis. In addition, we found that, in various cancer cells, the treatment with different HDI enhanced the ligand-dependent activity of ER beta more strongly than that of ER alpha. On the other hand, in MDA-MB231 and HeLa cells, the expression of ERs modified the transcriptional response to HDI. The use of deletion mutants of both receptors demonstrated that AF1 domain of the receptors was required. Finally, we show that ER beta expression led to a dramatic increased in the antiproliferative activity of HDI, which correlated with a modi. cation of the transcription of genes involved in cell cycle control by HDI. Altogether, these data demonstrate that the interference of ER beta and HDAC on the control of transcription and cell proliferation constitute a promising approach for cancer therapy.	INSERM, U540, F-34090 Montpellier, France; Hop Arnaud Villeneuve, Lab Biol Cellulaire & Hormonale, Montpellier, France; INRA, UMR 866, F-34060 Montpellier, France; Univ Illinois, Coll Med, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; INRAE; Universite de Montpellier; University of Illinois System; University of Illinois Urbana-Champaign	Cavailles, V (corresponding author), INSERM, U540, 60,Rue Navacelles, F-34090 Montpellier, France.	v.cavailles@montp.inserm.fr; lazennec@montp.inserm.fr	Cavailles, Vincent/Y-5379-2019; Lacroix, Matthieu/O-1928-2018; Margueron, Raphael F/B-9996-2015; cavailles, vincent/C-6277-2017	Cavailles, Vincent/0000-0002-7160-3074; Lacroix, Matthieu/0000-0002-1268-9058; Margueron, Raphael F/0000-0002-9093-7977; Lazennec, Gwendal/0000-0002-8522-1763	NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA018119, CA18119] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campbell-Thompson M, 2001, CANCER RES, V61, P632; Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025; Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; de Cremoux P, 2002, BIOCHEM PHARMACOL, V64, P507, DOI 10.1016/S0006-2952(02)01187-5; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fajas L, 2003, ONCOGENE, V22, P4186, DOI 10.1038/sj.onc.1206530; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENDERSON BE, 1988, CANCER RES, V48, P246; Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031; Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pujol P, 1998, CANCER RES, V58, P5367; Roger P, 2001, CANCER RES, V61, P2537; Ruh MF, 1999, ENDOCRINE, V11, P157, DOI 10.1385/ENDO:11:2:157; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; STANLEY F, 1984, J BIOL CHEM, V259, P9768; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Yang XW, 2000, CANCER RES, V60, P6890	36	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1799	1806		10.1038/sj.onc.1209102	http://dx.doi.org/10.1038/sj.onc.1209102			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16158045	Green Submitted, Green Accepted			2022-12-28	WOS:000236013700011
J	Sun, Y; Gao, D; Liu, Y; Huang, J; Lessnick, S; Tanaka, S				Sun, Y; Gao, D; Liu, Y; Huang, J; Lessnick, S; Tanaka, S			IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1	ONCOGENE			English	Article						SYT-SSX1; IGF2; apoptosis; synovial sarcoma	FACTOR-II GENE; CTCF-BINDING SITES; GROWTH-FACTORS; HUMAN CANCER; WILMS-TUMOR; SSX GENES; COLORECTAL-CANCER; TARGET GENE; SYT; EXPRESSION	Synovial sarcoma is an aggressive soft tissue tumor characterized by a specific chromosomal translocation between chromosome 18 and X. This translocation can generate a fusion transcript encoding SYT-SSX1, a transforming oncoprotein. We present evidence that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells. SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synthesis protects cells from anoikis and is required for tumor formation in vivo. We also found a loss of imprinting ( LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleotides critical for maintaining imprinting. These findings suggest that inhibition of the IGF2/IGF1-R signaling pathway may represent a significant therapeutic modality for treating synovial sarcoma.	Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Sch Med & Dent, Rochester, NY USA; Huntsman Canc Inst, Salt Lake City, UT USA; Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan	University of Rochester; University of Rochester; Huntsman Cancer Institute; Hokkaido University	Sun, Y (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	yin_sun@urmc.rochester.edu	Gao, Dingcheng/P-5889-2019; Tanaka, Shinya/D-3586-2011					Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Cui HM, 2002, CANCER RES, V62, P6442; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu QQ, 1996, CIRC RES, V79, P716, DOI 10.1161/01.RES.79.4.716; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; NIELSEN FC, 1994, CANCER, V73, P1312, DOI 10.1002/1097-0142(19940215)73:4<1312::AID-CNCR2820730429>3.0.CO;2-D; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PAL N, 1990, ONCOGENE, V5, P1665; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Stadnick MP, 1999, DEV GENES EVOL, V209, P239, DOI 10.1007/s004270050248; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; Xie YT, 1999, CANCER RES, V59, P3588; Xie YT, 2003, ONCOGENE, V22, P7628, DOI 10.1038/sj.onc.1207153; Zhang LJ, 1996, CANCER RES, V56, P1367	53	65	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1042	1052		10.1038/sj.onc.1209143	http://dx.doi.org/10.1038/sj.onc.1209143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247461				2022-12-28	WOS:000235361000009
J	Cesaire, R; Oliere, S; Sharif-Askari, E; Loignon, M; Lezin, A; Olindo, S; Panelatti, G; Kazanji, M; Aloyz, R; Panasci, L; Bell, JC; Hiscott, J				Cesaire, R; Oliere, S; Sharif-Askari, E; Loignon, M; Lezin, A; Olindo, S; Panelatti, G; Kazanji, M; Aloyz, R; Panasci, L; Bell, JC; Hiscott, J			Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia	ONCOGENE			English	Article						ATL; HTLV-1; HAM/TSP; VSV; apoptosis; oncolysis	CHRONIC LYMPHOCYTIC-LEUKEMIA; MATRIX PROTEIN; SIGNALING PATHWAYS; ANTIVIRAL DEFENSE; DNA FRAGMENTATION; INNATE IMMUNITY; IN-VIVO; APOPTOSIS; CANCER; INDUCTION	Treatments for hematological malignancies have improved considerably over the past decade, but the growing therapeutic arsenal has not benefited adult T-cell leukemia (ATL) patients. Oncolytic viruses such as vesicular stomatitis virus (VSV) have recently emerged as a potential treatment of solid tumors and leukemias in vitro and in vivo. In the current study, we investigated the ability of VSV to lyse primary human T-lymphotropic virus type 1 (HTLV-1)- infected T-lymphocytes from patients with ATL. Ex vivo primary ATL cells were permissive for VSV and underwent rapid oncolysis in a time-dependent manner. Importantly, VSV infection showed neither viral replication nor oncolysis in HTLV1- infected, nonleukemic cells from patients with HTLV-1associated myelopathy/ tropical spastic paraparesis (HAM/TSP), and in naive CD4+ T- lymphocytes from normal individuals or in ex vivo cell samples from patients with chronic lymphocytic leukemia (CLL). Interestingly, activation of primary CD4+ T- lymphocytes with antiCD3/ CD28 monoclonal antibody, and specifically with anti-CD3, was sufficient to induce limited viral replication and oncolysis. However, at a similar level of T- cell activation, VSV replication was increased fourfold in ATL cells compared to activated CD4+ T- lymphocytes, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. In conclusion, our findings provide the first essential information for the development of a VSV-based treatment for ATL.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; CHU Ft France, Lab Virol Immunol, Martinique, France; CHU Ft de France, INSERM, UMR433, Martinique, France; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; CHU Ft de France, Neurol Serv, Martinique, France; CHU Ft de France, Serv Med Interne, Martinique, France; Inst Pasteur, Retrovirus Lab, Cayenne, French Guiana; Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON, Canada	Lady Davis Institute; McGill University; CHU Martinique; CHU Martinique; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University; McGill University; CHU Martinique; CHU Martinique; University of Ottawa; Ottawa Hospital Research Institute	Hiscott, J (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Room 526,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca	Aloyz, Raquel S/N-6606-2013	Aloyz, Raquel S/0000-0002-6812-497X				Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016/S1470-2045(04)01608-0; BELKOWSKI LS, 1987, J VIROL, V61, P653, DOI 10.1128/JVI.61.3.653-660.1987; Bell J. C., 2002, Current Gene Therapy, V2, P243, DOI 10.2174/1566523024605582; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Cavrois M, 1996, ONCOGENE, V12, P2419; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Desforges M, 2002, VIROLOGY, V295, P63, DOI 10.1006/viro.2001.1329; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Eastman A, 1999, SEMIN ONCOL, V26, P7; Ebert O, 2003, CANCER RES, V63, P3605; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Gadaleta P, 2002, VIRUS RES, V86, P87, DOI 10.1016/S0168-1702(02)00049-7; GESSAIN A, 1985, LANCET, V2, P407; Grigera PR, 1996, J VIROL, V70, P8492, DOI 10.1128/JVI.70.12.8492-8501.1996; Gromeier M, 2001, CURR OPIN MOL THER, V3, P503; Hawkins LK, 2002, LANCET ONCOL, V3, P17, DOI 10.1016/S1470-2045(01)00618-0; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; Hobbs JA, 2003, HUM IMMUNOL, V64, P82, DOI 10.1016/S0198-8859(02)00702-4; Hobbs JA, 2001, VIRUS RES, V80, P53, DOI 10.1016/S0168-1702(01)00350-1; Huang TG, 2003, MOL THER, V8, P434, DOI 10.1016/S1525-0016(03)00204-1; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kopecky SA, 2003, J VIROL, V77, P5524, DOI 10.1128/JVI.77.9.5524-5528.2003; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; LINGE C, 1995, CANCER RES, V55, P4099; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matin SF, 2001, CANCER RES, V61, P2261; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meinhardt G, 1999, J MOL MED-JMM, V77, P282, DOI 10.1007/s001090050351; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Norman KL, 2001, CYTOKINE GROWTH F R, V12, P271, DOI 10.1016/S1359-6101(00)00024-1; Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003; OSAME M, 1986, LANCET, V1, P1031; Satoh M, 2002, ONCOGENE, V21, P2466, DOI 10.1038/sj.onc.1205329; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Steele TA, 2000, P SOC EXP BIOL MED, V223, P118, DOI 10.1046/j.1525-1373.2000.22317.x; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu JT, 2001, B MATH BIOL, V63, P731, DOI 10.1006/bulm.2001.0245; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	56	25	28	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					349	358		10.1038/sj.onc.1209055	http://dx.doi.org/10.1038/sj.onc.1209055			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186807				2022-12-28	WOS:000234714100003
J	Krystyniak, A; Garcia-Echeverria, C; Prigent, C; Ferrari, S				Krystyniak, A; Garcia-Echeverria, C; Prigent, C; Ferrari, S			Inhibition of Aurora A in response to DNA damage	ONCOGENE			English	Article						AurA; CDK1; DNA damage; mitosis; phosphorylation	ANAPHASE-PROMOTING COMPLEX; TUMOR AMPLIFIED KINASE; PROTEIN-KINASE; CENTROSOME AMPLIFICATION; MAMMALIAN-CELLS; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; CHECKPOINT	Mitotic kinases are the ultimate target of pathways sensing genotoxic damage and impinging on the cell cycle machinery. Here, we provide evidence that Aurora A (AurA) was inhibited upon generation of double-strand breaks in DNA. We demonstrate that AurA was not downstream of CDK1 and that inhibition of AurA and CDK1 by DNA damage occurred independently. Using a cell line functionally deficient in Chk2, a selective Chk1 inhibitor and siRNA to Chk1, we show that DNA-damage signals were delivered to AurA through a Chk1-dependent pathway. With regard to the molecular mechanism of AurA inhibition, we found that the point mutation Ser342 > Ala rendered AurA resistant to inhibition by DNA damage. By means of two distinct approaches we examined the impact of reconstitution of AurA activity in DNA-damaged cells: (i) transient expression of wild-type and Ser342 > Ala mutant, but not kinase-dead, AurA led to bypass of the DNA damage block; (ii) direct transduction of highly active wt-AurA into G2 arrested cells precisely after induction of DNA damage resulted in mitotic entry. We show that the mechanism through which AurA allowed entry into mitosis was reactivation of CDK1, thus indicating that AurA plays a key role upstream of CDK1. A model depicting the possible role of AurA at the onset of mitosis and upon DNA damage is presented.	Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; Novartis Pharmaceut, Dept Oncol, Basel, Switzerland; Univ Rennes 1, CNRS, UMR6061, Cell Cycle Grp, Rennes, France	University of Zurich; Novartis; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Ferrari, S (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	sferrari@imcr.unizh.ch	Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Maton G, 2003, J BIOL CHEM, V278, P21439, DOI 10.1074/jbc.M300811200; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	42	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					338	348		10.1038/sj.onc.1209056	http://dx.doi.org/10.1038/sj.onc.1209056			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158051				2022-12-28	WOS:000234714100002
J	Quaranta, MT; Spinello, I; Testa, U; Mariani, G; Diverio, D; Foa, R; Peschle, C; Labbaye, C				Quaranta, MT; Spinello, I; Testa, U; Mariani, G; Diverio, D; Foa, R; Peschle, C; Labbaye, C			PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells	ONCOGENE			English	Article						PLZF; VLA-4; mobilization; acute myeloid leukemia	ZINC-FINGER; HEMATOPOIETIC PROGENITORS; STEM-CELLS; PROTEIN; MOBILIZATION; DIFFERENTIATION; GENE; PROLIFERATION; FIBRONECTIN; INTERACTS	The promyelocytic leukemia zinc-finger protein (PLZF) is a transcriptional repressor. To investigate the role of PLZF in the regulation of cytoadhesion molecules involved in the mobilization of hemopoietic cells, we have analysed PLZF and very late antigen 4 ( VLA-4) expression in normal and leukemic cells. In hematopoiesis, we found a negative correlation between PLZF and VLA4 expression, except for the megakaryocytic lineage. In contrast, we observed a positive correlation between PLZF and VLA-4 expression in a panel of acute myeloid leukemia (AML) samples. In K562 cells expressing PLZF (K562-PLZF), we found that the expression of VLA-4 and c-kit was downmodulated. We have investigated the possibility for VLA-4 or the c-kit receptor to be direct target genes of PLZF in K562-PLZF cells and identified a PLZF DNA-binding site within the VLA-4 promoter. Furthermore, decrease in VLA-4 expression was associated with loss of adhesion on. bronectin-coated plates, which promotes drug-induced apoptosis of K562-PLZF cells. Our findings indicate that VLA-4 is a potential target gene of PLZF. However, in primary AMLs the control of PLZF on VLA-4 expression is lost. Altogether, we suggest that VLA-4 modulation by PLZF may represent an important step in the control of normal and leukemic cell mobilization.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	clabbaye@iss.it	SPINELLO, ISABELLA/J-8779-2016; Quaranta, Maria Teresa/AAC-2134-2019; Testa, Ugo/J-6472-2016; Labbaye, Catherine/J-9930-2016	Quaranta, Maria Teresa/0000-0002-5886-507X; Testa, Ugo/0000-0001-7900-8942; Labbaye, Catherine/0000-0003-1255-4396				Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Craddock CF, 1997, BLOOD, V90, P4779, DOI 10.1182/blood.V90.12.4779.4779_4779_4788; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gazitt Y, 2004, STEM CELLS, V22, P65, DOI 10.1634/stemcells.22-1-65; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mossuz P, 1997, BRIT J HAEMATOL, V98, P819, DOI 10.1046/j.1365-2141.1997.3013118.x; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Yuan Q, 1997, J EXP MED, V186, P313, DOI 10.1084/jem.186.2.313	31	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					399	408		10.1038/sj.onc.1209060	http://dx.doi.org/10.1038/sj.onc.1209060			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158049				2022-12-28	WOS:000234714100008
J	Baker, EK; Johnstone, RW; Zalcberg, JR; El-Osta, A				Baker, EK; Johnstone, RW; Zalcberg, JR; El-Osta, A			Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs	ONCOGENE			English	Article						cancer; chemotherapy; multidrug resistance; epigenetic modifications; chromatin	ACUTE MYELOID-LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; MESSENGER-RNA STABILIZATION; MULTIDRUG-RESISTANCE MDR1; GENE-EXPRESSION; HISTONE H3; PROMOTER REGION; ANTHRACYCLINE ANALOGS; DEOXYCYTIDINE KINASE; METHYLATION PATTERNS	The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the MDR1 locus, concomitant with MDR1 upregulation mediated by transcriptional activation, and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the MDR1 promoter. MDR1 upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modi. cations occurred within the 50 hypomethylated region of MDR1, directly correlating with MDR1 upregulation. Specifically, drug-induced upregulation of MDR1 was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the MDR1 locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the MDR1 promoter, and enhance the MDR phenotype.	Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Prahran, Vic 3181, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Gene Regulat Lab, Melbourne 3002, Australia; Peter MacCallum Canc Ctr, Dept Med Oncol & Haematol, Melbourne 3002, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	El-Osta, A (corresponding author), Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Commercial Rd, Prahran, Vic 3181, Australia.	assam.el-osta@baker.edu.au	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; El-Osta, Assam/0000-0003-2969-9137; Zalcberg, John/0000-0002-6624-0782; El-Osta, Assam/0000-0001-7968-7375				Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; CAMPOS L, 1992, BLOOD, V79, P473; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; El-Osta A, 2001, MOL BIOL REP, V28, P209, DOI 10.1023/A:1015744625049; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; FERGUSON PJ, 1988, CANCER RES, V48, P5956; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; GOLDIE JH, 1984, CANCER RES, V44, P3643; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Hu XF, 1999, BLOOD, V93, P4086, DOI 10.1182/blood.V93.12.4086.412k43_4086_4095; HU XF, 1995, BRIT J CANCER, V71, P931, DOI 10.1038/bjc.1995.180; Hu XF, 1999, BRIT J CANCER, V79, P831, DOI 10.1038/sj.bjc.6690133; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kantharidis P, 1997, CLIN CANCER RES, V3, P2025; Kinkel MD, 2003, J CELL BIOCHEM, V88, P941, DOI 10.1002/jcb.10442; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; KUWAZURU Y, 1990, CANCER, V66, P868, DOI 10.1002/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z; Leegwater PAJ, 1998, CANCER LETT, V130, P169, DOI 10.1016/S0304-3835(98)00131-1; Leith CP, 1997, BLOOD, V89, P3323; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mansson E, 2002, LEUKEMIA, V16, P386, DOI 10.1038/sj.leu.2402388; MARIE JP, 1991, BLOOD, V78, P586; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PIRKER R, 1991, J NATL CANCER I, V83, P708, DOI 10.1093/jnci/83.10.708; Radosevic N, 2001, LEUKEMIA, V15, P559, DOI 10.1038/sj.leu.2402092; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tada Y, 2000, CLIN CANCER RES, V6, P4618; TEBOEKHORST PAW, 1993, BLOOD, V82, P3157; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; vandenHeuvelEibrink MM, 1997, BRIT J HAEMATOL, V99, P76, DOI 10.1046/j.1365-2141.1997.3343148.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; WOOD P, 1994, BRIT J HAEMATOL, V87, P509, DOI 10.1111/j.1365-2141.1994.tb08305.x; Yague E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200; ZHOU DC, 1992, LEUKEMIA, V6, P879; ZOCHBAUER S, 1994, LEUKEMIA, V8, P974	52	159	176	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8061	8075		10.1038/sj.onc.1208955	http://dx.doi.org/10.1038/sj.onc.1208955			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091741				2022-12-28	WOS:000233656600012
J	Tsuda, M; Watanabe, T; Seki, T; Kimura, T; Sawa, H; Minami, A; Akagi, T; Isobe, K; Nagashima, K; Tanaka, S				Tsuda, M; Watanabe, T; Seki, T; Kimura, T; Sawa, H; Minami, A; Akagi, T; Isobe, K; Nagashima, K; Tanaka, S			Induction of p21(WAF1/CIP1) by human synovial sarcoma-associated chimeric oncoprotein SYT-SSX1	ONCOGENE			English	Article						p21(WAF1/CIP1); Sp1; synovial sarcoma; SYT-SSX	PROMOTER ACTIVITY; NIH3T3 CELLS; LIFE-SPAN; SYT; P53; SENESCENCE; PROTEINS; FUSION; SSX; EXPRESSION	Oncogenic protein provokes cell cycle arrest termed premature senescence. In this process Ras has been known to induce cyclin-dependent kinase inhibitor (CKI) p16(INK4A) in primary fibroblasts. Here, we present a novel finding that human chimeric oncoprotein SYT-SSX1 induces CKI p21(WAF1/CIP1) (p21) for suppression of cell growth. In human synovial sarcoma cell lines, the expression levels of p21 were high and the transcriptional activity of the p21 gene promoter was significantly elevated. The transient expression of SYT- SSX1-induced activation of the p21 gene promoter in human diploid fibroblasts. The N-terminus deletion form of SYT-SSX1, which failed to bind to hBRM one of the chromatin remodeling factors, preserved the p21 induction ability. This effect of SYT-SSX1 was similar in extent in both wild-type and p53-deficient HCT116 cell lines. Furthermore, the introduction of mutation in Sp1/Sp3 binding sites of the p21 gene promoter abolished the SYT-SSX1-induced transcriptional activity of its promoter. In SW13 cells, the stable expression of SYT-SSX1 suppressed cell growth in culture. These results suggest that SYT-SSX1 is able to induce p21 in a manner independent on hBRM and p53 but dependent on Sp1/Sp3.	Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Orthoped Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Osaka Biosci Inst, Osaka 5650874, Japan; Natl Inst Lingev Sci, Dept Basic Gerontol, Obu 4748511, Japan	Hokkaido University; Hokkaido University	Tanaka, S (corresponding author), Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	tanaka@med.hokudai.ac.jp	Sawa, Hirofumi/AAW-8816-2021; Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755				AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Lloyd AC, 2002, NAT CELL BIOL, V4, pE25, DOI 10.1038/ncb0202-e25; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nishio J, 2002, INT J ONCOL, V21, P17; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pollock RE, 1996, ONCOGENE, V12, P2035; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; Schneider-Stock R, 1999, VIRCHOWS ARCH, V435, P407, DOI 10.1007/s004280050418; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WEISS SW, 2001, ENZINGER WEISSS SOFT; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158	27	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7984	7990		10.1038/sj.onc.1208942	http://dx.doi.org/10.1038/sj.onc.1208942			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16103879				2022-12-28	WOS:000233656600005
J	Xiao, H; Goodrich, DW				Xiao, H; Goodrich, DW			The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes	ONCOGENE			English	Article						retinoblastoma tumor suppressor gene; topoisomerase II; etoposide; DNA damage; DNA repair	DOUBLE-STRAND BREAKS; E2F TARGET GENES; DAMAGE RESPONSE; LIGASE ACTIVITY; RB PROTEIN; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; GENOMIC INSTABILITY; BRCA1; BETA	Type II topoisomerases (TOP2) introduce transient double-stranded DNA breaks through a covalent TOP2 DNA intermediate. Anticancer agents like etoposide kill cells by trapping covalent TOP2-DNA cleavable complexes. Pathways influencing the repair of cleavable complexes are expected to be major determinants of therapeutic response to etoposide. Rb1 is required to enforce cell cycle checkpoints in response to DNA damage, but evidence for a direct role in the processing and repair of DNA lesions is lacking. We observe that degradation of trapped TOP2-cleavable complexes, liberation of DNA strand breaks, and repair of those breaks occurs more efficiently in cells expressing Rb1 protein (pRb). Cells lacking pRb are more sensitive to etoposide-induced cytotoxicity. Rb1-mediated processing and repair of TOP2-cleavable complexes is genetically separable from its ability to bind E2F and enforce DNA damage-induced cell cycle checkpoints. Rb1 protein binds both TOP2 and BRCA1 in intact cells, and pRb is required for association between TOP2 and BRCA1. These results suggest that pRb facilitates processing and repair of TOP2-cleavable complexes by recruiting proteins like BRCA1 to the damaged site. The functional status of pRb, therefore, may influence sensitivity to etoposide by facilitating the repair of trapped TOP2-DNA complexes as well as by enforcing cell cycle checkpoints.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	david.goodrich@roswellpark.org			NCI NIH HHS [R01 CA070292, R01 CA070292-07, CA70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Adachi N, 2004, BIOCHEM BIOPH RES CO, V318, P856, DOI 10.1016/j.bbrc.2004.04.099; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; GOVONI M, 1995, BIOCHEM BIOPH RES CO, V213, P282, DOI 10.1006/bbrc.1995.2127; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Naderi S, 2002, CELL CYCLE, V1, P193, DOI 10.4161/cc.1.3.125; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Niimi A, 2001, CHROMOSOMA, V110, P102, DOI 10.1007/s004120100140; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Otterson GA, 1999, AM J HUM GENET, V65, P1040, DOI 10.1086/302581; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100; Yamamoto Y, 1998, ONCOL REP, V5, P447; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	51	25	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8105	8113		10.1038/sj.onc.1208958	http://dx.doi.org/10.1038/sj.onc.1208958			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091739	Green Accepted			2022-12-28	WOS:000233809400003
J	Gyorffy, B; Serra, V; Jurchott, K; Abdul-Ghani, R; Garber, M; Stein, U; Petersen, I; Lage, H; Dietel, M; Schafer, R				Gyorffy, B; Serra, V; Jurchott, K; Abdul-Ghani, R; Garber, M; Stein, U; Petersen, I; Lage, H; Dietel, M; Schafer, R			Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival	ONCOGENE			English	Article						cancer chemoresistance; gene expression; microarray; breast cancer	COMPLETE PATHOLOGICAL RESPONSE; PANCREATIC-CARCINOMA CELLS; MULTIDRUG-RESISTANCE; CDNA MICROARRAY; CANCER-CELLS; NEOADJUVANT CHEMOTHERAPY; ANTICANCER DRUGS; CHEMORESISTANCE; TRANSPORTERS	Up to date clinical tests for predicting cancer chemotherapy response are not available and individual markers have shown little predictive value. We hypothesized that gene expression patterns attributable to chemotherapy-resistant cells can predict response and cancer prognosis. We contrasted the expression profiles of 13 different human tumor cell lines of gastric (EPG85-257), pancreatic (EPP85-181), colon (HT29) and breast (MCF7 and MDA-MB-231) origin and their counterparts resistant to the topoisomerase inhibitors daunorubicin, doxorubicin or mitoxantrone. We interrogated cDNA arrays with 43 000 cDNA clones (similar to 30 000 unique genes) to study the expression pattern of these cell lines. We divided gene expression profiles into two sets: we compared the expression patterns of the daunorubicin/doxorubicin- resistant cell lines and the mitoxantrone-resistant cell lines independently to the parental cell lines. For identifying predictive genes, the Prediction Analysis for Mircorarrays algorithm was used. The analysis revealed 79 genes best correlated with doxorubicin resistance and 70 genes with mitoxantrone resistance. In an independent classification experiment, we applied our model of resistance for predicting the sensitivity of 44 previously characterized breast cancer samples. The patient group characterized by the gene expression pro. le similar to those of doxorubicin-sensitive cell lines exhibited longer survival (49.7 +/- 26.1 months, n = 21, P = 0.034) than the resistant group (32.9 +/- 18.7 months, n = 23). The application of gene expression signatures derived from doxorubicin-resistant and -sensitive cell lines allowed to predict effectively clinical survival after doxorubicin monotherapy. Our approach demonstrates the significance of in vitro experiments in the development of new strategies for cancer response prediction.	Humboldt Univ, Inst Pathol, Charite, D-10117 Berlin, Germany; Semmelweis Univ, Dept Internal Med 2, H-1088 Budapest, Hungary; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Semmelweis University; Stanford University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gyorffy, B (corresponding author), Humboldt Univ, Inst Pathol, Charite, Schumannstr 20-21, D-10117 Berlin, Germany.	zsalab2@yahoo.com	Schäfer, Reinhold/AAB-5110-2021; Gyorffy, Balazs/AAA-9135-2021; Serra, Violeta/AAG-8328-2019	Gyorffy, Balazs/0000-0002-5772-3766; Serra, Violeta/0000-0001-6620-1065; Stein, Ulrike/0000-0001-7006-282X; Jurchott, Karsten/0000-0003-1589-0037				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alonso O, 2002, NUCL MED COMMUN, V23, P765, DOI 10.1097/00006231-200208000-00010; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Bodo A, 2003, TOXICOL LETT, V140, P133, DOI 10.1016/S0378-4274(02)00497-6; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chollet P, 2002, BRIT J CANCER, V86, P1041, DOI 10.1038/sj/bjc/6600210; DIETEL M, 1990, CANCER RES, V50, P6100; Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FISHER TC, 1993, CANCER RES, V53, P3321; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kudoh K, 2000, CANCER RES, V60, P4161; Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460; Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y; Lage H, 2000, INT J HYPERTHER, V16, P291, DOI 10.1080/02656730050074069; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Nooter K, 1995, CLIN CANCER RES, V1, P1301; Robert J, 2003, J MED CHEM, V46, P4805, DOI 10.1021/jm030183a; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Sciuto R, 2002, J NUCL MED, V43, P745; Sinha P, 1999, ELECTROPHORESIS, V20, P2961, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2961::AID-ELPS2961>3.0.CO;2-L; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Thomas Hilary, 2003, Cancer Control, V10, P159; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Zembutsu H, 2002, CANCER RES, V62, P518	39	55	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7542	7551		10.1038/sj.onc.1208908	http://dx.doi.org/10.1038/sj.onc.1208908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044152				2022-12-28	WOS:000233333800004
J	Lian, ZL; Di Cristofano, A				Lian, ZL; Di Cristofano, A			Class reunion: PTEN joins the nuclear crew	ONCOGENE			English	Article						PTEN; AKT; nucleus	TUMOR-SUPPRESSOR PTEN; LIPID PHOSPHATASE-ACTIVITY; FOCAL ADHESION KINASE; HUMAN PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; ENDOMETRIAL CARCINOMA; ATYPICAL HYPERPLASIA; MUTATIONAL SPECTRA; ESTROGEN-RECEPTOR	Several recent reports have brought conclusive evidence that the tumor suppressor PTEN, once considered a strictly cytoplasmic protein, shuttles to the nuclear compartment, where it joins a variety of components of the same pathway it regulates in the cytoplasm, among which PI3K, PDK1 and AKT. In this review, we focus on the growing supporting evidence for an important physiological role of this nuclear pathway and on the role that alteration of this novel regulatory circuit may play during cell transformation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Di Cristofano, A (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	antonio.dicristofano@fccc.edu	Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020	di cristofano, antonio/0000-0003-2537-3228	NATIONAL CANCER INSTITUTE [R01CA097097] Funding Source: NIH RePORTER; NCI NIH HHS [CA097097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014-5793(00)01758-0; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Deleris P, 2003, J BIOL CHEM, V278, P38884, DOI 10.1074/jbc.M300816200; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Ginn-Pease ME, 2003, CANCER RES, V63, P282; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guzeloglu-Kayisli O, 2003, J CLIN ENDOCR METAB, V88, P5017, DOI 10.1210/jc.2003-030414; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; Kokawa K, 1996, J CLIN ENDOCR METAB, V81, P4144, DOI 10.1210/jc.81.11.4144; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SH, 2002, APMIS, V110, P587, DOI 10.1034/j.1600-0463.2002.11007811.x; Levine RL, 1998, CANCER RES, V58, P3254; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martelli AM, 2003, J CELL BIOCHEM, V88, P455, DOI 10.1002/jcb.10379; Martelli AM, 2000, J BONE MINER RES, V15, P1716, DOI 10.1359/jbmr.2000.15.9.1716; Maxwell GL, 1998, CANCER RES, V58, P2500; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Montironi R, 2004, VIRCHOWS ARCH, V444, P503, DOI 10.1007/s00428-004-0996-2; Murphy ME, 2004, CELL CYCLE, V3, P836; Mutter GL, 2000, J CLIN ENDOCR METAB, V85, P2334, DOI 10.1210/jc.85.6.2334; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Neri LM, 1999, BIOCHEM BIOPH RES CO, V259, P314, DOI 10.1006/bbrc.1999.0786; NERI LM, 1994, CELL MOL BIOL, V40, P619; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; PEIFFER SL, 1995, CANCER RES, V55, P1922; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Saji M, 2005, BIOCHEM BIOPH RES CO, V332, P167, DOI 10.1016/j.bbrc.2005.04.109; Sano T, 1999, CANCER RES, V59, P1820; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; Syed NA, 2002, J CELL BIOCHEM, V86, P118, DOI 10.1002/jcb.10189; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tashiro H, 1997, CANCER RES, V57, P3935; Tell G, 2004, ENDOCRINOLOGY, V145, P4660, DOI 10.1210/en.2004-0282; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Van de Sande T, 2005, J PATHOL, V206, P214, DOI 10.1002/path.1760; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Yoshinaga K, 1998, JPN J CANCER RES, V89, P985, DOI 10.1111/j.1349-7006.1998.tb00485.x; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	89	88	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7394	7400		10.1038/sj.onc.1209089	http://dx.doi.org/10.1038/sj.onc.1209089			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288286				2022-12-28	WOS:000233201900002
J	Vogler, M; Giagkousiklidis, S; Genze, F; Gschwend, JE; Debatin, KM; Fulda, S				Vogler, M; Giagkousiklidis, S; Genze, F; Gschwend, JE; Debatin, KM; Fulda, S			Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity	ONCOGENE			English	Article						apoptosis; Smac; cancer; IAP	MITOCHONDRIA-DERIVED ACTIVATOR; OVARIAN-CARCINOMA CELLS; MEDIATED APOPTOSIS; IN-VIVO; LINKED INHIBITOR; PROSTATE-CANCER; IAP PROTEINS; SMAC/DIABLO; XIAP; CASPASES	While second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis, its effect on cell viability in the absence of apoptotic stimuli has remained unclear. Here, we report that Smac inhibits clonogenic tumor growth by blocking random migration and proliferation and by enhancing apoptosis in a cell density and cell type dependent manner in SH-EP neuroblastoma cells. Inhibition of clonogenic survival by overexpression of full-length or processed Smac strictly depended on low cell density, and was reversible by replatement at high density. We discovered that Smac inhibits cell motility and random migration at low cell density. In addition, Smac enhanced apoptosis and inhibited protein, but not mRNA expression of XIAP, survivin and other short-lived proteins (FLIP, p21), indicating that Smac may globally inhibit protein expression. Also, Smac inhibited proliferation and increased polynucleation with no evidence for polyploidy, cell cycle arrest or senescence indicating that Smac impaired cell division. Interestingly, inhibition of clonogenic capacity by Smac occurred independent of its apoptosis promoting activity. By demonstrating that Smac restrains clonogenic tumor growth, our findings may have important implications for control of tumor growth and/or its metastatic spread. Thus, Smac agonists may be useful in cancer therapy, for example, for tumor control in minimal residual disease.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Hosp, Dept Urol, D-89075 Ulm, Germany	Ulm University; Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Vogler, Meike/0000-0003-2650-586X; Fulda, Simone/0000-0002-0459-6417				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Creagh EM, 2004, J BIOL CHEM, V279, P26906, DOI 10.1074/jbc.M313859200; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Jia L, 2003, ONCOGENE, V22, P1589, DOI 10.1038/sj.onc.1206322; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; McNeish IA, 2005, EXP CELL RES, V302, P69, DOI 10.1016/j.yexcr.2004.08.029; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; Mizutani Y, 2005, J CLIN ONCOL, V23, P448, DOI 10.1200/JCO.2005.02.191; Ng CP, 2002, MOL CANCER THER, V1, P1051; Pei ZF, 2004, HEPATOLOGY, V39, P1371, DOI 10.1002/hep.20203; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yan Y, 2004, BRIT J CANCER, V91, P1349, DOI 10.1038/sj.bjc.6602127; Yang LL, 2003, CANCER RES, V63, P831; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	37	39	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7190	7202		10.1038/sj.onc.1208876	http://dx.doi.org/10.1038/sj.onc.1208876			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16091752				2022-12-28	WOS:000232990100008
J	Sokolov, MV; Smilenov, LB; Hall, EJ; Panyutin, IG; Bonner, WM; Sedelnikova, OA				Sokolov, MV; Smilenov, LB; Hall, EJ; Panyutin, IG; Bonner, WM; Sedelnikova, OA			Ionizing radiation induces DNA double-strand breaks in bystander primary human fibroblasts	ONCOGENE			English	Article						bystander effect; DNA double-strand break; gamma-H2AX	MEDIATED INTERCELLULAR COMMUNICATION; TARGETED CYTOPLASMIC IRRADIATION; HISTONE H2AX PHOSPHORYLATION; C3H 10T(1)/(2) CELLS; ALPHA-PARTICLES; GENOMIC INSTABILITY; MAMMALIAN-CELLS; NONIRRADIATED CELLS; DAMAGE; INDUCTION	That irradiated cells affect their unirradiated 'bystander' neighbors is evidenced by reports of increased clonogenic mortality, genomic instability, and expression of DNA-repair genes in the bystander cell populations. The mechanisms underlying the bystander effect are obscure, but genomic instability suggests DNA double-strand breaks (DSBs) may be involved. Formation of DSBs induces the phosphorylation of the tumor suppressor protein, histone H2AX and this phosphorylated form, named gamma-H2AX, forms foci at DSB sites. Here we report that irradiation of target cells induces gamma-H2AX focus formation in bystander cell populations. The effect is manifested by increases in the fraction of cells in a population that contains multiple gamma-H2AX foci. After 18 h coculture with cells irradiated with 20 alpha-particles, the fraction of bystander cells with multiple foci increased 3.7-fold. Similar changes occurred in bystander populations mixed and grown with cells irradiated with gamma-rays, and in cultures containing media conditioned on gamma-irradiated cells. DNA DSB repair proteins accumulated at gamma-H2AX foci, indicating that they are sites of DNA DSB repair. Lindane, which blocks gap-junctions, prevented the bystander effect in mixing but not in media transfer protocols, while c-PTIO and aminoguanidine, which lower nitric oxide levels, prevented the bystander effect in both protocols. Thus, multiple mechanisms may be involved in transmitting bystander effects. These studies show that H2AX phosphorylation is an early step in the bystander effect and that the DNA DSBs underlying gamma-H2AX focus formation may be responsible for its downstream manifestations.	NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD 20892 USA; Inst Cell Biol & Genet Engn, Dept Radiat Biol & Biophys, UA-03143 Kiev, Ukraine; Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Academy of Sciences Ukraine; Institute of Cell Biology & Genetic Engineering of the National Academy of Sciences of Ukraine; Columbia University	Bonner, WM (corresponding author), NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH, Bldg 37 Room 5050,9000 Rockville Pike, Bethesda, MD 20892 USA.	bonnerw@mail.nih.gov; sedelnio@mail.nih.gov		Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002033] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41-EB002033] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Azzam EI, 2004, CURR CANCER DRUG TAR, V4, P53, DOI 10.2174/1568009043481641; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bonner WM, 2004, MUTAT RES-FUND MOL M, V568, P33, DOI 10.1016/j.mrfmmm.2004.06.044; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900; Highfield D P, 1975, Methods Cell Biol, V9, P85, DOI 10.1016/S0091-679X(08)60070-9; Hill MA, 2005, RADIAT RES, V163, P36, DOI 10.1667/RR3282; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; MacPhail SH, 2003, RADIAT RES, V159, P759, DOI 10.1667/RR3003; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Marples B, 2003, RADIAT RES, V160, P38, DOI 10.1667/RR3013; Mitchell SA, 2004, INT J RADIAT BIOL, V80, P465, DOI 10.1080/09553000410001725116; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT RES, V157, P526, DOI 10.1667/0033-7587(2002)157[0526:RBRILD]2.0.CO;2; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; NAGASAWA H, 1992, CANCER RES, V52, P6394; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Ponnaiya B, 2004, RADIAT RES, V162, P426, DOI 10.1667/RR3236; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2004, INT J RADIAT BIOL, V80, P927, DOI 10.1080/09553000400017648; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao C, 2003, CANCER RES, V63, P8437; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Suzuki M, 2004, RADIAT RES, V162, P264, DOI 10.1667/RR3226; Ward JF, 2000, COLD SPRING HARB SYM, V65, P377, DOI 10.1101/sqb.2000.65.377; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	46	184	191	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7257	7265		10.1038/sj.onc.1208886	http://dx.doi.org/10.1038/sj.onc.1208886			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16170376				2022-12-28	WOS:000233142100001
J	Siegfried, G; Basak, A; Prichett-Pejic, W; Scamuffa, N; Ma, LM; Benjannet, S; Veinot, JP; Calvo, F; Seidah, N; Khatib, AM				Siegfried, G; Basak, A; Prichett-Pejic, W; Scamuffa, N; Ma, LM; Benjannet, S; Veinot, JP; Calvo, F; Seidah, N; Khatib, AM			Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases	ONCOGENE			English	Article						PDGF-B; proprotein convertases; prosegments; secretion; processing	GROWTH-FACTOR-A; PROTEASE-ACTIVATED LIGAND; CONNECTIVE-TISSUE; HUMAN-PLATELETS; ALPHA-RECEPTOR; BETA-RECEPTOR; FURIN; CELL; CHAIN; EXPRESSION	Platelet-derived growth factor-B (PDGF-B) is important for normal tissue growth and maintenance and its overexpression has been linked to several diseases, including cancer, fibrotic disease and atherosclerosis. Here, we show that synthesized as a precursor, proPDGF-B is converted to a mature form by proteolytic cleavage at two sites and its N-terminal cleavage is a prerequisite for processing at its C-terminus. The first cleavage occurs at residues RGRR(81)down arrow, and the second cleavage close to residues ARPVT(190), just before the C-terminal amino-acid sequence crucial for PDGF-B retention to cell surface. Cotransfection of a Furin-deficient cell line LoVo-C5 with proPDGF-B and different PC members revealed that Furin, PACE4, PC5, and PC7 are candidate proPDGF-B convertases. This finding is consistent with the in vitro digestions of a synthetic peptide mimicking the cleavage site of proPDGF-B. The processing of proPDGF-B is blocked by site-directed mutagenesis of the RGRR(81)down arrow sequence and by various PC inhibitors. Mutation of the PDGF-A and/or PDGF-B convertase sites, revealed that processing of both A and B chains is required for the formation of mature PDGF-B dimers and that the processing of the B chain controls the level of secreted and matrix-bound PDGF-BB forms. Our findings emphasize the importance of the convertase-directed processing of proPDGF-B at the RGRR(81)down arrow sequence for PDGF-B maturation and secretion.	INSERM, Inst Genet Mol, U716, Lab Pharmacol Expt & Clin, F-75010 Paris, France; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Ottawa Hlth Res Inst, Dis Ageing Unit, Reg Prot Chem Ctr, Ottawa, ON K1Y 4E9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Khatib, AM (corresponding author), INSERM, Inst Genet Mol, U716, Lab Pharmacol Expt & Clin, 27 Rue Juliette Dodu, F-75010 Paris, France.	majid.khatib@stlouis.inserm.fr	KHATIB, Abdel-Majid/A-9948-2015; Siegfried, Géraldine/N-6017-2018; Seidah, Nabil/I-3596-2013	KHATIB, Abdel-Majid/0000-0001-6957-0384; Seidah, Nabil/0000-0001-6503-9342; calvo, fabien/0000-0002-0298-7633; siegfried, geraldine/0000-0002-6346-5206				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANDERSSON M, 1994, J BIOL CHEM, V269, P926; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; Eming SA, 1999, AM J PATHOL, V154, P281, DOI 10.1016/S0002-9440(10)65274-1; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rolny C, 2002, J BIOL CHEM, V277, P19315, DOI 10.1074/jbc.M111805200; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Sundberg C, 1997, AM J PATHOL, V151, P479; ZHENG M, 1994, J NEUROSCI, V14, P4656; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	42	59	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6925	6935		10.1038/sj.onc.1208838	http://dx.doi.org/10.1038/sj.onc.1208838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007151				2022-12-28	WOS:000232701700007
J	Ropke, A; Buhtz, P; Bohm, M; Seger, J; Wieland, I; Allhoff, EP; Wieacker, PF				Ropke, A; Buhtz, P; Bohm, M; Seger, J; Wieland, I; Allhoff, EP; Wieacker, PF			Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer	ONCOGENE			English	Article						DICE1 (DDX26); promoter; hypermethylation; downregulation; prostate cancer	TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINE; LASER MICRODISSECTION; CHROMOSOME 13Q14.3; DNA METHYLATION; HIGH-RESOLUTION; BREAST-CANCER; ALLELIC LOSS; LUNG; INACTIVATION	A critical region of loss of heterozygosity on human chromosome 13q14 harbors the tumor suppressor gene DICE1 (DDX26). To elucidate the reduced DICE1 expression in tumor cells, the putative promoter sequence upstream of the DICE1 gene was analysed. This sequence shows a high GC content and is rich in CpG sites and binding sites of transcriptional factors. Promoter activity was identified within three overlapping fragments of the 800 bp sequence upstream of the DICE1 gene. A 13 bp deletion polymorphism detected in the DICE1 promoter region showed a decreased activity compared with the undeleted variant. However, this 13 bp deletion was seen in male control samples and patients with prostate cancer or benign prostatic hyperplasia at similar rates. A reduced DICE1 expression was observed in prostate cancer cell lines DU145 and LNCaP. This downregulation is associated with hypermethylation of the DICE1 promoter. Treatment of both prostate cancer cell lines with 5-azacytidine leads to upregulation of DICE1 expression. Hypermethylation of CpG sites of the DICE1 promoter was observed in four of eight analysed prostate cancers. This study suggests that transcriptional repression of DICE1 is caused by hypermethylation of the DICE1 promoter region in prostate cancer cells.	Univ Magdeburg, Inst Human Genet, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Pathol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Urol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Wieacker, PF (corresponding author), Univ Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.	peter.wieacker@medizin.uni-magdeburg.de		Wieland, Ilse/0000-0002-8017-3029				Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bohm M, 1997, AM J PATHOL, V151, P63; Bohm M, 1999, ONKOLOGIE, V22, P296, DOI 10.1159/000026978; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIBAS Z, 1984, CANCER GENET CYTOGEN, V11, P399, DOI 10.1016/0165-4608(84)90020-7; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Klein G, 2002, SEMIN CANCER BIOL, V12, P327, DOI 10.1016/S1044-579X(02)00052-4; Kuroki T, 2003, CANCER RES, V63, P3724; Li WJ, 2003, ONCOGENE, V22, P314, DOI 10.1038/sj.onc.1206098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ogawara K, 1998, INT J CANCER, V79, P312, DOI 10.1002/(SICI)1097-0215(19980821)79:4<312::AID-IJC2>3.0.CO;2-Y; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SOBIN LH, 1997, CLASSIFICATION MALIG, P170; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Tamura K, 1997, INT J CANCER, V74, P45, DOI 10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0; Ueda T, 1999, GENE CHROMOSOME CANC, V24, P183, DOI 10.1002/(SICI)1098-2264(199903)24:3<183::AID-GCC2>3.3.CO;2-A; Watanabe T, 2001, J NEUROPATH EXP NEUR, V60, P1181, DOI 10.1093/jnen/60.12.1181; Wieland I, 2004, ONCOL REP, V12, P207; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wieland I, 2001, ONCOL RES, V12, P491, DOI 10.3727/096504001108747503; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	35	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6667	6675		10.1038/sj.onc.1208824	http://dx.doi.org/10.1038/sj.onc.1208824			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007164				2022-12-28	WOS:000232367800008
J	Sun, SC; Yamaoka, S				Sun, SC; Yamaoka, S			Activation of NF-kappa B by HTLV-I and implications for cell transformation	ONCOGENE			English	Review						adult T-cell leukemia; HTLV-I; tax; NF-kappa B	VIRUS TYPE-I; RECEPTOR GENE-EXPRESSION; CYTOTOXIC T-LYMPHOCYTES; TYPE-1 TAX INDUCTION; ALPHA IKK-ALPHA; WILD-TYPE P53; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATOR; C-REL; CONSTITUTIVE ACTIVATION	T-cell transformation by the human T-cell leukemia virus type I ( HTLV-I) involves deregulation of cellular transcription factors, including members of the NF-kappa B family. In normal T cells, NF-kappa B activation occurs transiently in response to immune stimuli, which is required for antigen-stimulated T-cell proliferation and survival. However, HTLV-I induces persistent activation of NF-kappa B, causing deregulated expression of a large array of cellular genes, which in turn contributes to the induction of T-cell transformation. The HTLV-I transforming protein Tax functions as an intracellular stimulator of I kappa B kinase (IKK), a cellular kinase mediating NF-kappa B activation by diverse stimuli. Tax physically interacts with IKK and renders this inducible kinase constitutively active. By assembling different Tax/IKK complexes, Tax targets the persistent activation of both canonical and noncanonical NF-kappa B signaling pathways. Whereas Tax plays a primary role in HTLV-I-mediated NF-kappa B activation, recent studies reveal that the IKK/NF-kappa B signaling pathway is also activated in freshly isolated adult T-cell leukemia (ATL) cells that often lack detectable Tax expression. The mechanism underlying this Tax-independent pathway of NF-kappa B activation remains poorly understood. Clarifying the precise nature and consequences of the constitutive NF-kappa B activation in ATL cells is important for developing rational therapeutic strategies for this T-cell malignancy.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Tokyo Med & Dent Univ, Dept Mol Virol, Grad Sch Med, Bunkyo Ku, Tokyo 1138510, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Tokyo Medical & Dental University (TMDU)	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu; shojmmb@tmd.ac.jp			NCI NIH HHS [CA094922, CA68471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922, R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Al-Shamkhani A, 2004, CURR OPIN PHARMACOL, V4, P355, DOI 10.1016/j.coph.2004.02.007; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arima N, 1999, EXP HEMATOL, V27, P1168, DOI 10.1016/S0301-472X(99)00053-3; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azran I, 2004, RETROVIROLOGY, V1, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BINDHU M, 2005, FRONT BIOSCI, V10, P17; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Burmeister T, 2001, REV MED VIROL, V11, P369, DOI 10.1002/rmv.331; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CESARMAN E, 1992, BLOOD, V80, P3205; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; De la Fuente C, 2000, AIDS RES HUM RETROV, V16, P1695, DOI 10.1089/08892220050193164; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 2005, VIROLOGY, V333, P145, DOI 10.1016/j.virol.2004.12.008; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HARNETT MM, 2004, SCI STKE, pPE25; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; IMADA K, 1995, BLOOD, V86, P2350, DOI 10.1182/blood.V86.6.2350.bloodjournal8662350; Imura A, 1997, BLOOD, V89, P2951, DOI 10.1182/blood.V89.8.2951; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Inoue M, 1998, JPN J CANCER RES, V89, P53, DOI 10.1111/j.1349-7006.1998.tb00479.x; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Jang IK, 2003, CURR OPIN IMMUNOL, V15, P315, DOI 10.1016/S0952-7915(03)00048-7; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; KANNAGI M, 1993, INT J CANCER, V54, P582, DOI 10.1002/ijc.2910540411; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kehn K, 2004, FRONT BIOSCI-LANDMRK, V9, P2347, DOI 10.2741/1401; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Koga H, 2004, CANCER SCI, V95, P411, DOI 10.1111/j.1349-7006.2004.tb03224.x; KOGA Y, 1989, J IMMUNOL, V142, P4493; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANOIX J, 1994, ONCOGENE, V9, P841; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Miura H, 2005, EXP CELL RES, V308, P29, DOI 10.1016/j.yexcr.2005.04.005; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Mori N, 1999, BLOOD, V93, P2360; Mori N, 2000, BLOOD, V95, P3915; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; Nonaka M, 2005, ONCOGENE, V24, P3976, DOI 10.1038/sj.onc.1208564; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Pankow R, 2000, J IMMUNOL, V165, P263, DOI 10.4049/jimmunol.165.1.263; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; Pise-Masison CA, 2005, FRONT BIOSCI-LANDMRK, V10, P919, DOI 10.2741/1586; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2002, CANCER RES, V62, P3562; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REID RL, 1993, ONCOGENE, V8, P3029; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruland J, 2003, IMMUNOL REV, V193, P93, DOI 10.1034/j.1600-065X.2003.00049.x; SAKASHITA A, 1992, BLOOD, V79, P477; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; Takemoto S, 2000, BLOOD, V95, P3939; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THAKUR S, 1994, ONCOGENE, V9, P2335; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Younis I, 2005, FRONT BIOSCI-LANDMRK, V10, P431, DOI 10.2741/1539; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	189	182	188	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5952	5964		10.1038/sj.onc.1208969	http://dx.doi.org/10.1038/sj.onc.1208969			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155602				2022-12-28	WOS:000231623400005
J	Javelaud, D; Mauviel, A				Javelaud, D; Mauviel, A			Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis	ONCOGENE			English	Review						TGF-beta; Smad; MAP kinases; signal transduction; gene regulation; metastasis	GROWTH-FACTOR-BETA; P38 MAP KINASE; PRO-INFLAMMATORY CYTOKINES; BREAST EPITHELIAL-CELLS; E3 UBIQUITIN LIGASE; C-JUN; GENE-EXPRESSION; CANCER-CELLS; I RECEPTOR; TRANSCRIPTIONAL ACTIVATION	Transforming growth factor-beta (TGF-beta) superfamily members signal via membrane-bound heteromeric serine threonine kinase receptor complexes. Upon ligand-binding, receptor activation leads to phosphorylation of cytoplasmic protein substrates of the Smad family. Following phosphorylation and oligomerization, the latter move into the nucleus to act as transcription factors to regulate target gene expression. TGF-beta responses are not solely the result of the activation Smad cascade, but are highly cell-type specific and dependent upon interactions of Smad signaling with a variety of other intracellular signaling mechanisms, initiated or not by TGF-beta itself, that may either potentiate, synergize, or antagonize, the rather linear TGF-beta/Smad pathway. These include, (a), regulation of Smad activity by mitogen-activated protein kinases (MAPKs), (b), nuclear interaction of activated Smads with transcriptional cofactors, whether coactivators or corepressors, that may be themselves be regulated by diverse signaling mechanisms, and (c), negative feedback loops exerted by inhibitory Smads, transcriptional targets of the Smad cascade. This review focuses on how MAPKs modulate the outcome of Smad activation by TGF-beta, and how cross-signaling mechanisms between the Smad and MAPK pathways may take place and affect cell fate in the context of carcinogenesis.	Hop St Louis, INSERM, U697, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	Javelaud, Delphine/B-1129-2019; MAUVIEL, Alain/F-6251-2013	Javelaud, Delphine/0000-0002-7674-7739; Mauviel, Alain/0000-0002-0438-2793				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Engel ME, 1998, J CELL BIOCHEM, P111; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hill CS, 1999, INT J BIOCHEM CELL B, V31, P1249, DOI 10.1016/S1357-2725(99)00093-X; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3; Johansson N, 2000, J CELL SCI, V113, P227; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim ES, 2004, INT J ONCOL, V25, P1375; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Lutz M, 2002, CELL SIGNAL, V14, P977, DOI 10.1016/S0898-6568(02)00058-X; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; PESSAH M, 2002, J BIOL CHEM, V28, P28; Quan TH, 2005, J BIOL CHEM, V280, P8079, DOI 10.1074/jbc.M409647200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; REFFEY SB, 2001, J BIOL CHEM, V16, P16; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; Sanchez-Capelo A, 2005, CYTOKINE GROWTH F R, V16, P15, DOI 10.1016/j.cytogfr.2004.11.002; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Uchida K, 2001, BIOCHEM BIOPH RES CO, V289, P376, DOI 10.1006/bbrc.2001.5984; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; WHITMARSH AJ, 1999, SCI STKE, pPE1, DOI DOI 10.1126/STKE.1999.1.PE1; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yonekura A, 1999, ENDOCR J, V46, P545, DOI 10.1507/endocrj.46.545; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yoshida K, 2005, AM J PATHOL, V166, P1029, DOI 10.1016/S0002-9440(10)62324-3; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Yue JB, 2000, J BIOL CHEM, V275, P35656; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	114	340	366	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5742	5750		10.1038/sj.onc.1208928	http://dx.doi.org/10.1038/sj.onc.1208928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123807	Green Submitted			2022-12-28	WOS:000231452800009
J	Ballester, B; Ramuz, O; Gisselbrecht, C; Doucet, G; Loi, L; Loriod, B; Bertucci, F; Bouabdallah, R; Devilard, E; Carbuccia, N; Mozziconacci, MJ; Birnbaum, D; Brousset, P; Berger, F; Salles, G; Briere, J; Houlgatte, R; Gaulard, P; Xerri, L				Ballester, B; Ramuz, O; Gisselbrecht, C; Doucet, G; Loi, L; Loriod, B; Bertucci, F; Bouabdallah, R; Devilard, E; Carbuccia, N; Mozziconacci, MJ; Birnbaum, D; Brousset, P; Berger, F; Salles, G; Briere, J; Houlgatte, R; Gaulard, P; Xerri, L			Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas	ONCOGENE			English	Article						T-cell lymphoma; gene expression profiling; microarray	DNA MICROARRAYS; KAPPA-B; CLASSIFICATION; PREDICTION; SURVIVAL; PROTEIN; DISTINCT; LINES; OVEREXPRESSION; CHEMOTHERAPY	The classification of peripheral T-cell lymphomas (PTCL) is still a matter of debate. To establish a molecular classification of PTCL, we analysed 59 primary nodal T-cell lymphomas using cDNA microarrays, including 56 PTCL and three T-lymphoblastic lymphoma (T-LBL). The expression profiles could discriminate angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and T-LBL. In contrast, cases belonging to the broad category of 'PTCL, unspecified' (PTCL-U) did not share a single molecular pro. le. Using a multiclass predictor, we could separate PTCL-U into three molecular subgroups called U1, U2 and U3. The U1 gene expression signature included genes known to be associated with poor outcome in other tumors, such as CCND2. The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2. The U3 subgroup was mainly defined by overexpression of genes involved in the IFN/JAK/STAT pathway. It comprised a majority of histiocyte-rich PTCL samples. Gene Ontology annotations revealed different functional pro. le for each subgroup. These results suggest the existence of distinct subtypes of PTCL-U with specific molecular profiles, and thus provide a basis to improve their classification and to develop new therapeutic targets.	Inst J Paoli I Calmettes, Dept Biopathol, F-13273 Marseille 9, France; INSERM, TAGC, ERM206, Marseille, France; Univ Mediterranee, Marseille, France; CHU St Louis, Dept Hematopathol, Paris, France; Hop St Louis, Inst Hematol, Grp Etud Lymphomes Adulte, F-75010 Paris, France; Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; CHU Purpan, Dept Pathol, F-31052 Toulouse, France; CHU Lyon, Dept Pathol, Lyon, France; CHU Lyon, Dept Hematol, Lyon, France; Hop Henri Mondor, Dept Pathol, INSERM U 617, AP HP, F-94010 Creteil, France	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); CHU de Toulouse; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Xerri, L (corresponding author), Inst J Paoli I Calmettes, Dept Biopathol, F-13273 Marseille 9, France.	xerril@marseille.fnclcc.fr	Salles, Gilles/Z-2336-2019; Doucet, Gaelle/H-9367-2019; loriod, beatrice/L-2948-2016; Ballester, Benoit/N-6127-2016	Salles, Gilles/0000-0002-9541-8666; Doucet, Gaelle/0000-0003-4120-0474; gaulard, philippe/0000-0002-4243-905X; loriod, beatrice/0000-0001-5801-2264; Ballester, Benoit/0000-0002-0834-7135				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan WC, 1997, BLOOD, V89, P3909; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Dogan A, 2003, BRIT J HAEMATOL, V121, P681, DOI 10.1046/j.1365-2141.2003.04335.x; Fillmore GC, 2002, FEBS LETT, V522, P183, DOI 10.1016/S0014-5793(02)02914-9; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Gisselbrecht C, 1998, BLOOD, V92, P76; HARRIS NL, 1994, BLOOD, V84, P1361; Hiroi M, 2003, BIOCHEM J, V376, P393, DOI 10.1042/BJ20030842; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hisaoka M, 2004, CANCER GENET CYTOGEN, V152, P101, DOI 10.1016/j.cancergencyto.2003.11.011; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kagami Y, 1999, AM J SURG PATHOL, V23, P1184, DOI 10.1097/00000478-199910000-00003; Kari L, 2003, J EXP MED, V197, P1477, DOI 10.1084/jem.20021726; Li SY, 2001, AM J PATHOL, V158, P1231, DOI 10.1016/S0002-9440(10)64073-4; Lopez F, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-38; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Martinez-Delgado B, 2004, CLIN CANCER RES, V10, P4971, DOI 10.1158/1078-0432.CCR-04-0269; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Petit B, 2001, HUM PATHOL, V32, P196, DOI 10.1053/hupa.2001.21569; Pinet F, 2004, FASEB J, V18, P585, DOI 10.1096/fj.03-0939fje; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Rassidakis GZ, 2003, J PATHOL, V200, P240, DOI 10.1002/path.1346; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160; Tracey L, 2003, BLOOD, V102, P1042, DOI 10.1182/blood-2002-11-3574; Tsuchiya T, 2004, BLOOD, V103, P236, DOI 10.1182/blood-2002-05-1352; Villalva C, 2002, BRIT J HAEMATOL, V118, P791, DOI 10.1046/j.1365-2141.2002.03671.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	42	95	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1560	1570		10.1038/sj.onc.1209178	http://dx.doi.org/10.1038/sj.onc.1209178			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16288225				2022-12-28	WOS:000235890400013
J	Rodriguez-Viciana, P; Collins, CH; Moule, MG; Fried, M				Rodriguez-Viciana, P; Collins, CH; Moule, MG; Fried, M			Chromosomal instability at a mutational hotspot in polyoma middle T-antigen affects its ability to activate the ARF-p53 tumor suppressor pathway	ONCOGENE			English	Article						ARF; p53; polyoma virus middle T-antigen; REF52 cells; chromosomal instability; hot spot mutations	FRAMESHIFT MUTATION; REF52 CELLS; P53; TRANSFORMATION; ONCOGENES; GROWTH; MECHANISMS; PROTEINS; MUTANTS; ARREST	We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activate the ARF-p53 pathway based on their inability to block REF52 cell division. The REF52 cells containing these mutants have a. at untransformed morphological phenotype and do not express the ARF protein. The PyMT mutations in the different cell isolates so far analysed occur at a mutational hotspot in the PyMT sequence between nucleotides 1241 and 1249, which contains nine consecutive cytosines. In one set of mutants a single cytosine was deleted, while in another mutant set an additional cytosine was inserted. Both these mutations result in frameshifts, generating altered PyMT proteins containing amino-acid sequences derived from each of the two other alternative reading frames of the polyoma virus early region. Both types of mutations result in the loss of the C-terminal PyMT region containing the membrane-binding hydrophobic region and result is mislocalization of the PyMT mutant proteins. Revertant wild-type PyMT ( containing nine cytosines) was easily detected in transformants generated after infection of REF52 cells expressing high amounts of dominant negative p53 with retroviruses containing either mutation. We demonstrate that wild-type PyMT revertants are derived from mutations in the hotspot sequence of the integrated mutant PyMT sequences.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Fried, M (corresponding author), Univ Calif San Francisco, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94115 USA.	fried@cc.ucsf.edu		Moule, Madeleine/0000-0002-9612-4563	NCI NIH HHS [CA92454, CA101967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101967, R01CA092454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; KOHL NE, 1987, ONCOGENE, V2, P41; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; Lomax M, 2001, ONCOGENE, V20, P4951, DOI 10.1038/sj.onc.1204717; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCCLURE DB, 1984, EFFECT SY40 TRANSFOR; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; Prives C, 1999, J PATHOL, V187, P112; QUELLE DE, 1995, CELL, V83, P993; RAGOZZINO MM, 1991, ENVIRON HEALTH PERSP, V93, P97, DOI 10.1289/ehp.919397; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Steele RJC, 1998, BRIT J SURG, V85, P1460; Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6; STREISINGER G, 1985, GENETICS, V109, P633; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; WILSON JB, 1986, CELL, V44, P477, DOI 10.1016/0092-8674(86)90469-1	30	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1454	1462		10.1038/sj.onc.1209197	http://dx.doi.org/10.1038/sj.onc.1209197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261156				2022-12-28	WOS:000235890400003
J	Li, J; Zou, C; Bai, Y; Wazer, DE; Band, V; Gao, Q				Li, J; Zou, C; Bai, Y; Wazer, DE; Band, V; Gao, Q			DSS1 is required for the stability of BRCA2	ONCOGENE			English	Article						DSS1; BRCA2; DNA damage repair; tumor; suppressor gene; protein degradation; breast cancer	BREAST-CANCER SUSCEPTIBILITY; MAMMARY EPITHELIAL-CELLS; DNA-REPAIR; GENE BRCA2; RADIATION HYPERSENSITIVITY; SACCHAROMYCES-CEREVISIAE; CANDIDATE GENE; PROTEIN; RAD51; RECOMBINATION	DSS1 is an evolutionarily conserved acidic protein that binds to BRCA2. However, study of the function of DSS1 in mammalian cells has been hampered because endogenous DSS1 has not been detectable by Western blotting. Here, we developed a modified Western blotting protocol that detects endogenous DSS1 protein, and used it to study the function of DSS1 and its interaction with BRCA2 in mammalian cells. We found that essentially all BRCA2 in human cell lines is associated with DSS1. Importantly, we found that RNAi knockdown of DSS1 in human cell lines led to dramatic loss of BRCA2 protein, mainly due to its increased degradation. Furthermore, the stability of BRCA2 mutant devoid of the DSS1-binding domain is unaffected by the depletion of DSS1. Most notably, like BRCA2 depletion, DSS1 depletion also led to hypersensitivity to DNA damage. These results demonstrated that the stability of BRCA2 protein in mammalian cells depends on the presence of DSS1. Deletion or mutation of DSS1 or suppression of its expression by other mechanisms are therefore potential causative mechanisms for human breast and ovarian cancer. Such mechanisms may be relevant to sporadic as well as familiar breast cancer where BRCA1 and BRCA2 mutations are not present.	Northwestern Univ, Feinberg Sch Med, Div Canc Biol, Dept Med,Evanston Northwestern Healthcare Res Ins, Evanston, IL 60201 USA; Tufts Univ, Sch Med, Dept Radiat Oncol, New England Med Ctr, Boston, MA 02111 USA	Northwestern University; Feinberg School of Medicine; Tufts Medical Center; Tufts University	Gao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Canc Biol, Dept Med,Evanston Northwestern Healthcare Res Ins, 1001 Univ Pl, Evanston, IL 60201 USA.	Q-GAO@Northwestern.edu			NCI NIH HHS [R01 CA095221-04, R01 CA096986-03, R01 CA095221-03, R01 CA095221-02, R01 CA096986-04, R01 CA095221-01A1, R01 CA096986-01A1, R01 CA096986-02, R01 CA096986-05, R01 CA095221-05] Funding Source: Medline; NIAID NIH HHS [1 R01 CA095221-01AI, 1 R01 CA96986-01AI] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095221, R01CA096986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Isono E, 2004, J BIOL CHEM, V279, P27168, DOI 10.1074/jbc.M314231200; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tian XX, 2005, CANCER RES, V65, P4747, DOI 10.1158/0008-5472.CAN-05-0018; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang SC, 2002, CANCER RES, V62, P1311; Wang SC, 2001, CANCER RES, V61, P2838; Wei SJ, 2003, J BIOL CHEM, V278, P1758, DOI 10.1074/jbc.M206328200; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	40	95	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1186	1194		10.1038/sj.onc.1209153	http://dx.doi.org/10.1038/sj.onc.1209153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205630	Bronze			2022-12-28	WOS:000235537500006
J	Sterneck, E; Zhu, S; Ramirez, A; Jorcano, JL; Smart, RC				Sterneck, E; Zhu, S; Ramirez, A; Jorcano, JL; Smart, RC			Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis	ONCOGENE			English	Article						C/EBP; apoptosis; carcinogenesis	CCAAT/ENHANCER-BINDING-PROTEINS; GENE-EXPRESSION; CARCINOMA-CELLS; ONCOGENIC RAS; DIFFERENTIATION; INACTIVATION; APOPTOSIS; ARREST	The CCAAT/enhancer binding protein beta(C/EBP beta) is implicated in the regulation of many different molecular and physiological processes. Mice with a germline deletion of C/EBP beta (C/EBP beta(-/-)) display phenotypes in a multitude of cell types and organ systems, including skin where C/EBP beta(-/-) mice exhibit increased apoptosis in epidermal keratinocytes in response to carcinogen treatment and are completely resistant to carcinogen-induced skin tumorigenesis. To determine the contribution of systemic versus cell autonomous functions of C/EBP beta to specific phenotypes, mice with a conditional 'floxed' C/EBP beta null allele were generated. Epidermal-specific deletion of C/EBP beta was achieved by Cre recombinase expression from a keratin 5 (K5) promoter. Similar to C/EBP beta(-/-) mice, K5-Cre; C/EBP beta(fl)/(fl) mice were completely refractory to 7,12 dimethylbenz[a] anthracene (DMBA)-induced skin tumorigenesis and these mice displayed increased DMBA-induced apoptosis in epidermal keratinocytes compared to wild-type mice. In contrast, mice lacking the related gene, C/ EBP delta, were not resistant to DMBA-induced skin tumorigenesis, indicating a unique role of C/EBP beta in skin tumor development. Our findings demonstrate that C/EBP beta exerts an essential, keratinocyte-intrinsic role in cell survival in response to carcinogen treatment and the elimination of C/EBP beta in keratinocytes is sufficient to confer complete resistance of the skin to chemical carcinogenesis.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA; NCI, Mol Mech Dev Grp, Lab Prot Dynam & Signaling, Frederick, MD USA; CIEMAT, Repair & Tissue Engn Program, Madrid, Spain	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.	rcsmart@unity.ncsu.edu	Ramirez, Angel/A-4800-2018	Ramirez, Angel/0000-0001-7745-5108; Sterneck, Esta/0000-0001-7716-8766; Smart, Robert/0000-0002-6767-6756	NATIONAL CANCER INSTITUTE [Z01BC010307, R01CA046637, R29CA046637] Funding Source: NIH RePORTER; NCI NIH HHS [CA46637, R01 CA046637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUTWELL RK, 1983, CANCER RES, V43, P2465; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Klatt P, 2003, CARCINOGENESIS, V24, P817, DOI 10.1093/carcin/bgg057; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Ma WB, 2003, CANCER RES, V63, P5320; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Porter KL, 2002, TOXICOL SCI, V69, P42, DOI 10.1093/toxsci/69.1.42; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tessarollo L, 2000, METH MOL B, V158, P47; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	31	59	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1272	1276		10.1038/sj.onc.1209144	http://dx.doi.org/10.1038/sj.onc.1209144			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205634	Green Accepted			2022-12-28	WOS:000235537500014
J	Boggs, K; Reisman, D				Boggs, K; Reisman, D			Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter	ONCOGENE			English	Article						p53; transcription; gene expression; cell cycle	BINDING-PROTEIN-BETA; NUCLEAR EXPORT SIGNAL; TUMOR-SUPPRESSOR GENE; LI-FRAUMENI-SYNDROME; KAPPA-B; POTENTIAL MEDIATOR; C/EBP-BETA; EXPRESSION; DAMAGE; MDM2	p53 mRNA levels are tightly regulated during the cell cycle with its transcription being induced prior to DNA synthesis. However, the mechanism controlling this regulation is not well defined. Through characterizing an additional 1000 bp of upstream DNA sequences of the murine p53 gene, we identified new positive and negative regulatory elements. Furthermore, we found a trans-acting factor(s) that binds within a positive cis-acting element (-972/-953) in a manner indicative of regulation during the cell cycle. When Swiss3T3 cells are arrested by serum depletion p53 mRNA levels decrease and binding of this regulatory factor( s) to the promoter is reduced. Upon serum stimulation, the regulatory factor( s) binds the promoter and p53 mRNA levels increase prior to the cells entering S phase. When the factors are experimentally sequestered from the promoter or when the regulatory element is deleted from the promoter, p53 promoter activity is reduced. There is no further reduction in p53 promoter activity upon serum depletion and the kinetics of induction upon serum stimulation is delayed by approximately 5 h. These findings indicate that a factor( s) binding within the -972/-953 regulatory element on the p53 promoter is important for the proper regulation of p53 mRNA expression in response to mitogen stimulation. Our initial findings indicate that a member of the C/EBP family of transcription factors may play a role in this regulation.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Coker Life Sci Bldg,Sumter St, Columbia, SC 29208 USA.	reisman@biol.sc.edu						Arnett Brenda, 2003, Mol Cancer, V2, P21, DOI 10.1186/1476-4598-2-21; Balint E, 1996, CANCER RES, V56, P1648; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CANCER RES, V59, P1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1990, ONCOGENE, V5, P1285; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu L, 1999, MOL CELL BIOL, V19, P1202; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; MIYASHITA T, 1995, CELL, V80, P293; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Reisman D, 2001, GENE, V274, P129, DOI 10.1016/S0378-1119(01)00623-0; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sigal A, 2000, CANCER RES, V60, P6788; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; VALEV LV, 2002, J BIOL CHEM, V2111, P42438; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WU HY, 1994, J BIOL CHEM, V269, P20067; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao RB, 2000, GENE DEV, V14, P981	46	22	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					555	565		10.1038/sj.onc.1209076	http://dx.doi.org/10.1038/sj.onc.1209076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158047				2022-12-28	WOS:000234897400007
J	Qiao, W; Li, AG; Owens, P; Xu, X; Wang, XJ; Deng, CX				Qiao, W; Li, AG; Owens, P; Xu, X; Wang, XJ; Deng, CX			Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin	ONCOGENE			English	Article						squamous cell carcinoma; hair follicle cycle; Pten; AKT; cyclin D1	TUMOR-SUPPRESSOR SMAD4/DPC4; TGF-BETA RECEPTOR; TRANSGENIC MICE; CHEMICAL CARCINOGENESIS; JUVENILE POLYPOSIS; CYCLE ARREST; EXPRESSION; GENE; DIFFERENTIATION; DELETION	Smad4 is the common mediator for TGF beta signals, which play important functions in many biological processes. To study the role of Smad4 in skin development and epidermal tumorigenesis, we disrupted this gene in skin using the Cre-loxP approach. We showed that absence of Smad4 blocked hair follicle differentiation and cycling, leading to a progressive hair loss of mutant (MT) mice. MT hair follicles exhibited diminished expression of Lef1, and increased proliferative cells in the outer root sheath. Additionally, the skin of MT mice exhibited increased proliferation of basal keratinocytes and epidermal hyperplasia. Furthermore, we provide evidence that the absence of Smad4 resulted in a block of both TGFb and bone morphogenetic protein (BMP) signaling pathways, including p21, a well-known cyclin-dependent kinase inhibitor. Consequently, all MT mice developed spontaneous malignant skin tumors from 3 months to 13 months of age. The majority of tumors are malignant squamous cell carcinomas. A most notable finding is that tumorigenesis is accompanied by inactivation of phosphatase and tensin homolog deleted on chromosome 10 (Pten), activation of AKT, fast proliferation and nuclear accumulation of cyclin D1. These observations revealed the essential functions of Smad4-mediated signals in repressing skin tumor formation through the TGF beta/BMP pathway, which interacts with the Pten signaling pathway.	Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wang, XJ (corresponding author), Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA.	wangxiao@ohsu.edu	deng, chuxia/N-6713-2016	Owens, Philip/0000-0002-1452-9285	NCI NIH HHS [CA87849] Funding Source: Medline; NIAMS NIH HHS [AR47898] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056012, ZIADK056012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.3.CO;2-G; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Go C, 1999, CANCER RES, V59, P2861; Hahn SA, 1996, CANCER RES, V56, P490; He W, 2001, ONCOGENE, V20, P471, DOI 10.1038/sj.onc.1204117; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Li AG, 2003, CYTOKINE GROWTH F R, V14, P99, DOI 10.1016/S1359-6101(03)00005-4; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Redman RS, 2005, J ORAL PATHOL MED, V34, P23, DOI 10.1111/j.1600-0714.2004.00246.x; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Takaku K, 1999, CANCER RES, V59, P6113; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wang XJ, 2001, MICROSC RES TECHNIQ, V52, P420, DOI 10.1002/1097-0029(20010215)52:4<420::AID-JEMT1027>3.3.CO;2-Z; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079	44	78	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					207	217		10.1038/sj.onc.1209029	http://dx.doi.org/10.1038/sj.onc.1209029			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170355				2022-12-28	WOS:000234583600005
J	Zalcenstein, A; Weisz, L; Stambolsky, P; Bar, J; Rotter, V; Oren, M				Zalcenstein, A; Weisz, L; Stambolsky, P; Bar, J; Rotter, V; Oren, M			Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53	ONCOGENE			English	Article						p53; MSP; MST-1; apoptosis; RON	RECEPTOR TYROSINE KINASE; MACROPHAGE-STIMULATING PROTEIN; WILD-TYPE P53; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; OF-FUNCTION; TRANSCRIPTIONAL REPRESSION; HUMAN MDR1; RON; CELLS	Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the MSP ( MST-1/HGFL) gene, encoding the ligand of the receptor tyrosine kinase RON, implicated in a variety of cellular responses. Mutant p53 associates with the MSP gene promoter and represses its transcriptional activity, leading to a decrease in mRNA levels and a subsequent decrease in the levels of secreted MSP protein. Forced downregulation of MSP expression in H1299 cells, derived from a large-cell lung carcinoma, confers increased resistance against etoposide-induced cell death. These antiapoptotic consequences of MSP downregulation seemingly conflict with the well-documented ability of the RON receptor to promote cell survival and tumor progression when aberrantly hyperactive. Yet, they are consistent with the fact that reduced MSP expression was observed in many types of human cancer, including large-cell lung carcinoma. Thus, repression of MSP gene expression by mutant p53 may contribute to oncogenesis in a cell type-specific manner.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, 300 Herzl St, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R37 CA40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Camp ER, 2005, ANN SURG ONCOL, V12, P273, DOI 10.1245/ASO.2005.08.013; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Demidenko ZN, 2005, FEBS LETT, V579, P2231, DOI 10.1016/j.febslet.2005.03.012; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DIPPOLD W, 1993, Z GASTROENTEROL, V31, P24; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Gurova KV, 2003, CANCER RES, V63, P2905; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Miller AD, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-64; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sigal A, 2000, CANCER RES, V60, P6788; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Storz MN, 2003, J INVEST DERMATOL, V120, P865, DOI 10.1046/j.1523-1747.2003.12142.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang D, 2005, CARCINOGENESIS, V26, P27, DOI 10.1093/carcin/bgh284; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WANG MH, 1994, J BIOL CHEM, V269, P3436; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	65	45	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					359	369		10.1038/sj.onc.1209061	http://dx.doi.org/10.1038/sj.onc.1209061			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170349				2022-12-28	WOS:000234714100004
J	Cerone, MA; Autexier, C; Londono-Vallejo, JA; Bacchetti, S				Cerone, MA; Autexier, C; Londono-Vallejo, JA; Bacchetti, S			A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT	ONCOGENE			English	Article						telomere; ALT; telomerase	IMMORTAL HUMAN-CELLS; MUTANT TELOMERASE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; RNA COMPONENT; RECOMBINATION; MAINTENANCE; RECONSTITUTION; EXPRESSION; MECHANISM	In human somatic cells proliferation results in telomere shortening due to the end replication problem and the absence of adequate levels of telomerase activity. The progressive loss of telomeric DNA has been associated with replicative senescence. Maintenance of telomere structure and function is, therefore, an essential requisite for cells that proliferate indefinitely. Human cells that have acquired the immortal phenotype mostly rely on telomerase to compensate for telomere shortening with cell division. However, a certain percentage of immortalized cell lines and human tumors maintain their telomeres by Alternative Lengthening of Telomeres (ALT), a mechanism not fully understood but apparently based on homologous recombination. Here, we report the isolation of an immortal human cell line that is derived from an ALT cell line but maintains telomeres in the absence of key features of ALT and of telomerase. The properties of these cells suggest that the identification of ALT cells may not be reliably based on known ALT markers. This finding is of relevance for discriminating between the mortal and immortal phenotype among telomerase-negative cells in vitro and in vivo, particularly in regard to the development of pharmacological approaches for cancer treatment based on telomerase inhibition.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B4, Canada; Jewish Gen Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; Inst Curie, Telomeres & Canc Lab, F-75248 Paris, France; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McGill University; Lady Davis Institute; McGill University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; McMaster University	Bacchetti, S (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	bacchett@mcmaster.ca	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bailey SM, 2004, CYTOGENET GENOME RES, V107, P14, DOI 10.1159/000079565; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Chute I, 1997, GENOMICS, V46, P51, DOI 10.1006/geno.1997.5007; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Cornforth MN, 2001, MUTAGENESIS, V16, P85, DOI 10.1093/mutage/16.1.85; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Henson JD, 2005, CLIN CANCER RES, V11, P217; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; Lee SR, 2003, J BIOL CHEM, V278, P52531, DOI 10.1074/jbc.M311359200; Lin CY, 2005, EUKARYOT CELL, V4, P327, DOI 10.1128/EC.4.2.327-336.2005; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Topcu Z, 2005, P NATL ACAD SCI USA, V102, P3348, DOI 10.1073/pnas.0408770102; Ulaner GA, 2003, CANCER RES, V63, P1759; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Yeager TR, 1999, CANCER RES, V59, P4175; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	57	53	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7893	7901		10.1038/sj.onc.1208934	http://dx.doi.org/10.1038/sj.onc.1208934			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116482				2022-12-28	WOS:000233463000008
J	Steinman, HA; Hoover, KM; Keeler, ML; Sands, AT; Jones, SN				Steinman, HA; Hoover, KM; Keeler, ML; Sands, AT; Jones, SN			Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development	ONCOGENE			English	Article						Mdm4; Mdm2; development; tumorigenesis	EMBRYONIC LETHALITY; GROWTH-CHARACTERISTICS; MDM2-DEFICIENT MICE; MDM4-NULL MICE; CELL-GROWTH; P53; APOPTOSIS; DELETION; ABSENCE; DEATH	The Mdm2 and Mdm4 genes are amplified and overexpressed in a variety of human cancers and encode structurally related oncoproteins that bind to the p53 tumor suppressor protein and inhibit p53 activity. Mice deleted for either Mdm2 or Mdm4 die during embryogenesis, and the developmental lethality of either mouse model can be rescued by concomitant deletion of p53. However, the phenotypes of Mdm2 and Mdm4-deficient mice suggest that Mdm2 and Mdm4 play nonoverlapping roles in regulating p53 activity during development, with Mdm2 regulating p53-mediated cell death and Mdm4 regulating p53-mediated inhibition of cell growth. Here, we describe complete rescue of Mdm4-deficient mice by expression of an Mdm2 transgene, and demonstrate that Mdm2 can regulate both p53-mediated apoptosis and inhibition of cell growth in the absence of Mdm4 in primary cells. Furthermore, deletion of Mdm4 enhances the ability of Mdm2 to promote cell growth and tumor formation, indicating that Mdm4 has antioncogenic properties when Mdm2 is overexpressed.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; Lexicon Genet, The Woodlands, TX 77381 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Lexicon Pharmaceuticals	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S3-123,55 Lake Ave N, Worcester, MA 01655 USA.	Stephen.jones@umassmed.edu			NATIONAL CANCER INSTITUTE [R56CA077735, R01CA077735] Funding Source: NIH RePORTER; NCI NIH HHS [CA77735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; HARVEY M, 1993, ONCOGENE, V8, P2457; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; OLINER JD, 1992, NATURE, V358, P15; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Steinman HA, 2004, ONCOGENE, V23, P303, DOI 10.1038/sj.onc.1206925; Steinman HA, 2002, GENESIS, V32, P142, DOI 10.1002/gene.10035; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	27	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7935	7940		10.1038/sj.onc.1208930	http://dx.doi.org/10.1038/sj.onc.1208930			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027727				2022-12-28	WOS:000233463000012
J	Cheng, JQ; Lindsley, CW; Cheng, GZ; Yang, H; Nicosia, SV				Cheng, JQ; Lindsley, CW; Cheng, GZ; Yang, H; Nicosia, SV			The Akt/PKB pathway: molecular target for cancer drug discovery	ONCOGENE			English	Review						Akt; cancer; therapeutics; inhibitor	PROTEIN-KINASE-B; TRICYCLIC NUCLEOSIDE PHOSPHATE; PROSTATE INTRAEPITHELIAL NEOPLASIA; V-HA-RAS; PHASE-I; MAMMALIAN TARGET; PHOSPHOINOSITIDE 3-KINASE; STRUCTURAL BASIS; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC TRANSFORMATION	The serine/threonine kinase Akt/PKB pathway presents an exciting new target for molecular therapeutics, as it functions as a cardinal nodal point for transducing extracellular (growth factor and insulin) and intracellular (receptor tyrosine kinases, Ras and Src) oncogenic signals. In addition, alterations of the Akt pathway have been detected in a number of human malignancies. Ectopic expression of Akt, especially constitutively activated Akt, is sufficient to induce oncogenic transformation of cells and tumor formation in transgenic mice as well as chemoresistance. Akt has a wide range of downstream targets that regulate tumor-associated cell processes such as cell growth, cell cycle progression, survival, migration, epithelial-mesenchymal transition and angiogenesis. Blockage of Akt signaling results in apoptosis and growth inhibition of tumor cells with elevated Akt. The observed dependence of certain tumors on Akt signaling for survival and growth has wide implications for cancer therapy, offering the potential for preferential tumor cell killing. In the last several years, through combinatorial chemistry, high-throughput and virtual screening, and traditional medicinal chemistry, a number of inhibitors of the Akt pathway have been identified. This review focuses on ongoing translational efforts to therapeutically target the Akt pathway.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Tampa, FL 33612 USA; Merck & Co Inc, Dept Med Chem, West Point, PA 19486 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Merck & Company; Icahn School of Medicine at Mount Sinai	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12902 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	chengjq@moffitt.usf.edu						Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; ALTOMARE DA, 2002, ONCOGENE REV, V24, P7455; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Asnaghi L, 2004, ONCOGENE, V23, P5781, DOI 10.1038/sj.onc.1207698; Auguin D, 2004, J BIOL CHEM, V279, P35890, DOI 10.1074/jbc.M400364200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Breitenlechner CB, 2005, J MED CHEM, V48, P163, DOI 10.1021/jm049701n; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530; Chan S, 2004, BRIT J CANCER, V91, P1420, DOI 10.1038/sj.bjc.6602162; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen JS, 2003, DRUG RESIST UPDATE, V6, P129, DOI 10.1016/S1368-7646(03)00040-2; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CHUNG FL, 1980, J MED CHEM, V23, P1158, DOI 10.1021/jm00185a002; Clark M, 2000, IMMUNOL TODAY, V21, P397, DOI 10.1016/S0167-5699(00)01680-7; COBB WR, 1983, CANCER TREAT REP, V67, P173; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEGAFFENREID LA, 2004, CLIN CANCER RES, V10, P8059; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Edinger AL, 2003, CANCER RES, V63, P8451; Fan QW, 2003, CANCER RES, V63, P8930; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; FEUN LG, 1993, AM J CLIN ONCOL-CANC, V16, P506, DOI 10.1097/00000421-199312000-00010; FEUN LG, 1984, CANCER RES, V44, P3608; Finan PM, 2004, BIOCHEM SOC T, V32, P378, DOI 10.1042/BST0320378; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hoffman K, 1996, CANCER CHEMOTH PHARM, V37, P254; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Johnson MA, 2002, AUST J CHEM, V55, P13, DOI 10.1071/CH02047; JONES DD, 2005, MOL CANCER THER, V4, P271; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Kim D, 2005, FRONT BIOSCI-LANDMRK, V10, P975, DOI 10.2741/1592; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119; Kondapaka SB, 2003, MOL CANCER THER, V2, P1093; KOZIKOWSKI AP, 1995, J MED CHEM, V38, P1053, DOI 10.1021/jm00007a001; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 1998, CANCER RES, V58, P2973; Luo Y, 2004, BIOCHEMISTRY-US, V43, P1254, DOI 10.1021/bi034515p; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mandal M, 2005, BRIT J CANCER, V92, P1899, DOI 10.1038/sj.bjc.6602595; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Mende I, 2001, ONCOGENE, V20, P4419, DOI 10.1038/sj.onc.1204486; Meric-Bernstam F, 2004, SEMIN ONCOL, V31, P10, DOI 10.1053/j.seminoncol.2004.10.013; Migawa MT, 2005, J MED CHEM, V48, P3840, DOI 10.1021/jm0402014; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; MITTELMAN A, 1983, CANCER TREAT REP, V67, P159; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; POWIS G, 1991, CANCER CHEMOTH PHARM, V29, P95, DOI 10.1007/BF00687317; POWIS G, 1986, CANCER TREAT REP, V70, P359; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Rao RD, 2004, CURR CANCER DRUG TAR, V4, P621, DOI 10.2174/1568009043332718; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; SCHILCHER RB, 1986, CANCER RES, V46, P3147; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Semba S, 2002, CLIN CANCER RES, V8, P1957; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shin I, 2005, CANCER RES, V65, P2815, DOI 10.1158/0008-5472.CAN-04-2898; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tabellini G, 2005, J CELL PHYSIOL, V202, P623, DOI 10.1002/jcp.20153; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Van Ummersen L, 2004, CLIN CANCER RES, V10, P7450, DOI 10.1158/1078-0432.CCR-03-0406; Vink SR, 2005, INVEST NEW DRUG, V23, P279, DOI 10.1007/s10637-005-1436-0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; WOTRING LL, 1986, CANCER TREAT REP, V70, P491; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yakes FM, 2002, CANCER RES, V62, P4132; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao ZJ, 2005, BIOORG MED CHEM LETT, V15, P905, DOI 10.1016/j.bmcl.2004.12.062	130	430	458	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7482	7492		10.1038/sj.onc.1209088	http://dx.doi.org/10.1038/sj.onc.1209088			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288295				2022-12-28	WOS:000233201900011
J	Majumder, PK; Sellers, WR				Majumder, PK; Sellers, WR			Akt-regulated pathways in prostate cancer	ONCOGENE			English	Review						PTEN; AKT; prostate cancer; phosphoinostide; 3-kinase	GROWTH-FACTOR-I; TUMOR-SUPPRESSOR GENE; RECEPTOR KINASE INHIBITOR; HIGH GLEASON SCORE; STEM-CELL ANTIGEN; GERMLINE MUTATIONS; ANTITUMOR-ACTIVITY; COWDEN-DISEASE; PIK3CA GENE; INTRAEPITHELIAL NEOPLASIA	Prostate cancer remains a major cause of cancer-related mortality. Genetic clues to the molecular pathways driving the most aggressive forms of prostate cancer have been limited. Genetic inactivation of PTEN through either gene deletion or point mutation is reasonably common in metastatic prostate cancer and the resulting activation of phosphoinostide 3-kinase, AKT and mTOR provides a major therapeutic opportunity in this disease as mTOR inhibitors, HSP90 inhibitors and PI3K inhibitors begin to enter clinical development.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Cambridge, MA 02141 USA; MIT, Cambridge, MA 02141 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Sellers, WR (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	William_Sellers@dfci.harvard.edu						Abate-Shen C, 2003, CANCER RES, V63, P3886; Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Burtrum D, 2003, CANCER RES, V63, P8912; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheung KMJ, 2005, BIOORG MED CHEM LETT, V15, P3338, DOI 10.1016/j.bmcl.2005.05.046; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eaton SR, 1998, J MED CHEM, V41, P4329, DOI 10.1021/jm9802766; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; GRAY IC, 1995, CANCER RES, V55, P4800; Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426; Guldberg P, 1997, CANCER RES, V57, P3660; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hostein I, 2001, CANCER RES, V61, P4003; Hsieh CL, 2001, AM J HUM GENET, V69, P148, DOI 10.1086/321281; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Liu WG, 1997, CANCER RES, V57, P5254; Luo J, 2005, P NATL ACAD SCI USA, V102, P10238, DOI 10.1073/pnas.0504378102; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Maloney EK, 2003, CANCER RES, V63, P5073; Marsh DJ, 1997, CANCER RES, V57, P500; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; McMenamin ME, 1999, CANCER RES, V59, P4291; MCSHEEHY PM, 2005, SOC NUC MED; Meuillet EJ, 2004, ONCOL RES, V14, P513, DOI 10.3727/0965040042380487; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; Risinger JI, 1997, CANCER RES, V57, P4736; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Ruan WF, 1999, ENDOCRINOLOGY, V140, P1984, DOI 10.1210/en.140.5.1984; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; SELLERS WR, 2002, PROSTATE CANC PRINCI; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Solit DB, 2003, CANCER RES, V63, P2139; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Suzuki H, 1998, CANCER RES, V58, P204; Tabellini G, 2004, BRIT J HAEMATOL, V126, P574, DOI 10.1111/j.1365-2141.2004.05073.x; Tashiro H, 1997, CANCER RES, V57, P3935; THIMMAIAH KN, 2005, J BIOL CHEM; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Van de Sande T, 2005, J PATHOL, V206, P214, DOI 10.1002/path.1760; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SI, 1997, CANCER RES, V57, P4183; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Warshamana-Greene GS, 2005, CLIN CANCER RES, V11, P1563, DOI 10.1158/1078-0432.CCR-04-1544; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Workman P, 2004, BIOCHEM SOC T, V32, P393, DOI 10.1042/BST0320393; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Xu JF, 2001, AM J HUM GENET, V68, P901, DOI 10.1086/319513; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Zhong H, 2000, CANCER RES, V60, P1541	122	294	307	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7465	7474		10.1038/sj.onc.1209096	http://dx.doi.org/10.1038/sj.onc.1209096			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288293				2022-12-28	WOS:000233201900009
J	Veeramani, S; Igawa, T; Yuan, TC; Lin, FF; Lee, MS; Lin, JS; Johansson, SL; Lin, MF				Veeramani, S; Igawa, T; Yuan, TC; Lin, FF; Lee, MS; Lin, JS; Johansson, SL; Lin, MF			Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells	ONCOGENE			English	Article						p66(Shc); prostatic acid phosphatase; prostate cancer; cell proliferation	66-KDA SHC ISOFORM; ACID-PHOSPHATASE; CARCINOMA-CELLS; SIGNALING PATHWAY; OXIDATIVE STRESS; BREAST-CANCER; LIFE-SPAN; ANDROGEN; KINASE; ESTABLISHMENT	p66(Shc), an isoform of Shc adaptor proteins, is shown to mediate various signals, including cellular stress. However, little is known about its involvement in carcinogenesis. We previously showed that p66(Shc) protein level is upregulated by steroid hormones in human carcinoma cells and is higher in prostate cancer (PCa) specimens than adjacent noncancerous cells. In this study, we investigated the role of p66(Shc) protein in PCa cell proliferation. Among different PCa cell lines tested, p66(Shc) protein level showed positive correlation with cell proliferation, that is, rapid-growing cells expressed higher p66(Shc) protein than slow-growing cells. Exposure of slow-growing LNCaP C-33 cells to epidermal growth factor (EGF) and 5 alpha-dihydrotestosterone (DHT) led to upregulation of proliferation and p66(Shc) protein level. Conversely, growth suppression of fast-growing cells by cellular form of prostatic acid phosphatase (cPAcP) expression, a negative growth regulator, downregulated their p66(Shc) protein level. Additionally, increased expression of p66(Shc) protein by cDNA transfection in LNCaP C-33 cells resulted in increased cell proliferation. Cell cycle analyses showed higher percentage of p66(Shc)-overexpressing cells at S phase (24%) than control cells (17%), correlating with their growth rates. On the other hand, transient knock-down of p66(Shc) expression by RNAi in rapidly growing cells decreased their proliferation as evidenced by the reduced cell growth as well as S phase in p66(Shc)-knocked down cells. The p66(Shc) signaling in cell growth regulation is apparently mediated by extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK). Thus, our results indicate a novel role for p66(Shc) in prostate carcinogenesis, in part, promoting cell proliferation.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Coll Med, Med Ctr, Sect Urol Surg, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu	Lin, Jamie/F-4278-2015; Veeramani, Suresh/P-7838-2019	Lin, Jamie/0000-0002-7073-9658; LEE, MING-SHYUE/0000-0002-5884-4535; LEE, MING-SHYUE/0000-0002-8673-5088; Veeramani, Suresh/0000-0001-9217-0872	NCI NIH HHS [CA88184, P30 CA36727] Funding Source: Medline; NCRR NIH HHS [P20RR01879, P20RR017675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA088184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Davol PA, 2003, CANCER RES, V63, P6772; Gioeli D, 1999, CANCER RES, V59, P279; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; KAIGHN ME, 1979, INVEST UROL, V17, P16; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lee MS, 2004, ONCOGENE, V23, P3048, DOI 10.1038/sj.onc.1207451; Lee MS, 2004, INT J CANCER, V108, P672, DOI 10.1002/ijc.11621; Lim SD, 2005, PROSTATE, V62, P200, DOI 10.1002/pros.20137; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Liu SL, 2002, ARCH BIOCHEM BIOPHYS, V406, P173, DOI 10.1016/S0003-9861(02)00430-7; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; PONTES JE, 1981, J UROLOGY, V126, P187, DOI 10.1016/S0022-5347(17)54440-7; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; SAKAI H, 1993, J UROLOGY, V149, P1020, DOI 10.1016/S0022-5347(17)36285-7; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; Yang CPH, 2000, CANCER RES, V60, P5171	39	47	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 3	2005	24	48					7203	7212		10.1038/sj.onc.1208852	http://dx.doi.org/10.1038/sj.onc.1208852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170380				2022-12-28	WOS:000232990100009
J	Ito, H; Iwamoto, I; Morishita, R; Nozawa, Y; Narumiya, S; Asano, T; Nagata, KI				Ito, H; Iwamoto, I; Morishita, R; Nozawa, Y; Narumiya, S; Asano, T; Nagata, KI			Possible role of Rho/Rhotekin signaling in mammalian septin organization	ONCOGENE			English	Article						septin; Sept9; Rho; Rhotekin; actin	NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; FAMILY; PROTEINS; CELLS	There is growing evidence for crosstalk between septin. laments and actin cytoskeleton which is regulated by Rho family of GTPases. Here we show that active Rho disrupts septin filament structures in rat embryonic fibroblast REF52 cells. Among Rho effector molecules tested, Rhotekin induced morphological changes of septin. laments similar to those by activated Rho. The center region of Rhotekin was sufficient for the septin reorganization in the cells, and likely to interact indirectly with the C-terminal half of a septin Sept9b, where a GTPase domain is located. Rhotekin and Sept9b are colocalized mainly in perinuclear regions in serum-starved REF52 cells. Upon stimulation with lysophosphatidic acid, they translocated to actin stress fibers in 10 min and then redistributed again to cytoplasm after 90 min treatment. In neuroblastoma Neuro2a cells, Rhotekin and Sept9b were enriched in the tip of neurites, a location where cortical actin reorganization is induced upon stimulation with lysophosphatidic acid. Taken together, we propose that Rhotekin is a novel regulator organizing mammalian septin structures and provide a new link between the septin and Rho-signaling.	Aichi Human Serv Ctr, Dept Mol Neurobiol, Inst Dev Res, Kamiya, Kasugai 4800392, Japan; Gifu Int Inst Biotechnol, Gifu 5040838, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Nagata, KI (corresponding author), Aichi Human Serv Ctr, Dept Mol Neurobiol, Inst Dev Res, Kamiya, Kasugai 4800392, Japan.	knagata@inst-hsc.jp		Ito, Hidenori/0000-0002-6527-477X				Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2001, NAT CELL BIOL, V3, P861, DOI 10.1038/ncb1001-861; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata KI, 2005, ONCOGENE, V24, P65, DOI 10.1038/sj.onc.1208101; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519	19	49	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7064	7072		10.1038/sj.onc.1208862	http://dx.doi.org/10.1038/sj.onc.1208862			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007136				2022-12-28	WOS:000232833200008
J	Malchinkhuu, E; Sato, K; Horiuchi, Y; Mogi, C; Ohwada, S; Ishiuchi, S; Saito, N; Kurose, H; Tomura, H; Okajima, F				Malchinkhuu, E; Sato, K; Horiuchi, Y; Mogi, C; Ohwada, S; Ishiuchi, S; Saito, N; Kurose, H; Tomura, H; Okajima, F			Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells	ONCOGENE			English	Article						glioma; cell migration; lysophosphatidic acid; sphingosine-1-phosphate; MAP kinase	GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; CANCER CELLS; ACTIN REORGANIZATION; STIMULATES MOTILITY; LYSOPHOSPHOLIPASE-D; GLIOBLASTOMA CELLS; RAC ACTIVATION; MAP KINASE	A potential role for 1-oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) in the regulation of malignant diseases has been widely considered. In this study, we found that in transformed astroglial cells, the expression pro. le of lysophospholipid receptor mRNA and the action modes of LPA and S1P on cell motility were changed: there was a change in the acquisition of the ability of LPA to stimulate cell migration and a change in the migratory response to S1P from stimulation through S1P(1) to inhibition through S1P(2). LPA-induced cell migration was almost completely inhibited by either pertussis toxin, LPA(1) receptor antagonists including Ki16425(3(4[4([1(2chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfonyl) propanoic acid) or an inhibitor of phosphatidylinositol 3- kinase (PI3K) wortmannin. The LPA-induced action was also suppressed, although incompletely, by several specific inhibitors for intracellular signaling pathways including Rac1, Cdc42, p38 mitogen-activated protein kinase (p38MAPK) and c-Jun terminal kinase (JNK), but not extracellular signal-regulated kinase. Nearly complete inhibition of migration response to LPA, however, required simultaneous inhibition of both the p38MAPK and JNK pathways. Inhibition of Rac1 suppressed JNK but not p38MAPK, while the activity of p38MAPK was abolished by a dominant-negative form of Cdc42. These findings suggest that, in glioma cells, the PI3K/Cdc42/p38MAPK and PI3K/Rac1/JNK pathways are equally important for LPA1 receptor-mediated migration.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Grad Sch Med, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Dept Neurosurg, Maebashi, Gumma 3718511, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Fukuoka 8128582, Japan	Gunma University; Gunma University; Gunma University; Kyushu University	Sato, K (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	kosato@showa.gunma-u.ac.jp	Malchinkhuu, Enkhzol/AAH-4600-2019	Sato, Koichi/0000-0001-7694-4014; Malchinkhuu, Enkhzol/0000-0003-0744-079X				Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cara DC, 2001, J IMMUNOL, V167, P6552, DOI 10.4049/jimmunol.167.11.6552; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Gschwind A, 2002, CANCER RES, V62, P6329; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Ishizuka T, 2001, J IMMUNOL, V167, P2298, DOI 10.4049/jimmunol.167.4.2298; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Malchinkhuu E, 2003, BIOCHEM J, V370, P817, DOI 10.1042/BJ20020867; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rao TS, 2003, BRAIN RES, V990, P182, DOI 10.1016/S0006-8993(03)03527-3; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Shi GX, 2003, J IMMUNOL, V171, P3407, DOI 10.4049/jimmunol.171.7.3407; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANDENBERG SR, 1992, J NEUROPATH EXP NEUR, V51, P644, DOI 10.1097/00005072-199211000-00008; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200	55	68	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6676	6688		10.1038/sj.onc.1208805	http://dx.doi.org/10.1038/sj.onc.1208805			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007180				2022-12-28	WOS:000232367800009
J	Dentelli, P; Rosso, A; Garbarino, G; Calvi, C; Lombard, E; Di Stefano, P; Defilippi, P; Pegoraro, L; Brizzi, MF				Dentelli, P; Rosso, A; Garbarino, G; Calvi, C; Lombard, E; Di Stefano, P; Defilippi, P; Pegoraro, L; Brizzi, MF			The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovascularization	ONCOGENE			English	Article						interleukin-3; vascular endothelial growth factor; endothelial cells; cancer; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; GM-CSF; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; VESSEL FORMATION; POTENTIAL ROLE; BREAST-CANCER; CELL MOTILITY; RHO GTPASES	As vascular endothelial growth factor (VEGF), interleukin-3 (IL-3), released into the tumor microenvironment stimulates motogenic and mitogenic activity of normal and transformed cells. In the present study, we investigate the effects of IL-3 and VEGF on neoplastic vascular growth. Engagement of IL-3 receptor beta common (IL-3R beta c) contributes to both IL-3- and VEGF-induced Rac1 activation, cell migration and in vitro tube-like structure formation as shown by the expression of the dominant-negative IL-3R beta c construct (Delta 455). In normal and transformed endothelial cells (EC) as well as in HEK 293 cells expressing KDR and IL-3R, VEGF and IL-3 treatment induces the formation of a KDR/IL-3R beta c complex. Moreover, as shown by the IL-3R Delta 455 mutant or by the kinase dead KDR, functional receptors are required for this interaction. Consistent with the contribution of IL-3R beta c in both IL-3- and VEGF-mediated angiogenic signal, a reduced number of vessels inside tumors are found in mice injected with cells expressing the IL-3R Delta 455 mutant. Thus, these findings provide a novel mechanism through which IL-3 and VEGF support cell survival and tumor neovascularization.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	University of Turin; University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	DEFILIPPI, Paola/L-2232-2014; Brizzi, Maria Felice/J-7882-2016	Defilippi, Paola/0000-0001-6427-4906				Aronica MG, 1996, ONCOGENE, V13, P1017; Bachelder RE, 2001, CANCER RES, V61, P5736; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Biancone L, 1999, J IMMUNOL, V162, P5263; BOWMAN S, 1990, Technique (Philadelphia), V2, P254; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Konecny G, 2001, CLIN CANCER RES, V7, P2448; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rofstad EK, 2000, CANCER RES, V60, P4932; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; WIMPERIS JZ, 1989, BLOOD, V74, P1525; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	53	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6394	6405		10.1038/sj.onc.1208786	http://dx.doi.org/10.1038/sj.onc.1208786			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007196				2022-12-28	WOS:000232038200007
J	Caron, L; Bost, F; Prot, M; Hofman, P; Binetruy, B				Caron, L; Bost, F; Prot, M; Hofman, P; Binetruy, B			A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells	ONCOGENE			English	Article						HMGA2 transcription factor; ES cells; myogenesis	HMGI-C GENE; EXPRESSION; PATHWAY; DIFFERENTIATION; PROTEINS; LIPOMAS	The high mobility group type A-2 (HMGA2) transcription factor is involved in proliferation and differentiation, mainly during embryogenesis. Its activated form (HMGA2/T) presents oncogenic activities both in vivo and in vitro. However, its precise role during embryogenesis is unknown. We investigated its role during the commitment of mouse embryonic stem (ES) cells by constructing cell lines expressing either wild type (wt) or HMGA2/T forms of the gene. Following differentiation, control and wt HMGA2 ES cells did not display myotubes; whereas HMGA2/T ES cell lines massively formed contractile myotubes. Furthermore, as opposed to control cells, HMGA2/T ES cells highly expressed the muscle myosin heavy chain (MHC) marker. Interestingly, in experimental conditions inhibitory for myogenesis, we observed a strong expression of MyoD and myogenin in HMGA2/T cells. By contrast, commitment into adipocyte, neuron, and cardiomyocyte lineages was not affected. Teratocarcinomas induced by HMGA2/T ES cell lines presented numerous skeletal muscle-differentiated tissues that were not observed in wt HMGA2 or control tumours. Finally, rapamycin, an inhibitor of the mTOR kinase, downregulated endogenous HMGA-2 expression and inhibited myogenesis. This effect was prevented by overexpression of exogenous HMGA-2. Our results reveal a novel function of HMGA-2 in skeletal muscle differentiation.	Univ Nice Sophia Antipolis, INSERM, U568, Fac Med, F-06107 Nice, France; Univ Nice Sophia Antipolis, INSERM E0215, Fac Med, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Binetruy, B (corresponding author), Univ Nice Sophia Antipolis, INSERM, U568, Fac Med, Ave Valombrose, F-06107 Nice, France.	binetruy@unice.fr	Binetruy, Bernard/AFL-7188-2022; Hofman, Paul/P-7654-2018; Binetruy, Bernard/S-2062-2019; BOST, Frederic/AAN-4691-2020; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009; Caron, Leslie/AAE-3511-2022	Hofman, Paul/0000-0003-0431-9353; Binetruy, Bernard/0000-0001-8012-7092; BOST, Frederic/0000-0003-4509-4701; Caron, Leslie/0000-0003-4118-2974				Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Anisimov SV, 2002, MECH DEVELOP, V117, P25, DOI 10.1016/S0925-4773(02)00177-6; ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Chieffi P, 2002, ONCOGENE, V21, P3644, DOI 10.1038/sj/onc/1205501; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; Hunter DS, 2002, CANCER RES, V62, P3766; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noro B, 2003, BIOCHEMISTRY-US, V42, P4569, DOI 10.1021/bi026605k; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Tallini G, 2000, LAB INVEST, V80, P359, DOI 10.1038/labinvest.3780040; Vernochet C, 2002, FEBS LETT, V510, P94, DOI 10.1016/S0014-5793(01)03235-5; Wobus Anna M., 2001, Molecular Aspects of Medicine, V22, P149, DOI 10.1016/S0098-2997(01)00006-1; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	23	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6281	6291		10.1038/sj.onc.1208781	http://dx.doi.org/10.1038/sj.onc.1208781			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007198				2022-12-28	WOS:000231877100009
J	Kirk, GD; Lesi, OA; Mendy, M; Szymanska, K; Whittle, H; Goedert, JJ; Hainaut, P; Montesano, R				Kirk, GD; Lesi, OA; Mendy, M; Szymanska, K; Whittle, H; Goedert, JJ; Hainaut, P; Montesano, R			249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; aflatoxin; hepatitis B virus; TP53 gene; plasma DNA	AFLATOXIN-ALBUMIN ADDUCTS; CIRCULATING NUCLEIC-ACIDS; LIVER-CANCER RISK; REPUBLIC-OF-CHINA; WEST-AFRICA; P53 GENE; MOLECULAR PATHOGENESIS; VIRUS-INFECTION; STEM-CELLS; E-ANTIGEN	Hepatocellular carcinoma (HCC) from regions with high dietary exposure to aflatoxins and endemic for hepatitis B virus (HBV) often contain a specific mutation at codon 249 in TP53 (249(ser); AGG to AGT, Arg to Ser). This mutation is also detectable in circulating cell-free DNA from the plasma of HCC patients and healthy subjects in these regions. We have examined the joint effect of plasma 249(ser) and HBV infection in a case-control study design involving 348 control, 98 cirrhotic, and 186 HCC participants from The Gambia, West Africa, an area of high HCC incidence. The 249(ser) mutation was detected in 3.5% of controls, 15.3% of cirrhotics, and 39.8% of HCC cases (adjusted odds ratios (OR): 4.83, (95% confidence interval (CI): 1.71-13.7) for cirrhosis and 20.3 (8.19-50.0) for HCC). HBsAg positivity along with plasma 249(ser) was observed in 45/183 (24.6%) HCC cases compared to only one (0.3%) control. Risk for HCC was associated with markers of HBV alone (OR: 10.0, 95% CI: 5.16-19.6), 249(ser) alone (OR: 13.2, 95% CI: 4.99-35.0), and both markers present (OR: 399, 95% CI: 48.6-3270). These results suggest a multiplicative effect on HCC risk resulting from the mutational effect of aflatoxin on TP53, as monitored by detection of plasma 249(ser), with concomitant chronic infection with HBV.	Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, Baltimore, MD 21205 USA; Gambia Hepatitis Intervent Study, Banjul, Gambia; NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; MRC Labs, Banjul, Gambia; Int Agcy Res Canc, F-69372 Lyon, France	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); MRC Laboratory Molecular Biology; World Health Organization; International Agency for Research on Cancer (IARC)	Kirk, GD (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, 615 N Wolfe St,E-6533, Baltimore, MD 21205 USA.	gkirk@jhsph.edu	Kirk, Gregory/A-8484-2009; Hainaut, Pierre/B-6018-2012; Mendy, Maimuna/ABD-5038-2021	Hainaut, Pierre/0000-0002-1303-1610; LESI, Olufunmilayo/0000-0002-6958-1531	NATIONAL CANCER INSTITUTE [Z01CP010176, ZIACP010176] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791; AUTRUP H, 1987, CANCER RES, V47, P3430; Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730; BANNASCH P, 1995, CANCER RES, V55, P3318; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Chen CJ, 1996, HEPATOLOGY, V24, P38, DOI 10.1002/hep.510240108; COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Groopman JD, 1996, PROG CLIN BIOL RES, V395, P211; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; IARC, 2002, MON EV CARC RISKS HU, V82; IARC, 1994, MON EV CARC RISKS HU; Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101; Jackson PE, 1999, BEST PRACT RES CL GA, V13, P545, DOI 10.1053/bega.1999.0047; Jackson PE, 2001, CANCER RES, V61, P33; Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Liang TJ, 2002, NEW ENGL J MED, V347, P208, DOI 10.1056/NEJMe020060; LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Mandishona E, 1998, HEPATOLOGY, V27, P1563, DOI 10.1002/hep.510270614; Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34; MENDY ME, 1998, BRIT J BIOMED SCI, V55, P92; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Olubuyide I O, 1993, Afr J Med Med Sci, V22, P89; Omer RE, 2001, CANCER CAUSE CONTROL, V12, P23, DOI 10.1023/A:1008943200826; Omer RE, 1998, NUTR CANCER, V32, P174, DOI 10.1080/01635589809514737; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Payne RJH, 1996, P NATL ACAD SCI USA, V93, P6542, DOI 10.1073/pnas.93.13.6542; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; PONCHEL F, 1994, CANCER RES, V54, P2064; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; SELL S, 1993, INT J DEV BIOL, V37, P189; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617; Strain AJ, 2000, GUT, V46, P743, DOI 10.1136/gut.46.6.743; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103; Taback B, 2004, CURR OPIN MOL THER, V6, P273; Thorgeirsson S S, 1995, Princess Takamatsu Symp, V25, P163; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x; Vall Mayans M., 1990, Lancet, V336, P1107; van Rensburg S J, 1990, J Environ Pathol Toxicol Oncol, V10, P11; Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5&lt;620::AID-IJC5&gt;3.0.CO;2-W; Wang XW, 2002, TOXICOLOGY, V181, P43, DOI 10.1016/S0300-483X(02)00253-6; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112; Wild CP, 1996, CANCER EPIDEM BIOMAR, V5, P179; Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;1::AID-IJC1&gt;3.0.CO;2-I; WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271; WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229; WILD CP, 1987, INT J CANCER, V40, P328, DOI 10.1002/ijc.2910400308; WILD CP, 1992, TOXICOL LETT, V64-5, P455, DOI 10.1016/0378-4274(92)90219-A; Wogan GN, 2000, SEMIN CANCER BIOL, V10, P201, DOI 10.1006/scbi.2000.0320; Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8; Yan R Q, 1989, Zhonghua Bing Li Xue Za Zhi, V18, P19; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215	64	111	118	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2005	24	38					5858	5867		10.1038/sj.onc.1208732	http://dx.doi.org/10.1038/sj.onc.1208732			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007211				2022-12-28	WOS:000231590400008
J	Larsson, J; Karlsson, S				Larsson, J; Karlsson, S			The role of Smad signaling in hematopoiesis	ONCOGENE			English	Review						Smad signaling; hematopoiesis; stem cells	GROWTH-FACTOR-BETA; PROGENITOR-CELL PROLIFERATION; BONE MORPHOGENETIC PROTEIN-4; RETROVIRAL GENE-TRANSFER; NECROSIS-FACTOR-ALPHA; EX-VIVO EXPANSION; RECEPTOR-TYPE II; C-KIT LIGAND; TGF-BETA; STEM-CELLS	The TGF-beta family of ligands, including TGF-b, bone morphogenetic protein (BMP) and activin, signal through Smad pathways to regulate the fate of hematopoietic progenitor and stem cells during development and postnatally. BMP regulates hematopoietic stem cell (HSC) specification during development, while TGF-beta 1, 2 and 3 are not essential for the generation of HSCs. BMP4 can increase proliferation of human hematopoietic progenitors, while TGF-beta acts as a negative regulator of hematopoietic progenitor and stem cells in vitro. In contrast, TGF-beta signaling deficiency in vivo does not affect proliferation of HSCs and does not affect lineage choice either. Therefore, the outcome of Smad signaling is very context dependent in hematopoiesis and regulation of hematopoietic stem and progenitor cells is more complicated in the bone marrow microenvironment in vivo than is seen in liquid cultures ex vivo. Smad signaling regulates hematopoiesis by crosstalk with other regulatory signals and future research will de. ne in more detail how the various pathways interact and how the knowledge obtained can be used to develop advanced cell therapies.	Lund Univ, Inst Lab Med, S-22184 Lund, Sweden; Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, S-22184 Lund, Sweden; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med & Technol, Boston, MA 02115 USA	Lund University; Lund University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Karlsson, S (corresponding author), Lund Univ, Inst Lab Med, BMC A12, S-22184 Lund, Sweden.	Stefan.karlsson@molmed.lu.se						Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Attar EC, 2004, LEUKEMIA, V18, P1760, DOI 10.1038/sj.leu.2403515; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Bartelmez SH, 2000, BLOOD, V96, p474A; Batard P, 2000, J CELL SCI, V113, P383; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Bjornsson JM, 2001, BLOOD, V98, P3301, DOI 10.1182/blood.V98.12.3301; Blank U, 2004, BLOOD, V104, p162A, DOI 10.1182/blood.V104.11.561.561; Borge OJ, 1996, BLOOD, V88, P2859, DOI 10.1182/blood.V88.8.2859.bloodjournal8882859; Brakebusch C, 2002, IMMUNITY, V16, P465, DOI 10.1016/S1074-7613(02)00281-9; Brun ACM, 2004, BLOOD, V103, P4126, DOI 10.1182/blood-2003-10-3557; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chadwick K, 2005, BLOOD, V105, P1905, DOI 10.1182/blood-2004-03-0881; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Chang H, 1999, DEVELOPMENT, V126, P1631; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen CZ, 2002, P NATL ACAD SCI USA, V99, P15468, DOI 10.1073/pnas.202614899; Chen CZ, 2003, IMMUNITY, V19, P525, DOI 10.1016/S1074-7613(03)00265-6; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Cumano A, 2000, VACCINE, V18, P1621, DOI 10.1016/S0264-410X(99)00496-X; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; De Felice LD, 2005, CANCER RES, V65, P1505, DOI 10.1158/0008-5472.CAN-04-3063; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; DUBOIS CM, 1994, BLOOD, V83, P3138; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; DYBEDAL I, 1995, BLOOD, V86, P949; Dybedal I, 1997, BLOOD, V90, P3395, DOI 10.1182/blood.V90.9.3395; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fan XL, 2002, J IMMUNOL, V168, P755, DOI 10.4049/jimmunol.168.2.755; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Garbe A, 1997, BRIT J HAEMATOL, V99, P951, DOI 10.1046/j.1365-2141.1997.4893291.x; Gekas C, 2005, DEV CELL, V8, P365, DOI 10.1016/j.devcel.2004.12.016; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GOEY H, 1989, J IMMUNOL, V143, P877; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Grady WM, 1999, CANCER RES, V59, P320; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hatzfeld A, 1996, HUM GENE THER, V7, P207, DOI 10.1089/hum.1996.7.2-207; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Imbert AM, 1998, EXP HEMATOL, V26, P374; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; JACOBSEN FW, 1995, BLOOD, V86, P2957; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1990, BLOOD, V75, P596; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Komuro Hiroaki, 1999, Neoplasia (New York), V1, P253, DOI 10.1038/sj.neo.7900033; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krause DS, 2002, ONCOGENE, V21, P3262, DOI 10.1038/sj.onc.1205316; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lacaud G, 2001, ANN NY ACAD SCI, V938, P96; Langer JC, 2004, J EXP MED, V199, P5, DOI 10.1084/jem.20030980; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Lenox LE, 2005, BLOOD, V105, P2741, DOI 10.1182/blood-2004-02-0703; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; LI CL, 1994, BLOOD, V84, P408, DOI 10.1182/blood.V84.2.408.bloodjournal842408; Li W, 2001, BIOCHEM BIOPH RES CO, V286, P1163, DOI 10.1006/bbrc.2001.5529; Liu B, 2003, BLOOD, V101, P124, DOI 10.1182/blood-2002-02-0398; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mikkola HKA, 2002, J HEMATOTH STEM CELL, V11, P9, DOI 10.1089/152581602753448504; Miller CL, 1996, EXP HEMATOL, V24, P185; Miyake N, 2004, BLOOD, V104, p469A, DOI 10.1182/blood.V104.11.1688.1688; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; North T, 1999, DEVELOPMENT, V126, P2563; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OGAWA M, 1993, BLOOD, V81, P2844; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Ramsfjell V, 1996, BLOOD, V88, P4481, DOI 10.1182/blood.V88.12.4481.bloodjournal88124481; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SING GK, 1988, BLOOD, V72, P1504; Sitnicka E, 1996, BLOOD, V88, P82; Snyder A, 2004, J CELL BIOCHEM, V93, P224, DOI 10.1002/jcb.20191; Soma T, 1996, BLOOD, V87, P4561, DOI 10.1182/blood.V87.11.4561.bloodjournal87114561; Sorrentino BP, 2004, NAT REV IMMUNOL, V4, P878, DOI 10.1038/nri1487; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stier S, 2003, BLOOD, V102, P1260, DOI 10.1182/blood-2002-10-3053; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Takeuchi C, 2002, LEUKEMIA, V16, P956, DOI 10.1038/sj.leu.2402408; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; TEN DP, 1988, P NATL ACAD SCI USA, V85, P4715; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Veiby OP, 1996, J IMMUNOL, V157, P2953; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Woods NB, 2003, BLOOD, V101, P1284, DOI 10.1182/blood-2002-07-2238; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159; Yang LP, 2005, J IMMUNOL, V174, P752, DOI 10.4049/jimmunol.174.2.752; Yang X, 1999, DEVELOPMENT, V126, P1571; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6; Yoder MC, 2001, BLOOD, V98, P3, DOI 10.1182/blood.V98.1.3; Yu J, 1998, GENE THER, V5, P1265, DOI 10.1038/sj.gt.3300732; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; ZHANG Y, 1995, BLOOD, V86, P2930; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	192	124	132	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5676	5692		10.1038/sj.onc.1208920	http://dx.doi.org/10.1038/sj.onc.1208920			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123801				2022-12-28	WOS:000231452800003
J	Lee, JW; Kim, YG; Soung, YH; Han, KJ; Kim, SY; Rhim, HS; Min, WS; Nam, SW; Park, WS; Lee, JY; Yoo, NJ; Lee, SH				Lee, JW; Kim, YG; Soung, YH; Han, KJ; Kim, SY; Rhim, HS; Min, WS; Nam, SW; Park, WS; Lee, JY; Yoo, NJ; Lee, SH			The JAK2 V617F mutation in de novo acute myelogenous leukemias	ONCOGENE			English	Article						JAK2; acute myelogenous leukemia; mutation; cancer	TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; INHIBITOR	A missense somatic mutation in JAK2 gene (JAK2 V617F) has recently been reported in chronic myeloproliferative disorders, including polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia, strongly suggesting its role in the pathogenesis of myeloid disorders. As activation of JAK2 signaling is occurred in other malignancies as well, we have analysed 558 tissues from common human cancers, including colon, breast and lung carcinomas, and 143 acute adulthood leukemias by polymerase chain reaction - single strand conformation polymorphism analysis. We found three JAK2 mutations in the 113 acute myelogenous leukemias (AMLs)(2.7%), but none in other cancers. The mutations consisted of two V617F mutations and one K607N mutation. None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders. This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; Arteaga CL, 2002, SEMIN ONCOL, V29, P4, DOI 10.1053/sonc.2002.34047; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; DIEZMARTIN JL, 1991, MAYO CLIN PROC, V66, P287, DOI 10.1016/S0025-6196(12)61011-8; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Pallis M, 2003, LEUKEMIA RES, V27, P803, DOI 10.1016/S0145-2126(03)00012-2; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Steensma DP, 2005, BLOOD; SWOLIN B, 1988, BLOOD, V72, P386; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Wakeling AE, 2002, CANCER RES, V62, P5749	15	119	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1434	1436		10.1038/sj.onc.1209163	http://dx.doi.org/10.1038/sj.onc.1209163			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247455				2022-12-28	WOS:000235708200018
J	Talukder, AH; Meng, Q; Kumar, R				Talukder, AH; Meng, Q; Kumar, R			CRIPak, a novel endogenous Pak1 inhibitor	ONCOGENE			English	Article						Pak1; negative regulation; ER	P21-ACTIVATED-KINASE-1 PHOSPHORYLATES; CYCLIN D1; KINASE; ACTIVATION; EXPRESSION; ALPHA; INTERACTS; CELLS	p21-activated protein kinase 1 (Pak1) plays an important role in several cellular processes, including cytoskeleton reorganization, promotion of the cell survival, and the estrogen receptor ( ER) signaling. Pak1 expression and activity is deregulated in a number of cancers. Pak1 is activated by a variety of physiological signals; however, less is known about the negative regulators of Pak1. Here, we report a negative regulator of Pak1. By performing a yeast two-hybrid screen of a mammary gland library, we identified cysteine-rich inhibitor of Pak1 (CRIPak) as a novel Pak1-interacting protein. We found that CRIPak is an intronless gene that localized to chromosome 4p16.3. It contains 13 zinc-finger domains and has three trypsin inhibitor-like, cysteine-rich domains and is widely expressed in a number of human cells and tissues. We further found that CRIPak interacted with Pak1 through the N-terminal regulatory domain and inhibited Pak1 kinase in both in vitro and in vivo assays. CRIPak inhibited Pak1-mediated LIM kinase activation and enhancement of ER transactivation. Conversely, selective inhibition of the endogenous CRIPak resulted in an increased Pak1 activity, and consequently, increased cytoskeleton remodeling and Pak1-mediated ER transactivation activity. The hormonal stimulation of cells enhanced CRIPak expression and promoted its colocalization with ER in the nuclear compartment. Our findings suggest that CRIPak is a novel negative regulator of the Pak1 and has a role in the modulation of Pak1-mediated ER transactivation in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER; NCI NIH HHS [CA98823, CA90970, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Shivapurkar N, 1999, CANCER RES, V59, P3576; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Xia CZ, 2001, P NATL ACAD SCI USA, V98, P6174, DOI 10.1073/pnas.101137298	27	37	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1311	1319		10.1038/sj.onc.1209172	http://dx.doi.org/10.1038/sj.onc.1209172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16278681				2022-12-28	WOS:000235708200004
J	Gartel, AL				Gartel, AL			A new mode of transcriptional repression by c-myc: methylation	ONCOGENE			English	Editorial Material							GROWTH ARREST; DNA; METHYLTRANSFERASES; RECRUITMENT; ASSOCIATION; MECHANISMS; EXPRESSION; MIZ-1; GENES		Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60612 USA.	agartel@uic.edu						Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vaque JP, 2005, J BIOL CHEM, V280, P1112, DOI 10.1074/jbc.M409503200; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	14	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	14					1989	1990		10.1038/sj.onc.1209101	http://dx.doi.org/10.1038/sj.onc.1209101			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16170342				2022-12-28	WOS:000236359700001
J	Borzacchiello, G; Russo, V; Gentile, F; Roperto, F; Venuti, A; Nitsch, L; Campo, MS; Roperto, S				Borzacchiello, G; Russo, V; Gentile, F; Roperto, F; Venuti, A; Nitsch, L; Campo, MS; Roperto, S			Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours	ONCOGENE			English	Article						bovine papillomavirus type 2; E5; PDGF beta receptor; urinary bladder tumours	MHC CLASS-I; DOWN-REGULATION; INTERCELLULAR COMMUNICATION; TUMORIGENIC TRANSFORMATION; CELL-TRANSFORMATION; UROPLAKIN-III; BRACKEN-FERN; TYPE-4 E8; PROTEIN; EXPRESSION	Studies regarding the functions of the bovine papillomavirus (BPV) E5 oncoprotein in vivo are lacking and no E5-mediated mechanism underlying epithelial carcinogenesis is known. We have shown that BPV-2 DNA is present in the majority of naturally occurring urinary bladder tumours of cattle and that E5 is expressed in the cancer cells. Here we show that the interaction between the platelet-derived growth factor (PDGF) beta receptor and BPV E5, described in vitro in cultured cells, takes place in vivo in bovine urinary bladder cancers. In these cancers, E5 and PDGF beta receptor colocalize, as shown by confocal microscopy, and physically interact, as shown by coimmunoprecipitation. Furthermore, the PDGF b receptor associated with E5 is highly phosphorylated, suggesting the functional activation of the receptor upon E5 interaction. Our results demonstrate, for the first time, that E5-PDGF beta receptor interaction occurs during the natural history of bovine urinary bladder tumours, suggesting an important role for E5 in carcinogenesis. Finally, the system provides a suitable animal model of papillomavirus-associated cancer to test therapeutic vaccination against E5. Successful bladder tumour regression would provide a valuable model for therapeutic vaccination against papillomavirus-associated tumours.	Univ Naples Federico II, Fac Med Vet, Dept Pathol & Anim Hlth, I-80137 Naples, Italy; IEOS, CNR, Dept Cellular & Mol Biol & Pathol L Califano, Naples, Italy; Regina Elena Inst Canc Res, Virol Lab, Rome, Italy; Univ Glasgow, Div Pathol Sci, Inst Comparat Med, Glasgow, Lanark, Scotland	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Glasgow	Borzacchiello, G (corresponding author), Univ Naples Federico II, Fac Med Vet, Dept Pathol & Anim Hlth, Via F Delpino 1, I-80137 Naples, Italy.	borzacch@unina.it	; Venuti, Aldo/K-9637-2016	Borzacchiello, Giuseppe/0000-0003-3943-2604; roperto, sante/0000-0001-6210-5519; Venuti, Aldo/0000-0003-2322-6857				Ambrosio V, 2001, VET PATHOL, V38, P657, DOI 10.1354/vp.38-6-657; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; ANGLIANO AM, 1994, UROL INT, V52, P125; Araibi EH, 2004, J GEN VIROL, V85, P2809, DOI 10.1099/vir.0.80128-0; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; Borzacchiello G, 2003, VET PATHOL, V40, P455, DOI 10.1354/vp.40-4-455; Borzacchiello G, 2003, J COMP PATHOL, V128, P203, DOI 10.1053/jcpa.2002.0626; Borzacchiello G, 2003, J GEN VIROL, V84, P2921, DOI 10.1099/vir.0.19412-0; Borzacchiello G, 2001, VET PATHOL, V38, P113, DOI 10.1354/vp.38-1-113; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Campo MS, 1997, VET J, V154, P175, DOI 10.1016/S1090-0233(97)80019-6; CAMPO MS, 1992, CANCER RES, V52, P6898; CAMPO MS, 1994, RES VET SCI, V56, P151, DOI 10.1016/0034-5288(94)90097-3; Campo MS, 2002, VIRUS RES, V89, P249, DOI 10.1016/S0168-1702(02)00193-4; Chen YF, 2004, J VIROL, V78, P1333, DOI 10.1128/JVI.78.3.1333-1343.2004; COLTRERA MD, 1995, CANCER RES, V55, P2703; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; De Gaetani C, 1999, J CLIN PATHOL, V52, P103, DOI 10.1136/jcp.52.2.103; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; dos Santos RCS, 1998, J GEN VIROL, V79, P2127, DOI 10.1099/0022-1317-79-9-2127; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1991, MOL CARCINOGEN, V4, P441, DOI 10.1002/mc.2940040605; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Kaufmann O, 2000, AM J CLIN PATHOL, V113, P683, DOI 10.1309/PYQC-17CB-063T-Q07J; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liu DW, 2000, J VIROL, V74, P9083, DOI 10.1128/JVI.74.19.9083-9089.2000; Marchetti B, 2002, ONCOGENE, V21, P7808, DOI 10.1038/sj.onc.1205885; Mayer TJ, 2000, IN VITRO CELL DEV-AN, V36, P667; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; Oliver RTD, 1998, CANCER SURV, V31, P29; OLSON C, 1965, CANCER RES, V25, P840; PAMUKCU AM, 1976, VET PATHOL, V13, P110, DOI 10.1177/030098587601300205; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Ramos-Vara JA, 2003, VET PATHOL, V40, P55, DOI 10.1354/vp.40-1-55; Roperto S, 2005, VET PATHOL, V42, P812, DOI 10.1354/vp.42-6-812; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; SHIBUTANI YF, 1992, UROLOGY, V40, P15, DOI 10.1016/0090-4295(92)90429-Z; SMITH BL, 1997, HDB PLANT FUNGAL TOX; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Sun TT, 1999, ADV EXP MED BIOL, V462, P7; VENUTI A, 2002, PERSP MED V, V8, P143	53	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1251	1260		10.1038/sj.onc.1209152	http://dx.doi.org/10.1038/sj.onc.1209152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205631				2022-12-28	WOS:000235537500012
J	Bartholomeusz, C; Itamochi, H; Nitta, M; Saya, H; Ginsberg, MH; Ueno, NT				Bartholomeusz, C; Itamochi, H; Nitta, M; Saya, H; Ginsberg, MH; Ueno, NT			Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15	ONCOGENE			English	Article						adenovirus type 5 E1A; proliferation; ovarian neoplasms; PEA15; ERK	PROTEIN-KINASE-C; TUMOR SUPPRESSION; HUMAN BREAST; INDUCE APOPTOSIS; ADENOVIRUS-5 E1A; GENE-TRANSFER; CELL-GROWTH; PEA-15; EXPRESSION; TRANSFORMATION	The adenovirus type 5 gene E1A is known to suppress tumorigenicity by transcriptionally downregulating HER-2/neu (HER2) or by inducing apoptosis. We show here that E1A also suppressed the tumorigenicity of the low-HER2-expressing ovarian cancer cell line OVCAR- 3 by decreasing cell proliferation. We further found that the mechanism responsible for this reduced proliferation is the presence of PEA15 (phosphoprotein enriched in astro-cytes), which is upregulated by E1A in ovarian cancer; PEA15 promotes translocation of ERK from the nucleus to the cytoplasm, leading to inhibition of ERK-dependent transcription and proliferation. Indeed, siRNA-mediated knockdown of PEA15 expression in OVCAR-3 stable E1A transfectants resulted in a nuclear accumulation of the active form of ERK, followed by an increase in Elk-1 activity, DNA synthesis, and anchorage-independent growth. Finally, PEA15 by itself suppressed colony formation in breast and ovarian cancer cell lines, in which E1A is known to have antitumor activity. We conclude that part of the antitumor effect of E1A in ovarian cancer results from cytoplasmic sequestration of the activated form of ERK by PEA15.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Unit 448, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX USA; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto, Japan; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Kumamoto University; University of California System; University of California San Diego; University of Texas System; UTMD Anderson Cancer Center	Ueno, NT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Unit 448, 1515 Holcombe Blvd, Houston, TX 77030 USA.	nueno@mdanderson.org	Saya, Hideyuki/J-4325-2013		NCI NIH HHS [CA76450-1, CA16672-27, CA016672-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA076450, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BYRD PJ, 1988, ONCOGENE, V2, P477; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2004, CLIN CANCER RES, V10, P2905, DOI 10.1158/1078-0432.CCR-04-0644; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRISCH SM, 1990, ONCOGENE, V5, P75; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hao CH, 2001, CANCER RES, V61, P1162; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hwang S, 1997, GENOMICS, V42, P540, DOI 10.1006/geno.1997.4768; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Kubes M, 1998, J NEUROCHEM, V71, P1307; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Mymryk JS, 1996, ONCOGENE, V13, P1581; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Renault F, 2003, BIOCHEM PHARMACOL, V66, P1581, DOI 10.1016/S0006-2952(03)00514-8; RENGANAHAN H, 2005, BIOCH J 0526; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shao RP, 2000, CANCER RES, V60, P3123; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; TEODORO JG, 1995, ONCOGENE, V11, P467; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Ueno NT, 2000, CLIN CANCER RES, V6, P250; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xu FJ, 1999, CLIN CANCER RES, V5, P3653; YAN DH, 1991, ONCOGENE, V6, P343; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; Zang RY, 2001, INT J GYNECOL CANCER, V11, P18, DOI 10.1046/j.1525-1438.2001.011001018.x; ZHANG YJ, 1995, ONCOGENE, V10, P1947	60	32	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					79	90		10.1038/sj.onc.1209014	http://dx.doi.org/10.1038/sj.onc.1209014			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170361				2022-12-28	WOS:000234406400009
J	Gee, MFW; Tsuchida, R; Eichler-Jonsson, C; Das, B; Baruchel, S; Malkin, D				Gee, MFW; Tsuchida, R; Eichler-Jonsson, C; Das, B; Baruchel, S; Malkin, D			Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid	ONCOGENE			English	Article						autocrine signalling; vascular endothelial growth factor; rhabdomyosarcoma; all-trans-retinoic acid	TYROSINE-KINASE; VEGF RECEPTORS; ALVEOLAR RHABDOMYOSARCOMA; NEUROBLASTOMA-CELLS; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; PERMEABILITY FACTOR; TUMOR ANGIOGENESIS; COLORECTAL-CANCER; FACTOR FAMILY	Vascular endothelial growth factor ( VEGF) is a potent signalling molecule that acts through two tyrosine kinase receptors, VEGFR1 and VEGFR2. The upregulation of VEGF and its receptors is important in tumour-associated angiogenesis; however, recent studies suggest that several tumour cells express VEGF receptors and may be influenced by autocrine VEGF signalling. Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma, and is dependent on autocrine signalling for its growth. The alveolar subtype of RMS is often characterized by the presence of a PAX3-FKHR translocation, and when introduced into non-RMS cells, the resultant fusion protein induces expression of VEGFR1. In our study, we examined the expression of VEGF and its receptors in RMS, and autocrine effects of VEGF on cell growth. VEGF and receptor mRNA and protein were found to be expressed in RMS cells. Exogenous VEGF addition resulted in extracellular signal-regulated kinase-1/2 phosphorylation and cell proliferation, and both were reduced by VEGFR1 blockade. Growth was also slowed by VEGFR1 inhibitor alone. Treatment of RMS cells with all-trans-retinoic acid decreased VEGF secretion and slowed cell growth, which was rescued by VEGF. These data suggest that autocrine VEGF signalling likely in. uences RMS growth and its inhibition may be an effective treatment for RMS.	Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Malkin, D (corresponding author), Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	david.malkin@sickkids.ca	Das, Bikul/ABF-9292-2020; Malkin, David/AAW-8715-2021					Barber TD, 2002, GENOMICS, V79, P278, DOI 10.1006/geno.2002.6703; Barr FG, 1999, CANCER RES, V59, P5443; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Beierle EA, 2004, J SURG RES, V119, P56, DOI 10.1016/j.jss.2004.01.002; Beierle EA, 2003, J PEDIATR SURG, V38, P514, DOI 10.1053/jpsu.2003.50091; Borgstrom P, 1996, CANCER RES, V56, P4032; Brodowicz T, 1999, BRIT J CANCER, V80, P1350, DOI 10.1038/sj.bjc.6690528; Broggini M, 2003, LEUKEMIA, V17, P52, DOI 10.1038/sj.leu.2402788; Brower V, 2003, J NATL CANCER I, V95, P1425; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; CROUCH GD, 1991, CANCER RES, V51, P4882; Damert A, 2002, DEVELOPMENT, V129, P1881; DAS B, IN PRESS CANC RES; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Itokawa T, 2002, MOL CANCER THER, V1, P295; Joukov V, 1996, EMBO J, V15, P290; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KALEBIC T, 1994, CANCER RES, V54, P5531; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Ke LD, 1998, INT J ONCOL, V12, P1391; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kini AR, 2001, BLOOD, V97, P3919, DOI 10.1182/blood.V97.12.3919; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lu D, 2001, CANCER RES, V61, P7002; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Millauer B, 1996, CANCER RES, V56, P1615; Narendran A, 2003, EXP HEMATOL, V31, P693, DOI 10.1016/S0301-472X(03)00159-0; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ricaud S, 2003, ONCOGENE, V22, P8221, DOI 10.1038/sj.onc.1207177; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suzuki K, 1996, CANCER RES, V56, P3004; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weninger W, 1998, J INVEST DERMATOL, V111, P907, DOI 10.1046/j.1523-1747.1998.00393.x; Wey Jane S, 2004, Clin Adv Hematol Oncol, V2, P37; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	77	67	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8025	8037		10.1038/sj.onc.1208939	http://dx.doi.org/10.1038/sj.onc.1208939			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16116481				2022-12-28	WOS:000233656600009
J	Ishiko, J; Mizuki, M; Matsumura, I; Shibayama, H; Sugahara, H; Scholz, G; Serve, H; Kanakura, Y				Ishiko, J; Mizuki, M; Matsumura, I; Shibayama, H; Sugahara, H; Scholz, G; Serve, H; Kanakura, Y			Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant	ONCOGENE			English	Article						FLT3; activation loop; receptor tyrosine kinase; leukemia; Hsp90; Cdc37	ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; C-KIT MUTATION; CELL-LINES; INSULIN-RECEPTOR; GENE; IDENTIFICATION; JUXTAMEMBRANE	FLT3 tyrosine kinase domain ( TKD) mutations are detected in similar to 7% of acute myeloid leukemia patients, and suggested to correlate with poor prognosis and confer resistance to FLT3 inhibitors. To explore activation mechanism of FLT3 TKD mutation, we analysed critical tyrosine residues for the constitutive activation and downstream signaling of the mutant by generating a series of single Tyr -> Phe substitution mutant of all 22 cytoplasmic tyrosine residues of murine FLT3 TKD-mutant (mFLT3(Asp838Val)). Tyr845Phe, Tyr892Phe and Tyr922Phe substitutions suppressed the phosphorylation of mFLT3(Asp838Val) itself, the activation of Erk1/2, STAT3 and STAT5, and the factor-independent cell proliferation and survival. In contrast, these three Tyr -> Phe mutations partially suppressed but maintained the ligand-dependent activation and anti-apoptotic activity of wild-type FLT3, suggesting that these tyrosine residues were more critical for the constitutive activation and signaling of mFLT3(Asp838Val). These three Tyr -> Phe mutations also inhibited the constitutive activation of other FLT3 mutants bearing internal tandem duplication, Asp838Tyr or Ile839del. The suppression of mFLT3(Asp838Val) activation and signaling by these substitutions was partially recovered by shifting the culture temperature from 37 to 33 degrees C, or by the introduction of Cdc37 and Hsp90. Taken together, Tyr(845), Tyr(892) and Tyr(922) are the critical residues in mFLT3(Asp838Val) activation, possibly through stabilizing the active conformation of mFLT3(Asp838Val).	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany	Osaka University; Royal Melbourne Hospital; University of Melbourne; University of Munster	Mizuki, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mizuki@bldon.med.osaka-u.ac.jp		ISHIKO, JUN/0000-0003-3518-5108; Scholz, Glen/0000-0003-2722-6344				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Abu-Duhier FM, 2000, BRIT J HAEMATOL, V111, P190, DOI 10.1046/j.1365-2141.2000.02317.x; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; CARLESSO N, 1994, ONCOGENE, V9, P149; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Grundler R, 2003, BLOOD, V102, P646, DOI 10.1182/blood-2002-11-3441; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kiyoi H, 1999, BLOOD, V93, P3074; Li SQ, 2003, J BIOL CHEM, V278, P26007, DOI 10.1074/jbc.M302425200; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moreno I, 2003, HAEMATOLOGICA, V88, P19; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Nakao M, 1996, LEUKEMIA, V10, P1911; Reilly JT, 2002, BRIT J HAEMATOL, V116, P744, DOI 10.1046/j.0007-1048.2001.03294.x; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; Spiekermann K, 2003, BLOOD, V101, P1494, DOI 10.1182/blood-2002-04-1045; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yu JC, 2003, BLOOD, V102, p348A	35	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8144	8153		10.1038/sj.onc.1208957	http://dx.doi.org/10.1038/sj.onc.1208957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091740				2022-12-28	WOS:000233809400006
J	Bin Fang, W; Brantley-Sieders, DM; Parker, MA; Reith, AD; Chen, J				Bin Fang, W; Brantley-Sieders, DM; Parker, MA; Reith, AD; Chen, J			A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis	ONCOGENE			English	Article						EphA2 receptor tyrosine kinase; ephrin-A1; ligand; kinase activity; tumor malignancy; metastasis	TYROSINE KINASE; CELL-ADHESION; MULTISTAGE CARCINOGENESIS; PANCREATIC ADENOCARCINOMA; MALIGNANT-CELLS; SMALL GTPASES; KIT RECEPTOR; E-CADHERIN; IN-VIVO; PROTEIN	Receptor tyrosine kinases of the Eph family are upregulated in several different types of cancer. One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma. However, mechanisms by which EphA2 contributes to tumor progression are far from clear. In certain tumor cell lines, EphA2 receptor is underphosphorylated, raising the question of whether ligand-induced receptor phosphorylation and its kinase activity play a role in oncogenesis. To test directly the role of EphA2 receptor phosphorylation/kinase activity in tumor progression, we generated EphA2 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its kinase activity. Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor volume and increased tumor apoptosis in primary tumors. In addition, the numbers of lung metastases were significantly reduced in both experimental and spontaneous metastasis models. Reduced tumor volume and metastasis are not due to defects in tumor angiogenesis, as there is no significant difference in tumor vessel density between wild-type tumors and tumors expressing EphA2-signaling-defective mutants. In contrast, tumor cells expressing the EphA2 mutants are defective in RhoA GTPase activation and cell migration. Taken together, these results suggest that receptor phosphorylation and kinase activity of the EphA2 receptor, at least in part, contribute to tumor malignancy.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; UCL Branch, Ludwig Inst Canc Res, London, England; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Ludwig Institute for Cancer Research; University of London; University College London; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	NATIONAL CANCER INSTITUTE [T32CA078136, R01CA095004, R01CA114301] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL074517] Funding Source: NIH RePORTER; NCI NIH HHS [CA114301, CA95004, 2T32 CA78136] Funding Source: Medline; NHLBI NIH HHS [5F32 HL074517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Coffman KT, 2003, CANCER RES, V63, P7907; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Gurniak CB, 1996, ONCOGENE, V13, P777; Holder N, 1999, DEVELOPMENT, V126, P2033; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Madhusudan S, 2004, CLIN BIOCHEM, V37, P618, DOI 10.1016/j.clinbiochem.2004.05.006; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; Miao H, 2005, J BIOL CHEM, V280, P923, DOI 10.1074/jbc.M411383200; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Munarini N, 2002, J CELL SCI, V115, P25; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; Ridley AJ, 2001, J CELL SCI, V114, P2713; Saito T, 2004, ONCOL REP, V11, P605; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wicki A, 2001, INT J CANCER, V91, P763, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1128>3.0.CO;2-B; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926	54	105	118	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2005	24	53					7859	7868		10.1038/sj.onc.1208937	http://dx.doi.org/10.1038/sj.onc.1208937			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16103880				2022-12-28	WOS:000233463000005
J	Horinaka, M; Yoshida, T; Shiraishi, T; Nakata, S; Wakada, M; Nakanishi, R; Nishino, H; Matsui, H; Sakai, T				Horinaka, M; Yoshida, T; Shiraishi, T; Nakata, S; Wakada, M; Nakanishi, R; Nishino, H; Matsui, H; Sakai, T			Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells	ONCOGENE			English	Article						luteolin; DR5; apoptosis; caspase	TRAIL-INDUCED APOPTOSIS; IN-VIVO; TUMORICIDAL ACTIVITY; KILLER/DR5 GENE; LIGAND; INHIBITION; EXPRESSION; MUTATION; CANCER; FAMILY	Luteolin, a naturally occurring flavonoid, induces apoptosis in various cancer cells. Little is known however concerning the underlying molecular mechanisms responsible for this activity. In this report, we reveal a novel mechanism by which luteolin-induced apoptosis occurs, and show for the first time that the apoptosis by luteolin is mediated through death receptor 5 (DR5) upregulation. Luteolin markedly induced the expression of DR5, along with Bcl-2-interacting domain cleavage and the activation of caspase-8, -10, -9 and -3. In addition, suppression of DR5 expression with siRNA efficiently reduced luteolin-induced caspase activation and apoptosis. Human recombinant DR5/Fc also inhibited luteolin-induced apoptosis. On the other hand, luteolin induced neither DR5 protein expression nor apoptosis in normal human peripheral blood mononuclear cells. These results suggest that DR5 induced by luteolin plays a role in luteolin-induced apoptosis, and raises the possibility that treatment with luteolin might be promising as a new therapy against cancer.	Kyoto Prefectural Univ Med, Grad Sch Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ, Dept Appl Biochem, Sakyo Ku, Kyoto 6068522, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biochem & Mol Biol, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kawaramachi Hirokoji, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Dechant MJ, 2004, INT J CANCER, V109, P661, DOI 10.1002/ijc.20008; ELANGOVAN V, 1994, CANCER LETT, V87, P107, DOI 10.1016/0304-3835(94)90416-2; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HUANG MT, 1983, CARCINOGENESIS, V4, P1631, DOI 10.1093/carcin/4.12.1631; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jeng YM, 2002, CANCER LETT, V181, P205, DOI 10.1016/S0304-3835(02)00051-4; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Ko WG, 2002, PHYTOTHER RES, V16, P295, DOI 10.1002/ptr.871; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MAY E, 1991, ONCOGENE, V6, P1363; MERFORT I, 1994, PHARMAZIE, V49, P509; Miean KH, 2001, J AGR FOOD CHEM, V49, P3106, DOI 10.1021/jf000892m; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Pai SI, 1998, CANCER RES, V58, P3513; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Sheikh MS, 2004, CURR CANCER DRUG TAR, V4, P97, DOI 10.2174/1568009043481597; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimoi K, 1998, FEBS LETT, V438, P220, DOI 10.1016/S0014-5793(98)01304-0; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Ueda H, 2003, BIOL PHARM BULL, V26, P560, DOI 10.1248/bpb.26.560; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7	41	143	156	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7180	7189		10.1038/sj.onc.1208874	http://dx.doi.org/10.1038/sj.onc.1208874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007131				2022-12-28	WOS:000232990100007
J	Uddin, S; Hussain, AR; Manogaran, PS; Al-Hussein, K; Platanias, LC; Gutierrez, MI; Bhatia, KG				Uddin, S; Hussain, AR; Manogaran, PS; Al-Hussein, K; Platanias, LC; Gutierrez, MI; Bhatia, KG			Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma	ONCOGENE			English	Article						PEL; curcumin; cell death; NHL therapy	FACTOR-KAPPA-B; CYTOCHROME-C RELEASE; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; SIGNAL TRANSDUCER; DIETARY CURCUMIN; IN-VITRO; ACTIVATION; INHIBITION; KINASE	The mechanisms that regulate induction of the antiapoptotic state and mitogenic signals in primary effusion lymphoma (PEL) are not well known. In efforts to identify novel approaches to block the proliferation of PEL cells, we found that curcumin (diferuloylmethane), a natural compound isolated from the plant Curcuma Ionga, inhibits cell proliferation and induces apoptosis in a dose dependent manner in several PEL cell lines. Such effects of curcumin appear to result from suppression of the constitutively active STAT3 through inhibition of Janus kinase 1 (JAK1). Our data also demonstrate that curcumin induces loss of mitochondrial membrane potential with subsequent release of cytochrome c and activation of caspase-3, followed by polyadenosin-5'-diphosphate-ribose polymerase (PARP) cleavage. Altogether, our findings suggest a novel function for curcumin, acting as a suppressor of JAK-1 and STAT3 activation in PEL cells, leading to inhibition of proliferation and induction of caspase-dependent apoptosis. Therefore, curcumin may have a future therapeutic role in PEL and possibly other malignancies with constitutive activation of STAT3.	King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, BMR, Riyadh 11211, Saudi Arabia; Northwestern Univ, Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; NCI, Canc Diagnosis Program, Rockville, MD USA	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Uddin, S (corresponding author), King Fahad Natl Ctr Childrens Canc & Res, MBC98-16,POB 3354, Riyadh 11211, Saudi Arabia.	Shahab@kfshrc.edu.sa; Bhatiak@mail.nih.gov		Uddin, Shahab/0000-0003-1886-6710				Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Aoki Y, 2000, BLOOD, V96, P1599, DOI 10.1182/blood.V96.4.1599.h8001599_1599_1601; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Barton BE, 2004, MOL CANCER THER, V3, P1183; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Cannon ML, 2004, ONCOGENE, V23, P514, DOI 10.1038/sj.onc.1207021; Chen H, 1999, ANTICANCER RES, V19, P3675; Cheong JW, 2003, LEUKEMIA RES, V27, P1159, DOI 10.1016/S0145-2126(03)00102-4; Chuang SE, 2000, CARCINOGENESIS, V21, P331, DOI 10.1093/carcin/21.2.331; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697; Jones KD, 1999, BLOOD, V94, P2871; Kalechman Y, 2004, J BIOL CHEM, V279, P24724, DOI 10.1074/jbc.M312006200; Kawamori T, 1999, CANCER RES, V59, P597; Keller SA, 2000, BLOOD, V96, P2537; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Klepfish A, 2001, LEUKEMIA LYMPHOMA, V41, P439, DOI 10.3109/10428190109058002; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Limtrakul P, 1997, CANCER LETT, V116, P197, DOI 10.1016/S0304-3835(97)00187-0; Lodha R., 2000, Annals Academy of Medicine Singapore, V29, P37; MASOOD R, 1995, BLOOD, V85, P3423, DOI 10.1182/blood.V85.12.3423.bloodjournal85123423; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sredni B, 2004, CANCER RES, V64, P1843, DOI 10.1158/0008-5472.CAN-03-3179; Syng-ai C, 2004, MOL CANCER THER, V3, P1101; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Uddin S, 2005, CLIN CANCER RES, V11, P3102, DOI 10.1158/1078-0432.CCR-04-1857; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 2004, BIOCHEM BIOPH RES CO, V320, P932, DOI 10.1016/j.bbrc.2004.06.038; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Zhang CL, 2002, CLIN CANCER RES, V8, P1234	44	104	108	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7022	7030		10.1038/sj.onc.1208864	http://dx.doi.org/10.1038/sj.onc.1208864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044161				2022-12-28	WOS:000232833200004
J	Park, SW; Sung, MW; Heo, DS; Inoue, H; Shim, SH; Kim, KH				Park, SW; Sung, MW; Heo, DS; Inoue, H; Shim, SH; Kim, KH			Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines	ONCOGENE			English	Article						nitric oxide; NO; cyclooxygenase-2; COX-2; cAMP-response element; CRE	TRANSCRIPTION FACTOR; PROSTAGLANDIN E-2; KAPPA-B; EPITHELIAL-CELLS; CARCINOMA CELLS; NECK-CANCER; HEAD; SYNTHASE; GROWTH; COX-2	We previously showed that nitric oxide (NO) induces overexpression of cyclooxygenase-2 (COX-2) and production of prostaglandin E-2 in cancer cells. Here, we investigated the mechanisms by which NO induces COX-2 expression in cancer cells. We found that the cAMP-response element (CRE) is a critical factor in NO-induced COX-2 expression in all cells tested. We found that in cancer cells, three transcription factors (TFs) cAMP response element-binding protein (CREB), activating transcription factor-2 (ATF-2) and c-jun, bound the CRE in the COX-2 promoter, and their activities were increased by addition of the NO donor, S-nitroso-N-acetyl-D, L-penicillamine (SNAP). NO-induced activation of soluble guanylate cyclase (sGC), p38 and c-Jun NH2 terminal kinase (JNK) upregulated the three TFs, leading to COX-2 overexpression. Addition of dibutyryl-cGMP (db-cGMP) induced COX-2 expression in a manner similar to SNAP; this induction was blocked by a p38 inhibitor (SB202190), but not by a JNK inhibitor (SP600125). NO-induced cGMP was found to activate CREB and ATF-2 in a p38, but not c-jun- dependent manner,while NO induced JNK in a cGMP-independent manner, leading to subsequent activation of c-jun and ATF-2. These results suggest that the low concentrations of endogenous NO present in cancer cell may induce the expression of many genes, including COX-2, which promotes the growth and survival of tumor cells.	Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Clin Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Nara Womens Univ, Dept Food Sci & Nutr, Nara 630, Japan	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Nara Womens University	Sung, MW (corresponding author), Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 28 Yongon Dong, Seoul 110744, South Korea.	mwsung@snu.ac.kr	Kim, Kwang Hyun/J-5385-2012; Heo, Dae/J-2184-2012	Heo, Dae/0000-0001-5221-173X				Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chabot-Fletcher M., 1996, PHARM REV COMMUN, V8, P317; Chan G, 1999, CANCER RES, V59, P991; Chung PS, 2000, LARYNGOSCOPE, V110, P1312, DOI 10.1097/00005537-200008000-00016; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Habib A, 1997, J IMMUNOL, V158, P3845; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HEO DS, 1989, CANCER RES, V49, P5167; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Inoue H, 2000, J BIOL CHEM, V275, P28028; Lee DW, 2002, ANTICANCER RES, V22, P2089; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Liu YM, 2004, J BIOL CHEM, V279, P18694, DOI 10.1074/jbc.M308136200; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Nose F, 2002, AM J CLIN PATHOL, V117, P546; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Posadas I, 2000, N-S ARCH PHARMACOL, V361, P98, DOI 10.1007/s002109900150; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Son HJ, 2001, J CLIN GASTROENTEROL, V33, P383, DOI 10.1097/00004836-200111000-00008; Song SH, 2001, CANCER RES, V61, P4628; STADLER J, 1993, J LEUKOCYTE BIOL, V53, P165, DOI 10.1002/jlb.53.2.165; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Sun YJ, 2002, CANCER RES, V62, P6323; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943	38	46	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6689	6698		10.1038/sj.onc.1208816	http://dx.doi.org/10.1038/sj.onc.1208816			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007171				2022-12-28	WOS:000232367800010
J	Croonquist, PA; Van Ness, B				Croonquist, PA; Van Ness, B			The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype	ONCOGENE			English	Article						myeloma; ras; EZH2	HISTONE METHYLTRANSFERASE ACTIVITY; THERAPEUTIC RESPONSE; H3 METHYLTRANSFERASE; ACTIVATING MUTATIONS; DROSOPHILA ENHANCER; MULTIPLE-MYELOMA; PROSTATE-CANCER; LINE ANBL6; GENE; DIFFERENTIATION	Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation. We found that EZH2 protein expression is induced by interleukin 6 (IL-6) in growth factor-dependent cell lines and is constitutive in IL-6-independent cell lines. Furthermore, EZH2 expression correlates with proliferation and B-cell terminal differentiation. Significantly, EZH2 protein inhibition by short interference RNA treatment results in MM cell growth arrest. Conversely, EZH2 ectopic overexpression induces growth factor independence. We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N- or K-ras gene requires EZH2 activity. Finally, this is the first report to demonstrate that EZH2 has oncogenic activity in vivo, and that cell transformation and tumor formation require histone methyltransferase activity.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Mol Cellular Dev Biol & Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Canc Ctr Res Bldg,MMC 806,6-160 Jackson Hall,321, Minneapolis, MN 55455 USA.	vanne001@umn.edu			NATIONAL CANCER INSTITUTE [P01CA062242, T32CA009138] Funding Source: NIH RePORTER; NCI NIH HHS [CA09138, CA62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Bajusz I, 2001, GENETICS, V159, P1135; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Chen-Kiang S, 1995, Curr Top Microbiol Immunol, V194, P189; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Cheung WC, 2002, LEUKEMIA, V16, P1182, DOI 10.1038/sj.leu.2402481; Cheung WC, 2001, LEUKEMIA, V15, P264, DOI 10.1038/sj.leu.2402022; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; JELINEK DF, 1993, CANCER RES, V53, P5320; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Raaphorst FM, 2001, J IMMUNOL, V166, P5925, DOI 10.4049/jimmunol.166.10.5925; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	33	124	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6269	6280		10.1038/sj.onc.1208771	http://dx.doi.org/10.1038/sj.onc.1208771			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007202				2022-12-28	WOS:000231877100008
J	Thomas, M; Massimi, P; Navarro, C; Borg, JP; Banks, L				Thomas, M; Massimi, P; Navarro, C; Borg, JP; Banks, L			The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins	ONCOGENE			English	Article						HPV; PDZ proteins; tumour suppressor; polarity	LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; LETHAL-GIANT-LARVAE; PROLIFERATION CONTROL; DROSOPHILA EPITHELIA; MUTATIONAL ANALYSIS; HUMAN SCRIBBLE; CELL POLARITY; HUMAN HOMOLOG; PDZ DOMAIN	The E6 proteins of the high-risk Human papillomaviruses (HPV) types have a well-documented ability to target certain cellular proteins for ubiquitin-mediated degradation via the proteasome. Previous studies have shown that E6 proteins interact differently with different target proteins, and that the viral proteins, depending upon the target, may recruit diverse cellular ubiquitin-protein ligases. In this study, we have examined the abilities of E6 proteins from HPV-16 and HPV-18 to interact with and induce the degradation of two PDZ domain-containing targets, Dlg and hScrib. We have also mapped the binding site of E6 on hScrib and shown that the interaction of E6 with hScrib is distinct from its interactions with other PDZ domain-containing targets. This is reflected in the efficiency with which the two viral E6 proteins can inhibit hScrib's suppression of cell transformation. Dlg and hScrib have complementary activities in the control of epithelial cell polarity and the fact that both are targeted by high-risk HPV E6 proteins underlines their importance. Our finding that they are each targeted differently by HPV-16 and HPV-18 E6s suggests that the two viruses are subjected to somewhat different constraints and provides a possible explanation for the apparent redundancy in targeting both parts of this important control mechanism.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Inst J Paoli I Calmettes, INSERM, INst Rech Canc Marseille, UMR 599, F-13009 Marseille, France	International Center for Genetic Engineering & Biotechnology (ICGEB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382				Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Massimi P, 2003, EXP CELL RES, V290, P265, DOI 10.1016/S0014-4827(03)00317-3; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; PIM D, 1994, ONCOGENE, V9, P1869; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	40	100	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6222	6230		10.1038/sj.onc.1208757	http://dx.doi.org/10.1038/sj.onc.1208757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16103886				2022-12-28	WOS:000231877100003
J	Yan, SR; Joseph, RR; Rosen, K; Reginato, MJ; Jackson, A; Allaire, N; Brugge, JS; Jobin, C; Stadnyk, AW				Yan, SR; Joseph, RR; Rosen, K; Reginato, MJ; Jackson, A; Allaire, N; Brugge, JS; Jobin, C; Stadnyk, AW			Activation of NF-kappa B following detachment delays apoptosis in intestinal epithelial cells	ONCOGENE			English	Article						anoikis; intestinal epithelial cell; apoptosis; NF-kappa B; detachment	INDUCED NEUTROPHIL APOPTOSIS; ULCERATIVE-COLITIS; GENE-EXPRESSION; KINASE; ALPHA; RECEPTOR; ANOIKIS; PHOSPHORYLATION; INHIBITION; CANCER	We reported earlier that IL-1 beta, an NF-kappa B-regulated cytokine, was made by intestinal epithelial cells during detachment-induced apoptosis (anoikis) and that IL-1 was antiapoptotic for detached cells. Since surviving anoikis is a prerequisite for cancer progression and metastases, we are further exploring the link between anoikis and cytokines. Here we determined that multiple genes are expressed following detachment including a number of NF-kappa B- regulated products and therefore aimed to determine whether NF-kappa B signalling plays any role in regulating apoptosis. Using Western blotting, we detected that I kappa B alpha becomes phosphorylated immediately following detachment and that levels of phospho-I kappa B alpha peaked within 20 min. Phosphorylation of I kappa B alpha was followed by Rel A (p65) nuclear translocation. Increased NF-kappa B activity following detachment was confirmed using the detection of NF-kappa B-promoted luciferase gene expression delivered by adenovirus infection. Infection of cells with adenovirus expressing a super-repressor I kappa B alpha protein and pharmacological inhibitors of NF-kappa B resulted in the failure to phosphorylate I kappa B alpha, a more rapid activation of caspases and earlier apoptosis. We also detected that I kappa B kinase alpha (IKK alpha) and not IKK beta became phosphorylated following detachment. Since IKK alpha is activated by NF-kappa B-inducing kinase (NIK), we overexpressed native NIK using an adenovirus vector that resulted in enhanced phospho-I kappa B alpha and nuclear p65 in detached cells compared to control detached cells but did not result in a significantly greater number of cells surviving to 24 h. We conclude that detachment directly activates NF-kappa B, which, in addition to launching an inflammatory cytokine wave, contributes to a delay in apoptosis in intestinal epithelial cells.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4R2, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R2, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4R2, Canada; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Aventis Pharmaceut, Cambridge, MA USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Dalhousie University; Dalhousie University; Dalhousie University; Harvard University; Harvard Medical School; Sanofi-Aventis; University of North Carolina; University of North Carolina Chapel Hill	Stadnyk, AW (corresponding author), IWK Hlth Ctr, Mucosal Immunol Res, 5850 Univ Ave, Halifax, NS B3K 6R8, Canada.	astadnyk@dal.ca	Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094	NCI NIH HHS [R01 CA105134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bader T, 1996, J IMMUNOL, V157, P3089; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Biswas DK, 2003, CANCER RES, V63, P290; Bonner S, 2001, INFECT IMMUN, V69, P3143, DOI 10.1128/IAI.69.5.3143-3149.2001; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Elewaut D, 1999, J IMMUNOL, V163, P1457; Evertsson S, 2002, INT J MOL MED, V10, P547; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gill JS, 2000, NEUROBIOL DIS, V7, P448, DOI 10.1006/nbdi.2000.0312; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Jijon H, 2004, CELL SIGNAL, V16, P1023, DOI 10.1016/j.cellsig.2004.02.005; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Karlen P, 1999, AM J GASTROENTEROL, V94, P1047; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Ma A, 2001, MOL BIOL CELL, V12, P1; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Miller TL, 2002, IMMUNOLOGY, V105, P101, DOI 10.1046/j.0019-2805.2001.01352.x; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Russo MP, 2004, CELL SIGNAL, V16, P741, DOI 10.1016/j.cellsig.2003.11.007; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Scaife CL, 2002, CANCER RES, V62, P6870; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Shibata Y, 1996, J IMMUNOL, V156, P772; STADNYK AW, 1995, EXP CELL RES, V220, P298, DOI 10.1006/excr.1995.1319; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Theilhaber J, 2001, J COMPUT BIOL, V8, P585, DOI 10.1089/106652701753307502; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; van der Woude CJ, 2004, APOPTOSIS, V9, P123, DOI 10.1023/B:APPT.0000018794.26438.22; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Waterhouse CCM, 1999, CELL IMMUNOL, V193, P1, DOI 10.1006/cimm.1999.1468; Waterhouse CCM, 2001, EXP CELL RES, V269, P109, DOI 10.1006/excr.2001.5303; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	50	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6482	6491		10.1038/sj.onc.1208810	http://dx.doi.org/10.1038/sj.onc.1208810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007176	Green Accepted			2022-12-28	WOS:000232204100002
J	Ruscetti, FW; Akel, S; Bartelmez, SH				Ruscetti, FW; Akel, S; Bartelmez, SH			Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context	ONCOGENE			English	Review						transforming growth factor-beta 1; hematopoiesis; autocrine; stem cells	UMBILICAL-CORD BLOOD; PROTEIN-KINASE PATHWAY; HUMAN MARROW CULTURES; STEM-CELL QUIESCENCE; HUMAN-BONE-MARROW; RECEPTOR-TYPE II; TGF-BETA; SELF-RENEWAL; IN-VIVO; SIGNAL-TRANSDUCTION	Transforming growth factor-beta (TGF-beta) is a pleiotropic regulator of all stages of hematopoieis. The three mammalian isoforms (TGF-beta 1, 2 and 3) have distinct but overlapping effects on hematopoiesis. Depending on the differentiation stage of the target cell, the local environment and the concentration and isoform of TGF-beta, in vivo or in vitro, TGF-beta can be pro- or antiproliferative, pro- or antiapoptotic, pro- or antidifferentiative and can inhibit or increase terminally differentiated cell function. TGF-beta is a major regulator of stem cell quiescence, at least in vitro. TGF-beta can act directly or indirectly through effects on the bone marrow microenvironment. In addition, paracrine and autocrine actions of TGF-beta have overlapping but distinct regulatory effects on hematopoietic stem/progenitor cells. Since TGF-beta can act in numerous steps in the hematopoietic cascade, loss of function mutations in hematopoeitic stem cells (HSC) have different effects on hematopoiesis than transient blockade of autocrine TGF-beta 1. Transient neutralization of autocrine TGF-beta in HSC has therapeutic potential. In myeloid and erythroid leukemic cells, autocrine TGF-beta 1 and/or its Smad signals controls the ability of these cells to respond to various differentiation inducers, suggesting that this pathway plays a role in determining the cell fate of leukemic cells.	NCI, Expt Immunol Lab, Leukocyte Biol Sect, Canc Res Ctr, Frederick, MD 21702 USA; Hashemite Univ, Dept Med Lab Sci, Zarqa, Jordan; Hemogenix Inc, Colorado Springs, CO USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hashemite University	Ruscetti, FW (corresponding author), NCI, Expt Immunol Lab, Leukocyte Biol Sect, Canc Res Ctr, Bldg 567,RM 251, Frederick, MD 21702 USA.	Ruscettif@ncifcrf.gov			NATIONAL CANCER INSTITUTE [Z01BC009264, Z01BC010252] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R44EY028070] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NEI NIH HHS [R44 EY028070] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Akel S, 2003, STEM CELLS, V21, P557, DOI 10.1634/stemcells.21-5-557; ALGIETTA M, 1989, EXP HEMATOL, V17, P296; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bartelmez SH, 2000, BLOOD, V96, p474A; Batard P, 2000, J CELL SCI, V113, P383; Bertoncello Ivan, 2004, Methods Mol Biol, V263, P181; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Birchenall-Roberts MC, 2004, J BIOL CHEM, V279, P25605, DOI 10.1074/jbc.M402790200; Borkowski TA, 1997, J CLIN INVEST, V100, P575, DOI 10.1172/JCI119567; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; CASHMAN JD, 1990, BLOOD, V75, P96; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Chen CZ, 2002, P NATL ACAD SCI USA, V99, P15468, DOI 10.1073/pnas.202614899; Chen CZ, 2003, IMMUNITY, V19, P525, DOI 10.1016/S1074-7613(03)00265-6; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; DEXTER TM, 1979, ACTA HAEMATOL-BASEL, V62, P299, DOI 10.1159/000207593; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DUBOIS CM, 1994, BLOOD, V83, P3138; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; DYBEDAL I, 1995, BLOOD, V86, P949; Dybedal I, 1997, BLOOD, V90, P3395, DOI 10.1182/blood.V90.9.3395; EAVES CJ, 1991, BLOOD, V78, P110; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fan XL, 2002, J IMMUNOL, V168, P755, DOI 10.4049/jimmunol.168.2.755; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Grady WM, 1999, CANCER RES, V59, P320; GREENBERGER JS, 1983, FED PROC, V42, P2762; Hampson J, 1989, GROWTH FACTORS, V1, P193, DOI 10.3109/08977198909029128; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hatzfeld A, 1996, HUM GENE THER, V7, P207, DOI 10.1089/hum.1996.7.2-207; HATZFELD J, 1994, BLOOD CELLS, V20, P430; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Imbert AM, 1998, EXP HEMATOL, V26, P374; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1994, EXP HEMATOL, V22, P985; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Kalina U, 2001, EXP HEMATOL, V29, P602, DOI 10.1016/S0301-472X(01)00628-2; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1990, BLOOD, V75, P596; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kitamura K, 2000, BLOOD, V95, P3371, DOI 10.1182/blood.V95.11.3371.011k37_3371_3379; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; KUTER DJ, 1992, BLOOD, V79, P619; Langer JC, 2004, J EXP MED, V199, P5, DOI 10.1084/jem.20030980; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Laughlin MJ, 2001, BONE MARROW TRANSPL, V27, P1, DOI 10.1038/sj.bmt.1702740; LETTERIO J, 1998, J CLIN INVEST, V98, P2109; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Lieb E, 2004, TISSUE ENG, V10, P1414, DOI 10.1089/ten.2004.10.1414; LORD BI, 1990, INT J CELL CLONING, V8, P317, DOI 10.1002/stem.5530080501; LU L, 1993, EXP HEMATOL, V21, P1442; Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood-2004-08-3207; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474-9728.2004.00127.x; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NARA N, 1989, LEUKEMIA, V3, P572; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; NOLTA JA, 1990, HUM GENE THER, V1, P257, DOI 10.1089/hum.1990.1.3-257; OGAWA M, 1993, BLOOD, V81, P2844; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OMAY SB, 1995, EXP HEMATOL, V23, P244; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; Pierelli L, 2000, BLOOD, V95, P3001; PLOEMACHER RE, 1993, STEM CELLS, V11, P336, DOI 10.1002/stem.5530110412; Quesenberry PJ, 1998, P NATL ACAD SCI USA, V95, P15155, DOI 10.1073/pnas.95.26.15155; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; ROJNUCKARIN P, 1995, BLOOD, V85, P402; Rooke HM, 1999, LEUKEMIA, V13, P535, DOI 10.1038/sj.leu.2401384; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; Ruscetti FW, 1999, BLOOD, V94, p466A; Sakamaki S, 1999, BLOOD, V94, P1961, DOI 10.1182/blood.V94.6.1961.418k17_1961_1970; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SING GK, 1988, BLOOD, V72, P1504; Sitnicka E, 1996, BLOOD, V88, P82; Soma T, 1996, BLOOD, V87, P4561, DOI 10.1182/blood.V87.11.4561.bloodjournal87114561; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sorrentino BP, 2004, NAT REV IMMUNOL, V4, P878, DOI 10.1038/nri1487; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Stier S, 2003, BLOOD, V102, P1260, DOI 10.1182/blood-2002-10-3053; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; TESSIER N, 1988, BLOOD, V72, P159; Tsimberidou Apostolia-Maria, 2002, Expert Rev Anticancer Ther, V2, P437, DOI 10.1586/14737140.2.4.437; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; WAEGELL WO, 1994, EXP HEMATOL, V22, P1051; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wiesmann A, 2000, EXP HEMATOL, V28, P128, DOI 10.1016/S0301-472X(99)00141-1; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; WOLF NS, 1993, EXP HEMATOL, V21, P614; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159; Yang LP, 2005, J IMMUNOL, V174, P752, DOI 10.4049/jimmunol.174.2.752; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; Yu J, 1998, GENE THER, V5, P1265, DOI 10.1038/sj.gt.3300732; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhu T, 1997, ARCH BIOCHEM BIOPHYS, V339, P210, DOI 10.1006/abbi.1996.9835	141	79	90	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5751	5763		10.1038/sj.onc.1208921	http://dx.doi.org/10.1038/sj.onc.1208921			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123808				2022-12-28	WOS:000231452800010
J	Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L				Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L			Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression	ONCOGENE			English	Article						ELF; Smad4; spectrin; gastrointestinal cancer; E-cadherin	CELL-CELL ADHESION; GASTRIC-CANCER; MESENCHYMAL TRANSITION; LIVER DEVELOPMENT; IN-VITRO; SPECTRIN; CARCINOMA; MEMBRANE; PROTEIN; MICE	Inactivation of the transforming growth factor-beta (TGF-beta) pathway occurs often in malignancies of the gastrointestinal (GI) system. However, only a fraction of sporadic GI tumors exhibit inactivating mutations in early stages of cancer formation, suggesting that other mechanisms play a critical role in the inactivation of this pathway. Here, we show a wide range of GI tumors, including those of the stomach, liver and colon in elf(+/-) and elf(+/-)/Smad4(+/-) mutant mice. We found that embryonic liver fodrin ( ELF), a beta-Spectrin originally identified in endodermal stem/progenitor cells committed to foregut lineage, possesses potent antioncogenic activity and is frequently inactivated in GI cancers. Specifically, E-cadherin accumulation at cell-cell contacts and E-cadherin-beta-catenin-dependent epithelial cell-cell adhesion is disrupted in elf(+/-)/Smad4(+)/(-) mutant gastric epithelial cells, and could be rescued by ectopic expression of full-length elf, but not Smad3 or Smad4. Subcellular fractionation revealed that E-cadherin is expressed mainly at the cell membrane after TGF-beta stimulation. In contrast, elf(+/-)/Smad4(+/-) mutant tissues showed abnormal distribution of E-cadherin that could be rescued by overexpression of ELF but not Smad3 or Smad4. Our results identify a group of common lethal malignancies in which inactivation of TGF-beta signaling, which is essential for tumor suppression, is disrupted by inactivation of the ELF adaptor protein.	Georgetown Univ, Lab Canc Genet Digest Dis & Dev Mol Biol, Dept Surg, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dept Surg, Washington, DC USA; Dept Vet Affairs, Washington, DC USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mishra, B (corresponding author), Georgetown Univ, Lab Canc Genet Digest Dis & Dev Mol Biol, Dept Surg, Vincent T Lombardi Canc Res Ctr, Med Dent Bldg NW 210-212,3900 Reservoir Rd,NW, Washington, DC 20007 USA.	bm72@georgetown.edu; lopamishra@yahoo.com	Reddy, E. Premkumar/F-6233-2011; deng, chuxia/N-6713-2016	Mishra, Lopa/0000-0002-6850-0808	NCI NIH HHS [R01 CA106614A, R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111, R01 DK056111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111, Z01DK056012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Brooks-Wilson AR, 2004, J MED GENET, V41, P508, DOI 10.1136/jmg.2004.018275; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hadzija MP, 2004, MUTAT RES-FUND MOL M, V548, P61, DOI 10.1016/j.mrfmmm.2003.12.018; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, CANCER RES, V59, P4506; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Pinder JC, 2000, NATURE, V406, P253, DOI 10.1038/35018679; ROBERTS AB, 1990, TRANSFORMING GROWTH; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Scartozzi M, 2004, CANCER TREAT REV, V30, P451, DOI 10.1016/j.ctrv.2004.01.001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sormunen RT, 1999, J PATHOL, V187, P416; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	35	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1871	1886		10.1038/sj.onc.1209211	http://dx.doi.org/10.1038/sj.onc.1209211			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288220	Green Accepted			2022-12-28	WOS:000236224800004
J	Lin, M; Smith, LT; Smiraglia, DJ; Kazhiyur-Mannar, R; Lang, JC; Schuller, DE; Kornacker, K; Wenger, R; Plass, C				Lin, M; Smith, LT; Smiraglia, DJ; Kazhiyur-Mannar, R; Lang, JC; Schuller, DE; Kornacker, K; Wenger, R; Plass, C			DNA copy number gains in head and neck squamous cell carcinoma	ONCOGENE			English	Article						amplification; HNSCC; RLGS	COMPARATIVE-GENOMIC-HYBRIDIZATION; GENE AMPLIFICATION; CANDIDATE ONCOGENE; 3Q GAIN; C-MYC; CANCER; IDENTIFICATION; SEQUENCES; REGIONS; OVARIAN	Gene amplification, a common mechanism for oncogene activation in cancer, has been used as a tag for the identification of novel oncogenes. DNA amplification is frequently observed in head and neck squamous cell carcinoma (HNSCC) and potential oncogenes have already been reported. We applied restriction landmark genome scanning (RLGS) to study gene amplifications and low-level copy number changes in HNSCC in order to locate previously uncharacterized regions with copy number gains in primary tumor samples. A total of 63 enhanced RLGS fragments, indicative of DNA copy number changes, including gains of single alleles, were scored. Enhanced sequences were identified from 33 different chromosomal regions including those previously reported (e.g. 3q26.3 and 11q13.3) as well as novel regions (e.g. 3q29, 8q13.1, 8q22.3, 9q32, 10q24.32, 14q32.32, 17q25.1 and 20q13.33). Furthermore, our data suggest that amplicons 11q13.3 and 3q26.3-q29 may be divided into possibly two and three independent amplicons, respectively, an observation supported by published microarray expression data.	Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Otolaryngol, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; Roswell Pk Canc Inst, Dept Canc Genet & Comprehens Canc Ctr, Buffalo, NY USA; Ohio State Univ, Comp Informat Sci Dept, Columbus, OH USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Roswell Park Cancer Institute; University System of Ohio; Ohio State University	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, 420 W 12th Ave,Room 464A, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	Reever, Larson/H-9685-2019; Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Reever, Larson/0000-0002-5692-4793; Smiraglia, Dominic/0000-0001-8852-1510; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13123-02] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arai H, 2003, CANCER GENET CYTOGEN, V146, P16, DOI 10.1016/S0165-4608(03)00106-7; Bitzer M, 2003, ANTICANCER RES, V23, P1489; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Costello JF, 1997, CANCER RES, V57, P1250; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; Du Plessis L, 1999, CANCER RES, V59, P1877; Estilo CL, 2003, CLIN CANCER RES, V9, P2300; Fan CS, 2000, HUM PATHOL, V31, P169, DOI 10.1016/S0046-8177(00)80216-6; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermsen M, 2001, J PATHOL, V194, P177; HIROTSUNE S, 1992, CANCER RES, V52, P3642; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Knuutila S, 1998, AM J PATHOL, V152, P1107; Komiyama T, 1997, JPN J CANCER RES, V88, P476, DOI 10.1111/j.1349-7006.1997.tb00406.x; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Lukasova E, 2004, CHROMOSOMA, V112, P221, DOI 10.1007/s00412-003-0263-3; Lyons SK, 1997, BRIT MED BULL, V53, P554; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Matsumura K, 2000, GENE CHROMOSOME CANC, V29, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1032>3.0.CO;2-U; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Oga A, 2001, CANCER GENET CYTOGEN, V127, P24, DOI 10.1016/S0165-4608(00)00430-1; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; Racz A, 1999, EUR J CANCER, V35, P641, DOI 10.1016/S0959-8049(98)00419-5; Rao PH, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-5; Redon R, 2002, CANCER RES, V62, P6211; Riazimand SH, 2002, ONCOLOGY-BASEL, V63, P385, DOI 10.1159/000066220; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHIMKE RT, 1990, CANCER CELL-MON REV, V2, P149; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh B, 2001, CANCER RES, V61, P4506; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; SPEICHER MR, 1995, CANCER RES, V55, P1010; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tang TCM, 2002, CANCER RES, V62, P7157; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Wu R, 2003, AM J PATHOL, V162, P1603, DOI 10.1016/S0002-9440(10)64294-0	45	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1424	1433		10.1038/sj.onc.1209166	http://dx.doi.org/10.1038/sj.onc.1209166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247453				2022-12-28	WOS:000235708200017
J	Josson, S; Xu, Y; Fang, F; Dhar, SK; St Clair, DK; St Clair, WH				Josson, S; Xu, Y; Fang, F; Dhar, SK; St Clair, DK; St Clair, WH			RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells	ONCOGENE			English	Article						RelB; radiation; MnSOD	NF-KAPPA-B; NF-KAPPA-B2 P100; INDUCTION; TRANSCRIPTION; SPECIFICITY; RESPONSES; ASSAY	The relationship between NF-kappa B and resistance to radiation treatment in many tumor cell types has been generally well recognized. However, which members of the NF-kappa B family contribute to radiation resistance is unclear. In the present study, we demonstrate that RelB plays an important radioprotective role in aggressive prostate cancer cells, in part by the induction of antioxidant and antiapoptotic manganese superoxide dismutase (MnSOD) gene. RelB is both constitutively present and is inducible by radiation in aggressive prostate cancer cells. Using ectopically expressed dominant negative inhibitor, p100 mutant, and the siRNA approach, we demonstrate that selective inhibition of RelB significantly decreases the levels of MnSOD resulting in a significant increase in the sensitivity of prostate cancer cells to radiation treatment. These results demonstrate that RelB plays an important role in redox regulation of the cell and protects aggressive prostate cancer cells against radiation-induced cell death. Thus, inhibition of RelB could be a novel mechanism to radiosensitize prostate cancer.	Univ Kentucky, Chandler Med Ctr, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, WH (corresponding author), Univ Kentucky, Chandler Med Ctr, Dept Radiat Med, 800 Rose St N-10, Lexington, KY 40536 USA.	stclair@uky.edu			NATIONAL CANCER INSTITUTE [R01CA049797, R29CA049797] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA049797, R01 CA049797-14, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LESSARD L, 2005, P AM ASSOC CANC RES, V46, P3160; Murley JS, 2004, RADIAT RES, V162, P536, DOI 10.1667/RR3256; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401	19	72	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1554	1559		10.1038/sj.onc.1209186	http://dx.doi.org/10.1038/sj.onc.1209186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261162	Green Accepted			2022-12-28	WOS:000235890400012
J	Klein, F; Feldhahn, N; Herzog, S; Sprangers, M; Mooster, JL; Jumaa, H; Muschen, M				Klein, F; Feldhahn, N; Herzog, S; Sprangers, M; Mooster, JL; Jumaa, H; Muschen, M			BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells	ONCOGENE			English	Article						lineage commitment; lymphopoiesis; RNA; interference; alternative splicing	EXPRESSION; GENE; RECEPTOR; DIFFERENTIATION; LEUKEMOGENESIS; ISOFORM	Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement exhibit an undifferentiated phenotype. Comparing the genome-wide gene expression profiles of normal B-cell subsets and BCR-ABL1(+) pre-B lymphoblastic leukemia cells by SAGE, the leukemia cells show loss of B lymphoid identity and aberrant expression of myeloid lineage-specific molecules. Consistent with this, BCR-ABL1(+) pre-B lymphoblastic leukemia cells exhibit defective expression of IKAROS, a transcription factor needed for early lymphoid lineage commitment. As shown by inducible expression of BCR-ABL1 in human and murine B-cell precursor cell lines, BCR-ABL1 induces the expression of a dominant-negative IKAROS splice variant, termed IK6. Comparing matched leukemia sample pairs from patients before and during therapy with the BCR-ABL1 kinase inhibitor STI571 (Imatinib), inhibition of BCR-ABL1 partially corrected aberrant expression of IK6 and lineage infidelity of the leukemia cells. To elucidate the contribution of IK6 to lineage infidelity in BCR-ABL1(+) cell lines, IK6 expression was silenced by RNA interference. Upon inhibition of IK6, BCR-ABL1(+) leukemia cells partially restored B lymphoid lineage commitment. Therefore, we propose that BCR-ABL1 induces aberrant splicing of IKAROS, which interferes with lineage identity and differentiation of pre-B lymphoblastic leukemia cells.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunobiol, Freiburg, Germany	Heinrich Heine University Dusseldorf; Max Planck Society	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5,Bldg 14-80, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de		Herzog, Sebastian/0000-0001-7167-3489				Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Feldhahn N, 2002, J EXP MED, V196, P1291, DOI 10.1084/jem.20020881; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Kirstetter P, 2002, EUR J IMMUNOL, V32, P720, DOI 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Klein F, 2003, P NATL ACAD SCI USA, V100, P6747, DOI 10.1073/pnas.1031503100; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Laurent E, 2001, CANCER RES, V61, P2343; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Muschen M, 2002, P NATL ACAD SCI USA, V99, P10014, DOI 10.1073/pnas.152327399; Nakase K, 2000, CANCER RES, V60, P4062; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Salesse S, 2004, LEUKEMIA, V18, P727, DOI 10.1038/sj.leu.2403310; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tonnelle C, 2001, BLOOD, V98, P2673, DOI 10.1182/blood.V98.9.2673; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	20	49	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1118	1124		10.1038/sj.onc.1209133	http://dx.doi.org/10.1038/sj.onc.1209133			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205638				2022-12-28	WOS:000235361000016
J	Russell, JL; Weaks, RL; Berton, TR; Johnson, DG				Russell, JL; Weaks, RL; Berton, TR; Johnson, DG			E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway	ONCOGENE			English	Article						E2F; p53; p21; p19ARF	TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; TUMOR-SUPPRESSOR; DNA-DAMAGE; MOUSE SKIN; P53-DEPENDENT APOPTOSIS; E2F-1-INDUCED APOPTOSIS; P53-MEDIATED APOPTOSIS; DEREGULATED EXPRESSION; TRANSGENIC MODEL	The E2F1 transcription factor, which is deregulated in most human cancers by mutations in the p16-cyclin D-Rb pathway, has both oncogenic and tumor-suppressive properties. This is dramatically illustrated by the phenotype of an E2F1 transgenic mouse model that spontaneously develops tumors in the skin and other epithelial tissues but is resistant to papilloma formation when subjected to a two-stage carcinogenesis protocol. Here, this E2F1 transgenic model was used to further explore the tumor-suppressive property of E2F1. Transgenic expression of E2F1 was found to inhibit ras-driven skin carcinogenesis at the promotion stage independent of the type of promoting agent used. E2F1 transgenic epidermis displayed increased expression of p19(ARF), p53, and p21(Cip1). Inactivation of either p53 or Arf in E2F1 transgenic mice restored sensitivity to two-stage skin carcinogenesis. While Arf inactivation impaired tumor suppression and p21 induction by E2F1, it did not reduce the level of apoptosis observed in E2F1 transgenic mice. Based on these findings, we propose that E2F1 suppresses ras-driven skin carcinogenesis through a nonapoptotic mechanism involving ARF and p53.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	djohnson@mdanderson.org		Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA 09480, CA 79648, CA 16672] Funding Source: Medline; NIEHS NIH HHS [ES 07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, T32CA009480, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FISCHER SM, 1987, CARCINOGENESIS, V8, P421, DOI 10.1093/carcin/8.3.421; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lin WC, 2001, GENE DEV, V15, P1833; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell DL, 1999, CANCER RES, V59, P2875; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Powers JT, 2004, MOL CANCER RES, V2, P203; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CANCER RES, V60, P3689; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang DW, 2001, MOL CARCINOGEN, V31, P90, DOI 10.1002/mc.1044; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					867	876		10.1038/sj.onc.1209120	http://dx.doi.org/10.1038/sj.onc.1209120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205640				2022-12-28	WOS:000235212700006
J	Xia, G; Kumar, SP; Stein, JP; Singh, J; Krasnoperov, V; Zhu, S; Hassanieh, L; Smith, DL; Buscarini, M; Broek, D; Quinn, DI; Weaver, FA; Gill, PS				Xia, G; Kumar, SP; Stein, JP; Singh, J; Krasnoperov, V; Zhu, S; Hassanieh, L; Smith, DL; Buscarini, M; Broek, D; Quinn, DI; Weaver, FA; Gill, PS			EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival	ONCOGENE			English	Article						receptor tyrosine kinase; bladder cancer; cell growth; EphB4	LIGAND EPHRIN-B2; CARCINOMA; PROTEIN; CISPLATIN; P53; CHEMOTHERAPY; METHOTREXATE; GEMCITABINE; VINBLASTINE; PROGRESSION	We sought to evaluate the biological function of the receptor tyrosine kinase EphB4 in bladder cancer. All of the nine bladder cancer cell lines examined express EphB4 and the receptor could be phosphorylated following stimulation with its cognate ligand, EphrinB2. Out of the 15 fresh bladder cancer specimens examined, 14 expressed EphB4 with a mean sevenfold higher level of expression compared to adjacent normal urothelium. EphB4 expression was regulated by several mechanisms: EPHB4 gene locus was amplified in 27% tumor specimens and 33% cell lines studied; inhibition of EGFR signaling downregulated EphB4 levels; and forced expression of wild-type p53 reduced EphB4 expression. EphB4 knockdown using specific siRNA and antisense oligodeoxynucleotides molecules led to a profound inhibition in cell viability associated with apoptosis via activation of caspase-8 pathway and downregulation of anti apoptotic factor, bcl-xl. Furthermore, EphB4 knockdown significantly inhibited tumor cell migration and invasion. EphB4 knockdown in an in vivo murine tumor xenograft model led to a nearly 80% reduction in tumor volume associated with reduced tumor proliferation, increased apoptosis and reduced tumor microvasculature. EphB4 is thus a potential candidate as a predictor of disease outcome in bladder cancer and as target for novel therapy.	Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA; VasGene Therapeut Inc, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Gill, PS (corresponding author), Univ So Calif, Keck Sch Med, Dept Med, 1441 Eastlake Ave,Norris Canc Res,NOR 6330, Los Angeles, CA 90033 USA.	parkashg@usc.edu	Quinn, David I/F-4343-2015; Singh, J B/ABF-5574-2021; Quinn, David/N-3730-2019; Reever, Larson/H-9685-2019	Quinn, David I/0000-0002-1411-0417; Singh, J B/0000-0001-9029-2462; Quinn, David/0000-0002-1411-0417; Reever, Larson/0000-0002-5692-4793; buscarini, maurizio/0000-0002-9228-3348; Smith, Lynne/0000-0003-2400-659X	NCI NIH HHS [R01CA72918] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Berclaz G, 2003, ANN ONCOL, V14, P220, DOI 10.1093/annonc/mdg072; Buscarini M, 2005, BJU INT, V95, P739, DOI 10.1111/j.1464-410X.2005.05393.x; Chatterjee SJ, 2004, J CLIN ONCOL, V22, P1007, DOI 10.1200/JCO.2004.05.174; Chow NH, 2001, CLIN CANCER RES, V7, P1957; COOPER MJ, 1994, ONCOL RES, V6, P569; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Gontero P, 2004, EUR UROL, V46, P296, DOI 10.1016/j.eururo.2004.04.001; Hara I, 2001, J UROLOGY, V165, P1769, DOI 10.1016/S0022-5347(05)66411-7; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Holder N, 1999, DEVELOPMENT, V126, P2033; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; LOGOTHETIS CJ, 1990, J CLIN ONCOL, V8, P1050, DOI 10.1200/JCO.1990.8.6.1050; LUTZEYER W, 1982, J UROLOGY, V127, P250, DOI 10.1016/S0022-5347(17)53725-8; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Masood R, 2005, BLOOD, V105, P1310, DOI 10.1182/blood-2004-03-0933; Masood R, 2003, INT J CANCER, V104, P603, DOI 10.1002/ijc.10996; Munarini N, 2002, J CELL SCI, V115, P25; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Oates AC, 1999, MECH DEVELOP, V83, P77, DOI 10.1016/S0925-4773(99)00036-2; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Sternberg CN, 2001, CANCER, V92, P2993, DOI 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2; Takai N, 2001, ONCOL REP, V8, P567; Tickle C, 1999, CURR OPIN GENET DEV, V9, P455, DOI 10.1016/S0959-437X(99)80069-0; Vasala K, 2003, UROLOGY, V62, P952, DOI 10.1016/S0090-4295(03)00660-5; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; XIA G, 2005, CLIN CANCER RES, V11, P405; Xia GB, 2005, CANCER RES, V65, P4623, DOI 10.1158/0008-5472.CAN-04-2667	42	78	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					769	780		10.1038/sj.onc.1209108	http://dx.doi.org/10.1038/sj.onc.1209108			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205642				2022-12-28	WOS:000235068800012
J	Hausel, P; Latado, H; Courjault-Gautier, F; Felley-Bosco, E				Hausel, P; Latado, H; Courjault-Gautier, F; Felley-Bosco, E			Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase	ONCOGENE			English	Article						inducible nitric oxide synthase; Src kinase; tyrosine phosphorylation	INTESTINAL EPITHELIAL-CELLS; ULCERATIVE-COLITIS; TYROSINE KINASES; CROHNS-DISEASE; PROTEIN-KINASE; EXPRESSION; ACTIVATION; PATHWAY; INDUCTION; CANCER	Inducible nitric oxide synthase ( iNOS) expression is regulated at both the transcriptional and post-transcriptional level in epithelial cells. The aim of this study was to characterize the effects of tyrosine phosphorylation on iNOS activity. In a human intestinal epithelial cell line stimulated with cytokines, tyrosine phosphorylation of human iNOS protein was observed after 30 min exposure to pervanadate (PV), an inhibitor of protein tyrosine phosphatases. 4-Amino-5-(4-chlorophenyl)7-(t-butyl) pyrazolo[3,4-d] pyrimidine, a specific inhibitor of Src tyrosine kinases, abolished the PV-induced iNOS tyrosine phosphorylation. Cotransfection of Src with iNOS cDNA in human embryonic kidney (HEK) 293 cells resulted in a threefold (P < 0.001) increase of iNOS protein levels and tyrosine phosphorylation of iNOS. In the presence of Src, 76% of wild-type (wt) iNOS was redistributed to detergent-insoluble domains and iNOS activity was decreased by 28% (P < 0.05) despite increased iNOS protein levels. Analysis of iNOS tyrosine mutants revealed decreased Src-induced effects in Y151F iNOS mutant. Using a GST-fusion protein containing a domain encompassing Y151, we show that Y151 is a direct substrate for active Src in vitro. These findings indicate a role for iNOS tyrosine phosphorylation in the regulation of iNOS activity and the implication of Src tyrosine kinases in this pathway.	Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Felley-Bosco, E (corresponding author), Dept Pharmacol & Toxicol, Rue Burgnon 27, CH-1005 Lausanne, Switzerland.	emanuela.felley-bosco@unil.ch	Felley-Bosco, Emanuela/E-7484-2017	Felley-Bosco, Emanuela/0000-0002-3408-0294				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Ambs S, 1998, CANCER RES, V58, P334; Andre M, 2005, BIOCHEM PHARMACOL, V69, P595, DOI 10.1016/j.bcp.2004.11.007; Andre M, 2003, FEBS LETT, V546, P223, DOI 10.1016/S0014-5793(03)00576-3; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chiu T, 2002, AM J PHYSIOL-CELL PH, V282, pC434, DOI 10.1152/ajpcell.00240.2001; COBBS CS, 1995, CANCER RES, V55, P727; Espey MG, 2000, J BIOL CHEM, V275, P11341, DOI 10.1074/jbc.275.15.11341; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; FELLEYBOSCO E, 1994, AM J RESP CELL MOL, V11, P159, DOI 10.1165/ajrcmb.11.2.7519434; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kimura H, 1997, DIGEST DIS SCI, V42, P1047, DOI 10.1023/A:1018849405922; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Miller MJS, 1999, AM J PHYSIOL-GASTR L, V276, pG795, DOI 10.1152/ajpgi.1999.276.4.G795; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; Navarro-Lerida I, 2004, J BIOL CHEM, V279, P55682, DOI 10.1074/jbc.M406621200; Paccani SR, 2005, BLOOD, V105, P2042, DOI 10.1182/blood-2004-04-1299; Pan JM, 1996, BIOCHEM J, V314, P889, DOI 10.1042/bj3140889; POSNER BI, 1994, J BIOL CHEM, V269, P4596; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Rumbo M, 2005, FEBS J, V272, P444, DOI 10.1111/j.1742-4658.2004.04484.x; Salh B, 1998, J IMMUNOL, V161, P6947; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Sondermann H, 2005, CELL, V121, P158, DOI 10.1016/j.cell.2005.04.001; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Vecchini F, 1997, CELL GROWTH DIFFER, V8, P261; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914	44	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					198	206		10.1038/sj.onc.1209030	http://dx.doi.org/10.1038/sj.onc.1209030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116474				2022-12-28	WOS:000234583600004
J	Wicks, SJ; Haros, K; Maillard, M; Song, L; Cohen, RE; ten Dijke, P; Chantry, A				Wicks, SJ; Haros, K; Maillard, M; Song, L; Cohen, RE; ten Dijke, P; Chantry, A			The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling	ONCOGENE			English	Article						transforming growth factor-beta; Smads; ubiquitin	UBIQUITIN LIGASE; PATHWAY; DEGRADATION; MEMBRANE; RECEPTOR; TARGETS; BINDS	Disruption of components in the transforming growth factor-beta (TGF-beta) signalling cascade is a common occurrence in human cancers. TGF-beta pathway activation is accomplished via serine/threonine kinase receptors and intracellular Smad transcription factors. A key regulatory step involves specific ubiquitination by Smurfs that mediate the proteasomal degradation of Smads and/or receptors. Here, we report a novel interaction between Smads and ubiquitin C-terminal hydrolase UCH37, a deubiquitinating enzyme that could potentially reverse Smurf-mediated ubiquitination. In GST pull down experiments, UCH37 bound weakly to Smad2 and Smad3, and bound very strongly to Smad7 in a region that is distinct from the -PY- motif in Smad7 that interacts with Smurf ubiquitin ligases. Endogenous Smad7 and UCH37 formed a stable complex in U4A/JAK1 cells, and FLAG-Smad7 co- immunoprecipitated with HA-UCH37 in transfected HEK-293 cells. In addition, we show that UCH37 can deubiquitinate and stabilize the type I TGF-beta receptor. Furthermore, overexpression of UCH37 upregulates TGF-beta-dependent transcription, and this effect is reversed in cells subject to RNAi-mediated knockdown of endogenous UCH37. These findings support a new role for deubiquitinating enzymes in the control of the TGF-beta signalling pathway, and provide a novel molecular target for the design of inhibitors with therapeutic potential in cancer.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands	University of East Anglia; University of Iowa; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Chantry, A (corresponding author), Univ E Anglia, Sch Biol Sci, Earlham Rd, Norwich NR4 7TJ, Norfolk, England.	a.chantry@uea.ac.uk	Song, Ling/HGA-5011-2022; 高, 雨莉/HGU-8187-2022; Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X	NIGMS NIH HHS [R01 GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	15	139	149	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8080	8084		10.1038/sj.onc.1208944	http://dx.doi.org/10.1038/sj.onc.1208944			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027725				2022-12-28	WOS:000233656600014
J	Melnikova, VO; Pacifico, A; Chimenti, S; Peris, K; Ananthaswamy, HN				Melnikova, VO; Pacifico, A; Chimenti, S; Peris, K; Ananthaswamy, HN			Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development	ONCOGENE			English	Article						UVB carcinogenesis; p53; tumor progression; differentiation; skin tumor	ULTRAVIOLET-B IRRADIATION; GROWTH-FACTOR; MUTANT P53; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; HAIRLESS MICE; FAS-LIGAND; DNA-REPAIR; RECEPTOR; ACTIVATION	Chronic exposure to ultraviolet (UV) radiation causes skin cancer in humans and mice. We have previously shown that in hairless SKH-hr1 mice, UVB-induced p53 mutations arise very early, well before tumor development. In this study, we investigated whether discontinuation of UVB exposure before the onset of skin tumors results in the disappearance of p53 mutations in the skin of hairless SKH-hr1 mice. Irradiation of mice at a dose of 2.5 kJ/m(2) three times a week for 8 weeks induced p53 mutations in the epidermal keratinocytes of 100% of the mice. UVB irradiation was discontinued after 8 weeks, but p53 mutations at most hotspot codons were still present even 22 weeks later. During that period, the percent of mice carrying p53(V154A/R155C), p53(H175H/H176Y), and p53(R275C) mutant alleles remained at or near 100%, whereas the percentage of mice with p53(R270C) mutation decreased by 45%. As expected, discontinuation of UVB after 8 weeks resulted in a delay in tumor development. A 100% of tumors carried p53(V154A/R155C) mutant alleles, 76% carried p53(H175H/H176Y) mutants, and 24 and 19% carried p53(R270C) and p53(R275C) mutants, respectively. These results suggest that different UVB-induced p53 mutants may provide different survival advantages to keratinocytes in the absence of further UVB exposure and that skin cancer development can be delayed but not prevented by avoidance of further exposure to UVB radiation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; Univ Aquila, Dept Dermatol, I-67100 Laquila, Italy	University of Texas System; UTMD Anderson Cancer Center; University of Rome Tor Vergata; University of L'Aquila	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, POB 301402, Houston, TX 77030 USA.	hanantha@mdanderson.org	Pacifico, Alessia/AAE-9908-2019; Pacifico, Alessia/J-3525-2018	Pacifico, Alessia/0000-0003-0348-0620; Pacifico, Alessia/0000-0003-0348-0620; Peris, Ketty/0000-0002-5237-0463	NCI NIH HHS [CA 16672, CA 46523, U01 CA105345] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, U01CA105345, R01CA046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Blum HF, 1969, BIOL EFFECTS ULTRAVI, P543; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; CHUNG KY, 1993, CANCER RES, V53, P1676; COFFER PJ, 1995, ONCOGENE, V11, P561; DEGRUIJL FR, 1991, CANCER RES, V51, P979; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EPSTEIN JH, 1962, J INVEST DERMATOL, V39, P455, DOI 10.1038/jid.1962.142; GILCHREST BA, 1990, ANNU REV MED, V41, P199; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jost M, 2000, EUR J DERMATOL, V10, P505; KANJILAL S, 1995, CANCER RES, V55, P3604; KANJILAL S, 1993, CANCER RES, V53, P2961; KIESER A, 1994, ONCOGENE, V9, P963; KRIPKE M L, 1991, Journal of Dermatology (Tokyo), V18, P429; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Leffell DJ, 1996, SCI AM, V275, P52, DOI 10.1038/scientificamerican0796-52; Li G, 1996, AM J PATHOL, V148, P1113; LIN JY, 1995, ONCOGENE, V10, P2387; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Marconi A, 1999, J INVEST DERMATOL, V113, P920, DOI 10.1046/j.1523-1747.1999.00773.x; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mudgil AV, 2003, J INVEST DERMATOL, V121, P191, DOI 10.1046/j.1523-1747.2003.12320.x; Ouhtit A, 2000, AM J PATHOL, V157, P1975, DOI 10.1016/S0002-9440(10)64836-5; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; Rebel H, 2001, CANCER RES, V61, P977; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; Ren ZP, 1996, ONCOGENE, V12, P765; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sigal A, 2000, CANCER RES, V60, P6788; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Ullrich SE, 2000, BIOCHEMICAL MODULATION OF SKIN REACTIONS, P281; URBACH F, 1991, DERMATOL CLIN, V9, P751; Urbach F, 1997, J PHOTOCH PHOTOBIO B, V40, P3, DOI 10.1016/S1011-1344(97)00029-8; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	53	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7055	7063		10.1038/sj.onc.1208863	http://dx.doi.org/10.1038/sj.onc.1208863			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007135				2022-12-28	WOS:000232833200007
J	Lomonosova, E; Subramanian, T; Chinnadurai, G				Lomonosova, E; Subramanian, T; Chinnadurai, G			Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K	ONCOGENE			English	Article						adenovirus; apoptosis; mitochondria; p53; E1B-19K	WILD-TYPE P53; COLORECTAL-CANCER CELLS; TUMOR-SUPPRESSOR P53; BCL-2 PROTEINS; E1B 19K; TRANSCRIPTIONAL ACTIVATION; E4ORF6 PROTEIN; P53-DEPENDENT APOPTOSIS; SV40-TRANSFORMED CELLS; HOST PROTEIN	Recent results have revealed that the p53 tumor suppressor protein possesses a direct transcription-independent apoptotic activity. During apoptosis induced by genotoxic stress, a small fraction of p53 is targeted to mitochondria where it initiates apoptosis by causing mitochondrial dysfunction. In adenovirus-infected cells, the expression of E1A protein enhances the accumulation of p53 during early phases of infection and during late times after infection, it is targeted for degradation by the combined action of E1B-55K and E4-orf6 proteins. The functional significance of E1A-mediated accumulation of p53 during early phases of viral replication is not known. Our studies with isogenic epithelial cell lines that differ only on the status of p53 indicate that Ad infection induces apoptosis by p53-dependent and -independent pathways and both pathways are suppressed by E1B-19K. We show that during early phase of Ad infection, a fraction of p53 is targeted to the mitochondria. In virus infected cells, a large fraction of the viral antiapoptosis protein E1B-19K is also localized in mitochondria during early and late phases of infection. Coimmunoprecipitation analysis has revealed that p53 and E1B-19K form a complex in mitochondria. The interaction of 19K involves two noncontiguous regions located around amino-acid residues 14-15 and 123-124. On p53, the mutations within the DNA-binding domain reduce interaction with E1B-19K. Our studies also suggest that 19K may additionally complex with the multidomain mitochondrial proapoptotic protein BAK, thereby reducing the level of p53 interaction with BAK. We suggest that p53-induced apoptosis may be important for efficient cell lysis and viral spread and that E1B-19K may neutralize the apoptotic activity of p53 at multiple levels.	St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BACCHETTI S, 1993, INT J ONCOL, V3, P781; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BECK GR, 1998, HUMAN TUMOR VIRUSES, P51; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; BETT AJ, 1995, VIRUS RES, V39, P75; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BOYD JM, 1995, ONCOGENE, V11, P1921; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Collett, 2003, MODELLING SURVIVAL D; Collot-Teixeira S, 2004, REV MED VIROL, V14, P301, DOI 10.1002/rmv.431; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Degenhardt K, 2000, Symp Soc Exp Biol, V52, P241; Dix BR, 2000, CANCER RES, V60, P2666; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2004, CELL CYCLE, V3, P1492, DOI 10.4161/cc.3.12.1318; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hale TK, 1999, J BIOL CHEM, V274, P23777, DOI 10.1074/jbc.274.34.23777; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Han J, 1996, MOL CELL BIOL, V16, P5857; HAN J, 1996, WANG, V10, P461; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Koch P, 2001, CANCER RES, V61, P5941; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mahyar-Roemer M, 2004, ONCOGENE, V23, P6226, DOI 10.1038/sj.onc.1207637; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2003, MOL CANCER RES, V1, P1001; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Subramanian T, 1995, ONCOGENE, V11, P2403; Subramanian T, 2003, J CELL BIOCHEM, V89, P1102, DOI 10.1002/jcb.10573; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TARODI B, 1993, INT J ONCOL, V3, P467; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Theodorakis P, 2002, CANCER RES, V62, P3373; Theodorakis P, 1996, ONCOGENE, V12, P1707; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang GD, 2004, ONCOL REP, V12, P955; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	99	36	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6796	6808		10.1038/sj.onc.1208836	http://dx.doi.org/10.1038/sj.onc.1208836			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007153				2022-12-28	WOS:000232527800007
J	Romanov, VV; James, CH; Sherrington, PD; Pettitt, AR				Romanov, VV; James, CH; Sherrington, PD; Pettitt, AR			Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia	ONCOGENE			English	Article						p53; basic fibroblast growth factor (bFGF); chronic lymphocytic leukaemia (CLL); microenvironment; MDM2; ATM	SYNDECAN-1 CD138 EXPRESSION; PHOSPHORYLATION; MDM2; APOPTOSIS; KINASE; INTERNALIZATION; UBIQUITINATION; ANGIOGENESIS; DYSFUNCTION; RESISTANCE	p53 is the most frequently inactivated gene in human cancers, reflecting its pivotal role in maintaining genomic integrity. The present study was conducted to explore the possibility that tumour cells with no intrinsic defects of the p53 pathway might nevertheless acquire p53 dysfunction through extrinsic suppression of the pathway by microenvironmental factors. Neoplastic cells from patients with chronic lymphocytic leukaemia (CLL) were cultured in the presence or absence of basic fibroblast growth factor ( bFGF) and exposed to ionizing radiation (IR) to induce p53 accumulation. bFGF is greatly increased in the plasma of CLL patients and can suppress p53 activation in some experimental models. IR induced a marked increase in p53 levels in 28 samples from 24 patients. bFGF inhibited IR-induced p53 accumulation to some extent in most of these samples and by more than 50% in seven samples from seven patients. Suppression of p53 activation by bFGF was frequently but not always accompanied by upregulation of the p53-inhibitory protein MDM2 and/or phosphorylation of MDM2 at serine 166, and was associated with impaired transcriptional activation of the p53 target gene p21. These observations provide the first demonstration in human cancer cells that the p53 pathway can be suppressed by factors in the tumour-cell microenvironment.	Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Pettitt, AR (corresponding author), Royal Liverpool Univ Hosp, Dept Haematol, Level 2 Duncan Bldg,Prescot St, Liverpool L7 8XP, Merseyside, England.	andrew.pettitt@rlbuht.nhs.uk						Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Ashton AW, 2004, CIRC RES, V94, P735, DOI 10.1161/01.RES.0000122043.11286.57; Bairey O, 2001, BRIT J HAEMATOL, V113, P400, DOI 10.1046/j.1365-2141.2001.02731.x; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Deguchi Y, 2002, J NEUROCHEM, V83, P381, DOI 10.1046/j.1471-4159.2002.01129.x; Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gora-Tybor J, 2003, MEDIAT INFLAMM, V12, P167, DOI 10.1080/0962935031000134888; Gora-Tybor J, 2002, NEOPLASMA, V49, P145; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4688, DOI 10.1210/en.139.11.4688; Kay NE, 2002, LEUKEMIA, V16, P911, DOI 10.1038/sj.leu.2402467; Krejci P, 2001, LEUKEMIA, V15, P228, DOI 10.1038/sj.leu.2402012; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Molica S, 2002, BRIT J CANCER, V86, P31, DOI 10.1038/sj.bjc.6600022; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Qiao DH, 2003, J BIOL CHEM, V278, P16045, DOI 10.1074/jbc.M211259200; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; Sebestyen A, 1997, EUR J CANCER, V33, P2273, DOI 10.1016/S0959-8049(97)00248-7; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Sutcliffe M, 2000, BRIT J HAEMATOL, V110, P239, DOI 10.1046/j.1365-2141.2000.02072-5.x; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Witzig TE, 1998, LEUKEMIA LYMPHOMA, V31, P167, DOI 10.3109/10428199809057596; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	41	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6855	6860		10.1038/sj.onc.1208895	http://dx.doi.org/10.1038/sj.onc.1208895			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16103882				2022-12-28	WOS:000232527800014
J	Taylor, GP; Matsuoka, M				Taylor, GP; Matsuoka, M			Natural history of adult T-cell leukemia/lymphoma and approaches to therapy	ONCOGENE			English	Review						ATLL; HTLV-I; tax; chemotherapy; transplantation; prevention	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; LEUKEMIA-LYMPHOMA; HTLV-I; COMBINATION CHEMOTHERAPY; MONOCLONAL-ANTIBODY; INFECTED-CELLS; KAPPA-B; PROTEASOME INHIBITOR; RECEPTOR ACTIVATOR	After cell-to-cell transmission, HTLV-I increases its viral genome by de novo infection and proliferation of infected cells. Proliferation of infected cells is clonal and persistent in vivo. During the carrier state, infected cells are selected in vivo by the host's immune system, the genetic and epigenetic environment of proviral integration sites, and other factors. In leukemic cells, tax gene expression is frequently impaired by genetic and epigenetic mechanisms. Such loss of Tax expression enables ATL cells to escape the host immune system. On the other hand, ATL cells acquire the ability to proliferate without Tax by intracellular genetic and epigenetic changes. Despite advances in support and the development of novel treatment agents, the prognosis for ATLL remains poor. A number of therapies, however, do appear to improve prognosis compared to CHOP (VEPA). These include interferon-alpha plus zidovudine (probably after 1-2 cycles of CHOP), intensive chemotherapy as in LSG-15 with G-CSF support and Allo-SCT (which includes the potential for cure). Emerging novel approaches include HDAC inhibitors, monoclonal antibodies, and proteasome inhibitors. Comparison between different therapeutic approaches is complicated by the range of natural history of ATLL, different recruitments of naive-to-therapy, refractory or relapsed patients, and variations in the reporting of outcome that frequently excludes difficult-to-evaluate patients. Moreover, results from relatively small proof-of-principle studies have not been extended with randomized, controlled trials. As a result, currently, there is no clear evidence to support the value of any particular treatment approach over others. To avoid further unnecessary patient suffering and to identify optimal therapy as rapidly as possible, large randomized, controlled trials encompassing multicenter, international collaborations will be necessary.	Kyoto Univ, Inst Virus Res, Ctr AIDS Res, Lab Virus Immunol,Sakyo Ku, Kyoto 6068507, Japan; Imperial Coll Sch Med, Fac Med, Dept GU Med & Communicable Dis, London W2 1PG, England	Kyoto University; Imperial College London	Matsuoka, M (corresponding author), Kyoto Univ, Inst Virus Res, Ctr AIDS Res, Lab Virus Immunol,Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	mmatsuok@virus.kyoto-u.ac.jp		Matsuoka, Masao/0000-0002-0473-754X				Ando Y, 2004, J OBSTET GYNAECOL RE, V30, P436, DOI 10.1111/j.1447-0756.2004.00227.x; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Arima N, 1999, Gan To Kagaku Ryoho, V26, P619; Arisawa K, 2002, CANCER CAUSE CONTROL, V13, P657, DOI 10.1023/A:1019511224501; Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176; Bangham CRM, 2003, INT J HEMATOL, V78, P297, DOI 10.1007/BF02983553; BARNARD AL, 2005, BLOOD           0414; Besson C, 2002, LEUKEMIA LYMPHOMA, V43, P2275, DOI 10.1080/1042819021000039983; Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017; Borg A, 1996, BRIT J HAEMATOL, V94, P713, DOI 10.1046/j.1365-2141.1996.02338.x; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Dierov J, 1999, CLIN CANCER RES, V5, P2540; DOI K, 2005, BLOOD, V19; Etoh K, 1999, INT J CANCER, V81, P859, DOI 10.1002/(SICI)1097-0215(19990611)81:6<859::AID-IJC4>3.0.CO;2-K; Etoh K, 1997, CANCER RES, V57, P4862; EZAKI K, 1991, CANCER, V68, P695, DOI 10.1002/1097-0142(19910815)68:4<695::AID-CNCR2820680405>3.0.CO;2-K; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Franchini G, 2003, INT J HEMATOL, V78, P280, DOI 10.1007/BF02983552; Fukushima T, 2005, LEUKEMIA, V19, P829, DOI 10.1038/sj.leu.2403682; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Han YF, 2004, J VIROL, V78, P6122, DOI 10.1128/JVI.78.12.6122-6133.2004; Harasawa H, 2002, LEUKEMIA, V16, P1799, DOI 10.1038/sj.leu.2402570; Harashima N, 2004, CANCER RES, V64, P391, DOI 10.1158/0008-5472.CAN-03-1452; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038/sj.thj.6200374; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038/sj.thj.6200195; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Kami M, 2003, BRIT J HAEMATOL, V120, P304, DOI 10.1046/j.1365-2141.2003.04054.x; Kannagi Mari, 2004, Expert Rev Anticancer Ther, V4, P369, DOI 10.1586/14737140.4.3.369; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; KATSUKI T, 1987, JPN J CANCER RES, V78, P639; KIKUCHI K, 1982, JPN J CLIN ONCOL, V12, P227; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Krueger A, 2003, IMMUNOL REV, V193, P58, DOI 10.1034/j.1600-065X.2003.00047.x; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; KUWAZURU Y, 1990, BLOOD, V76, P2065; Li HC, 2004, J INFECT DIS, V190, P1275, DOI 10.1086/423941; Mahieux R, 2005, LEUKEMIA LYMPHOMA, V46, P347, DOI 10.1080/10428190400019966; Makino T, 1994, Rinsho Ketsueki, V35, P42; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Matsuoka M, 2005, CANCER RES, V65, P4467, DOI 10.1158/0008-5472.CAN-05-0559; Matsushita K, 1999, LEUKEMIA LYMPHOMA, V36, P67, DOI 10.3109/10428199909145950; Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046/j.1365-2141.2001.02794.x; MERCIECA J, 1994, J CLIN ONCOL, V12, P2588, DOI 10.1200/JCO.1994.12.12.2588; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; MORRIS JC, 2001, 10 INT C HUM RETR S, V17, pS29; Nakane M, 1999, BONE MARROW TRANSPL, V24, P219, DOI 10.1038/sj.bmt.1701870; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182/blood-2002-09-2986; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Ogata M, 2002, BONE MARROW TRANSPL, V30, P699, DOI 10.1038/sj.bmt.1703702; Ohashi T, 2000, J VIROL, V74, P9610, DOI 10.1128/JVI.74.20.9610-9616.2000; OHNO R, 1993, CANCER, V71, P2217, DOI 10.1002/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8; Okamura J, 2005, BLOOD, V105, P4143, DOI 10.1182/blood-2004-11-4193; Okayama A, 2004, INT J CANCER, V110, P621, DOI 10.1002/ijc.20144; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Pawson R, 1998, LEUKEMIA LYMPHOMA, V31, P177, DOI 10.3109/10428199809057597; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P1088, DOI 10.1200/JCO.1988.6.7.1088; Shimoyama M., 1992, ADV ADULT T CELL LEU, P43; Siegel R S, 2001, Curr Treat Options Oncol, V2, P291, DOI 10.1007/s11864-001-0022-8; Taguchi H, 1996, J ACQ IMMUN DEF SYND, V12, P182, DOI 10.1097/00042560-199606010-00012; Tajima K, 2000, INT J HEMATOL, V71, P290; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; TAMIYA S, 1995, LEUKEMIA, V9, P1768; Tan C, 2002, CANCER RES, V62, P1083; Tanaka G, 2005, J INFECT DIS, V191, P1140, DOI 10.1086/428625; Taylor GP, 2001, AIDS RES HUM RETROV, V17, pS69; TGUCHI T, 1997, GAN TO KAGAKU RYOHO, V24, P1263; Thompson C, 2004, CURR OPIN PHARMACOL, V4, P408, DOI 10.1016/j.coph.2004.05.001; Tobinai K, 2003, INT J HEMATOL, V77, P512, DOI 10.1007/BF02986621; TOBINAI K, 1992, JPN J CLIN ONCOL, V22, P164; Tobinai K, 1994, P AN M AM SOC CLIN, V13, P378; Toyota M, 1999, CANCER RES, V59, P2307; TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038/bjc.1994.394; Tsukasaki K, 2003, INT J HEMATOL, V77, P164, DOI 10.1007/BF02983215; TSUKASAKI K, 1993, LEUKEMIA RES, V17, P157, DOI 10.1016/0145-2126(93)90061-O; Uike N, 1998, INTERNAL MED, V37, P411, DOI 10.2169/internalmedicine.37.411; UOZUMI K, 1995, LEUKEMIA LYMPHOMA, V18, P317, DOI 10.3109/10428199509059624; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1988, BLOOD, V72, P1805; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamada Y, 2003, LEUKEMIA LYMPHOMA, V44, P611, DOI 10.1080/1042819021000055039; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482; Zhang Z, 2003, CANCER RES, V63, P6453	103	159	163	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6047	6057		10.1038/sj.onc.1208979	http://dx.doi.org/10.1038/sj.onc.1208979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155611				2022-12-28	WOS:000231623400014
J	Porstmann, T; Griffiths, B; Chung, YL; Delpuech, O; Griffiths, JR; Downward, J; Schulze, A				Porstmann, T; Griffiths, B; Chung, YL; Delpuech, O; Griffiths, JR; Downward, J; Schulze, A			PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP	ONCOGENE			English	Article						PKB/Akt; SREBP; cholesterol and fatty acid biosynthesis; transcription; microarray	STEROL-REGULATORY-ELEMENT; PROTEIN-KINASE-B; NF-KAPPA-B; LIVER-X-RECEPTOR; BINDING-PROTEIN; PROSTATE-CANCER; SYNTHASE PROMOTER; GENE-EXPRESSION; DIFFERENTIAL REGULATION; TARGET PROMOTERS	Protein kinase B (PKB/Akt) has been shown to play a role in protection from apoptosis, cell proliferation and cell growth. It is also involved in mediating the effects of insulin, such as lipogenesis, glucose uptake and conversion of glucose into fatty acids and cholesterol. Sterol-regulatory element binding proteins (SREBPs) are the major transcription factors that regulate genes involved in fatty acid and cholesterol synthesis. It has been postulated that constitutive activation of the phosphatidylinositol 3 kinase/Akt pathway may be involved in fatty acid and cholesterol accumulation that has been described in several tumour types. In this study, we have analysed changes in gene expression in response to Akt activation using DNA microarrays. We identied several enzymes involved in fatty acid and cholesterol synthesis as targets for Akt-regulated transcription. Expression of these enzymes has previously been shown to be regulated by the SREBP family of transcription factors. Activation of Akt induces synthesis of full-length SREBP-1 and SREBP-2 proteins as well as expression of fatty acid synthase (FAS), the key regulatory enzyme in lipid biosynthesis. We also show that Akt leads to the accumulation of nuclear SREBP-1 but not SREBP-2, and that activation of SREBP is required for Akt-induced activation of the FAS promoter. Finally, activation of Akt induces an increase in the concentration of cellular fatty acids as well as phosphoglycerides, the components of cellular membranes. Our data indicate that activation of SREBP by Akt leads to the induction of key enzymes of the cholesterol and fatty acid biosynthesis pathways, and thus membrane lipid biosynthesis.	Canc Res UK, London Res Inst, Gene Express Anal Lab, London WC2A 3PX, England; Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, Canc Res UK Biomed Magnet Resonance Res Grp, London SW17 0RE, England; Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK; St Georges University London; Cancer Research UK	Schulze, A (corresponding author), Canc Res UK, London Res Inst, Gene Express Anal Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	almut.schulze@cancer.org.uk	Schulze, Almut/E-1496-2013; Griffiths, John R/F-2853-2010; Downward, Julian/A-3251-2012; Chung, Yuen-Li/K-2269-2019; Schulze, Almut/AAX-8257-2020	Chung, Yuen-Li/0000-0003-0807-1658; Schulze, Almut/0000-0002-8199-6422; Downward, Julian/0000-0002-2331-4729				Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bobard A, 2005, J BIOL CHEM, V280, P199, DOI 10.1074/jbc.M406522200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brower V, 2003, J NATL CANCER I, V95, P844, DOI 10.1093/jnci/95.12.844; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; BURERING BM, 2002, TRENDS BIOCHEM SCI, V27, P352; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Datta S, 2005, J BIOL CHEM, V280, P3338, DOI 10.1074/jbc.M411222200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim KH, 2004, J BIOL CHEM, V279, P51999, DOI 10.1074/jbc.M405522200; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kotzka J, 2000, J LIPID RES, V41, P99; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Rashid A, 1997, AM J PATHOL, V150, P201; Rawson RB, 2003, BIOCHEM SOC SYMP, V70, P221, DOI 10.1042/bss0700221; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Swinnen JV, 2004, J STEROID BIOCHEM, V92, P273, DOI 10.1016/j.jsbmb.2004.10.013; SZE DY, 1990, BIOCHIM BIOPHYS ACTA, V1054, P198, DOI 10.1016/0167-4889(90)90241-5; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tiwari G, 2003, MOL CANCER RES, V1, P475; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106; Zhang CK, 2005, BIOCHEM J, V386, P161, DOI 10.1042/BJ20041514; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	76	321	339	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6465	6481		10.1038/sj.onc.1208802	http://dx.doi.org/10.1038/sj.onc.1208802			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007182	Bronze			2022-12-28	WOS:000232204100001
J	Xia, WL; Gerard, CM; Liu, LH; Baudson, NM; Ory, TL; Spector, NL				Xia, WL; Gerard, CM; Liu, LH; Baudson, NM; Ory, TL; Spector, NL			Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells	ONCOGENE			English	Article						survivin; vaccine; tyrosine kinase; ErbB2; antibodies; breast cancer	MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; SINGLE-AGENT; IN-VIVO; RECEPTOR; PROTEIN; GROWTH; HER-2/NEU; SURVIVIN; CHEMOTHERAPY	Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of action. Here, apoptosis of ErbB2-over-expressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and(ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein. Treating ErbB2-over-expressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline. Exposure to pAb alone reduced total ErbB2 protein, disrupting ErbB3 transactivation, leading to a marked inhibition of p-Akt; however, survivin protein levels remained unchanged and apoptosis only increased slightly. Treatment with trastuzumab alone had relatively little effect on survivin and apoptosis was unaffected. Combining lapatinib with either pAb or trastuzumab markedly downregulated survivin protein and enhanced tumor cell apoptosis. The association between the inhibition of survivin and enhanced apoptosis following the combination of ErbB2-targeted therapies provides a biological effect in order to identify therapeutic strategies that promote tumor cell apoptosis and might improve clinical response.	GlaxoSmithKline Inc, Dept Discovery Med, Res Triangle Pk, NC 27709 USA; GlasoSmithKline Biol, Canc Vaccine Program, Rixensart, Belgium	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline Inc, Dept Discovery Med, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.	Neil.L.Spector@gsk.com						Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; ARTEAGA CL, 2004, BREAST CANC RES TR S, V88, pA25; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Baselga J, 1998, CANCER RES, V58, P2825; Brognard J, 2001, CANCER RES, V61, P3986; BURRIS HA, 2004, BREAST CANC RES T S1, V88, pA3043; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fry DW, 2003, EXP CELL RES, V284, P131, DOI 10.1016/S0014-4827(02)00095-2; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HERBST RS, 2004, J CLIN ONCOL, V22, P759; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; JOHNSON DH, 2002, ANN ONCOL, V13, P127; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; MAIER LA, 1991, CANCER RES, V51, P5361; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moulder SL, 2001, CANCER RES, V61, P8887; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Park J W, 1992, Cancer Treat Res, V61, P193; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; Rusnak DW, 2001, CANCER RES, V61, P7196; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1999, SEMIN ONCOL S12, V26, P14661; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Tamm I, 1998, CANCER RES, V58, P5315; Tenzer A, 2001, CANCER RES, V61, P8203; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	51	225	238	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2005	24	41					6213	6221		10.1038/sj.onc.1208774	http://dx.doi.org/10.1038/sj.onc.1208774			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16091755				2022-12-28	WOS:000231877100002
J	Hornberg, JJ; Binder, B; Bruggeman, FJ; Schoeberl, B; Heinrich, R; Westerhoff, HV				Hornberg, JJ; Binder, B; Bruggeman, FJ; Schoeberl, B; Heinrich, R; Westerhoff, HV			Control of MAPK signalling: from complexity to what really matters	ONCOGENE			English	Article						MAPK signalling; control analysis; kinetic model; systems biology	EPIDERMAL-GROWTH-FACTOR; METABOLIC CONTROL ANALYSIS; PROTEIN-KINASE CASCADES; FACTOR RECEPTOR; MATHEMATICAL-MODELS; DNA-SYNTHESIS; HUMAN CANCER; ACTIVATION; PATHWAY; PHOSPHORYLATION	Oncogenesis results from changes in kinetics or in abundance of proteins in signal transduction networks. Recently, it was shown that control of signalling cannot reside in a single gene product, and might well be dispersed over many components. Which of the reactions in these complex networks are most important, and how can the existing molecular information be used to understand why particular genes are oncogenes whereas others are not? We implement a new method to help address such questions. We apply control analysis to a detailed kinetic model of the epidermal growth factor-induced mitogen-activated protein kinase network. We determine the control of each reaction with respect to three biologically relevant characteristics of the output of this network: the amplitude, duration and integrated output of the transient phosphorylation of extracellular signal-regulated kinase (ERK). We confirm that control is distributed, but far from randomly: a small proportion of reactions substantially control signalling. In particular, the activity of Raf is in control of all characteristics of the transient profile of ERK phosphorylation, which may clarify why Raf is an oncogene. Most reactions that really matter for one signalling characteristic are also important for the other characteristics. Our analysis also predicts the effects of mutations and changes in gene expression.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, Inst Mol Cell Biol, NL-1085 HV Amsterdam, Netherlands; Merrimack Pharmaceut, Cambridge, England; Humboldt Univ, Dept Theoret Biophys, Berlin, Germany; Univ Amsterdam, Swammerdan Inst Life Sci, NL-1012 WX Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Humboldt University of Berlin; University of Amsterdam	Westerhoff, HV (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, Inst Mol Cell Biol, Boelelaan 1085, NL-1085 HV Amsterdam, Netherlands.	hw@bio.vu.nl	Westerhoff, Hans V/I-5762-2012; damiani, chiara/R-4256-2016; Bruggeman, Frank/AAS-8371-2020; Bruggeman, Frank/C-4356-2015	Westerhoff, Hans V/0000-0002-0443-6114; Bruggeman, Frank/0000-0002-0255-4766; Bruggeman, Frank/0000-0002-0255-4766	Biotechnology and Biological Sciences Research Council [BB/C008219/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asthagiri AR, 2001, BIOTECHNOL PROGR, V17, P227, DOI 10.1021/bp010009k; Asthagiri AR, 2000, J CELL SCI, V113, P4499; Bakker BM, 1999, J BIOL CHEM, V274, P14551, DOI 10.1074/jbc.274.21.14551; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BOS JL, 1989, CANCER RES, V49, P4682; Bruggeman FJ, 2000, BIOL CHEM, V381, P965, DOI 10.1515/BC.2000.119; Bruggeman FJ, 2002, J THEOR BIOL, V218, P507, DOI 10.1006/jtbi.2002.3096; BUDAY L, 1995, ONCOGENE, V11, P1327; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GROEN AK, 1982, J BIOL CHEM, V257, P2754; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hornberg JJ, 2005, FEBS J, V272, P244, DOI 10.1111/j.1432-1033.2004.04404.x; Hornberg JJ, 2004, EUR J BIOCHEM, V271, P3905, DOI 10.1111/j.1432-1033.2004.04327.x; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; KHOLODENKO BN, 1993, FEBS LETT, V320, P71, DOI 10.1016/0014-5793(93)81660-R; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Periwal V, 2002, NAT BIOTECHNOL, V20, P345, DOI 10.1038/nbt0402-345; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SCHUSTER R, 1995, EUR J BIOCHEM, V229, P403, DOI 10.1111/j.1432-1033.1995.0403k.x; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Snoep JL, 2004, CURR GENOMICS, V5, P687, DOI 10.2174/1389202043348553; Teusink B, 2000, EUR J BIOCHEM, V267, P5313, DOI 10.1046/j.1432-1327.2000.01527.x; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tombes RM, 1998, BIOCHEM J, V330, P1451; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Westerhoff H., 1987, THERMODYNAMICS CONTR	54	142	141	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5533	5542		10.1038/sj.onc.1208817	http://dx.doi.org/10.1038/sj.onc.1208817			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007170				2022-12-28	WOS:000231296100001
J	Haller, K; Kibler, KV; Kasai, T; Chi, YH; Peloponese, JM; Yedavalli, VSRK; Jeang, KT				Haller, K; Kibler, KV; Kasai, T; Chi, YH; Peloponese, JM; Yedavalli, VSRK; Jeang, KT			The N-terminus of rodent and human MAD1 confers species-specific stringency to spindle assembly checkpoint	ONCOGENE			English	Article						aneuploidy; spindle assembly checkpoint; cellular transformation; chromosomal instability; mitotic arrest	VIRUS TYPE-I; MITOTIC CHECKPOINT; SACCHAROMYCES-CEREVISIAE; CELLULAR-TRANSFORMATION; GENOMIC INSTABILITY; GENETIC INSTABILITY; RAT FIBROBLASTS; TAX PROTEIN; LEUKEMIA; CANCER	The spindle assembly checkpoint (SAC) guards against chromosomal mis-segregation and the emergence of aneuploidy. SAC in higher eukaryotes includes at least 10 proteins including MAD1-3, BUB1-3, and Msp1. A long-standing observation has been that rodent cells are more tolerant of microtubule toxins than primate cells indicating that SAC function is more relaxed in the former than the latter. Here, we report on an unexpected functional difference between the rodent and human MAD1 component of the respective SAC. Ectopic expression of human MAD1 in mouse and hamster cells corrected a relaxed SAC to a more stringent form. Our findings posit MAD1 as a species-specific determinant which influences the stringency of cellular response to microtubule depolymerization and spindle damage.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Chi, Ya-Hui/ABE-8550-2020; Jeang, Kuan-Teh/A-2424-2008; Chi, Ya-Hui/B-1080-2010	Chi, Ya-Hui/0000-0002-9216-0938; Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI001023, ZIAAI000547, Z01AI001023] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Azran Inbal, 2004, Retrovirology, V1, P20; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; DOWNES CS, 1990, J CELL BIOL, V110, P1855, DOI 10.1083/jcb.110.6.1855; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gallardo MH, 2003, J EVOLUTION BIOL, V16, P163, DOI 10.1046/j.1420-9101.2003.00507.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lee MS, 2004, P NATL ACAD SCI USA, V101, P10655, DOI 10.1073/pnas.0404102101; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 2004, NAT GENET, V36, P1144, DOI 10.1038/ng1104-1144; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIDGLEY AR, 1959, SCIENCE, V130, P40, DOI 10.1126/science.130.3366.40; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861	59	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2137	2147		10.1038/sj.onc.1209259	http://dx.doi.org/10.1038/sj.onc.1209259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288203	Bronze			2022-12-28	WOS:000236581200001
J	Roversi, G; Pfundt, R; Moroni, RF; Magnani, I; van Reijmersdal, S; Pollo, B; Straatman, H; Larizza, L; Schoenmakers, EFPM				Roversi, G; Pfundt, R; Moroni, RF; Magnani, I; van Reijmersdal, S; Pollo, B; Straatman, H; Larizza, L; Schoenmakers, EFPM			Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines	ONCOGENE			English	Article						glioma; array-based CGH; copy number changes; chromosome 19	TUMOR-SUPPRESSOR GENE; BRAIN-TUMORS; COPY NUMBER; CHROMOSOMAL IMBALANCES; MOLECULAR SUBTYPES; ARRAY-CGH; HYBRIDIZATION; EXPRESSION; CANCER; REGION	Identification of genetic copy number changes in glial tumors is of importance in the context of improved/refined diagnostic, prognostic procedures and therapeutic decision-making. In order to detect recurrent genomic copy number changes that might play a role in glioma pathogenesis and/or progression, we characterized 25 primary glioma cell lines including 15 non glioblastoma (non GBM) (I-III WHO grade) and 10 GBM (IV WHO grade), by array comparative genomic hybridization, using a DNA microarray comprising approx. 3500 BACs covering the entire genome with a 1Mb resolution and additional 800 BACs covering chromosome 19 at tiling path resolution. Combined evaluation by single clone and whole chromosome analysis plus 'moving average (MA) approach' enabled us to confirm most of the genetic abnormalities previously identified to be associated with glioma progression, including +1q32, +7, -10, -22q, PTEN and p16 loss, and to disclose new small genomic regions, some correlating with grade malignancy. Grade I-III gliomas exclusively showed losses at 3p26 (53%), 4q13-21 (33%) and 7p15-p21 (26%), whereas only GBMs exhibited 4p16.1 losses (40%). Other recurrent imbalances, such as losses at 4p15, 5q22-q23, 6p23-25, 12p13 and gains at 11p11-q13, were shared by different glioma grades. Three intervals with peak of loss could be further refined for chromosome 10 by our MA approach. Data analysis of full-coverage chromosome 19 highlighted two main regions of copy number gain, never described before in gliomas, at 19p13.11 and 19q13.13-13.2. The well-known 19q13.3 loss of heterozygosity area in gliomas was not frequently affected in our cell lines. Genomic hotspot detection facilitated the identification of small intervals resulting in positional candidate genes such as PRDM2 (1p36.21), LRP1B (2q22.3), ADARB2 (10p15.3), BCCIP (10q26.2) and ING1 (13q34) for losses and ECT2 (3q26.3), MDK, DDB2, IG20 (11p11.2) for gains. These data increase our current knowledge about cryptic genetic changes in gliomas and may facilitate the further identification of novel genetic elements, which may provide us with molecular tools for the improved diagnostics and therapeutic decision-making in these tumors.	Univ Milan, Dept Biol & Genet Med Sci, I-20133 Milan, Italy; Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Ist Neurol Besta, Milan, Italy; Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, Nijmegen, Netherlands	University of Milan; Radboud University Nijmegen; IRCCS Istituto Neurologico Besta; Radboud University Nijmegen	Larizza, L (corresponding author), Univ Milan, Dept Biol & Genet Med Sci, Via Viotti 3-5, I-20133 Milan, Italy.	lidia.larizza@unimi.it	Pollo, Bianca/K-5347-2018; van Reijmersdal, Simon V/E-9529-2016; Pfundt, Rolph/L-4576-2015	Pollo, Bianca/0000-0002-5523-4256; Moroni, Ramona Frida/0000-0002-0461-3213				Bakir A, 1998, CANCER GENET CYTOGEN, V103, P46, DOI 10.1016/S0165-4608(97)00364-6; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; BIGNER SH, 1987, CANCER GENET CYTOGEN, V24, P163, DOI 10.1016/0165-4608(87)90094-X; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Buschges R, 1999, BRAIN PATHOL, V9, P435; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Cowell JK, 2004, CANCER GENET CYTOGEN, V151, P36, DOI 10.1016/j.cancergencyto.2003.09.012; Cowell JK, 2004, J NEUROPATH EXP NEUR, V63, P151, DOI 10.1093/jnen/63.2.151; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; FISCHER H, 1985, CANCER GENET CYTOGEN, V17, P257, DOI 10.1016/0165-4608(85)90017-2; Hackett CS, 2003, CANCER RES, V63, P5266; Harada K, 2000, GENOMICS, V67, P268, DOI 10.1006/geno.2000.6257; Hartmann C, 2002, CANCER RES, V62, P4100; Hawkins CJ, 2004, VITAM HORM, V67, P427; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Ino Y, 2001, CLIN CANCER RES, V7, P839; Jeuken JWM, 2004, J NEURO-ONCOL, V70, P161, DOI 10.1007/s11060-004-2748-1; Kanno H, 1997, CANCER RES, V57, P1035; Kitange G, 2005, GENE CHROMOSOME CANC, V42, P68, DOI 10.1002/gcc.20108; Kitange GJ, 2003, CURR OPIN ONCOL, V15, P197, DOI 10.1097/00001622-200305000-00003; Kleihues P, 2000, P ICMTS2000 MARCH MO, P99; Kohler B, 2004, INT J CANCER, V111, P644, DOI 10.1002/ijc.20302; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Liu CX, 2000, CANCER RES, V60, P1961; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Magnani I, 2005, CANCER GENET CYTOGEN, V161, P140, DOI 10.1016/j.cancergencyto.2005.02.010; Magnani I, 1999, CANCER GENET CYTOGEN, V110, P82, DOI 10.1016/S0165-4608(98)00190-3; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; Manni I, 2002, BRIT J CANCER, V86, P477, DOI 10.1038/sj.bjc.6600065; Marschang P, 2004, MOL CELL BIOL, V24, P3782, DOI 10.1128/MCB.24.9.3782-3793.2004; Meng XB, 2004, CELL CYCLE, V3, P343; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Noble M, 2004, TRENDS NEUROSCI, V27, P148, DOI 10.1016/j.tins.2003.12.007; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; PEREGO P, 1994, J CANCER RES CLIN, V120, P585, DOI 10.1007/BF01212812; REY JA, 1989, CANCER GENET CYTOGEN, V41, P175, DOI 10.1016/0165-4608(89)90244-6; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rong Y, 2005, CANCER RES, V65, P1406, DOI 10.1158/0008-5472.CAN-04-3376; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Schraders M, 2005, BLOOD, V105, P1686, DOI 10.1182/blood-2004-07-2730; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shapiro JR, 2002, AM J MED GENET, V115, P194, DOI 10.1002/ajmg.10690; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Sun CL, 2005, MOL PHARMACOL, V67, P1307, DOI 10.1124/mol.104.008797; Tallen G, 2004, INT J CANCER, V109, P476, DOI 10.1002/ijc.11715; Veltman JA, 2003, CANCER RES, V63, P2872; Veltman JA, 2003, AM J HUM GENET, V72, P1578, DOI 10.1086/375695; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; Weber RG, 1996, ONCOGENE, V13, P983; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	64	76	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1571	1583		10.1038/sj.onc.1209177	http://dx.doi.org/10.1038/sj.onc.1209177			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247447	Green Published			2022-12-28	WOS:000235890400014
J	Vahsen, N; Cande, C; Dupaigne, P; Giordanetto, F; Kroemer, RT; Herker, E; Scholz, S; Modjtahedi, N; Madeo, F; Le Cam, E; Kroemer, G				Vahsen, N; Cande, C; Dupaigne, P; Giordanetto, F; Kroemer, RT; Herker, E; Scholz, S; Modjtahedi, N; Madeo, F; Le Cam, E; Kroemer, G			Physical interaction of apoptosis-inducing factor with DNA and RNA	ONCOGENE			English	Article						apoptosis; chromatin condensation; mitochondria	CELL-DEATH; REGULATES APOPTOSIS; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; CANCER-CELLS; AIF; CASPASE; PROTEIN; DEGRADATION; PATHWAYS	Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein, which upon apoptosis induction translocates to the nucleus where it interacts with DNA by virtue of positive charges clustered on the AIF surface. Here we show that the AIF interactome, as determined by mass spectroscopy, contains a large panel of ribonucleoproteins, which apparently bind to AIF through the RNA moiety. However, AIF is devoid of any detectable RNAse activity both in vitro and in vivo. Recombinant AIF can directly bind to DNA as well as to RNA. This binding can be visualized by electron microscopy, revealing that AIF can condense DNA, showing a preferential binding to single-stranded over double-stranded DNA. AIF also binds and aggregates single-stranded and structured RNA in vitro. Single-stranded poly A, poly G and poly C, as well double-stranded A/T and G/C RNA competed with DNA for AIF binding with a similar efficiency, thus corroborating a computer-calculated molecular model in which the binding site within AIF is the same for distinct nucleic acid species, without a clear sequence specificity. Among the preferred electron donors and acceptors of AIF, nicotine adenine dinucleotide phosphate (NADP) was particularly efficient in enhancing the generation of higher-order AIF/DNA and AIF/RNA complexes. Altogether, these data support a model in which a direct interaction of AIF contributes to the compaction of nucleic acids within apoptotic cells.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, Lab Microscopie Mol & Cellulaire, UMR 8126,IGR,UPS, F-94805 Villejuif, France; AstraZeneca R&D, Molndal, Sweden; Sanofi Aventis, Ctr Rech VA, Vitry Sur Seine, France; Karl Franzens Univ Graz, IMB, A-8010 Graz, Austria	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; AstraZeneca; Sanofi-Aventis; Sanofi France; University of Graz	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Giordanetto, Fabrizio/E-2811-2012; Herker, Eva/AAQ-1944-2021; Herker, Eva/B-9699-2014; Dupaigne, Pauline/C-6873-2019; MODJTAHEDI, Nazanine/D-4377-2017; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	Herker, Eva/0000-0001-9644-2484; KROEMER, Guido/0000-0002-9334-4405; Madeo, Frank/0000-0002-5070-1329; Dupaigne, Pauline/0000-0001-7033-4055; MODJTAHEDI, NAZANINE/0000-0002-1832-0710; Le cam, Eric/0000-0002-6832-6117				Asselbergs FAM, 2003, ANAL BIOCHEM, V318, P221, DOI 10.1016/S0003-2697(03)00218-5; Beloin C, 2003, J BIOL CHEM, V278, P5333, DOI 10.1074/jbc.M207489200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Delain E, 1995, VISUALIZATION NUCL A, P35; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Giordanetto F, 2004, J CHEM INF COMP SCI, V44, P882, DOI 10.1021/ci0499626; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Halicka HD, 2000, EXP CELL RES, V260, P248, DOI 10.1006/excr.2000.5027; Hameau L, 2001, J VIROL, V75, P3301, DOI 10.1128/JVI.75.7.3301-3313.2001; Hassan M, 1996, MOL DIVERS, V2, P64, DOI 10.1007/BF01718702; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Le Cam E, 1998, BIOPOLYMERS, V45, P217, DOI 10.1002/(SICI)1097-0282(199803)45:3&lt;217::AID-BIP4&gt;3.0.CO;2-U; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rutjes SK, 1999, J BIOL CHEM, V274, P24799, DOI 10.1074/jbc.274.35.24799; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	49	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1763	1774		10.1038/sj.onc.1209206	http://dx.doi.org/10.1038/sj.onc.1209206			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278674				2022-12-28	WOS:000236013700008
J	Kichina, JV; Zeremski, M; Aris, L; Gurova, KV; Walker, E; Franks, R; Nikitin, AY; Kiyokawa, H; Gudkov, AV				Kichina, JV; Zeremski, M; Aris, L; Gurova, KV; Walker, E; Franks, R; Nikitin, AY; Kiyokawa, H; Gudkov, AV			Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas	ONCOGENE			English	Article						ING1; gene knockout; lymphoma; mouse; radiation sensitivity	CANDIDATE TUMOR-SUPPRESSOR; SQUAMOUS-CELL CARCINOMAS; PHD FINGER PROTEINS; GENE ING1; ALTERNATIVE TRANSCRIPTS; P53 EXPRESSION; MELANOMA-CELLS; MESSENGER-RNA; HUMAN HEAD; P33(ING1)	Ing1 belongs to the family of evolutionary conserved genes encoding nuclear PHD finger-containing proteins implicated in a variety of processes, including tumorigenesis, replicative senescence, excision repair and response to genotoxic stress. We have generated mice deficient in all the isoforms of Ing1 by targeted disruption of the exon that is common for all ing1 transcripts. Embryonic fibroblasts from ing1-knockout mice were similar to the wild-type cells in their growth characteristics, replicative lifespan in culture, p53 induction and sensitivity to various cytotoxic treatments with minor alterations in cell cycle distribution in response to genotoxic stress. ing1-deficient animals are characterized by reduced size with no obvious morphological, physiological or behavioral abnormalities, indicating that ing1 function is dispensable for the viability of mice under normal physiological conditions. Loss of ing1 was associated with earlier onset and higher incidence of lymphomas. Consistent with the possible involvement of Ing1 in DNA repair, ing1-deficient mice were more sensitive to total body gamma radiation. Our observations are well in line with the suggested role of ing1 as a candidate tumor suppressor gene involved in control of DNA damage response.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; Cleveland BioLabs Inc, Cleveland, OH USA; Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; Cornell University	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.	gudkov@ccf.org		Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA 60730, CA 17579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Campos EI, 2004, INT J ONCOL, V25, P73; Campos EI, 2002, BRIT J DERMATOL, V146, P574, DOI 10.1046/j.1365-2133.2002.04641.x; Chen LS, 2001, CANCER RES, V61, P4345; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gunduz M, 2000, CANCER RES, V60, P3143; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Helbing CC, 1997, CANCER RES, V57, P1255; Ito K, 2002, AM J HEMATOL, V69, P141, DOI 10.1002/ajh.10031; Kichina JV, 2003, ONCOGENE, V22, P4911, DOI 10.1038/sj.onc.1206741; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Maestro R, 1996, CANCER RES, V56, P1146; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Ohgi T, 2002, SCAND J GASTROENTERO, V37, P1440, DOI 10.1080/003655202762671332; Ohmori M, 1999, AM J HEMATOL, V62, P118; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; Ramirez-Solis Ramiro, 1994, Current Opinion in Biotechnology, V5, P528, DOI 10.1016/0958-1669(94)90069-8; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sanchez-Cespedes M, 2000, GENE CHROMOSOME CANC, V27, P319, DOI 10.1002/(SICI)1098-2264(200003)27:3<319::AID-GCC13>3.0.CO;2-P; Sarela AI, 1999, EUR J CANCER, V35, P1264, DOI 10.1016/S0959-8049(99)00104-5; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Ward JM, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P161; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zeremski M, 1997, SOMAT CELL MOLEC GEN, V23, P233, DOI 10.1007/BF02721376	48	60	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					857	866		10.1038/sj.onc.1209118	http://dx.doi.org/10.1038/sj.onc.1209118			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170338				2022-12-28	WOS:000235212700005
J	Cruz-Munoz, W; Kim, I; Khokha, R				Cruz-Munoz, W; Kim, I; Khokha, R			TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis	ONCOGENE			English	Article						TIMP-3; host stroma; B16F10; teratoma; angiogenesis	TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; CELL-DEATH; GENE; EXPRESSION; SUPPRESSION; CANCER; COMBINATION; MEMBRANE; PROMOTER	Tumor cells, stromal cell compartment and the extracellular matrix (ECM) together generate a multifaceted tumor microenvironment. Matrix metalloproteinases and their tissue inhibitors (TIMPs) provide a means for tumor-stromal interaction during tumorigenesis. Among TIMPs, TIMP-3 is uniquely localized to the ECM and is frequently silenced in human cancers. Here, we asked whether the absence of TIMP-3 in the tumor cell or the host affects the process of tumorigenesis. Timp-3(-/-) ES-cell clones were generated and used to develop teratomas in nude mice. Timp-3(-/-) teratomas showed similar tumor take, growth, and angiogenesis compared to timp-3(-/-) teratomas. To study the effect of TIMP-3 ablation in the host stroma, we measured the growth kinetics of subcutaneous B16F10 melanomas in timp-3(-/-) and wildtype littermates. Tumors grew significantly faster in timp3(-/-) than in wild-type mice and their CD31 content was significantly higher indicating increased angiogenesis. Augmented angiogenesis in timp-3(-/-) mice was directly tested using Matrigel plug and Gelfoam assays. In response to FGF-2, timp-3(-/-) endothelial cells invaded more efficiently, leading to enhanced formation of functional blood vessels. Thus, TIMP-3 deficiency in the host, but not in the tumor per se, leads to enhanced tumor growth and angiogenesis. TIMP-3 located within the tumor microenvironment inhibits tumorigenesis.	Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Dept Lab Med & Pathobiol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca						AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Bachman KE, 1999, CANCER RES, V59, P798; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BOOKS PC, 1996, CELL, V85, P683; Boulay A, 2001, CANCER RES, V61, P2189; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DeClerck YA, 2000, EUR J CANCER, V36, P1258, DOI 10.1016/S0959-8049(00)00094-0; Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Itoh T, 1998, CANCER RES, V58, P1048; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Martin DC, 1996, ONCOGENE, V13, P569; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; McCarty MF, 2002, INT J ONCOL, V21, P5; Michael M, 1999, J CLIN ONCOL, V17, P1802, DOI 10.1200/JCO.1999.17.6.1802; Mori M, 2000, INT J CANCER, V88, P575, DOI 10.1002/1097-0215(20001115)88:4<575::AID-IJC9>3.0.CO;2-C; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PASSANITI A, 1992, LAB INVEST, V67, P519; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Remacle A, 2000, INT J CANCER, V89, P118, DOI 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8; Sang Q X, 1998, Cell Res, V8, P171; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sogawa K, 2003, CANCER, V98, P1822, DOI 10.1002/cncr.11725; Soloway PD, 1996, ONCOGENE, V13, P2307; Spurbeck WW, 2003, CANCER GENE THER, V10, P161, DOI 10.1038/sj.cgt.7700577; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Sun Y, 1996, ANTICANCER RES, V16, P1; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	44	41	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					650	655		10.1038/sj.onc.1209104	http://dx.doi.org/10.1038/sj.onc.1209104			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186800				2022-12-28	WOS:000234897400016
J	Fischer, U; Stroh, C; Schulze-Osthoff, K				Fischer, U; Stroh, C; Schulze-Osthoff, K			Unique and overlapping substrate specificities of caspase-8 and caspase-10	ONCOGENE			English	Article						apoptosis; caspase-10; caspase-8; Bid; RIP	FACTOR-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; DEATH DOMAIN PROTEIN; SIGNALING COMPLEXES; MEDIATED APOPTOSIS; ACTIVATION; CLEAVAGE; RECEPTORS; LYMPHOCYTE; RIP	Although caspase-8 has an established role as an initiator of death receptor-mediated apoptosis, the function of its closest homolog, caspase-10, is almost completely unknown. To gain a closer insight into the physiological function of caspase-10, we compared the cleavage of known caspase-8 substrates by both initiator caspases. We demonstrate that caspase-10 and -8 have overlapping cleavage preferences for several substrates such as the kinases RIP and PAK2. Interestingly, in other substrates, such as the Bcl-2 protein Bid, we found additional and distinct cleavage sites for both caspases, which might have important consequences for mitochondrial targeting and propagation of the death signal. Caspase-8 and -10 also caused different interchain cleavage patterns of their enzyme precursors. Together, these results suggest that caspase-8 and -10, despite having overlapping functions, also have selective substrate cleavage specificities and might thereby exert nonredundant roles in apoptosis signaling.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Fischer, U (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	ute.fischer@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; DEGLIESPOSTI M, 2003, J BIOL CHEM, V278, P15479; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kruidering M, 2001, J BIOL CHEM, V276, P38417, DOI 10.1074/jbc.M103471200; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	45	73	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					152	159		10.1038/sj.onc.1209015	http://dx.doi.org/10.1038/sj.onc.1209015			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16186808				2022-12-28	WOS:000234406400017
J	Isachenko, N; Dyakova, N; Aushev, V; Chepurnych, T; Gurova, K; Tatosyan, A				Isachenko, N; Dyakova, N; Aushev, V; Chepurnych, T; Gurova, K; Tatosyan, A			High expression of shMDG1 gene is associated with low metastatic potential of tumor cells	ONCOGENE			English	Article						shMDG1; metastasis; v-src transformation; chaperones; glycosylation	ROUS-SARCOMA VIRUS; IN-VITRO; CHROMOSOME; CANCER; OLIGOSACCHARIDES; DIFFERENTIATION; IDENTIFICATION; GLYCOPEPTIDES; STRESS; MDG1	Metastasis is the primary cause of mortality associated with cancer. Molecular mechanisms leading to metastatic spread are poorly studied. To get a better understanding of this process, we compared the gene expression pattern of two isogenic cell lines, HET-SR and HET-SR1 (Rous Sarcoma Virus-transformed embryo hamster fibroblasts) with different metastatic activity using the differential display technique. A novel cDNA of hamster gene shMDG1 (Syrian hamster homologue of microvascular differentiation gene 1), which had 94% homology with rat MDG1 gene, was identified. Expression of shMDG1 was increased in low metastatic HET-SR cell line in comparison to high metastatic HET-SR1. Sequence analysis of the ORF of shMDG1 gene showed that it belongs to the DnaJ/heat-shock proteins of 40 kDa (HSP40) chaperones family, considered to function as a cochaperone of HSP70 family. In order to confirm involvement of shMDG1 in metastasis, we injected parental and shMDG1 overexpressed cells into animals. We showed that overexpression of the shMDG1 gene significantly diminished the metastatic activity of both HET-SR and HET-SR1 cells. The shMDG1-induced repression of metastasis was not connected with alterations in cell proliferation and motility in vitro, but correlated well with a decrease in content of the Asn-linked beta 1-6 branched oligosaccharides on cell surface.	Canc Res Ctr, Inst Carcinogenesis, Viral & Cellular Oncogenes Lab, Moscow 115478, Russia; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA	Cleveland Clinic Foundation	Isachenko, N (corresponding author), Canc Res Ctr, Inst Carcinogenesis, Viral & Cellular Oncogenes Lab, Kashirskoye Sh 24, Moscow 115478, Russia.	isachenko@crc.umos.ru	Aushev, Vasily N./A-7209-2008	Aushev, Vasily N./0000-0001-8003-358X				Blomer U, 1997, J VIROL, V71, P6641; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHEPURNYKH TV, 2000, CELL MOL BIOL, V34, P907; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dichamp C, 2004, J NEURO-ONCOL, V67, P281, DOI 10.1023/B:NEON.0000024218.68120.8d; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PIERCE M, 1986, J BIOL CHEM, V261, P772; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Prols F, 1997, CYTOGENET CELL GENET, V79, P149, DOI 10.1159/000134706; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Tatosyan A, 1996, VIROLOGY, V216, P347, DOI 10.1006/viro.1996.0070; Thorstensen L, 2001, SCAND J GASTROENTERO, V36, P1327; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; YOCHEM J, 1978, MOL GEN GENET, V4, P9	22	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2006	25	2					317	322		10.1038/sj.onc.1209022	http://dx.doi.org/10.1038/sj.onc.1209022			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16205647				2022-12-28	WOS:000234583600017
J	Seiden-Long, IM; Brown, KR; Shih, W; Wigle, DA; Radulovich, N; Jurisica, I; Tsao, MS				Seiden-Long, IM; Brown, KR; Shih, W; Wigle, DA; Radulovich, N; Jurisica, I; Tsao, MS			Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer	ONCOGENE			English	Article						hepatocyte growth factor; protein-protein interaction; microarray; real-time RT-PCR; tumor markers; tissue array	FACTOR SCATTER FACTOR; FACTOR-RECEPTOR; C-MYC; MEDIATED APOPTOSIS; BETA-CATENIN; MET; CELLS; GENE; EXPRESSION; PATHWAY	Both Ki-ras mutation and hepatocyte growth factor (HGF) receptor Met overexpression occur at high frequency in colon cancer. This study investigates the transcriptional changes induced by Ki-ras oncogene and HGF/Met signaling activation in colon cancer cell lines in vitro and in vivo. The model system used in these studies included the DLD-1 colon cancer cell line with a mutated Ki-ras allele, and the DKO-4 cell line generated from DLD-1, with its mutant Ki-ras allele inactivated by targeted disruption. These cell lines were transduced with cDNAs of full-length Met receptor. Microarray transcriptional pro. ling was conducted on cell lines stimulated with HGF, as well as on tumor xenograft tissues. Overlapping genes between in vitro and in vivo microarray data sets were selected as a subset of HGF/Met and Ki-ras oncogene-regulated targets. Using the Online Predicted Human Interaction Database, novel HGF/Met and Ki-ras regulated proteins with putative functional linkage were identifi. ed. Novel proteins identified included histone acetyltransferase 1, phosphoribosyl pyrophosphate synthetase 2, chaperonin containing TCP1, subunit 8, CSE1 chromosome segregation 1-like (yeast)/cellular apoptosis susceptibility (mammals), CCR4-NOT transcription complex, subunit 8, and cyclin H. Transcript levels for these Met-signaling targets were correlated with Met expression levels, and were significantly elevated in both primary and metastatic human colorectal cancer samples compared to normal colorectal mucosa. These genes represent novel Met and/ or Ki-ras transcriptionally coregulated genes with a high degree of validation in human colorectal cancers.	Univ Toronto, Ontario Canc Inst, Dept Pathol, Princess Margaret Hosp,Univ Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Tsao, MS (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Pathol, Princess Margaret Hosp,Univ Hlth Network, Room 4-302,610 Univ Ave,9-610, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Brown, Kevin/0000-0002-5514-2538				Balkovetz DF, 2004, AM J PHYSIOL-RENAL, V286, pF702, DOI 10.1152/ajprenal.00270.2003; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Behrens P, 2003, APOPTOSIS, V8, P39, DOI 10.1023/A:1021644918117; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Conner EA, 1999, CARCINOGENESIS, V20, P583, DOI 10.1093/carcin/20.4.583; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALABAN R, 1992, ONCOGENE, V7, P2195; Jiang MC, 2004, J EXP CLIN CANC RES, V23, P325; Jiang MC, 2002, BIOCHEM BIOPH RES CO, V294, P900, DOI 10.1016/S0006-291X(02)00551-X; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; LIU C, 1992, ONCOGENE, V7, P181; Liu J, 2004, ONCOGENE, V23, P6316, DOI 10.1038/sj.onc.1207795; Martinez-Garza SG, 1999, DIGEST DIS, V17, P225, DOI 10.1159/000016940; Monga SPS, 2002, CANCER RES, V62, P2064; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SEIDENLONG I, 2003, MOL CANCER RES, V1, P393; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sultan M, 2002, Bioinformatics, V18 Suppl 1, pS111; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098	42	63	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					91	102		10.1038/sj.onc.1209005	http://dx.doi.org/10.1038/sj.onc.1209005			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16158056				2022-12-28	WOS:000234406400010
J	Zhou, JM; Zhu, XF; Lu, YJ; Deng, R; Huang, ZS; Mei, YP; Wang, Y; Huang, WL; Liu, ZC; Gu, LQ; Zeng, YX				Zhou, JM; Zhu, XF; Lu, YJ; Deng, R; Huang, ZS; Mei, YP; Wang, Y; Huang, WL; Liu, ZC; Gu, LQ; Zeng, YX			Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines	ONCOGENE			English	Article						G-quadruplex; telomerase inhibition; senescence	INHIBITS TUMOR-GROWTH; DRUG DESIGN; IN-VIVO; DNA; MAINTENANCE; TARGET; COMPOUND; LIGANDS; BINDING; LENGTH	Agents stabilizing G-quadruplexes have the potential to interfere with telomere replication by blocking the elongation step catalysed by telomerase or telomerase-independent mechanism and could therefore act as antitumor agents. In this study, we found that quindoline derivatives interacted preferentially with intramolecular G-quadruplex structures and were novel potent telomerase inhibitors. Treatment with quindoline derivatives reproducibly inhibited telomerase activity in human leukemia K562 cells and colon cancer SW620 cells. N'-(10H-Indolo [3,2-b] quinolin-11-yl)- N, N-dimethylpropane- 1,3-diamine (SYUIQ-5), (one of quindoline derivatives), when added to K562 and SW620 cell culture at nonacute cytotoxic concentrations, increased time of population doublings of K562 and SW620 cells, induced a marked cessation in cell growth and cellular senescence phenotype after 35 and 18 days, respectively. Growth cessation was accompanied by a shortening of telomere length, and induction of p16, p21 and p27 protein expression. However, another compound SYUIQ-7 with greater IC50 for telomerase had no obvious cellular effect in nonacute cytotoxic concentrations. These results indicate that quindoline derivatives as novel potent G-quadruplex interactive agents induce senescence and telomere shortening in cancer cells and therefore are promising agents for cancer treatment.	Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Peoples R China; Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510060, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, 651 Dongfeng Rd E, Guangzhou 510060, Peoples R China.	xfzhu70@public.guangzhou.gd.cn; yxzeng@gzsums.edu.cn	huang, wen/GXW-0661-2022					Bierer DE, 1998, J MED CHEM, V41, P2754, DOI 10.1021/jm970735n; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bonjean K, 1998, BIOCHEMISTRY-US, V37, P5136, DOI 10.1021/bi972927q; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Burger AM, 2005, CANCER RES, V65, P1489, DOI 10.1158/0008-5472.CAN-04-2910; Caprio V, 2000, BIOORG MED CHEM LETT, V10, P2063, DOI 10.1016/S0960-894X(00)00378-4; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Dixon IM, 2005, CHEMBIOCHEM, V6, P123, DOI 10.1002/cbic.200400113; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Grand CL, 2002, MOL CANCER THER, V1, P565; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; ISHIKAWA Y, 2001, NUCL ACIDS RES S, V1, P107; Izbicka E, 1999, CANCER RES, V59, P639; Keith WN, 2001, J PATHOL, V195, P404; Kelland LR, 2001, LANCET ONCOL, V2, P95, DOI 10.1016/S1470-2045(00)00226-6; Kerwin SM, 2000, CURR PHARM DESIGN, V6, P441, DOI 10.2174/1381612003400849; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lisgarten JN, 2002, NAT STRUCT BIOL, V9, P57, DOI 10.1038/nsb729; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pennarun G, 2005, ONCOGENE, V24, P2917, DOI 10.1038/sj.onc.1208468; Perry PJ, 1999, ANTI-CANCER DRUG DES, V14, P373; Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q; Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schultes CM, 2004, BIOORG MED CHEM LETT, V14, P4347, DOI 10.1016/j.bmcl.2004.05.090; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3	41	94	102	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					503	511		10.1038/sj.onc.1209067	http://dx.doi.org/10.1038/sj.onc.1209067			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170347				2022-12-28	WOS:000234897400002
J	Takada, H; Imoto, I; Tsuda, H; Nakanishi, Y; Ichikura, T; Mochizuki, H; Mitsufuji, S; Hosoda, F; Hirohashi, S; Ohki, M; Inazawa, J				Takada, H; Imoto, I; Tsuda, H; Nakanishi, Y; Ichikura, T; Mochizuki, H; Mitsufuji, S; Hosoda, F; Hirohashi, S; Ohki, M; Inazawa, J			ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation	ONCOGENE			English	Article						CGH-array; gastric cancer; ADAM23; homozygous deletion; methylation	COMPARATIVE GENOMIC HYBRIDIZATION; EPIDERMAL-GROWTH-FACTOR; CELL-LINES; ABNORMAL EXPRESSION; COPY-NUMBER; AMPLIFICATION; DNA; IDENTIFICATION; DISINTEGRIN; CARCINOMA	Array-based comparative genomic hybridization (CGH-array) has a powerful potential for high-throughput identification of genetic aberrations in cell genomes. We identified a homozygous loss of ADAM23 (2q33.3) in the course of a program to screen a panel of gastric cancer ( GC) cell lines (1/32, 3.1%) for genomic copy-number aberrations using our custom-made CGH-array. Infrequent homozygous deletion of ADAM23 was also seen in primary gastric tumors (1/39, 2.6%). ADAM23 mRNA was expressed in normal stomach tissue, but not in the majority of GC cell lines without homozygous deletion of this gene. Expression of ADAM23 mRNA was restored to gene-silenced GC cells after treatment with 5-aza 2'-deoxycytidine. The methylation status of the ADAM23 CpG island, which showed promoter activity, correlated inversely with its expression. Methylation of this CpG island was observed both in GC cell lines and in primary GC tissues; in primary tumors with a hypermethylated CpG island, expression of ADAM23 was lower than in adjacent noncancerous tissues. Moreover, restoration of ADAM23 in GC cells reduced their numbers in colony-formation assays. These results suggest that genetic or epigenetic silencing by hypermethylation of the ADAM23 CpG-rich promoter region leads to loss of ADAM23 function, which may be a factor in gastric carcinogenesis.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Inst Med Res, Bunkyo Ku, Tokyo 1138510, Japan; JST, CREST, Hon Mach Kawaguchi, Saitama, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Gastroenterol & Hepatol, Kamigyo Ku, Kyoto, Japan; Natl Def Med Coll, Dept Pathol, Tokorozawa, Saitama 359, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 104, Japan; Natl Def Med Coll, Dept Surg 1, Tokorozawa, Saitama 359, Japan; Natl Canc Ctr, Res Inst, Canc Genom Project, Tokyo 104, Japan; Tokyo Med & Dent Univ, COE Program Frontier Res Mol Destruct & Reconstru, Bunkyo Ku, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; National Defense Medical College - Japan; National Cancer Center - Japan; National Defense Medical College - Japan; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Inst Med Res, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020	Imoto, Issei/0000-0002-4150-7938				Akama Y, 1996, JPN J CANCER RES, V87, P824, DOI 10.1111/j.1349-7006.1996.tb02106.x; Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Carl-McGrath S, 2005, INT J ONCOL, V26, P17; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Gorringe KL, 2005, GENE CHROMOSOME CANC, V42, P247, DOI 10.1002/gcc.20136; Huiping C, 2002, EUR J CANCER, V38, P728, DOI 10.1016/S0959-8049(01)00432-4; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kimura Y, 2004, MODERN PATHOL, V17, P1328, DOI 10.1038/modpathol.3800180; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Koo SH, 2000, CANCER GENET CYTOGEN, V117, P97, DOI 10.1016/S0165-4608(99)00152-1; McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078-0432.CCR-0846-3; Noguchi M, 1997, PATHOL INT, V47, P685, DOI 10.1111/j.1440-1827.1997.tb04442.x; O'Shea C, 2003, INT J CANCER, V105, P754, DOI 10.1002/ijc.11161; Peng DF, 2003, J PATHOL, V201, P439, DOI 10.1002/path.1459; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shintani Y, 2004, CANCER RES, V64, P4190, DOI 10.1158/0008-5472.CAN-03-3235; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Tanabe C, 2003, GENE CHROMOSOME CANC, V38, P168, DOI 10.1002/gcc.10269; Tay ST, 2003, CANCER RES, V63, P3309; Weiss MM, 2004, CELL ONCOL, V26, P307; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x	32	56	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8051	8060		10.1038/sj.onc.1208952	http://dx.doi.org/10.1038/sj.onc.1208952			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16103878				2022-12-28	WOS:000233656600011
J	Chan, AY; Coniglio, SJ; Chuang, YY; Michaelson, D; Knaus, UG; Philips, MR; Symons, M				Chan, AY; Coniglio, SJ; Chuang, YY; Michaelson, D; Knaus, UG; Philips, MR; Symons, M			Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion	ONCOGENE			English	Article						Rac1; Rac3; glioma; invasion; migration; RNA interference	GUANINE-NUCLEOTIDE EXCHANGE; RHO-FAMILY GTPASES; ALPHA-6-BETA-4 INTEGRIN; GROWTH-FACTOR; MIGRATION; ACTIVATION; KINASE; RNAS; CDC42; LOCALIZATION	Members of the Rho family of small GTPases have been shown to be involved in tumorigenesis and metastasis. Currently, most of the available information on the function of Rho proteins in malignant transformation is based on the use of dominant-negative mutants of these GTPases. The specificity of these dominant-negative mutants is limited however. In this study, we used small interfering RNA directed against either Rac1 or Rac3 to reduce their expression specifically. In line with observations using dominant-negative Rac1 in other cell types, we show that RNA interference-mediated depletion of Rac1 strongly inhibits lamellipodia formation, cell migration and invasion in SNB19 glioblastoma cells. Surprisingly however, Rac1 depletion has a much smaller inhibitory effect on SNB19 cell proliferation and survival. Interestingly, whereas depletion of Rac3 strongly inhibits SNB19 cell invasion, it does not affect lamellipodia formation and has only minor effects on cell migration and proliferation. Similar results were obtained in BT549 breast carcinoma cells. Thus, functional analysis of Rac1 and Rac3 using RNA interference reveals a critical role for these GTPases in the invasive behavior of glioma and breast carcinoma cells.	N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Dept Surg, Manhasset, NY 11030 USA; N Shore LIJ, Med Res Inst, Manhasset, NY 11030 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; NYU, Dept Med, Sch Med, New York, NY 10016 USA; NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Northwell Health; Northwell Health; Yeshiva University; Albert Einstein College of Medicine; New York University; New York University; Scripps Research Institute	Symons, M (corresponding author), N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Dept Surg, 350 Community Dr, Manhasset, NY 11030 USA.	msymons@nshs.edu		Mark, Philips/0000-0002-1179-8156; Chan, yan fan (Amanda)/0000-0001-5720-7270	NATIONAL CANCER INSTITUTE [R01CA087567] Funding Source: NIH RePORTER; NCI NIH HHS [CA87567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chuang YY, 2004, CANCER RES, V64, P8271, DOI 10.1158/0008-5472.CAN-04-2097; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joyce PL, 2003, CANCER RES, V63, P7959; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; REPESH LA, 1989, INVAS METAST, V9, P192; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Ruggieri R, 2001, MOL MED, V7, P293, DOI 10.1007/BF03402212; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Senger DL, 2002, CANCER RES, V62, P2131; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; VAN AL, 1997, GENE DEV, V11, P2295; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	50	197	207	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7821	7829		10.1038/sj.onc.1208909	http://dx.doi.org/10.1038/sj.onc.1208909			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027728				2022-12-28	WOS:000233463000001
J	Kim, H; Chan, R; Dankort, DL; Zuo, DM; Najoukas, M; Park, M; Muller, WJ				Kim, H; Chan, R; Dankort, DL; Zuo, DM; Najoukas, M; Park, M; Muller, WJ			The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation	ONCOGENE			English	Article						receptor; activation; kinase; transformation; tumorigenesis	EPIDERMAL-GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR RECEPTOR; MAMMARY-TUMORS; TRANSGENIC MICE; NEU ONCOGENE; FAMILY KINASES; POINT MUTATION; ACTIVATION; PHOSPHORYLATION	c-Src associates with and is activated by the ErbB-2 receptor tyrosine kinase, but is unable to bind the EGFR. Although c-Src has been found to interact directly and specifically with the ErbB-2 receptor, the significance of this interaction is unclear. Using both chimeric receptor and site-directed mutagenesis approaches, the region of interaction of c-Src on ErbB-2 was identified. Significantly, EGFR could be converted into a receptor capable of binding c-Src by replacement of a catalytic domain of ErbB-2. We further demonstrated that MDCK cells that express mutant EGFR that are competent in c-Src recruitment lose epithelial polarity in organoid cultures, whereas cells overexpressing the wild-type EGFR retain a polarized phenotype. ErbB-2-dependent activation of c-Src results in disruption of epithelial cell-cell contacts leading to cell dispersal that correlates with the re-localization of phospho-MAPK to focal adhesions. Taken together, these observations suggest that recruitment of c-Src to these closely related EGFR family members plays a critical role in modulating cell polarity.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4L8, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4L8, Canada; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Calif San Francisco, Inst Canc Res, Ctr Comprehens Canc, San Francisco, CA 94115 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada	McGill University; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; McGill University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; McMaster University	Muller, WJ (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca		Dankort, David/0000-0002-5862-6829				Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tapon N, 2003, CANCER CELL, V4, P333, DOI 10.1016/S1535-6108(03)00279-4; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820	37	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7599	7607		10.1038/sj.onc.1208898	http://dx.doi.org/10.1038/sj.onc.1208898			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16170374				2022-12-28	WOS:000233333800009
J	Larue, L; Bellacosa, A				Larue, L; Bellacosa, A			Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 ' kinase/AKT pathways	ONCOGENE			English	Review						epithelial; mesenchymal transition; PI3K; AKT; E-cadherin; invasion; metastasis	INTEGRIN-LINKED KINASE; SMAD-INTERACTING PROTEIN-1; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; GROWTH-FACTOR-BETA; MOUSE PREIMPLANTATION EMBRYOS; CARCINOMA CELL-LINE; HIRSCHSPRUNG-DISEASE; TUMOR-CELLS; ONCOGENIC TRANSFORMATION	Epithelial-mesenchymal transition (EMT) is an important process during development by which epithelial cells acquire mesenchymal, fibroblast-like properties and show reduced intercellular adhesion and increased motility. Accumulating evidence points to a critical role of EMT-like events during tumor progression and malignant transformation, endowing the incipient cancer cell with invasive and metastatic properties. Several oncogenic pathways (peptide growth factors, Src, Ras, Ets, integrin, Wnt/beta-catenin and Notch) induce EMT and a critical molecular event is the downregulation of the cell adhesion molecule E-cadherin. Recently, activation of the phosphatidylinositol 30 kinase (PI3K)/AKT axis is emerging as a central feature of EMT. In this review, we discuss the role of PI3K/AKT pathways in EMT during development and cancer with a focus on E-cadherin regulation. Interactions between PI3K/AKT and other EMT-inducing pathways are presented, along with a discussion of the therapeutic implications of modulating EMT in order to achieve cancer control.	Ctr Univ, CNRS, UMR 146, Inst Curie, F-91405 Orsay, France; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Fox Chase Cancer Center	Larue, L (corresponding author), Ctr Univ, CNRS, UMR 146, Inst Curie, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr; alfonso.bellacosa@fccc.edu	Larue, Lionel/F-7355-2013; Larue, Lionel/I-6532-2016		NCI NIH HHS [CA06927, CA105008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA105008, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Amiel J, 2001, J MED GENET, V38, P729, DOI 10.1136/jmg.38.11.729; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLABLETZ T, 2005, CELLS TISSUES ORGANS, V179, P56; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brognard J, 2001, CANCER RES, V61, P3986; Butz S, 1995, CELL ADHES COMMUN, V3, P337, DOI 10.3109/15419069509081018; Cacheux V, 2001, HUM MOL GENET, V10, P1503, DOI 10.1093/hmg/10.14.1503; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Edme N, 2002, J CELL SCI, V115, P2591; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; GAVRILOVIC J, 1990, CELL REGUL, V1, P1003, DOI 10.1091/mbc.1.13.1003; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Grille SJ, 2003, CANCER RES, V63, P2172; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kemler R, 2004, DEVELOPMENT, V131, P5817, DOI 10.1242/dev.01458; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Larue L, 1996, DEVELOPMENT, V122, P3185; Lee YI, 2004, BIOCHEM BIOPH RES CO, V316, P997, DOI 10.1016/j.bbrc.2004.02.150; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Logan CY, 1999, DEVELOPMENT, V126, P345; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Murillo MM, 2005, ONCOGENE, V24, P4580, DOI 10.1038/sj.onc.1208664; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Park BK, 2001, CANCER RES, V61, P7647; Perkins J, 2002, MOL MED, V8, P847, DOI 10.1007/BF03402090; Piek E, 1999, J CELL SCI, V112, P4557; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Qiu Q, 2004, REPRODUCTION, V128, P355, DOI 10.1530/rep.1.00234; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ringel MD, 2001, CANCER RES, V61, P6105; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Soo K, 2002, DEV BIOL, V247, P251, DOI 10.1006/dbio.2002.0699; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Suriano G, 2003, HUM MOL GENET, V12, P575, DOI 10.1093/hmg/ddg048; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thiery JP, 2004, NAT MED, V10, P777, DOI 10.1038/nm0804-777; Thiery JP, 2003, CURR OPIN GENET DEV, V13, P365, DOI 10.1016/S0959-437X(03)00088-1; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; Veeraraghavalu K, 2005, J VIROL, V79, P7889, DOI 10.1128/JVI.79.12.7889-7898.2005; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakamatsu N, 2001, NAT GENET, V27, P369, DOI 10.1038/86860; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamada K, 2001, AM J HUM GENET, V69, P1178, DOI 10.1086/324343; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	101	969	1010	3	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2005	24	50					7443	7454		10.1038/sj.onc.1209091	http://dx.doi.org/10.1038/sj.onc.1209091			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288291				2022-12-28	WOS:000233201900007
J	Passioura, T; Shen, S; Symonds, G; Dolnikov, A				Passioura, T; Shen, S; Symonds, G; Dolnikov, A			A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells	ONCOGENE			English	Article						N-ras; IRF-2; leukemia	FULL-LENGTH HUMAN; MESSENGER-RNA; ONCOGENIC RAS; P53; EXPRESSION; PML; DIFFERENTIATION; PROLIFERATION; PROTOONCOGENES; ACTIVATION	Activating mutations of the N- ras gene occur at relatively high frequency in acute myeloid leukemia and myelodysplastic syndrome. Somewhat paradoxically, ectopic expression of activated N-ras in primary hematopoietic cells and myeloid cell lines (in some cases) can lead to inhibition of proliferation. Expression of mutant N-ras in murine hematopoietic stem/progenitor cells is sufficient to induce myeloid malignancies, but these pathologies occur with long latency. This suggests that mutations that disable the growth suppressive properties of N-ras in hematopoietic cells are required for the development of frank malignancy. In the present work, the growth suppression induced by a mutant N- ras gene in U937 myeloid cells was used as the basis to screen a retroviral cDNA library for genes that prevent mutant N-ras-induced growth suppression (i.e., putative cooperating oncogenes). This screen identifi. ed the gene for the transcription factor interferon regulatory factor-2 ( IRF-2), and as con. firmation of the screen, overexpression of this gene in U937 cells was shown to inhibit mutant N-ras-induced growth suppression. Also recovered from the screen were two truncated clones of an uncharacterized gene ( interim of. ficial symbol: PP2135). Overexpression of this truncated PP2135 gene in U937 cells did not appear to abrogate mutant N-ras-induced growth suppression, but rather appeared to confer an increased sensitivity of U937 cells to retroviral infection, accounting for the recovery of this gene from the genetic screen.	Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; Johnson & Johnson Res, Childrens Canc Inst Australia, Sydney, NSW 2012, Australia	University of New South Wales Sydney; Children's Cancer Institute; Johnson & Johnson	Symonds, G (corresponding author), Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia.	gsymonds@medau.jnj.com		Passioura, Toby/0000-0002-6089-5067				Appelbaum F R, 2001, Hematology Am Soc Hematol Educ Program, P62; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Dolnikov A, 2000, CANCER GENE THER, V7, P1491, DOI 10.1038/sj.cgt.7700229; Dolnikov A, 2003, J GEN VIROL, V84, P3131, DOI 10.1099/vir.0.19099-0; Dolnikov A, 2003, CANCER GENE THER, V10, P745, DOI 10.1038/sj.cgt.7700603; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferbeyre G, 2000, GENE DEV, V14, P2015; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Lallemand C, 2002, EMBO REP, V3, P153, DOI 10.1093/embo-reports/kvf032; Lallemand C, 1997, J BIOL CHEM, V272, P29801, DOI 10.1074/jbc.272.47.29801; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Maher J, 1996, LEUKEMIA, V10, P83; Matsumura I, 2000, BLOOD, V96, P2440; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; NEUBAUER A, 1994, LEUKEMIA, V8, P638; NEUBAUER A, 1994, BLOOD, V83, P1603; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Passioura T, 2005, CANCER RES, V65, P797; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Preisler HD, 2001, AM J HEMATOL, V68, P23, DOI 10.1002/ajh.1144; Rubinstein YR, 2000, ONCOGENE, V19, P1411, DOI 10.1038/sj.onc.1203435; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen SW, 2004, EXP HEMATOL, V32, P852, DOI 10.1016/j.exphem.2004.06.001; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; Stadler M, 1995, ONCOGENE, V11, P2565; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xi HK, 2003, MOL IMMUNOL, V39, P677, DOI 10.1016/S0161-5890(02)00214-6; Xie RL, 2002, CANCER RES, V62, P2510	39	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7327	7336		10.1038/sj.onc.1208877	http://dx.doi.org/10.1038/sj.onc.1208877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007130				2022-12-28	WOS:000233142100009
J	Helguero, LA; Faulds, MH; Gustafsson, JA; Haldosen, LA				Helguero, LA; Faulds, MH; Gustafsson, JA; Haldosen, LA			Estrogen receptors alfa (ER alpha) and beta (ER beta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11	ONCOGENE			English	Article						estrogen receptors; mammary epithelial cells; estradiol; estrogen receptor-selective ligands; proliferation; apoptosis	HUMAN BREAST-CANCER; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; IN-VIVO; QUANTITATIVE-ANALYSIS; MOLECULAR MECHANISMS; BCL-2; PROTEIN; LIGANDS; PHENOTYPE	The mitogenic effect of 17 beta-estradiol (E2) on the breast is mediated by estrogen receptor alfa (ER alpha), hence ER alpha antagonists are effective in the treatment of breast cancer. The possible use of estrogen receptor beta (ER beta) as a target in treatment of breast cancer is under investigation. The mouse mammary cell line HC11 expresses both ERs and was used to study the role of the two receptors in proliferation. E2 had no effect on proliferation. The ER alpha-selective agonist 4,4',4''-(4- propyl-(1H)- pyrazole- 1,3,5-triyl) trisphenol (PPT) stimulated proliferation. The ER beta-selective agonist 2,3-bis(4-hydroxy-phenyl)- propionitrile (DPN) inhibited cell growth and induced apoptosis. PPT upregulated while DPN downregulated cyclin D1 and proliferating cell nuclear antigen (PCNA). Upon inhibition of ER alpha expression with RNA interference, E2 caused a decrease in cyclin D1 and PCNA, and increased apoptosis. When ER beta expression was blocked, E2 induced proliferation and cells gained the capacity to grow in soft agar. In summary, in HC11 mammary epithelial cells, ER alpha drives proliferation in response to E2 while ER beta is growth inhibitory. The lack of effect of E2 on HC11 cell growth is the result of the combined actions of ER alpha (proliferation) and ER beta (apoptosis). We suggest that use of ER beta agonists will be a useful addition in treatment of breast cancer, which, at present, is only aimed at inhibition of ER alpha.	Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden	Karolinska Institutet	Haldosen, LA (corresponding author), Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.	lars-arne.haldosen@mednut.ki.se	Cruz e Silva, Odete/AAH-5595-2020; Helguero, Luisa/B-1221-2013	Helguero, Luisa/0000-0001-8237-2390				BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Clarke R, 1996, Cancer Treat Res, V87, P263; Deugnier MA, 1999, J CELL SCI, V112, P1035; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Faulds MH, 2004, MOL ENDOCRINOL, V18, P412, DOI 10.1210/me.2003-0290; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fuqua SAW, 2003, CANCER RES, V63, P2434; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Imamov O, 2004, P NATL ACAD SCI USA, V101, P9375, DOI 10.1073/pnas.0403041101; Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lamb CA, 2003, BREAST CANCER RES TR, V79, P25, DOI 10.1023/A:1023324827225; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Leygue E, 1998, CANCER RES, V58, P3197; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Margeat E, 2003, J MOL BIOL, V326, P77, DOI 10.1016/S0022-2836(02)01355-4; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; Omoto Y, 2003, ONCOGENE, V22, P5011, DOI 10.1038/sj.onc.1206787; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; SHYAMALA G, 1982, ENDOCRINOLOGY, V110, P1249, DOI 10.1210/endo-110-4-1249; Speirs V, 1999, CANCER RES, V59, P525; Speirs V, 2004, LANCET ONCOL, V5, P174, DOI 10.1016/S1470-2045(04)01413-5; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Vanzulli S, 2002, CARCINOGENESIS, V23, P749, DOI 10.1093/carcin/23.5.749; VisserWisselaar HA, 1997, ENDOCRINOLOGY, V138, P1180, DOI 10.1210/en.138.3.1180; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8	42	207	217	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6605	6616		10.1038/sj.onc.1208807	http://dx.doi.org/10.1038/sj.onc.1208807			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007178				2022-12-28	WOS:000232367800002
J	Hastie, C; Saxton, M; Akpan, A; Cramer, R; Masters, JR; Naaby-Hansen, S				Hastie, C; Saxton, M; Akpan, A; Cramer, R; Masters, JR; Naaby-Hansen, S			Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells	ONCOGENE			English	Article						affinity labelling; mass spectrometry; cell surface proteins; prostate cancer; interferons; CD9	MEMBRANE PROTEINS; IDENTIFICATION; PROTEOMICS; ELECTROPHORESIS; MAP	Differences in the expression of cell surface proteins between a normal prostate epithelial (1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same patient were investigated. A combination of affinity chromatographic purification of biotin-tagged surface proteins with mass spectrometry analysis identified 26 integral membrane proteins and 14 peripheral surface proteins. The findings confirm earlier reports of altered expression in prostate cancer for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor regulatory protein. In addition, several novel findings of differential expression were made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1. Cell surface protein expression changed both qualitatively and quantitatively when the cells were grown in the presence of either or both interferon INF alpha and INF gamma. Costimulation with type I and II interferons had additive or synergistic effects on the membrane density of several, mainly peripherally attached surface proteins. Concerted upregulation of surface exposed antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive prostate cancer. In conclusion, this study demonstrates that differences in the expression of membrane proteins between normal and prostate cancer cells are reproducibly detectable following vectorial labelling with biotin, and that detailed analysis of extracellular-induced surface changes can be achieved by combining surface-specific labelling with high-resolution two-dimensional gel electrophoresis and mass spectrometry.	Royal Free & UCL, Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; Royal Free & UCL, Sch Med, Prostate Canc Res Ctr, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Naaby-Hansen, S (corresponding author), Royal Free & UCL, Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	soren@ludwig.ucl.ac.uk	aukim-hastie, claire/A-7485-2011; Masters, John R/C-5694-2011	Cramer, Rainer/0000-0002-8037-2511	MRC [G0100116] Funding Source: UKRI; Medical Research Council [G0100116] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bright RK, 1997, CANCER RES, V57, P995; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Coonrod SA, 1999, DEV BIOL, V207, P334, DOI 10.1006/dbio.1998.9161; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Jans R, 2004, ARCH DERMATOL RES, V296, P30, DOI 10.1007/s00403-004-0469-0; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; NAABYHANSEN S, 1990, J REPROD IMMUNOL, V17, P167, DOI 10.1016/0165-0378(90)90001-M; NAABYHANSEN S, 2003, PROSTATE CANC METHOD, V81, P277; Nagano K, 2004, ONCOGENE, V23, P1693, DOI 10.1038/sj.onc.1207297; Nouwens AS, 2000, ELECTROPHORESIS, V21, P3797, DOI 10.1002/1522-2683(200011)21:17<3797::AID-ELPS3797>3.0.CO;2-P; Ong SE, 2003, METHODS, V29, P124, DOI 10.1016/S1046-2023(02)00303-1; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Quaranta S, 2001, ELECTROPHORESIS, V22, P1810, DOI 10.1002/1522-2683(200105)22:9&lt;1810::AID-ELPS1810&gt;3.0.CO;2-M; Righetti PG, 1997, J CHROMATOGR B, V699, P77, DOI 10.1016/S0378-4347(96)00151-X; Scadden ADJ, 2001, METHOD ENZYMOL, V341, P126, DOI 10.1016/S0076-6879(01)41149-9; Shetty J, 2001, ELECTROPHORESIS, V22, P3053, DOI 10.1002/1522-2683(200108)22:14<3053::AID-ELPS3053>3.0.CO;2-K; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	20	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5905	5913		10.1038/sj.onc.1208747	http://dx.doi.org/10.1038/sj.onc.1208747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007208				2022-12-28	WOS:000231590400013
J	Hsieh, SY; Chen, WY; Yeh, TS; Sheen, IS; Huang, SF				Hsieh, SY; Chen, WY; Yeh, TS; Sheen, IS; Huang, SF			High-frequency Alu-mediated genomic recombination/deletion within the caspase-activated DNase gene in human hepatoma	ONCOGENE			English	Article						DNA fragmentation factor B; CAPN; caspase-activated Dnase; CAD; Alu repetitive elements; hepatoma	CHROMATIN CONDENSATION; REPEATS; INHIBITOR; REARRANGEMENTS; FRAGMENTATION; NEUROBLASTOMA; SEQUENCES; ELEMENTS; HETEROZYGOSITY; TUMORIGENICITY	The Alu repetitive elements, which constitute 10% of human genome, may serve as bridges for genomic recombination. However, their roles in tumorigenesis remain to be elucidated. Caspase-activated DNase (CAD), whose gene (hCAD) is mapped at chromosome 1p36, a region frequently displaying hemizygote deletion in many human cancers, is the key enzyme for nucleosome fragmentation during apoptosis. Recently, we detected many aberrant mRNAs for hCAD in many human hepatoma cells. To elucidate the genetic basis leading to the mRNA aberration, we used PCR-based chromosome walking to clone the corresponding genomic DNA identifying a novel Alu/Alu homologous recombination/ deletion within hCAD in HepG2 and Hep3B cells. We then detected similar recombination events in 13 out of the 20 hepatoma tissues and in eight of the para-cancerous cirrhotic livers. The recombination was inclined to occur in males (P = 0.031) and had marginal association with high-grade hepatoma (P = 0.070) and tumor recurrence (P = 0.070). The recombination caused exon-3 deletion, which in turn led to exon-3 skipping or replacement with a partial Alu-sequence, and consequential C-truncation of CAD. Our findings of high frequency of Alu-mediated hCAD deletion in human hepatoma not only underscore the implication of hCAD in hepatocarcinogenesis, but also highlight the potential roles of human repetitive sequences in mediating genome instability in human cancers.	Chang Gung Mem Hosp, Liver Res Unit, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Clin Proteom Ctr, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Sch Med, Dept Microbiol & Immunol, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Dept Gen Surg, Taoyuan 333, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; National Health Research Institutes - Taiwan	Hsieh, SY (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 5 Fu Hsin Rd, Taoyuan 333, Taiwan.	siming@adm.cgmh.org.tw	Huang, Shiu-Feng Kathy/E-3977-2010					BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHENG NC, 1995, ONCOGENE, V10, P291; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsieh SY, 1997, P NATL ACAD SCI USA, V94, P3206, DOI 10.1073/pnas.94.7.3206; Hsieh SY, 2003, BRIT J CANCER, V88, P210, DOI 10.1038/sj.bjc.6600695; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; Lin CH, 2001, CANCER RES, V61, P4238; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lobachev KS, 2000, EMBO J, V19, P3822, DOI 10.1093/emboj/19.14.3822; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nagase H, 2003, CELL DEATH DIFFER, V10, P142, DOI 10.1038/sj.cdd.4401139; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Rowold DJ, 2000, GENETICA, V108, P57, DOI 10.1023/A:1004099605261; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; SIMON D, 1991, ONCOGENE, V6, P765; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Stenger JE, 2001, GENOME RES, V11, P12, DOI 10.1101/gr.158801; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; TANAKA K, 1993, ONCOGENE, V8, P2253; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	38	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6584	6589		10.1038/sj.onc.1208803	http://dx.doi.org/10.1038/sj.onc.1208803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007181				2022-12-28	WOS:000232204100012
J	Zhu, YH; Denhardt, DT; Cao, HB; Sutphin, PD; Koong, AC; Giaccia, AJ; Le, QT				Zhu, YH; Denhardt, DT; Cao, HB; Sutphin, PD; Koong, AC; Giaccia, AJ; Le, QT			Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a ras-activated enhancer	ONCOGENE			English	Article						Akt; hypoxia; osteopontin; ras; regulation	ENDOTHELIAL GROWTH-FACTOR; SOLID TUMORS; GENE-EXPRESSION; MESSENGER-RNA; SECRETED PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; TRANSFORMED-CELLS; SIGNALING PATHWAY; CANCER-THERAPY; PROTEIN	Osteopontin (OPN) is a secreted phosphoglycoprotein that has been linked to tumor progression and survival in several solid tumors, including head and neck cancers. Previous studies showed that OPN expression is induced by tumor hypoxia, and its plasma levels can serve as a surrogate marker for tumor hypoxia and treatment outcome in head and neck cancer patients. In this study, we investigate the transcriptional mechanism by which hypoxia enhances OPN expression. We found that OPN is induced in head and neck squamous cell carcinoma (HNSCC) cell lines and in NIH3T3 cells by hypoxia at both mRNA and protein levels in a time-dependent manner. Actinomycin D chase experiments showed that hypoxic induction of OPN was not due to increased mRNA stability. Deletion analyses of the mouse OPN promoter regions indicated that a ras-activated enhancer (RAE) located at -731 to -712 relative to the transcription start site was essential for hypoxia-enhanced OPN transcription. Using electrophoretic mobility shift assays with the RAE DNA sequence, we found that hypoxia induced sequence-specific DNA-binding complexes. Furthermore, hypoxia and ras exposure resulted in an additive induction of OPN protein and mRNA levels that appeared to be mediated by the RAE. Induction of OPN through the RAE element by hypoxia is mediated by an Akt-kinase signaled pathway as decreasing Akt levels with dominant negative constructs resulted in inhibition of OPN induction by hypoxia. Taken together, these results have identified a new hypoxia responsive transcriptional enhancer that is regulated by Akt signaling.	Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08855 USA	Stanford University; Rutgers State University New Brunswick	Le, QT (corresponding author), Stanford Univ, Dept Radiat Oncol, 875 Blake Wilbur Dr,R CC-G228, Stanford, CA 94305 USA.	qle@stanford.edu		Le, Quynh Thu/0000-0002-3682-1439; Koong, Albert/0000-0001-9824-1643	NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Bedogni B, 2004, CANCER RES, V64, P2552, DOI 10.1158/0008-5472.CAN-03-3327; Brizel DM, 1996, CANCER RES, V56, P5347; Brown JM, 1998, CANCER RES, V58, P1408; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P27142; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; Hockel M, 1996, CANCER RES, V56, P4509; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HWANG SM, 1994, J CELL PHYSIOL, V160, P61, DOI 10.1002/jcp.1041600108; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koong AC, 2000, CANCER RES, V60, P883; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Le QT, 2003, CLIN CANCER RES, V9, P59; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Liaw L, 1998, J CLIN INVEST, V101, P1468; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Noiri E, 1999, KIDNEY INT, V56, P74, DOI 10.1046/j.1523-1755.1999.00526.x; Pollmann C, 2001, CANCER RES, V61, P8416; Sodhi CP, 2001, DIABETES, V50, P1482, DOI 10.2337/diabetes.50.6.1482; Sodhi CP, 2000, KIDNEY INT, V58, P691, DOI 10.1046/j.1523-1755.2000.00215.x; TEICHER BA, 1990, CANCER RES, V50, P3339; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X; Zhu YH, 2002, CELL GROWTH DIFFER, V13, P431; Zhu YH, 1999, BIOCHEM BIOPH RES CO, V258, P87, DOI 10.1006/bbrc.1999.0586; Zhu YH, 2003, STROKE, V34, P2483, DOI 10.1161/01.STR.0000088644.60368.ED	52	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6555	6563		10.1038/sj.onc.1208800	http://dx.doi.org/10.1038/sj.onc.1208800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007184				2022-12-28	WOS:000232204100009
J	Varga, AC; Wrana, JL				Varga, AC; Wrana, JL			The disparate role of BMP in stem cell biology	ONCOGENE			English	Article						BMP; cell fate; mouse and human embryonic stem cell; neural crest stem cell	NEURAL CREST; SELF-RENEWAL; BETA-CATENIN; MULTILINEAGE DIFFERENTIATION; SIGNAL-TRANSDUCTION; WNT; PLURIPOTENCY; TERATOCARCINOMA; MAINTENANCE; ACTIVATION	Stem cells share several characteristics of cancer cells including loss of contact inhibition and immortality. Therefore, stem cells represent an excellent model system in which to define the molecular mechanisms underlying cancer development and progression. Several signal transduction pathways including leukemia inhibitory factor, Wnt and FGF have been demonstrated to function in stem cell self-renewal and differentiation. However, more recently bone morphogenetic proteins (BMPs) have emerged as key regulators of stem cell fate commitment. Intriguingly, BMPs have disparate roles in regulating the biology of embryonic stem (ES) cells compared with neural crest stem cells (NCSCs). Furthermore, although BMPs block neural differentiation of ES cells from both mouse and human, they contribute to self-renewal specically in mouse ES cells. These observations strongly suggest that combinations of extracellular factors regulate stem cells, and that crosstalk between intracellular signaling pathways precisely defines stem cell fate commitment. In this review, we focus on the role of BMP signaling in mouse and human ES cells compared with NCSCs. We then discuss how the molecular effectors of BMP signaling may contribute to cancer, and thus represent potential targets for therapeutic intervention.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Wrana, JL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada.	wrana@mshri.on.ca	Wrana, Jeffrey/F-8857-2013					Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Anderson DJ, 2000, PHILOS T R SOC B, V355, P953, DOI 10.1098/rstb.2000.0631; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Benchabane H, 2003, MOL CELL BIOL, V23, P6646, DOI 10.1128/MCB.23.18.6646-6661.2003; Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390; Chai Y, 2003, CRIT REV ORAL BIOL M, V14, P78, DOI 10.1177/154411130301400202; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Donovan PJ, 2001, INT J DEV BIOL, V45, P523; Draper JS, 2003, ARCH MED RES, V34, P558, DOI 10.1016/j.arcmed.2003.08.006; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Gammill LS, 2002, DEVELOPMENT, V129, P5731, DOI 10.1242/dev.00175; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Joseph NM, 2004, DEVELOPMENT, V131, P5599, DOI 10.1242/dev.01429; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Le Douarin NM, 2003, CURR OPIN GENET DEV, V13, P529, DOI 10.1016/j.gde.2003.08.002; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Lo KC, 2003, J UROLOGY, V170, P2453, DOI 10.1097/01.ju.0000087170.97532.ff; Martinez CEA, 2002, BIOCHEM BIOPH RES CO, V291, P655, DOI 10.1006/bbrc.2002.6502; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Pera ME, 1998, REPROD FERT DEVELOP, V10, P551, DOI 10.1071/RD98097; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; POMP O, 2005, IN PRESS STEM CELLS; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHMIDT C, 2005, IN PRESS ANAT EMBRYO; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shibamoto S, 2004, EXP CELL RES, V292, P11, DOI 10.1016/j.yexcr.2003.08.009; Tanaka M, 2000, METH MOL B, V158, P135; Tiedemann H, 2001, DEV GROWTH DIFFER, V43, P469; Wang GW, 2005, BIOCHEM BIOPH RES CO, V330, P934, DOI 10.1016/j.bbrc.2005.03.058; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhang WJ, 2002, J BIOL CHEM, V277, P45435, DOI 10.1074/jbc.M208056200	56	154	170	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5713	5721		10.1038/sj.onc.1208919	http://dx.doi.org/10.1038/sj.onc.1208919			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123804				2022-12-28	WOS:000231452800006
J	Ryu, CH; Kim, SW; Lee, KH; Lee, JY; Kim, H; Lee, WK; Choi, BH; Lim, Y; Kim, YH; Lee, KH; Hwang, TK; Jun, TY; Rha, HK				Ryu, CH; Kim, SW; Lee, KH; Lee, JY; Kim, H; Lee, WK; Choi, BH; Lim, Y; Kim, YH; Lee, KH; Hwang, TK; Jun, TY; Rha, HK			The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity	ONCOGENE			English	Article						NF2; merlin; tumor suppressor; RalGDS; oncogenic signals	GROWTH-FACTOR RECEPTOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; CELLULAR-TRANSFORMATION; BINDING PROTEIN-1; SIGNALING PATHWAY; SPLICED ISOFORMS; FERM DOMAIN; SCHWANNOMIN; ACTIVATION	Neurofibromatosis type 2 (NF2) is the most commonly mutated gene in benign tumors of the human nervous system such as schwannomas and meningiomas. The NF2 gene encodes a protein called schwannomin or merlin, which is involved in regulating cell growth and proliferation through protein-protein interactions with various cellular proteins. In order to better understand the mechanism by which merlin exerts its function, yeast two-hybrid screening was performed and Ral guanine nucleotide dissociation stimulator (RalGDS), a downstream molecule of Ras, was identified as a merlin-binding protein. The direct interaction between merlin and RalGDS was confirmed both in vitro and in the NIH3T3 cells. The domain analyses revealed that the broad C-terminal region of merlin (aa 141-595) is necessary for the interaction with the C-terminal Ras-binding domain (RBD) of RalGDS. Functional studies showed that merlin inhibits the RalGDS-induced RalA activation, the colony formation and the cell migration in mammalian cells. These results suggest that merlin can function as a tumor suppressor by inhibiting the RalGDS-mediated oncogenic signals.	Catholic Univ Korea, Catholic Neurosci Ctr, Dept Psychiat, Seoul 137701, South Korea; Catholic Univ, Dept Urol, Seoul 137701, South Korea; Catholic Univ, Dept Pharmacol, Seoul 137701, South Korea; Catholic Univ, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ, Dept Psychiat, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Jun, TY (corresponding author), Catholic Univ Korea, Catholic Neurosci Ctr, Dept Psychiat, 505 Banpo Dong, Seoul 137701, South Korea.	ngrc@catholic.ac.kr						Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gildea JJ, 2002, CANCER RES, V62, P982; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Joffe E B, 2001, Medicina (B Aires), V61, P658; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Lee IK, 2004, BIOCHEM BIOPH RES CO, V325, P774, DOI 10.1016/j.bbrc.2004.10.095; Lee JY, 2004, J BIOL CHEM, V279, P30265, DOI 10.1074/jbc.M312083200; Lee T, 1996, DEVELOPMENT, V122, P409; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Matthews J N S, 2002, Dev Biol (Basel), V107, P87; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Sainio M, 1997, J CELL SCI, V110, P2249; Schmucker B, 1999, HUM MOL GENET, V8, P1561, DOI 10.1093/hmg/8.8.1561; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Scoles DR, 2002, BIOCHEM BIOPH RES CO, V290, P366, DOI 10.1006/bbrc.2001.6178; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Takaya A, 2004, MOL BIOL CELL, V15, P2549, DOI 10.1091/mbc.E03-11-0857; THOMAS G, 1994, EUR J CANCER, V30A, P1981, DOI 10.1016/0959-8049(94)00390-Q; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	52	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5355	5364		10.1038/sj.onc.1208633	http://dx.doi.org/10.1038/sj.onc.1208633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007223				2022-12-28	WOS:000231158500009
J	Sun, YP; Lowther, W; Kato, K; Bianco, C; Kenney, N; Strizzi, L; Raafat, D; Hirota, M; Khan, NI; Bargo, S; Jones, B; Salomon, D; Callahan, R				Sun, YP; Lowther, W; Kato, K; Bianco, C; Kenney, N; Strizzi, L; Raafat, D; Hirota, M; Khan, NI; Bargo, S; Jones, B; Salomon, D; Callahan, R			Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling	ONCOGENE			English	Article						Notch4ICD; Smad3; TGF-beta	GROWTH-FACTOR-BETA; MAMMARY EPITHELIAL-CELLS; TRUNCATED INT3 GENE; NEOPLASTIC TRANSFORMATION; BRANCHING MORPHOGENESIS; TUMOR-SUPPRESSOR; MAMMALIAN NOTCH; CROSS-TALK; EXPRESSION; RECEPTORS	We present evidence that Notch4ICD attenuates TGF-beta signaling. Cells expressing the activated form of the Notch4 receptor (ICD4) were resistant to the growth-inhibitory effects of TGF-beta. Notch4ICD was found to bind to Smad2, Smad3 and Smad4 but with higher affinity to Smad3. Deletion analysis showed that binding of Smad3 to ICD4 was mediated by its MH2 domain and was not dependent on the presence of the RAM23 region in ICD4. Using two TGF-beta/Activin reporter luciferase assays, RT-PCR and Western blot analysis, we demonstrate that ICD4 and ICD4 delta RAM23 inhibit Smad-binding element and 3TP luciferase reporter activity and PAI-1 gene expression. MCF-7 human breast cancer cells express Notch4ICD (ICD4) and are resistant to the growth-inhibitory effects of TGF-beta. Blockage of Notch4 processing to ICD4 by gamma-secretase inhibitor renders MCF-7 cells sensitive to growth inhibition by TGF-beta. The interplay between these two signaling pathways may be a significant determinant during mammary tumorigenesis.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; NCI, Oncogenesis Sect, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Salomon, D (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA.	salomond@mail.nih.gov; Callahro@mail.nih.gov		Hirota, Morihisa/0000-0001-5682-0911	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallahan D, 1996, CANCER RES, V56, P1775; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, J CELL SCI, V113, P1101; Moustakas A, 2001, J CELL SCI, V114, P4359; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Rao P, 2003, MOL CELL BIOL, V23, P6694, DOI 10.1128/MCB.23.18.6694-6701.2003; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Sun Y, 2001, MOL CELL ENDOCRINOL, V172, P177, DOI 10.1016/S0303-7207(00)00370-1; Sun YP, 2002, J BIOL CHEM, V277, P19080, DOI 10.1074/jbc.M200936200; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xie W, 2002, CANCER RES, V62, P497; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066	54	72	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5365	5374		10.1038/sj.onc.1208528	http://dx.doi.org/10.1038/sj.onc.1208528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007227				2022-12-28	WOS:000231158500010
J	Alberici, P; Jagmohan-Changur, S; De Pater, E; Van Der Valk, M; Smits, R; Hohenstein, P; Fodde, R				Alberici, P; Jagmohan-Changur, S; De Pater, E; Van Der Valk, M; Smits, R; Hohenstein, P; Fodde, R			Smad4 haploinsufficiency in mouse models for intestinal cancer	ONCOGENE			English	Article						Smad4; Apc; haploinsufficiency; TGF-beta signaling; LOH; Wnt signaling; gastrointestinal cancer	STEM-CELL DIFFERENTIATION; COLORECTAL CANCERS; JUVENILE POLYPOSIS; BETA-CATENIN; GENE; APC; TUMORIGENESIS; PATHWAY; TUMORS; MUTATIONS	The Smad4(+/E6sad) mouse carries a null mutation in the endogenous Smad4 gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majority of the tumors appear at 9 months of age, somatic loss of the wild-type Smad4 allele occurs only at later stages of tumor progression. Hence, haploinsufficiency underlies Smad4-driven tumor initiation in the GI tract. As both the Apc and Smad4 tumor suppressor genes map to mouse chromosome 18, we have bred Smad4(+/E6sad) with the Apc(+/1638N) model to generate two distinct compound heterozygous lines carrying both mutations either in cis ( CAS) or in trans ( TAS). Strikingly, both models show increased tumor multiplicities when compared with the single mutant littermates, although CAS mice are more severely affected and became moribund at only 5-6 weeks of age. Phenotypic and molecular analyses indicate that Smad4 haploinsufficiency is sufficient to significantly affect tumor initiation and progression both prior to and upon loss of Apc function. Moreover, complete loss of Smad4 strongly enhances Apc-driven tumor formation.	ErasmusMC, Dept Pathol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, Amsterdam, Netherlands; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; University of Edinburgh	Fodde, R (corresponding author), ErasmusMC, Dept Pathol, Josephine Nefkens Inst, POB 1738, NL-3000 DR Rotterdam, Netherlands.	r.fodde@erasmusmc.nl	Fodde, Riccardo/AAW-9394-2021; Hohenstein, Peter/Y-2428-2018	Fodde, Riccardo/0000-0001-9839-4324; de Pater, Emma/0000-0002-7195-6769; Hohenstein, Peter/0000-0001-8548-4734				Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gaspar C, 2004, INT J DEV BIOL, V48, P377, DOI 10.1387/ijdb.041807cg; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hohenstein P, 2003, GENE CHROMOSOME CANC, V36, P273, DOI 10.1002/gcc.10169; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jass JR, 2001, J PATHOL, V193, P283, DOI 10.1002/1096-9896(200103)193:3<283::AID-PATH799>3.0.CO;2-9; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5; Lei S, 2004, J BIOL CHEM, V279, P42492, DOI 10.1074/jbc.M404025200; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Satterwhite DJ, 2004, CELL CYCLE, V3, P1069; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504	33	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1841	1851		10.1038/sj.onc.1209226	http://dx.doi.org/10.1038/sj.onc.1209226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288217				2022-12-28	WOS:000236224800001
J	Ren, B; Yu, G; Tseng, GC; Cieply, K; Gavel, T; Michalopoulos, G; Yu, YP; Luo, JH				Ren, B; Yu, G; Tseng, GC; Cieply, K; Gavel, T; Michalopoulos, G; Yu, YP; Luo, JH			MCM7 amplification and overexpression are associated with prostate cancer progression	ONCOGENE			English	Article						MCM7; metastasis; prostate cancer; amplification	COMPARATIVE GENOMIC HYBRIDIZATION; MINICHROMOSOME-MAINTENANCE PROTEIN-7; DNA-REPLICATION; TUMOR-GROWTH; S-PHASE; COMPLEX; EXPRESSION; IDENTIFICATION; LOCALIZATION; MICROARRAYS	The genomic DNA profiles of prostate cancers with aggressive features were compared to the profiles of matched normal DNA to identify genes that are selectively amplified in the cancer cells. One of the identified genes, MCM7, which is a component of the DNA replication licensing complex, has been studied extensively both at the DNA and protein levels in human prostate tissues. Approximately half of the prostate cancer specimens studied showed MCM7 gene amplification, and 60% of the aggressive prostate cancer specimens had increased MCM7 protein expression. Amplification or overexpression of MCM7 was significantly associated with relapse, local invasion and a worse tumor grade. Constitutive expression of MCM7 in a human prostate cancer cell line, DU145, resulted in markedly increased DNA synthesis and cell proliferation compared to vector-only controls, and an increased cell invasion in vitro. Indeed, MCM7 overexpression produced primary tumors 12 times larger than vector-only controls and resulted in a rapid demise of mice bearing those tumors. These studies implicate MCM7, and the DNA replication licensing gene family, in prostate cancer progression, growth and invasion.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Scaife Hall A-725,3550 Terrace St, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu	Yu, Yan/GYV-4514-2022		NATIONAL CANCER INSTITUTE [U01CA088110, R01CA098249] Funding Source: NIH RePORTER; NCI NIH HHS [1 UO1CA88110-01, R01 CA098249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brake T, 2003, CANCER RES, V63, P8173; Clark J, 2003, ONCOGENE, V22, P1247, DOI 10.1038/sj.onc.1206247; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Laitinen S, 2002, GENE CHROMOSOME CANC, V35, P66, DOI 10.1002/gcc.10097; Lu ZH, 1999, MOL BIOL CELL, V10, P4091, DOI 10.1091/mbc.10.12.4091; LUO JH, 2003, EXPERT REV MOL MED, P1; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Wolter H, 2002, EUR UROL, V41, P328, DOI 10.1016/S0302-2838(02)00035-0; Xue WC, 2003, HISTOPATHOLOGY, V43, P485, DOI 10.1046/j.1365-2559.2003.01728.x; Yoshida K, 2003, FEBS LETT, V553, P213, DOI 10.1016/S0014-5793(03)01018-4	25	144	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1090	1098		10.1038/sj.onc.1209134	http://dx.doi.org/10.1038/sj.onc.1209134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247466				2022-12-28	WOS:000235361000013
J	Dang, L; Fan, X; Chaudhry, A; Wang, M; Gaiano, N; Eberhart, CG				Dang, L; Fan, X; Chaudhry, A; Wang, M; Gaiano, N; Eberhart, CG			Notch3 signaling initiates choroid plexus tumor formation	ONCOGENE			English	Article						choroid plexus papilloma; Notch3	MULTIPLE FUNCTIONAL ROLES; RADIAL GLIAL IDENTITY; BRAIN-DEVELOPMENT; TRANSGENIC MICE; GROWTH; EXPRESSION; CANCER; DIFFERENTIATION; TUMORIGENESIS; DELTA-LIKE-1	Notch3 has been studied in the context of brain development, but whether it plays a role in the formation of brain tumors is unclear. We demonstrate that the introduction of constitutively active Notch3 into periventricular cells of embryonic day 9.5 mice causes the formation of choroid plexus tumors (CPTs). Tumors arose in the fourth ventricles in 83% of animals and were associated with hydrocephalus. They were microscopically highly similar to choroid plexus papillomas in humans, with an ongoing proliferation rate of 4-6%. Signs of Notch pathway activity were also present in human choroid plexus lesions, and receptor mRNA levels in papillomas were elevated over those in non-neoplastic choroid plexus. Notch2 was overexpressed approximately 500-fold in one case, suggesting that the role of this pathway in CPTs may not be specific to Notch3. Our findings indicate that activated Notch3 can function as an oncogene in the developing brain, and link the Notch pathway to human CPT pathogenesis.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University	Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Bldg 558, Baltimore, MD 21205 USA.	gaiano@jhmi.edu; ceberha@jhmi.edu		Dang, Louis/0000-0003-4853-4952	NINDS NIH HHS [K08NS43279, K08NS041342] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041342, K08NS043279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Irvin DK, 2001, J COMP NEUROL, V436, P167, DOI 10.1002/cne.1059.abs; Irvin DK, 2004, J NEUROSCI RES, V75, P330, DOI 10.1002/jnr.10843; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; KLEIHUES P, 2000, TUMORS NERVOUS SYSTE; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rickert CH, 2002, AM J PATHOL, V160, P1105, DOI 10.1016/S0002-9440(10)64931-0; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004; Yoon KJ, 2004, J NEUROSCI, V24, P9497, DOI 10.1523/JNEUROSCI.0993-04.2004	21	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					487	491		10.1038/sj.onc.1209074	http://dx.doi.org/10.1038/sj.onc.1209074			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186803				2022-12-28	WOS:000234714100017
J	Tsai, MH; Chen, X; Chandramouli, GVR; Chen, Y; Yan, H; Zhao, S; Keng, P; Liber, HL; Coleman, CN; Mitchell, JB; Chuang, EY				Tsai, MH; Chen, X; Chandramouli, GVR; Chen, Y; Yan, H; Zhao, S; Keng, P; Liber, HL; Coleman, CN; Mitchell, JB; Chuang, EY			Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells	ONCOGENE			English	Article						microarray; radiation; p53R2; TK6	NF-KAPPA-B; RIBONUCLEOTIDE REDUCTASE GENE; NUCLEOTIDE EXCISION-REPAIR; THYMIDINE KINASE LOCUS; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; CYCLE CHECKPOINT; MAMMALIAN-CELLS; CANCER CELLS; APOPTOSIS	The p53 protein has been implicated in multiple cellular responses related to DNA damage. Alterations in any of these cellular responses could be related to increased genomic instability. Our previous study has shown that mutations in p53 lead to hypermutability to ionizing radiation. To investigate further how p53 is involved in regulating mutational processes, we used 8K cDNA microarrays to compare the patterns of gene expression among three closely related human cell lines with different p53 status including TK6 (wild-type p53), NH32 (p53null), and WTK1 (mutant p53). Total RNA samples were collected at 1, 3, 6, 9, and 24 h after 10 Gy gamma-irradiation. Template-based clustering analysis of the gene expression over the time course showed that 464 genes are either up or downregulated by at least twofold following radiation treatment. In addition, cluster analyses of gene expression profiles among these three cell lines revealed distinct patterns. In TK6, 165 genes were upregulated, while 36 genes were downregulated. In contrast, in WTK1 75 genes were upregulated and 12 genes were downregulated. In NH32, only 54 genes were upregulated. Furthermore, we found several genes associated with DNA repair namely p53R2, DDB2, XPC, PCNA, BTG2, and MSH2 that were highly induced in TK6 compared to WTK1 and NH32. p53R2, which is regulated by the tumor suppressor p53, is a small subunit of ribonucleotide reductase. To determine whether it is involved in radiation-induced mutagenesis, p53R2 protein was inhibited by siRNA in TK6 cells and followed by 2Gy radiation. The background mutation frequencies at the TK locus of siRNA-transfected TK6 cells were about three times higher than those seen in TK6 cells. The mutation frequencies of siRNA-transfected TK6 cells after 2 Gy radiation were significantly higher than the irradiated TK6 cells without p53R2 knock down. These results indicate that p53R2 was induced by p53 protein and is involved in protecting against radiation-induced mutagenesis.	NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Oncol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Ctr Adv Technol, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA; Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; Natl Taiwan Univ, Dept Elect Engn, Taipei 10764, Taiwan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Rochester; Colorado State University; National Taiwan University	Chuang, EY (corresponding author), NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bldg 10,Room B3-B69, Bethesda, MD 20892 USA.	chuange@mail.nih.gov		TSAI, MONG-HSUN/0000-0001-8777-5818				Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Backlund MG, 2001, CANCER RES, V61, P6577; BARCELLOS CK, 1994, BRAZ J MED BIOL RES, V27, P1111; BENJAMIN MB, 1991, P NATL ACAD SCI USA, V88, P6652, DOI 10.1073/pnas.88.15.6652; Chen XF, 2002, CANCER RES, V62, P1213; Chuang YYE, 1999, CANCER RES, V59, P3073; Chuang YYE, 2002, CANCER RES, V62, P6246; Coelho D, 2002, RADIAT RES, V157, P446, DOI 10.1667/0033-7587(2002)157[0446:IOTIAI]2.0.CO;2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Ewan KB, 2002, CANCER RES, V62, P5627; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Geffrotin C, 1998, RADIAT RES, V149, P472, DOI 10.2307/3579787; Gong BD, 2000, CANCER RES, V60, P5754; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Holbrook N J, 1996, EXS, V77, P273; Kawai H, 1999, CANCER RES, V59, P6038; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Peng YL, 2002, CANCER RES, V62, P6400; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; XIA F, 1995, CANCER RES, V55, P12; Xue LJ, 2003, CANCER RES, V63, P980; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yang O, 2004, ONCOGENE, V23, P3749, DOI 10.1038/sj.onc.1207462; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; Yu YJ, 1998, CANCER RES, V58, P4277; Zhao WL, 2001, CANCER RES, V61, P5537	48	34	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					622	632		10.1038/sj.onc.1209082	http://dx.doi.org/10.1038/sj.onc.1209082			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247478	Green Submitted			2022-12-28	WOS:000234897400013
J	Debacq, C; Heraud, JM; Asquith, B; Bangham, C; Merien, F; Moules, V; Mortreux, F; Wattel, E; Burny, AN; Kettmann, R; Kazanji, M; Willems, L				Debacq, C; Heraud, JM; Asquith, B; Bangham, C; Merien, F; Moules, V; Mortreux, F; Wattel, E; Burny, AN; Kettmann, R; Kazanji, M; Willems, L			Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1	ONCOGENE			English	Article						HTLV-1; leukemia; BrdU; turnover	I-ASSOCIATED MYELOPATHY; LEUKEMIA-VIRUS; HTLV-I; ANIMAL-MODEL; SAIMIRI-SCIUREUS; HIV-1 INFECTION; TRANSGENIC RATS; VACCINIA VIRUS; TAX; DNA	Understanding cell dynamics in animal models have implications for therapeutic strategies elaborated against leukemia in human. Quanti. cation of the cell turnover in closely related primate systems is particularly important for rare and aggressive forms of human cancers, such as adult T-cell leukemia. For this purpose, we have measured the death and proliferation rates of the CD4(+) T lymphocyte population in squirrel monkeys (Saimiri sciureus) infected by human T-lymphotropic virus type 1 (HTLV-1). The kinetics of in vivo bromodeoxyuridine labeling revealed no modulation of the cell turnover in HTLV-1-infected monkeys with normal CD4 cell counts. In contrast, a substantial decrease in the proliferation rate of the CD4(+) T population was observed in lymphocytic monkeys (e.g. characterized by excessive proportions of CD4(+) T lymphocytes and by the presence of abnormal flower-like cells). Unexpectedly, onset of HTLV-associated leukemia thus occurs in the absence of increased CD4(+) T-cell proliferation. This dynamics significantly differs from the generalized activation of the T-cell turnover induced by other primate lymphotropic viruses like HIV and SIV.	FUSAG, Ctr Basic Biol, B-5030 Gembloux, Belgium; Inst Pasteur, Lab Retrovirol, Cayenne, French Guiana; Imperial Coll Sch Med, Dept Immunol, London, England; Ctr Leon Berard, CNRS UMR 5537, Unite Oncogenese Virale, F-69373 Lyon, France	Imperial College London; UNICANCER; Centre Leon Berard	Willems, L (corresponding author), FUSAG, Ctr Basic Biol, 13 Ave Marechal Juin, B-5030 Gembloux, Belgium.	willems.l@fsagx.ac.be	mortreux, franck/M-5944-2014; mortreux, franck/T-4564-2019; Heraud, Jean-Michel/O-1464-2013	mortreux, franck/0000-0002-4840-021X; mortreux, franck/0000-0002-4840-021X; Heraud, Jean-Michel/0000-0003-1107-0859; Asquith, Becca/0000-0002-5911-3160; Bangham, Charles/0000-0003-2624-3599; Willems, Luc/0000-0002-0563-2213				Akari H, 1998, AIDS RES HUM RETROV, V14, P367, DOI 10.1089/aid.1998.14.367; Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BENVENISTY N, 1992, ONCOGENE, V7, P2399; Bomford R, 1996, AIDS RES HUM RETROV, V12, P403, DOI 10.1089/aid.1996.12.403; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Debacq C, 2003, J VIROL, V77, P13073, DOI 10.1128/JVI.77.24.13073-13083.2003; Debacq C, 2002, P NATL ACAD SCI USA, V99, P10048, DOI 10.1073/pnas.142100999; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; GESSAIN A, 1985, LANCET, V2, P407; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hasegawa A, 2003, J VIROL, V77, P2956, DOI 10.1128/JVI.77.5.2956-2963.2003; Ibuki K, 1997, J GEN VIROL, V78, P147, DOI 10.1099/0022-1317-78-1-147; ICHIMARU M, 1991, CANCER DETECT PREV, V15, P177; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2001, J VIROL, V75, P5939, DOI 10.1128/JVI.75.13.5939-5948.2001; Kazanji M, 2000, AIDS RES HUM RETROV, V16, P1741, DOI 10.1089/08892220050193245; Kazanji M, 1997, INT J CANCER, V71, P300, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;300::AID-IJC27&gt;3.0.CO;2-J; Kikuchi K, 2002, INT J EXP PATHOL, V83, P247, DOI 10.1046/j.1365-2613.2003.00233.x; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; LAIRMORE MD, 1992, INT J CANCER, V50, P124, DOI 10.1002/ijc.2910500125; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; Nakamaru Y, 2001, PATHOBIOLOGY, V69, P11, DOI 10.1159/000048752; Ohashi T, 2002, J VIROL, V76, P7010, DOI 10.1128/JVI.76.14.7010-7019.2002; Ohashi T, 2000, J VIROL, V74, P9610, DOI 10.1128/JVI.74.20.9610-9616.2000; OSAME M, 1986, LANCET, V1, P1031; PAGLIUCA A, 1988, BRIT MED J, V297, P1456, DOI 10.1136/bmj.297.6661.1456; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Ribeiro RM, 2002, P NATL ACAD SCI USA, V99, P15572, DOI 10.1073/pnas.242358099; Rosenzweig M, 1998, P NATL ACAD SCI USA, V95, P6388, DOI 10.1073/pnas.95.11.6388; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Silic-Benussi M, 2004, P NATL ACAD SCI USA, V101, P6629, DOI 10.1073/pnas.0305502101; Simpson RM, 1998, AIDS RES HUM RETROV, V14, P711, DOI 10.1089/aid.1998.14.711; Sugaya T, 2002, EXP MOL PATHOL, V72, P56, DOI 10.1006/exmp.2001.2415; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; Yamaguchi K, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P770; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YAMANOUCHI K, 1985, JPN J CANCER RES, V76, P481; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	53	9	9	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7514	7523		10.1038/sj.onc.1208896	http://dx.doi.org/10.1038/sj.onc.1208896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16091751				2022-12-28	WOS:000233333800002
J	Starczynowski, DT; Reynolds, JG; Gilmore, TD				Starczynowski, DT; Reynolds, JG; Gilmore, TD			Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; malignant transformation; lymphoma; tumor necrosis factor	NF-KAPPA-B; MANGANESE SUPEROXIDE-DISMUTASE; CHICKEN SPLEEN-CELLS; V-REL; UP-REGULATION; DNA-BINDING; LINE RC-K8; LYMPHOMA; PROTEIN; ACTIVATION	The human c-rel gene (REL), encoding an NF-KB transcription factor, is amplifi. ed or mutated in several human B-cell lymphomas and can transform chicken lymphoid cells in vitro. We have previously shown that certain deletions of C-terminal transactivation sequences enhance REL's transforming ability in chicken spleen cells. In this report, we have analysed the effect of single amino-acid changes at select serine residues in the C-terminal transactivation domain on REL's transforming ability. Mutation of either of two TNF alpha-inducible serine residues (Ser460 and Ser471) to nonphosphorylatable residues (alanine, asparagine, phenylalanine) made REL more effi. cient at transforming chicken spleen cells in vitro. In contrast, mutation of Ser471 to a phosphorylation mimetic aspartate residue impaired REL's transforming ability, even though it increased REL's inherent transactivation ability as a GAL4-fusion protein. Alanine mutations of several other serine residues within the transactivation domain did not substantially affect REL's transforming ability. Transactivation by GAL4-REL fusion proteins containing either transformation enhancing or nonenhancing mutations at serine residues was generally similar to wild-type GAL4-REL. However, more transforming mutants with mutations at either Ser460 or Ser471 differed from wild-type REL in their ability to transactivate certain KB-site reporter genes. In particular, the SOD2 promoter, encoding manganese superoxide dismutase, was activated less strongly by the more transforming REL mutant REL-S471N transient assays, but REL-S471N-transformed chicken spleen cells had increased levels of MnSOD protein as compared to wild- type REL-transformed cells. Taken together, our results show that mutations of certain serine residues can enhance REL's transforming ability in vitro and suggest that these mutations increase REL-mediated transformation by altering REL's ability to modulate the expression of select target genes. Furthermore, phosphorylation of Ser471 may be involved in REL-mediated modulation of transformation-specific target gene expression. Lastly, these results suggest that similar mutations in the REL transactivation domain contribute to the development of certain human B-cell lymphomas.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bernard D, 2001, CANCER RES, V61, P2656; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; FEUERHAKE F, 2005, IN PRESS BLOOD; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huguet C, 1999, APOPTOSIS, V4, P31, DOI 10.1023/A:1009678015249; Iwai K, 2005, FEBS LETT, V579, P141, DOI 10.1016/j.febslet.2004.11.060; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; LU D, 1991, ONCOGENE, V6, P1235; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7	42	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7355	7368		10.1038/sj.onc.1208902	http://dx.doi.org/10.1038/sj.onc.1208902			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027730				2022-12-28	WOS:000233142100012
J	Kamrava, M; Simpkins, F; Alejandro, E; Michener, C; Meltzer, E; Kohn, EC				Kamrava, M; Simpkins, F; Alejandro, E; Michener, C; Meltzer, E; Kohn, EC			Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer	ONCOGENE			English	Article						ovarian cancer; progranulin; apoptosis; EPAC; signaling	DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; CARCINOMA CELLS; COUPLED RECEPTORS; CYCLIC-AMP; SIGNALING PATHWAYS; ALPHA SUBUNIT; FACTOR PCDGF; ACTIVATION; EPAC	Granulin-epithelin precursor (GEP/progranulin) is an autocrine growth factor for ovarian cancer. We examined the production and function of GEP and report that: (1) GEP production is regulated by endothelin (ET-1), lysophosphatidic acid (LPA), and cAMP; (2) cAMP signals GEP production through exchange protein activated by cAMP (EPAC); (3) ET-1 and cAMP/EPAC induce GEP through ERK1/2; and (4) neutralization of GEP results in apoptosis. Exposure of HEY-A8 and OVCAR3 ovarian cancer cells to LPA and ET-1 yielded GEP production and secretion in a dose- and time-dependent fashion; neither stimulated significant concentrations of cAMP directly. Stimulation of cAMP production with pertussis and cholera toxin, or forskolin induced GEP in a PKA-independent fashion. EPAC, an intracellular cAMP receptor, is activated specifically by the cAMP analog, 8-CPT-2'-O-Me-cAMP (8-CPT); 8-CPT treatment stimulated GEP production and secretion. The MEK inhibitor, U0126, abrogated GEP production in response to ET-1 and 8-CPT, confirming involvement of MAPK. A partial inhibition of basal and stimulated GEP production was observed when cells were treated with a internal calcium chelator, BAPTA. Neutralizing anti-GEP antibody reversed basal as well as LPA, ET-1 and 8CPT-induced ovarian cancer cell growth and induced apoptosis as demonstrated by caspase-3 and PARP cleavage, DNA fragmentation, and nuclear condensation. These results indicate that GEP is a growth and survival factor for ovarian cancer, induced by LPA and ET-1 and cAMP/EPAC through ERK1/2.	NCI, Pathol Lab, Mol Signaling Sect, Canc Res Ctr, Bethesda, MD 20892 USA; NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	Kohn, EC (corresponding author), NCI, Pathol Lab, Mol Signaling Sect, Canc Res Ctr, 10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	ek1b@nih.gov		Alejandro, Emilyn/0000-0002-7941-8439	NATIONAL CANCER INSTITUTE [Z01SC009163, ZIASC009163] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alper O, 1999, ONCOGENE, V18, P4999, DOI 10.1038/sj.onc.1202830; Amsterdam A, 1999, TRENDS ENDOCRIN MET, V10, P255, DOI 10.1016/S1043-2760(99)00164-2; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Del Bufalo D, 2002, CLIN SCI, V103, p302S, DOI 10.1042/CS103S302S; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Goetzl EJ, 1999, CANCER RES, V59, P4732; Guirland C, 2003, J NEUROSCI, V23, P2274; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones MB, 2003, CLIN CANCER RES, V9, P44; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Keiper M, 2004, J BIOL CHEM, V279, P46497, DOI 10.1074/jbc.M403604200; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Lu RQ, 1999, BIOCHEM BIOPH RES CO, V256, P204, DOI 10.1006/bbrc.1999.0253; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, P NATL ACAD SCI USA, V98, P142, DOI 10.1073/pnas.011525198; McDaid HM, 1999, BRIT J CANCER, V79, P933, DOI 10.1038/sj.bjc.6690149; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nicosia SV, 2003, HEMATOL ONCOL CLIN N, V17, P927, DOI 10.1016/S0889-8588(03)00056-X; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rosano L, 2003, CANCER RES, V63, P2447; Rosano L, 2001, CANCER RES, V61, P8340; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Salani D, 2002, CLIN SCI, V103, p318S, DOI 10.1042/CS103S318S; SHABB JB, 1990, J BIOL CHEM, V265, P5267; Vacca F, 2000, CANCER RES, V60, P5310; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	47	55	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7084	7093		10.1038/sj.onc.1208857	http://dx.doi.org/10.1038/sj.onc.1208857			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044162				2022-12-28	WOS:000232833200010
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Differential responses of Mcl-1 in photosensitized epithelial vs lymphoid-derived human cancer cells	ONCOGENE			English	Article						Mcl-1; Bcl-2; apoptosis; photodynamic therapy	THERAPY-INDUCED APOPTOSIS; BCL-2 FAMILY-MEMBERS; PHOTODYNAMIC THERAPY; ENDOPLASMIC-RETICULUM; MEDIATED APOPTOSIS; INDUCED DEATH; CYTOCHROME-C; CLEAVAGE; PROTEIN; STAUROSPORINE	The antiapoptotic Bcl-2-family proteins, Bcl-2 and BclxL, are recognized phototargets of photodynamic therapy (PDT) with the mitochondrion-targeting phthalocyanine photosensitizer Pc 4. In the present study, we found that myeloid cell leukemia 1 (Mcl-1), another antiapoptotic member of the Bcl-2 family, was not photodamaged in Pc 4-PDT-treated human carcinoma cells MCF-7c3, MDA-MB468, DU145, and A431, although Mcl-1 turnover was observed after exposure of HeLa or MCF-7c3 cells to a supralethal dose of UVC. In contrast, when human lymphoma U937 and Jurkat cells were treated with Pc 4-PDT, staurosporine (STS) or UVC, Mcl-1 was cleaved to generate a 28-kDa fragment over a 2 - 4 h period. The cleavage of Mcl-1 was accompanied by the activation of caspases-3, - 9, and - 8. The broad-specificity caspase inhibitor z-VAD-fmk completely blocked Mcl-1 cleavage induced by PDT, STS or UVC, providing evidence for Mcl-1 as a substrate for caspases. Western blot analysis localized Mcl-1 to mitochondria, ER, and cytosol of both MCF-7c3 and U937 cells, suggesting that Mcl-1 protein, unlike Bcl-2 and Bcl-xL, is not a target for Pc 4-PDT, probably due to its localization to sites removed from those of Pc 4 binding. The 28-kDa cleaved fragment of Mcl-1, which has proapoptotic activity, was produced in PDT-treated lymphoid-derived cells, but not in cells of epithelial origin, suggesting that PDT-induced rapid and extensive apoptosis in lymphoma cells may result in part from the sensitivity of their Mcl-1 to caspase cleavage, removing an important negative control on apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA083917, P30CA043703, P01CA048735] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48735, R01 CA83917, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chiu SM, 2001, CANCER LETT, V165, P51, DOI 10.1016/S0304-3835(01)00422-0; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; Kitada S, 2000, BLOOD, V96, P393; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Vrana JA, 2002, CANCER RES, V62, P892; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Xue LY, 2003, ONCOGENE, V22, P9197, DOI 10.1038/sj.onc.1207019; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	49	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6987	6992		10.1038/sj.onc.1208837	http://dx.doi.org/10.1038/sj.onc.1208837			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007152				2022-12-28	WOS:000232701700014
J	Baldassarre, G; Belletti, B; Battista, S; Nicoloso, MS; Pentimalli, F; Fedele, M; Croce, CM; Fusco, A				Baldassarre, G; Belletti, B; Battista, S; Nicoloso, MS; Pentimalli, F; Fedele, M; Croce, CM; Fusco, A			HMGA1 protein expression sensitizes cells to cisplatin-induced cell death	ONCOGENE			English	Article						HMGA1; BRCA1; knockout; ES cells; apoptosis; DNA damage	NUCLEOTIDE EXCISION-REPAIR; HMGI(Y) PROTEIN; GENE-EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; BRCA1; CARCINOMA; TRANSFORMATION; CHEMOTHERAPY; APOPTOSIS	HMGA1 proteins belong to a family of nonhistone chromatin proteins able to bind DNA in AT-rich regions and to interact with various transcription factors thus enhancing or inhibiting gene transcription by acting as architectural proteins. Although their expression is very low or absent in many adult tissues, HMGA1 proteins have been frequently found to be upregulated in human cancers and are expressed at high levels during embryogenesis, suggesting they could have a role in highly proliferating cells. We have previously demonstrated that HMGA1 expression in primary breast cancer and mammary carcinoma derived cell lines inversely correlated with BRCA1 expression and that HMGA1 is able to downregulate the expression of BRCA1 gene by binding directly to its promoter region. Being BRCA1 protein expression strictly linked to the DNA repair activity of the cell, we investigated whether HMGA1 expression was able to influence cellular responses to DNA damage. Here, we report that high expression levels of HMGA1 proteins in MCF-7 or mouse embryonic stem cells results in diminished BRCA1 expression and enhanced sensitivity to Cisplatin and Bleomycin. The increased DNA damage-induced cell death in HMGA1-expressing cells is likely due to a diminished cellular DNA repair activity. Therefore, we propose that high expression of HMGA1 protein in human malignant neoplasias, acting on BRCA1 expression, could contribute to the progression of malignant transformation influencing the response of the cells to the damaged DNA.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, I-80131 Naples, Italy; Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; New Jersey Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; NOGEC Naple Oncogenom Ctr, CEINGE, Ctr Biotecnol Avanzate, I-80145 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Aviano (CRO); Jefferson University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Young, Richard A/F-6495-2012; Pentimalli, Francesca/K-4936-2014; Baldassarre, Gustavo/K-1350-2016; Nicoloso, Milena S/K-6411-2012; Belletti, Barbara/J-2028-2018; Fedele, Monica/C-1417-2015; Battista, Sabrina/AAY-2981-2020	Young, Richard A/0000-0001-8855-8647; Pentimalli, Francesca/0000-0003-4740-6801; Baldassarre, Gustavo/0000-0002-9750-8825; Nicoloso, Milena S/0000-0003-4231-9303; Belletti, Barbara/0000-0003-2249-0285; Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Fusco, Alfredo/0000-0003-3332-5197	NATIONAL CANCER INSTITUTE [P30CA056036, P01CA076259] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA56036, P01CA76259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Battista S, 2003, FASEB J, V17, P1496, DOI 10.1096/fj.02-0977fje; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Buschfort-Papewalis C, 2002, BLOOD, V100, P845, DOI 10.1182/blood-2002-01-0022; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Husain A, 1998, CANCER RES, V58, P1120; ITO M, 2005, J GENE MED, V8; Liu WM, 1999, CANCER RES, V59, P5695; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; Quinn JE, 2003, CANCER RES, V63, P6221; RAM TG, 1993, CANCER RES, V53, P2655; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Rosen EM, 2001, CANCER INVEST, V19, P396, DOI 10.1081/CNV-100103134; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Takaha N, 2002, CANCER RES, V62, P647; TAMIMI Y, 1993, CANCER RES, V53, P5512; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852	26	22	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6809	6819		10.1038/sj.onc.1208831	http://dx.doi.org/10.1038/sj.onc.1208831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007157				2022-12-28	WOS:000232527800008
J	Kashanchi, F; Brady, JN				Kashanchi, F; Brady, JN			Transcriptional and post-transcriptional gene regulation of HTLV-1	ONCOGENE			English	Review						HTLV-1; tax; transcription; p53; chromatin; Rex	T-CELL-LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; ELEMENT-BINDING PROTEIN; CAMP-RESPONSIVE ELEMENT; TYPE-1 TAX PROTEIN; TROPICAL SPASTIC PARAPARESIS; NUCLEOLAR TARGETING SIGNAL; DOMINANT-NEGATIVE MUTANTS	Adult T-cell leukemia (ATL) is an aggressive hematologic malignancy caused by human T-cell leukemia virus type I (HTLV-1). Tax, encoded by the HTLV-1 pX region, has been recognized by its pleiotropic actions to play a critical role in leukemogenesis. Three highly conserved 21-bp repeat elements located within the long terminal repeat, commonly referred to as Tax-responsive element 1 (TRE-1), are critical to Tax-mediated viral transcriptional activation through complex interaction with cyclic AMP-responsive element binding protein (CREB), CBP/ p300 and PCAF. Tax has also been shown to activate transcription from a number of critical cellular genes through the NF-kappa B and serum-responsive factor pathways. Tax transactivation has been attributed to the protein's interaction with transcription factors, chromatin remodeling complexes, cell cycle and repair genes. In this review, we will discuss some of the latest findings on this fascinating viral activator and highlight its regulation of cellular factors including CREB, p300/CBP and their effect on RNA polymerase II and chromatin remodeling, as well as its role in cytoplasmic and nuclear function. W e will highlight the possible contribution of each factor, discuss Tax's critical peptide domains and highlight its post-transcriptional modi. cations. It is quite obvious that, collectively, Tax's effects on a wide variety of cellular targets cooperate in promoting cell proliferation and leukemogenesis. In addition, the post-transcriptional effects of Rex play an important role in virus replication. Understanding these interactions at a molecular level will facilitate the targeted development of drugs to effectively inhibit or treat ATL.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20299 USA; NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA	George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St,NW,Ross Hall,Room 551, Washington, DC 20299 USA.	bcmfxk@gwumc.eduz			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R29AI044357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44357, AI43894] Funding Source: Medline; PHS HHS [13969] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADACHI Y, 1992, J BIOL CHEM, V267, P21977; ADACHI Y, 1990, BIOCHEM BIOPH RES CO, V169, P469, DOI 10.1016/0006-291X(90)90355-Q; ADACHI Y, 1993, J BIOL CHEM, V268, P13930; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; Azran Inbal, 2004, Retrovirology, V1, P20; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Barnhart MK, 1997, J VIROL, V71, P337, DOI 10.1128/JVI.71.1.337-344.1997; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN S, 1991, J VIROL, V65, P81; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Ching Yick-Pang, 2004, Retrovirology, V1, P18, DOI 10.1186/1742-4690-1-18; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; de la Fuente Cynthia, 2004, Retrovirology, V1, P19, DOI 10.1186/1742-4690-1-19; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Dodon MD, 2002, J BIOL CHEM, V277, P18744, DOI 10.1074/jbc.M109087200; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Fujisawa J, 1993, Hum Cell, V6, P266; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Georges SA, 2003, MOL CELL BIOL, V23, P3392, DOI 10.1128/MCB.23.10.3392-3404.2003; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; GREENE WC, 1986, SCIENCE, V232, P877, DOI 10.1126/science.3010456; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; Grone M, 1996, VIROLOGY, V218, P316, DOI 10.1006/viro.1996.0200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; Hivin P, 2004, VIROLOGY, V318, P556, DOI 10.1016/j.virol.2003.10.027; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KANNAGI M, 1993, INT J CANCER, V54, P582, DOI 10.1002/ijc.2910540411; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kehn K, 2004, FRONT BIOSCI-LANDMRK, V9, P2347, DOI 10.2741/1401; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; King JA, 1998, ONCOGENE, V16, P3309, DOI 10.1038/sj.onc.1201884; KIRA JI, 1994, MOL NEUROBIOL, V8, P139, DOI 10.1007/BF02780664; Kress E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-8; Kuo YL, 2000, AIDS RES HUM RETROV, V16, P1607, DOI 10.1089/08892220050193038; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Livengood JA, 2004, FRONT BIOSCI-LANDMRK, V9, P3058, DOI 10.2741/1459; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MARRIOTT SJ, 1992, ONCOGENE, V7, P1749; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Newbound GC, 2000, J MED VIROL, V62, P286, DOI 10.1002/1096-9071(200010)62:2<286::AID-JMV22>3.3.CO;2-P; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; Osame M, 1990, Tanpakushitsu Kakusan Koso, V35, P1320; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pique C, 1996, J VIROL, V70, P4919, DOI 10.1128/JVI.70.8.4919-4926.1996; Pise-Masison CA, 2005, FRONT BIOSCI-LANDMRK, V10, P919, DOI 10.2741/1586; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Princler GL, 2003, VIROLOGY, V317, P136, DOI 10.1016/j.virol.2003.09.010; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Suzuki T, 1996, Tanpakushitsu Kakusan Koso, V41, P1249; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takatsuki K, 1984, Princess Takamatsu Symp, V15, P51; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; Uchiumi F, 1996, BIOCHEM BIOPH RES CO, V220, P411, DOI 10.1006/bbrc.1996.0419; Van Orden K, 2000, GENE EXPRESSION, V9, P29; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P21; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P10; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; YAMAGUCHI K, 1984, BLOOD, V63, P1235; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; YOSHIDA M, 1987, LANCET, V1, P1085; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	157	119	132	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5938	5951		10.1038/sj.onc.1208973	http://dx.doi.org/10.1038/sj.onc.1208973			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155601	Bronze			2022-12-28	WOS:000231623400004
J	Gapuzan, MER; Schmah, O; Pollock, AD; Hoffmann, A; Gilmore, TD				Gapuzan, MER; Schmah, O; Pollock, AD; Hoffmann, A; Gilmore, TD			Immortalized fibroblasts from NF-kappa B RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras	ONCOGENE			English	Article						RelA; NF-kappa B; Ras; malignant transformation; mouse knockout cells; tumor necrosis factor	CELLULAR-TRANSFORMATION; MEDIATED TRANSFORMATION; EMBRYONIC LETHALITY; INCREASED APOPTOSIS; ONCOGENIC RAS; C-MYC; ACTIVATION; P53; MOUSE; SUPPRESSOR	Activation of the NF-kappa B pathway can either promote or block apoptosis and oncogenesis in different cell types and circumstances. In this report, we show that independently derived immortalized mouse embryonic fibroblast cell lines prepared from RelA knockout mice have different phenotypes, based on their sensitivity to tumor necrosis factor alpha (TNF alpha)-induced apoptosis, morphology, ability to form colonies in soft agar, and the presence of distinct kappa B site-binding complexes. In addition, these RelA-deficient cell lines appear to have distinct alterations in the p53 pathway, which correlate with the normal vs transformed status of individual cell lines. We have also infected mouse embryonic fibroblasts lacking RelA, c-Rel or p50 with a retrovirus for the expression of v-Ha-Ras to determine whether individual NF-kappa B family members are required for Ras-mediated transformation. All three NF-kappa B-deficient cell types could be transformed by v-Ha-Ras. However, v-Ras-infected RelA-deficient cells formed colonies in soft agar at an approximately fourfold reduced efficiency compared to v-Ras-transformed control mouse 3T3 and p50-deficient cells. Ras transformation did not alter the sensitivity of RelA-deficient cells to TNF alpha-induced apoptosis, and Ras transformation did not affect the general resistance of 3T3, c-Rel-deficient, and p50-deficient cells to TNF alpha-induced apoptosis. However, TNF alpha specifically and dose-dependently decreased the ability of v-Ras-transformed RelA-deficient cells to form colonies in soft agar. These results suggest that RelA is a potential protein target for human tumors driven by oncogenic Ras mutations, but caution that inhibition of RelA may promote tumorigenesis in some circumstances.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Boston University; University of California System; University of California San Diego	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Baldwin AS, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P393; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Hanson JL, 2004, CANCER RES, V64, P7248, DOI 10.1158/0008-5472.CAN-03-3898; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Loop T, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Sigal A, 2000, CANCER RES, V60, P6788; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 1999, CANCER RES, V59, P3299; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	51	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6574	6583		10.1038/sj.onc.1208809	http://dx.doi.org/10.1038/sj.onc.1208809			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16027734				2022-12-28	WOS:000232204100011
J	Hahn, MA; Marsh, DJ				Hahn, MA; Marsh, DJ			Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin	ONCOGENE			English	Article						HRPT2; parafibromin; nuclear localization signal; hyperparathyroidism	EXPORT SIGNAL; PROTEIN; HRPT2; HYPERPARATHYROIDISM; MUTATIONS; EXPRESSION; SEQUENCE; COMPLEX; GENE	Parafibromin is a putative tumor suppressor encoded by HRPT2, mutations in which have been implicated in the familial tumor syndrome hyperparathyroidism jaw tumor syndrome (HPT-JT), and sporadic parathyroid carcinoma. Recently, parafibromin has been shown to be an accessory factor for RNA polymerase II as part of the human Paf1 complex, suggesting, as has been shown for its yeast homologue (Cdc73), that it may have a role as an important regulator of transcription. Parafibromin has also been shown to interact with a histone methyltransferase complex that methylates histone H3 and to inhibit proliferation when overexpressed in mammalian cell lines. Despite these findings, the cellular localization of parafibromin has been controversial, with reports of both nuclear and nucleocytoplasmic localization. We have expressed wild-type and mutant parafibromin tagged with enhanced green fluorescent protein and have identified a functional bipartite nuclear localization signal (NLS) at residues 125-139 (nucleotides 373-417), KRAADEV-LAEAKKPR, that is evolutionarily conserved and critical for the nuclear localization of parafibromin. We have also shown that the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. In support of these findings, specific HRPT2 mutations identified in HPT-JT or sporadic parathyroid carcinoma predicted to truncate parafibromin upstream of or within this NLS disrupt nuclear localization.	Univ Sydney, Royal N Shore Hosp, Dept Mol Med, Kolling Inst Med Res, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Marsh, DJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Dept Mol Med, Kolling Inst Med Res, Sydney, NSW 2065, Australia.	debbie_marsh@med.usyd.edu.au	Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931				Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Chen JD, 2003, J INTERN MED, V253, P634, DOI 10.1046/j.1365-2796.2003.01168.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Porter SE, 2005, EUKARYOT CELL, V4, P209, DOI 10.1128/EC.4.1.209-220.2005; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; van Koningsbruggen S, 2004, J MED GENET, V41, DOI 10.1136/jmg 2003.012781; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Zhang L, 2003, CANCER GENE THER, V10, P611, DOI 10.1038/sj.cgt.7700608	23	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6241	6248		10.1038/sj.onc.1208778	http://dx.doi.org/10.1038/sj.onc.1208778			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16116486				2022-12-28	WOS:000231877100005
J	Bhatt, AS; Erdjument-Bromage, H; Tempst, P; Craik, CS; Moasser, MM				Bhatt, AS; Erdjument-Bromage, H; Tempst, P; Craik, CS; Moasser, MM			Adhesion signaling by a novel mitotic substrate of src kinases	ONCOGENE			English	Article						src; Trask; MT-SP1; matriptase; yes; CDCP1	PROTEIN-TYROSINE KINASES; HUMAN-COLON-CARCINOMA; HUMAN COLORECTAL-CANCER; C-SRC; SERINE-PROTEASE; TRANSGENIC MICE; MAMMARY-TUMORS; CELLS; ACTIVATION; MITOSIS	Src kinases are activated and relocalize to the cytoplasm during mitosis, but their mitotic function has remained elusive. We describe here a novel mitotic substrate of src kinases. Trask (transmembrane and associated with src kinases) is a 140 kDa type I transmembrane glycoprotein unrelated to currently known protein families. Src kinases phosphorylate Trask in vitro and mediate its mitotic hyperphosphorylation in vivo. Trask associates with both yes and src, is localized to the cell membrane during interphase, and undergoes cytoplasmic relocalization during mitosis. Overexpression of Trask leads to cell rounding and a loss of adhesion phenotype. Consistent with a function in cell adhesion, Trask interacts with a number of adhesion and matrix proteins including cadherins, syndecans, and the membrane-type serine protease 1 (MT-SP1), and is proteolytically cleaved by MT-SP1. Trask is unique among cell adhesion molecules in that it is under cell cycle regulation and thus links src kinases with the mitotic regulation of cell adhesion. This suggests a potential pathway by which hyperactive src kinases in tumors can deregulate adhesion signaling and mediate the metastatic phenotype.	Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, UCSF Box 0875,2340 Sutter St,Rm 144, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu		Tempst, Paul/0000-0002-6680-3987; Bhatt, Ami/0000-0001-8099-2975; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [R01 CA113952-02, CA 72006, P01 CA072006, R01 CA113952, R01 CA113952-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA113952, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Bhatt AS, 2003, BIOL CHEM, V384, P257, DOI 10.1515/BC.2003.029; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Mizenina OA, 2004, CELL CYCLE, V3, P796; Moasser MM, 1999, CANCER RES, V59, P6145; MUSTELIN T, 2002, SCI STKE, V115, pPE3; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849	44	106	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5333	5343		10.1038/sj.onc.1208582	http://dx.doi.org/10.1038/sj.onc.1208582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007225	Green Accepted			2022-12-28	WOS:000231158500007
J	Machida, T; Fujita, T; Ooo, ML; Ohira, M; Isogai, E; Mihara, M; Hirato, J; Tomotsune, D; Hirata, T; Fujimori, M; Adachi, W; Nakagawara, A				Machida, T; Fujita, T; Ooo, ML; Ohira, M; Isogai, E; Mihara, M; Hirato, J; Tomotsune, D; Hirata, T; Fujimori, M; Adachi, W; Nakagawara, A			Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas	ONCOGENE			English	Article						BMCC1; neuroblastoma; apoptosis; BNIP2; Cdc42GAP; BCH domain	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; RHO-FAMILY GTPASES; SIGNALING PATHWAY; INDUCED APOPTOSIS; SYMPATHETIC NEURONS; BCL-2 PROTEINS; GENOMIC DNA; JUN KINASE	Differential screening of the genes obtained from cDNA libraries of primary neuroblastomas ( NBLs) between the favorable and unfavorable subsets has identified a novel gene BCH motif-containing molecule at the carboxyl terminal region 1 (BMCC1). Its 350 kDa protein product possessed a Bcl2-/adenovirus E1B nineteen kDa-interacting protein 2 (BNIP2) and Cdc42GAP homology domain in the COOH-terminus in addition to P-loop and a coiled-coil region near the NH2-terminus. High levels of BMCC1 expression were detected in the human nervous system as well as spinal cord, brain and dorsal root ganglion in mouse embryo. The immunohistochemical study revealed that BMCC1 was positively stained in the cytoplasm of favorable NBL cells but not in unfavorable ones with MYCN amplification. The quantitative real-time reverse transcription-PCR using 98 primary NBLs showed that high expression of BMCC1 was a significant indicator of favorable NBL. In primary culture of newborn mice superior cervical ganglion ( SCG) neurons, mBMCC1 expression was downregulated after nerve growth factor (NGF)-induced differentiation, and upregulated during the NGF-depletion-induced apoptosis. Furthermore, the proapoptotic function of BMCC1 was also suggested by increased expression in CHP134 NBL cells undergoing apoptosis after treatment with retinoic acid, and by an enhanced apoptosis after depletion of NGF in the SCG neurons obtained from newborn mice transgenic with BMCC1 in primary culture. Thus, BMCC1 is a new member of prognostic factors for NBL and may play an important role in regulating differentiation, survival and aggressiveness of the tumor cells.	Childrens Canc Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390, Japan; Gunma Univ, Sch Med, Dept Pathol, Maebashi, Gumma 371, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo, Japan	Shinshu University; Gunma University; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Childrens Canc Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Fujimori, Maiko/N-2883-2019					BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; Cahill MA, 1996, ONCOGENE, V13, P2087; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; FAVROT MC, 1993, NEW ENGL J MED, V329, P1965, DOI 10.1056/NEJM199312233292615; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Garnier M, 1997, J NEUROSCI, V17, P4591; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; LEE VM, 1980, NEUROSCIENCE, V5, P2239, DOI 10.1016/0306-4522(80)90140-2; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; Nagai M, 2000, INT J ONCOL, V16, P907; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura Y, 1998, BIOCHEM BIOPH RES CO, V243, P722, DOI 10.1006/bbrc.1998.8112; Ohira M, 2003, CANCER LETT, V197, P63, DOI 10.1016/S0304-3835(03)00085-5; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OLTVAI ZN, 1993, CELL, V74, P619; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Solovyev VV, 1999, NUCLEIC ACIDS RES, V27, P248, DOI 10.1093/nar/27.1.248; Subramanian T, 1995, ONCOGENE, V11, P2403; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; Vegeto E, 1999, FASEB J, V13, P793, DOI 10.1096/fasebj.13.8.793; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	48	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1931	1942		10.1038/sj.onc.1209225	http://dx.doi.org/10.1038/sj.onc.1209225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288218				2022-12-28	WOS:000236224800010
J	Heckman, CA; Duan, H; Garcia, PB; Boxer, LM				Heckman, CA; Duan, H; Garcia, PB; Boxer, LM			Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; Oct; Bob-1	NF-KAPPA-B; IMMUNOGLOBULIN GENE-TRANSCRIPTION; T-CELLS; SOMATIC MUTATION; CREB PROTEINS; BINDING-SITE; MYB; ACTIVATION; INDUCTION; APOPTOSIS	Oct-1 and Oct-2 are members of the POU homeodomain family of transcriptional regulators and are critical for normal embryonic development. Gene-targeting studies showed that Oct-1 and Oct-2 are largely dispensable for B-cell development and immunoglobulin production, although both Oct-2 and Bob-1 are required for a proper immune response and germinal center formation. In these studies, we investigated the role of Oct factors in B-cell lymphomas. Recent investigations have shown increased expression of Oct-2 and Bob-1 in lymphomas, and we observed greatly increased levels of Oct-2 in lymphoma cells with the t(14; 18) translocation. Decreased expression of Oct-1, Oct-2, or Bob-1 by RNA interference resulted in apoptosis and down-regulation of bcl-2 expression. Furthermore, Oct-2 induced bcl-2 promoter activity and mediated this effect through three regions in the bcl-2 P2 promoter. Although these regions did not contain canonical octamer motifs, we observed the direct interaction of Oct-2 with all three sites both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. Moreover, by mutation analysis we found that the ability of Oct-2 to activate bcl-2 required C/EBP, Cdx, and TATA-binding sites. Oct-2, therefore, acts as a cell survival factor in t(14; 18) lymphoma cells by directly activating the antiapoptotic gene bcl-2.	VAHCS, Ctr Mol Biol Med, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA USA	Stanford University	Boxer, LM (corresponding author), Stanford Univ, Dept Hematol, Sch Med, 269 Campus Dr,CCSR 1155, Stanford, CA 94305 USA.	lboxer@stanford.edu		Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA 56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; Bendall HH, 1997, J BIOL CHEM, V272, P28826, DOI 10.1074/jbc.272.46.28826; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; Dunn TL, 1996, BLOOD, V88, P4072, DOI 10.1182/blood.V88.10.4072a.bloodjournal88104072a; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Grassilli E, 1999, CANCER RES, V59, P2451; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Grenfell SJ, 1996, BIOCHEM J, V315, P889, DOI 10.1042/bj3150889; Hatada EN, 2000, EUR J IMMUNOL, V30, P174, DOI 10.1002/1521-4141(200001)30:1<174::AID-IMMU174>3.0.CO;2-T; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Jin TR, 2001, J BIOL CHEM, V276, P14752, DOI 10.1074/jbc.M008277200; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; Lossos IS, 2000, BLOOD, V96, P635; Marafioti T, 2003, AM J PATHOL, V162, P861, DOI 10.1016/S0002-9440(10)63882-5; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; Nagy M, 2002, BRIT J HAEMATOL, V116, P429, DOI 10.1046/j.1365-2141.2002.03271.x; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Pileri SA, 2003, LEUKEMIA LYMPHOMA, V44, pS21, DOI 10.1080/10428190310001623810; Pileri SA, 2003, AM J PATHOL, V162, P243, DOI 10.1016/S0002-9440(10)63815-1; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; Robetorye RS, 2002, J MOL DIAGN, V4, P123, DOI 10.1016/S1525-1578(10)60693-9; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Sauter P, 1997, IMMUNOBIOLOGY, V198, P207, DOI 10.1016/S0171-2985(97)80041-1; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Sepulveda MA, 2004, J IMMUNOL, V172, P1054, DOI 10.4049/jimmunol.172.2.1054; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	53	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					888	898		10.1038/sj.onc.1209127	http://dx.doi.org/10.1038/sj.onc.1209127			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16186795				2022-12-28	WOS:000235212700008
J	Li, H; Zhang, Y; Su, T; Santella, RM; Weinstein, IB				Li, H; Zhang, Y; Su, T; Santella, RM; Weinstein, IB			Hint1 is a haplo-insufficient tumor suppressor in mice	ONCOGENE			English	Article						Hint1; PKCI-1; Fhit; tumorigenesis; tumor-suppressor gene	NUCLEOTIDE-BINDING PROTEIN; HISTIDINE TRIAD PROTEINS; C-INTERACTING PROTEIN-1; FHIT-DEFICIENT MICE; TRANSGENIC MICE; MAMMARY-TUMORS; MAST-CELLS; CANCER; FAMILY; GENE	The HINT1 protein, a member of the histidine triad ( HIT) family, is highly conserved in diverse species and ubiquitously expressed in mammalian tissues. However, its precise function in mammalian cells is not known. As a result of its structural similarity to the tumor-suppressor protein FHIT, we used homozygous-deleted Hint1 mice to study its role in tumorigenesis. We discovered that after 2 to 3 years of age the spontaneous tumor incidence in Hint1 -/- mice was significantly greater than that in wildtype Hint1 +/+ mice (P < 0.05). Using a well-established mouse model of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis we found a marked and significant (P < 0.05) increase in the incidence of mammary and ovarian tumors in both, Hint1 -/- and +/- mice versus +/+ mice. The Hint1 -/- and +/- mice had similar tumor incidence and similar tumor histologies. Therefore, deletion of Hint1 in mice enhances both spontaneous tumor development and susceptibility to tumor induction by DMBA. In addition, since the Hint1 +/- tumors retained expression of the unmutated wild type allele, Hint1 is haplo-insufficient with respect to tumor suppression in this model system.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, 701 W 168th St,HHSC 1509, New York, NY 10032 USA.	ibw1@columbia.edu			NATIONAL CANCER INSTITUTE [R37CA026056, R01CA026056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005116, P30ES009089] Funding Source: NIH RePORTER; NCI NIH HHS [CA26056-24] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089, P30ES09089, ES05116, R01 ES005116] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; ARCHULETA MM, 1992, TOXICOL APPL PHARM, V113, P133, DOI 10.1016/0041-008X(92)90017-M; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Buters J, 2003, CARCINOGENESIS, V24, P327, DOI 10.1093/carcin/24.2.327; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; Guranowski A, 2004, FRONT BIOSCI-LANDMRK, V9, P1398, DOI 10.2741/1338; GURANOWSKI A, 1989, BIOCHEM J, V262, P241, DOI 10.1042/bj2620241; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ingvarsson S, 2001, SEMIN CANCER BIOL, V11, P361, DOI 10.1006/scbi.2001.0391; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Jackson RJ, 2003, CANCER RES, V63, P3021; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; MALKINSON AM, 1986, CANCER RES, V46, P1694; MEDINA D, 1980, CANCER RES, V40, P368; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Qing WG, 1997, CARCINOGENESIS, V18, P553, DOI 10.1093/carcin/18.3.553; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Vartanian A, 1999, FEBS LETT, V456, P175, DOI 10.1016/S0014-5793(99)00956-4; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WITTY JP, 1995, CANCER RES, V55, P1401; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	44	91	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					713	721		10.1038/sj.onc.1209111	http://dx.doi.org/10.1038/sj.onc.1209111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186798				2022-12-28	WOS:000235068800007
J	Hummerich, L; Muller, R; Hess, J; Kokocinski, F; Hahn, M; Furstenberger, G; Mauch, C; Lichter, P; Angel, P				Hummerich, L; Muller, R; Hess, J; Kokocinski, F; Hahn, M; Furstenberger, G; Mauch, C; Lichter, P; Angel, P			Cation of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development	ONCOGENE			English	Article						multistage carcinogenesis; papilloma; squamous cell carcinoma; gene expression profiling; self-organizing maps	MALIGNANCY-ASSOCIATED REGIONS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; DNA MICROARRAYS; CARCINOMA ESCC; HUMAN PROSTATE; CDNA; IDENTIFICATION; PROGRESSION; PROFILE	Chemically induced mouse skin carcinogenesis represents the most extensively utilized animal model to unravel the multistage nature of tumour development and to design novel therapeutic concepts of human epithelial neoplasia. We combined this tumour model with comprehensive gene expression analysis and could identify a large set of novel tumour-associated genes that have not been associated with epith elial skin cancer development yet. Expression data of selected genes were con. firmed by semiquantitative and quantitative RT-PCR as well as in situ hybridization and immuno. fluorescence analysis on mouse tumour sections. Enhanced expression of genes identified in our screen was also demonstrated in mouse keratinocyte cell lines that form tumours in vivo. Self-organizing map clustering was performed to identify different kinetics of gene expression and coregulation during skin cancer progression. Detailed analysis of differential expressed genes according to their functional annotation confirmed the involvement of several biological processes, such as regulation of cell cycle, apoptosis, extracellular proteolysis and cell adhesion, during skin malignancy. Finally, we detected high transcript levels of ANXA1, LCN2 and S100A8 as well as reduced levels for NDR2 protein in human skin tumour specimens demonstrating that tumour associated genes identified in the chemically induced tumour model might be of great relevance for the understanding of human epithelial malignancies as well.	Deutsch Krebsforschungszentrum, Div Mol Genet, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-6900 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Biochem Tissue Specif Regulat, D-6900 Heidelberg, Germany; Univ Cologne, Dept Dermatol & Venerol, D-5000 Cologne 41, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.macleod@dkfz.de	Piris, Miguel A/AAP-1445-2020; Hess, Jochen/ABE-1144-2021	Piris, Miguel A/0000-0001-5839-3634; Hess, Jochen/0000-0003-3493-1711; Kokocinski, Felix/0000-0002-8472-9207				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chen Y, 2003, CANCER RES, V63, P1927; Clarke PA, 2001, BIOCHEM PHARMACOL, V62, P1311, DOI 10.1016/S0006-2952(01)00785-7; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diehl F, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e38; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dooley TP, 2003, BIOCHEM BIOPH RES CO, V306, P1026, DOI 10.1016/S0006-291X(03)01099-4; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FURSTENBERGER G, 1995, CARCINOGENESIS, V16, P61, DOI 10.1093/carcin/16.1.61; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Glinsky GV, 2003, CANCER LETT, V201, P67, DOI 10.1016/S0304-3835(03)00419-1; Glinsky GV, 2003, NEOPLASIA, V5, P218, DOI 10.1016/S1476-5586(03)80054-4; Gogali A, 2004, EXP ONCOL, V26, P106; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hu YC, 2001, CLIN CANCER RES, V7, P3519; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Ishikawa N, 2004, CLIN CANCER RES, V10, P8363, DOI 10.1158/1078-0432.CCR-04-1436; Ito N, 1995, CRIT REV ONCOL HEMAT, V21, P105, DOI 10.1016/1040-8428(94)00169-3; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Ko MSH, 2000, DEVELOPMENT, V127, P1737; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; Li J, 2002, PHYSIOL GENOMICS, V9, P137, DOI 10.1152/physiolgenomics.00003.2002; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Luo AP, 2004, ONCOGENE, V23, P1291, DOI 10.1038/sj.onc.1207218; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nair KS, 2005, J CLIN PATHOL, V58, P343, DOI 10.1136/jcp.2004.018036; Patil MA, 2005, ONCOGENE, V24, P3737, DOI 10.1038/sj.onc.1208479; Petroziello J, 2004, ONCOGENE, V23, P7734, DOI 10.1038/sj.onc.1207921; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.0.CO;2-3; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Stern MC, 1997, MOL CARCINOGEN, V20, P137, DOI 10.1002/(SICI)1098-2744(199709)20:1<137::AID-MC15>3.0.CO;2-2; STRICKLAND JE, 1988, CANCER RES, V48, P165; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tsai WC, 2004, ORAL ONCOL, V40, P418, DOI 10.1016/j.oraloncology.2003.09.015; Wrobel G, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng067; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	52	62	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					111	121		10.1038/sj.onc.1209016	http://dx.doi.org/10.1038/sj.onc.1209016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247483				2022-12-28	WOS:000234406400012
J	Smakman, N; Veenendaal, LM; van Diest, P; Bos, R; Offringa, R; Rinkes, IHMB; Kranenburg, O				Smakman, N; Veenendaal, LM; van Diest, P; Bos, R; Offringa, R; Rinkes, IHMB; Kranenburg, O			Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy	ONCOGENE			English	Article						Ras; interleukin-18; colorectal; immune-evasion; malignancy	KIRSTEN RAS MUTATIONS; COLORECTAL-CANCER; RNA INTERFERENCE; KI-RAS; COLON; GENE; INTERLEUKIN-18; CELLS; EXPRESSION; INDUCTION	Activating mutations in the human KRAS proto-oncogene are acquired during the earliest stages of colorectal cancer development. If mutant KRAS is to be used as a target for therapy in colorectal cancer, tumor growth should depend on its continued presence. Here, we report that stable knockdown of Kras(D12) in murine C26 colorectal cancer cells by RN A interference resulted in loss of transformed properties in vitro. The incidence of subcutaneous tumor formation was reduced by 60% and the lag time was increased sevenfold. Kras(D12)-knockdown tumors grew noninvasively and did not cause morbidity. Remarkably, some of the Kras(D12)-knockdown tumors regressed spontaneously, which rendered these mice resistant to parental C26 tumor growth. In immune-deficient hosts, the incidence of tumor formation by Kras(D12)-knockdown cells was 100%. None of these tumors regressed spontaneously. We conclude that the reduced incidence of tumor formation by Kras(D12)-knockdown cells is due to tumor cell clearance by the host immune system, but not to an intrinsic inability of these cells to grow out as tumors. Interestingly, Kras(D12) knockdown resulted in increased production of interleukin 18 (Il-18), an immune-stimulatory cytokine that has been implicated in limiting colorectal tumor formation. Thus, mutant Kras(D12) suppresses Il-18 production in colorectal tumor cells, which may contribute to evasion of the local immune system during tumor development.	Univ Utrecht, Med Ctr, Dept Surg, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Tumor Immunol Grp, NL-2333 ZA Leiden, Netherlands	Utrecht University; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kranenburg, O (corresponding author), Univ Utrecht, Med Ctr, Dept Surg, POB 85500, NL-3508 GA Utrecht, Netherlands.	o.kranenburg@azu.nl	Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Campbell I, 2000, CANCER GENE THER, V7, P37, DOI 10.1038/sj.cgt.7700116; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; CORBETT TH, 1975, CANCER RES, V35, P2434; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GRISWOLD DP, 1975, CANCER, V36, P2441, DOI 10.1002/1097-0142(197512)36:6<2441::AID-CNCR2820360627>3.0.CO;2-P; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Leng JH, 2003, CHINESE MED J-PEKING, V116, P1475; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; Pages F, 2000, IMMUNOL LETT, V75, P9, DOI 10.1016/S0165-2478(00)00285-6; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Velde EAT, 2002, BRIT J SURG, V89, P1302, DOI 10.1046/j.1365-2168.2002.02183.x; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	20	30	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8338	8342		10.1038/sj.onc.1208995	http://dx.doi.org/10.1038/sj.onc.1208995			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091732				2022-12-28	WOS:000233956500012
J	Stoter, M; Bamberger, AM; Aslan, B; Kurth, M; Speidel, D; Loning, T; Frank, HG; Kaufmann, P; Lohler, J; Henne-Bruns, D; Deppert, W; Knippschild, U				Stoter, M; Bamberger, AM; Aslan, B; Kurth, M; Speidel, D; Loning, T; Frank, HG; Kaufmann, P; Lohler, J; Henne-Bruns, D; Deppert, W; Knippschild, U			Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells	ONCOGENE			English	Article						casein kinase I delta; trophoblast; choriocarcinoma; apoptosis; IC261	WILD-TYPE P53; POLYMORPHIC VARIANTS; PROTEIN-KINASES; MOLECULAR-CLONING; CENTROSOME; PHOSPHORYLATION; EXPRESSION; EPSILON; LOCALIZATION; INSTABILITY	The serine/threonine-specific casein kinase I delta (CKI delta) is ubiquitously expressed in all tissues, is p53 dependently induced in stress situations and plays an important role in various cellular processes. Our immunohistochemical analysis of the human placenta revealed strongest expression of CKId in extravillous trophoblast cells and in choriocarcinomas. Investigation of the functional role of CKId in an extravillous trophoblast hybrid cell line revealed that CKId was constitutively localized at the centrosomes and the mitotic spindle. Inhibition of CKId with the CKI-specific inhibitor IC261 led to structural alterations of the centrosomes, the formation of multipolar spindles, the inhibition of mitosis and, in contrast to other cell lines, the induction of apoptosis. Our findings indicate that CKId plays an important role in the mitotic progression and in the survival of cells of trophoblast origin. Therefore, IC261 could provide a new tool in treating choriocarcinomas.	Univ Ulm, Dept Visceral & Transplantat Surg, Ulm, Germany; Univ Hosp Eppendorf, Inst Pathol, Dept Gynecopathol, Hamburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Hamburg, Germany; Rhein Westfal TH Aachen, Dept Anat 2, Aachen, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; RWTH Aachen University	Knippschild, U (corresponding author), Univ Ulm Klinikum, Steinhovelstr 9, D-89075 Ulm, Germany.	uwe.knippschild@medizin.uni-ulm.de	Frank, Hans-Georg/G-6038-2012; Speidel, Daniel/I-4244-2012	Frank, Hans-Georg/0000-0002-3562-138X; 				Bamberger AM, 1997, ENDOCRINE, V6, P111, DOI 10.1007/BF02738953; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Bischof P, 2000, HUM REPROD, V15, P51; Bornens M, 1999, METHOD CELL BIOL, V61, P13; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Chakraborty C, 2002, CAN J PHYSIOL PHARM, V80, P116, DOI 10.1139/Y02-016; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Frank HG, 2000, CANCER GENET CYTOGEN, V116, P16, DOI 10.1016/S0165-4608(99)00107-7; Funayama H., 1997, PLACENTA, V18, P191; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Marchal C, 2002, J CELL SCI, V115, P217; Maritzen T, 2003, EUR J CELL BIOL, V82, P369, DOI 10.1078/0171-9335-00323; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Milne DM, 2001, EXP CELL RES, V263, P43, DOI 10.1006/excr.2000.5100; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okamura A, 2004, BLOOD, V103, P2997, DOI 10.1182/blood-2003-08-2768; Panek HR, 2000, J CELL SCI, V113, P4545; Pihan GA, 1998, CANCER RES, V58, P3974; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Thomas M, 1999, MOL CELL BIOL, V19, P1092; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; YAGEL S, 1988, J CELL PHYSIOL, V136, P455, DOI 10.1002/jcp.1041360309; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang JR, 1996, BIOCHEMISTRY-US, V35, P16319, DOI 10.1021/bi9614444; Zhao Y, 2004, J BIOL CHEM, V279, P30844, DOI 10.1074/jbc.M404651200; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	50	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7964	7975		10.1038/sj.onc.1208941	http://dx.doi.org/10.1038/sj.onc.1208941			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027726				2022-12-28	WOS:000233656600003
J	Ogishima, T; Shiina, H; Breault, JE; Terashima, M; Honda, S; Enokida, H; Urakami, S; Tokizane, T; Kawakami, T; Ribeiro, LA; Fujime, M; Kane, CJ; Carroll, PR; Igawa, M; Dahiya, R				Ogishima, T; Shiina, H; Breault, JE; Terashima, M; Honda, S; Enokida, H; Urakami, S; Tokizane, T; Kawakami, T; Ribeiro, LA; Fujime, M; Kane, CJ; Carroll, PR; Igawa, M; Dahiya, R			Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer	ONCOGENE			English	Article						heparanase; methylation; epigenetics; bladder cancer	HUMAN BREAST-CANCER; MAMMALIAN HEPARANASE; PANCREATIC-CANCER; DNA METHYLATION; PROSTATE-CANCER; TUMOR INVASION; GENE; CELLS; HYPERMETHYLATION; METASTASIS	Heparanase plays a critical role in the degradation of extracellular matrix and cell membrane and is frequently upregulated in malignant tumors. Transcription factor, early growth response 1 (EGR1), is closely associated with inducible transcription of the heparanase gene. We hypothesized that promoter CpG hypomethylation with increased EGR1 expression could determine heparanase expression during the pathogenesis of bladder cancer. Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored heparanase expression after 5-Aza-dC treatment. Transfection of EGR1 siRNA with T24 bladder cancer cell line significantly downregulated heparanase expression compared to the control siRNA transfection. In 54 bladder cancer and paired normal bladder samples, heparanase expression was significantly higher in bladder cancer than in normal bladder (P < 0.01). We performed methylation-specific PCR targeting the CpG sites within the core-binding consensus motifs of EGR1 (GGCG) and Sp1 (GGGCGG). Methylation prevalence was significantly higher in normal bladder than in bladder cancer (P < 0.05) and inversely correlated with heparanase expression (P = 0.055). In the total series of bladder cancer and normal bladder samples, the combination of promoter CpG methylation and EGR1 expression regulated heparanase expression in a stepwise manner, where heparanase expression was the lowest in methylation-positive and EGR1-negative samples and the highest in methylation-negative and EGR1-positive samples. To our knowledge, this is the first study demonstrating that increased heparanase expression during the pathogenesis of bladder cancer is due to promoter hypomethylation and transcription factor EGR1.	Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA; Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6930085, Japan; Univ Sao Paulo, Sch Med, Dept Urol, Sao Paulo, Brazil; Juntendo Univ, Sch Med, Dept Urol, Tokyo 1130082, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Shimane University; Universidade de Sao Paulo; Juntendo University	Dahiya, R (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	rdahiya@urol.ucsf.edu			FIC NIH HHS [R01TW006215] Funding Source: Medline; NCI NIH HHS [R01CA1018447] Funding Source: Medline; NIA NIH HHS [R01AG21418] Funding Source: Medline; NIDDK NIH HHS [T32DK07790] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021418] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson E, 2003, CANCER BIOL THER, V2, P617; Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Dahiya R, 1997, INT J CANCER, V72, P762, DOI 10.1002/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Koliopanos A, 2001, CANCER RES, V61, P4655; Kosir MA, 1997, J SURG RES, V67, P98, DOI 10.1006/jsre.1996.4976; Marchetti D, 1996, CANCER RES, V56, P2856; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Simon R, 1998, J PATHOL, V185, P345; Sobin, 2009, UICC TNM CLASSIFICAT; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662	27	74	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6765	6772		10.1038/sj.onc.1208811	http://dx.doi.org/10.1038/sj.onc.1208811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007175				2022-12-28	WOS:000232527800004
J	Xu, Q; Briggs, J; Park, S; Niu, GL; Kortylewski, M; Zhang, SM; Gritsko, T; Turkson, J; Kay, H; Semenza, GL; Cheng, JQ; Jove, R; Yu, H				Xu, Q; Briggs, J; Park, S; Niu, GL; Kortylewski, M; Zhang, SM; Gritsko, T; Turkson, J; Kay, H; Semenza, GL; Cheng, JQ; Jove, R; Yu, H			Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways	ONCOGENE			English	Article						stat3; HIF-1; VEGF; Akt; angiogenesis	DNA-BINDING ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; TUMOR ANGIOGENESIS; V-SRC; CANCER; INTERLEUKIN-6; TRANSCRIPTION; CELLS; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) upregulation is induced by many receptor and intracellular oncogenic proteins commonly activated in cancer, rendering molecular targeting of VEGF expression a complex challenge. While VEGF inducers abound, only two major transcription activators have been identified for its promoter: hypoxia inducible factor-1 (HIF-1) and signal transducer and activator of transcription (Stat3). Both HIF-1 expression and Stat3 activity are upregulated in diverse cancers. Here, we provide evidence that Stat3 is required for both basal and growth signal-induced expression of HIF-1. Moreover, induction of VEGF by diverse oncogenic growth stimuli, including IL-6R, c-Src, Her2/Neu, is attenuated in cells without Stat3 signaling. We further demonstrate that Stat3 regulates expression of Akt, which is required for growth signal-induced HIF-1 upregulation. Targeting Stat3 with a small-molecule inhibitor blocks HIF-1 and VEGF expression in vitro and inhibits tumor growth and angiogenesis in vivo. Furthermore, tumor cells' in vivo angiogenic capacity induced by IL-6R, which simultaneously activates Jak/TAT and PI3K/Akt pathways, is abrogated when Stat3 is inhibited. Activation of Stat3 signaling by various growth signaling is prevalent in diverse cancers. Results presented here demonstrate that Stat3 is an effective target for inhibiting tumor VEGF expression and angiogenesis.	Univ S Florida, H Lee Moffitt Canc Ctr, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Coll Publ Hlth, Tampa, FL 33612 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins University	Yu, H (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Program Immunol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	chengjq@moffitt.usf.edu; huayu@moffitt.usf.edu	Kortylewski, Marcin/H-8052-2019	Kortylewski, Marcin/0000-0002-6003-1816; XU, QING/0000-0002-4785-2994; YU, Hua/0000-0003-0931-1000	NCI NIH HHS [CA75243, CA82533, CA78038, CA89693] Funding Source: Medline; NIMH NIH HHS [R43 MH096663, R43 MH090939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089693, P01CA078038, R29CA075243, P01CA082533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R43MH096663, R43MH090939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Huss WJ, 2003, MOL CANCER THER, V2, P611; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1997, CANCER RES, V57, P5328; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu AX, 1998, CANCER RES, V58, P2973; Mora LB, 2002, CANCER RES, V62, P6659; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood-2004-07-2909; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Repovic P, 2003, ONCOGENE, V22, P8117, DOI 10.1038/sj.onc.1206922; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wen Y, 2000, CANCER RES, V60, P6841; Xie KP, 2004, CYTOKINE GROWTH F R, V15, P297, DOI 10.1016/j.cytogfr.2004.04.003; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	445	492	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5552	5560		10.1038/sj.onc.1208719	http://dx.doi.org/10.1038/sj.onc.1208719			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007214				2022-12-28	WOS:000231296100003
J	Li, Y; Clevenger, CV; Minkovsky, N; Kumar, KGS; Raghunath, PN; Tomaszewski, JE; Spiegelman, VS; Fuchs, SY				Li, Y; Clevenger, CV; Minkovsky, N; Kumar, KGS; Raghunath, PN; Tomaszewski, JE; Spiegelman, VS; Fuchs, SY			Stabilization of prolactin receptor in breast cancer cells	ONCOGENE			English	Article						prolactin; receptor; beta-TrCP; ubiquitin; E3 ligase; breast cancer	E3 UBIQUITIN LIGASE; MAMMARY-CARCINOMA; TRANSGENIC MICE; GROWTH-HORMONE; ACTIVATION; EXPRESSION; INDUCTION; TUMORS; RISK; GENE	The role of the hormone prolactin (PRL) in the pathogenesis of breast cancer is mediated by its cognate receptor (PRLr). Ubiquitin-dependent degradation of the PRLr that negatively regulates PRL signaling is triggered by PRL-mediated phosphorylation of PRLr on Ser349 followed by the recruitment of the beta-transducin repeats-containing protein ( beta-TrCP) ubiquitin-protein isopeptide ligase. We report here for the first time that interaction between PRLr and beta-TrCP is less efficient in human breast cancer cells than in non-tumorigenic human mammary epithelial cells. Furthermore, we demonstrate that both PRLr degradation and PRLr phosphorylation on Ser349 are impaired in breast tumor cells and tissues, an observation that directly correlates with enhanced expression of the PRLr in malignant breast epithelium. These findings represent a novel mechanism through which altered PRLr stability may directly influence the pathogenesis of breast cancer.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Wisconsin, Dept Dermatol, Madison, WI USA	University of Pennsylvania; Northwestern University; University of Pennsylvania; University of Wisconsin System; University of Wisconsin Madison	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E VET, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu		Spiegelman, Vladimir S/0000-0003-4847-155X; Minkovsky, Natalie/0000-0002-2707-0506	NCI NIH HHS [CA069294, R01 CA115281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115281, R01CA069294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Canbay E, 2004, CURR MED RES OPIN, V20, P533, DOI 10.1185/030079904125003232; CARTUN RW, 1989, J HISTOTECHNOL, V12, P273; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Glasow A, 2001, J CLIN ENDOCR METAB, V86, P3826, DOI 10.1210/jc.86.8.3826; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Harvey PW, 2005, J APPL TOXICOL, V25, P179, DOI 10.1002/jat.1063; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kline JB, 2002, MOL ENDOCRINOL, V16, P2310, DOI 10.1210/me.2001-0033; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; Perks CC, 2004, BRIT J CANCER, V91, P305, DOI 10.1038/sj.bjc.6601947; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Tworoger SS, 2004, CANCER RES, V64, P6814, DOI 10.1158/0008-5472.CAN-04-1870; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	24	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1896	1902		10.1038/sj.onc.1209214	http://dx.doi.org/10.1038/sj.onc.1209214			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16278670				2022-12-28	WOS:000236224800006
J	Barnache, S; Le Scolan, E; Kosmider, O; Denis, N; Moreau-Gachelin, F				Barnache, S; Le Scolan, E; Kosmider, O; Denis, N; Moreau-Gachelin, F			Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene	ONCOGENE			English	Article						phosphatidylinositol phosphatase; erythroleukemia; erythropoietin; transcriptional regulation	INOSITOL POLYPHOSPHATE 4-PHOSPHATASE; TRANSCRIPTION FACTOR PU.1; PHOSPHOINOSITIDE 3-KINASE; PROLIFERATION; INTERLEUKIN-3; SURVIVAL; RECEPTOR; PROTEIN; KINASE; FAMILY	The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistep process. At disease onset, preleukemic cells are arrested in differentiation at the proerythroblast stage (HS1 stage) and their survival and growth are under the tight control of erythropoietin (Epo). During disease progression, malignant proerythroblasts characterized by Epo autonomous growth and in vivo tumorigenicity can be isolated (HS2 stage). During analysis of transcriptional pro. ling representive of discrete stages of leukemic progression, we found that the phosphatidylinositol 4-phosphatase type II gene was turned off in malignant cells. PI-4-phosphatase II is an enzyme that hydrolyses the 4-phosphate position of phosphatidylinositol-3-4-bisphosphate (PtdIns(3,4) P-2) to form PtdIns (3) P. Using malignant cells engineered to stably express PI-4-phosphatase II, we showed that PI-4-phosphatase II reduced Akt activation level. Moreover, stimulation of malignant cells with Epo-induced PI-4-phosphatase II transcription pointing this gene as an Epo-responsive gene. This study provides first insight for a physiological role of PI-4-phosphatase II in the proerythroblast by controlling Epo responsiveness through a negative regulation of the PI3K/Akt pathway.	INSERM, Inst Curie, U528, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), INSERM, Inst Curie, U528, 26 Rue Ulm, Paris, France.	framoreau@curie.fr		KOSMIDER, olivier/0000-0002-6021-4057				Barnache S, 2001, BLOOD, V98, P2372, DOI 10.1182/blood.V98.8.2372; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Ivetac I, 2005, MOL BIOL CELL, V16, P2218, DOI 10.1091/mbc.e04-09-0799; KOMATSU N, 1991, CANCER RES, V51, P341; Liang P, 1997, Methods Mol Biol, V85, P3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Munday AD, 1999, P NATL ACAD SCI USA, V96, P3640, DOI 10.1073/pnas.96.7.3640; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P23859, DOI 10.1074/jbc.272.38.23859; Nystuen A, 2001, NEURON, V32, P203, DOI 10.1016/S0896-6273(01)00468-8; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Tilbrook PA, 1999, INT J BIOCHEM CELL B, V31, P1001, DOI 10.1016/S1357-2725(99)00071-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	22	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1420	1423		10.1038/sj.onc.1209187	http://dx.doi.org/10.1038/sj.onc.1209187			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247441				2022-12-28	WOS:000235708200016
J	Jacquel, A; Herrant, M; Defamie, V; Belhacene, N; Colosetti, P; Marchetti, S; Legros, L; Deckert, M; Mari, B; Cassuto, JP; Hofman, P; Auberger, P				Jacquel, A; Herrant, M; Defamie, V; Belhacene, N; Colosetti, P; Marchetti, S; Legros, L; Deckert, M; Mari, B; Cassuto, JP; Hofman, P; Auberger, P			A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis	ONCOGENE			English	Article						megakaryocyte differentiation; PKC; MAPK; c-DNA array; leukemia	PROTEIN-KINASE-C; CHRONIC MYELOID-LEUKEMIA; ERYTHROID-DIFFERENTIATION; PHORBOL ESTER; EPH RECEPTORS; T-CELLS; ACTIVATION; INHIBITION; EXPRESSION; SURVIVAL	The K562 cell line serves as a model to study the molecular mechanisms associated with leukemia differentiation. We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage. Electronic microscopy analysis showed that K562 cells treated with PMA+SB exhibited characteristic features of physiological megakaryocytic differentiation including the presence of vacuoles and demarcation membranes. Differentiation was also accompanied by a net increase in megakaryocytic markers and a reduction of erythroid markers, especially when both effectors were present. PMA effect was selectively mediated by new PKC isoforms. Differentiation of K562 cells by the combination of PMA and SB required Erk1/2 activation, a threshold of JNK activation and p38 MAPK inhibit ion. Interestingly, higher concentrations of SB, which drastically activated JNK, blocked megakaryocytic differentiation, and considerably increased cell death in the presence of PMA. c-DNA microarray membranes and PCR analysis allow us to identify a set of genes modulated during PMA-induced K562 cell differentiation. Several gene families identified in our screening, including ephrins receptors and some angiogenic factors, had never been reported so far to be regulated during megakaryocytic differentiation.	Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France; CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Hop Archet, Hematol Serv, F-06202 Nice 2, France; Hop Archet, INSERM, U576, F-06202 Nice, France; Univ Nice Sophia Antipolis, INSERM, U721, IFR50,Fac Med, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Mari, Bernard/Q-5832-2019; Mari, Bernard P/D-7445-2015; Jacquel, Arnaud/AAJ-4760-2021; Deckert, Marcel/T-3566-2019; Mari, Bernard P/GVS-3100-2022; Marchetti, Sandrine/P-6479-2016; AUBERGER, Patrick/G-1491-2013; Jacquel, Arnaud/O-1928-2017; Mari, Bernard P/F-8960-2013; Colosetti, Pascal/ABH-4585-2020; Deckert, Marcel/M-4998-2016; Hofman, Paul/P-7654-2018	Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Jacquel, Arnaud/0000-0001-5062-8048; Deckert, Marcel/0000-0003-2094-559X; Mari, Bernard P/0000-0002-0422-9182; Marchetti, Sandrine/0000-0001-8326-5730; AUBERGER, Patrick/0000-0002-2481-8275; Jacquel, Arnaud/0000-0001-5062-8048; Mari, Bernard P/0000-0002-0422-9182; Hofman, Paul/0000-0003-0431-9353; Defamie, Virginie/0000-0002-6405-0539				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Belhacene N, 1998, FASEB J, V12, P531; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; CHENG T, 1994, J BIOL CHEM, V269, P30848; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Goldfarb AN, 2001, J BIOL CHEM, V276, P29526, DOI 10.1074/jbc.M103825200; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; Huang M, 2004, LEUKEMIA, V18, P1857, DOI 10.1038/sj.leu.2403490; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, LEUKEMIA RES, V28, P623, DOI 10.1016/j.leukres.2003.10.022; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Legros L, 2004, BLOOD, V104, P495, DOI 10.1182/blood-2003-08-2695; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; Matsumura I, 2000, BLOOD, V96, P2440; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MOORE DC, 1991, BLOOD, V77, P1452; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NAMCIU S, 1994, ONCOGENE, V9, P1407; NEUBAUER A, 1994, BLOOD, V84, P1931; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Pettiford SM, 2003, LEUKEMIA, V17, P366, DOI 10.1038/sj.leu.2402767; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Ruan GR, 2004, LEUKEMIA RES, V28, P763, DOI 10.1016/j.leukres.2003.11.017; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Shelly C, 1998, LEUKEMIA, V12, P1951, DOI 10.1038/sj.leu.2401221; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Wang XN, 2001, J CELL BIOCHEM, V82, P68, DOI 10.1002/jcb.1141; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	47	67	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					781	794		10.1038/sj.onc.1209119	http://dx.doi.org/10.1038/sj.onc.1209119			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186797				2022-12-28	WOS:000235068800013
J	Speidel, D; Helmbold, H; Deppert, W				Speidel, D; Helmbold, H; Deppert, W			Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress	ONCOGENE			English	Article						p53; Bax; non-transcriptional apoptosis; transcription; senescence; fibroblasts	TUMOR-SUPPRESSOR P53; DNA-BINDING; IN-VIVO; APOPTOSIS; CELLS; PROTEIN; BAX; TRANSACTIVATION; MITOCHONDRIA; ACTIVATION	Following genotoxic stress, p53 either rescues a damaged cell or promotes its elimination. The parameters determining a specific outcome of the p53 response are largely unknown. In mouse. broblasts treated with different irradiation schemes, we monitored transcriptional and non-transcriptional p53 activities and identifi. ed determinants that initiate an anti- or a pro-apoptotic p53 response within the context of p53-independent stress signaling. The primary, transcription-mediated p53 response in these cells is anti-apoptotic, while induction of p53-dependent apoptosis requires an additional, transcription-independent p53 activity, provided by high intracellular levels of activated p53. High intracellular levels of p53 were selectively generated after apoptosis-inducing high-dose UV-irradiation, and correlated with a strongly delayed upregulation of Mdm2. Following high-dose UV-irradiation, p53 accumulated in the cytoplasm and led to activation of the pro-apoptotic protein Bax. As p53-dependent Bax-activation is transcription-independent, we postulated that certain transcription-deficient mutant p53 proteins might also exert this activity. Indeed we found an endogenous, transcription-inactive mutant p53 that upon genotoxic stress induced Bax-activation in vivo. Our results demonstrate the impact and in vivo relevance of non-transcriptional mechanisms for wild- type and mutant p53-mediated apoptosis.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de	Speidel, Daniel/I-4244-2012					Chen X, 2002, CELL RES, V12, P229, DOI 10.1038/sj.cr.7290129; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERMEKING H, 2003, NAT REV CANCER, V2, P594; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1993, ONCOGENE, V8, P2001; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Roninson IB, 2003, CANCER RES, V63, P2705; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZIEGLER C, 1998, THESIS U HAMBURG HAM	33	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					940	953		10.1038/sj.onc.1209126	http://dx.doi.org/10.1038/sj.onc.1209126			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247471				2022-12-28	WOS:000235212700013
J	Park, HU; Jeong, SJ; Jeong, JH; Chung, JH; Brady, JN				Park, HU; Jeong, SJ; Jeong, JH; Chung, JH; Brady, JN			Human T-cell leukemia virus type 1 Tax attenuates gamma-irradiation-induced apoptosis through physical interaction with Chk2	ONCOGENE			English	Article						HTLV-1 Tax; Chk2; interaction; attenuation; apoptosis	NF-KAPPA-B; DNA-DAMAGE; CHECKPOINT KINASE; P53-MEDIATED TRANSACTIVATION; PHASE PROGRESSION; TUMOR-SUPPRESSOR; P53 INACTIVATION; GENE-EXPRESSION; PROTEIN; LYMPHOCYTES	Checkpoint kinase 2 (Chk2) is known to mediate diverse cellular responses to genotoxic stress. The fundamental role of Chk2 is to regulate the network of genomesurveillance pathways that coordinate cell-cycle progression withDN A repair and cell survival or death. Defects in Chk2 contribute to the development of both hereditary and sporadic human cancers. We now present evidence that the human T-cell leukemia virus type-1 (HTLV-1) Tax protein directly interacts with Chk2 and the kinase activity of Chk2 is inhibited by Tax. The physical interaction of Chk2 and Tax was observed by co-immunoprecipitation assays in HTLV-1-infected T cells (C81) as well as GST pull-down assays using purified proteins. Binding and kinase activity inhibition studies with Tax deletion mutants indicated that at least two domains of Tax mediate the interaction with Chk2. We have analysed the functional consequence of de novo expression of Tax upon the cellular DNA-damage-induced apoptosis, which is mediated by Chk2. Using transient transfection and TUNEL assay, we found that cirradiation-induced apoptosis was decreased in 293T and HCT-116 (p53 (-/-)) cells expressing HTLV-1 Tax. Our studies demonstrate an important potential target of Tax in cellular transformation.	NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bldg 41-B201,41 Medlars Dr,9000 Rockville Pike, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005691, ZIABC005691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002243, ZIAHL002243] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; COOGAN TP, 1992, TOXICOL APPL PHARM, V113, P227, DOI 10.1016/0041-008X(92)90118-C; COOGAN TP, 1994, J TOXICOL ENV HEALTH, V41, P233, DOI 10.1080/15287399409531839; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Matsuda T, 2005, J VIROL, V79, P1367, DOI 10.1128/JVI.79.3.1367-1378.2005; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; SEGAWA K, 1993, ONCOGENE, V8, P543; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Sieburg M, 2004, J VIROL, V78, P10399, DOI 10.1128/JVI.78.19.10399-10409.2004; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	59	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					438	447		10.1038/sj.onc.1209059	http://dx.doi.org/10.1038/sj.onc.1209059			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158050				2022-12-28	WOS:000234714100012
J	Piu, F; Gauthier, NK; Wang, F				Piu, F; Gauthier, NK; Wang, F			beta-arrestin 2 modulates the activity of nuclear receptor RAR beta 2 through activation of ERK2 kinase	ONCOGENE			English	Article						nuclear receptor; arrestin; MAP kinase; activation	LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; BETA-ARRESTIN; CRYSTAL-STRUCTURE; RXR-ALPHA; DOWN-REGULATION; ACID; PATHWAY	The activity of retinoid receptors activity can be regulated by various extracellular stimuli. In an effort to understand the molecular basis for this phenomenon, the role of beta-arrestins was investigated. beta-Arrestins constitute a class of proteins involved in the internalization of agonist-activated receptors. They have also been linked to MAPK activation suggesting a direct involvement in signaling cascades. Here, we report that beta-arrestin 2 stimulates the transcriptional activation of the retinoid RAR and RXR receptors. Of all the retinoid receptors, the RAR beta 2 subtype showed the strongest sensitivity to beta-arrestin 2 action. Interestingly, this event requires the presence of the MAP kinase ERK2, but not that of JNK or P38. Site-directed mutagenesis showed that Ser 22 and Leu 217 are critical residues of the RAR b2 receptor through which b-arrestin 2 effects are mediated. More importantly, we demonstrate that the induction of PC12 growth inhibition by Nerve Growth Factor is indeed dependent upon RAR b2 transcriptional activation in a beta-arrestin 2- and ERK2-dependent manner.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Piu, F (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	fpiu@acadia-pharm.com						Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; Corcoran J, 1999, NAT NEUROSCI, V2, P307, DOI 10.1038/7214; Cosgaya JM, 2001, J NEUROCHEM, V76, P661, DOI 10.1046/j.1471-4159.2001.00078.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Harish S, 2000, BIOCHEM BIOPH RES CO, V279, P853, DOI 10.1006/bbrc.2000.4043; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; Klaholz BP, 2000, J MOL BIOL, V302, P155, DOI 10.1006/jmbi.2000.4032; Koutsilieris M, 1997, ANTICANCER RES, V17, P1461; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KYRIAKIS JM, 2000, SCI STKE 2000, pE1; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MILLER LA, 1993, CANCER RES, V53, P2527; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Ostrowski J, 1998, J BIOL CHEM, V273, P3490, DOI 10.1074/jbc.273.6.3490; Piu F, 2002, ONCOGENE, V21, P3579, DOI 10.1038/sj.onc.1205444; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Schmidt P, 2001, MOL ENDOCRINOL, V15, P553, DOI 10.1210/me.15.4.553; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Vo HP, 1998, INT J ONCOL, V13, P1127; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	47	16	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					218	229		10.1038/sj.onc.1209024	http://dx.doi.org/10.1038/sj.onc.1209024			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170358				2022-12-28	WOS:000234583600006
J	Xie, Y; Xu, K; Dai, B; Guo, Z; Jiang, T; Chen, H; Qiu, Y				Xie, Y; Xu, K; Dai, B; Guo, Z; Jiang, T; Chen, H; Qiu, Y			The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs	ONCOGENE			English	Article						kinase; cancer; phosphorylation; signal transduction; apoptosis	HETEROCHROMATIN PROTEIN-1 HP1; PLECKSTRIN-HOMOLOGY DOMAIN; PIM-1 TRANSGENIC MICE; C-MYC; PHOSPHORYLATION; ACTIVATION; ANDROGEN; LEUKEMIA; LYMPHOMAGENESIS; EXPRESSION	Protein kinase Pim-1 has been implicated in the development of hematopoietic and prostatic malignancies. Here, we present the evidence that two isoforms, the 44 and 33 kDa Pim-1, are expressed in all human prostate cancer cell lines examined. The subcellular localization of human 44 kDa Pim-1 is primarily on the plasma membrane, while the 33 kDa isoform is present in both the cytosol and nucleus in PCA cells. The 44 kDa Pim-1 contains the proline-rich motif at the N-terminus and directly binds to the SH3 domain of tyrosine kinase Etk. Such interaction leads to the activation of Etk kinase activity possibly by competing with the tumor suppressor p53. This is corroborated by the fact that overexpression of the 44 kDa Pim-1 in prostate cancer cells confers the resistance to chemotherapeutic drugs. Our results suggest that these two isoforms of Pim-1 kinase may regulate distinct substrates and the 44 kDa Pim-1 may play a more prominent role in drug resistance in prostate cancer cells.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; CUYPERS HT, 1984, CELL, V37, P141; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gregory CW, 2001, CANCER RES, V61, P2892; Imasato Y, 2000, J UROLOGY, V164, P1819, DOI 10.1016/S0022-5347(05)67113-3; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Jiang TY, 2004, J BIOL CHEM, V279, P50181, DOI 10.1074/jbc.M409108200; Kim O, 2004, ONCOGENE, V23, P1838, DOI 10.1038/sj.onc.1207304; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VONLINDERN M, 1989, ONCOGENE, V4, P75; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Zhao T, 2001, J BIOL CHEM, V276, P9512, DOI 10.1074/jbc.M010098200	26	90	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					70	78		10.1038/sj.onc.1209058	http://dx.doi.org/10.1038/sj.onc.1209058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16186805				2022-12-28	WOS:000234406400008
J	Liu, YN; Lee, WW; Wang, CY; Chao, TH; Chen, Y; Chen, JH				Liu, YN; Lee, WW; Wang, CY; Chao, TH; Chen, Y; Chen, JH			Regulatory mechanisms controlling human E-cadherin gene expression	ONCOGENE			English	Article						E-cadherin; gene expression; HNF3 (Hepatocyte Nuclear Factor); metastasis	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; GASTRIC-CANCER; P-CADHERIN; PROMOTER; BINDING; REPRESSION; CELLS	In cancer cells, loss of E-cadherin gene expression caused dysfunction of the cell-cell junction system, triggering cancer invasion and metastasis. Therefore, E-cadherin is an important tumor-suppressor gene. To understand how E-cadherin gene expression is regulated in cancer cells, we have used E-cadherin-positive and -negative expressing cells to find out the possible up- or downregulating transcription factors in human E-cadherin regulatory sequences. Functional analysis of human E-cadherin regulatory sequences constructs indicated that AML1, Sp1, and p300 may play important roles in promoting E-cadherin expression. In addition, we found there are four HNF3-binding sites in human E-cadherin regulatory sequences. The exogenous HNF3 can enhance the E-cadherin promoter activity in metastatic breast cancer cells and the metastatic breast cancer cells stably transfected with HNF3 showed re-expression of E-cadherin. The HNF3 stable transfectants changed from mesenchymal-like into epithelial morphology. The transwell assays showed the re-expressed E-cadherin reduced cell motility of metastatic breast cancer cells. These results suggested HNF3 may play important roles in the upregulation of the E-cadherin promoter, with the consequent re-expression of E-cadherin, thus reducing the metastatic potential of breast cancer cells. These findings suggested HNF3 plays important roles in the upregulation of the E-cadherin gene and may be able to reduce the motility of metastatic breast cancer cells.	Tzu Chi Univ, Coll Life Sci, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Tzu Chi Univ, Grad Inst Med Sci, Hualien 970, Taiwan; Tzu Chi Univ, Dept Life Sci, Hualien 970, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Coll Life Sci, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd Sec 3, Hualien 970, Taiwan.	jhc@mail.tcu.edu.tw						Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1291, DOI 10.1006/bbrc.1994.2322; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHANG HW, 2000, CANCER, V94, P386; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Duband JL, 1995, ACTA ANAT, V154, P63; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; GRAFF JR, 1995, CANCER RES, V55, P5195; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SHIGEAKI L, 2002, FASEB J, V16, P1444; Si HX, 2001, CANCER LETT, V173, P71, DOI 10.1016/S0304-3835(01)00646-2; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Viebahn C, 1995, ACTA ANAT, V154, P79; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	53	156	169	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8277	8290		10.1038/sj.onc.1208991	http://dx.doi.org/10.1038/sj.onc.1208991			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16116478				2022-12-28	WOS:000233956500007
J	Datta, K; Mondal, S; Sinha, S; Li, JP; Wang, EF; Knebelmann, B; Karumanchi, SA; Mukhopadhyay, D				Datta, K; Mondal, S; Sinha, S; Li, JP; Wang, EF; Knebelmann, B; Karumanchi, SA; Mukhopadhyay, D			Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma	ONCOGENE			English	Article						VPF; VPF/VEGF; mRNA stability; angiogenesis; renal cell carcinoma; VHL; HuR	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; 3' UNTRANSLATED REGION; INDUCIBLE FACTOR-ALPHA; KINASE-C-ZETA; POSTTRANSCRIPTIONAL REGULATION; TUMOR ANGIOGENESIS; HIF-ALPHA; PROTEIN; HYPOXIA	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a key mediator of angiogenesis for both physiological and pathological conditions. It is well established that the hypoxic induction of VPF/VEGF is in large part an increase in the stability of its mRNA. A Hu family ubiquitously expressed RNA-binding protein HuR has recently been shown to be important for VPF/VEGF mRNA stabilization. In renal cancer cells, the inactivation of the tumor suppressor protein von Hippel Lindau (VHL) leads to an increase in VPF/VEGF expression. VHL not only inhibits the transcription of VPF/VEGF but also plays a significant role in decreasing its mRNA stability. Here we delineate a possible mechanism by which VHL can control the function of HuR in order to regulate the stability of VPF/VEGF mRNA. The experiments presented here suggest that the association of the elongin-binding domain of VHL with a specific RNA-binding domain of HuR (RRM1) is important for the destabilizing function of VHL on VPF/VEGF mRNA.	Mayo Clin Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hop Necker Enfants Malad, Paris, France	Mayo Clinic; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mukhopadhyay, D (corresponding author), Mayo Clin Fdn, Dept Biochem & Mol Biol, Gugg 1401A,200 1st St SW, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu	Karumanchi, Subbian Ananth/AAI-1694-2021		NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline; NIDDK NIH HHS [DK 02825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chung J, 2004, CANCER RES, V64, P4711, DOI 10.1158/0008-5472.CAN-04-0347; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Datta K, 2004, CANCER RES, V64, P456, DOI 10.1158/0008-5472.CAN-03-2706; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1991, PRINCESS TAKAMATSU S, V11, P339; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1997, KIDNEY INT, V51, P575, DOI 10.1038/ki.1997.82; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi W, 2002, BRIT J CANCER, V87, P119, DOI 10.1038/sj.bjc.6600416; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7850	7858		10.1038/sj.onc.1208912	http://dx.doi.org/10.1038/sj.onc.1208912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16170373				2022-12-28	WOS:000233463000004
J	Mohr, I				Mohr, I			To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control	ONCOGENE			English	Review						translational control; oncolytic virus	HERPES-SIMPLEX-VIRUS; VESICULAR STOMATITIS-VIRUS; HOST SHUTOFF PROTEIN; CAP-DEPENDENT TRANSLATION; INITIATION-FACTOR 4E; RNA-BINDING-PROTEIN; TYPE-1 MUTANT G207; MESSENGER-RNA; GAMMA(1)34.5 PROTEIN; WILD-TYPE	To ensure that their mRNAs are translated and that the viral proteins necessary for assembling the next generation of infectious progeny are produced, viruses must effectively seize control of the translational machinery within their host cells. In many cases, the ability to productively engage host translational components can determine if a given cell type can support viral replication, illustrating the critical importance of this task in the viral life cycle. Failure to interface properly with the host translational apparatus can compromise the productive growth cycle, resulting in an abortive infection and radically restricting viral replication. Not only have viruses become facile at commandeering this machinery, they are also particularly adept at manipulating cellular translation control pathways for their own ends. In this review, the mechanisms by which numerous viruses manipulate host translational control circuits are discussed. Furthermore, particular attention is devoted to understanding how interfering with the ability of a virus to properly regulate translation in its host can be exploited to generate oncolytic strains that selectively replicate in cancer cells.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Mohr, I (corresponding author), NYU, Sch Med, Dept Microbiol, MSB-214,550 1st Ave, New York, NY 10016 USA.	ian.mohr@med.nyu.edu						Advani SJ, 1999, CANCER RES, V59, P2055; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahmed M, 2004, VIROLOGY, V330, P34, DOI 10.1016/j.virol.2004.08.039; Andreansky S, 1997, CANCER RES, V57, P1502; Andreansky SS, 1996, P NATL ACAD SCI USA, V93, P11313, DOI 10.1073/pnas.93.21.11313; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; BARTKOSKI M, 1976, J VIROL, V20, P583, DOI 10.1128/JVI.20.3.583-588.1976; BOLOVAN CA, 1994, J VIROL, V68, P48, DOI 10.1128/JVI.68.1.48-55.1994; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; CAI WH, 1993, J VIROL, V67, P7501, DOI 10.1128/JVI.67.12.7501-7512.1993; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Cerveny M, 2003, VIROLOGY, V307, P290, DOI 10.1016/S0042-6822(02)00075-2; CHAMBERS R, 1995, P NATL ACAD SCI USA, V92, P1411, DOI 10.1073/pnas.92.5.1411; Cheng GF, 2001, VIROLOGY, V290, P115, DOI 10.1006/viro.2001.1148; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Chung RY, 1999, J VIROL, V73, P7556, DOI 10.1128/JVI.73.9.7556-7564.1999; Connor JH, 2004, J VIROL, V78, P8960, DOI 10.1128/JVI.78.17.8960-8970.2004; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; Doepker RC, 2004, J VIROL, V78, P4684, DOI 10.1128/JVI.78.9.4684-4699.2004; Duerst RJ, 2004, VIROLOGY, V322, P158, DOI 10.1016/j.virol.2004.01.019; ELSHIEKH NA, 1991, J VIROL, V65, P6430, DOI 10.1128/JVI.65.12.6430-6437.1991; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everly DN, 2002, J VIROL, V76, P8560, DOI 10.1128/JVI.76.17.8560-8571.2002; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Feng PH, 2001, J VIROL, V75, P10272, DOI 10.1128/JVI.75.21.10272-10280.2001; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Hunter WD, 1999, J VIROL, V73, P6319, DOI 10.1128/JVI.73.8.6319-6326.1999; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; JACQUEMONT B, 1975, J VIROL, V15, P707, DOI 10.1128/JVI.15.4.707-713.1975; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kauder SE, 2004, J CLIN INVEST, V113, P1743, DOI 10.1172/JCI200421323; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KESARI S, 1995, LAB INVEST, V73, P636; Kesari S, 1998, J GEN VIROL, V79, P525, DOI 10.1099/0022-1317-79-3-525; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Khoo D, 2002, J VIROL, V76, P11971, DOI 10.1128/JVI.76.23.11971-11981.2002; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Lasner TM, 1998, J NEUROVIROL, V4, P100, DOI 10.3109/13550289809113487; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Lichtenstein DL, 2004, CANCER GENE THER, V11, P819, DOI 10.1038/sj.cgt.7700765; Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Lium EK, 1997, J VIROL, V71, P8602, DOI 10.1128/JVI.71.11.8602-8614.1997; MACLEAN AR, 1991, J GEN VIROL, V72, P631, DOI 10.1099/0022-1317-72-3-631; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARKERT JM, 1993, NEUROSURGERY, V32, P597, DOI 10.1227/00006123-199304000-00016; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Markovitz NS, 1997, J VIROL, V71, P5560, DOI 10.1128/JVI.71.7.5560-5569.1997; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Mohr I, 2004, INT REV IMMUNOL, V23, P199, DOI 10.1080/08830180490265600; Mohr I, 2003, EXPERT OPIN BIOL TH, V3, P113, DOI 10.1517/eobt.3.1.113.20950; Mohr I, 1996, EMBO J, V15, P4759, DOI 10.1002/j.1460-2075.1996.tb00853.x; Mohr I, 2001, J VIROL, V75, P5189, DOI 10.1128/JVI.75.11.5189-5196.2001; Mulvey M, 2004, J VIROL, V78, P10193, DOI 10.1128/JVI.78.18.10193-10196.2004; Mulvey M, 2003, J VIROL, V77, P10917, DOI 10.1128/JVI.77.20.10917-10928.2003; Mulvey M, 1999, J VIROL, V73, P3375, DOI 10.1128/JVI.73.4.3375-3385.1999; Murphy JA, 2003, J VIROL, V77, P9337, DOI 10.1128/JVI.77.17.9337-9345.2003; Nakamura H, 2002, J CLIN INVEST, V109, P871, DOI 10.1172/JCI10623; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pe'ery T, 2000, COLD SPRING HARBOR M, V39, P371; Peters GA, 2002, J VIROL, V76, P11054, DOI 10.1128/JVI.76.21.11054-11064.2002; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; QUIROZ E, 1988, AM J TROP MED HYG, V39, P312, DOI 10.4269/ajtmh.1988.39.312; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; RANDAZZO BP, 1995, VIROLOGY, V211, P94, DOI 10.1006/viro.1995.1382; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; READ GS, 1983, J VIROL, V46, P498, DOI 10.1128/JVI.46.2.498-512.1983; Rodriguez LL, 2002, VIRUS RES, V85, P211, DOI 10.1016/S0168-1702(02)00026-6; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; ROIZMAN B, 2001, FIELDS VIROLOGY, P2239; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sandri-Goldin RM, 2004, J VIROL, V78, P4389, DOI 10.1128/JVI.78.9.4389-4396.2004; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; Smith TJ, 2002, J VIROL, V76, P2054, DOI 10.1128/JVI.76.5.2054-2061.2002; STANNERS CP, 1971, J CELL PHYSIOL, V77, P31, DOI 10.1002/jcp.1040770105; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; STRELOW LI, 1995, J VIROL, V69, P6779, DOI 10.1128/JVI.69.11.6779-6786.1995; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Taneja S, 2001, P NATL ACAD SCI USA, V98, P8804, DOI 10.1073/pnas.161011798; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; THOMAS G, 1979, CELL BIOL INT REP, V3, P307, DOI 10.1016/S0309-1651(79)80001-6; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Xi QR, 2004, GENE DEV, V18, P1997, DOI 10.1101/gad.1212504; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	127	23	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7697	7709		10.1038/sj.onc.1209053	http://dx.doi.org/10.1038/sj.onc.1209053			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299530	Bronze			2022-12-28	WOS:000233372600006
J	Working, PK; Lin, A; Borellini, F				Working, PK; Lin, A; Borellini, F			Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses	ONCOGENE			English	Review						oncolytic adenovirus; product development; manufacturing	HUMAN CELL-LINE; MOLECULAR CHARACTERIZATION; E1-POSITIVE PARTICLES; TUMOR-CELLS; GM-CSF; REPLICATION; CANCER; VECTORS; AGENTS; RECOMBINATION	Oncolytic adenoviruses have been considered for use as anticancer therapy for decades, and numerous means of conferring tumor selectivity have been developed. As with any new therapy, the trip from the laboratory bench to the clinic has revealed a number of significant development hurdles. Viral therapies are subject to specific regulations and must meet a variety of well-defined criteria for purity, potency, stability, and product characterization prior to their use in the clinic. Published regulatory guidelines, although developed specifically for biotechnology-derived products, are applicable to the production of oncolytic adenoviruses and other cell-based products, and they should be consulted early during development. Most importantly, both the manufacturing process and the development of characterization and release assays should be science-driven, use the best available science and technology, and must consider the unique nature of the product: a living, and mutatable, virus. Potentially significant impacts on product quality and safety stem from the possibility of genetic instability related to overengineering the viruses ( as evidenced by their recombination and/or occasional reversion to wild-type virus during manufacturing). This report provides examples of some of the critical components affecting the development and production of clinical grade material and summarizes the significant progress made in recent years.	Cell Genesys Inc, San Francisco, CA 94080 USA	Cell Genesys Inc	Working, PK (corresponding author), Cell Genesys Inc, 500 Forbes Blvd, San Francisco, CA 94080 USA.	peter.working@cellgenesys.com						Alemany R, 1999, CANCER GENE THER, V6, P21, DOI 10.1038/sj.cgt.7700001; Alemany R, 2001, GENE THER, V8, P1347, DOI 10.1038/sj.gt.3301515; Bernt K, 2002, J VIROL, V76, P10994, DOI 10.1128/JVI.76.21.10994-11002.2002; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bristol JA, 2003, MOL THER, V7, P755, DOI 10.1016/S1525-0016(03)00103-5; Douglas JT, 1999, NAT BIOTECHNOL, V17, P470, DOI 10.1038/8647; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; FARSON D, 2005, P AM SOC GEN THER AN; FARSON D, 2004, P AM SOC GEN THER AN; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Haviv Yosef S., 2003, Current Gene Therapy, V3, P357, DOI 10.2174/1566523034578311; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hemminki A, 2001, CANCER RES, V61, P6377; Henderson D.R., 2002, ADENOVIRAL VECTORS G, P287; HENDERSON DR, 2001, REPLICATION COMPETEN, P56; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; JONES SD, 2004, PRECLINICA, V2, P301; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Lusky M, 2005, HUM GENE THER, V16, P281, DOI 10.1089/hum.2005.16.281; Murakami P, 2004, J VIROL, V78, P6200, DOI 10.1128/JVI.78.12.6200-6208.2004; Murakami P, 2002, HUM GENE THER, V13, P909, DOI 10.1089/10430340252939023; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; Ryan PC, 2004, CANCER GENE THER, V11, P555, DOI 10.1038/sj.cgt.7700735; SHEN Y, 2003, 12 INT C GEN THER CA; Smith JG, 1999, CANCER GENE THER, V6, P475, DOI 10.1038/sj.cgt.7700062; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Wakimoto H, 2003, GENE THER, V10, P983, DOI 10.1038/sj.gt.3302038; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517; Yu DC, 2002, CURR OPIN MOL THER, V4, P435	35	27	32	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2005	24	52					7792	7801		10.1038/sj.onc.1209045	http://dx.doi.org/10.1038/sj.onc.1209045			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299538				2022-12-28	WOS:000233372600014
J	Testa, JR; Tsichlis, PN				Testa, JR; Tsichlis, PN			AKT signaling in normal and malignant cells	ONCOGENE			English	Article						AKT/ PKB pathway; tumor suppressor genes	MOLECULAR-CLONING; PROTEIN-KINASE; ONCOGENE	AKT/protein kinase B (PKB) is a cardinal node in diverse signaling cascades important in both normal cellular physiology and various disease states. AKT signaling regulates cell proliferation and survival, cell growth ( size), glucose metabolism, cell motility and angiogenesis. Aberrant regulation of these processes result in cellular perturbations considered hallmarks of cancer, and numerous studies testify to the frequent hyperactivation of AKT signaling in many human cancers. Various oncoproteins and tumor suppressors intersect the AKT signal transduction pathway and are activated or inactivated, respectively, in cancer. This issue of Oncogene Reviews includes a collection of perspectives on the normal cellular functions of various components of the AKT pathway, as well as biological consequences of alterations of these proteins as related to tumorigenesis. Two reviews focus on AKT regulation, one of which addresses various aspects of phosphoinositide metabolism, while the other emphasizes the role of AKT-interacting proteins in AKT activation. Several reviews highlight the role of major AKT substrates involved in cellular metabolism, transcription and translation; another focuses on the role of AKT signaling in epithelial-mesenchymal transition. Also included are articles on the involvement of AKT pathway deregulation in human cancer and certain hereditary cancer syndromes, as well as in murine models of cancer based on AKT pathway activation. Additional articles discuss current approaches to identify selective inhibitors of the AKT pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Fox Chase Cancer Center; Tufts Medical Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu			NCI NIH HHS [CA06927, CA57436, CA77429, CA83638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, P50CA083638, R01CA057436, R01CA077429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHENG JQ, ONCOGENE REV, V24, P7482; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065	10	215	226	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7391	7393		10.1038/sj.onc.1209100	http://dx.doi.org/10.1038/sj.onc.1209100			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288285				2022-12-28	WOS:000233201900001
J	Dominguez, PL; Kolodney, MS				Dominguez, PL; Kolodney, MS			Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens	ONCOGENE			English	Article						polymerase chain reaction (PCR); locked nucleic acid (LNA); BRAF; melanoma	POINT MUTATIONS; DNA; PCR	Detection and sequencing of mutations from clinical specimens is often complicated by the presence of an excess of nonmutated cells. To facilitate the detection and sequencing of minority mutations from clinical specimens, we developed wild-type blocking polymerase chain reaction (WTB-PCR). This technique allows sensitive detection of minority mutations in a tissue sample containing excess wild-type DNA. In WTB-PCR, a nonextendable locked nucleic acid (LNA) oligonucleotide binds tightly to a region of wild-type DNA known to develop point mutations. This LNA sequence blocks amplification of wild-type DNA during PCR while permitting amplification of mutant exon 15. Our results show that the LNA blocking oligonucleotide inhibits amplification of wild-type DNA in a dose-dependent manner. WTB-PCR was able to detect mutant DNA in clinical samples of melanoma tissue containing an excess of nonmelanoma cells. This method was also able to detect small amounts of point mutated or tandem mutated DNA diluted with a much larger concentration of wild-type DNA. This rapid and simple assay overcomes the limitations of current methods to detect minority mutations. The potential applications of WTB-PCR include early diagnosis and prognosis of various cancers.	Harbor UCLA Med Ctr, Div Dermatol, Dept Med, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kolodney, MS (corresponding author), Harbor UCLA Med Ctr, Div Dermatol, Dept Med, 1000 W Carson St,Box 459, Torrance, CA 90509 USA.	mkolodney@labiomed.org		kolodney, Michael/0000-0003-1931-8644				Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Kaur M, 2002, MUTAGENESIS, V17, P365, DOI 10.1093/mutage/17.5.365; Latorra D, 2003, MOL CELL PROBE, V17, P253, DOI 10.1016/S0890-8508(03)00062-8; Liu Q, 2002, BIOTECHNIQUES, V33, P129, DOI 10.2144/02331rr04; Makrigiorgos GM, 2004, HUM MUTAT, V23, P406, DOI 10.1002/humu.20024; Miller CJ, 2004, J INVEST DERMATOL, V123, P990, DOI 10.1111/j.0022-202X.2004.23468.x; Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27; Oliver DH, 2000, J MOL DIAGN, V2, P202, DOI 10.1016/S1525-1578(10)60638-1; Parsons BL, 1997, MUTAT RES-REV MUTAT, V387, P97, DOI 10.1016/S1383-5742(97)00026-4; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Yu D, 1997, BIOTECHNIQUES, V23, P714, DOI 10.2144/97234st06; YU D, 1997, BIOTECHNIQUES, V23, P718	12	72	106	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6830	6834		10.1038/sj.onc.1208832	http://dx.doi.org/10.1038/sj.onc.1208832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16116485				2022-12-28	WOS:000232527800010
J	Lee, JO; Kwun, HJ; Jung, JK; Choi, KH; Min, DS; Jang, KL				Lee, JO; Kwun, HJ; Jung, JK; Choi, KH; Min, DS; Jang, KL			Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1	ONCOGENE			English	Article						DNA methyltransferase 1; E-cadherin; hepatitis B virus X; hepatocellular carcinoma; metastasis; tumor invasion	CELL-CELL-ADHESION; HEPATOCELLULAR-CARCINOMA; CPG METHYLATION; HBX PROTEIN; TRANSCRIPTIONAL ACTIVITY; DOWN-REGULATION; GENE; CANCER; INVASION; SYSTEM	E-cadherin is a key cell adhesion molecule implicated as a tumor suppressor, which is frequently altered in hepatocellular carcinoma, especially in hepatitis B virus (HBV)-related tumors. Here, we report that HBV X protein (HBx) represses E-cadherin expression at the transcription level. Based on the differential effects of HBx natural variants, we determined that Lys-130 in the transactivation domain of HBx is critical for the E-cadherin repression. The repression effect of HBx was abolished after treatment with DNA methyltransferase inhibitor, 5'-Aza-2'dC. In addition, methylation-specific PCR analysis revealed that the CpG island 1 of E-cadherin promoter is hypermethylated by HBx. Furthermore, HBx induces DNA methyltransferase 1 expression by stimulating its transcription. Therefore, we conclude that HBx represses E-cadherin expression by inducing methylation-mediated promoter inactivation. The reduced E-cadherin expression results in dramatic morphological changes of the HBx-expressing cells. In addition, HBx-expressing cells aggregate poorly in suspension culture, reflecting their altered intercellular interactions. The biological significance was further demonstrated by the increased collagen invasion ability of HBx-expressing cells. Therefore, the present study suggests that HBx plays a role during hepatocellular carcinogenesis by favoring cell detachment from the surrounding cells and migration outside of the primary tumor site.	Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea	Pusan National University	Jang, KL (corresponding author), Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea.	kljang@pusan.ac.kr	Kwun, Hyun jin/AAJ-3365-2020; Kwun, Hyun Jin/F-5511-2011; Kwun, Hyun Jin/AAH-2706-2020	Kwun, Hyun jin/0000-0002-8926-746X; Kwun, Hyun Jin/0000-0002-8926-746X; 				Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Berx G, 1996, ONCOGENE, V13, P1919; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574; Chu CHC, 1996, LANCET, V348, P625, DOI 10.1016/S0140-6736(05)64851-9; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Foty RA, 2004, INT J DEV BIOL, V48, P397, DOI 10.1387/ijdb.041810rf; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; Kanai Y, 1997, INT J CANCER, V71, P355; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kwun HJ, 2004, NUCLEIC ACIDS RES, V32, P2202, DOI 10.1093/nar/gkh553; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Melki JR, 2000, BLOOD, V95, P3208; MIYASAKA M, 1995, CLIN ORTHOP RELAT R, V312, P10; Nabi IR, 1999, J CELL SCI, V112, P1803; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Takahashi K, 1998, ARCH VIROL, V143, P2313, DOI 10.1007/s007050050463; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Venard V, 2000, J MED VIROL, V62, P177, DOI 10.1002/1096-9071(200010)62:2&lt;177::AID-JMV8&gt;3.0.CO;2-V; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	48	157	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6617	6625		10.1038/sj.onc.1208827	http://dx.doi.org/10.1038/sj.onc.1208827			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007161				2022-12-28	WOS:000232367800003
J	Sato, M; Sasaki, H; Kazui, T; Yokota, J; Kohno, T				Sato, M; Sasaki, H; Kazui, T; Yokota, J; Kohno, T			Probing the chromosome 9p21 region susceptible to DNA double-strand breaks in human cells in vivo by restriction enzyme transfer	ONCOGENE			English	Article						DNA double-strand break; chromosome deletion; p16; tumor suppressor gene; restriction enzyme	BREAKPOINT-CLUSTER REGION; ALTERED CHROMATIN-STRUCTURE; HUMAN LUNG-CANCER; ALTERNATIVE MECHANISMS; MLL GENE; METHYLATION; DELETIONS; CLEAVAGE; LEUKEMIA; TRANSLOCATIONS	A restriction enzyme, MspI, was introduced into cultured human cells as a probe to detect genomic regions susceptible to DNA double-strand breaks ( DSBs). A 2 h exposure to MspI at a concentration of 8U/mu l produced DSBs at MspI sites in more than 80% of HeLa cells. The sensitivity to digestion was examined on chromosomal DNAs for the region containing the p16 tumor suppressor gene and two other related genes, p14ARF and p15, by Southern blot hybridization analysis and linker-mediated capture of DNA fragments digested in vivo. DNAs for the promoter regions of the three genes, respectively, were sensitive to MspI digestion in HeLa cells, while DNA for the p16 promoter region was less sensitive in lung cancer cells with hypermethylation of the region. Breakpoints for interstitial 9p21 deletions removing the p16/p14ARF/p15 locus in a variety of human cancers were significantly over-represented in the three sensitive regions. The results suggest that the MspI sensitivity in vivo of each genomic region reflects its susceptibility to DSBs that trigger chromosome aberrations in human cells. This method could help us understand the pathogenic significance of differential susceptibility to DSBs among genomic regions in human carcinogenesis.	Natl Canc Ctr, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka 4313192, Japan; Natl Canc Ctr, Div Genet, Tokyo 1040045, Japan	National Cancer Center - Japan; Hamamatsu University School of Medicine; National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Div Biol, Chuo Ku, 1-1 Tsukiji 5-Chome,, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Costello JF, 1996, CANCER RES, V56, P2405; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Folle GA, 1998, MUTAT RES-FUND MOL M, V404, P17, DOI 10.1016/S0027-5107(98)00090-6; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; KAMB A, 1994, SCIENCE, V264, P440; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khobta A, 2004, CANCER RES, V64, P2656, DOI 10.1158/0008-5472.CAN-03-1126; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kuwahara Y, 2004, GENE CHROMOSOME CANC, V41, P125, DOI 10.1002/gcc.20075; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moiseenko VV, 1998, INT J RADIAT BIOL, V74, P533, DOI 10.1080/095530098141113; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raschke S, 2005, GENE CHROMOSOME CANC, V42, P58, DOI 10.1002/gcc.20119; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Stanulla M, 2001, HUM MOL GENET, V10, P2481, DOI 10.1093/hmg/10.22.2481; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WINEGAR RA, 1990, SOMAT CELL MOLEC GEN, V16, P251, DOI 10.1007/BF01233361; Xing EP, 1999, CLIN CANCER RES, V5, P2704	38	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 8	2005	24	40					6108	6118		10.1038/sj.onc.1208750	http://dx.doi.org/10.1038/sj.onc.1208750			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007206	Green Submitted			2022-12-28	WOS:000231718100005
J	Marriott, SJ; Semmes, OJ				Marriott, SJ; Semmes, OJ			Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response	ONCOGENE			English	Review						HTLV-I; tax; cell cycle; DNA repair; genome instability	VIRUS TYPE-1 TAX; ANAPHASE-PROMOTING COMPLEX; NUCLEOTIDE EXCISION-REPAIR; ONCOGENE PRODUCT TAX; MITOTIC CHECKPOINT GENES; KAPPA-B PATHWAY; MICROSATELLITE INSTABILITY; SPINDLE CHECKPOINT; LEUKEMIA-LYMPHOMA; TRANSCRIPTIONAL ACTIVATION	Human T-cell lymphotropic virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia (ATL), a rapidly progressing, clonal malignancy of CD4+ T lymphocytes. Fewer than one in 20 infected individuals typically develop ATL and the onset of this cancer occurs after decades of relatively symptom-free infection. Leukemic cells from ATL patients display extensive and varied forms of chromosomal abnormalities and this genomic instability is thought to be a major contributor to the development of ATL. HTLV-I encodes a regulatory protein, Tax, which is necessary and sufficient to transform cells and is therefore considered to be the viral oncoprotein. Tax interacts with numerous cellular proteins to reprogram cellular processes including, but not limited to, transcription, cell cycle regulation, DNA repair, and apoptosis. This review presents an overview of the impact of HTLV-I infection in general, and Tax expression in particular, on cell cycle progression and the repair of DNA damage. The contribution of these activities to genome instability and cellular transformation will be discussed.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23508 USA	Baylor College of Medicine; Eastern Virginia Medical School	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Pl, Houston, TX 77030 USA.	susanm@bcm.tmc.edu	Semmes, Oliver/GQA-5179-2022		NATIONAL CANCER INSTITUTE [R01CA076595, R01CA077371, R01CA055684, U01CA085067] Funding Source: NIH RePORTER; NCI NIH HHS [CA-76595, CA-55684, CA-77371, CA-85067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Akagi T, 1996, ONCOGENE, V12, P1645; ARLETT CF, 1989, MUTAGENESIS, V4, P482, DOI 10.1093/mutage/4.6.482; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Elder RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD349, DOI 10.2741/elder; Franzese O, 2002, AIDS RES HUM RETROV, V18, P249, DOI 10.1089/088922202753472810; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hanawalt P C, 1986, Basic Life Sci, V38, P489; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harper Jane V., 2004, V296, P113; Hatta Y, 1997, BRIT J HAEMATOL, V99, P665; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; Hatta Y, 1998, BRIT J HAEMATOL, V101, P341, DOI 10.1046/j.1365-2141.1998.00710.x; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Hayami Y, 1999, LEUKEMIA LYMPHOMA, V32, P345, DOI 10.3109/10428199909167395; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; ITOYAMA T, 1990, CANCER GENET CYTOGEN, V49, P157, DOI 10.1016/0165-4608(90)90137-Y; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMADA Y, 1992, CANCER, V70, P861, DOI 10.1002/1097-0142(19920815)70:4&lt;861::AID-CNCR2820700423&gt;3.0.CO;2-4; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Kino T, 2004, DNA CELL BIOL, V23, P193, DOI 10.1089/104454904773819789; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; LABAER J, 1997, GENE DEV, V8, P1750; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemoine FJ, 2002, ONCOGENE, V21, P7230, DOI 10.1038/sj.onc.1205898; Lemoine FJ, 2001, DIS MARKERS, V17, P129, DOI 10.1155/2001/263567; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARUYAMA K, 1990, CANCER RES, V50, pS5697; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Morimoto H, 2005, AM J HEMATOL, V78, P100, DOI 10.1002/ajh.20259; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohshima K, 1998, CANCER LETT, V132, P203, DOI 10.1016/S0304-3835(98)00188-8; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; PARRY JM, 1987, MUTAT RES, V181, P267, DOI 10.1016/0027-5107(87)90104-7; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SAKASHITA A, 1992, BLOOD, V79, P477; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SANDBERG AA, 1980, CANCER, V46, P2221, DOI 10.1002/1097-0142(19801115)46:10<2221::AID-CNCR2820461019>3.0.CO;2-8; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMSON EJ, 1988, MUTAGENESIS, V3, P415, DOI 10.1093/mutage/3.5.415; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Tsumuki H, 2001, RHEUMATOL INT, V20, P175; Tyler KL, 2001, TRENDS MICROBIOL, V9, P560, DOI 10.1016/S0966-842X(01)02103-5; Uchida N, 1999, LEUKEMIA RES, V23, P311, DOI 10.1016/S0145-2126(98)00170-2; Van Orden K, 2000, GENE EXPRESSION, V9, P29; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	115	132	136	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5986	5995		10.1038/sj.onc.1208976	http://dx.doi.org/10.1038/sj.onc.1208976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155605				2022-12-28	WOS:000231623400008
J	Khaleque, MA; Bharti, A; Sawyer, D; Gong, JL; Benjamin, IJ; Stevenson, MA; Calderwood, SK				Khaleque, MA; Bharti, A; Sawyer, D; Gong, JL; Benjamin, IJ; Stevenson, MA; Calderwood, SK			Induction of heat shock proteins by heregulin beta 1 leads to protection from apoptosis and anchorage-independent growth	ONCOGENE			English	Article						heregulin; heat shock protein; HSF1; anchorage independent growth; signal transduction	BREAST-CANCER; GENE-EXPRESSION; FACTOR-I; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; ESTROGEN-RECEPTOR; CELL-SURVIVAL; PHOSPHORYLATION; FACTOR-1; STRESS	Elevation of heat shock protein (HSP) levels is widespread in cancer and predicts a poor prognosis and resistance to therapy. We show that HSP elevation in tumor cells can be induced by the highly malignant factor heregulin beta 1 (HRG beta 1), which induces HSP expression through heat shock transcription factor 1 (HSF1). Inactivation of the hsf1 gene prevents HSP induction by HRG beta 1. HSP expression is induced through a cascade response initiated by HRG beta 1 binding to c-erbB receptors on the cell surface and which leads to the inhibition of intracellular HSF1 antagonist glycogen synthase kinase 3. HSF1 activated by this pathway plays a key role in the protection of cells from apoptosis and the mediation of anchorage independent growth by HRGb1, indicating a role for HSF1 in this tumorigenic pathway.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Univ Utah, Ctr Hlth Sci, Dept Internal Med, Salt Lake City, UT 84132 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Utah System of Higher Education; University of Utah	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, 21-27 Burlington Ave, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Bharti, Ajit/0000-0001-7972-6688; Gong, Jianlin/0000-0003-0910-014X; Khaleque, Md Abdul/0000-0002-6873-9165	NATIONAL CANCER INSTITUTE [R01CA047407, R01CA050642, P01CA031303] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA47407, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Blagosklonny MV, 2001, J NATL CANCER I, V93, P239, DOI 10.1093/jnci/93.3.239-a; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cornford PA, 2000, CANCER RES, V60, P7099; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; FADOK VA, 1992, J IMMUNOL, V148, P2207; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232	54	86	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6564	6573		10.1038/sj.onc.1208798	http://dx.doi.org/10.1038/sj.onc.1208798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007186				2022-12-28	WOS:000232204100010
J	Fraser, M; Chan, SL; Chan, SSL; Fiscus, RR; Tsang, BK				Fraser, M; Chan, SL; Chan, SSL; Fiscus, RR; Tsang, BK			Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; apoptosis; soluble guanylyl cyclase; cGMP; p53	X-LINKED INHIBITOR; INSULIN-RECEPTOR SUBSTRATE-1; CISPLATIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; ENDOGENOUS NITRIC-OXIDE; CYCLIC-GMP; DNA-DAMAGE; PC12 CELLS; GUANOSINE-MONOPHOSPHATE; NATRIURETIC PEPTIDES	Dysregulated apoptosis plays a critical role in the development of a number of aberrant cellular processes, including tumorigenesis and chemoresistance. However, the mechanisms that govern the normal apoptotic program are not completely understood. Soluble guanylyl cyclase (sGC) and cyclic guanosine monophosphate ( cGMP) promote mammalian cell viability via an unknown mechanism and p53 status is a key determinant of cell fate in human ovarian cancer cells. Whether an interaction exists between these two determinants of cell fate is unknown. We hypothesized that basal sGC activity reduces p53 content and attenuates p53-dependent apoptosis in human ovarian cancer cells. Suppression of sGC activity with the specific inhibitor 1H-[1,2,4] oxadiazolo[ 4,3-a] quinoxalin-1-one (ODQ) lowered cGMP content, and increased p53 protein content and induced apoptosis in three ovarian cancer cell lines, effects which were attenuated by the cGMP analog 8-Br-cGMP and by Atrial Natriuretic Factor, an activator of particulate guanylyl cyclase, which circumvent the inhibition of sGC. ODQ prolonged p53 half-life, induced phosphorylation of p53 on Ser15, and upregulated the p53- dependent gene products p21, murine double minute-2, and the proapoptotic, p53- responsive gene product Bax. ODQ activated caspase-3, and ODQ-induced apoptosis was inhibited by overexpression of X-linked inhibitor of apoptosis Protein. Pretreatment with the specific p53 inhibitor pifithrin or downregulation of p53 using a specific small inhibitory RNA significantly attenuated ODQ-induced apoptosis. Moreover, ODQ-induced upregulation of p21 and Bax and ODQ-induced apoptosis were significantly reduced in a p53 mutant cell line relative to the wild-type parental cell line. Thus, the current study establishes that basal sGC/cGMP activity regulates p53 protein stability, content, and function, possibly by altering p53 phosphorylation and stabilization, and promotes cell survival in part through regulation of caspase-3 and p53.	Univ Ottawa, Reprod Biol Unit, Ottawa, ON, Canada; Univ Ottawa, Dept Obstet & Gynecol, Div Gynecol Oncol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular & Mol Biol, Ottawa, ON, Canada; Ottawa Hosp, Hlth Res Inst, Hormones Growth & Dev Program, Ottawa, ON, Canada; Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Gerontol & Geriatr, Shatin, Hong Kong, Peoples R China	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Chinese University of Hong Kong; Chinese University of Hong Kong	Tsang, BK (corresponding author), Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca		Tsang, Benjamin K./0000-0003-1213-3946				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Asselin E, 2001, CANCER RES, V61, P1862; Chan SL, 2003, MOL HUM REPROD, V9, P775, DOI 10.1093/molehr/gag094; Chen HW, 2001, FERTIL STERIL, V75, P1163, DOI 10.1016/S0015-0282(01)01780-0; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Estevez AG, 1998, PROG BRAIN RES, V118, P269; Falcone S, 2002, BIOCHEM J, V366, P165, DOI 10.1042/bj20020017; Fiscus RR, 2002, J CARDIAC SURG, V17, P336; Fiscus RR, 2002, NEUROSIGNALS, V11, P175, DOI 10.1159/000065431; Fiscus RR, 2001, NEUROREPORT, V12, P185, DOI 10.1097/00001756-200102120-00003; Flamigni F, 2001, BIOCHEM PHARMACOL, V62, P319, DOI 10.1016/S0006-2952(01)00646-3; Fraser M, 2003, CANCER RES, V63, P7081; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Havrilesky L, 2003, J CLIN ONCOL, V21, P3814, DOI 10.1200/JCO.2003.11.052; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Jadeski LC, 2003, INT J CANCER, V106, P496, DOI 10.1002/ijc.11268; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; LEVINE EL, 1995, RADIOTHER ONCOL, V37, P1, DOI 10.1016/0167-8140(95)01622-N; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LUESLEY DM, 1987, BRIT J OBSTET GYNAEC, V94, P461, DOI 10.1111/j.1471-0528.1987.tb03126.x; LUESLEY DM, 1986, BRIT J OBSTET GYNAEC, V93, P380; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Orucevic A, 1999, INT J CANCER, V81, P889, DOI 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2; Panahian N, 2001, J NEUROCHEM, V76, P539, DOI 10.1046/j.1471-4159.2001.00023.x; Panahian N, 1999, J NEUROCHEM, V72, P1187; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REAP EA, 1995, J IMMUNOL, V154, P936; Sasaki H, 2000, CANCER RES, V60, P5659; Sasaki H, 2002, GYNECOL ONCOL, V85, P339, DOI 10.1006/gyno.2002.6632; Sheets EE, 1997, ANN MED, V29, P121, DOI 10.3109/07853899709113697; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Suenobu N, 1999, ARTERIOSCL THROM VAS, V19, P140, DOI 10.1161/01.ATV.19.1.140; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; Tejedo JR, 2004, ENDOCRINOLOGY, V145, P2319, DOI 10.1210/en.2003-1489; TURNER GA, 1982, BRIT J OBSTET GYNAEC, V89, P760, DOI 10.1111/j.1471-0528.1982.tb05105.x; TURNER GA, 1982, J CLIN PATHOL, V35, P800, DOI 10.1136/jcp.35.8.800; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	55	65	68	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2203	2212		10.1038/sj.onc.1209251	http://dx.doi.org/10.1038/sj.onc.1209251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288207				2022-12-28	WOS:000236581200007
J	Marchetti, B; Ashrafi, GH; Dornan, ES; Araibi, EH; Ellis, SA; Campo, MS				Marchetti, B; Ashrafi, GH; Dornan, ES; Araibi, EH; Ellis, SA; Campo, MS			The E5 protein of BPV-4 interacts with the heavy chain of MHC class I and irreversibly retains the MHC complex in the Golgi apparatus	ONCOGENE			English	Article						BPV-4; E5; MHC class I; heavy chain; interaction; immunoevasion	BOVINE PAPILLOMAVIRUS TYPE-4; FACTOR-BETA RECEPTOR; GROWTH-FACTOR; CELL-TRANSFORMATION; DOWN-REGULATION; INTERCELLULAR COMMUNICATION; IMMUNE EVASION; E8 PROTEIN; ONCOPROTEIN; EXPRESSION	BPV-4 E5 inhibits transcription of the bovine MHC class I heavy chain (HC) gene, increases degradation of HC and downregulates surface expression of MHC class I by retaining the complex in the Golgi apparatus (GA). Here we report that transcription inhibition can be alleviated by interferon treatment and the degradation of HC can be reversed by treatment with inhibitors of proteasomes and lysosomes. However, the inhibition of transport of MHC class I to the cell surface is irreversible. We show that E5 is capable of physically interacting with HC. Together with the inhibition of the vacuolar ATPase ( due to the interaction between E5 and 16k subunit c), the interaction between E5 and HC is likely to be responsible for retention of MHC class I in the GA. C-terminus deletion mutants of E5 are incapable of either downregulating surface MHC class I or interacting with HC, establishing that the C-terminus domain of E5 is important in the inhibition of MHC class I.	Univ Glasgow, Inst Comparat Med, Div Pathol Sci, Glasgow G61 1QH, Lanark, Scotland; Inst Anim Hlth, Immunol & Pathol Div, Compton, Berks, England	University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Campo, MS (corresponding author), Univ Glasgow, Inst Comparat Med, Div Pathol Sci, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk		Ashrafi, G. Hossein/0000-0002-4516-5111				Agrawal S, 2000, J HEMATOTH STEM CELL, V9, P795, DOI 10.1089/152581600750062237; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; Araibi EH, 2004, J GEN VIROL, V85, P2809, DOI 10.1099/vir.0.80128-0; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2005, INT J CANCER, V113, P276, DOI 10.1002/ijc.20558; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; BENSAID A, 1989, ANIM GENET, V20, P241; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Chevalier MS, 2002, J VIROL, V76, P8265, DOI 10.1128/JVI.76.16.8265-8275.2002; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; Ellis SA, 1996, IMMUNOGENETICS, V43, P156, DOI 10.1007/BF00176677; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; Furman MH, 2002, J VIROL, V76, P11753, DOI 10.1128/JVI.76.22.11753-11756.2002; Gaddum RM, 1996, IMMUNOGENETICS, V43, P238, DOI 10.1007/BF00587307; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GRAHAM SP, 1995, J COMP PATHOL, V112, P185, DOI 10.1016/S0021-9975(05)80060-X; Grindlay GJ, 2005, VIRUS RES, V108, P29, DOI 10.1016/j.virusres.2004.07.010; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Kasper MR, 2003, J VIROL, V77, P3041, DOI 10.1128/JVI.77.5.3041-3049.2003; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Marchetti B, 2002, ONCOGENE, V21, P7808, DOI 10.1038/sj.onc.1205885; O'Brien PM, 2003, TRENDS MICROBIOL, V11, P300, DOI 10.1016/S0966-842X(03)00145-8; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; O'Brien V, 2001, J BIOL CHEM, V276, P33861, DOI 10.1074/jbc.M100958200; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Pichowski JS, 1996, IMMUNOGENETICS, V43, P253, DOI 10.1007/BF00587314; Piguet V, 2005, CURR TOP MICROBIOL, V285, P199; Sawhney SMS, 1996, GENE, V171, P281, DOI 10.1016/0378-1119(96)00096-0; SAWHNEY SMS, 1995, IMMUNOGENETICS, V41, P246, DOI 10.1007/BF00172066; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Tirabassi RS, 2002, J VIROL, V76, P6832, DOI 10.1128/JVI.76.13.6832-6835.2002; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Williams M, 2005, J VIROL, V79, P632, DOI 10.1128/JVI.79.1.632-636.2005; Williams M, 2002, J VIROL, V76, P12173, DOI 10.1128/JVI.76.23.12173-12184.2002; Zago M, 2004, J GEN VIROL, V85, P3585, DOI 10.1099/vir.0.80313-0	46	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2254	2263		10.1038/sj.onc.1209245	http://dx.doi.org/10.1038/sj.onc.1209245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288210	Green Accepted			2022-12-28	WOS:000236581200012
J	Brunori, M; Mathieu, N; Ricoul, M; Bauwens, S; Koering, CE; de Climens, AR; Belleville, A; Wang, Q; Puisieux, I; Decimo, D; Puisieux, A; Sabatier, L; Gilson, E				Brunori, M; Mathieu, N; Ricoul, M; Bauwens, S; Koering, CE; de Climens, AR; Belleville, A; Wang, Q; Puisieux, I; Decimo, D; Puisieux, A; Sabatier, L; Gilson, E			TRF2 inhibition promotes anchorage-independent growth of telomerase-positive human fibroblasts	ONCOGENE			English	Article						telomere; TRF2; malignant transformation	REPEAT BINDING-FACTORS; NORMAL HUMAN-CELLS; HUMAN TUMOR-CELLS; TO-END FUSIONS; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; EPITHELIAL-CELLS; CANCER-CELLS; MOUSE CELLS; DNA-DAMAGE	Although telomere instability is observed in human tumors and is associated with the development of cancers in mice, it has yet to be established that it can contribute to the malignant transformation of human cells. We show here that in checkpoint-compromised telomerase-positive human. fibroblasts an episode of TRF2 inhibition promotes heritable changes that increase the ability to grow in soft agar, but not tumor growth in nude mice. This transforming activity is associated to a burst of telomere instability but is independent of an altered control of telomere length. Moreover, it cannot be recapitulated by an increase in chromosome breaks induced by an exposure to gamma-radiations. Since it can be revealed in the context of telomerase-proficient human cells, telomere dysfunction might contribute to cancer progression even at late stages of the oncogenesis process, after the telomerase reactivation step.	Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR,INRA,ENS, F-69364 Lyon 07, France; CEA, Commissariat Energ Atom, Lab Radiobiol & Oncol, Fontenay Aux Roses, France; Ctr Leon Berard, INSERM, Unite Oncol Mol, Unite 590, F-69373 Lyon, France; Ctr Hosp Lyon Sud, Tumor Biol Unit, F-69310 Pierre Benite, France; Ecole Normale Super Lyon, Lab Human Virol, INSERM, ENS, F-69364 Lyon, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gilson, E (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR,INRA,ENS, 46 Allee Italie, F-69364 Lyon 07, France.	Eric.Gilson@ens-lyon.fr		PUISIEUX, Alain/0000-0002-9938-3798; Sabatier, Laure/0000-0003-0552-6549; Decimo, Didier/0000-0002-0390-1205				Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Callen E, 2004, MUTAT RES-REV MUTAT, V567, P85, DOI 10.1016/j.mrrev.2004.06.003; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Colgin L, 2004, CURR BIOL, V14, pR901, DOI 10.1016/j.cub.2004.09.075; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Klapper W, 2003, LEUKEMIA, V17, P2007, DOI 10.1038/sj.leu.2403086; Koering CE, 2002, EMBO REP, V3, P1055, DOI 10.1093/embo-reports/kvf215; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lechel A, 2005, EMBO REP, V6, P275, DOI 10.1038/sj.embor.7400352; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Miyachi K, 2002, J EXP CLIN CANC RES, V21, P269; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakanishi K, 2003, CLIN CANCER RES, V9, P1105; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Yamada K, 2002, ANTICANCER RES, V22, P1315; Yamada M, 2002, ANTICANCER RES, V22, P3303; Zhang AJ, 2004, ONCOGENE, V23, P7441, DOI 10.1038/sj.onc.1207527; Zimonjic D, 2001, CANCER RES, V61, P8838	59	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	7					990	997		10.1038/sj.onc.1209135	http://dx.doi.org/10.1038/sj.onc.1209135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205637				2022-12-28	WOS:000235361000004
J	Putz, G; Rosner, A; Nuesslein, I; Schmitz, N; Buchholz, F				Putz, G; Rosner, A; Nuesslein, I; Schmitz, N; Buchholz, F			AML1 deletion in adult mice causes splenomegaly and lymphomas	ONCOGENE			English	Article						AML1; conditional allele; hematopoiesis; splenomegaly; lymphoma	ACUTE MYELOID-LEUKEMIA; CORE-BINDING FACTOR; N-RAS ONCOGENE; MYELODYSPLASTIC SYNDROME; DEFINITIVE HEMATOPOIESIS; POINT MUTATIONS; RUNT DOMAIN; AML1/PEBP2-ALPHA-B GENE; ACQUIRED TRISOMY-21; EMBRYONIC LETHALITY	AML1 (RUNX1) encodes a DNA- binding subunit of the CBF transcription factor family and is required for the establishment of defi. nitive hematopoiesis. AML1 is one of the most frequently mutated genes associated with human acute leukemia, suggesting that genetic alterations of the gene contribute to leukemogenesis. Here, we report the analysis of mice e carrying conditional AML1 knockout alleles that were inactivated using the Cre/loxP system. AML1 was deleted in adult mice by inducing Cre activity to replicate AML1 deletions found in human MDS, familial platelet disorder and rare de novo human AML. At a latency of 2 months after induction, the thymus was reduced in size and frequently populated by immature double negative thymocytes, indicating defective T-lymphocyte maturation, resulting in lymphatic diseases with 50% penetrance, including atypical hyperplasia and thymic lymphoma. Metastatic lymphomas to the liver and the meninges were observed. Mice also developed splenomegaly with an expansion of the myeloid compartment. Increased Howell-Jolly body counts indicated splenic hypofunction. Thrombocytopenia occurred due to immaturity of mini-megakaryocytes in the bone marrow. Together with mild lymphocytopenia in the peripheral blood and increased fractions of immature cells in the bone marrow, AML1 deficient mice display features of a myelodysplastic syndrome, suggesting a preleukemic state.	Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany; Tech Univ Dresden, Klin & Polklin Strahlentherapie & Radioonkol, Expt Zentrum, Med Fak Carl Gustav Carus, D-8027 Dresden, Germany	Max Planck Society; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Buchholz, F (corresponding author), Pfotenhauer Str 108, D-01037 Dresden, Germany.	buchholz@mpi-cbg.de	Buchholz, Frank/B-4700-2017	Buchholz, Frank/0000-0002-4577-3344				Bourgeois E, 2001, LEUKEMIA, V15, P950, DOI 10.1038/sj.leu.2402129; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Dunnick JK, 1997, TOXICOL PATHOL, V25, P533, DOI 10.1177/019262339702500601; Fredrickson TN, 2000, ATLAS MOUSE HEMATOPA; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HIRAI H, 1988, BLOOD, V71, P256; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; Morohashi K, 1999, BLOOD, V93, P1586; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Rhoades KL, 2000, BLOOD, V96, P2108; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schiering A, 1999, ATHEROSCLEROSIS, V144, P73, DOI 10.1016/S0021-9150(99)00045-3; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Steensma DP, 2005, EUR J HAEMATOL, V74, P47, DOI 10.1111/j.1600-0609.2004.00363.x; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	41	97	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					929	939		10.1038/sj.onc.1209136	http://dx.doi.org/10.1038/sj.onc.1209136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247465				2022-12-28	WOS:000235212700012
J	Kuphal, S; Wallner, S; Schimanski, CC; Bataille, F; Hofer, P; Strand, S; Strand, D; Bosserhoff, AK				Kuphal, S; Wallner, S; Schimanski, CC; Bataille, F; Hofer, P; Strand, S; Strand, D; Bosserhoff, AK			Expression of Hugl-1 is strongly reduced in malignant melanoma	ONCOGENE			English	Article						Lgl; Hugl; human; tumor; suppressor gene; malignant melanoma; cancer	TUMOR-SUPPRESSOR GENE; LETHAL-GIANT-LARVAE; II HEAVY-CHAIN; BREAST-CARCINOMA; CELL POLARITY; HUMAN HOMOLOG; IN-VIVO; DROSOPHILA; PROTEIN; CANCER	The human gene Hugl-1 (Llgl/Lgl1) has significant homology to the Drosophila tumor suppressor gene lethal(2) giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that is involved in maintaining cell polarity and epithelial integrity. We speculate that Hugl-1 might play a role in epithelial mesenchymal transition (EMT) and that loss of Hugl-1 expression plays a role in the development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of Hugl-1 transcription. We found that Hugl-1 was downregulated or lost in all cell lines and in most of the tumor samples analysed, and that these losses were associated with advanced stage of the disease. Redu ced Hugl-1 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction (RT-PCR) analysis. Fun ctional assays with stable Hugl-1-transfected cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Further, downregulation of MMP2 and MMP14 (MT1- MMP) and re-expression of E-cadherin was found in the Hugl-1-expressing cell clones supporting a role of Hugl-1 in EMT. Our studies thus indicate that loss of Hugl-1 expression contributes to melanoma progression.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany	University of Regensburg; Johannes Gutenberg University of Mainz	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Borg JP, 2004, PATHOL BIOL, V52, P328, DOI 10.1016/j.patbio.2003.09.015; DANEN EHJ, 1995, CANCER SURV, V24, P43; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Haass NK, 2004, J MOL HISTOL, V35, P309; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; Jankowski JA, 1997, J CLIN PATHOL-MOL PA, V50, P289; Justice N, 2003, CURR BIOL, V13, P778, DOI 10.1016/S0960-9822(03)00288-4; Kalmes A, 1996, J CELL SCI, V109, P1359; Kuphal S, 2005, MELANOMA RES, V15, P305, DOI 10.1097/00008390-200508000-00012; Li G, 2004, EXP CELL RES, V297, P142, DOI 10.1016/j.yexcr.2004.03.012; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	35	97	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					103	110		10.1038/sj.onc.1209008	http://dx.doi.org/10.1038/sj.onc.1209008			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170365				2022-12-28	WOS:000234406400011
J	Vera, J; Jaumot, M; Estanyol, JM; Brun, S; Agell, N; Bachs, O				Vera, J; Jaumot, M; Estanyol, JM; Brun, S; Agell, N; Bachs, O			Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor	ONCOGENE			English	Article						SET protein; hnRNPA2; PP2A; cell cycle	LUNG-CANCER DETECTION; ACTIVATING FACTOR-I; PHOSPHATASE 2A; GRANZYME-A; MESSENGER-RNA; FISSION YEAST; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; CELL-CYCLE; HNRNP A2	The oncoprotein SET participates in a diversity of cellular functions including cell proliferation. Its role on cell cycle progression is likely mediated by inhibiting cyclin B-cdk1 and the protein phosphatase 2A (PP2A). On identifying new SET cellular partners, we found that SET interacts in vitro and in vivo with the heterogeneous nuclear ribonucleoprotein A2(hnRNPA2); a protein involved in various aspects of mRNA biogenesis. The SET-binding region of hnRNPA2 is the RNP1 sequence that belongs to the RNA-binding domain (RBD) of this protein. We also found that hnRNPA2 has much higher affinity for single-standed DNA than for SET. On analysing the effect of hnRNPA2 on PP2A inhibition by SET, we observed that hnRNPA2 cooperates with SET on PP2A inhibition. This is because we found that hnRNPA2 is also a PP2A inhibitor. HnRNPA2 interacts with PP2A by the RNP1 sequence; however, to inhibit PP2A activity, the complete RBD is needed. We also observed that overexpression of hnRNPA2 inhibits PP2A activity and stimulates cell proliferation. Interestingly, the overexpression of the complete RBD is sufficient to stimulate proliferation. As hnRNPA2 is overexpressed in a variety of human tumors, our results suggest that hnRNPA2 might participate in oncogenesis by stimulating cell proliferation.	Univ Barcelona, Fac Med, Dept Cell Biol & Pathol, Barcelona, Spain	University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016; Jaumot, Montserrat/F-2640-2016; Brun, Sonia/AAA-4585-2019	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; Brun, Sonia/0000-0002-2056-3180; Jaumot, Montserrat/0000-0003-2864-357X				Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; BOSSER R, 1995, MOL CELL BIOL, V15, P661; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fielding P, 1999, CLIN CANCER RES, V5, P4048; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moran-Jones K, 2005, NUCLEIC ACIDS RES, V33, P486, DOI 10.1093/nar/gki203; Mulshine JL, 2000, CANCER-AM CANCER SOC, V89, P2465; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Patry C, 2003, CANCER RES, V63, P7679; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; VON LM, 1992, MOL CELL BIOL, V12, P3346; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yan-Sanders Y, 2002, CANCER LETT, V183, P215, DOI 10.1016/S0304-3835(02)00168-4; Zhou J, 2001, BREAST CANCER RES TR, V66, P217, DOI 10.1023/A:1010631915831	44	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					260	270		10.1038/sj.onc.1209050	http://dx.doi.org/10.1038/sj.onc.1209050			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170352				2022-12-28	WOS:000234583600010
J	Homer, C; Knight, DA; Hananeia, L; Sheard, P; Risk, J; Lasham, A; Royds, JA; Braithwaite, AW				Homer, C; Knight, DA; Hananeia, L; Sheard, P; Risk, J; Lasham, A; Royds, JA; Braithwaite, AW			Y-box factor YB1 controls p53 apoptotic function	ONCOGENE			English	Article						YB1; nuclear localization; p53 functions; apoptosis	BINDING-PROTEIN YB-1; MAMMARY EPITHELIAL-CELLS; MDR1 GENE-EXPRESSION; NUCLEAR EXPRESSION; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; P16(INK4) EXPRESSION; P-GLYCOPROTEIN; LOCALIZATION; DOMAIN	Nuclear localization and high levels of the Y-box-binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we have continued to explore YB1/p53 interactions. We report that transcriptionally active p53 is required for nuclear localization of YB1. We go on to show that nuclear YB1 regulates p53 function. Our data demonstrate that YB1 inhibits the ability of p53 to cause cell death and to transactivate cell death genes, but does not interfere with the ability of p53 to transactivate the CDKN1A gene, encoding the kinase p21(WAF1/CIP1) required for cell cycle arrest, nor the MDM2 gene. We also show that nuclear YB1 is associated with a failure to increase the level of the Bax protein in normal mammary epithelial cells after stress activation of p53. Together these data suggest that (nuclear) YB1 selectively alters p53 activity, which may in part provide an explanation for the correlation of nuclear YB1 with drug resistance and poor tumor prognosis.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin 9001, Otago, New Zealand; Univ Otago, Sch Med Sci, Dept Physiol, Dunedin, New Zealand; Genesis Res & Dev Corp Ltd, Auckland, New Zealand	University of Otago; University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin 9001, Otago, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz	Risk, Joanna/A-1998-2010					ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Chen CY, 2000, GENE DEV, V14, P1236; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Huschtscha LI, 1998, CANCER RES, V58, P3508; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Levenson VV, 2000, CANCER RES, V60, P5027; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Prives C, 1999, J PATHOL, V187, P112; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SAKURA H, 1988, GENE, V73, P499; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; SUTHERLAND BW, 2005, ADV ONLINE PUBLICATI; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	47	73	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8314	8325		10.1038/sj.onc.1208998	http://dx.doi.org/10.1038/sj.onc.1208998			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16158057				2022-12-28	WOS:000233956500010
J	Yang, XH; Liu, DH; Murray, TJ; Mitchell, GC; Hesterman, EV; Karchner, SI; Merson, RR; Hahn, ME; Sherr, DH				Yang, XH; Liu, DH; Murray, TJ; Mitchell, GC; Hesterman, EV; Karchner, SI; Merson, RR; Hahn, ME; Sherr, DH			The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cell	ONCOGENE			English	Review						aryl hydrocarbon receptor; c-Myc; mammary tumorigenesis	NF-KAPPA-B; BREAST-CANCER CELLS; AH RECEPTOR; AROMATIC-HYDROCARBON; ESTROGEN-RECEPTOR; GENE-EXPRESSION; RECEPTOR/TRANSCRIPTION FACTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; RETINOBLASTOMA PROTEIN; TRANSIENT EXPRESSION	The aryl hydrocarbon receptor (AhR) is an environmental carcinogen-activated transcription factor associated with tumorigenesis. High levels of apparently active AhR characterize a variety of tumors, even in the absence of environmental ligands. Despite this association between transformation and AhR upregulation, little is known of the transcriptional consequences of constitutive AhR activation. Here, the effects of constitutively active and environmental ligand-induced AhR on c-myc, an oncogene whose promoter contains six AhR-binding sites (AhREs (aryl hydrocarbon response elements)), were investigated. A reporter containing the human c-myc promoter, with its six AhREs and two NF-kappa B-binding sites, was constructed. This vector, and variants with deletions in the NF-kappa B and/or AhR-binding sites, was transfected into a human breast cancer cell line, Hs578T, which expresses high levels of apparently active, nuclear AhR. Results indicate that: (1) the AhR constitutively binds the c-myc promoter; (2) there is a low but significant baseline level of c-myc promoter activity, which is not regulated by NF-kappa B and is not affected by an environmental AhR ligand; (3) deletion of any one of the AhREs has no effect on constitutive reporter activity, while deletion of all six increases reporter activity approximately fivefold; (4) a similar increase in reporter activity occurs when constitutively active AhR is suppressed by transfection with an AhR repressor plasmid (AhRR); (5) AhRR transfection significantly increases background levels of endogenous c-myc mRNA and c-Myc protein. These results suggest that the AhR influences the expression of c-Myc, a protein critical to malignant transformation.	Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Furman Univ, Dept Biol, Greenville, SC 29613 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Boston University; Woods Hole Oceanographic Institution	Sherr, DH (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,R-408, Boston, MA 02118 USA.	dsherr@bu.edu	Hahn, Mark/AAV-7516-2020	Hahn, Mark/0000-0003-4358-2082; Sherr, David/0000-0003-3353-0553	NIEHS NIH HHS [P01-ES11624, P42-ES07381, R01-ES06086] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624, R01ES006086, P42ES007381] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Allan LL, 2005, MOL PHARMACOL, V67, P1740, DOI 10.1124/mol.104.009100; Baba T, 2001, J BIOL CHEM, V276, P33101, DOI 10.1074/jbc.M011497200; Beischlag TV, 2005, J BIOL CHEM, V280, P21607, DOI 10.1074/jbc.C500090200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Blaustein JD, 2004, ENDOCRINOLOGY, V145, P1075, DOI 10.1210/en.2003-1485; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Caruso JA, 2004, MOL PHARMACOL, V65, P1016, DOI 10.1124/mol.65.4.1016; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; CHEN HS, 1994, J BIOL CHEM, V269, P27554; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Chesire DR, 2004, CANCER RES, V64, P2523, DOI 10.1158/0008-5472.CAN-03-3309; CHRISTOU M, 1987, CARCINOGENESIS, V8, P73, DOI 10.1093/carcin/8.1.73; Corton JC, 1996, TOXICOL LETT, V85, P67, DOI 10.1016/0378-4274(96)03636-3; DANIEL FB, 1984, CARCINOGENESIS, V5, P1021, DOI 10.1093/carcin/5.8.1021; DAS SK, 1989, CANCER RES, V49, P920; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DEAN M, 1988, CURR TOP MICROBIOL, V141, P216; Dertinger SD, 2001, CARCINOGENESIS, V22, P171, DOI 10.1093/carcin/22.1.171; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fallone F, 2004, BIOCHEM BIOPH RES CO, V322, P551, DOI 10.1016/j.bbrc.2004.07.153; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Han D, 2004, BIOFACTORS, V20, P11, DOI 10.1002/biof.5520200102; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003; Ishibe N, 1998, CANCER RES, V58, P667; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Karchner SI, 2002, J BIOL CHEM, V277, P6949, DOI 10.1074/jbc.M110779200; KESSLER DJ, 1992, ONCOGENE, V7, P2447; Kikuchi Y, 2003, J BIOCHEM, V134, P83, DOI 10.1093/jb/mvg115; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Korkalainen M, 2004, BIOCHEM BIOPH RES CO, V315, P123, DOI 10.1016/j.bbrc.2004.01.028; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lai ZW, 1996, CHEM-BIOL INTERACT, V100, P97, DOI 10.1016/0009-2797(96)03691-5; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; LARSEN M, 1997, FUND APPL TOXICOL, V36, P24; Latil A, 2000, INT J CANCER, V89, P172; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Levine-Fridman A, 2004, MOL PHARMACOL, V65, P461, DOI 10.1124/mol.65.2.461; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liao DJ, 2003, LAB INVEST, V83, P1437, DOI 10.1097/01.LAB.0000090153.13977.AE; Liu CQ, 2003, J BIOL CHEM, V278, P44857, DOI 10.1074/jbc.M304489200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maecker B, 2003, BLOOD, V102, P3287, DOI 10.1182/blood-2003-05-1374; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marcus RS, 1998, J PHARMACOL EXP THER, V287, P1113; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; Negri E, 2003, EUR J CANCER PREV, V12, P509, DOI 10.1097/00008469-200312000-00010; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND AP, 1974, J BIOL CHEM, V249, P5599; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Rushing SR, 2002, ARCH BIOCHEM BIOPHYS, V403, P189, DOI 10.1016/S0003-9861(02)00233-3; RUSSO J, 1987, LAB INVEST, V57, P112; Ryu HY, 2003, J IMMUNOL, V170, P4897, DOI 10.4049/jimmunol.170.10.4897; SADEK CM, 1994, J BIOL CHEM, V269, P31505; Saez AI, 2003, LAB INVEST, V83, P143, DOI 10.1097/01.LAB.0000057000.41585.FD; Safe S, 1998, TOXICOL LETT, V103, P343; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Sulentic CEW, 2000, J PHARMACOL EXP THER, V295, P705; Sulentic CEW, 1998, MOL PHARMACOL, V53, P623, DOI 10.1124/mol.53.4.623; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; Thomsen JS, 2004, MOL PHARMACOL, V65, P165, DOI 10.1124/mol.65.1.165; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tohkin M, 2000, MOL PHARMACOL, V58, P845, DOI 10.1124/mol.58.4.845; Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670; Vaziri C, 1996, J BIOL CHEM, V271, P25921, DOI 10.1074/jbc.271.42.25921; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; Wang F, 2001, MOL CELL ENDOCRINOL, V172, P91, DOI 10.1016/S0303-7207(00)00379-8; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang WL, 1996, BRIT J CANCER, V73, P316, DOI 10.1038/bjc.1996.55; WANG XH, 1995, EUR J PHARM-ENVIRON, V293, P191, DOI 10.1016/S0922-4106(05)80044-6; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Watanabe T, 2001, J HUM GENET, V46, P342, DOI 10.1007/s100380170070; WEIGEL NL, 1995, J STEROID BIOCHEM, V53, P509, DOI 10.1016/0960-0760(95)00098-K; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Wu M, 1996, MOL CELL BIOL, V16, P5015; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322; Ziccardi MH, 2000, TOXICOL SCI, V54, P183, DOI 10.1093/toxsci/54.1.183; [No title captured]	119	63	72	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7869	7881		10.1038/sj.onc.1208938	http://dx.doi.org/10.1038/sj.onc.1208938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091746				2022-12-28	WOS:000233463000006
J	Greer, EL; Brunet, A				Greer, EL; Brunet, A			FOXO transcription factors at the interface between longevity and tumor suppression	ONCOGENE			English	Review						FOXO family of Forkhead transcription factors; longevity; tumor suppression; Akt; p53; SIRT1; stress stimuli	PROTEIN-KINASE-B; EXTENDS LIFE-SPAN; PAX3-FKHR FUSION PROTEIN; PROMOTES CELL-SURVIVAL; FACTOR AFX FOXO4; NF-KAPPA-B; CAENORHABDITIS-ELEGANS; FACTOR FKHR; OXIDATIVE STRESS; GENE-EXPRESSION	A wide range of human diseases, including cancer, has a striking age-dependent onset. However, the molecular mechanisms that connect aging and cancer are just beginning to be unraveled. FOXO transcription factors are promising candidates to serve as molecular links between longevity and tumor suppression. These factors are major substrates of the protein kinase Akt. In the presence of insulin and growth factors, FOXO proteins are relocalized from the nucleus to the cytoplasm and degraded via the ubiquitin-proteasome pathway. In the absence of growth factors, FOXO proteins translocate to the nucleus and upregulate a series of target genes, thereby promoting cell cycle arrest, stress resistance, or apoptosis. Stress stimuli also trigger the relocalization of FOXO factors into the nucleus, thus allowing an adaptive response to stress stimuli. Consistent with the notion that stress resistance is highly coupled with lifespan extension, activation of FOXO transcription factors in worms and flies increases longevity. Emerging evidence also suggests that FOXO factors play a tumor suppressor role in a variety of cancers. Thus, FOXO proteins translate environmental stimuli into changes in gene expression programs that may coordinate organismal longevity and tumor suppression.	Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, 300 Pasteur Dr,Alway M336, Stanford, CA 94305 USA.	anne.brunet@stanford.edu	Gimenez, Luis E Diaz/D-9291-2011	Greer, Eric/0000-0002-7501-7371	NCI NIH HHS [CA09302] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; DAVIS RJ, 1994, CANCER RES, V54, P2869; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaestner KH, 2000, GENE DEV, V14, P142; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; LEMIEUX ME, 2005, MECH AGEING DEV; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakae J, 2002, NAT GENET, V3, P3; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TANG TT, 2002, J BIOL CHEM, V2, P2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; VANDERHEIDE LP, 2005, BIOCH J; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Wessells RJ, 2004, NAT GENET, V36, P1275, DOI 10.1038/ng1476; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Xuan ZY, 2005, MECH AGEING DEV, V126, P209, DOI 10.1016/j.mad.2004.09.021; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; Zheng WH, 2002, J NEUROCHEM, V80, P1049, DOI 10.1046/j.0022-3042.2002.00783.x; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	133	1021	1068	4	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7410	7425		10.1038/sj.onc.1209086	http://dx.doi.org/10.1038/sj.onc.1209086			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288288				2022-12-28	WOS:000233201900004
J	Cismasiu, VB; Adamo, K; Gecewicz, J; Duque, J; Lin, QS; Avram, D				Cismasiu, VB; Adamo, K; Gecewicz, J; Duque, J; Lin, QS; Avram, D			BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter	ONCOGENE			English	Article						BCL11B; NuRD; transcriptional repression	METASTASIS-ASSOCIATED PROTEIN-1; ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REPRESSION; SIR2-ALPHA PROTEIN; CELL-FATE; P53; SUBUNIT; FAMILY; SIR2; GENE	BCL11 genes play crucial roles in lymphopoiesis and have been associated with hematopoietic malignancies. Specifically, disruption of the BCL11B (B-cell chronic lymphocytic leukemia/lymphoma 11B) locus is linked to T-cell acute lymphoblastic leukemia, and the loss of heterozygosity in mice results in T-cell lymphoma. BCL11 proteins are related C2H2 zinc-finger transcription factors that act as transcriptional repressors. Here, we demonstrate the association of the endogenous BCL11B with the nucleosome remodeling and histone deacetylase (NuRD) complex, one of the major transcriptional corepressor complexes in mammalian cells. BCL11B complexes from T lymphocytes possess trichostatin A-sensitive histone deacetylase activity, confirming the functionality of the complexes. Analysis of the BCL11B-NuRD association demonstrated that BCL11B directly interacted with the metastasis-associated proteins MTA1 and MTA2 through the amino-terminal region. We provide evidence for the functional requirement of MTA1 in transcriptional repression mediated by BCL11B through the following: (1) overexpression of MTA1 enhanced the transcriptional repression mediated by BCL11B, (2) knockdown of MTA1 expression by small interfering RNA inhibited BCL11B transcriptional repression activity and (3) MTA1 was specifically recruited to a BCL11B targeted promoter. Taken together, these data support the hypothesis that the NuRD complex mediates transcriptional repression function of BCL11B.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; SUNY Albany, Ctr Funct Genom, Rensselaer, NY 12144 USA	Albany Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Avram, D (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave MC 165, Albany, NY 12208 USA.	avramd@mail.amc.edu	Cismasiu, Valeriu Bogdan/F-1512-2011	Lin, Qishan/0000-0002-1756-1432	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002194] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01-AR02194] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Douagi I, 2002, SEMIN IMMUNOL, V14, P361, DOI 10.1016/S1044532302000702; Durum SK, 2003, NAT IMMUNOL, V4, P512, DOI 10.1038/ni0603-512; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Gururaja T, 2002, J PROTEOME RES, V1, P253, DOI 10.1021/pr0255147; HONG W, 2005, IN PRESS EMBO J; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Liberg D, 1999, CRIT REV IMMUNOL, V19, P127; Lin AC, 2004, J BIOL CHEM, V279, P55017, DOI 10.1074/jbc.M411240200; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McBurney MW, 2003, MOL CANCER RES, V1, P402; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Medina KL, 2005, CURR OPIN HEMATOL, V12, P203, DOI 10.1097/01.moh.0000160735.67596.a0; Miyazawa T, 2002, JPN J CANCER RES, V93, P994, DOI 10.1111/j.1349-7006.2002.tb02475.x; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Warren LA, 2003, CURR OPIN IMMUNOL, V15, P166, DOI 10.1016/S0952-7915(03)00011-6; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	58	127	133	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6753	6764		10.1038/sj.onc.1208904	http://dx.doi.org/10.1038/sj.onc.1208904			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16091750				2022-12-28	WOS:000232527800003
J	Wang, Y; Zhang, Z; Lubet, RA; You, M				Wang, Y; Zhang, Z; Lubet, RA; You, M			A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice	ONCOGENE			English	Article						lung; cancer; progression; ras; p53; transgenic mice	ONCOGENE ACTIVATION; SUPPRESSOR GENE; LIVER-TUMORS; MUTATIONS; PROTOONCOGENE; ADENOCARCINOMAS; ABSENCE; A/J; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; PREDISPOSITION	Although ras and p53 are the most commonly found oncogene and tumor suppressor gene, respectively, in human cancers, their collective roles in tumor progression have yet to be defined in animal models. Here, we demonstrated the synergistic effect between ras and p53 in promoting tumor progression during lung tumorigenesis using bitransgenic mice. Mice with a heterozygous knockout of K-ras (K-ras(wt/ko)) were mated to p53 transgenic mice (p53(val135/wt)) in lung tumorigenesis ( K-ras(wt/ko) x p53(val135/wt)). F-1 mice exhibited a significant increase in lung tumor load (tumor multiplicity x tumor volume) when compared to those seen in either K-ras(wt/ko) mice or p53(val135/wt) mice alone. Furthermore, over 50% of the lung tumors were lung adenocarcinomas in bitransgenic mice compared to only 3% in wild-type mice. Alterations of ras and p53 appear to promote the development of lung adenocarcinomas. These results provide the in vivo experimental evidence of synergistic interactions of ras and p53 in lung tumor progression.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Chemoprevent Branch, Bethesda, MD USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78797, R01CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CANDRIAN U, 1991, CANCER RES, V51, P1148; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; Diaz R, 2004, CARCINOGENESIS, V25, P535, DOI 10.1093/carcin/bgh026; Diaz R, 2002, CANCER RES, V62, P4514; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Herzog CR, 1997, J CELL BIOCHEM, P49; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Hwang SJ, 2003, HUM GENET, V113, P238, DOI 10.1007/s00439-003-0968-7; James RM, 2003, MOL CANCER RES, V1, P820; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lubet R, 2005, EXP LUNG RES, V31, P117, DOI 10.1080/01902140490495499; Lubet RA, 2000, EXP LUNG RES, V26, P581, DOI 10.1080/01902140150216684; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; Thompson TA, 2002, ONCOGENE, V21, P2797, DOI 10.1038/sj.onc.1205391; Vachtenheim J, 1997, NEOPLASMA, V44, P145; Wang Y, 2003, CANCER RES, V63, P4389; WANG Y, 1993, CANCER RES, V53, P1620; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; WESTRA WH, 1993, AM J SURG PATHOL, V17, P213, DOI 10.1097/00000478-199303000-00001; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1991, EXP LUNG RES, V17, P389, DOI 10.3109/01902149109064426; YOU M, 1993, CARCINOGENESIS, V14, P1247, DOI 10.1093/carcin/14.6.1247; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, ONCOGENE, V22, P6257, DOI 10.1038/sj.onc.1206630; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024	40	15	16	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1277	1280		10.1038/sj.onc.1209182	http://dx.doi.org/10.1038/sj.onc.1209182			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247444				2022-12-28	WOS:000235537500015
J	Goncalves, A; Esterni, B; Bertucci, F; Sauvan, R; Chabannon, C; Cubizolles, M; Bardou, VJ; Houvenaegel, G; Jacquemier, J; Granjeaud, S; Meng, XY; Fung, ET; Birnbaum, D; Maraninchi, D; Viens, P; Borg, JP				Goncalves, A; Esterni, B; Bertucci, F; Sauvan, R; Chabannon, C; Cubizolles, M; Bardou, VJ; Houvenaegel, G; Jacquemier, J; Granjeaud, S; Meng, XY; Fung, ET; Birnbaum, D; Maraninchi, D; Viens, P; Borg, JP			Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy	ONCOGENE			English	Article						proteomics; breast cancer; prognosis; chemotherapy; SELDI-TOF MS; serum profiling	PARTIAL LEAST-SQUARES; TUMOR CLASSIFICATION; CELL-MIGRATION; BIOMARKERS; GROWTH; IDENTIFICATION; HAPTOGLOBIN; DISCOVERY; DIAGNOSIS; VARIANTS	A total of 30 - 50% of early breast cancer ( EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite standard adjuvant systemic treatment. A means to better predict clinical outcome is needed to optimize and individualize therapeutic decisions. To identify a protein signature correlating with metastatic relapse, we performed surface-enhanced laser desorption/ionization-time of flight mass spectrometry profiling of early postoperative serum from 81 high-risk EBC patients. Denatured and fractionated serum samples were incubated with IMAC30 and CM10 ProteinChip arrays. Several protein peaks were differentially expressed according to clinical outcome. By combining partial least squares and logistic regression methods, we built a multiprotein model that correctly predicted outcome in 83% of patients. The 5-year metastasis-free survival in 'good prognosis' and 'poor prognosis' patients as defined using the multiprotein index were strikingly different ( 83 and 22%, respectively; P < 0.0001, log-rank test). In a multivariate Cox regression including conventional pathological factors and multiprotein index, the latter retained the strongest independent prognostic significance for metastatic relapse. Major components of the multiprotein index included haptoglobin, C3a complement fraction, transferrin, apolipoprotein C1 and apolipoprotein A1. Therefore, postoperative serum protein pattern may have an important prognostic value in high-risk EBC.	Inst J Paoli I Calmettes, Dept Med Oncol, INSERM, UMR599, F-13273 Marseille 9, France; Inst J Paoli I Calmettes, Dept Mol Pharmacol, UMR599, INSERM, F-13009 Marseille, France; Univ Mediterranee, UFR Med, Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Biol Resource Ctr, UMR599, INSERM, F-13009 Marseille, France; Ciphergen Biosyst, Fremont, CA USA; Inst J Paoli I Calmettes, Dept Pathol, UMR599, INSERM, F-13009 Marseille, France; INSERM, ERM 206, TAGC, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Goncalves, A (corresponding author), Inst J Paoli I Calmettes, Dept Med Oncol, INSERM, UMR599, 273 Blvd St Marguerite, F-13273 Marseille 9, France.	goncalvesa@marseille.fnclcc.fr	Cubizolles, Myriam/AAZ-7719-2021; Borg, Jean-Paul/AAX-8096-2020; Granjeaud, Samuel/AAE-6488-2022	Borg, Jean-Paul/0000-0001-8418-3382; Granjeaud, Samuel/0000-0001-9245-1535				Abe O, 1998, LANCET, V352, P930; Adam BL, 2002, CANCER RES, V62, P3609; Ahmed N, 2004, BRIT J CANCER, V91, P129, DOI 10.1038/sj.bjc.6601882; Antoniadis A, 2003, BIOINFORMATICS, V19, P563, DOI 10.1093/bioinformatics/btg062; Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bharti A, 2004, ANTICANCER RES, V24, P1031; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cavanaugh PG, 1998, J CELL PHYSIOL, V174, P48, DOI 10.1002/(SICI)1097-4652(199801)174:1<48::AID-JCP6>3.0.CO;2-G; Cavanaugh PG, 1999, BREAST CANCER RES TR, V56, P203; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COX DR, 1972, J R STAT SOC B, V34, P187; de Kleijn DPV, 2002, FASEB J, V16, P1123, DOI 10.1096/fj.02-0019fje; Demicheli R, 1997, ANN ONCOL, V8, P1075, DOI 10.1023/A:1008263116022; Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; FISHER B, 1989, CANCER RES, V49, P1996; Fung ET, 2005, INT J CANCER, V115, P783, DOI 10.1002/ijc.20928; Fung ET, 2001, CURR OPIN BIOTECH, V12, P65, DOI 10.1016/S0958-1669(00)00167-1; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Koopmann J, 2004, CLIN CANCER RES, V10, P860, DOI 10.1158/1078-0432.CCR-1167-3; Kozak KR, 2003, P NATL ACAD SCI USA, V100, P12343, DOI 10.1073/pnas.2033602100; Kwak JY, 2004, EXP HEMATOL, V32, P836, DOI 10.1016/j.exphem.2004.06.006; NABHOLTZ JM, 2002, P ASCO, V21, P141; Nguyen DV, 2002, BIOINFORMATICS, V18, P1216, DOI 10.1093/bioinformatics/18.9.1216; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; NICOLSON GL, 1992, J NATL CANCER I MONO, V13, P153; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Rozanov DV, 2004, J BIOL CHEM, V279, P46551, DOI 10.1074/jbc.M405284200; Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Tolson J, 2004, LAB INVEST, V84, P845, DOI 10.1038/labinvest.3700097; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Vlahou Antonia, 2003, Clin Breast Cancer, V4, P203, DOI 10.3816/CBC.2003.n.026; Wadsworth JT, 2004, CLIN CANCER RES, V10, P1625, DOI 10.1158/1078-0432.CCR-0297-3; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746	50	95	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					981	989		10.1038/sj.onc.1209131	http://dx.doi.org/10.1038/sj.onc.1209131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16186794				2022-12-28	WOS:000235361000003
J	Ivanova, IA; D'Souza, SJA; Dagnino, L				Ivanova, IA; D'Souza, SJA; Dagnino, L			E2F1 stability is regulated by a novel-PKC/p38 beta MAP kinase signaling pathway during keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation	ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; EPIDERMAL-KERATINOCYTES; MESSENGER-RNA; DEGRADATION; DELTA; RETINOBLASTOMA; GROWTH; PROLIFERATION; EXPRESSION	E2F transcription factors regulate proliferation, differentiation, DNA repair and apoptosis. Tight E2F regulation is crucial for epidermal formation and regeneration. However, virtually nothing is known about the molecular events modulating E2F during epidermal keratinocyte differentiation. Elucidation of these events is essential to understand epidermal morphogenesis, transformation and repair. Here we show that, in differentiating keratinocytes, Ca2(+) -induced protein kinase C (PKC) activation downregulates E2F1 protein levels. Further, we have identified PKC delta and eta as those isoforms specifically involved in induction of E2F1 proteasomal degradation. We also demonstrate that E2F1 downregulation by novel PKC isozymes requires activation of p38 beta mitogenactivated protein kinase ( MAPK). This is the first example of regulation in the E2F transcription factor family by activation of PKC and MAPK in the context of biologically significant differentiation stimuli in epithelia.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Alt A, 2001, CANCER RES, V61, P4591; Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Cazzolli R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1204, DOI 10.1152/ajpendo.00487.2001; Chang WY, 2004, J BIOL CHEM, V279, P51343, DOI 10.1074/jbc.M408635200; Chida K, 2003, CANCER RES, V63, P2404; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Koster MI, 2004, EUR J CELL BIOL, V83, P625, DOI 10.1078/0171-9335-00387; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Li LW, 1999, MOL CELL BIOL, V19, P8547; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Penuelas S, 2003, EUR J BIOCHEM, V270, P4809, DOI 10.1046/j.1432-1033.2003.03874.x; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; Romanova LY, 1998, BIOCHEMISTRY-US, V37, P5558, DOI 10.1021/bi9731807; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280	44	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					430	437		10.1038/sj.onc.1208999	http://dx.doi.org/10.1038/sj.onc.1208999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16116476				2022-12-28	WOS:000234714100011
J	Koinuma, K; Yamashita, Y; Liu, W; Hatanaka, H; Kurashina, K; Wada, T; Takada, S; Kaneda, R; Choi, YL; Fujiwara, SI; Miyakura, Y; Nagai, H; Mano, H				Koinuma, K; Yamashita, Y; Liu, W; Hatanaka, H; Kurashina, K; Wada, T; Takada, S; Kaneda, R; Choi, YL; Fujiwara, SI; Miyakura, Y; Nagai, H; Mano, H			Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability	ONCOGENE			English	Article						epigenetics; colorectal carcinoma; microsatellite instability; AXIN2; MLH1	ISLAND METHYLATOR PHENOTYPE; ADENOMATOUS-POLYPOSIS-COLI; BETA-CATENIN; MISMATCH REPAIR; HMLH1 PROMOTER; DNA METHYLATION; CELL-LINES; CANCER; MUTATIONS; HOMOLOG	Mutation or epigenetic silencing of mismatch repair genes, such as MLH1 and MSH2, results in microsatellite instability (MSI) in the genome of a subset of colorectal carcinomas (CRCs). However, little is yet known of genes that directly contribute to tumor formation in such cancers. To characterize MSI-dependent changes in gene expression, we have now compared transcriptomes between fresh CRC specimens positive or negative for MSI (n= 10 for each) with the use of high-density oligonucleotide microarrays harboring > 44 000 probe sets. Correspondence analysis of the expression patterns of isolated MSI-associated genes revealed that the transcriptome of MSI+ CRCs is clearly distinct from that of MSI- CRCs. Such MSI-associated genes included that for AXIN2, an important component of the WNT signaling pathway. AXIN2 was silenced, apparen tly as a result of extensive methylation of its promoter region, specifi. cally in MSI+ CRC specimens. Forced expression of AXIN2, either by treatment with 50 '-azacytidine or by transfection with AXIN2 cDNA, resul ted in rapid cell death in an MSI+ CRC cell line. These data indicate that epigenetic silencing of AXIN2 is specifically associated with carcinogenesis in MSI+ CRCs.	Jichi Med Sch, Div Funct Genom, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Surg, Minami Kawachi, Tochigi 3290498, Japan; Mayo Clin & Mayo Grad Sch Med, Div Expt Pathol, Rochester, MN USA	Jichi Medical University; Jichi Medical University; Mayo Clinic	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Fujiwara, Shin-ichiro/ABH-2030-2020	Fujiwara, Shin-ichiro/0000-0002-4523-2994; Takada, Shuji/0000-0002-9406-4683				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cunningham JM, 1998, CANCER RES, V58, P3455; Esteller M, 2000, CANCER RES, V60, P4366; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Ohki-Kaneda R, 2004, BIOCHEM BIOPH RES CO, V320, P1328, DOI 10.1016/j.bbrc.2004.06.090; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Wu R, 2001, CANCER RES, V61, P8247; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Zysman M, 2002, CANCER RES, V62, P3663	34	77	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					139	146		10.1038/sj.onc.1209009	http://dx.doi.org/10.1038/sj.onc.1209009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247484				2022-12-28	WOS:000234406400015
J	Ota, H; Tokunaga, E; Chang, K; Hikasa, M; Iijima, K; Eto, M; Kozaki, K; Akishita, M; Ouchi, Y; Kaneki, M				Ota, H; Tokunaga, E; Chang, K; Hikasa, M; Iijima, K; Eto, M; Kozaki, K; Akishita, M; Ouchi, Y; Kaneki, M			Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells	ONCOGENE			English	Article						Sirt1; sirtinol; cellular senescence; Ras; MAPK; Akt/PKB	HISTONE DEACETYLASE INHIBITORS; TERMINAL PROLIFERATION ARREST; CELLULAR SENESCENCE; TUMOR-CELLS; HUMAN-FIBROBLASTS; IN-VIVO; DEPSIPEPTIDE FR901228; TRANSCRIPTION FACTORS; PROTEIN DEACETYLASES; PC12 CELLS	The induction of senescence-like growth arrest has emerged as a putative contributor to the anticancer effects of chemotherapeutic agents. Clinical trials are underway to evaluate the efficacy of inhibitors for class I and II histone deacetylases to treat malignancies. However, a potential antiproliferative effect of inhibitor for Sirt1, which is an NAD(+)-dependent deacetylase and belongs to class III histone deacetylases, has not yet been explored. Here, we show that Sirt1 inhibitor, Sirtinol, induced senescence-like growth arrest characterized by induction of senescence-associated beta-galactosidase activity and increased expression of plasminogen activator inhibitor 1 in human breast cancer MCF-7 cells and lung cancer H1299 cells. Sirtinol-induced senescence-like growth arrest was accompanied by impaired activation of mitogen-activated protein kinase ( MAPK) pathways, namely, extracellular-regulated protein kinase, c-jun N-terminal kinase and p38 MAPK, in response to epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I). Active Ras was reduced in Sirtinol-treated senescent cells compared with untreated cells. However, tyrosine phosphorylation of the receptors for EGF and IGF-I and Akt/PKB activation were unaltered by Sirtinol treatment. These results suggest that inhibitors for Sirt1 may have anticancer potential, and that impaired activation of Ras-MAPK pathway might take part in a senescence-like growth arrest program induced by Sirtinol.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan; Shriners Hosp Children, Boston, MA USA	Harvard University; Massachusetts General Hospital; University of Tokyo	Kaneki, M (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 149 13th St,Rm 6604, Charlestown, MA 02129 USA.	mkaneki@partners.org		Eto, Masato/0000-0002-6036-3431	NIDDK NIH HHS [R01DK058127] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058127] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Aviv H, 2001, ATHEROSCLEROSIS, V159, P281, DOI 10.1016/S0021-9150(01)00506-8; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Christov KT, 2003, EUR J CANCER, V39, P230, DOI 10.1016/S0959-8049(02)00497-5; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elegbede JA, 2002, LIFE SCI, V71, P421; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; Kahlem P, 2004, J CLIN INVEST, V113, P169, DOI 10.1172/JCI200420784; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kim JH, 2003, BIOCHEM J, V373, P523, DOI 10.1042/BJ20030363; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; McLaughlin Fiona, 2004, Current Drug Targets - Inflammation and Allergy, V3, P213, DOI 10.2174/1568010043343859; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Munro J, 2004, EXP CELL RES, V295, P525, DOI 10.1016/j.yexcr.2004.01.017; Pelicci PG, 2004, J CLIN INVEST, V113, P4, DOI 10.1172/JCI200420750; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2002, DRUG RESIST UPDATE, V5, P204, DOI 10.1016/S1368764602001103; Rosato RR, 2004, EXPERT OPIN INV DRUG, V13, P21, DOI 10.1517/eoid.13.1.21.25283; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Sandor V, 2002, CLIN CANCER RES, V8, P718; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sugita H, 2005, J BIOL CHEM, V280, P14203, DOI 10.1074/jbc.M411226200; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; te Poele RH, 2002, CANCER RES, V62, P1876; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; Tresini M, 2001, EXP CELL RES, V269, P287, DOI 10.1006/excr.2001.5334; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vigushin DM, 2004, CURR CANCER DRUG TAR, V4, P205, DOI 10.2174/1568009043481560; Wagner M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wang XH, 2003, CURR CANCER DRUG TAR, V3, P153, DOI 10.2174/1568009033482001; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	67	348	369	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					176	185		10.1038/sj.onc.1209049	http://dx.doi.org/10.1038/sj.onc.1209049			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170353				2022-12-28	WOS:000234583600002
J	Taylor, JR; Brownlow, N; Domin, J; Dibb, NJ				Taylor, JR; Brownlow, N; Domin, J; Dibb, NJ			FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance	ONCOGENE			English	Article						imatinib; FMS; CSF-1; M-CSF; D802V; v-fms	PROTO-ONCOGENE PRODUCT; CELL-LINE FDC-P1; C-FMS; TYROSINE KINASE; GROWTH-FACTOR; ACTIVATING MUTATIONS; LUNG-CANCER; WILD-TYPE; IN-VITRO; STI-571 INHIBITION	The kinase inhibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets either the KIT or PDGF tyrosine kinase receptors. Here, we report that imatinib is also an effective inhibitor of the closely related FMS receptor for macrophage colony stimulating factor and that mutation of Asp 802 of FMS to Val confers imatinib resistance. Imatinib readily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the oncogene v-fms and also inhibited the growth of the Bacl. 2F5 macrophage cell line. The cellular IC50 value of imatinib for FMS was similar to those for Bcr-Abl and KIT. Consequently, imatinib may also prove effective for the treatment of diseases whose progression is dependent upon macrophage-colony stimulating factor, this includes certain aspects of cancer and inflammation.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Div Med, London W12 0NN, England	Imperial College London; Imperial College London	Dibb, NJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	n.dibb@imperial.ac.uk	Taylor, James R/F-7960-2014; brownlow, nicola/H-6826-2015	brownlow, nicola/0000-0003-4733-9960				Aldskogius H., 2001, EXPER OPIN THER TAR, V5, P655; BAKER DA, 1994, LEUKEMIA, V8, P141; Bohmer FD, 2003, J BIOL CHEM, V278, P5148, DOI 10.1074/jbc.M209861200; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; CARUANA G, 1993, EXP HEMATOL, V21, P761; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood-2004-10-3967; Dewar AL, 2003, LEUKEMIA, V17, P1713, DOI 10.1038/sj.leu.2403071; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Frost MJ, 2002, MOL CANCER THER, V1, P1115; GLOVER HR, 1995, ONCOGENE, V11, P1347; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Morley GM, 1999, ONCOGENE, V18, P3076, DOI 10.1038/sj.onc.1202646; Mundy GR, 2002, ANNU REV MED, V53, P337, DOI 10.1146/annurev.med.53.082901.104047; Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pollard JW, 1997, MOL REPROD DEV, V46, P54, DOI 10.1002/(SICI)1098-2795(199701)46:1&lt;54::AID-MRD9&gt;3.0.CO;2-Q; Pollard JW, 1997, MOL REPROD DEV, V46, P60; Reilly JT, 2002, BRIT J HAEMATOL, V116, P744, DOI 10.1046/j.0007-1048.2001.03294.x; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Sweet MJ, 2003, ARCH IMMUNOL THER EX, V51, P169; Uden M, 1999, ONCOGENE, V18, P3846, DOI 10.1038/sj.onc.1202743; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	44	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					147	151		10.1038/sj.onc.1209007	http://dx.doi.org/10.1038/sj.onc.1209007			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170366				2022-12-28	WOS:000234406400016
J	Bharadwaj, S; Thanawala, R; Bon, G; Falcioni, R; Prasad, GL				Bharadwaj, S; Thanawala, R; Bon, G; Falcioni, R; Prasad, GL			Resensitization of breast cancer cells to anoikis by Tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion	ONCOGENE			English	Article						cytoskeleton; breast cancer; anoikis; adhesion; integrins; Rho kinase signaling; tropomyosin	INTESTINAL EPITHELIAL-CELLS; ABL TYROSINE KINASE; FOCAL ADHESIONS; TRANSFORMED PHENOTYPE; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; ACTIN DYNAMICS; STRESS FIBERS; SUBCELLULAR-LOCALIZATION; HOST MICROENVIRONMENT	Two most common properties of malignant cells are the presence of aberrant actin cytoskeleton and resistance to anoikis. Suppression of several key cytoskeletal proteins, including tropomyosin-1 (TM1), during neoplastic transformation is hypothesized to contribute to the altered cytoskeleton and neoplastic phenotype. Using TM1 as a paradigm, we have shown that cytoskeletal proteins induce anoikis in breast cancer (MCF-7 and MDA MB 231) cells. Here, we have tested the hypothesis that TM1-mediated cytoskeletal changes regulate integrin activity and the sensitivity to anoikis. TM1 expression in MDA MB 231 cells promotes the assembly of stress fibers, induces rapid anoikis via caspase-dependent pathways involving the release of cytochrome c. Further, TM1 inhibits binding of MDA MB 231 cells to collagen I, but promotes adhesion to laminin. Inhibition of Rho kinase disrupts TM1-mediated cytoskeletal reorganization and adhesion to the extracellular matrix components, whereas the parental cells attach to collagen I, spread and form extensive actin meshwork in the presence of Rho kinase inhibitor, underscoring the differences in parental and TM1-transduced breast cancer cells. Further, treatment with the cytoskeletal disrupting drugs rescues the cells from TM1-induced anoikis. These new findings demonstrate that the aberrant cytoskeleton contributes to neoplastic transformation by conferring resistance to anoikis. Restoration of stress fiber network through enhanced expression of key cytoskeletal proteins may modulate the activity of focal adhesions and sensitize the neoplastic cells to anoikis.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	Wake Forest University; Wake Forest Baptist Medical Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gprasad@wfubmc.edu	Falcioni, Rita/H-8869-2017; Bon, Giulia/ABH-6498-2020	Falcioni, Rita/0000-0002-3745-4327; Bon, Giulia/0000-0002-5409-5864	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alford D, 1998, BIOCHEM SOC SYMP, P245; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 2001, J CELL BIOL, V155, P187, DOI 10.1083/jcb.200107116; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Bharadwaj S, 2004, J BIOL CHEM, V279, P14039, DOI 10.1074/jbc.M310934200; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Braverman RH, 1996, ONCOGENE, V13, P537; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caruso DA, 2001, CELL DEATH DIFFER, V8, P665, DOI 10.1038/sj.cdd.4400865; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Chrenek MA, 2001, BREAST CANCER RES, V3, P224, DOI 10.1186/bcr300; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chung J, 2004, CANCER RES, V64, P4711, DOI 10.1158/0008-5472.CAN-04-0347; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Davies MA, 1998, CANCER RES, V58, P5285; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FALCIONI R, 1988, CANCER RES, V48, P816; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Janes SM, 2004, J CELL BIOL, V166, P419, DOI 10.1083/jcb.200312074; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MAEMURA M, 1995, CLIN EXP METASTAS, V13, P223, DOI 10.1007/BF00133478; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Marco RAW, 2003, J CELL BIOCHEM, V88, P1038, DOI 10.1002/jcb.10465; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Park HB, 2004, BIOCHEM J, V378, P559, DOI 10.1042/BJ20031392; Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Swan EA, 2003, ORAL ONCOL, V39, P648, DOI 10.1016/S1368-8375(03)00049-6; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	86	67	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8291	8303		10.1038/sj.onc.1208993	http://dx.doi.org/10.1038/sj.onc.1208993			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170368				2022-12-28	WOS:000233956500008
J	Christmann, M; Tomicic, MT; Origer, J; Kaina, B				Christmann, M; Tomicic, MT; Origer, J; Kaina, B			Fen1 is induced p53 dependently and involved in the recovery from UV- light-induced replication inhibition	ONCOGENE			English	Article						DNA repair; inducible response; UV sensitivity	REPAIR PROTEINS MSH2; BASE EXCISION-REPAIR; DNA-DAMAGE; FLAP ENDONUCLEASE-1; C-FOS; MOUSE CELLS; S-PHASE; PHOSPHORYLATION; RADIATION; FIBROBLASTS	Mouse embryonic fibroblasts (MEFs) that lack p53 are hypersensitive to the cytotoxic and genotoxic effect of ultraviolet (UV-C) light. They also display a defect in the recovery from UV-C-induced DNA replication inhibition. An enzyme involved in processing stalled DNA replication forks is flap endonuclease 1 (Fen1). Gene expression pro. ling of UV-C-irradiated MEFs revealed fen1 to be upregulated, which was confirmed by RT-PCR and Western blot experiments. Increased Fen1 levels upon UV-C exposure are due to transcriptional activation, as revealed by inhibitor studies. Fen1 induction was dose- and time-dependent; it occurred on protein level already 3 h after irradiation. Induction of Fen1 by UV-C requires p53 since it was observed in p53 wild-type (wt) but not in p53 null (p53-/-) fibroblasts. Fen1 upregulation paralleled the increase in p53 protein level in replicating wt cells, whereas in nonreplicating cells both Fen1 and p53 were not induced by UV-C. The mouse fen1 promoter was cloned and shown to harbor a p53 consensus sequence to which p53 binds. In cotransfection experiments, p53 stimulated the expression of a fen1 promoter-reporter construct. Transgenic expression of Fen1 in p53 null cells attenuated UV-C light-induced DNA replication inhibition, supporting the hypothesis that Fen1 induction is involved in the recovery of cells from DNA damage.	Univ Mainz, Dept Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Kaina, Bernd/AAE-4692-2020; Tomicic, Maja/S-1377-2019	Tomicic, Maja/0000-0001-9289-4168				Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Christmann M, 2002, NUCLEIC ACIDS RES, V30, P1959, DOI 10.1093/nar/30.9.1959; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Cistulli CA, 1998, CANCER RES, V58, P1993; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hawkins DS, 1996, CANCER RES, V56, P892; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim IS, 1998, EXP MOL MED, V30, P252, DOI 10.1038/emm.1998.37; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ruggiero BL, 2004, J BIOL CHEM, V279, P23088, DOI 10.1074/jbc.M313170200; Rumbaugh JA, 1999, J BIOL CHEM, V274, P14602, DOI 10.1074/jbc.274.21.14602; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shi BS, 2001, ACTA BIOCH BIOPH SIN, V33, P309; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Tomicic MT, 2003, MOL PHARMACOL, V63, P439, DOI 10.1124/mol.63.2.439; Warbrick E, 1998, J PATHOL, V186, P319; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313	36	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8304	8313		10.1038/sj.onc.1208994	http://dx.doi.org/10.1038/sj.onc.1208994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103874				2022-12-28	WOS:000233956500009
J	Beiter, K; Hiendlmeyer, E; Brabletz, T; Hlubek, F; Haynl, A; Knoll, C; Kirchner, T; Jung, A				Beiter, K; Hiendlmeyer, E; Brabletz, T; Hlubek, F; Haynl, A; Knoll, C; Kirchner, T; Jung, A			beta-Catenin regulates the expression of tenascin-C in human colorectal tumors	ONCOGENE			English	Article						beta-catenin; tenascin-C; Wnt signalling; colorectal cancer	INVASION FRONT; CANCER; CELLS; TRANSCRIPTION; GASTRULATION; TARGET	Tenascin-C (TN-C) is a component of the extracellular matrix (ECM). It is expressed during development and re-expressed in many types of cancers, where it is involved in the modulation of adhesion and proliferation. TN-C expression is especially high at sites of epithelial mesenchymal transition (EMT), which are found frequently at the invasion front of well-differentiated human colorectal adenocarcinomas. Tumor cells in this compartment are characterized by a strong nuclear expression of the oncogenic transcription factor beta-catenin. Here, we demonstrate that TN-C is a beta-catenin target gene in human colorectal tumors. Thus, by far the most common mutations in colorectal tumors, found in the Wnt-signaling pathway and leading to the stabilizing of beta-catenin, might influence invasion by altering adhesive properties and EMT of tumor cells.	Univ Erlangen Nurnberg, Inst Pathol Anat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Jung, A (corresponding author), Univ Erlangen Nurnberg, Inst Pathol Anat, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	andreas.jung@patho.imed.uni-erlangen.de						Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Kodjabachian L, 1999, DEV BIOL, V213, P231, DOI 10.1006/dbio.1999.9392; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Verma UN, 2003, CLIN CANCER RES, V9, P1291	22	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8200	8204		10.1038/sj.onc.1208960	http://dx.doi.org/10.1038/sj.onc.1208960			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091738				2022-12-28	WOS:000233809400011
J	Katuri, V; Tang, Y; Marshall, B; Rashid, A; Jogunoori, W; Volpe, EA; Sidawy, AN; Evans, S; Blay, J; Gallicano, GI; Reddy, EA; Mishra, L; Mishra, B				Katuri, V; Tang, Y; Marshall, B; Rashid, A; Jogunoori, W; Volpe, EA; Sidawy, AN; Evans, S; Blay, J; Gallicano, GI; Reddy, EA; Mishra, L; Mishra, B			Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer	ONCOGENE			English	Article						TGF-beta; ELF; Smad4; gastric cancer; E-cadherin; cell adhesion	GROWTH-FACTOR-BETA; E-CADHERIN EXPRESSION; CELL-CELL ADHESION; TGF-BETA; GASTRIC-CANCER; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; MESENCHYMAL TRANSITION; LIVER DEVELOPMENT; GENE-EXPRESSION	TGF-beta/Smads regulate a wide variety of biological responses through transcriptional regulation of target genes. ELF, a beta-spectrin, plays a key role in the transmission of TGF-beta-mediated transcriptional response through Smads. ELF was originally identified as a key protein involved in endodermal stem/progenitor cells committed to foregut lineage. Also, as a major dynamic adaptor and scaffolding protein, ELF is important for the generation of functionally distinct membranes, protein sorting and the development of polarized differentiated epithelial cells. Disruption of elf results in the loss of Smad3/Smad4 activation and, there fore, a disruption of the TGF-beta pathway. These observations led us to pursue the function of ELF in gastrointestinal (GI) epithelial cell-cell adhesion and tumor suppression. Here, we show a significant loss of ELF and reduced Smad4 expression in human gastric cancer tissue samples. Also, of the six human gastric cancer cell lines examined, three show deficient ELF expression. Furthermore, we demonstrate the rescue of E-cadherin-dependent homophilic cell-cell adhesion by ectopic expression of full-length elf. Our results suggest that ELF has an essential role in tumor suppression in GI cancers.	Georgetown Univ, Dept Surg Sci, Lombardi Canc Ctr, Lab Dev Mol Biol, Washington, DC 20007 USA; Dept Vet Affairs Med Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Surg, Washington, DC 20007 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4R2, Canada; Georgetown Univ, Dept Cell Biol, Washington, DC 20007 USA; Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Georgetown University; Georgetown University; University of Texas System; UTMD Anderson Cancer Center; Dalhousie University; Georgetown University	Mishra, L (corresponding author), Georgetown Univ, Dept Surg Sci, Lombardi Canc Ctr, Lab Dev Mol Biol, Med Dent Bldg NW 210-213,3900 Reservoir Rd, Washington, DC 20007 USA.	lm229@georgeown.edu; bm72@georgetown.edu	Reddy, E. Premkumar/F-6233-2011; Volpe, Eugene A./D-2000-2012; Blay, Jean-Yves/N-3966-2016	Volpe, Eugene A./0000-0002-9128-754X; Blay, Jean-Yves/0000-0001-7190-120X; Mishra, Lopa/0000-0002-6850-0808				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Behrens J, 1992, Semin Cell Biol, V3, P169; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; DORUDI S, 1993, AM J PATHOL, V142, P981; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GAMALLO C, 1993, AM J PATHOL, V142, P987; Goggins M, 1998, CANCER RES, V58, P5329; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Goodman KJ, 2001, EPIDEMIOLOGY, V12, P266, DOI 10.1097/00001648-200103000-00023; Grady WM, 1999, CANCER RES, V59, P320; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hippo Y, 2002, CANCER RES, V62, P233; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; Lin WC, 2000, ONCOGENE, V19, P5680, DOI 10.1038/sj.onc.1203924; MA TY, 1993, J LAB CLIN MED, V122, P590; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, CANCER RES, V59, P4506; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Murray PG, 1996, J PATHOL, V178, P44, DOI 10.1002/(SICI)1096-9896(199601)178:1<44::AID-PATH471>3.0.CO;2-0; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; Pepper I, 1997, REV MED CHILE, V125, P107; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Powell SM, 1997, CANCER RES, V57, P4221; ROBERTS AB, 1990, TRANSFORMING GROWTH; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Schutte M, 1996, CANCER RES, V56, P2527; Setiawan VW, 2001, CANCER CAUSE CONTROL, V12, P673, DOI 10.1023/A:1011261602940; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sporn MB, 1999, MICROBES INFECT, V1, P1251, DOI 10.1016/S1286-4579(99)00260-9; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UCHINO S, 1992, CANCER RES, V52, P3099; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; Werner M, 2001, J CANCER RES CLIN, V127, P207, DOI 10.1007/s004320000195; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zhang QP, 2001, J CELL SCI, V114, P4485; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	68	32	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8012	8024		10.1038/sj.onc.1208946	http://dx.doi.org/10.1038/sj.onc.1208946			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16158060				2022-12-28	WOS:000233656600008
J	Henderson, CC; Zhang, ZQ; Manson, SR; Riehm, JJ; Kataoka, M; Flye, MW; Garbow, JR; You, M; Weintraub, SJ				Henderson, CC; Zhang, ZQ; Manson, SR; Riehm, JJ; Kataoka, M; Flye, MW; Garbow, JR; You, M; Weintraub, SJ			A moderate reduction of Bcl-X-L expression protects against tumorigenesis; however, it also increases susceptibility to tissue injury	ONCOGENE			English	Article						Bcl-X-L; lung cancer; tumorigenesis; carcinogen; apoptosis; tissue injury	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; HEPATOCYTE APOPTOSIS; MEDIATED APOPTOSIS; LIVER-INJURY; INDUCTION; ALCOHOL; DEATH; INTERLEUKIN-6	Little consideration has been given to the possibility that there could be variations in protein expression that alter susceptibility to tumorigenesis without causing other obvious phenotypic effects. Therefore, we sought to determine if haploinsufficiency for the antiapoptotic protein Bcl-x(L) would affect tumorigenesis. We chose to study Bcl-x(L) because although bcl-x(+/-) mice were thought to be phenotypically normal, we and others found that haploinsufficiency for Bcl-x(L) lowers fibroblast resistance to apoptosis in tissue culture. Since resistance to certain forms of apoptosis is required for tumor formation, this suggested that decreased Bcl-xL expression would afford protection against tumorigenesis. Indeed, we demonstrate here that bcl-x(+/-) mice are strikingly resistant to carcinogen-induced tumorigenesis. However, we found that they pay a price for their resistance in that they are more susceptible to clinically relevant forms of tissue injury - they suffer increased hepatic injury in a model of binge alcohol abuse and in response to TNF-alpha treatment. These findings are important because they suggest that even minor variations in Bcl-x(L) expression could affect susceptibility to cancer and other diseases. Additionally, they indicate that the potential for increased susceptibility to tissue injury must be considered in the design of chemopreventative and antineoplastic strategies that involve inhibition of Bcl-x(L) activity.	Washington Univ, Sch Med, Div Urol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Weintraub, SJ (corresponding author), Washington Univ, Sch Med, Div Urol, Campus Box 8242, St Louis, MO 63110 USA.	weintraub@wustl.edu	Weintraub, Steve/GSE-3366-2022		NATIONAL CANCER INSTITUTE [R01CA098605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098605-05] Funding Source: Medline; NIDDK NIH HHS [P30-DK52574] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amundson SA, 2000, CANCER RES, V60, P6101; Becker U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513; Bergsland EK, 2001, SEMIN ONCOL, V28, P521, DOI 10.1053/sonc.2001.26955; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Colantoni A, 2003, ALCOHOL CLIN EXP RES, V27, P1184, DOI 10.1097/01.ALC.0000075834.52279.F9; Cossentino Mark J, 2003, Semin Gastrointest Dis, V14, P128; Day CP, 2001, J HEPATOL, V34, P330, DOI 10.1016/S0168-8278(00)00110-0; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Dvorakova K, 2004, CLIN CANCER RES, V10, P2020, DOI 10.1158/1078-0432.CCR-0437-03; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hong F, 2002, ONCOGENE, V21, P32, DOI 10.1038/sj.onc.1205016; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; LEIST M, 1994, J IMMUNOL, V153, P1778; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; MUTO Y, 1988, LANCET, V2, P72; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Natori S, 2001, J HEPATOL, V34, P248, DOI 10.1016/S0168-8278(00)00089-1; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Riegman PHJ, 2001, CANCER RES, V61, P3164; Sato N, 2001, ALCOHOL CLIN EXP RES, V25, p40S, DOI 10.1111/j.1530-0277.2001.tb02371.x; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Tzung SP, 1997, AM J PATHOL, V150, P1985; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wetscher GJ, 1998, AM J SURG, V176, P569, DOI 10.1016/S0002-9610(98)00258-X; Yoon JH, 2002, J HEPATOL, V37, P400, DOI 10.1016/S0168-8278(02)00209-X; Zhang H, 2003, J PHARMACOL EXP THER, V307, P24, DOI 10.1124/jpet.103.050435; Ziol M, 2001, J HEPATOL, V34, P254, DOI 10.1016/S0168-8278(00)00047-7; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	40	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7120	7124		10.1038/sj.onc.1208887	http://dx.doi.org/10.1038/sj.onc.1208887			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007126				2022-12-28	WOS:000232833200014
J	Yu, QY; Ciemerych, MA; Sicinski, P				Yu, QY; Ciemerych, MA; Sicinski, P			Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins	ONCOGENE			English	Article						D-cyclins; oncogenic transformation; Ras; Myc	TRANSCRIPTIONAL INDUCTION; EXPRESSION; GENE; TRANSFORMATION; KINASE; PATHWAYS; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; SEQUESTRATION	D-type cyclins serve as cell cycle recipients of several oncogenic pathways. The specific sequences of the promoters of the cyclin D genes are thought to render particular D-cyclins responsive to specific oncogenic pathways. For instance, the Ras oncogene was postulated to signal through cyclin D1, while Myc can impact the cell cycle machinery by transcriptionally upregulating cyclin D2. In the current study we engineered mouse fibroblasts to express only cyclin D1, only D2, or only D3. These 'single-cyclin' cells allowed us to rigorously test the ability of cyclin D1, D2, or D3, when expressed on their own, to serve as recipients of the Ras- and Myc-driven oncogenic pathways. We found that each of the D-cyclins was sufficient to drive oncogenic proliferation of mouse fibroblasts. This, together with our recent observations that cells lacking all three D-cyclins show greatly reduced susceptibility to the oncogenic action of Ras and Myc, reveals that the Ras and Myc oncogenes can impact the core cell cycle machinery through all three D-cyclins.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Cell Biol, Beijing 100034, Peoples R China; Univ Warsaw, Inst Zool, Dept Embryol, PL-02089 Warsaw, Poland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Peking University; University of Warsaw	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	peter_sicinski@dfci.harvard.edu		Ciemerych, Maria A./0000-0003-0387-4179	NATIONAL CANCER INSTITUTE [R01CA083688] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002-0356; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Terada Y, 2003, J AM SOC NEPHROL, V14, P1223, DOI 10.1097/01.ASN.0000060577.94532.06; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Yang M, 1998, BIOCHEM MOL BIOL INT, V44, P51; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	43	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7114	7119		10.1038/sj.onc.1208853	http://dx.doi.org/10.1038/sj.onc.1208853			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16103884				2022-12-28	WOS:000232833200013
J	Suzuki, A; Iida, S; Kato-Uranishi, M; Tajima, E; Zhan, FH; Hanamura, I; Huang, YS; Ogura, T; Takahashi, S; Ueda, R; Barlogie, B; Shaughnessy, J; Esumi, H				Suzuki, A; Iida, S; Kato-Uranishi, M; Tajima, E; Zhan, FH; Hanamura, I; Huang, YS; Ogura, T; Takahashi, S; Ueda, R; Barlogie, B; Shaughnessy, J; Esumi, H			ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma	ONCOGENE			English	Article						ARK5; multiple myeloma; Large-MAF family; invasion; IGF-1	ACTIVATED PROTEIN-KINASE; INTEGRIN-LINKED KINASE; GROWTH-FACTOR; BONE-MARROW; CHROMOSOMAL TRANSLOCATIONS; TUMOR INVASION; PLASMA-CELLS; INSULIN; PROLIFERATION; EXPRESSION	ARK5, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer. In this study, we found ARK5 expression in multiple myeloma cell lines expressing c-MAF and MAFB. In addition, gene expression profiling of 351 clinical specimens revealed ARK5 expression in primary myelomas expressing c-MAF and MAFB, suggesting that ARK5 may be a transcriptional target of the Large-MAF family. Sequence analysis of the ARK5 gene promoter revealed that it contains two putative MAF-recognition element (MARE) sequences. In support of this hypothesis, ARK5 was induced when an MAFB or c-MAF expression vector was introduced into non-ARK5-expressing colon cancer cells. Furthermore, ARK5 promoter activity was dramatically decreased by mutation or deletion of MARE sequences. Chromatin immunoprecipitation assays revealed an interaction between the Large-MAF family proteins and MARE sequences in the ARK5 promoter. Moreover, in ARK5 mRNA- expressing multiple myeloma lines, but not in ARK5-negative lines, insulin-like growth factor (IGF)-1 increased invasion activity. IGF-1-induced invasion was reproduced when ARK5 was overexpressed in Burkitt's lymphoma and plasmacytoma lines. Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas.	Natl Canc Ctr, Res Inst E, Canc Physiol Project, Kashiwa, Chiba 2778577, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Nagoya, Aichi 4678601, Japan; Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA; Univ Tsukuba, Dept Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan	National Cancer Center - Japan; Nagoya City University; University of Arkansas System; University of Arkansas Medical Sciences; University of Tsukuba	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Canc Physiol Project, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp			NCI NIH HHS [CA55819, CA97513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R33CA097513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Asosingh K, 2003, Verh K Acad Geneeskd Belg, V65, P127; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Drevs J, 2003, ANTICANCER RES, V23, P1159; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hayman S R, 2001, Curr Treat Options Oncol, V2, P205, DOI 10.1007/s11864-001-0034-4; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Huang K, 2000, GENE, V242, P419, DOI 10.1016/S0378-1119(99)00500-4; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Iida S, 2000, INT J HEMATOL, V72, P85; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Ishikawa H, 2003, LEUKEMIA LYMPHOMA, V44, P1477, DOI 10.1080/1042819031000097339; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Kusakai G, 2004, J EXP CLIN CANC RES, V23, P263; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Ria R, 2003, LEUKEMIA, V17, P1961, DOI 10.1038/sj.leu.2403076; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Tai YT, 2003, CANCER RES, V63, P5850; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Yoshida S, 1999, LEUKEMIA, V13, P1812, DOI 10.1038/sj.leu.2401563; ZHAN F, 2004, BLOOD, V104, P26; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	45	56	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6936	6944		10.1038/sj.onc.1208844	http://dx.doi.org/10.1038/sj.onc.1208844			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16044163				2022-12-28	WOS:000232701700008
J	Casanovas, O; Hager, JH; Chun, MGH; Hanahan, D				Casanovas, O; Hager, JH; Chun, MGH; Hanahan, D			Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis	ONCOGENE			English	Article						oncogenesis; retinoblastoma protein ( Rb); tumor suppressor genes; transgenic mice; RIP-Tag2	CERVICAL CARCINOMAS; INSULIN; INTERMEDIATE; EXPRESSION; MUTATION; CELLS; MICE	Here, we describe the surprising residual capability of the Rb pathway to negatively regulate proliferation and tumorigenesis in a SV40 large T antigen (Tag)-driven mouse model of pancreatic islet carcinogenesis. Heterogeneous Tag expression during all progression stages suggested that a threshold level of the T antigen oncoprotein might be deterministic for beta-cell hyperproliferation and led us to hypothesize that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Moreover, genomic pro. ling of these tumors by array CGH pointed to regions of loss on chromosomes 6 and 14, where the Rb pathway inhibitor p27 and Rb itself, respectively, reside. Indeed, genetic ablation of the p27(Kip1) or Rb genes accentuated Tag-induced tumorigenesis, with loss of Rb in particular broadly enhancing multiple parameters of tumorigenesis including the frequency and growth rates of premalignant lesions, of nascent solid tumors, and of invasive carcinomas. The data indicate that attenuation rather than complete inactivation of Rb tumor suppressor gene function, in the context of p53 inhibition, is sufficient to initiate tumorigenesis in this model of islet cell cancer, with the demonstrable possibility that subsequent losses of Rb or its regulators can enhance malignant progression. The results may be relevant to human papillomavirus (HPV)-induced cervical neoplasias where E7 oncogene expression levels or activity (in the case of intermediate/low-risk HPV subtypes) incompletely inhibits Rb tumor suppressor functions, as well as to other neoplasias where initiating oncogenic or tumor suppressor events reduce but do not abrogate Rb function.	Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Hanahan, D (corresponding author), Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, 513 Parnassus Ave,HSW-1090, San Francisco, CA 94143 USA.	dh@biochem.ucsf.edu	Casanovas, Oriol/L-5210-2014	Casanovas, Oriol/0000-0002-4298-3995				BADER JL, 1980, LANCET, V2, P582; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; BROWNSTEIN S, 1984, ARCH OPHTHALMOL-CHIC, V102, P257, DOI 10.1001/archopht.1984.01040030207028; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Giannoudis A, 2000, CANCER, V89, P1300, DOI 10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U; Hager JH, 2004, CANCER RES, V64, P2406, DOI 10.1158/0008-5472.CAN-03-3522; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kim HJ, 2001, EUR J OBSTET GYN R B, V98, P213, DOI 10.1016/S0301-2115(01)00309-8; LO KW, 1992, ANTICANCER RES, V12, P1989; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marino S, 2000, GENE DEV, V14, P994; Nakagawa S, 1999, BRIT J CANCER, V79, P1139, DOI 10.1038/sj.bjc.6690181; Peters MG, 2004, ONCOL REP, V12, P1143; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SANG BC, 1992, P NATL ACAD SCI USA, V89, P8063, DOI 10.1073/pnas.89.17.8063; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154	26	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6597	6604		10.1038/sj.onc.1208823	http://dx.doi.org/10.1038/sj.onc.1208823			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007165				2022-12-28	WOS:000232367800001
J	Grasemann, C; Gratias, S; Stephan, H; Schuler, A; Schramm, A; Klein-Hitpass, L; Rieder, H; Schneider, S; Kappes, F; Eggert, A; Lohmann, DR				Grasemann, C; Gratias, S; Stephan, H; Schuler, A; Schramm, A; Klein-Hitpass, L; Rieder, H; Schneider, S; Kappes, F; Eggert, A; Lohmann, DR			Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma	ONCOGENE			English	Article						retinoblastoma; tumour progression; chromosome 6p; oncogene; microarray analysis; quantitative PCR	COMPARATIVE GENOMIC HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; CHROMATIN PROTEIN DEK; TUMOR-SUPPRESSOR; BLADDER-CANCER; AMPLIFICATION; GENE; EXPRESSION; OSTEOSARCOMA; INVOLVEMENT	The paediatric eye tumour retinoblastoma is initiated by inactivation of RB1, a tumour suppressor on chromosome 13q. In addition to RB1 loss, many retinoblastomas show other genetic alterations including gains on chromosomes 6p21-pter and 1q31-q32. Recently, the minimal region of gains on chromosome 6 was narrowed to band p22. We examined genomic gains and expression changes in primary retinoblastomas to identify potential target genes in 6p22. Quantitative multiplex PCR detected copy numbers >= 3 in 25 (33%) tumours and no gains in 31 of 76 (40%) tumours. The remaining 20 (26%) samples showed gains only at some loci, most often including E2F3 and DEK in 6p22.3. Analysis of RNA from 21 primary retinoblastomas showed that expression levels of these and some other genes in 6p22 correspond to DNA gains. However, KIF 13A, a reported candidate oncogene on 6p, was expressed at low levels or absent. Clinical manifestation of tumours with gains at all 6p22 loci was distinct in that distribution of age at diagnosis was markedly shifted to older age compared to tumours with no or partial gains. In summary, our results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma.	Univ Klinikum Essen, Inst Humangenet, D-45122 Essen, Germany; Univ Childrens Hosp Essen, Univ Klinikum Essen, D-45122 Essen, Germany; Univ Klinikum Essen, Augenklin, D-45122 Essen, Germany; Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany; Univ Dusseldorf, Inst Human Genet & Anthropol, D-40225 Dusseldorf, Germany; Univ Klinikum Marburg, Inst Klin Genet, D-35033 Marburg, Germany; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen; Heinrich Heine University Dusseldorf; University of Konstanz	Lohmann, DR (corresponding author), Univ Klinikum Essen, Inst Humangenet, D-45122 Essen, Germany.	dietmar.lohmann@uni-essen.de	Ferdinand, Kappes/H-4445-2014; Schramm, Alexander/G-5688-2010; Lohmann, Dietmar R/B-4041-2013; Eggert, Angelika/AAE-6907-2022; Grasemann, Corinna/AAG-3861-2021; Stephan, Harald/AAT-6802-2021; Lohmann, Dietmar R./X-4895-2019	Ferdinand, Kappes/0000-0002-0369-0065; Schramm, Alexander/0000-0001-7670-7529; Lohmann, Dietmar R/0000-0002-2624-9889; Eggert, Angelika/0000-0003-3476-8184; Lohmann, Dietmar R./0000-0002-2624-9889; Grasemann, Corinna/0000-0003-1793-4603				Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Boonstra R, 2003, VIRCHOWS ARCH, V443, P164, DOI 10.1007/s00428-003-0836-9; CANO J, 1994, CANCER GENET CYTOGEN, V76, P112, DOI 10.1016/0165-4608(94)90459-6; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; Chen D, 2002, CANCER RES, V62, P967; Chen DN, 2001, CANCER GENET CYTOGEN, V129, P57, DOI 10.1016/S0165-4608(01)00427-7; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gallie BL, 1999, CANCER RES, V59, p1731S; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; Herzog S, 2001, HUM GENET, V108, P98, DOI 10.1007/s004390000450; Hoglund M, 2004, INT J CANCER, V108, P57, DOI 10.1002/ijc.11558; HORSTHEMKE B, 1992, CANCER GENET CYTOGEN, V63, P1, DOI 10.1016/0165-4608(92)90055-D; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Kappes F, 2004, MOL CELL BIOL, V24, P6011, DOI 10.1128/MCB.24.13.6011-6020.2004; Kappes F, 2004, MOL CELL BIOL, V24, P6000, DOI 10.1128/MCB.24.13.6000-6010.2004; Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Micci F, 2003, CANCER GENET CYTOGEN, V144, P119, DOI 10.1016/S0165-4608(03)00025-6; Mittnacht S, 2005, EUR J CELL BIOL, V84, P97, DOI 10.1016/j.ejcb.2004.12.012; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Partheen K, 2004, GENE CHROMOSOME CANC, V40, P342, DOI 10.1002/gcc.20053; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sitwala KV, 2003, ANTICANCER RES, V23, P2155; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; van der Wal JE, 2003, J CLIN PATHOL, V56, P26, DOI 10.1136/jcp.56.1.26; VOGEL F, 1979, HUM GENET, V52, P1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687	37	81	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6441	6449		10.1038/sj.onc.1208792	http://dx.doi.org/10.1038/sj.onc.1208792			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007192				2022-12-28	WOS:000232038200011
J	Fernandez-Garcia, NI; Palmer, HG; Garcia, M; Gonzalez-Martin, A; del Rio, M; Barettino, D; Volpert, O; Munoz, A; Jimenez, B				Fernandez-Garcia, NI; Palmer, HG; Garcia, M; Gonzalez-Martin, A; del Rio, M; Barettino, D; Volpert, O; Munoz, A; Jimenez, B			1 alpha, 25-Dihydroxyvitamin D-3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells	ONCOGENE			English	Article						Id; 1 alpha, 25( OH)(2)D-3; colon carcinoma; angiogenesis; E-cadherin	LOOP-HELIX PROTEINS; VITAMIN-D ANALOGS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; CYCLE CONTROL; PHASE-I; DIFFERENTIATION; CANCER; PROLIFERATION; INHIBITION; 1,25-DIHYDROXYVITAMIN-D3	1 alpha,25-Dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) has antitumor activity in addition to its classical action on calcium metabolism and bone tissue biology. It is thought to regulate the expression of multiple target genes and thus modulate processes critical for tumor growth and metastases. Here we show that 1 alpha, 25(OH)(2)D-3 differentially regulates the expression of Id1 and Id2 genes, members of a family of transcriptional regulators of cell proliferation and differentiation. 1 alpha,25(OH)(2)D-3 induced epithelial differentiation in SW480-ADH human colon carcinoma cell line by promoting expression of the proteins implicated in adherent junction formation, including E-cadherin, and by inhibiting beta-catenin transcriptional activity. 1 alpha,25(OH)(2)D-3 activated the human Id1 gene promoter and rapidly induced Id1 RNA and protein. E-cadherin, overexpression of Id1 was not sufficient to induce E-cadherin, which was critical for the morphological changes induced by 1 alpha,25(OH)(2)D-3 in SW480-ADH cells. Conversely, Id2 transcription rate, RNA and protein levels were decreased by 1 alpha,25(OH)(2)D-3. Id2 downregulation by 1 alpha,25(OH)(2)D-3 mediated the antiproliferative effect of 1 alpha,25(OH)(2)D-3 on SW480-ADH cells. In addition, we showed that 1 alpha,25(OH)(2)D-3 changed the levels of the inducer of angiogenesis, vascular endothelial growth factor and the potent antiangiogenic factor thrombospondin-1, leading to a balanced change in the angiogenic potential of SW480-ADH human colon carcinoma cells.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; Univ Autonoma Madrid, Dept Biochem, Madrid 28029, Spain; Canc Res, London WC2A 3PX, England; CIEMAT, Project Damage, Repair & Tissue Engn, E-28040 Madrid, Spain; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Northwestern University	Jimenez, B (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Artuto Duperier 4, Madrid 28029, Spain.	bjimenez@iib.uam.es	Gonzalez-Martin, Alicia/B-1702-2017; DEL RIO, MARCELA/H-2796-2015; Palmer, Héctor G./AAG-8332-2019; Cuenca, Benilde Jimenez/K-9959-2014; Munoz, Alberto/O-6393-2014	Gonzalez-Martin, Alicia/0000-0002-6179-089X; DEL RIO, MARCELA/0000-0003-2910-7189; Munoz, Alberto/0000-0003-3890-4251; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Palmer, Hector/0000-0002-9823-5638				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dalhoff K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Diaz GD, 2000, CANCER RES, V60, P2304; Evans SRT, 2000, INT J ONCOL, V16, P1249; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Gulliford T, 1998, BRIT J CANCER, V78, P6, DOI 10.1038/bjc.1998.434; Gumireddy K, 2003, BIOCHEM PHARMACOL, V65, P1943, DOI 10.1016/S0006-2952(03)00205-3; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; HALLINE AG, 1994, ENDOCRINOLOGY, V134, P1710, DOI 10.1210/en.134.4.1710; Hewitt RE, 2000, J PATHOL, V192, P446; Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q; Israel MA, 1999, CANCER RES, V59, p1726S; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; Koli K, 2000, CELL GROWTH DIFFER, V11, P221; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Liu YH, 2004, MOL CELL BIOL, V24, P2662, DOI 10.1128/MCB.24.7.2662-2672.2004; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nishii Y, 2001, STEROIDS, V66, P137, DOI 10.1016/S0039-128X(00)00227-0; Palmer HG, 2003, CANCER RES, V63, P7799; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Ramsauer M, 2002, J CLIN INVEST, V110, P1615, DOI 10.1172/JCI200217326; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Scaglione-Sewell BA, 2000, ENDOCRINOLOGY, V141, P3931, DOI 10.1210/en.141.11.3931; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Smith DC, 1999, CLIN CANCER RES, V5, P1339; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wilson JW, 2001, CANCER RES, V61, P8803; Woo PL, 2000, J BIOL CHEM, V275, P28649, DOI 10.1074/jbc.M910373199; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	48	81	88	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6533	6544		10.1038/sj.onc.1208801	http://dx.doi.org/10.1038/sj.onc.1208801			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007183				2022-12-28	WOS:000232204100007
J	Lu, CH; Shen, Q; DuPre, E; Kim, H; Hilsenbeck, S; Brown, PH				Lu, CH; Shen, Q; DuPre, E; Kim, H; Hilsenbeck, S; Brown, PH			cFos is critical for MCF-7 breast cancer cell growth	ONCOGENE			English	Article						cFos; cJun; AP-1; breast cancer; cell proliferation	DOMINANT-NEGATIVE MUTANT; C-FOS; AP-1 ACTIVITY; MATRIX-METALLOPROTEINASE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; KINASE-ACTIVITY; RETINOIC ACID; ANTISENSE RNA; JUN	The activating protein-1 (AP-1) transcription factor is a converging point of multiple signal transduction pathways in many cells. We have previously demonstrated that overexpressing Tam67, a dominant-negative (DN) form of cJun, blocks AP-1 activity and inhibits breast cancer cell growth. We hypothesized that Tam67 forms dimers with other AP-1 proteins to suppress the growth of breast cancer cells. In the present study, we used immunoprecipitation-Western blotting to demonstrate that Tam67 binds all Jun and Fos proteins in breast cancer cells. In addition, we used two variants of the Tam67 mutant to investigate whether Jun or Fos protein was required for breast cancer cell growth. We created a Tam/Fos mutant in which the cJun dimerization domain was replaced by the cFos dimerization domain, and a Tam/Squelcher mutant in which the cJun dimerization domain was deleted. We then isolated MCF-7 cell lines that stably expressed these cJun-DN mutants under the control of an inducible promoter. Using AP-1-dependent reporter assays, we observed that Tam67 and Tam/Fos mutants inhibited AP-1 transcriptional activity, while the Tam/Squelcher mutant did not. We then determined whether Tam/Fos or Tam/Squelcher inhibited breast cell growth as well as Tam67. We found that while Tam67 repressed cell growth, neither Tam/Fos nor Tam/Squelcher mutant affected cell growth. These results indicate that Tam67 likely inactivates Fos family member proteins to suppress breast cancer cell growth. Finally, we performed antisense experiments to knock down the expression of individual family members (cJun or cFos). Our results demonstrated that antisense cFos inhibited breast cancer cell proliferation and colony formation, while antisense cJun did not. These results suggest that Tam67 suppresses breast cancer cell growth by interacting with Fos family members, specifically with cFos, to produce an inactive AP-1 complex.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Biol Celular, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Pl,MS600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu		Brown, Powel/0000-0002-3398-163X; Shen, Qiang/0000-0002-1491-5434				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Arteaga CL, 1996, CANCER RES, V56, P1098; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLAND KI, 1995, ANN SURG, V221, P706, DOI 10.1097/00000658-199506000-00010; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GEE JMW, 1995, INT J CANCER, V64, P269, DOI 10.1002/ijc.2910640410; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lin F, 2000, CANCER RES, V60, P3271; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MACKAY AR, 1992, INVAS METAST, V12, P168; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Preston GA, 1996, MOL CELL BIOL, V16, P211; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBINSONBENION C, 1994, LEUKEMIA, V8, pS152; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	47	58	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6516	6524		10.1038/sj.onc.1208905	http://dx.doi.org/10.1038/sj.onc.1208905			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16027729				2022-12-28	WOS:000232204100005
J	Yamamichi, N; Yamamichi-Nishina, M; Mizutani, T; Watanabe, H; Minoguchi, S; Kobayashi, N; Kimura, S; Ito, T; Yahagi, N; Ichinose, M; Omata, M; Iba, H				Yamamichi, N; Yamamichi-Nishina, M; Mizutani, T; Watanabe, H; Minoguchi, S; Kobayashi, N; Kimura, S; Ito, T; Yahagi, N; Ichinose, M; Omata, M; Iba, H			The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential	ONCOGENE			English	Article						Brm; SWI/SNF complex; HDAC inhibitors; post-transcriptional regulation; retroviral gene silencing	HISTONE DEACETYLASE INHIBITOR; MAMMALIAN SWI/SNF COMPLEXES; CHROMATIN REMODELING FACTOR; TUMOR-SUPPRESSOR; RHABDOID TUMORS; CYCLE ARREST; LUNG-CANCER; SNF COMPLEX; EXPRESSION; PROTEIN	The mammalian SWI/SNF chromatin remodeling complex is composed of more than 10 protein subunits, and plays important roles in epigenetic regulation. Each complex includes a single BRG1 or Brm molecule as the catalytic subunit. We previously reported that loss of Brm, but not BRG1, causes transcriptional gene silencing of murine leukemia virus-based retrovirus vectors. To understand the biological function and biogenesis of Brm protein, we examined seven cell lines derived from various human tumors that do not produce Brm protein. We show here that these Brm-deficient cell lines transcribe the Brm genes efficiently as detected by nuclear run-on transcription assay, whereas Brm mRNA and Brm hnRNA were undetectable by reverse transcription-polymerase c am reaction analysis. These results indicate that expression of Brm is strongly and promptly suppressed at the posttranscriptional level, through processing and transport of the primary transcript or through stability of mature Brm mRNA. This suppression was attenuated by transient treatment of these cell tines with HDAC inhibitors probably through indirect mechanism. Importantly, all of the treated cells showed prolonged induction of Brm expression after the removal of HDAC inhibitors, and acquired the ability to maintain retroviral gene expression. These results indicate that these Brm-deficient human tumor cell tines carry a functional Brm gene. Treatment with HDAC inhibitors or introduction of exogenous Brm into Brm-deficient cell lines significantly reduced the oncogenic potential as assessed by colony-forming activity in soft agar or invasion into collagen gel, indicating that, like BRG1, Brm is involved in tumor suppression.	Univ Tokyo, Inst Med Sci, Div Host Parasite Interact, Dept Microbiol & Immunol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Fac Med, Dept Gastroenterol, Tokyo 113, Japan; Wakayama Med Coll, Dept Internal Med, Wakayama 640, Japan	University of Tokyo; University of Tokyo; Wakayama Medical University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Host Parasite Interact, Dept Microbiol & Immunol,Minato Ku, 4-6-1,Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp	Ichinose, Masao/HAB-1645-2022					Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Furumai R, 2002, CANCER RES, V62, P4916; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Komatsu Y, 2001, CANCER RES, V61, P4459; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	40	86	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5471	5481		10.1038/sj.onc.1208716	http://dx.doi.org/10.1038/sj.onc.1208716			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007216				2022-12-28	WOS:000231222300007
J	Masselli, A; Wang, JYJ				Masselli, A; Wang, JYJ			Phosphorylation site mutated RB exerts contrasting effects on apoptotic response to different stimuli	ONCOGENE			English	Article						tetracycline-regulated gene expression; p53	RETINOBLASTOMA PROTEIN; CELL-DEATH; G(1) ARREST; INHIBITION; NECROSIS; STAUROSPORINE; ACTIVATION; CLEAVAGE; PRB; DEGRADATION	The retinoblastoma tumor-suppressor protein (RB) is an important regulator of cell cycle and apoptosis. RB is phosphorylated by cyclin-dependent protein kinase during cell cycle progression. A phosphorylation site mutated (PSM)-RB has previously been shown to cause G1 arrest and to interfere with S phase progression. In this study, we examined the effect of inducible PSM-RB expression on the apoptotic response to three different death stimuli: doxorubicin (DOXO), staurosporine (STS) and tumor necrosis factor (TNF) in Rat-16 cells. Induced expression of PSM-RB attenuated caspase activation by DOXO as a result of cell cycle arrest. STS has been shown to cause RB-dependent G1 arrest or apoptosis; however, expression of PSM-RB did not prevent caspase activation by STS. Surprisingly, induced expression of PSM-RB stimulated the apoptotic response to TNF in Rat-16 cells, which mostly undergo necrosis in the absence of PSM-RB. These results show that PSM-RB exerts disparate effects on apoptotic response to different stimuli, and that cell cycle arrest does not always associate with resistance to apoptosis.	Univ Calif San Diego, Sch Med, Div Hematol Oncol & Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Sch Med, Div Hematol Oncol & Moores Canc Ctr, Dept Med, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA 58320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen XM, 2000, JNCI-J NATL CANCER I, V92, P1999, DOI 10.1093/jnci/92.24.1999; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; GERA JF, 1993, J IMMUNOL, V151, P3746; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Humphreys DT, 1999, CYTOKINE, V11, P773, DOI 10.1006/cyto.1998.0492; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1998, CANC J SCI AM S1, V4, P77; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Siu WY, 1999, FEBS LETT, V461, P299, DOI 10.1016/S0014-5793(99)01481-7; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Wagner S, 2005, BIOCHEM PHARMACOL, V69, P1059, DOI 10.1016/j.bcp.2004.12.017; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100	48	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1290	1298		10.1038/sj.onc.1209161	http://dx.doi.org/10.1038/sj.onc.1209161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16205627				2022-12-28	WOS:000235708200002
J	Higuchi, M; Kudo, T; Suzuki, S; Evans, TT; Sasaki, R; Wada, Y; Shirakawa, T; Sawyer, JR; Gotoh, A				Higuchi, M; Kudo, T; Suzuki, S; Evans, TT; Sasaki, R; Wada, Y; Shirakawa, T; Sawyer, JR; Gotoh, A			Mitochondrial DNA determines androgen dependence in prostate cancer cell lines	ONCOGENE			English	Article						mitochondrial DNA; prostate cancer; hormone dependence	FACTOR-KAPPA-B; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; SACCHAROMYCES-CEREVISIAE; MULTIPLE DELETIONS; MUTATOR PHENOTYPE; POINT MUTATIONS; MTDNA; ACTIVATION; EXPRESSION; CARCINOMA	Prostate cancer progresses from an androgen-dependent to androgen-independent stage after androgen ablation therapy. Mitochondrial DNA plays a role in cell death and metastatic competence. Further, heteroplasmic large-deletion mitochondrial DNA is very common in prostate cancer. To investigate the role of mitochondrial DNA in androgen dependence of prostate cancers, we tested the changes of normal and deleted mitochondrial DNA in accordance with the progression of prostate cancer. We demonstrated that the androgen-independent cell line C4-2, established by inoculation of the androgen-dependent LNCaP cell line into castrated mice, has a greatly reduced amount of normal mitochondrial DNA and an accumulation of large-deletion DNA. Strikingly, the depletion of mitochondrial DNA from androgen-dependent LNCaP resulted in a loss of androgen dependence. Reconstitution of normal mitochondrial DNA to the mitochondrial DNA-depleted clone restored androgen dependence. These results indicate that mitochondrial DNA determines androgen dependence of prostate cancer cell lines. Further, mitochondrial DNA-deficient cells formed tumors in castrated athymic mice, whereas LNCaP did not. The accumulation of large deletion and depletion of mitochondrial DNA may thus play a role in the development of androgen independence, leading to progression of prostate cancers.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; VA Med Ctr, Houston, TX USA; Dept Neurol, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Kobe Univ, Sch Med, Dept Radiol, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Dept Clin Genet, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Dept Urol, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Int Ctr Med Res, Chuo Ku, Kobe, Hyogo 657, Japan; Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Baylor College of Medicine; Kobe University; Kobe University; Kobe University; Kobe University; University of Arkansas System; University of Arkansas Medical Sciences	Higuchi, M (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham Slot 516, Little Rock, AR 72205 USA.	mhiguchi@uams.edu	Suzuki, Seigo/G-5378-2012	Shirakawa, Toshiro/0000-0003-3925-8730	NATIONAL CANCER INSTITUTE [R01CA100846] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100846-06, R01 CA100846-03, R01 CA100846-02, R01 CA100846-01A1, R01 CA100846-04, R01 CA100846, R01 CA100846-05, CA100846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen JJZ, 2002, CANCER RES, V62, P6470; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Higuchi M, 2002, ANTIOXID REDOX SIGN, V4, P945, DOI 10.1089/152308602762197489; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kawarada Y, 1998, J BIOCHEM-TOKYO, V123, P492; Kimura K, 2001, CANCER RES, V61, P5611; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Loeb LA, 2001, CANCER RES, V61, P3230; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Rasmussen AK, 2003, NUCLEIC ACIDS RES, V31, P3909, DOI 10.1093/nar/gkg446; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381; Sommer A, 2003, CURR OPIN DRUG DISC, V6, P702; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333	44	64	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1437	1445		10.1038/sj.onc.1209190	http://dx.doi.org/10.1038/sj.onc.1209190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278679	Green Accepted			2022-12-28	WOS:000235890400001
J	Iwanaga, R; Komori, H; Ishida, S; Okamura, N; Nakayama, K; Nakayama, KI; Ohtani, K				Iwanaga, R; Komori, H; Ishida, S; Okamura, N; Nakayama, K; Nakayama, KI; Ohtani, K			Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners	ONCOGENE			English	Article						cell cycle; E2F; target gene; p27(Kip1); growth stimulation	S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F; DNA-REPLICATION; CHECKPOINT RESPONSE; MICROARRAY ANALYSIS; TUMOR-SUPPRESSOR; IN-VIVO; EXPRESSION; APOPTOSIS; GROWTH	The transcription factor E2F mediates cell cycle-dependent expression of genes important for cell proliferation in response to growth stimulation. To further understand the role of E2F, we utilized a sensitive subtraction method to explore new E2F1 targets, which are expressed at low levels and might have been unrecognized in previous studies. We identified 33 new E2F1-inducible genes, including checkpoint genes Claspin and Rad51ap1, and four genes with unknown function required for cell cycle progression. Moreover, we found three groups of E2F1-inducible genes that were not induced by growth stimulation. At least, two groups of genes were directly induced by E2F1, indicating that E2F1 can regulate expression of genes not induced during the cell cycle. One included Neogenin, WASF1 and SGEF genes, which may have a role in differentiation or development. The other was the cyclin-dependent kinase inhibitor p27(Kip1), which was involved in suppression of inappropriate cell cycle progression induced by deregulated E2F. E2F1-responsive regions of these genes were located more upstream than those of typical E2F targets and did not have typical E2F sites. These results indicate that there are groups of E2F1 targets, which are regulated in a distinct manner from that of typical E2F targets.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 158, Japan; Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Lab Microbiol & Immunol, Bunkyo Ku, Tokyo, Japan; Tohoku Univ, Grad Sch Med, Dept Dev Biol, Ctr Translat & Adv Anim Res Human Dis,Aoba Ku, Sendai, Miyagi 980, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Tokyo Medical & Dental University (TMDU); National Institute of Health Sciences - Japan; Tokyo Medical & Dental University (TMDU); Tohoku University; Kyushu University	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp						Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; BALZER HJ, 1994, NUCLEIC ACIDS RES, V22, P2853, DOI 10.1093/nar/22.14.2853; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito E, 1999, GENE, V228, P93, DOI 10.1016/S0378-1119(99)00022-0; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Qi H, 2003, ENDOCRINOLOGY, V144, P1742, DOI 10.1210/en.2002-220984; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shieh SY, 2000, GENE DEV, V14, P289; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	34	50	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1786	1798		10.1038/sj.onc.1209210	http://dx.doi.org/10.1038/sj.onc.1209210			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288221				2022-12-28	WOS:000236013700010
J	Langenfeld, EM; Kong, Y; Langenfeld, J				Langenfeld, EM; Kong, Y; Langenfeld, J			Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5	ONCOGENE			English	Article						BMP-2; lung cancer; Smad-1/5; proliferation; Id-1; metastasis	CANCER CELL-PROLIFERATION; OSTEOBLAST-LIKE CELLS; GENE-EXPRESSION; TOOTH DEVELOPMENT; ACTIVITY GRADIENT; A549 CELLS; DIFFERENTIATION; TRANSFORMATION; INDUCTION; ID-1	Morphogenetic protein 2 (BMP-2) is normally expressed in the embryo promoting the development of several organs. Aberrant expression of BMP-2 occurs in approximately 98% of lung carcinomas, however, its role in regulating tumor growth is poorly understood. We show that BMP-2 induces Id-1 expression in lung cancer cell lines through its activation of Smad-1/ 5, which is dependent on cell culture conditions. A549 cells in DMEM/5% FCS BMP-2 activated S mad-1/5 and caused a transient increase in proliferation. In serum-free medium, BMP-2 induced significantly less Smad-1/ 5 activation and Id-1 expression, and produced significant growth inhibition. The affect of BMP-2 on tumor growth in vivo was substantially more significant. Recombinant BMP-2 coinjected with A549 cells, into nude mice increased proliferation and produced an increase in Id-1 expression. Forced expression of BMP-2 in A549 cells significantly enhanced tumor growth in the lungs following intravenous injection but not of subcutaneous tumors. Tumors in the lung were found to have an activatedSmad 1/5 and expressed Id-1. Subcutaneous tumors expressed less activated Smad-1/5 and Id-1 than that of controls. Human lung carcinomas were also found to express an activated Smad-1/5 and Id-1. We provide evidence that BMP-2 promotes tumor growth. This paper highlights that cell culture experiments may not reveal the full biological affects of BMP-2, and its activity varies depending of the local environment.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Thorac Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Surg Sci, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Langenfeld, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Thorac Surg, MEB 536,1 Robert Wood Johnson Pl,POB 19, New Brunswick, NJ 08903 USA.	langenje@umdnj.edu			NATIONAL CANCER INSTITUTE [K22CA091919] Funding Source: NIH RePORTER; NCI NIH HHS [K22 CA91919-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Clement JH, 2000, J CANCER RES CLIN, V126, P271, DOI 10.1007/s004320050342; CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Han MJ, 2003, DEVELOPMENT, V130, P5123, DOI 10.1242/dev.00710; Ide H, 1997, CANCER RES, V57, P5022; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Kameda T, 1999, GENES CELLS, V4, P175, DOI 10.1046/j.1365-2443.1999.00250.x; LANGENFELD E, 2005, IN PRESS ANN THORACI; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lee TKW, 2003, CARCINOGENESIS, V24, P1729, DOI 10.1093/carcin/bgg145; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592; Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100; Myers DC, 2002, DEV BIOL, V243, P81, DOI 10.1006/dbio.2001.0523; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Norton JD, 2000, J CELL SCI, V113, P3897; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pizette S, 2001, DEVELOPMENT, V128, P4463; Pouliot F, 2003, CANCER RES, V63, P277; Rothhammer T, 2005, CANCER RES, V65, P448; Souza CJH, 2002, REPRODUCTION, V123, P363, DOI 10.1530/rep.0.1230363; Sutherland DJ, 2003, DEVELOPMENT, V130, P5705, DOI 10.1242/dev.00801; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tada A, 1998, ONCOL REP, V5, P1137; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tucker AS, 1998, SCIENCE, V282, P1136, DOI 10.1126/science.282.5391.1136; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Weaver M, 1999, DEVELOPMENT, V126, P4005; Willette RN, 1999, J VASC RES, V36, P120, DOI 10.1159/000025634; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7	48	108	124	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					685	692		10.1038/sj.onc.1209110	http://dx.doi.org/10.1038/sj.onc.1209110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247476				2022-12-28	WOS:000235068800004
J	Mitsuuchi, Y; Powell, DR; Gallo, JM				Mitsuuchi, Y; Powell, DR; Gallo, JM			Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor	ONCOGENE			English	Article						endothelial cells; drug delivery; adenovirus; VEGF; apoptosis	ANGIOGENESIS; MECHANISMS; VEHICLES; PROTEIN; CANCER; DELIVERY; RECEPTOR; SYSTEM; DRUGS; GENE	A second generation genetically-engineered cell-based drug delivery system, referred to as apoptotic-induced drug delivery (AIDD), was developed using endothelial cells (ECs) that undergo apoptosis upon binding of vascular endothelial growth factor (VEGF) to a Flk-1: Fas fusion protein (FF). This new AIDD was redesigned using mouse brain derived ECs, bEnd3cells, and an adenovirus vector in order to enhance and control the expression of FF. The FF was tagged with a HA epitope (FFHA) and designed to be coexpressed with green. fluorescence protein (GFP) by the regulation of cytomegalovirus promoters in the adenovirus vector. bEnd3 ce lls showed favorable coexpression of FFHA and GFP consistent with the multiplicity of infection of the adenovirus. Immunofluorescence analysis demonstrated that FFHA was localized at the plasma membrane, whereas GFP was predominantly located in the cytoplasm of ECs. Cell death was induced by VEGF, but not by platelet derived growth factor or. fibroblast growth factor in a dose-dependent manner (range 2 - 20 ng/ml), and revealed caspase-dependent apoptotic profiles. The FFHA expressing bEnd3cells underwent apoptosis when cocultured with a glioma cell (SF188V +) line able to overexpress VEGF. The combined data indicated that the FFHA adenovirus system can induce apoptotic signaling in ECs in response to VEGF, and thus, is an instrumental modi. cation to the development of AIDD.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Gallo, JM (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 333 Cottham Ave, Philadelphia, PA 19111 USA.	jmgallo@temple.edu			NATIONAL CANCER INSTITUTE [R01CA085577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 085577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Carpenito C, 2002, INT J RADIAT ONCOL, V54, P1473, DOI 10.1016/S0360-3016(02)03921-4; CHINNAIYAN AM, 1995, CELL, V81, P512; Dass CR, 2002, J PHARM PHARMACOL, V54, P3, DOI 10.1211/0022357021771887; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Hallmann R, 2000, ENDOTHELIUM-J ENDOTH, V7, P135, DOI 10.3109/10623320009072208; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; ITOH N, 1993, J BIOL CHEM, V268, P10932; Le Ricousse-Roussanne S, 2004, CARDIOVASC RES, V62, P176, DOI 10.1016/j.cardiores.2004.01.017; Ma J, 1998, APOPTOSIS, V3, P195, DOI 10.1023/A:1009603023214; Ma JG, 1998, CLIN EXP METASTAS, V16, P559, DOI 10.1023/A:1006598419541; Ma JG, 2002, CANCER RES, V62, P1382; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pereboeva L, 2003, STEM CELLS, V21, P389, DOI 10.1634/stemcells.21-4-389; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Quinn TP, 2001, CANCER RES, V61, P8629; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200	22	4	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					954	958		10.1038/sj.onc.1209142	http://dx.doi.org/10.1038/sj.onc.1209142			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247462				2022-12-28	WOS:000235212700014
J	Niiya, F; Tatsumoto, T; Lee, KS; Miki, T				Niiya, F; Tatsumoto, T; Lee, KS; Miki, T			Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA	ONCOGENE			English	Article						protooncogene; Rho GTPase; exchange factor; polo-box domain; interacting protein	POLO-BOX DOMAIN; CELL-DIVISION; EXCHANGE FACTOR; FAMILY GTPASES; SPINDLE; EXPRESSION; PROTEINS; SRF	The epithelial cell transforming gene 2 (ECT2) proto-oncogene encodes a Rho exchange factor, and regulates cytokinesis. ECT2 is phosphorylated in G2/M phases, but its role in the biological function is not known. Here we show that two mitotic kinases, Cdk1 and polo-like kinase 1 (Plk1), phosphorylate ECT2 in vitro. We identified an in vitro Cdk1 phosphorylation site (T412) in ECT2, which comprises a consensus phosphospecific-binding module for the Plk1 polo-box domain (PBD). Endogenous ECT2 in mitotic cells strongly associated with Plk1 PBD, and this binding was inhibited by phosphatase treatment. A phosphorylation-deficient mutant form of ECT2, T412A, did not exhibit strong association with Plk1 PBD compared with wild-type (WT) ECT2. Moreover, ECT2 T412A, but not phosphomimic T412D, displayed a diminished accumulation of GTP-bound RhoA compared with WT ECT2, suggesting that phosphorylation of Thr-412 is critical for the catalytic activity of ECT2. Moreover, while overexpression of WT ECT2 or the T412D mutant caused cortical hyperactivity in U2OS cells during cell division, this activity was not observed in cells expressing ECT2 T412A. These results suggest that ECT2 is regulated by Cdk1 and Plk1 in concert.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bldg 37 Rm 2144,37 Convent Dr, Bethesda, MD 20892 USA.	toru@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Lee JS, 2004, EXP CELL RES, V293, P275, DOI 10.1016/j.yexcr.2003.10.015; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Reiter NJ, 2002, BIOCHEMISTRY-US, V41, P1051, DOI 10.1021/bi011577b; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Seong YS, 2003, CANCER RES, V63, P7384; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	29	91	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					827	837		10.1038/sj.onc.1209124	http://dx.doi.org/10.1038/sj.onc.1209124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247472				2022-12-28	WOS:000235212700002
J	Hasina, R; Pontier, AL; Fekete, MJ; Martin, LE; Qi, XM; Brigaudeau, C; Pramanik, R; Cline, EI; Coignet, LJ; Lingen, MW				Hasina, R; Pontier, AL; Fekete, MJ; Martin, LE; Qi, XM; Brigaudeau, C; Pramanik, R; Cline, EI; Coignet, LJ; Lingen, MW			NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype	ONCOGENE			English	Article						cervical cancer; nucleolus; tumor suppressor gene; angiogenesis; VEGF; TSP-1	THROMBOSPONDIN-1 EXPRESSION; P53 GENE; IN-VIVO; CARCINOMA; RNA; IDENTIFICATION; PROGRESSION; REPRESSION; INDUCTION; LEUKEMIA	Cervical cancer is associated with human papilloma virus infection. However, this infection is insufficient to induce transformation and progression. Loss of heterozygosity analyses suggest the presence of a tumor suppressor gene (TSG) on chromosome 6p21.3-p25. Here we report the cloning NOL7, its mapping to chromosome band 6p23, and localization of the protein to the nucleolus. Fluorescence in situ hybridization analysis demonstrated an allelic loss of an NOL7 in cultured tumor cells and human tumor samples. Transfection of NOL7 into cervical carcinoma cells inhibited their growth in mouse xenografts, confirming its in vivo tumor suppressor activity. The induction of tumor dormancy correlated with an angiogenic switch caused by a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These data suggest that NOL7 may function as a TSG in part by modulating the expression of the angiogenic phenotype.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Vet Affairs Edward Hines Jr Hosp, Maywood, IL USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Chicago; University of Chicago; University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Roswell Park Cancer Institute	Lingen, MW (corresponding author), Univ Chicago, Dept Pathol, MC 6101,5841 S Maryland Ave, Chicago, IL 60637 USA.	mark.lingen@uchospitals.edu			NIDCR NIH HHS [DE12322, DE00470] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012322] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; CHEN TM, 1993, CANCER RES, V53, P1167; Chen Z, 2000, CANCER GENET CYTOGEN, V121, P22, DOI 10.1016/S0165-4608(00)00222-3; Claudio PP, 2001, CANCER RES, V61, P462; Coignet LJA, 1999, GENE CHROMOSOME CANC, V25, P222, DOI 10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO;2-C; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huettner PC, 1998, HUM PATHOL, V29, P364, DOI 10.1016/S0046-8177(98)90117-4; Jinawath N, 2004, CANCER SCI, V95, P430, DOI 10.1111/j.1349-7006.2004.tb03227.x; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.0.CO;2-7; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lingen MW, 1998, CANCER RES, V58, P5551; Lingen MW, 1997, CARCINOGENESIS, V18, P329, DOI 10.1093/carcin/18.2.329; LINGEN MW, 2002, WOUND HEALING METHOD, P337; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; MITRA AB, 1994, CANCER RES, V54, P4481; MONTGOMERY KD, 1995, GENE CHROMOSOME CANC, V14, P97, DOI 10.1002/gcc.2870140203; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muliokandov MR, 1996, CANCER RES, V56, P197; Nagai H, 1999, GENE CHROMOSOME CANC, V25, P277, DOI 10.1002/(SICI)1098-2264(199907)25:3<277::AID-GCC10>3.0.CO;2-L; Nakase K, 2000, LEUKEMIA RES, V24, P79, DOI 10.1016/S0145-2126(99)00139-3; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Rader JS, 2000, GENE CHROMOSOME CANC, V27, P373, DOI 10.1002/(SICI)1098-2264(200004)27:4<373::AID-GCC6>3.3.CO;2-M; RAK J, 1995, CANCER RES, V55, P4575; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Takeshita A, 2004, CANCER GENET CYTOGEN, V152, P56, DOI 10.1016/j.cancergencyto.2003.10.002; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wolf JK, 2001, CANCER INVEST, V19, P621, DOI 10.1081/CNV-100104290; YAGINUMA Y, 1991, CANCER RES, V51, P6506; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	45	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					588	598		10.1038/sj.onc.1209070	http://dx.doi.org/10.1038/sj.onc.1209070			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16205646	Bronze			2022-12-28	WOS:000234897400010
J	Samraj, AK; Stroh, C; Fischer, U; Schulze-Osthoff, K				Samraj, AK; Stroh, C; Fischer, U; Schulze-Osthoff, K			The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression	ONCOGENE			English	Article						apoptosis; Bak; Bax; Lck; mitochondria	SRC-FAMILY KINASES; INDUCED CELL-DEATH; NF-KAPPA-B; BCL-2 FAMILY; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; GENETIC-EVIDENCE; ALPHA-TOXIN; T-CELLS; RECEPTOR	Tyrosine kinases of the Src family have been implicated in key biological processes. Here, we provide evidence that p56(Lck), a lymphoid-specific Src kinase, is involved in the activation of the mitochondrial apoptosis pathway. Lck-deficient T cells were completely resistant to anticancer drugs. In contrast, apoptosis sensitivity to death receptors was not altered, indicating a specific interference of Lck with the mitochondrial pathway. Re-expression of Lck restored sensitivity to drug-induced apoptosis and triggered mitochondrial cytochrome c release and caspase activation. Further analysis identified that the sensitization by Lck was independent of classical mediators of T-cell signaling, but essentially involved the Bcl-2 protein Bak. Expression of Bak was completely absent in Lck-deficient cells, while re-expression of Lck transcriptionally triggered Bak expression and conferred sensitivity to apoptosis, associated with a proapoptotic conformational change of Bak. Furthermore, in vitro the truncated fragment of Bid specifically activated Bak and cytochrome c release only from mitochondria of Lck-expressing cells. These results do not only demonstrate a sentinel role of Lck in drug resistance but also delineate a hitherto unknown pathway of Src kinases in regulation of Bcl-2 proteins.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	KSO@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bantel H, 2001, J CELL BIOL, V155, P637, DOI 10.1083/jcb.200105081; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hernandez-Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224; Hur YG, 2004, J IMMUNOL, V172, P79, DOI 10.4049/jimmunol.172.1.79; Iwamoto KS, 1996, CANCER RES, V56, P3862; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Knudson CM, 2001, CANCER RES, V61, P659; Kondo S, 2000, CANCER RES, V60, P4328; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Melendez J, 2004, J BIOL CHEM, V279, P53516, DOI 10.1074/jbc.M408475200; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Seddon B, 2000, SCIENCE, V290, P127, DOI 10.1126/science.290.5489.127; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Singer AL, 2002, SCIENCE, V296, P1639, DOI 10.1126/science.1071551; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x	63	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					186	197		10.1038/sj.onc.1209034	http://dx.doi.org/10.1038/sj.onc.1209034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116473				2022-12-28	WOS:000234583600003
J	Sankpal, NV; Moskaluk, CA; Hampton, GM; Powell, SM				Sankpal, NV; Moskaluk, CA; Hampton, GM; Powell, SM			Overexpression of CEBP beta correlates with decreased TFF1 in gastric cancer	ONCOGENE			English	Article						gastric cancer; c/EBP beta overexpression; TFF1	BINDING-PROTEIN-BETA; C/EBP-BETA; GENE-EXPRESSION; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; BREAST-CANCER; MICE LACKING; ACTIVATION; INVASIVENESS; ENHANCER	CCAAT element binding protein beta (C/EBP beta) is an important regulator of cell growth, differentiation and in promoting tumor invasiveness. C/EBP beta is located on chromosome 20q, which is amplified in many solid tumors including gastric cancers ( GC). We sought to characterize the status of C/EBP beta expression in GCs, which was recently found to repres TFF1 gene. Microarray analysis revealed overexpression of C/EBP beta in 25 of 27 (93%) GC when compared to 12 normal gastric tissue samples. RT-PCR analysis confirmed the overexpression of C/EBP beta b transcripts in 54 of 59 (91%) GC. In total, 15 of 18 gastric tumors exhibited at least fivefold higher C/EBPb transcript levels compared to their corresponding adjacent normal gastric tissue samples. Moreover, immunohistochemistry analysis demonstrated increased nuclear staining of C/EBP beta in 10 of 13 GC and at least fourfold overexpression of C/EBP beta in three primary GC compared to adjacent normal gastric tissue. Furthermore, a striking correlation of decreased TFF1 expression with increased C/EBP beta was observed in the gastric tumors studied. Microarray analysis demonstrated a loss of TFF1 expression in all 27 GC cases examined, of which 25 exhibited high C/EBP beta expression compared to normal gastric tissue. RT-PCR analysis revealed loss of TFF1 expression in 56 of 59 gastric tumors in which 54 of these tumors exhibited overexpression of C/EBP beta. Immunohistochemical analysis revealed overexpression of C/EBP beta in 10 of 13 gastric tumors that exhibited low expression of TFF1 at the protein level. Thus, overexpression of the transcription factor C/EBP beta in the majority of GCs is a novel finding.	Univ Virginia, Hlth Syst, Digest Hlth Ctr Excellence, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Novartis Res Fdn, Genom Inst, San Diego, CA USA	University of Virginia; University of Virginia; Novartis	Powell, SM (corresponding author), Univ Virginia, Hlth Syst, Digest Hlth Ctr Excellence, Dept Internal Med, POB 800708, Charlottesville, VA 22908 USA.	powell@virginia.edu			NATIONAL CANCER INSTITUTE [R29CA067900, R01CA067900] Funding Source: NIH RePORTER; NCI NIH HHS [CA67900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beckler AD, 2003, CANCER, V98, P2184, DOI 10.1002/cncr.11789; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Dossinger V, 2002, CELL PHYSIOL BIOCHEM, V12, P197, DOI 10.1159/000066279; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hasegawa S, 2002, CANCER RES, V62, P7012; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kagan BL, 2003, CANCER RES, V63, P1696; Kang KW, 2003, J NATL CANCER I, V95, P53, DOI 10.1093/jnci/95.1.53; Kintscher J, 2004, ONCOGENE, V23, P5807, DOI 10.1038/sj.onc.1207722; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Oya M, 2003, CLIN CANCER RES, V9, P1021; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887	23	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					643	649		10.1038/sj.onc.1209081	http://dx.doi.org/10.1038/sj.onc.1209081			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247479				2022-12-28	WOS:000234897400015
J	Bouleau, S; Grimal, H; Rincheval, V; Godefroy, N; Mignotte, B; Vayssiere, JL; Renaud, F				Bouleau, S; Grimal, H; Rincheval, V; Godefroy, N; Mignotte, B; Vayssiere, JL; Renaud, F			FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway	ONCOGENE			English	Article						FGF1; p53; apoptosis	FIBROBLAST-GROWTH-FACTOR; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; WILD-TYPE P53; MESSENGER-RNA; EXPRESSION; SURVIVAL; GENE; BCL-2; FIBROBLAST-GROWTH-FACTOR-1; PROTEIN	We analysed the relationships between p53-induced apoptosis and the acidic fibroblast growth factor 1 (FGF1) survival pathway. We found that p53 activation in rat embryonic fibroblasts induced the downregulation of FGF1 expression. These data suggest that the fgf1 gene is a repressed target of p53. Unlike extracellular FGF1, which has no effect on p53-dependent pathways, intracellular FGF1 inhibits both p53-dependent apoptosis and cell growth arrest via an intracrine pathway. FGF1 increases MDM2 expression at both mRNA and protein levels. This increase is associated with an acceleration of p53 degradation, which may partly account for the ability of endogenous FGF1 to counteract p53 pathways. In the presence of FGF1, p53 was unable to transactivate bax, but no modi. cation of p21 gene transactivation was observed. As Bax is an essential component of the p53-dependent apoptosis pathway, this suggests that intracellular FGF1 inhibits p53 pathways not only by decreasing the stability of p53, but also by modifying some of its transactivation properties. In conclusion, we showed that p53 and FGF1 pathways may interact in the cell to determine cell fate. Deregulation of one of these pathways modifies the balance between cell proliferation and cell death and may lead to tumor progression.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78035 Versailles, France; Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Renaud, F (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	frenaud@genetique.uvsq.fr	Godefroy, Nelly/AAG-2052-2020; Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518				Ashe PC, 2003, PROG NEURO-PSYCHOPH, V27, P199, DOI 10.1016/S0278-5846(03)00016-2; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; CRUMLEY GR, 1989, GENE, V85, P489, DOI 10.1016/0378-1119(89)90443-5; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Desire L, 1998, EXP CELL RES, V241, P210, DOI 10.1006/excr.1998.4048; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Godefroy N, 2004, NUCLEIC ACIDS RES, V32, P4480, DOI 10.1093/nar/gkh773; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Murray SA, 2003, ONCOGENE, V22, P1703, DOI 10.1038/sj.onc.1206327; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ornitz DM, 2001, GENOME BIOL, V2; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PHILIPPE JM, 1992, BIOCHEM BIOPH RES CO, V188, P843, DOI 10.1016/0006-291X(92)91133-B; Philippe JM, 1996, DNA CELL BIOL, V15, P703, DOI 10.1089/dna.1996.15.703; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Prudovsky I, 2002, J CELL BIOL, V158, P201, DOI 10.1083/jcb.200203084; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; RENAUD F, 1992, BIOCHEM BIOPH RES CO, V184, P945, DOI 10.1016/0006-291X(92)90682-B; Renaud F, 1996, BIOCHEM BIOPH RES CO, V219, P679, DOI 10.1006/bbrc.1996.0294; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006-291X(02)02454-3; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	48	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7839	7849		10.1038/sj.onc.1208932	http://dx.doi.org/10.1038/sj.onc.1208932			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091747				2022-12-28	WOS:000233463000003
J	Mathis, JM; Stoff-Khalili, MA; Curiel, DT				Mathis, JM; Stoff-Khalili, MA; Curiel, DT			Oncolytic adenoviruses - selective retargeting to tumor cells	ONCOGENE			English	Review						adenovirus; oncolytic; transduction; retargeting; virotherapy	REPLICATION-COMPETENT ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; GROWTH-FACTOR RECEPTOR; CANCER GENE-THERAPY; PHASE-I TRIAL; 2 CANINE ADENOVIRUSES; PSEUDOTYPED RETROVIRAL VECTORS; MEDIATED TRANSGENE EXPRESSION; RECURRENT PROSTATE-CANCER; EPITHELIAL OVARIAN-CANCER	Virotherapy is an approach for the treatment of cancer, in which the replicating virus itself is the anticancer agent. Virotherapy exploits the lytic property of virus replication to kill tumor cells. As this approach relies on viral replication, the virus can self-amplify and spread in the tumor from an initial infection of only a few cells. The success of this approach is fundamentally based on the ability to deliver the replication-competent viral genome to target cells with a requisite level of efficiency. With virotherapy, while a number of transcriptional retargeting strategies have been utilized to restrict viral replication to tumor cells, this review will focus primarily on transductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect tumor cells. Using the adenoviral vector paradigm, there are three broad strategies useful for viral retargeting. One strategy uses heterologous retargeting ligands that are bispecific in that they bind both to the viral vector as well as to a cell surface target. A second strategy uses genetically modified viral vectors in which a cellular retargeting ligand is incorporated. A third strategy involves the construction of chimeric recombinant vectors, in which a capsid protein from one virus is exchanged for that of another. These transductional retargeting strategies have the potential for reducing deleterious side effects, and increasing the therapeutic index of virotherapeutic agents.	Univ Alabama, Dept Med, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Curiel, DT (corresponding author), Univ Alabama, Dept Med, Div Human & Gene Therapy, 901 19th St S,BMR2-508, Birmingham, AL 35294 USA.	david.curiel@ccc.uab.edu	Mathis, J. Michael/J-1379-2018	Mathis, J. Michael/0000-0001-5528-5195	NATIONAL CANCER INSTITUTE [P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA86306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, CANCER RES, V61, P7882; Akalu A, 1999, J VIROL, V73, P6182, DOI 10.1128/JVI.73.7.6182-6187.1999; Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Alemany R, 2001, GENE THER, V8, P1347, DOI 10.1038/sj.gt.3301515; Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Arnberg N, 2000, J VIROL, V74, P42, DOI 10.1128/JVI.74.1.42-48.2000; Arnberg N, 2002, VIROLOGY, V302, P33, DOI 10.1006/viro.2002.1503; Asaoka K, 2000, J NEUROSURG, V92, P1002, DOI 10.3171/jns.2000.92.6.1002; Atkins GJ, 2004, CURR CANCER DRUG TAR, V4, P597, DOI 10.2174/1568009043332754; Banerjee NS, 2004, MOL CANCER THER, V3, P437; Barker SD, 2003, GENE THER, V10, P1198, DOI 10.1038/sj.gt.3301974; Baxi MK, 2000, VIROLOGY, V278, P234, DOI 10.1006/viro.2000.0661; Belousova N, 2003, J VIROL, V77, P11367, DOI 10.1128/JVI.77.21.11367-11377.2003; Belousova N, 2002, J VIROL, V76, P8621, DOI 10.1128/JVI.76.17.8621-8631.2002; Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackwell JL, 1999, ARCH OTOLARYNGOL, V125, P856, DOI 10.1001/archotol.125.8.856; Blackwell JL, 2000, HUM GENE THER, V11, P1657, DOI 10.1089/10430340050111313; Borovjagin AV, 2005, CANCER GENE THER, V12, P475, DOI 10.1038/sj.cgt.7700806; Breidenbach M, 2004, HUM GENE THER, V15, P509, DOI 10.1089/10430340460745829; Brunetti-Pierri N, 2004, HUM GENE THER, V15, P35, DOI 10.1089/10430340460732445; Buller RE, 2002, CANCER GENE THER, V9, P553, DOI 10.1038/sj.cgt.7700472; Cashman SM, 2004, VIROLOGY, V324, P129, DOI 10.1016/j.virol.2004.04.001; Chen J, 2005, GENE THER, V12, P1079, DOI 10.1038/sj.gt.3302494; Chen J, 2001, HUM GENE THER, V12, P61, DOI 10.1089/104303401450979; Cherenova LV, 2004, VIRUS RES, V100, P257, DOI 10.1016/j.virusres.2003.11.018; Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021; Cho JY, 2002, GENE THER, V9, P1139, DOI 10.1038/sj.gt.3301787; Christ M, 2000, HUM GENE THER, V11, P415, DOI 10.1089/10430340050015888; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; Cosset FL, 1996, GENE THER, V3, P946; Cripe TP, 2001, CANCER RES, V61, P2953; Csatary LK, 2004, J NEURO-ONCOL, V67, P83, DOI 10.1023/B:NEON.0000021735.85511.05; Curiel D, 2002, ADENOVIRAL VECTORS G; CURTIS R, 1983, VET REC, V112, P347, DOI 10.1136/vr.112.15.347; Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008-5472.CAN-04-0064; Denby L, 2004, HUM GENE THER, V15, P1054, DOI 10.1089/1043034042431083; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; DeWeese TL, 2001, CANCER RES, V61, P7464; Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233; Dirven CMF, 2002, J NEUROSURG, V97, P441, DOI 10.3171/jns.2002.97.2.0441; Dmitriev I, 2000, J VIROL, V74, P6875, DOI 10.1128/JVI.74.15.6875-6884.2000; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dmitriev IP, 2002, J VIROL, V76, P6893, DOI 10.1128/JVI.76.14.6893-6899.2002; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Ebert O, 2005, CANCER GENE THER, V12, P350, DOI 10.1038/sj.cgt.7700794; Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Everett RS, 2003, HUM GENE THER, V14, P1715, DOI 10.1089/104303403322611737; Everts M, 2005, GENE THER, V12, P1042, DOI 10.1038/sj.gt.3302491; Farina SF, 2001, J VIROL, V75, P11603, DOI 10.1128/JVI.75.23.11603-11613.2001; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fuxe J, 2003, INT J CANCER, V103, P723, DOI 10.1002/ijc.10891; Galanis E, 2001, BRIT J CANCER, V85, P1432, DOI 10.1054/bjoc.2001.2129; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; Gall J, 1996, J VIROL, V70, P2116, DOI 10.1128/JVI.70.4.2116-2123.1996; Ganly I, 2000, CLIN CANCER RES, V6, P798; Ganly I, 2001, GENE THER, V8, P369, DOI 10.1038/sj.gt.3301402; Geoerger B, 2003, BRIT J CANCER, V89, P577, DOI 10.1038/sj.bjc.6601102; Glasgow JN, 2004, VIROLOGY, V324, P103, DOI 10.1016/j.virol.2004.03.028; Glotzer JB, 2001, J VIROL, V75, P2421, DOI 10.1128/JVI.75.5.2421-2434.2001; Goldman CK, 1997, CANCER RES, V57, P1447; Goossens PH, 2001, ARTHRITIS RHEUM, V44, P570, DOI 10.1002/1529-0131(200103)44:3<570::AID-ANR105>3.0.CO;2-Y; Grill J, 2001, CLIN CANCER RES, V7, P641; GRUBER WC, 1993, VIROLOGY, V196, P603, DOI 10.1006/viro.1993.1516; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Haisma HJ, 2000, CANCER GENE THER, V7, P901, DOI 10.1038/sj.cgt.7700198; Hallden G, 2003, MOL THER, V8, P412, DOI 10.1016/S1525-0016(03)00199-0; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hammond JM, 2005, VET J, V169, P17, DOI 10.1016/j.tvjl.2003.09.007; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Haviv YS, 2002, CANCER RES, V62, P4273; Hay JG, 2004, TRENDS BIOTECHNOL, V22, P501, DOI 10.1016/j.tibtech.2004.08.002; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; HEDLEY SJ, 2005, IN PRESS GENE THERAP; HEINZERLING L, 2005, BLOOD           0616; Hemmi S, 1998, HUM GENE THER, V9, P2363, DOI 10.1089/hum.1998.9.16-2363; Hemminki A, 2001, MOL THER, V4, P223, DOI 10.1006/mthe.2001.0446; Henning P, 2005, GENE THER, V12, P211, DOI 10.1038/sj.gt.3302408; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HERRERO YC, 2004, INT J CANCER, V109, P76, DOI DOI 10.1002/IJC.11626; Herschman HR, 2004, ADV CANCER RES, V92, P29, DOI 10.1016/S0065-230X(04)92003-9; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; Hu J, 2003, MOL THER, V8, P611, DOI 10.1016/S1525-0016(03)00239-9; Irving J, 2004, CANCER GENE THER, V11, P174, DOI 10.1038/sj.cgt.7700666; Itoh A, 2003, J GENE MED, V5, P929, DOI 10.1002/jgm.430; Joung I, 2005, BIOCHEM BIOPH RES CO, V328, P1182, DOI 10.1016/j.bbrc.2005.01.080; Kanerva A, 2002, CLIN CANCER RES, V8, P275; Kanerva A, 2005, GENE THER, V12, P87, DOI 10.1038/sj.gt.3302387; Kanerva A, 2004, GENE THER, V11, P552, DOI 10.1038/sj.gt.3302181; Kashentseva EA, 2002, CANCER RES, V62, P609; Kawakami Y, 2003, CANCER RES, V63, P1262; Kawashima H, 2003, CANCER SCI, V94, P70, DOI 10.1111/j.1349-7006.2003.tb01354.x; Kelly FJ, 2000, CLIN CANCER RES, V6, P4323; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kim J, 2002, J VIROL, V76, P1892, DOI 10.1128/JVI.76.4.1892-1903.2002; Kim M, 2003, BRIT J CANCER, V88, P1411, DOI 10.1038/sj.bjc.6600932; Kim M, 2002, EUR J CANCER, V38, P1917, DOI 10.1016/S0959-8049(02)00131-4; Kim SH, 2005, EUR J CANCER, V41, P313, DOI 10.1016/j.ejca.2004.10.018; Kirby TO, 2004, CLIN CANCER RES, V10, P8697, DOI 10.1158/1078-0432.CCR-04-1166; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Koizumi N, 2003, J GENE MED, V5, P267, DOI 10.1002/jgm.348; Korn T, 2004, J GENE MED, V6, P642, DOI 10.1002/jgm.555; Korokhov N, 2003, J VIROL, V77, P12931, DOI 10.1128/JVI.77.24.12931-12940.2003; Kraaij R, 2005, PROSTATE, V62, P253, DOI 10.1002/pros.20150; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; Kremer EJ, 2004, J GENE MED, V6, pS139, DOI 10.1002/jgm.497; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Lam JT, 2004, J GENE MED, V6, P1333, DOI 10.1002/jgm.635; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508; Le LP, 2004, MOL IMAGING, V3, P105, DOI 10.1162/1535350041464874; Lee H, 2001, GENE THER, V8, P268, DOI 10.1038/sj.gt.3301390; Lehmberg E, 1999, J CHROMATOGR B, V732, P411, DOI 10.1016/S0378-4347(99)00316-3; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Li J, 2005, VIROLOGY, V338, P247, DOI 10.1016/j.virol.2005.04.005; Liang Q, 2002, GENE THER, V9, P1659, DOI 10.1038/sj.gt.3301899; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Liu RB, 2005, CANCER RES, V65, P1532, DOI 10.1158/0008-5472.CAN-04-3353; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Lu W, 2004, WORLD J GASTROENTERO, V10, P3634, DOI 10.3748/wjg.v10.i24.3634; Lutz P, 1997, J VIROL, V71, P5102, DOI 10.1128/JVI.71.7.5102-5109.1997; Magnusson MK, 2002, J GENE MED, V4, P356, DOI 10.1002/jgm.285; Magnusson MK, 2001, J VIROL, V75, P7280, DOI 10.1128/JVI.75.16.7280-7289.2001; Makower D, 2003, CLIN CANCER RES, V9, P693; MARUSYK RG, 1972, MICROBIOS, V5, P259; MARUSYK RG, 1972, CAN J MICROBIOL, V18, P817, DOI 10.1139/m72-127; MARUSYK RG, 1970, J VIROL, V5, P507, DOI 10.1128/JVI.5.4.507-512.1970; MARUSYK RG, 1971, CAN J MICROBIOL, V17, P151, DOI 10.1139/m71-026; Mastrangeli A, 1996, HUM GENE THER, V7, P79, DOI 10.1089/hum.1996.7.1-79; McDonald D, 1999, GENE THER, V6, P1512, DOI 10.1038/sj.gt.3301006; Mercier GT, 2004, P NATL ACAD SCI USA, V101, P6188, DOI 10.1073/pnas.0400542101; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; MICHAEL SI, 1995, GENE THER, V2, P660; Miller CR, 1998, CANCER RES, V58, P5738; Miyazawa N, 1999, J VIROL, V73, P6056, DOI 10.1128/JVI.73.7.6056-6065.1999; Mizuguchi H, 2001, GENE THER, V8, P730, DOI 10.1038/sj.gt.3301453; Mulvihlll S, 2001, GENE THER, V8, P308, DOI 10.1038/sj.gt.3301398; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Myers R, 2005, CANCER GENE THER, V12, P593, DOI 10.1038/sj.cgt.7700823; Nakamura T, 2003, J VIROL, V77, P2512, DOI 10.1128/JVI.77.4.2512-2521.2003; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Nettelbeck DM, 2002, CANCER RES, V62, P4663; Nicklin SA, 2001, MOL THER, V4, P534, DOI 10.1006/mthe.2001.0489; Nicol CG, 2004, MOL THER, V10, P344, DOI 10.1016/j.ymthe.2004.05.020; Nilson BHK, 1996, GENE THER, V3, P280; Nilsson M, 2004, J GENE MED, V6, P631, DOI 10.1002/jgm.543; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; NOUREDDINI SC, 2005, IN PRESS J VIROL; Pagliaro LC, 2003, J CLIN ONCOL, V21, P2247, DOI 10.1200/JCO.2003.09.138; Parikh NS, 2005, PEDIATR BLOOD CANCER, V44, P469, DOI 10.1002/pbc.20268; Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527; Penuelas I, 2005, GASTROENTEROLOGY, V128, P1787, DOI 10.1053/j.gastro.2005.03.024; Portella G, 2002, J CLIN ENDOCR METAB, V87, P2525, DOI 10.1210/jc.87.6.2525; Qin M, 2003, CLIN CANCER RES, V9, P4992; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Raykov Z, 2004, INT J CANCER, V109, P742, DOI 10.1002/ijc.20013; Reddy PS, 2003, VIROLOGY, V311, P384, DOI 10.1016/S0042-6822(03)00161-2; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Rein DT, 2005, CLIN CANCER RES, V11, P1327; Reynolds PN, 2000, MOL THER, V2, P562, DOI 10.1006/mthe.2000.0205; Rivera AA, 2004, GENE THER, V11, P1694, DOI 10.1038/sj.gt.3302346; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Sachs MD, 2002, UROLOGY, V60, P531, DOI 10.1016/S0090-4295(02)01748-X; Sauthoff H, 2002, HUM GENE THER, V13, P1859, DOI 10.1089/104303402760372954; Schaack J, 2005, VIRAL IMMUNOL, V18, P79, DOI 10.1089/vim.2005.18.79; Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; Segerman A, 2003, J VIROL, V77, P1157, DOI 10.1128/JVI.77.2.1157-1162.2003; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Shayakhmetov DM, 2005, J VIROL, V79, P7478, DOI 10.1128/JVI.79.12.7478-7491.2005; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; Shi J, 2005, CANCER RES, V65, P1687, DOI 10.1158/0008-5472.CAN-04-2749; Shillitoe EJ, 2005, CLIN CANCER RES, V11, P3109, DOI 10.1158/1078-0432.CCR-04-2302; Shinoura N, 2000, JPN J CANCER RES, V91, P1028, DOI 10.1111/j.1349-7006.2000.tb00881.x; Shinozaki K, 2004, MOL THER, V9, P368, DOI 10.1016/j.ymthe.2003.12.004; Short JJ, 2004, VIROLOGY, V322, P349, DOI 10.1016/j.virol.2004.02.016; Sinclair AM, 1997, GENE THER, V4, P918, DOI 10.1038/sj.gt.3300479; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; Sirena D, 2004, J VIROL, V78, P4454, DOI 10.1128/JVI.78.9.4454-4462.2004; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STOFFKHALILI MA, 2005, GENE THERAPY    0721; Stone D, 2005, J VIROL, V79, P5090, DOI 10.1128/JVI.79.8.5090-5104.2005; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Tekant Y, 2005, SURGERY, V137, P527, DOI 10.1016/j.surg.2004.12.014; Ternovoi VV, 2005, J VIROL, V79, P1308, DOI 10.1128/JVI.79.2.1308-1311.2005; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Toth K, 2005, HUM GENE THER, V16, P139, DOI 10.1089/hum.2005.16.139; Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917; Tseng JC, 2004, CANCER RES, V64, P6684, DOI 10.1158/0008-5472.CAN-04-1924; UCHINO J, 2005, CANC GENE THER  0429; Unno Y, 2005, CLIN CANCER RES, V11, P4553, DOI 10.1158/1078-0432.CCR-04-2610; van Beusechem VW, 2000, GENE THER, V7, P1940, DOI 10.1038/sj.gt.3301323; van der Poel HG, 2002, J UROLOGY, V168, P266, DOI 10.1016/S0022-5347(05)64905-1; Vanderkwaak TJ, 1999, GYNECOL ONCOL, V74, P227, DOI 10.1006/gyno.1999.5432; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; Vasey PA, 2002, J CLIN ONCOL, V20, P1562, DOI 10.1200/JCO.20.6.1562; Vellinga J, 2005, J GEN VIROL, V86, P1581, DOI 10.1099/vir.0.80877-0; Vellinga J, 2004, J VIROL, V78, P3470, DOI 10.1128/JVI.78.7.3470-3479.2004; Vigne E, 1999, J VIROL, V73, P5156, DOI 10.1128/JVI.73.6.5156-5161.1999; Voeks D, 2002, GENE THER, V9, P759, DOI 10.1038/sj.gt.3301698; Vollmer CM, 1999, CANCER RES, V59, P4369; Volpers C, 2003, J VIROL, V77, P2093, DOI 10.1128/JVI.77.3.2093-2104.2003; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; Wesseling JG, 2001, GENE THER, V8, P969, DOI 10.1038/sj.gt.3301473; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Witlox AM, 2004, CLIN CANCER RES, V10, P61, DOI 10.1158/1078-0432.CCR-0609-03; Wolf JK, 2004, GYNECOL ONCOL, V94, P442, DOI 10.1016/j.ygyno.2004.05.041; Wu E, 2004, J VIROL, V78, P3897, DOI 10.1128/JVI.78.8.3897-3905.2004; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703; Wu H, 2004, GENE THER, V11, P874, DOI 10.1038/sj.gt.3302249; Wu HJ, 2005, J VIROL, V79, P3382, DOI 10.1128/JVI.79.6.3382-3390.2005; Wu HJ, 2002, HUM GENE THER, V13, P1647, DOI 10.1089/10430340260201734; Xia HB, 2000, J VIROL, V74, P11359, DOI 10.1128/JVI.74.23.11359-11366.2000; Yamamoto M, 2003, GASTROENTEROLOGY, V125, P1203, DOI 10.1016/S0016-5085(03)01196-X; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503; You ZB, 2001, CANCER GENE THER, V8, P168, DOI 10.1038/sj.cgt.7700284; Yun CO, 2005, HUM GENE THER, V16, P248, DOI 10.1089/hum.2005.16.248; Zabner J, 1999, J VIROL, V73, P8689, DOI 10.1128/JVI.73.10.8689-8695.1999; Zakhartchouk A, 2003, VIROLOGY, V313, P377, DOI 10.1016/S0042-6822(03)00286-1; Zeimet AG, 2003, LANCET ONCOL, V4, P415, DOI 10.1016/S1470-2045(03)01139-2; Zhang J, 2004, J GENE MED, V6, P1082, DOI 10.1002/jgm.605; Zhang LN, 2005, VIRUS RES, V110, P169, DOI 10.1016/j.virusres.2005.02.008; Zhang LO, 2003, J GEN VIROL, V84, P687, DOI 10.1099/vir.0.18666-0; Zhu ZB, 2005, INT J ONCOL, V27, P237; Zhu ZB, 2004, VIROLOGY, V325, P116, DOI 10.1016/j.virol.2004.04.021; Zinn KR, 2000, J NUCL MED, V41, P887	250	99	109	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7775	7791		10.1038/sj.onc.1209044	http://dx.doi.org/10.1038/sj.onc.1209044			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299537				2022-12-28	WOS:000233372600013
J	Jeanblanc, M; Mousli, M; Hopfner, R; Bathami, K; Martinet, N; Abbady, AQ; Siffert, JC; Mathieu, E; Muller, CD; Bronner, C				Jeanblanc, M; Mousli, M; Hopfner, R; Bathami, K; Martinet, N; Abbady, AQ; Siffert, JC; Mathieu, E; Muller, CD; Bronner, C			The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle	ONCOGENE			English	Article						cell cycle; ICBP90; methylated promoter; retinoblastoma protein	II-ALPHA EXPRESSION; CCAAT-BINDING-PROTEIN; S-PHASE ENTRY; TRANSCRIPTIONAL REPRESSION; CONTACT INHIBITION; DOWN-REGULATION; CPG ISLAND; RB; CANCER; ARREST	The retinoblastoma protein (pRB) is encoded by the RB1 gene whose promoter contains several putative binding sites for ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcriptional regulator of the topoisomerase II alpha gene. ICBP90 has two consensus binding sites for pRB in its primary sequence. Here, we show that pRB and ICBP90 co-immunoprecipitate in cell extracts of proliferating human lung fibroblasts and of proliferating or confluent Jurkat cells. GST pull-down assays and immunocytochemistry, after cell synchronization in late G1 phase, con. firmed this interaction. Overexpression of ICBP90 induces downregulation of pRB expression in lung. fibroblasts as a result of mRNA decrease. DNA chromatin immunoprecipitation experiment shows that ICBP90 binds to the RB1 gene promoter under its methylated status. Overexpression of ICBP90 increases the S and G2/M phase cell fractions of serum-starved lung fibroblasts as assessed by. flow cytometry analysis and increases topoisomerase IIa expression. Together, these results show that ICBP90 regulates pRB at the protein and gene transcription levels, thus favoring the entry into the S phase of the cells. We propose that ICBP90 overexpression, found in cancer cells, is involved in the altered checkpoint controls occurring in cancerogenesis.	INSERM, UMR S392, Fac Pharm, F-60024 Illkirch Graffenstaden, France; CNRS, UMR 7034, Fac Pharm, F-67401 Illkirch Graffenstaden, France; INSERM, EMI 0014, Fac Med, F-54511 Vandoeuvre Les Nancy, France; Ctr Hosp Belfort Montbeliard, Lab Biochim Immunochim, F-90016 Belfort, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Bronner, C (corresponding author), INSERM, UMR S392, Fac Pharm, 74 Route Rhin,BP 60024, F-60024 Illkirch Graffenstaden, France.	bronner@pharma.u-strasbg.fr	Mousli, Marc/Q-1722-2017; Bronner, Christian/R-8488-2016; Abbady, Abdul Qader/O-2761-2015; MULLER, Christian D./F-8399-2010	Mousli, Marc/0000-0001-9759-6864; Bronner, Christian/0000-0002-3101-9279; Abbady, Abdul Qader/0000-0002-3898-5269; MULLER, Christian D./0000-0002-3463-1025				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bronner C, 2002, ANTICANCER RES, V22, P605; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Gonzalez-Gomez P, 2003, BRIT J CANCER, V88, P109, DOI 10.1038/sj.bjc.6600737; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Meerson A, 2004, FEBS LETT, V559, P152, DOI 10.1016/S0014-5793(04)00027-4; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Muto M, 2002, J BIOL CHEM, V277, P34549, DOI 10.1074/jbc.M205189200; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; Roncalli M, 1998, LAB INVEST, V78, P1049; Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149; Simpson DJ, 2000, CANCER RES, V60, P1211; SLACK RS, 1993, ONCOGENE, V8, P1585; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	51	100	111	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7337	7345		10.1038/sj.onc.1208878	http://dx.doi.org/10.1038/sj.onc.1208878			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007129				2022-12-28	WOS:000233142100010
J	Kawaguchi, T; Kato, S; Otsuka, K; Watanabe, G; Kumabe, T; Tominaga, T; Yoshimoto, T; Ishioka, C				Kawaguchi, T; Kato, S; Otsuka, K; Watanabe, G; Kumabe, T; Tominaga, T; Yoshimoto, T; Ishioka, C			The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	ONCOGENE			English	Article						p53; oligomerization; transactivation	PROLYL ISOMERASE PIN1; TUMOR-SUPPRESSOR P53; LI-FRAUMENI SYNDROME; TETRAMERIZATION DOMAIN; DNA-BINDING; WILD-TYPE; P53-INDUCED APOPTOSIS; TRANSFORMING DOMAIN; CRYSTAL-STRUCTURE; MUTANTS	Tumor suppressor p53 forms a homo-tetramer through its COOH-terminal oligomerization domain and acts as a sequence-specific transcription factor. We have analysed the interrelation among the transcriptional activities, the structure and the cancer-related mutations in the oligomerization domain by using a comprehensive missense mutation library. Here, we examined the ability of 184 mutant p53s in the domain to form an oligomer by expressing these mutant p53s in yeast, and compared the data with the previous information. We showed that specific residues in the alpha-helix and the beta-strand of the oligomerization domain were critical for both oligomer formation and sequence-specific transactivation, and the activities were closely related. In particular, the alpha-helix was more sensitive to amino-acid substitutions than the beta-strand. We found identity in the interrelation between the two activities, that is, monomer mutants were transcriptionally inactive whereas dimer and tetramer mutants retained their transcriptional activities. In TP53 mutation databases, a small number of mutations have been reported in this domain. Surprisingly, most do not encode p53s defective in functional properties. These results indicate that, although oligomer formation is essential for p53 transactivation function, the inactivation of oligomer formation and therefore the inactivation of transactivation may not be essential for tumor suppression by p53 because they do not lead to oncogenic proteins.	Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ Hosp, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 8908574, Japan	Tohoku University; Tohoku University	Ishioka, C (corresponding author), Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	chikashi@idac.tohoku.ac.jp	Kato, Shunsuke/F-7607-2014	Ishioka, Chikashi/0000-0002-3023-1227				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Varley JM, 1996, ONCOGENE, V12, P2437; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	41	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6976	6981		10.1038/sj.onc.1208839	http://dx.doi.org/10.1038/sj.onc.1208839			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007150				2022-12-28	WOS:000232701700012
J	Martin, NL; Saba-El-Leil, MK; Sadekova, S; Meloche, S; Sauvageau, G				Martin, NL; Saba-El-Leil, MK; Sadekova, S; Meloche, S; Sauvageau, G			EN2 is a candidate oncogene in human breast cancer	ONCOGENE			English	Article						Engrailed-2; homeobox; breast cancer; RNAi; transplantation	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; HOMEOBOX GENES; IN-VIVO; C-MYC; MOUSE; CELLS; MICE; TRANSFORMATION; PHENOTYPE	Only a few critical oncogenes have been identified in the more commonly occurring cases of sporadic breast cancer. We provide evidence that EN2 is ectopically expressed in a subset of human breast cancer and may have a causal role in mammary tumorigenesis. Nontumorigenic mammary cell lines engineered to ectopically express En-2 have a marked reduction in their cycling time, lose cell contact inhibition, become sensitive to 17-AAG treatment, fail to differentiate when exposed to lactogenic hormones and induce mammary tumors when transplanted into cleared mammary glands of syngeneic hosts. RNA interference studies suggest that EN2 expression is required for the maintenance of the transformed phenotype of a human breast tumor cell line.	Inst Rech Immunol & Cancerol, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; Inst Rech Immunol & Cancerol, Lab Signaling & Cell Growth, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2B4, Canada; Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Leukemia Cell Bank Quebec, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Rech Immunol & Cancerol, Lab Mol Genet Hematopoiet Stem Cells, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	sylvain.meloche@umontreal.ca; guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1; Bieche I, 1999, CANCER RES, V59, P2759; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGUET EL, 1994, CANCER RES, V54, P2615; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; LIZARDNACOL S, 1995, CANCER RES, V55, P4416; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Neckers L, 2003, NATURE, V425, P357, DOI 10.1038/425357a; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Ross JS, 2003, EXPERT REV MOL DIAGN, V3, P573, DOI 10.1586/14737159.3.5.573; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8	39	44	56	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6890	6901		10.1038/sj.onc.1208840	http://dx.doi.org/10.1038/sj.onc.1208840			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007149				2022-12-28	WOS:000232701700004
J	Dolloff, NG; Shulby, SS; Nelson, AV; Stearns, ME; Johannes, GJ; Thomas, JD; Meucci, O; Fatatis, A				Dolloff, NG; Shulby, SS; Nelson, AV; Stearns, ME; Johannes, GJ; Thomas, JD; Meucci, O; Fatatis, A			Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor	ONCOGENE			English	Article						prostate cancer; metastasis; PDGF; EGF; Akt	IN-VIVO; EXPRESSION; INVOLVEMENT; PROGRESSION; MIGRATION; SURVIVAL; AKT	Prostate adenocarcinoma metastasizes to the skeleton more frequently than any other organ. An underlying cause of this phenomenon may be the ability of bone-produced factors to specifically select disseminated prostate cancer cells that are susceptible to their trophic effects. Platelet-derived growth factor ( PDGF), a potent mitogen for both normal and tumor cells, is produced in several tissues including bone, where it is synthesized by both osteoblasts and osteoclasts. Here, we show that PDGF causes a significantly stronger activation of the Akt/PKB survival pathway in bone-metastatic prostate cancer cells compared to nonmetastatic cells. Normal prostate epithelial cells and DU-145 prostate cells, originally derived from a brain metastasis, are not responsive to PDGF. In contrast, epidermal growth factor stimulates Akt to the same extent in all prostate cells tested. This difference in PDGF responsiveness depends on the higher expression of alpha-PDGFR in bone-metastatic compared to nonmetastatic prostate cells and the lack of alpha-PDGFR expression in normal and metastatic prostate cells derived from tissues other than bone. Thus, alpha-PDGFR expression might identify prostate cancer cells with the highest propensity to metastasize to the skeleton.	Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St,New Coll Bldg MS488, Philadelphia, PA 19102 USA.	af39@drexel.edu			NCI NIH HHS [CA076639, R01 CA076639, CA112096] Funding Source: Medline; NIDA NIH HHS [R01 DA015014-01, R01 DA019808-03, R01 DA015014-04, DA19808, R01 DA019808-02, R01 DA019808, R01 DA019808-01, R01 DA015014-02, R01 DA015014-03, R01 DA015014, DA15014] Funding Source: Medline; NIGMS NIH HHS [GM067892, R01 GM067892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019808, R01DA015014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FUDGE K, 1994, MODERN PATHOL, V7, P549; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Mundy GR, 2000, CANCER AND THE SKELETON, P1; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Russell PJ, 1998, CLIN CHEM, V44, P705; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Watson PH, 1996, J MOL ENDOCRINOL, V17, P45, DOI 10.1677/jme.0.0170045; Xu WP, 2003, CANCER RES, V63, P7777; Yang DH, 2000, CYTOKINE, V12, P1271, DOI 10.1006/cyto.2000.0707	19	52	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6848	6854		10.1038/sj.onc.1208815	http://dx.doi.org/10.1038/sj.onc.1208815			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007172	Green Accepted			2022-12-28	WOS:000232527800013
J	Yoshida, M				Yoshida, M			Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis	ONCOGENE			English	Article						HTLV-1; transcription; tumor-suppressor genes; cell cycle; epidemiology	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; TAX ONCOPROTEIN; PROVIRUS GENOME; GENE-EXPRESSION; PROTEIN; LYMPHOMA; TYPE-1	I briefly review the discovery and characterization of the. first human retrovirus, human T-cell leukemia virus type 1, focusing on contributions from Japanese researchers. The unique regulatory mechanisms for the viral regulation with Tax and Rex, etiology of ATL and possible leukemogenic mechanism with Tax are also discussed briefly.	Banyu Pharmaceut Co Ltd, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Yoshida, M (corresponding author), Banyu Pharmaceut Co Ltd, Banyu Tsukuba Res Inst, 3 Ohkubo, Tsukuba, Ibaraki 3002611, Japan.	mitsuaki_yoshida@merck.com						Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GESSAIN A, 1985, LANCET, V2, P407; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINO S, 1994, LEUKEMIA S, V1, pS68; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HINUMA Y, 1981, INT J CANCER, V15, P631; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISOBE M, 1990, CANCER RES, V50, P6171; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1984, GANN, V75, P747; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MIYOSHI I, 1980, GANN, V71, P155; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1986, LANCET, V1, P1031; POEISZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1986, P NATL ACAD SCI USA, V83, P4524, DOI 10.1073/pnas.83.12.4524; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGIYAMA H, 1986, J MED VIROL, V20, P253, DOI 10.1002/jmv.1890200307; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Suzuki T, 2000, VIROLOGY, V270, P291, DOI 10.1006/viro.2000.0266; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; TAJIMA K, 1986, HEMATOL ONCOL, V4, P31, DOI 10.1002/hon.2900040106; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEICH N, 1985, RNA TUMOR VIRUSES, P785; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	45	97	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					5931	5937		10.1038/sj.onc.1208981	http://dx.doi.org/10.1038/sj.onc.1208981			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155600				2022-12-28	WOS:000231623400003
J	O'Keefe, LV; Liu, YH; Perkins, A; Dayan, S; Saint, R; Richards, RI				O'Keefe, LV; Liu, YH; Perkins, A; Dayan, S; Saint, R; Richards, RI			FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila	ONCOGENE			English	Article						chromosomal fragile site; oxidoreductase; radiation sensitivity; gene rescue	TUMOR-SUPPRESSOR GENE; DOMAIN-CONTAINING OXIDOREDUCTASE; CELL LUNG-CANCER; HOMOZYGOUS DELETIONS; DNA-DAMAGE; WWOX; EXPRESSION; CARCINOMA; PARKIN; IDENTIFICATION	Fragile sites are chromosomal structures that have been proposed to have a determining role in cancer-associated DNA instability. The human WWOX gene spans the FRA16D chromosomal fragile site, the common minimal region of homozygous deletion found in adenocarcinomas and three out of five translocation breakpoints in multiple myeloma. Transcripts from the alternatively spliced WWOX gene encode proteins with common N-terminal WW domains and variable homology to the oxidoreductase family of proteins. In this study, the Drosophila orthologue of the WWOX gene was identified and subjected to mutagenesis via homologous recombination. The resultant DmWWOX(1) mutants were viable but exhibited an increased sensitivity to ionizing radiation. This radiation sensitivity was rescued by reintroduction and expression of either the wild-type Drosophila or human WWOX genes. Thus, the protective function of DmWWOX in response to irradiation in Drosophila is conserved with human WWOX (hWWOX). This is consistent with a protective role for hWWOX where aberrant expression, as a result of breakage at the associated fragile site, could contribute directly to cancer progression.	Univ Adelaide, Sch Mol & Biomed Sci, Res Network Genes & Environm Dev, ARC,NHMRC, Adelaide, SA 5005, Australia; Univ Adelaide, ARC, Special Res Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	University of Adelaide; University of Adelaide; Australian National University	Richards, RI (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Res Network Genes & Environm Dev, ARC,NHMRC, Mol Life Sci Bldg,Gate 8,Victoria Dr, Adelaide, SA 5005, Australia.	robert.richards@adelaide.edu.au	O'Keefe, Louise V/B-9856-2008; Saint, Robert/A-4190-2008; Dayan, Sonia/D-7960-2013; Dayan, Sonia/U-9400-2017; Richards, Robert/ABE-6423-2020	Saint, Robert/0000-0002-7989-6043; Dayan, Sonia/0000-0002-5616-7542; Dayan, Sonia/0000-0002-5616-7542; Richards, Robert Ian/0000-0002-5978-6453				Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Glover TW, 1998, CANCER RES, V58, P3409; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Ishii H, 2003, MOL CANCER RES, V1, P940; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Kuroki T, 2002, CANCER RES, V62, P2258; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nioi P, 2004, MUTAT RES-FUND MOL M, V555, P149, DOI 10.1016/j.mrfmmm.2004.05.023; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Rozier L, 2004, ONCOGENE, V23, P6872, DOI 10.1038/sj.onc.1207809; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Watanabe A, 2003, CANCER RES, V63, P8629; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yendamuri S, 2003, CANCER RES, V63, P878; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	39	19	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6590	6596		10.1038/sj.onc.1208806	http://dx.doi.org/10.1038/sj.onc.1208806			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007179				2022-12-28	WOS:000232204100013
J	Perez-Losada, J; Wu, D; DelRosario, R; Balmain, A; Mao, JH				Perez-Losada, J; Wu, D; DelRosario, R; Balmain, A; Mao, JH			p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo	ONCOGENE			English	Article						p53; p63; p73; tumor suppressor; radiation; lymphoma	LI-FRAUMENI-SYNDROME; KINASE C-ABL; P53 HOMOLOG; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; TUMORIGENESIS; CARCINOMA; ONCOGENE	p53 is one of the most important tumor suppressor genes in human cancer, but the roles of its homologues p63 and p73 in tumor suppression, alone or in collaboration with p53, remains controversial. Both p63 and p73 can be deregulated after DNA damage, and induce cell cycle arrest and apoptosis, but mice carrying inactive alleles of these genes do not develop spontaneous tumors. Since heterozygous loss of p53 confers strong sensitization to radiation-induced lymphoma development, we investigated the possibility that radiation exposure may reveal previously undetected tumor suppressor properties in p63 or p73, alone or in combination with p53. Animals heterozygous for p63 or p73, as well as both double heterozygous p53/p63 or p53/p73 mice, showed no significant differences in tumor latency, spectrum or frequency after gamma-radiation, compared to their control counterparts. Deletions were found near the p63 locus on chromosome 16 in radiation-induced tumors, but these frequently included the knockout allele. No deletions or LOH involving the p73 gene were detected, and expression of both genes was maintained in the tumors. We conclude that P53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu; jmao@cc.ucsf.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gong JG, 1999, NATURE, V399, P806; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Liefer KM, 2000, CANCER RES, V60, P4016; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Park JJ, 2000, AM J SURG PATHOL, V24, P1414, DOI 10.1097/00000478-200010000-00012; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257	25	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5521	5524		10.1038/sj.onc.1208799	http://dx.doi.org/10.1038/sj.onc.1208799			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007185				2022-12-28	WOS:000231222300012
J	Ichimura, K; Mungall, AJ; Fiegler, H; Pearson, DM; Dunham, I; Carter, NP; Collins, VP				Ichimura, K; Mungall, AJ; Fiegler, H; Pearson, DM; Dunham, I; Carter, NP; Collins, VP			Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH	ONCOGENE			English	Article						brain tumour; molecular cytogenetics; array-CGH; glioblastoma; astrocytoma	COMPARATIVE GENOMIC HYBRIDIZATION; RECESSIVE JUVENILE PARKINSONISM; SUPPRESSOR GENE; WAF1/CIP1 GENE; OVARIAN-CANCER; EXPRESSION; MUTATIONS; GLIOMAS; ABNORMALITIES; MICROARRAY	Deletions of chromosome 6 are a common abnormality in diverse human malignancies including astrocytic tumours, suggesting the presence of tumour suppressor genes (TSG). In order to help identify candidate TSGs, we have constructed a chromosome 6 tile path microarray. The array contains 1780 clones (778 P1-derived artificial chromosome and 1002 bacterial artificial chromosome) that cover 98.3% of the published chromosome 6 sequences. A total of 104 adult astrocytic tumours (10 diffuse astrocytomas, 30 anaplastic astrocytomas (AA), 64 glioblastomas (GB)) were analysed using this array. Single copy number change was successfully detected and the result was in general concordant with a microsatellite analysis. The pattern of copy number change was complex with multiple interstitial deletions/ gains. However, a predominance of telomeric 6q deletions was seen. Two small common and overlapping regions of deletion at 6q26 were identified. One was 1002 kb in size and contained PACRG and QKI, while the second was 199 kb and harbours a single gene, AR1D1B. The data show that the chromosome 6 tile path array is useful in mapping copy number changes with high resolution and accuracy. We confirmed the high frequency of chromosome 6 deletions in AA and GB, and identified two novel commonly deleted regions that may harbour TSGs.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England; Wellcome Trust Sanger Inst, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute	Ichimura, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Level 3,Lab Block,Box 231, Cambridge CB2 2QQ, England.	ki212@cam.ac.uk	Mungall, Andrew J./U-7067-2018	Mungall, Andrew J./0000-0002-0905-2742; Dunham, Ian/0000-0003-2525-5598	Cancer Research UK [A6618] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; BHATIA K, 1995, CANCER RES, V55, P1431; BIGNER SH, 1988, CANCER RES, V48, P405; Buschges R, 1999, BRAIN PATHOL, V9, P435; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cowell JK, 2004, CANCER GENET CYTOGEN, V151, P36, DOI 10.1016/j.cancergencyto.2003.09.012; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Ekong R, 2004, HUM MUTAT, V24, P76, DOI 10.1002/humu.20059; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; GAO X, 1995, ONCOGENE, V11, P1395; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2; Imai Y, 2003, J BIOL CHEM, V278, P51901, DOI 10.1074/jbc.M309655200; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Kleihues P, 2000, PATHOLOGY GENETICS T; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Li ZZ, 2002, JPN J CANCER RES, V93, P167, DOI 10.1111/j.1349-7006.2002.tb01255.x; Liu L, 2000, J NEUROPATH EXP NEUR, V59, P1087, DOI 10.1093/jnen/59.12.1087; Liu Y, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-20; Miyakawa A, 2000, BRIT J CANCER, V82, P543; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; Tagawa H, 2004, CANCER RES, V64, P5948, DOI 10.1158/0008-5472.CAN-03-4056; Tchinda J, 2004, BRIT J HAEMATOL, V126, P495, DOI 10.1111/j.1365-2141.2004.05082.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399	43	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1261	1271		10.1038/sj.onc.1209156	http://dx.doi.org/10.1038/sj.onc.1209156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205629	Green Accepted			2022-12-28	WOS:000235537500013
J	Ying, J; Li, H; Seng, TJ; Langford, C; Srivastava, G; Tsao, SW; Putti, T; Murray, P; Chan, ATC; Tao, Q				Ying, J; Li, H; Seng, TJ; Langford, C; Srivastava, G; Tsao, SW; Putti, T; Murray, P; Chan, ATC; Tao, Q			Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation	ONCOGENE			English	Article						Protocadherin; tumor suppressor gene; methylation; epigenetic; promoter; carcinoma	REPRESENTATIONAL DIFFERENCE ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; E-CADHERIN; ABERRANT METHYLATION; ADHESION MOLECULE; GASTRIC-CANCER; CELL-ADHESION; CO-REPRESSOR; HUMAN BREAST; H-CADHERIN	Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumorspecific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3-a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42-51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2'-deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG that is frequently inactivated epigenetically in multiple carcinomas.	Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China; Wellcome Trust Sanger Inst, Microarray Facil, Cambridge, England; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Natl Univ Singapore Hosp, Dept Pathol, Singapore 117548, Singapore; Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England	Chinese University of Hong Kong; Wellcome Trust Sanger Institute; University of Hong Kong; University of Hong Kong; National University of Singapore; Cancer Research UK; University of Birmingham	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Tsao, George/C-4422-2009	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; 				Angst BD, 2001, J CELL SCI, V114, P629; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185; DI PF, 2001, NAT GENET, V27, P103; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P615, DOI 10.1016/0955-0674(95)80101-4; Hirano S, 1999, J NEUROSCI, V19, P995; Hukku B, 1997, CANCER GENET CYTOGEN, V93, P125, DOI 10.1016/S0165-4608(96)00210-5; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Nakao S, 2005, MOL BRAIN RES, V134, P294, DOI 10.1016/j.molbrainres.2004.11.017; Okazaki N, 2002, CARCINOGENESIS, V23, P1139, DOI 10.1093/carcin/23.7.1139; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Toyooka KO, 2001, CANCER RES, V61, P4556; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Wolverton T, 2001, GENOMICS, V76, P66, DOI 10.1006/geno.2001.6592; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Yagi T, 2000, GENE DEV, V14, P1169; YING J, 2005, IN PRESS CLIN CANC R; Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	52	225	245	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1070	1080		10.1038/sj.onc.1209154	http://dx.doi.org/10.1038/sj.onc.1209154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247458				2022-12-28	WOS:000235361000011
J	Nguyen, QD; De Wever, O; Bruyneel, E; Hendrix, A; Xie, WZ; Lombet, A; Leibl, M; Mareel, M; Gieseler, F; Bracke, M; Gespach, C				Nguyen, QD; De Wever, O; Bruyneel, E; Hendrix, A; Xie, WZ; Lombet, A; Leibl, M; Mareel, M; Gieseler, F; Bracke, M; Gespach, C			Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment	ONCOGENE			English	Article						PKG; hypoxia; SPARC/BM-40; tenascin-C; peritoneal and pleural effusions; metastasis and thrombosis	PROTEASE-ACTIVATED RECEPTOR-1; VASCULAR SMOOTH-MUSCLE; GROWTH-FACTOR RECEPTOR; THROMBIN RECEPTOR; EPITHELIAL-CELLS; NEOPLASTIC PROGRESSION; TREFOIL PEPTIDES; FOCAL ADHESIONS; STRESS FIBERS; EXPRESSION	We recently reported that proteinase-activated receptors type I (PAR-1) are coupled to both negative and positive invasion pathways in colonic and kidney cancer cells cultured on collagen type I gels. Here, we found that treatments with the cell-permeant analog 8-Br-cGMP and the soluble guanylate cyclase activator BAY41-2272, and Rho kinase (ROK) inhibit ion by Y27632 or a dominant negative form of ROK lead to PAR-1-mediated invasion through differential Rac1 and Cdc42 signaling. Hypoxia or the counteradhesive matricellular protein SPARC/BM-40 ( SPARC: secreted protein acidic rich in cysteine) overexpressed during cancer progression also commutated PAR-1 to cellular invasion through the cGMP/protein kinase G (PKG) cascade, RhoA inactivation, and Rac1-dependent or -independent signaling. Cultured primary cancer cells isolated from peritoneal and pleural effusions from patients with colon cancer or other malignant tumors harbored PAR-1, as shown by RT-PCR and FACS analyses. These malignant effusions also contained high levels of activated thrombin and fibrin, and induced a proinvasive response in HCT8/S11 human colorectal cancer cells. Our data underline the essential role of the tumor microenvironment and of several commutators targeting cGMP/PKG signaling and the RhoA-ROK axis in the control of PAR-1 proinvasive activity and metastatic potential of cancer cells in distant organs and peritoneal or pleural cavities. We also add new insights into the mechanisms linking the coagulation mediators thrombin and PAR-1 in the context of blood coagulation disorders and venous thrombosis often observed in cancer patients, as described in 1865 by Armand Trousseau.	Hop St Antoine, INSERM, U673, F-75571 Paris, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Kiel, Dept Internal Med, D-24105 Kiel, Germany; Zhejiang Univ, Affiliated Hosp 1, Coll Med, Zhejiang, Peoples R China; Hop Marie Lannelongue, CNRS, UMR8078, F-92350 Le Plessis Robinson, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; University of Kiel; Zhejiang University; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	gespach@st-antoine.inserm.fr	Gieseler, Frank/L-4668-2013; Hendrix, An/L-5918-2019; de wever, olivier/J-3094-2013; Gieseler, Frank/E-8386-2012	de wever, olivier/0000-0002-5453-760X; Gieseler, Frank/0000-0001-6409-3822				Ahn B, 2001, CANCER RES, V61, P8357; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BRACKE ME, 2000, COLLAGEN INVASION AS, V58, P81; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Darmoul D, 2004, MOL CANCER RES, V2, P514; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; EMAMI S, 1984, BIOCHIM BIOPHYS ACTA, V804, P77, DOI 10.1016/0167-4889(84)90101-0; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hou YL, 2004, CELL SIGNAL, V16, P1061, DOI 10.1016/j.cellsig.2004.03.002; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kamath L, 2001, CANCER RES, V61, P5933; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kisley LR, 2002, CANCER RES, V62, P6850; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Maschler S, 2004, ONCOGENE, V23, P3622, DOI 10.1038/sj.onc.1207403; McHardy LM, 2004, CANCER RES, V64, P1468, DOI 10.1158/0008-5472.CAN-03-2733; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Ricort JM, 2002, FEBS LETT, V527, P293, DOI 10.1016/S0014-5793(02)03250-7; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; Thomas R, 2000, CLIN CANCER RES, V6, P1140; VanObberghenSchilling E, 1995, ANN NY ACAD SCI, V766, P431, DOI 10.1111/j.1749-6632.1995.tb26692.x; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Xie WZ, 2005, BIOMED PHARMACOTHER, V59, P70, DOI 10.1016/j.biopha.2005.01.001; Zhao DZ, 2004, J BIOL CHEM, V279, P43547, DOI 10.1074/jbc.M401453200	55	42	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8240	8251		10.1038/sj.onc.1208990	http://dx.doi.org/10.1038/sj.onc.1208990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091733				2022-12-28	WOS:000233956500003
J	Seo, J; Chung, YS; Sharma, GG; Moon, E; Burack, WR; Pandita, TK; Choi, K				Seo, J; Chung, YS; Sharma, GG; Moon, E; Burack, WR; Pandita, TK; Choi, K			Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53	ONCOGENE			English	Article						Cdt1; genomic instability; p53; cancer	DNA-REPLICATION; CELL-CYCLE; CANCER; GEMININ; GENE; EXPRESSION; REREPLICATION; INHIBITION; PROTEIN; MARKER	The exact duplication of chromosomal DNA during each cell cycle ensures the correct inheritance of genetic material from mother to daughter cells. In eukaryotic cells, DNA replication can occur only when the origin of DNA replication is accurately marked by a group of proteins termed licensing proteins. One such protein is Cdt1, which is recruited first to the origin of DNA replication followed by cell division cycle 6 (Cdc6) and mini-chromosome maintenance proteins (Mcms). We previously reported that NIH3T3 cells overexpressing Cdt1 readily formed tumors in mice. To further investigate its oncogenic mechanism, we generated transgenic mice expressing Cdt1 in thymocytes. Our studies demonstrated that T-cell-directed Cdt1 transgenic mice showed normal T-cell development. However, such transgenic mice developed thymic lymphoblastic lymphoma when crossed with p53 null mice. Furthermore, tumor cells derived from NIH3T3 cells overexpressing Cdt1 displayed numerical and structural chromosomal aberrations in the form of ploidy, double minutes, translocation, inversion, chromosome end-to-end fusion and robertsonian mutation. Collectively, our studies suggest that Cdt1 overexpression most likely contributes to tumorigenecity by causing genomic instability.	Washington Univ, Sch Med, Dept Pathol & Immunol, Suwon, South Korea; Ajou Univ, Dept Biol Sci, Suwon 441749, South Korea; Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA	Ajou University; Washington University (WUSTL)	Choi, K (corresponding author), Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	kchoi@pathology.wustl.edu	Pandita, Tej K/AAM-9188-2020		NCI NIH HHS [CA10445] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Bond L, 2002, ARCH PATHOL LAB MED, V126, P1163; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJITA M, 1999, FRONT BIOSCI, V4, P816; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HIRAMA T, 1995, BLOOD, V86, P841; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; KAMB A, 1994, SCIENCE, V264, P440; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; MOIR D, 1982, GENETICS, V100, P547; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohta S, 2001, ONCOL REP, V8, P1063; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; Saxena S, 2003, CELL CYCLE, V2, P283, DOI 10.4161/cc.2.4.443; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shreeram S, 2003, Prog Cell Cycle Res, V5, P287; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wharton SB, 2004, BRIT J CANCER, V91, P262, DOI 10.1038/sj.bjc.6601949; Whittaker AJ, 2000, GENE DEV, V14, P1765; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Xouri G, 2004, EUR J BIOCHEM, V271, P3368, DOI 10.1111/j.1432-1033.2004.04271.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8176	8186		10.1038/sj.onc.1208881	http://dx.doi.org/10.1038/sj.onc.1208881			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16261166				2022-12-28	WOS:000233809400009
J	Wang, M; Kirk, JS; Venkataraman, S; Domann, FE; Zhang, HJ; Schafer, FQ; Flanagan, SW; Weydert, CJ; Spitz, DR; Buettner, GR; Oberley, LW				Wang, M; Kirk, JS; Venkataraman, S; Domann, FE; Zhang, HJ; Schafer, FQ; Flanagan, SW; Weydert, CJ; Spitz, DR; Buettner, GR; Oberley, LW			Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor	ONCOGENE			English	Article						HIF-1; VEGF; angiogenesis; hypoxia; MnSOD	INDUCIBLE FACTOR-I; NF-KAPPA-B; LINDAU TUMOR-SUPPRESSOR; REDOX REGULATION; GLUTATHIONE-PEROXIDASE; INDUCED ANGIOGENESIS; ANTIOXIDANT ENZYMES; CELL PHENOTYPE; NITRIC-OXIDE; CANCER CELLS	Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that governs cellular responses to reduced O-2 availability by mediating crucial homeostatic processes. HIF-1 is composed of an HIF-1 alpha subunit and an HIF-1 beta subunit. HIF-1 alpha is degraded following enzyme-dependent hydroxylation of prolines of HIF-1 alpha in the presence of molecular oxygen, Fe2+, alpha-ketoglutarate, and ascorbate. These cofactors contribute to the redox environment of cells. The antioxidant enzyme manganese superoxide dismutase (MnSOD) also modulates the cellular redox environment. Here we show that MnSOD suppressed hypoxic accumulation of HIF-1 alpha protein in human breast carcinoma MCF-7 cells. This suppression was biphasic depending on MnSOD activity. At low levels of MnSOD activity, HIF-1 alpha protein accumulated under hypoxic conditions. At moderate levels of MnSOD activity (two-to six-fold increase compared to parent cells), these accumulations were blocked. However, at higher levels of MnSOD activity (> 6-fold increase), accumulation of HIF-1 alpha protein was again observed. This biphasic modulation was observed under both 1 and 4% O-2. Coexpression of mitochondrial hydrogen peroxide-removing proteins prevented the accumulation of HIF-1 alpha protein in cells with high levels of MnSOD; this effect demonstrates that the restabilization of HIF-1 alpha observed in high MnSOD overexpressors is probably due to hydrogen peroxide, most likely produced from MnSOD. Hypoxic induction of vascular endothelial growth factor ( VEGF) protein was also suppressed by elevated MnSOD activity and its levels reflected HIF-1 alpha protein levels. These observations demonstrated that HIF-1 alpha accumulation and VEGF expression could be modulated by the antioxidant enzyme MnSOD.	Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa	Oberley, LW (corresponding author), Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, B180 Med Labs, Iowa City, IA 52242 USA.	larry-oberley@uiowa.edu		Buettner, Garry/0000-0002-5594-1903; Domann, Frederick/0000-0002-0489-2179; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [CA66081, CA81090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081090, P01CA066081] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BROWN LF, 1997, EXS, V79, P233; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Collingridge DR, 1997, RADIAT RES, V147, P329, DOI 10.2307/3579340; DARR D, 1986, BIOCHEM PHARMACOL, V35, P3642, DOI 10.1016/0006-2952(86)90639-8; DEWHIRST MW, 1989, INT J RADIAT ONCOL, V17, P91, DOI 10.1016/0360-3016(89)90375-1; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hockel M, 1996, CANCER RES, V56, P4509; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; MOULDER JE, 1984, RADIAT RES, V98, P536, DOI 10.2307/3576486; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Park JH, 2003, CLIN CANCER RES, V9, P433; Powis G, 1997, Adv Pharmacol, V38, P329; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Semenza GL, 1998, CHEST, V114, p40S, DOI 10.1378/chest.114.1_Supplement.40S; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 1999, ANN NY ACAD SCI, V874, P262, DOI 10.1111/j.1749-6632.1999.tb09241.x; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SHAHYUKICH AA, 1988, LAB INVEST, V58, P236; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; TULCHIN N, 1976, ANAL BIOCHEM, V72, P485, DOI 10.1016/0003-2697(76)90558-3; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Wheeler MD, 2003, MOL CANCER RES, V1, P871; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	68	96	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8154	8166		10.1038/sj.onc.1208986	http://dx.doi.org/10.1038/sj.onc.1208986			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16170370				2022-12-28	WOS:000233809400007
J	Du, KY; Tsichlis, PN				Du, KY; Tsichlis, PN			Regulation of the Akt kinase by interacting proteins	ONCOGENE			English	Review						Akt; PKB; protein-protein interaction; phosphoinositide 3-kinase	T-CELL PROLIFERATIONS; SIGNAL-TRANSDUCTION; AKT/PKB ACTIVATION; NEGATIVE REGULATOR; MOLECULAR-CLONING; DOCKING SITE; HSP90; TCL1; PHOSPHORYLATION; IDENTIFICATION	Ten years ago, it was observed that the Akt kinase is activated by phosphorylation via a phosphoinositide 3-kinase (PI-3K)-dependent process. This discovery generated enormous interest because it provided a link between PI-3K, an enzyme known to play a critical role in cellular physiology, and its downstream targets. Subsequently, it was shown that the activity of the core components of the 'PI-3K/Akt pathway' is modulated by a complex network of regulatory proteins and pathways. Some of the Akt-binding partners modulate its activation by external signals by interacting with different domains of the Akt protein. This review focuses on the Akt interacting proteins and the mechanisms by which they regulate Akt activation.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Tufts Medical Center	Tsichlis, PN (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	ptsichlis@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA057436] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200; Bagatell R, 2004, MOL CANCER THER, V3, P1021; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barnouin Karin, 2004, Methods Mol Biol, V261, P479; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Cestra G, 2005, P NATL ACAD SCI USA, V102, P1731, DOI 10.1073/pnas.0409376102; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Chang-Liao KS, 2001, ELEC SOC S, V2001, P1; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fowler Amy M, 2004, Sci STKE, V2004, ptr11, DOI 10.1126/stke.2622004tr11; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Fukushima K, 2003, BIOL REPROD, V68, P1771, DOI 10.1095/biolreprod.102.010314; Glazer RI, 1998, CURR PHARM DESIGN, V4, P277; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gritti C, 1997, ONCOGENE, V15, P1329, DOI 10.1038/sj.onc.1201303; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Ingley E, 2000, FEBS LETT, V478, P253, DOI 10.1016/S0014-5793(00)01866-4; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; Klingenspor M, 1999, J BIOL CHEM, V274, P23078, DOI 10.1074/jbc.274.33.23078; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lim MA, 2004, FRONT BIOSCI-LANDMRK, V9, P387, DOI 10.2741/1226; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Madani A, 1996, BLOOD, V87, P1923; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Miller John, 2004, Methods Mol Biol, V261, P247; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Pekarsky Y, 2004, HEMATOL ONCOL CLIN N, V18, P863, DOI 10.1016/j.hoc.2004.04.007; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Petock John M, 2002, ScientificWorldJournal, V2, P1876; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Rorth P, 2000, MOL CELL, V6, P23; Saka Y, 2004, DEV BIOL, V273, P210, DOI 10.1016/j.ydbio.2004.05.032; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Siegel DH, 2002, CURR OPIN PEDIATR, V14, P419, DOI 10.1097/00008480-200208000-00011; Simpson F, 2005, TRAFFIC, V6, P442, DOI 10.1111/j.1600-0854.2005.00289.x; Song JJ, 2005, J BIOL CHEM, V280, P26845, DOI 10.1074/jbc.M502318200; Stagljar Igor, 2003, Sci STKE, V2003, ppe56; Sun LG, 2004, J CELL SCI, V117, P3021, DOI 10.1242/jcs.01142; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Vilenchik M, 2004, CHEM BIOL, V11, P787, DOI 10.1016/j.chembiol.2004.04.008; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Xi W, 2005, BIOCHEM BIOPH RES CO, V332, P200, DOI 10.1016/j.bbrc.2005.04.111; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang L, 2003, J BIOL CHEM, V278, P16820, DOI 10.1074/jbc.M213163200; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yuan ZQ, 2005, J BIOL CHEM, V280, P21483, DOI 10.1074/jbc.M500097200; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200	103	113	123	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7401	7409		10.1038/sj.onc.1209099	http://dx.doi.org/10.1038/sj.onc.1209099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288287				2022-12-28	WOS:000233201900003
J	Mei, YD; Du, WJ; Yang, YH; Wu, MA				Mei, YD; Du, WJ; Yang, YH; Wu, MA			Puma* Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1	ONCOGENE			English	Article						apoptosis; colocalization; protein stabilization; Puma; Mcl-1	COLORECTAL-CANCER CELLS; HAMSTER OVARY CELLS; BCL-2 FAMILY; CYTOCHROME-C; DNA-DAMAGE; IN-VIVO; APOPTOSIS; P53; PROTEIN; DEATH	Although Puma (p53 upregulated modulator of apoptosis) was known as a principal mediator of cell death in response to diverse apoptotic signals, the molecular mechanism underlying its proapoptotic regulation remains largely uncharacterized. Here we reported that myeloid cell leukemia-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family with a rapid turnover rate, interacts with Puma. The Puma/Mcl-1 interaction was verified by both yeast two-hybrid assay and co-immunoprecipation studies. Their binding sites were mapped to BH3 (Bcl-2 homology) domain of Puma and BH1 domain of Mcl-1, respectively. Mcl-1 and Puma was shown to colocalize at the mitochondria by immunostaining. The level of Mcl-1 was increased when coexpressed with Puma, indicating Puma is able to stabilize Mcl-1. Puma binding to Mcl-1 via its BH3 domain is the prerequisite for this effect, which is further supported by the finding that Puma mutant lacking BH3 domain no longer promotes Mcl-1 protein stability. This Puma-enhanced Mcl-1 stabilization was validated in vivo under nonoverexpression conditions. We also showed that BH1 domain is essential for Mcl-1 to inhibit Puma-induced apoptosis, since Mcl-1 mutant lacking BH1 domain completely abrogates its protective function. In addition, we concluded that binding of Puma to BH1 domain of Mcl-1 is necessary, but not sufficient to prevent rapid degradation of Mcl-1. In addition to PEST (proline, glutamic acid, serine, and threonine) and BH1 domain, some additional degradation signal is expected to reside in the C-terminal region of Mcl-1. In conclusion, our results provide the first evidence that the interaction between Mcl-1 and Puma may represent a novel mechanism by which Mcl-1 prevents apoptosis by increasing its stability through binding to Puma.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, MA (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Wu, Mian/H-2494-2018; du, wenjing/A-2530-2013; Mei, Yide/M-4468-2013	du, wenjing/0000-0002-3967-9984; Wu, Mian/0000-0002-2714-0500				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Prives C, 1999, J PATHOL, V187, P112; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Unkila M, 2001, J BIOL CHEM, V276, P39132, DOI 10.1074/jbc.M104986200; VILLUNGER A, 2003, SCIENCE         0918; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoon JH, 2002, CANCER RES, V62, P6500; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	37	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7224	7237		10.1038/sj.onc.1208873	http://dx.doi.org/10.1038/sj.onc.1208873			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007132				2022-12-28	WOS:000232990100011
J	Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H				Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H			Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer	ONCOGENE			English	Article						cDNA array; hyperthermia; low pH; HDAC3; head and neck cancer	HISTONE DEACETYLASE INHIBITOR; EPIDERMAL-GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; RANDOMIZED-TRIAL; NITRIC-OXIDE; TUMOR-GROWTH; EXPRESSION; CELLS; P53	To elucidate the molecular mechanisms for the enhancement of heat-induced apoptosis on exposure to acidic conditions, human maxillary carcinoma IMC-3 cells were heat-shocked at 44 degrees C for 30 min at either pH 7.4 or 6.7. Analyses with cDNA arrays, the reverse transcription polymerase chain reaction (RT-PCR), and Western blotting were performed. We found that histone deacetylase 3 (HDAC3) was specifically induced after hyperthermia at 44 degrees C for 30 min at pH 6.7. Although the cytotoxicity of heating at 44 degrees C for 30 min was enhanced by decreasing the pH from 7.4 to 6.7, it was enhanced even more by antisense RNA oligonucleotides for HDAC3. The induction of G(2)/M arrest after heating occurred earlier at pH 6.7 than at pH 7.4. The inhibition of HDAC3 by the antisense RNA oligonucleotides suppressed partially the induction of G2/M arrest, resulting in an enhancement of the apoptosis caused by the heating under acidic conditions. Antisense RNA oligonucleotides for HDAC3 enhanced apoptosis 48 h after hyperthermia at 43 degrees C for 30 min in vivo. Analyses of p65 activity suggested that NF-KB is involved in this enhancement of hyperthermia. HDAC3 may be a novel target enhancing hyperthermia and combined treatment with hyperthermia and HDAC inhibitors is a possible modality for cancer therapy.	Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan; Univ Fukui, Fac Med Sci, Dept Expt Radiol & Hlth Phys, Matsuoka, Fukui 9101193, Japan	University of Fukui; University of Fukui	Narita, N (corresponding author), Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan.	norihiko@fmsrsa.fukui-med.ac.jp	Narita, Norihiko/AAA-4801-2022	Narita, Norihiko/0000-0001-9765-9669				AKIN RE, 2004, J BIOL CHEM, V297, P51218; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Dahl O, 2002, INT J HYPERTHER, V18, P25, DOI 10.1080/02656730110083756; ENGIN K, 1995, CLIN CANCER RES, V1, P139; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; Huang YH, 2002, CANCER RES, V62, P2913; Jin ZH, 2004, INT J RADIAT ONCOL, V59, P852, DOI 10.1016/j.ijrobp.2004.01.033; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Levenson VV, 2000, CANCER RES, V60, P5027; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; Matsumoto H, 1997, INT J RADIAT ONCOL, V38, P1089, DOI 10.1016/S0360-3016(97)00300-3; Matsumoto H, 1998, INT J ONCOL, V13, P741; Matsumoto H, 1998, INT J RADIAT ONCOL, V41, P915, DOI 10.1016/S0360-3016(98)00121-7; Matsumoto H, 1999, CANCER RES, V59, P3239; MIZOGUCHI H, 1991, INT J CANCER, V49, P738, DOI 10.1002/ijc.2910490518; MORONI MC, 1992, J BIOL CHEM, V267, P2714; Mukhopadhyay T, 1996, CRIT REV ONCOGENESIS, V7, P151, DOI 10.1615/CritRevOncog.v7.i3-4.20; Murata M, 2000, JPN J CANCER RES, V91, P1154, DOI 10.1111/j.1349-7006.2000.tb00899.x; Narita N, 2002, INT J RADIAT ONCOL, V53, P190, DOI 10.1016/S0360-3016(02)02727-X; Ohnishi K, 2001, INT J HYPERTHER, V17, P415, DOI 10.1080/02656730110063604; Ohtsubo T, 2001, INT J RADIAT ONCOL, V49, P1391, DOI 10.1016/S0360-3016(00)01590-X; Ohtsubo T, 2000, INT J HYPERTHER, V16, P481, DOI 10.1080/02656730050199331; OVERGAARD J, 1995, LANCET, V345, P540, DOI 10.1016/S0140-6736(95)90463-8; Park HJ, 1999, BRIT J CANCER, V80, P1892, DOI 10.1038/sj.bjc.6690617; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; RHEE JG, 1984, INT J RADIAT ONCOL, V10, P393, DOI 10.1016/0360-3016(84)90060-9; Ru K, 1999, ONCOL RES, V11, P505; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Takahashi A, 2003, INT J HYPERTHER, V19, P145, DOI 10.1080/02656730210166131; Takahashi I, 2002, SURGERY, V131, pS78, DOI 10.1067/msy.2002.119308; Takasu T, 1998, CANCER RES, V58, P2504; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yu XD, 2002, J NATL CANCER I, V94, P504	43	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7346	7354		10.1038/sj.onc.1208879	http://dx.doi.org/10.1038/sj.onc.1208879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044157				2022-12-28	WOS:000233142100011
J	Scholz, C; Richter, A; Lehmann, M; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Scholz, C; Richter, A; Lehmann, M; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway	ONCOGENE			English	Article						arsenic trioxide; apoptosis; caspase-8; FADD; death receptor; CD95/Fas	ACUTE PROMYELOCYTIC LEUKEMIA; DRUG-INDUCED APOPTOSIS; CD95/FAS RECEPTOR; CYCLE ARREST; ACTIVATION; CASPASE-8; INDUCTION; BCL-2; MANNER; LINES	Arsenic trioxide (As2O3, arsenite) efficiently kills cells from various hematologic malignancies and has successfully been employed especially for the treatment of acute promyelocytic leukemia. There and in lymphoid cells, we demonstrated that As2O3 induces cell death in a caspase-2- and -9-independent fashion. Here, we address a potential role of death receptor signaling through the FADD/caspase-8 death-inducing signaling complex in As2O3-induced cell death. In detail, we demonstrate that As2O3 induces cell death independently of caspase-8 or FADD and cannot be blocked by disruption of CD95/Fas receptor ligand interaction. Unlike in death receptor ligation-induced apoptosis, As2O3-induced cell death was not blocked by the broad-spectrum caspase inhibitor z-VAD-fmk or the caspase-8-specific inhibitor z- IETD-fmk. Nevertheless, As2O3-induced cell death occurred in a regulated manner and was abrogated upon Bcl-2 overexpression. In contrast, As2O3-induced cell demise was neither blocked by the caspase-9 inhibitor z-LEHD-fmk nor substantially inhibited through the expression of a dominant negative caspase-9 mutant. Altogether our data demonstrate that As2O3-induced cell death occurs independently of the extrinsic death receptor pathway of apoptosis. Cell death proceeds entirely via an intrinsic, Bcl-2-controlled mitochondrial pathway that does, however, not rely on caspase-9.	Humboldt Univ, Med Ctr, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Humboldt University of Berlin; Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Daniel, PT (corresponding author), Charite Univ, Campus Virchow Klinikum, Med Ctr, Augustenburger Platz 1, D-13353 Berlin, Germany.	pdaniel@mdc-berlin.de	Scholz, Christian W/Q-2778-2017; Lehmann, Mario/G-6090-2016; Schulze-Osthoff, Klaus/N-9025-2013	Scholz, Christian W/0000-0001-6260-4086; Lehmann, Mario/0000-0001-8284-5071; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1998, BLOOD, V92, P4750, DOI 10.1182/blood.V92.12.4750.424k34_4750_4757; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hossain K, 2000, J IMMUNOL, V165, P4290, DOI 10.4049/jimmunol.165.8.4290; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Woo SH, 2004, INT J CANCER, V112, P596, DOI 10.1002/ijc.20433; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu JB, 2003, ONCOL REP, V10, P705; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	40	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7031	7042		10.1038/sj.onc.1208868	http://dx.doi.org/10.1038/sj.onc.1208868			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007134				2022-12-28	WOS:000232833200005
J	Morales, C; Ribas, M; Aiza, G; Peinado, MA				Morales, C; Ribas, M; Aiza, G; Peinado, MA			Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells	ONCOGENE			English	Article						drug resistance; colorectal cancer; genetic instability; tumor classification	COMPARATIVE GENOMIC HYBRIDIZATION; DIHYDROFOLATE-REDUCTASE; FRAGILE SITES; CHROMOSOME; AMPLIFICATION; PATHWAYS; TUMOR; INSTABILITY; EXPRESSION; HYDROLASE	Alternative genetic pathways characterized by specific genetic profiles and exhibiting distinctive biological and clinical features have been proposed in colorectal carcinogenesis. Methotrexate (MTX) is a potent inhibitor of the dihydrofolate reductase (DHFR) enzyme, which is essential for DNA synthesis and cell growth. We have evaluated the association between different genetic features and the capacity to develop MTX resistance in colon cancer cell lines representative of alternative genetic pathways. Three aneuploid cell lines (HT-29, SW480, and SK-CO-1) showed pre-existing amplifications, but only one (HT-29) developed MTX resistance, showing amplification of the DHFR gene at 5q12-14 (> 20-fold amplification and presence of extrachromosomal double minutes). Failure to develop resistance was attributed to the absence of two complete chromosomes 5 in SW480 and SK-CO-1 cells. Four near-diploid cell lines (LoVo, HCT116, DLD-1 and KM12C) and two aneuploid KM12C-derived metastases (KM12SM and KM12L4A) developed MTX resistance but none exhibited DHFR amplification. All resistant cells without DHFR gene amplification showed microsatellite instability. We conclude that chemoresistance capacity and the mechanism of chemoresistance are related with the genetic pathway and the karyotypic features of colon cancer cells.	Inst Recerca Oncol, IDIBELL, Barcelona 08907, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Peinado, MA (corresponding author), Inst Recerca Oncol, IDIBELL, Granvia Km 2-7,Hosp, Barcelona 08907, Spain.	mpeinado@iro.es	Peinado, Miguel A./A-5591-2008	Peinado, Miguel A./0000-0002-4090-793X				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.3.CO;2-N; Bosson G, 2003, BRIT J BIOMED SCI, V60, P117, DOI 10.1080/09674845.2003.11783687; Camps J, 2004, INT J CANCER, V110, P869, DOI 10.1002/ijc.20195; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chu E, 1996, STEM CELLS, V14, P41, DOI 10.1002/stem.140041; Cole PD, 2001, CANCER RES, V61, P4599; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Goel A, 2003, CANCER RES, V63, P1608; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Heppner GH, 1998, INT REV CYTOL, V177, P1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2001, CANCER RES, V61, P3230; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Masramon L, 1998, BRIT J CANCER, V77, P2349, DOI 10.1038/bjc.1998.390; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; NUNBERG JH, 1978, P NATL ACAD SCI USA, V75, P5553, DOI 10.1073/pnas.75.11.5553; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ribas M, 2002, FASEB J, V16, P289, DOI 10.1096/fj.02-0425fje; Risques RA, 2003, CANCER RES, V63, P7206; Rots MG, 2000, BRIT J HAEMATOL, V110, P791, DOI 10.1046/j.1365-2141.2000.02070.x; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Ruggiero T, 2003, NUCLEIC ACIDS RES, V31, P6561, DOI 10.1093/nar/gkg858; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; [No title captured]	45	29	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6842	6847		10.1038/sj.onc.1208834	http://dx.doi.org/10.1038/sj.onc.1208834			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007155				2022-12-28	WOS:000232527800012
J	Buchholz, M; Braun, M; Heidenblut, A; Kestler, HA; Kloppel, G; Schmiegel, W; Hahn, SA; Luttges, J; Gress, TM				Buchholz, M; Braun, M; Heidenblut, A; Kestler, HA; Kloppel, G; Schmiegel, W; Hahn, SA; Luttges, J; Gress, TM		German Pancreatic Cancer Net Deuts	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions	ONCOGENE			English	Article						PanIN progression; gene expression; early diagnosis; target genes	K-RAS MUTATIONS; DUCTAL ADENOCARCINOMA; EXTRACELLULAR-MATRIX; CANCER; EXPRESSION; INACTIVATION; RESECTION; TUMORS; MODEL; CLASSIFICATION	Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours. Both the late clinical presentation of patients, due to lack of early symptoms, as well as the rapid and aggressive course of the disease contribute to the extremely high mortality of this malignancy. Recently, a multistep progression model for PDAC integrating morphological, clinical and molecular evidence has been proposed. Putative precursor lesions, termed pancreatic intraepithelial neoplasia (PanIN), are classified into three different grades (PanIN-1 through -3) based on the degree of cellular atypia they display. We have conducted large-scale expression pro. ling analyses of microdissected cells from normal pancreatic ducts, PanINs of different grades and PDACs using whole-genome oligonucleotide microarrays. Veri. cation of hybridisation results for selected genes was performed using quantitative real-time PCR and immunohistochemical analyses on PanIN tissue microarrays. Comparison of the expression profiles demonstrated that the greatest changes in gene expression occur between PanIN stages 1B and 2, suggesting that PanIN-2 may represent the first truly preneoplastic stage in PDAC progression. Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.	Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Ruhr Univ Bochum, Dept Internal Med, D-4630 Bochum, Germany; Univ Kiel, Dept Pathol, D-2300 Kiel, Germany	Ulm University; Ruhr University Bochum; University of Kiel	Gress, TM (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.gress@medizin.uni-ulm.de	Kestler, Hans A./D-5799-2012; Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Kestler, Hans A./0000-0002-4759-5254; Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741; Gress, Thomas/0000-0002-9333-5461				Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Buchholz M, 2003, CANCER RES, V63, P4945; Canto MI, 2004, CLIN GASTROENTEROL H, V2, P606, DOI 10.1016/S1542-3565(04)00244-7; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X; Gronborg M, 2004, J PROTEOME RES, V3, P1042, DOI 10.1021/pr0499085; Heinmoller E, 2000, AM J PATHOL, V157, P83, DOI 10.1016/S0002-9440(10)64520-8; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Hruban RH, 2001, DIGEST DIS, V19, P76, DOI 10.1159/000050656; Huflejt ME, 2003, GLYCOCONJUGATE J, V20, P247, DOI 10.1023/B:GLYC.0000025819.54723.a0; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kawakami K, 2001, CANCER RES, V61, P6194; Kloppel Gunter, 2004, Curr Gastroenterol Rep, V6, P111, DOI 10.1007/s11894-004-0037-y; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Luttges J, 2004, CANCER-AM CANCER SOC, V100, P173, DOI 10.1002/cncr.11860; Luttges J, 2000, CANCER, V88, P2495, DOI 10.1002/1097-0142(20000601)88:11<2495::AID-CNCR10>3.0.CO;2-B; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Luttges J, 1999, VIRCHOWS ARCH, V435, P461, DOI 10.1007/s004280050428; LYNCH HT, 1994, ARCH SURG-CHICAGO, V129, P266; LYNCH HT, 1990, AM J GASTROENTEROL, V85, P54; Lynch HT, 1996, SEMIN ONCOL, V23, P251; Maitra A, 2003, MODERN PATHOL, V16, P902, DOI 10.1097/01.MP.0000086072.56290.FB; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Strojan P, 2004, CLIN CHIM ACTA, V344, P155, DOI 10.1016/j.cccn.2004.02.011; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suomela S, 2004, J INVEST DERMATOL, V122, P717, DOI 10.1111/j.0022-202X.2004.22322.x; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Trede M, 2001, SURG CLIN N AM, V81, P595, DOI 10.1016/S0039-6109(05)70146-8; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vimalachandran Dale, 2004, Cancer Control, V11, P6; Wilentz RE, 1998, CANCER RES, V58, P4740; Wilentz RE, 2000, CANCER RES, V60, P2002; Yamakawa T, 1998, BBA-GENE STRUCT EXPR, V1395, P202, DOI 10.1016/S0167-4781(97)00149-8; Yeo CJ, 1998, LANGENBECK ARCH SURG, V383, P129, DOI 10.1007/s004230050104; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	48	155	161	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6626	6636		10.1038/sj.onc.1208804	http://dx.doi.org/10.1038/sj.onc.1208804			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16103885				2022-12-28	WOS:000232367800004
J	Andrews, PD				Andrews, PD			Aurora kinases: shining lights on the therapeutic horizon?	ONCOGENE			English	Review						aurora kinase; microtubule; spindle checkpoint; centrosome; kinetochore; therapy	INNER CENTROMERE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; KINETOCHORE-MICROTUBULE ATTACHMENT; CHROMOSOMAL PASSENGER PROTEIN; MITOTIC SPINDLE; BUDDING YEAST; CENTROSOME AMPLIFICATION; A OVEREXPRESSION; CELL-DIVISION; IN-VIVO	The Aurora kinases have been implicated in tumorigenesis and are important regulators of diverse cell cycle events, ranging from the entry into mitosis, centrosome function, mitotic spindle formation, chromosome biorientation and segregation, and cytokinesis. The recent identification of novel binding partners and key downstream effectors, together with new small-molecule inhibitors that display efficacy against tumours, heralds an upsurge of interest in these critical kinases. This review details new developments in the field and analyses the potential of Aurora kinases as anticancer targets.	Univ Dundee, Div Gene Regulat & Express, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Andrews, PD (corresponding author), Univ Dundee, Div Gene Regulat & Express, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	p.d.andrews@dundee.ac.uk		Andrews, Paul/0000-0001-7699-5604	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Bar-Shira A, 2002, CANCER RES, V62, P6803; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Brown JR, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-39; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Fraizer GC, 2004, INT J ONCOL, V25, P1631; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gruss OJ, 2004, J CELL BIOL, V166, P949, DOI 10.1083/jcb.200312112; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; Jiang Y, 2003, ONCOGENE, V22, P8293, DOI 10.1038/sj.onc.1206873; Kamada K, 2004, ONCOL REP, V12, P593; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lengauer C, 2004, NAT GENET, V36, P1144, DOI 10.1038/ng1104-1144; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Moore A, 2004, TRENDS CELL BIOL, V14, P537, DOI 10.1016/j.tcb.2004.09.001; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ning S, 2004, INT J ONCOL, V25, P1065; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Ohi R, 2003, DEV CELL, V5, P309, DOI 10.1016/S1534-5807(03)00229-6; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Ovechkina Y, 2003, TRAFFIC, V4, P367, DOI 10.1034/j.1600-0854.2003.00099.x; Pagliaro L, 2004, CURR OPIN CHEM BIOL, V8, P442, DOI 10.1016/j.cbpa.2004.06.006; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Petersen J, 2003, CURR BIOL, V13, P590, DOI 10.1016/S0960-9822(03)00205-7; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; RAJAGOPALAN H, 2004, NAT CANC REV, V3, P659; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Romano A, 2003, J CELL BIOL, V161, P229, DOI 10.1083/jcb.200207117; Sager JA, 2003, CANCER BIOL THER, V2, P452, DOI 10.4161/cbt.2.4.448; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Shang C, 2003, MOL BIOL CELL, V14, P3342, DOI 10.1091/mbc.E02-11-0765; Song ZY, 2004, MOL BIOL CELL, V15, P1287, DOI 10.1091/mbc.E03-07-0512; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Sun T, 2004, CARCINOGENESIS, V25, P2225, DOI 10.1093/carcin/bgh244; Tanaka T, 1999, CANCER RES, V59, P2041; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Tu SP, 2005, GASTROENTEROLOGY, V128, P361, DOI 10.1053/j.gastro.2004.11.058; Uchida H, 2004, MOL THER, V10, P162, DOI 10.1016/j.ymthe.2004.05.006; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153	100	164	175	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5005	5015		10.1038/sj.onc.1208752	http://dx.doi.org/10.1038/sj.onc.1208752			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	16049526				2022-12-28	WOS:000230816900001
J	He, B; Mirza, M; Weber, GF				He, B; Mirza, M; Weber, GF			An osteopontin splice variant induces anchorage independence in human breast cancer cells	ONCOGENE			English	Article						breast cancer; alternative splicing; cell adhesion; metastasis; soft agar	FALSE DISCOVERY RATE; METASTATIC PHENOTYPE; SIGNALING PATHWAY; MOUSE OSTEOPONTIN; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; GENE; ACTIVATION; LIGAND	In malignant tumors, metastasis genes are typically deregulated by aberrant expression or splicing. Osteopontin is expressed at high levels by various cancers and contributes importantly to their invasive potential. In contrast, osteopontin derived from host cells induces cellular immunity and could bolster antitumor protection by cytotoxic T lymphocytes. Here we show that breast cancer cells express multiple splice variants of osteopontin. According to RT-PCR analysis of human breast tissue specimens, the splice variant osteopontin-c is a highly specific marker for transformed cells, which is not expressed in their surrounding normal tissue. The full-length form of osteopontin aggregates in the presence of physiologic amounts of calcium and, in this state, leads to enhanced cell adhesion. Ostensibly, this effect is inhibitory for tumor cell dissemination. The shortest splice variant, osteopontin-c, does not aggregate in the presence of calcium and enhances clone formation in soft agar. According to microarray analysis, osteopontin-c induces the expression of oxidoreductases, consistent with protection from anoikis during anchorage-independent growth. These studies de. ne a third functional domain of osteopontin, beside the C-terminal CD44-binding site and the central integrin-binding site. They also provide evidence for a bifunctional character of osteopontin, with the soluble form supporting invasiveness and the aggregated form promoting adhesion.	Univ Cincinnati, Med Ctr, Coll Pharm, Cincinnati, OH 45267 USA; Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA USA	University System of Ohio; University of Cincinnati; Tufts Medical Center	Weber, GF (corresponding author), Univ Cincinnati, Med Ctr, Coll Pharm, 3225 Eden Ave, Cincinnati, OH 45267 USA.	georg.weber@uc.edu			NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER; NCI NIH HHS [CA76176] Funding Source: Medline; NCRR NIH HHS [M01 RR 08084] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adler B, 2001, CELL IMMUNOL, V210, P30, DOI 10.1006/cimm.2001.1800; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Barraclough R, 1998, BIOCHEM SOC SYMP, P273; Bayless KJ, 1998, J CELL SCI, V111, P1165; BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Chen PW, 1996, ANN NY ACAD SCI, V795, P325, DOI 10.1111/j.1749-6632.1996.tb52683.x; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani MK, 2001, ONCOGENE, V20, P1793, DOI 10.1038/sj.onc.1204358; Goldsmith HL, 2002, ANN BIOMED ENG, V30, P840, DOI 10.1114/1.1497383; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HWANG S, 1994, J BIOL CHEM, V269, P711; KARYALA S, 2003, CARDIOVASC TOXICOL, V4, P47; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; Kon S, 2000, J CELL BIOCHEM, V77, P487; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; O'Regan AW, 2000, J LEUKOCYTE BIOL, V68, P495; Oates AJ, 1996, ONCOGENE, V13, P97; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306; Rudland PS, 2002, CANCER RES, V62, P3417; SAITOH Y, 1995, LAB INVEST, V72, P55; Sartor M, 2004, BIOTECHNIQUES, V36, P790, DOI 10.2144/04365ST02; Seraj MJ, 2000, CANCER RES, V60, P2764; Singhal H, 1997, CLIN CANCER RES, V3, P605; Sung V, 1998, EXP CELL RES, V241, P273, DOI 10.1006/excr.1998.4029; TANABE KK, 1995, ANN SURG, V222, P493; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Weber GF, 2000, J MOL MED-JMM, V78, P404, DOI 10.1007/s001090000138; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; Weber GF, 2000, BRAIN RES BULL, V53, P421, DOI 10.1016/S0361-9230(00)00379-8; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEBER GF, 1999, INFLAMMATORY CELLS M, P97; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x	48	139	149	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2192	2202		10.1038/sj.onc.1209248	http://dx.doi.org/10.1038/sj.onc.1209248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288209				2022-12-28	WOS:000236581200006
J	Carles, A; Millon, R; Cromer, A; Ganguli, G; Lemaire, F; Young, J; Wasylyk, C; Muller, D; Schultz, I; Rabouel, Y; Dembele, D; Zhao, C; Marchal, P; Ducray, C; Bracco, L; Abecassis, J; Poch, O; Wasylyk, B				Carles, A; Millon, R; Cromer, A; Ganguli, G; Lemaire, F; Young, J; Wasylyk, C; Muller, D; Schultz, I; Rabouel, Y; Dembele, D; Zhao, C; Marchal, P; Ducray, C; Bracco, L; Abecassis, J; Poch, O; Wasylyk, B			Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display	ONCOGENE			English	Article						macroarray; microarray; integrative genomics; bioinformatics	GENE-EXPRESSION; IDENTIFICATION; CANCER; 11Q13; GENERATION; ARHGAP10; ADAPTER	Head and neck squamous cell carcinoma (HNSCC) is common worldwide and is associated with a poor rate of survival. Identification of new markers and therapeutic targets, and understanding the complex transformation process, will require a comprehensive description of genome expression, that can only be achieved by combining different methodologies. We report here the HNSCC transcriptome that was determined by exhaustive differential display (DD) analysis coupled with validation by different methods on the same patient samples. The resulting 820 nonredundant sequences were analysed by high throughput bioinformatics analysis. Human proteins were identified for 73% (596) of the DD sequences. A large proportion (> 50%) of the remaining unassigned sequences match ESTs (expressed sequence tags) from human tumours. For the functionally annotated proteins, there is significant enrichment for relevant biological processes, including cell motility, protein biosynthesis, stress and immune responses, cell death, cell cycle, cell proliferation and/or maintenance and transport. Three of the novel proteins (TMEM16A, PHLDB2 and ARH-GAP21) were analysed further to show that they have the potential to be developed as therapeutic targets.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Lab Biol Tumorale, UPRES EA 34 30, Strasbourg, France; Exonhit Therapeut, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Dembélé, Doulaye/O-6513-2017; Wasylyk, Bohdan/ABG-6778-2020; Young, Julia/A-7219-2013; Indra, Gitali/G-2963-2016	Dembélé, Doulaye/0000-0003-3879-6940; Wasylyk, Bohdan/0000-0002-1718-1237; RABOUEL, Yannick/0000-0001-8201-7209; Young, Julia/0000-0001-7219-7824				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Basseres DS, 2002, BIOCHEM BIOPH RES CO, V294, P579; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Broude Natalia E, 2002, Expert Rev Mol Diagn, V2, P209, DOI 10.1586/14737159.2.3.209; Chalmel F, 2005, BIOINFORMATICS, V21, P2095, DOI 10.1093/bioinformatics/bti252; Cirelli C, 2000, BRAIN RES, V885, P303, DOI 10.1016/S0006-8993(00)03008-0; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dancey JE, 2004, ANN ONCOL, V15, P233, DOI 10.1093/annonc/mdh932; Ding CM, 2004, J BIOCHEM MOL BIOL, V37, P1; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Draghici S, 2003, BIOINFORMATICS, V19, P1348, DOI 10.1093/bioinformatics/btg165; Hasina R, 2004, SEMIN ONCOL, V31, P718, DOI 10.1053/j.seminoncol.2004.09.012; Heilig M, 2004, NEUROTOX RES, V6, P363, DOI 10.1007/BF03033310; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Huang Zhong-xi, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P798; Katoh M, 2003, INT J ONCOL, V22, P1375; Katoh M, 2004, INT J ONCOL, V25, P1201; Katsanis N, 2002, P NATL ACAD SCI USA, V99, P14326, DOI 10.1073/pnas.222409099; Lemaire F, 2003, BRIT J CANCER, V89, P1940, DOI 10.1038/sj.bjc.6601373; Liang P, 2003, NAT REV CANCER, V3, P869, DOI 10.1038/nrc1214; Liang P, 1998, METHODS, V16, P361, DOI 10.1006/meth.1998.0690; Liang P, 2002, BIOTECHNIQUES, V33, P338, DOI 10.2144/02332rv01; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Oetting WS, 2000, PIGM CELL RES, V13, P21, DOI 10.1034/j.1600-0749.2000.130105.x; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Paranavitane V, 2003, J BIOL CHEM, V278, P1328, DOI 10.1074/jbc.M208352200; Pascal T, 2005, FEBS LETT, V579, P3651, DOI 10.1016/j.febslet.2005.05.056; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Stein J, 2002, CELL MOL LIFE SCI, V59, P1235, DOI 10.1007/s00018-002-8501-z; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Trenkle T, 1999, BIOTECHNIQUES, V27, P554, DOI 10.2144/99273rr03; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wells JM, 1999, ALZ DIS ASSOC DIS, V13, pS78; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787	40	91	100	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1821	1831		10.1038/sj.onc.1209203	http://dx.doi.org/10.1038/sj.onc.1209203			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261155				2022-12-28	WOS:000236013700015
J	Spillare, EA; Wang, XW; von Kobbe, C; Bohr, VA; Hickson, ID; Harris, CC				Spillare, EA; Wang, XW; von Kobbe, C; Bohr, VA; Hickson, ID; Harris, CC			Redundancy of DNA helicases in p53-mediated apoptosis	ONCOGENE			English	Article						helicases; apoptosis; microinjection	BLOOMS-SYNDROME PROTEIN; WERNERS-SYNDROME GENES; SACCHAROMYCES-CEREVISIAE; GENOMIC INSTABILITY; XERODERMA-PIGMENTOSUM; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; RECQ HELICASES; SYNDROME CELLS; SGS1 MUTANT	A subset of DNA helicases, the RecQ family, has been found to be associated with the p53-mediated apoptotic pathway and is involved in maintaining genomic integrity. This family contains the BLM and WRN helicases, in which germline mutations are responsible for Bloom and Werner syndromes, respectively. TFIIH DNA helicases, XPB and XPD, are also components in this apoptotic pathway. We hypothesized that there may be some redundancy between helicases in their ability to complement the attenuated p53-mediated apoptotic levels seen in cells from individuals with diseases associated with these defective helicase genes. The attenuated apoptotic phenotype in Bloom syndrome cells was rescued not only by ectopic expression of BLM, but also by WRN or XPB, both 30-50 helicases, but not expression of the 50-30 helicase XPD. Overexpression of Sgs1, a WRN/BLM yeast homolog, corrected the reduction in BS cells only, which is consistent with Sgs1 being evolutionarily most homologous to BLM. A restoration of apoptotic levels in cells from WS, XPB or XPD patients was attained only by overexpression of the specific helicase. Our data suggest a limited redundancy in the pathways of these RecQ helicases in p53-induced apoptosis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NIA, Lab Mol Gerontol, DHHS, NIH, Baltimore, MD USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020; Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Hickson, Ian/0000-0002-0583-566X; von Kobbe, Cayetano/0000-0003-3895-3790	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 BC005795-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ajima J, 2002, MUTAT RES-FUND MOL M, V504, P157, DOI 10.1016/S0027-5107(02)00089-1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Lane D, 2004, CARCINOGENESIS, V25, P1077, DOI 10.1093/carcin/bgh186; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lillard-Wetherell K, 2005, CANCER RES, V65, P5520, DOI 10.1158/0008-5472.CAN-05-0632; Machwe A, 2004, ONCOGENE, V23, P149, DOI 10.1038/sj.onc.1206906; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Robles AI, 2001, ACTA ONCOL, V40, P696; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sanz MM, 2000, AM J HUM GENET, V67, P89; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Watt PM, 1996, GENETICS, V144, P935; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	40	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2119	2123		10.1038/sj.onc.1209242	http://dx.doi.org/10.1038/sj.onc.1209242			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288211	Green Accepted			2022-12-28	WOS:000236359700015
J	Wu, D; Chen, B; Parihar, K; He, L; Fan, C; Zhang, J; Liu, L; Gillis, A; Bruce, A; Kapoor, A; Tang, D				Wu, D; Chen, B; Parihar, K; He, L; Fan, C; Zhang, J; Liu, L; Gillis, A; Bruce, A; Kapoor, A; Tang, D			ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function	ONCOGENE			English	Article						hydroxyurea; MEK1; Erk; ATR; S-phase checkpoint	ATAXIA TELANGIECTASIA CELLS; PROTEIN-KINASE KINASE; HISTONE H2AX; SUSTAINED ACTIVATION; CYCLIN D1; P53; INHIBITORS; REPAIR; TRANSFORMATION; INSTABILITY	Although Erk kinase has been recently reported to function in the DNA damage response, the mechanism governing this process is unknown. We report here that hydroxyurea (HU) activates Erk via MEK1, a process that is sensitized by a constitutively active MEK1 (MEK1Q56P) and attenuated by a dominant-negative MEK1 (MEK1K97M). While ectopic MEK1Q56P sensitized HU-induced S-phase arrest, inhibition of Erk activation via U0126, PD98059, and MEK1K97M attenuated the arrest, and thereby enhanced cells to HU-induced toxicity. Taken together, we demonstrate an important contribution of Erk to the activation of the S-phase DNA damage checkpoint. This can be attributed to Erk's regulatory role in modulating ATR function. Inhibition of Erk activation with U0126/PD98059 and MEK1K97M substantially reduced HU-induced ATR nuclear foci, leading to a dramatic reduction of gamma H2AX and its nuclear foci. Reduction of MEK1 function by a small interference RNA ( siRNA) MEK1 and ectopic MEK1K97M significantly decreased HU-induced gamma H2AX. Conversely, ectopic MEK1Q56P enhanced gamma H2AX foci. Furthermore, immunofluorescent and cell fractioning experiments revealed cytosolic and nuclear localization of ATR. HU treatment caused the redistribution of ATR from the cytosol to the nucleus, a process that is inhibited by U0126. Collectively, we show that Erk kinase modulates HU-initiated DNA damage response by regulating ATR function.	St Joseph Hosp, Father Sean Sullivan Res Inst, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Tang, D (corresponding author), St Joseph Hosp, Father Sean Sullivan Res Inst, T3310,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Kapoor, Anil/AAQ-7184-2021	Tang, Damu/0000-0002-3282-9521; Kapoor, Anil/0000-0001-9180-8029				Ahn NG, 2001, METHOD ENZYMOL, V332, P417; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Johns DG, 1998, BIOCHEM PHARMACOL, V55, P1551, DOI 10.1016/S0006-2952(97)00664-3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Krepinsky J, 2002, EXPERT OPIN THER PAT, V12, P1795, DOI 10.1517/13543776.12.12.1795; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; LEHMANN AR, 1979, NUCLEIC ACIDS RES, V6, P1953, DOI 10.1093/nar/6.5.1953; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pippin JW, 2003, J CLIN INVEST, V111, P877, DOI 10.1172/JCI200315645; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 1982, CARCINOGENESIS, V3, P815, DOI 10.1093/carcin/3.7.815; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TAYLOR AMR, 1979, CANCER RES, V39, P1046; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	49	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1153	1164		10.1038/sj.onc.1209148	http://dx.doi.org/10.1038/sj.onc.1209148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16186792				2022-12-28	WOS:000235537500003
J	Fukuyama, T; Ogita, H; Kawakatsu, T; Inagaki, M; Takai, Y				Fukuyama, T; Ogita, H; Kawakatsu, T; Inagaki, M; Takai, Y			Activation of Rac by cadherin through the c-Src-Rap1-phosphatidylinositol 3-kinase-Vav2 pathway	ONCOGENE			English	Article						cell protrusion; E-cadherin; signaling pathway	CELL-CELL-ADHESION; SMALL G-PROTEINS; NECTIN-LIKE MOLECULES; ADHERENS JUNCTIONS; TRANS-INTERACTIONS; TIGHT JUNCTIONS; FORCE MEASUREMENTS; C-SRC; CDC42; RAP1	Cadherin first forms homo-cis-dimerson the cell surface of the same cells, followed by formation of homo-trans-dimers(trans interactions) in a Ca2+ dependent manner, eventually causing adherens junctions. In addition, transinteracting cadherin induces activatio n of Rac small G protein, which stabilizes non-trans-interacting cadherin on the plasma membrane by inhibiting its endocytosis through the reorganization of the actin cytoskeleton. However, it has not fully been understood how cadherin induces the activation of Rac. We examined here the molecular mechanism of the activation of Rac by transinteracting cadherin in. fibroblasts and epithelial cells. Trans-interacting cadherin induced activation of c-Src locally at the cadherin-based cell-cell adhesion sites. c-Src then tyrosine- phosphorylated Vav2, one of the Rac-GDP/GTP exchange factors(GEFs), and induced activation of C3G, one of the Rap1-GEFs, through Crk adaptor protein, resulting in the activation of Rap1 locally at the cadherin-based cell-cell adhesion sites. The c-Src-catalysed tyrosine phosphorylation was not suf. cient for the activation of Vav2 and the c-Src-induced activation of Rap1 was additionally necessary for it, although activated Rap1 alone was not suf. cient for the activation of non-tyrosine-phosphorylated Vav2. This effect of Rap1 on Vav2 was mediated by phosphatidylinositol 3- kinase. We describe here the signaling pathway from trans-interacting cadherin to the activation of Rac.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Ogita, Hisakazu/0000-0001-6750-1668				Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Martinez-Rico C, 2005, J BIOL CHEM, V280, P4753, DOI 10.1074/jbc.M412544200; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Yagi T, 2000, GENE DEV, V14, P1169; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	43	67	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					8	19		10.1038/sj.onc.1209010	http://dx.doi.org/10.1038/sj.onc.1209010			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170364				2022-12-28	WOS:000234406400002
J	Hu, YF; Ghosh, S; Amleh, A; Yue, W; Lu, YZ; Katz, A; Li, R				Hu, YF; Ghosh, S; Amleh, A; Yue, W; Lu, YZ; Katz, A; Li, R			Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression	ONCOGENE			English	Article						BRCA1; aromatase; ovarian granulosa cells; preadipocytes; tissue-specific tumor suppression; estrogen biosynthesis	BREAST; GENE; OVARIAN; DIFFERENTIATION; OOPHORECTOMY; PROMOTER; PARTNER; BARD1	Mutations in BRCA1 increase risks of familial breast and ovarian cancers, particularly among premenopausal women. While BRCA1 plays an active role in DNA repair, this function alone may not be sufficient to explain why BRCA1-associated tumors predominantly occur in estrogen-responsive tissues. Aromatase is the rate-limiting enzyme in estrogen biosynthesis and a key target in breast cancer treatment. Aromatase expression in ovarian granulosa cells dictates levels of circulating estrogen in premenopausal women, and its aberrant overexpression in breast adipose tissues promotes breast cancer growth. Here, we show that BRCA1 modulates aromatase expression in ovarian granulosa cells and primary preadipocytes. The cyclic AMP-dependent expression of aromatase in ovarian granulosa cells is inversely correlated with the protein level of BRCA1. Importantly, transient knockdown of BRCA1 enhances aromatase expression in both ovarian granulosa cells and primary preadipocytes. We propose that BRCA1 deficiency in epithelial and certain nonepithelial cells may result in combined effects of aberrant estrogen biosynthesis and compromised DNA repair capability, which in turn may lead to specific cancers in the breast and ovary.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Div Endocrinol, Charlottesville, VA 22908 USA; Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; Univ Virginia, Sch Med, Dept Plast & Reconstruct Surg, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; Fudan University; University of Virginia	Hu, YF (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	yh4b@virginia.edu; rl2t@virginia.edu		Amleh, Asma/0000-0003-3613-3182; Lu, Yunzhe/0000-0001-7542-6848	NCI NIH HHS [CA093506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Chen SU, 2001, J STEROID BIOCHEM, V79, P35, DOI 10.1016/S0960-0760(01)00132-7; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Ghosh S, 2005, ONCOGENE, V24, P2236, DOI 10.1038/sj.onc.1208415; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Huo ZM, 2002, RADIOLOGY, V225, P519, DOI 10.1148/radiol.2252010845; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Key T J, 1999, Breast Cancer Res, V1, P18, DOI 10.1186/bcr7; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Phillips KW, 1997, LAB INVEST, V76, P419; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Tekmal RR, 1999, ENDOCR-RELAT CANCER, V6, P307, DOI 10.1677/erc.0.0060307; Turner KJ, 2002, J ENDOCRINOL, V172, P21, DOI 10.1677/joe.0.1720021; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Yue W, 1997, J STEROID BIOCHEM, V63, P317, DOI 10.1016/S0960-0760(97)00072-1; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454	29	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8343	8348		10.1038/sj.onc.1208985	http://dx.doi.org/10.1038/sj.onc.1208985			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170371				2022-12-28	WOS:000233956500013
J	Jarvis, MC; Gray, TJB; Palmer, CNA				Jarvis, MC; Gray, TJB; Palmer, CNA			Both PPAR gamma and PPAR delta influence sulindac sulfide-mediated p21(WAF1/CIP1) upregulation in a human prostate epithelial cell line	ONCOGENE			English	Article						PPAR gamma; PPAR delta; p21; prostate cancer; NSAIDs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED RECEPTOR-GAMMA; COLON-CANCER CELLS; COLORECTAL-CANCER; CARCINOGENESIS; PROLIFERATION; EXPRESSION; PROTEINS; TARGET; ALPHA	Nonsteroidal anti-inflammatory drugs (NSAIDs) including sulindac sulfide are known to exert cancer chemo-preventative activity in a range of cell lines. This activity has been shown to involve the upregulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). It is also known that NSAIDs can act as peroxisome proliferator-activated receptor (PPAR) agonists and antagonists. In this study, we show that sulindac sulfide acts both as a PPARc agonist and a PPAR delta antagonist in an immortalized prostatic epithelial cell line (PNT1A). We utilized siRNA technology to show that PPAR gamma is required for both growth inhibition and p21(WAF1/CIP1) upregulation in response to sulindac sulfide treatment in PNT1A cells. In addition, the overexpression of PPARd partially rescued these cells from growth inhibition and also dramatically inhibited sulindac sulfide-mediated p21(WAF1/CIP1) upregulation. Together these data identify a novel link between PPAR gamma/PPAR delta/p21(WAF1/CIP1) and the cancer chemo-preventative properties of NSAIDs.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Sanofi Aventis, Dept Toxicol, Alnwick, England	University of Dundee; Sanofi-Aventis	Palmer, CNA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.	colin.palmer@cancer.org.uk	Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560				Adamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Goldberg Y, 1996, ONCOGENE, V12, P893; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LUPULESCU A, 1978, NATURE, V272, P634, DOI 10.1038/272634a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Morrison RF, 1999, J CELL BIOCHEM, P59; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Nelson JE, 2000, ONCOL REP, V7, P169; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Piazza GA, 1997, CANCER RES, V57, P2909; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Yang WC, 2001, CANCER RES, V61, P6297; Young V, 2002, RHEUMATOLOGY, V41, P869, DOI 10.1093/rheumatology/41.8.869	23	26	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8211	8215		10.1038/sj.onc.1208983	http://dx.doi.org/10.1038/sj.onc.1208983			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091736				2022-12-28	WOS:000233809400013
J	Pim, D; Massimi, P; Dilworth, SM; Banks, L				Pim, D; Massimi, P; Dilworth, SM; Banks, L			Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A	ONCOGENE			English	Article						PKB/Akt; PI3 kinase; human papillomavirus; E7; PP2A	HUMAN-PAPILLOMAVIRUS TYPE-16; PLECKSTRIN HOMOLOGY DOMAIN; MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSFORMING ACTIVITY; BINDING-PROTEIN; PHOSPHATASE 2A; CELL-SURVIVAL; IN-VITRO; AKT	Protein kinase B (PKB) or Akt is one of several second messenger kinases that are activated by cell attachment and growth factor signaling, and that transmit signals to the cell nucleus to inhibit apoptosis and thereby increase cell survival during proliferation. Other viral proteins target this pathway by increasing PKB/Akt phosphorylation, and this pathway has been implicated in the transformation of human keratinocytes by HPV E6 and E7, together with activated notch 1. Here, we examine how HPV E7 expression affects the phosphorylation of PKB. We show that HPV-16 E7 increases the level of phosphorylation of PKB in response to serum stimulation, by a mechanism independent of downregulation of PTEN phosphatase, a known inhibitor of the PI3K (PI3 kinase) pathway. The use of specific antibodies shows that some proportion of PKB/Akt that is phosphorylated both on threonine 308 and serine 473 is maintained in the presence of E7 in a PI3 kinase-independent manner, and is activated for phosphorylation of BAD, a known downstream target of PKB/Akt. Use of E7 mutants has ruled out both an inhibition of IGFBP-3, a known E7 target and PKB/Akt modulator, and the interaction of E7 with cellular pocket proteins, as being the mechanism for the PKB/Akt stimulation. PKB binds PP2A and is a known substrate of PP2A. Here, we show that HPV E7 also binds to both the 35 kDa catalytic and 65 kDa structural subunits of PP2A, an interaction that sequesters these subunits and inhibits their interaction with PKB, thereby maintaining PKB/Akt signaling by inhibiting its dephosphorylation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ London Imperial Coll Sci & Technol, Dept Metab Med, London W12 0NN, England	International Center for Genetic Engineering & Biotechnology (ICGEB); Imperial College London	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99,Area Sci Pk, I-34012 Trieste, Italy.	pim@icgeb.org			Biotechnology and Biological Sciences Research Council [C19979, BBS/B/06962] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BANKS L, 1990, ONCOGENE, V5, P1383; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Johnston D, 1999, CANCER RES, V59, P968; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; MUNGER K, 1989, J VIROL, V63, P4417; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; PIM D, 1992, ONCOGENE, V7, P27; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Pouliot N, 2002, EXP DERMATOL, V11, P387, DOI 10.1034/j.1600-0625.2002.110501.x; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Xu WP, 2003, CANCER RES, V63, P7777; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	50	127	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7830	7838		10.1038/sj.onc.1208935	http://dx.doi.org/10.1038/sj.onc.1208935			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16044149				2022-12-28	WOS:000233463000002
J	Berk, AJ				Berk, AJ			Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus	ONCOGENE			English	Review						mediator; CtBP; chromatin; aggresome; ubiqutin ligase; apoptosis	VIRAL-DNA REPLICATION; E4 ORF3 PROTEIN; MESSENGER-RNA; HOST-CELL; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; CO-REPRESSOR; ZINC-FINGER; ONCOGENIC TRANSFORMATION; MOLECULAR-MECHANISMS	Adenovirus continues to be an important model system for investigating basic aspects of cell biology. Interactions of several cellular proteins with E1A conserved regions ( CR) 1 and 2, and inhibition of apoptosis by E1B proteins are required for oncogenic transformation. CR2 binds RB family members, de-repressing E2F transcription factors, thus activating genes required for cell cycling. E1B-19K is a BCL2 homolog that binds and inactivates proapoptotic BAK and BAX. E1B-55K binds p53, inhibiting its transcriptional activation function. In productively infected cells, E1B-55K and E4orf6 assemble a ubiquitin ligase with cellular proteins Elongins B and C, Cullin 5 and RBX1 that polyubiquitinates p53 and one or more subunits of the MRN complex involved in DNA double-strand break repair, directing them to proteosomal degradation. E1A CR3 activates viral transcription by interacting with the MED23 Mediator subunit, stimulating preinitiation complex assembly on early viral promoters and probably also the rate at which they initiate transcription. The viral E1B-55K/E4orf6 ubiquitin ligase is also required for efficient viral late protein synthesis in many cell types, but the mechanism is not understood. E1A CR1 binds several chromatin-modifying complexes, but how this contributes to stimulation of cellular DNA synthesis and transformation is not clear. E1A CR4 binds the CtBP corepressor, but the mechanism by which this modulates the frequency of transformation remains to be determined. Clearly, adenovirus has much left to teach us about fundamental cellular processes.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Berk, AJ (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, 611 Charles Young Dr E, Los Angeles, CA 90095 USA.	berk@mbi.ucla.edu	BERK, ARNOLD/AAF-7052-2020					Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brockmann D, 2003, CURR TOP MICROBIOL, V272, P97; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cantin GT, 2003, P NATL ACAD SCI USA, V100, P12003, DOI 10.1073/pnas.2035253100; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chan HM, 2001, J CELL SCI, V114, P2363; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chinnadurai G, 2004, CURR TOP MICROBIOL, V273, P139; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Duval A, 2000, CANCER RES, V60, P3872; DYSON N, 1992, CANCER SURV, V12, P161; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Evans JD, 2005, J VIROL, V79, P6207, DOI 10.1128/JVI.79.10.6207-6215.2005; Evans JD, 2003, J VIROL, V77, P5295, DOI 10.1128/JVI.77.9.5295-5304.2003; Fang L, 2004, J VIROL, V78, P12888, DOI 10.1128/JVI.78.23.12888-12900.2004; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Goodman RH, 2000, GENE DEV, V14, P1553; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Kim TW, 2004, P NATL ACAD SCI USA, V101, P12153, DOI 10.1073/pnas.0401985101; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LIU Y, 2005, IN PRESS J VIROL; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Nomura H, 1998, BIOCHEM BIOPH RES CO, V248, P228, DOI 10.1006/bbrc.1998.8950; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Polakis P, 2000, GENE DEV, V14, P1837; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Saeki H, 2001, ONCOLOGY-BASEL, V61, P156, DOI 10.1159/000055367; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Satyanarayana A, 2004, J CLIN INVEST, V114, P1237, DOI 10.1172/JCI200423437; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SHENK T, 2001, ADENOVIRUSES; Shepard RN, 2004, J VIROL, V78, P9924, DOI 10.1128/JVI.78.18.9924-9935.2004; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Steinberg D, 2003, J CLIN ETHIC, V14, P18; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WAGN G, 2005, MOL CELL, V17, P683; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Williams JF, 2004, CURR TOP MICROBIOL, V273, P245; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200; Zhao HX, 2003, J VIROL, V77, P11006, DOI 10.1128/JVI.77.20.11006-11015.2003; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	185	270	278	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7673	7685		10.1038/sj.onc.1209040	http://dx.doi.org/10.1038/sj.onc.1209040			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299528				2022-12-28	WOS:000233372600004
J	Rogulski, K; Li, YJ; Rothermund, K; Pu, LX; Watkins, S; Yi, FH; Prochownik, EV				Rogulski, K; Li, YJ; Rothermund, K; Pu, LX; Watkins, S; Yi, FH; Prochownik, EV			Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway	ONCOGENE			English	Article						c-Myc; p53; Mdm2; Akt; PTEN; Max; apoptosis; green. fluorescent protein; PI-3 kinase; p19(ARF); shRNA	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; P53 STABILITY; DNA METHYLTRANSFERASES; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; CXXC MOTIF; IN-VITRO; MDM2	The c-Myc oncoprotein is a general transcription factor whose target genes dictate the c-Myc phenotype. One such target of c-Myc, 'onzin', is normally expressed at high levels in myeloid cells and is dramatically downregulated in response to c-Myc overexpression. We show here that short hairpin interfering RNA-mediated knockdown of endogenous onzin results in a reduced growth rate and a proapoptotic phenotype. In contrast, onzin overexpression in fibroblasts is associated with an increased growth rate, resistance to apoptotic stimuli, loss of the G2/M checkpoint, and tumorigenic conversion. Onzin-overexpressing cells fail to induce p53 in response to apoptotic stimuli and contain higher levels of the active, phosphorylated forms of Akt1 and, more strikingly, of Mdm2. Using yeast two-hybrid and coimmunoprecipitation assays, we show that onzin directly interacts with both proteins. Green fluorescent protein tagging also confirms directly that Akt1 and Mdm2 colocalize with onzin, although the precise subcellular distribution of each protein is dependent on its relative abundance. Collectively, our results identify onzin as a novel regulator of several p53-dependent aspects of the c-Myc phenotype via its dramatic effect on Mdm2. This is reminiscent of the c-Myc -> p19(ARF)-vertical bar Mdm2 pathway and might function as a complementary arm to ensure the proper cellular response to oncogenic and/or apoptotic stimuli.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Collet JF, 2003, J BIOL CHEM, V278, P45325, DOI 10.1074/jbc.M307818200; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; Guo QM, 2000, CANCER RES, V60, P5922; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; KAUFMANN SH, 1998, BIOCHIM BIOPHYS ACTA, V400, P195; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 2001, Harvey Lect, V97, P57; Paez Juan, 2003, Cancer Treat Res, V115, P145; Page C, 2000, ANTICANCER RES, V20, P407; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Prescott JE, 2001, J BIOL CHEM, V276, P48276, DOI 10.1074/jbc.M107357200; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269; Wood LJ, 2000, CANCER RES, V60, P4256; Yang CW, 2003, MOL CARCINOGEN, V36, P15, DOI 10.1002/mc.10086; Yi FH, 2003, CANCER RES, V63, P2923; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	78	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7524	7541		10.1038/sj.onc.1208897	http://dx.doi.org/10.1038/sj.onc.1208897			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16170375				2022-12-28	WOS:000233333800003
J	Kumar, CC; Madison, V				Kumar, CC; Madison, V			AKT crystal structure and AKT-specific inhibitors	ONCOGENE			English	Article						AKT crystal structure; Akt inhibitors; ATP competitive; PH domain; peptide substrate; apoptosis; chemoresistance	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; SUPPRESSES TUMOR-GROWTH; ETHER LIPID ANALOGS; CANCER-CELLS; SELECTIVE INHIBITORS; LUNG-CANCER; PROMOTES APOPTOSIS; MOLECULAR-BASIS; PKB INHIBITORS	AKT kinases are attractive targets for small molecule drug discovery because of their key role in tumor cell survival/proliferation and their overexpression/activation in many human cancers. This review summarizes studies that support the rationale for targeting AKT kinases in new drug discovery efforts. Structural features of AKT kinase in its inactive and active states, as determined by crystal structure analysis, are described. Recent efforts in the development and biological evaluation of small molecule inhibitors of AKT, and the challenges remaining are summarized. Inhibitors targeting the ATP binding site, PH domain and protein substrate binding site, as well as isoform selective allosteric inhibitors are reviewed. Structure-based design using PKA mutants as surrogates and computer modeling in the discovery of selective inhibitors is discussed. The issues and challenges facing the development of different classes of inhibitors as therapeutics are also discussed.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	chandra.kumar@spcorp.com						Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Breitenlechner CB, 2005, J MED CHEM, V48, P163, DOI 10.1021/jm049701n; Breitenlechner CB, 2004, J MED CHEM, V47, P1375, DOI 10.1021/jm0310479; Brognard J, 2001, CANCER RES, V61, P3986; Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHENG JQ, 2005, ONCOGENE REV, V24, P7428; Clark AS, 2002, MOL CANCER THER, V1, P707; DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Frolov A, 2003, MOL CANCER THER, V2, P699; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; GARRETT M, 2004, EU J CANC S16, V2; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Jetzt A, 2003, CANCER RES, V63, P6697; Kawauchi K, 2003, BLOOD CELL MOL DIS, V31, P11, DOI 10.1016/S1079-9796(03)00070-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kumar CC, 2001, BBA-GEN SUBJECTS, V1526, P257, DOI 10.1016/S0304-4165(01)00143-X; Li J, 1998, CANCER RES, V58, P5667; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Luo Y, 2004, BIOCHEMISTRY-US, V43, P1254, DOI 10.1021/bi034515p; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Ohashi A, 2004, INT J CANCER, V111, P317, DOI 10.1002/ijc.20305; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pandolfi PP, 2004, NEW ENGL J MED, V351, P2337, DOI 10.1056/NEJMcibr043143; Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Saito Y, 2003, GENE THER, V10, P1961, DOI 10.1038/sj.gt.3302100; SCHEID M, 2003, FEBS LETT, P1; She QB, 2003, CLIN CANCER RES, V9, P4340; Shin I, 2005, CANCER RES, V65, P2815, DOI 10.1158/0008-5472.CAN-04-2898; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Thomas CC, 2001, BIOCHEM J, V358, P287, DOI 10.1042/0264-6021:3580287; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yakes FM, 2002, CANCER RES, V62, P4132; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao ZJ, 2005, BIOORG MED CHEM LETT, V15, P905, DOI 10.1016/j.bmcl.2004.12.062	50	156	171	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2005	24	50					7493	7501		10.1038/sj.onc.1209087	http://dx.doi.org/10.1038/sj.onc.1209087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288296				2022-12-28	WOS:000233201900012
J	Ruggero, D; Sonenberg, N				Ruggero, D; Sonenberg, N			The Akt of translational control	ONCOGENE			English	Review						Akt; ribosome biogenesis; eIF4E; translation control; cancer	MESSENGER-RNA TRANSLATION; CAP-DEPENDENT TRANSLATION; PROTEIN-KINASE-B; EIF4E GENE AMPLIFICATION; INITIATION-FACTOR EIF-4E; FACTOR 4E GENE; P70 S6 KINASE; EUKARYOTIC TRANSLATION; CELL-GROWTH; MAMMALIAN TARGET	The oncogene AKT (also called protein kinase B (PKB)) signals to the translational machinery, and activation of protein synthesis by Akt is associated with cancer formation. Akt directly stimulates the activity of translation initiation factors and upregulates ribosome biogenesis. Activation of protein synthesis by Akt is phylogenetically conserved from Drosophila to humans, and is important for regulating cell growth, proliferation and cell survival. Consequently, translation defects due to aberrant Akt activation may be a crucial mechanism leading to tumorigenesis. However, few in vivo studies have established a causative role for aberrant protein synthesis control in cancer. A major challenge in the future will be to identify the specific mRNAs regulated at the level of translation control directly relevant for cellular transformation. In this review, we highlight and discuss the emerging molecular and genetic evidence that support a model by which deregulation of specific or global protein synthesis contributes to cancer.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Fox Chase Cancer Center; McGill University; McGill University	Ruggero, D (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	davide.ruggero@fccc.edu; nahum.sonenberg@mcgill.ca						Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Baserga Renato, 2004, VVolume 42, P235; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; Dmitriev SE, 2003, MOL CELL BIOL, V23, P8925, DOI 10.1128/MCB.23.24.8925-8933.2003; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Filonenko VV, 2004, EXP ONCOL, V26, P294; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hornstein E, 2001, COLD SPRING HARB SYM, V66, P477, DOI 10.1101/sqb.2001.66.477; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito T, 1996, MOL CELL BIOL, V16, P943; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Loreni F, 2000, EUR J BIOCHEM, V267, P6594, DOI 10.1046/j.1432-1327.2000.01753.x; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MADER S, 1995, MOL CELL BIOL, V15, P4990; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Mende I, 2001, ONCOGENE, V20, P4419, DOI 10.1038/sj.onc.1204486; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Montagne Jacques, 2004, VVolume 42, P265; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; NIELSEN PJ, 1981, EUR J BIOCHEM, V120, P523, DOI 10.1111/j.1432-1033.1981.tb05731.x; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rathmell JC, 2003, EUR J IMMUNOL, V33, P2223, DOI 10.1002/eji.200324048; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rousseau D, 1996, ONCOGENE, V13, P2415; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Savinska LO, 2004, EXP ONCOL, V26, P24; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shuda M, 2000, ANTICANCER RES, V20, P2489; Sonenberg N, 2000, TRANSLATION CONTROL; Sonenberg Nahum, 1993, Gene Expression, V3, P317; Sorrells DL, 1999, J SURG RES, V85, P37, DOI 10.1006/jsre.1999.5653; Sorrells DL, 1999, HEAD NECK-J SCI SPEC, V21, P60, DOI 10.1002/(SICI)1097-0347(199901)21:1<60::AID-HED8>3.3.CO;2-A; Sorrells DL, 1998, ANN SURG ONCOL, V5, P232, DOI 10.1007/BF02303778; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	132	149	159	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7426	7434		10.1038/sj.onc.1209098	http://dx.doi.org/10.1038/sj.onc.1209098			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288289	Green Published			2022-12-28	WOS:000233201900005
J	Barnes, DJ; Schultheis, B; Adedeji, S; Melo, JV				Barnes, DJ; Schultheis, B; Adedeji, S; Melo, JV			Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia	ONCOGENE			English	Article						chronic myeloid leukemia; Bcr-Abl; growth factor dependence; tumorigenicity; adhesion	CHRONIC MYELOGENOUS LEUKEMIA; MURINE HEMATOPOIETIC-CELLS; INTEGRIN-MEDIATED ADHESION; TYROSINE KINASE-ACTIVITY; BONE-MARROW; PROGENITOR CELLS; NOD/SCID MICE; CD34(+) CELLS; CHRONIC-PHASE; EXPRESSION	Chronic myeloid leukemia (CML) is caused by Bcr-Abl, an activated tyrosine kinase. The amounts of Bcr-Abl mRNA and protein in cells from patients in blast crisis (BC) are higher than in those chronic phase (CP), indicating that their expression rises with disease progression. In order to study this phenomenon on cells with the same genetic background, we transfected the 32D cell line with the BCR-ABL transgene and selected clones with graded expression of Bcr-Abl within the range found in cells from CP to BC. In vitro, we found that Bcr-Abl exerted dose-dependent effects upon growth factor dependence, clonogenicity and migration. How ever, the relationship between Bcr-Abl expression and cellular adhesion to fibronectin was more complex: rather than a direct positive correlation, clones that expressed low, but not high, levels of Bcr-Abl were less adhesive than growth factor stimulated, parental BCR-ABL-negative 32D cells. This finding parallels the situation with normal and CML-CP progenitors where the latter exhibit defective adhesion to fibronectin. Treatment with the tyrosine kinase inhibitor imatinib mesylate reversed the adhesion deficient phenotype of clones expressing low levels of Bcr-Abl. When injected subcutaneously into syngeneic mice, cell lines expressing high levels of Bcr-Abl rapidly induced tumors, whereas low-expressing clones led to tumor formation only after a prolonged latency. These findings suggest that the level of Bcr-Abl may be essential in determining the phenotype of the leukemic clone at different stages of the disease.	Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Haematol, London W12 0NN, England	Imperial College London	Melo, JV (corresponding author), Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Haematol, Du Cane Rd, London W12 0NN, England.	j.melo@imperial.ac.uk	Schultheis, Beate/M-5889-2017	Barnes, David/0000-0002-7937-2004				AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; Bhatia R, 2001, BRIT J HAEMATOL, V115, P845, DOI 10.1046/j.1365-2141.2001.03192.x; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Dazzi F, 1998, BLOOD, V92, P1390, DOI 10.1182/blood.V92.4.1390.416k09_1390_1396; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Elmaagacli AH, 2000, ANN HEMATOL, V79, P424, DOI 10.1007/s002770000169; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GUO JQ, 1991, CANCER RES, V51, P3048; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Schleuning M, 1999, EUR J HAEMATOL, V62, P149; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406	32	53	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6432	6440		10.1038/sj.onc.1208796	http://dx.doi.org/10.1038/sj.onc.1208796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007188				2022-12-28	WOS:000232038200010
J	Andrianifahanana, M; Agrawal, A; Singh, AP; Moniaux, N; van Seuningen, I; Aubert, JP; Meza, J; Batra, SK				Andrianifahanana, M; Agrawal, A; Singh, AP; Moniaux, N; van Seuningen, I; Aubert, JP; Meza, J; Batra, SK			Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways	ONCOGENE			English	Article						MUC4 mucin; IFN gamma; retinoic acid; synergism; gene regulation; pancreatic cancer	MEMBRANE-ASSOCIATED MUCIN; SIALOMUCIN COMPLEX; CANCER-CELLS; MOLECULAR-CLONING; EPISIALIN MUC1; EXPRESSION; GROWTH; LINES; INHIBITION; RECEPTOR	The transmembrane mucin, MUC4, is aberrantly expressed with a high incidence in human pancreatic adenocarcinomas and plays an important role in the pathogenesis of the disease. Our recent studies have shown that interferon-gamma ( IFN gamma) and retinoic acid ( RA) are important regulators of MUC4 in pancreatic tumour cells. Induction of MUC4 by IFN gamma occurs via a novel pathway involving upregulation of the signal transducer and activator of transcription 1 ( STAT-1), whereas its stimulation by RA requires mediation by the transforming growth factor beta-2 ( TGF beta-2). In this study, we have investigated the molecular mechanisms underlying the interaction of IFN gamma and RA in MUC4 regulation in pancreatic tumour cells. We demonstrate that these reagents exert a synergistic induction of MUC4. Interestingly, while the upregulation of STAT-1 by IFN gamma is partially inhibited by RA, IFN gamma is shown to repress RA-driven TGFb-2 induction, pointing to the involvement of alternative mechanism( s) in IFN gamma-RA synergism. Moreover, a dose-dependent and cooperative induction of MUC4 promoter activity suggests a regulation at the transcriptional level, most likely by STAT-1 and RAR/RXR ( RA receptor/retinoic X receptor) or other IFN gamma/RA-induced secondary intermediate effectors. Our findings provide potential mechanisms that may account for the aberrant expression of MUC4 in pancreatic tumour cells and expose a novel molecular mechanism of gene induction, whereby a reprogramming of signalling pathway through alternative route(s) operates during a synergistic interaction of biological modifiers.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Omaha, NE 68198 USA; INSERM, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	sbatra@unmc.edu	Singh, Ajay/AAF-4414-2020; VAN SEUNINGEN, Isabelle/N-6176-2016; Moniaux, Nicolas/Y-3243-2018	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Moniaux, Nicolas/0000-0001-9718-1386; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [CA 78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Andrianifahanana Mahefatiana, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P607; Andrianifahanana Mahefatiana, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1135; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Guzhova I, 2001, INT J CANCER, V94, P97, DOI 10.1002/ijc.1443; Hara I, 2001, INT J ONCOL, V19, P959; HO CK, 1985, CANCER RES, V45, P5348; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hu W, 2002, INT J GYNECOL CANCER, V12, P202, DOI 10.1046/j.1525-1438.2002.01084.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jesnowski R, 2002, PANCREATOLOGY, V2, P421, DOI 10.1159/000065091; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kondo K, 1998, CANCER RES, V58, P2014; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MATSUBARA N, 1991, INT J PANCREATOL, V8, P235; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Niitsu N, 2002, LEUKEMIA RES, V26, P745, DOI 10.1016/S0145-2126(01)00202-8; Park C, 1998, METHODS, V15, P175, DOI 10.1006/meth.1998.0622; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Reber H, 1998, PANCREATIC CANC PATH; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sirivatanauksorn V, 1998, LANGENBECK ARCH SURG, V383, P105, DOI 10.1007/s004230050101; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Widschwendter M, 1997, INT J CANCER, V71, P497; Windbichler GH, 1996, GYNECOL ONCOL, V61, P387, DOI 10.1006/gyno.1996.0162; WU K, 1994, J BIOL CHEM, V269, P11950; Yang JB, 2001, J BIOL CHEM, V276, P20989, DOI 10.1074/jbc.M011488200	43	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6143	6154		10.1038/sj.onc.1208756	http://dx.doi.org/10.1038/sj.onc.1208756			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007204				2022-12-28	WOS:000231718100008
J	Barrier, A; Lemoine, A; Boelle, PY; Tse, C; Brault, D; Chiappini, F; Breittschneider, J; Lacaine, F; Houry, S; Huguier, M; Van der Laan, MJ; Speed, T; Debuire, B; Flahault, A; Dudoit, S				Barrier, A; Lemoine, A; Boelle, PY; Tse, C; Brault, D; Chiappini, F; Breittschneider, J; Lacaine, F; Houry, S; Huguier, M; Van der Laan, MJ; Speed, T; Debuire, B; Flahault, A; Dudoit, S			Colon cancer prognosis prediction by gene expression profiling	ONCOGENE			English	Article						functional genomics; colon cancer; prognosis prediction; non-neoplastic mucosa; cross-validation	CDNA MICROARRAYS; COLORECTAL-CANCER; SURVIVAL; TISSUES; TUMOR; ADENOCARCINOMA; CLASSIFICATION; IDENTIFICATION; FLUOROURACIL; CHEMOTHERAPY	This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients. Tumour ( T) and non-neoplastic mucosa ( NM) mRNA samples from 18 patients ( nine with a recurrence, nine with no recurrence) were pro. led using the Affymetrix HGU133A GeneChip. The k-nearest neighbour method was used for prognosis prediction using T and NM gene expression measures. Six-fold cross-validation was applied to select the number of neighbours and the number of informative genes to include in the predictors. Based on this information, one T-based and one NM-based predictor were proposed and their accuracies were estimated by double cross-validation. In six-fold cross-validation, the lowest numbers of informative genes giving the lowest numbers of false predictions ( two out of 18) were 30 and 70 with the T and NM gene expression measures, respectively. A 30-gene T-based predictor and a 70-gene NM-based predictor were then built, with estimated accuracies of 78 and 83%, respectively. This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.	Univ Paris 06, Hop Tenon, Serv Chirurg Digest, Assistance Publ, F-75020 Paris, France; Univ Paris 06, Fac Med St Antoine, INSERM U444, F-75571 Paris, France; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; Univ Paris 11, Hop Paul Brousse, Serv Biochem, INSERM U602, F-94800 Villejuif, France; Univ Paris 06, Hop Tenon, Serv Biochem, Assistance Publ, F-75020 Paris, France; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley	Barrier, A (corresponding author), Univ Paris 06, Hop Tenon, Serv Chirurg Digest, Assistance Publ, F-75020 Paris, France.	barrier@stat.Berkeley.edu	Speed, Terence P/B-8085-2009; Chiappini, Franck/AAB-9894-2021	Speed, Terence P/0000-0002-5403-7998; Chiappini, Franck/0000-0002-2684-1241				Agrawal D, 2002, J NATL CANCER I, V94, P513; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Boland CR, 1998, CANCER RES, V58, P5248; Bustin SA, 2002, TUMOR BIOL, V23, P130, DOI 10.1159/000064029; Cersosimo RJ, 2005, ANN PHARMACOTHER, V39, P128, DOI 10.1345/aph.1E319; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Dudoit S, 2003, STAT SCI, V18, P71, DOI 10.1214/ss/1056397487; Dudoit S, 2003, INTERDISC STAT, P93; Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Frederiksen CM, 2003, J CANCER RES CLIN, V129, P263, DOI 10.1007/s00432-003-0434-x; Hedge P, 2001, CANCER RES, V61, P7792; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Irizarry R. A., 2003, ANAL GENE EXPRESSION, P102; Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200; Kitahara O, 2001, CANCER RES, V61, P3544; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Notterman DA, 2001, CANCER RES, V61, P3124; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Williams NS, 2003, CLIN CANCER RES, V9, P931; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	38	79	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6155	6164		10.1038/sj.onc.1208984	http://dx.doi.org/10.1038/sj.onc.1208984			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16091735	Green Published			2022-12-28	WOS:000231718100009
J	Caterina, C; Marcella, M; Giordano, A				Caterina, C; Marcella, M; Giordano, A			Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer	ONCOGENE			English	Article						methylation; Rb2/p130 silencing; tumor markers; lung tumors; Rb2/p130 mutations	DNA METHYLATION; PROTEIN; FAMILY; TRANSCRIPTION; PROGRESSION; EXPRESSION; COMPLEXES; MEMBER; CELLS; P130	Genetic alterations in Rb2/p130 gene have been reported in several tumors, but till now there are insufficient and conflicting data linking the loss of pRb2/p130 expression with the mutational status of this gene in lung cancer. We recently reported that loss or lowering of pRb2/p130 expression is mainly due to aberrant Rb2/p130 promoter methylation, in retinoblastoma tumors, and indicated that epigenetic silencing of Rb2/p130 can impair its function to negatively regulate cell cycle progression as well as apoptotic response. In order to clarify Rb2/p130 gene inactivation in lung cancer, we investigated whether epigenetic events could impair the expression of this gene in NSLC. Here, we show that specific Rb2-exon 1 homozygous mutations, occurring in an Rb2/p130, region, rich in CpG dinucleotides, could be the 'hit event' that predispose this gene to epigenetic changes, leading to Rb2/p130 gene silencing in lung cancer. Moreover, these homozygous mutations, found in different tumor histotypes, could represent tumor-specific markers.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Univ Siena, CNR, Inst Clin Physiol, I-53100 Siena, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Siena; University of Siena	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Biolife Sci Bldg,1900 N 12th St,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369	NATIONAL CANCER INSTITUTE [R01CA066999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA066999-09A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 1997, CLIN CANCER RES, V3, P1691; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 2000, CANCER RES, V60, P372; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Jun HX, 2003, MOL CARCINOGEN, V38, P124, DOI 10.1002/mc.10152; KALEBIC T, 2003, ANN ACAD SCI, V293, P278; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Macaluso M, 2005, ANN ONCOL, V16, P20, DOI 10.1093/annonc/mdi903; Macaluso M, 2004, TUMORI J, V90, P367, DOI 10.1177/030089160409000401; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MACALUSO M, 2005, IN PRESS SEMIN ONCOL; MAYOL X, 1993, ONCOGENE, V8, P2561; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Russo G, 2003, ONCOGENE, V22, P6959, DOI 10.1038/sj.onc.1206866; Scarano MI, 2005, J CELL PHYSIOL, V204, P21, DOI 10.1002/jcp.20280; Suzuki M, 2005, LUNG CANCER, V47, P309, DOI 10.1016/j.lungcan.2004.08.006; TOSI GM, 2005, IN PRESS ONCOGENE; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	24	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5821	5826		10.1038/sj.onc.1208880	http://dx.doi.org/10.1038/sj.onc.1208880			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16044156				2022-12-28	WOS:000231590400004
J	Nagayama, S; Fukukawa, C; Katagiri, T; Okamoto, T; Aoyama, T; Oyaizu, N; Imamura, M; Toguchida, J; Nakamura, Y				Nagayama, S; Fukukawa, C; Katagiri, T; Okamoto, T; Aoyama, T; Oyaizu, N; Imamura, M; Toguchida, J; Nakamura, Y			Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; antibody-based therapy; FZD10; ADCC; xenograft	SOFT-TISSUE SARCOMAS; FRIZZLED GENE FAMILY; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; DEVELOPING KIDNEY; CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; SSX; SYT	Genome-wide expression pro. ling revealed overexpression of the gene encoding frizzled homologue 10 (FZD10), a cell-surface receptor for molecules in the Wnt pathway, as a potential contributor to synovial sarcomas (SS). Northern blotting and immunohistochemical staining confirmed that expression levels of FZD10 were very high in nearly all SS tumors and cell lines examined but absent in most normal organs or in some cancers arising in other tissues. Treatment of human SS cells with small-interfering RNA ( siRNA) to FZD10 decreased the amount of its product and suppressed growth of SS cells. Moreover, a polyclonal antibody specifically recognizing the extracellular domain (ECD) of FZD10 was markedly effective in mediating ADCC against FZD10-overexpressing synovial sarcoma cells in vitro. Injection of the antibody into SS xenografts in nude mice attenuated tumor growth, and TUNEL assays revealed clusters of apoptotic cells in antibody-treated xenografts. Taken together, these findings suggest that a humanized antibody against FZD10 might be a promising treatment for patients with tumors that over-express FZD10; minimal or no adverse reactions would be expected because FZD10 protein is not abundant in vital organs.	Univ Tokyo, Mol Med Lab, Human Genome Ctr, Inst Med Sci, Tokyo 1088639, Japan; Kyoto Univ, Dept Surg & Surg Basic Sci, Grad Sch Med, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan; Kyoto Univ, Dept Orthopaed Surg, Grad Sch Med, Kyoto 6068507, Japan; Univ Tokyo, Dept Lab Med, Div Pathol, Hosp Inst Med Sci, Tokyo 1088639, Japan	University of Tokyo; Kyoto University; Kyoto University; Kyoto University; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Human Genome Ctr, Inst Med Sci, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012					Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Edmonson JH, 2002, CANCER, V94, P786, DOI 10.1002/cncr.10259; FENDLY BM, 1990, CANCER RES, V50, P1550; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kirikoshi H, 2001, INT J ONCOL, V19, P767; Kispert A, 1998, DEVELOPMENT, V125, P4225; Koike J, 1999, BIOCHEM BIOPH RES CO, V262, P39, DOI 10.1006/bbrc.1999.1161; Maloney DG, 1997, BLOOD, V90, P2188; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Sato Y, 2002, J IMMUNOL, V169, P1611, DOI 10.4049/jimmunol.169.3.1611; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Terasaki H, 2002, INT J MOL MED, V9, P107; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; Worley BS, 2001, CANCER RES, V61, P6868; Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020, DOI 10.2106/00004623-199807000-00011	23	97	116	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6201	6212		10.1038/sj.onc.1208780	http://dx.doi.org/10.1038/sj.onc.1208780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007199				2022-12-28	WOS:000231877100001
J	Jin, J; Woodgett, JR				Jin, J; Woodgett, JR			Chronic activation of protein kinase B beta/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis	ONCOGENE			English	Article						PKB; Akt; cell fusion; tumorigenesis; tamoxifen-induced; cytokinesis; endomitosis/endoreplication; phagocytosis; pinocytosis; autophagy	HUMAN BREAST; HUMAN CANCER; PHOSPHOINOSITIDE 3-KINASE; CENTROSOME AMPLIFICATION; TRANSCRIPTION FACTOR; PATHWAY; AKT; PHOSPHORYLATION; OVEREXPRESSION; DICTYOSTELIUM	Most cancers arise from the stepwise accumulation of genetic changes. There is also evidence for defects in the machinery and checkpoints for maintenance of normal diploid chromosome complements, resulting in genetic instability that helps fuel the accumulation of mutations that contribute to the development of cancer. The protooncogene protein kinase B (PKB/Akt), and its regulators including phosphatidylinositol 3' kinase and PTEN, has been shown to play critical roles in the regulation of multiple cellular functions such as transcription, cell survival, cell cycle progression, angiogenesis and cell motility - all of which are important to the malignant process. Here, we report the use of a membrane targeted PKB beta, the activation of which is under the control of a 4-hydroxy-Tamoxifen-responsive estrogen-receptor (ER) ligand binding domain. Induction of PKB beta-ER activity in human kidney epithelial cells (HEK293) resulted in changes in cellular growth, size, and in the appearance of aneuploid cells. Over time, in a PKB beta-dependent manner, cells also underwent extensive multinucleation caused due to a combination of both endomitosis and cell fusion. These findings suggest that chronic activation of PKB beta may contribute to genetic instability and autophagy, properties commonly found in tumor cells.	Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Woodgett, JR (corresponding author), Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jwoodget@uhnres.utoronto.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Arboleda MJ, 2003, CANCER RES, V63, P196; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Botelho RJ, 2004, CURR TOP MICROBIOL, V282, P1; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Funakoshi E, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-12; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jin J, 2001, DEV CELL, V1, P817, DOI 10.1016/S1534-5807(01)00090-9; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kenerson HL, 2002, CANCER RES, V62, P5645; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Rupper A, 2001, MOL BIOL CELL, V12, P2813, DOI 10.1091/mbc.12.9.2813; Rupper AC, 2001, J CELL SCI, V114, P1283; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	50	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5459	5470		10.1038/sj.onc.1208704	http://dx.doi.org/10.1038/sj.onc.1208704			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007218				2022-12-28	WOS:000231222300006
J	Rossetti, S; Van Unen, L; Touw, IP; Hoogeveen, AT; Sacchi, N				Rossetti, S; Van Unen, L; Touw, IP; Hoogeveen, AT; Sacchi, N			Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation	ONCOGENE			English	Article						epigenetic regulation; AML1-MTG16; Csf1r; myelogenesis	STIMULATING FACTOR-RECEPTOR; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LEUKEMIC-CELLS; METHYLATION; AML1; IDENTIFICATION; PROMOTER; FUSION	De novo epigenetic changes at histone and DNA level that affect gene transcription in cancer may be less random than we originally thought. Leukemia fusion proteins associated with specific chromosome translocations could mechanistically determine the epigenetic fate of specific target genes critical for normal hematopoiesis. This seems to be the case with AML1-MTG16, a fusion protein resulting from the t(16;21) translocation, a hallmark of therapy-related leukemia and myelodysplastic syndrome. Here we show that AML1-MTG16 blocks both myeloid differentiation and proliferation in the 32D/WT1-mouse myeloid cell line. These biological effects can be traced to the AML1 and MTG16 moieties of the fusion protein, respectively. Further, we show that AML1-MTG16 can induce epigenetic repressive changes at the histone and DNA level of the AML1 target gene Csf1r (c-fms), encoding the macrophage colony stimulating factor receptor. We observed that, concomitant with Csf1r downregulation, 32D/WT1 cells lost the ability to undergo myeloid differentiation in response to the granulocyte macrophage colony-stimulating factor (GM-CSF). Thus, there seems to be an association between AML1-MTG16-induced myeloid maturation block and epigenetic changes of a myeloid master gene.	Erasmus Med Ctr, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Erasmus Med Ctr, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Roswell Park Cancer Institute; Erasmus University Rotterdam; Erasmus MC	Hoogeveen, AT (corresponding author), Erasmus Med Ctr, Dept Clin Genet, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	a.hoogeveen@erasmusmc.nl; nicoletta.sacchi@roswellpark.org						Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; ERICKSON P, 1992, BLOOD, V80, P1825; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; FELGNER J, 1991, PATHOBIOLOGY, V59, P293; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOZU T, 1993, BLOOD, V82, P1270; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Rossetti S, 2004, GENOMICS, V84, P1, DOI 10.1016/j.ygeno.2004.02.011; Shi HD, 2003, CANCER RES, V63, P2164; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	27	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5325	5332		10.1038/sj.onc.1208651	http://dx.doi.org/10.1038/sj.onc.1208651			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007222				2022-12-28	WOS:000231158500006
J	Wu, X; Jia, HL; Wang, YF; Ren, N; Ye, QH; Sun, HC; Wang, L; Liu, YK; Tang, ZY; Qin, LX				Wu, X; Jia, HL; Wang, YF; Ren, N; Ye, QH; Sun, HC; Wang, L; Liu, YK; Tang, ZY; Qin, LX			HTPAP gene on chromosome 8p is a candidate metastasis suppressor for human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; metastasis; chromosome 8p; HTPAP gene	PUTATIVE-TUMOR-SUPPRESSOR; PROSTATE-CANCER METASTASIS; BLADDER-CANCER; LOCALIZATION; EXPRESSION; HETEROZYGOSITY; DELETION; IDENTIFICATION; IMBALANCE; INTERVAL	Our previous studies suggested that chromosome 8p deletion is associated with metastasis of hepatocellular carcinoma (HCC), in which some novel metastasis suppressor genes might be harbored. The present study aimed to identify the metastatic suppressor gene(s). A cDNA chip was constructed with the expressed sequence tags (ESTs) from chromosome 8p and used to compare the difference of expression pro. ling between the MHCC97-H and MHCC97-L cell lines with different metastatic potentials and similar genetic backgrounds. In all, 10 ESTs were significantly downregulated in MHCC97-H cell line with higher metastatic potential. One full-length gene, HTPAP (phosphatidic acid phosphatase type 2 domain containing 1B), was identified at chromosome 8p12. Sequencing and bioinformatic analyses revealed that HTPAP has 826 bp and encodes a putative protein of 175 amino acids with a transmembrane segment at the NH2 terminus, two protein kinase C phosphorylation site and one tyrosine kinase phosphorylation site. Its expression level in metastatic tumor tissues was much lower than that of primary HCC tissues. Both in vitro and in vivo assays suggested that HTPAP could suppress the invasion and metastasis of HCC. These suggested that HTPAP is a novel metastatic suppressor gene for HCC. The mechanism of the effect of HTPAP on HCC metastasis is not clear yet and deserves further investigation.	Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China; Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Qin, LX (corresponding author), Fudan Univ, Liver Canc Inst, 180 Feng Lin Rd, Shanghai 200032, Peoples R China.	lxqin@zshospital.com	Wu, Xin/B-2244-2010	Ren, Ning/0000-0001-9776-2471; Sun, Hui-Chuan/0000-0003-3761-7058				Arai T, 1998, INT J CANCER, V79, P418, DOI 10.1002/(SICI)1097-0215(19980821)79:4<418::AID-IJC18>3.0.CO;2-0; Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740; Berger JC, 2004, ANTI-CANCER DRUG, V15, P559, DOI 10.1097/01.cad.0000132233.36512.fa; Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Giannelli G, 2002, AM J PATHOL, V161, P183, DOI 10.1016/S0002-9440(10)64170-3; Hussain SA, 2001, ANN ONCOL, V12, P161, DOI 10.1023/A:1008370324827; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Keller ET, 2004, CANCER LETT, V207, P131, DOI 10.1016/j.canlet.2004.02.006; Kujawski M, 1999, GENE CHROMOSOME CANC, V26, P253, DOI 10.1002/(SICI)1098-2264(199911)26:3<253::AID-GCC10>3.0.CO;2-A; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Li Y, 2004, J CANCER RES CLIN, V130, P460, DOI 10.1007/s00432-004-0564-9; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Muscheck M, 2000, LAB INVEST, V80, P1089, DOI 10.1038/labinvest.3780114; Nihei N, 2002, CANCER RES, V62, P367; Nonaka D, 2005, CANCER RES, V65, P1207, DOI 10.1158/0008-5472.CAN-04-3461; Ohgaki K, 1999, GENE CHROMOSOME CANC, V25, P1, DOI 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3; Parada LA, 1999, CLIN EXP METASTAS, V17, P471, DOI 10.1023/A:1006646901556; Park WS, 2002, CANCER LETT, V178, P199, DOI 10.1016/S0304-3835(01)00841-2; Petersen S, 2000, BRIT J CANCER, V82, P65; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Takanishi DM, 1997, MOL DIAGN, V2, P3, DOI 10.1016/S1084-8592(97)80003-3; Takeo S, 2001, CANCER GENET CYTOGEN, V130, P127, DOI 10.1016/S0165-4608(01)00479-4; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tang ZY, 2000, J GASTROEN HEPATOL, V15, pG1, DOI 10.1046/j.1440-1746.2000.02257.x; Tantivejkul K, 2004, J CELL BIOCHEM, V91, P706, DOI 10.1002/jcb.10664; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Wagner U, 1997, AM J PATHOL, V151, P753; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; Xu L, 2001, CANCER RES, V61, P3176; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5	40	26	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1832	1840		10.1038/sj.onc.1209191	http://dx.doi.org/10.1038/sj.onc.1209191			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261160				2022-12-28	WOS:000236013700016
J	Roccio, M; Bos, JL; Zwartkruis, FJT				Roccio, M; Bos, JL; Zwartkruis, FJT			Regulation of the small GTPase Rheb by amino acids	ONCOGENE			English	Article						Rheb; mTOR; S6 kinase	TUBEROUS SCLEROSIS COMPLEX-1; TUMOR-SUPPRESSOR PROTEINS; TOP MESSENGER-RNAS; P70 S6 KINASE; CELL-GROWTH; MAMMALIAN TARGET; GENE-PRODUCTS; RPS6 PHOSPHORYLATION; RAPAMYCIN; MTOR	The mTOR/S6K/4E-BP1 pathway integrates extracellular signals derived from growth factors, and intracellular signals, determined by the availability of nutrients like amino acids and glucose. Activation of this pathway requires inhibition of the tumor suppressor complex TSC1/2. TSC2 is a GTPase-activating protein for the small GTPase Ras homologue enriched in brain ( Rheb), GTP loading of which activates mTOR by a yet unidentified mechanism. The level at which this pathway senses the availability of amino acids is unknown but is suggested to be at the level of TSC2. Here, we show that amino-acid depletion completely blocks insulin- and TPA-induced Rheb activation. This indicates that amino-acid sensing occurs upstream of Rheb. Despite this, amino-acid depletion can still inhibit mTOR/S6 kinase signaling in TSC2(-/-). broblasts. Since under these conditions Rheb-GTP levels remain high, a second level of amino-acid sensing exists, affecting mTOR activity in a Rhebin-dependent fashion.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University	Zwartkruis, FJT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	g.j.t.zwartkruis@med.uu.nl		Roccio, Marta/0000-0001-7568-9429				Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grammer TC, 1996, CANCER SURV, V27, P271; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	39	114	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					657	664		10.1038/sj.onc.1209106	http://dx.doi.org/10.1038/sj.onc.1209106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16170341				2022-12-28	WOS:000235068800001
J	Li, X; Luwor, R; Lu, Y; Liang, K; Fan, Z				Li, X; Luwor, R; Lu, Y; Liang, K; Fan, Z			Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells	ONCOGENE			English	Article						EGF receptor inhibitors; alkylphospholipids; PTEN; Akt; targeted therapy	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; NEGATIVE REGULATION; PROSTATE-CANCER; SOLID TUMORS; PHASE-II; PATHWAY; MILTEFOSINE	Mutational inactivation or deletion of the phosphatase and tensin homologue deleted on chromosome 10 ( PTEN)/MMAC1/TEP gene in human cancer cells leads to a constitutively active status of the phosphatidylinositol 3-kinase/Akt pathway in the cells and has been linked to the lack of responses of the cells to the epidermal growth factor (EGF) receptor-targeted therapeutics. Akt is strongly inhibited by perifosine, an orally active alkyl-lysophospholipid currently being evaluated as an anticancer agent in phase 1 and 2 clinical trials. To determine whether perifosine may enhance the antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/ C225 in PTEN-deficient cancer cells, we exposed MDA468 breast cancer cells ( which contain mutated PTEN gene) and PC3 prostate cancer cells ( in which the PTEN gene is deleted) to perifosine and cetuximab, alone and in combination. Treatment of the cells with perifosine reduced baseline levels of phosphorylated Akt, phosphorylated p44/42 mitogen-activated protein kinase ( MAPK) and p38MAPK, and increased baseline levels of phosphorylated stress-activated protein kinase ( SAPK)/c-jun NH2-terminal kinase (JNK). A 72-h exposure of the MDA468 and PC3 cells to perifosine alone resulted in cell death in a dose-dependent manner, which was enhanced by cetuximab. Addition of subtoxic doses of perifosine to cetuximab treatment also enhanced the cetuximabinduced growth inhibition. The combination treatment enhanced the inhibition of phosphorylation of Akt, p44/ 42MAPK and p38MAPK, but offset the phosphorylation of SAPK/JNK that was activated by perifosine treatment alone. Taken together, the data showed that perifosine enhances the antitumor activity of cetuximab in PTEN deficient cancer cells. Further evaluation of the combination treatment in preclinical and clinical studies is warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zfan@mdanderson.org		Luwor, Rodney/0000-0002-3020-4245				Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Clive S, 1997, LANCET, V349, P621, DOI 10.1016/S0140-6736(05)61570-X; Clive S, 1999, CANCER CHEMOTH PHARM, V44, pS29, DOI 10.1007/s002800051114; Crul M, 2002, EUR J CANCER, V38, P1615, DOI 10.1016/S0959-8049(02)00127-2; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DUMMER R, 1992, PROG EXP TUMOR RES, V34, P160; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; HILGARD P, 1993, CANCER CHEMOTH PHARM, V32, P90, DOI 10.1007/BF00685608; Hilgard P, 1997, EUR J CANCER, V33, P442; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kondapaka SB, 2003, MOL CANCER THER, V2, P1093; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liang K, 2003, MOL CANCER THER, V2, P1113; Liu B, 2000, BRIT J CANCER, V82, P1991; Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; Ruiter GA, 2002, INT J CANCER, V102, P343, DOI 10.1002/ijc.10741; Ruiter GA, 1999, CANCER RES, V59, P2457; She QB, 2003, CLIN CANCER RES, V9, P4340; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Teng DHF, 1997, CANCER RES, V57, P5221; Terwogt JMM, 1999, BRIT J CANCER, V79, P1158, DOI 10.1038/sj.bjc.6690184; UNGER C, 1992, PROG EXP TUMOR RES, V34, P153; Van Ummersen L, 2004, CLIN CANCER RES, V10, P7450, DOI 10.1158/1078-0432.CCR-03-0406; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; VERWEIJ J, 1993, EUR J CANCER, V29A, P778, DOI 10.1016/S0959-8049(05)80369-7; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877	48	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					525	535		10.1038/sj.onc.1209075	http://dx.doi.org/10.1038/sj.onc.1209075			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170346				2022-12-28	WOS:000234897400004
J	Sakai, M; Shimokawa, T; Kobayashi, T; Matsushima, S; Yamada, Y; Nakamura, Y; Furukawa, Y				Sakai, M; Shimokawa, T; Kobayashi, T; Matsushima, S; Yamada, Y; Nakamura, Y; Furukawa, Y			Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor	ONCOGENE			English	Article						colon; cancer; C10orf3; TSG101	GENOME-WIDE ANALYSIS; METASTATIC COLORECTAL-CANCER; GENE-EXPRESSION; TSG101 PROTEIN; BREAST-CANCER; CDNA MICROARRAY; CELL-GROWTH; PROFILES; CARCINOGENESIS; IDENTIFICATION	After analysing gene-expression profiles of colon cancers on a cDNA microarray containing cDNAs corresponding to 23 040 human genes, we focused on a gene annotated as C10orf3 ( chromosome 10 open reading frame 3), whose expression was elevated in colorectal cancers (CRC) as well as in tumors arising in the stomach, lung, pancreas, and breast. The gene encodes a putative 464-amino-acid protein containing a domain known as AAA ( ATPases associated witha variety of cellular activities). Western blot analysis using an antibody to the gene product confirmed that the protein was overexpressed in nine of the 15 clinical cancer tissues examined, compared to corresponding noncancerous epithelial cells. A subsequent proteomics analysis revealed that C10orf3 product associated with the product of tumor susceptibility gene 101 (TSG101), and that C10orf3 downregulated TSG101 in a post-transcriptional manner. Expression of short interfering RNA in cells derived from CRC caused significant decreases in C10orf3 expression and inhibited growth of the transfected cells, which was associated with increased apoptotic cells. These data suggest that elevated C10orf3 expression might play an essential role in the growth of cancer cells, and that suppression of C10orf3-mediated signal transduction may be a novel therapeutic strategy to a wide range of human tumors.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, Tokyo 1088639, Japan; Yokohama City Univ, Sch Med, Dept Anesthesiol, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,, Tokyo 1088639, Japan	University of Tokyo; Yokohama City University; University of Tokyo	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp	Sakai, Michihiro/B-8755-2011; Shimokawa, Takashi/AAA-5870-2020	Shimokawa, Takashi/0000-0001-6549-9277				Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gridelli C, 2003, ONCOGENE, V22, P6629, DOI 10.1038/sj.onc.1206957; Hasegawa S, 2002, CANCER RES, V62, P7012; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Molina MA, 2001, CANCER RES, V61, P4744; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Neuwald AF, 1999, GENOME RES, V9, P27; Nishidate T, 2004, INT J ONCOL, V25, P797; O'Dwyer ME, 2000, CURR OPIN ONCOL, V12, P594, DOI 10.1097/00001622-200011000-00013; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Okabe H, 2001, CANCER RES, V61, P2129; Okabe H, 2003, CANCER RES, V63, P3043; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Shimokawa T, 2003, CANCER RES, V63, P6116; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Walt G, 2004, BRIT MED J, V328, P6, DOI 10.1136/bmj.328.7430.6; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1998, CANCER RES, V58, P2699; Zhu G, 2004, INT J CANCER, V109, P541, DOI 10.1002/ijc.20014	27	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					480	486		10.1038/sj.onc.1209051	http://dx.doi.org/10.1038/sj.onc.1209051			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170351				2022-12-28	WOS:000234714100016
J	Zhou, L; Isenberg, JS; Cao, Z; Roberts, DD				Zhou, L; Isenberg, JS; Cao, Z; Roberts, DD			Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1	ONCOGENE			English	Article						3D culture; endothelial cells; angiogenesis inhibitors; collagens	GROWTH-FACTOR-BETA; ENDOTHELIAL-CELL RESPONSES; TUMOR-GROWTH; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CAPILLARY MORPHOGENESIS; ACTIVATION; VIVO; MECHANISMS; APOPTOSIS	Three-dimensional explant cultures of muscle tissue were used to characterize secreted proteins regulated by endogenous levels of the angiogenesis modulator thrombospondin (TSP)-1. Explants from TSP1 null mice exhibit enhanced neovascularization associated with increased endothelial outgrowth but decreased outgrowth of perivascular smooth muscle cells. The absence of endogenous TSP1 did not diminish activation of latent transforming growth factor-beta and moderately decreased matrix metal-loproteinase levels. However, significant changes in other secreted proteins were observed. Endogenous TSP1 decreased mRNA levels for collagens I alpha 1, I alpha 2, and III alpha 1 and laminin alpha 4 and increased collagen IV alpha 1 mRNA expression. Endogenous TSP1 also decreased the level of type I collagen protein produced by the vascular out-growths. Collagens Ia1, Ia2, and IIIa1 are known tumor endothelial markers, suggesting that TSP1 coordinately regulates a set of extracellular matrix genes that reverse the angiogenic switch. Suppression of collagen Ia1 or Ia2 mRNAs using antisense morpholinos inhibited outgrowth in TSP1 null explants and proliferation of TSP1 null endothelial cells, indicating that type I collagen synthesis is limiting for this neovascularization response.	NCI, Biochem Pathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Biochem Pathol Sect, Pathol Lab, NIH, Bldg 10,Room 2A33,10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC009172, Z01SC009172] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelouahed M, 2000, J BIOL CHEM, V275, P17933, DOI 10.1074/jbc.275.24.17933; Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; ALBINI A, 1987, CANCER RES, V47, P3239; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bell SE, 2001, J CELL SCI, V114, P2755; Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen DH, 1999, AM J PHYSIOL-HEART C, V277, pH1100, DOI 10.1152/ajpheart.1999.277.3.H1100; CHOI ME, 1995, J BIOL CHEM, V270, P21144, DOI 10.1074/jbc.270.36.21144; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; de Fraipont F, 2004, ONCOGENE, V23, P3642, DOI 10.1038/sj.onc.1207438; DeHahn KC, 2004, EXP CELL RES, V294, P281, DOI 10.1016/j.yexcr.2003.11.006; Donnini S, 2004, LIFE SCI, V74, P2975, DOI 10.1016/j.lfs.2003.09.075; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; FOUSER L, 1991, J BIOL CHEM, V266, P18345; GONZALEZ AM, 2002, P NATL ACAD SCI USA, V26, P26; Guo NH, 1997, J PEPT RES, V50, P210; Guo NH, 1997, CANCER RES, V57, P1735; Hamano Y, 2004, CANCER RES, V64, P1570, DOI 10.1158/0008-5472.CAN-03-3126; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Isenberg JS, 2005, MATRIX BIOL, V24, P110, DOI 10.1016/j.matbio.2005.01.002; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Keezer SM, 2003, CANCER RES, V63, P6405; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Maeda K, 2001, ONCOL REP, V8, P763; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; Mazzanti CM, 2004, GENOME RES, V14, P1585, DOI 10.1101/gr.2552804; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; St Croix B, 2000, SCIENCE, V289, P1197; Streit M, 2002, CANCER RES, V62, P2004; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Taraboletti G, 2000, FASEB J, V14, P1674; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Westphal JR, 2004, CURR OPIN MOL THER, V6, P451; Yakubenko VP, 2000, EXP CELL RES, V260, P73, DOI 10.1006/excr.2000.5002; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	66	30	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					536	545		10.1038/sj.onc.1209069	http://dx.doi.org/10.1038/sj.onc.1209069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247480				2022-12-28	WOS:000234897400005
J	Carvalho, R; Milne, ANA; Polak, M; Corver, WE; Offerhaus, GJA; Weterman, MAJ				Carvalho, R; Milne, ANA; Polak, M; Corver, WE; Offerhaus, GJA; Weterman, MAJ			Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas	ONCOGENE			English	Article						RUNX3; gastric carcinoma; EOGC; TSG	TRANSCRIPTION FACTOR; CLEIDOCRANIAL DYSPLASIA; REGULATED EXPRESSION; CANCER; CELLS; HYBRIDIZATION; SURVIVAL; NEURONS; PROTEIN; REGION	Recent studies claim a critical role for RUNX3 in gastric epithelial homeostasis. However, conflicting results exist regarding RUNX3 expression in the stomach and its potential role as a tumour-suppressor gene (TSG) in gastric carcinogenesis. Our aim was to evaluate the role of RUNX3 in early-onset gastric carcinomas (EOGCs). We analysed 41 EOGCs for RUNX3 aberrations using loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analyses. LOH of markers flanking RUNX3 was relatively common, indicating that loss of the gene may play a role in gastric carcinogenesis. However, FISH analysis of selected cases and a panel of 14 gastric carcinoma-derived cell lines showed widespread presence of multiple copies of centromere 1. While RUNX3 copy numbers were generally equal to or fewer than those of centromere 1, at least two copies were present in almost all cells analysed. Accordingly, a subpopulation of tumour cells in 12/37 cases showed RUNX3 protein expression. However, expression was not detected in the adjacent nontumorous mucosa of any case. Together, these observations indicate that chromosome 1 aberrations occur frequently in EOGCs and are rejected in the LOH and IHC patterns found. Our findings refute a role for RUNX3 as a TSG in EOGCs.	Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Carvalho, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9,Room L2-114, NL-1105 AZ Amsterdam, Netherlands.	r.p.carvalho@amc.uva.nl	Corver, Willem/T-6576-2018	Corver, Willem/0000-0001-8313-3658				Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Carvalho R, 2004, J PATHOL, V204, P75, DOI 10.1002/path.1602; Corver WE, 2005, J PATHOL, V206, P233, DOI 10.1002/path.1765; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Igarashi J, 2000, JPN J CANCER RES, V91, P797, DOI 10.1111/j.1349-7006.2000.tb01016.x; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Kokkola A, 1998, CANCER GENET CYTOGEN, V107, P32, DOI 10.1016/S0165-4608(98)00092-2; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Miki R, 2004, J VET MED SCI, V66, P797, DOI 10.1292/jvms.66.797; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osaki M, 2004, EUR J CLIN INVEST, V34, P605, DOI 10.1111/j.1365-2362.2004.01401.x; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SANO T, 1991, CANCER RES, V51, P2926; TANAKA K, 1993, ONCOGENE, V8, P2253; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Varis A, 2003, BRIT J CANCER, V88, P1914, DOI 10.1038/sj.bjc.6600969; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wu CW, 2002, GENE CHROMOSOME CANC, V35, P219, DOI 10.1002/gcc.10106	38	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 15	2005	24	56					8252	8258		10.1038/sj.onc.1208963	http://dx.doi.org/10.1038/sj.onc.1208963			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091737				2022-12-28	WOS:000233956500004
J	Ko, D; Hawkins, L; Yu, DC				Ko, D; Hawkins, L; Yu, DC			Development of transcriptionally regulated oncolytic adenoviruses	ONCOGENE			English	Review						cancer virotherapy; transcriptionally regulated; oncolytic adenovirus	REPLICATION-COMPETENT ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; CANCER-SPECIFIC ADENOVIRUS; POLYMER-COATED ADENOVIRUS; RECURRENT PROSTATE-CANCER; TUMOR-NECROSIS-FACTOR; HERPES-SIMPLEX-VIRUS; SUICIDE GENE-THERAPY; IN-VIVO; TRANSGENE EXPRESSION	Changes initiated at the cellular and systemic levels as a result of viral infection or neoplastic transformation share significant overlap. Therefore, the use of replicating viruses to treat tumors has long been postulated as a promising avenue for oncolytic therapy. Over the last 10 years, transcriptionally regulated adenoviruses have become a popular platform for the development of such oncolytic viruses. Placement of heterologous promoters in front of key adenoviral transcription units to achieve tumor- or tissue-specific viral replication is well documented. Various derivatives of this general strategy have led to considerable insight into its limitations, pitfalls, and potential. Although a general process can be described by which to develop transcriptionally regulated adenoviruses, it is apparent that few set rules can yet be defined as to what constitutes a safe, stable, and therapeutically effective vector. Clinical experiences to date suggest the short-term potential for this class of therapeutics lies in combination therapy regimens. Such lessons from the clinic suggest the next generation of transcriptionally regulated oncolytic adenoviruses take advantage of the ability of the platform to carry transgenes in order to deliver a multimodal therapy from a single agent. Beyond this 'arming' of the vectors lies the detargeting, retargeting, and coating of adenoviruses to improve the delivery of the agent to the treatment site( s). As a therapeutic platform, transcriptionally regulated adenoviruses are at an early stage of development with considerable opportunities for advancement.	Cell Genesys Inc, San Francisco, CA 94080 USA	Cell Genesys Inc	Yu, DC (corresponding author), Cell Genesys Inc, San Francisco, CA 94080 USA.	mich204@yahoo.com						ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BELL JA, 1956, AM J PUBLIC HEALTH N, V46, P1130, DOI 10.2105/AJPH.46.9.1130; BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bristol JA, 2003, MOL THER, V7, P755, DOI 10.1016/S1525-0016(03)00103-5; Chen Y, 2001, CANCER RES, V61, P5453; Cripe TP, 2001, CANCER RES, V61, P2953; DEWEESE T, 2003, MOL THER S1, V7; DeWeese TL, 2001, CANCER RES, V61, P7464; Dilley J, 2005, CANCER GENE THER, V12, P715, DOI 10.1038/sj.cgt.7700835; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Douglas JT, 2001, CANCER RES, V61, P813; Fisher KD, 2001, GENE THER, V8, P341, DOI 10.1038/sj.gt.3301389; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Giedlin MA, 2003, CANCER CELL, V4, P241, DOI 10.1016/S1535-6108(03)00251-4; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; Green NK, 2004, GENE THER, V11, P1256, DOI 10.1038/sj.gt.3302295; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; Hemminki A, 2001, CANCER RES, V61, P6377; Henderson D.R., 2002, ADENOVIRAL VECTORS G, P287; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HERMISTON TW, 1993, J VIROL, V67, P5289, DOI 10.1128/JVI.67.9.5289-5298.1993; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; HOFFMANN D, 2005, J GENE MED      0609; HUNEYCUTT BS, 1993, J VIROL, V67, P6698, DOI 10.1128/JVI.67.11.6698-6706.1993; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; Ilan Y, 1997, P NATL ACAD SCI USA, V94, P2587, DOI 10.1073/pnas.94.6.2587; Jakubczak JL, 2003, CANCER RES, V63, P1490; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KRAJCSI P, 1992, VIROLOGY, V187, P492, DOI 10.1016/0042-6822(92)90451-T; Li YH, 2001, CANCER RES, V61, P6428; Lichtenstein DL, 2004, J VIROL, V78, P12297, DOI 10.1128/JVI.78.22.12297-12307.2004; Lichtenstein DL, 2002, J VIROL, V76, P11329, DOI 10.1128/JVI.76.22.11329-11342.2002; Lipinski KS, 2001, MOL THER, V4, P365, DOI 10.1006/mthe.2001.0468; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MITSUI Y, 1957, AM J OPHTHALMOL, V43, P84, DOI 10.1016/0002-9394(57)91484-8; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OSBORNE TF, 1983, J VIROL, V45, P594, DOI 10.1128/JVI.45.2.594-599.1983; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Polakis P, 2000, GENE DEV, V14, P1837; RAMESH N, 2005, UNPUB CLIN CANC RES; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; Rodriguez R, 1997, CANCER RES, V57, P2559; Rubinchik S, 2001, GENE THER, V8, P247, DOI 10.1038/sj.gt.3301364; Ryan PC, 2004, CANCER GENE THER, V11, P555, DOI 10.1038/sj.cgt.7700735; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; SHEN Y, 2003, 12 INT C GEN THER CA; SMALL EM, 2002, 5 ANN M AM SCOIET GE; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Toth K, 2004, CANCER RES, V64, P3638, DOI 10.1158/0008-5472.CAN-03-3882; Varghese S, 2002, CANCER GENE THER, V9, P967, DOI 10.1038/sj.cgt.7700537; Wakimoto H, 2003, GENE THER, V10, P983, DOI 10.1038/sj.gt.3302038; WARD TG, 1955, SCIENCE, V122, P1086, DOI 10.1126/science.122.3179.1086; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517; Yu DC, 1999, CANCER RES, V59, P1498; Zhu MZ, 2005, J VIROL, V79, P5455, DOI 10.1128/JVI.79.9.5455-5465.2005	82	65	72	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7763	7774		10.1038/sj.onc.1209048	http://dx.doi.org/10.1038/sj.onc.1209048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299536				2022-12-28	WOS:000233372600012
J	O'Shea, CC				O'Shea, CC			Viruses - seeking and destroying the tumor program	ONCOGENE			English	Review						viruses; oncolytic viral therapy; cancer; transformation; systems biology; adenovirus	HUMAN-PAPILLOMAVIRUS TYPE-16; ADENOVIRUS-INFECTED CELLS; REVERSE-TRANSCRIPTASE PROMOTER; PROTEIN-INTERACTION NETWORKS; E1B 55-KILODALTON PROTEIN; CERVICAL-CARCINOMA CELLS; LATE GENE-EXPRESSION; E2F TARGET GENES; CANCER-THERAPY; MESSENGER-RNA	DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Benedict CA, 2001, VIROLOGY, V289, P1, DOI 10.1006/viro.2001.1109; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Cuesta R, 2004, J VIROL, V78, P7707, DOI 10.1128/JVI.78.14.7707-7716.2004; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eisenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.138701; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hann B, 2003, J VIROL, V77, P11588, DOI 10.1128/JVI.77.21.11588-11595.2003; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hart LS, 2005, J BIOL CHEM, V280, P1474, DOI 10.1074/jbc.M409934200; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HAYES BW, 1990, J VIROL, V64, P2732, DOI 10.1128/JVI.64.6.2732-2742.1990; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; HO YS, 1982, VIROLOGY, V122, P109, DOI 10.1016/0042-6822(82)90381-6; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Huang SL, 2001, CANCER RES, V61, P3373; Huang W, 1998, J VIROL, V72, P225, DOI 10.1128/JVI.72.1.225-235.1998; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Ito A, 2003, HISTOL HISTOPATHOL, V18, P1313, DOI 10.14670/HH-18.1313; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2001, EXPERT OPIN BIOL TH, V1, P525, DOI 10.1517/14712598.1.3.525; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Lichtenstein DL, 2004, INT REV IMMUNOL, V23, P75, DOI 10.1080/08830180490265556; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; McCormick F, 2003, CANCER BIOL THER, V2, pS157; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; O'Connor RJ, 2000, J VIROL, V74, P5819, DOI 10.1128/JVI.74.13.5819-5824.2000; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Reid T, 2002, CANCER RES, V62, P6070; Ries S, 2002, BRIT J CANCER, V86, P5, DOI 10.1038/sj.bjc.6600006; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rudin CM, 2003, J CLIN ONCOL, V21, P4546, DOI 10.1200/JCO.2003.03.544; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; Seidel ER, 1997, BRIT J PHARMACOL, V120, P571, DOI 10.1038/sj.bjp.0700936; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Tarakanova VL, 2003, J VIROL, V77, P9324, DOI 10.1128/JVI.77.17.9324-9336.2003; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Thorne SH, 2005, J VIROL, V79, P581, DOI 10.1128/JVI.79.1.581-591.2005; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tollefson AE, 2003, J VIROL, V77, P7764, DOI 10.1128/JVI.77.14.7764-7778.2003; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Verma SC, 2004, J VIROL, V78, P10348, DOI 10.1128/JVI.78.19.10348-10359.2004; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wagner A, 2003, P ROY SOC B-BIOL SCI, V270, P457, DOI 10.1098/rspb.2002.2269; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Weitzman MD, 2004, DNA REPAIR, V3, P1165, DOI 10.1016/j.dnarep.2004.03.018; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045; YEN A, 1979, SCIENCE, V204, P1315, DOI 10.1126/science.451539; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986; Yook SH, 2004, PROTEOMICS, V4, P928, DOI 10.1002/pmic.200300636; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	180	49	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7640	7655		10.1038/sj.onc.1209047	http://dx.doi.org/10.1038/sj.onc.1209047			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299526	Green Submitted			2022-12-28	WOS:000233372600002
J	Godon, C; Coullet, S; Baus, B; Alonso, B; Davin, AH; Delcuze, Y; Marchetti, C; Hainaut, P; Kazmaier, M; Quemeneur, E				Godon, C; Coullet, S; Baus, B; Alonso, B; Davin, AH; Delcuze, Y; Marchetti, C; Hainaut, P; Kazmaier, M; Quemeneur, E			Quantitation of p53 nuclear relocation in response to stress using a yeast functional assay: effects of irradiation and modulation by heavy metal ions	ONCOGENE			English	Article						p53; genotoxic stress; nuclear relocation	TUMOR-SUPPRESSOR PROTEIN; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; EXPORT SIGNAL; DNA-DAMAGE; IN-VIVO; LOCALIZATION; ACTIVATION; GENE; YAP1	Many regulatory proteins undergo transient nuclear relocation under physical or chemical stress. This phenomenon is, however, difficult to assess due to the lack of sensitive and standardized biological assays. Here, we describe a new quantitative nuclear relocation assay (QNR), based on expression in yeasts of chimeric proteins in which an artificial transcription factor is fused to a target protein acting as driver for relocation. This assay combines the experimental versatility of yeast with quantitation of nuclear relocation at low levels of protein expression. We have assessed the nuclear relocation of yeast Yap1 and human p53, two transcription factors that relocate to the nucleus in response to oxidative-stress and DNA damage, respectively. We show that p53 efficiently drives the relocation of the chimeric reporter in response to irradiation and that this process requires the C-terminal nuclear export signal (NES). Cd2+ and Hg2+, two metal ions inducing DNA damage as well as conformational changes in p53, have opposite effects on p53 relocation in response to DNA damage. Whereas Hg2+ effects are synergistic to DNA damage, Cd2+ inhibits relocation and sequesters p53 into the cytoplasm. These results demonstrate the effectiveness of QNR to investigate the regulation of p53 shuttling in response to stress signals including suspected environmental carcinogens.	CEA Valrho, DSV, DIEP, SBTN, F-30207 Bagnols Sur Ceze, France; CEN Cadarache, DSV, DEVM, LBC, F-13108 St Paul Les Durance, France; IARC Lyon, Unit Mol Carcinogenesis, F-69372 Lyon, France	CEA; CEA; World Health Organization; International Agency for Research on Cancer (IARC)	Godon, C (corresponding author), CEA Valrho, DSV, DIEP, SBTN, F-30207 Bagnols Sur Ceze, France.	christian.godon@cea.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FRITSCHE M, 1993, ONCOGENE, V8, P307; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kitagawa K, 2002, BIOTECHNIQUES, V33, P288, DOI 10.2144/02332bm07; Klibanov SA, 2001, J CELL SCI, V114, P1867; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kungolos A, 1999, ECOTOX ENVIRON SAFE, V43, P149, DOI 10.1006/eesa.1999.1767; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sutton DJ, 2002, INT J MOL SCI, V3, P965, DOI 10.3390/i3090965; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; WU AL, 1993, J BIOL CHEM, V268, P18850; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	28	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 22	2005	24	42					6459	6464		10.1038/sj.onc.1208785	http://dx.doi.org/10.1038/sj.onc.1208785			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007197				2022-12-28	WOS:000232038200013
J	Bauer, DE; Hatzivassiliou, G; Zhao, FP; Andreadis, C; Thompson, CB				Bauer, DE; Hatzivassiliou, G; Zhao, FP; Andreadis, C; Thompson, CB			ATP citrate lyase is an important component of cell growth and transformation	ONCOGENE			English	Article						ATP citrate lyase; Akt; glucose metabolism; lipid synthesis; cell growth; transformation	FACTOR-INDEPENDENT SURVIVAL; DEPENDENT PROTEIN-KINASE; GLUCOSE-TRANSPORTER; CANCER-CELLS; AKT; PHOSPHORYLATION; METABOLISM; PURIFICATION; APOPTOSIS; ACTIVATION	Cell proliferation requires a constant supply of lipids and lipid precursors to fuel membrane biogenesis and protein modi. cation. Cytokine stimulation of hematopoietic cells directly stimulates glucose utilization in excess of bioenergetic demand, resulting in a shift from oxidative to glycolytic metabolism. A potential benefit of this form of metabolism is the channeling of glucose into biosynthetic pathways. Here we report that glucose supports de novo lipid synthesis in growing hematopoietic cells in a manner regulated by cytokine availability and the PI3K/Akt signaling pathway. The net conversion of glucose to lipid is dependent on the ability of cells to produce cytosolic acetyl CoA from mitochondria-derived citrate through the action of ATP citrate lyase (ACL). Stable knockdown of ACL leads to a significant impairment of glucose-dependent lipid synthesis and an elevation of mitochondrial membrane potential. Cells with ACL knockdown display decreased cytokine-stimulated cell proliferation. In contrast, these cells resist cell death induced by either cytokine or glucose withdrawal. However, ACL knockdown significantly impairs Akt-mediated tumorigenesis in vivo. These data suggest that enzymes involved in the conversion of glucose to lipid may be targets for the treatment of pathologic cell growth.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Hematol Oncol, Dept Med, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Sch Med, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Andreadis, Charalambos/A-1076-2007					Alli PM, 2005, ONCOGENE, V24, P39, DOI 10.1038/sj.onc.1208174; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; Beigneux AP, 2004, J BIOL CHEM, V279, P9557, DOI 10.1074/jbc.M310512200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bentley J, 2003, J BIOL CHEM, V278, P39337, DOI 10.1074/jbc.M305689200; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Board M, 1996, BIOCHEM MOL BIOL INT, V40, P1047; Boudreau DM, 2004, CANCER-AM CANCER SOC, V100, P2308, DOI 10.1002/cncr.20271; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PIERCE MW, 1981, J BIOL CHEM, V256, P8867; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Potapova IA, 2000, BIOCHEMISTRY-US, V39, P1169, DOI 10.1021/bi992159y; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Russo Patrizia, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P123, DOI 10.2174/1568011043482098; Srere P A, 1972, Curr Top Cell Regul, V5, P229; SRERE PA, 1959, J BIOL CHEM, V234, P2544; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; SUMI S, 1992, GASTROENTEROLOGY, V103, P982, DOI 10.1016/0016-5085(92)90032-T; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; YU KT, 1990, BIOCHEM J, V268, P539, DOI 10.1042/bj2680539	45	375	393	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6314	6322		10.1038/sj.onc.1208773	http://dx.doi.org/10.1038/sj.onc.1208773			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007201				2022-12-28	WOS:000231877100012
J	Minchiotti, G				Minchiotti, G			Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology	ONCOGENE			English	Article						Cripto; cardiomyocytes; neurons; tumors; nodal signaling	ONE-EYED-PINHEAD; MOUSE EMBRYOS; DOPAMINERGIC-NEURONS; MAMMARY-GLAND; NEURAL FATE; IN-VITRO; DIFFERENTIATION; GENE; INDUCTION; FAMILY	Embryonic stem (ES) cells have provided a valid model to understand early events of mammalian lineage specification and differentiation, leading to important insights into the mechanisms that control embryogenesis at the molecular and cellular levels. Furthermore, ES cells have recently evoked great scientific interest as ideal candidates for the generation of tissues for transplantation therapies. In this respect, particular attention has been paid to the molecules and signaling pathways triggering ES cell differentiation. The EGF-CFC Cripto protein is a key regulator of ES cells fate. The cripto gene is expressed both in ES cells and during the early phases of embryo development, while, in the adult, it is reactivated in a wide range of epithelial cancers. This review will discuss recent findings on the molecular basis of Cripto signaling in ES cell differentiation, providing an intriguing link between stem cell and tumor biology.	CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Minchiotti, G (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Via Petro Castellino 111, I-80131 Naples, Italy.	minchiot@igb.cnr.it		Minchiotti, Gabriella/0000-0003-0225-9043				Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Arenas E, 2002, BRAIN RES BULL, V57, P795, DOI 10.1016/S0361-9230(01)00772-9; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Castelo-Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Chung S, 2002, EUR J NEUROSCI, V16, P1829, DOI 10.1046/j.1460-9568.2002.02255.x; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; Dell'Era P, 2003, CIRC RES, V93, P414, DOI 10.1161/01.RES.0000089460.12061.E1; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Isacson O, 2003, ANN NEUROL, V53, pS135, DOI 10.1002/ana.10482; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Liguori GL, 2003, DEV BIOL, V264, P537, DOI 10.1016/j.ydbio.2003.08.023; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Minchiotti G, 2001, DEVELOPMENT, V128, P4501; Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Parish CL, 2005, STEM CELLS, V23, P471, DOI 10.1634/stemcells.2004-0294; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Persico MG, 2001, BBA-REV CANCER, V1552, P87, DOI 10.1016/S0304-419X(01)00039-7; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; ROSA FM, 2002, SCI STKE, pPE47; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 2003, J CLIN INVEST, V112, P500, DOI 10.1172/JCI200319546; Shen MM, 1997, DEVELOPMENT, V124, P429; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Sonntag KC, 2005, MOL CELL NEUROSCI, V28, P417, DOI 10.1016/j.mcn.2004.06.003; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Xu CH, 1999, DEVELOPMENT, V126, P483; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	70	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5668	5675		10.1038/sj.onc.1208917	http://dx.doi.org/10.1038/sj.onc.1208917			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123800				2022-12-28	WOS:000231452800002
J	Wang, JD; Kataoka, H; Suzuki, M; Sato, N; Nakamura, R; Tao, H; Maruyama, K; Isogaki, J; Kanaoka, S; Ihara, M; Tanaka, M; Kanamori, M; Nakamura, T; Shinmura, K; Sugimura, H				Wang, JD; Kataoka, H; Suzuki, M; Sato, N; Nakamura, R; Tao, H; Maruyama, K; Isogaki, J; Kanaoka, S; Ihara, M; Tanaka, M; Kanamori, M; Nakamura, T; Shinmura, K; Sugimura, H			Downregulation of EphA7 by hypermethylation in colorectal cancer	ONCOGENE			English	Article						EphA7; colorectal cancer; DNA methylation	RECEPTOR TYROSINE KINASES; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; BREAST-CARCINOMA; COLON-CANCER; C-ELEGANS; OVEREXPRESSION; METHYLATION; EXPRESSION; LIGANDS	A significant reduction of EphA7 expression in human colorectal cancers was shown using semiquantitative reverse transcription-polymerase chain reaction analysis in 59 colorectal cancer tissues, compared to corresponding normal mucosas (P=0.008), and five colon cancer cell lines. To investigate the mechanism of EphA7 down-regulation in colorectal cancer, we examined the methylation status of the 5'CpG island around the translation start site in five colon cancer cell lines using restriction enzymes, methylation-specific PCR, and bisulfite sequencing and found evidence of aberrant methylation. The expression of EphA7 in colon cancer cell lines was restored after treatment with 5-aza-2'-deoxycytidine. Analysis of methylation status in totally 75 tumors compared to clinicopathological parameters revealed that hypermethylation of colorectal cancers was more frequent in male than in female (P=0.0078), and in moderately differentiated than in well-differentiated adenocarcinomas (P=0.0361). There was a tendency that hypermethylation in rectal cancers was more frequent than in colon cancers (P=0.0816). Hypermethylation was also observed in colorectal adenomas. This is the first report describing the downregulation of an Eph family gene in a solid tumor via aberrant 5'CpG island methylation. It provides the evidence that EphA7 gene is involved in human colorectal carcinogenesis.	Hamamatsu Univ Sch Med, Dept Pathol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Clin Nursing, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Surg, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Publ Hlth, Hamamatsu, Shizuoka 4313192, Japan; Biwako Seikei Sport Coll, Dept Lifelong Sport, Shiga 5200503, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp	Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Brock MV, 2003, CLIN CANCER RES, V9, P2912; Chin-Sang ID, 2002, DEVELOPMENT, V129, P5499, DOI 10.1242/dev.00122; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; CIOSSEK T, 1995, ONCOGENE, V10, P97; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cunningham JM, 1998, CANCER RES, V58, P3455; Dottori M, 1999, BLOOD, V94, P2477, DOI 10.1182/blood.V94.7.2477.419k13_2477_2486; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; ENDO Y, 1995, PATHOL INT, V45, P602, DOI 10.1111/j.1440-1827.1995.tb03509.x; Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hsieh CJ, 1998, CANCER RES, V58, P3942; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kataoka H, 2002, J CANCER RES CLIN, V128, P343, DOI 10.1007/s00432-002-0355-0; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Sullivan DD, 2003, BRIT J CANCER, V89, P228, DOI 10.1038/sj.bjc.6601107; Tang XX, 1999, CLIN CANCER RES, V5, P455; Tao H, 2004, CARCINOGENESIS, V25, P1859, DOI 10.1093/carcin/bgh206; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; Wiencke JK, 1999, CANCER EPIDEM BIOMAR, V8, P501; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405	34	90	108	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 25	2005	24	36					5637	5647		10.1038/sj.onc.1208720	http://dx.doi.org/10.1038/sj.onc.1208720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007213				2022-12-28	WOS:000231296100010
